<SEC-DOCUMENT>0001193125-13-432814.txt : 20131107
<SEC-HEADER>0001193125-13-432814.hdr.sgml : 20131107
<ACCEPTANCE-DATETIME>20131107161059
ACCESSION NUMBER:		0001193125-13-432814
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20130930
FILED AS OF DATE:		20131107
DATE AS OF CHANGE:		20131107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		131200750

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d595270d10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington,&nbsp;D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 10-Q
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</B> <B> </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the quarterly period ended September&nbsp;30, 2013 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OR </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the transition period from
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Commission File No.&nbsp;000-21392 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Amarin
Corporation plc </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in its Charter) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>England and Wales</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not applicable</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporation or Organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2 Pembroke House, Upper Pembroke Street 28-32</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dublin 2, Ireland</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: +353 (0)&nbsp;1 6699 020 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or
for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past
90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;YES&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to
Rule&nbsp;405 of Regulation&nbsp;S-T (&#167;229.405 of this chapter) during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;YES&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; accelerated filer&#148; and &#147;smaller
reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if smaller reporting company)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the
Act).&nbsp;&nbsp;&nbsp;&nbsp;YES&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">172,195,467 shares held as American Depository Shares (ADS), each representing one Ordinary Share, 50 pence par value per share, and 468,546 ordinary shares, were outstanding as of November&nbsp;1, 2013.
</FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>INDEX TO FORM 10-Q </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A HREF="#toc595270_1">PART&nbsp;I &#150; Financial Information</A></B></FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A HREF="#toc595270_1"></A>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;1.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial Statements (Unaudited):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc595270_2">Condensed Consolidated Balance Sheets at September 30, 2013 and December 31, 2012</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc595270_3">Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2013 and
 2012</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc595270_4">Condensed Consolidated Statement of Changes in Deficit at September 30, 2013 and September 30,
2012</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc595270_5">Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2013 and
2012</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc595270_6">Notes to Condensed Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;2.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc595270_7">Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;3.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc595270_8">Quantitative and Qualitative Disclosures about Market Risk</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;4.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc595270_9">Controls and Procedures</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A HREF="#toc595270_10">PART&nbsp;II &#150; Other Information</A></B></FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A HREF="#toc595270_10"></A>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc595270_11">Legal Proceedings</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;1A.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc595270_12">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;5.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc595270_13">Other Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;6.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc595270_14">Exhibits</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc595270_15">SIGNATURES</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc595270_1"></A>PART I </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc595270_2"></A>A<SMALL>MARIN</SMALL> C<SMALL>ORPORATION</SMALL> <SMALL>PLC</SMALL> </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Unaudited, in thousands, except share amounts) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,<BR>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ASSETS</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current Assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">225,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260,242</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,721</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventory, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,083</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,262</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax asset</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">936</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">937</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,253</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">262,562</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">285,694</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property, plant and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">811</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax asset</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,044</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other non-current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,335</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,951</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intangible asset, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,870</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TOTAL ASSETS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">293,846</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">310,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LIABILITIES AND STOCKHOLDERS&#146; DEFICIT</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current Liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,233</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued interest payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,901</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,520</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,617</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses and other liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,548</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,224</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-Term Liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrant derivative liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,598</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exchangeable senior notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">145,316</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">134,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,319</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">85,153</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term debt redemption feature</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other long-term liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">811</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">816</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">311,543</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">314,852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commitments and contingencies (Note&nbsp;7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders&#146; Deficit:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, &pound;0.50&nbsp;par value, unlimited authorized; 172,664,013 issued, 172,643,934 outstanding at September&nbsp;30,
2013; 150,360,933 issued, 150,340,854 outstanding at December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">141,455</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">124,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">739,524</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">619,266</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Treasury stock; 20,079 shares at September&nbsp;30, 2013 and December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(898,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(747,643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,697</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,997</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TOTAL LIABILITIES AND STOCKHOLDERS&#146; DEFICIT</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">293,846</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">310,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">See notes to unaudited condensed consolidated financial statements. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc595270_3"></A>A<SMALL>MARIN</SMALL> C<SMALL>ORPORATION</SMALL>
<SMALL>PLC</SMALL> </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Unaudited, in thousands, except per share amounts) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;months&nbsp;ended&nbsp;September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine&nbsp;months&nbsp;ended&nbsp;September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,245</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating Expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of goods sold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,682</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,813</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,913</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,735</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Selling, general and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,274</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,397</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101,502</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,059</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,310</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">165,463</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80,794</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40,374</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(34,310</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(149,218</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(80,794</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Loss) gain on change in fair value of derivative liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,454</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,059</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(68,686</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(26,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other (expense) income, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(411</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss from operations before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(50,519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(22,853</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(155,643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(162,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Benefit from (provision for) income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,635</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,827</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(48,884</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(26,426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(150,816</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(168,617</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss per share:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average shares:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">170,187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">149,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">157,105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">141,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">See notes to unaudited condensed consolidated financial statements. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc595270_4"></A>A<SMALL>MARIN</SMALL> C<SMALL>ORPORATION</SMALL>
<SMALL>PLC</SMALL> </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN DEFICIT </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Unaudited, in thousands, except share amounts) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common<BR>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common<BR>Stock</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Additional<BR>Paid-in<BR>Capital</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Treasury<BR>Stock</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>Deficit</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>At January&nbsp;1, 2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>150,360,933</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>124,597</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>619,266</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(217</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(747,643</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3,997</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock issued in equity financing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,700,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">104,805</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">121,206</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vesting of restricted stock units</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">386,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">292</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">335</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">627</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax benefits realized from stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">966</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">966</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares issued for services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,170</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,170</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(150,816</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(150,816</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>At September&nbsp;30, 2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>172,664,013</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>141,455</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>739,524</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(217</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(898,459</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(17,697</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common<BR>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common<BR>Stock</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Additional<BR>Paid-in<BR>Capital</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Treasury<BR>Stock</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>Deficit</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>At January&nbsp;1, 2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>135,832,542</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>113,321</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>449,393</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(217</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(568,459</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(5,962</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,881,276</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,407</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,119</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,526</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer of fair value of warrants exercised from liabilities to equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">103,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">103,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conversion option contained in exchangeable notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,898</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,898</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,107,913</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,439</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax benefits realized from stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vesting of restricted stock units</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">97,398</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares issued for services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,293</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(168,617</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(168,617</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>At September&nbsp;30, 2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>149,921,422</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>124,244</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>613,087</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(217</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(737,076</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>38</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">See notes to unaudited condensed consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc595270_5"></A>A<SMALL>MARIN</SMALL> C<SMALL>ORPORATION</SMALL>
<SMALL>PLC</SMALL> </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Unaudited, in thousands) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CASH FLOWS FROM OPERATING ACTIVITIES:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(150,816</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(168,617</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments to reconcile net loss to net cash used in operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">179</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">123</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,170</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation&#151;warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,179</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,037</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares issued for services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Excess tax benefit from stock-based awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(966</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued interest payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,381</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,094</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of intangible asset</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">485</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of debt discount and debt issuance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,232</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,365</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in lease liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Gain) loss on change in fair value of derivative liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(21,059</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68,686</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,721</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,989</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(283</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,273</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other non-current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(384</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable, accrued expenses and other liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,714</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(157,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(78,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CASH FLOWS FROM INVESTING ACTIVITIES:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase of long-term investment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases of equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(477</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,715</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CASH FLOWS FROM FINANCING ACTIVITIES:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuance of common stock, net of transaction costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">121,206</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from exercise of stock options, net of transaction costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">627</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from exercise of warrants, net of transaction costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,526</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Excess tax benefit from stock-based awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">966</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuance of exchangeable debt, net of transaction costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">144,316</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments under capital leases</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">122,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">178,762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(34,357</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,508</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260,242</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">116,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CASH AND CASH EQUIVALENTS, END OF PERIOD</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">225,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">215,110</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supplemental disclosure of cash flow information:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash paid during the year for:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">697</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash transactions:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer from derivative liability to equity, fair value of warrants exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">103,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">See notes to unaudited condensed consolidated financial statements. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc595270_6"></A>A<SMALL>MARIN</SMALL> C<SMALL>ORPORATION</SMALL>
<SMALL>PLC</SMALL> </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notes to Unaudited Condensed Consolidated Financial Statements </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of this Quarterly Report on Form 10-Q, our ordinary shares may also be referred to as &#147;common shares&#148; or &#147;common stock.&#148;
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(1)</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Nature of Business and Basis of Presentation </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Nature of Business </U></I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Amarin Corporation plc, &#147;Amarin&#148; or the &#147;Company&#148;, is a public limited company with its primary stock market listing in the United States on the NASDAQ Global Market. Amarin was
originally incorporated in England as a private limited company on March&nbsp;1, 1989 under the Companies Act 1985, and re-registered in England as a public limited company on March&nbsp;19, 1993. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Amarin is a biopharmaceutical company with expertise in lipid science focused on the commercialization and development of
therapeutics to improve cardiovascular health. On July&nbsp;26, 2012, the Company received approval from the U.S. Food and Drug Administration, or FDA, to market and sell its lead product Vascepa<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (icosapent ethyl) capsules (formerly known as AMR 101) as an adjunct to diet to reduce triglyceride levels in adult patients with severe (TG <U>&gt;</U>500mg/dL)
hypertriglyceridemia, which the Company sometimes refers to as the MARINE indication. Triglycerides are fats in the blood. Vascepa became commercially available in the United States by prescription in January 2013, when the Company commenced sales
and shipments to its network of U.S.-based wholesalers and specialty pharmacy providers. On January&nbsp;28, 2013, the Company commenced its full commercial launch of Vascepa in the United States for use in the MARINE indication. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amarin is also developing Vascepa for the treatment of patients with high triglyceride levels (TG <U>&gt;</U>200 mg/dL and &lt;500 mg/dL) who are also on
statin therapy for elevated LDL-C levels. This indication is referred to as mixed dyslipidemia or the ANCHOR indication. In February 2013, the Company submitted a supplemental New Drug Application, or sNDA, to the FDA seeking approval of Vascepa for
the ANCHOR indication. On October&nbsp;16, 2013, the FDA convened an advisory committee to review the Company&#146;s sNDA for the ANCHOR indication and the advisory committee voted 9 to 2 against recommending approval of the ANCHOR indication based
on information presented at the meeting. The FDA will consider the recommendation of the advisory committee, but the final decision regarding the approval of the sNDA will be made by the FDA. The application is subject to a standard review and has
been assigned a Prescription Drug User Fee Act, or PDUFA, date of December&nbsp;20, 2013. The PDUFA date is the target date for the FDA to complete its review of the sNDA. The FDA could complete its review of the sNDA prior to this date and there
can be no assurance that the FDA will complete its review of the sNDA by this date. If the FDA does not approve the ANCHOR indication, it would have a material impact on the Company&#146;s future results of operations and financial condition (see
Note 9&#151;Subsequent Events). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Basis of Presentation </U></I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The condensed consolidated financial statements included herein have been prepared by the Company, without audit, in accordance with accounting principles
generally accepted in the United States of America (the &#147;U.S.&#148; or the &#147;United States&#148;) and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#147;SEC&#148;). Certain information in the notes to
the financial statements (the &#147;Notes&#148;) has been condensed or omitted where it substantially duplicates information provided in the Company&#146;s latest audited consolidated financial statements, in accordance with the rules and
regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the Company&#146;s audited consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended
December&nbsp;31, 2012, filed with the SEC (the &#147;2012 Form 10-K&#148;). The balance sheet amounts at December&nbsp;31, 2012 in this report were derived from the Company&#146;s audited 2012 consolidated financial statements included in the 2012
Form 10-K. The condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the Company&#146;s financial position, results of operations and cash flows for the periods
indicated. The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#147;GAAP&#148;) requires management to make estimates and assumptions that affect the reported amounts and classifications of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three and nine months
ended September&nbsp;30, 2013 and 2012, respectively, are not necessarily indicative of the results for the entire fiscal year or any future period. The Company has evaluated subsequent events from September&nbsp;30, 2013 through the date of the
issuance of these condensed consolidated financial statements and has disclosed subsequent events in Note 9. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying consolidated
financial statements of the Company and subsidiaries have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in
the normal course of business. Prior to 2004, the Company was in the business of selling a previous biopharmaceutical compound, which has since been discontinued. The Company&#146;s current focus is on the commercialization and development of
Vascepa, which received approval from the FDA in 2012 and for which the Company commenced marketing and sales in 2013. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">At September&nbsp;30, 2013, the Company had cash and cash equivalents of $225.9&nbsp;million. See also Note
8&#151;Equity for a description of a public offering completed in July 2013 resulting in net proceeds to the Company of approximately $121.2 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s consolidated balance sheet also includes derivative liabilities (see Note 5&#151;Warrants and Warrant Derivative Liability) as well as long term debt and exchangeable senior notes (see
Note 6&#151;Debt). The warrant derivative liability reflects the fair value of outstanding warrants to purchase shares of the Company&#146;s common stock. This liability can only be settled in shares of the Company&#146;s stock. The long term debt
is not callable except upon a change in control. The Exchangeable Senior Notes (the Notes) may be redeemed on or after January&nbsp;19, 2017 at the option of the holders. The Notes are exchangeable under certain circumstances into cash, American
Depository Shares, or ADSs, or a combination of cash and ADSs, at the Company&#146;s election. Accordingly, the warrant derivative liability, long term debt and Exchangeable Senior Notes do not present a short term claim on the liquid assets of the
Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company believes its cash and cash equivalents will be sufficient to fund its projected operations for at least the next twelve
months. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(2)</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Significant Accounting Policies </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Use of Estimates </U></I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The preparation of the Company&#146;s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting
period. Accounting estimates are based on historical experience and other factors that are considered reasonable under the circumstances. Actual results could differ from those estimates. The preparation of the Company&#146;s condensed consolidated
financial statements in accordance with GAAP requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and
liabilities. On an on-going basis, the Company evaluates its estimates and judgments and methodologies, including those related to revenue recognition and related allowances, clinical trial expenses, the valuation of inventory, impairment and
amortization of intangibles, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments and derivative instruments. The Company bases its estimates on historical experience and on
various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Revenue Recognition </U></I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company sells Vascepa principally to a limited number of major wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its Distributors, that in turn
resell Vascepa to retail pharmacies for subsequent resale to patients and health care providers. Patients are required to have a prescription in order to purchase Vascepa. In accordance with GAAP, the Company&#146;s revenue recognition policy
requires that: (i)&nbsp;there is persuasive evidence that an arrangement exists between the Company and the Distributor, (ii)&nbsp;delivery has occurred, (iii)&nbsp;collectability is reasonably assured and (iv)&nbsp;the price is fixed or
determinable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company commenced its commercial launch in the United States on January&nbsp;28, 2013. Prior to 2013, the Company
recognized no revenue from Vascepa sales. In accordance with GAAP, until the Company has the ability to reliably estimate returns of Vascepa from its Distributors, revenue will be recognized based on the resale of Vascepa for the purposes of filling
patient prescriptions, and not based on sales from the Company to such Distributors. Consistent with industry practice, once the Company achieves sufficient history such that it can reliably estimate returns, the Company will recognize revenue based
on sales to its Distributors. The Company currently defers Vascepa revenue recognition until the earlier of the product being resold for purposes of filling patient prescriptions; or the expiration of the right of return (twelve months after the
expiration date of the product). The Company also defers the related cost of product sales and records such amounts as finished goods inventory held by others until revenue related to such product sales is recognized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has contracts with its primary Distributors and delivery occurs when a Distributor receives Vascepa. The Company evaluates the
creditworthiness of each of its Distributors to determine whether revenues can be recognized upon delivery, subject to satisfaction of the other requirements, or whether recognition is required to be delayed until receipt of payment or when the
product is utilized. In order to conclude that the price is fixed or determinable, the Company must be able to (i)&nbsp;calculate its gross product revenues from the sales to Distributors and (ii)&nbsp;reasonably estimate its net product revenues.
The Company calculates gross product revenues based on the wholesale acquisition cost that the Company charges its Distributors for Vascepa. The Company estimates its net product revenues by deducting from its gross product revenues (a)&nbsp;trade
allowances, such as invoice discounts for prompt payment and distributor fees, (b)&nbsp;estimated government and private payor rebates, chargebacks and discounts, such as Medicaid reimbursements, (c)&nbsp;reserves for expected product returns and
(d)&nbsp;estimated costs of incentives offered to certain indirect customers, including patients. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Trade Allowances: </I>The Company generally provides invoice discounts on
Vascepa sales to its Distributors for prompt payment and pays fees for distribution services, such as fees for certain data that Distributors provide to the Company. The payment terms for sales to Distributors generally include a 2% discount for
payment within 30&nbsp;days. Based on the Company&#146;s judgment and experience, the Company expects its Distributors to earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and
accounts receivable at the time such revenues are recognized. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Rebates, Chargebacks and Discounts: </I>The
Company contracts with Medicaid, other government agencies and various private organizations, or collectively, Third-party Payors, so that Vascepa will be eligible for purchase by, or partial or full reimbursement from, such Third-party Payors. The
Company estimates the rebates, chargebacks and discounts it will provide to Third-party Payors and deducts these estimated amounts from its gross product revenues at the time the revenues are recognized. The Company estimates the rebates,
chargebacks and discounts that it will provide to Third-party Payors based upon (i)&nbsp;the Company&#146;s contracts with these Third-party Payors, (ii)&nbsp;the government-mandated discounts applicable to government-funded programs,
(iii)&nbsp;information obtained from the Company&#146;s Distributors and (iv)&nbsp;information obtained from other third parties regarding the payor mix for Vascepa. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Product Returns: </I>The Company&#146;s Distributors have the right to return unopened unprescribed Vascepa during the
18-month period beginning six months prior to the labeled expiration date and ending twelve months after the labeled expiration date. The expiration date for Vascepa is three years after it has been converted into capsule form, which is the last
step in the manufacturing process for Vascepa and generally occurs within a few months before Vascepa is delivered to Distributors. As of September&nbsp;30, 2013, the Company had experienced a deminimus quantity of product returns. During the nine
months ended September&nbsp;30, 2013, the period in which the Company began selling Vascepa, the Company was not able to reasonably estimate product returns for all product sold to Distributors but the Company was able to reasonably estimate product
returns for certain sales of Vascepa based on product used to fill patient prescriptions as determined by inventory estimated to be in the distribution channel and third party reports of prescriptions filled. In making this assessment, the Company
used (i)&nbsp;data provided to the Company by its Distributors (including weekly reporting of Distributors&#146; sales and inventory held by Distributors that provided the Company with visibility into the distribution channel in order to determine
what quantities were sold to retail pharmacies and other providers), (ii)&nbsp;information provided to the Company from retail pharmacies, (iii)&nbsp;data provided to the Company by a third party data provider which collects and publishes
prescription data, and other third parties, (iv)&nbsp;historical industry information regarding return rates for similar pharmaceutical products, (v)&nbsp;the estimated remaining shelf life of Vascepa previously shipped and currently being shipped
to Distributors and (vi)&nbsp;contractual agreements intended to limit the amount of inventory maintained by the Company&#146;s Distributors. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Other Incentives:&nbsp;</I>Other incentives that the Company offers to indirect customers include co-pay mitigation rebates provided by the Company to commercially insured patients who have coverage
for Vascepa and who reside in states that permit co-pay mitigation programs. The Company&#146;s co-pay mitigation program is intended to reduce each participating patient&#146;s portion of the financial responsibility for Vascepa&#146;s purchase
price to a specified dollar amount. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of
patients that it expects to participate in the program in order to establish its accruals for co-pay mitigation rebates and deducts these estimated amounts from its gross product revenues at the time the revenues are recognized. The Company&#146;s
co-pay mitigation rebates offered to date will expire on December&nbsp;31, 2013. The Company adjusts its accruals for co-pay mitigation rebates based on its estimates regarding the portion of issued rebates that it estimates will not be redeemed. In
addition, as is customary prior to the launch of new drugs, the Company provided certain of its Distributors with financial incentives to begin stocking Vascepa prior to the Company&#146;s commercial launch of Vascepa in order to ensure that Vascepa
was readily available to fill patient prescriptions upon launch. Such incentives were only offered on purchases of initial launch quantities of Vascepa stocked by Distributors in January 2013. The amount of these financial incentives were recorded
by the Company as a reduction to revenues on a pro-rata basis for each of the bottles subject to such financial incentives. The Company estimates that all of these initial launch quantities stocked by its primary Distributors in January 2013 were
resold by such Distributors prior to September&nbsp;30, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes activity in each of the product revenue
allowance and reserve categories described above for the nine months ended September&nbsp;30, 2013 (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Trade<BR>Allowances</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Rebates,<BR>Chargebacks<BR>and&nbsp;Discounts</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Product<BR>Returns</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Other<BR>Incentives</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at January&nbsp;1, 2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provision related to current period and deferred sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,839</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,418</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,347</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Credits/payments made for current period and deferred sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,951</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,835</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at September&nbsp;30, 2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B> 888</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B> 934</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B> 72</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B> 183</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B> 2,077</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes product revenue recognized and deferred during the nine months ended
September&nbsp;30, 2013 (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,&nbsp;2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,&nbsp;2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product revenue recognized</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,245</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred product revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,617</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>17,862</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In conjunction with the Company&#146;s recognition and deferral of product revenues, the Company expensed and capitalized
the associated cost of goods, as follows, during the nine months ended September&nbsp;30, 2013 (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,&nbsp;2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,&nbsp;2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of goods sold expensed</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,813</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finished goods inventory held by others</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8,454</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Cash and Cash Equivalents </U></I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents consist of cash, deposits held at call with banks and short term highly liquid instruments with remaining maturities at the date of purchase of 90&nbsp;days or less. Restricted
cash represents cash and cash equivalents pledged to guarantee repayment of certain expenses which may be incurred for business travel under corporate credit cards held by employees. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Inventory </U></I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company states inventories at the lower of cost or market value. Cost is determined based on actual cost using the average cost method. An allowance
is established when management determines that certain inventories may not be saleable. If inventory cost exceeds expected market value due to obsolescence, damage or quantities in excess of expected demand, the Company will record a reserve for the
difference between cost and market value. The Company received FDA approval for Vascepa on July&nbsp;26, 2012 and after that date began capitalizing inventory purchases of saleable product from approved suppliers. Until an API supplier is approved,
all Vascepa API purchased from such supplier is included as a component of research and development expense. Upon sNDA approval of each additional supplier, the Company capitalizes subsequent Vascepa API purchases from such supplier as inventory.
Purchases of Vascepa API received and expensed before such regulatory approvals is not subsequently capitalized, and all such purchases are quarantined and not used for commercial supply until such time as the sNDA for the supplier that produced the
API is approved. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Intangible Asset, net </U></I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Intangible assets consist of a milestone payment paid to the former shareholders of Laxdale Limited related to the 2004 acquisition of our rights to Vascepa, which is the result of Vascepa receiving
marketing approval for the first indication and is amortized over its estimated useful life on a straight-line basis. The Company concluded that use of the straight-line method was appropriate as the majority of cash flows are expected to be
generated ratably over the estimated useful life and no degradation of the cash flows over time is currently anticipated. See Note 7&#151;Commitments and Contingencies for further information regarding other obligations related to the acquisition of
Laxdale Limited. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Deferred Revenue </U></I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue represents product shipments to Distributors for which the Company has invoiced the Distributors but not recognized revenue because the product was not reported to the Company as having
been resold for the purpose of filling prescriptions on or before September&nbsp;30, 2013. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Research and Development
Costs </U></I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company charges research and development costs to operations as incurred. Research and development expenses are
comprised of costs incurred by the Company in performing research and development activities, including salary and benefits; stock-based compensation expense; laboratory supplies and other direct expenses; contractual services, including clinical
trial and pharmaceutical development costs; commercial supply investment in its drug candidates; and infrastructure costs, including facilities costs and depreciation expense. In addition, research and development costs include the costs of product
supply received from suppliers when such receipt by the Company is prior to regulatory approval of the supplier. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Selling, General and Administrative Costs </U></I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company charges sales, general and administrative costs to operations as incurred. Selling, general and administrative costs include costs of
salaries, programs and infrastructure necessary for the general conduct of the Company&#146;s business, including the 2013 commercial launch of Vascepa in the United States for the MARINE indication. Included as part of selling, general and
administrative costs is warrant-related expense from non-cash changes in fair value of the derivative liability associated with warrants issued in October 2009 to former officers of Amarin which is recorded as compensation income (expense).
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Income Taxes </U></I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Deferred tax assets and liabilities are recognized for the future tax consequences of differences between the carrying amounts and tax bases of assets and liabilities and operating loss carry-forwards and
other attributes using enacted rates expected to be in effect when those differences reverse. Valuation allowances are provided against deferred tax assets that are not more likely than not to be realized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company provides reserves for potential payments of tax to various tax authorities or does not recognize tax benefits related to uncertain tax
positions and other issues. Tax benefits for uncertain tax positions are based on a determination of whether a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized, assuming that the matter in
question will be decided based on its technical merits. The Company&#146;s policy is to record interest and penalties in the provision for income taxes. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Derivative Instruments </U></I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Derivative financial liabilities are recorded at fair
value, with gains and losses arising for changes in fair value recognized in the statement of operations at each period end while such instruments are outstanding. If the Company issues shares to discharge the liability, the derivative financial
liability is derecognized and common stock and additional paid-in capital are recognized on the issuance of those shares. The warrants are valued using a Black-Scholes option pricing model due to the nature of the instrument. The long term debt
redemption feature is valued using a probability-weighted model incorporating management estimates for potential change in control, and by determining the fair value of the debt with and without the change in control provision included. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the terms of warrants that initially require the warrant to be classified as a derivative financial liability lapse, the derivative financial
liability is reclassified out of financial liabilities into equity at its fair value on that date. At the applicable settlement date, if the instruments are settled in shares, the carrying value of the warrants are derecognized and transferred to
equity at their fair value at that date. The cash proceeds received from exercises of warrants are recorded in common stock and additional paid-in capital. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Loss per Share </U></I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic net loss per share is determined by dividing net loss
by the weighted average shares of common stock outstanding during the period. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect,
if any, of potentially dilutive common shares, such as common stock options and warrants calculated using the treasury stock method and convertible notes using the &#147;if-converted&#148; method. In periods with reported net operating losses, all
common stock options and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Debt Instruments </U></I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Debt instruments are initially recorded at fair value, with
coupon interest and amortization of debt issuance discounts recognized in the statement of operations as interest expense at each period end while such instruments are outstanding. If the Company issues shares to discharge the liability, the debt
obligation is derecognized and common stock and additional paid-in capital are recognized on the issuance of those shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s
exchangeable notes contain a conversion option which is classified as equity. The fair value of the liability component of the debt instrument was deducted from the initial proceeds to determine the proceeds to be allocated to the conversion option.
The embedded conversion option is indexed to the Company&#146;s stock and treated as equity on the balance sheet. The conversion option is evaluated on a quarterly basis to determine if it still meets the criteria to be equity classified. The excess
principal amount of the debt over the carrying value of the liability is amortized to interest expense over the term of the debt. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Company&#146;s December 2012 debt financing agreement contains a redemption feature triggered upon a change of control, which has been classified as an embedded derivative. The fair value of the derivative was recorded as a reduction to the fair
value of the note payable. The fair value of this warrant derivative liability is remeasured at each reporting period, with changes in fair value recognized in the statement of operations. The discount recorded to the note payable is being amortized
to interest expense over the term of the note payable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Fair Value of Financial Instruments </U></I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company provides disclosure of financial assets and financial liabilities that are carried at fair value based on the price that would be received
upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&nbsp;Fair value measurements may be classified based on the amount of subjectivity associated with the inputs to
fair valuation of these assets and liabilities using the following three levels: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level 1&#151;Inputs are unadjusted quoted prices in active
markets for identical assets or liabilities that the Company has the ability to access at the measurement date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level 2&#151;Inputs include
quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e.,
interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Level 3&#151;Unobservable inputs that reflect the Company&#146;s estimates of the assumptions that market participants would use in pricing the asset or liability.&nbsp;The Company develops these inputs
based on the best information available, including its own data. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table presents information about the Company&#146;s assets and
liabilities as of September&nbsp;30, 2013 and December&nbsp;31, 2012 that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30, 2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><I>In millions</I></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;3</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Asset:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash equivalents&#151;money markets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liabilities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrant derivative liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term debt redemption feature</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foreign currency contracts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31, 2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><I>In millions</I></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Level&nbsp;3</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Asset:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash equivalents&#151;money markets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;64.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;64.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liability:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrant derivative liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term debt redemption feature</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The carrying amounts of cash, cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate
fair value because of their short-term nature. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Warrant Derivative Liability </U></I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2012, the fair value of the warrant derivative liability was determined to be $54.9 million using the Black-Scholes option valuation
model applying the following assumptions: (i)&nbsp;risk-free rate of 0.25%, (ii)&nbsp;remaining term of 1.8 years, (iii)&nbsp;no dividend yield, (iv)&nbsp;volatility of 95% and (v)&nbsp;the stock price on the date of measurement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">At September&nbsp;30, 2013, the fair value of the warrant derivative liability was determined to be $39.6 million using the Black-Scholes option
valuation model applying the following assumptions: (i)&nbsp;risk-free rate of 0.1%, (ii)&nbsp;remaining term of 1.0 year, (iii)&nbsp;no dividend yield, (iv)&nbsp;volatility of 91%, and (v)&nbsp;the stock price on the date of measurement.&nbsp;The
$3.6 million increase in the fair value of the warrant liability during the three months ended September&nbsp;30, 2013 was recognized as: (i)&nbsp;a $3.3 million loss on change in fair value of the remaining derivative liability and (ii)&nbsp;$0.3
million in compensation expense for change in fair value of warrants issued to former employees. The $15.3 million decrease in the fair value of the warrant liability during the nine months ended September&nbsp;30, 2013 was recognized as: (i)&nbsp;a
$14.1 million gain on change in fair value of the remaining derivative liability and (ii)&nbsp;$1.2 million in compensation income for change in fair value of warrants issued to former employees. Both amounts are included in the consolidated
statement of operations for the nine months ended September&nbsp;30, 2013.&nbsp;The fair value of this warrant liability is determined using the Black-Scholes option valuation model and is therefore sensitive to changes in the market price and
volatility of the Company&#146;s common stock among other factors.&nbsp;In the event of a hypothetical 10% increase in the market price of the Company&#146;s common shares ($6.95 based on the $6.32 market price of the Company&#146;s stock at
September&nbsp;30, 2013) on which the September&nbsp;30, 2013 valuation was based, the value of the derivative liability would have increased by $5.0 million.&nbsp;Such increase would have been reflected as a loss on change in fair value of the
warrant derivative liability in the Company&#146;s statement of operations. Significant increases (decreases) in this input in isolation would result in a significantly higher (lower) fair value asset measurement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Long Term Debt Redemption Feature </U></I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s December 2012 financing agreement with BioPharma Secured Debt Fund II Holdings Cayman, L.P, or BioPharma, contains a redemption feature
whereby, upon a change of control, the Company would be required to pay $140 million, less any previously repaid amount, if the change of control occurs on or before December&nbsp;31, 2013, or required to repay $150 million, less any previously
repaid amount, if the change of control event occurs after December&nbsp;31, 2013. The Company determined this redemption feature to be an embedded derivative, which is carried at fair value and is classified as Level 3 in the fair value hierarchy
due to the use of significant unobservable inputs.&nbsp;The fair value of the embedded derivative was calculated using a probability-weighted model incorporating management estimates for potential change in control, and by determining the fair value
of the debt with and without the change in control provision included. The difference between the two fair values of the debt was determined to be the fair value of the embedded derivative. At December&nbsp;31, 2012, the fair value of the derivative
was determined to be $14.6 million, and the debt was valued by comparing debt issues of similar companies with (i)&nbsp;terms of between 4.8 and 8.0 years, (ii)&nbsp;coupon rates of between 3.0% and 11.5% and (iii)&nbsp;market yields of between
10.7% and 27.7%. At September&nbsp;30, 2013, the fair value of the derivative was determined to be $7.2 million, and the debt was valued by comparing debt issues of similar companies with (i)&nbsp;remaining terms of between 3.5 and 4.4 years,
(ii)&nbsp;coupon rates of between 9.9% and 12.5% and (iii)&nbsp;market yields of between 10.4% and 25.8%. The Company recognized a gain of $1.4 million and $7.4 million on the change in fair value of this derivative liability for the three and nine
months ended September&nbsp;30, 2013, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Foreign Currency </U></I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">All subsidiaries use the United States dollar as the functional currency. Monetary assets and liabilities denominated in a foreign currency are remeasured
into United States dollars at period-end exchange rates. Non-monetary assets and liabilities carried in a foreign currency are remeasured into United States dollars using rates of exchange prevailing when such assets or liabilities were obtained or
incurred, and expenses are generally remeasured using rates of exchange prevailing when such expenses are incurred. Gains and losses from the remeasurement are included in other (expense) income, net in the consolidated statements of operations. For
transactions settled during the applicable period, gains and losses are included in other (expense) income, net in the consolidated statements of operations. The Company periodically uses foreign exchange forward contracts to hedge against changes
in exchange rates for inventory purchases denominated in foreign currency. As of&nbsp;September 30, 2013, the Company held one foreign exchange forward contract with a notional amount of $4.5 million. As of&nbsp;September 30, 2013, the outstanding
foreign exchange forward contract derivative liability had a net fair value of $0.4 million. The Company included this $0.4 million as a component of change in fair value of derivative liabilities and in other current liabilities at
September&nbsp;30, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The change in the fair value of financial instruments is as follows (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>October</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2009</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;Warrants&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Debt</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;Redemption&nbsp;
&nbsp;</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Feature</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Foreign</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exchange</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;Contracts&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;Totals&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at January&nbsp;1, 2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>123,125</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>123,125</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss on change in fair value of derivative liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68,686</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68,686</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compensation expense for change in fair value of warrants issued to former employees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,037</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,037</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfers to equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(103,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(103,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at September&nbsp;30, 2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>90,963</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>90,963</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>October</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2009</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;Warrants&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Debt</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;Redemption&nbsp;
&nbsp;</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Feature</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Foreign</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exchange</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;Contracts&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;Totals&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at January&nbsp;1, 2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>54,854</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14,577</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>69,431</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Gain) loss on change in fair value of derivative liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(21,059</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compensation income for change in fair value of warrants issued to former employees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,179</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,179</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfers to equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at September&nbsp;30, 2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>39,598</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7,200</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>395</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>47,193</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Segment and Geographical Information </U></I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the three and nine months ended September&nbsp;30, 2013 and 2012, the Company has reported its business as a single reporting segment. The
Company&#146;s chief decision maker, who is the Chief Executive Officer, regularly evaluates the Company on a consolidated basis. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Recent Accounting Pronouncements </U></I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, new accounting
pronouncements are issued by the Financial Accounting Standards Board, or FASB, and are adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued but not yet adopted accounting pronouncements
will not have a material impact on consolidated financial position, results of operations, and cash flows, or do not apply to the Company&#146;s operations. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3)</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intangible Asset </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intangible asset consists of technology rights for Vascepa and have an estimated remaining useful life of 16.8 years. The carrying
value as of September&nbsp;30, 2013 and December&nbsp;31, 2012 is as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,&nbsp;2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,&nbsp;2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Technology rights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,624</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,624</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,870</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(4)</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Inventory </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">After approval of Vascepa on July&nbsp;26, 2012 by the FDA, the Company began capitalizing its purchases of saleable inventory of
Vascepa from suppliers that have been qualified by the FDA. Inventories consist of the following at September&nbsp;30, 2013 and December&nbsp;31, 2012 (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,&nbsp;2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,&nbsp;2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Raw materials</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,465</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Work in process</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,471</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finished goods</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,283</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">326</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finished goods inventory held by others</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,083</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,262</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventory is valued at lower of cost or market value. During the three months ended September&nbsp;30, 2013, the Company
recorded an inventory reserve of $1.8 million related to certain inventories that are not recoverable in their current form. The materials are currently under investigation by the supplier and the Company. The reserve was recorded within research
and development expense in the statement of operations as this supplier has yet to produce material qualified for commercial sale. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(5)</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Warrants and Warrant Derivative Liability </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company had 9,816,826 warrants to purchase common shares outstanding at September&nbsp;30, 2013 at a weighted-average exercise
price of $1.44, as summarized in the following table: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD style="width:17pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:17pt"></TD>
<TD VALIGN="bottom" WIDTH="23%"></TD>
<TD style="width:14pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:14pt"></TD>
<TD VALIGN="bottom" WIDTH="23%"></TD>
<TD style="width:24pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:24pt"></TD>
<TD VALIGN="bottom" WIDTH="23%"></TD>
<TD style="width:27pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:27pt"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Issue Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise&nbsp;Price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Expiration&nbsp;Date</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4/27/07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/17/14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7/31/09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,684,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7/30/14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10/16/09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,487,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10/15/14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10/16/09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">627,050</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10/15/14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9,816,826</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.44</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>October 2009 Warrant derivative liability </U></I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;16, 2009, the Company completed a $70.0 million private placement with both existing and new investors resulting in $62.3 million in net
proceeds and an additional $3.6 million from bridge notes converted in conjunction with the private placement. In consideration for the $62.3 million in net cash proceeds Amarin issued 66.4&nbsp;million units, each unit consisting of (i)&nbsp;one
ADS (representing one ordinary share) at a purchase price of $1.00 and (ii)&nbsp;a warrant with a five year term to purchase 0.5 of an ADS at an exercise price of $1.50 per ADS. In consideration for the conversion of $3.6 million of convertible
bridge notes, Amarin issued 4.0&nbsp;million units, each unit consisting of (i)&nbsp;one ADS (representing one ordinary share) at a purchase price of $0.90 and (ii)&nbsp;a warrant with a five year term to purchase 0.5 of an ADS at an exercise price
of $1.50 per ADS. The total number of warrants issued in conjunction with the financing was 35.2&nbsp;million of which 7.5&nbsp;million are outstanding at September&nbsp;30, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In conjunction with the October 2009 financing, the Company issued an additional 0.9&nbsp;million warrants to three former officers of which 0.6&nbsp;million are outstanding as of September&nbsp;30, 2013.
The warrants issued in connection with the October 2009 financing contained a pricing variability feature which provided for an increase to the exercise price if the exchange rate between the U.S. dollar and British pound adjusts such that the
warrants could be exercised at a price less than the &pound;0.5 par value of the common stock &#150; that is, if the exchange rate exceeded U.S. $3.00 per &pound;1.0 sterling. Due to the potential variable nature of the exercise price, the warrants
are not considered to be indexed to the Company&#146;s common stock. Accordingly, the warrants do not qualify for the exception to classify the warrants within equity and are classified as a derivative liability. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair value of this warrant derivative liability is remeasured at each reporting period, with changes in fair value recognized in the statement of
operations. Upon exercise, the fair value of the warrants exercised is remeasured and reclassified from warrant liability to additional paid-in capital. Although the warrants contain a pricing variability feature, the number of warrants issuable
remains fixed. Therefore, the maximum number of common shares issuable as a result of the October 2009 private placement is 36.1 million. The change in fair value of the warrant derivative liability is discussed in Note 2. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>July 2009 and April 2007 Warrants </U></I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company issued certain warrants in July 2009 and April 2007. As of September&nbsp;30, 2013 and December&nbsp;31, 2012 these warrants have been classified as equity instruments and have been included
in the Company&#146;s consolidated balance sheet within additional paid-in-capital. During the nine months ended September&nbsp;30, 2013, 120,000 of the July 2009 warrants were exercised resulting in proceeds to the Company of $0.1 million.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(6)</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Debt </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Long term debt&#151;December 2012 Financing </U></I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;6, 2012, the Company entered into an agreement with BioPharma. Under this agreement, the Company granted to BioPharma a security interest in future receivables associated with the Vascepa
patent rights in exchange for $100.0 million received at the closing of the agreement, which closing occurred in December 2012. The Company has agreed to repay BioPharma up to $150&nbsp;million of future revenue and receivables. The first scheduled
repayment under the agreement is a repayment of $2.5&nbsp;million of interest due to be paid to BioPharma in November 2013 for the fiscal quarter ended September&nbsp;30, 2013, subject to the limitation described below. Additional quarterly
repayments are scheduled to be paid thereafter in accordance with the following schedule: $2.5 million of interest in the first quarter of 2014; $8.0 million per quarter in each of the next four quarters, $10.0 million per quarter in each of the
next four quarters, $15.0 million per quarter in each of the next four quarters and a final payment of $13.0 million scheduled for payment in May 2017. The quarterly repayments through the third quarter of September 2014 represent interest only.
Quarterly payments do not begin to reduce the principal balance until the fourth quarter of 2014. These quarterly payments are subject to a quarterly threshold amount whereby, if a calculated threshold, based on quarterly Vascepa revenues, is not
achieved, the quarterly payment payable in that quarter can at the Company&#146;s election be reduced, with the reduction carried forward without interest for payment in a future period. The payment of any carried forward amount is subject to
similarly calculated threshold repayment amounts based on Vascepa revenue levels. Except upon a change of control in Amarin, the agreement does not expire until $150 million has been repaid. Under the agreement, upon a change of control, the Company
would be required to pay $140 million, less any previously repaid amount, if the change of control occurs on or before December&nbsp;31, 2013, or required to repay $150 million, less any previously repaid amount, if the change of control event
occurs after December&nbsp;31, 2013. The Company can prepay after October&nbsp;1, 2013, an amount equal to $150 million less any previously repaid amount. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company determined the redemption feature upon a change of control to be an embedded derivative requiring bifurcation. The fair value of the embedded derivative was calculated by determining the fair
value of the debt with the change in control provision included and also without the change in control provision. The difference between the two fair values of the debt was determined to be the fair value of the embedded derivative, and upon
closing, the Company recorded a derivative liability of $14.6 million as a reduction to the note payable. The fair value of this derivative liability is remeasured at each reporting period, with changes in fair value recognized in the statement of
operations. The fair value of the derivative liability at September&nbsp;30, 2013 was $7.2 million and the Company recognized a gain on change in fair value of derivative liability of $1.4 million and $7.4 million for the three and nine
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
month periods ended September&nbsp;30, 2013, respectively. For the nine months ended September&nbsp;30, 2013, the Company recorded $9.7&nbsp;million and $2.2 million of cash and non-cash interest
expense, respectively related to the BioPharma debt. For the three months ended September&nbsp;30, 2013, the Company recorded $2.7&nbsp;million and $0.6 million of cash and non-cash interest expense, respectively related to the BioPharma debt. The
Company will periodically evaluate the remaining term of the agreement and the effective interest will be recalculated each period based on the Company&#146;s most current estimate of repayment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company currently estimates that its Vascepa revenue levels will not be high enough in each quarter to support repayment to BioPharma in accordance
with threshold amounts in the repayment schedule. For the three months ended September&nbsp;30, 2013, revenues were below the contractual threshold amount such that a cash payment of $0.8 million is due in November 2013 reflecting the calculated
optional reduction amount as opposed to the contractual threshold payment of $2.5 million. In accordance with the agreement with BioPharma, quarterly differences between the calculated optional reduction amounts and the repayment schedule amounts
are rescheduled for payment beginning in the second quarter of 2017. Any such deferred repayments will remain subject to continued application of the quarterly ceiling in amounts due established by the calculated threshold based on quarterly Vascepa
revenues. Additionally, the revised assumptions yielded a decrease in the calculated effective interest rate resulting in a decrease in interest expense during the three months ended September&nbsp;30, 2013 as compared to the three months ended
June&nbsp;30, 2013 and March&nbsp;31, 2013. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Exchangeable Senior Notes </U></I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2012, the Company issued $150.0 million in principal amount of 3.5% exchangeable senior notes due 2032, or the Senior Notes. The Senior Notes
were issued by Corsicanto Limited, an Irish limited company acquired by Amarin in January 2012. Corsicanto Limited is a wholly-owned subsidiary of Amarin. The general, unsecured, senior obligations are fully and unconditionally guaranteed by Amarin
but not by any of the Company&#146;s subsidiaries. Corsicanto Limited has no assets, operations, revenues or cash flows other than those related to the issuance, administration and repayment of the Senior Notes.&nbsp;There are no significant
restrictions on the ability of Amarin to obtain funds from Corsicanto Limited in the form of cash dividends, loans, or advances.&nbsp;Net proceeds to the Company, after payment of underwriting fees and expenses, were approximately $144.3 million.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Senior Notes have a stated interest rate of 3.5%&nbsp;per year, payable semiannually in arrears on January&nbsp;15 and July&nbsp;15 of
each year beginning on July&nbsp;15, 2012, and ending upon the Senior Notes&#146; maturity on January&nbsp;15, 2032. The Senior Notes are subject to repurchase by the Company at the option of the holders on each of January&nbsp;19,
2017,&nbsp;January&nbsp;19, 2022, and January&nbsp;19, 2027, at a price equal to 100% of the principal amount of the Senior Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date. The Senior Notes are
exchangeable under certain circumstances into cash, ADSs, or a combination of cash and ADSs, at the Company&#146;s election, with an initial exchange rate of 113.4752 ADSs per $1,000 principal amount of Senior Notes. It is the Company&#146;s current
intention to settle these obligations in cash. If the Company elected physical settlement, the Senior Notes would initially be exchangeable into 17,021,280 ADSs. Based on the closing price of the Company&#146;s stock at September&nbsp;30, 2013, the
principal amount of the Senior Notes would exceed the value of the shares if converted on that date by $42.4 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional covenants
include: (i)&nbsp;limitations on future indebtedness under certain circumstances, (ii)&nbsp;the timely filing of documents and reports pursuant to Section&nbsp;13 or 15(d) of the Exchange Act with both the SEC and the Trustee, and
(iii)&nbsp;maintaining the tradability of the Senior Notes. The Company is required to use commercially reasonable efforts to procure and maintain the listing of the Senior Notes on the Global Exchange Market operated under the supervision of the
Irish Stock Exchange (or other recognized stock exchange as defined in the Note Indenture) prior to July&nbsp;15, 2012. If the Senior Notes are not freely tradable, as a result of restrictions pursuant to U.S. securities law or the terms of the
Indenture or the Senior Notes, the Company shall pay additional interest on the Senior Notes at the rate of 0.50%&nbsp;per annum of the principal amount of Senior Notes outstanding for each day during such period for which the Company&#146;s failure
to file has occurred and is continuing or for which the Senior Notes are not freely tradable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company may not redeem the Senior Notes
prior to January&nbsp;19, 2017, other than in connection with certain changes in the tax law of a relevant taxing jurisdiction that results in additional amounts becoming due with respect to payments and/or deliveries on the Senior Notes. On or
after January&nbsp;19, 2017 and prior to the maturity date, the Company may redeem for cash all or part of the Senior Notes at a redemption price equal to 100% of the principal amount of the Senior Notes to be redeemed, plus accrued and unpaid
interest to, but excluding, the redemption date. There is no prepayment penalty or sinking fund provided for the Senior Notes. If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or part of their
Senior Notes at a repurchase price equal to 100% of the principal amount of the Senior Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Senior Notes are the Company&#146;s
senior unsecured obligations and rank senior in right of payment to the Company&#146;s future indebtedness that is expressly subordinated in right of payment to the Senior Notes and equal in right of payment to the Company&#146;s future unsecured
indebtedness that is not so subordinated. The Senior Notes are effectively junior in right of payment to future secured indebtedness to the extent of the value of the assets securing such indebtedness. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Senior Notes are exchangeable under certain circumstances. The Company calculated the fair value of the liability component of the Senior Notes to be
$126.2 million, and the excess of the principal amount of the debt over the liability component of $23.8 million was allocated to the conversion option resulting in a discount on the debt. The discount created from allocating proceeds to the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
conversion option is being amortized to interest expense using the effective interest method over the Senior Notes&#146; estimated remaining life, which was calculated to be a period of
twenty-four months. The effective interest rate of the Senior Notes is 14.5%. As of September&nbsp;30, 2013, the unamortized discount created from the allocation of the proceeds to the conversion option was $3.9 million. The conversion option will
not be subsequently remeasured as long as it continues to meet the criteria for equity classification. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company also recorded a debt
discount to reflect the value of the underwriters&#146; discounts and offering costs. A portion of the debt discount from underwriter&#146;s discounts and offering costs was allocated to the equity and liability components of the Notes in proportion
to the proceeds allocated to each component. The portion of the debt discount from underwriters&#146; discounts and offering costs allocated to the liability component is being amortized as interest expense over the estimated remaining life of the
Senior Notes of twenty-four months. As of September&nbsp;30, 2013, the unamortized debt discount was $0.8 million and was recorded as a direct reduction of the related debt on the balance sheet. The carrying value of the Notes, net of the
unamortized discount, was $145.3 million. During the three months ended September&nbsp;30, 2013, the Company recognized interest expense of $5.2 million related to the Notes, of which $3.2 million represents amortization of the debt discount created
upon allocation of proceeds to the conversion option, $1.3 million represents contractual coupon interest, and $0.7 million represents the amortization of the discount from the underwriter&#146;s discounts and offering costs. During the nine months
ended September&nbsp;30, 2013, the Company recognized interest expense of $15.0 million related to the Notes, of which $9.2 million represents amortization of the debt discount created upon allocation of proceeds to the conversion option, $3.9
million represents contractual coupon interest, and $1.9 million represents the amortization of the discount from the underwriter&#146;s discounts and offering costs. At September&nbsp;30, 2013, the Company had accrued interest of $1.1 million.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January and July 2013, the interest payments due of $2.6 million were paid as scheduled. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(7)</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commitments and Contingencies </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Royalty and Milestone Obligations </U></I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company is party to certain milestone and royalty obligations under several product development agreements, as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s active pharmaceutical ingredient, or API, supply agreement with Nisshin Pharma, Inc. (&#147;Nisshin&#148;), provided for minimum
supply purchase obligations on behalf of the Company to enable Amarin to maintain exclusivity with this supplier, and to prevent potential termination of the agreement based on Company estimated minimum purchase requirements. As of
September&nbsp;30, 2013, the API aggregate minimum purchase obligations under this supply agreement had been achieved and as a result, the Company has no future minimum purchase obligation from Nisshin. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2011, the Company entered into agreements with two additional suppliers, Chemport, Inc. (&#147;Chemport&#148;) and BASF (formerly Equateq Limited)
for the supply of API materials for Vascepa. In 2012, the Company agreed to terms with a fourth API supplier, Slanmhor Pharmaceutical, Inc., or Slanmhor. These agreements include requirements for the suppliers to qualify their materials and
facilities with applicable regulatory authorities including the FDA. The Company anticipates incurring certain costs associated with the qualification of product produced by these suppliers as described below. In each case, following qualification
of the supplier for the manufacture of API for commercial sale, these agreements include annual purchase levels to enable Amarin to maintain exclusivity with each respective supplier, and to prevent potential termination of the agreements. The
Company is not obligated to pay in cash any shortfall in the minimum purchase obligations pursuant to the Chemport and BASF agreements. The agreement with Slanmhor contains a provision requiring the Company to pay Slanmhor in cash for any shortfall
in the minimum purchase obligations, which will become effective upon the approval for manufacture by the FDA of supply from Slanmhor. Chemport and BASF were approved by the FDA to manufacture API for commercial sale in April 2013. The Company has
begun to purchase commercial supply from Chemport. BASF must complete production of validation batches before the Company will begin to purchase commercial supply. The 2011 supply agreements include commitments for the Company to fund
(i)&nbsp;development fees up to a maximum of $0.5&nbsp;million (ii)&nbsp;material purchases of up to $5.0 million for initial raw materials, which amount will be credited against future API purchases and (iii)&nbsp;a raw material purchase commitment
of $1.1&nbsp;million. Under these agreements, during the nine months ended September&nbsp;30, 2013, the Company made payments of $4.8 million and $0.1 million to Chemport and BASF, respectively. The agreement with Slanmhor provides for development
fees of up to $2.3 million and a commitment of up to $15.0 million, which will be credited against future API material purchases. The $15.0 million commitment fee is contingent upon the mutually agreed upon expansion of Slanmhor&#146;s API
manufacturing capacity. Under this agreement, during the nine months ended September&nbsp;30, 2013, the Company made payments of $6.1 million to Slanmhor related to stability and technical batches and advances on future API purchases.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the 2004 share repurchase agreement with Laxdale Limited, or Laxdale, upon approval of Vascepa by the FDA on July&nbsp;26, 2012, the Company was
required to make a milestone payment to Laxdale of &pound;7.5&nbsp;million. The Company made this payment in 2012 and capitalized this Laxdale milestone ($11.6 million on July&nbsp;26, 2012) as an intangible asset. This long-term asset is being
amortized over the estimated useful life of the intellectual property the Company acquired from Laxdale and the Company recognized amortization expense of $0.5 million during the nine months ended September&nbsp;30,
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
2013. Also under the Laxdale agreement, upon receipt of marketing approval in Europe for the first indication for Vascepa (or first indication of any product containing Amarin Neuroscience
intellectual property acquired from Laxdale in 2004), the Company must make an aggregate stock or cash payment to the former shareholders of Laxdale (at the sole option of each of the sellers) of &pound;7.5&nbsp;million (approximately $12.1 million
at September&nbsp;30, 2013). Also under the Laxdale agreement, upon receipt of a marketing approval in the U.S. or Europe for a further indication of Vascepa (or further indication of any other product using Amarin Neuroscience intellectual
property), the Company must make an aggregate stock or cash payment (at the sole option of each of the sellers) of &pound;5&nbsp;million (approximately $8.1 million at September&nbsp;30, 2013) for each of the two potential market approvals (i.e.
&pound;10&nbsp;million maximum, or approximately $16.1 million at September&nbsp;30, 2013). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has no provision
for any of the obligations above since the amounts are either not probable or estimable at September&nbsp;30, 2013. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(8)</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Equity </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Common stock </U></I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;12, 2013, the Company completed a public offering of 21,700,000 ADSs. The underwriters purchased the ADSs from Amarin at a price of $5.60 per ADS, resulting in net proceeds to Amarin of
approximately $121.2 million, after deducting estimated offering expenses payable by the Company. Amarin also granted the underwriters a 30-day option to purchase an additional 3,255,000 ADSs, which was not exercised. The stated use of proceeds in
connection with this offering were as follows: primarily to continue the commercial launch of Vascepa capsules in the MARINE indication, prepare for and commercially launch Vascepa in the ANCHOR indication, if approved, advance the Company&#146;s
REDUCE-IT cardiovascular outcomes trial, and for general corporate and working capital purposes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the nine months ended
September&nbsp;30, 2013 and 2012, the Company issued 386,000 and 3,107,913 shares, respectively, as a result of the exercise of stock options. Gross and net proceeds resulting from the exercise of stock options amounted to $0.6 million for the nine
months ended September&nbsp;30, 2013. For the nine months ended September&nbsp;30, 2012, gross proceeds amounted to $7.9 million and net proceeds amounted to $7.8 million resulting from the exercise of stock options. In addition, during the nine
months ended September&nbsp;30, 2013 and 2012, the Company issued 120,000 and 10,881,276 shares, respectively, as a result of the exercise of warrants. Gross and net proceeds resulting from the exercise of warrants amounted to $0.1 million for the
nine months ended September&nbsp;30, 2013. For the nine months ended September&nbsp;30, 2012, gross proceeds amounted to $16.6 million and net proceeds amounted to $16.5 million resulting from the exercise of warrants. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August and September of 2013, the Company granted a total of 44,000 restricted stock units (&#147;RSUs&#148;) to several employees under the Amarin
Corporation plc 2011 Stock Incentive Plan (&#147;2011 Plan&#148;). As of September&nbsp;30, 2013, no RSU&#146;s were forfeited and no shares were issued as a result of vesting. These RSUs vest upon the achievement of certain operational milestones
and expire on December&nbsp;31, 2013 if none of the milestones are achieved by such date. The RSUs will become fully vested upon a change of control of the Company. Upon vesting of each RSU, the participant shall be entitled to a payment equal to
the fair market value of one share of Amarin common stock. The payment shall be paid to the participant in cash, or at the sole discretion of the Compensation Committee in shares or a combination of cash or shares. The fair value of the RSUs was
determined on the date of grant, and compensation expense related to the RSUs is recognized once the related milestone is deemed probable. The Company recorded no expense during the nine months ended September&nbsp;30, 2013 related to the vesting of
these RSUs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July of 2013, the Company granted a total of 54,000 deferred stock units (&#147;DSUs&#148;) to members of the Company&#146;s
Board of Directors under the Amarin Corporation plc 2011 Stock Incentive Plan (&#147;2011 Plan&#148;). As of September&nbsp;30, 2013, no DSU&#146;s were forfeited and no shares were issued as a result of vesting. The DSU&#146;s vest over a three
year period. The DSUs will become fully vested upon a change of control of the Company. Upon termination of service to the Company, each Director shall be entitled to a payment equal to the fair market value of one share of Amarin common stock,
which is required to be made in shares. The Company recorded expense during the nine months ended September&nbsp;30, 2013 of $47,000 related to the vesting of these DSUs.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In January 2013, the Company granted 454,875 RSUs to several employees under the 2011 Plan. As of September&nbsp;30, 2013, 32,500 RSUs were forfeited and no shares were issued as a result of vesting.
These RSUs vest upon the achievement of certain operational milestones and expire on August&nbsp;3, 2015 if none of the milestones are achieved by such date. The RSUs will become fully vested upon a change of control of the Company. Upon vesting of
each RSU, the participant shall be entitled to a payment equal to the fair market value of one share of Amarin common stock. The payment shall be paid to the participant in cash, or at the sole discretion of the Compensation Committee in shares or a
combination of cash or shares. The fair value of the RSUs was determined on the date of grant, and compensation expense related to the RSUs is recognized once the related milestone is deemed probable. The Company recorded no expense during the nine
months ended September&nbsp;30, 2013 related to the vesting of these RSUs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2012, the Company granted 584,400 RSUs to several
employees under the 2011 Plan. As of September&nbsp;30, 2013, a total of 90,684 RSUs were forfeited. These RSUs vest upon the achievement of certain regulatory and time-based milestones. The RSUs
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
will become fully vested upon a change of control of the Company. Upon vesting of each RSU, the participant shall be entitled to a payment equal to the fair market value of one share of Amarin
common stock. The payment shall be paid to the participant in cash, or at the sole discretion of the Compensation Committee in shares or a combination of cash or shares. During the nine months ended September&nbsp;30, 2013 and 2012, the Company
issued 93,048 and 97,398 shares, respectively, as a result of the vesting of these RSUs. The fair value of the RSUs was determined on the date of grant, and compensation expense related to the RSUs is recognized once the related milestone is deemed
probable. During the nine months ended September&nbsp;30, 2013 and 2012, the Company recorded expense of $0.3 million and $1.2 million, respectively, related to the vesting of these RSUs. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(9)</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Subsequent Events </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;16, 2013, the Company announced that an advisory committee to the FDA voted 9 to 2 against recommending approval of the
use of Vascepa capsules for the ANCHOR indication based on information presented at the advisory committee meeting. The FDA is scheduled to make its decision on whether to approve the ANCHOR sNDA on the December&nbsp;20, 2013 PDUFA goal date for the
application, however, the FDA could complete its review of the sNDA prior to this date and there can be no assurance that the FDA will complete its review of the sNDA by this date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;22, 2013, in an effort to reduce operating expenses following the recommendation of the advisory committee to the FDA, the Company implemented a worldwide reduction in force of
approximately fifty percent of its staff positions worldwide. The majority of affected staff members are sales professionals who have supported the initial commercial launch of Vascepa. The Company estimates that it will incur approximately $3
million in charges related to the reduction in force, all of which includes cash expenditures for one-time termination benefits and associated costs. The Company expects to record the charges in the fourth quarter of 2013 and make the related
payments by the end of the first quarter of 2014. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;29, 2013, the FDA notified the Company that it has rescinded the ANCHOR
study Special Protocol Assessment, or SPA, agreement because in their view a substantial scientific issue essential to determining the effectiveness of Vascepa in the studied population from the ACCORD-Lipid and AIM-HIGH outcome trials, as well as
the publicly presented results from the HPS2-THRIVE outcome trial, which the FDA stated in its October&nbsp;29, 2013 notice to the Company, fail to support the hypothesis that a triglyceride-lowering drug significantly reduces the risk for
cardiovascular events among statin-treated patients. Thus, the FDA stated that it no longer considers a change in serum triglyceride levels as sufficient to establish the effectiveness of a drug intended to reduce cardiovascular risk in subjects
with serum triglyceride levels below 500 mg/dL. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November 1, 2013, a purported investor of Amarin filed a putative class action lawsuit
against Amarin and the Company&#146;s Chief Executive Officer in the U.S. District Court for the District of New Jersey, Steven Sklar v. Amarin Corporation plc and Joseph S. Zakrzewski, No. 13-cv-6954 (D.N.J. Nov. 1, 2013). The lawsuit alleges that,
during the period July 9, 2009 through October 15, 2013, the Company misled investors regarding the FDA&#146;s willingness to approve Vascepa&#146;s ANCHOR indication and the potential relevance of data from the ongoing REDUCE-IT trial to that
approval, thereby artificially inflating the price of the Company&#146;s securities. Based on these allegations, the suit asserts claims under the Securities Exchange Act of 1934 and seeks unspecified monetary damages and attorneys&#146; fees and
costs. The Company believes that it has valid defenses and will vigorously defend against the claims. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November 5, 2013, a purported
investor of Amarin filed a putative class action lawsuit against Amarin and certain of the Company&#146;s officers in the U.S. District Court for the Southern District of New York, Joseph A. Bove and Joseph J. Bove v. Amarin Corporation, PLC.,
Joseph S. Zakrzewski, John F. Thero, and Steven B. Ketchum, No. 13-CIV-7882 (S.D.N.Y. Nov. 5, 2013). The lawsuit alleges, similar to the <I>Sklar</I> case, that, during the period August 8, 2012 until October 16, 2013, the Company misled investors
regarding the FDA&#146;s willingness to approve Vascepa&#146;s ANCHOR indication and the potential relevance of data from the ongoing REDUCE-IT trial to that approval, thereby artificially inflating the price of the Company&#146;s securities. Based
on these allegations, the suit asserts claims under the Securities Exchange Act of 1934 and seeks unspecified monetary damages and attorneys&#146; fees and costs. The Company believes that it has valid defenses and will vigorously defend against the
claims. </FONT></P>
 <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc595270_7"></A>Item&nbsp;2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations </I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as
amended. These forward-looking statements reflect our plans, estimates and beliefs. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially
different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#147;anticipates,&#148; &#147;believes,&#148;
&#147;could,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;potential,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;should,&#148; &#147;would&#148; and similar expressions
intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Because of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report may not transpire. We discuss many of these risks in Part I, Item&nbsp;1A under the heading &#147;Risk Factors&#148; of our Annual Report on Form 10-K for the fiscal year ended
December&nbsp;31, 2012 and below under Part II, Item IA, &#147;Risk Factors&#148;. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Given these uncertainties, you should not place
undue reliance on these forward-looking statements. Also, forward-looking statements represent our estimates and assumptions only as of the date of this document. You should read this document with the understanding that our actual future results
may be materially different from what we expect. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statements contained in this report, whether as a result of new information, future
events or otherwise. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are a biopharmaceutical company with expertise in lipid science focused on the commercialization and development of therapeutics to improve cardiovascular health. On July&nbsp;26, 2012, we received
U.S. Food and Drug Administration, or FDA, approval to market and sell our lead product Vascepa<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (icosapent
ethyl) capsules (formerly known as AMR 101) as an adjunct to diet to reduce triglyceride levels in adult patients with severe (TG&nbsp;<U>&gt;</U>500mg/dL) hypertriglyceridemia, which we sometimes refer to as the MARINE indication. Triglycerides are
fats in the blood. Hypertriglyceridemia refers to a condition in which patients have high levels of triglycerides in the bloodstream. It is estimated that over 40&nbsp;million adults in the United States have elevated triglyceride levels (TG
<U>&gt;</U>200mg/dL) and approximately 4.0&nbsp;million people in the United States have severely high triglyceride levels (TG&nbsp;<U>&gt;</U>500mg/dL), commonly known as very high triglyceride levels. According to <I>The&nbsp;American Heart
Association Scientific Statement on Triglycerides </I> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<I>and Cardiovascular Disease </I>(2011), triglycerides also provide important information as a marker associated with the risk for heart disease and stroke, especially when an individual also
has low high-density lipoprotein cholesterol, or HDL-C (often referred to as &#147;good&#148; cholesterol), and elevated levels of LDL-C (often referred to as &#147;bad&#148; cholesterol). Guidelines for the management of very high triglyceride
levels suggest that reducing triglyceride levels is the primary goal in patients to reduce the risk of acute pancreatitis. The effect of Vascepa on cardiovascular mortality and morbidity, or the risk for pancreatitis, in patients with
hypertriglyceridemia has not been determined. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vascepa became commercially available in the United States by prescription in
January 2013, when we commenced sales and shipments to its network of U.S.-based wholesalers and specialty pharmacy providers. On January&nbsp;28, 2013, we commenced our full commercial launch of Vascepa in the United States for use in the MARINE
indication with approximately 275 sales representatives. In October 2013, we reduced our number of sales representatives to approximately 130, excluding sales management, in the United States to focus on the sales territories that we believe have
demonstrated the greatest potential for Vascepa sales growth. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also developing Vascepa for the treatment of patients
with high triglyceride levels (TG <U>&gt;</U>200 mg/dL and &lt;500 mg/dL) who are also on statin therapy for elevated LDL-C levels. This indication is referred to as mixed dyslipidemia or the ANCHOR indication. In February 2013, we submitted a
supplemental New Drug Application, or sNDA, to the FDA seeking approval of Vascepa for the ANCHOR indication. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
October&nbsp;16, 2013, the FDA convened an advisory committee to review the Company&#146;s sNDA for the ANCHOR indication and the advisory committee voted 9 to 2 against recommending approval of the ANCHOR indication based on information presented
at the meeting. The FDA will consider the recommendation of the advisory committee, but the final decision regarding the approval of the sNDA will be made by the FDA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A Special Protocol Assessment, or SPA, agreement is an agreement with the FDA that Phase 3 trial protocol design, clinical endpoints, and planned statistical analyses are acceptable to support regulatory
approval. A SPA is generally binding upon the FDA except in limited circumstances, such as if the FDA identifies a substantial scientific issue essential to determining safety or efficacy after the study begins, or if the study sponsor fails to
follow the protocol that was agreed upon with the FDA. On October&nbsp;29, 2013, the FDA notified us that it rescinded the ANCHOR study SPA because the FDA determined that a substantial scientific issue essential to determining the effectiveness of
Vascepa in the studied population was identified after testing began. Specifically, consistent with discussion at the advisory committee meeting, the FDA determined that results from outcome studies of other triglyceride lowering drugs failed to
support the hypothesis that a triglyceride-lowering drug significantly reduces the risk for cardiovascular events among the population studied in the ANCHOR trial. Thus, the FDA stated that it no longer considers a change in serum triglyceride
levels as sufficient to establish the effectiveness of a drug intended to reduce cardiovascular risk in subjects with serum triglyceride levels below 500 mg/dL. On November 7, 2013, we submitted to the FDA a formal appeal of its decision to rescind
the SPA including documents outlining why we believe the SPA was wrongfully rescinded. There can be no assurance that the FDA will agree with our arguments. The ANCHOR indication sNDA is subject to a standard review and has been assigned a
Prescription Drug User Fee Act, or PDUFA, date of December&nbsp;20, 2013. The PDUFA date is the target date for the FDA to complete its review of the sNDA. The FDA could complete its review of the sNDA prior to this date and there can be no
assurance that the FDA will complete its review of the sNDA by this date. If the FDA does not approve the ANCHOR indication, it would have a material adverse impact on our future results of operations and financial condition. Based on the
recommendation of the advisory committee and the rescinding of the ANCHOR SPA, we believe there is a significant possibility that FDA may not approve the ANCHOR sNDA and require, as a condition of any possible approval, additional preclinical
studies or clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;22, 2013, in an effort to reduce operating expenses following the recommendation
of the advisory committee to the FDA, we implemented a worldwide reduction in force of approximately fifty percent of our staff positions worldwide. The majority of affected staff members are sales professionals who have supported the initial
commercial launch of Vascepa. We estimate that we will incur approximately $3 million in charges related to the reduction in force, all of which includes cash expenditures for one-time termination benefits and associated costs. We expect to record
the charges in the fourth quarter of 2013 and make the related payments by the end of the first quarter of 2014. As part of the reduction in force, we retained approximately 130 sales representatives in the United States in sales territories that we
believe have demonstrated the greatest potential for Vascepa sales growth. We plan to have this team cover the target base of physicians responsible for the majority of Vascepa prescription volume and growth since its launch in early 2013.&nbsp;With
these changes and resulting target base coverage, Amarin anticipates continued Vascepa revenue growth over time.&nbsp;Amarin further anticipates that such sales growth may be inconsistent from period to period.</FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2011, we announced commencement of patient dosing in our cardiovascular outcomes study of Vascepa, titled REDUCE-IT
(Reduction of Cardiovascular Events with EPA &#150; Intervention Trial), which is designed to evaluate the efficacy of Vascepa in reducing major cardiovascular events in a high risk patient population on statin therapy. The final results of the
REDUCE-IT study may be required for FDA approval of Vascepa for the ANCHOR indication. In September 2013, we announced that over 6,000 patients were, in aggregate, enrolled in REDUCE-IT. Amarin currently estimates that it will complete patient
enrollment in this study in the first half of 2015. However, if we do not receive FDA approval of the ANCHOR indication, we plan to re-evaluate the REDUCE-IT study, including the likelihood of REDUCE-IT providing clinically and commercially useful
results, the likelihood of FDA approval for an expanded indication for Vascepa based on these results and whether it is advisable to continue or discontinue the study.&nbsp;We anticipate that in any such re-evaluation we will seek further feedback
from the FDA.&nbsp;If continued, the REDUCE-IT study will be completed after reaching an aggregate number of cardiovascular events. Based on event rates in other outcomes studies, Amarin estimates completing the REDUCE-IT study in or about 2017.
Based on the results of REDUCE-IT, we may seek additional indications for VASCEPA beyond the indications studied in the ANCHOR or MARINE trials. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August 2013, we completed dosing of AMR102, a fixed dose combination of Vascepa and a
leading statin product. The study is a randomized, open-label, single-dose, 4-way cross-over study to continue testing of the relative bioavailability of AMR102 capsules, Vascepa capsules with the selected statin taken concomitantly, Vascepa taken
alone and the selected statin taken alone.&nbsp;We anticipate results from this study either in the fourth quarter of 2013 or in the first half of 2014. If we do not receive FDA approval for the ANCHOR indication, we may discontinue development of
AMR102. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The potential efficacy and safety of Vascepa was studied in the MARINE trial and the ANCHOR trial, each of which were
Phase 3 clinical trials. At a daily dose of 4 grams of Vascepa, the dose at which Vascepa is FDA-approved for the MARINE indication, these trials showed favorable clinical results in their respective patient populations in reducing triglyceride
levels without increasing LDL-C levels in the MARINE trial and with a statistically significant decrease in LDL-C levels in the ANCHOR trial, in each case as compared to placebo. These trials also showed favorable results, particularly with the
4-gram dose of Vascepa, in other important lipid and inflammation biomarkers, including apolipoprotein B (apo B), non-high-density lipoprotein cholesterol (non-HDL-C), total-cholesterol (TC), very low-density lipoprotein cholesterol (VLDL-C),
lipoprotein-associated phospholipase A2 (Lp-PLA2), and high sensitivity C-reactive protein (hs-CRP). In these trials, the most commonly reported adverse reaction (incidence &gt;2% and greater than placebo) in patients treated with Vascepa was
arthralgia (joint pain) (2.3% for Vascepa vs. 1.0% for placebo). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Commercialization Update </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vascepa became commercially available in the United States by prescription in January 2013 when we commenced sales and shipments to our
network of U.S.-based wholesalers. On January&nbsp;28, 2013, we commenced our full commercial launch of Vascepa in the United States. In preparation for our commercial launch, we hired and trained a direct sales force of approximately 275 sales
representatives, which was subsequently reduced by approximately 50% in October 2013. We also employ various marketing and medical affairs personnel to support our commercialization of Vascepa. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2013, we completed our eighth full calendar month of marketing and selling Vascepa. Based on monthly compilations of data
provided by a third party, the estimated number of normalized total Vascepa prescriptions (TRx) for the first three quarters of 2013 post-launch of Vascepa were as follows: 10,484 (Q1); 47,335 (Q2); and 74,576 (Q3). Normalized total prescriptions
represent the estimated total number of Vascepa prescriptions shipped to patients, calculated on a normalized basis (i.e., total capsules shipped divided by 120 capsules, or one month&#146;s supply). The data reported above is based on information
made available to us from a third party resource and may be subject to adjustment and may overstate or understate actual prescriptions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of November&nbsp;1, 2013, over 13,000 clinicians had written prescriptions for Vascepa. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Although we believe these data are prepared on a period-to-period basis in a manner that is generally consistent and that such results are generally indicative of current prescription trends, these data
are based on estimates and should not be relied upon as definitive. In addition, because of our limited selling history, during the nine months ended September&nbsp;30, 2013, we only recognized revenue on product that was resold for purposes of
filling prescriptions. Those prescription data may differ from data reported by other third parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to commencing our
U.S. commercial launch of Vascepa in January 2013, we had no revenue from Vascepa. Because of our limited selling history, we do not believe that we can provide a reasonably accurate forecast of Vascepa prescriptions or revenues. We provide no
guidance regarding anticipated levels of Vascepa prescriptions or revenues and no such guidance should be inferred from the operating metrics described above. We believe that investors should view the above-referenced operating metrics with caution,
as data for this limited period may not be representative of a trend consistent with the results presented or otherwise predictive of future results. Seasonal fluctuations in pharmaceutical sales, for example, may affect future prescription trends
of Vascepa, as could changes in prescriber sentiment and other factors. We believe investors should consider our results over several quarters, or longer, before making an assessment about potential future performance. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The commercial launch of a new pharmaceutical product is a complex undertaking, and our ability to effectively and profitably launch
Vascepa will depend in part on our ability to generate market demand for Vascepa through education, marketing and sales activities, our ability to achieve market acceptance of Vascepa, our ability to generate product revenue and our ability to
receive adequate levels of reimbursement from third-party payers. See &#147;<I>Risk Factors&#151;Risks Related to the Commercialization and Development of Vascepa</I>.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Commercial Supply Update </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the nine months ended September&nbsp;30,
2013, we acquired approximately $20.4 million of Vascepa active pharmaceutical ingredient, or API, of which $16.7 million was capitalized to inventory as of September&nbsp;30, 2013. The balance of such Vascepa API purchase costs was included as a
component of research and development expense because it was received from suppliers that had not yet been qualified by the FDA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In April 2013, the FDA approved our sNDAs covering Chemport, Inc. and BASF (formerly Equateq Limited) as additional Vascepa API suppliers. We are working with Slanmhor Pharmaceuticals, Inc. to pursue FDA
approval for Slanmhor to manufacture Vascepa API and submitted an sNDA in August 2013. Until an API supplier is approved, all Vascepa API purchased from such supplier is included as a component of research and development expense. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amount of supply purchases in 2014 and beyond will depend on the level of growth of
Vascepa revenues, which will be significantly impacted by the outcome of the FDA&#146;s decision on approval of the ANCHOR indication. We anticipate that our gross margin from Vascepa sales will be lower in 2013 than in subsequent years due to
multiple factors, including API supply pricing with our earliest approved supplier, Nisshin. This is the case particularly as it relates to our earliest volume of purchases from Nisshin being higher than supply pricing later agreed with other
suppliers, tiered supply pricing at certain suppliers such that cost per kilogram of supply purchases are scheduled to decline as volume of purchases increase, recent improvement in currency exchange rates, geographic location of our suppliers,
special initial stocking discounts provided to wholesalers and pharmacies to encourage them to stock Vascepa in advance of Vascepa&#146;s January 2013 commercial launch, and rebate cards offered to consumers filling prescriptions for Vascepa to
reduce the size of the consumer&#146;s co-payment requirements while we work with payors to migrate Vascepa coverage from &#147;tier-3&#148; to &#147;tier-2&#148; in these payors&#146; drug pricing systems. We anticipate rebate amounts that we will
agree to provide payors for tier-2 insurance coverage on sales of Vascepa will cost us less than our current rebate card program. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Financial Position </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that our cash and cash equivalents balance of $225.9 million
at September&nbsp;30, 2013, which includes $121.2 million in net proceeds received from our offering of ADSs in July 2013, will be sufficient to fund our projected operations for at least the next twelve months. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Operations Overview </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Revenue.</I> All of our revenue is derived from product sales of Vascepa, net of allowances, discounts, incentives, rebates, chargebacks and returns.
We sell product to a limited number of major wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, our Distributors, who resell the product to retail pharmacies for purposes of their reselling the
product to fill patient prescriptions. In accordance with GAAP, until we have the ability to reliably estimate returns of Vascepa from our Distributors, revenue will be recognized based on the resale of Vascepa for the purposes of filling patient
prescriptions, and not based on sales from us to such Distributors. Consistent with industry practice, once we achieve sufficient history such that we can reliably estimate returns based on sales to our Distributors, we anticipate that our revenues
will be recognized based on sales to our Distributors. We currently defer Vascepa revenue recognition until the earlier of the product being resold for purposes of filling patient prescriptions; and the expiration of the right of return (twelve
months after the expiration date of the product). We also defer the related cost of product sales and record such amounts as finished goods inventory held by others until revenue related to such product sales is recognized. As of September&nbsp;30,
2013, product returns were deminimus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cost of Goods Sold.</I> Cost of goods sold includes the cost of API for Vascepa on which revenue was
recognized during the period, as well as the associated costs for encapsulation, packaging, shipment, supply management, insurance and quality assurance. The cost of the API included in cost of goods sold reflects the average cost method of
inventory valuation and relief. This average cost reflects the actual purchase price of Vascepa API, the majority of which through September&nbsp;30, 2013 was from Nisshin, our first approved API supplier. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research and Development Expense.</I> Research and development expense consists primarily of fees paid to professional service providers in
conjunction with independent monitoring of our clinical trials and acquiring and evaluating data in conjunction with our clinical trials, fees paid to independent researchers, costs of qualifying contract manufacturers, services expenses incurred in
developing and testing products and product candidates, salaries and related expenses for personnel, including stock-based compensation expense, costs of materials, depreciation, rent, utilities and other facilities costs. In addition, research and
development expenses include the cost to support current development efforts, including patent costs and milestone payments. We expense research and development costs as incurred. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Selling, General and Administrative Expense.</I> Selling, general and administrative expense consists primarily of salaries and other related costs for personnel, including stock-based compensation
expense, in our sales, marketing, executive, business development, finance and information technology functions. Other costs primarily include facility costs and professional fees for accounting, consulting and legal services. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Interest and Other (Expense) Income, Net.</I> Interest expense consists of interest incurred under lease obligations, interest incurred under our 3.5%
exchangeable debt and interest incurred under our December 2012 financing arrangement with BioPharma Secured Debt Fund II Holdings Cayman LP, or BioPharma. Interest expense under our 3.5% exchangeable debt includes the amortization of the conversion
option related to our exchangeable debt, the amortization of the related debt discount and debt obligation coupon interest. Interest income consists of interest earned on our cash and cash equivalents. Other (expense) income, net, consists primarily
of foreign exchange losses and gains.<I> </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements and
notes, which have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of
assets, liabilities, revenue and expenses. On an ongoing basis, we evaluate our estimates and judgments, including those related to derivative financial liabilities. We base our estimates on historical experience and on various other assumptions
that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from
these estimates under different assumptions or conditions. A summary of our significant accounting policies is contained in Note&nbsp;2 to our consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. We believe the
following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Revenue Recognition</I>&#151;We sell Vascepa principally to a limited number of Distributors, that in turn resell Vascepa to retail pharmacies that subsequently resell it to patients and health care
providers. In accordance with GAAP, our revenue recognition policy requires that: (i)&nbsp;there is persuasive evidence that an arrangement exists between us and the Distributor, (ii)&nbsp;delivery has occurred, (iii)&nbsp;collectability is
reasonably assured and (iv)&nbsp;the price is fixed or determinable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We began recognizing revenue from the sale of Vascepa following our
commercial launch in the United States in January 2013. Prior to 2013, we recognized no revenue from Vascepa sales. In accordance with GAAP, until we have the ability to reliably estimate returns of Vascepa from our Distributors, revenue will be
recognized based on the resale of Vascepa for the purposes of filling patient prescriptions, and not based on sales from us to such Distributors. Consistent with industry practice, once we achieve sufficient history such that we can reliably
estimate returns based on sales to our Distributors, we anticipate that our revenues will be recognized based on sales to our Distributors. We currently defer Vascepa revenue recognition until the earlier of the product being resold for purposes of
filling patient prescriptions; and the expiration of the right of return (twelve months after the expiration date of the product). We also defer the related cost of product sales and record such amounts as finished goods inventory held by others
until revenue related to such product sales is recognized. As of September&nbsp;30, 2013, we had experienced deminimus product returns. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
have written contracts with our Distributors, and delivery occurs when a Distributor receives Vascepa. We evaluate the creditworthiness of each of our Distributors to determine whether revenues can be recognized upon delivery, subject to
satisfaction of the other requirements, or whether recognition is required to be delayed until receipt of payment. In order to conclude that the price is fixed or determinable, we must be able to (i)&nbsp;calculate our gross product revenues from
the sales to Distributors and (ii)&nbsp;reasonably estimate our net product revenues. We calculate gross product revenues based on the wholesale acquisition cost that we charge our Distributors for Vascepa. We estimate our net product revenues by
deducting from our gross product revenues (a)&nbsp;trade allowances, such as invoice discounts for prompt payment and distributor fees, (b)&nbsp;estimated government and private payor rebates, chargebacks and discounts, such as Medicaid
reimbursements, (c)&nbsp;reserves for expected product returns and (d)&nbsp;estimated costs of incentives offered to certain indirect customers, including patients. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Derivative Financial Liabilities</I>&#151;Derivative financial liabilities are initially recorded at fair value. They are subsequently held at fair value, with gains and losses arising for changes in
fair value recognized in the statement of operations.&nbsp;The fair value of derivative financial liabilities is determined using valuation techniques; typically we use the Black-Scholes option pricing model. We use our judgment to select a variety
of methods and make assumptions that are mainly based on market conditions existing at each balance sheet date. Fluctuations in the assumptions used in the valuation model would result in adjustments to the fair value of the warrant derivative
liability reflected on our balance sheet and, therefore, our statement of operations. If we issue shares to discharge the liability, the derivative financial liability is derecognized and common stock and additional paid-in capital are recognized on
the issuance of those shares. For options and warrants treated as derivative financial liabilities, at settlement date the carrying value of the options and warrants are transferred to equity.&nbsp;The cash proceeds received from shareholders for
additional shares are recorded in common stock and additional paid-in capital. We recorded a financial derivative related the change in control provision associated with our December 2012 debt financing. During 2013 we recorded a derivative on our
forward foreign exchange contracts. The fair value of these derivatives could fluctuate based on changes in the assumptions used in the valuation models. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Inventory Capitalization</I>&#151;Prior to July&nbsp;26, 2012, when we received approval from the FDA to market and sell Vascepa in the United States for the MARINE indication, Vascepa was considered a
product candidate under development. All supply of Vascepa purchased prior to July&nbsp;26, 2012 was not capitalized and instead charged as a component of research and development expense in the period received. After Vascepa was approved, we began
to capitalize inventory purchased from Nisshin, the API supplier approved in the NDA. Prior to April 2013, only Nisshin was an FDA-approved supplier of API for Vascepa. In April 2013, the FDA approved our sNDAs covering Chemport and BASF as
additional Vascepa API suppliers. All supply from Chemport and BASF prior to FDA approval of these API suppliers was not capitalized and instead charged as a component of research and development expense in the period received. Subsequent to the
approval of these suppliers, we capitalize API purchases from them. We are working with Slanmhor to pursue FDA approval for Slanmhor to manufacture Vascepa API and submitted an sNDA in August 2013. Until an API supplier is approved, all Vascepa API
purchased from such supplier is included as a component of research and development expense. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Upon sNDA approval of each additional supplier, we capitalize subsequent Vascepa API purchases from such supplier as inventory. Purchases of Vascepa API received and expensed before such
regulatory approvals are not subsequently capitalized, and all such purchases are quarantined and not used for commercial supply until such time as the sNDA for the supplier that produced the API is approved. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Accounting Pronouncements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">From
time to time, new accounting pronouncements are issued by FASB and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued accounting pronouncements will not have a material
impact on consolidated financial position, results of operations, and cash flows, or do not apply to our operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Comparison of Three Months Ended September&nbsp;30, 2013 versus September&nbsp;30, 2012 </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Revenue.</I> We recorded revenue of $8.4 million during the three months ended September&nbsp;30, 2013. We commenced our full commercial launch of
Vascepa in the United States for use in the MARINE indication on January&nbsp;28, 2013. We recorded no revenue in 2012. All of our revenue in the three months ended September&nbsp;30, 2013 was derived from product sales of Vascepa, net of
allowances, discounts, incentives, rebates, chargebacks and returns. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We sell Vascepa to Distributors. In accordance with our revenue
recognition policy, until we have more experience with the sale of Vascepa and can better estimate product returns, we currently recognize revenue only for product which has been used for of the purpose of filling prescriptions. During the three
month period ended September&nbsp;30, 2013, we invoiced Distributors for $11.7 million. The excess of the amount billed and the amount recognized as revenue for the three months ended September&nbsp;30, 2013, net of applicable discounts and rebates,
has been recorded as deferred revenue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the three months ended September&nbsp;30, 2013, our net product revenues included an adjustment
for co-pay mitigation rebates provided by us to commercially insured patients. Such rebates are intended to offset the differential for patients of Vascepa not covered by commercial insurers at the time of launch on tier 2, resulting in higher
co-pay amounts for such patients. Our cost for these co-payment mitigation rebates is up to $75 dollars per prescription filled during 2013. Commencing in March and April 2013, certain third-party payors added Vascepa to their tier 2 coverage, which
results in lower co-payments for patients covered by these third-party payors. As of November&nbsp;1, 2013, approximately 92&nbsp;million lives covered by medical insurance were under insurance plans that have added Vascepa to their tier 2 coverage.
In connection with the start of such tier 2 coverage, we have agreed to pay customary rebates to these third-party payors on the resale of Vascepa to patients covered by these third-party payors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As is typical for the pharmaceutical industry, the majority of Vascepa sales are to major commercial wholesalers which then resell Vascepa to retail
pharmacies. As of November&nbsp;1, 2013, over 13,000 clinicians had written prescriptions for Vascepa. As of November&nbsp;1, 2013, we are not aware of any clinician who is responsible for 10% or more of the aggregate prescriptions written for
Vascepa. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;22, 2013, in an effort to reduce operating expenses following the recommendation of the advisory committee to the
FDA, we implemented a worldwide reduction in force including a reduction of approximately fifty percent of our sales representatives. Following the reduction in force, we retained approximately 130 sales representatives in the United States in sales
territories which have demonstrated what we believe is the greatest potential for Vascepa sales growth.&nbsp;This team will cover the target base of physicians responsible for the majority of Vascepa prescription volume and growth since its launch
in early 2013.&nbsp;With these changes and resulting target base coverage, we anticipate continued Vascepa revenue growth over time. We further anticipate that such revenue growth may be inconsistent from period to period.</FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cost of Goods Sold.</I> Cost of goods sold during the three months ended September&nbsp;30, 2013 was $3.7 million, and includes the cost of API for
Vascepa on which revenue was recognized during the period, as well as the associated costs for encapsulation, packaging, shipment, supply management, insurance and quality assurance. The cost of the API included in cost of goods sold reflects the
average cost of API included in inventory. This average cost reflects the actual purchase price of Vascepa API, as well as a portion of API carried at zero cost for material which was purchased prior to FDA approval of Vascepa on July&nbsp;26, 2012
or was purchased prior to the sNDA approval of our suppliers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The majority of API included in the calculation of the average cost of goods
sold during the three months ended September&nbsp;30, 2013 was sourced from one API supplier. The contracted cost of supply from this API supplier for initial purchase volumes is higher than the contracted cost from our other API suppliers.
Contracted purchase costs from this initial API supplier reflect that they were working with Amarin prior to commencement of the MARINE and ANCHOR clinical trials and are anticipated to decline as additional API volume is purchased. In the future,
we anticipate making continued purchases from this initial supplier at substantially lower unit pricing than the pricing of the initial purchases from this supplier and to make additional lower unit cost purchases of Vascepa API from other API
suppliers, including Chemport and BASF, both of which were approved by the FDA in April 2013 to produce Vascepa API. The Company began purchasing lower unit cost API from Chemport in the three months ended June&nbsp;30, 2013. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the three months ended September&nbsp;30, 2013, no product was sold that was previously expensed and
thus had a carrying value of zero. We expect current inventories with a carrying value of zero to be utilized in 2014. The Company may have additional zero cost inventories in the future to the extent that we receive approval of the sNDA for our
fourth commercial supplier. As of September&nbsp;30, 2013, the Company maintained inventory with a carrying value of zero and an acquisition cost of $0.6 million, which has an estimated net realizable value of $2.6 million based on our average net
selling price for the three months ended September&nbsp;30, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our gross margin improved from 45% and 48% in the three months ended
March&nbsp;31 and June&nbsp;30, 2013, respectively, to 56% in the three months ended September&nbsp;30, 2013, which was primarily driven by lower unit cost API purchases. In addition to expected continued lower average unit cost purchases of API, we
also expect that API costs will be lower in the future due to recent improvements in foreign currency exchange rates and potential advantages derived from the geographical mix of our suppliers. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research and Development Expense.</I> Research and development expense for the three months ended September&nbsp;30, 2013 was $16.8 million, versus
$20.9 million in the prior year period, a decrease of $4.1 million, or 19.6%. Research and development expenses for the three months ended September&nbsp;30, 2013 and 2012 are summarized in the table below (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">REDUCE-IT study (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other clinical trial programs (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">461</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">160</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-approval commercial supply (3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,623</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,826</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regulatory filing fees and expenses (4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">242</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Internal staffing, overhead and other (5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,045</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,793</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expense, excluding non-cash expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,231</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,943</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash stock-based compensation (6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">970</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,913</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The decrease in research and development expenses for the three months ended September&nbsp;30, 2013, as compared to the
same period in 2012, is primarily due to a decrease in pre-approval commercial supply purchases as described further below. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2011, we announced commencement of patient dosing in our cardiovascular outcomes study of Vascepa, titled REDUCE-IT, which is designed to evaluate the
efficacy of Vascepa in reducing major cardiovascular events in a high risk patient population on statin therapy. The study duration is dependent on the rate of clinical events in the study, which rate may be affected by the number of patients
enrolled in the study and the epidemiology of the patients enrolled in the study. We manage the study through a contract research organization (CRO) through which all costs for this outcomes study are incurred with the exception of costs for
clinical trial material (CTM) and costs for internal management. Our internal personnel are responsible for managing multiple projects and their costs are not specifically allocated to REDUCE-IT or any other individual project. In September 2013, we
announced that, in aggregate, over 6,000 patients have been enrolled in REDUCE-IT. We estimate that we will complete patient enrollment in this study in the first half of 2015. The REDUCE-IT study will be completed after reaching an aggregate number
of cardiovascular events. Based on event rates in other outcomes studies, we estimate completing the REDUCE-IT study in or about 2017. For 2013, we anticipate incurring expense through our CRO in connection with this trial of between $30 million and
$40 million, inclusive of the amounts spent during the nine months ended September&nbsp;30, 2013. Inclusive of CTM costs, we anticipate combined CRO and CTM costs in 2013 for REDUCE-IT will total approximately $40 million to $45 million, inclusive
of the amounts spent during the nine months ended September&nbsp;30, 2013. We expense costs for CTM upon receipt. The aggregate cost of this outcomes study will depend on the rate of clinical events in the study. We currently estimate that quarterly
costs incurred for this study in the remainder of 2013 and 2014 will continue at approximately the same levels as we have incurred on a quarterly average in 2013. Excluding 2013 costs, based on our current assumptions of CRO and CTM costs, we
estimate that aggregate remaining costs to complete the REDUCE-IT study and evaluate its results to likely exceed $100 million. We anticipate that our costs for this outcomes study will continue to represent the most significant component of our
research and development expenditures. However, if we do not receive FDA approval of the ANCHOR indication, we plan to re-evaluate the REDUCE-IT study, including the likelihood of REDUCE-IT providing clinically and commercially useful results, the
likelihood of FDA approval for an expanded indication for Vascepa based on these results and whether it is advisable to continue or discontinue the study.&nbsp;We anticipate that in any such re-evaluation we will seek further feedback from the
FDA.</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2012 and 2013, other clinical trial programs consisted of fixed-dose combination studies. In December 2012, we completed dosing and pharmacokinetic
sampling in a study to test a fixed-dose combination of Vascepa capsules and a </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
leading statin which we refer to as AMR102. In August 2013, we completed dosing in a randomized, open-label, single-dose, 4-way cross-over study to continue testing of the relative
bioavailability of AMR102 capsules, Vascepa capsules with a selected statin taken concomitantly, Vascepa taken alone and the selected statin taken alone.&nbsp;We anticipate results from this study either late in the second half of 2013 or in the
first half of 2014. We expect that additional costs to complete the study, excluding costs of our internal personnel, will be less than $1 million. Future costs related to the development of AMR102 beyond the ongoing study cannot be reasonably
estimated until we evaluate the results of the ongoing study. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Until an API supplier is approved by the FDA to manufacture commercial supply of Vascepa, all Vascepa purchased from such supplier is included as a component of
research and development expense. Upon approval of the supplier, we capitalize subsequent Vascepa API purchases from such supplier as inventory. Purchases of Vascepa API received and expensed before such regulatory approvals are not subsequently
capitalized, and all such purchases are quarantined and not used for commercial supply until such time as the supplier that produced the API is approved. The commercial supply expense for the periods shown above represents inventory received from
Nisshin prior to NDA approval of Vascepa on July&nbsp;26, 2012 or received from our other suppliers prior to their sNDA approvals. In April 2013, sNDAs were approved for two of our additional suppliers, BASF and Chemport. An sNDA was submitted in
August 2013 for Novasep as part of the Slanmhor consortium. The amount of commercial supply that we receive from Novasep prior to sNDA approval depends upon production schedules at Novasep and the timing of regulatory approval, and we are unable to
estimate these amounts at this time. We will continue to expense inventory received from the unapproved supplier until such time as FDA approval is obtained. Additionally, during the three months ended September&nbsp;30, 2013, we recorded an
inventory reserve of $1.8 million related to certain product in development that is not recoverable in its current form. This product is from a supplier from which no supply has yet been released for commercial use. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The regulatory filing fees primarily represent costs incurred in connection with regulatory filings associated with requests for regulatory approvals, such as the sNDA
for the ANCHOR indication and annual FDA fees for maintaining manufacturing sites. In the three months ended September, 30, 2013, such fees also include costs associated with preparing for the October&nbsp;16, 2013 FDA advisory committee meeting.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Internal staffing, overhead and other research and development expenses primarily relate to the costs of our personnel employed to managed research, development and
regulatory affairs activities and related overhead costs including consulting and other professional fees that are not allocated to specific projects. Such costs also include costs related to qualifying suppliers and legal costs. We anticipate a
reduction in such costs in 2014 compared to 2013 levels as a result of a company-wide reduction in force announced in October 2013. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash stock-based compensation expense represents the costs associated with equity awards issued to internal staff supporting our research and development and
regulatory functions. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Selling, General and Administrative Expense.</I> Selling, general and administrative expense for the
three months ended September&nbsp;30, 2013 was $28.3 million, versus $13.4 million in the prior year period, an increase of $14.9 million, or 111.2%. Selling, general and administrative expenses for the three months ended September&nbsp;30, 2013 and
2012 are summarized in the table below (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three Months Ended<BR>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Selling, general and administrative expenses, excluding non-cash expenses&nbsp;(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,926</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash stock based compensation expense&nbsp;(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,665</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,665</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash warrant related compensation expense (income)&nbsp;(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">276</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,194</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total selling, general and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,274</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,397</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Selling, general and administrative expense, excluding non-cash compensation charges for stock compensation and warrants, for the three months ended September&nbsp;30,
2013 was $24.3 million, versus $10.9 million in the prior year period, an increase of $13.4 million, or 122.9%. The increase was primarily due to cost increases in 2013 for sales force staffing, an increase in marketing program spending and
increased general and administrative costs incurred in connection with the initial commercialization of Vascepa. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock based compensation expense for each of the three month periods ended September&nbsp;30, 2013 and 2012 was $3.7 million. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrant related compensation expense for the three months ended September&nbsp;30, 2013 was $0.3 million as compared to income of $1.2 million in the prior year period.
Warrant related compensation expense (income) reflects the non-cash change in fair value of the warrant derivative liability associated with warrants issued in October 2009 to three former employees of Amarin. The increase in the fair value of the
warrants for the three months ended September&nbsp;30, 2013 is due primarily to an increase in our stock price between June&nbsp;30, 2013 and September&nbsp;30, 2013. The value of this warrant derivative liability may increase or decrease from
period to period based upon changes in the price of our common stock. Such non-cash changes in valuation could be significant as the history of our stock price has been volatile. The gain or loss resulting from such non-cash changes in valuation
could have a material impact on our reported net income or loss from period to period. In particular, if the price of our stock increases, the change in valuation of this warrant derivative liability will add to our history of operating losses.
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Selling, general and administrative costs in 2013 have increased over 2012 levels as we continue to support
the commercialization of Vascepa, including costs for market research, sales force staffing and support costs and investments in infrastructure. We anticipate a reduction in the level of such costs in 2014 as a result of the worldwide reduction in
force announced in October 2013 and expected reductions in certain marketing program expenditures and other overhead costs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(Loss) Gain on
Change in Fair Value of Derivative Liabilities</I>. (Loss) gain on change in fair value of derivative liabilities for the three months ended September&nbsp;30, 2013 was a loss of $1.4 million versus a gain of $16.5 million in the prior year period.
(Loss) gain on change in fair value of derivative liabilities is comprised of (i)&nbsp;the change in fair value of the warrant derivative liability, (ii)&nbsp;the change in fair value of the derivative liability related to the change in control
provision associated with the December 2012 BioPharma financing and (iii)&nbsp;an unrealized loss on foreign exchange contracts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The warrant
derivative liability is related to the change in fair value of warrants issued in conjunction with the October 2009 private placement. In October 2009 we issued 36.1&nbsp;million warrants at an exercise price of $1.50 and recorded a $48.3 million
warrant derivative liability, representing the fair value of the warrants issued. As these warrants have been classified as a derivative liability, they are revalued at each reporting period, with changes in fair value recognized in the statement of
operations. The fair value of the warrant derivative liability at June&nbsp;30, 2012 was $120.2 million and we recognized a $16.5 million gain on change in fair value of derivative liability for the three months ended September&nbsp;30, 2012 for
these warrants. The fair value of the warrant derivative liability at June&nbsp;30, 2013 was $36.0&nbsp;million and we recognized a $3.3 million loss on change in fair value of derivative liability for the three months ended September&nbsp;30, 2013.
The change in fair value of the warrant derivative liability is due primarily to the decrease or increase in the price of our common stock on the date of valuation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our December 2012 financing agreement with BioPharma contains a redemption feature whereby, upon a change of control, we would be required to pay $140 million, less any previously repaid amount, if the
change of control occurs on or before December&nbsp;31, 2013, or required to repay $150 million, less any previously repaid amount, if the change of control event occurs after December&nbsp;31, 2013. The fair value of the derivative liability is
recalculated at each reporting period using a probability-weighted model incorporating management estimates for potential change in control, and by determining the fair value of the debt with and without the change in control provision included. The
difference between the two fair values of the debt was determined to be the fair value of the embedded derivative. At June&nbsp;30, 2013, the fair value of the derivative was determined to be $8.6 million, and at September&nbsp;30, 2013, the fair
value of the derivative was determined to be $7.2 million. We recognized a $1.4 million gain on change in fair value of derivative liability for the three months ended September&nbsp;30, 2013. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We use foreign exchange forward contracts to hedge against changes in exchange rates for inventory purchases denominated in foreign currency. As
of&nbsp;September&nbsp;30, 2013 we had one outstanding foreign exchange forward contract with a notional amount of $4.5 million. For the three months ended&nbsp;September&nbsp;30, 2013, we recognized an unrealized gain of $0.5 million related to the
change in fair value of the foreign exchange forward contract derivative liability, which was included as a component of change in fair value of derivative liabilities. There is a balance of $0.4 million within other current liabilities at
September&nbsp;30, 2013 representing the fair value of the outstanding forward exchange forward contract as of such date. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Interest Expense, net.</I> Net interest expense for the three months ended September&nbsp;30, 2013 was
$8.4 million, versus $4.6 million in the prior year period, an increase of $3.8 million, or 82.6%. Net interest expense for the three months ended September&nbsp;30, 2013 and 2012 is summarized in the table below (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exchangeable senior notes:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of debt discount created upon allocation of proceeds to the conversion option</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,213</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractual coupon interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,298</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of the discount from the underwriter&#146;s discounts and offering costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total exchangeable senior notes interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term debt - BioPharma financing (1):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash interest - current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash interest - deferred</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">632</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total long-term debt interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,291</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total interest expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and non-cash interest expenses related to the BioPharma financing for the three months ended September&nbsp;30, 2013 were $2.7 million and $0.6 million,
respectively. These amounts reflect a change in the assumption from prior quarters that our Vascepa revenue levels will be high enough to support repayment to BioPharma in accordance with the repayment schedule without the optional reduction which
is allowed to be elected by us if the threshold revenue levels are not achieved. For the three months ended September&nbsp;30, 2013, our revenues were below the contractual threshold amount such that we have a cash payment of $0.8 million due in
November 2013 reflecting the calculated optional reduction amount as opposed to the contractual threshold payment of $2.5 million. Additionally, the revised assumptions yielded a decrease in the calculated effective interest rate resulting in a
decrease in interest expense during the three months ended September&nbsp;30, 2013 as compared to the three months ended June&nbsp;30, 2013 and March&nbsp;31, 2013. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income for the three months ended September&nbsp;30, 2013 was $22 thousand, versus $73 thousand in the prior year period, a decrease of $51 thousand, or 69.9%.
Interest income represents income earned on cash balances. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Other (Expense) Income, net</I>. Other (expense) income, net
primarily consists of losses and gains on foreign exchange transactions, including realized gains and losses on foreign exchange forward contracts. Other expense for the three months ended September&nbsp;30, 2012 included an unrealized loss due to
the fluctuation in the exchange rate of the Laxdale accrual in the amount of $0.5 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Benefit from (Provision for) Income Taxes</I>.
Benefit from (provision for) income taxes primarily consists of tax obligations for one of our subsidiaries. During the three months ended September&nbsp;30, 2013 and 2012, we recorded a benefit from (provision for) income taxes of $1.6 million and
$(3.6) million, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Comparison of Nine Months Ended September&nbsp;30, 2013 versus September&nbsp;30, 2012
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Revenue.</I> We recorded revenue of $16.2 million during the nine months ended September&nbsp;30, 2013. We commenced our full
commercial launch of Vascepa in the United States for use in the MARINE indication on January&nbsp;28, 2013. We recorded no revenue in 2012. All of our revenue in the nine months ended September&nbsp;30, 2013 was derived from product sales of
Vascepa, net of allowances, discounts, incentives, rebates, chargebacks and returns. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We sell Vascepa to Distributors. In accordance with our
revenue recognition policy, until we have more experience with the sale of Vascepa and can better estimate product returns, we currently recognize revenue only for product which has been used for purposes of filling prescriptions. During the nine
month period ended September&nbsp;30, 2013, we invoiced Distributors for $25.2 million. The excess of the amount billed and the amount recognized as revenue for the nine months ended September&nbsp;30, 2013, net of applicable discounts and rebates,
has been recorded as deferred revenue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the nine months ended September&nbsp;30, 2013, our net product revenues included an adjustment
for co-pay mitigation rebates provided by us to commercially insured patients. Such rebates are intended to offset the differential for patients of Vascepa not covered by commercial insurers at the time of launch on tier 2, resulting in higher
co-pay amounts for such patients. Our cost for these co-payment mitigation rebates is up to $75 dollars per prescription filled during 2013. Commencing in March and April 2013, certain third-party payors added Vascepa to their tier 2 coverage, which
results in lower co-payments for patients covered by these third-party payors. As of November&nbsp;1, 2013, approximately 92&nbsp;million lives covered by medical insurance were under insurance plans that have added Vascepa to their tier 2 coverage.
In connection with the start of such tier 2 coverage, we have agreed to pay customary rebates to these third-party payors on the resale of Vascepa to patients covered by these third-party payors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As is typical for the pharmaceutical industry, the majority of Vascepa sales are to major commercial
wholesalers which then resell Vascepa to retail pharmacies. As of November&nbsp;1, 2013, over 13,000 clinicians had written prescriptions for Vascepa. As of November&nbsp;1, 2013, we are not aware of any clinician who is responsible for 10% or more
of the aggregate prescriptions written for Vascepa. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;22, 2013, in an effort to reduce operating expenses following the
recommendation of the advisory committee to the FDA, we implemented a worldwide reduction in force including a reduction of approximately fifty percent of our sales representatives. Following the reduction in force, we retained approximately 130
sales representatives in the United States in sales territories which have demonstrated what we believe is the greatest potential for Vascepa sales growth.&nbsp;This team will cover the target base of physicians responsible for the vast majority of
Vascepa prescription volume and growth since its launch in early 2013.&nbsp;With these changes and resulting target base coverage, Amarin anticipates continued Vascepa revenue growth over time. Amarin further anticipates that such sales growth may
be inconsistent from period to period.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cost of Goods Sold.</I> Cost of goods sold during the nine months ended September&nbsp;30, 2013 was
$7.8 million, and includes the cost of API for Vascepa on which revenue was recognized during period, as well as the associated costs for encapsulation, packaging, shipment, supply management, insurance and quality assurance. The cost of the API
included in cost of goods sold reflects the average cost of API included in inventory. This average cost reflects the actual purchase price of Vascepa API, as well as a portion of API carried at zero cost for material which was purchased prior to
FDA approval of Vascepa on July&nbsp;26, 2012 or was purchased prior to the sNDA approval of our suppliers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The majority of API included in
the calculation of the average cost of goods sold during the nine months ended September&nbsp;30, 2013 was sourced from one API supplier. The contracted cost of supply from this API supplier for initial purchase volumes is higher than the contracted
cost from our other API suppliers. Contracted purchase costs from this initial API supplier reflect that they were working with Amarin prior to commencement of the MARINE and ANCHOR clinical trials and are anticipated to decline as additional API
volume is purchased. In the future, we anticipate making continued purchases from this initial supplier at substantially lower unit pricing than the pricing of the initial purchases from this supplier and to make additional lower unit cost purchases
of Vascepa API from other API suppliers, including Chemport and BASF, both of which were approved by the FDA in April 2013 to produce Vascepa API. We began purchasing lower unit cost API from Chemport in the three months ended June&nbsp;30, 2013.
During the nine months ended September&nbsp;30, 2013, the cost basis of product sold that had a carrying value of zero was approximately $4.0 million. Had such inventories been valued at acquisition cost, it would have resulted in an increase in
cost of goods sold and a decrease in gross margin during such periods. We expect current inventories with a carrying value of zero to be utilized in 2014. We may have additional zero cost inventories in the future to the extent that we receive
approval of the sNDA for our fourth commercial supplier. As of September&nbsp;30, 2013, we maintained inventory with a carrying value of zero and an acquisition cost of $0.6 million, which has an estimated net realizable value of $2.6 million based
on our average net selling price for the three months ended September&nbsp;30, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our gross margin improved from 45% and 48% in the three
months ended March&nbsp;31 and June&nbsp;30, 2013, respectively, to 56% in the three months ended September&nbsp;30, 2013, which was primarily driven by lower unit cost API purchases and resulted in a gross margin of 52% for the nine months ended
September&nbsp;30, 2013. In addition to expected continued lower average unit cost purchases of API, we also expect that API costs will be lower in the future due to recent improvements in foreign currency exchange rates and potential advantages
derived from the geographical mix of our suppliers. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research and Development Expense.</I> Research and development expense for the nine months ended
September&nbsp;30, 2013 was $56.1 million, versus $39.7 million in the prior year period, an increase of $16.4 million, or 41.3%. Research and development expenses for the nine months ended September&nbsp;30, 2013 and 2012 are summarized in the
table below: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine Months Ended<BR>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">REDUCE-IT study (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,154</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,941</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other clinical trial programs (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">932</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-approval commercial supply (3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,783</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,503</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regulatory filing fees and expenses (4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,098</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Internal staffing, overhead and other (5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,420</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,983</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expense, excluding non-cash expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash stock-based compensation (6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,735</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The increase in research and development expenses for the nine months ended September&nbsp;30, 2013, as compared to the
prior year period, is primarily due to an increase in costs associated with the REDUCE-IT study as further described below. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2011, we announced commencement of patient dosing in our cardiovascular outcomes study of Vascepa, titled REDUCE-IT, which is designed to evaluate the
efficacy of Vascepa in reducing major cardiovascular events in a high risk patient population on statin therapy. The study duration is dependent on the rate of clinical events in the study, which rate may be affected by the number of patients
enrolled in the study and the epidemiology of the patients enrolled in the study. We manage the study through a contract research organization (CRO) through which all costs for this outcomes study are incurred with the exception of costs for
clinical trial material (CTM) and costs for internal management. Our internal personnel are responsible for managing multiple projects and their costs are not specifically allocated to REDUCE-IT or any other individual project. In September 2013, we
announced that, in aggregate, over 6,000 patients have been enrolled in REDUCE-IT. We estimate that we will complete patient enrollment in this study in the first half of 2015. The REDUCE-IT study will be completed after reaching an aggregate number
of cardiovascular events. Based on event rates in other outcomes studies, we estimate completing the REDUCE-IT study in or about 2017. For 2013, we anticipate incurring expense through our CRO in connection with this trial of between $30 million and
$40 million, inclusive of the amounts spent during the nine months ended September&nbsp;30, 2013. Inclusive of CTM costs, we anticipate combined CRO and CTM costs in 2013 for REDUCE-IT will total approximately $40 million to $45 million, inclusive
of the amounts spent during the nine months ended September&nbsp;30, 2013. We expense costs for CTM upon receipt. The aggregate cost of this outcomes study will depend on the rate of clinical events in the study. We currently estimate that quarterly
costs incurred for this study in the remainder of 2013 and 2014 will continue at approximately the same levels as we have incurred on a quarterly average in 2013. Excluding 2013 costs, based on our current assumptions of CRO and CTM costs, we
estimate that aggregate remaining costs to complete the REDUCE-IT study and evaluate its results to likely exceed $100 million. We anticipate that our costs for this outcomes study will continue to represent the most significant component of our
research and development expenditures. However, if we do not receive FDA approval of the ANCHOR indication, we plan to re-evaluate the REDUCE-IT study, including the likelihood of REDUCE-IT providing clinically and commercially useful results, the
likelihood of FDA approval for an expanded indication for Vascepa based on these results and whether it is advisable to continue or discontinue the study.&nbsp;We anticipate that in any such re-evaluation we will seek further feedback from the
FDA.</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2012 and 2013, other clinical trial programs consisted of fixed-dose combination studies. In December 2012, we completed dosing and pharmacokinetic sampling in a
study to test a fixed-dose combination of Vascepa capsules and a leading statin which we refer to as AMR102. In August 2013, we completed dosing in a randomized, open-label, single-dose, 4-way cross-over study to continue testing of the relative
bioavailability of AMR102 capsules, Vascepa capsules with a selected statin taken concomitantly, Vascepa taken alone and the selected statin taken alone.&nbsp;We anticipate results from this study either late in the second half of 2013 or in the
first half of 2014. We expect that additional costs to complete the study, excluding costs of our internal personnel, will be less than $1 million. Future costs related to the development of AMR102 beyond the ongoing study cannot be reasonably
estimated until we evaluate the results of the ongoing study. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Until an API supplier is approved by the FDA to manufacture commercial supply of Vascepa, all Vascepa purchased from such supplier is included as a
component of research and development expense. Upon approval of the supplier, we capitalize subsequent Vascepa API purchases from such supplier as inventory. Purchases of Vascepa API received and expensed before
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
such regulatory approvals are not subsequently capitalized, and all such purchases are quarantined and not used for commercial supply until such time as the supplier that produced the API is
approved. The commercial supply expense for the periods shown above represents inventory received from Nisshin prior to NDA approval of Vascepa on July&nbsp;26, 2012 or received from our other suppliers prior to their sNDA approvals. In April 2013,
sNDAs were approved for two of our additional suppliers, BASF and Chemport. A sNDA was submitted in August 2013 for Novasep as part of the Slanmhor consortium. The amount of commercial supply that we receive from Novasep prior to sNDA approval
depends upon production schedules at Novasep and the timing of regulatory approval, and we are unable to estimate these amounts at this time. We will continue to expense inventory received from the unapproved supplier until such time as FDA approval
is obtained. Additionally, during the nine months ended September&nbsp;30, 2013, we recorded an inventory reserve of $1.8 million related to certain product in development that is not recoverable in its current form. This product is from a supplier
from which no supply has yet been released for commercial use. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The regulatory filing fees primarily represent costs incurred in connection with regulatory filings associated with requests for regulatory approvals, such as the sNDA
for the ANCHOR indication and annual FDA fees for maintaining manufacturing sites. In the nine months ended September, 30, 2013, such fees also include costs associated with preparing for the October&nbsp;16, 2013 FDA advisory committee meeting. In
the nine months ended September&nbsp;30, 2012, the regulatory filing fees balance was a net credit as a result of the reimbursement of $1.5 million in fees by the FDA related to the NDA filing for Vascepa. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Internal staffing, overhead and other research and development expenses primarily relate to the costs of our personnel employed to managed research, development and
regulatory affairs activities and related overhead costs including consulting and other professional fees that are not allocated to specific projects. Such costs also include costs related to qualifying suppliers and legal costs. We anticipate a
reduction in such costs in 2014 compared to 2013 levels as a result of a company-wide reduction in force announced in October 2013. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash stock-based compensation expense represents the costs associated with equity awards issued to internal staff supporting our research and development and
regulatory functions. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Selling, General and Administrative Expense.</I> Selling, general and administrative expense for the
nine months ended September&nbsp;30, 2013 was $101.5 million, versus $41.1 million in the prior year period, an increase of $60.4 million, or 147.0%. Selling, general and administrative expenses for the nine months ended September&nbsp;30, 2013 and
2012 are summarized in the table below: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine Months Ended<BR>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Selling, general and administrative expenses, excluding non-cash expenses&nbsp;(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90,664</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash stock based compensation expense&nbsp;(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,439</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash warrant related compensation (income) expense (3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,179</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,037</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total selling, general and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101,502</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,059</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Selling, general and administrative expense, excluding non-cash compensation charges for stock compensation and warrants, for the nine months ended September&nbsp;30,
2013 was $90.7 million, versus $27.6 million in the prior year period, an increase of $63.1 million, or 228.6%. The increase was primarily due to cost increases in 2013 for sales force staffing, an increase in marketing program spending and
increased general and administrative costs incurred in connection with the initial commercialization of Vascepa. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock based compensation expense for the nine months ended September&nbsp;30, 2013 was $12.0 million, versus $10.4 million in the prior year period, an increase of $1.6
million primarily reflecting an increase in the number of awards outstanding during the period ending September&nbsp;30, 2013 versus the prior period. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrant related compensation (income) expense for the nine months ended September&nbsp;30, 2013 was income of $1.2 million, versus expense of $3.0
million in the prior year period. Warrant related compensation (income) expense reflects the non-cash change in fair value of the warrant derivative liability associated with warrants issued in October 2009 to three former employees of Amarin. The
decrease in the fair value of the warrants for the nine months ended September&nbsp;30, 2013 is due primarily to a decrease in our stock price between December&nbsp;31, 2012 and September&nbsp;30, 2013. The value of this warrant derivative liability
may increase or decrease from period to period based upon changes in the price of our common stock. Such non-cash changes in valuation could be significant as the history of our stock price has been volatile. The gain or loss resulting
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
from such non-cash changes in valuation could have a material impact on our reported net income or loss from period to period. In particular, if the price of our stock increases, the change in
valuation of this warrant derivative liability will add to our history of operating losses. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Selling, general and administrative
costs in 2013 have increased over 2012 levels as we continue to support the commercialization of Vascepa, including costs for market research, sales force staffing and support costs and investments in infrastructure. We anticipate a reduction in the
level of such costs in 2014 as a result of the reduction in force announced in October 2013 and expected reductions in certain marketing program spend and other overhead costs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>(Loss) Gain on Change in Fair Value of Derivative Liabilities</I>. (Loss) gain on change in fair value of derivative liabilities for the nine months ended September&nbsp;30, 2013 was a gain of $21.1
million versus a loss of $68.7 million in the prior year period. (Loss) gain on change in fair value of derivative liabilities is comprised of (i)&nbsp;the change in fair value of the warrant derivative liability, (ii)&nbsp;the change in fair value
of the derivative liability related to the change in control provision associated with the December 2012 BioPharma financing and (iii)&nbsp;an unrealized loss on foreign exchange contracts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The warrant derivative liability is related to the change in fair value of warrants issued in conjunction with the October 2009 private placement. In October 2009 we issued 36.1&nbsp;million warrants at
an exercise price of $1.50 and recorded a $48.3 million warrant derivative liability, representing the fair value of the warrants issued. As these warrants have been classified as a derivative liability, they are revalued at each reporting period,
with changes in fair value recognized in the statement of operations. The fair value of the warrant derivative liability at December&nbsp;31, 2012 was $54.9 million and we recognized a $14.1 million gain on change in fair value of derivative
liability for the nine months ended September&nbsp;30, 2013 for these warrants. The fair value of the warrant derivative liability at December&nbsp;31, 2011 was $123.1&nbsp;million and we recognized a $68.7 million loss on change in fair value of
derivative liability for the nine months ended September&nbsp;30, 2012. The change in fair value of the warrant derivative liability is due primarily to the decrease or increase in the price of our common stock on the date of valuation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our December 2012 financing agreement with BioPharma contains a redemption feature whereby, upon a change of control, we would be required to pay $140
million, less any previously repaid amount, if the change of control occurs on or before December&nbsp;31, 2013, or required to repay $150 million, less any previously repaid amount, if the change of control event occurs after December&nbsp;31,
2013. The fair value of the derivative liability is recalculated at each reporting period using a probability-weighted model incorporating management estimates for potential change in control, and by determining the fair value of the debt with and
without the change in control provision included. The difference between the two fair values of the debt was determined to be the fair value of the embedded derivative. At December&nbsp;31, 2012, the fair value of the derivative was determined to be
$14.6 million, and at September&nbsp;30, 2013, the fair value of the derivative was determined to be $7.2 million. We recognized a $7.4 million gain on change in fair value of derivative liability for the nine months ended September&nbsp;30, 2013.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We use foreign exchange forward contracts to hedge against changes in exchange rates for inventory purchases denominated in foreign currency.
As of&nbsp;September&nbsp;30, 2013 we had one outstanding foreign exchange forward contract with a notional amount of $4.5 million. For the nine months ended&nbsp;September&nbsp;30, 2013, we recognized an unrealized loss of $0.4 million related to
the change in fair value of the foreign exchange forward contract derivative liability, which was included as a component of change in fair value of derivative liabilities and in other current liabilities at September&nbsp;30, 2013. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Interest Expense, net.</I> Net interest expense for the nine months ended September&nbsp;30, 2013 was $26.6 million, versus $12.8 million in the prior
year period, an increase of $13.8 million, or 107.8%. Net interest expense for the nine months ended September&nbsp;30, 2013 and 2012 is summarized in the table below (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exchangeable senior notes:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of debt discount created upon allocation of proceeds to the conversion option</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,798</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractual coupon interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of the discount from the underwriter&#146;s discounts and offering costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,851</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total exchangeable senior notes interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,171</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term debt - BioPharma financing (1):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash interest - current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash interest - deferred</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total long-term debt interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,860</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(218</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total interest expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and non-cash interest expenses related to the BioPharma financing for the nine months ended September&nbsp;30, 2013 were $9.7 million and $2.2 million,
respectively. These amounts reflect a change in the assumption from prior quarters that our Vascepa revenue levels will be high enough to support repayment to BioPharma in accordance with the repayment schedule without the optional reduction which
is allowed to be elected by us if the threshold revenue levels are not achieved. For the three months ended September&nbsp;30, 2013, our revenues were below the contractual threshold amount such that we have a cash payment of $0.8 million due in
November 2013 reflecting the calculated optional reduction amount as opposed to the contractual threshold payment of $2.5 million. Additionally, the revised assumptions yielded a decrease in the calculated effective interest rate resulting in a
decrease in interest expense during the three months ended September&nbsp;30, 2013 as compared to the three months ended June&nbsp;30, 2013 and March&nbsp;31, 2013. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income for the nine months ended September&nbsp;30, 2013 was $0.2 million, versus $0.3 million in the prior year period, a decrease of $0.1 million, or 33.3%.
Interest income represents income earned on cash balances. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Other (Expense) Income, net</I>. Other (expense) income, net
primarily includes realized gains and losses on foreign exchange transactions, including foreign exchange forward contracts. Other expense for the nine months ended September&nbsp;30, 2012 included an unrealized loss due to the fluctuation in the
exchange rate of the Laxdale accrual in the amount of $0.5 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Benefit from (Provision for) Income Taxes</I>. Benefit from (provision
for) income taxes primarily consists of tax obligations for one of our subsidiaries. During the nine months ended September&nbsp;30, 2013 and 2012, we recorded a benefit from (provision for) income taxes of $4.8 million and $(5.9) million,
respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our sources of liquidity as of September&nbsp;30, 2013 include cash and cash equivalents of $225.9&nbsp;million. On July&nbsp;12, 2013, we completed a public offering of 21,700,000 American Depositary
Shares, or ADSs. The underwriters purchased the ADSs from us at a price of $5.60 per ADS, resulting in net proceeds to us of approximately $121.2 million, after deducting estimated offering expenses payable by us. Our cash flows from operating,
investing and financing activities, as reflected in the consolidated statements of cash flows, are summarized in the following table (in millions): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash (used in) provided by continuing operations:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(157.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(78.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">122.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">178.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Decrease) increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(34.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;6, 2012 we entered into a financing agreement with BioPharma. Under this agreement, we granted to
BioPharma a security interest in future receivables and all related rights to Vascepa, in exchange for $100 million received at the closing of the agreement which closing occurred in December 2012. We have agreed to repay BioPharma up to $150
million of future revenue and receivables. The first repayment under the agreement is a repayment of $0.8 million of interest due to BioPharma in November 2013, reflective of the option reduction described below. Additional quarterly repayments are
due thereafter in accordance with the following schedule: $2.5&nbsp;million of interest in the first quarter of 2014; $8.0 million per quarter in each of the next four quarters, $10.0 million per quarter in each of the next four quarters, $15.0
million per quarter in each of the next four quarters and a final payment of $13.0&nbsp;million due in May 2017. The quarterly repayments through the third quarter of September 2014 represent interest only. Quarterly payments do not begin to reduce
the principal balance until the fourth quarter of 2014. For the three months ended September&nbsp;30, 2013, revenues were below the contractual threshold amount such that a cash payment of $0.8 million is due in November 2013 reflecting the
calculated optional reduction amount as opposed to the contractual threshold payment of $2.5 million. In accordance with the agreement with BioPharma, quarterly differences between the calculated optional reduction amounts and the repayment schedule
amounts are rescheduled for payment beginning in the second quarter of 2017. Any such deferred payments will remain subject to continued application of the quarterly ceiling in amounts due established by the calculated threshold based on quarterly
Vascepa revenues. Additionally, the revised assumptions yielded a decrease in the calculated effective interest rate resulting in a decrease in interest expense during the three months ended September&nbsp;30, 2013 as compared to the three months
ended June&nbsp;30, 2013 and March&nbsp;31, 2013. Except upon a change of control in Amarin, the agreement does not expire until $150 million has been repaid. Under the agreement, upon a change of control, we would be required to pay $140 million,
less any previously repaid amount, if the change of control occurs on or before December&nbsp;31, 2013, or required to repay $150 million, less any previously repaid amount, if the change of control event occurs after December&nbsp;31, 2013. We can
prepay after October&nbsp;1, 2013, an amount equal to $150 million less any previously repaid amount. We currently estimate that Vascepa revenue levels will not be high enough in each quarter to support repayment to BioPharma in accordance with
threshold amounts in the repayment schedule. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;9, 2012, Amarin, through our wholly-owned subsidiary Corsicanto Limited, or Corsicanto, a
private limited company incorporated under the laws of Ireland, completed a private placement of $150.0 million in aggregate principal amount of its 3.5% exchangeable senior notes due 2032. The proceeds we received from the January 2012 debt
offering were approximately $144.3 million, net of fees and transaction costs. These notes were issued pursuant to an indenture dated as of January&nbsp;9, 2012, by and among Corsicanto, us as guarantor, and Wells Fargo Bank, National Association,
as trustee. The notes are the senior unsecured obligations of Corsicanto and are guaranteed by us. The notes bear interest at a rate of 3.5%&nbsp;per annum, payable semi-annually in arrears on January&nbsp;15 and July&nbsp;15 of each year, beginning
on July&nbsp;15, 2012. The notes mature on January&nbsp;15, 2032, unless earlier repurchased, redeemed or exchanged. On or after January&nbsp;19, 2017, we may elect to redeem for cash all or a portion of the notes for the principal amount of the
notes plus accrued and unpaid interest. On each of January&nbsp;19, 2017,&nbsp;January&nbsp;19, 2022 and January&nbsp;19, 2027, the holders of the notes may require that we repurchase in cash the principal amount of the notes plus accrued and unpaid
interest. At any time prior to January&nbsp;15, 2032, upon certain circumstances, which circumstances include our issuing a notice of redemption to the note holders, the price of our shares trading above 130% of the exchange price, or certain other
events defined in the note agreement, the holders of the notes may elect to convert the notes. The exchange rate for conversion is 113.4752 ADSs per $1,000 principal amount of the notes (equivalent to an initial exchange price of approximately
$8.8125 per ADS), subject to adjustment in certain circumstances, including adjustment if we pay cash dividends. Upon exchange, the notes may be settled, at our election, subject to certain conditions, in cash, ADSs or a combination of cash and
ADSs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of September&nbsp;30, 2013, we had cash and cash equivalents of $225.9 million, a decrease of $34.3 million from December&nbsp;31,
2012.&nbsp;The decrease is primarily due to net cash used in operating activities in support of the commercial launch of Vascepa, net of proceeds from financing activities. We have incurred annual operating losses since our inception and, as a
result, had an accumulated deficit of $898.5 million as of September&nbsp;30, 2013. We believe that our cash and cash equivalents balance of $225.9 million at September&nbsp;30, 2013 will be sufficient to fund our projected operations for at least
the next twelve months. We estimate that our operating activities in the fourth quarter of 2013 will result in a net use of cash no more than reported for the third quarter of 2013. We also estimate that during 2014 our operating activities will
result in a net use of cash of not more than $80 million. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contractual Obligations </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes our contractual obligations at September&nbsp;30, 2013 and the effects such obligations are expected to have on our
liquidity and cash flows in future periods (in millions): </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Payments Due by Period </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014<BR>to&nbsp;2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016<BR>to&nbsp;2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>After&nbsp;2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractual Obligations:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase obligations (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating lease obligations (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest payment obligations&#151;exchangeable debt (3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Principal&nbsp;&amp; Interest payment obligations&#151;BioPharma&nbsp;(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total contractual cash obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">155.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have agreements with API suppliers which include minimum annual purchase levels to enable Amarin to maintain exclusivity with each respective supplier, and to
prevent potential termination of the agreements based on our estimated minimum purchase requirements. Except under our API agreement with Slanmhor, we are not obligated to pay in cash any shortfall in the minimum purchase obligations pursuant to its
supply agreements. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Represents operating lease costs, primarily consisting of leases for facilities in Dublin, Ireland, Bedminster, NJ and Groton, CT. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Represents interest payments due under the terms of our 3.5% exchangeable senior notes (&#147;notes&#148;) due 2032, assuming they remain outstanding for 24 months and
have not been exchanged for ADRs. The above table does not reflect the repayment of the $150.0 million notes as they may be exchanged for ADRs. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Represents principal and interest payments that we anticipate paying under the terms of the agreement entered into with BioPharma. Under this
agreement, we granted to BioPharma a security interest in future receivables and all rights to Vascepa, in exchange for $100 million received at the closing of the agreement which closing occurred in December 2012. We have agreed to repay BioPharma
up to $150 million of future revenue and receivables. The first repayment under the agreement is a payment of $0.8 million of interest due to BioPharma in November 2013, which is reflective of the option reduction described below. Additional
quarterly repayments are due thereafter in accordance with the following schedule: $2.5 million of interest in the first quarter of 2014; $8.0 million per quarter in each of the next four quarters, $10.0 million per quarter in each of the next four
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
quarters, $15.0 million per quarter in each of the next four quarters and a final payment of $13.0 million due in May 2017. The quarterly repayments through the third quarter of September 2014
represent interest only. Quarterly payments do not begin to reduce the principal balance until the fourth quarter of 2014. In accordance with the agreement with BioPharma, quarterly differences between the calculated optional reduction amounts and
the repayment schedule amounts are rescheduled for payment beginning in the second quarter of 2017 subject at that time to continued application of the quarterly ceiling in amounts due established by the calculated threshold based on quarterly
Vascepa revenues. In 2014 and beyond, the table above reflects payment in full of the scheduled quarterly amounts without such potential elected reductions. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We do not enter into financial instruments for trading or speculative purposes. At September&nbsp;30, 2013, we had one outstanding forward exchange contract with a notional amount of $4.5 million to hedge
payments made in foreign currency for API supply. As of September&nbsp;30, 2013 we recorded an unrealized loss of $0.4 million for one outstanding foreign exchange contract. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The above table also does not reflect potential material purchases under our API supply agreements with the consortium led by Slanmhor Pharmaceuticals. In April 2013, we announced the approval by the FDA
of the sNDAs covering two of our API suppliers, Chemport, Inc. and BASF (formerly Equateq Limited). These commercial supply agreements provide access to additional API supply that is incremental to supply from Nisshin, our other existing
FDA-approved API supplier. Each of these additional API agreements contemplates a phased capacity expansion plan aimed at creating sufficient capacity to meet anticipated demand for API material for Vascepa following commercial launch. These API
suppliers are self-funding these expansion plans with contributions from us. These agreements include requirements for the suppliers to qualify their materials and facilities. We anticipate incurring certain costs associated with the qualification
of product produced by these suppliers. These agreements include annual purchase levels enabling us to maintain supply exclusivity with each respective supplier, and to prevent potential termination of the agreements and because the agreements with
Chemport and BASF do not require any shortfall in the minimum purchase commitments to be paid in cash, have been excluded from the table above. The sNDA for the consortium led by Slanmhor, our intended fourth API supplier, is not yet approved, and
as such any minimum purchase commitments that could result in a future cash obligation have also been excluded from the above table. The two supply agreements entered into in 2011 with BASF and Chemport also include (i)&nbsp;development fees up to a
maximum of $0.5&nbsp;million, (ii)&nbsp;material commitments of up to $5.0&nbsp;million for initial raw materials, which will be credited against future API purchases, and is refundable to us if a supplier does not successfully develop and qualify
the API by a certain date, and (iii)&nbsp;a raw material purchase commitment of $1.1&nbsp;million. Under these agreements, during the nine months ended September&nbsp;30, 2013 we purchased approximately $20.4 million of Vascepa API. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The agreement with Slanmhor provides for development fees of up to $2.3 million and a commitment of up to $15.0 million, which will be credited against
future API material purchases. The $15.0 million commitment fee is contingent upon the mutually agreed upon expansion of Slanmhor&#146;s API manufacturing capacity. Under this agreement, during the nine months ended September&nbsp;30, 2013 we made
payments of $6.1 million to Slanmhor related to stability and technical batches and advances on future API purchases. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the 2004 share
repurchase agreement with Laxdale Limited, or Laxdale, upon approval of Vascepa by the FDA on July&nbsp;26, 2012, we were required to make a milestone payment to Laxdale of &pound;7.5&nbsp;million. We made this payment in 2012 and capitalized this
Laxdale milestone payment of $11.6 million as a component of other long term assets. This long-term asset is being amortized over the estimated useful life of the intellectual property we acquired from Laxdale and we recognized amortization expense
of $0.5 million during the nine months ended September&nbsp;30, 2013. Also under the Laxdale agreement, upon receipt of marketing approval in Europe for the first indication for Vascepa (or first indication of any product containing Amarin
Neuroscience intellectual property acquired from Laxdale in 2004), we must make an aggregate stock or cash payment to the former shareholders of Laxdale (at the sole option of each of the sellers) of &pound;7.5&nbsp;million (approximately $12.1
million at September&nbsp;30, 2013). Also under the Laxdale agreement, upon receipt of a marketing approval in the U.S. or Europe for a further indication of Vascepa (or further indication of any other product using Amarin Neuroscience intellectual
property), we must make an aggregate stock or cash payment (at the sole option of each of the sellers) of &pound;5&nbsp;million (approximately $8.1 million at September&nbsp;30, 2013) for each of the two potential market approvals (i.e.
&pound;10&nbsp;million maximum, or approximately $16.1 million at September&nbsp;30, 2013). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the obligations in the table
above, we have recorded a liability of approximately $0.8 million for uncertain tax positions that is classified in long-term liabilities at September&nbsp;30, 2013. We are not able to reasonably estimate in which future periods these amounts will
ultimately be settled. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Off-Balance Sheet Arrangements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We do not have any special purpose entities or other off-balance sheet arrangements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Shelf
Registration Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;29, 2011, we filed with the Securities and Exchange Commission a universal shelf registration
statement on Form S-3 (Registration No.&nbsp;333-173132), which provides for the offer, from time to time, of an indeterminate and unlimited amount of: ordinary shares, which may be represented by American Depositary Shares; preference shares, which
may be represented by American </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Depositary Shares; senior or subordinated debt securities; warrants to purchase any of these securities; and any combination of these securities, individually or as units. In addition, if we
identify any security holder(s) in a prospectus supplement, they may also offer identified securities under this registration statement although we will not receive any of the proceeds from the sale of securities by any of these selling security
holders. This universal shelf registration statement was automatically effective upon its filing. The addition of any newly issued equity securities into the market may be dilutive to existing stockholders and new issuances by us or sales by our
selling security holders could have an adverse effect on the price of our securities. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc595270_8"></A>Item&nbsp;3.</B><B><I></I></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Quantitative and Qualitative Disclosures about Market Risk </I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There have been no material changes with respect to the information appearing in PART II, Item&nbsp;7A &#147;Quantitative and Qualitative Disclosures about Market Risk&#148; of our Annual Report on Form
10-K filed with the Securities and Exchange Commission on February&nbsp;28, 2013. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc595270_9"></A>Item&nbsp;4.</B><B><I></I></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Controls and Procedures </I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Evaluation of Disclosure Controls and Procedures </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities and Exchange Act of 1934 is
(1)&nbsp;recorded, processed, summarized, and reported within the time periods specified in the SEC&#146;s rules and forms and (2)&nbsp;accumulated and communicated to our management, including our principal executive officer and principal financial
officer, to allow timely decisions regarding required disclosure. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of September&nbsp;30, 2013, our management, with the participation of
our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934). Our management
recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship
of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of September&nbsp;30, 2013, our disclosure controls and procedures were effective
at the reasonable assurance level. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Changes in Internal Control over Financial Reporting </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the quarter ended September&nbsp;30, 2013, there have been no changes in our internal control over financial reporting, as such term is defined in
Rules&nbsp;13a-15(f) and 15(d)-15(f) promulgated under the Securities Exchange Act of 1934, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc595270_10"></A>PART II </B></FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc595270_11"></A>Item&nbsp;1.</B><B><I></I></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Legal Proceedings</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On November 1, 2013, a purported investor of Amarin filed a putative class action lawsuit against Amarin and our Chief Executive Officer in the U.S. District Court for the District of New Jersey, Steven
Sklar v. Amarin Corporation plc and Joseph S. Zakrzewski, No. 13-cv-6954 (D.N.J. Nov. 1, 2013). The lawsuit alleges that, during the period July 9, 2009 through October 15, 2013, we misled investors regarding the FDA&#146;s willingness to approve
Vascepa&#146;s ANCHOR indication and the potential relevance of data from the ongoing REDUCE-IT trial to that approval, thereby artificially inflating the price of our securities. Based on these allegations, the suit asserts claims under the
Securities Exchange Act of 1934 and seeks unspecified monetary damages and attorneys&#146; fees and costs. We believe that we have valid defenses and we will vigorously defend against the claims. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November 5, 2013, a purported investor of Amarin filed a putative class action lawsuit against Amarin and certain of our officers in
the U.S. District Court for the Southern District of New York, Joseph A. Bove and Joseph J. Bove v. Amarin Corporation, PLC., Joseph S. Zakrzewski, John F. Thero, and Steven B. Ketchum,<I> </I>No. 13-CIV-7882 (S.D.N.Y. Nov. 5, 2013).<I> </I>The
lawsuit alleges, similar to the <I>Sklar</I> case, that, during the period August 8, 2012 until October 16, 2013, we misled investors regarding the FDA&#146;s willingness to approve Vascepa&#146;s ANCHOR indication and the potential relevance of
data from the ongoing REDUCE-IT trial to that approval, thereby artificially inflating the price of our securities. Based on these allegations, the suit asserts claims under the Securities Exchange Act of 1934 and seeks unspecified monetary damages
and attorneys&#146; fees and costs. We believe that we have valid defenses and we will vigorously defend against the claims. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the above, in the ordinary course of business, we are from time to time involved in lawsuits, claims, investigations,
proceedings, and threats of litigation relating to intellectual property, commercial arrangements and other matters. While the outcome of these proceedings and claims cannot be predicted with certainty, as of September&nbsp;30, 2013, we were not
party to any legal or arbitration proceedings that may have, or have had in the recent past, significant effects on our financial position or profitability. No governmental proceedings are pending or, to our knowledge, contemplated against us. We
are not a party to any material proceedings in which any director, member of senior management or affiliate of ours is either a party adverse to us or our subsidiaries or has a material interest adverse to us or our subsidiaries. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc595270_12"></A>Item&nbsp;1A.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Risk Factors </I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This Quarterly Report on Form 10-Q contains forward-looking information based on our current expectations. Because our actual results may differ
materially from any forward-looking statements that we make or that are made on our behalf, this section includes a discussion of important factors that could affect our actual future results, including, but not limited to, our capital resources,
our ability to successfully commercially launch Vascepa, the progress and timing of our clinical programs, the safety and efficacy of our product candidates, risks associated with regulatory filings, risks associated with determinations made by
regulatory agencies, the potential clinical benefits and market potential of our product candidates, commercial market estimates, future development efforts, patent protection, effects of healthcare reform, reliance on third parties, and other risks
set forth below. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Those risk factors below denoted with a &#147;*&#148; are newly added or have been materially updated from our Annual
Report on 10-K filed with the Securities and Exchange Commission on February&nbsp;28, 2013. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to the Commercialization and
Development of Vascepa </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>*Our ability to generate increased revenue over the next few years depends, in part, on FDA
approval for the use of Vascepa in the ANCHOR indication in the United States and we may be delayed in obtaining, or never obtain, such approval. In October 2013 an advisory committee convened by the FDA voted 9 to 2 against recommending approval of
Vascepa in the ANCHOR indication, as a result of which there is a significant risk that FDA will not approve Vascepa for this indication. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">While we are currently marketing Vascepa for use in the MARINE indication in the United States, our ability to commercialize Vascepa in the ANCHOR indication in the United States or market Vascepa for
either indication outside of the United States is dependent upon receiving additional regulatory approvals. In April 2013, the FDA accepted our Supplemental New Drug Application, or sNDA, which seeks approval for the use of Vascepa in patients with
high triglyceride levels (TG <U>&gt;</U>200 mg/dL and &lt;500 mg/dL) who are also on statin therapy for elevated LDL-C levels, which we refer to as the ANCHOR indication, and the FDA has assigned the sNDA a Prescription Drug User Fee Act, or PDUFA,
date of December&nbsp;20, 2013 for the completion of its review. The PDUFA date is the goal date for the FDA to complete its review of the sNDA. The FDA may complete its review of the sNDA earlier than this date and there can be no assurance that
the FDA will complete its review by this date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;18, 2013, the FDA informed us that it planned to convene an
advisory committee meeting on October&nbsp;16, 2013 to review the sNDA for the ANCHOR indication. On October&nbsp;11, 2013, the FDA posted on its website executive summary briefing documents from both the FDA and Amarin for the advisory committee
consideration. Included in these materials was the voting question posed to the advisory committee, which was stated in its entirety as follows: &#147;Taking into account the described efficacy and safety data for Vascepa, do you believe that its
effects on the described lipid/lipoprotein parameters are sufficient to grant approval for co-administration with statin therapy for the treatment of patients with mixed dyslipidemia and CHD or CHD risk equivalent prior to the completion of
REDUCE-IT?&#148; On October&nbsp;16, 2013, the advisory committee voted 9 to 2 against recommending approval of Vascepa, based on the question posed to the advisory committee by the FDA. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the advisory committee meeting, based in part on the briefing materials prepared by the FDA for the meeting, the advisory
committee reviewed the safety and efficacy data observed in the ANCHOR trial. This included a discussion regarding observed nominally statistically significant changes from baseline in an adverse direction, while on background statin therapy, in
certain lipid parameters, including TGs, in the placebo group, raising the possibility that the mineral oil placebo used in the ANCHOR trial (and in the REDUCE-IT trial) was not biologically inert and might be viewed as artificially exaggerating the
clinical effect of Vascepa when measured against placebo in the ANCHOR trial. Because no strong evidence for biological activity of mineral oil was identified by the FDA in the MARINE trial, ultimately it was concluded that the between-group
differences likely provided the most appropriate descriptions of the treatment effect of Vascepa and that whatever factor(s) led to the within-group changes over time in the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
placebo group were likely randomly distributed to all treatment groups. Thus, FDA approved Vascepa for use in the MARINE indication in July 2012. Following this discussion at the advisory
committee meeting, while no formal vote was taken related to the inert nature of the placebo, we believe that the consensus of the advisory committee, although not unanimous, and the FDA was that, based on the information made available to the
advisory committee and FDA at the meeting, Vascepa appeared to be safe and effective for the reduction of TGs in patients with mixed dyslipidemia on statin therapy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">However, there was also extensive discussion during the advisory committee meeting regarding the expected clinical benefit of a reduction in TGs in this patient population. That is, whether the clinical
data derived from the ANCHOR trial, without more, was a sufficient basis for approval. In particular, the advisory committee and FDA noted the lack of prospective, controlled clinical trial data demonstrating that pharmacological reduction of TGs in
patients with mixed dyslipidemia on statin therapy significantly reduces residual cardiovascular risk in these patients. The FDA noted that prior clinical outcomes studies conducted by others, albeit in different patient populations, evaluating
different drugs with different mechanisms of action, failed to demonstrate a statistically significant reduction in cardiovascular events following concomitant use of drug therapy in patients on statin therapy. We believe that the negative vote of
the advisory committee was principally due to the lack of recent conclusive data in these clinical outcomes studies in favor of the hypothesis that TG reduction will result in reduced cardiovascular risk. The FDA is not bound by the recommendations
of the advisory board, but it generally follows such recommendations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A Special Protocol Assessment, or SPA, agreement is an
agreement with the FDA that Phase 3 trial protocol design, clinical endpoints, and planned statistical analyses are acceptable to support regulatory approval. A SPA is generally binding upon the FDA except in limited circumstances, such as if the
FDA identifies a substantial scientific issue essential to determining safety or efficacy after the study begins, or if the study sponsor fails to follow the protocol that was agreed upon with the FDA. On October&nbsp;29, 2013, the FDA notified us
that it rescinded the SPA agreement we entered into for the ANCHOR trial protocol because the FDA determined that a substantial scientific issue essential to determining the effectiveness of Vascepa in the studied population was identified after
testing began. Specifically, consistent with discussion at the advisory committee meeting, the FDA determined that results from outcome studies of other triglyceride lowering drugs failed to support the hypothesis that a triglyceride-lowering drug
significantly reduces the risk for cardiovascular events among the population studied in the ANCHOR trial. Thus, the FDA stated that it no longer considers a change in serum triglyceride levels as sufficient to establish the effectiveness of a drug
intended to reduce cardiovascular risk in subjects with serum triglyceride levels below 500 mg/dL. On November 7, 2013, we submitted to the FDA a formal appeal of its decision to rescind the SPA including documents outlining why we believe the SPA
was wrongfully rescinded. There can be no assurance that the FDA will agree with our arguments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the recommendation
of the advisory committee and the rescinding of the ANCHOR SPA, we believe there is a significant possibility that the FDA may not approve the ANCHOR sNDA and require, as a condition of any possible approval, additional preclinical studies or
clinical trials, including the REDUCE-IT cardiovascular outcomes trial. If we do not receive FDA approval of the ANCHOR indication, we plan to re-evaluate the REDUCE-IT study, including the likelihood of REDUCE-IT providing clinically and
commercially useful results, the likelihood of FDA approval for an expanded indication for Vascepa based on these results and whether it is best to continue or discontinue the study.&nbsp;We anticipate that in any such re-evaluation we will seek
further feedback from the FDA.&nbsp;The aggregate cost to complete REDUCE-IT is estimated to exceed $100 million which is a significant financial burden given our current financial position. To the extent the FDA conditions approval of Vascepa for
the ANCHOR indication on its review of the data from the REDUCE-IT trial, Vascepa may never be approved for this indication. Any delay in obtaining, or an inability to obtain, marketing approval in this indication would prevent us from growing
revenue and achieving profitability and could have a material adverse effect on our operations and financial condition, including our ability to reach profitability. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Even if we obtain additional regulatory approvals for Vascepa, the timing or scope of any approvals may prohibit or reduce our ability to commercialize the product successfully. For example, if the
approval process for the ANCHOR indication takes too long, we may miss market opportunities and give other companies the ability to develop competing products or establish market dominance. Additionally, the terms of any approvals, including the
approval received from the FDA in July 2012 for the MARINE indication, may prove to not have the scope or breadth needed for us to successfully commercialize Vascepa or become profitable. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>*Our SPA for ANCHOR has been rescinded and our SPA for REDUCE-IT is not a guarantee of FDA approval of Vascepa for the proposed
REDUCE-IT indication. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A Special Protocol Assessment, or SPA, is an evaluation by the FDA of a protocol with the goal
of reaching an agreement that the Phase 3 trial protocol design, clinical endpoints, and statistical analyses are acceptable to support regulatory approval of the drug product candidate with respect to effectiveness for the indication studied. The
ANCHOR trial was, and the REDUCE-IT trial is, being conducted under an SPA with the FDA. In each case, the FDA agreed that, based on the information we submitted to the agency, the design and planned analysis of the ANCHOR trial is adequate to
support use of the conducted study as the primary basis for approval with respect to effectiveness. A SPA is generally binding upon the FDA except in limited circumstances, such as if the FDA identifies a substantial scientific issue essential to
determining safety or efficacy after the study begins, or if the study sponsor fails to follow the protocol that was agreed upon with the FDA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;29, 2013, the FDA notified us that it rescinded the ANCHOR study SPA because the FDA determined that a substantial scientific issue essential to determining the effectiveness of Vascepa in
the studied </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
population was identified after testing began. Specifically, consistent with discussion at the advisory committee meeting, the FDA determined that results from outcome studies of other
triglyceride lowering drugs failed to support the hypothesis that a triglyceride-lowering drug significantly reduces the risk for cardiovascular events among the population studied in the ANCHOR trial. Thus, the FDA stated that it no longer
considers a change in serum triglyceride levels as sufficient to establish the effectiveness of a drug intended to reduce cardiovascular risk in subjects with serum triglyceride levels below 500 mg/dL. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thus, even though we have received regulatory approval of Vascepa for the MARINE indication under an SPA, our ANCHOR SPA was rescinded
and there is no assurance that the FDA will not rescind our REDUCE-IT SPA. Any delay in obtaining, or an inability to obtain, marketing approval in either the ANCHOR or REDUCE-IT indications would prevent us from growing revenue and could have a
material adverse effect on our operations and financial condition, including our ability to reach profitability. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>*If we
do not obtain FDA approval of the ANCHOR indication, we may choose to discontinue our ongoing REDUCE-IT outcome study of Vascepa, which is designed to determine whether Vascepa is effective in reducing major cardiovascular events in a high risk
patient population on statin therapy and our development of AMR102, a fixed dose combination of Vascepa and a leading statin product. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our ongoing REDUCE-IT cardiovascular outcome study was designed to determine whether Vascepa, when added to statin therapy, would reduce the risk of major cardiovascular events in an at-risk patient
population. We expect the ongoing incremental cost of the REDUCE-IT study to us over the next several years will exceed $100 million as the study currently involves over 450 clinical trial sites in eleven countries. The timing of completion of the
REDUCE-IT study is based on the rate of cardiovascular events for patients in the study. If it takes longer for such events to accrue than we expect, the trial could take longer to complete and cost more than we currently expect. AMR102, a fixed
dose combination of Vascepa and a leading statin product, is in early stage development with relatively minimal current expense associated with ongoing development, but significant expense associated with development over the next several years. We
have not been profitable in any of the last five fiscal years. Our cash and cash equivalents at September&nbsp;30, 2013 was $225.9 million. For the fiscal year ended December&nbsp;31, 2012, we reported a loss of approximately $179.2 million. For the
nine months ended September&nbsp;30, 2013, we reported a loss of approximately $150.8 million and we had an accumulated deficit at September&nbsp;30, 2013 of $898.5 million. For the nine months ended September&nbsp;30, 2013, net revenue from the
sale of Vascepa based on the MARINE indication was $16.2 million. Given the substantial ongoing cost of the REDUCE-IT cardiovascular outcome study, our current capital resources and the current sales of Vascepa resulting from FDA approval of Vascepa
for use in the MARINE indication, we may not be able to continue the study with our current financial resources and anticipated revenues from Vascepa without the additional revenues that may be available to us from the sale of Vascepa following an
FDA approval of the ANCHOR indication. If we do not receive FDA approval of the ANCHOR indication, we plan to re-evaluate the REDUCE-IT study, including the likelihood of REDUCE-IT providing clinically and commercially useful results, the likelihood
of FDA approval for an expanded indication for Vascepa based on these results and whether it is advisable to continue or discontinue the study.&nbsp;We anticipate that in any such re-evaluation we will seek further feedback from the FDA.&nbsp;If we
do not receive FDA approval of the ANCHOR indication and do not continue the ongoing REDUCE-IT trial or our development of AMR102, our ability to generate revenue now and over the next several years will be substantially dependent on sales of
Vascepa resulting from FDA approval of Vascepa for use in the MARINE indication. Accordingly, our prospects for substantially increasing future revenue from sales of Vascepa beyond what might be expected from the MARINE indication labeling alone
will be substantially diminished. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are dependent upon the success of Vascepa, which we launched commercially in the
MARINE indication in January 2013. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result of our reliance on a single product and our primary focus on the U.S.
market in the near-term, much of our near-term results and value as a company depends on our ability to execute our commercial strategy for Vascepa in the United States, which we only recently launched in January 2013. If commercialization efforts
for Vascepa in the MARINE indication or, if approved, the ANCHOR indication, are not successful, our business will be materially and adversely affected. Even if we are able to develop additional products from our research and development efforts,
the development time cycle for products typically takes several years. This restricts our ability to respond to adverse business conditions for Vascepa. If we are not successful in developing any future product or products, or if there is not
adequate demand for Vascepa or the market for such product develops less rapidly than we anticipate, we may not have the ability to effectively shift our resources to the development of alternative products or do so in a timely manner without
suffering material adverse effects on our business. As a result, the lack of alternative products we develop could constrain our ability to generate revenues and achieve profitability. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>*We launched Vascepa in the MARINE indication in the United States in January 2013
with our own, newly established sales and marketing teams and distribution channels and we may not be successful. Historical results may not be consistent with or predictive of future results.</I></B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In late January 2013, we began selling and marketing Vascepa in the United States through our own, newly established sales and marketing
teams and through a newly established third-party commercial distribution infrastructure. We hired key personnel in these areas over the last several years and hired and trained a professional sales force in early January 2013. On October&nbsp;22,
2013, following an FDA advisory committee recommendation against approval for the ANCHOR indication, we announced a plan to reduce our workforce and our team of sales professionals in half. The commercial launch of a new pharmaceutical product is a
complex undertaking for a company to manage, and we have very limited experience as a company operating in this area. Factors related to building and managing our own sales and marketing organization that can inhibit our efforts to successfully
commercialize Vascepa on our own include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our inability to attract and retain adequate numbers of effective sales and marketing personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our inability to adequately train our sales and marketing personnel, in particular as it relates to various healthcare regulatory requirements
applicable to the marketing and sale of pharmaceutical products, and our inability to adequately monitor compliance with these requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the inability of our new sales personnel, working for us as a new market entrant, to obtain access to or persuade adequate numbers of physicians to
prescribe Vascepa; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effect of our recent reduction in force on our ability to contact potential purchasers of Vascepa in an efficient manner;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more
extensive product lines; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unforeseen costs and expenses associated with operating a new independent sales and marketing organization. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we believe that investors should view with caution both the results for the nine months ended September&nbsp;30, 2013, as
data for this limited period may not be representative of a trend consistent with the results presented or otherwise predictive of future results, especially in light of the recent negative advisory committee vote and the approximately 50% reduction
in our sales force. We commenced our commercial launch of Vascepa on January&nbsp;28, 2013. Accordingly, there is a very limited amount of information available at this time to determine the actual number of total prescriptions for Vascepa. We
believe investors should consider our results for the nine months ended September&nbsp;30, 2013 together with results over several future quarters, or longer, before making an assessment about potential future performance. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the factors identified above, seasonal fluctuations in pharmaceutical sales, for example, may affect future prescription
trends of Vascepa. Moreover, in accordance with our revenue recognition policy and U.S. Generally Accepted Account Principles, or GAAP, until we have more experience with the commercialization of Vascepa and can reasonably estimate any product
returns, we plan to recognize revenue based on the resale of Vascepa for the purposes of filling prescriptions, and not based on sales from us to such distributors. Accordingly, because of our limited selling history, during the nine months ended
September&nbsp;30, 2013, we only recognized revenue on product that we could substantiate being resold by retailers, such as pharmacies, for purposes of filling prescriptions. These prescription data may differ from the data reported by third
parties. The value of product shipped to distributors but not resold by the distributors to retailers has been deferred until we have evidence that the product was resold by retailers or until we gain sufficient history with our customers to be able
to estimate product returns. This is the case even where invoices for such shipments have been collected in full. From launch through September&nbsp;30, 2013, the Company had experienced a deminimus quantity of product returns. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have to compete with other pharmaceutical and life sciences companies to recruit, hire, train and retain sales and marketing
personnel, and turnover in our sales force and marketing personnel following our recent approximately 50% worldwide reduction in force could negatively affect sales of Vascepa. If we are not successful in our efforts to market and sell Vascepa on
our own, market acceptance of Vascepa may be harmed, our anticipated revenues will be materially and negatively affected, and we may need additional funding or seek a strategic licensing or co-promotion transaction as a means of raising additional
funds. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>*Vascepa may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and
others in the medical community necessary for commercial success. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We only recently began marketing and selling
Vascepa for use in the MARINE indication in January 2013. Vascepa may fail to&nbsp;gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. If Vascepa does not achieve an adequate level of
acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of Vascepa for the MARINE indication and any future approved indications will depend on a number of factors, including:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the perceived efficacy, safety and potential advantages of Vascepa, as compared to alternative treatments; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to offer Vascepa for sale at competitive prices; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">convenience and ease of administration compared to alternative treatments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope, effectiveness and strength of product education, marketing and distribution support, including our sales and marketing team (which was
affected by our recent reduction in force); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">publicity concerning Vascepa or competing products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sufficient third-party coverage or reimbursement; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the actual efficacy of the product and the prevalence and severity of any side effects, including any limitations or warnings contained in
Vascepa&#146;s approved labeling.</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>*We may not be able to compete effectively against our
competitors&#146; pharmaceutical products.</I></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The pharmaceutical industry is highly competitive. In attempting to
achieve the widespread commercialization of Vascepa, we will face competition to the extent other pharmaceutical companies have on the market, or are able to develop, products for the treatment of similar indications. Potential competitors in this
market include companies with greater experience in commercializing pharmaceutical products, and greater resources and name recognition than we have. Furthermore, to the extent we are able to acquire or develop additional marketable products in the
future, such products will compete with a variety of other products within the United States or elsewhere, possibly including established drugs and major brand names and also generic versions of these products. Competitive factors, including generic
competition, could force us to lower prices or could result in reduced sales. In addition, new products developed by others could emerge as competitors to our future products. Products based on new technologies or new drugs could render our products
obsolete or uneconomical. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The success of Vascepa and any of our future products will also depend in large part on the
willingness of physicians to prescribe these products to their patients. Vascepa will, and our future products may, compete against products that have achieved broad recognition and acceptance among medical professionals. In order to achieve an
acceptable level of prescriptions for Vascepa or any future product, we must be able to meet the needs of both the medical community and end users with respect to cost, efficacy and other factors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our potential competitors both in the United States and Europe include large, well-established pharmaceutical companies, specialty
pharmaceutical sales and marketing companies, and specialized cardiovascular treatment companies. These companies include GlaxoSmithKline plc, which currently markets Lovaza, a prescription-only omega-3 fatty acid indicated for patients with severe
hypertriglyceridemia, and AbbVie, Inc., which currently markets Tricor and Trilipix for the treatment of severe hypertriglyceridemia and mixed dyslipidemia and Niaspan, which is primarily used to raise HDL-C, but is also used to lower triglycerides.
In March 2011, Pronova BioPharma Norge AS, now owned by BASF, which owns the patents for Lovaza, entered into an agreement with Apotex Corp. and Apotex Inc. to settle their patent litigation in the United States related to Lovaza. Pursuant to the
terms of the settlement agreement, Pronova/BASF granted Apotex a license to enter the United States market with a generic version of Lovaza in the first quarter of 2015, or earlier depending on circumstances. We expect Apotex to compete against us
as well. In addition, in April 2009, Pronova /BASF filed a patent infringement lawsuit in Delaware against Teva Pharmaceuticals USA Inc and Par Pharmaceutical Inc, to prevent them from bringing out a generic version of Lovaza. In September 2013,
U.S. Court of Appeals for the Federal Circuit ruled that one of these patents was invalid. Pronova/BASF appealed this decision in October 2013. Because the other patent has expired, this decision could potentially clear the way for third parties to
market a generic version of the product. Other companies are also seeking to introduce generic versions of Lovaza. These competitors have greater resources than we do, including financial, product development, marketing, personnel and other
resources. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we are aware of other pharmaceutical companies that are developing products that, if approved and
marketed, would compete with Vascepa.&nbsp;These include a free fatty acid form of omega-3 (comprised of 55% EPA and 20% DHA) developed by Omthera Pharmaceuticals, which in April 2012 announced its top-line Phase&nbsp;3 clinical trial results. In
July 2013, Omthera Pharmaceuticals announced the submission of an NDA to the U.S. Food and Drug Administration, or FDA, seeking approval of its drug candidate for the treatment of severe hypertriglyceridemia. Later in July 2013, AstraZeneca PLC
acquired Omthera Pharmaceuticals. We expect AstraZeneca will utilize its substantial commercial resources to seek to market Omthera Pharmaceuticals&#146; product, if approved. We also understand that another company, Trygg Pharma AS, has completed a
Phase 3 study of an omega-3 based drug candidate for severe hypertriglyceridemia, but we believe Trygg has not yet announced results from that study. It is possible that Trygg Pharma has filed for FDA approval of its product candidate. In addition,
Acasti Pharma, a subsidiary of Neptune Technologies&nbsp;&amp; Bioresources Inc., announced in late 2012 that it intends to conduct a Phase 3 clinical program to assess the safety and efficacy of its omega-3 prescription drug candidate derived from
krill oil for the treatment of hypertriglyceridemia. We believe </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
Resolvyx Pharmaceuticals and Catabasis Pharmaceuticals are also developing potential treatments for hypertriglyceridemia based on omega-3 fatty acids but, to our knowledge, neither has initiated
a Phase 2 clinical trial of its product. In addition, we are aware that Matinas BioPharma, Inc. is developing an omega-3-based therapeutic for the treatment of severe hypertriglyceridemia and mixed dyslipidemia. Matinas BioPharma, Inc. has reported
that it is preparing to file an Investigational New Drug Application with the FDA and conduct a human study in 2013. Isis Pharmaceuticals recently announced favorable Phase 2 results of ISIS-APOCIII</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">Rx</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">, a drug candidate administered through weekly subcutaneous
injections,&nbsp;in patients with high triglycerides and type 2 diabetes. Isis is also evaluating ISIS-APOCIII</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">Rx</SUB></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;in a separate Phase 2 study in patients with moderate to severe high triglycerides and has announced plans to report data from this study in the summer of 2013. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>*Competitors may seek approval of generic versions of Vascepa.</I></B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2013, the FDA published draft guidance for companies that may seek to develop generic versions of Vascepa. If an application for
a generic version of Vascepa were filed and if new chemical entity, or NCE, exclusivity is not granted to Vascepa, the FDA may accept the filing for review and we would likely engage in costly litigation with the applicant to protect our patent
rights. If the generic filer is ultimately successful in patent litigation against us, meets the requirements for a generic version of Vascepa to the satisfaction of the FDA (after any applicable regulatory exclusivity period and, typically, the
litigation-related 30-month stay period expires), and is able to supply the product in significant commercial quantities, the generic company could, with the market introduction of a generic version of Vascepa, limit our U.S. sales, which would have
an adverse impact on our business and results of operations. In addition, even if a competitor&#146;s effort to introduce a generic product is ultimately unsuccessful, the perception that such development is in progress and/or news related to such
progress could materially affect the perceived value of our company and its stock price. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Vascepa is a prescription-only
omega-3 fatty acid. Omega-3 fatty acids are also marketed by other companies as non-prescription dietary supplements. As a result, Vascepa would be subject to non-prescription competition and consumer substitution.</I></B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our only current product, Vascepa, is a prescription-only omega-3 fatty acid. Mixtures of omega-3 fatty acids are naturally occurring
substances contained in various foods, including fatty fish. Omega-3 fatty acids are also marketed by others as non-prescription dietary supplements. We cannot be sure physicians will view the pharmaceutical grade purity of Vascepa as having a
superior therapeutic profile to naturally occurring omega-3 fatty acids and dietary supplements. To the extent the price of Vascepa is significantly higher than the prices of commercially available omega-3 fatty acids marketed by other companies as
dietary supplements (through that lack of coverage by insurers or otherwise), physicians may recommend these commercial alternatives instead of writing prescriptions for Vascepa or patients may elect on their own to take commercially available
omega-3 fatty acids. Either of these outcomes may adversely impact our results of operations by limiting how we price our product and limiting the revenue we receive from the sale of Vascepa due to reduced market acceptance. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are not successful marketing and selling Vascepa on our own, we may need to find collaborative partners to help market and
sell the product.</I></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are not successful marketing and selling Vascepa on our own, we may need to find
collaborative partners to help market and sell the product or otherwise outsource these functions to third parties. Until such time as we choose to, and actually do, complete a strategic transaction with a third party to market and sell Vascepa, if
ever, we will continue to market and sell Vascepa on our own. We are actively exploring collaboration opportunities for the continued marketing and sale of Vascepa as we approach the potential approval of Vascepa in the ANCHOR indication, assuming
its regulatory approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may choose not to enter into a collaboration to help market and sell Vascepa or, if we determine
such a collaborative partner is necessary we may not be successful in finding a collaborative partner, or may be delayed in doing so. We face significant competition in seeking appropriate collaborators, and these collaborations are complex and
time-consuming to negotiate and document. We may not be able to negotiate collaborations on acceptable terms, or at all. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and
attention to sell and market our products effectively. If that were to occur, depending on Vascepa revenues, we may have to curtail the continued development of Vascepa for approval for additional indications or increase our planned expenditures and
undertake additional development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, depending on Vascepa&#146;s revenues, we may need to obtain
additional capital, which may not be available to us on acceptable terms, or at all, or which may not be possible due to our other financing arrangements, including our Purchase and Sale Agreement with BioPharma Secured Debt Fund II Holdings Cayman,
L.P., or BioPharma. If we do not generate sufficient funds from the sale of Vascepa or, to the extent needed to supplement funds generated from product revenue, cannot raise sufficient funds, we may not be able to devote resources sufficient to
market and sell Vascepa on our own in a manner required to realize the full market potential of Vascepa. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The commercial value to us of the MARINE and ANCHOR indications may be smaller than we
anticipate.</I></B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There can be no assurance as to the adequacy for commercial success of the scope and breadth of the MARINE
indication or, if approved, the ANCHOR indication. Even if we obtain marketing approval for additional indications, the FDA may impose restrictions on the product&#146;s conditions for use, distribution or marketing and in some cases may impose
ongoing requirements for post-market surveillance, post-approval studies or clinical trials. Also, with regard to the MARINE indication and any other indications for which we may gain approval, the number of actual patients with the condition
included in such approved indication may be smaller than we anticipate. If any such approved indication is narrower than we anticipate, the market potential for our product would suffer. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>*Our products will be subject to extensive post-approval government regulation.</I></B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Once a product candidate receives FDA marketing approval, numerous post-approval requirements apply. Among other things, the holder of an
approved NDA is subject to periodic and other monitoring and reporting obligations enforced by the FDA and other regulatory bodies, including obligations to monitor and report adverse events and instances of the failure of a product to meet the
specifications in the approved application. Application holders must also submit advertising and other promotional material to regulatory authorities and report on ongoing clinical trials. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With respect to sales and marketing activities including direct-to-consumer advertising and promotional activities involving the
Internet, advertising and promotional materials must comply with FDA rules in addition to other applicable federal and local laws in the United States and in other countries. Industry-sponsored scientific and educational activities also must comply
with FDA and other requirements. In the United States, the distribution of product samples to physicians must comply with the requirements of the U.S. Prescription Drug Marketing Act. Manufacturing facilities remain subject to FDA inspection and
must continue to adhere to the FDA&#146;s current good manufacturing practice requirements, or cGMPs. Application holders must obtain FDA approval for product and manufacturing changes, depending on the nature of the change. We also are subject to
the new federal transparency requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, which require manufacturers of certain drugs, devices, biologics, and medical supplies to
report to the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, information related to payments and other transfers of value to physicians and teaching hospitals and physician ownership and investment interests. We may also be subject,
directly or indirectly through our customers and partners, to various fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute, U.S. False Claims Act, and similar state laws, which impact, among other things, our proposed
sales, marketing, and scientific/educational grant programs. If we participate in the U.S. Medicaid Drug Rebate Program, the Federal Supply Schedule of the U.S. Department of Veterans Affairs, or other government drug programs, we will be subject to
complex laws and regulations regarding reporting and payment obligations. All of these activities are also potentially subject to U.S. federal and state consumer protection and unfair competition laws. Similar requirements exist in many of these
areas in other countries. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depending on the circumstances, failure to meet these post-approval requirements can result in
criminal prosecution, fines or other penalties, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, or refusal to allow us to enter into supply contracts,
including government contracts. In addition, even if we or our potential partners comply with FDA and other requirements, new information regarding the safety or effectiveness of a product could lead the FDA to modify or withdraw a product approval.
Adverse regulatory action, whether pre- or post-approval, can potentially lead to product liability claims and increase our product liability exposure. We or our potential partners must also compete against other products in qualifying for coverage
and reimbursement under applicable third party payment and insurance programs. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>*The commercial value of Vascepa may be
negatively affected by the advisory committee recommendation against approval of Vascepa in the ANCHOR indication or any subsequent rejection of the pending FDA application with the FDA for the use of Vascepa in the ANCHOR indication.</I></B>
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Though we are restricted from promoting Vascepa under applicable law for any indication other than the FDA-approved MARINE
indication, healthcare professionals are not restricted from prescribing Vascepa for such so-called off-labeled uses. A significant amount of the sales of Vascepa may, in fact, be attributable to so-called off-labeled uses of the drug. We expect
that among the off-labeled uses of Vascepa are uses that would fall into, or be closely related to, the proposed ANCHOR indication. The recent negative recommendation of the advisory committee meeting against approval of Vascepa in the ANCHOR
indication, the recent rescission by the FDA of the ANCHOR SPA, and/or a subsequent decision by the FDA to not approve Vascepa in the ANCHOR indication may negatively and materially affect the perception of the utility of Vascepa for use in the
ANCHOR indication or for other purposes and thus negatively and materially affect sales of Vascepa. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The FDA and other regulatory agencies strictly regulate the promotional claims that
may be made about prescription products. If we are found to have improperly promoted off-label uses, we may become subject to significant fines and other liability.</I></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by
the FDA or such other regulatory agencies as reflected in the product&#146;s approved labeling. Even though we received FDA marketing approval for Vascepa for the MARINE indication, physicians may still prescribe Vascepa to their patients for use in
the treatment of conditions that are not included as part of the indication statement in our FDA-approved Vascepa label. If we are found to have promoted such off-label uses, we may become subject to significant government fines and other related
liability. For example, the Federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that
companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, incentives exist under applicable laws that encourage competitors, employees and physicians to report violations of rules governing promotional activities for pharmaceutical products. These
incentives could lead to so-called whistleblower lawsuits as part of which such persons seek to collect a portion of moneys allegedly overbilled to government agencies due to, for example, promotion of pharmaceutical products beyond labeled claims.
These incentives could also lead to suits that we have mischaracterized a competitor&#146;s product in the marketplace and may, as a result, be sued for alleged damages to our competitors. Such lawsuits, whether with or without merit, are typically
time-consuming and costly to defend. Such suits may also result in related shareholder lawsuits, which are also costly to defend. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>*The REDUCE-IT cardiovascular outcomes trial may fail to show that Vascepa can reduce major cardiovascular events in an at-risk patient population on statin therapy, and the long-term clinical
results of Vascepa may not be consistent with the clinical results we observed in our Phase 3 clinical trial, in which case our sales of Vascepa may then suffer.</I></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In accordance with the SPA for our MARINE and ANCHOR trials, efficacy was evaluated in these trials compared to placebo at twelve weeks. No placebo-controlled studies have been conducted regarding the
long-term effect of Vascepa on lipids, and no outcomes study has been conducted evaluating Vascepa. The REDUCE-IT study is designed to evaluate the efficacy of Vascepa in reducing major cardiovascular events in an at-risk patient population on
statin therapy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outcomes studies of certain other lipid-modifying therapies have failed to achieve the endpoints of such
studies. For example, in 2010, the results of the ACCORD-Lipid trial were published. This trial studied the effect of adding fenofibrate onto open-label simvastatin therapy on cardiovascular outcomes. The addition of fenofibrate did not show any
treatment benefit on cardiovascular outcomes over simvastatin monotherapy in this study. In 2011, the results of the AIM-HIGH trial were published. This trial studied the effect of adding a second lipid-altering agent, extended-release niacin, to
simvastatin therapy on cardiovascular outcomes in people at high risk for cardiovascular events. No significant incremental treatment benefit with extended-release niacin was observed. In addition, in September 2012, researchers published in the
<I>Journal of the American Medical Association, </I>or<I> JAMA, </I>the results of a retrospective meta-analysis of twenty previously conducted studies regarding the use of omega-3 supplements across various patient populations. This meta-analysis
suggested that the use of such supplements was not associated with a lower risk of all-cause death, cardiac death, sudden death, heart attack, or stroke. We believe the results of these studies may not be directly applicable to the use of Vascepa
over time. For instance, the outcomes studies for fenofibrates and niacin were conducted in patient populations in which the majority of patients studied had triglycerides below 200 mg/dL and fenofibrates and niacin are believed to work differently
than Vascepa in the body and do not have as favorable a side-effect profile, and nineteen of the twenty studies included in the JAMA meta-analysis involved the use of omega-3 supplements containing a mixture of EPA and DHA, and most were evaluated
at relatively lower doses. In addition, in May 2013, <I>The New England Journal of Medicine</I> published the results of an outcome study of 1 gram per day of an omega-3 acid ethyl ester composition. In that study, the composition failed to show a
benefit in reducing the rate of death from cardiovascular causes or hospitalization for cardiovascular causes when administered to patients with cardiovascular risk factors under different study conditions than in the REDUCE-IT study. Vascepa is
comprised of highly-pure ethyl-EPA, and has been approved by the FDA for use in patients with severe hypertriglyceridemia at a dose of 4 grams per day. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The only other outcomes study involving the use of a highly-pure formulation of ethyl-EPA, called the Japan EPA Lipid Intervention Study (JELIS), suggested that use of a highly-pure formulation of
ethyl-EPA in Japan, when used in conjunction with statins, reduced cardiovascular events by 19% compared to the use of statins alone. However, there are several limitations to the JELIS study. First, the patient population was exclusively Japanese,
the majority of the participants were women, and at baseline patients had a much higher LDL, limiting its generalizability to the intended target population. Second, a low dose of statins was used. It is unknown whether the positive treatment
effects would have persisted if these patients had been optimally treated with statins using contemporary LDL targets in the United States. Third, JELIS was an open-label trial, which could influence patient and
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
physician behavior and reporting of symptoms, decisions regarding hospitalization, and referral of events for adjudication. This may be particularly relevant since hospitalizations for unstable
angina was a primary contributor of the overall positive result, and is considered a softer endpoint than fatal cardiovascular events. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Although we believe the results of the JAMA meta-analysis and other studies are not directly applicable to the potential long-term clinical experience with Vascepa, there can be no assurance that the
endpoints of the REDUCE-IT cardiovascular outcomes study will be achieved or that the lipid-modifying effects of Vascepa in REDUCE-IT or any other study of Vascepa will not be subject to variation beyond twelve weeks. If the REDUCE-IT trial fails to
achieve its clinical endpoints or if the results of these long-term studies are not consistent with the 12-week clinical results, it could prevent us from expanding the label of any approved product or even call into question the efficacy of any
approved product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may not be successful in developing or marketing future products if we cannot meet the extensive
regulatory requirements of the FDA and other regulatory agencies for quality, safety and efficacy.</I></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The success of our
research and development efforts is dependent in part upon our ability, and the ability of our partners or potential partners, to meet regulatory requirements in the jurisdictions where we or our partners or potential partners ultimately intend to
sell such products once approved. The development, manufacture and marketing of pharmaceutical products are subject to extensive regulation by governmental authorities in the United States, the European Union, Japan and elsewhere. In the United
States, the FDA generally requires pre-clinical testing and clinical trials of each drug to establish its safety and efficacy and extensive pharmaceutical development to ensure its quality before its introduction into the market. Regulatory
authorities in other jurisdictions impose similar requirements. The process of obtaining regulatory approvals is lengthy and expensive and the issuance of such approvals is uncertain. The commencement and rate of completion of clinical trials and
the timing of obtaining marketing approval from regulatory authorities may be delayed by many factors, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the lack of efficacy during clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the inability to manufacture sufficient quantities of qualified materials under cGMPs for use in clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">slower than expected rates of patient recruitment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the inability to observe patients adequately after treatment; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in regulatory requirements for clinical or preclinical studies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the emergence of unforeseen safety issues in clinical or preclinical studies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay, suspension, or termination of a trial by the institutional review board responsible for overseeing the study at a particular study site;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unanticipated changes to the requirements imposed by regulatory authorities on the extent, nature or timing of studies to be conducted on quality,
safety and efficacy; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">government or regulatory delays or &#147;clinical holds&#148; requiring suspension or termination of a trial. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if we obtain positive results from early stage pre-clinical or clinical trials, we may
not achieve the same success in future trials. Clinical trials that we or potential partners conduct may not provide sufficient safety and efficacy data to obtain the requisite regulatory approvals for product candidates. The failure of clinical
trials to demonstrate safety and efficacy for our desired indications could harm the development of that product candidate as well as other product candidates, and our business and results of operations would suffer. For example, the efficacy
results of our Vascepa Phase 3 clinical trials for the treatment of Huntington&#146;s disease were negative. As a result, we stopped development of that product candidate, revised our clinical strategy and shifted our focus to develop Vascepa for
use in the treatment of cardiovascular disease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any approvals that are obtained may be limited in scope, may require
additional post-approval studies or may require the addition of labeling statements focusing on product safety that could affect the commercial potential for our product candidates. Any of these or similar circumstances could adversely affect our
ability to earn revenues from the sale of such products. Even in circumstances where products are approved by a regulatory body for sale, the regulatory or legal requirements may change over time, or new safety or efficacy information may be
identified concerning a product, which may lead to the withdrawal of a product from the market or similar use restrictions. The discovery of previously unknown problems with a product or in connection with the manufacturer of products may result in
restrictions on that product or manufacturer, including withdrawal of the product from the market, which would have a negative impact on our potential revenue stream. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Legislative or regulatory reform of the health care system in the United States and foreign jurisdictions may affect our ability to profitably sell Vascepa.</I></B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to commercialize our future products successfully, alone or with collaborators, will depend in part on the extent to which
coverage and reimbursement for the products will be available from government and health administration authorities, private health insurers and other third-party payors. The continuing efforts of the U.S. and foreign governments, insurance
companies, managed care organizations and other payors of health care services to contain or reduce health care costs may adversely affect our ability to set prices for our products which we believe are fair, and our ability to generate revenues and
achieve and maintain profitability. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Specifically, in both the United States and some foreign jurisdictions, there have been a
number of legislative and regulatory proposals to change the health care system in ways that could affect our ability to sell our products profitably. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and
Education Reconciliation Act, or collectively the PPACA, enacted in March 2010, substantially changes the way healthcare is financed by both governmental and private insurers. Among other cost-containment measures, PPACA establishes: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">An annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A new Medicare Part D coverage gap discount program, in which pharmaceutical manufacturers who wish to have their drugs covered under Part D must offer
discounts to eligible beneficiaries during their coverage gap period; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A new formula that increases the rebates a manufacturer must pay under the Medicaid Drug Rebate Program. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect further federal and state proposals and health care reforms to continue to be proposed by legislators, which could limit the
prices that can be charged for the products we develop and may limit our commercial opportunity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The continuing efforts of
government and other third-party payors to contain or reduce the costs of health care through various means may limit our commercial opportunity. It will be time consuming and expensive for us to go through the process of seeking coverage and
reimbursement from Medicare and private payors. Our products may not be considered cost effective, and government and third-party private health insurance coverage and reimbursement may not be available to patients for any of our future products or
sufficient to allow us to sell our products on a competitive and profitable basis. Our results of operations could be adversely affected by PPACA and by other health care reforms that may be enacted or adopted in the future. In addition, increasing
emphasis on managed care in the United States will continue to put pressure on the pricing of pharmaceutical products. Cost control initiatives could decrease the price that we or any potential collaborators could receive for any of our future
products and could adversely affect our profitability. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In some foreign countries, including major markets in the European Union and Japan, the
pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take 6 to 12 months or longer after the receipt of regulatory marketing approval for a product. To
obtain reimbursement or pricing approval in some countries, we may be required to conduct a pharmacoeconomic study that compares the cost-effectiveness of Vascepa to other available therapies. Such pharmacoeconomic studies can be costly and the
results uncertain. Our business could be harmed if reimbursement of our products is unavailable or limited in scope or amount or if pricing is set at unsatisfactory levels. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>As we evolve from a company primarily involved in research and development to a company also focused on establishing an infrastructure for commercializing Vascepa, we may encounter difficulties in
managing our growth and expanding our operations successfully.</I></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We only recently hired and trained a professional
sales force of approximately 275 sales representatives and commenced our commercial launch of Vascepa in the MARINE indication in the United States in early January 2013. The process of establishing a commercial infrastructure is difficult,
expensive and time-consuming. Our recent worldwide reduction in force, which included the termination of approximately 50% of the then-staffed sales force, will likely make this process more difficult. As our operations expand, we expect that we
will need to manage additional relationships with various collaborative partners, suppliers and other third parties. Future growth will impose significant added responsibilities on members of management, including the need to identify, recruit,
maintain and integrate additional employees. Our future financial performance and our ability to commercialize Vascepa and to compete effectively will depend, in part, on our ability to manage our future growth effectively. To that end, we must be
able to manage our development efforts effectively, and hire, train, integrate and retain additional management, administrative and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish any of
them could prevent us from successfully growing our company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to our Reliance on Third Parties </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>*If we do not realize the expected benefits from recent worldwide reductions in our workforce and from future cost savings
initiatives that we may implement, the value of our company and our assets and the market price of our ADSs could materially decline.</I></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;22, 2013, we announced a plan to reduce our worldwide workforce by approximately 50%. We cannot guarantee that we will be able to realize the cost savings and other anticipated benefits
from our recent worldwide reductions in force. If we experience excessive unanticipated inefficiencies or incremental costs in connection with restructuring activities, such as unanticipated inefficiencies caused by reducing headcount, we may be
unable to meaningfully realize cost savings and we may incur expenses in excess of what we anticipate. Either of these outcomes could prevent us from meeting our strategic objectives and could adversely affect our results of operations and financial
condition. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>*Our supply of product for commercial supply and clinical trials is dependent upon relationships with third
party manufacturers and key suppliers.</I></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have no in-house manufacturing capacity and rely on contract manufacturers
for our clinical and commercial product supply. We cannot assure you that we will successfully manufacture any product we may develop, either independently or under manufacturing arrangements, if any, with our third party manufacturers. Moreover, if
any manufacturer should cease doing business with us or experience delays, shortages of supply or excessive demands on their capacity, we may not be able to obtain adequate quantities of product in a timely manner, or at all. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any manufacturing problem, natural disaster affecting manufacturing facilities, or the loss of a contract manufacturer could be
disruptive to our operations and result in lost sales. Additionally, we will be reliant on third parties to supply the raw materials needed to manufacture our potential products. Any reliance on suppliers may involve several risks, including a
potential inability to obtain critical materials and reduced control over production costs, delivery schedules, reliability and quality. Any unanticipated disruption to future contract manufacture caused by problems at suppliers could delay shipment
of products, increase our cost of goods sold and result in lost sales. If our suppliers were unable to supply us with adequate supply of ethyl-EPA it would have a material adverse effect on our ability to continue to commercialize Vascepa.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We initially purchased all of our supply of the bulk compound (ethyl-EPA), which constitutes
the only active pharmaceutical ingredient, or API, of Vascepa, from a single supplier, Nisshin Pharma, or Nisshin, located in Japan. Nisshin was approved by the FDA as a Vascepa API supplier as part of our FDA marketing approval for the MARINE
indication in July 2012. In April 2013, we announced the approval by the FDA of Chemport, Inc. and BASF (formerly Equateq Limited) as additional Vascepa API suppliers. We now plan to use and purchase additional commercial supply from Chemport and
BASF in addition to Nisshin. Each of the API manufacturers obtains supply of the key raw material to manufacture API from other third party sources of supply. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">While we have contractual freedom to source the API for Vascepa and have entered into supply agreements with multiple suppliers who also rely on other third party suppliers of the key raw material to
manufacture the API for Vascepa, Nisshin currently supplies a large majority of our API for Vascepa. Our strategy in adding API suppliers beyond Nisshin has been to expand manufacturing capacity and to partially mitigate the risk of reliance on one
supplier Both Chemport and BASF continue to expand their API manufacturing capacity and bring to three the number of qualified worldwide suppliers of API for Vascepa. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Also, in December 2012 we announced the addition of an exclusive consortium of companies led by Slanmhor Pharmaceutical, Inc., or Slanmhor, to our planned API global supply chain for Vascepa. Slanmhor was
spun-out from Ocean Nutrition Canada, or ONC, prior to the May 2012 acquisition of ONC by Royal DSM N.V., a global leader in life sciences and materials sciences. Amarin now has a total of four suppliers for Vascepa API to utilize in supporting the
global commercialization of Vascepa, subject to appropriate regulatory approval of Slanmhor. We intend to submit an additional sNDA for Slanmhor after it successfully completes the qualification process. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expanding manufacturing capacity and qualifying such capacity is difficult and subject to numerous regulations and other operational
challenges. The resources of our suppliers are limited and costs associated with projected expansion and qualification can be significant. The resources of our suppliers vary. For example, Chemport, which was approved as one of our API supplier in
April 2013, is a privately-held company and their commitment to Vascepa supply has required them to seek additional resources. There can be no assurance that the expansion plans of any of our suppliers will be successful. Our aggregate capacity to
produce API is dependent upon the qualification of our API suppliers. Each of our API suppliers has outlined plans for potential further capacity expansion. If no additional API supplier is approved by the FDA, our API supply will be limited to the
API we purchase from Nisshin, Chemport and BASF. If our third party manufacturing capacity is not expanded and compliant with application regulatory requirements, we may not be able to supply sufficient quantities of Vascepa to meet anticipated
demand. We cannot assure you that we can contract with any future manufacturer on acceptable terms or that any such alternative supplier will not require capital investment from us in order for them to meet our requirements. Alternatively, our
purchase of supply may exceed actual demand for Vascepa. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently rely on two suppliers, Banner and Catalent, for the
encapsulation of API for all capsules of Vascepa. While we have contractual freedom to source the API encapsulation for Vascepa elsewhere, Banner and Catalent are the only encapsulators approved by the FDA for encapsulation of API for Vascepa. There
can be no guarantee that additional other suppliers with which we have contracted to encapsulate API will be qualified to manufacture the product to our specifications or that these and any future suppliers will have the manufacturing capacity to
meeting anticipated demand for Vascepa. We cannot assure you that we can contract with any future manufacturer on acceptable terms or that any such alternative supplier will not require capital investment from us in order for them to meet our
requirements. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>*We may not be able to maintain our exclusivity with our third-party Vascepa suppliers if we do not meet
minimum purchase obligations due to lower than anticipated sales of Vascepa.</I></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our agreements with our suppliers
include minimum purchase obligations and limited exclusivity provisions based on such minimum purchase obligations. If we do not meet the respective minimum purchase obligations in our supply agreements, our suppliers will be free to sell the active
pharmaceutical ingredient of Vascepa to potential generic competitors of Vascepa. While we anticipate that potential FDA regulatory exclusivity and intellectual property barriers to entry will be the primary means to protect the commercial potential
of Vascepa, the availability of Vascepa active pharmaceutical ingredient from our suppliers to our potential competitors would make our competitors&#146; entry into the market easier and more attractive. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We do not have sufficient experience with the commercial sale of Vascepa, and such inexperience may cause us to purchase too much or
not enough supply to satisfy actual demand, which could have a material adverse effect on our financial results and financial condition.</I></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our agreements with our suppliers include minimum purchase obligations and limited exclusivity provisions. These purchases are generally made on the basis of rolling twelve-month forecasts which in part
are binding on us and the balance of which are subject to adjustment by us subject to certain limitations. We have no experience with the commercial sale of Vascepa, and as such </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
expectations regarding expected demand may be wrong. We may not purchase sufficient quantities of Vascepa to meet actual demand or our purchase of supply may exceed actual demand. In either case,
such event could have a material adverse effect on our financial results and financial condition. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The manufacture and
packaging of pharmaceutical products such as Vascepa are subject to FDA requirements and those of similar foreign regulatory bodies. If we or our third party manufacturers fail to satisfy these requirements, our product development and
commercialization efforts may be materially harmed.</I></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The manufacture and packaging of pharmaceutical products, such as
Vascepa, are regulated by the FDA and similar foreign regulatory bodies and must be conducted in accordance with the FDA&#146;s current good manufacturing practices, or cGMPs, and comparable requirements of foreign regulatory bodies. There are a
limited number of manufacturers that operate under these cGMPs regulations who are both capable of manufacturing Vascepa and willing to do so. Failure by us or our third party manufacturers to comply with applicable regulations, requirements, or
guidelines could result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, license
revocation, seizures or recalls of product, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business. For example, Nisshin plans to expand its capacity to supply API to us by further
expanding their current facility. If we are not able to manufacture Vascepa to required specifications through Nisshin, Chemport and BASF, or other potential API suppliers, we may be delayed in successfully supplying the product to meet anticipated
demand and our anticipated future revenues and financial results may be materially adversely affected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in the
manufacturing process or procedure, including a change in the location where the product is manufactured or a change of a third party manufacturer, may require prior FDA review and approval of the manufacturing process and procedures in accordance
with the FDA&#146;s cGMPs, or cGMPs. Any new facility may be subject to a pre-approval inspection by the FDA and would again require us to demonstrate product comparability to the FDA. There are comparable foreign requirements. This review may be
costly and time consuming and could delay or prevent the launch of a product. For example, we have plans to file a supplemental NDA to add Slanmhor as an additional API supplier for Vascepa. If Slanmhor cannot establish, to the satisfaction of the
FDA, that it is in substantial compliance with cGMPs, and that the product manufactured at its site meets FDA requirements, we may not be able to manufacture API from that site, our supply of API for Vascepa may be delayed, and our anticipated
future revenues and financial results may be materially adversely affected if such supply cannot be satisfied by our other three API suppliers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Furthermore, the FDA and foreign regulatory agencies require that we be able to consistently produce the API and the finished product in commercial quantities and of specified quality on a repeated basis,
including proven product stability, and document our ability to do so. This requirement is referred to as process validation. This includes stability testing, measurement of impurities and testing of other product specifications by validated test
methods. If the FDA does not consider the result of the process validation or required testing to be satisfactory, the commercial supply of Vascepa may be delayed, or we may not be able to supply sufficient quantities of Vascepa to meet anticipated
demand. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA and similar foreign regulatory bodies may also implement new standards, or change their interpretation and
enforcement of existing standards and requirements, for manufacture, packaging or testing of products at any time. If we are unable to comply, we may be subject to regulatory, civil actions or penalties which could significantly and adversely affect
our business. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We rely on third parties to conduct our clinical trials, and those third parties may not perform
satisfactorily, including failing to meet established deadlines for the completion of such clinical trials.</I></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
reliance on third parties for clinical development activities reduces our control over these activities. However, if we sponsor clinical trials, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the
general investigational plan and protocols for the trials. Moreover, the FDA requires us to comply with standards, commonly referred to as good clinical practices, for conducting, recording, and reporting the results of clinical trials to assure
that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Our reliance on third parties does not relieve us of these responsibilities and requirements.
Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be delayed in
obtaining regulatory approvals for our product candidates and may be delayed in our efforts to successfully commercialize our product candidates for targeted diseases. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to our Intellectual Property and Regulatory Exclusivity </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>*We are dependent on patents, proprietary rights and confidentiality to protect the commercial potential of Vascepa.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because of the significant time and expense involved in developing new products and obtaining regulatory approvals,
it is very important to obtain patent and preserve trade secret protection for new technologies, products and processes. Our ability to successfully implement our business plan will depend in large part on our ability to: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtain, defend and maintain patent protection and market exclusivity for our current and future products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">preserve any trade secrets relating to our current and future products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">acquire patented or patentable products and technologies; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">operate without infringing the proprietary rights of third parties. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of October&nbsp;31, 2013, we had 37 patent applications in the United States that have been either issued or allowed and more than 30
additional patent applications are pending in the United States. Of such 37 allowed and issued applications, we currently have: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 issued U.S. patents directed to a pharmaceutical composition of Vascepa in a capsule that have terms that expire in 2020 and 2030, respectively,
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 issued U.S. patent covering a composition containing highly pure EPA that expires in 2021, </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 U.S. patents covering the use of Vascepa in either the MARINE or anticipated ANCHOR indication that have terms that expire in 2030,
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 additional patent applications for which the United States Patent and Trademark Office, or USPTO, has issued a Notice of Allowance each of which with
terms that expire in 2030 and are related to the use of Vascepa in either the MARINE or anticipated ANCHOR indication, and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 additional patent application for which the USPTO has issued a Notice of Allowance with a term that expires in 2030 related to the use of a
pharmaceutical composition comprised of free fatty acids to treat the ANCHOR patient population. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A Notice of Allowance is
issued after the USPTO makes a determination that a patent can be granted from an application. A Notice of Allowance does not afford patent protection until the underlying patent is issued by the USPTO. In October 2013, we submitted additional
information to the USPTO related to the October&nbsp;16, 2013 FDA advisory committee meeting in all pending patent applications that are related to the use of Vascepa for the ANCHOR indication, including five for which we had already received a
Notice of Allowance.&nbsp;This information has thus far been considered by the USPTO in one of the cases, resulting in a re-issuance of the Notice of Allowance. No assurance can be given that applications with issued notices of allowance will be
issued as patents or that any of our pending patent applications will issue as patents.&nbsp;No assurance can be given that, if and when issued, our patents will prevent competitors from competing with Vascepa. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also pursuing patent applications related to Vascepa in multiple jurisdictions outside&nbsp;the United States. We may be dependent
in some cases upon third party licensors to pursue filing, prosecution and maintenance of patent rights or applications </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
owned or controlled by those parties. It is possible that third parties will obtain patents or other proprietary rights that might be necessary or useful to us. In cases where third parties are
first to invent a particular product or technology, or first to file after various provisions of the America Invents Act of 2011 went into effect on March&nbsp;16, 2013, it is possible that those parties will obtain patents that will be sufficiently
broad so as to prevent us from utilizing such technology or commercializing our current and future products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we
intend to make reasonable efforts to protect our current and future intellectual property rights and to ensure that any proprietary technology we acquire or develop does not infringe the rights of other parties, we may not be able to ascertain the
existence of all potentially conflicting claims. Therefore, there is a risk that third parties may make claims of infringement against our current or future products or technologies. In addition, third parties may be able to obtain patents that
prevent the sale of our current or future products or require us to obtain a license and pay significant fees or royalties in order to continue selling such products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may in the future discover the existence of products that infringe patents that we own or that have been licensed to us. If we were to initiate legal proceedings against a third party to stop such an
infringement, such proceedings could be costly and time consuming, regardless of the outcome. No assurances can be given that we would prevail, and it is possible that, during such a proceeding, our patent rights could be held to be invalid,
unenforceable or both. Although we intend to protect our trade secrets and proprietary know-how through confidentiality agreements with our manufacturers, employees and consultants, we may not be able to prevent parties subject to such
confidentiality agreements from breaching these agreements or third parties from independently developing or learning of our trade secrets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We anticipate that competitors may from time to time oppose our efforts to obtain patent protection for new technologies or to submit patented technologies for regulatory approvals. Competitors may seek
to oppose our patent applications to delay the approval process or to challenge our granted patents, for example, by requesting a reexamination of our patent at the USPTO, or by filing an opposition in a foreign patent office, even if the opposition
or challenge has little or no merit. Such proceedings are generally highly technical, expensive, and time consuming, and there can be no assurance that such a challenge would not result in the narrowing or complete revocation of any patent of ours
that was so challenged. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our issued patents and our pending patents, if and when issued, may not prevent competitors from
competing with Vascepa.</I></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We plan to vigorously defend our rights under issued patents.&nbsp;Other drug companies may
challenge the validity, enforceability, or both of our patents and seek to design its products around our issued patent claims and gain marketing approval for generic versions of Vascepa or branded competitive products based on new clinical
studies.&nbsp;The pharmaceutical industry is highly competitive and many of our competitors have greater experience and resources than we have. Any such competition could undermine sales, marketing and collaboration efforts for Vascepa, and thus
reduce, perhaps materially, the revenue potential for Vascepa. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if we are successful in enforcing our issued patents, we
may incur substantial costs and divert management&#146;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. Patent litigation is costly and time consuming, and we may not have sufficient resources to
bring these actions to a successful conclusion. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>There can be no assurance that any of our pending patent applications
relating to Vascepa or its use will issue as patents.</I></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have filed and are prosecuting numerous families of patent
applications in the United States and internationally with claims designed to protect the proprietary position of Vascepa. For certain of these patent families, we have filed multiple patent applications. Collectively the patent applications include
numerous independent claims and dependent claims. Several of our patent applications contain claims that are based upon what we believe are unexpected and favorable findings from the MARINE and ANCHOR trials. If granted, many of the resulting
granted patents would expire in 2030 or beyond. However, no assurance can be given that any of our pending patent applications will be granted or, if they grant, that they will prevent competitors from competing with Vascepa. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Securing patent protection for a product is a complex process involving many legal and factual questions. The patent applications we have
filed in the United States and internationally are at varying stages of examination, the timing of which is outside our control. The process to getting a patent granted can be lengthy and claims initially submitted are often modified in order to
satisfy the requirements of the patent office. This process includes written and public communication with the patent office. The process can also include direct discussions with the patent examiner. There can be no assurance that the patent office
will accept our arguments with respect to any patent application or with respect to any claim therein. The timing of the patent review process is independent of and has no effect on the timing of the FDA&#146;s review of our NDA or sNDA submissions.
We cannot predict the timing or results of any patent application. In addition, we may elect to submit, or the patent office may require, additional evidence to support certain of the claims we are pursuing. Furthermore, third parties may attempt to
submit publications for consideration by the patent office during </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
examination of our patent applications. Providing such additional evidence and publications could prolong the patent office&#146;s review of our applications and result in us incurring additional
costs. We cannot be certain what commercial value any granted patent in our patent estate will provide to us. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>*If
Vascepa is not granted new chemical entity exclusivity protection from the FDA our business may be materially harmed.</I></B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Sections 505(c)(3)(E)(ii) and 505(j)(5)(F)(ii) of the Food Drug and Cosmetic Act, or FDCA, as amended by the Drug Price Competition
and Patent Term Restoration Act of 1984, as amended, or the Hatch-Waxman Amendments, a drug that is granted regulatory approval may be eligible for five years of marketing exclusivity in the United States following regulatory approval if that drug
is classified as a new chemical entity, or NCE. A drug can be classified as an NCE if the FDA has not previously approved any other drug containing the same active moiety. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The FDA typically publishes a determination on the marketing exclusivity of recently approved products in a cumulative supplement to its&nbsp;<I>Approved Drug Products with Therapeutic Equivalence
Evaluations</I>, also known as the Orange Book, mid-month in the month following the drug&#146;s approval. Vascepa was approved by the FDA in July 2012, but we have not yet been informed of a determination by the FDA on our pending exclusivity
request for Vascepa. Since prior to FDA approval of the Vascepa new drug application, we have had an active dialogue with the FDA related to our marketing exclusivity request for Vascepa, which requested NCE status for Vascepa. We have repeatedly
followed up with the FDA seeking a determination. While we continue to believe our arguments in support of an NCE determination for Vascepa are strong, the FDA may not agree with our arguments. Based on our discussions with the FDA, we have not been
told and do not know what determination the FDA will reach regarding the pending exclusivity request for Vascepa or when the FDA will make such determination. Based on our communications with the FDA, we cannot make a reliable prediction as to when
the FDA will communicate a determination on the matter. There can be no assurance that Vascepa will be granted NCE exclusivity, or that the FDA will make a determination on the pending exclusivity request in a timely manner. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NCE marketing exclusivity, if granted, would preclude approval during the five-year exclusivity period of certain 505(b)(2) applications
or abbreviated new drug applications submitted by another company for another version of the drug. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. In this case,
Amarin may be afforded the benefit of a 30-month stay against the launch of such a competitive product that would extend from the end of the five-year exclusivity period, and may also be afforded other extensions under applicable regulations,
including a six-month pediatric exclusivity extension or a judicial extension if applicable requirements are met. If we are not able to gain or exploit the period of marketing exclusivity, we may face significant competitive threats to our
commercialization of these compounds from other manufacturers, including the manufacturers of generic alternatives. Further, even if Vascepa is considered to be a NCE and we are able to gain five-year marketing exclusivity, another company could
challenge that decision to seek to overturn FDA&#146;s determination. Another company could also gain such marketing exclusivity under the provisions of the FDCA, as amended by the Hatch-Waxman Amendments, if such company can, under certain
circumstances, complete a human clinical trial process and obtain regulatory approval of its product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If Vascepa is not
granted NCE marketing exclusivity, we expect it will be granted three years of new product exclusivity under the Hatch-Waxman Amendments. A three-year period of exclusivity is granted under the Hatch-Waxman Amendments for a drug product that
contains an active moiety that has been previously approved when the application contains reports of new clinical investigations (other than bioavailability studies) conducted by the sponsor that were essential to approval of the application. Our
MARINE trial was a new clinical investigation that was essential to the approval of our new drug application. We are entitled to at least three-year exclusivity even if the FDA determines that the EPA moiety was previously approved in Lovaza because
our MARINE clinical investigation was essential for the approval of our new drug product, Vascepa. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Such three-year
exclusivity protection would preclude the FDA from approving a marketing application for a duplicate of Vascepa, a product candidate that the FDA views as having the same conditions of approval as Vascepa (for example, the same indication and/or
other conditions of use), or a 505(b)(2) NDA submitted to the FDA with Vascepa as the reference product, for a period of three years from the date of FDA approval, although the FDA may accept and commence review of such applications during the
exclusivity period. Such three-year exclusivity grant would not prevent a company from challenging the validity of our patents at any time. In this case, Amarin may be afforded the benefit of a 30-month stay against the launch of such a competitive
product that would extend from the period that Amarin responds to a pending patent challenge, and may also be afforded other extensions under applicable regulations, including a six-month pediatric exclusivity extension or a judicial extension if
applicable requirements are met. This three-year form of exclusivity may also not prevent the FDA from approving an NDA that relies only on its own data to support the change or innovation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Despite the use of confidentiality agreements and/or proprietary rights agreements,
which themselves may be of limited effectiveness, it may be difficult for us to protect our trade secrets. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will
also rely upon trade secrets and know-how to help protect our competitive position. We rely on trade secrets to protect technology in cases when we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to
protect. While we require certain of our academic collaborators, contractors and consultants to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other proprietary information. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to our Business </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Potential technological changes in our field of business create considerable uncertainty. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are engaged in the biopharmaceutical field, which is characterized by extensive research efforts and rapid technological progress. New developments in research are expected to continue at a rapid pace
in both industry and academia. We cannot assure you that research and discoveries by others will not render some or all of our programs or product candidates uncompetitive or obsolete. Our business strategy is based in part upon new and unproven
technologies to the development of therapeutics to improve cardiovascular health. We cannot assure you that unforeseen problems will not develop with these technologies or applications or that any commercially feasible products will ultimately be
developed by us. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are subject to potential product liability. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following the commercial launch of Vascepa, we will be subject to the potential risk of product liability claims relating to the
manufacturing and marketing of Vascepa. Any person who is injured as a result of using Vascepa may have a product liability claim against us without having to prove that we were at fault. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we could be subject to product liability claims by persons who took part in clinical trials involving our current or former
development stage products. A successful claim brought against us could have a material adverse effect on our business. We cannot guarantee that a product liability claim will not be asserted against us in the future. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may become subject to liability in connection with the wind-down of our EN101 program. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2007, we purchased Ester Neurosciences Limited, an Israeli pharmaceutical company, and its lead product candidate, EN101, an AChE-R
mRNA inhibitor for the treatment of myasthenia gravis, or MG, a debilitating neuromuscular disease. In connection with the acquisition, we assumed a license to certain intellectual property assets related to EN101 from the Yissum Research
Development Company of The Hebrew University of Jerusalem. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2009, in keeping with our decision to re-focus our efforts
on developing improved treatments for cardiovascular disease and cease development of all product candidates outside of our cardiovascular disease focus, we amended the terms of our acquisition agreement with the original shareholders of Ester.
Under the terms of this amendment, Amarin was released from all research and development diligence obligations contained in the original agreement and was authorized to seek a partner for EN101. The amendment agreement also provided that any future
payment obligations payable by us to the former shareholders of Ester would be made only out of income received from potential partners. In connection with this amendment agreement, in August 2009 we issued 1,315,789 ordinary shares to the former
Ester shareholders. Under the terms of this amendment agreement, the former Ester shareholders have the option of reacquiring the original share capital of Ester if we are unable to successfully partner EN101. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following our decision to cease development of EN101, Yissum terminated its license agreement with us. In June 2011, Yissum announced
that it had entered into a license agreement with BiolineRX Ltd for the development of EN101 in a different indication, inflammatory bowel disease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have received several communications on behalf of the former shareholders of Ester asserting that we are in breach of its amended agreement due to the fact that Yissum terminated its license and we
failed to return shares of Ester, and assets relating to EN101, to the shareholders, as was required under certain circumstances under the amended agreement. We do not believe these circumstances constitute a breach of the amended agreement, but
there can be no assurance as to the outcome of this dispute. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>A change in our tax residence could have a negative effect on our future
profitability. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under current UK legislation, a company incorporated in England and Wales, or which is centrally
managed and controlled in the UK, is regarded as resident in the UK for taxation purposes. Under current Irish legislation, a company is regarded as resident for tax purposes in Ireland if it is centrally managed and controlled in Ireland, or, in
certain circumstances, if it is incorporated in Ireland. Where a company is treated as tax resident under the domestic laws of both the UK and Ireland then the provisions of article 4(3) of the Double Tax Convention between the UK and Ireland
provides that such enterprise shall be treated as resident only in the jurisdiction in which its place of effective management is situated. We have sought to conduct our affairs in such a way so as to be resident only in Ireland for tax purposes by
virtue of having our place of effective management situated in Ireland. Trading income of an Irish company is generally taxable at the Irish corporation tax rate of 12.5%. Non-trading income of an Irish company (e.g., interest income, rental income
or other passive income), is taxable at a rate of 25%. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">However, we cannot assure you that we are or will continue to be
resident only in Ireland for tax purposes. It is possible that in the future, whether as a result of a change in law or the practice of any relevant tax authority or as a result of any change in the conduct of our affairs, we could become, or be
regarded as having become resident in a jurisdiction other than Ireland. Should we cease to be an Irish tax resident, we may be subject to a charge to Irish capital gains tax on our assets. Similarly, if the tax residency of any of our subsidiaries
were to change from their current jurisdiction for any of the reasons listed above, we may be subject to a charge to local capital gains tax charge on the assets. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>*The loss of key personnel could have an adverse effect on our business. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are highly dependent upon the efforts of our senior management. The loss of the services of one or more members of senior management could have a material adverse effect on us. As a small company with
a streamlined management structure, the departure of any key person could have a significant impact and would be potentially disruptive to our business until such time as a suitable replacement is hired. Furthermore, because of the specialized
nature of our business, as our business plan progresses we will be highly dependent upon our ability to attract and retain qualified scientific, technical and key management personnel. As we evolve from a development stage company to a commercial
stage company we may experience turnover among members of our senior management team. We may have difficulty identifying and integrating new executives to replace any such losses. There is intense competition for qualified personnel in the areas of
our activities. In this environment, we may not be able to attract and retain the personnel necessary for the development of our business, particularly if we do not achieve profitability. Furthermore, the lessened probability that we will obtain FDA
approval for the ANCHOR indication could have an adverse impact on our ability to retain and recruit qualified personnel. In addition, on October&nbsp;22, 2013, we eliminated approximately fifty percent of our staff positions worldwide as part of a
restructuring following the FDA advisory committee&#146;s recommendation against the potential Vascepa label expansion. Even though all employees were offered severance pay in exchange for signing a comprehensive release of claims, this
restructuring could lead to claims by former employees related to their termination. The restructuring could also have an adverse impact on our ability to retain and recruit qualified personnel. The failure to recruit key scientific, technical and
management personnel would be detrimental to our ability to implement our business plan. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to our Financial Position and
Capital Requirements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have a history of operating losses and anticipate that we will incur continued losses for an
indefinite period of time. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not been profitable in any of the last five fiscal years. For the fiscal years
ended December&nbsp;31, 2012, 2011, and 2010, we reported losses of approximately $179.2 million, $69.1 million and $249.6 million, respectively, and we had an accumulated deficit at December&nbsp;31, 2012 of $747.6 million. For the nine months
ended September&nbsp;30, 2013 and 2012, we reported losses of approximately $150.8 million and $168.6 million, respectively, and we had an accumulated deficit at September&nbsp;30, 2013 of $898.5 million. Substantially all of our operating losses
resulted from costs incurred in connection with our research and development programs, from general and administrative costs associated with our operations, and from non-cash losses on changes in the fair value of warrant derivative liabilities.
Additionally, as a result of our significant expenses relating to research and development and to commercialization, we expect to continue to incur significant operating losses for an indefinite period, even after we begin to generate revenues from
our commercialization of Vascepa. Because of the numerous risks and uncertainties associated with developing and commercializing pharmaceutical products, we are unable to predict the magnitude of these future losses. Our historic losses, combined
with expected future losses, have had and will continue to have an adverse effect on our cash resources, shareholders&#146; deficit and working capital. We expect our research and development expenses to be substantial for both 2014 and the
remainder of 2013 in connection with our REDUCE-IT cardiovascular outcomes study for Vascepa and other activities. In addition, we may incur significant sales, marketing, in-licensing and outsourced manufacturing expenses as we attempt to
commercialize Vascepa. Our shift in focus from research and development to commercialization, and the changes in operating costs relating to that shift, will also require us to make changes to our accounting results and procedures, which may have an
adverse effect on our reported revenue or profit, if any. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Although we began generating revenue from Vascepa in January 2013, we may never be
profitable. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to become profitable depends upon our ability to generate revenue. In January 2013, we began
to generate revenue from the marketing of Vascepa for use in the MARINE indication, but we may not be able to generate sufficient revenue to attain profitability. Our ability to generate profits on sales of Vascepa is subject to the market
acceptance and commercial success of Vascepa and our ability to manufacture commercial quantities of Vascepa through third parties at acceptable cost levels, and may also depend upon our ability to enter into one or more strategic collaborations to
effectively market and sell Vascepa. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even though Vascepa has been approved by the FDA for marketing in the United States in
the MARINE indication, it may not gain market acceptance or achieve commercial success and it may never be approved for the ANCHOR indication or any other indication. In addition, we anticipate continuing to incur significant costs associated with
commercializing Vascepa. We may not achieve profitability soon after generating product sales, if ever. If we are unable to generate sufficient product revenues, we will not become profitable and may be unable to continue operations without
continued funding. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our historical financial results do not form an accurate basis for assessing our current business.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a consequence of the many years developing Vascepa for commercialization and the recent commercial launch of
Vascepa in the MARINE indication in the United States, our historical financial results do not form an accurate basis upon which investors should base their assessment of our business and prospects. In addition, we expect that our costs will
increase substantially as we continue to commercialize Vascepa in the MARINE indication and seek to obtain additional regulatory approval of Vascepa in the ANCHOR indication, including the continuation of the REDUCE-IT cardiovascular outcomes study.
Accordingly, our historical financial results reflect a substantially different business from that currently being conducted and from that expected in the future. In addition, we have a limited history of obtaining regulatory approval for, and no
demonstrated ability to successfully commercialize, a product candidate. Consequently, any predictions about our future performance may not be as accurate as they could be if we had a history of successfully developing and commercializing
pharmaceutical products. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>*Our operating results are unpredictable and may fluctuate. If our operating results are below
the expectations of securities analysts or investors, the trading price of our stock could decline. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our operating
results are difficult to predict and will likely fluctuate from quarter to quarter and year to year, and Vascepa prescription figures will likely fluctuate from month to month. Due to the recent approval by the FDA of Vascepa and the lack of
historical sales data, Vascepa sales will be difficult to predict from period to period and as a result, you should not rely on Vascepa sales results in any period as being indicative of future performance, and sales of Vascepa may be below the
expectation of securities analysts or investors in the future. We believe that our quarterly and annual results of operations may be affected by a variety of factors, including: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the level of demand for Vascepa; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the extent to which coverage and reimbursement for Vascepa is available from government and health administration authorities, private health insurers,
managed care programs and other third-party payers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing, cost and level of investment in our sales and marketing efforts to support Vascepa sales and the resulting effectiveness of those efforts;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">additional developments regarding our intellectual property portfolio and regulatory exclusivity protections, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the results of our sNDA application for the ANCHOR indication and the results of the REDUCE-IT study or post-approval studies for Vascepa;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">outcomes of litigation and other legal proceedings, regulatory matters and tax matters; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether we continue the REDUCE-IT study; and. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the impact of the restructuring of the company implemented on October&nbsp;22, 2013. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>*We may require substantial additional resources to fund our operations. If we cannot
find additional capital resources, we will have difficulty in operating as a going concern and growing our business. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently operate with limited resources. We believe that our cash and cash equivalents balance of $225.9 million at
September&nbsp;30, 2013 will be sufficient to fund our projected operations for at least the next twelve months. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to
fully realize the market potential of Vascepa, we may need to enter into a strategic collaboration or raise additional capital. We may also need additional capital to fully complete our REDUCE-IT cardiovascular outcomes trial. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our future capital requirements will depend on many factors, including: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">revenue generated from the commercial sale of Vascepa in the MARINE indication and, subject to FDA approval, the ANCHOR indication;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs associated with commercializing Vascepa for the MARINE indication in the United States and for additional indications in the United States
and in jurisdictions in which we receive regulatory approval, if any, including the cost of sales and marketing capabilities, and the cost and timing of securing commercial supply of Vascepa and the timing of entering into strategic collaboration
with others relating to the commercialization of Vascepa, if at all, and the terms of any such collaboration; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the continued cost associated with our REDUCE-IT cardiovascular outcomes study, if we continue that study; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the time and costs involved in obtaining additional regulatory approvals for Vascepa; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the extent to which we continue to develop internally, acquire or in-license new products, technologies or businesses; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we require additional funds and adequate funds are not available to us in amounts or on terms acceptable to us or on a timely basis,
or at all, our commercialization efforts for Vascepa may suffer materially, and we may need to delay the advancement of the REDUCE-IT cardiovascular outcomes trial. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>*As a result of recent worldwide reductions in our workforce, we are in the process of reallocating certain employment responsibilities and may outsource certain corporate functions. As a result, we
may be more dependent on third parties to perform these corporate functions than we have been in the past. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a
result of the recent worldwide reductions in our workforce, we have been required to outsource certain corporate functions. This has made us more dependent on third-parties for the performance of these functions. Our ongoing results of operations
could be adversely affected to the extent that we are unable to effectively reallocate employee responsibilities, retain key employees, maintain effective internal control over financial reporting and effective disclosure controls and procedures,
establish and maintain agreements with competent third-party contractors on terms that are acceptable to us, and effectively manage the work performed by any retained third-party contractors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Continued negative economic conditions would likely have a negative effect on our
ability to obtain financing on acceptable terms. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While we may seek additional funding through public or private
financings, we may not be able to obtain financing on acceptable terms, or at all. There can be no assurance that we will be able to access equity or credit markets in order to finance our current operations or expand development programs for
Vascepa, or that there will not be a further deterioration in financial markets and confidence in economies. We may also have to scale back or further restructure our operations. If we are unable to obtain additional funding on a timely basis, we
may be required to curtail or terminate some or all of our research or development programs or our commercialization strategies. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Raising additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish
rights. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent we are permitted under our Purchase and Sale Agreement with BioPharma, we may seek additional
capital through a combination of private and public equity offerings, debt financings and collaboration, strategic and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a shareholder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of September&nbsp;30, 2013, there were warrants outstanding for the purchase of up to 9,816,826 ADSs each representing one of our ordinary shares, with a weighted average exercise price of $1.44 per
share. We may issue additional warrants to purchase ADSs or ordinary shares in connection with any future financing we may conduct. In addition, on January&nbsp;9, 2012, we issued $150 million in aggregate principal amount of 3.50% exchangeable
senior notes due 2032, or the notes. The notes are exchangeable under certain circumstances into cash, our ADS, or a combination of cash and ADS, at our election, with a current exchange rate of 113.4752 ADS per $1,000 principal amount of notes.
Although we intend to settle these notes in cash, if we elected physical settlement, the notes would initially be exchangeable into 17,021,280 ADS. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring additional debt, making capital expenditures or
declaring dividends. If we raise additional funds through collaboration, strategic alliance and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, Vascepa or product candidates beyond the rights
we have already relinquished, or grant licenses on terms that are not favorable to us. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Potential business combinations
or other strategic transactions may disrupt our business or divert management&#146;s attention. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On a regular basis,
we explore potential business combination transactions, including an acquisition of us by a third party, exclusive licenses of Vascepa or other strategic transactions or collaborations with third parties. The consummation and performance of any such
future transactions or collaborations will involve risks, such as: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">diversion of managerial resources from day-to-day operations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">exposure to litigation from the counterparties to any such transaction, other third parties or our shareholders; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">misjudgment with respect to the value; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">higher than expected transaction costs; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an inability to successfully consummate any such transaction or collaboration. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result of these risks, we may not be able to achieve the expected benefits of any such
transaction or collaboration or deliver the value thereof to our shareholders. If we are unsuccessful in consummating any such transaction or collaboration, we may be required to reevaluate our business only after we have incurred substantial
expenses and devoted significant management time and resources. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Ownership of our ADSs and Common Shares </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The price of our ADSs and common shares may be volatile. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The stock market has from time to time experienced significant price and volume fluctuations that may be unrelated to the operating
performance of particular companies.&nbsp;In addition, the market prices of the securities of many pharmaceutical and medical technology companies have been especially volatile in the past, and this trend is expected to continue in the future.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of November&nbsp;1, 2013 we had 172,664,013 common shares outstanding including 172,195,467 shares held as ADSs and
468,546 held as common shares (which are not held in the form of ADSs).&nbsp;In our October 2009 private placement we issued 66.4&nbsp;million ADSs and warrants to purchase an additional 33.2&nbsp;million ADSs. There is a risk that there may not be
sufficient liquidity in the market to accommodate significant increases in selling activity or the sale of a large block of our securities.&nbsp;Our ADSs have historically had limited trading volume, which may also result in volatility.&nbsp;If any
of our large investors, such as the participants in our October 2009 private placement, seek to sell substantial amounts of our ADSs, particularly if these sales are in a rapid or disorderly manner, or other investors perceive that these sales could
occur, the market price of our ADSs could decrease significantly. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The market price of our ADSs and common shares may also be
affected by factors such as: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the status of our pending exclusivity request with the FDA for Vascepa; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developments or disputes concerning ongoing patent prosecution efforts and any future patent or proprietary rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory developments in the United States, the European Union or other countries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">actual or potential medical results relating to our products or our competitors&#146; products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">interim failures or setbacks in product development; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">innovation by us or our competitors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">currency exchange rate fluctuations; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">period-to-period variations in our results of operations. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>A share price of less than $1.00 may impact our NASDAQ listing. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As
of the date of this Quarterly Report, our ADSs are currently trading above $1.00; however, recent market activity has resulted in a decrease in our stock price, and our stock price may fall below the $1.00 threshold. If our closing bid price is less
than $1.00 for 30 consecutive trading days, we would receive a NASDAQ staff deficiency letter indicating that we are not in compliance with the minimum bid price requirement for continued listing. Such a letter would trigger an automatic 180
calendar day period within which the company could regain compliance. Compliance is regained at any time during this period if the Amarin closing bid price is $1.00 per share or more for a minimum of 10 consecutive trading days. If we do not regain
compliance during this period, our ADSs could be delisted from The NASDAQ Global Market, transferred to a listing on The NASDAQ Capital Market, or delisted from the NASDAQ markets altogether. The failure to maintain our listing on The NASDAQ Global
Market could harm the liquidity of our ADSs and could have an adverse effect on the market price of our ADSs. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Actual or potential sales of our common shares by our employees, including members of
our senior management team, pursuant to pre-arranged stock trading plans could cause our stock price to fall or prevent it from increasing for numerous reasons, and actual or potential sales by such persons could be viewed negatively by other
investors. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In accordance with the guidelines specified under Rule&nbsp;10b5-1 of the Securities and Exchange Act of
1934 and our policies regarding stock transactions, a number of our directors and employees, including members of our senior management team, have adopted and may continue to adopt pre-arranged stock trading plans to sell a portion of our common
stock. Generally, sales under such plans by members of our senior management team and directors require public filings. Actual or potential sales of our ADSs by such persons could cause the price of our ADSs to fall or prevent it from increasing for
numerous reasons. For example, a substantial amount of our ADSs becoming available (or being perceived to become available) for sale in the public market could cause the market price of our ADSs to fall or prevent it from increasing. Also, actual or
potential sales by such persons could be viewed negatively by other investors. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>*We may be a passive foreign investment
company, or PFIC, which would result in adverse U.S. federal tax consequences to U.S. investors. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amarin Corporation
plc and certain of our subsidiaries may be classified as &#147;passive foreign investment companies,&#148; or PFICs, for U.S. federal income tax purposes. The tests for determining PFIC status for a taxable year depend upon the relative values of
certain categories of assets and the relative amounts of certain kinds of income. The application of these factors depends upon our financial results, which are beyond our ability to predict or control, and which may be subject to legal and factual
uncertainties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe it prudent to assume that we were classified as a PFIC in 2012. However, it is possible that,
because of the commencement of sales and marketing of Vascepa, we may not be classified as a PFIC in 2013 or in future years, although there can be no assurance in this regard. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are a PFIC, U.S. holders of notes, ordinary shares or ADSs would be subject to adverse U.S. federal income tax consequences, such
as ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements under U.S. federal income tax laws and regulations. Whether
or not U.S. holders of our ADSs make a timely &#147;QEF election&#148; or &#147;mark-to-market election&#148; may affect the U.S. federal income tax consequences to U.S. holders with respect to the acquisition, ownership and disposition of Amarin
ADSs and any distributions such U.S. Holders may receive. A QEF election and other elections that may mitigate the effect of our being classified as a PFIC are unavailable with respect to the notes. Investors should consult their own tax advisors
regarding all aspects of the application of the PFIC rules to the notes, ordinary shares and ADSs. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Failure to meet our
obligations under our Purchase and Sale Agreement with BioPharma could adversely affect our financial results and liquidity. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to our December 2012 Purchase and Sale Agreement with BioPharma, we are obligated to make payments to BioPharma based on the amount of our net product sales of Vascepa and any future products
based on ethyl-EPA, or covered products, subject to certain quarterly caps. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to this agreement, we may not, among
other things: (i)&nbsp;incur indebtedness greater than a specified amount, which we refer to as the Indebtedness Covenant; (ii)&nbsp;pay a dividend or other cash distribution, unless we have cash and cash equivalents in excess of a specified amount
after such payment; (iii)&nbsp;amend or restate our memorandum and articles of association unless such amendments or restatements do not affect BioPharma&#146;s interests under the transaction; (iv)&nbsp;encumber any of the collateral securing our
performance under the agreement; and (v)&nbsp;abandon certain patent rights, in each case without the consent of BioPharma. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon a transaction resulting in a change of control of Amarin, as defined in the agreement, BioPharma will be automatically entitled to
receive any amounts not previously paid, up to our maximum repayment obligation. As defined in the agreement, &#147;change of control&#148; includes, among other things, (i)&nbsp;a greater than 50 percent change in the ownership of Amarin,
(ii)&nbsp;a sale or disposition of any collateral securing our debt with BioPharma and (iii), unless BioPharma has been paid a certain amount under the indebtedness, the licensing of Vascepa to a third party for sale in the United States. The
acceleration of the payment obligation in the event of a change of control transaction may make us less attractive to potential acquirers, and the payment of such funds out of our available cash or acquisition proceeds would reduce acquisition
proceeds for our stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To secure our obligations under the agreement, we granted BioPharma a security interest in our
rights in patents, trademarks, trade names, domain names, copyrights, know-how and regulatory approvals related to the covered products, all books and records </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
relating to the foregoing and all proceeds of the foregoing, which we refer to as the collateral. If we (i)&nbsp;fail to deliver a payment when due and do not remedy that failure within specific
notice period, (ii)&nbsp;fail to maintain a first-priority perfected security interest in the collateral in the United States and do not remedy that failure after receiving notice of such failure or (iii)&nbsp;become subject to an event of
bankruptcy, then BioPharma may attempt to collect the maximum amount payable by us under this agreement (after deducting any payments we have already made). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There can be no assurance that we will not breach the covenants or other terms of, or that an event of default will not occur under, this agreement and, if a breach or event of default occurs, there can
be no assurance that we will be able to cure the breach within the time permitted. Any failure to pay our obligations when due, any breach or default of our covenants or other obligations, or any other event that causes an acceleration of payment at
a time when we do not have sufficient resources to meet these obligations, could have a material adverse effect on our business, results of operations, financial condition and future viability. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our existing indebtedness could adversely affect our financial condition. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our existing indebtedness, which we entered into in January 2012, consists of $150.0&nbsp;million in aggregate principal amount of
3.50%&nbsp;exchangeable senior notes due 2032, with provisions for the notes to be called on or after January&nbsp;19, 2017. Our indebtedness and the related annual debt service requirements may adversely impact our business, operations and
financial condition in the future. For example, they could: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">increase our vulnerability to general adverse economic and industry conditions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limit our ability to raise additional funds by borrowing or engaging in equity sales in order to fund future working capital, capital expenditures,
research and development and other general corporate requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">require us to dedicate a substantial portion of our cash to service payments on our debt;&nbsp;or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limit our flexibility to react to changes in our business and the industry in which we operate or to pursue certain strategic opportunities that may
present themselves. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The accounting method for convertible debt securities that may be settled in cash,
such as our notes, could have a material effect on our reported financial results. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the FASB Accounting
Standards Codification, or ASC, we may be required to separately account for the liability and equity components of the convertible debt instruments (such as the notes) that may be settled entirely or partially in cash upon conversion in a manner
that reflects the issuer&#146;s economic interest cost. The effect of ASC&nbsp;on the accounting for our outstanding convertible notes may be that the equity component is required to be included in the additional paid-in capital section of
stockholders&#146; equity on our consolidated balance sheets and the value of the equity component would be treated as original issue discount for purposes of accounting for the debt component of the notes. As a result, we may be required to record
non-cash interest expense as a result of the amortization of the discounted carrying value of the notes to their face amount over the term of the notes. We may be required to report higher interest expense in our financial results because
ASC&nbsp;may require interest to include both the current period&#146;s amortization of the debt discount and the instrument&#146;s coupon interest, which could adversely affect our reported or future financial results and the trading price of our
ADSs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Servicing our debt may require a significant amount of cash, and we may not have sufficient cash flow from our business
to provide the funds sufficient to pay our substantial debt. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to make scheduled payments of the principal of, to
pay interest on or to refinance our indebtedness, including the notes, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not continue to generate cash flow
from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital
markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations, including the notes, and have a
material adverse effect on the trading price of our ADSs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may be able to incur substantial additional debt in the future,
subject to the restrictions contained in our future debt instruments, if any, which would intensify the risks discussed above. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The conditional exchange feature of the notes, if triggered, may adversely affect our financial condition and operating results.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event the conditional exchange feature of the notes is triggered, holders of notes will be entitled to
exchange the notes at any time during specified periods at their option. If one or more holders elect to exchange their notes, unless we elect to satisfy its exchange obligation by delivering solely the ADSs (other than cash in lieu of any
fractional ADS), we would be required to settle a portion or all of its exchange obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to exchange their notes, we could be
required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the notes as a current rather than long-term liability, which would result in a material reduction of our net working capital. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The fundamental change repurchase feature of the notes may delay or prevent an otherwise beneficial takeover attempt of us.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The indenture governing the notes will require us to repurchase the notes for cash upon the occurrence of a
fundamental change of Amarin and, in certain circumstances, to increase the exchange rate for a holder that exchanges its notes in connection with a make-whole fundamental change. A takeover of us may trigger the requirement that we purchase the
notes and/or increase the exchange rate, which could make it more costly for a potential acquirer to engage in a combinatory transaction with us. Such additional costs may have the effect of delaying or preventing a takeover of us that would
otherwise be beneficial to investors. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We do not intend to pay cash dividends on the ordinary shares in the foreseeable
future. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have never paid dividends on ordinary shares and do not anticipate paying any cash dividends on the
ordinary shares in the foreseeable future. Under English law, any payment of dividends would be subject to relevant legislation and our Articles of Association, which requires that all dividends must be approved by our Board of Directors and, in
some cases, our shareholders, and may only be paid from our distributable profits available for the purpose, determined on an unconsolidated basis. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are incorporated under English law. The rights of holders of ordinary shares and, therefore, certain of the rights of holders of ADSs, are governed by English law, including the provisions of the
Companies Act 2006, and by our Articles of Association. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations. The principal differences include the following: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under English law and our Articles of Association, each shareholder present at a meeting has only one vote unless demand is made for a vote on a poll,
in which case each holder gets one vote per share owned. Under U.S. law, each shareholder typically is entitled to one vote per share at all meetings. Under English law, it is only on a poll that the number of shares determines the number of votes a
holder may cast. You should be aware, however, that the voting rights of ADSs are also governed by the provisions of a deposit agreement with our depositary bank. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under English law, subject to certain exceptions and disapplications, each shareholder generally has preemptive rights to subscribe on a proportionate
basis to any issuance of ordinary shares or rights to subscribe for, or to convert securities into, ordinary shares for cash. Under U.S. law, shareholders generally do not have preemptive rights unless specifically granted in the certificate of
incorporation or otherwise. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under English law and our Articles of Association, certain matters require the approval of 75% of the shareholders who vote (in person or by proxy) on
the relevant resolution (or on a poll shareholders representing 75% of the ordinary shares voting (in person or by proxy)), including amendments to the Articles of Association. This may make it more difficult for us to complete corporate
transactions deemed advisable by our board of directors. Under U.S. law, generally only majority shareholder approval is required to amend the certificate of incorporation or to approve other significant transactions. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United Kingdom, takeovers may be structured as takeover offers or as schemes of arrangement. Under English law, a bidder seeking to acquire us
by means of a takeover offer would need to make an offer for all of our outstanding ordinary shares/ADSs. If acceptances are not received for 90% or more of the ordinary shares/ADSs under the offer, under English law, the bidder cannot complete a
&#147;squeeze out&#148; to obtain 100% control of us. Accordingly, acceptances of 90% of our outstanding ordinary shares/ADSs will likely be a condition in any takeover offer to acquire us, not 50% as is more common in tender offers for corporations
organized under Delaware law. By contrast, a scheme of arrangement, the successful completion of which would result in a bidder obtaining 100% control of us, requires the approval of a majority of shareholders voting at the meeting and representing
75% of the ordinary shares voting for approval. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under English law and our Articles of Association, shareholders and other persons whom we know or have reasonable cause to believe are, or have been,
interested in our shares may be required to disclose information regarding their interests in our shares upon our request, and the failure to provide the required information could result in the loss or restriction of rights attaching to the shares,
including prohibitions on certain transfers of the shares, withholding of dividends and loss of voting rights. Comparable provisions generally do not exist under U.S. law. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The quorum requirement for a shareholders&#146; meeting is a minimum of two shareholders entitled to vote at the meeting and present in person or by
proxy or, in the case of a shareholder which is a corporation, represented by a duly authorized officer. Under U.S. law, a majority of the shares eligible to vote must generally be present (in person or by proxy) at a shareholders&#146; meeting in
order to constitute a quorum. The minimum number of shares required for a quorum can be reduced pursuant to a provision in a company&#146;s certificate of incorporation or bylaws, but typically not below one-third of the shares entitled to vote at
the meeting. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>U.S. shareholders may not be able to enforce civil liabilities against us.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are incorporated under the laws of England and Wales, and our subsidiaries are incorporated in various
jurisdictions, including foreign jurisdictions. A number of the officers and directors of each of our subsidiaries are non-residents of the United States, and all or a substantial portion of the assets of such persons are located outside the United
States. As a result, it may not be possible for investors to affect service of process within the United States upon such persons or to enforce against them judgments obtained in U.S. courts predicated upon the civil liability provisions of the
federal securities laws of the United States. We have been advised by our English solicitors that there is doubt as to the enforceability in England in original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities
to the extent predicated upon the federal securities laws of the United States. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>U.S. holders of the ADSs or ordinary
shares may be subject to U.S. federal income taxation at ordinary income tax rates on undistributed earnings and profits. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There is a risk that we will be classified as a controlled foreign corporation, or CFC, for U.S. federal income tax purposes. If we are classified as a CFC, any ADS holder or shareholder that is a U.S.
person that owns directly, indirectly or by attribution, 10% or more of the voting power of our outstanding shares may be subject to U.S. income taxation at ordinary income tax rates on all or a portion of our undistributed earnings and profits
attributable to &#147;subpart F income.&#148; Such 10% holder may also be taxable at ordinary income tax rates on any gain realized on a sale of ordinary shares or ADS, to the extent of our current and accumulated earnings and profits attributable
to such shares. The CFC rules are complex and U.S. Holders of the ordinary shares or ADSs are urged to consult their own tax advisors regarding the possible application of the CFC rules to them in their particular circumstances. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc595270_13"></A>Item&nbsp;5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Information </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">None </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc595270_14"></A>Item&nbsp;6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following
exhibits are incorporated by reference or filed as part of this report. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;31.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Chief Executive Officer (Principal Executive Officer) pursuant to Section 302 of Sarbanes-Oxley Act of 2002</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;31.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of President (Principal Financial Officer) pursuant to Section 302 of Sarbanes-Oxley Act of 2002</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;32.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Chief Executive Officer (Principal Executive Officer) and President (Principal Financial Officer) pursuant to Section 906 of Sarbanes-Oxley Act of
2002</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.INS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Instance Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.SCH</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Schema Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.CAL</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Calculation Linkbase Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.DEF</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Definition Linkbase Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.LAB</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Label Linkbase Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.PRE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Presentation Linkbase Document</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc595270_15"></A>SIGNATURE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">A<SMALL>MARIN</SMALL> C<SMALL>ORPORATION</SMALL> P<SMALL>LC</SMALL></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John F. Thero</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">John F. Thero</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>President </I>(Principal Financial Officer)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(On behalf of the Registrant)</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: November&nbsp;7, 2013 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d595270dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 31.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I, Joseph Zakrzewski, certify that: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">I have reviewed this quarterly report on Form 10-Q of Amarin Corporation plc; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">d.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal
quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial
reporting. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: November&nbsp;7, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Joseph Zakrzewski</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joseph Zakrzewski</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Principal Executive Officer)</FONT></P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d595270dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit&nbsp;31.2 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I, John
F. Thero, certify that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">I have reviewed this quarterly report on Form 10-Q of Amarin Corporation plc; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">d.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal
quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial
reporting. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: November&nbsp;7, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John F. Thero</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">John F. Thero</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">President (Principal Financial Officer)</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d595270dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 32.1 </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>STATEMENT PURSUANT TO 18 U.S.C. &#167; 1350 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirement set forth in
Rule&nbsp;13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and Section&nbsp;1350 of Chapter&nbsp;63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Joseph Zakrzweski, Chief Executive Officer
(Principal Executive Officer) of Amarin Corporation plc (the &#147;Company&#148;) and John F. Thero, President (Principal Financial Officer) of the Company, each hereby certifies that, to the best of his knowledge: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Quarterly Report on Form 10-Q for the period ended September&nbsp;30, 2013, to which this Certification is attached as Exhibit&nbsp;32.1 (the
&#147;Quarterly Report&#148;) fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the end
of such year. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Joseph Zakrzewski</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: November 7, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joseph Zakrzewski</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer&nbsp;(Principal Executive Officer)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John F. Thero</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: November 7, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">John F. Thero</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President (Principal Financial Officer)</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange
Commission and is not incorporated by reference into any filing of Amarin Corporation plc under the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation
language contained in such filing. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>amrn-20130930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2013-11-07T16:17:48Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:amrn="http://www.amarincorp.com/20130930" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="amrn-20130930.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE46938---1310-Q0010_STD_0_20120131_0_714378x714242" unitRef="pure" decimals="3" id="id_2597911_C81A56F2-CAC6-4F34-855A-4A365BDD70FA_1002_1">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20120131_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C81A56F2-CAC6-4F34-855A-4A365BDD70FA_1002_0">150000000</us-gaap:DebtInstrumentFaceAmount>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20131101_0_711196x820302" unitRef="shares" decimals="INF" id="id_2597911_74C72283-5A7D-4033-87E4-AE6EFDCA23FC_1002_500006">468546</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20131101_0_711196x826933" unitRef="shares" decimals="INF" id="id_2597911_74C72283-5A7D-4033-87E4-AE6EFDCA23FC_2002_500008">172195467</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20120726_0_735055x740537" unitRef="iso4217_USD" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_1004_2">11600000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
  <us-gaap:SharesIssuedPricePerShare contextRef="eol_PE46938---1310-Q0010_STD_0_20130712_0_711196x826933" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_1D61FE80-A594-44A7-A935-1CB6D6D7D63F_2001_1">5.60</us-gaap:SharesIssuedPricePerShare>
  <amrn:OptionsGrantedDuringPeriod contextRef="eol_PE46938---1310-Q0010_STD_0_20130712_0_711196x826933" unitRef="shares" decimals="INF" id="id_2597911_1D61FE80-A594-44A7-A935-1CB6D6D7D63F_2001_3">3255000</amrn:OptionsGrantedDuringPeriod>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_708566x815040_711171x716792_714777x781108_716763x740788" unitRef="shares" decimals="1" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_3002_13">0.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_708566x815040_711171x716792_714777x781108_716763x740788" unitRef="iso4217_USD_per_Right" decimals="2" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_3002_14">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <amrn:ClassOfWarrantOrRightTerm contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_708566x815040_711171x716792_714777x781108_716763x740788" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_3002_12">P5Y</amrn:ClassOfWarrantOrRightTerm>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_708566x815040_714777x781108_716763x740788" unitRef="shares" decimals="1" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_4002_7">0.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_708566x815040_714777x781108_716763x740788" unitRef="iso4217_USD_per_Right" decimals="2" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_4002_8">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <amrn:ClassOfWarrantOrRightTerm contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_708566x815040_714777x781108_716763x740788" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_4002_6">P5Y</amrn:ClassOfWarrantOrRightTerm>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_711171x716792_714777x781108" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_1002_11">0.90</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <amrn:ClassOfWarrantOrRightIssued contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_711672x709584_714777x781108" unitRef="shares" decimals="-5" id="id_2597911_7F878E9E-D8EE-41BB-9795-4232131D4A48_2003_1">900000</amrn:ClassOfWarrantOrRightIssued>
  <amrn:ClassOfWarrantOrRightIssued contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_714777x781108_716763x740788" unitRef="shares" decimals="-5" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_6002_15">35200000</amrn:ClassOfWarrantOrRightIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_3006_900026">38000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_3004_5">90963000</us-gaap:DerivativeLiabilities>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_3002_36">215110000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x708572" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_3004_700026">-217000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_3003_600026">613087000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_3001_400026">149921422</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_3001_500026">124244000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_3005_800026">-737076000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_3001_5">90963000</us-gaap:DerivativeLiabilities>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_32">172664013</us-gaap:CommonStockSharesIssued>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD_per_Right" decimals="2" id="id_2597911_DDE7128E-D36A-49A3-8555-561178852E60_1_1">1.44</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:SharePrice contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_4FC3D6D7-5949-4643-9AB9-201691591606_2_1">6.32</us-gaap:SharePrice>
  <us-gaap:TreasuryStockShares contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_36">20079</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_GBP_per_shares" decimals="INF" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_3001_31">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2597911_DDE7128E-D36A-49A3-8555-561178852E60_1_0">9816826</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_33">172643934</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_17">10901000</us-gaap:InterestPayableCurrent>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_3005_4">2077000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_28" />
  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C377772F-1A22-40AC-8919-88EDD42BD5C6_3002_1">7200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_20">31299000</us-gaap:LiabilitiesCurrent>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_23">145316000</us-gaap:SeniorLongTermNotes>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_24">87319000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_19">12548000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_16">6233000</us-gaap:AccountsPayableCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_26">811000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_38">-17697000</us-gaap:StockholdersEquity>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_34">739524000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_3004_5">47193000</us-gaap:DerivativeLiabilities>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_37">-898459000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_18">1617000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:Liabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_27">311543000</us-gaap:Liabilities>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7B444E14-2115-4D5C-B17C-9B3DA6FC21FF_1_1">754000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:CommonStockValue contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_30">141455000</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_39">293846000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:InventoryValuationReserves contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6984A716-29BF-44EE-86C4-DC0DAC87190C_1_0">1800000</us-gaap:InventoryValuationReserves>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_11">5335000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_3">1400000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_4">3721000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:InventoryNet contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_5">27083000</us-gaap:InventoryNet>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_496CD27E-C265-4A5B-9299-92FB1C0BEBDF_1_2">9283000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_6">936000</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_496CD27E-C265-4A5B-9299-92FB1C0BEBDF_1_0">4993000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:TreasuryStockValue contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_35">217000</us-gaap:TreasuryStockValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_9">646000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_10">14433000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:Assets contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_13">293846000</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_2">225885000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_12">10870000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_7">3537000</us-gaap:OtherAssetsCurrent>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_496CD27E-C265-4A5B-9299-92FB1C0BEBDF_1_1">12166000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7B444E14-2115-4D5C-B17C-9B3DA6FC21FF_1_0">11624000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_93C82523-9507-4569-B77F-B34C2F307077_1001_1">641000</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
  <us-gaap:AssetsCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_8">262562000</us-gaap:AssetsCurrent>
  <amrn:CashDiscountPercent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="pure" decimals="2" id="id_2597911_1349199C-F8FD-4AA1-B735-F2AFAE180B22_1001_0">0.02</amrn:CashDiscountPercent>
  <amrn:ExcessFairValueOverPrincipalValue contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_8D03C0E3-066F-40AB-A953-18E4FF9D66D4_3_4">42400000</amrn:ExcessFairValueOverPrincipalValue>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_707278x822778_755443x829211" unitRef="iso4217_USD" decimals="-5" id="id_2597911_CDDC2253-BD43-40B8-A3B8-7B4E68FEB086_1001_0">800000</amrn:FutureMinimumGuaranteePayments>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_711502x716112_735055x740537" unitRef="iso4217_GBP" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_2002_6">10000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_711502x716112_735055x740537" unitRef="iso4217_USD" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_2001_6">16100000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_735055x740537_764190x779644" unitRef="iso4217_GBP" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_3002_5">5000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_735055x740537_764190x779644" unitRef="iso4217_USD" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_3001_5">8100000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_735055x740537_764190x829979" unitRef="iso4217_GBP" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_4002_4">5000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_735055x740537_764190x829979" unitRef="iso4217_USD" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_4001_4">8100000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:SharePrice contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x784846" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_4FC3D6D7-5949-4643-9AB9-201691591606_1002_0">6.95</us-gaap:SharePrice>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x830088_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_981EFCF9-3AA2-400F-BBDC-3448AB47D971_2001_4">3900000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x834798_735055x740537_764190x779644" unitRef="iso4217_GBP" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_5002_1">7500000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x834798_735055x740537_764190x779644" unitRef="iso4217_USD" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_5001_1">12100000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x834798_735055x740537_764190x829979" unitRef="iso4217_GBP" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_6002_0">7500000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x834798_735055x740537_764190x829979" unitRef="iso4217_USD" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_6001_0">12100000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x708572" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_7004_700013">-217000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_7003_600013">739524000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_7001_400013">172664013</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_7001_500013">141455000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_7005_800013">-898459000</us-gaap:StockholdersEquity>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709711x709050" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_3001_4">888000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709711x713749" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_3003_4">72000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709711x824442" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_3004_4">183000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709711x825682" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_3002_4">934000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_710256x715225" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1001_25">7200000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_710256x715581" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2001_22">39598000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_711502x716112_714777x781108_716763x740788" unitRef="shares" decimals="-5" id="id_2597911_7B4516AF-319C-4ECD-BD82-57CF9AFE62A0_1001_0">36100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_711672x709584_714777x781108" unitRef="shares" decimals="-5" id="id_2597911_7F878E9E-D8EE-41BB-9795-4232131D4A48_2001_2">600000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7E3A309C-E704-4A5D-B78E-6E0066F0D1C2_1_3">39600000</us-gaap:DerivativeLiabilities>
  <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7E3A309C-E704-4A5D-B78E-6E0066F0D1C2_1_5">400000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7E3A309C-E704-4A5D-B78E-6E0066F0D1C2_1_4">7200000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7E3A309C-E704-4A5D-B78E-6E0066F0D1C2_1_1">113500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349_715757x707740" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7E3A309C-E704-4A5D-B78E-6E0066F0D1C2_2_1">113500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349_715757x715798" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7E3A309C-E704-4A5D-B78E-6E0066F0D1C2_4_3">39600000</us-gaap:DerivativeLiabilities>
  <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349_715757x715798" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7E3A309C-E704-4A5D-B78E-6E0066F0D1C2_4_5">400000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349_715757x715798" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7E3A309C-E704-4A5D-B78E-6E0066F0D1C2_4_4">7200000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x725855" unitRef="iso4217_USD_per_Right" decimals="2" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1004_2">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x725855" unitRef="shares" decimals="INF" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1004_1">627050</us-gaap:ClassOfWarrantOrRightOutstanding>
  <amrn:ClassOfWarrantOrRightExpirationDate contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x725855" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1004_3">10/15/14</amrn:ClassOfWarrantOrRightExpirationDate>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x797754" unitRef="iso4217_USD_per_Right" decimals="2" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1002_2">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x797754" unitRef="shares" decimals="INF" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1002_1">1684888</us-gaap:ClassOfWarrantOrRightOutstanding>
  <amrn:ClassOfWarrantOrRightExpirationDate contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x797754" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1002_3">7/30/14</amrn:ClassOfWarrantOrRightExpirationDate>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x815051" unitRef="iso4217_USD_per_Right" decimals="2" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1001_2">17.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x815051" unitRef="shares" decimals="INF" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1001_1">17500</us-gaap:ClassOfWarrantOrRightOutstanding>
  <amrn:ClassOfWarrantOrRightExpirationDate contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x815051" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1001_3">1/17/14</amrn:ClassOfWarrantOrRightExpirationDate>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x821234" unitRef="iso4217_USD_per_Right" decimals="2" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1003_2">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x821234" unitRef="shares" decimals="INF" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1003_1">7487388</us-gaap:ClassOfWarrantOrRightOutstanding>
  <amrn:ClassOfWarrantOrRightExpirationDate contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x821234" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1003_3">10/15/14</amrn:ClassOfWarrantOrRightExpirationDate>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_714378x714242" unitRef="pure" decimals="3" id="id_2597911_981EFCF9-3AA2-400F-BBDC-3448AB47D971_3001_3">0.145</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_3001_7">1100000</us-gaap:InterestPayableCurrent>
  <us-gaap:ConvertibleDebt contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_3001_2">145300000</us-gaap:ConvertibleDebt>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_981EFCF9-3AA2-400F-BBDC-3448AB47D971_3001_1">126200000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_3001_1">800000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_714777x781108_716763x740788" unitRef="shares" decimals="-5" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_6003_16">7500000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x710071" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_3003_5">395000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x711232" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_3002_5">7200000</us-gaap:DerivativeLiabilities>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x711232" unitRef="iso4217_USD" decimals="-5" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_3004_2">7200000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:DerivativeAssetNotionalAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x716981" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7740EE47-7093-403F-9241-796D7DDCD866_2001_0">4500000</us-gaap:DerivativeAssetNotionalAmount>
  <us-gaap:ForeignCurrencyDerivativesAtFairValueNet contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x716981" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7740EE47-7093-403F-9241-796D7DDCD866_2001_2">400000</us-gaap:ForeignCurrencyDerivativesAtFairValueNet>
  <amrn:NumberOfForeignCurrencyForwardContractsOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x716981" unitRef="Contract" decimals="INF" id="id_2597911_7740EE47-7093-403F-9241-796D7DDCD866_2001_1">1</amrn:NumberOfForeignCurrencyForwardContractsOutstanding>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_3001_5">39598000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_716763x715581" unitRef="iso4217_USD" decimals="-5" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_2001_0">39600000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_1006_900014">-5962000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_1004_1">123125000</us-gaap:DerivativeLiabilities>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_4001_35">116602000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x708572" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_1004_700014">-217000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_1003_600014">449393000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_1001_400014">135832542</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_1001_500014">113321000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_1005_800014">-568459000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_1001_1">123125000</us-gaap:DerivativeLiabilities>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_32">150360933</us-gaap:CommonStockSharesIssued>
  <us-gaap:TreasuryStockShares contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_36">20079</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_GBP_per_shares" decimals="INF" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_3002_31">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_33">150340854</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_17">2520000</us-gaap:InterestPayableCurrent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_28" />
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_20">25202000</us-gaap:LiabilitiesCurrent>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_23">134250000</us-gaap:SeniorLongTermNotes>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_24">85153000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_19">5224000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_16">17458000</us-gaap:AccountsPayableCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_26">816000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_38">-3997000</us-gaap:StockholdersEquity>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_34">619266000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_1004_1">69431000</us-gaap:DerivativeLiabilities>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_37">-747643000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C377772F-1A22-40AC-8919-88EDD42BD5C6_1_0">14600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:Liabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_27">314852000</us-gaap:Liabilities>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7B444E14-2115-4D5C-B17C-9B3DA6FC21FF_2_1">269000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:CommonStockValue contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_30">124597000</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_39">310855000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_11">4951000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:InventoryNet contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_5">21262000</us-gaap:InventoryNet>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_496CD27E-C265-4A5B-9299-92FB1C0BEBDF_2_2">326000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_6">937000</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_496CD27E-C265-4A5B-9299-92FB1C0BEBDF_2_0">5465000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:TreasuryStockValue contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_35">217000</us-gaap:TreasuryStockValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_9">811000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_10">8044000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:Assets contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_13">310855000</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_2">260242000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_12">11355000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_7">3253000</us-gaap:OtherAssetsCurrent>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_496CD27E-C265-4A5B-9299-92FB1C0BEBDF_2_1">15471000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7B444E14-2115-4D5C-B17C-9B3DA6FC21FF_2_0">11624000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:AssetsCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_8">285694000</us-gaap:AssetsCurrent>
  <us-gaap:OtherCommitment contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778" unitRef="iso4217_USD" decimals="-6" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_1001_1">150000000</us-gaap:OtherCommitment>
  <amrn:ChangeInControlObligations contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778" unitRef="iso4217_USD" decimals="-6" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_1001_8">140000000</amrn:ChangeInControlObligations>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x735492" unitRef="iso4217_USD" decimals="-5" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_3001_3">8000000</amrn:FutureMinimumGuaranteePayments>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x770088" unitRef="iso4217_USD" decimals="-5" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_4001_4">10000000</amrn:FutureMinimumGuaranteePayments>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x796385" unitRef="iso4217_USD" decimals="-5" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_5001_6">13000000</amrn:FutureMinimumGuaranteePayments>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x824056" unitRef="iso4217_USD" decimals="-5" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_6001_5">15000000</amrn:FutureMinimumGuaranteePayments>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x829211" unitRef="iso4217_USD" decimals="-5" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_7001_2">2500000</amrn:FutureMinimumGuaranteePayments>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x708572" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_5004_700001">-217000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_5003_600001">619266000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_5001_400001">150360933</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_5001_500001">124597000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_5005_800001">-747643000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_710256x715225" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1002_25">14577000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_710256x715581" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2002_22">54854000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349" unitRef="iso4217_USD" decimals="-5" id="id_2597911_38A77765-DC80-471A-84B5-C1BA6A3A19FA_1_3">54900000</us-gaap:DerivativeLiabilities>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349" unitRef="iso4217_USD" decimals="-5" id="id_2597911_38A77765-DC80-471A-84B5-C1BA6A3A19FA_1_4">14600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349" unitRef="iso4217_USD" decimals="-5" id="id_2597911_38A77765-DC80-471A-84B5-C1BA6A3A19FA_1_1">64100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349_715757x707740" unitRef="iso4217_USD" decimals="-5" id="id_2597911_38A77765-DC80-471A-84B5-C1BA6A3A19FA_2_1">64100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349_715757x715798" unitRef="iso4217_USD" decimals="-5" id="id_2597911_38A77765-DC80-471A-84B5-C1BA6A3A19FA_4_3">54900000</us-gaap:DerivativeLiabilities>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349_715757x715798" unitRef="iso4217_USD" decimals="-5" id="id_2597911_38A77765-DC80-471A-84B5-C1BA6A3A19FA_4_4">14600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <amrn:AdditionalPercentageInterestRatePenalty contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_714378x714242" unitRef="pure" decimals="4" id="id_2597911_3DD88501-E130-4B19-9C2D-962B239A5397_1001_0">0.0050</amrn:AdditionalPercentageInterestRatePenalty>
  <us-gaap:OtherCommitment contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_715632x711232" unitRef="iso4217_USD" decimals="-6" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_3002_1">150000000</us-gaap:OtherCommitment>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_715632x711232" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_1002_1">14577000</us-gaap:DerivativeLiabilities>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_715632x711232" unitRef="iso4217_USD" decimals="-5" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_3002_10">14600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <amrn:ChangeInControlObligations contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_715632x711232" unitRef="iso4217_USD" decimals="-6" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_3002_0">140000000</amrn:ChangeInControlObligations>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_1001_1">54854000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_716763x715581" unitRef="iso4217_USD" decimals="-3" id="id_2597911_538A9757-F2B2-4DE7-B327-B013BC0D66E0_1001_0">54854000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE46938---1310-Q0010_STD_12_20130712_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_4CBDAAEF-95FB-4C02-AFC3-583D5EB15E1E_2_1">121200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1310-Q0010_STD_12_20130712_0_711196x826933" unitRef="shares" decimals="INF" id="id_2597911_1D61FE80-A594-44A7-A935-1CB6D6D7D63F_1001_0">21700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE46938---1310-Q0010_STD_12_20130712_0_711196x826933" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1D61FE80-A594-44A7-A935-1CB6D6D7D63F_1001_2">121200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <amrn:OptionsExercisablePeriod contextRef="eol_PE46938---1310-Q0010_STD_12_20130712_0_711196x826933" id="id_2597911_1D61FE80-A594-44A7-A935-1CB6D6D7D63F_1001_4">P30D</amrn:OptionsExercisablePeriod>
  <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="eol_PE46938---1310-Q0010_STD_22_20131022_0_710720x714667" unitRef="pure" decimals="2" id="id_2597911_D268E364-FF07-42AE-AD68-34F990115211_1001_0">0.50</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
  <us-gaap:RestructuringAndRelatedCostExpectedCost contextRef="eol_PE46938---1310-Q0010_STD_22_20131022_0_710720x714667" unitRef="iso4217_USD" decimals="-6" id="id_2597911_D268E364-FF07-42AE-AD68-34F990115211_1001_1">3000000</us-gaap:RestructuringAndRelatedCostExpectedCost>
  <dei:TradingSymbol contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_74C72283-5A7D-4033-87E4-AE6EFDCA23FC_1_400000">AMRN</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_74C72283-5A7D-4033-87E4-AE6EFDCA23FC_1_400001">AMARIN CORP PLC\UK</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_A53FE596-E0EC-4849-B468-3BE46E1D088A_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_74C72283-5A7D-4033-87E4-AE6EFDCA23FC_1_400004">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_A53FE596-E0EC-4849-B468-3BE46E1D088A_1_3">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_A53FE596-E0EC-4849-B468-3BE46E1D088A_1_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_A53FE596-E0EC-4849-B468-3BE46E1D088A_1_2">2013-09-30</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_74C72283-5A7D-4033-87E4-AE6EFDCA23FC_1_400002">0000897448</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_74C72283-5A7D-4033-87E4-AE6EFDCA23FC_1_400003">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_A53FE596-E0EC-4849-B468-3BE46E1D088A_1_4">Q3</dei:DocumentFiscalPeriodFocus>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_A64BDB45-B941-4889-B4EE-414D5DB3DB47_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Intangible Asset, net&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Intangible assets consist
 of a milestone payment paid to the former shareholders of Laxdale
 Limited related to the 2004 acquisition of our rights to Vascepa,
 which is the result of Vascepa receiving marketing approval for the
 first indication and is amortized over its estimated useful life on
 a straight-line basis. The Company concluded that use of the
 straight-line method was appropriate as the majority of cash flows
 are expected to be generated ratably over the estimated useful life
 and no degradation of the cash flows over time is currently
 anticipated. See Note 7&amp;#x2014;Commitments and Contingencies for
 further information regarding other obligations related to the
 acquisition of Laxdale Limited.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:DebtPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_578464EA-926A-4F73-A31D-62058E2EADB4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Debt
 Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Debt instruments are
 initially recorded at fair value, with coupon interest and
 amortization of debt issuance discounts recognized in the statement
 of operations as interest expense at each period end while such
 instruments are outstanding. If the Company issues shares to
 discharge the liability, the debt obligation is derecognized and
 common stock and additional paid-in capital are recognized on the
 issuance of those shares.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 exchangeable notes contain a conversion option which is classified
 as equity. The fair value of the liability component of the debt
 instrument was deducted from the initial proceeds to determine the
 proceeds to be allocated to the conversion option. The embedded
 conversion option is indexed to the Company&amp;#x2019;s stock and
 treated as equity on the balance sheet. The conversion option is
 evaluated on a quarterly basis to determine if it still meets the
 criteria to be equity classified. The excess principal amount of
 the debt over the carrying value of the liability is amortized to
 interest expense over the term of the debt.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 December 2012 debt financing agreement contains a redemption
 feature triggered upon a change of control, which has been
 classified as an embedded derivative. The fair value of the
 derivative was recorded as a reduction to the fair value of the
 note payable. The fair value of this warrant derivative liability
 is remeasured at each reporting period, with changes in fair value
 recognized in the statement of operations. The discount recorded to
 the note payable is being amortized to interest expense over the
 term of the note payable.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_65EFD2A1-8064-4E64-877B-7F25E20FCDA9_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;(6)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Long term
 debt&amp;#x2014;December 2012 Financing&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;On December&amp;#xA0;6, 2012,
 the Company entered into an agreement with BioPharma. Under this
 agreement, the Company granted to BioPharma a security interest in
 future receivables associated with the Vascepa patent rights in
 exchange for $100.0 million received at the closing of the
 agreement, which closing occurred in December 2012. The Company has
 agreed to repay BioPharma up to $150&amp;#xA0;million of future revenue
 and receivables. The first scheduled repayment under the agreement
 is a repayment of $2.5&amp;#xA0;million of interest due to be paid to
 BioPharma in November 2013 for the fiscal quarter ended
 September&amp;#xA0;30, 2013, subject to the limitation described below.
 Additional quarterly repayments are scheduled to be paid thereafter
 in accordance with the following schedule: $2.5 million of interest
 in the first quarter of 2014; $8.0 million per quarter in each of
 the next four quarters, $10.0 million per quarter in each of the
 next four quarters, $15.0 million per quarter in each of the next
 four quarters and a final payment of $13.0 million scheduled for
 payment in May 2017. The quarterly repayments through the third
 quarter of September 2014 represent interest only. Quarterly
 payments do not begin to reduce the principal balance until the
 fourth quarter of 2014. These quarterly payments are subject to a
 quarterly threshold amount whereby, if a calculated threshold,
 based on quarterly Vascepa revenues, is not achieved, the quarterly
 payment payable in that quarter can at the Company&amp;#x2019;s election
 be reduced, with the reduction carried forward without interest for
 payment in a future period. The payment of any carried forward
 amount is subject to similarly calculated threshold repayment
 amounts based on Vascepa revenue levels. Except upon a change of
 control in Amarin, the agreement does not expire until $150 million
 has been repaid. Under the agreement, upon a change of control, the
 Company would be required to pay $140 million, less any previously
 repaid amount, if the change of control occurs on or before
 December&amp;#xA0;31, 2013, or required to repay $150 million, less any
 previously repaid amount, if the change of control event occurs
 after December&amp;#xA0;31, 2013. The Company can prepay after
 October&amp;#xA0;1, 2013, an amount equal to $150 million less any
 previously repaid amount.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company determined the
 redemption feature upon a change of control to be an embedded
 derivative requiring bifurcation. The fair value of the embedded
 derivative was calculated by determining the fair value of the debt
 with the change in control provision included and also without the
 change in control provision. The difference between the two fair
 values of the debt was determined to be the fair value of the
 embedded derivative, and upon closing, the Company recorded a
 derivative liability of $14.6 million as a reduction to the note
 payable. The fair value of this derivative liability is remeasured
 at each reporting period, with changes in fair value recognized in
 the statement of operations. The fair value of the derivative
 liability at September&amp;#xA0;30, 2013 was $7.2 million and the
 Company recognized a gain on change in fair value of derivative
 liability of $1.4 million and $7.4 million for the three and nine
 month periods ended September&amp;#xA0;30, 2013, respectively. For the
 nine months ended September&amp;#xA0;30, 2013, the Company recorded
 $9.7&amp;#xA0;million and $2.2 million of cash and non-cash interest
 expense, respectively related to the BioPharma debt. For the three
 months ended September&amp;#xA0;30, 2013, the Company recorded
 $2.7&amp;#xA0;million and $0.6 million of cash and non-cash interest
 expense, respectively related to the BioPharma debt. The Company
 will periodically evaluate the remaining term of the agreement and
 the effective interest will be recalculated each period based on
 the Company&amp;#x2019;s most current estimate of repayment.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company currently
 estimates that its Vascepa revenue levels will not be high enough
 in each quarter to support repayment to BioPharma in accordance
 with threshold amounts in the repayment schedule. For the three
 months ended September&amp;#xA0;30, 2013, revenues were below the
 contractual threshold amount such that a cash payment of $0.8
 million is due in November 2013 reflecting the calculated optional
 reduction amount as opposed to the contractual threshold payment of
 $2.5 million. In accordance with the agreement with BioPharma,
 quarterly differences between the calculated optional reduction
 amounts and the repayment schedule amounts are rescheduled for
 payment beginning in the second quarter of 2017. Any such deferred
 repayments will remain subject to continued application of the
 quarterly ceiling in amounts due established by the calculated
 threshold based on quarterly Vascepa revenues. Additionally, the
 revised assumptions yielded a decrease in the calculated effective
 interest rate resulting in a decrease in interest expense during
 the three months ended September&amp;#xA0;30, 2013 as compared to the
 three months ended June&amp;#xA0;30, 2013 and March&amp;#xA0;31,
 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Exchangeable Senior Notes&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In January 2012, the Company
 issued $150.0 million in principal amount of 3.5% exchangeable
 senior notes due 2032, or the Senior Notes. The Senior Notes were
 issued by Corsicanto Limited, an Irish limited company acquired by
 Amarin in January 2012. Corsicanto Limited is a wholly-owned
 subsidiary of Amarin. The general, unsecured, senior obligations
 are fully and unconditionally guaranteed by Amarin but not by any
 of the Company&amp;#x2019;s subsidiaries. Corsicanto Limited has no
 assets, operations, revenues or cash flows other than those related
 to the issuance, administration and repayment of the Senior
 Notes.&amp;#xA0;There are no significant restrictions on the ability of
 Amarin to obtain funds from Corsicanto Limited in the form of cash
 dividends, loans, or advances.&amp;#xA0;Net proceeds to the Company,
 after payment of underwriting fees and expenses, were approximately
 $144.3 million.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Senior Notes have a
 stated interest rate of 3.5%&amp;#xA0;per year, payable semiannually in
 arrears on January&amp;#xA0;15 and July&amp;#xA0;15 of each year beginning
 on July&amp;#xA0;15, 2012, and ending upon the Senior Notes&amp;#x2019;
 maturity on January&amp;#xA0;15, 2032. The Senior Notes are subject to
 repurchase by the Company at the option of the holders on each of
 January&amp;#xA0;19, 2017,&amp;#xA0;January&amp;#xA0;19, 2022, and
 January&amp;#xA0;19, 2027, at a price equal to 100% of the principal
 amount of the Senior Notes to be repurchased, plus accrued and
 unpaid interest to, but excluding, the repurchase date. The Senior
 Notes are exchangeable under certain circumstances into cash, ADSs,
 or a combination of cash and ADSs, at the Company&amp;#x2019;s election,
 with an initial exchange rate of 113.4752 ADSs per $1,000 principal
 amount of Senior Notes. It is the Company&amp;#x2019;s current intention
 to settle these obligations in cash. If the Company elected
 physical settlement, the Senior Notes would initially be
 exchangeable into 17,021,280 ADSs. Based on the closing price of
 the Company&amp;#x2019;s stock at September&amp;#xA0;30, 2013, the principal
 amount of the Senior Notes would exceed the value of the shares if
 converted on that date by $42.4 million.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Additional covenants
 include: (i)&amp;#xA0;limitations on future indebtedness under certain
 circumstances, (ii)&amp;#xA0;the timely filing of documents and reports
 pursuant to Section&amp;#xA0;13 or 15(d) of the Exchange Act with both
 the SEC and the Trustee, and (iii)&amp;#xA0;maintaining the tradability
 of the Senior Notes. The Company is required to use commercially
 reasonable efforts to procure and maintain the listing of the
 Senior Notes on the Global Exchange Market operated under the
 supervision of the Irish Stock Exchange (or other recognized stock
 exchange as defined in the Note Indenture) prior to July&amp;#xA0;15,
 2012. If the Senior Notes are not freely tradable, as a result of
 restrictions pursuant to U.S. securities law or the terms of the
 Indenture or the Senior Notes, the Company shall pay additional
 interest on the Senior Notes at the rate of 0.50%&amp;#xA0;per annum of
 the principal amount of Senior Notes outstanding for each day
 during such period for which the Company&amp;#x2019;s failure to file
 has occurred and is continuing or for which the Senior Notes are
 not freely tradable.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company may not redeem
 the Senior Notes prior to January&amp;#xA0;19, 2017, other than in
 connection with certain changes in the tax law of a relevant taxing
 jurisdiction that results in additional amounts becoming due with
 respect to payments and/or deliveries on the Senior Notes. On or
 after January&amp;#xA0;19, 2017 and prior to the maturity date, the
 Company may redeem for cash all or part of the Senior Notes at a
 redemption price equal to 100% of the principal amount of the
 Senior Notes to be redeemed, plus accrued and unpaid interest to,
 but excluding, the redemption date. There is no prepayment penalty
 or sinking fund provided for the Senior Notes. If the Company
 undergoes a fundamental change, holders may require the Company to
 repurchase for cash all or part of their Senior Notes at a
 repurchase price equal to 100% of the principal amount of the
 Senior Notes to be repurchased, plus accrued and unpaid interest
 to, but excluding, the fundamental change repurchase date. The
 Senior Notes are the Company&amp;#x2019;s senior unsecured obligations
 and rank senior in right of payment to the Company&amp;#x2019;s future
 indebtedness that is expressly subordinated in right of payment to
 the Senior Notes and equal in right of payment to the
 Company&amp;#x2019;s future unsecured indebtedness that is not so
 subordinated. The Senior Notes are effectively junior in right of
 payment to future secured indebtedness to the extent of the value
 of the assets securing such indebtedness.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Senior Notes are
 exchangeable under certain circumstances. The Company calculated
 the fair value of the liability component of the Senior Notes to be
 $126.2 million, and the excess of the principal amount of the debt
 over the liability component of $23.8 million was allocated to the
 conversion option resulting in a discount on the debt. The discount
 created from allocating proceeds to the conversion option is being
 amortized to interest expense using the effective interest method
 over the Senior Notes&amp;#x2019; estimated remaining life, which was
 calculated to be a period of twenty-four months. The effective
 interest rate of the Senior Notes is 14.5%. As of
 September&amp;#xA0;30, 2013, the unamortized discount created from the
 allocation of the proceeds to the conversion option was $3.9
 million. The conversion option will not be subsequently remeasured
 as long as it continues to meet the criteria for equity
 classification.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company also recorded a
 debt discount to reflect the value of the underwriters&amp;#x2019;
 discounts and offering costs. A portion of the debt discount from
 underwriter&amp;#x2019;s discounts and offering costs was allocated to
 the equity and liability components of the Notes in proportion to
 the proceeds allocated to each component. The portion of the debt
 discount from underwriters&amp;#x2019; discounts and offering costs
 allocated to the liability component is being amortized as interest
 expense over the estimated remaining life of the Senior Notes of
 twenty-four months. As of September&amp;#xA0;30, 2013, the unamortized
 debt discount was $0.8 million and was recorded as a direct
 reduction of the related debt on the balance sheet. The carrying
 value of the Notes, net of the unamortized discount, was $145.3
 million. During the three months ended September&amp;#xA0;30, 2013, the
 Company recognized interest expense of $5.2 million related to the
 Notes, of which $3.2 million represents amortization of the debt
 discount created upon allocation of proceeds to the conversion
 option, $1.3 million represents contractual coupon interest, and
 $0.7 million represents the amortization of the discount from the
 underwriter&amp;#x2019;s discounts and offering costs. During the nine
 months ended September&amp;#xA0;30, 2013, the Company recognized
 interest expense of $15.0 million related to the Notes, of which
 $9.2 million represents amortization of the debt discount created
 upon allocation of proceeds to the conversion option, $3.9 million
 represents contractual coupon interest, and $1.9 million represents
 the amortization of the discount from the underwriter&amp;#x2019;s
 discounts and offering costs. At September&amp;#xA0;30, 2013, the
 Company had accrued interest of $1.1 million.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In January and July 2013,
 the interest payments due of $2.6 million were paid as
 scheduled.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_1DB718A5-8EB7-48E1-BF0A-4FE847B5B501_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company sells Vascepa
 principally to a limited number of major wholesalers, as well as
 selected regional wholesalers and specialty pharmacy providers, or
 collectively, its Distributors, that in turn resell Vascepa to
 retail pharmacies for subsequent resale to patients and health care
 providers. Patients are required to have a prescription in order to
 purchase Vascepa. In accordance with GAAP, the Company&amp;#x2019;s
 revenue recognition policy requires that: (i)&amp;#xA0;there is
 persuasive evidence that an arrangement exists between the Company
 and the Distributor, (ii)&amp;#xA0;delivery has occurred,
 (iii)&amp;#xA0;collectability is reasonably assured and (iv)&amp;#xA0;the
 price is fixed or determinable.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company commenced its
 commercial launch in the United States on January&amp;#xA0;28, 2013.
 Prior to 2013, the Company recognized no revenue from Vascepa
 sales. In accordance with GAAP, until the Company has the ability
 to reliably estimate returns of Vascepa from its Distributors,
 revenue will be recognized based on the resale of Vascepa for the
 purposes of filling patient prescriptions, and not based on sales
 from the Company to such Distributors. Consistent with industry
 practice, once the Company achieves sufficient history such that it
 can reliably estimate returns, the Company will recognize revenue
 based on sales to its Distributors. The Company currently defers
 Vascepa revenue recognition until the earlier of the product being
 resold for purposes of filling patient prescriptions; or the
 expiration of the right of return (twelve months after the
 expiration date of the product). The Company also defers the
 related cost of product sales and records such amounts as finished
 goods inventory held by others until revenue related to such
 product sales is recognized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has contracts
 with its primary Distributors and delivery occurs when a
 Distributor receives Vascepa. The Company evaluates the
 creditworthiness of each of its Distributors to determine whether
 revenues can be recognized upon delivery, subject to satisfaction
 of the other requirements, or whether recognition is required to be
 delayed until receipt of payment or when the product is utilized.
 In order to conclude that the price is fixed or determinable, the
 Company must be able to (i)&amp;#xA0;calculate its gross product
 revenues from the sales to Distributors and (ii)&amp;#xA0;reasonably
 estimate its net product revenues. The Company calculates gross
 product revenues based on the wholesale acquisition cost that the
 Company charges its Distributors for Vascepa. The Company estimates
 its net product revenues by deducting from its gross product
 revenues (a)&amp;#xA0;trade allowances, such as invoice discounts for
 prompt payment and distributor fees, (b)&amp;#xA0;estimated government
 and private payor rebates, chargebacks and discounts, such as
 Medicaid reimbursements, (c)&amp;#xA0;reserves for expected product
 returns and (d)&amp;#xA0;estimated costs of incentives offered to
 certain indirect customers, including patients.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Trade
 Allowances:&lt;/i&gt; The Company generally provides invoice discounts on
 Vascepa sales to its Distributors for prompt payment and pays fees
 for distribution services, such as fees for certain data that
 Distributors provide to the Company. The payment terms for sales to
 Distributors generally include a 2% discount for payment within
 30&amp;#xA0;days. Based on the Company&amp;#x2019;s judgment and experience,
 the Company expects its Distributors to earn these discounts and
 fees, and deducts the full amount of these discounts and fees from
 its gross product revenues and accounts receivable at the time such
 revenues are recognized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Rebates,
 Chargebacks and Discounts:&lt;/i&gt; The Company contracts with Medicaid,
 other government agencies and various private organizations, or
 collectively, Third-party Payors, so that Vascepa will be eligible
 for purchase by, or partial or full reimbursement from, such
 Third-party Payors. The Company estimates the rebates, chargebacks
 and discounts it will provide to Third-party Payors and deducts
 these estimated amounts from its gross product revenues at the time
 the revenues are recognized. The Company estimates the rebates,
 chargebacks and discounts that it will provide to Third-party
 Payors based upon (i)&amp;#xA0;the Company&amp;#x2019;s contracts with these
 Third-party Payors, (ii)&amp;#xA0;the government-mandated discounts
 applicable to government-funded programs, (iii)&amp;#xA0;information
 obtained from the Company&amp;#x2019;s Distributors and
 (iv)&amp;#xA0;information obtained from other third parties regarding
 the payor mix for Vascepa.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Product
 Returns:&lt;/i&gt; The Company&amp;#x2019;s Distributors have the right to
 return unopened unprescribed Vascepa during the 18-month period
 beginning six months prior to the labeled expiration date and
 ending twelve months after the labeled expiration date. The
 expiration date for Vascepa is three years after it has been
 converted into capsule form, which is the last step in the
 manufacturing process for Vascepa and generally occurs within a few
 months before Vascepa is delivered to Distributors. As of
 September&amp;#xA0;30, 2013, the Company had experienced a deminimus
 quantity of product returns. During the nine months ended
 September&amp;#xA0;30, 2013, the period in which the Company began
 selling Vascepa, the Company was not able to reasonably estimate
 product returns for all product sold to Distributors but the
 Company was able to reasonably estimate product returns for certain
 sales of Vascepa based on product used to fill patient
 prescriptions as determined by inventory estimated to be in the
 distribution channel and third party reports of prescriptions
 filled. In making this assessment, the Company used (i)&amp;#xA0;data
 provided to the Company by its Distributors (including weekly
 reporting of Distributors&amp;#x2019; sales and inventory held by
 Distributors that provided the Company with visibility into the
 distribution channel in order to determine what quantities were
 sold to retail pharmacies and other providers),
 (ii)&amp;#xA0;information provided to the Company from retail
 pharmacies, (iii)&amp;#xA0;data provided to the Company by a third
 party data provider which collects and publishes prescription data,
 and other third parties, (iv)&amp;#xA0;historical industry information
 regarding return rates for similar pharmaceutical products,
 (v)&amp;#xA0;the estimated remaining shelf life of Vascepa previously
 shipped and currently being shipped to Distributors and
 (vi)&amp;#xA0;contractual agreements intended to limit the amount of
 inventory maintained by the Company&amp;#x2019;s
 Distributors.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Other
 Incentives:&amp;#xA0;&lt;/i&gt;Other incentives that the Company offers to
 indirect customers include co-pay mitigation rebates provided by
 the Company to commercially insured patients who have coverage for
 Vascepa and who reside in states that permit co-pay mitigation
 programs. The Company&amp;#x2019;s co-pay mitigation program is intended
 to reduce each participating patient&amp;#x2019;s portion of the
 financial responsibility for Vascepa&amp;#x2019;s purchase price to a
 specified dollar amount. Based upon the terms of the program and
 information regarding programs provided for similar specialty
 pharmaceutical products, the Company estimates the average co-pay
 mitigation amounts and the percentage of patients that it expects
 to participate in the program in order to establish its accruals
 for co-pay mitigation rebates and deducts these estimated amounts
 from its gross product revenues at the time the revenues are
 recognized. The Company&amp;#x2019;s co-pay mitigation rebates offered
 to date will expire on December&amp;#xA0;31, 2013. The Company adjusts
 its accruals for co-pay mitigation rebates based on its estimates
 regarding the portion of issued rebates that it estimates will not
 be redeemed. In addition, as is customary prior to the launch of
 new drugs, the Company provided certain of its Distributors with
 financial incentives to begin stocking Vascepa prior to the
 Company&amp;#x2019;s commercial launch of Vascepa in order to ensure
 that Vascepa was readily available to fill patient prescriptions
 upon launch. Such incentives were only offered on purchases of
 initial launch quantities of Vascepa stocked by Distributors in
 January 2013. The amount of these financial incentives were
 recorded by the Company as a reduction to revenues on a pro-rata
 basis for each of the bottles subject to such financial incentives.
 The Company estimates that all of these initial launch quantities
 stocked by its primary Distributors in January 2013 were resold by
 such Distributors prior to September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes activity in each of the product revenue allowance and
 reserve categories described above for the nine months ended
 September&amp;#xA0;30, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Trade&lt;br /&gt;
 Allowances&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Rebates,&lt;br /&gt;
 Chargebacks&lt;br /&gt;
 and&amp;#xA0;Discounts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Product&lt;br /&gt;
 Returns&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Other&lt;br /&gt;
 Incentives&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to
 current period and deferred sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,839&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,418&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;72&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,018&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,347&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 current period and deferred sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,951&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,484&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,835&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(5,270&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;888&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;934&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;72&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;183&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;2,077&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes product revenue recognized and deferred during the nine
 months ended September&amp;#xA0;30, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Product revenue
 recognized&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;16,245&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred product
 revenue&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,617&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;17,862&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In conjunction with the
 Company&amp;#x2019;s recognition and deferral of product revenues, the
 Company expensed and capitalized the associated cost of goods, as
 follows, during the nine months ended September&amp;#xA0;30, 2013 (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cost of goods sold
 expensed&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,813&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods inventory
 held by others&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;641&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;8,454&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="pure" decimals="2" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1_4">0.91</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_E7F46C52-BD98-489C-9FC3-86D68D77210A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company had 9,816,826
 warrants to purchase common shares outstanding at
 September&amp;#xA0;30, 2013 at a weighted-average exercise price of
 $1.44, as summarized in the following table:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"&gt;
 &lt;tr&gt;
 &lt;td style="WIDTH: 17pt"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 17pt"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="23%"&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 14pt"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 14pt"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="23%"&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 24pt"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 24pt"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="23%"&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 27pt"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 27pt"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Issue
 Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Expiration&amp;#xA0;Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4/27/07&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17,500&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17.90&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1/17/14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7/31/09&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,684,888&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.00&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7/30/14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/16/09&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,487,388&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.50&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/15/14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/16/09&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;627,050&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.50&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/15/14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;9,816,826&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;1.44&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_384953FF-8901-4154-B43B-51A2260DBF0C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Inventories consist of the
 following at September&amp;#xA0;30, 2013 and December&amp;#xA0;31, 2012 (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Raw materials&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4,993&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,465&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Work in process&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;12,166&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,471&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9,283&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;326&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods inventory
 held by others&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;641&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;27,083&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;21,262&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_18CC318F-1DCB-48F0-95C2-1FBD25DC93D2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The change in the fair
 value of financial instruments is as follows (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Warrants&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Redemption&amp;#xA0; &amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exchange&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Contracts&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Totals&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2012&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Loss on change in fair
 value of derivative liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;68,686&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;68,686&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation expense for
 change in fair value of warrants issued to former
 employees&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,037&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,037&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
 equity&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(103,885&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(103,885&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2012&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;90,963&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;90,963&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Warrants&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Redemption&amp;#xA0; &amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exchange&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Contracts&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Totals&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;54,854&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;14,577&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;69,431&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(Gain) loss on change in
 fair value of derivative liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(14,077&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(7,377&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;395&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(21,059&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation income for
 change in fair value of warrants issued to former
 employees&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,179&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,179&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
 equity&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;39,598&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;7,200&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;395&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;47,193&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
  <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_A6512D9D-1A64-4E3D-8571-AA55DDD825D4_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(5)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Warrants and Warrant
 Derivative Liability&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company had 9,816,826
 warrants to purchase common shares outstanding at
 September&amp;#xA0;30, 2013 at a weighted-average exercise price of
 $1.44, as summarized in the following table:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"&gt;
 &lt;tr&gt;
 &lt;td style="WIDTH: 17pt"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 17pt"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="23%"&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 14pt"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 14pt"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="23%"&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 24pt"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 24pt"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="23%"&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 27pt"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 27pt"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Issue
 Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Expiration&amp;#xA0;Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4/27/07&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17,500&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17.90&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1/17/14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7/31/09&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,684,888&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.00&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7/30/14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/16/09&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,487,388&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.50&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/15/14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/16/09&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;627,050&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.50&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/15/14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;9,816,826&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;1.44&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;October
 2009 Warrant derivative liability&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On October&amp;#xA0;16, 2009,
 the Company completed a $70.0 million private placement with both
 existing and new investors resulting in $62.3 million in net
 proceeds and an additional $3.6 million from bridge notes converted
 in conjunction with the private placement. In consideration for the
 $62.3 million in net cash proceeds Amarin issued 66.4&amp;#xA0;million
 units, each unit consisting of (i)&amp;#xA0;one ADS (representing one
 ordinary share) at a purchase price of $1.00 and (ii)&amp;#xA0;a
 warrant with a five year term to purchase 0.5 of an ADS at an
 exercise price of $1.50 per ADS. In consideration for the
 conversion of $3.6 million of convertible bridge notes, Amarin
 issued 4.0&amp;#xA0;million units, each unit consisting of (i)&amp;#xA0;one
 ADS (representing one ordinary share) at a purchase price of $0.90
 and (ii)&amp;#xA0;a warrant with a five year term to purchase 0.5 of an
 ADS at an exercise price of $1.50 per ADS. The total number of
 warrants issued in conjunction with the financing was
 35.2&amp;#xA0;million of which 7.5&amp;#xA0;million are outstanding at
 September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In conjunction with the
 October 2009 financing, the Company issued an additional
 0.9&amp;#xA0;million warrants to three former officers of which
 0.6&amp;#xA0;million are outstanding as of September&amp;#xA0;30, 2013. The
 warrants issued in connection with the October 2009 financing
 contained a pricing variability feature which provided for an
 increase to the exercise price if the exchange rate between the
 U.S. dollar and British pound adjusts such that the warrants could
 be exercised at a price less than the &amp;#xA3;0.5 par value of the
 common stock &amp;#x2013; that is, if the exchange rate exceeded U.S.
 $3.00 per &amp;#xA3;1.0 sterling. Due to the potential variable nature
 of the exercise price, the warrants are not considered to be
 indexed to the Company&amp;#x2019;s common stock. Accordingly, the
 warrants do not qualify for the exception to classify the warrants
 within equity and are classified as a derivative
 liability.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The fair value of this
 warrant derivative liability is remeasured at each reporting
 period, with changes in fair value recognized in the statement of
 operations. Upon exercise, the fair value of the warrants exercised
 is remeasured and reclassified from warrant liability to additional
 paid-in capital. Although the warrants contain a pricing
 variability feature, the number of warrants issuable remains fixed.
 Therefore, the maximum number of common shares issuable as a result
 of the October 2009 private placement is 36.1 million. The change
 in fair value of the warrant derivative liability is discussed in
 Note 2.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;July 2009
 and April 2007 Warrants&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company issued certain
 warrants in July 2009 and April 2007. As of September&amp;#xA0;30, 2013
 and December&amp;#xA0;31, 2012 these warrants have been classified as
 equity instruments and have been included in the Company&amp;#x2019;s
 consolidated balance sheet within additional paid-in-capital.
 During the nine months ended September&amp;#xA0;30, 2013, 120,000 of
 the July 2009 warrants were exercised resulting in proceeds to the
 Company of $0.1 million.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="pure" decimals="-6" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1_3">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:DerivativesEmbeddedDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_6B36ECFA-67A1-4F50-B4F4-060BF42A31C1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Long
 Term Debt Redemption Feature&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 December 2012 financing agreement with BioPharma Secured Debt Fund
 II Holdings Cayman, L.P, or BioPharma, contains a redemption
 feature whereby, upon a change of control, the Company would be
 required to pay $140 million, less any previously repaid amount, if
 the change of control occurs on or before December&amp;#xA0;31, 2013,
 or required to repay $150 million, less any previously repaid
 amount, if the change of control event occurs after
 December&amp;#xA0;31, 2013. The Company determined this redemption
 feature to be an embedded derivative, which is carried at fair
 value and is classified as Level 3 in the fair value hierarchy due
 to the use of significant unobservable inputs.&amp;#xA0;The fair value
 of the embedded derivative was calculated using a
 probability-weighted model incorporating management estimates for
 potential change in control, and by determining the fair value of
 the debt with and without the change in control provision included.
 The difference between the two fair values of the debt was
 determined to be the fair value of the embedded derivative. At
 December&amp;#xA0;31, 2012, the fair value of the derivative was
 determined to be $14.6 million, and the debt was valued by
 comparing debt issues of similar companies with (i)&amp;#xA0;terms of
 between 4.8 and 8.0 years, (ii)&amp;#xA0;coupon rates of between 3.0%
 and 11.5% and (iii)&amp;#xA0;market yields of between 10.7% and 27.7%.
 At September&amp;#xA0;30, 2013, the fair value of the derivative was
 determined to be $7.2 million, and the debt was valued by comparing
 debt issues of similar companies with (i)&amp;#xA0;remaining terms of
 between 3.5 and 4.4 years, (ii)&amp;#xA0;coupon rates of between 9.9%
 and 12.5% and (iii)&amp;#xA0;market yields of between 10.4% and 25.8%.
 The Company recognized a gain of $1.4 million and $7.4 million on
 the change in fair value of this derivative liability for the three
 and nine months ended September&amp;#xA0;30, 2013,
 respectively.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DerivativesEmbeddedDerivatives>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_E6328F84-C10A-4501-937F-997914A61836_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Income
 Taxes&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred tax assets and
 liabilities are recognized for the future tax consequences of
 differences between the carrying amounts and tax bases of assets
 and liabilities and operating loss carry-forwards and other
 attributes using enacted rates expected to be in effect when those
 differences reverse. Valuation allowances are provided against
 deferred tax assets that are not more likely than not to be
 realized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides
 reserves for potential payments of tax to various tax authorities
 or does not recognize tax benefits related to uncertain tax
 positions and other issues. Tax benefits for uncertain tax
 positions are based on a determination of whether a tax benefit
 taken by the Company in its tax filings or positions is more likely
 than not to be realized, assuming that the matter in question will
 be decided based on its technical merits. The Company&amp;#x2019;s
 policy is to record interest and penalties in the provision for
 income taxes.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_5A5093AC-2FDD-49E6-8396-D439A72F6CC3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Selling, General and Administrative
 Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company charges sales,
 general and administrative costs to operations as incurred.
 Selling, general and administrative costs include costs of
 salaries, programs and infrastructure necessary for the general
 conduct of the Company&amp;#x2019;s business, including the 2013
 commercial launch of Vascepa in the United States for the MARINE
 indication. Included as part of selling, general and administrative
 costs is warrant-related expense from non-cash changes in fair
 value of the derivative liability associated with warrants issued
 in October 2009 to former officers of Amarin which is recorded as
 compensation income (expense).&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_2D60251D-CEE9-4F58-935B-AADDCF29ABDB_1_0">P16Y9M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_43097B0B-FE68-4CA0-95D0-A09E29308B70_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 presents information about the Company&amp;#x2019;s assets and
 liabilities as of September&amp;#xA0;30, 2013 and December&amp;#xA0;31,
 2012 that are measured at fair value on a recurring basis and
 indicates the fair value hierarchy of the valuation techniques the
 Company utilized to determine such fair value:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,
 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;113.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;113.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liabilities:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
 liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;39.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;39.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt redemption
 feature&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7.2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7.2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign currency
 contracts&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.4&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.4&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;64.1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;64.1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liability:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
 liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt redemption
 feature&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:InventoryDisclosureTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_3086312D-8916-4FC6-AE46-1D1303AD63B9_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(4)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Inventory&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;After approval of Vascepa
 on July&amp;#xA0;26, 2012 by the FDA, the Company began capitalizing
 its purchases of saleable inventory of Vascepa from suppliers that
 have been qualified by the FDA. Inventories consist of the
 following at September&amp;#xA0;30, 2013 and December&amp;#xA0;31, 2012 (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Raw materials&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4,993&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,465&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Work in process&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;12,166&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,471&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9,283&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;326&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods inventory
 held by others&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;641&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;27,083&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;21,262&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Inventory is valued at
 lower of cost or market value. During the three months ended
 September&amp;#xA0;30, 2013, the Company recorded an inventory reserve
 of $1.8 million related to certain inventories that are not
 recoverable in their current form. The materials are currently
 under investigation by the supplier and the Company. The reserve
 was recorded within research and development expense in the
 statement of operations as this supplier has yet to produce
 material qualified for commercial sale.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_EACE6450-13EA-4D30-81D1-0E0C86A1F0BC_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;(8)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Equity&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Common
 stock&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;On July&amp;#xA0;12, 2013, the
 Company completed a public offering of 21,700,000 ADSs. The
 underwriters purchased the ADSs from Amarin at a price of $5.60 per
 ADS, resulting in net proceeds to Amarin of approximately $121.2
 million, after deducting estimated offering expenses payable by the
 Company. Amarin also granted the underwriters a 30-day option to
 purchase an additional 3,255,000 ADSs, which was not exercised. The
 stated use of proceeds in connection with this offering were as
 follows: primarily to continue the commercial launch of Vascepa
 capsules in the MARINE indication, prepare for and commercially
 launch Vascepa in the ANCHOR indication, if approved, advance the
 Company&amp;#x2019;s REDUCE-IT cardiovascular outcomes trial, and for
 general corporate and working capital purposes.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;During the nine months ended
 September&amp;#xA0;30, 2013 and 2012, the Company issued 386,000 and
 3,107,913 shares, respectively, as a result of the exercise of
 stock options. Gross and net proceeds resulting from the exercise
 of stock options amounted to $0.6 million for the nine months ended
 September&amp;#xA0;30, 2013. For the nine months ended
 September&amp;#xA0;30, 2012, gross proceeds amounted to $7.9 million
 and net proceeds amounted to $7.8 million resulting from the
 exercise of stock options. In addition, during the nine months
 ended September&amp;#xA0;30, 2013 and 2012, the Company issued 120,000
 and 10,881,276 shares, respectively, as a result of the exercise of
 warrants. Gross and net proceeds resulting from the exercise of
 warrants amounted to $0.1 million for the nine months ended
 September&amp;#xA0;30, 2013. For the nine months ended
 September&amp;#xA0;30, 2012, gross proceeds amounted to $16.6 million
 and net proceeds amounted to $16.5 million resulting from the
 exercise of warrants.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In August and September of
 2013, the Company granted a total of 44,000 restricted stock units
 (&amp;#x201C;RSUs&amp;#x201D;) to several employees under the Amarin
 Corporation plc 2011 Stock Incentive Plan (&amp;#x201C;2011
 Plan&amp;#x201D;). As of September&amp;#xA0;30, 2013, no RSU&amp;#x2019;s were
 forfeited and no shares were issued as a result of vesting. These
 RSUs vest upon the achievement of certain operational milestones
 and expire on December&amp;#xA0;31, 2013 if none of the milestones are
 achieved by such date. The RSUs will become fully vested upon a
 change of control of the Company. Upon vesting of each RSU, the
 participant shall be entitled to a payment equal to the fair market
 value of one share of Amarin common stock. The payment shall be
 paid to the participant in cash, or at the sole discretion of the
 Compensation Committee in shares or a combination of cash or
 shares. The fair value of the RSUs was determined on the date of
 grant, and compensation expense related to the RSUs is recognized
 once the related milestone is deemed probable. The Company recorded
 no expense during the nine months ended September&amp;#xA0;30, 2013
 related to the vesting of these RSUs.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In July of 2013, the Company
 granted a total of 54,000 deferred stock units (&amp;#x201C;DSUs&amp;#x201D;)
 to members of the Company&amp;#x2019;s Board of Directors under the
 Amarin Corporation plc 2011 Stock Incentive Plan (&amp;#x201C;2011
 Plan&amp;#x201D;). As of September&amp;#xA0;30, 2013, no DSU&amp;#x2019;s were
 forfeited and no shares were issued as a result of vesting. The
 DSU&amp;#x2019;s vest over a three year period. The DSUs will become
 fully vested upon a change of control of the Company. Upon
 termination of service to the Company, each Director shall be
 entitled to a payment equal to the fair market value of one share
 of Amarin common stock, which is required to be made in shares. The
 Company recorded expense during the nine months ended
 September&amp;#xA0;30, 2013 of $47,000 related to the vesting of these
 DSUs.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In January 2013, the Company
 granted 454,875 RSUs to several employees under the 2011 Plan. As
 of September&amp;#xA0;30, 2013, 32,500 RSUs were forfeited and no
 shares were issued as a result of vesting. These RSUs vest upon the
 achievement of certain operational milestones and expire on
 August&amp;#xA0;3, 2015 if none of the milestones are achieved by such
 date. The RSUs will become fully vested upon a change of control of
 the Company. Upon vesting of each RSU, the participant shall be
 entitled to a payment equal to the fair market value of one share
 of Amarin common stock. The payment shall be paid to the
 participant in cash, or at the sole discretion of the Compensation
 Committee in shares or a combination of cash or shares. The fair
 value of the RSUs was determined on the date of grant, and
 compensation expense related to the RSUs is recognized once the
 related milestone is deemed probable. The Company recorded no
 expense during the nine months ended September&amp;#xA0;30, 2013
 related to the vesting of these RSUs.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In February 2012, the
 Company granted 584,400 RSUs to several employees under the 2011
 Plan. As of September&amp;#xA0;30, 2013, a total of 90,684 RSUs were
 forfeited. These RSUs vest upon the achievement of certain
 regulatory and time-based milestones. The RSUs will become fully
 vested upon a change of control of the Company. Upon vesting of
 each RSU, the participant shall be entitled to a payment equal to
 the fair market value of one share of Amarin common stock. The
 payment shall be paid to the participant in cash, or at the sole
 discretion of the Compensation Committee in shares or a combination
 of cash or shares. During the nine months ended September&amp;#xA0;30,
 2013 and 2012, the Company issued 93,048 and 97,398 shares,
 respectively, as a result of the vesting of these RSUs. The fair
 value of the RSUs was determined on the date of grant, and
 compensation expense related to the RSUs is recognized once the
 related milestone is deemed probable. During the nine months ended
 September&amp;#xA0;30, 2013 and 2012, the Company recorded expense of
 $0.3 million and $1.2 million, respectively, related to the vesting
 of these RSUs.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="pure" decimals="3" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1_1">0.001</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:InventoryPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_4C96250E-471E-44A8-9AB6-6B6A087B624F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Inventory&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company states
 inventories at the lower of cost or market value. Cost is
 determined based on actual cost using the average cost method. An
 allowance is established when management determines that certain
 inventories may not be saleable. If inventory cost exceeds expected
 market value due to obsolescence, damage or quantities in excess of
 expected demand, the Company will record a reserve for the
 difference between cost and market value. The Company received FDA
 approval for Vascepa on July&amp;#xA0;26, 2012 and after that date
 began capitalizing inventory purchases of saleable product from
 approved suppliers. Until an API supplier is approved, all Vascepa
 API purchased from such supplier is included as a component of
 research and development expense. Upon sNDA approval of each
 additional supplier, the Company capitalizes subsequent Vascepa API
 purchases from such supplier as inventory. Purchases of Vascepa API
 received and expensed before such regulatory approvals is not
 subsequently capitalized, and all such purchases are quarantined
 and not used for commercial supply until such time as the sNDA for
 the supplier that produced the API is approved.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:DebtInstrumentCallDateEarliest contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_674A5308-E3DB-409A-850D-E5F2823646DE_1_0">2017-01-19</us-gaap:DebtInstrumentCallDateEarliest>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_8F826B9E-5ED6-4BC9-BADA-FAE92BB7A707_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Cash
 and Cash Equivalents&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash and cash equivalents
 consist of cash, deposits held at call with banks and short term
 highly liquid instruments with remaining maturities at the date of
 purchase of 90&amp;#xA0;days or less. Restricted cash represents cash
 and cash equivalents pledged to guarantee repayment of certain
 expenses which may be incurred for business travel under corporate
 credit cards held by employees.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_21">-157255000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_1_0">386000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_526E763C-CFCB-49E6-A394-D0BDBF41DB8A_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Intangible
 Asset&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Intangible asset consists
 of technology rights for Vascepa and have an estimated remaining
 useful life of 16.8 years. The carrying value as of
 September&amp;#xA0;30, 2013 and December&amp;#xA0;31, 2012 is as follows
 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Technology
 rights&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,624&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,624&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accumulated
 amortization&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(754&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(269&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,870&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,355&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_671E62FF-4BF2-4005-AD1D-0A43473D683A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Segment and Geographical
 Information&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;For the three and nine
 months ended September&amp;#xA0;30, 2013 and 2012, the Company has
 reported its business as a single reporting segment. The
 Company&amp;#x2019;s chief decision maker, who is the Chief Executive
 Officer, regularly evaluates the Company on a consolidated
 basis.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_91A74ED8-CE8C-4EA2-B362-E9806B51F05C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The carrying value as of
 September&amp;#xA0;30, 2013 and December&amp;#xA0;31, 2012 is as follows
 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Technology
 rights&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,624&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,624&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accumulated
 amortization&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(754&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(269&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,870&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,355&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_03F0DA79-D1A6-40B2-A459-6E4CE3ADA30C_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Significant Accounting
 Policies&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Use of
 Estimates&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The preparation of the
 Company&amp;#x2019;s consolidated financial statements in conformity
 with accounting principles generally accepted in the United States
 of America, or GAAP, requires management to make estimates and
 assumptions that affect the reported amounts of assets and
 liabilities, disclosure of contingent assets and liabilities at the
 date of the financial statements, and the reported amounts of
 revenues and expenses during the reporting period. Accounting
 estimates are based on historical experience and other factors that
 are considered reasonable under the circumstances. Actual results
 could differ from those estimates. The preparation of the
 Company&amp;#x2019;s condensed consolidated financial statements in
 accordance with GAAP requires management to make estimates,
 judgments and assumptions that may affect the reported amounts of
 assets, liabilities, revenues and expenses, and related disclosure
 of contingent assets and liabilities. On an on-going basis, the
 Company evaluates its estimates and judgments and methodologies,
 including those related to revenue recognition and related
 allowances, clinical trial expenses, the valuation of inventory,
 impairment and amortization of intangibles, share-based
 compensation, income taxes including the valuation allowance for
 deferred tax assets, valuation of investments and derivative
 instruments. The Company bases its estimates on historical
 experience and on various other assumptions that are believed to be
 reasonable, the results of which form the basis for making
 judgments about the carrying values of assets and liabilities.
 Actual results may differ from these estimates.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company sells Vascepa
 principally to a limited number of major wholesalers, as well as
 selected regional wholesalers and specialty pharmacy providers, or
 collectively, its Distributors, that in turn resell Vascepa to
 retail pharmacies for subsequent resale to patients and health care
 providers. Patients are required to have a prescription in order to
 purchase Vascepa. In accordance with GAAP, the Company&amp;#x2019;s
 revenue recognition policy requires that: (i)&amp;#xA0;there is
 persuasive evidence that an arrangement exists between the Company
 and the Distributor, (ii)&amp;#xA0;delivery has occurred,
 (iii)&amp;#xA0;collectability is reasonably assured and (iv)&amp;#xA0;the
 price is fixed or determinable.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company commenced its
 commercial launch in the United States on January&amp;#xA0;28, 2013.
 Prior to 2013, the Company recognized no revenue from Vascepa
 sales. In accordance with GAAP, until the Company has the ability
 to reliably estimate returns of Vascepa from its Distributors,
 revenue will be recognized based on the resale of Vascepa for the
 purposes of filling patient prescriptions, and not based on sales
 from the Company to such Distributors. Consistent with industry
 practice, once the Company achieves sufficient history such that it
 can reliably estimate returns, the Company will recognize revenue
 based on sales to its Distributors. The Company currently defers
 Vascepa revenue recognition until the earlier of the product being
 resold for purposes of filling patient prescriptions; or the
 expiration of the right of return (twelve months after the
 expiration date of the product). The Company also defers the
 related cost of product sales and records such amounts as finished
 goods inventory held by others until revenue related to such
 product sales is recognized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has contracts
 with its primary Distributors and delivery occurs when a
 Distributor receives Vascepa. The Company evaluates the
 creditworthiness of each of its Distributors to determine whether
 revenues can be recognized upon delivery, subject to satisfaction
 of the other requirements, or whether recognition is required to be
 delayed until receipt of payment or when the product is utilized.
 In order to conclude that the price is fixed or determinable, the
 Company must be able to (i)&amp;#xA0;calculate its gross product
 revenues from the sales to Distributors and (ii)&amp;#xA0;reasonably
 estimate its net product revenues. The Company calculates gross
 product revenues based on the wholesale acquisition cost that the
 Company charges its Distributors for Vascepa. The Company estimates
 its net product revenues by deducting from its gross product
 revenues (a)&amp;#xA0;trade allowances, such as invoice discounts for
 prompt payment and distributor fees, (b)&amp;#xA0;estimated government
 and private payor rebates, chargebacks and discounts, such as
 Medicaid reimbursements, (c)&amp;#xA0;reserves for expected product
 returns and (d)&amp;#xA0;estimated costs of incentives offered to
 certain indirect customers, including patients.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Trade
 Allowances:&lt;/i&gt; The Company generally provides invoice discounts on
 Vascepa sales to its Distributors for prompt payment and pays fees
 for distribution services, such as fees for certain data that
 Distributors provide to the Company. The payment terms for sales to
 Distributors generally include a 2% discount for payment within
 30&amp;#xA0;days. Based on the Company&amp;#x2019;s judgment and experience,
 the Company expects its Distributors to earn these discounts and
 fees, and deducts the full amount of these discounts and fees from
 its gross product revenues and accounts receivable at the time such
 revenues are recognized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Rebates,
 Chargebacks and Discounts:&lt;/i&gt; The Company contracts with Medicaid,
 other government agencies and various private organizations, or
 collectively, Third-party Payors, so that Vascepa will be eligible
 for purchase by, or partial or full reimbursement from, such
 Third-party Payors. The Company estimates the rebates, chargebacks
 and discounts it will provide to Third-party Payors and deducts
 these estimated amounts from its gross product revenues at the time
 the revenues are recognized. The Company estimates the rebates,
 chargebacks and discounts that it will provide to Third-party
 Payors based upon (i)&amp;#xA0;the Company&amp;#x2019;s contracts with these
 Third-party Payors, (ii)&amp;#xA0;the government-mandated discounts
 applicable to government-funded programs, (iii)&amp;#xA0;information
 obtained from the Company&amp;#x2019;s Distributors and
 (iv)&amp;#xA0;information obtained from other third parties regarding
 the payor mix for Vascepa.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Product
 Returns:&lt;/i&gt; The Company&amp;#x2019;s Distributors have the right to
 return unopened unprescribed Vascepa during the 18-month period
 beginning six months prior to the labeled expiration date and
 ending twelve months after the labeled expiration date. The
 expiration date for Vascepa is three years after it has been
 converted into capsule form, which is the last step in the
 manufacturing process for Vascepa and generally occurs within a few
 months before Vascepa is delivered to Distributors. As of
 September&amp;#xA0;30, 2013, the Company had experienced a deminimus
 quantity of product returns. During the nine months ended
 September&amp;#xA0;30, 2013, the period in which the Company began
 selling Vascepa, the Company was not able to reasonably estimate
 product returns for all product sold to Distributors but the
 Company was able to reasonably estimate product returns for certain
 sales of Vascepa based on product used to fill patient
 prescriptions as determined by inventory estimated to be in the
 distribution channel and third party reports of prescriptions
 filled. In making this assessment, the Company used (i)&amp;#xA0;data
 provided to the Company by its Distributors (including weekly
 reporting of Distributors&amp;#x2019; sales and inventory held by
 Distributors that provided the Company with visibility into the
 distribution channel in order to determine what quantities were
 sold to retail pharmacies and other providers),
 (ii)&amp;#xA0;information provided to the Company from retail
 pharmacies, (iii)&amp;#xA0;data provided to the Company by a third
 party data provider which collects and publishes prescription data,
 and other third parties, (iv)&amp;#xA0;historical industry information
 regarding return rates for similar pharmaceutical products,
 (v)&amp;#xA0;the estimated remaining shelf life of Vascepa previously
 shipped and currently being shipped to Distributors and
 (vi)&amp;#xA0;contractual agreements intended to limit the amount of
 inventory maintained by the Company&amp;#x2019;s
 Distributors.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Other
 Incentives:&amp;#xA0;&lt;/i&gt;Other incentives that the Company offers to
 indirect customers include co-pay mitigation rebates provided by
 the Company to commercially insured patients who have coverage for
 Vascepa and who reside in states that permit co-pay mitigation
 programs. The Company&amp;#x2019;s co-pay mitigation program is intended
 to reduce each participating patient&amp;#x2019;s portion of the
 financial responsibility for Vascepa&amp;#x2019;s purchase price to a
 specified dollar amount. Based upon the terms of the program and
 information regarding programs provided for similar specialty
 pharmaceutical products, the Company estimates the average co-pay
 mitigation amounts and the percentage of patients that it expects
 to participate in the program in order to establish its accruals
 for co-pay mitigation rebates and deducts these estimated amounts
 from its gross product revenues at the time the revenues are
 recognized. The Company&amp;#x2019;s co-pay mitigation rebates offered
 to date will expire on December&amp;#xA0;31, 2013. The Company adjusts
 its accruals for co-pay mitigation rebates based on its estimates
 regarding the portion of issued rebates that it estimates will not
 be redeemed. In addition, as is customary prior to the launch of
 new drugs, the Company provided certain of its Distributors with
 financial incentives to begin stocking Vascepa prior to the
 Company&amp;#x2019;s commercial launch of Vascepa in order to ensure
 that Vascepa was readily available to fill patient prescriptions
 upon launch. Such incentives were only offered on purchases of
 initial launch quantities of Vascepa stocked by Distributors in
 January 2013. The amount of these financial incentives were
 recorded by the Company as a reduction to revenues on a pro-rata
 basis for each of the bottles subject to such financial incentives.
 The Company estimates that all of these initial launch quantities
 stocked by its primary Distributors in January 2013 were resold by
 such Distributors prior to September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes activity in each of the product revenue allowance and
 reserve categories described above for the nine months ended
 September&amp;#xA0;30, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Trade&lt;br /&gt;
 Allowances&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Rebates,&lt;br /&gt;
 Chargebacks&lt;br /&gt;
 and&amp;#xA0;Discounts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Product&lt;br /&gt;
 Returns&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Other&lt;br /&gt;
 Incentives&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to
 current period and deferred sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,839&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,418&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;72&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,018&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,347&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 current period and deferred sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,951&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,484&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,835&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(5,270&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;888&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;934&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;72&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;183&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;2,077&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes product revenue recognized and deferred during the nine
 months ended September&amp;#xA0;30, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Product revenue
 recognized&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;16,245&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred product
 revenue&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,617&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;17,862&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In conjunction with the
 Company&amp;#x2019;s recognition and deferral of product revenues, the
 Company expensed and capitalized the associated cost of goods, as
 follows, during the nine months ended September&amp;#xA0;30, 2013 (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cost of goods sold
 expensed&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,813&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods inventory
 held by others&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;641&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;8,454&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Cash
 and Cash Equivalents&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash and cash equivalents
 consist of cash, deposits held at call with banks and short term
 highly liquid instruments with remaining maturities at the date of
 purchase of 90&amp;#xA0;days or less. Restricted cash represents cash
 and cash equivalents pledged to guarantee repayment of certain
 expenses which may be incurred for business travel under corporate
 credit cards held by employees.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Inventory&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company states
 inventories at the lower of cost or market value. Cost is
 determined based on actual cost using the average cost method. An
 allowance is established when management determines that certain
 inventories may not be saleable. If inventory cost exceeds expected
 market value due to obsolescence, damage or quantities in excess of
 expected demand, the Company will record a reserve for the
 difference between cost and market value. The Company received FDA
 approval for Vascepa on July&amp;#xA0;26, 2012 and after that date
 began capitalizing inventory purchases of saleable product from
 approved suppliers. Until an API supplier is approved, all Vascepa
 API purchased from such supplier is included as a component of
 research and development expense. Upon sNDA approval of each
 additional supplier, the Company capitalizes subsequent Vascepa API
 purchases from such supplier as inventory. Purchases of Vascepa API
 received and expensed before such regulatory approvals is not
 subsequently capitalized, and all such purchases are quarantined
 and not used for commercial supply until such time as the sNDA for
 the supplier that produced the API is approved.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Intangible Asset, net&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Intangible assets consist
 of a milestone payment paid to the former shareholders of Laxdale
 Limited related to the 2004 acquisition of our rights to Vascepa,
 which is the result of Vascepa receiving marketing approval for the
 first indication and is amortized over its estimated useful life on
 a straight-line basis. The Company concluded that use of the
 straight-line method was appropriate as the majority of cash flows
 are expected to be generated ratably over the estimated useful life
 and no degradation of the cash flows over time is currently
 anticipated. See Note 7&amp;#x2014;Commitments and Contingencies for
 further information regarding other obligations related to the
 acquisition of Laxdale Limited.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Deferred Revenue&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred revenue represents
 product shipments to Distributors for which the Company has
 invoiced the Distributors but not recognized revenue because the
 product was not reported to the Company as having been resold for
 the purpose of filling prescriptions on or before
 September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Research and Development Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company charges
 research and development costs to operations as incurred. Research
 and development expenses are comprised of costs incurred by the
 Company in performing research and development activities,
 including salary and benefits; stock-based compensation expense;
 laboratory supplies and other direct expenses; contractual
 services, including clinical trial and pharmaceutical development
 costs; commercial supply investment in its drug candidates; and
 infrastructure costs, including facilities costs and depreciation
 expense. In addition, research and development costs include the
 costs of product supply received from suppliers when such receipt
 by the Company is prior to regulatory approval of the
 supplier.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Selling, General and Administrative
 Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company charges sales,
 general and administrative costs to operations as incurred.
 Selling, general and administrative costs include costs of
 salaries, programs and infrastructure necessary for the general
 conduct of the Company&amp;#x2019;s business, including the 2013
 commercial launch of Vascepa in the United States for the MARINE
 indication. Included as part of selling, general and administrative
 costs is warrant-related expense from non-cash changes in fair
 value of the derivative liability associated with warrants issued
 in October 2009 to former officers of Amarin which is recorded as
 compensation income (expense).&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Income
 Taxes&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred tax assets and
 liabilities are recognized for the future tax consequences of
 differences between the carrying amounts and tax bases of assets
 and liabilities and operating loss carry-forwards and other
 attributes using enacted rates expected to be in effect when those
 differences reverse. Valuation allowances are provided against
 deferred tax assets that are not more likely than not to be
 realized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides
 reserves for potential payments of tax to various tax authorities
 or does not recognize tax benefits related to uncertain tax
 positions and other issues. Tax benefits for uncertain tax
 positions are based on a determination of whether a tax benefit
 taken by the Company in its tax filings or positions is more likely
 than not to be realized, assuming that the matter in question will
 be decided based on its technical merits. The Company&amp;#x2019;s
 policy is to record interest and penalties in the provision for
 income taxes.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Derivative Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Derivative financial
 liabilities are recorded at fair value, with gains and losses
 arising for changes in fair value recognized in the statement of
 operations at each period end while such instruments are
 outstanding. If the Company issues shares to discharge the
 liability, the derivative financial liability is derecognized and
 common stock and additional paid-in capital are recognized on the
 issuance of those shares. The warrants are valued using a
 Black-Scholes option pricing model due to the nature of the
 instrument. The long term debt redemption feature is valued using a
 probability-weighted model incorporating management estimates for
 potential change in control, and by determining the fair value of
 the debt with and without the change in control provision
 included.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;If the terms of warrants
 that initially require the warrant to be classified as a derivative
 financial liability lapse, the derivative financial liability is
 reclassified out of financial liabilities into equity at its fair
 value on that date. At the applicable settlement date, if the
 instruments are settled in shares, the carrying value of the
 warrants are derecognized and transferred to equity at their fair
 value at that date. The cash proceeds received from exercises of
 warrants are recorded in common stock and additional paid-in
 capital.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Loss
 per Share&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Basic net loss per share is
 determined by dividing net loss by the weighted average shares of
 common stock outstanding during the period. Diluted net loss per
 share is determined by dividing net loss by diluted weighted
 average shares outstanding. Diluted weighted average shares
 reflects the dilutive effect, if any, of potentially dilutive
 common shares, such as common stock options and warrants calculated
 using the treasury stock method and convertible notes using the
 &amp;#x201C;if-converted&amp;#x201D; method. In periods with reported net
 operating losses, all common stock options and warrants are deemed
 anti-dilutive such that basic net loss per share and diluted net
 loss per share are equal.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Debt
 Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Debt instruments are
 initially recorded at fair value, with coupon interest and
 amortization of debt issuance discounts recognized in the statement
 of operations as interest expense at each period end while such
 instruments are outstanding. If the Company issues shares to
 discharge the liability, the debt obligation is derecognized and
 common stock and additional paid-in capital are recognized on the
 issuance of those shares.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 exchangeable notes contain a conversion option which is classified
 as equity. The fair value of the liability component of the debt
 instrument was deducted from the initial proceeds to determine the
 proceeds to be allocated to the conversion option. The embedded
 conversion option is indexed to the Company&amp;#x2019;s stock and
 treated as equity on the balance sheet. The conversion option is
 evaluated on a quarterly basis to determine if it still meets the
 criteria to be equity classified. The excess principal amount of
 the debt over the carrying value of the liability is amortized to
 interest expense over the term of the debt.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 December 2012 debt financing agreement contains a redemption
 feature triggered upon a change of control, which has been
 classified as an embedded derivative. The fair value of the
 derivative was recorded as a reduction to the fair value of the
 note payable. The fair value of this warrant derivative liability
 is remeasured at each reporting period, with changes in fair value
 recognized in the statement of operations. The discount recorded to
 the note payable is being amortized to interest expense over the
 term of the note payable.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Fair
 Value of Financial Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides
 disclosure of financial assets and financial liabilities that are
 carried at fair value based on the price that would be received
 upon sale of an asset or paid to transfer a liability in an orderly
 transaction between market participants at the measurement
 date.&amp;#xA0;Fair value measurements may be classified based on the
 amount of subjectivity associated with the inputs to fair valuation
 of these assets and liabilities using the following three
 levels:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 1&amp;#x2014;Inputs are
 unadjusted quoted prices in active markets for identical assets or
 liabilities that the Company has the ability to access at the
 measurement date.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 2&amp;#x2014;Inputs
 include quoted prices for similar assets and liabilities in active
 markets, quoted prices for identical or similar assets or
 liabilities in markets that are not active, inputs other than
 quoted prices that are observable for the asset or liability (i.e.,
 interest rates, yield curves, etc.) and inputs that are derived
 principally from or corroborated by observable market data by
 correlation or other means (market corroborated inputs).&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 3&amp;#x2014;Unobservable
 inputs that reflect the Company&amp;#x2019;s estimates of the
 assumptions that market participants would use in pricing the asset
 or liability.&amp;#xA0;The Company develops these inputs based on the
 best information available, including its own data.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 presents information about the Company&amp;#x2019;s assets and
 liabilities as of September&amp;#xA0;30, 2013 and December&amp;#xA0;31,
 2012 that are measured at fair value on a recurring basis and
 indicates the fair value hierarchy of the valuation techniques the
 Company utilized to determine such fair value:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,
 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;113.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;113.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liabilities:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
 liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;39.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;39.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt redemption
 feature&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7.2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7.2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign currency
 contracts&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.4&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.4&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;64.1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;64.1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liability:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
 liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt redemption
 feature&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The carrying amounts of
 cash, cash equivalents, accounts receivable, accounts payable and
 accrued liabilities approximate fair value because of their
 short-term nature.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Warrant Derivative Liability&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At December&amp;#xA0;31, 2012,
 the fair value of the warrant derivative liability was determined
 to be $54.9 million using the Black-Scholes option valuation model
 applying the following assumptions: (i)&amp;#xA0;risk-free rate of
 0.25%, (ii)&amp;#xA0;remaining term of 1.8 years, (iii)&amp;#xA0;no
 dividend yield, (iv)&amp;#xA0;volatility of 95% and (v)&amp;#xA0;the stock
 price on the date of measurement.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At September&amp;#xA0;30, 2013,
 the fair value of the warrant derivative liability was determined
 to be $39.6 million using the Black-Scholes option valuation model
 applying the following assumptions: (i)&amp;#xA0;risk-free rate of
 0.1%, (ii)&amp;#xA0;remaining term of 1.0 year, (iii)&amp;#xA0;no dividend
 yield, (iv)&amp;#xA0;volatility of 91%, and (v)&amp;#xA0;the stock price on
 the date of measurement.&amp;#xA0;The $3.6 million increase in the fair
 value of the warrant liability during the three months ended
 September&amp;#xA0;30, 2013 was recognized as: (i)&amp;#xA0;a $3.3 million
 loss on change in fair value of the remaining derivative liability
 and (ii)&amp;#xA0;$0.3 million in compensation expense for change in
 fair value of warrants issued to former employees. The $15.3
 million decrease in the fair value of the warrant liability during
 the nine months ended September&amp;#xA0;30, 2013 was recognized as:
 (i)&amp;#xA0;a $14.1 million gain on change in fair value of the
 remaining derivative liability and (ii)&amp;#xA0;$1.2 million in
 compensation income for change in fair value of warrants issued to
 former employees. Both amounts are included in the consolidated
 statement of operations for the nine months ended
 September&amp;#xA0;30, 2013.&amp;#xA0;The fair value of this warrant
 liability is determined using the Black-Scholes option valuation
 model and is therefore sensitive to changes in the market price and
 volatility of the Company&amp;#x2019;s common stock among other
 factors.&amp;#xA0;In the event of a hypothetical 10% increase in the
 market price of the Company&amp;#x2019;s common shares ($6.95 based on
 the $6.32 market price of the Company&amp;#x2019;s stock at
 September&amp;#xA0;30, 2013) on which the September&amp;#xA0;30, 2013
 valuation was based, the value of the derivative liability would
 have increased by $5.0 million.&amp;#xA0;Such increase would have been
 reflected as a loss on change in fair value of the warrant
 derivative liability in the Company&amp;#x2019;s statement of
 operations. Significant increases (decreases) in this input in
 isolation would result in a significantly higher (lower) fair value
 asset measurement.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Long
 Term Debt Redemption Feature&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 December 2012 financing agreement with BioPharma Secured Debt Fund
 II Holdings Cayman, L.P, or BioPharma, contains a redemption
 feature whereby, upon a change of control, the Company would be
 required to pay $140 million, less any previously repaid amount, if
 the change of control occurs on or before December&amp;#xA0;31, 2013,
 or required to repay $150 million, less any previously repaid
 amount, if the change of control event occurs after
 December&amp;#xA0;31, 2013. The Company determined this redemption
 feature to be an embedded derivative, which is carried at fair
 value and is classified as Level 3 in the fair value hierarchy due
 to the use of significant unobservable inputs.&amp;#xA0;The fair value
 of the embedded derivative was calculated using a
 probability-weighted model incorporating management estimates for
 potential change in control, and by determining the fair value of
 the debt with and without the change in control provision included.
 The difference between the two fair values of the debt was
 determined to be the fair value of the embedded derivative. At
 December&amp;#xA0;31, 2012, the fair value of the derivative was
 determined to be $14.6 million, and the debt was valued by
 comparing debt issues of similar companies with (i)&amp;#xA0;terms of
 between 4.8 and 8.0 years, (ii)&amp;#xA0;coupon rates of between 3.0%
 and 11.5% and (iii)&amp;#xA0;market yields of between 10.7% and 27.7%.
 At September&amp;#xA0;30, 2013, the fair value of the derivative was
 determined to be $7.2 million, and the debt was valued by comparing
 debt issues of similar companies with (i)&amp;#xA0;remaining terms of
 between 3.5 and 4.4 years, (ii)&amp;#xA0;coupon rates of between 9.9%
 and 12.5% and (iii)&amp;#xA0;market yields of between 10.4% and 25.8%.
 The Company recognized a gain of $1.4 million and $7.4 million on
 the change in fair value of this derivative liability for the three
 and nine months ended September&amp;#xA0;30, 2013,
 respectively.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Foreign Currency&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;All subsidiaries use the
 United States dollar as the functional currency. Monetary assets
 and liabilities denominated in a foreign currency are remeasured
 into United States dollars at period-end exchange rates.
 Non-monetary assets and liabilities carried in a foreign currency
 are remeasured into United States dollars using rates of exchange
 prevailing when such assets or liabilities were obtained or
 incurred, and expenses are generally remeasured using rates of
 exchange prevailing when such expenses are incurred. Gains and
 losses from the remeasurement are included in other (expense)
 income, net in the consolidated statements of operations. For
 transactions settled during the applicable period, gains and losses
 are included in other (expense) income, net in the consolidated
 statements of operations. The Company periodically uses foreign
 exchange forward contracts to hedge against changes in exchange
 rates for inventory purchases denominated in foreign currency. As
 of&amp;#xA0;September 30, 2013, the Company held one foreign exchange
 forward contract with a notional amount of $4.5 million. As
 of&amp;#xA0;September 30, 2013, the outstanding foreign exchange
 forward contract derivative liability had a net fair value of $0.4
 million. The Company included this $0.4 million as a component of
 change in fair value of derivative liabilities and in other current
 liabilities at September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The change in the fair
 value of financial instruments is as follows (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Warrants&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Redemption&amp;#xA0; &amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exchange&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Contracts&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Totals&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2012&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Loss on change in fair
 value of derivative liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;68,686&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;68,686&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation expense for
 change in fair value of warrants issued to former
 employees&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,037&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,037&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
 equity&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(103,885&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(103,885&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2012&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;90,963&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;90,963&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Warrants&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Redemption&amp;#xA0; &amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exchange&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Contracts&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Totals&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;54,854&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;14,577&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;69,431&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(Gain) loss on change in
 fair value of derivative liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(14,077&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(7,377&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;395&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(21,059&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation income for
 change in fair value of warrants issued to former
 employees&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,179&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,179&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
 equity&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;39,598&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;7,200&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;395&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;47,193&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Segment and Geographical
 Information&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;For the three and nine
 months ended September&amp;#xA0;30, 2013 and 2012, the Company has
 reported its business as a single reporting segment. The
 Company&amp;#x2019;s chief decision maker, who is the Chief Executive
 Officer, regularly evaluates the Company on a consolidated
 basis.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Recent
 Accounting Pronouncements&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;From time to time, new
 accounting pronouncements are issued by the Financial Accounting
 Standards Board, or FASB, and are adopted by the Company as of the
 specified effective date. The Company believes that the impact of
 recently issued but not yet adopted accounting pronouncements will
 not have a material impact on consolidated financial position,
 results of operations, and cash flows, or do not apply to the
 Company&amp;#x2019;s operations.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:DerivativesPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_DE547759-A99B-4EFA-AD0A-1DC0B0919B0F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Derivative Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Derivative financial
 liabilities are recorded at fair value, with gains and losses
 arising for changes in fair value recognized in the statement of
 operations at each period end while such instruments are
 outstanding. If the Company issues shares to discharge the
 liability, the derivative financial liability is derecognized and
 common stock and additional paid-in capital are recognized on the
 issuance of those shares. The warrants are valued using a
 Black-Scholes option pricing model due to the nature of the
 instrument. The long term debt redemption feature is valued using a
 probability-weighted model incorporating management estimates for
 potential change in control, and by determining the fair value of
 the debt with and without the change in control provision
 included.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;If the terms of warrants
 that initially require the warrant to be classified as a derivative
 financial liability lapse, the derivative financial liability is
 reclassified out of financial liabilities into equity at its fair
 value on that date. At the applicable settlement date, if the
 instruments are settled in shares, the carrying value of the
 warrants are derecognized and transferred to equity at their fair
 value at that date. The cash proceeds received from exercises of
 warrants are recorded in common stock and additional paid-in
 capital.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_3B420B2D-7877-46F0-AAE3-FFF7003EC03E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Foreign Currency&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;All subsidiaries use the
 United States dollar as the functional currency. Monetary assets
 and liabilities denominated in a foreign currency are remeasured
 into United States dollars at period-end exchange rates.
 Non-monetary assets and liabilities carried in a foreign currency
 are remeasured into United States dollars using rates of exchange
 prevailing when such assets or liabilities were obtained or
 incurred, and expenses are generally remeasured using rates of
 exchange prevailing when such expenses are incurred. Gains and
 losses from the remeasurement are included in other (expense)
 income, net in the consolidated statements of operations. For
 transactions settled during the applicable period, gains and losses
 are included in other (expense) income, net in the consolidated
 statements of operations. The Company periodically uses foreign
 exchange forward contracts to hedge against changes in exchange
 rates for inventory purchases denominated in foreign currency. As
 of&amp;#xA0;September 30, 2013, the Company held one foreign exchange
 forward contract with a notional amount of $4.5 million. As
 of&amp;#xA0;September 30, 2013, the outstanding foreign exchange
 forward contract derivative liability had a net fair value of $0.4
 million. The Company included this $0.4 million as a component of
 change in fair value of derivative liabilities and in other current
 liabilities at September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The change in the fair
 value of financial instruments is as follows (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Warrants&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Redemption&amp;#xA0; &amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exchange&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Contracts&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Totals&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2012&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Loss on change in fair
 value of derivative liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;68,686&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;68,686&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation expense for
 change in fair value of warrants issued to former
 employees&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,037&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,037&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
 equity&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(103,885&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(103,885&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2012&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;90,963&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;90,963&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Warrants&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Redemption&amp;#xA0; &amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exchange&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Contracts&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Totals&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;54,854&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;14,577&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;69,431&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(Gain) loss on change in
 fair value of derivative liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(14,077&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(7,377&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;395&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(21,059&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation income for
 change in fair value of warrants issued to former
 employees&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,179&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,179&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
 equity&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;39,598&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;7,200&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;395&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;47,193&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:UseOfEstimates contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_5334E423-AE61-4BBD-B466-982E40B330AF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Use of
 Estimates&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The preparation of the
 Company&amp;#x2019;s consolidated financial statements in conformity
 with accounting principles generally accepted in the United States
 of America, or GAAP, requires management to make estimates and
 assumptions that affect the reported amounts of assets and
 liabilities, disclosure of contingent assets and liabilities at the
 date of the financial statements, and the reported amounts of
 revenues and expenses during the reporting period. Accounting
 estimates are based on historical experience and other factors that
 are considered reasonable under the circumstances. Actual results
 could differ from those estimates. The preparation of the
 Company&amp;#x2019;s condensed consolidated financial statements in
 accordance with GAAP requires management to make estimates,
 judgments and assumptions that may affect the reported amounts of
 assets, liabilities, revenues and expenses, and related disclosure
 of contingent assets and liabilities. On an on-going basis, the
 Company evaluates its estimates and judgments and methodologies,
 including those related to revenue recognition and related
 allowances, clinical trial expenses, the valuation of inventory,
 impairment and amortization of intangibles, share-based
 compensation, income taxes including the valuation allowance for
 deferred tax assets, valuation of investments and derivative
 instruments. The Company bases its estimates on historical
 experience and on various other assumptions that are believed to be
 reasonable, the results of which form the basis for making
 judgments about the carrying values of assets and liabilities.
 Actual results may differ from these estimates.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_AFA8C7EB-FE9B-4729-80F4-E256994A8A23_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Nature of Business and
 Basis of Presentation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Nature
 of Business&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Amarin Corporation plc,
 &amp;#x201C;Amarin&amp;#x201D; or the &amp;#x201C;Company&amp;#x201D;, is a public
 limited company with its primary stock market listing in the United
 States on the NASDAQ Global Market. Amarin was originally
 incorporated in England as a private limited company on
 March&amp;#xA0;1, 1989 under the Companies Act 1985, and re-registered
 in England as a public limited company on March&amp;#xA0;19,
 1993.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Amarin is a
 biopharmaceutical company with expertise in lipid science focused
 on the commercialization and development of therapeutics to improve
 cardiovascular health. On July&amp;#xA0;26, 2012, the Company received
 approval from the U.S. Food and Drug Administration, or FDA, to
 market and sell its lead product Vascepa&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="POSITION: relative; BOTTOM: 0.8ex; VERTICAL-ALIGN: baseline"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 (icosapent ethyl) capsules (formerly known as AMR 101) as an
 adjunct to diet to reduce triglyceride levels in adult patients
 with severe (TG &lt;u&gt;&amp;gt;&lt;/u&gt;500mg/dL) hypertriglyceridemia, which
 the Company sometimes refers to as the MARINE indication.
 Triglycerides are fats in the blood. Vascepa became commercially
 available in the United States by prescription in January 2013,
 when the Company commenced sales and shipments to its network of
 U.S.-based wholesalers and specialty pharmacy providers. On
 January&amp;#xA0;28, 2013, the Company commenced its full commercial
 launch of Vascepa in the United States for use in the MARINE
 indication.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Amarin is also developing
 Vascepa for the treatment of patients with high triglyceride levels
 (TG &lt;u&gt;&amp;gt;&lt;/u&gt;200 mg/dL and &amp;lt;500 mg/dL) who are also on statin
 therapy for elevated LDL-C levels. This indication is referred to
 as mixed dyslipidemia or the ANCHOR indication. In February 2013,
 the Company submitted a supplemental New Drug Application, or sNDA,
 to the FDA seeking approval of Vascepa for the ANCHOR indication.
 On October&amp;#xA0;16, 2013, the FDA convened an advisory committee to
 review the Company&amp;#x2019;s sNDA for the ANCHOR indication and the
 advisory committee voted 9 to 2 against recommending approval of
 the ANCHOR indication based on information presented at the
 meeting. The FDA will consider the recommendation of the advisory
 committee, but the final decision regarding the approval of the
 sNDA will be made by the FDA. The application is subject to a
 standard review and has been assigned a Prescription Drug User Fee
 Act, or PDUFA, date of December&amp;#xA0;20, 2013. The PDUFA date is
 the target date for the FDA to complete its review of the sNDA. The
 FDA could complete its review of the sNDA prior to this date and
 there can be no assurance that the FDA will complete its review of
 the sNDA by this date. If the FDA does not approve the ANCHOR
 indication, it would have a material impact on the Company&amp;#x2019;s
 future results of operations and financial condition (see Note
 9&amp;#x2014;Subsequent Events).&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Basis
 of Presentation&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The condensed consolidated
 financial statements included herein have been prepared by the
 Company, without audit, in accordance with accounting principles
 generally accepted in the United States of America (the
 &amp;#x201C;U.S.&amp;#x201D; or the &amp;#x201C;United States&amp;#x201D;) and pursuant
 to the rules and regulations of the Securities and Exchange
 Commission (the &amp;#x201C;SEC&amp;#x201D;). Certain information in the
 notes to the financial statements (the &amp;#x201C;Notes&amp;#x201D;) has
 been condensed or omitted where it substantially duplicates
 information provided in the Company&amp;#x2019;s latest audited
 consolidated financial statements, in accordance with the rules and
 regulations of the SEC. These condensed consolidated financial
 statements should be read in conjunction with the Company&amp;#x2019;s
 audited consolidated financial statements and notes included in its
 Annual Report on Form 10-K for the fiscal year ended
 December&amp;#xA0;31, 2012, filed with the SEC (the &amp;#x201C;2012 Form
 10-K&amp;#x201D;). The balance sheet amounts at December&amp;#xA0;31, 2012
 in this report were derived from the Company&amp;#x2019;s audited 2012
 consolidated financial statements included in the 2012 Form 10-K.
 The condensed consolidated financial statements reflect all
 adjustments that, in the opinion of management, are necessary to
 present fairly the Company&amp;#x2019;s financial position, results of
 operations and cash flows for the periods indicated. The
 preparation of financial statements in conformity with U.S.
 Generally Accepted Accounting Principles (&amp;#x201C;GAAP&amp;#x201D;)
 requires management to make estimates and assumptions that affect
 the reported amounts and classifications of assets and liabilities
 and disclosure of contingent assets and liabilities at the date of
 the financial statements and the reported amounts of revenues and
 expenses during the reporting period. The results of operations for
 the three and nine months ended September&amp;#xA0;30, 2013 and 2012,
 respectively, are not necessarily indicative of the results for the
 entire fiscal year or any future period. The Company has evaluated
 subsequent events from September&amp;#xA0;30, 2013 through the date of
 the issuance of these condensed consolidated financial statements
 and has disclosed subsequent events in Note 9.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The accompanying
 consolidated financial statements of the Company and subsidiaries
 have been prepared on a basis which assumes that the Company will
 continue as a going concern, which contemplates the realization of
 assets and the satisfaction of liabilities and commitments in the
 normal course of business. Prior to 2004, the Company was in the
 business of selling a previous biopharmaceutical compound, which
 has since been discontinued. The Company&amp;#x2019;s current focus is
 on the commercialization and development of Vascepa, which received
 approval from the FDA in 2012 and for which the Company commenced
 marketing and sales in 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At September&amp;#xA0;30, 2013,
 the Company had cash and cash equivalents of $225.9&amp;#xA0;million.
 See also Note 8&amp;#x2014;Equity for a description of a public offering
 completed in July 2013 resulting in net proceeds to the Company of
 approximately $121.2 million.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 consolidated balance sheet also includes derivative liabilities
 (see Note 5&amp;#x2014;Warrants and Warrant Derivative Liability) as
 well as long term debt and exchangeable senior notes (see Note
 6&amp;#x2014;Debt). The warrant derivative liability reflects the fair
 value of outstanding warrants to purchase shares of the
 Company&amp;#x2019;s common stock. This liability can only be settled in
 shares of the Company&amp;#x2019;s stock. The long term debt is not
 callable except upon a change in control. The Exchangeable Senior
 Notes (the Notes) may be redeemed on or after January&amp;#xA0;19, 2017
 at the option of the holders. The Notes are exchangeable under
 certain circumstances into cash, American Depository Shares, or
 ADSs, or a combination of cash and ADSs, at the Company&amp;#x2019;s
 election. Accordingly, the warrant derivative liability, long term
 debt and Exchangeable Senior Notes do not present a short term
 claim on the liquid assets of the Company.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company believes its
 cash and cash equivalents will be sufficient to fund its projected
 operations for at least the next twelve months.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_E07B60E0-06A5-464D-A066-6D9D085BD329_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Loss
 per Share&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Basic net loss per share is
 determined by dividing net loss by the weighted average shares of
 common stock outstanding during the period. Diluted net loss per
 share is determined by dividing net loss by diluted weighted
 average shares outstanding. Diluted weighted average shares
 reflects the dilutive effect, if any, of potentially dilutive
 common shares, such as common stock options and warrants calculated
 using the treasury stock method and convertible notes using the
 &amp;#x201C;if-converted&amp;#x201D; method. In periods with reported net
 operating losses, all common stock options and warrants are deemed
 anti-dilutive such that basic net loss per share and diluted net
 loss per share are equal.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_8836C1A4-2FDE-4E91-8279-AB57E7A8EF29_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Fair
 Value of Financial Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides
 disclosure of financial assets and financial liabilities that are
 carried at fair value based on the price that would be received
 upon sale of an asset or paid to transfer a liability in an orderly
 transaction between market participants at the measurement
 date.&amp;#xA0;Fair value measurements may be classified based on the
 amount of subjectivity associated with the inputs to fair valuation
 of these assets and liabilities using the following three
 levels:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 1&amp;#x2014;Inputs are
 unadjusted quoted prices in active markets for identical assets or
 liabilities that the Company has the ability to access at the
 measurement date.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 2&amp;#x2014;Inputs
 include quoted prices for similar assets and liabilities in active
 markets, quoted prices for identical or similar assets or
 liabilities in markets that are not active, inputs other than
 quoted prices that are observable for the asset or liability (i.e.,
 interest rates, yield curves, etc.) and inputs that are derived
 principally from or corroborated by observable market data by
 correlation or other means (market corroborated inputs).&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 3&amp;#x2014;Unobservable
 inputs that reflect the Company&amp;#x2019;s estimates of the
 assumptions that market participants would use in pricing the asset
 or liability.&amp;#xA0;The Company develops these inputs based on the
 best information available, including its own data.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 presents information about the Company&amp;#x2019;s assets and
 liabilities as of September&amp;#xA0;30, 2013 and December&amp;#xA0;31,
 2012 that are measured at fair value on a recurring basis and
 indicates the fair value hierarchy of the valuation techniques the
 Company utilized to determine such fair value:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,
 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;113.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;113.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liabilities:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
 liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;39.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;39.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt redemption
 feature&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7.2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7.2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign currency
 contracts&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.4&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.4&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;64.1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;64.1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liability:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
 liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt redemption
 feature&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The carrying amounts of
 cash, cash equivalents, accounts receivable, accounts payable and
 accrued liabilities approximate fair value because of their
 short-term nature.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_14">-0.96</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_EF0A4F54-A449-41AF-98E5-BB9E6F9A3180_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;/p&gt;
 &lt;table style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; LETTER-SPACING: normal; BORDER-COLLAPSE: collapse; FONT-FAMILY: &apos;Times New Roman&apos;; WORD-SPACING: 0px; -webkit-text-stroke-width: 0px" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: &apos;Times New Roman&apos;" size="2"&gt;&lt;b&gt;(9)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: &apos;Times New Roman&apos;" size="2"&gt;&lt;b&gt;Subsequent
 Events&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium &apos;Times New Roman&apos;; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;font size="2"&gt;&lt;font style="FONT-FAMILY: &apos;Times New Roman&apos;" size="2"&gt;On October&amp;#xA0;16, 2013, the Company announced that an
 advisory committee to the FDA voted 9 to 2 against recommending
 approval of the use of Vascepa capsules for the ANCHOR indication
 based on information presented at the advisory committee meeting.
 The FDA is scheduled to make its decision on whether to approve the
 ANCHOR sNDA on the December&amp;#xA0;20, 2013 PDUFA goal date for the
 application, however, the FDA could complete its review of the sNDA
 prior to this date and there can be no assurance that the FDA will
 complete its review of the sNDA by this date.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium &apos;Times New Roman&apos;; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;font size="2"&gt;&lt;font style="FONT-FAMILY: &apos;Times New Roman&apos;" size="2"&gt;On October&amp;#xA0;22, 2013, in an effort to reduce operating
 expenses following the recommendation of the advisory committee to
 the FDA, the Company implemented a worldwide reduction in force of
 approximately fifty percent of its staff positions worldwide. The
 majority of affected staff members are sales professionals who have
 supported the initial commercial launch of Vascepa. The Company
 estimates that it will incur approximately $3 million in charges
 related to the reduction in force, all of which includes cash
 expenditures for one-time termination benefits and associated
 costs. The Company expects to record the charges in the fourth
 quarter of 2013 and make the related payments by the end of the
 first quarter of 2014.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium &apos;Times New Roman&apos;; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;font size="2"&gt;&lt;font style="FONT-FAMILY: &apos;Times New Roman&apos;" size="2"&gt;On October&amp;#xA0;29, 2013, the FDA notified the Company that it
 has rescinded the ANCHOR study Special Protocol Assessment, or SPA,
 agreement because in their view a substantial scientific issue
 essential to determining the effectiveness of Vascepa in the
 studied population from the ACCORD-Lipid and AIM-HIGH outcome
 trials, as well as the publicly presented results from the
 HPS2-THRIVE outcome trial, which the FDA stated in its
 October&amp;#xA0;29, 2013 notice to the Company, fail to support the
 hypothesis that a triglyceride-lowering drug significantly reduces
 the risk for cardiovascular events among statin-treated patients.
 Thus, the FDA stated that it no longer considers a change in serum
 triglyceride levels as sufficient to establish the effectiveness of
 a drug intended to reduce cardiovascular risk in subjects with
 serum triglyceride levels below 500 mg/dL.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium &apos;Times New Roman&apos;; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;font size="2"&gt;&lt;font style="FONT-FAMILY: &apos;Times New Roman&apos;" size="2"&gt;On November 1, 2013, a purported investor of Amarin filed a
 putative class action lawsuit against Amarin and the
 Company&amp;#x2019;s Chief Executive Officer in the U.S. District Court
 for the District of New Jersey, Steven Sklar v. Amarin Corporation
 plc and Joseph S. Zakrzewski, No. 13-cv-6954 (D.N.J. Nov. 1, 2013).
 The lawsuit alleges that, during the period July 9, 2009 through
 October 15, 2013, the Company misled investors regarding the
 FDA&amp;#x2019;s willingness to approve Vascepa&amp;#x2019;s ANCHOR
 indication and the potential relevance of data from the ongoing
 REDUCE-IT trial to that approval, thereby artificially inflating
 the price of the Company&amp;#x2019;s securities. Based on these
 allegations, the suit asserts claims under the Securities Exchange
 Act of 1934 and seeks unspecified monetary damages and
 attorneys&amp;#x2019; fees and costs. The Company believes that it has
 valid defenses and will vigorously defend against the
 claims.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium &apos;Times New Roman&apos;; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;font size="2"&gt;&lt;font style="FONT-FAMILY: &apos;Times New Roman&apos;" size="2"&gt;On November 5, 2013, a purported investor of Amarin filed a
 putative class action lawsuit against Amarin and certain of the
 Company&amp;#x2019;s officers in the U.S. District Court for the
 Southern District of New York, Joseph A. Bove and Joseph J. Bove v.
 Amarin Corporation, PLC., Joseph S. Zakrzewski, John F. Thero, and
 Steven B. Ketchum, No. 13-CIV-7882 (S.D.N.Y. Nov. 5, 2013). The
 lawsuit alleges, similar to the&amp;#xA0;&lt;i&gt;Sklar&lt;/i&gt;&amp;#xA0;case, that, during the period
 August 8, 2012 until October 16, 2013, the Company misled investors
 regarding the FDA&amp;#x2019;s willingness to approve Vascepa&amp;#x2019;s
 ANCHOR indication and the potential relevance of data from the
 ongoing REDUCE-IT trial to that approval, thereby artificially
 inflating the price of the Company&amp;#x2019;s securities. Based on
 these allegations, the suit asserts claims under the Securities
 Exchange Act of 1934 and seeks unspecified monetary damages and
 attorneys&amp;#x2019; fees and costs. The Company believes that it has
 valid defenses and will vigorously defend against the
 claims.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_F994BDC1-789E-4113-929F-22E6422209B2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Research and Development Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company charges
 research and development costs to operations as incurred. Research
 and development expenses are comprised of costs incurred by the
 Company in performing research and development activities,
 including salary and benefits; stock-based compensation expense;
 laboratory supplies and other direct expenses; contractual
 services, including clinical trial and pharmaceutical development
 costs; commercial supply investment in its drug candidates; and
 infrastructure costs, including facilities costs and depreciation
 expense. In addition, research and development costs include the
 costs of product supply received from suppliers when such receipt
 by the Company is prior to regulatory approval of the
 supplier.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1_2">P1Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_F7744D13-3636-47A1-954E-AAC01451FB5B_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;(7)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Commitments and
 Contingencies&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Royalty
 and Milestone Obligations&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company is party to
 certain milestone and royalty obligations under several product
 development agreements, as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td width="2%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2022;&lt;/font&gt;&lt;/td&gt;
 &lt;td width="1%" valign="top"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;
 &lt;p align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company&amp;#x2019;s active pharmaceutical ingredient, or API,
 supply agreement with Nisshin Pharma, Inc. (&amp;#x201C;Nisshin&amp;#x201D;),
 provided for minimum supply purchase obligations on behalf of the
 Company to enable Amarin to maintain exclusivity with this
 supplier, and to prevent potential termination of the agreement
 based on Company estimated minimum purchase requirements. As of
 September&amp;#xA0;30, 2013, the API aggregate minimum purchase
 obligations under this supply agreement had been achieved and as a
 result, the Company has no future minimum purchase obligation from
 Nisshin.&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td width="2%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2022;&lt;/font&gt;&lt;/td&gt;
 &lt;td width="1%" valign="top"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;
 &lt;p align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In 2011, the Company entered into agreements with two
 additional suppliers, Chemport, Inc. (&amp;#x201C;Chemport&amp;#x201D;) and
 BASF (formerly Equateq Limited) for the supply of API materials for
 Vascepa. In 2012, the Company agreed to terms with a fourth API
 supplier, Slanmhor Pharmaceutical, Inc., or Slanmhor. These
 agreements include requirements for the suppliers to qualify their
 materials and facilities with applicable regulatory authorities
 including the FDA. The Company anticipates incurring certain costs
 associated with the qualification of product produced by these
 suppliers as described below. In each case, following qualification
 of the supplier for the manufacture of API for commercial sale,
 these agreements include annual purchase levels to enable Amarin to
 maintain exclusivity with each respective supplier, and to prevent
 potential termination of the agreements. The Company is not
 obligated to pay in cash any shortfall in the minimum purchase
 obligations pursuant to the Chemport and BASF agreements. The
 agreement with Slanmhor contains a provision requiring the Company
 to pay Slanmhor in cash for any shortfall in the minimum purchase
 obligations, which will become effective upon the approval for
 manufacture by the FDA of supply from Slanmhor. Chemport and BASF
 were approved by the FDA to manufacture API for commercial sale in
 April 2013. The Company has begun to purchase commercial supply
 from Chemport. BASF must complete production of validation batches
 before the Company will begin to purchase commercial supply. The
 2011 supply agreements include commitments for the Company to fund
 (i)&amp;#xA0;development fees up to a maximum of $0.5&amp;#xA0;million
 (ii)&amp;#xA0;material purchases of up to $5.0 million for initial raw
 materials, which amount will be credited against future API
 purchases and (iii)&amp;#xA0;a raw material purchase commitment of
 $1.1&amp;#xA0;million. Under these agreements, during the nine months
 ended September&amp;#xA0;30, 2013, the Company made payments of $4.8
 million and $0.1 million to Chemport and BASF, respectively. The
 agreement with Slanmhor provides for development fees of up to $2.3
 million and a commitment of up to $15.0 million, which will be
 credited against future API material purchases. The $15.0 million
 commitment fee is contingent upon the mutually agreed upon
 expansion of Slanmhor&amp;#x2019;s API manufacturing capacity. Under
 this agreement, during the nine months ended September&amp;#xA0;30,
 2013, the Company made payments of $6.1 million to Slanmhor related
 to stability and technical batches and advances on future API
 purchases.&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td width="2%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2022;&lt;/font&gt;&lt;/td&gt;
 &lt;td width="1%" valign="top"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;
 &lt;p align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Under the 2004 share repurchase agreement with Laxdale Limited,
 or Laxdale, upon approval of Vascepa by the FDA on July&amp;#xA0;26,
 2012, the Company was required to make a milestone payment to
 Laxdale of &amp;#xA3;7.5&amp;#xA0;million. The Company made this payment in
 2012 and capitalized this Laxdale milestone ($11.6 million on
 July&amp;#xA0;26, 2012) as an intangible asset. This long-term asset is
 being amortized over the estimated useful life of the intellectual
 property the Company acquired from Laxdale and the Company
 recognized amortization expense of $0.5 million during the nine
 months ended September&amp;#xA0;30, 2013. Also under the Laxdale
 agreement, upon receipt of marketing approval in Europe for the
 first indication for Vascepa (or first indication of any product
 containing Amarin Neuroscience intellectual property acquired from
 Laxdale in 2004), the Company must make an aggregate stock or cash
 payment to the former shareholders of Laxdale (at the sole option
 of each of the sellers) of &amp;#xA3;7.5&amp;#xA0;million (approximately
 $12.1 million at September&amp;#xA0;30, 2013). Also under the Laxdale
 agreement, upon receipt of a marketing approval in the U.S. or
 Europe for a further indication of Vascepa (or further indication
 of any other product using Amarin Neuroscience intellectual
 property), the Company must make an aggregate stock or cash payment
 (at the sole option of each of the sellers) of &amp;#xA3;5&amp;#xA0;million
 (approximately $8.1 million at September&amp;#xA0;30, 2013) for each of
 the two potential market approvals (i.e. &amp;#xA3;10&amp;#xA0;million
 maximum, or approximately $16.1 million at September&amp;#xA0;30,
 2013).&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company has no provision
 for any of the obligations above since the amounts are either not
 probable or estimable at September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9006_900003">121206000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_24">14000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_15">1400000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_7">21059000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9006_900007">627000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_40">1395000</us-gaap:IncomeTaxesPaid>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_9">-838000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_8">-26646000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_7">966000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_18">283000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5005_2">7347000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_39">5250000</us-gaap:InterestPaid>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_10">-155643000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_16">3721000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:Revenues contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_0">16245000</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_19">384000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_6">-149218000</us-gaap:OperatingIncomeLoss>
  <us-gaap:GainOnDerivativeInstrumentsPretax contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C377772F-1A22-40AC-8919-88EDD42BD5C6_2_2">7400000</us-gaap:GainOnDerivativeInstrumentsPretax>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9006_900008">966000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_12">-150816000</us-gaap:NetIncomeLoss>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_32">7000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_17">5821000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9006_900011">14170000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_2">7813000</us-gaap:CostOfGoodsSold>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_11">-6389000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_10">13232000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_33">122912000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_30">966000</us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_3">179000</us-gaap:DepreciationAndAmortization>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_34">-34357000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_20">-1714000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_8">8381000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:OperatingExpenses contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_5">165463000</us-gaap:OperatingExpenses>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_4">101502000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_11">-4827000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_29">120000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5005_3">5270000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_27">121206000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_28">627000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_9">485000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:DirectOperatingCosts contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_93C82523-9507-4569-B77F-B34C2F307077_1_2">8454000</us-gaap:DirectOperatingCosts>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_25">-14000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_3">56148000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_6">27000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <amrn:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="shares" decimals="0" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_16">157105</amrn:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <amrn:ProductSales contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FE09FBCA-69E5-4850-909A-245A033C95A9_1_2">17862000</amrn:ProductSales>
  <amrn:RecentAccountingPronouncementsPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_788FE4D0-39B4-43C8-A6C4-10004CBC9574_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Recent
 Accounting Pronouncements&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;From time to time, new
 accounting pronouncements are issued by the Financial Accounting
 Standards Board, or FASB, and are adopted by the Company as of the
 specified effective date. The Company believes that the impact of
 recently issued but not yet adopted accounting pronouncements will
 not have a material impact on consolidated financial position,
 results of operations, and cash flows, or do not apply to the
 Company&amp;#x2019;s operations.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</amrn:RecentAccountingPronouncementsPolicyTextBlock>
  <amrn:DeferredRevenuePolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_EF0B4EB2-19B3-47E6-BCC1-86657D3711AC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Deferred Revenue&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred revenue represents
 product shipments to Distributors for which the Company has
 invoiced the Distributors but not recognized revenue because the
 product was not reported to the Company as having been resold for
 the purpose of filling prescriptions on or before
 September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</amrn:DeferredRevenuePolicyTextBlock>
  <amrn:RevenuesTableTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_6DED42BF-3A73-4E43-9CFA-4C623A593F11_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes product revenue recognized and deferred during the nine
 months ended September&amp;#xA0;30, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Product revenue
 recognized&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;16,245&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred product
 revenue&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,617&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;17,862&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</amrn:RevenuesTableTextBlock>
  <amrn:SummaryOfValuationAllowancesTableTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_83344DD5-0B62-4463-8311-C7D30E6EFB15_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes activity in each of the product revenue allowance and
 reserve categories described above for the nine months ended
 September&amp;#xA0;30, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Trade&lt;br /&gt;
 Allowances&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Rebates,&lt;br /&gt;
 Chargebacks&lt;br /&gt;
 and&amp;#xA0;Discounts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Product&lt;br /&gt;
 Returns&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Other&lt;br /&gt;
 Incentives&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to
 current period and deferred sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,839&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,418&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;72&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,018&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,347&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 current period and deferred sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,951&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,484&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,835&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(5,270&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;888&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;934&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;72&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;183&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;2,077&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</amrn:SummaryOfValuationAllowancesTableTextBlock>
  <amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_1_3">120000</amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <amrn:ScheduleOfCostOfRevenueTableTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_D95DC88D-EC98-4F40-B5C5-3651C862660E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In conjunction with the
 Company&amp;#x2019;s recognition and deferral of product revenues, the
 Company expensed and capitalized the associated cost of goods, as
 follows, during the nine months ended September&amp;#xA0;30, 2013 (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cost of goods sold
 expensed&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,813&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods inventory
 held by others&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;641&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;8,454&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</amrn:ScheduleOfCostOfRevenueTableTextBlock>
  <amrn:ProceedsFromStockOptionExerciseAndOther contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_1_2">600000</amrn:ProceedsFromStockOptionExerciseAndOther>
  <amrn:SignificantAssumptionsInMarketPriceOfStock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="pure" decimals="2" id="id_2597911_4FC3D6D7-5949-4643-9AB9-201691591606_1_3">0.10</amrn:SignificantAssumptionsInMarketPriceOfStock>
  <amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9006_900010">27000</amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims>
  <amrn:CashDiscountInvoiceTerms contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_1349199C-F8FD-4AA1-B735-F2AFAE180B22_1_1">P30D</amrn:CashDiscountInvoiceTerms>
  <amrn:ProceedsFromExerciseOfStockOptionsAndWarrants contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_1_5">100000</amrn:ProceedsFromExerciseOfStockOptionsAndWarrants>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9006_900004">120000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <amrn:ProceedsFromStockOptionsExercisedGross contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_1_1">600000</amrn:ProceedsFromStockOptionsExercisedGross>
  <amrn:ProceedsFromWarrantExercisesGross contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_1_4">100000</amrn:ProceedsFromWarrantExercisesGross>
  <amrn:IncreaseDecreaseInLeaseRelatedLiabilities contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_12">3000</amrn:IncreaseDecreaseInLeaseRelatedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_707278x822778_708873x711289" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C377772F-1A22-40AC-8919-88EDD42BD5C6_1002_3">9700000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_707278x822778_708873x796972" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C377772F-1A22-40AC-8919-88EDD42BD5C6_2002_4">2200000</us-gaap:InterestExpense>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x750970_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_1001_6">1900000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x759819_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_E00ED253-0C2A-4F88-9757-F52882E4955F_1002_3">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x759819_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_E00ED253-0C2A-4F88-9757-F52882E4955F_1002_2">32500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x759819_713115x715834_713879x768003" unitRef="iso4217_USD" decimals="-6" id="id_2597911_E00ED253-0C2A-4F88-9757-F52882E4955F_1002_4">0</us-gaap:RestrictedStockExpense>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x784846" unitRef="iso4217_USD" decimals="-5" id="id_2597911_4FC3D6D7-5949-4643-9AB9-201691591606_1001_2">5000000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x808971_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_483213D0-891A-4C90-9074-639C08A88D98_1002_3">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x808971_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_483213D0-891A-4C90-9074-639C08A88D98_1002_2">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x808971_713115x715834_713879x768003" unitRef="iso4217_USD" decimals="-6" id="id_2597911_483213D0-891A-4C90-9074-639C08A88D98_1002_4">0</us-gaap:RestrictedStockExpense>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x813756_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_78085F95-519B-44A7-AFE4-BB7FE2357738_1001_2">93048</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x813756_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_78085F95-519B-44A7-AFE4-BB7FE2357738_1001_1">90684</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x813756_713115x715834_713879x768003" unitRef="iso4217_USD" decimals="-5" id="id_2597911_78085F95-519B-44A7-AFE4-BB7FE2357738_1001_3">300000</us-gaap:RestrictedStockExpense>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9003_600003">104805000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9003_600007">335000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9003_600008">966000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9003_600006">-71000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9003_600011">14170000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9003_600010">24000</amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9003_600004">29000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_400002">21700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_400005">93048</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_400007">386000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_500003">16401000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_500007">292000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_500006">71000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <amrn:StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="shares" decimals="0" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_400009">4032</amrn:StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices>
  <amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_400004">120000</amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_500010">3000</amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_500004">91000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9005_800012">-150816000</us-gaap:NetIncomeLoss>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x709050" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5001_2">2839000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x709050" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5001_3">1951000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x713749" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5003_2">72000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x824442" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5004_2">2018000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x824442" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5004_3">1835000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x825682" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5002_2">2418000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x825682" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5002_3">1484000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711196x826933_714378x714242" unitRef="pure" decimals="4" id="id_2597911_8D03C0E3-066F-40AB-A953-18E4FF9D66D4_1001_0">113.4752</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711196x826933_714378x714242" unitRef="shares" decimals="INF" id="id_2597911_8D03C0E3-066F-40AB-A953-18E4FF9D66D4_1001_1">17021280</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711461x739938" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_6004_2">21059000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711461x739938_715632x710071" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_6003_2">-395000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711461x739938_715632x711232" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_6002_2">7377000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711461x739938_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_6001_2">14077000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x711169_715632x711232" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_1003_11">P3Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x711169_715632x711232" unitRef="pure" decimals="3" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_1003_15">0.104</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <amrn:FairValueInputsCouponRate contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x711169_715632x711232" unitRef="pure" decimals="3" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_1003_13">0.099</amrn:FairValueInputsCouponRate>
  <amrn:MaturityPeriodUsedToClassifyInvestments contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112" id="id_2597911_062753C6-15FB-4582-AFDC-FFB1C2C4678E_1001_0">P90D</amrn:MaturityPeriodUsedToClassifyInvestments>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_715632x711232" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_2003_12">P4Y4M24D</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_715632x711232" unitRef="pure" decimals="3" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_2003_16">0.258</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <amrn:FairValueInputsCouponRate contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_715632x711232" unitRef="pure" decimals="3" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_2003_14">0.125</amrn:FairValueInputsCouponRate>
  <us-gaap:LongTermPurchaseCommitmentAmount contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_735055x785391" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_1001_7">15000000</us-gaap:LongTermPurchaseCommitmentAmount>
  <amrn:DevelopmentFeesCommitted contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_735055x785391" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_1001_6">2300000</amrn:DevelopmentFeesCommitted>
  <us-gaap:LongTermPurchaseCommitmentAmount contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_735055x819032" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_2001_2">5000000</us-gaap:LongTermPurchaseCommitmentAmount>
  <amrn:DevelopmentFeesCommitted contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_735055x819032" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_2001_1">500000</amrn:DevelopmentFeesCommitted>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x715581" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1001_5">-1179000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x715581_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_7001_3">-1179000</us-gaap:ShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x738662_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_9E7202ED-46A3-44DC-ABA2-A57FCA54FA91_1002_4">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x738662_713879x768003" id="id_2597911_9E7202ED-46A3-44DC-ABA2-A57FCA54FA91_1002_1">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x738662_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_9E7202ED-46A3-44DC-ABA2-A57FCA54FA91_1002_3">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x738662_713879x768003" unitRef="iso4217_USD" decimals="-6" id="id_2597911_9E7202ED-46A3-44DC-ABA2-A57FCA54FA91_1002_2">47000000000</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x740402" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2001_4">14170000</us-gaap:ShareBasedCompensation>
  <us-gaap:DerivativesPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_713399x715581" id="id_2597911_EF0A994A-606C-4B8D-8A67-D556ED63FBEE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Warrant Derivative Liability&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At December&amp;#xA0;31, 2012,
 the fair value of the warrant derivative liability was determined
 to be $54.9 million using the Black-Scholes option valuation model
 applying the following assumptions: (i)&amp;#xA0;risk-free rate of
 0.25%, (ii)&amp;#xA0;remaining term of 1.8 years, (iii)&amp;#xA0;no
 dividend yield, (iv)&amp;#xA0;volatility of 95% and (v)&amp;#xA0;the stock
 price on the date of measurement.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At September&amp;#xA0;30, 2013,
 the fair value of the warrant derivative liability was determined
 to be $39.6 million using the Black-Scholes option valuation model
 applying the following assumptions: (i)&amp;#xA0;risk-free rate of
 0.1%, (ii)&amp;#xA0;remaining term of 1.0 year, (iii)&amp;#xA0;no dividend
 yield, (iv)&amp;#xA0;volatility of 91%, and (v)&amp;#xA0;the stock price on
 the date of measurement.&amp;#xA0;The $3.6 million increase in the fair
 value of the warrant liability during the three months ended
 September&amp;#xA0;30, 2013 was recognized as: (i)&amp;#xA0;a $3.3 million
 loss on change in fair value of the remaining derivative liability
 and (ii)&amp;#xA0;$0.3 million in compensation expense for change in
 fair value of warrants issued to former employees. The $15.3
 million decrease in the fair value of the warrant liability during
 the nine months ended September&amp;#xA0;30, 2013 was recognized as:
 (i)&amp;#xA0;a $14.1 million gain on change in fair value of the
 remaining derivative liability and (ii)&amp;#xA0;$1.2 million in
 compensation income for change in fair value of warrants issued to
 former employees. Both amounts are included in the consolidated
 statement of operations for the nine months ended
 September&amp;#xA0;30, 2013.&amp;#xA0;The fair value of this warrant
 liability is determined using the Black-Scholes option valuation
 model and is therefore sensitive to changes in the market price and
 volatility of the Company&amp;#x2019;s common stock among other
 factors.&amp;#xA0;In the event of a hypothetical 10% increase in the
 market price of the Company&amp;#x2019;s common shares ($6.95 based on
 the $6.32 market price of the Company&amp;#x2019;s stock at
 September&amp;#xA0;30, 2013) on which the September&amp;#xA0;30, 2013
 valuation was based, the value of the derivative liability would
 have increased by $5.0 million.&amp;#xA0;Such increase would have been
 reflected as a loss on change in fair value of the warrant
 derivative liability in the Company&amp;#x2019;s statement of
 operations. Significant increases (decreases) in this input in
 isolation would result in a significantly higher (lower) fair value
 asset measurement.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
  <us-gaap:DebtInstrumentTerm contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_714378x714242" id="id_2597911_981EFCF9-3AA2-400F-BBDC-3448AB47D971_1001_2">P24M</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1 contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_714378x714242" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_2001_0">P24M</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_2001_3">15000000</us-gaap:InterestExpenseDebt>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_2001_5">9200000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_2001_4">3900000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_981EFCF9-3AA2-400F-BBDC-3448AB47D971_1001_0">23800000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <us-gaap:EmbeddedDerivativeDescriptionOfHostContract contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_714777x781108_716763x740788" id="id_2597911_7F878E9E-D8EE-41BB-9795-4232131D4A48_1001_0">The warrants issued in connection with the October 2009 financing contained apricing variability feature which provided for an increase to the exercise priceif the exchange rate between the U.S. dollar and British pound adjusts such thatthe warrants could be exercised at a price less than the 0.5 par value of thecommon stock - that is, if the exchange rate exceeded U.S. $3.00 per 1.0sterling. Due to the potential variable nature of the exercise price, thewarrants are not considered to be indexed to the Company&apos;s common stock.Accordingly, the warrants do not qualify for the exception to classify thewarrants within equity and are classified as a derivative liability.</us-gaap:EmbeddedDerivativeDescriptionOfHostContract>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_715632x711232" unitRef="iso4217_USD" decimals="-5" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_3003_9">7400000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_715632x716981_715990x713938" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7740EE47-7093-403F-9241-796D7DDCD866_1001_3">400000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_716763x740788" unitRef="iso4217_USD" decimals="-5" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1001_6">14100000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_716763x740788" unitRef="iso4217_USD" decimals="-5" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1001_7">-1200000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_716763x740788" unitRef="iso4217_USD" decimals="-5" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1001_5">-15300000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_716763x840926" unitRef="iso4217_USD" decimals="-5" id="id_2597911_4BA651FB-DADC-4840-BF05-FE6CC569E5B1_1001_1">100000</us-gaap:ProceedsFromWarrantExercises>
  <amrn:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_716763x840926" unitRef="shares" decimals="INF" id="id_2597911_4BA651FB-DADC-4840-BF05-FE6CC569E5B1_1001_0">120000</amrn:ClassOfWarrantOrRightExercisedInPeriod>
  <us-gaap:AdjustmentForAmortization contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x740537" unitRef="iso4217_USD" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_1003_3">500000</us-gaap:AdjustmentForAmortization>
  <us-gaap:PaymentsForPurchaseOfOtherAssets1 contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x770274" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_3001_5">100000</us-gaap:PaymentsForPurchaseOfOtherAssets1>
  <us-gaap:PaymentsForPurchaseOfOtherAssets1 contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x775542" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_4001_4">4800000</us-gaap:PaymentsForPurchaseOfOtherAssets1>
  <us-gaap:PaymentsForPurchaseOfOtherAssets1 contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x781952" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_5001_8">6100000</us-gaap:PaymentsForPurchaseOfOtherAssets1>
  <us-gaap:LongTermPurchaseCommitmentAmount contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x819032" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_6001_3">1100000</us-gaap:LongTermPurchaseCommitmentAmount>
  <amrn:NumberOfAgreements contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x819032" unitRef="Contract" decimals="0" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_6001_0">2</amrn:NumberOfAgreements>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_21">-78539000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="shares" decimals="INF" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_2_0">3107913</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_14">-1.19</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4006_900016">103885000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_24">477000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_7">-68686000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_23">1238000</us-gaap:PaymentsToAcquireLongtermInvestments>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4006_900018">7834000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_40">697000</us-gaap:IncomeTaxesPaid>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_9">-411000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_8">-12838000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_7">10106000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_18">2273000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_39">2713000</us-gaap:InterestPaid>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_10">-162729000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_19">17355000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_6">-80794000</us-gaap:OperatingIncomeLoss>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4006_900017">22898000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4006_900019">10106000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_12">-168617000</us-gaap:NetIncomeLoss>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_32">20000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_17">8989000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4006_900024">13344000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_10">9365000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_33">178762000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_30">10106000</us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_3">123000</us-gaap:DepreciationAndAmortization>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_34">98508000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_20">33075000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_8">1094000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:OperatingExpenses contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_5">80794000</us-gaap:OperatingExpenses>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_4">41059000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_31">144316000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_11">5888000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_29">16526000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_28">7834000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_9">108000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_25">-1715000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_3">39735000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_6">24000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <amrn:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="shares" decimals="0" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_16">141947</amrn:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <amrn:DerivativeLiabilitiesTransferredToStockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_5004_4">103885000</amrn:DerivativeLiabilitiesTransferredToStockholdersEquity>
  <amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="shares" decimals="INF" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_2_3">10881276</amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <amrn:ProceedsFromStockOptionExerciseAndOther contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_2_2">7800000</amrn:ProceedsFromStockOptionExerciseAndOther>
  <amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4006_900023">24000</amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims>
  <amrn:ProceedsFromExerciseOfStockOptionsAndWarrants contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_2_5">16500000</amrn:ProceedsFromExerciseOfStockOptionsAndWarrants>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4006_900015">16526000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <amrn:ProceedsFromStockOptionsExercisedGross contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_2_1">7900000</amrn:ProceedsFromStockOptionsExercisedGross>
  <amrn:ProceedsFromWarrantExercisesGross contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_2_4">16600000</amrn:ProceedsFromWarrantExercisesGross>
  <amrn:ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_42">103885000</amrn:ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital>
  <amrn:IncreaseDecreaseInLeaseRelatedLiabilities contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_12">-55000</amrn:IncreaseDecreaseInLeaseRelatedLiabilities>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_708873x813756_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_78085F95-519B-44A7-AFE4-BB7FE2357738_1002_2">97398</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_708873x813756_713115x715834_713879x768003" unitRef="iso4217_USD" decimals="-5" id="id_2597911_78085F95-519B-44A7-AFE4-BB7FE2357738_1002_3">1200000</us-gaap:RestrictedStockExpense>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4003_600016">103885000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4003_600018">5395000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4003_600017">22898000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4003_600019">10106000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4003_600021">-76000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4003_600024">13344000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4003_600023">23000</amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4003_600015">8119000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4001_400020">97398</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4001_400018">3107913</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4001_500018">2439000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4001_500021">76000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <amrn:StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713" unitRef="shares" decimals="0" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4001_400022">2293</amrn:StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices>
  <amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4001_400015">10881276</amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4001_500023">1000</amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4001_500015">8407000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4005_800025">-168617000</us-gaap:NetIncomeLoss>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_711461x739938" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_6004_2">-68686000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_711461x739938_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_6001_2">-68686000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_713115x715581" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1002_5">3037000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_713115x715581_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_7001_3">3037000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_713115x740402" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2002_4">13344000</us-gaap:ShareBasedCompensation>
  <amrn:DerivativeLiabilitiesTransferredToStockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_5001_4">103885000</amrn:DerivativeLiabilitiesTransferredToStockholdersEquity>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1310-Q0010_STD_29_20120229_0_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_78085F95-519B-44A7-AFE4-BB7FE2357738_2003_0">584400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1310-Q0010_STD_31_20091031_0_711171x716792_714777x781108" unitRef="shares" decimals="-5" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_1001_9">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE46938---1310-Q0010_STD_31_20091031_0_711171x716792_714777x781108" unitRef="iso4217_USD" decimals="-5" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_1001_2">3600000</us-gaap:DebtConversionOriginalDebtAmount1>
  <amrn:AmericanDepositorySharesToSharesRatio contextRef="eol_PE46938---1310-Q0010_STD_31_20091031_0_711171x716792_714777x781108" unitRef="pure" decimals="0" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_1001_10">1</amrn:AmericanDepositorySharesToSharesRatio>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1310-Q0010_STD_31_20091031_0_714777x781108" unitRef="shares" decimals="-5" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_2001_3">66400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE46938---1310-Q0010_STD_31_20091031_0_714777x781108" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_2001_5">1.00</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1310-Q0010_STD_31_20091031_0_714777x781108" unitRef="iso4217_USD" decimals="-5" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_2001_0">70000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE46938---1310-Q0010_STD_31_20091031_0_714777x781108" unitRef="iso4217_USD" decimals="-5" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_2001_1">62300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <amrn:AmericanDepositorySharesToSharesRatio contextRef="eol_PE46938---1310-Q0010_STD_31_20091031_0_714777x781108" unitRef="pure" decimals="0" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_2001_4">1</amrn:AmericanDepositorySharesToSharesRatio>
  <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="eol_PE46938---1310-Q0010_STD_31_20120131_0" unitRef="pure" decimals="2" id="id_2597911_DB29AC07-14C9-46D0-BC2B-72CC30A8D00F_1_0">1.00</us-gaap:DebtInstrumentRedemptionPricePercentage>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE46938---1310-Q0010_STD_31_20120131_0_714378x714242" id="id_2597911_8D03C0E3-066F-40AB-A953-18E4FF9D66D4_2002_3">2032-01-15</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="eol_PE46938---1310-Q0010_STD_31_20120131_0_714378x714242" id="id_2597911_8D03C0E3-066F-40AB-A953-18E4FF9D66D4_2002_2">2012-07-15</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE46938---1310-Q0010_STD_31_20120131_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C81A56F2-CAC6-4F34-855A-4A365BDD70FA_1001_3">144300000</us-gaap:ProceedsFromConvertibleDebt>
  <amrn:DebtInstrumentMaturityDateYear contextRef="eol_PE46938---1310-Q0010_STD_31_20120131_0_714378x714242" id="id_2597911_C81A56F2-CAC6-4F34-855A-4A365BDD70FA_1001_2">2032</amrn:DebtInstrumentMaturityDateYear>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1310-Q0010_STD_31_20130131_0_708321x810357_714378x716441" unitRef="iso4217_USD" decimals="-5" id="id_2597911_5E5412D7-D0D4-4411-A002-B4AC5761F192_1001_0">2600000</us-gaap:InterestPaid>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="eol_PE46938---1310-Q0010_STD_31_20130131_0_713115x715834_713879x768003" id="id_2597911_E00ED253-0C2A-4F88-9757-F52882E4955F_2001_1">2015-08-03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1310-Q0010_STD_31_20130131_0_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_E00ED253-0C2A-4F88-9757-F52882E4955F_2001_0">454875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1310-Q0010_STD_31_20130731_0_708321x810357_714378x716441" unitRef="iso4217_USD" decimals="-5" id="id_2597911_5E5412D7-D0D4-4411-A002-B4AC5761F192_1002_0">2600000</us-gaap:InterestPaid>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0" unitRef="pure" decimals="2" id="id_2597911_538A9757-F2B2-4DE7-B327-B013BC0D66E0_1_4">0.95</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0" unitRef="pure" decimals="INF" id="id_2597911_538A9757-F2B2-4DE7-B327-B013BC0D66E0_1_3">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0" unitRef="pure" decimals="4" id="id_2597911_538A9757-F2B2-4DE7-B327-B013BC0D66E0_1_1">0.0025</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0" id="id_2597911_538A9757-F2B2-4DE7-B327-B013BC0D66E0_1_2">P1Y9M18D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0_707278x822778" unitRef="iso4217_USD" decimals="-5" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_1002_0">100000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <amrn:AgreementExpirationDate contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0_707278x822778" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_1002_7">2013-12-31</amrn:AgreementExpirationDate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0_711502x711169_715632x711232" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_1001_3">P4Y9M18D</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0_711502x711169_715632x711232" unitRef="pure" decimals="3" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_1001_7">0.107</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <amrn:FairValueInputsCouponRate contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0_711502x711169_715632x711232" unitRef="pure" decimals="3" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_1001_5">0.030</amrn:FairValueInputsCouponRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0_711502x716112_715632x711232" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_2001_4">P8Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0_711502x716112_715632x711232" unitRef="pure" decimals="3" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_2001_8">0.277</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <amrn:FairValueInputsCouponRate contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0_711502x716112_715632x711232" unitRef="pure" decimals="3" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_2001_6">0.115</amrn:FairValueInputsCouponRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="eol_PE46938---1310-Q0010_STD_61_20130930_0_713115x715834_713879x768003" id="id_2597911_483213D0-891A-4C90-9074-639C08A88D98_2001_1">2013-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1310-Q0010_STD_61_20130930_0_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_483213D0-891A-4C90-9074-639C08A88D98_2001_0">44000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_14">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_7">16454000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_9">-427000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_8">-4570000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_10">-22853000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_6">-34310000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_12">-26426000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_5">34310000</us-gaap:OperatingExpenses>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_4">13397000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_11">3573000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_3">20913000</us-gaap:ResearchAndDevelopmentExpense>
  <amrn:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="shares" decimals="0" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_16">149200</amrn:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_14">-0.29</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_7">-1402000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_9">-302000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_8">-8441000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_10">-50519000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:Revenues contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_0">8403000</us-gaap:Revenues>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_6">-40374000</us-gaap:OperatingIncomeLoss>
  <us-gaap:GainOnDerivativeInstrumentsPretax contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C377772F-1A22-40AC-8919-88EDD42BD5C6_3_2">1400000</us-gaap:GainOnDerivativeInstrumentsPretax>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_12">-48884000</us-gaap:NetIncomeLoss>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_2">3682000</us-gaap:CostOfGoodsSold>
  <us-gaap:OperatingExpenses contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_5">48777000</us-gaap:OperatingExpenses>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_4">28274000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_11">-1635000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_3">16821000</us-gaap:ResearchAndDevelopmentExpense>
  <amrn:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="shares" decimals="0" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_16">170187</amrn:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <us-gaap:InterestExpense contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_707278x822778_708873x711289" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C377772F-1A22-40AC-8919-88EDD42BD5C6_1003_3">2700000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_707278x822778_708873x796972" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C377772F-1A22-40AC-8919-88EDD42BD5C6_2003_4">600000</us-gaap:InterestExpense>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_708873x750970_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_1002_6">700000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_713115x738662_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_9E7202ED-46A3-44DC-ABA2-A57FCA54FA91_1001_0">54000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_2002_3">5200000</us-gaap:InterestExpenseDebt>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_2002_5">3200000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_2002_4">1300000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_715632x711232" unitRef="iso4217_USD" decimals="-5" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_3005_9">1400000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_716763x740788" unitRef="iso4217_USD" decimals="-5" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1002_6">-3300000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_716763x740788" unitRef="iso4217_USD" decimals="-5" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1002_7">300000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_716763x740788" unitRef="iso4217_USD" decimals="-5" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1002_5">3600000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <context id="eol_PE46938---1310-Q0010_STD_92_20130930_0_716763x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_92_20130930_0_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_92_20130930_0_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_92_20130930_0_713115x738662_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amrn:DeferredStockUnitsDSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_92_20130930_0_708873x750970_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:DebtOfferingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_92_20130930_0_707278x822778_708873x796972">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_92_20130930_0_707278x822778_708873x711289">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_92_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_92_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_61_20130930_0_713115x715834_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-08-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_366_20121231_0_711502x716112_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_366_20121231_0_711502x711169_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_366_20121231_0_707278x822778">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_366_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_31_20130731_0_708321x810357_714378x716441">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">amrn:FinanceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_31_20130131_0_713115x715834_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_31_20130131_0_708321x810357_714378x716441">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">amrn:FinanceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_31_20120131_0_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_31_20120131_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_31_20091031_0_714777x781108">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_31_20091031_0_711171x716792_714777x781108">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_29_20120229_0_713115x715834_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-02-01</startDate>
      <endDate>2012-02-29</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_713115x740402">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amrn:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_713115x715581_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_713115x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_711461x739938_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_711461x739938">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_708873x813756_713115x715834_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:Group3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x819032">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:AmrOneHundredOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x781952">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:SupplierThreeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x775542">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:SupplierOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x770274">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:SupplierTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x740537">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_716763x840926">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedJulyTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_716763x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_715632x716981_715990x713938">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_714777x781108_716763x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_713399x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x740402">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amrn:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x738662_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amrn:DeferredStockUnitsDSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x715581_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_735055x819032">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:AmrOneHundredOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_735055x785391">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:SupplierDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x711169_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711461x739938_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711461x739938_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711461x739938_715632x710071">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711461x739938">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711196x826933_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x825682">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:RebatesChargebacksAndDiscountsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x824442">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:OtherIncentiveProgramsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x713749">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x709050">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForTradeReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x813756_713115x715834_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:Group3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x808971_713115x715834_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:Group1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x784846">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:ScenarioOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x759819_713115x715834_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:Group2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x750970_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:DebtOfferingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_707278x822778_708873x796972">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_707278x822778_708873x711289">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_22_20131022_0_710720x714667">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-10-22</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_12_20130712_0_711196x826933">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-07-12</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_12_20130712_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-07-12</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_716763x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349_715757x715798">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349_715757x707740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_710256x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_710256x715225">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x708572">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x829211">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x824056">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x796385">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x770088">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x735492">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20111231_0_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x708572">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_716763x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x716981">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x710071">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_714777x781108_716763x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x821234">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">amrn:WarrantThreeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x815051">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">amrn:WarrantOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x797754">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">amrn:WarrantTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x725855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">amrn:WarrantFourMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349_715757x715798">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349_715757x707740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_711672x709584_714777x781108">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_711502x716112_714777x781108_716763x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_710256x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_710256x715225">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_709711x825682">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:RebatesChargebacksAndDiscountsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_709711x824442">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:OtherIncentiveProgramsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_709711x713749">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_709711x709050">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForTradeReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x708572">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x834798_735055x740537_764190x829979">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:PotentialMarketingApprovalOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FirstIndicationForAmrOneZeroOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x834798_735055x740537_764190x779644">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:PotentialMarketingApprovalTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FirstIndicationForAmrOneZeroOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x830088_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:ProceedsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x784846">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:ScenarioOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_735055x740537_764190x829979">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:PotentialMarketingApprovalOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FurtherIndicationForAmrOneZeroOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_735055x740537_764190x779644">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:PotentialMarketingApprovalTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FurtherIndicationForAmrOneZeroOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_711502x716112_735055x740537">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FurtherIndicationForAmrOneZeroOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_707278x822778_755443x829211">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20120930_0_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x708572">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20091016_0_714777x781108_716763x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20091016_0_711672x709584_714777x781108">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20091016_0_711171x716792_714777x781108">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20091016_0_708566x815040_714777x781108_716763x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EnergyAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20091016_0_708566x815040_711171x716792_714777x781108_716763x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EnergyAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130712_0_711196x826933">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-07-12</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20120726_0_735055x740537">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-07-26</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20131101_0_711196x826933">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-11-01</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20131101_0_711196x820302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:OrdinarySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-11-01</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20120131_0_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_USD_per_Right">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>amrn:Right</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_GBP_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:GBP</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_GBP">
    <measure>iso4217:GBP</measure>
  </unit>
  <unit id="Contract">
    <measure>amrn:Contract</measure>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>amrn-20130930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2013-11-07T16:17:48Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31"
  xmlns:us-types="http://fasb.org/us-types/2013-01-31"
  xmlns:amrn="http://www.amarincorp.com/20130930"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://www.amarincorp.com/20130930"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfIncomeAlternative" id="Role_StatementOfIncomeAlternative">
        <link:definition>105 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>106 - Statement - Condensed Consolidated Statements of Changes in Deficit</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>107 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <link:definition>108 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>109 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" id="Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
        <link:definition>110 - Disclosure - Intangible Asset</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock" id="Role_NotesToFinancialStatementsInventoryDisclosureTextBlock">
        <link:definition>111 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="Role_NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
        <link:definition>112 - Disclosure - Warrants and Warrant Derivative Liability</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock" id="Role_NotesToFinancialStatementsDebtDisclosureTextBlock">
        <link:definition>113 - Disclosure - Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>114 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>115 - Disclosure - Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>116 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>117 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
        <link:definition>118 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables">
        <link:definition>119 - Disclosure - Intangible Asset (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
        <link:definition>120 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlockTables">
        <link:definition>121 - Disclosure - Warrants and Warrant Derivative Liability (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation" id="DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation">
        <link:definition>122 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation" id="DisclosureSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>123 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesActivityOfTheProductRevenueAllowanceAndReserveCategories" id="DisclosureSummarizesActivityOfTheProductRevenueAllowanceAndReserveCategories">
        <link:definition>124 - Disclosure - Summarizes Activity of the Product Revenue Allowance and Reserve Categories (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureProductRevenueRecognizedAndDeferred" id="DisclosureProductRevenueRecognizedAndDeferred">
        <link:definition>125 - Disclosure - Product Revenue Recognized and Deferred (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCapitalizedAndExpensed" id="DisclosureCapitalizedAndExpensed">
        <link:definition>126 - Disclosure - Capitalized and Expensed (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis" id="DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis">
        <link:definition>127 - Disclosure - Assets and Liability Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureChangeInFairValueOfFinancialInstruments" id="DisclosureChangeInFairValueOfFinancialInstruments">
        <link:definition>128 - Disclosure - Change in Fair Value of Financial Instruments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssetAdditionalInformation" id="DisclosureIntangibleAssetAdditionalInformation">
        <link:definition>129 - Disclosure - Intangible Asset - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCarryingValueOfIntangibleAsset" id="DisclosureCarryingValueOfIntangibleAsset">
        <link:definition>130 - Disclosure - Carrying Value of Intangible Asset (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureInventory" id="DisclosureInventory">
        <link:definition>131 - Disclosure - Inventory (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureInventoryAdditionalInformation" id="DisclosureInventoryAdditionalInformation">
        <link:definition>132 - Disclosure - Inventory - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation" id="DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation">
        <link:definition>133 - Disclosure - Warrants and Warrant Derivative Liability - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsToPurchaseCommonSharesOutstanding" id="DisclosureWarrantsToPurchaseCommonSharesOutstanding">
        <link:definition>134 - Disclosure - Warrants to Purchase Common Shares Outstanding (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureDebtAdditionalInformation" id="DisclosureDebtAdditionalInformation">
        <link:definition>135 - Disclosure - Debt - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesAdditionalInformation">
        <link:definition>136 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureEquityAdditionalInformation" id="DisclosureEquityAdditionalInformation">
        <link:definition>137 - Disclosure - Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation" id="DisclosureSubsequentEventsAdditionalInformation">
        <link:definition>138 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="amrn-20130930_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="amrn-20130930_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="amrn-20130930_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="amrn-20130930_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2013-01-31" schemaLocation="http://xbrl.sec.gov/exch/2013/exch-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AdditionalPercentageInterestRatePenalty" id="amrn_AdditionalPercentageInterestRatePenalty" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AgreementExpirationDate" id="amrn_AgreementExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmericanDepositaryShareMember" id="amrn_AmericanDepositaryShareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmericanDepositorySharesMember" id="amrn_AmericanDepositorySharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmericanDepositorySharesToSharesRatio" id="amrn_AmericanDepositorySharesToSharesRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmrOneHundredOneMember" id="amrn_AmrOneHundredOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BiopharmaceuticalMember" id="amrn_BiopharmaceuticalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessDevelopmentDomain" id="amrn_BusinessDevelopmentDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessDevelopmentsAxis" id="amrn_BusinessDevelopmentsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="CashDiscountInvoiceTerms" id="amrn_CashDiscountInvoiceTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashDiscountPercent" id="amrn_CashDiscountPercent" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashPaidDuringPeriodForAbstract" id="amrn_CashPaidDuringPeriodForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChangeInControlObligations" id="amrn_ChangeInControlObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightExercisedInPeriod" id="amrn_ClassOfWarrantOrRightExercisedInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightExpirationDate" id="amrn_ClassOfWarrantOrRightExpirationDate" type="us-types:dateStringItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightIssued" id="amrn_ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightTerm" id="amrn_ClassOfWarrantOrRightTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentsAndContingenciesDisclosureLineItems" id="amrn_CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentsAndContingenciesDisclosureTable" id="amrn_CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="ComponentOfOperatingCostAndExpenseLineItems" id="amrn_ComponentOfOperatingCostAndExpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ComponentOfOperatingCostAndExpenseTable" id="amrn_ComponentOfOperatingCostAndExpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DebtDisclosureLineItems" id="amrn_DebtDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtDisclosureTable" id="amrn_DebtDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DebtInstrumentMaturityDateYear" id="amrn_DebtInstrumentMaturityDateYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtOfferingMember" id="amrn_DebtOfferingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredRevenuePolicyTextBlock" id="amrn_DeferredRevenuePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredStockUnitsDSUsMember" id="amrn_DeferredStockUnitsDSUsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DerivativeInstrumentMember" id="amrn_DerivativeInstrumentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DerivativeLiabilitiesTransferredToStockholdersEquity" id="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DevelopmentFeesCommitted" id="amrn_DevelopmentFeesCommitted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="amrn_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ExcessFairValueOverPrincipalValue" id="amrn_ExcessFairValueOverPrincipalValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueAndDerivativeInstrumentsTable" id="amrn_FairValueAndDerivativeInstrumentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="FairValueAssumptionsComparableYieldToMaturity" id="amrn_FairValueAssumptionsComparableYieldToMaturity" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueInputsCouponRate" id="amrn_FairValueInputsCouponRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FinanceMember" id="amrn_FinanceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FirstIndicationForAmrOneZeroOneMember" id="amrn_FirstIndicationForAmrOneZeroOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FurtherIndicationForAmrOneZeroOneMember" id="amrn_FurtherIndicationForAmrOneZeroOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FutureMinimumGuaranteePayments" id="amrn_FutureMinimumGuaranteePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="Group1Member" id="amrn_Group1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="Group2Member" id="amrn_Group2Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="Group3Member" id="amrn_Group3Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInLeaseRelatedLiabilities" id="amrn_IncreaseDecreaseInLeaseRelatedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IntangibleAssetsDisclosureLineItems" id="amrn_IntangibleAssetsDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IntangibleAssetsDisclosureTable" id="amrn_IntangibleAssetsDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="LaxdaleLimitedMember" id="amrn_LaxdaleLimitedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LiabilitiesForCommitmentsAxis" id="amrn_LiabilitiesForCommitmentsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="LiabilitiesForCommitmentsDomain" id="amrn_LiabilitiesForCommitmentsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MaturityPeriodUsedToClassifyInvestments" id="amrn_MaturityPeriodUsedToClassifyInvestments" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonCashMember" id="amrn_NonCashMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfAgreements" id="amrn_NumberOfAgreements" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfForeignCurrencyForwardContractsOutstanding" id="amrn_NumberOfForeignCurrencyForwardContractsOutstanding" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OctoberTwentyZeroNinePrivatePlacementMember" id="amrn_OctoberTwentyZeroNinePrivatePlacementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OptionsExercisablePeriod" id="amrn_OptionsExercisablePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OptionsGrantedDuringPeriod" id="amrn_OptionsGrantedDuringPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrdinarySharesMember" id="amrn_OrdinarySharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" id="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" id="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="OtherIncentiveProgramsMember" id="amrn_OtherIncentiveProgramsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodAxis" id="amrn_PeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="PeriodDomain" id="amrn_PeriodDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodFiveMember" id="amrn_PeriodFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodFourMember" id="amrn_PeriodFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodOneMember" id="amrn_PeriodOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodThreeMember" id="amrn_PeriodThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodTwoMember" id="amrn_PeriodTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialMarketingApprovalOneMember" id="amrn_PotentialMarketingApprovalOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialMarketingApprovalTwoMember" id="amrn_PotentialMarketingApprovalTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromExerciseOfStockOptionsAndWarrants" id="amrn_ProceedsFromExerciseOfStockOptionsAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromStockOptionExerciseAndOther" id="amrn_ProceedsFromStockOptionExerciseAndOther" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromStockOptionsExercisedGross" id="amrn_ProceedsFromStockOptionsExercisedGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromWarrantExercisesGross" id="amrn_ProceedsFromWarrantExercisesGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsMember" id="amrn_ProceedsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProductSales" id="amrn_ProductSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RebatesChargebacksAndDiscountsMember" id="amrn_RebatesChargebacksAndDiscountsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RecentAccountingPronouncementsPolicyTextBlock" id="amrn_RecentAccountingPronouncementsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital" id="amrn_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenuesLineItems" id="amrn_RevenuesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenuesTableTextBlock" id="amrn_RevenuesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScenarioOneMember" id="amrn_ScenarioOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfCostOfRevenueTableTextBlock" id="amrn_ScheduleOfCostOfRevenueTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfRevenuesTable" id="amrn_ScheduleOfRevenuesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="SignificantAccountingPoliciesLineItems" id="amrn_SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SignificantAccountingPoliciesTable" id="amrn_SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="SignificantAssumptionsInMarketPriceOfStock" id="amrn_SignificantAssumptionsInMarketPriceOfStock" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockholdersEquityNoteLineItems" id="amrn_StockholdersEquityNoteLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockholdersEquityNoteTable" id="amrn_StockholdersEquityNoteTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="StockIncentivePlanTwentyElevenMember" id="amrn_StockIncentivePlanTwentyElevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims" id="amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices" id="amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesStockWarrantsExercised" id="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodValueStockWarrantsExercised" id="amrn_StockIssuedDuringPeriodValueStockWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockOptionsAndRestrictedStockUnitsMember" id="amrn_StockOptionsAndRestrictedStockUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SummaryOfValuationAllowancesTableTextBlock" id="amrn_SummaryOfValuationAllowancesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SupplierDMember" id="amrn_SupplierDMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SupplierOneMember" id="amrn_SupplierOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SupplierThreeMember" id="amrn_SupplierThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SupplierTwoMember" id="amrn_SupplierTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantFourMember" id="amrn_WarrantFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantOneMember" id="amrn_WarrantOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantsIssuedJulyTwentyZeroNineMember" id="amrn_WarrantsIssuedJulyTwentyZeroNineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantsIssuedOctoberTwentyZeroNineMember" id="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantThreeMember" id="amrn_WarrantThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantTwoMember" id="amrn_WarrantTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract" id="amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageNumberBasicDilutedSharesOutstanding" id="amrn_WeightedAverageNumberBasicDilutedSharesOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>amrn-20130930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2013-11-07T16:17:48Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DocumentandEntityInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureSummarizesActivityOfTheProductRevenueAllowanceAndReserveCategories" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesActivityOfTheProductRevenueAllowanceAndReserveCategories"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureProductRevenueRecognizedAndDeferred" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureProductRevenueRecognizedAndDeferred"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureCapitalizedAndExpensed" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCapitalizedAndExpensed"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureChangeInFairValueOfFinancialInstruments" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureChangeInFairValueOfFinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureIntangibleAssetAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssetAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureCarryingValueOfIntangibleAsset" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCarryingValueOfIntangibleAsset"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureInventory" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureInventory"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureInventoryAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureInventoryAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureWarrantsToPurchaseCommonSharesOutstanding" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsToPurchaseCommonSharesOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureDebtAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureDebtAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureEquityAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredTaxAssetsNetCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" order="1.2300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_CostOfGoodsSold" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1.0500" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xlink:label="us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.2600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="1.1800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1900" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesActivityOfTheProductRevenueAllowanceAndReserveCategories">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureProductRevenueRecognizedAndDeferred">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCapitalizedAndExpensed">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureChangeInFairValueOfFinancialInstruments">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssetAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCarryingValueOfIntangibleAsset">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0200" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureInventory">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureInventoryAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsToPurchaseCommonSharesOutstanding">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureDebtAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureEquityAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>amrn-20130930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2013-11-07T16:17:48Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DocumentandEntityInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureSummarizesActivityOfTheProductRevenueAllowanceAndReserveCategories" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesActivityOfTheProductRevenueAllowanceAndReserveCategories"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureProductRevenueRecognizedAndDeferred" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureProductRevenueRecognizedAndDeferred"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureCapitalizedAndExpensed" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCapitalizedAndExpensed"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureChangeInFairValueOfFinancialInstruments" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureChangeInFairValueOfFinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureIntangibleAssetAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssetAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureCarryingValueOfIntangibleAsset" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCarryingValueOfIntangibleAsset"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureInventory" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureInventory"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureInventoryAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureInventoryAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureWarrantsToPurchaseCommonSharesOutstanding" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsToPurchaseCommonSharesOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureDebtAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureDebtAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureEquityAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_AmericanDepositorySharesMember" xlink:label="amrn_AmericanDepositorySharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_OrdinarySharesMember" xlink:label="amrn_OrdinarySharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amrn_OrdinarySharesMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amrn_AmericanDepositorySharesMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_EntitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_EntitiesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetCurrent" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_WarrantMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_LongTermDebtMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_SeniorLongTermNotes" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.1300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract" xlink:label="amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="amrn_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract" xlink:to="amrn_WeightedAverageNumberBasicDilutedSharesOutstanding" order="1.0100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims" xlink:label="amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices" xlink:label="amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="amrn_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_StockIssuedDuringPeriodValueStockWarrantsExercised" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_CashPaidDuringPeriodForAbstract" xlink:label="amrn_CashPaidDuringPeriodForAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_IncreaseDecreaseInLeaseRelatedLiabilities" xlink:label="amrn_IncreaseDecreaseInLeaseRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xlink:label="us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital" xlink:label="amrn_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockOptionsAndRestrictedStockUnitsMember" xlink:label="amrn_StockOptionsAndRestrictedStockUnitsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="amrn_IncreaseDecreaseInLeaseRelatedLiabilities" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="amrn_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_InterestPaid" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="amrn_StockOptionsAndRestrictedStockUnitsMember" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="amrn_CashPaidDuringPeriodForAbstract" order="1.0200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentCallDateEarliest" xlink:label="us-gaap_DebtInstrumentCallDateEarliest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentCallDateEarliest" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_CashDiscountInvoiceTerms" xlink:label="amrn_CashDiscountInvoiceTerms"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_CashDiscountPercent" xlink:label="amrn_CashDiscountPercent"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ChangeInControlObligations" xlink:label="amrn_ChangeInControlObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount" xlink:label="us-gaap_DerivativeAssetNotionalAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_FairValueAssumptionsComparableYieldToMaturity" xlink:label="amrn_FairValueAssumptionsComparableYieldToMaturity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_FairValueInputsCouponRate" xlink:label="amrn_FairValueInputsCouponRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyDerivativesAtFairValueNet" xlink:label="us-gaap_ForeignCurrencyDerivativesAtFairValueNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignExchangeForwardMember" xlink:label="us-gaap_ForeignExchangeForwardMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_MaturityPeriodUsedToClassifyInvestments" xlink:label="amrn_MaturityPeriodUsedToClassifyInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_NumberOfForeignCurrencyForwardContractsOutstanding" xlink:label="amrn_NumberOfForeignCurrencyForwardContractsOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ScenarioOneMember" xlink:label="amrn_ScenarioOneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_SignificantAccountingPoliciesLineItems" xlink:label="amrn_SignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_SignificantAccountingPoliciesTable" xlink:label="amrn_SignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_SignificantAssumptionsInMarketPriceOfStock" xlink:label="amrn_SignificantAssumptionsInMarketPriceOfStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeForwardMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_ScenarioOneMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_SignificantAccountingPoliciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_CashDiscountPercent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_CashDiscountInvoiceTerms" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_MaturityPeriodUsedToClassifyInvestments" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharePrice" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_SignificantAssumptionsInMarketPriceOfStock" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_ChangeInControlObligations" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherCommitment" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_FairValueInputsCouponRate" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_FairValueAssumptionsComparableYieldToMaturity" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DerivativeAssetNotionalAmount" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_NumberOfForeignCurrencyForwardContractsOutstanding" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ForeignCurrencyDerivativesAtFairValueNet" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementScenarioAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesActivityOfTheProductRevenueAllowanceAndReserveCategories">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllowanceForSalesReturnsMember" xlink:label="us-gaap_AllowanceForSalesReturnsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllowanceForTradeReceivablesMember" xlink:label="us-gaap_AllowanceForTradeReceivablesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_OtherIncentiveProgramsMember" xlink:label="amrn_OtherIncentiveProgramsMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_RebatesChargebacksAndDiscountsMember" xlink:label="amrn_RebatesChargebacksAndDiscountsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_AllowanceForTradeReceivablesMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="amrn_RebatesChargebacksAndDiscountsMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_AllowanceForSalesReturnsMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="amrn_OtherIncentiveProgramsMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureProductRevenueRecognizedAndDeferred">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ProductSales" xlink:label="amrn_ProductSales"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_RevenuesLineItems" xlink:label="amrn_RevenuesLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ScheduleOfRevenuesTable" xlink:label="amrn_ScheduleOfRevenuesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amrn_RevenuesLineItems" xlink:to="amrn_ScheduleOfRevenuesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_RevenuesLineItems" xlink:to="us-gaap_Revenues" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_RevenuesLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_RevenuesLineItems" xlink:to="amrn_ProductSales" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_ScheduleOfRevenuesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCapitalizedAndExpensed">
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ComponentOfOperatingCostAndExpenseLineItems" xlink:label="amrn_ComponentOfOperatingCostAndExpenseLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ComponentOfOperatingCostAndExpenseTable" xlink:label="amrn_ComponentOfOperatingCostAndExpenseTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DirectOperatingCosts" xlink:label="us-gaap_DirectOperatingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amrn_ComponentOfOperatingCostAndExpenseLineItems" xlink:to="amrn_ComponentOfOperatingCostAndExpenseTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_ComponentOfOperatingCostAndExpenseLineItems" xlink:to="us-gaap_CostOfGoodsSold" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_ComponentOfOperatingCostAndExpenseLineItems" xlink:to="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_ComponentOfOperatingCostAndExpenseLineItems" xlink:to="us-gaap_DirectOperatingCosts" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_ComponentOfOperatingCostAndExpenseTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" order="1.1000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureChangeInFairValueOfFinancialInstruments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DerivativeInstrumentMember" xlink:label="amrn_DerivativeInstrumentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" xlink:label="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="us-gaap_DerivativesFairValueLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_FairValueAndDerivativeInstrumentsTable" xlink:label="amrn_FairValueAndDerivativeInstrumentsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_DerivativeInstrumentMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="amrn_FairValueAndDerivativeInstrumentsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_FairValueAndDerivativeInstrumentsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_FairValueAndDerivativeInstrumentsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_FairValueAndDerivativeInstrumentsTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_FairValueAndDerivativeInstrumentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" order="1.1100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssetAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_IntangibleAssetsDisclosureLineItems" xlink:label="amrn_IntangibleAssetsDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_IntangibleAssetsDisclosureTable" xlink:label="amrn_IntangibleAssetsDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amrn_IntangibleAssetsDisclosureLineItems" xlink:to="amrn_IntangibleAssetsDisclosureTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_IntangibleAssetsDisclosureLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_IntangibleAssetsDisclosureTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCarryingValueOfIntangibleAsset">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureInventory">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryCurrentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryNet" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureInventoryAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryCurrentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_AmericanDepositaryShareMember" xlink:label="amrn_AmericanDepositaryShareMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_AmericanDepositorySharesToSharesRatio" xlink:label="amrn_AmericanDepositorySharesToSharesRatio"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ClassOfWarrantOrRightExercisedInPeriod" xlink:label="amrn_ClassOfWarrantOrRightExercisedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ClassOfWarrantOrRightIssued" xlink:label="amrn_ClassOfWarrantOrRightIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ClassOfWarrantOrRightTerm" xlink:label="amrn_ClassOfWarrantOrRightTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmbeddedDerivativeDescriptionOfHostContract" xlink:label="us-gaap_EmbeddedDerivativeDescriptionOfHostContract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EnergyAxis" xlink:label="us-gaap_EnergyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EnergyDomain" xlink:label="us-gaap_EnergyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EnergyDomain" xlink:label="us-gaap_EnergyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="us-gaap_EquityIssuancePerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_OctoberTwentyZeroNinePrivatePlacementMember" xlink:label="amrn_OctoberTwentyZeroNinePrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficerMember" xlink:label="us-gaap_OfficerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WarrantsIssuedJulyTwentyZeroNineMember" xlink:label="amrn_WarrantsIssuedJulyTwentyZeroNineMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amrn_WarrantsIssuedJulyTwentyZeroNineMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_BridgeLoanMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_AmericanDepositorySharesToSharesRatio" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_EquityIssuancePerShareAmount" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_ClassOfWarrantOrRightTerm" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_ClassOfWarrantOrRightIssued" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_EmbeddedDerivativeDescriptionOfHostContract" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_ClassOfWarrantOrRightExercisedInPeriod" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DerivativeTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_RangeAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_EnergyAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EnergyAxis" xlink:to="us-gaap_EnergyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EnergyAxis" xlink:to="us-gaap_EnergyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EnergyDomain" xlink:to="amrn_AmericanDepositaryShareMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_OfficerMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amrn_OctoberTwentyZeroNinePrivatePlacementMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsToPurchaseCommonSharesOutstanding">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ClassOfWarrantOrRightExpirationDate" xlink:label="amrn_ClassOfWarrantOrRightExpirationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="us-gaap_DerivativeByNatureAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="us-gaap_DerivativeNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="us-gaap_DerivativeNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WarrantFourMember" xlink:label="amrn_WarrantFourMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WarrantOneMember" xlink:label="amrn_WarrantOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WarrantThreeMember" xlink:label="amrn_WarrantThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WarrantTwoMember" xlink:label="amrn_WarrantTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="amrn_ClassOfWarrantOrRightExpirationDate" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_DerivativeByNatureAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="us-gaap_DerivativeNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="us-gaap_DerivativeNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="amrn_WarrantOneMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="amrn_WarrantTwoMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="amrn_WarrantThreeMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="amrn_WarrantFourMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureDebtAdditionalInformation">
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_AdditionalPercentageInterestRatePenalty" xlink:label="amrn_AdditionalPercentageInterestRatePenalty"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_AgreementExpirationDate" xlink:label="amrn_AgreementExpirationDate"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_AmericanDepositorySharesMember" xlink:label="amrn_AmericanDepositorySharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_BiopharmaceuticalMember" xlink:label="amrn_BiopharmaceuticalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ChangeInControlObligations" xlink:label="amrn_ChangeInControlObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DebtDisclosureLineItems" xlink:label="amrn_DebtDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DebtDisclosureTable" xlink:label="amrn_DebtDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DebtInstrumentMaturityDateYear" xlink:label="amrn_DebtInstrumentMaturityDateYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DebtOfferingMember" xlink:label="amrn_DebtOfferingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ExcessFairValueOverPrincipalValue" xlink:label="amrn_ExcessFairValueOverPrincipalValue"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_FinanceMember" xlink:label="amrn_FinanceMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_FutureMinimumGuaranteePayments" xlink:label="amrn_FutureMinimumGuaranteePayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainOnDerivativeInstrumentsPretax" xlink:label="us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_NonCashMember" xlink:label="amrn_NonCashMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PeriodAxis" xlink:label="amrn_PeriodAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PeriodDomain" xlink:label="amrn_PeriodDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PeriodDomain" xlink:label="amrn_PeriodDomain_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PeriodFiveMember" xlink:label="amrn_PeriodFiveMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PeriodFourMember" xlink:label="amrn_PeriodFourMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PeriodOneMember" xlink:label="amrn_PeriodOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PeriodThreeMember" xlink:label="amrn_PeriodThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PeriodTwoMember" xlink:label="amrn_PeriodTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ProceedsMember" xlink:label="amrn_ProceedsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amrn_AmericanDepositorySharesMember" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_DebtDisclosureTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_OtherCommitment" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_FutureMinimumGuaranteePayments" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_AgreementExpirationDate" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_ChangeInControlObligations" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_GainOnDerivativeInstrumentsPretax" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestExpense" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_DebtInstrumentMaturityDateYear" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_ExcessFairValueOverPrincipalValue" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_AdditionalPercentageInterestRatePenalty" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_ConvertibleDebt" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestPaid" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_StatementScenarioAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="amrn_PeriodAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_SecuritiesFinancingTransactionAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_NotesPayableOtherPayablesMember" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="amrn_PeriodAxis" xlink:to="amrn_PeriodDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="amrn_PeriodAxis" xlink:to="amrn_PeriodDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodOneMember" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodTwoMember" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodThreeMember" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodFourMember" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodFiveMember" order="1.4700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_CashMember" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_NonCashMember" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_ProceedsMember" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_DebtOfferingMember" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SecuritiesFinancingTransactionAxis" xlink:to="us-gaap_SecuritiesFinancingTransactionTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SecuritiesFinancingTransactionAxis" xlink:to="us-gaap_SecuritiesFinancingTransactionTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:to="amrn_FinanceMember" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="amrn_BiopharmaceuticalMember" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_AmrOneHundredOneMember" xlink:label="amrn_AmrOneHundredOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_BusinessDevelopmentDomain" xlink:label="amrn_BusinessDevelopmentDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_BusinessDevelopmentDomain" xlink:label="amrn_BusinessDevelopmentDomain_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_BusinessDevelopmentsAxis" xlink:label="amrn_BusinessDevelopmentsAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="amrn_CommitmentsAndContingenciesDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_CommitmentsAndContingenciesDisclosureTable" xlink:label="amrn_CommitmentsAndContingenciesDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DevelopmentFeesCommitted" xlink:label="amrn_DevelopmentFeesCommitted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_FirstIndicationForAmrOneZeroOneMember" xlink:label="amrn_FirstIndicationForAmrOneZeroOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_FurtherIndicationForAmrOneZeroOneMember" xlink:label="amrn_FurtherIndicationForAmrOneZeroOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_LaxdaleLimitedMember" xlink:label="amrn_LaxdaleLimitedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_LiabilitiesForCommitmentsAxis" xlink:label="amrn_LiabilitiesForCommitmentsAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_LiabilitiesForCommitmentsDomain" xlink:label="amrn_LiabilitiesForCommitmentsDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_LiabilitiesForCommitmentsDomain" xlink:label="amrn_LiabilitiesForCommitmentsDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_NumberOfAgreements" xlink:label="amrn_NumberOfAgreements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PotentialMarketingApprovalOneMember" xlink:label="amrn_PotentialMarketingApprovalOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PotentialMarketingApprovalTwoMember" xlink:label="amrn_PotentialMarketingApprovalTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_SupplierDMember" xlink:label="amrn_SupplierDMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_SupplierOneMember" xlink:label="amrn_SupplierOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_SupplierThreeMember" xlink:label="amrn_SupplierThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_SupplierTwoMember" xlink:label="amrn_SupplierTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_BusinessDevelopmentDomain" xlink:to="amrn_PotentialMarketingApprovalOneMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_BusinessDevelopmentDomain" xlink:to="amrn_PotentialMarketingApprovalTwoMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="amrn_BusinessDevelopmentsAxis" xlink:to="amrn_BusinessDevelopmentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="amrn_BusinessDevelopmentsAxis" xlink:to="amrn_BusinessDevelopmentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="amrn_CommitmentsAndContingenciesDisclosureTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="amrn_NumberOfAgreements" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="amrn_DevelopmentFeesCommitted" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AdjustmentForAmortization" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_StatementScenarioAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="amrn_LiabilitiesForCommitmentsAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RangeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="amrn_BusinessDevelopmentsAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="amrn_LiabilitiesForCommitmentsAxis" xlink:to="amrn_LiabilitiesForCommitmentsDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="amrn_LiabilitiesForCommitmentsAxis" xlink:to="amrn_LiabilitiesForCommitmentsDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_LiabilitiesForCommitmentsDomain" xlink:to="amrn_LaxdaleLimitedMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_LiabilitiesForCommitmentsDomain" xlink:to="amrn_AmrOneHundredOneMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_LiabilitiesForCommitmentsDomain" xlink:to="amrn_SupplierOneMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_LiabilitiesForCommitmentsDomain" xlink:to="amrn_SupplierTwoMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_LiabilitiesForCommitmentsDomain" xlink:to="amrn_SupplierDMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_LiabilitiesForCommitmentsDomain" xlink:to="amrn_SupplierThreeMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_FurtherIndicationForAmrOneZeroOneMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_FirstIndicationForAmrOneZeroOneMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_AmericanDepositorySharesMember" xlink:label="amrn_AmericanDepositorySharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DeferredStockUnitsDSUsMember" xlink:label="amrn_DeferredStockUnitsDSUsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_Group1Member" xlink:label="amrn_Group1Member"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_Group2Member" xlink:label="amrn_Group2Member"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_Group3Member" xlink:label="amrn_Group3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_OptionsExercisablePeriod" xlink:label="amrn_OptionsExercisablePeriod"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_OptionsGrantedDuringPeriod" xlink:label="amrn_OptionsGrantedDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:label="amrn_ProceedsFromExerciseOfStockOptionsAndWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ProceedsFromStockOptionExerciseAndOther" xlink:label="amrn_ProceedsFromStockOptionExerciseAndOther"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ProceedsFromStockOptionsExercisedGross" xlink:label="amrn_ProceedsFromStockOptionsExercisedGross"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ProceedsFromWarrantExercisesGross" xlink:label="amrn_ProceedsFromWarrantExercisesGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockholdersEquityNoteLineItems" xlink:label="amrn_StockholdersEquityNoteLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockholdersEquityNoteTable" xlink:label="amrn_StockholdersEquityNoteTable"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockIncentivePlanTwentyElevenMember" xlink:label="amrn_StockIncentivePlanTwentyElevenMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amrn_AmericanDepositorySharesMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="amrn_StockIncentivePlanTwentyElevenMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_Group1Member" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_Group2Member" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_Group3Member" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="amrn_DeferredStockUnitsDSUsMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_StockholdersEquityNoteTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_OptionsGrantedDuringPeriod" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_OptionsExercisablePeriod" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_ProceedsFromStockOptionsExercisedGross" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_ProceedsFromStockOptionExerciseAndOther" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_ProceedsFromWarrantExercisesGross" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_ProceedsFromExerciseOfStockOptionsAndWarrants" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_RestrictedStockExpense" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_PlanNameAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_StatementScenarioAxis" order="5.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DeferredRevenuePolicyTextBlock" xlink:label="amrn_DeferredRevenuePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="us-gaap_DerivativeByNatureAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="us-gaap_DerivativeNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesEmbeddedDerivatives" xlink:label="us-gaap_DerivativesEmbeddedDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_RecentAccountingPronouncementsPolicyTextBlock" xlink:label="amrn_RecentAccountingPronouncementsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="us-gaap_DerivativeNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="us-gaap_WarrantMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UseOfEstimates" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryPolicyTextBlock" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_DeferredRevenuePolicyTextBlock" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtPolicyTextBlock" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativesEmbeddedDerivatives" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_RecentAccountingPronouncementsPolicyTextBlock" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeByNatureAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_RevenuesTableTextBlock" xlink:label="amrn_RevenuesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ScheduleOfCostOfRevenueTableTextBlock" xlink:label="amrn_ScheduleOfCostOfRevenueTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_SummaryOfValuationAllowancesTableTextBlock" xlink:label="amrn_SummaryOfValuationAllowancesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_SummaryOfValuationAllowancesTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_RevenuesTableTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_ScheduleOfCostOfRevenueTableTextBlock" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>amrn-20130930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no" ?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2013-11-07T16:17:48Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <label id="id_2597911_713053_1_1" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label id="id_2597911_713053_2_1" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <label id="id_2597911_718248_1_1" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable Current</label>
    <label id="id_2597911_718248_2_1" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <label id="id_2597911_721894_1_1" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable Net Current</label>
    <label id="id_2597911_721894_2_1" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator"/>
    <label id="id_2597911_718202_1_1" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities And Other Liabilities</label>
    <label id="id_2597911_718202_2_1" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <label id="id_2597911_718773_1_1" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid In Capital Common Stock</label>
    <label id="id_2597911_718773_2_1" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <label id="id_2597911_710802_1_1" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label id="id_2597911_710802_2_1" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_AdditionalPercentageInterestRatePenalty" xlink:label="amrn_AdditionalPercentageInterestRatePenalty" xlink:type="locator"/>
    <label id="id_2597911_844277_3_1" xlink:label="amrn_AdditionalPercentageInterestRatePenalty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Percentage Interest Rate Penalty</label>
    <label id="id_2597911_844277_1_1" xlink:label="amrn_AdditionalPercentageInterestRatePenalty_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Percentage Interest Rate Penalty</label>
    <label id="id_2597911_844277_2_1" xlink:label="amrn_AdditionalPercentageInterestRatePenalty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional interest rate on notes per annum</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_AdditionalPercentageInterestRatePenalty" xlink:to="amrn_AdditionalPercentageInterestRatePenalty_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" xlink:type="locator"/>
    <label id="id_2597911_722798_1_1" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment For Amortization</label>
    <label id="id_2597911_722798_2_1" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="locator"/>
    <label id="id_2597911_719833_1_1" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt</label>
    <label id="id_2597911_719833_2_1" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion option contained in exchangeable notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="locator"/>
    <label id="id_2597911_717151_1_1" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital Other</label>
    <label id="id_2597911_717151_2_1" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer of fair value of warrants exercised from liabilities to equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <label id="id_2597911_720768_1_1" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label id="id_2597911_720768_2_1" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:type="locator"/>
    <label id="id_2597911_720349_1_1" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation</label>
    <label id="id_2597911_720349_2_1" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefits realized from stock-based compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <label id="id_2597911_715215_1_1" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label id="id_2597911_715215_2_1" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_AgreementExpirationDate" xlink:label="amrn_AgreementExpirationDate" xlink:type="locator"/>
    <label id="id_2597911_842095_3_1" xlink:label="amrn_AgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement Expiration Date</label>
    <label id="id_2597911_842095_1_1" xlink:label="amrn_AgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement Expiration Date</label>
    <label id="id_2597911_842095_2_1" xlink:label="amrn_AgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement expiration date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_AgreementExpirationDate" xlink:to="amrn_AgreementExpirationDate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllowanceForSalesReturnsMember" xlink:label="us-gaap_AllowanceForSalesReturnsMember" xlink:type="locator"/>
    <label id="id_2597911_713749_1_1" xlink:label="us-gaap_AllowanceForSalesReturnsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Sales Returns [Member]</label>
    <label id="id_2597911_713749_2_1" xlink:label="us-gaap_AllowanceForSalesReturnsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for Sales Returns</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForSalesReturnsMember" xlink:to="us-gaap_AllowanceForSalesReturnsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllowanceForTradeReceivablesMember" xlink:label="us-gaap_AllowanceForTradeReceivablesMember" xlink:type="locator"/>
    <label id="id_2597911_709050_1_1" xlink:label="us-gaap_AllowanceForTradeReceivablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Trade Receivables [Member]</label>
    <label id="id_2597911_709050_2_1" xlink:label="us-gaap_AllowanceForTradeReceivablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for Trade Receivables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForTradeReceivablesMember" xlink:to="us-gaap_AllowanceForTradeReceivablesMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <label id="id_2597911_705992_1_1" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</label>
    <label id="id_2597911_705992_2_1" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_AmericanDepositaryShareMember" xlink:label="amrn_AmericanDepositaryShareMember" xlink:type="locator"/>
    <label id="id_2597911_815040_3_1" xlink:label="amrn_AmericanDepositaryShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">American Depositary Share</label>
    <label id="id_2597911_815040_1_1" xlink:label="amrn_AmericanDepositaryShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">American Depositary Share [Member]</label>
    <label id="id_2597911_815040_2_1" xlink:label="amrn_AmericanDepositaryShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">American Depositary Share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_AmericanDepositaryShareMember" xlink:to="amrn_AmericanDepositaryShareMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_AmericanDepositorySharesMember" xlink:label="amrn_AmericanDepositorySharesMember" xlink:type="locator"/>
    <label id="id_2597911_826933_3_1" xlink:label="amrn_AmericanDepositorySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">American Depository Shares [Member]</label>
    <label id="id_2597911_826933_1_1" xlink:label="amrn_AmericanDepositorySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">American Depository Shares [Member]</label>
    <label id="id_2597911_826933_2_1" xlink:label="amrn_AmericanDepositorySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">American Depository Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_AmericanDepositorySharesMember" xlink:to="amrn_AmericanDepositorySharesMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_AmericanDepositorySharesToSharesRatio" xlink:label="amrn_AmericanDepositorySharesToSharesRatio" xlink:type="locator"/>
    <label id="id_2597911_825622_3_1" xlink:label="amrn_AmericanDepositorySharesToSharesRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">American Depository Shares to Shares Ratio</label>
    <label id="id_2597911_825622_1_1" xlink:label="amrn_AmericanDepositorySharesToSharesRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">American Depository Shares To Shares Ratio</label>
    <label id="id_2597911_825622_2_1" xlink:label="amrn_AmericanDepositorySharesToSharesRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares that each ADS represents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_AmericanDepositorySharesToSharesRatio" xlink:to="amrn_AmericanDepositorySharesToSharesRatio_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <label id="id_2597911_722361_1_1" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Debt Discount Premium</label>
    <label id="id_2597911_722361_2_1" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, amortization of discount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="locator"/>
    <label id="id_2597911_721490_1_1" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Financing Costs And Discounts</label>
    <label id="id_2597911_721490_2_1" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount and debt issuance costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <label id="id_2597911_723715_1_1" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Intangible Assets</label>
    <label id="id_2597911_723715_2_1" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible asset</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_AmrOneHundredOneMember" xlink:label="amrn_AmrOneHundredOneMember" xlink:type="locator"/>
    <label id="id_2597911_819032_3_1" xlink:label="amrn_AmrOneHundredOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amr One Hundred One [Member]</label>
    <label id="id_2597911_819032_1_1" xlink:label="amrn_AmrOneHundredOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amr One Hundred One [Member]</label>
    <label id="id_2597911_819032_2_1" xlink:label="amrn_AmrOneHundredOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amr One Hundred One</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_AmrOneHundredOneMember" xlink:to="amrn_AmrOneHundredOneMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <label id="id_2597911_722688_1_1" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</label>
    <label id="id_2597911_722688_6_1" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <label id="id_2597911_712527_1_1" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</label>
    <label id="id_2597911_712527_2_1" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <label id="id_2597911_724901_1_1" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Current</label>
    <label id="id_2597911_724901_6_1" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <label id="id_2597911_708149_1_1" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Current [Abstract]</label>
    <label id="id_2597911_708149_2_1" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Assets:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator"/>
    <label id="id_2597911_711278_1_1" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Fair Value Disclosure [Abstract]</label>
    <label id="id_2597911_711278_2_1" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <label id="id_2597911_713115_1_1" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</label>
    <label id="id_2597911_713115_2_1" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <label id="id_2597911_715990_1_1" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</label>
    <label id="id_2597911_715990_2_1" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <label id="id_2597911_711823_1_1" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</label>
    <label id="id_2597911_711823_2_1" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_BiopharmaceuticalMember" xlink:label="amrn_BiopharmaceuticalMember" xlink:type="locator"/>
    <label id="id_2597911_822778_3_1" xlink:label="amrn_BiopharmaceuticalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biopharmaceutical [Member]</label>
    <label id="id_2597911_822778_1_1" xlink:label="amrn_BiopharmaceuticalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biopharmaceutical [Member]</label>
    <label id="id_2597911_822778_2_1" xlink:label="amrn_BiopharmaceuticalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioPharma Debt</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_BiopharmaceuticalMember" xlink:to="amrn_BiopharmaceuticalMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember" xlink:type="locator"/>
    <label id="id_2597911_716792_1_1" xlink:label="us-gaap_BridgeLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Loan [Member]</label>
    <label id="id_2597911_716792_2_1" xlink:label="us-gaap_BridgeLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge Loan</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BridgeLoanMember" xlink:to="us-gaap_BridgeLoanMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_BusinessDevelopmentDomain" xlink:label="amrn_BusinessDevelopmentDomain" xlink:type="locator"/>
    <label id="id_2597911_848258_3_1" xlink:label="amrn_BusinessDevelopmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Development [Domain]</label>
    <label id="id_2597911_848258_1_1" xlink:label="amrn_BusinessDevelopmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Development [Domain]</label>
    <label id="id_2597911_848258_2_1" xlink:label="amrn_BusinessDevelopmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Development [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_BusinessDevelopmentDomain" xlink:to="amrn_BusinessDevelopmentDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_BusinessDevelopmentsAxis" xlink:label="amrn_BusinessDevelopmentsAxis" xlink:type="locator"/>
    <label id="id_2597911_764190_3_1" xlink:label="amrn_BusinessDevelopmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Developments [Axis]</label>
    <label id="id_2597911_764190_1_1" xlink:label="amrn_BusinessDevelopmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Developments [Axis]</label>
    <label id="id_2597911_764190_2_1" xlink:label="amrn_BusinessDevelopmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Developments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_BusinessDevelopmentsAxis" xlink:to="amrn_BusinessDevelopmentsAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <label id="id_2597911_722785_1_1" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents At Carrying Value</label>
    <label id="id_2597911_722785_4_1" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF PERIOD</label>
    <label id="id_2597911_722785_5_1" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</label>
    <label id="id_2597911_722785_2_1" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <label id="id_2597911_722672_1_1" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents Fair Value Disclosure</label>
    <label id="id_2597911_722672_2_1" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents-money markets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <label id="id_2597911_721794_1_1" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents Period Increase Decrease</label>
    <label id="id_2597911_721794_6_1" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <label id="id_2597911_712759_1_1" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents Policy [Text Block]</label>
    <label id="id_2597911_712759_2_1" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_CashDiscountInvoiceTerms" xlink:label="amrn_CashDiscountInvoiceTerms" xlink:type="locator"/>
    <label id="id_2597911_814959_3_1" xlink:label="amrn_CashDiscountInvoiceTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Discount Invoice Terms</label>
    <label id="id_2597911_814959_1_1" xlink:label="amrn_CashDiscountInvoiceTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Discount Invoice Terms</label>
    <label id="id_2597911_814959_2_1" xlink:label="amrn_CashDiscountInvoiceTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales discount term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_CashDiscountInvoiceTerms" xlink:to="amrn_CashDiscountInvoiceTerms_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_CashDiscountPercent" xlink:label="amrn_CashDiscountPercent" xlink:type="locator"/>
    <label id="id_2597911_802426_3_1" xlink:label="amrn_CashDiscountPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Discount Percent</label>
    <label id="id_2597911_802426_1_1" xlink:label="amrn_CashDiscountPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Discount Percent</label>
    <label id="id_2597911_802426_2_1" xlink:label="amrn_CashDiscountPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales discount percentage</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_CashDiscountPercent" xlink:to="amrn_CashDiscountPercent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <label id="id_2597911_707508_1_1" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</label>
    <label id="id_2597911_707508_2_1" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash transactions:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" xlink:type="locator"/>
    <label id="id_2597911_711289_1_1" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash [Member]</label>
    <label id="id_2597911_711289_2_1" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_CashPaidDuringPeriodForAbstract" xlink:label="amrn_CashPaidDuringPeriodForAbstract" xlink:type="locator"/>
    <label id="id_2597911_770492_3_1" xlink:label="amrn_CashPaidDuringPeriodForAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Paid During Period For [Abstract]</label>
    <label id="id_2597911_770492_1_1" xlink:label="amrn_CashPaidDuringPeriodForAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Paid During Period For [Abstract]</label>
    <label id="id_2597911_770492_2_1" xlink:label="amrn_CashPaidDuringPeriodForAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid during the year for:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_CashPaidDuringPeriodForAbstract" xlink:to="amrn_CashPaidDuringPeriodForAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ChangeInControlObligations" xlink:label="amrn_ChangeInControlObligations" xlink:type="locator"/>
    <label id="id_2597911_790912_3_1" xlink:label="amrn_ChangeInControlObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Control Obligations</label>
    <label id="id_2597911_790912_1_1" xlink:label="amrn_ChangeInControlObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Control Obligations</label>
    <label id="id_2597911_790912_2_1" xlink:label="amrn_ChangeInControlObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change of control obligation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ChangeInControlObligations" xlink:to="amrn_ChangeInControlObligations_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <label id="id_2597911_710800_1_1" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Stock [Domain]</label>
    <label id="id_2597911_710800_2_1" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <label id="id_2597911_716763_1_1" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right [Axis]</label>
    <label id="id_2597911_716763_2_1" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <label id="id_2597911_713026_1_1" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right [Domain]</label>
    <label id="id_2597911_713026_2_1" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ClassOfWarrantOrRightExercisedInPeriod" xlink:label="amrn_ClassOfWarrantOrRightExercisedInPeriod" xlink:type="locator"/>
    <label id="id_2597911_751698_3_1" xlink:label="amrn_ClassOfWarrantOrRightExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised in Period</label>
    <label id="id_2597911_751698_1_1" xlink:label="amrn_ClassOfWarrantOrRightExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Exercised In Period</label>
    <label id="id_2597911_751698_2_1" xlink:label="amrn_ClassOfWarrantOrRightExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ClassOfWarrantOrRightExercisedInPeriod" xlink:to="amrn_ClassOfWarrantOrRightExercisedInPeriod_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:type="locator"/>
    <label id="id_2597911_711170_1_1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights</label>
    <label id="id_2597911_711170_2_1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ClassOfWarrantOrRightExpirationDate" xlink:label="amrn_ClassOfWarrantOrRightExpirationDate" xlink:type="locator"/>
    <label id="id_2597911_749534_3_1" xlink:label="amrn_ClassOfWarrantOrRightExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expiration Date</label>
    <label id="id_2597911_749534_1_1" xlink:label="amrn_ClassOfWarrantOrRightExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Expiration Date</label>
    <label id="id_2597911_749534_2_1" xlink:label="amrn_ClassOfWarrantOrRightExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ClassOfWarrantOrRightExpirationDate" xlink:to="amrn_ClassOfWarrantOrRightExpirationDate_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ClassOfWarrantOrRightIssued" xlink:label="amrn_ClassOfWarrantOrRightIssued" xlink:type="locator"/>
    <label id="id_2597911_798281_3_1" xlink:label="amrn_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Issued</label>
    <label id="id_2597911_798281_1_1" xlink:label="amrn_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Issued</label>
    <label id="id_2597911_798281_2_1" xlink:label="amrn_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ClassOfWarrantOrRightIssued" xlink:to="amrn_ClassOfWarrantOrRightIssued_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="locator"/>
    <label id="id_2597911_714553_1_1" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right [Line Items]</label>
    <label id="id_2597911_714553_2_1" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <label id="id_2597911_709169_1_1" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</label>
    <label id="id_2597911_709169_2_1" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued, number of shares called by the warrant</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <label id="id_2597911_715384_1_1" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Outstanding</label>
    <label id="id_2597911_715384_2_1" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount</label>
    <label id="id_2597911_715384_12_1" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of warrant outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:type="locator"/>
    <label id="id_2597911_712424_1_1" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right [Table]</label>
    <label id="id_2597911_712424_2_1" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ClassOfWarrantOrRightTerm" xlink:label="amrn_ClassOfWarrantOrRightTerm" xlink:type="locator"/>
    <label id="id_2597911_759235_3_1" xlink:label="amrn_ClassOfWarrantOrRightTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</label>
    <label id="id_2597911_759235_1_1" xlink:label="amrn_ClassOfWarrantOrRightTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Term</label>
    <label id="id_2597911_759235_2_1" xlink:label="amrn_ClassOfWarrantOrRightTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ClassOfWarrantOrRightTerm" xlink:to="amrn_ClassOfWarrantOrRightTerm_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <label id="id_2597911_717342_1_1" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies</label>
    <label id="id_2597911_717342_2_1" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 7)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator"/>
    <label id="id_2597911_716008_1_1" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies Disclosure [Abstract]</label>
    <label id="id_2597911_716008_2_1" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator"/>
    <label id="id_2597911_806031_3_1" xlink:label="amrn_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Line Items]</label>
    <label id="id_2597911_806031_1_1" xlink:label="amrn_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies Disclosure [Line Items]</label>
    <label id="id_2597911_806031_2_1" xlink:label="amrn_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="amrn_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_CommitmentsAndContingenciesDisclosureTable" xlink:label="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator"/>
    <label id="id_2597911_785276_3_1" xlink:label="amrn_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Table]</label>
    <label id="id_2597911_785276_1_1" xlink:label="amrn_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies Disclosure [Table]</label>
    <label id="id_2597911_785276_2_1" xlink:label="amrn_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="amrn_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_2597911_716962_1_1" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies Disclosure [Text Block]</label>
    <label id="id_2597911_716962_2_1" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <label id="id_2597911_713713_1_1" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</label>
    <label id="id_2597911_713713_2_1" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <label id="id_2597911_714811_1_1" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Par Or Stated Value Per Share</label>
    <label id="id_2597911_714811_2_1" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <label id="id_2597911_707767_1_1" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Shares Issued</label>
    <label id="id_2597911_707767_2_1" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <label id="id_2597911_716560_1_1" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Shares Outstanding</label>
    <label id="id_2597911_716560_2_1" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <label id="id_2597911_720509_1_1" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Value</label>
    <label id="id_2597911_720509_2_1" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, &#xA3;0.50 par value, unlimited authorized; 172,664,013 issued, 172,643,934 outstanding at September 30, 2013; 150,360,933 issued, 150,340,854 outstanding at December 31, 2012</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ComponentOfOperatingCostAndExpenseLineItems" xlink:label="amrn_ComponentOfOperatingCostAndExpenseLineItems" xlink:type="locator"/>
    <label id="id_2597911_759434_3_1" xlink:label="amrn_ComponentOfOperatingCostAndExpenseLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Component Of Operating Cost And Expense [Line Items]</label>
    <label id="id_2597911_759434_1_1" xlink:label="amrn_ComponentOfOperatingCostAndExpenseLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Component Of Operating Cost And Expense [Line Items]</label>
    <label id="id_2597911_759434_2_1" xlink:label="amrn_ComponentOfOperatingCostAndExpenseLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component Of Operating Cost And Expense [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ComponentOfOperatingCostAndExpenseLineItems" xlink:to="amrn_ComponentOfOperatingCostAndExpenseLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ComponentOfOperatingCostAndExpenseTable" xlink:label="amrn_ComponentOfOperatingCostAndExpenseTable" xlink:type="locator"/>
    <label id="id_2597911_778991_3_1" xlink:label="amrn_ComponentOfOperatingCostAndExpenseTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Component Of Operating Cost And Expense [Table]</label>
    <label id="id_2597911_778991_1_1" xlink:label="amrn_ComponentOfOperatingCostAndExpenseTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Component Of Operating Cost And Expense [Table]</label>
    <label id="id_2597911_778991_2_1" xlink:label="amrn_ComponentOfOperatingCostAndExpenseTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component Of Operating Cost And Expense [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ComponentOfOperatingCostAndExpenseTable" xlink:to="amrn_ComponentOfOperatingCostAndExpenseTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" xlink:type="locator"/>
    <label id="id_2597911_717210_1_1" xlink:label="us-gaap_ConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt</label>
    <label id="id_2597911_717210_2_1" xlink:label="us-gaap_ConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, carrying amount net of unamortized discount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" xlink:type="locator"/>
    <label id="id_2597911_714242_1_1" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</label>
    <label id="id_2597911_714242_2_1" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <label id="id_2597911_721097_1_1" xlink:label="us-gaap_CostOfGoodsSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost Of Goods Sold</label>
    <label id="id_2597911_721097_2_1" xlink:label="us-gaap_CostOfGoodsSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</label>
    <label id="id_2597911_721097_12_1" xlink:label="us-gaap_CostOfGoodsSold_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold expensed</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <label id="id_2597911_706049_1_1" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label id="id_2597911_706049_2_1" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <label id="id_2597911_711171_1_1" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion By Unique Description [Axis]</label>
    <label id="id_2597911_711171_2_1" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion by Unique Description</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <label id="id_2597911_713516_1_1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Converted Instrument Shares Issued 1</label>
    <label id="id_2597911_713516_2_1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, total ADS into which the debt is exchangeable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <label id="id_2597911_712435_1_1" xlink:label="us-gaap_DebtConversionNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Name [Domain]</label>
    <label id="id_2597911_712435_2_1" xlink:label="us-gaap_DebtConversionNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_DebtConversionNameDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <label id="id_2597911_717290_1_1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Original Debt Amount 1</label>
    <label id="id_2597911_717290_2_1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge notes converted in conjunction with the private placement, amount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:type="locator"/>
    <label id="id_2597911_712818_1_1" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <label id="id_2597911_712818_2_1" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_DebtDisclosureLineItems" xlink:label="amrn_DebtDisclosureLineItems" xlink:type="locator"/>
    <label id="id_2597911_736187_3_1" xlink:label="amrn_DebtDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Line Items]</label>
    <label id="id_2597911_736187_1_1" xlink:label="amrn_DebtDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Line Items]</label>
    <label id="id_2597911_736187_2_1" xlink:label="amrn_DebtDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_DebtDisclosureLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_DebtDisclosureTable" xlink:label="amrn_DebtDisclosureTable" xlink:type="locator"/>
    <label id="id_2597911_790961_3_1" xlink:label="amrn_DebtDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Table]</label>
    <label id="id_2597911_790961_1_1" xlink:label="amrn_DebtDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Table]</label>
    <label id="id_2597911_790961_2_1" xlink:label="amrn_DebtDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DebtDisclosureTable" xlink:to="amrn_DebtDisclosureTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_2597911_707944_1_1" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <label id="id_2597911_707944_2_1" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <label id="id_2597911_711461_1_1" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</label>
    <label id="id_2597911_711461_2_1" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentCallDateEarliest" xlink:label="us-gaap_DebtInstrumentCallDateEarliest" xlink:type="locator"/>
    <label id="id_2597911_712629_1_1" xlink:label="us-gaap_DebtInstrumentCallDateEarliest_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Call Date Earliest</label>
    <label id="id_2597911_712629_2_1" xlink:label="us-gaap_DebtInstrumentCallDateEarliest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, earliest redemption date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCallDateEarliest" xlink:to="us-gaap_DebtInstrumentCallDateEarliest_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <label id="id_2597911_707441_1_1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Conversion Price 1</label>
    <label id="id_2597911_707441_2_1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge notes converted in conjunction with the private placement, price per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="locator"/>
    <label id="id_2597911_707195_1_1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Conversion Ratio 1</label>
    <label id="id_2597911_707195_2_1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, exchange rate of ADS per $1,000 principal amount of notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="locator"/>
    <label id="id_2597911_713009_1_1" xlink:label="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Remaining Discount Amortization Period 1</label>
    <label id="id_2597911_713009_2_1" xlink:label="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt discount amortization period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:type="locator"/>
    <label id="id_2597911_716888_1_1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Date Of First Required Payment 1</label>
    <label id="id_2597911_716888_2_1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, payment start date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <label id="id_2597911_719268_1_1" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Face Amount</label>
    <label id="id_2597911_719268_2_1" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, principal amount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" xlink:type="locator"/>
    <label id="id_2597911_719711_1_1" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Fair Value</label>
    <label id="id_2597911_719711_2_1" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of the liability component</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <label id="id_2597911_709457_1_1" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Interest Rate Effective Percentage</label>
    <label id="id_2597911_709457_2_1" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <label id="id_2597911_708434_1_1" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Interest Rate Stated Percentage</label>
    <label id="id_2597911_708434_2_1" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, stated interest rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:type="locator"/>
    <label id="id_2597911_711407_1_1" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Maturity Date</label>
    <label id="id_2597911_711407_2_1" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, maturity date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_DebtInstrumentMaturityDateYear" xlink:label="amrn_DebtInstrumentMaturityDateYear" xlink:type="locator"/>
    <label id="id_2597911_800102_3_1" xlink:label="amrn_DebtInstrumentMaturityDateYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Maturity Date Year</label>
    <label id="id_2597911_800102_1_1" xlink:label="amrn_DebtInstrumentMaturityDateYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Maturity Date Year</label>
    <label id="id_2597911_800102_2_1" xlink:label="amrn_DebtInstrumentMaturityDateYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, due date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DebtInstrumentMaturityDateYear" xlink:to="amrn_DebtInstrumentMaturityDateYear_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <label id="id_2597911_714290_1_1" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Name [Domain]</label>
    <label id="id_2597911_714290_2_1" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="locator"/>
    <label id="id_2597911_711904_1_1" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Redemption Price Percentage</label>
    <label id="id_2597911_711904_2_1" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, repurchase price at option of the issuer</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <label id="id_2597911_708071_1_1" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Term</label>
    <label id="id_2597911_708071_2_1" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note, estimated remaining life</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator"/>
    <label id="id_2597911_724151_1_1" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Unamortized Discount</label>
    <label id="id_2597911_724151_2_1" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt discount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_DebtOfferingMember" xlink:label="amrn_DebtOfferingMember" xlink:type="locator"/>
    <label id="id_2597911_750970_3_1" xlink:label="amrn_DebtOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Offering [Member]</label>
    <label id="id_2597911_750970_1_1" xlink:label="amrn_DebtOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Offering [Member]</label>
    <label id="id_2597911_750970_2_1" xlink:label="amrn_DebtOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Offering</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DebtOfferingMember" xlink:to="amrn_DebtOfferingMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:type="locator"/>
    <label id="id_2597911_707792_1_1" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Policy [Text Block]</label>
    <label id="id_2597911_707792_2_1" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instruments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <label id="id_2597911_724259_1_1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense</label>
    <label id="id_2597911_724259_2_1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Stock units, Expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <label id="id_2597911_721154_1_1" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense Benefit</label>
    <label id="id_2597911_721154_2_1" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <label id="id_2597911_719153_1_1" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Current</label>
    <label id="id_2597911_719153_2_1" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred product revenue</label>
    <label id="id_2597911_719153_12_1" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_DeferredRevenuePolicyTextBlock" xlink:label="amrn_DeferredRevenuePolicyTextBlock" xlink:type="locator"/>
    <label id="id_2597911_778631_3_1" xlink:label="amrn_DeferredRevenuePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Policy [Text Block]</label>
    <label id="id_2597911_778631_1_1" xlink:label="amrn_DeferredRevenuePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Policy [Text Block]</label>
    <label id="id_2597911_778631_2_1" xlink:label="amrn_DeferredRevenuePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DeferredRevenuePolicyTextBlock" xlink:to="amrn_DeferredRevenuePolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_DeferredStockUnitsDSUsMember" xlink:label="amrn_DeferredStockUnitsDSUsMember" xlink:type="locator"/>
    <label id="id_2597911_738662_3_1" xlink:label="amrn_DeferredStockUnitsDSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Stock Units D S Us [Member]</label>
    <label id="id_2597911_738662_1_1" xlink:label="amrn_DeferredStockUnitsDSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock Units D S Us [Member]</label>
    <label id="id_2597911_738662_2_1" xlink:label="amrn_DeferredStockUnitsDSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Stock Units (DSUs)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DeferredStockUnitsDSUsMember" xlink:to="amrn_DeferredStockUnitsDSUsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent" xlink:type="locator"/>
    <label id="id_2597911_722102_1_1" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Net Current</label>
    <label id="id_2597911_722102_2_1" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetCurrent" xlink:to="us-gaap_DeferredTaxAssetsNetCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:type="locator"/>
    <label id="id_2597911_722671_1_1" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Net Noncurrent</label>
    <label id="id_2597911_722671_2_1" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <label id="id_2597911_721752_1_1" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation And Amortization</label>
    <label id="id_2597911_721752_2_1" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount" xlink:label="us-gaap_DerivativeAssetNotionalAmount" xlink:type="locator"/>
    <label id="id_2597911_708659_1_1" xlink:label="us-gaap_DerivativeAssetNotionalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset Notional Amount</label>
    <label id="id_2597911_708659_2_1" xlink:label="us-gaap_DerivativeAssetNotionalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional amounts, foreign exchange forward contracts</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetNotionalAmount" xlink:to="us-gaap_DerivativeAssetNotionalAmount_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="us-gaap_DerivativeByNatureAxis" xlink:type="locator"/>
    <label id="id_2597911_713399_1_1" xlink:label="us-gaap_DerivativeByNatureAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative By Nature [Axis]</label>
    <label id="id_2597911_713399_2_1" xlink:label="us-gaap_DerivativeByNatureAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, by Nature</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="us-gaap_DerivativeByNatureAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <label id="id_2597911_712395_1_1" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract Type [Domain]</label>
    <label id="id_2597911_712395_2_1" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="locator"/>
    <label id="id_2597911_717408_1_1" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Fair Value Of Derivative Liability</label>
    <label id="id_2597911_717408_2_1" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of derivative liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_DerivativeInstrumentMember" xlink:label="amrn_DerivativeInstrumentMember" xlink:type="locator"/>
    <label id="id_2597911_739938_3_1" xlink:label="amrn_DerivativeInstrumentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Member]</label>
    <label id="id_2597911_739938_1_1" xlink:label="amrn_DerivativeInstrumentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Member]</label>
    <label id="id_2597911_739938_2_1" xlink:label="amrn_DerivativeInstrumentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DerivativeInstrumentMember" xlink:to="amrn_DerivativeInstrumentMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <label id="id_2597911_715632_1_1" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument Risk [Axis]</label>
    <label id="id_2597911_715632_2_1" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <label id="id_2597911_708894_1_1" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments And Hedging Activities Disclosure [Abstract]</label>
    <label id="id_2597911_708894_2_1" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_2597911_710178_1_1" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments And Hedging Activities Disclosure [Text Block]</label>
    <label id="id_2597911_710178_2_1" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Warrant Derivative Liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xlink:type="locator"/>
    <label id="id_2597911_718993_1_1" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liabilities</label>
    <label id="id_2597911_718993_4_1" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</label>
    <label id="id_2597911_718993_5_1" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</label>
    <label id="id_2597911_718993_2_1" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant derivative liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator"/>
    <label id="id_2597911_720427_1_1" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liabilities Noncurrent</label>
    <label id="id_2597911_720427_2_1" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability</label>
    <label id="id_2597911_720427_12_1" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrant derivative liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" xlink:label="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" xlink:type="locator"/>
    <label id="id_2597911_755689_3_1" xlink:label="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Liabilities Transferred to Stockholders' Equity</label>
    <label id="id_2597911_755689_1_1" xlink:label="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liabilities Transferred To Stockholders Equity</label>
    <label id="id_2597911_755689_14_1" xlink:label="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Transfers to equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" xlink:to="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems" xlink:type="locator"/>
    <label id="id_2597911_716071_1_1" xlink:label="us-gaap_DerivativeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</label>
    <label id="id_2597911_716071_2_1" xlink:label="us-gaap_DerivativeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="us-gaap_DerivativeNameDomain" xlink:type="locator"/>
    <label id="id_2597911_713662_1_1" xlink:label="us-gaap_DerivativeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Name [Domain]</label>
    <label id="id_2597911_713662_2_1" xlink:label="us-gaap_DerivativeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="us-gaap_DerivativeNameDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesEmbeddedDerivatives" xlink:label="us-gaap_DerivativesEmbeddedDerivatives" xlink:type="locator"/>
    <label id="id_2597911_710791_1_1" xlink:label="us-gaap_DerivativesEmbeddedDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives Embedded Derivatives</label>
    <label id="id_2597911_710791_2_1" xlink:label="us-gaap_DerivativesEmbeddedDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long Term Debt Redemption Feature</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesEmbeddedDerivatives" xlink:to="us-gaap_DerivativesEmbeddedDerivatives_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="us-gaap_DerivativesFairValueLineItems" xlink:type="locator"/>
    <label id="id_2597911_711916_1_1" xlink:label="us-gaap_DerivativesFairValueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives Fair Value [Line Items]</label>
    <label id="id_2597911_711916_2_1" xlink:label="us-gaap_DerivativesFairValueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativesFairValueLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:type="locator"/>
    <label id="id_2597911_714521_1_1" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives Policy [Text Block]</label>
    <label id="id_2597911_714521_2_1" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable" xlink:type="locator"/>
    <label id="id_2597911_713208_1_1" xlink:label="us-gaap_DerivativeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Table]</label>
    <label id="id_2597911_713208_2_1" xlink:label="us-gaap_DerivativeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_DerivativeTable_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_DevelopmentFeesCommitted" xlink:label="amrn_DevelopmentFeesCommitted" xlink:type="locator"/>
    <label id="id_2597911_768509_3_1" xlink:label="amrn_DevelopmentFeesCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Fees Committed</label>
    <label id="id_2597911_768509_1_1" xlink:label="amrn_DevelopmentFeesCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Fees Committed</label>
    <label id="id_2597911_768509_2_1" xlink:label="amrn_DevelopmentFeesCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development fees committed</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DevelopmentFeesCommitted" xlink:to="amrn_DevelopmentFeesCommitted_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DirectOperatingCosts" xlink:label="us-gaap_DirectOperatingCosts" xlink:type="locator"/>
    <label id="id_2597911_723759_1_1" xlink:label="us-gaap_DirectOperatingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct Operating Costs</label>
    <label id="id_2597911_723759_2_1" xlink:label="us-gaap_DirectOperatingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Direct Operating Costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectOperatingCosts" xlink:to="us-gaap_DirectOperatingCosts_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_DocumentAndEntityInformationAbstract" xlink:label="amrn_DocumentAndEntityInformationAbstract" xlink:type="locator"/>
    <label id="id_2597911_739630_3_1" xlink:label="amrn_DocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <label id="id_2597911_739630_1_1" xlink:label="amrn_DocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <label id="id_2597911_739630_2_1" xlink:label="amrn_DocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DocumentAndEntityInformationAbstract" xlink:to="amrn_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <label id="id_2597911_706064_1_1" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label id="id_2597911_706064_2_1" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <label id="id_2597911_706019_1_1" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label id="id_2597911_706019_2_1" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <label id="id_2597911_705969_1_1" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</label>
    <label id="id_2597911_705969_2_1" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <label id="id_2597911_706034_1_1" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</label>
    <label id="id_2597911_706034_2_1" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <label id="id_2597911_706029_1_1" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</label>
    <label id="id_2597911_706029_2_1" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <label id="id_2597911_715782_1_1" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label id="id_2597911_715782_2_1" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per share:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <label id="id_2597911_715198_1_1" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Basic And Diluted</label>
    <label id="id_2597911_715198_2_1" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <label id="id_2597911_714967_1_1" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Policy [Text Block]</label>
    <label id="id_2597911_714967_2_1" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per Share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmbeddedDerivativeDescriptionOfHostContract" xlink:label="us-gaap_EmbeddedDerivativeDescriptionOfHostContract" xlink:type="locator"/>
    <label id="id_2597911_709926_1_1" xlink:label="us-gaap_EmbeddedDerivativeDescriptionOfHostContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative Description Of Host Contract</label>
    <label id="id_2597911_709926_2_1" xlink:label="us-gaap_EmbeddedDerivativeDescriptionOfHostContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of pricing variability feature and classification of warrants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeDescriptionOfHostContract" xlink:to="us-gaap_EmbeddedDerivativeDescriptionOfHostContract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="locator"/>
    <label id="id_2597911_719290_1_1" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative Fair Value Of Embedded Derivative Liability</label>
    <label id="id_2597911_719290_32_1" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:type="resource" xml:lang="en-US">Long-term debt redemption feature</label>
    <label id="id_2597911_719290_2_1" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of Embedded derivative liability</label>
    <label id="id_2597911_719290_12_1" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long term debt redemption feature</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:type="locator"/>
    <label id="id_2597911_711232_1_1" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative Financial Instruments [Member]</label>
    <label id="id_2597911_711232_2_1" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Embedded Derivative Financial Instruments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:to="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EnergyAxis" xlink:label="us-gaap_EnergyAxis" xlink:type="locator"/>
    <label id="id_2597911_708566_1_1" xlink:label="us-gaap_EnergyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Energy [Axis]</label>
    <label id="id_2597911_708566_2_1" xlink:label="us-gaap_EnergyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instrument</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EnergyAxis" xlink:to="us-gaap_EnergyAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EnergyDomain" xlink:label="us-gaap_EnergyDomain" xlink:type="locator"/>
    <label id="id_2597911_715597_1_1" xlink:label="us-gaap_EnergyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Energy [Domain]</label>
    <label id="id_2597911_715597_2_1" xlink:label="us-gaap_EnergyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Energy [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EnergyDomain" xlink:to="us-gaap_EnergyDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable" xlink:type="locator"/>
    <label id="id_2597911_705990_1_1" xlink:label="dei_EntitiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</label>
    <label id="id_2597911_705990_2_1" xlink:label="dei_EntitiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitiesTable" xlink:to="dei_EntitiesTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <label id="id_2597911_706042_1_1" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</label>
    <label id="id_2597911_706042_2_1" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <label id="id_2597911_706087_1_1" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock Shares Outstanding</label>
    <label id="id_2597911_706087_2_1" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <label id="id_2597911_706015_1_1" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</label>
    <label id="id_2597911_706015_2_1" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <label id="id_2597911_706000_1_1" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</label>
    <label id="id_2597911_706000_2_1" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <label id="id_2597911_705982_1_1" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</label>
    <label id="id_2597911_705982_2_1" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:type="locator"/>
    <label id="id_2597911_710583_1_1" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</label>
    <label id="id_2597911_710583_2_1" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <label id="id_2597911_709383_1_1" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</label>
    <label id="id_2597911_709383_2_1" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="us-gaap_EquityIssuancePerShareAmount" xlink:type="locator"/>
    <label id="id_2597911_714918_1_1" xlink:label="us-gaap_EquityIssuancePerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Issuance Per Share Amount</label>
    <label id="id_2597911_714918_2_1" xlink:label="us-gaap_EquityIssuancePerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under private placement, price per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityIssuancePerShareAmount" xlink:to="us-gaap_EquityIssuancePerShareAmount_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ExcessFairValueOverPrincipalValue" xlink:label="amrn_ExcessFairValueOverPrincipalValue" xlink:type="locator"/>
    <label id="id_2597911_823375_3_1" xlink:label="amrn_ExcessFairValueOverPrincipalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Excess Fair Value over Principal Value</label>
    <label id="id_2597911_823375_1_1" xlink:label="amrn_ExcessFairValueOverPrincipalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excess Fair Value Over Principal Value</label>
    <label id="id_2597911_823375_2_1" xlink:label="amrn_ExcessFairValueOverPrincipalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of shares in excess of principal amount of Notes based on closing price</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ExcessFairValueOverPrincipalValue" xlink:to="amrn_ExcessFairValueOverPrincipalValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="locator"/>
    <label id="id_2597911_718611_1_1" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excess Tax Benefit From Share Based Compensation Operating Activities</label>
    <label id="id_2597911_718611_14_1" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Excess tax benefit from stock-based awards</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_FairValueAndDerivativeInstrumentsTable" xlink:label="amrn_FairValueAndDerivativeInstrumentsTable" xlink:type="locator"/>
    <label id="id_2597911_761277_3_1" xlink:label="amrn_FairValueAndDerivativeInstrumentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value And Derivative Instruments [Table]</label>
    <label id="id_2597911_761277_1_1" xlink:label="amrn_FairValueAndDerivativeInstrumentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value And Derivative Instruments [Table]</label>
    <label id="id_2597911_761277_2_1" xlink:label="amrn_FairValueAndDerivativeInstrumentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value And Derivative Instruments [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_FairValueAndDerivativeInstrumentsTable" xlink:to="amrn_FairValueAndDerivativeInstrumentsTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator"/>
    <label id="id_2597911_710219_1_1" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <label id="id_2597911_710219_2_1" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator"/>
    <label id="id_2597911_710349_1_1" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <label id="id_2597911_710349_2_1" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator"/>
    <label id="id_2597911_711739_1_1" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]</label>
    <label id="id_2597911_711739_2_1" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and Liability Measured at Fair Value on a Recurring Basis</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_FairValueAssumptionsComparableYieldToMaturity" xlink:label="amrn_FairValueAssumptionsComparableYieldToMaturity" xlink:type="locator"/>
    <label id="id_2597911_758542_3_1" xlink:label="amrn_FairValueAssumptionsComparableYieldToMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Comparable Yield to Maturity</label>
    <label id="id_2597911_758542_1_1" xlink:label="amrn_FairValueAssumptionsComparableYieldToMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions Comparable Yield To Maturity</label>
    <label id="id_2597911_758542_2_1" xlink:label="amrn_FairValueAssumptionsComparableYieldToMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability fair value assumptions, market yields</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_FairValueAssumptionsComparableYieldToMaturity" xlink:to="amrn_FairValueAssumptionsComparableYieldToMaturity_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <label id="id_2597911_710636_1_1" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions Expected Dividend Rate</label>
    <label id="id_2597911_710636_2_1" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant derivative liability fair value assumptions, dividend yield</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="locator"/>
    <label id="id_2597911_716741_1_1" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions Expected Term</label>
    <label id="id_2597911_716741_2_1" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability fair value assumptions, term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <label id="id_2597911_708853_1_1" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions Expected Volatility Rate</label>
    <label id="id_2597911_708853_2_1" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant derivative liability fair value assumptions, volatility rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <label id="id_2597911_712618_1_1" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions Risk Free Interest Rate</label>
    <label id="id_2597911_712618_2_1" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant derivative liability fair value assumptions, risk-free rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <label id="id_2597911_715757_1_1" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <label id="id_2597911_715757_2_1" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <label id="id_2597911_712546_1_1" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value By Measurement Frequency [Axis]</label>
    <label id="id_2597911_712546_2_1" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Measurement Frequency</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:type="locator"/>
    <label id="id_2597911_713878_1_1" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <label id="id_2597911_713878_2_1" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_FairValueInputsCouponRate" xlink:label="amrn_FairValueInputsCouponRate" xlink:type="locator"/>
    <label id="id_2597911_800593_3_1" xlink:label="amrn_FairValueInputsCouponRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Inputs Coupon Rate</label>
    <label id="id_2597911_800593_1_1" xlink:label="amrn_FairValueInputsCouponRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Inputs Coupon Rate</label>
    <label id="id_2597911_800593_2_1" xlink:label="amrn_FairValueInputsCouponRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability fair value assumption, coupon rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_FairValueInputsCouponRate" xlink:to="amrn_FairValueInputsCouponRate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <label id="id_2597911_707740_1_1" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Inputs Level 1 [Member]</label>
    <label id="id_2597911_707740_2_1" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <label id="id_2597911_715798_1_1" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Inputs Level 3 [Member]</label>
    <label id="id_2597911_715798_2_1" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <label id="id_2597911_709566_1_1" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Frequency [Domain]</label>
    <label id="id_2597911_709566_2_1" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <label id="id_2597911_713468_1_1" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label id="id_2597911_713468_2_1" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <label id="id_2597911_711349_1_1" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements Recurring [Member]</label>
    <label id="id_2597911_711349_2_1" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <label id="id_2597911_715008_1_1" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Financial Instruments Policy</label>
    <label id="id_2597911_715008_2_1" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_FinanceMember" xlink:label="amrn_FinanceMember" xlink:type="locator"/>
    <label id="id_2597911_810357_3_1" xlink:label="amrn_FinanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance [Member]</label>
    <label id="id_2597911_810357_1_1" xlink:label="amrn_FinanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance [Member]</label>
    <label id="id_2597911_810357_2_1" xlink:label="amrn_FinanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_FinanceMember" xlink:to="amrn_FinanceMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <label id="id_2597911_720467_1_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite Lived Intangible Assets Accumulated Amortization</label>
    <label id="id_2597911_720467_14_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <label id="id_2597911_724357_1_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite Lived Intangible Assets Gross</label>
    <label id="id_2597911_724357_2_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technology rights</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator"/>
    <label id="id_2597911_716482_1_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite Lived Intangible Assets [Line Items]</label>
    <label id="id_2597911_716482_2_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <label id="id_2597911_723095_1_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite Lived Intangible Assets Net</label>
    <label id="id_2597911_723095_2_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset, net</label>
    <label id="id_2597911_723095_6_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible asset, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <label id="id_2597911_711145_1_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite Lived Intangible Asset Useful Life</label>
    <label id="id_2597911_711145_2_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets estimated remaining useful life</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_FirstIndicationForAmrOneZeroOneMember" xlink:label="amrn_FirstIndicationForAmrOneZeroOneMember" xlink:type="locator"/>
    <label id="id_2597911_834798_3_1" xlink:label="amrn_FirstIndicationForAmrOneZeroOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Indication for AMR101 [Member]</label>
    <label id="id_2597911_834798_1_1" xlink:label="amrn_FirstIndicationForAmrOneZeroOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Indication For Amr One Zero One [Member]</label>
    <label id="id_2597911_834798_2_1" xlink:label="amrn_FirstIndicationForAmrOneZeroOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Indication for AMR101</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_FirstIndicationForAmrOneZeroOneMember" xlink:to="amrn_FirstIndicationForAmrOneZeroOneMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="locator"/>
    <label id="id_2597911_719017_1_1" xlink:label="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts Liability Fair Value Disclosure</label>
    <label id="id_2597911_719017_2_1" xlink:label="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency contracts</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyDerivativesAtFairValueNet" xlink:label="us-gaap_ForeignCurrencyDerivativesAtFairValueNet" xlink:type="locator"/>
    <label id="id_2597911_721913_1_1" xlink:label="us-gaap_ForeignCurrencyDerivativesAtFairValueNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Derivatives At Fair Value Net</label>
    <label id="id_2597911_721913_2_1" xlink:label="us-gaap_ForeignCurrencyDerivativesAtFairValueNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net fair value, foreign exchange forward contracts</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyDerivativesAtFairValueNet" xlink:to="us-gaap_ForeignCurrencyDerivativesAtFairValueNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <label id="id_2597911_714839_1_1" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions And Translations Policy [Text Block]</label>
    <label id="id_2597911_714839_2_1" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <label id="id_2597911_710071_1_1" xlink:label="us-gaap_ForeignExchangeContractMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</label>
    <label id="id_2597911_710071_2_1" xlink:label="us-gaap_ForeignExchangeContractMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignExchangeContractMember" xlink:to="us-gaap_ForeignExchangeContractMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignExchangeForwardMember" xlink:label="us-gaap_ForeignExchangeForwardMember" xlink:type="locator"/>
    <label id="id_2597911_716981_1_1" xlink:label="us-gaap_ForeignExchangeForwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Forward [Member]</label>
    <label id="id_2597911_716981_2_1" xlink:label="us-gaap_ForeignExchangeForwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Exchange Forward</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignExchangeForwardMember" xlink:to="us-gaap_ForeignExchangeForwardMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_FurtherIndicationForAmrOneZeroOneMember" xlink:label="amrn_FurtherIndicationForAmrOneZeroOneMember" xlink:type="locator"/>
    <label id="id_2597911_783044_3_1" xlink:label="amrn_FurtherIndicationForAmrOneZeroOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Further Indication for AMR101 [Member]</label>
    <label id="id_2597911_783044_1_1" xlink:label="amrn_FurtherIndicationForAmrOneZeroOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Further Indication For Amr One Zero One [Member]</label>
    <label id="id_2597911_783044_2_1" xlink:label="amrn_FurtherIndicationForAmrOneZeroOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Further Indication for AMR101</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_FurtherIndicationForAmrOneZeroOneMember" xlink:to="amrn_FurtherIndicationForAmrOneZeroOneMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_FutureMinimumGuaranteePayments" xlink:label="amrn_FutureMinimumGuaranteePayments" xlink:type="locator"/>
    <label id="id_2597911_827557_3_1" xlink:label="amrn_FutureMinimumGuaranteePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Minimum Guarantee Payments</label>
    <label id="id_2597911_827557_1_1" xlink:label="amrn_FutureMinimumGuaranteePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Guarantee Payments</label>
    <label id="id_2597911_827557_2_1" xlink:label="amrn_FutureMinimumGuaranteePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum repayment under agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_FutureMinimumGuaranteePayments" xlink:to="amrn_FutureMinimumGuaranteePayments_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainOnDerivativeInstrumentsPretax" xlink:label="us-gaap_GainOnDerivativeInstrumentsPretax" xlink:type="locator"/>
    <label id="id_2597911_719878_1_1" xlink:label="us-gaap_GainOnDerivativeInstrumentsPretax_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain On Derivative Instruments Pretax</label>
    <label id="id_2597911_719878_2_1" xlink:label="us-gaap_GainOnDerivativeInstrumentsPretax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on change in fair value of derivative liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOnDerivativeInstrumentsPretax" xlink:to="us-gaap_GainOnDerivativeInstrumentsPretax_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator"/>
    <label id="id_2597911_710175_1_1" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill And Intangible Assets Disclosure [Abstract]</label>
    <label id="id_2597911_710175_2_1" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_Group1Member" xlink:label="amrn_Group1Member" xlink:type="locator"/>
    <label id="id_2597911_808971_3_1" xlink:label="amrn_Group1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Group 1 [Member]</label>
    <label id="id_2597911_808971_1_1" xlink:label="amrn_Group1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Group 1 [Member]</label>
    <label id="id_2597911_808971_2_1" xlink:label="amrn_Group1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Group 1</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_Group1Member" xlink:to="amrn_Group1Member_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_Group2Member" xlink:label="amrn_Group2Member" xlink:type="locator"/>
    <label id="id_2597911_759819_3_1" xlink:label="amrn_Group2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Group 2 [Member]</label>
    <label id="id_2597911_759819_1_1" xlink:label="amrn_Group2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Group 2 [Member]</label>
    <label id="id_2597911_759819_2_1" xlink:label="amrn_Group2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Group 2</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_Group2Member" xlink:to="amrn_Group2Member_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_Group3Member" xlink:label="amrn_Group3Member" xlink:type="locator"/>
    <label id="id_2597911_813756_3_1" xlink:label="amrn_Group3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Group 3 [Member]</label>
    <label id="id_2597911_813756_1_1" xlink:label="amrn_Group3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Group 3 [Member]</label>
    <label id="id_2597911_813756_2_1" xlink:label="amrn_Group3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Group 3</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_Group3Member" xlink:to="amrn_Group3Member_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <label id="id_2597911_719127_1_1" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments</label>
    <label id="id_2597911_719127_6_1" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations before income taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <label id="id_2597911_709908_1_1" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</label>
    <label id="id_2597911_709908_2_1" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <label id="id_2597911_717783_1_1" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</label>
    <label id="id_2597911_717783_2_1" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <label id="id_2597911_722444_1_1" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense Benefit</label>
    <label id="id_2597911_722444_14_1" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Benefit from (provision for) income taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <label id="id_2597911_710792_1_1" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Policy [Text Block]</label>
    <label id="id_2597911_710792_2_1" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="locator"/>
    <label id="id_2597911_722051_1_1" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Accounts Payable And Other Operating Liabilities</label>
    <label id="id_2597911_722051_2_1" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable, accrued expenses and other liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <label id="id_2597911_719147_1_1" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Accounts Receivable</label>
    <label id="id_2597911_719147_14_1" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="locator"/>
    <label id="id_2597911_723516_1_1" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Derivative Liabilities</label>
    <label id="id_2597911_723516_2_1" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in the fair value of warrant derivative liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <label id="id_2597911_722289_1_1" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Interest Payable Net</label>
    <label id="id_2597911_722289_2_1" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <label id="id_2597911_720574_1_1" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Inventories</label>
    <label id="id_2597911_720574_14_1" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_IncreaseDecreaseInLeaseRelatedLiabilities" xlink:label="amrn_IncreaseDecreaseInLeaseRelatedLiabilities" xlink:type="locator"/>
    <label id="id_2597911_847807_3_1" xlink:label="amrn_IncreaseDecreaseInLeaseRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Lease Related Liabilities</label>
    <label id="id_2597911_847807_1_1" xlink:label="amrn_IncreaseDecreaseInLeaseRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Lease Related Liabilities</label>
    <label id="id_2597911_847807_2_1" xlink:label="amrn_IncreaseDecreaseInLeaseRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in lease liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_IncreaseDecreaseInLeaseRelatedLiabilities" xlink:to="amrn_IncreaseDecreaseInLeaseRelatedLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <label id="id_2597911_708625_1_1" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Operating Capital [Abstract]</label>
    <label id="id_2597911_708625_2_1" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator"/>
    <label id="id_2597911_718744_1_1" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Other Current Assets</label>
    <label id="id_2597911_718744_14_1" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator"/>
    <label id="id_2597911_719664_1_1" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Other Noncurrent Assets</label>
    <label id="id_2597911_719664_14_1" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <label id="id_2597911_717326_1_1" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Restricted Cash</label>
    <label id="id_2597911_717326_14_1" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_IntangibleAssetsDisclosureLineItems" xlink:label="amrn_IntangibleAssetsDisclosureLineItems" xlink:type="locator"/>
    <label id="id_2597911_744151_3_1" xlink:label="amrn_IntangibleAssetsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Line Items]</label>
    <label id="id_2597911_744151_1_1" xlink:label="amrn_IntangibleAssetsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Line Items]</label>
    <label id="id_2597911_744151_2_1" xlink:label="amrn_IntangibleAssetsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_IntangibleAssetsDisclosureLineItems" xlink:to="amrn_IntangibleAssetsDisclosureLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_IntangibleAssetsDisclosureTable" xlink:label="amrn_IntangibleAssetsDisclosureTable" xlink:type="locator"/>
    <label id="id_2597911_809280_3_1" xlink:label="amrn_IntangibleAssetsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Table]</label>
    <label id="id_2597911_809280_1_1" xlink:label="amrn_IntangibleAssetsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Table]</label>
    <label id="id_2597911_809280_2_1" xlink:label="amrn_IntangibleAssetsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_IntangibleAssetsDisclosureTable" xlink:to="amrn_IntangibleAssetsDisclosureTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_2597911_713813_1_1" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <label id="id_2597911_713813_2_1" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <label id="id_2597911_707362_1_1" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Finite Lived Policy</label>
    <label id="id_2597911_707362_2_1" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <label id="id_2597911_722986_1_1" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</label>
    <label id="id_2597911_722986_2_1" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <label id="id_2597911_722293_1_1" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense Debt</label>
    <label id="id_2597911_722293_2_1" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, interest expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="locator"/>
    <label id="id_2597911_723367_1_1" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense Debt Excluding Amortization</label>
    <label id="id_2597911_723367_2_1" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, contractual coupon interest accrual</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <label id="id_2597911_718605_1_1" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income Expense Nonoperating Net</label>
    <label id="id_2597911_718605_2_1" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xlink:type="locator"/>
    <label id="id_2597911_718952_1_1" xlink:label="us-gaap_InterestPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</label>
    <label id="id_2597911_718952_2_1" xlink:label="us-gaap_InterestPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest</label>
    <label id="id_2597911_718952_12_1" xlink:label="us-gaap_InterestPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest payment on notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <label id="id_2597911_717109_1_1" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable Current</label>
    <label id="id_2597911_717109_2_1" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest on convertible note</label>
    <label id="id_2597911_717109_12_1" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable" xlink:type="locator"/>
    <label id="id_2597911_707946_1_1" xlink:label="us-gaap_InventoryCurrentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Current [Table]</label>
    <label id="id_2597911_707946_2_1" xlink:label="us-gaap_InventoryCurrentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:type="locator"/>
    <label id="id_2597911_713176_1_1" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
    <label id="id_2597911_713176_2_1" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_2597911_712054_1_1" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label id="id_2597911_712054_2_1" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <label id="id_2597911_722016_1_1" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Finished Goods Net Of Reserves</label>
    <label id="id_2597911_722016_2_1" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems" xlink:type="locator"/>
    <label id="id_2597911_710939_1_1" xlink:label="us-gaap_InventoryLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</label>
    <label id="id_2597911_710939_2_1" xlink:label="us-gaap_InventoryLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <label id="id_2597911_721908_1_1" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Net</label>
    <label id="id_2597911_721908_2_1" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</label>
    <label id="id_2597911_721908_6_1" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <label id="id_2597911_712628_1_1" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Policy [Text Block]</label>
    <label id="id_2597911_712628_2_1" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <label id="id_2597911_722172_1_1" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Raw Materials Net Of Reserves</label>
    <label id="id_2597911_722172_2_1" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" xlink:type="locator"/>
    <label id="id_2597911_720637_1_1" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Valuation Reserves</label>
    <label id="id_2597911_720637_2_1" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory reserve</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <label id="id_2597911_723630_1_1" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Work In Process Net Of Reserves</label>
    <label id="id_2597911_723630_2_1" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <label id="id_2597911_710256_1_1" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</label>
    <label id="id_2597911_710256_2_1" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <label id="id_2597911_710825_1_1" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Member]</label>
    <label id="id_2597911_710825_2_1" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <label id="id_2597911_724870_1_1" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Stock And Warrants For Services Or Claims</label>
    <label id="id_2597911_724870_2_1" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued for services</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_LaxdaleLimitedMember" xlink:label="amrn_LaxdaleLimitedMember" xlink:type="locator"/>
    <label id="id_2597911_740537_3_1" xlink:label="amrn_LaxdaleLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laxdale Limited [Member]</label>
    <label id="id_2597911_740537_1_1" xlink:label="amrn_LaxdaleLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laxdale Limited [Member]</label>
    <label id="id_2597911_740537_2_1" xlink:label="amrn_LaxdaleLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laxdale Limited</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_LaxdaleLimitedMember" xlink:to="amrn_LaxdaleLimitedMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <label id="id_2597911_705999_1_1" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</label>
    <label id="id_2597911_705999_2_1" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <label id="id_2597911_720217_1_1" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</label>
    <label id="id_2597911_720217_2_1" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <label id="id_2597911_720602_1_1" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities And Stockholders Equity</label>
    <label id="id_2597911_720602_6_1" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <label id="id_2597911_708470_1_1" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities And Stockholders Equity [Abstract]</label>
    <label id="id_2597911_708470_2_1" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' DEFICIT</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <label id="id_2597911_717569_1_1" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities Current</label>
    <label id="id_2597911_717569_6_1" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <label id="id_2597911_715754_1_1" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities Current [Abstract]</label>
    <label id="id_2597911_715754_2_1" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator"/>
    <label id="id_2597911_713172_1_1" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities Fair Value Disclosure [Abstract]</label>
    <label id="id_2597911_713172_2_1" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_LiabilitiesForCommitmentsAxis" xlink:label="amrn_LiabilitiesForCommitmentsAxis" xlink:type="locator"/>
    <label id="id_2597911_735055_3_1" xlink:label="amrn_LiabilitiesForCommitmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities For Commitments [Axis]</label>
    <label id="id_2597911_735055_1_1" xlink:label="amrn_LiabilitiesForCommitmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities For Commitments [Axis]</label>
    <label id="id_2597911_735055_2_1" xlink:label="amrn_LiabilitiesForCommitmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities For Commitments [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_LiabilitiesForCommitmentsAxis" xlink:to="amrn_LiabilitiesForCommitmentsAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_LiabilitiesForCommitmentsDomain" xlink:label="amrn_LiabilitiesForCommitmentsDomain" xlink:type="locator"/>
    <label id="id_2597911_813898_3_1" xlink:label="amrn_LiabilitiesForCommitmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities For Commitments [Domain]</label>
    <label id="id_2597911_813898_1_1" xlink:label="amrn_LiabilitiesForCommitmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities For Commitments [Domain]</label>
    <label id="id_2597911_813898_2_1" xlink:label="amrn_LiabilitiesForCommitmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities For Commitments [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_LiabilitiesForCommitmentsDomain" xlink:to="amrn_LiabilitiesForCommitmentsDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <label id="id_2597911_714360_1_1" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities Noncurrent [Abstract]</label>
    <label id="id_2597911_714360_2_1" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember" xlink:type="locator"/>
    <label id="id_2597911_715225_1_1" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Debt [Member]</label>
    <label id="id_2597911_715225_2_1" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long Term Debt</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMember" xlink:to="us-gaap_LongTermDebtMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <label id="id_2597911_717888_1_1" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Debt Noncurrent</label>
    <label id="id_2597911_717888_2_1" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <label id="id_2597911_714378_1_1" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Longterm Debt Type [Axis]</label>
    <label id="id_2597911_714378_2_1" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <label id="id_2597911_707980_1_1" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Longterm Debt Type [Domain]</label>
    <label id="id_2597911_707980_2_1" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="locator"/>
    <label id="id_2597911_719048_1_1" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Purchase Commitment Amount</label>
    <label id="id_2597911_719048_2_1" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw material purchase commitment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_MaturityPeriodUsedToClassifyInvestments" xlink:label="amrn_MaturityPeriodUsedToClassifyInvestments" xlink:type="locator"/>
    <label id="id_2597911_740969_3_1" xlink:label="amrn_MaturityPeriodUsedToClassifyInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity Period Used to Classify Investments</label>
    <label id="id_2597911_740969_1_1" xlink:label="amrn_MaturityPeriodUsedToClassifyInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity Period Used To Classify Investments</label>
    <label id="id_2597911_740969_2_1" xlink:label="amrn_MaturityPeriodUsedToClassifyInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short term highly liquid instruments, maturity date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_MaturityPeriodUsedToClassifyInvestments" xlink:to="amrn_MaturityPeriodUsedToClassifyInvestments_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <label id="id_2597911_716112_1_1" xlink:label="us-gaap_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</label>
    <label id="id_2597911_716112_2_1" xlink:label="us-gaap_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <label id="id_2597911_711169_1_1" xlink:label="us-gaap_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</label>
    <label id="id_2597911_711169_2_1" xlink:label="us-gaap_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <label id="id_2597911_721507_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided By Used In Financing Activities</label>
    <label id="id_2597911_721507_6_1" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <label id="id_2597911_708682_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label id="id_2597911_708682_2_1" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <label id="id_2597911_724159_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided By Used In Investing Activities</label>
    <label id="id_2597911_724159_6_1" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <label id="id_2597911_708507_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label id="id_2597911_708507_2_1" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <label id="id_2597911_712906_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided By Used In Operating Activities</label>
    <label id="id_2597911_712906_2_1" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <label id="id_2597911_713979_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label id="id_2597911_713979_2_1" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <label id="id_2597911_720460_1_1" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income Loss</label>
    <label id="id_2597911_720460_2_1" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss for the period</label>
    <label id="id_2597911_720460_6_1" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</label>
    <label id="id_2597911_720460_12_1" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_NonCashMember" xlink:label="amrn_NonCashMember" xlink:type="locator"/>
    <label id="id_2597911_796972_3_1" xlink:label="amrn_NonCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Cash [Member]</label>
    <label id="id_2597911_796972_1_1" xlink:label="amrn_NonCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash [Member]</label>
    <label id="id_2597911_796972_2_1" xlink:label="amrn_NonCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non Cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_NonCashMember" xlink:to="amrn_NonCashMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember" xlink:type="locator"/>
    <label id="id_2597911_716441_1_1" xlink:label="us-gaap_NotesPayableOtherPayablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable Other Payables [Member]</label>
    <label id="id_2597911_716441_2_1" xlink:label="us-gaap_NotesPayableOtherPayablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.5% exchangeable senior notes due 2032</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableOtherPayablesMember" xlink:to="us-gaap_NotesPayableOtherPayablesMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_NumberOfAgreements" xlink:label="amrn_NumberOfAgreements" xlink:type="locator"/>
    <label id="id_2597911_737544_3_1" xlink:label="amrn_NumberOfAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Agreements</label>
    <label id="id_2597911_737544_1_1" xlink:label="amrn_NumberOfAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Agreements</label>
    <label id="id_2597911_737544_2_1" xlink:label="amrn_NumberOfAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of signed agreements</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_NumberOfAgreements" xlink:to="amrn_NumberOfAgreements_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_NumberOfForeignCurrencyForwardContractsOutstanding" xlink:label="amrn_NumberOfForeignCurrencyForwardContractsOutstanding" xlink:type="locator"/>
    <label id="id_2597911_823580_3_1" xlink:label="amrn_NumberOfForeignCurrencyForwardContractsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Foreign Currency Forward Contracts Outstanding</label>
    <label id="id_2597911_823580_1_1" xlink:label="amrn_NumberOfForeignCurrencyForwardContractsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Foreign Currency Forward Contracts Outstanding</label>
    <label id="id_2597911_823580_2_1" xlink:label="amrn_NumberOfForeignCurrencyForwardContractsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of foreign exchange forward contract</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_NumberOfForeignCurrencyForwardContractsOutstanding" xlink:to="amrn_NumberOfForeignCurrencyForwardContractsOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_OctoberTwentyZeroNinePrivatePlacementMember" xlink:label="amrn_OctoberTwentyZeroNinePrivatePlacementMember" xlink:type="locator"/>
    <label id="id_2597911_781108_3_1" xlink:label="amrn_OctoberTwentyZeroNinePrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">October 2009 Private Placement [Member]</label>
    <label id="id_2597911_781108_1_1" xlink:label="amrn_OctoberTwentyZeroNinePrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">October Twenty Zero Nine Private Placement [Member]</label>
    <label id="id_2597911_781108_2_1" xlink:label="amrn_OctoberTwentyZeroNinePrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">October 2009 Private Placement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_OctoberTwentyZeroNinePrivatePlacementMember" xlink:to="amrn_OctoberTwentyZeroNinePrivatePlacementMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficerMember" xlink:label="us-gaap_OfficerMember" xlink:type="locator"/>
    <label id="id_2597911_709584_1_1" xlink:label="us-gaap_OfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Officer [Member]</label>
    <label id="id_2597911_709584_2_1" xlink:label="us-gaap_OfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued to three former officers</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficerMember" xlink:to="us-gaap_OfficerMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <label id="id_2597911_722298_1_1" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</label>
    <label id="id_2597911_722298_6_1" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <label id="id_2597911_709967_1_1" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label id="id_2597911_709967_2_1" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <label id="id_2597911_719696_1_1" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income Loss</label>
    <label id="id_2597911_719696_6_1" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_OptionsExercisablePeriod" xlink:label="amrn_OptionsExercisablePeriod" xlink:type="locator"/>
    <label id="id_2597911_744452_3_1" xlink:label="amrn_OptionsExercisablePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options Exercisable Period</label>
    <label id="id_2597911_744452_1_1" xlink:label="amrn_OptionsExercisablePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Exercisable Period</label>
    <label id="id_2597911_744452_2_1" xlink:label="amrn_OptionsExercisablePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option,exercisable period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_OptionsExercisablePeriod" xlink:to="amrn_OptionsExercisablePeriod_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_OptionsGrantedDuringPeriod" xlink:label="amrn_OptionsGrantedDuringPeriod" xlink:type="locator"/>
    <label id="id_2597911_738747_3_1" xlink:label="amrn_OptionsGrantedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options Granted During Period</label>
    <label id="id_2597911_738747_1_1" xlink:label="amrn_OptionsGrantedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Granted During Period</label>
    <label id="id_2597911_738747_2_1" xlink:label="amrn_OptionsGrantedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted for purchase of additional shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_OptionsGrantedDuringPeriod" xlink:to="amrn_OptionsGrantedDuringPeriod_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_OrdinarySharesMember" xlink:label="amrn_OrdinarySharesMember" xlink:type="locator"/>
    <label id="id_2597911_820302_3_1" xlink:label="amrn_OrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ordinary Shares</label>
    <label id="id_2597911_820302_1_1" xlink:label="amrn_OrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary Shares [Member]</label>
    <label id="id_2597911_820302_2_1" xlink:label="amrn_OrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_OrdinarySharesMember" xlink:to="amrn_OrdinarySharesMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator"/>
    <label id="id_2597911_709883_1_1" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Abstract]</label>
    <label id="id_2597911_709883_2_1" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:type="locator"/>
    <label id="id_2597911_841516_3_1" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</label>
    <label id="id_2597911_841516_1_1" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</label>
    <label id="id_2597911_841516_2_1" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:type="locator"/>
    <label id="id_2597911_781720_3_1" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Table]</label>
    <label id="id_2597911_781720_1_1" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</label>
    <label id="id_2597911_781720_2_1" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_2597911_714928_1_1" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</label>
    <label id="id_2597911_714928_2_1" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Business and Basis of Presentation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:type="locator"/>
    <label id="id_2597911_719739_1_1" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities Noncurrent</label>
    <label id="id_2597911_719739_2_1" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liability payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <label id="id_2597911_723569_1_1" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets Current</label>
    <label id="id_2597911_723569_2_1" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <label id="id_2597911_720829_1_1" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets Noncurrent</label>
    <label id="id_2597911_720829_2_1" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" xlink:type="locator"/>
    <label id="id_2597911_718186_1_1" xlink:label="us-gaap_OtherCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</label>
    <label id="id_2597911_718186_2_1" xlink:label="us-gaap_OtherCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum repayment of future revenue and receivables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <label id="id_2597911_713938_1_1" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</label>
    <label id="id_2597911_713938_2_1" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesMember" xlink:to="us-gaap_OtherCurrentLiabilitiesMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_OtherIncentiveProgramsMember" xlink:label="amrn_OtherIncentiveProgramsMember" xlink:type="locator"/>
    <label id="id_2597911_824442_3_1" xlink:label="amrn_OtherIncentiveProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Incentive Programs [Member]</label>
    <label id="id_2597911_824442_1_1" xlink:label="amrn_OtherIncentiveProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Incentive Programs [Member]</label>
    <label id="id_2597911_824442_2_1" xlink:label="amrn_OtherIncentiveProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Incentive Programs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_OtherIncentiveProgramsMember" xlink:to="amrn_OtherIncentiveProgramsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:type="locator"/>
    <label id="id_2597911_724844_1_1" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Inventory Materials Supplies And Merchandise Under Consignment</label>
    <label id="id_2597911_724844_2_1" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods inventory held by others</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <label id="id_2597911_718646_1_1" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Noncurrent</label>
    <label id="id_2597911_718646_2_1" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <label id="id_2597911_718560_1_1" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income Expense</label>
    <label id="id_2597911_718560_2_1" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:type="locator"/>
    <label id="id_2597911_717678_1_1" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Purchase Of Other Assets 1</label>
    <label id="id_2597911_717678_2_1" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment made under the agreements</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:type="locator"/>
    <label id="id_2597911_717612_1_1" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Acquire Longterm Investments</label>
    <label id="id_2597911_717612_14_1" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of long-term investment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <label id="id_2597911_717252_1_1" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Acquire Property Plant And Equipment</label>
    <label id="id_2597911_717252_14_1" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_PeriodAxis" xlink:label="amrn_PeriodAxis" xlink:type="locator"/>
    <label id="id_2597911_755443_3_1" xlink:label="amrn_PeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period [Axis]</label>
    <label id="id_2597911_755443_1_1" xlink:label="amrn_PeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period [Axis]</label>
    <label id="id_2597911_755443_2_1" xlink:label="amrn_PeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PeriodAxis" xlink:to="amrn_PeriodAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_PeriodDomain" xlink:label="amrn_PeriodDomain" xlink:type="locator"/>
    <label id="id_2597911_740942_3_1" xlink:label="amrn_PeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period [Domain]</label>
    <label id="id_2597911_740942_1_1" xlink:label="amrn_PeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period [Domain]</label>
    <label id="id_2597911_740942_2_1" xlink:label="amrn_PeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_PeriodFiveMember" xlink:label="amrn_PeriodFiveMember" xlink:type="locator"/>
    <label id="id_2597911_796385_3_1" xlink:label="amrn_PeriodFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period 5 [Member]</label>
    <label id="id_2597911_796385_1_1" xlink:label="amrn_PeriodFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Five [Member]</label>
    <label id="id_2597911_796385_2_1" xlink:label="amrn_PeriodFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final payment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PeriodFiveMember" xlink:to="amrn_PeriodFiveMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_PeriodFourMember" xlink:label="amrn_PeriodFourMember" xlink:type="locator"/>
    <label id="id_2597911_824056_3_1" xlink:label="amrn_PeriodFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period 4 [Member]</label>
    <label id="id_2597911_824056_1_1" xlink:label="amrn_PeriodFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Four [Member]</label>
    <label id="id_2597911_824056_2_1" xlink:label="amrn_PeriodFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per quarter in each of the next four quarters</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PeriodFourMember" xlink:to="amrn_PeriodFourMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_PeriodOneMember" xlink:label="amrn_PeriodOneMember" xlink:type="locator"/>
    <label id="id_2597911_829211_3_1" xlink:label="amrn_PeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period 1 [Member]</label>
    <label id="id_2597911_829211_1_1" xlink:label="amrn_PeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period One [Member]</label>
    <label id="id_2597911_829211_2_1" xlink:label="amrn_PeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">November 2013 for the fiscal quarter ended September 30, 2013</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PeriodOneMember" xlink:to="amrn_PeriodOneMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_PeriodThreeMember" xlink:label="amrn_PeriodThreeMember" xlink:type="locator"/>
    <label id="id_2597911_770088_3_1" xlink:label="amrn_PeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period 3 [Member]</label>
    <label id="id_2597911_770088_1_1" xlink:label="amrn_PeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Three [Member]</label>
    <label id="id_2597911_770088_2_1" xlink:label="amrn_PeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per quarter in each of the next four quarters</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PeriodThreeMember" xlink:to="amrn_PeriodThreeMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_PeriodTwoMember" xlink:label="amrn_PeriodTwoMember" xlink:type="locator"/>
    <label id="id_2597911_735492_3_1" xlink:label="amrn_PeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period 2 [Member]</label>
    <label id="id_2597911_735492_1_1" xlink:label="amrn_PeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Two [Member]</label>
    <label id="id_2597911_735492_2_1" xlink:label="amrn_PeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per quarter in each of the next four quarters</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PeriodTwoMember" xlink:to="amrn_PeriodTwoMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <label id="id_2597911_713879_1_1" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</label>
    <label id="id_2597911_713879_2_1" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <label id="id_2597911_714456_1_1" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</label>
    <label id="id_2597911_714456_2_1" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_PotentialMarketingApprovalOneMember" xlink:label="amrn_PotentialMarketingApprovalOneMember" xlink:type="locator"/>
    <label id="id_2597911_829979_3_1" xlink:label="amrn_PotentialMarketingApprovalOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Marketing Approval 1 [Member]</label>
    <label id="id_2597911_829979_1_1" xlink:label="amrn_PotentialMarketingApprovalOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Marketing Approval One [Member]</label>
    <label id="id_2597911_829979_2_1" xlink:label="amrn_PotentialMarketingApprovalOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Marketing Approval 1</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PotentialMarketingApprovalOneMember" xlink:to="amrn_PotentialMarketingApprovalOneMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_PotentialMarketingApprovalTwoMember" xlink:label="amrn_PotentialMarketingApprovalTwoMember" xlink:type="locator"/>
    <label id="id_2597911_779644_3_1" xlink:label="amrn_PotentialMarketingApprovalTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Marketing Approval 2 [Member]</label>
    <label id="id_2597911_779644_1_1" xlink:label="amrn_PotentialMarketingApprovalTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Marketing Approval Two [Member]</label>
    <label id="id_2597911_779644_2_1" xlink:label="amrn_PotentialMarketingApprovalTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Marketing Approval 2</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PotentialMarketingApprovalTwoMember" xlink:to="amrn_PotentialMarketingApprovalTwoMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xlink:label="us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xlink:type="locator"/>
    <label id="id_2597911_721704_1_1" xlink:label="us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds And Excess Tax Benefit From Sharebased Compensation</label>
    <label id="id_2597911_721704_2_1" xlink:label="us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess tax benefit from stock-based awards</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xlink:to="us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <label id="id_2597911_722440_1_1" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Convertible Debt</label>
    <label id="id_2597911_722440_2_1" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, net proceeds</label>
    <label id="id_2597911_722440_12_1" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of exchangeable debt, net of transaction costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="locator"/>
    <label id="id_2597911_723657_1_1" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Debt Net Of Issuance Costs</label>
    <label id="id_2597911_723657_2_1" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds allocated to conversion option</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:label="amrn_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:type="locator"/>
    <label id="id_2597911_834030_3_1" xlink:label="amrn_ProceedsFromExerciseOfStockOptionsAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Exercise Of Stock Options And Warrants</label>
    <label id="id_2597911_834030_1_1" xlink:label="amrn_ProceedsFromExerciseOfStockOptionsAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Exercise Of Stock Options And Warrants</label>
    <label id="id_2597911_834030_2_1" xlink:label="amrn_ProceedsFromExerciseOfStockOptionsAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from exercise of warrants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:to="amrn_ProceedsFromExerciseOfStockOptionsAndWarrants_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <label id="id_2597911_723060_1_1" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Common Stock</label>
    <label id="id_2597911_723060_2_1" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of transaction costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <label id="id_2597911_721070_1_1" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Private Placement</label>
    <label id="id_2597911_721070_2_1" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under private placement, net proceeds</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <label id="id_2597911_724868_1_1" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Or Sale Of Equity</label>
    <label id="id_2597911_724868_2_1" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ADS issued in public offering, net proceeds</label>
    <label id="id_2597911_724868_12_1" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from public offering</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="locator"/>
    <label id="id_2597911_721283_1_1" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Payments For Other Financing Activities</label>
    <label id="id_2597911_721283_2_1" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount received at the closing of the agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ProceedsFromStockOptionExerciseAndOther" xlink:label="amrn_ProceedsFromStockOptionExerciseAndOther" xlink:type="locator"/>
    <label id="id_2597911_805009_3_1" xlink:label="amrn_ProceedsFromStockOptionExerciseAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Stock Option Exercise And Other</label>
    <label id="id_2597911_805009_1_1" xlink:label="amrn_ProceedsFromStockOptionExerciseAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Stock Option Exercise And Other</label>
    <label id="id_2597911_805009_2_1" xlink:label="amrn_ProceedsFromStockOptionExerciseAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from exercise of stock options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ProceedsFromStockOptionExerciseAndOther" xlink:to="amrn_ProceedsFromStockOptionExerciseAndOther_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <label id="id_2597911_723323_1_1" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Stock Options Exercised</label>
    <label id="id_2597911_723323_2_1" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options, net of transaction costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ProceedsFromStockOptionsExercisedGross" xlink:label="amrn_ProceedsFromStockOptionsExercisedGross" xlink:type="locator"/>
    <label id="id_2597911_847016_3_1" xlink:label="amrn_ProceedsFromStockOptionsExercisedGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised Gross</label>
    <label id="id_2597911_847016_1_1" xlink:label="amrn_ProceedsFromStockOptionsExercisedGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Stock Options Exercised Gross</label>
    <label id="id_2597911_847016_2_1" xlink:label="amrn_ProceedsFromStockOptionsExercisedGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from exercise of stock options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ProceedsFromStockOptionsExercisedGross" xlink:to="amrn_ProceedsFromStockOptionsExercisedGross_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <label id="id_2597911_722678_1_1" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Warrant Exercises</label>
    <label id="id_2597911_722678_2_1" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceed from exercise of warrants</label>
    <label id="id_2597911_722678_12_1" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants, net of transaction costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ProceedsFromWarrantExercisesGross" xlink:label="amrn_ProceedsFromWarrantExercisesGross" xlink:type="locator"/>
    <label id="id_2597911_847114_3_1" xlink:label="amrn_ProceedsFromWarrantExercisesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises Gross</label>
    <label id="id_2597911_847114_1_1" xlink:label="amrn_ProceedsFromWarrantExercisesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Warrant Exercises Gross</label>
    <label id="id_2597911_847114_2_1" xlink:label="amrn_ProceedsFromWarrantExercisesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from exercise of warrants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ProceedsFromWarrantExercisesGross" xlink:to="amrn_ProceedsFromWarrantExercisesGross_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ProceedsMember" xlink:label="amrn_ProceedsMember" xlink:type="locator"/>
    <label id="id_2597911_830088_3_1" xlink:label="amrn_ProceedsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds [Member]</label>
    <label id="id_2597911_830088_1_1" xlink:label="amrn_ProceedsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds [Member]</label>
    <label id="id_2597911_830088_2_1" xlink:label="amrn_ProceedsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ProceedsMember" xlink:to="amrn_ProceedsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ProductSales" xlink:label="amrn_ProductSales" xlink:type="locator"/>
    <label id="id_2597911_762256_3_1" xlink:label="amrn_ProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Sales</label>
    <label id="id_2597911_762256_1_1" xlink:label="amrn_ProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Sales</label>
    <label id="id_2597911_762256_2_1" xlink:label="amrn_ProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Sales</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ProductSales" xlink:to="amrn_ProductSales_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <label id="id_2597911_722476_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Plant And Equipment Net</label>
    <label id="id_2597911_722476_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <label id="id_2597911_711502_1_1" xlink:label="us-gaap_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</label>
    <label id="id_2597911_711502_2_1" xlink:label="us-gaap_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <label id="id_2597911_713888_1_1" xlink:label="us-gaap_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Member]</label>
    <label id="id_2597911_713888_2_1" xlink:label="us-gaap_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_RebatesChargebacksAndDiscountsMember" xlink:label="amrn_RebatesChargebacksAndDiscountsMember" xlink:type="locator"/>
    <label id="id_2597911_825682_3_1" xlink:label="amrn_RebatesChargebacksAndDiscountsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rebates Chargebacks And Discounts [Member]</label>
    <label id="id_2597911_825682_1_1" xlink:label="amrn_RebatesChargebacksAndDiscountsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rebates Chargebacks And Discounts [Member]</label>
    <label id="id_2597911_825682_2_1" xlink:label="amrn_RebatesChargebacksAndDiscountsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates Chargebacks And Discounts</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_RebatesChargebacksAndDiscountsMember" xlink:to="amrn_RebatesChargebacksAndDiscountsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_RecentAccountingPronouncementsPolicyTextBlock" xlink:label="amrn_RecentAccountingPronouncementsPolicyTextBlock" xlink:type="locator"/>
    <label id="id_2597911_768748_3_1" xlink:label="amrn_RecentAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recent accounting pronouncements , Policy [Text Block]</label>
    <label id="id_2597911_768748_1_1" xlink:label="amrn_RecentAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements Policy [Text Block]</label>
    <label id="id_2597911_768748_2_1" xlink:label="amrn_RecentAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_RecentAccountingPronouncementsPolicyTextBlock" xlink:to="amrn_RecentAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital" xlink:label="amrn_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital" xlink:type="locator"/>
    <label id="id_2597911_847198_3_1" xlink:label="amrn_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification Of Derivative Liabilities To Additional Paid In Capital</label>
    <label id="id_2597911_847198_1_1" xlink:label="amrn_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Of Derivative Liabilities To Additional Paid In Capital</label>
    <label id="id_2597911_847198_2_1" xlink:label="amrn_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer from derivative liability to equity, fair value of warrants exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital" xlink:to="amrn_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <label id="id_2597911_710338_1_1" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</label>
    <label id="id_2597911_710338_2_1" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <label id="id_2597911_711672_1_1" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions By Related Party [Axis]</label>
    <label id="id_2597911_711672_2_1" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions, by Related Party</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="locator"/>
    <label id="id_2597911_720532_1_1" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments Of Long Term Capital Lease Obligations</label>
    <label id="id_2597911_720532_14_1" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments under capital leases</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <label id="id_2597911_724274_1_1" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense</label>
    <label id="id_2597911_724274_2_1" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <label id="id_2597911_715843_1_1" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense Policy</label>
    <label id="id_2597911_715843_2_1" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <label id="id_2597911_720883_1_1" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash And Cash Equivalents At Carrying Value</label>
    <label id="id_2597911_720883_2_1" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense" xlink:type="locator"/>
    <label id="id_2597911_721468_1_1" xlink:label="us-gaap_RestrictedStockExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Expense</label>
    <label id="id_2597911_721468_2_1" xlink:label="us-gaap_RestrictedStockExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock units, Expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <label id="id_2597911_715834_1_1" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units R S U [Member]</label>
    <label id="id_2597911_715834_2_1" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost" xlink:type="locator"/>
    <label id="id_2597911_722618_1_1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring And Related Cost Expected Cost</label>
    <label id="id_2597911_722618_2_1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost due to staff reduction in force</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedCost" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator"/>
    <label id="id_2597911_714078_1_1" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring And Related Cost Number Of Positions Eliminated Period Percent</label>
    <label id="id_2597911_714078_2_1" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Staff reduction in force, approximate percentage</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <label id="id_2597911_719144_1_1" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings Accumulated Deficit</label>
    <label id="id_2597911_719144_2_1" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <label id="id_2597911_715280_1_1" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</label>
    <label id="id_2597911_715280_2_1" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <label id="id_2597911_708341_1_1" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition Policy [Text Block]</label>
    <label id="id_2597911_708341_2_1" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <label id="id_2597911_719383_1_1" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</label>
    <label id="id_2597911_719383_2_1" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue recognized</label>
    <label id="id_2597911_719383_12_1" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Product revenues</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_RevenuesLineItems" xlink:label="amrn_RevenuesLineItems" xlink:type="locator"/>
    <label id="id_2597911_834666_3_1" xlink:label="amrn_RevenuesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues [Line Items]</label>
    <label id="id_2597911_834666_1_1" xlink:label="amrn_RevenuesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Line Items]</label>
    <label id="id_2597911_834666_2_1" xlink:label="amrn_RevenuesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_RevenuesLineItems" xlink:to="amrn_RevenuesLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_RevenuesTableTextBlock" xlink:label="amrn_RevenuesTableTextBlock" xlink:type="locator"/>
    <label id="id_2597911_789493_3_1" xlink:label="amrn_RevenuesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues Table [Text Block]</label>
    <label id="id_2597911_789493_1_1" xlink:label="amrn_RevenuesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues Table [Text Block]</label>
    <label id="id_2597911_789493_2_1" xlink:label="amrn_RevenuesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Revenue Recognized and Deferred</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_RevenuesTableTextBlock" xlink:to="amrn_RevenuesTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:type="locator"/>
    <label id="id_2597911_719431_1_1" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Guarantees Commitments Amount</label>
    <label id="id_2597911_719431_2_1" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential aggregate stock or cash payment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <label id="id_2597911_714660_1_1" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock Name Of Transaction [Domain]</label>
    <label id="id_2597911_714660_2_1" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ScenarioOneMember" xlink:label="amrn_ScenarioOneMember" xlink:type="locator"/>
    <label id="id_2597911_784846_3_1" xlink:label="amrn_ScenarioOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Scenario 1 [Member]</label>
    <label id="id_2597911_784846_1_1" xlink:label="amrn_ScenarioOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario One [Member]</label>
    <label id="id_2597911_784846_2_1" xlink:label="amrn_ScenarioOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of a hypothetical 10% increase in the market price of common shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ScenarioOneMember" xlink:to="amrn_ScenarioOneMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <label id="id_2597911_713961_1_1" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario Unspecified [Domain]</label>
    <label id="id_2597911_713961_2_1" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ScheduleOfCostOfRevenueTableTextBlock" xlink:label="amrn_ScheduleOfCostOfRevenueTableTextBlock" xlink:type="locator"/>
    <label id="id_2597911_793526_3_1" xlink:label="amrn_ScheduleOfCostOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Cost of Revenue [Table Text Block]</label>
    <label id="id_2597911_793526_1_1" xlink:label="amrn_ScheduleOfCostOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Cost Of Revenue Table [Text Block]</label>
    <label id="id_2597911_793526_2_1" xlink:label="amrn_ScheduleOfCostOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expensed and Capitalized Cost of Goods</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ScheduleOfCostOfRevenueTableTextBlock" xlink:to="amrn_ScheduleOfCostOfRevenueTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="locator"/>
    <label id="id_2597911_709777_1_1" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Derivative Liabilities At Fair Value Table [Text Block]</label>
    <label id="id_2597911_709777_2_1" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value of Financial Instruments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator"/>
    <label id="id_2597911_713098_1_1" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Finite Lived Intangible Assets [Table]</label>
    <label id="id_2597911_713098_2_1" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <label id="id_2597911_713970_1_1" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Finite Lived Intangible Assets Table [Text Block]</label>
    <label id="id_2597911_713970_2_1" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Value of Intangible Asset</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <label id="id_2597911_709616_1_1" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Inventory Current Table [Text Block]</label>
    <label id="id_2597911_709616_2_1" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_ScheduleOfRevenuesTable" xlink:label="amrn_ScheduleOfRevenuesTable" xlink:type="locator"/>
    <label id="id_2597911_809975_3_1" xlink:label="amrn_ScheduleOfRevenuesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Revenues [Table]</label>
    <label id="id_2597911_809975_1_1" xlink:label="amrn_ScheduleOfRevenuesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Revenues [Table]</label>
    <label id="id_2597911_809975_2_1" xlink:label="amrn_ScheduleOfRevenuesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Revenues [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ScheduleOfRevenuesTable" xlink:to="amrn_ScheduleOfRevenuesTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <label id="id_2597911_709054_1_1" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]</label>
    <label id="id_2597911_709054_2_1" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to Purchase Common Shares Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis" xlink:type="locator"/>
    <label id="id_2597911_708321_1_1" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Financing Transaction [Axis]</label>
    <label id="id_2597911_708321_2_1" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Financing Transaction [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesFinancingTransactionAxis" xlink:to="us-gaap_SecuritiesFinancingTransactionAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:type="locator"/>
    <label id="id_2597911_714324_1_1" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Financing Transaction Type [Domain]</label>
    <label id="id_2597911_714324_2_1" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Financing Transaction [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:to="us-gaap_SecuritiesFinancingTransactionTypeDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <label id="id_2597911_715074_1_1" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment [Domain]</label>
    <label id="id_2597911_715074_2_1" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <label id="id_2597911_713945_1_1" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Policy Policy [Text Block]</label>
    <label id="id_2597911_713945_2_1" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment and Geographical Information</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <label id="id_2597911_722432_1_1" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling General And Administrative Expense</label>
    <label id="id_2597911_722432_2_1" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator"/>
    <label id="id_2597911_710955_1_1" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling General And Administrative Expenses Policy [Text Block]</label>
    <label id="id_2597911_710955_2_1" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes" xlink:type="locator"/>
    <label id="id_2597911_717799_1_1" xlink:label="us-gaap_SeniorLongTermNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Long Term Notes</label>
    <label id="id_2597911_717799_2_1" xlink:label="us-gaap_SeniorLongTermNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchangeable senior notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorLongTermNotes" xlink:to="us-gaap_SeniorLongTermNotes_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <label id="id_2597911_721665_1_1" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation</label>
    <label id="id_2597911_721665_2_1" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense (income) for change in fair value of warrants issued to former employees</label>
    <label id="id_2597911_721665_12_1" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <label id="id_2597911_712118_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period 1</label>
    <label id="id_2597911_712118_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock units,Vesting Period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <label id="id_2597911_716215_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</label>
    <label id="id_2597911_716215_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock units, forfeited</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <label id="id_2597911_716402_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</label>
    <label id="id_2597911_716402_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock units granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="locator"/>
    <label id="id_2597911_715984_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Expiration Date</label>
    <label id="id_2597911_715984_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock units, Expiration date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <label id="id_2597911_712670_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label id="id_2597911_712670_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <label id="id_2597911_712630_1_1" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</label>
    <label id="id_2597911_712630_2_1" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market price of common stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <label id="id_2597911_712361_1_1" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Price Per Share</label>
    <label id="id_2597911_712361_2_1" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ADS issued in public offering, price per ADS</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <label id="id_2597911_716698_1_1" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Outstanding</label>
    <label id="id_2597911_716698_4_1" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in shares)</label>
    <label id="id_2597911_716698_5_1" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in shares)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_SignificantAccountingPoliciesLineItems" xlink:label="amrn_SignificantAccountingPoliciesLineItems" xlink:type="locator"/>
    <label id="id_2597911_740131_3_1" xlink:label="amrn_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <label id="id_2597911_740131_1_1" xlink:label="amrn_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <label id="id_2597911_740131_2_1" xlink:label="amrn_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_SignificantAccountingPoliciesLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_SignificantAccountingPoliciesTable" xlink:label="amrn_SignificantAccountingPoliciesTable" xlink:type="locator"/>
    <label id="id_2597911_750992_3_1" xlink:label="amrn_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <label id="id_2597911_750992_1_1" xlink:label="amrn_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <label id="id_2597911_750992_2_1" xlink:label="amrn_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="amrn_SignificantAccountingPoliciesTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <label id="id_2597911_714159_1_1" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label id="id_2597911_714159_2_1" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_SignificantAssumptionsInMarketPriceOfStock" xlink:label="amrn_SignificantAssumptionsInMarketPriceOfStock" xlink:type="locator"/>
    <label id="id_2597911_809980_3_1" xlink:label="amrn_SignificantAssumptionsInMarketPriceOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant Assumptions in Market Price Of Stock</label>
    <label id="id_2597911_809980_1_1" xlink:label="amrn_SignificantAssumptionsInMarketPriceOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Assumptions In Market Price Of Stock</label>
    <label id="id_2597911_809980_2_1" xlink:label="amrn_SignificantAssumptionsInMarketPriceOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hypothetical increase in market price of common shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_SignificantAssumptionsInMarketPriceOfStock" xlink:to="amrn_SignificantAssumptionsInMarketPriceOfStock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <label id="id_2597911_707278_1_1" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement Business Segments [Axis]</label>
    <label id="id_2597911_707278_2_1" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <label id="id_2597911_711196_1_1" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement Class Of Stock [Axis]</label>
    <label id="id_2597911_711196_2_1" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <label id="id_2597911_709650_1_1" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement Equity Components [Axis]</label>
    <label id="id_2597911_709650_2_1" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Equity Components</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <label id="id_2597911_711635_1_1" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</label>
    <label id="id_2597911_711635_2_1" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <label id="id_2597911_710972_1_1" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
    <label id="id_2597911_710972_2_1" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <label id="id_2597911_708775_1_1" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
    <label id="id_2597911_708775_2_1" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <label id="id_2597911_711354_1_1" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement Of Stockholders Equity [Abstract]</label>
    <label id="id_2597911_711354_2_1" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <label id="id_2597911_708873_1_1" xlink:label="us-gaap_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement Scenario [Axis]</label>
    <label id="id_2597911_708873_2_1" xlink:label="us-gaap_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Scenario</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <label id="id_2597911_711836_1_1" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</label>
    <label id="id_2597911_711836_2_1" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <label id="id_2597911_718765_1_1" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity</label>
    <label id="id_2597911_718765_4_1" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</label>
    <label id="id_2597911_718765_5_1" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</label>
    <label id="id_2597911_718765_6_1" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' deficit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <label id="id_2597911_707190_1_1" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity [Abstract]</label>
    <label id="id_2597911_707190_2_1" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Deficit:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_2597911_712192_1_1" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity Note Disclosure [Text Block]</label>
    <label id="id_2597911_712192_2_1" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_StockholdersEquityNoteLineItems" xlink:label="amrn_StockholdersEquityNoteLineItems" xlink:type="locator"/>
    <label id="id_2597911_814464_3_1" xlink:label="amrn_StockholdersEquityNoteLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders Equity Note [Line Items]</label>
    <label id="id_2597911_814464_1_1" xlink:label="amrn_StockholdersEquityNoteLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity Note [Line Items]</label>
    <label id="id_2597911_814464_2_1" xlink:label="amrn_StockholdersEquityNoteLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders Equity Note [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_StockholdersEquityNoteLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_StockholdersEquityNoteTable" xlink:label="amrn_StockholdersEquityNoteTable" xlink:type="locator"/>
    <label id="id_2597911_775437_3_1" xlink:label="amrn_StockholdersEquityNoteTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders Equity Note [Table]</label>
    <label id="id_2597911_775437_1_1" xlink:label="amrn_StockholdersEquityNoteTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity Note [Table]</label>
    <label id="id_2597911_775437_2_1" xlink:label="amrn_StockholdersEquityNoteTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders Equity Note [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="amrn_StockholdersEquityNoteTable_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_StockIncentivePlanTwentyElevenMember" xlink:label="amrn_StockIncentivePlanTwentyElevenMember" xlink:type="locator"/>
    <label id="id_2597911_768003_3_1" xlink:label="amrn_StockIncentivePlanTwentyElevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2011 [Member]</label>
    <label id="id_2597911_768003_1_1" xlink:label="amrn_StockIncentivePlanTwentyElevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan Twenty Eleven [Member]</label>
    <label id="id_2597911_768003_2_1" xlink:label="amrn_StockIncentivePlanTwentyElevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2011</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_StockIncentivePlanTwentyElevenMember" xlink:to="amrn_StockIncentivePlanTwentyElevenMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims" xlink:label="amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <label id="id_2597911_810396_3_1" xlink:label="amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of restricted stock or stock options granted to nonemployees as payment for services rendered or acknowledged claims.</label>
    <label id="id_2597911_810396_1_1" xlink:label="amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Of Stock And Warrants For Services Or Claims</label>
    <label id="id_2597911_810396_2_1" xlink:label="amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued for services</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims" xlink:to="amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:type="locator"/>
    <label id="id_2597911_710728_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Employee Stock Ownership Plan</label>
    <label id="id_2597911_710728_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Stock units, issued as a result of vesting</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <label id="id_2597911_711089_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares New Issues</label>
    <label id="id_2597911_711089_32_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:type="resource" xml:lang="en-US">Stock issued in equity financing (in shares)</label>
    <label id="id_2597911_711089_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ADS issued in public offering, number</label>
    <label id="id_2597911_711089_12_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under private placement, shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices" xlink:label="amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices" xlink:type="locator"/>
    <label id="id_2597911_768550_3_1" xlink:label="amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Of Stock And Warrants For Services</label>
    <label id="id_2597911_768550_1_1" xlink:label="amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Of Stock And Warrants For Services</label>
    <label id="id_2597911_768550_2_1" xlink:label="amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issued for services (in shares)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices" xlink:to="amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <label id="id_2597911_712312_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures</label>
    <label id="id_2597911_712312_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units,issued as a result of vesting</label>
    <label id="id_2597911_712312_12_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock units (in shares)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <label id="id_2597911_713738_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Stock Options Exercised</label>
    <label id="id_2597911_713738_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</label>
    <label id="id_2597911_713738_12_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued, exercise of stock options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:type="locator"/>
    <label id="id_2597911_793158_3_1" xlink:label="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued during the period as a result of the exercise of warrants.</label>
    <label id="id_2597911_793158_1_1" xlink:label="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Stock Warrants Exercised</label>
    <label id="id_2597911_793158_2_1" xlink:label="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of warrants (in shares)</label>
    <label id="id_2597911_793158_12_1" xlink:label="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued, exercise of warrants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <label id="id_2597911_717250_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value New Issues</label>
    <label id="id_2597911_717250_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under private placement, value</label>
    <label id="id_2597911_717250_12_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock issued in equity financing</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <label id="id_2597911_720495_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures</label>
    <label id="id_2597911_720495_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock units</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <label id="id_2597911_717723_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value Stock Options Exercised</label>
    <label id="id_2597911_717723_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="amrn_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:type="locator"/>
    <label id="id_2597911_839170_3_1" xlink:label="amrn_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value stock issued during the period as a result of the exercise of warrants.</label>
    <label id="id_2597911_839170_1_1" xlink:label="amrn_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value Stock Warrants Exercised</label>
    <label id="id_2597911_839170_2_1" xlink:label="amrn_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="amrn_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_StockOptionsAndRestrictedStockUnitsMember" xlink:label="amrn_StockOptionsAndRestrictedStockUnitsMember" xlink:type="locator"/>
    <label id="id_2597911_740402_3_1" xlink:label="amrn_StockOptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</label>
    <label id="id_2597911_740402_1_1" xlink:label="amrn_StockOptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</label>
    <label id="id_2597911_740402_2_1" xlink:label="amrn_StockOptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options and Restricted Stock Units</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_StockOptionsAndRestrictedStockUnitsMember" xlink:to="amrn_StockOptionsAndRestrictedStockUnitsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xlink:type="locator"/>
    <label id="id_2597911_717050_1_1" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label id="id_2597911_717050_2_1" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <label id="id_2597911_714667_1_1" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</label>
    <label id="id_2597911_714667_2_1" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:type="locator"/>
    <label id="id_2597911_707774_1_1" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label id="id_2597911_707774_2_1" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <label id="id_2597911_715486_1_1" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label id="id_2597911_715486_2_1" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xlink:type="locator"/>
    <label id="id_2597911_713783_1_1" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</label>
    <label id="id_2597911_713783_2_1" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <label id="id_2597911_710720_1_1" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label id="id_2597911_710720_2_1" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <label id="id_2597911_715840_1_1" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label id="id_2597911_715840_2_1" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <label id="id_2597911_714777_1_1" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary Sale Of Stock [Axis]</label>
    <label id="id_2597911_714777_2_1" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_SummaryOfValuationAllowancesTableTextBlock" xlink:label="amrn_SummaryOfValuationAllowancesTableTextBlock" xlink:type="locator"/>
    <label id="id_2597911_790747_3_1" xlink:label="amrn_SummaryOfValuationAllowancesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Valuation Allowances Table [Text Block]</label>
    <label id="id_2597911_790747_1_1" xlink:label="amrn_SummaryOfValuationAllowancesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Valuation Allowances Table [Text Block]</label>
    <label id="id_2597911_790747_2_1" xlink:label="amrn_SummaryOfValuationAllowancesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summarizes Activity of the Product Revenue Allowance and Reserve Categories</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_SummaryOfValuationAllowancesTableTextBlock" xlink:to="amrn_SummaryOfValuationAllowancesTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <label id="id_2597911_713511_1_1" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label id="id_2597911_713511_2_1" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_SupplierDMember" xlink:label="amrn_SupplierDMember" xlink:type="locator"/>
    <label id="id_2597911_785391_3_1" xlink:label="amrn_SupplierDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplier D [Member]</label>
    <label id="id_2597911_785391_1_1" xlink:label="amrn_SupplierDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier D [Member]</label>
    <label id="id_2597911_785391_2_1" xlink:label="amrn_SupplierDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fourth API supplier</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_SupplierDMember" xlink:to="amrn_SupplierDMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_SupplierOneMember" xlink:label="amrn_SupplierOneMember" xlink:type="locator"/>
    <label id="id_2597911_775542_3_1" xlink:label="amrn_SupplierOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplier One [Member]</label>
    <label id="id_2597911_775542_1_1" xlink:label="amrn_SupplierOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier One [Member]</label>
    <label id="id_2597911_775542_2_1" xlink:label="amrn_SupplierOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chemport</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_SupplierOneMember" xlink:to="amrn_SupplierOneMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_SupplierThreeMember" xlink:label="amrn_SupplierThreeMember" xlink:type="locator"/>
    <label id="id_2597911_781952_3_1" xlink:label="amrn_SupplierThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplier Three [Member]</label>
    <label id="id_2597911_781952_1_1" xlink:label="amrn_SupplierThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Three [Member]</label>
    <label id="id_2597911_781952_2_1" xlink:label="amrn_SupplierThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Slanhmor</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_SupplierThreeMember" xlink:to="amrn_SupplierThreeMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_SupplierTwoMember" xlink:label="amrn_SupplierTwoMember" xlink:type="locator"/>
    <label id="id_2597911_770274_3_1" xlink:label="amrn_SupplierTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplier Two [Member]</label>
    <label id="id_2597911_770274_1_1" xlink:label="amrn_SupplierTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Two [Member]</label>
    <label id="id_2597911_770274_2_1" xlink:label="amrn_SupplierTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BASF</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_SupplierTwoMember" xlink:to="amrn_SupplierTwoMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <label id="id_2597911_705972_1_1" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</label>
    <label id="id_2597911_705972_2_1" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xlink:type="locator"/>
    <label id="id_2597911_708572_1_1" xlink:label="us-gaap_TreasuryStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</label>
    <label id="id_2597911_708572_2_1" xlink:label="us-gaap_TreasuryStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" xlink:type="locator"/>
    <label id="id_2597911_713816_1_1" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock Shares</label>
    <label id="id_2597911_713816_2_1" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <label id="id_2597911_722320_1_1" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock Value</label>
    <label id="id_2597911_722320_14_1" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock; 20,079 shares at September 30, 2013 and December 31, 2012</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="locator"/>
    <label id="id_2597911_717463_1_1" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain Loss On Derivatives</label>
    <label id="id_2597911_717463_2_1" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Loss) gain on change in fair value of derivative liabilities</label>
    <label id="id_2597911_717463_12_1" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on change in fair value of derivative liabilities</label>
    <label id="id_2597911_717463_14_1" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on change in fair value of derivative liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <label id="id_2597911_714925_1_1" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use Of Estimates</label>
    <label id="id_2597911_714925_2_1" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="locator"/>
    <label id="id_2597911_717188_1_1" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves Balance</label>
    <label id="id_2597911_717188_4_1" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at September 30, 2013</label>
    <label id="id_2597911_717188_5_1" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at January 1, 2013</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator"/>
    <label id="id_2597911_718795_1_1" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves Charged To Cost And Expense</label>
    <label id="id_2597911_718795_2_1" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision related to current period and deferred sales</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="locator"/>
    <label id="id_2597911_722926_1_1" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves Deductions</label>
    <label id="id_2597911_722926_14_1" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits/payments made for current period and deferred sales</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator"/>
    <label id="id_2597911_708057_1_1" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves [Domain]</label>
    <label id="id_2597911_708057_2_1" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator"/>
    <label id="id_2597911_709711_1_1" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves Type [Axis]</label>
    <label id="id_2597911_709711_2_1" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:label="us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:type="locator"/>
    <label id="id_2597911_714229_1_1" xlink:label="us-gaap_ValuationAndQualifyingAccountsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation And Qualifying Accounts [Abstract]</label>
    <label id="id_2597911_714229_2_1" xlink:label="us-gaap_ValuationAndQualifyingAccountsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:to="us-gaap_ValuationAndQualifyingAccountsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="locator"/>
    <label id="id_2597911_707711_1_1" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation And Qualifying Accounts Disclosure [Line Items]</label>
    <label id="id_2597911_707711_2_1" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="locator"/>
    <label id="id_2597911_707641_1_1" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation And Qualifying Accounts Disclosure [Table]</label>
    <label id="id_2597911_707641_2_1" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAndQualifyingAccountsDisclosureTable_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_WarrantFourMember" xlink:label="amrn_WarrantFourMember" xlink:type="locator"/>
    <label id="id_2597911_725855_3_1" xlink:label="amrn_WarrantFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant 4 [Member]</label>
    <label id="id_2597911_725855_1_1" xlink:label="amrn_WarrantFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Four [Member]</label>
    <label id="id_2597911_725855_2_1" xlink:label="amrn_WarrantFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant issued on 10/16/09</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_WarrantFourMember" xlink:to="amrn_WarrantFourMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <label id="id_2597911_715581_1_1" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</label>
    <label id="id_2597911_715581_2_1" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_WarrantOneMember" xlink:label="amrn_WarrantOneMember" xlink:type="locator"/>
    <label id="id_2597911_815051_3_1" xlink:label="amrn_WarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant 1 [Member]</label>
    <label id="id_2597911_815051_1_1" xlink:label="amrn_WarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant One [Member]</label>
    <label id="id_2597911_815051_2_1" xlink:label="amrn_WarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant issued on 4/27/07</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_WarrantOneMember" xlink:to="amrn_WarrantOneMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_WarrantsIssuedJulyTwentyZeroNineMember" xlink:label="amrn_WarrantsIssuedJulyTwentyZeroNineMember" xlink:type="locator"/>
    <label id="id_2597911_840926_3_1" xlink:label="amrn_WarrantsIssuedJulyTwentyZeroNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued July 2009 [Member]</label>
    <label id="id_2597911_840926_1_1" xlink:label="amrn_WarrantsIssuedJulyTwentyZeroNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued July Twenty Zero Nine [Member]</label>
    <label id="id_2597911_840926_2_1" xlink:label="amrn_WarrantsIssuedJulyTwentyZeroNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Issued July 2009</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_WarrantsIssuedJulyTwentyZeroNineMember" xlink:to="amrn_WarrantsIssuedJulyTwentyZeroNineMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:type="locator"/>
    <label id="id_2597911_740788_3_1" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued October 2009 [Member]</label>
    <label id="id_2597911_740788_1_1" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued October Twenty Zero Nine [Member]</label>
    <label id="id_2597911_740788_2_1" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Issued October 2009</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:to="amrn_WarrantsIssuedOctoberTwentyZeroNineMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_WarrantThreeMember" xlink:label="amrn_WarrantThreeMember" xlink:type="locator"/>
    <label id="id_2597911_821234_3_1" xlink:label="amrn_WarrantThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant 3 [Member]</label>
    <label id="id_2597911_821234_1_1" xlink:label="amrn_WarrantThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Three [Member]</label>
    <label id="id_2597911_821234_2_1" xlink:label="amrn_WarrantThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant issued on 10/16/09</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_WarrantThreeMember" xlink:to="amrn_WarrantThreeMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_WarrantTwoMember" xlink:label="amrn_WarrantTwoMember" xlink:type="locator"/>
    <label id="id_2597911_797754_3_1" xlink:label="amrn_WarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant 2 [Member]</label>
    <label id="id_2597911_797754_1_1" xlink:label="amrn_WarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Two [Member]</label>
    <label id="id_2597911_797754_2_1" xlink:label="amrn_WarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant issued on 7/31/09</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_WarrantTwoMember" xlink:to="amrn_WarrantTwoMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract" xlink:label="amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract" xlink:type="locator"/>
    <label id="id_2597911_835343_3_1" xlink:label="amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Number Basic And Diluted, Shares Outstanding [Abstract]</label>
    <label id="id_2597911_835343_1_1" xlink:label="amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Basic And Diluted Shares Outstanding [Abstract]</label>
    <label id="id_2597911_835343_2_1" xlink:label="amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract" xlink:to="amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20130930.xsd#amrn_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="amrn_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:type="locator"/>
    <label id="id_2597911_731170_3_1" xlink:label="amrn_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Number Basic Diluted Shares Outstanding</label>
    <label id="id_2597911_731170_1_1" xlink:label="amrn_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Basic Diluted Shares Outstanding</label>
    <label id="id_2597911_731170_2_1" xlink:label="amrn_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:to="amrn_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xlink:type="arc"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>amrn-20130930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2013-11-07T16:17:48Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DocumentandEntityInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureSummarizesActivityOfTheProductRevenueAllowanceAndReserveCategories" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesActivityOfTheProductRevenueAllowanceAndReserveCategories"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureProductRevenueRecognizedAndDeferred" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureProductRevenueRecognizedAndDeferred"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureCapitalizedAndExpensed" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCapitalizedAndExpensed"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureChangeInFairValueOfFinancialInstruments" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureChangeInFairValueOfFinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureIntangibleAssetAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssetAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureCarryingValueOfIntangibleAsset" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCarryingValueOfIntangibleAsset"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureInventory" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureInventory"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureInventoryAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureInventoryAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureWarrantsToPurchaseCommonSharesOutstanding" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsToPurchaseCommonSharesOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureDebtAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureDebtAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureEquityAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20130930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_AmericanDepositorySharesMember" xlink:label="amrn_AmericanDepositorySharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DocumentAndEntityInformationAbstract" xlink:label="amrn_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_OrdinarySharesMember" xlink:label="amrn_OrdinarySharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amrn_OrdinarySharesMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amrn_AmericanDepositorySharesMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DocumentAndEntityInformationAbstract" xlink:to="dei_EntitiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_DocumentInformationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetCurrent" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_WarrantMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_LongTermDebtMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_SeniorLongTermNotes" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract" xlink:label="amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="amrn_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract" xlink:to="amrn_WeightedAverageNumberBasicDilutedSharesOutstanding" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims" xlink:label="amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices" xlink:label="amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="amrn_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_StockIssuedDuringPeriodValueStockWarrantsExercised" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_2" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_CashPaidDuringPeriodForAbstract" xlink:label="amrn_CashPaidDuringPeriodForAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_IncreaseDecreaseInLeaseRelatedLiabilities" xlink:label="amrn_IncreaseDecreaseInLeaseRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xlink:label="us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital" xlink:label="amrn_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockOptionsAndRestrictedStockUnitsMember" xlink:label="amrn_StockOptionsAndRestrictedStockUnitsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" order="1.0900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="amrn_IncreaseDecreaseInLeaseRelatedLiabilities" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.1500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="amrn_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_InterestPaid" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.2900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.3000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.3100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="1.3200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1.3300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.4000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="1.2600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="amrn_StockOptionsAndRestrictedStockUnitsMember" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="amrn_CashPaidDuringPeriodForAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentCallDateEarliest" xlink:label="us-gaap_DebtInstrumentCallDateEarliest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentCallDateEarliest" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_CashDiscountInvoiceTerms" xlink:label="amrn_CashDiscountInvoiceTerms"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_CashDiscountPercent" xlink:label="amrn_CashDiscountPercent"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ChangeInControlObligations" xlink:label="amrn_ChangeInControlObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount" xlink:label="us-gaap_DerivativeAssetNotionalAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_FairValueAssumptionsComparableYieldToMaturity" xlink:label="amrn_FairValueAssumptionsComparableYieldToMaturity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_FairValueInputsCouponRate" xlink:label="amrn_FairValueInputsCouponRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyDerivativesAtFairValueNet" xlink:label="us-gaap_ForeignCurrencyDerivativesAtFairValueNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignExchangeForwardMember" xlink:label="us-gaap_ForeignExchangeForwardMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_MaturityPeriodUsedToClassifyInvestments" xlink:label="amrn_MaturityPeriodUsedToClassifyInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_NumberOfForeignCurrencyForwardContractsOutstanding" xlink:label="amrn_NumberOfForeignCurrencyForwardContractsOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ScenarioOneMember" xlink:label="amrn_ScenarioOneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_SignificantAccountingPoliciesLineItems" xlink:label="amrn_SignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_SignificantAccountingPoliciesTable" xlink:label="amrn_SignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_SignificantAssumptionsInMarketPriceOfStock" xlink:label="amrn_SignificantAssumptionsInMarketPriceOfStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amrn_SignificantAccountingPoliciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeForwardMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_ScenarioOneMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_CashDiscountPercent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_CashDiscountInvoiceTerms" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_MaturityPeriodUsedToClassifyInvestments" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharePrice" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_SignificantAssumptionsInMarketPriceOfStock" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_ChangeInControlObligations" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherCommitment" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_FairValueInputsCouponRate" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_FairValueAssumptionsComparableYieldToMaturity" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DerivativeAssetNotionalAmount" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_NumberOfForeignCurrencyForwardContractsOutstanding" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ForeignCurrencyDerivativesAtFairValueNet" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementScenarioAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="amrn_SignificantAccountingPoliciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesActivityOfTheProductRevenueAllowanceAndReserveCategories">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllowanceForSalesReturnsMember" xlink:label="us-gaap_AllowanceForSalesReturnsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllowanceForTradeReceivablesMember" xlink:label="us-gaap_AllowanceForTradeReceivablesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_OtherIncentiveProgramsMember" xlink:label="amrn_OtherIncentiveProgramsMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_RebatesChargebacksAndDiscountsMember" xlink:label="amrn_RebatesChargebacksAndDiscountsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:label="us-gaap_ValuationAndQualifyingAccountsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_AllowanceForTradeReceivablesMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="amrn_RebatesChargebacksAndDiscountsMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_AllowanceForSalesReturnsMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="amrn_OtherIncentiveProgramsMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:to="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureProductRevenueRecognizedAndDeferred">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ProductSales" xlink:label="amrn_ProductSales"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_RevenuesLineItems" xlink:label="amrn_RevenuesLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ScheduleOfRevenuesTable" xlink:label="amrn_ScheduleOfRevenuesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amrn_ScheduleOfRevenuesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_RevenuesLineItems" xlink:to="us-gaap_Revenues" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_RevenuesLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_RevenuesLineItems" xlink:to="amrn_ProductSales" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_ScheduleOfRevenuesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_ScheduleOfRevenuesTable" xlink:to="amrn_RevenuesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCapitalizedAndExpensed">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ComponentOfOperatingCostAndExpenseLineItems" xlink:label="amrn_ComponentOfOperatingCostAndExpenseLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ComponentOfOperatingCostAndExpenseTable" xlink:label="amrn_ComponentOfOperatingCostAndExpenseTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DirectOperatingCosts" xlink:label="us-gaap_DirectOperatingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amrn_ComponentOfOperatingCostAndExpenseTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_ComponentOfOperatingCostAndExpenseLineItems" xlink:to="us-gaap_CostOfGoodsSold" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_ComponentOfOperatingCostAndExpenseLineItems" xlink:to="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_ComponentOfOperatingCostAndExpenseLineItems" xlink:to="us-gaap_DirectOperatingCosts" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_ComponentOfOperatingCostAndExpenseTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_ComponentOfOperatingCostAndExpenseTable" xlink:to="amrn_ComponentOfOperatingCostAndExpenseLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureChangeInFairValueOfFinancialInstruments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DerivativeInstrumentMember" xlink:label="amrn_DerivativeInstrumentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" xlink:label="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="us-gaap_DerivativesFairValueLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_FairValueAndDerivativeInstrumentsTable" xlink:label="amrn_FairValueAndDerivativeInstrumentsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_DerivativeInstrumentMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilities_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_FairValueAndDerivativeInstrumentsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_FairValueAndDerivativeInstrumentsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_FairValueAndDerivativeInstrumentsTable" xlink:to="us-gaap_AwardTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_FairValueAndDerivativeInstrumentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_FairValueAndDerivativeInstrumentsTable" xlink:to="us-gaap_DerivativesFairValueLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="amrn_FairValueAndDerivativeInstrumentsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssetAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_IntangibleAssetsDisclosureLineItems" xlink:label="amrn_IntangibleAssetsDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_IntangibleAssetsDisclosureTable" xlink:label="amrn_IntangibleAssetsDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="amrn_IntangibleAssetsDisclosureTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_IntangibleAssetsDisclosureLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_IntangibleAssetsDisclosureTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_IntangibleAssetsDisclosureTable" xlink:to="amrn_IntangibleAssetsDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCarryingValueOfIntangibleAsset">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureInventory">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryCurrentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryNet" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureInventoryAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryCurrentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_AmericanDepositaryShareMember" xlink:label="amrn_AmericanDepositaryShareMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_AmericanDepositorySharesToSharesRatio" xlink:label="amrn_AmericanDepositorySharesToSharesRatio"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ClassOfWarrantOrRightExercisedInPeriod" xlink:label="amrn_ClassOfWarrantOrRightExercisedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ClassOfWarrantOrRightIssued" xlink:label="amrn_ClassOfWarrantOrRightIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ClassOfWarrantOrRightTerm" xlink:label="amrn_ClassOfWarrantOrRightTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmbeddedDerivativeDescriptionOfHostContract" xlink:label="us-gaap_EmbeddedDerivativeDescriptionOfHostContract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EnergyAxis" xlink:label="us-gaap_EnergyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EnergyDomain" xlink:label="us-gaap_EnergyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="us-gaap_EquityIssuancePerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_OctoberTwentyZeroNinePrivatePlacementMember" xlink:label="amrn_OctoberTwentyZeroNinePrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficerMember" xlink:label="us-gaap_OfficerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WarrantsIssuedJulyTwentyZeroNineMember" xlink:label="amrn_WarrantsIssuedJulyTwentyZeroNineMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amrn_WarrantsIssuedJulyTwentyZeroNineMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_BridgeLoanMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_AmericanDepositorySharesToSharesRatio" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_EquityIssuancePerShareAmount" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_ClassOfWarrantOrRightTerm" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_ClassOfWarrantOrRightIssued" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_EmbeddedDerivativeDescriptionOfHostContract" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_ClassOfWarrantOrRightExercisedInPeriod" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_RangeAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_EnergyAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_DerivativeLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EnergyAxis" xlink:to="us-gaap_EnergyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EnergyDomain" xlink:to="amrn_AmericanDepositaryShareMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_OfficerMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amrn_OctoberTwentyZeroNinePrivatePlacementMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsToPurchaseCommonSharesOutstanding">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ClassOfWarrantOrRightExpirationDate" xlink:label="amrn_ClassOfWarrantOrRightExpirationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="us-gaap_DerivativeByNatureAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="us-gaap_DerivativeNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WarrantFourMember" xlink:label="amrn_WarrantFourMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WarrantOneMember" xlink:label="amrn_WarrantOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WarrantThreeMember" xlink:label="amrn_WarrantThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_WarrantTwoMember" xlink:label="amrn_WarrantTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="amrn_ClassOfWarrantOrRightExpirationDate" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_DerivativeByNatureAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="us-gaap_DerivativeNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="amrn_WarrantOneMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="amrn_WarrantTwoMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="amrn_WarrantThreeMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="amrn_WarrantFourMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureDebtAdditionalInformation">
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_AdditionalPercentageInterestRatePenalty" xlink:label="amrn_AdditionalPercentageInterestRatePenalty"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_AgreementExpirationDate" xlink:label="amrn_AgreementExpirationDate"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_AmericanDepositorySharesMember" xlink:label="amrn_AmericanDepositorySharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_BiopharmaceuticalMember" xlink:label="amrn_BiopharmaceuticalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ChangeInControlObligations" xlink:label="amrn_ChangeInControlObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DebtDisclosureLineItems" xlink:label="amrn_DebtDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DebtDisclosureTable" xlink:label="amrn_DebtDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DebtInstrumentMaturityDateYear" xlink:label="amrn_DebtInstrumentMaturityDateYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DebtOfferingMember" xlink:label="amrn_DebtOfferingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ExcessFairValueOverPrincipalValue" xlink:label="amrn_ExcessFairValueOverPrincipalValue"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_FinanceMember" xlink:label="amrn_FinanceMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_FutureMinimumGuaranteePayments" xlink:label="amrn_FutureMinimumGuaranteePayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainOnDerivativeInstrumentsPretax" xlink:label="us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_NonCashMember" xlink:label="amrn_NonCashMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PeriodAxis" xlink:label="amrn_PeriodAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PeriodDomain" xlink:label="amrn_PeriodDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PeriodFiveMember" xlink:label="amrn_PeriodFiveMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PeriodFourMember" xlink:label="amrn_PeriodFourMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PeriodOneMember" xlink:label="amrn_PeriodOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PeriodThreeMember" xlink:label="amrn_PeriodThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PeriodTwoMember" xlink:label="amrn_PeriodTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ProceedsMember" xlink:label="amrn_ProceedsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amrn_AmericanDepositorySharesMember" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="amrn_DebtDisclosureTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_OtherCommitment" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_FutureMinimumGuaranteePayments" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_AgreementExpirationDate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_ChangeInControlObligations" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_GainOnDerivativeInstrumentsPretax" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestExpense" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_DebtInstrumentMaturityDateYear" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_ExcessFairValueOverPrincipalValue" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_AdditionalPercentageInterestRatePenalty" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_ConvertibleDebt" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestPaid" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_StatementScenarioAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="amrn_PeriodAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_SecuritiesFinancingTransactionAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="amrn_DebtDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_NotesPayableOtherPayablesMember" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_PeriodAxis" xlink:to="amrn_PeriodDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodOneMember" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodTwoMember" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodThreeMember" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodFourMember" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodFiveMember" order="1.4700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_CashMember" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_NonCashMember" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_ProceedsMember" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_DebtOfferingMember" order="1.4600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecuritiesFinancingTransactionAxis" xlink:to="us-gaap_SecuritiesFinancingTransactionTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:to="amrn_FinanceMember" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="amrn_BiopharmaceuticalMember" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_AmrOneHundredOneMember" xlink:label="amrn_AmrOneHundredOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_BusinessDevelopmentDomain" xlink:label="amrn_BusinessDevelopmentDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_BusinessDevelopmentsAxis" xlink:label="amrn_BusinessDevelopmentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="amrn_CommitmentsAndContingenciesDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_CommitmentsAndContingenciesDisclosureTable" xlink:label="amrn_CommitmentsAndContingenciesDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DevelopmentFeesCommitted" xlink:label="amrn_DevelopmentFeesCommitted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_FirstIndicationForAmrOneZeroOneMember" xlink:label="amrn_FirstIndicationForAmrOneZeroOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_FurtherIndicationForAmrOneZeroOneMember" xlink:label="amrn_FurtherIndicationForAmrOneZeroOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_LaxdaleLimitedMember" xlink:label="amrn_LaxdaleLimitedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_LiabilitiesForCommitmentsAxis" xlink:label="amrn_LiabilitiesForCommitmentsAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_LiabilitiesForCommitmentsDomain" xlink:label="amrn_LiabilitiesForCommitmentsDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_NumberOfAgreements" xlink:label="amrn_NumberOfAgreements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PotentialMarketingApprovalOneMember" xlink:label="amrn_PotentialMarketingApprovalOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_PotentialMarketingApprovalTwoMember" xlink:label="amrn_PotentialMarketingApprovalTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_SupplierDMember" xlink:label="amrn_SupplierDMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_SupplierOneMember" xlink:label="amrn_SupplierOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_SupplierThreeMember" xlink:label="amrn_SupplierThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_SupplierTwoMember" xlink:label="amrn_SupplierTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_BusinessDevelopmentDomain" xlink:to="amrn_PotentialMarketingApprovalOneMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_BusinessDevelopmentDomain" xlink:to="amrn_PotentialMarketingApprovalTwoMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_BusinessDevelopmentsAxis" xlink:to="amrn_BusinessDevelopmentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="amrn_CommitmentsAndContingenciesDisclosureTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="amrn_NumberOfAgreements" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="amrn_DevelopmentFeesCommitted" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AdjustmentForAmortization" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_StatementScenarioAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="amrn_LiabilitiesForCommitmentsAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RangeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="amrn_BusinessDevelopmentsAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="amrn_CommitmentsAndContingenciesDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LiabilitiesForCommitmentsAxis" xlink:to="amrn_LiabilitiesForCommitmentsDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LiabilitiesForCommitmentsDomain" xlink:to="amrn_LaxdaleLimitedMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LiabilitiesForCommitmentsDomain" xlink:to="amrn_AmrOneHundredOneMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LiabilitiesForCommitmentsDomain" xlink:to="amrn_SupplierOneMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LiabilitiesForCommitmentsDomain" xlink:to="amrn_SupplierTwoMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LiabilitiesForCommitmentsDomain" xlink:to="amrn_SupplierDMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LiabilitiesForCommitmentsDomain" xlink:to="amrn_SupplierThreeMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_FurtherIndicationForAmrOneZeroOneMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_FirstIndicationForAmrOneZeroOneMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_AmericanDepositorySharesMember" xlink:label="amrn_AmericanDepositorySharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DeferredStockUnitsDSUsMember" xlink:label="amrn_DeferredStockUnitsDSUsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_Group1Member" xlink:label="amrn_Group1Member"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_Group2Member" xlink:label="amrn_Group2Member"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_Group3Member" xlink:label="amrn_Group3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_OptionsExercisablePeriod" xlink:label="amrn_OptionsExercisablePeriod"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_OptionsGrantedDuringPeriod" xlink:label="amrn_OptionsGrantedDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:label="amrn_ProceedsFromExerciseOfStockOptionsAndWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ProceedsFromStockOptionExerciseAndOther" xlink:label="amrn_ProceedsFromStockOptionExerciseAndOther"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ProceedsFromStockOptionsExercisedGross" xlink:label="amrn_ProceedsFromStockOptionsExercisedGross"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ProceedsFromWarrantExercisesGross" xlink:label="amrn_ProceedsFromWarrantExercisesGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockholdersEquityNoteLineItems" xlink:label="amrn_StockholdersEquityNoteLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockholdersEquityNoteTable" xlink:label="amrn_StockholdersEquityNoteTable"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockIncentivePlanTwentyElevenMember" xlink:label="amrn_StockIncentivePlanTwentyElevenMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amrn_AmericanDepositorySharesMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="amrn_StockholdersEquityNoteTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="amrn_StockIncentivePlanTwentyElevenMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_Group1Member" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_Group2Member" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_Group3Member" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="amrn_DeferredStockUnitsDSUsMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_OptionsGrantedDuringPeriod" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_OptionsExercisablePeriod" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_ProceedsFromStockOptionsExercisedGross" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_ProceedsFromStockOptionExerciseAndOther" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_ProceedsFromWarrantExercisesGross" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_ProceedsFromExerciseOfStockOptionsAndWarrants" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_RestrictedStockExpense" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_PlanNameAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_AwardTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_StatementScenarioAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="amrn_StockholdersEquityNoteLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_DeferredRevenuePolicyTextBlock" xlink:label="amrn_DeferredRevenuePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="us-gaap_DerivativeByNatureAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="us-gaap_DerivativeNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesEmbeddedDerivatives" xlink:label="us-gaap_DerivativesEmbeddedDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_RecentAccountingPronouncementsPolicyTextBlock" xlink:label="amrn_RecentAccountingPronouncementsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="us-gaap_DerivativeNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="us-gaap_WarrantMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UseOfEstimates" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryPolicyTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_DeferredRevenuePolicyTextBlock" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtPolicyTextBlock" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativesEmbeddedDerivatives" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_RecentAccountingPronouncementsPolicyTextBlock" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeByNatureAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_RevenuesTableTextBlock" xlink:label="amrn_RevenuesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_ScheduleOfCostOfRevenueTableTextBlock" xlink:label="amrn_ScheduleOfCostOfRevenueTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="amrn-20130930.xsd#amrn_SummaryOfValuationAllowancesTableTextBlock" xlink:label="amrn_SummaryOfValuationAllowancesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_SummaryOfValuationAllowancesTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_RevenuesTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_ScheduleOfCostOfRevenueTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4AAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SummaryOfValuationAllowancesTableTextBlock', window );">Summarizes Activity of the Product Revenue Allowance and Reserve Categories</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The following table
 summarizes activity in each of the product revenue allowance and
 reserve categories described above for the nine months ended
 September&#xA0;30, 2013 (in thousands):</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Trade<br />
 Allowances</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Rebates,<br />
 Chargebacks<br />
 and&#xA0;Discounts</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Product<br />
 Returns</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Other<br />
 Incentives</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 January&#xA0;1, 2013</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Provision related to
 current period and deferred sales</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,839</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,418</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">72</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,018</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,347</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Credits/payments made for
 current period and deferred sales</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,951</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,484</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,835</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(5,270</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 September&#xA0;30, 2013</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>888</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>934</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>72</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>183</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2,077</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_RevenuesTableTextBlock', window );">Product Revenue Recognized and Deferred</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The following table
 summarizes product revenue recognized and deferred during the nine
 months ended September&#xA0;30, 2013 (in thousands):</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="14%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="14%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>September&#xA0;30,&#xA0;2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Product revenue
 recognized</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,245</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred product
 revenue</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,617</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>17,862</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ScheduleOfCostOfRevenueTableTextBlock', window );">Expensed and Capitalized Cost of Goods</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">In conjunction with the
 Company&#x2019;s recognition and deferral of product revenues, the
 Company expensed and capitalized the associated cost of goods, as
 follows, during the nine months ended September&#xA0;30, 2013 (in
 thousands):</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="14%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="14%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>September&#xA0;30,&#xA0;2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cost of goods sold
 expensed</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,813</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Finished goods inventory
 held by others</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">641</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>8,454</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Assets and Liability Measured at Fair Value on a Recurring Basis</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The following table
 presents information about the Company&#x2019;s assets and
 liabilities as of September&#xA0;30, 2013 and December&#xA0;31,
 2012 that are measured at fair value on a recurring basis and
 indicates the fair value hierarchy of the valuation techniques the
 Company utilized to determine such fair value:</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>September&#xA0;30,
 2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="1"><b><i>In millions</i></b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;1</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;2</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;3</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Asset:</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash
 equivalents&#x2014;money markets</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">113.5</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">113.5</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Liabilities:</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Warrant derivative
 liability</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">39.6</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">39.6</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term debt redemption
 feature</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.2</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.2</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign currency
 contracts</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.4</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.4</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,
 2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="1"><b><i>In millions</i></b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;1</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;2</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;3</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Asset:</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash
 equivalents&#x2014;money markets</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;64.1</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;64.1</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Liability:</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Warrant derivative
 liability</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">54.9</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">54.9</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term debt redemption
 feature</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14.6</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14.6</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Change in Fair Value of Financial Instruments</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The change in the fair
 value of financial instruments is as follows (in
 thousands):</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>October</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>2009</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Warrants&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Debt</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Redemption&#xA0; &#xA0;</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Feature</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Foreign</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Exchange</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Contracts&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;&#xA0;&#xA0;Totals&#xA0;&#xA0;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 January&#xA0;1, 2012</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>123,125</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#x2014;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#x2014;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>123,125</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Loss on change in fair
 value of derivative liability</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">68,686</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">68,686</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Compensation expense for
 change in fair value of warrants issued to former
 employees</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,037</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,037</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Transfers to
 equity</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(103,885</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(103,885</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 September&#xA0;30, 2012</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>90,963</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#x2014;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#x2014;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>90,963</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>October</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>2009</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Warrants&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Debt</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Redemption&#xA0; &#xA0;</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Feature</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Foreign</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Exchange</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Contracts&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;&#xA0;&#xA0;Totals&#xA0;&#xA0;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 January&#xA0;1, 2013</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>54,854</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>14,577</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#x2014;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>69,431</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">(Gain) loss on change in
 fair value of derivative liabilities</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,077</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(7,377</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">395</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(21,059</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Compensation income for
 change in fair value of warrants issued to former
 employees</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,179</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,179</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Transfers to
 equity</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 September&#xA0;30, 2013</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>39,598</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>7,200</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>395</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>47,193</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_RevenuesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenues Table [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_RevenuesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ScheduleOfCostOfRevenueTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule of Cost of Revenue [Table Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_ScheduleOfCostOfRevenueTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_SummaryOfValuationAllowancesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Summary Of Valuation Allowances Table [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_SummaryOfValuationAllowancesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a,b,bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=SL7498348-110258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19279-110258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of derivative liabilities at fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0"I^C`/Y@$``,P7```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F-%JVS`8A>\+>P>CVQ$K
MDM:N&W%ZL767;:'=`VC6G]C$EH2DMLG;5W;:4DJ6$A;8N8E)+/WGB\`?^,PN
MUGU7/%"(K;,5$^64%61K9UJ[K-CONU^3<U;$I*W1G;-4L0U%=C'_=#*[VWB*
M1=YM8\6:E/QWSF/=4*]CZ3S9?&?A0J]3_AJ6W.MZI9?$Y71ZQFMG$]DT2<,,
M-I_]I(6^[U)QN<X_;TD"=9$5/[8+AZR*:>^[MM8ID_(':]ZE3)X3RKQS7!.;
MUL?/&8/QG0G#G;\'/.^[SD<36D/%C0[I2O<9@Z\[_NC"ZH]SJW+_D!V4;K%H
M:S*NON_S"931!](F-D2I[\KQ6O:ZM2_<>_+'Q9&/%W%DD.'_C8,/Y)`@'`J$
MXPL(QRD(QQD(QU<0CG,0CF\@'&**`H)B5(&B5('B5($B58%B58&B58'B58$B
M5H%B5HEB5HEB5HEB5HEB5HEB5HEB5HEB5HEB5HEB5HEB5H5B5H5B5H5B5H5B
M5H5B5H5B5H5B5O6_S)IR5TI\_/SW!W<<\T%9%].FHWCD%^SMT(^2&QW(W*:0
M6^6C`[R=O8\C=ZXWP?F8V^=`AY_"2[T\[)[X/(A":NFU8-Y5U+XFYN;Z\,!W
M33$-W;@ALR.;CUW\_`D``/__`P!02P,$%``&``@````A`+55,"/U````3`(`
M``L`"`)?<F5L<R\N<F5L<R"B!`(HH``"````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````````",DL].
MPS`,QN](O$/D^^IN2`BAI;M,2+LA5![`).X?M8VC)$#W]H0#@DICV]'VY\\_
M6][NYFE4'QQB+T[#NBA!L3-B>]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24
MFV+7^ZBRBXL:NI3\(V(T'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&OQY0+3S5
MP6H(!WL'JC[Z//FRMS1-;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:0LM)@Q7S
MG-,1R?LB8P.>)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A
M363X8<'%#U1?````__\#`%!+`P04``8`"````"$`\*#N9/0!``#)%@``&@`(
M`7AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS(*($`2B@``$`````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````O)C/3N,P$,;O*_$.D>_4G9E2_HBT%[12
MKRP\@)6X346;1+9AZ=MC%384B?UV#]%<(ME1QI\^C^<WSNWR=;\K7GR(VZXM
M#4VFIO!MU=7;=E.:QX>?YU>FB,FUM=MUK2_-P4>S7)S]N+WW.Y?R1['9]K'(
M4=I8FB:E_L;:6#5^[^*DZWV;WZR[L'<I#\/&]JYZ<AMO>3J=VW`:PRR^Q"Q6
M=6G"JB8QQ<.ASTO_.WBW7F\K?]=5SWO?IF_6L+^[\!0;[U,.ZL+&I](,4]$>
MWY!,LF9C_R(G^Z$KYPK)X;FR')XC.7(]IIR8#KN<;L-.O8_1^DQCKC]DQJ>$
M8>HC69B0')DIRY$9DG.IK.82B2%65D,,Y6B;0]`=OE!VAR^0.Z)=A`4681FU
M"*<,*Y_M_N#!<6B/3WBXM?,7IZ\V!PAR@',;H4I)GJ+TY5&Q-##@,V>&J3]8
MN$9RM"$%TU@[<6#>D+HUT!O6YC=#?HMVR1%8<T0;F0*1.1NUYL3&!5__2B%?
MA$Y;T--I=,:U^0WQ3=IJ",IA[6Z"83?!HW83`PH`'>"53K0KLN"2/.JQ^@]W
M"**<M%%.$.6B#2R!P-+F%<25]D[!C2)M:PAZP]HH9XARUD8Y0Y2+=LT16'-$
M&Y\"\:F-*TPKY8O>0'+[Y0?TX@T``/__`P!02P,$%``&``@````A`.@L)__.
M`P``P@L```\```!X;"]W;W)K8F]O:RYX;6R45E%OFSH8?9]T_P/B?2-`DJU5
MTZEM4MU(VU3=]K:/E@-.L`9V9INFV:_?`1KZ`5W6/24&?'R^X_,=^^SS4Y%[
MC\)8J=7,#S^,?$^H1*=2;6;^_W?7[S_YGG5<I3S72LS\O;#^Y_-_WIWMM/F^
MTOJ[!P!E9W[FW/8T"&R2B8+;#WHK%-ZLM2FXP]!L`KLU@J<V$\(5>1"-1M.@
MX%+Y#<*I>0N&7J]E(N8Z*0NA7`-B1,X=Z-M,;JU_?K:6N;AO*O+X=ON-%^#]
ME/M>SJU;I-*)=.9/,-0[T7E@RNUE*7.\/8E'L1^<MT7>&"\5:U[F[@[E'="A
M5S2.HFGU927%O10[^S*I&GI/#U*E>E=]"FGW[2@&@5W]ZD&F+L/[T6C4/OM7
MR$WF#@\!'Q#\6D&L4_]ZJB[OH`C#3K&%<M+MV5(UZDN-+:Q47Z*R&/MI3B7^
MF64:5LPIS)56J5!6I`S_K,YERJ$6N^0Y5XF@,"<$)OH[F)#B$)A:\3>PN74@
M55`V8X(R?B.99Q1*9HP=:K69_!U.1(J:$IC:'+2H;]R51C"]9I>EE4I86^_9
M);?2,KI38U!KV7SLL[F5&R71"UPY=I$DNL2>JPV[P9XELJ,-F+4PG_HP2X7>
MWLA5+MB%M<*1*L8QF7@RG/B(!M1F3V?0?0A'_2D/W!C0;>I]'K"Y,/(1[?M(
M<=`'+>5P8-*Y6'5X4KG#5[Q8%-)5:=$L#&-72B'D)*+LI3'&'^FB`R\N?I3H
M*?I]IY$&KKLM5U;\*+$L6U1*=9:BS1,.C'9\:ZEA)]2PX<!JQX&H8R?4:^'`
M;'V7L#L.Q]"2)M1EX2LV>W;+*S.IS<*!SXZ;IB,&=1_"MA=MQ_N.`D54#`QZ
M0,=5135MUD94%`SZ0&51<"-_"HL.1@=4F8U8<)E@-X8F040EPJ"'@X_3,G'L
M/P&12X'?1",<?B*X<1I0/AV%!I:]XEOI>'Z8R!9/.,.KLV`N')<4A_9G-/!O
M'21-LWV1?"7SJK"O@EOD7LHH#NW<YABE27F5(9H$DXI=<VG8/<]1'`2ZE@JG
M$<&9=/C\V;T7*2X!N##P'&<DP8EH2V/0T_D*^;6O0K9E0ON"X$PZ=0TLO52'
M9JB%Q<6D=<R$AE`\\/#+S$X)S\<\Q:&5Q`,+'V^J3C#0J(H'%FZ!G&8WI4DR
M;@6N#D6A%;O-"*&86AB#GK15I+/7:@+.G)YF4YIX\=#"6/JW84^M-Z4]CKM8
MCT^3]K]C1.J:TA:/APG</P4ZD`0G[FQ\;>&@=@7N>0G/$UQ`JY_J!E>[(CA<
MO\]_`0``__\#`%!+`P04``8`"````"$`PJ<D"D8%```7%```&````'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;)28VXZC.!"&[U?:=T#<)\%@3E&2T7#HW9%F
MI=5J#]<T<1+4`2*@.]UOOV5,@JLR0](STDPG_OWCKZJPJ[WZ\EX>C3?1M$5=
MK4TVMTQ#5'F]+:K]VOSG[Z=98!IMEU7;[%A78FU^B-;\LOGUE]6Y;E[:@Q"=
M`0Y5NS8/77=:+A9M?A!EUL[KDZA@9%<W9=;!QV:_:$^-R+;]I/*XL"W+6Y19
M49G*8=D\XE'O=D4NDCI_+475*9-&'+,.UM\>BE-[<2OS1^S*K'EY/<WRNCR!
MQ7-Q++J/WM0TRGSY;5_53?9\!.YWQK/\XMU_N+$OB[RIVWK7S<%NH19ZRQPN
MP@4X;5;;`@ADV(U&[-;F5[9,66@N-JL^0/\6XMQJ/QOMH3[_UA3;[T4E(-J0
M)YF!Y[I^D=)O6_D53%[<S'[J,_!G8VS%+GL]=G_5Y]]%L3]TD&X7B"38<ON1
MB#:'B(+-W':E4UX?80'PKU$6LC0@(ME[__^YV':'M>EX<]>W'`9RXUFTW5,A
M+4TC?VV[NOQ/B=A@I4SLP01F#";,GMN!RUSOOLM"K:@'3+(NVZR:^FQ`U<`S
MVU,F:Y`MP?E"IM9Q9?T9*C!*DZ_2I?<"BA;R\[;Q[=7B#4*:#Y)(27S3&"4<
M2^*+1`90VB:7+\8Y#$])+PJ9/2"Z8D&P*)8#:?]QPBX4<A*A</#SHEL)X8QO
M%;Z+39);"3%);Q6:"0)U,.@TH!2O33`?<^#AM45*$O0Y#+A%^&,US'4';)#H
M!LRS.8%/IQP0&3Q$3^$TF13#6Z6OR\<+BY1D8NGQ745R5Y%.*1`>O&R/XTDQ
M25Q`\)3$ZQ/G>`&IJ%@-3]`GNH$?,)+Y=,H`@7F?`9-B`A82,"518`S`R!80
MZ^.V%=*%)_JXZS%.`I?JXT[H.V/!(BS8N1[/EQ1CK,`B6$JBL.S`]NEFJ(\S
M!Q:&YR=HW&*N13*>Z@+.+'>,*^*2/8IV`$R_9E),N$@Z(B517#SP?;+N6!]W
MN,-(7!)]G'DN]V@AZH+`\L,Q<(@K_`R7%!,N$LY(2137##;&FX0AP8_(D(#Q
MT&:T%)%B@HW!4:8G39[:]X^W?A:A),&-!LV`R3BMJA@)F,?=,?S#F2W7MC:'
MPD9UUPM2Y##S`OA[+6V4028/]X=+LU<3.K*V:-`,=`'GI'AC+.#0HEV7-M"I
MAF-PL#V/CXL?\)""V8$S9AGCR4/^<3S5$NAG=S#N5/VC(Z8TO#\#9LYM[M`X
MM\FKF>#Y^L('-#R?C='#8/*(U\`>K$[5&"!`$MN(*<T0?==RV;BI]4N,L<*&
M]IA4>((5S'4]3B0ID7BV;X_/P:CRN/\\JFH2$"K)1<241J$R3SN5!E!]?.:X
M/H%(D`&'`P97<HK&9VX0_*Q,Y<&O(4X?$/*W(KJ3CL9#F2J-ZC%G')Y,WM-X
M<!D4ML=M4@D)5L#I%S`B28D$MADVQ@!G4;8`CR.JAD'O-8.Q/`9$I8$<C9TV
MCG_,[DJ2^Y)T4H(A93_P.*3J'O02#<E>&#&E"=5V`[_Z!B'Z0_(>4ST]_A(J
M"&]2BI[(YMKKCUEEC_`XJ^HH](2&X]8V)%1I)A-Z5Y*PNY)T4H(A9;?P.*3J
M+:83JO<?S+=8,+XPPZZ#%-#"6*0H$KB&&8]_YOK0`.#"EQ<UFH*SD(]/48#J
M'D9=4Y2BV8M8'(^MD=>O\H[%AGJ[?JON?R*VA,L#N`,@WR?R7JB_V;D.P+7,
M*=N+/[)F7U2M<10[L+3F/NQ)C;K841^Z^M1?!3S7'5S(]#\>X`).P+6$-0?Q
MKJZ[RP=Y^7"]TMO\#P``__\#`%!+`P04``8`"````"$`.['LA/P'``#$,0``
M&0```'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6R<FUMOXL@6A=^/=/X#XKT!
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M:\M8UX?CA[N\@?ZW3]ZRVM^#["5]<R[[7;@_)=3:U$^B!Q[3](=`O9T(T<7C
MQM5VW@-_7@:[Y&GS>KC^E;ZYR?[YY4K=/:,[$C>VW/TVDVQ++4HR(WTFE+;I
M@2I`OP?'O;`&M<CF5_[ZMM]=7^Z'T_EHMIA,-<('CTEVM?="<CC8OF;7]/A_
M"6F%E!31"Q%Z+40T_=,BTT*$7M]%])N9-IM_HBI&H4*OA8I.?_:\#[KCO#'H
MM;SX=G0SFQGSFT7_UI@7*HM*Y0M-2N,SK\IM):)_H2H:^4EVKS#6E_M7JUQ2
M:];^U1E+S^46-C?7S</=)7T;T+Q`LMEY(V89;:F1=&E>:;7*SA^YF6PL5+X+
MF?LA-3<9-:,A^//!F"[NQC]IV&P+9M5D-)58EX08(T+6Y`%+!NAWK9P;5<4N
MF5+%X0&W#'2H>"53JOAEX/TB5OU`$HM\7(KJASP0E1JE:%P+C*E'JFZA8:QT
M2_M<4K:^H$7KE[*K,O!>5UUMI'636,Q4Q)0(U;!J:R9B-0G#F*@J=I-A*DZ3
M,(RIJN*V,:PDKXUA.GZ38;4)FD2C-F$/)FHRK*2X2=1+4NQ`$_(G["!HQ0X\
ML.8!4P;J?6U,;]4^L%H8@PT!NP?C]&#<'HS7@_%[,$$/)NS!1#V8N)M1^IPF
M8Z7/Q<P\I36D>RH05RE]SP-K'C!E0&XGQ+1E\8!=!MYG`L-@;G9Z,&X;8Z@N
M\WHP?@LS8;-!T(,)>S!1#R;N9I1>I3V,TJO=O2EHI3=Y8,T#I@S4>I,';!YP
M>,#E`8\'?!X(>"`L`W7/L!4F:C+3!9MUXB9C&.^>4=J6=GV?:%M!*VW+`VL>
M,&6@UK8\8/.`PP,N#W@\X/-`P`,A#T0\$)>!]M976HTV;9]H-4'3/%3;%!C&
M7!W"*\G0H*@V#FPKN(:$"0D+$C8D'$BXD/`@X4,B@$0(B0@2<1>A6$)D)NH/
M!=V3E*#OA[2;J;K;,%B'KR0SSY\,;F^T^8W.3+.61(=I3$A8D+#K]9A/Q(_J
M70=*N)#P(.'7J[&8M=0C@!HA)")(Q%V$X@AZ!OZ$(P3-'<&>TE:2,7)':*/:
ME)X_^:W+C]]-Q2QE0L*"A`T)!Q(N)#Q(^)`((!&6A'CXUD9\J2T__;`]XY+@
MURL^$-D,Q0C]=J7Y9=P1;*5?%="-M(2NZ1,Q0M7QN2Z@KGD"(Y92U"(??[PD
M&\LX&'$QXF'$QTB`D1`C$4;B3D0UB\ANU->1GF:121%E09DQ'ZQ$/HSFF`X?
MK#%B8L0J$+ETS?5IRV1M8QD'(RY&/(SX&`DP$F(DPDC<B:A6$<F0+UA%YE!4
MJ["<Q$J34*=5(&)B%0LC-D8<C+@%(CTY;=O'>%C%QTB`D1`C$4;B3D1UBDBA
M?,$I,O.B.H7E,%::A#J=`A$3JU@%4DPJ<Z-U4H$E.;@D5RE)EL.F4@^K^!@)
M,!)B),)(W(FH5J&._(I5Q&5LLS)CB>25^*X$K3\0,;&*52'YODS=#=G5AQ]N
MZQR,N!724H17??AA$3Y&`HR$&(DP$G<BJCM$9ND+$XE,2*D3R7M"*G]Z68FO
M?Y$[(&)B%:M`BCTS=P<LPL%%N!CQ,.)C),!(B)$((W$GHGI$Y-'J'NG.A&@R
M[:9Z@SV)K0J()H<J7\(>;=<8,3%B8<3&B(,1%R,>1GR,!!@)6Q!CQG)-40O$
MNB!N0>HZJDM$8JWNDI[/.3(?I[J%U6.E=27M9*H$(R9&+(S8&'$PXF+$PXB/
MD0`C886(E6_22)H4'Y?[;*UEFQ9_**%:1&3:N$4,FI_!A"(3=*I%>"9-Z\KB
M%1:!B(E5+(S8&'$PXF+$*Y#;/%DT&;%<DH\5`HR$&(DP$G<BJDM$#J[N$N`.
MF;)3W<%:8J65>;V.Y08B)E:Q,&)CQ"D0.>1N6P:<BT4\C/@8"92J3&=TJI)^
MU"U6B&4BC,2=B.(0O2W_2B?TT$227\>>:>;L9E8%U+4SP8B)$0LC-D8<C+@8
M\3#BMR#&G&69@A:(K>4A1B*,Q)V(:A:>?^V>3O26O.N<IT@*J-,C,#5K%BIR
ME%.BOS&P+%R.C1$'(RY&/(SX&`DP$F(DPDC<B:@&H:7C$^L-':)N)$;F/#%2
M0.6W.,VN7:O$?*8WO^8Q54:(L,G**H@.(]H8<3#B8L3#B(^1`",A1B*,B,/P
M'V<GI$'D87=Y4OB87)Z3=7(X9(-M^BH.LL]HUU5%JT/VW^?B`"J+K[0EG>)M
MQ@-M2<=CF_&5OERUZ:SU)9W'(7Y<%4!GZ,^;YR3:7)[WIVQP2)ZH:I.1."9^
MD:?PY9MK>L[/.3^F5SH]G__Y0O\MD=!1-]KR#P=/:7HMWX@"JO^_>/@7``#_
M_P,`4$L#!!0`!@`(````(0#PAKG36P(``#X%```9````>&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;)14R6[;,!"]%^@_$+Q'M!8O,2P'<8.T`1J@*+J<:6HD
M$1%%@:27_'V'I"VX2=&F%TD4W[R9]V;(U<U1=60/QDK=ES1-)I1`+W0E^Z:D
MW[_=7RTHL8[W%>]T#R5]!DMOUN_?K0[:/-D6P!%DZ&U)6^>&)6-6M*"X3?0`
M/>[4VBCN<&D:9@<#O`I!JF/99#)CBLN>1H:E>0N'KFLIX$Z+G8+>11(#'7=8
MOVWE8,]L2KR%3G'SM!NNA%8#4FQE)]US(*5$B>5#TVO#MQWJ/J8%%V?NL'A%
MKZ0PVNK:)4C'8J&O-5^S:X9,ZU4E48&WG1BH2WJ;+C<%9>M5\.>'A(.]^":V
MU8>/1E:?90]H-K;)-V"K]9.'/E3^%P:S5]'WH0%?#*F@YKO.?=6'3R";UF&W
MIRC(ZUI6SW=@!1J*-$DV]4Q"=U@`/HF2?C+0$'X,[X.L7%O2?)9,YY,\13C9
M@G7WTE-2(G;6:?4S@M(3523)3B3X/I&D69(MINET]F\6%BL*`N^XX^N5T0>"
M0X,Y[<#]"*9+9/;*<O3GS\I0DH^Y]4$A%-$6N[%?%WFQ8GNT4)PPFXB94S)B
MLA'!,/E8`6:]K.#OF3WX9>;IR!NJVT3,/'3T,E'^/XD\&*VX*+_(\Q>)(J:X
MP,Q'Q&\2$?)VB1Y<4A0Q&E?DLY$W2HR8ZV!]FBS&W9@USG%LLP+3P`?H.DN$
MWOD933%J_!N/SP:/3Q;\&C=P?`?>P",WC>PMZ:#&T$DRQWDU\0#$A=-#Z,=6
M.QS<\-GB/04X)I,$P;76[KSP1VR\^=:_````__\#`%!+`P04``8`"````"$`
M2I:52OH"```O"```&0```'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R45<EN
MVS`0O1?H/Q"\1[OD!;:#6$':`"U0%%W.M$191"11(.DX^?L.25N;"]>]V"+G
MS>.;A</5_5M=H5<J)./-&ON.AQ%M,IZS9K_&/W\\W<TQDHHT.:EX0]?XG4I\
MO_GX877DXD66E"H$#(U<XU*I=NFZ,BMI3:3#6]J`I>"B)@J68N_*5E"2&Z>Z
M<@//2]R:L`9;AJ6XA8,7!<OH(\\.-6V4)1&T(@KTRY*U\LQ69[?0U42\'-J[
MC-<M4.Q8Q=2[(<6HSI;/^X8+LJL@[C<_(MF9VRPNZ&N6"2YYH1R@<ZW0RY@7
M[L(%ILTJ9Q"!3CL2M%CC!W^9SK&[69G\_&+T*`??2);\^$FP_`MK*"0;RJ0+
ML./\14.?<[T%SNZ%]Y,IP#>!<EJ00Z6^\^-GRO:E@FK'$)".:YF_/U*904*!
MQ@EBS93Q"@3`+ZJ9[@Q("'DS_T>6JW*-P\2)9U[H`QSMJ%1/3%-BE!VDXO5O
M"_)/5)8D.)&$H/YD#YQ@'OMQ\F\6URHR`3X2138KP8\(F@;.E"W1+>@O@?GO
M$4$H&ON@P<8%Q$JHPNLF"H.5^PJIRTZ8K<7,,.HP$T1ZB0B]CL0%79TX"'DH
M3J<]A.)=%ZF=QB*#14=OXMA:R,RD5P>6#C9&`B`C0P'7#]9@$#B(/`K#R<D6
M$PTPLS$BO888:0.2V[5I\!I#F'U5%O[XY*W%S&U=%XN)]'1HCJ,D[KQ'JJ"?
M;U>EP5-5DV[96DQB5/F!GR3=N::6Z<@>1[,^JI&NY']T:?!4UR0=6XNQNA;!
M?&).K3DRLL.@%ST2!;=DF*S;^EL[3<1YDR;:6HP]/8GZE-B4G:U],_3^(WWZ
M^;IY.&CP6%?8]XB]=Q9B.RR8>1=)&]G](.E[P<JR`]K.KYJ*/4UI54F4\8,>
MO@$DN]NU[\+67\)EAX$\V4_AO3#[;F>`>=V2/?U*Q)XU$E6T`$K/F4%_"3OQ
M[4+QUDR7'5<PJ<UG"0\SA3'B.0`N.%?GA7Y3NJ=^\P<``/__`P!02P,$%``&
M``@````A`$2^]B.S`@``"@<``!D```!X;"]W;W)K<VAE971S+W-H965T,CDN
M>&ULE%5=;YLP%'V?M/]@^;V8;Q(44C54W2IMTC3MX]D!`U8!(]MIVG^_:YRD
M@6Q=^Y)@WW,/YYYK7U;73UV+'IE47/09]AP7(]87HN1]G>&?/^ZN%A@I3?N2
MMJ)G&7YF"E^O/WY8[85\4`UC&@%#KS+<:#VDA*BB81U5CAA8#Y%*R(YJ6,J:
MJ$$R6HY)74M\UXU)1WF/+4,JW\(AJHH7[%84NX[UVI)(UE(-^E7#!W5DZXJW
MT'54/NR&JT)T`U!L><OU\TB*45>D]W4O)-VV4/>3%]+BR#TN+N@[7DBA1*4=
MH"-6Z&7-2[(DP+1>E1PJ,+8CR:H,WWAI'F.R7HW^_.)LK\Z>D6K$_I/DY1?>
M,S`;VF0:L!7BP4#O2[,%R>0B^VYLP#>)2E;17:N_B_UGQNM&0[<C*,C4E9;/
MMTP58"C0.'YDF`K1@@#X11TW)P,,H4_C_YZ7NLEP$#M1X@8>P-&6*7W'#25&
MQ4YIT?VV(.]`94G\`TD`Z@]QW_$7D1?%_V<A5M%8X"W5=+V28H_@T,`[U4#-
M$?128#:5!>#/WRN#DDS.C4D:4P&MH!N/ZS!P5^01+"P.F(W%)!B=,/X4D5\B
MSD@(Z#N)A-+?+](D347ZRZF"C84DH\VFL/QL8R(`G'F_`),$;IXY$`;>3('%
MA&>89(K(7T-,-`+)N<;7.VC`&89R7[JSB*=OWEC,8NROY\5^.(WG_XY/=,$)
M?[LN`Y[KFCFRL9APU'651'-9D[`?O_1\HBI^CRH#GJH*YXVTD(-9[B*970>8
M3H;B:&8012<SK2P[>^S5[)BL6<[:5J%"[,Q<\:'8TZX=>1LOA?,+LV:VG\,H
M'/?)*0"C:*`U^TIES7N%6E8!I>LDX)2TP\PNM!C&"[,5&H;0^-C`-X?!S7`=
M`%="Z./"C,O35VS]!P``__\#`%!+`P04``8`"````"$`PT;HWV0"``!C!0``
M&0```'AL+W=O<FMS:&5E=',O<VAE970R."YX;6R,5%UOFS`4?9^T_V#YO3@0
MTGP(J-I5W2IMTC3MX]DQ%["*,;*=)OGWN\8)HVLWY06P.??<<^Z]=G9S4"UY
M!F.E[G(:1S-*H!.ZE%V=TQ_?'ZY6E%C'NY*WNH.<'L'2F^+]NVROS9-M`!Q!
MAL[FM'&NWS!F10.*VTCWT.&?2AO%'2Y-S6QO@)=#D&I9,IM=,\5E1P/#QES"
MH:M*"KC78J>@<X'$0,L=ZK>-[.V938E+Z!0W3[O^2FC5(\56MM(=!U)*E-@\
MUITV?-NB[T.<<G'F'A:OZ)441EM=N0CI6!#ZVO.:K1DR%5DIT8$O.S%0Y?0V
MWMREE!794)^?$O9V\DULH_<?C2P_RPZPV-@FWX"MUD\>^ECZ+0QFKZ(?A@9\
M-:2$BN]:]TWO/X&L&X?=7J`A[VM3'N_!"BPHTD3)PC,)W:(`?!(E_61@0?AA
M>.]EZ9J<SJ^CQ7(VCQ%.MF#=@_24E(B==5K]"J#X1!5(DA,)OD\D21JER6*Y
MNH"%!46#P7ON>)$9O2<X-)C3]MR/8+Q!YK.SH&/T^B^KZ-&3W'J6G"XI01<6
MV_-<I,EUQIZQIN*$N0L8?(Z8>$0P5#-*0AE326\7^9S9@WUF7W0OY2YL3-,D
M;Z>9OTSCG<]Q,OZ?S@<A;F(B398C?U`0,.D$\P?QPBA"ID8O4^"#<HHNQS*F
MR>HO!0$S59`FZQ$3-(1A#[.@P-3P`=K6$J%W?I!C;.*X.YZQVV0X)N,/G/&>
MU_"%FUIVEK108>@L6N)0FW!*PL+I?IBTK78XW<-G@Y<98+]F$8(KK=UYX<_A
M>#T6OP$``/__`P!02P,$%``&``@````A`$V^A?MO!@``:B$``!D```!X;"]W
M;W)K<VAE971S+W-H965T,C<N>&ULG)I;;^(Z$,??CW2^`\I[(0F!`"I=+83[
M_7;.<PH!H@6"DG2[^^UW'&,:C],,755J8?SS/^/QC./$??[VZWPJ_/3"R`\N
M3<THZEK!NVR#G7\Y-+7-NOM4TPI1[%YV[BFX>$WMMQ=IWU[^_>?Y/0A_1$?/
MBPN@<(F:VC&.KXU2*=H>O;,;%8.K=X&6?1">W1B^AH=2=`T]=Y=T.I]*IJY7
M2V?7OVA<H1$^HA'L]_[6<X+MV]F[Q%PD]$YN#/Y'1_\:";7S]A&YLQO^>+L^
M;8/S%21>_9,?_TY$M<)YVQ@<+D'HOIY@W+\,R]T*[>2+(G_VMV$0!?NX"'(E
M[J@ZYGJI7@*EE^>=#R-@82^$WKZI?3<:&T/72B_/28#^\[WW*/6Y$!V#]U[H
M[\;^Q8-HPSRQ&7@-@A\,'>R8"3J7E-[=9`;F86'G[=VW4[P,WON>?SC&,-T5
M&!$;6&/WV_&B+4049(IFA2EM@Q,X`+\+9Y^E!D3$_97\??=W\;&IE:O%BJV7
M#<`+KUX4=WTFJ16V;U$<G/_GD'&3XB+F301ZW$0,LVC6*D:E^@65ZDW%OJN8
M>M$V]'K9?MP5R.MD//6[R-^X`C-V"PLX=1N2:1=KE8I5K7W!&P/&PL/[X<_?
MQ%>X8\(\"'>L1V-3XE.>9)#CQN[+<QB\%Z`L02RZNJS(C093%KG#9_J>39\E
M$V014_G.9!(QR),(*N#GBV7JSZ6?D+7;&]/B#$3CSMB6C+0%PG*4Z3K"\-''
MD+MT!"&Z=+&AAPU];!A@PQ`;1MS`,YXY-L:&B>CRJ:=300A/9]@PQX8%-\#O
M3T.V%'T^$!2AE2#$==="51@VPI"E48)$N6<+%+F2+65(S.R51B0'ZR4GAUF7
M9['%D71NF#+15@F[(B..BB"1CDI@D2Y'("+WD".1GDI@D;Z*()&!2F"1(8V,
M5`1=9ZP29527$Q5!(E.5P,[.5`2)S%4"BRQ4!(DL26)%$FN2V.014CV4_ZH>
M6"]6#Z+^6MQ@WPUM;'"PH8,-76Y(YZUEHI6@]P#35YEJ6:ZS`8T,5<324=Z-
M'F#&#S"3!YCI`\SL`6;^`+-0F7(-Y_$#S.H!9JTREHFNM<EGI'RV4#[GK^N,
MEO*8&U)YC`T.-G2PH<L-'\71PX8^-@RP88@-(VP88\-$&#Z6?:5\I@\P,Y7!
MY3.GD85`Q`JQQ(:5,.3XNQ:,4-D(0W8G*1-@MRW=Z?,S@='PU)"Z:5HF6C5:
MG`$7[C=66UY7VB3AD$2')+HDT2.)/DD,2&)($B.2&)/$A"2F)#$CB3E)+$AB
M21(KDEB3Q":/D`H`'OJ^4`",;FJP;[@GMV6BAYL69_(*@"0<3M22)ZQJW2JC
M.WPGW6Z8[`%>KK$N>8D>2?1)8D`20T[P@60Y.DH#Y7JE7I,',DZW5ZQ:!45[
M0KHP)8D92<Q)8D$22T[<0F%5;+0LKDB%=5H!8B5':I/77TIY>/R24IZ]"Z"?
M[E@O.?4-G)8MSE23M#4L'>U0VNGF)Z-JX<ET),`T]`IZ?NRD@6H-?N08=-/M
M3QD"O320(=#G[3G%.R")(4F,2&),$A-.\%@_0;!Q/DW30,909^0EYB2Q2%^#
M.8'V_DNIW5;:5W)[&8]A37JP$01[%Y6N"2GCV1MP_/;+@EM$_FZ']9(SWM+1
M0MSB3$Z^M$G"(8D.271)HD<2?4Z(C#)L5'R#='M9+Z/U:TA>8$028Y*8D,24
M)&:<^'2@\W2[.M`%>8$E2:Q(8DT2FSQ"2G]X(2VE?W[:,UI.>]-&*WF+,WEI
M3Q(.270X(>9)+]=JZ)[7)35Z)-$GB0%)##F1X^F(U!B3Q(0DIB0Q(XDY22Q(
M8DD2*Y)8D\0FCY`*@)WQ?*$"$EPN`0OOL%LWB._G+-NHHP?AM@34]3I^0>!(
M0(9"1P(R%+HW(*<.>S32IY$!C0QO"(]'AK,C"<C:ZDM`UEZ?]F)*(S,:F=/(
MXH;PX=IP$B[O1)=$^XJ^Q%J22.]MDC,S=M3,%NKLR>?ISX^2^4'@V0L/7ML[
MG:+"-GACQ\3,][N5'V&WC`8<SL&+)&1WC`8<EJGVB=&`TRS5OC0:<!ZEVEMF
MHV5EV-MFHYUE=\P&O$M4=3IF`UXI@KUT=Q1.NJ_NP9NXX<&_1(63MX<APJ$R
M;/-"?E;.O\3!-3FD>@UB..-./A[A?QH\..W3BP#O@R`67]@%[O\E\?('``#_
M_P,`4$L#!!0`!@`(````(0"I3&D<;`0``'84```9````>&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;)2878^J2!"&[S?9_T"X/T(KXF#4DR,PNR<YFVPV^W'-
M8*MDA#8T,\[\^ZVF&`_=.-5X(Z(/K_U6=7>5O?KZ5IZ<5U[+0E1KETU\U^%5
M+G9%=5B[__S]^.7!=6235;OL)"J^=M^Y=+]N?OUE=1'ULSQRWCB@4,FU>VR:
M\]+S9'[D928GXLPK^&8OZC)KX+8^>/)<\VS7/E2>O*GOAUZ9%96+"LMZC(;8
M[XN<)R)_*7G5H$C-3UD#XY?'XBP_U,I\C%R9U<\OYR^Y*,\@\52<BN:]%76=
M,E]^/U2BSIY.X/N-!5G^H=W>#.3+(J^%%/MF`G(>#G3H.?(B#Y0VJUT!#E38
MG9KOU^XWMDQ9Y'J;51N@?PM^D;WWCCR*RV]UL?M15!RB#7E2&7@2XEFAWW?J
M(WC8&SS]V&;@S]K9\7WV<FK^$I??>7$X-I#N.3A2QI:[]X3+'"(*,I/I7"GE
MX@0#@%>G+-34@(AD;^WU4NR:X]J=A9/YPI\QP)TG+IO'0DFZ3OXB&U'^AQ#K
MI%!DVHD$,/KN^^ED^C!G\_`.%?B]=BAP_:DR<B@>VFJCE&1-MEG5XN+`U(.!
MRW.F)C);@K`*3P#7V^&!N*AGOJF'VD>!EI#3UTW`YBOO%?*0=\QVR$QU(AX2
M,U]'DB&R,'XG'2*S>725\<#FU2NDH>^5]JA@2+;K7#U.@^"JV\9ABPQD]<HL
M="*V$HF52"E"\P>#'>]/P6L7M*]CGP9&;+?(/&"&%RR:^;Z1H;B/A%$P8P,D
MZ2.1'X5#E;2/L*E:6WT9S21$>[Q)!9LF0SU%6V2H)"(1MF%@00A#,\.06$52
MBM`,PNH;;U#!NL&`F0:1H0Q:B<1*I!2A^0OO\:=@<Q4:^\@6&<J?E4BL1$H1
MFK_%/?X4;.;/V$.VR'33C\W4TC#G7]QGPD`M0A-)$"'"E%*$9E$U1[VB06^D
M"C93:&ZDR!!CBZU$8B52BM#\1??X4[">PN%&B@RF<!;=VD'B/C(/HEL91(2(
M4DH1FD,&C=3X%+:TZ='<9CH(32Z@S1U,P5A#/ME).X9R22*Z3=4=C)ZI#'L)
MO2::J[&#T&9PTR7*$`Z23H1`4A+13:H&H6=2]7`SR"^]+!FV%7VS`7LP:F,'
M$>.,[4AB1U(2T=VJ7J'GUN(2.PMX[;4Y9@%A")$NK4AB5TE)1'<)@[G#I:+U
M]1FPP<1%B*XCK`]]4D@Z!LAK3(W?2DE$-ZKZAEXZ1TY>[#;TR?NSZ\?N7/W-
M@Z@0XXSM2&)'4A+1W:HNHN?6,GFQY]`GKUDZ&=68M(&([4AB1U(2T5VJ1F*\
M2VP[^KD<%E"&$%E!->:3$MHQQ)Q(243WJ1J*\3ZQ_=!]#HHH0F01[2.?%5%D
M2)L4HMM47<5XF]B#Z#:-_6$+)SYJ:7;_+&\64:J5::=UTHF0)BD5-(DG1W@F
M<LX._(^L/A25=$Y\#]N;/UG`+E+CN1'>-.+<GGT\B0;.>]JW1SC?XW`PXD\`
MW@O1?-RHDZGKB>'F?P```/__`P!02P,$%``&``@````A`-?B+=63`@``WP8`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C4N>&ULE%5=;]HP%'V?M/]@^;UQ
M$D*@B%`5$%NE39JF?3P;QR%6XSBR36G__:YM2@ETB+X`QN>>G'/NM3.]>Y8-
M>N+:"-46.(EBC'C+5"G:38%__UK=C#$REK8E;53+"_S"#;Z;??XTW2G]:&K.
M+0*&UA2XMK:;$&)8S24UD>IX"SN5TI):6.H-,9WFM/1%LB%I'.=$4M'BP##1
MUW"HJA*,+Q7;2M[:0*)Y0RWH-[7HS"N;9-?02:H?M]T-4[(#BK5HA'WQI!A)
M-GG8M$K3=0.^GY.,LE=NOSBCEX)I951E(Z`C0>BYYUMR2X!I-BT%.'"Q(\VK
M`M\GDT6.R6SJ\_DC^,X<_4:F5KLO6I3?1,LA;&B3:\!:J4<'?2C=7U!,SJI7
MO@$_-"IY1;>-_:EV7[G8U!:Z/01#SM>D?%ERPR!0H(G2H6-BJ@$!\(FD<),!
M@=!G_[T3I:T+/,BCX2@>)`!':V[L2CA*C-C66"7_!E"RIPHDZ9YD`.KW^\,H
M2X>C\14L)"CR!I?4TME4JQV"H8%GFHZZ$4PFP.R<#2"?]YV!)5=S[XI\*:`-
M=.-IEB7IE#Q!A&R/F9]C1ED?LCB')`<$`7T'D6#]XR)=45]D>GN@]S[F[T#Z
MB,4E1$\B9/=QB:X(\L;H*,=!7\$\8+(CS*B/6%Q"]#0"R;'&RSUVX`*#_X.V
M-,[[3YX'S-A/P"`?GXS`XG@;IO3-64\5G(!C5==-H"LZ57>2RSQ@,J\NS]Y&
MR_=^\;_=GK:\K^UR8@[<UY0E)R,_#Q@(YI#JB6JXQAQ+R'2<#=\(@K!P1X4C
MW-$-_T[U1K0&-;P"RC@:@2\=;JBPL*KSIV"M+-PL_F<-+Q(.YSB.`%PI95\7
M[@X\O)IF_P```/__`P!02P,$%``&``@````A`(AL#:F=`P``S0X``!D```!X
M;"]W;W)K<VAE971S+W-H965T,S,N>&ULE%=;;YLP&'V?M/^`>"]@0H!$2:I6
M5;=)FS1-NSP[X"16`2/L-NV_W^=+N.8">4A"<GS.=^-@K^[?\\QZ(Q6GK%C;
MR/%LBQ0)2VFQ7]M_?C_?Q;;%!2Y2G+&"K.T/PNW[S>=/JR.K7OB!$&$!0\'7
M]D&(<NFZ/#F0''.'E:2`?W:LRK&`RVKO\K(B.%6+\LSU/2]T<TP+6S,LJS$<
M;+>C"7EBR6M."J%)*I)A`?'S`RWYB2U/QM#EN'IY+>\2EI=`L:49%1^*U+;R
M9/EM7[`*;S/(^QT%.#EQJXL!?4Z3BG&V$P[0N3K08<X+=^$"TV:54LA`EMVJ
MR&YM/Z#EHQ_8[F:E"O27DB-O?;?X@1V_5#3]3@L"U88^R0YL&7N1T&^I_`D6
MNX/5SZH#/RLK)3O\FHE?[/B5T/U!0+OGD)%,;)E^/!&>0$6!QO'GDBEA&00`
M[U9.Y6A`1?"[^CS25!S6]BQTYI$W0P"WMH2+9RHI;2MYY8+E_S0(&2I-XAL2
M^#0DR'?\>([FX6T65T>D$GS"`F]6%3M:,#6@R4LL9Q`M@5EF-H/ZG,\,4I)K
M'N0BM130'-KQM@G"8.6^00D3@WD<8OP:X8)X'0&HMB.XKBS!$*%MM93G-:^*
M[E%C@A8FJA$=9:`9KRS!:QNX:V5_$=>\6EEC0E6118S"V`]K1$<9@ANO+,%=
MY2#H*VM,H)21$S3-Z,C"L(V7E>">;-BDHQ/6F!&E#J<H2_"M)FO,".5HBK($
M=W,>-EEC=)-1-/>\\RV6WM^ZL:Z/M01W=8<MUAC3XLB)%YW7^2`64X*0X%X0
M87/GZ(9K3+OL0=C,8F?8$-C(^`HH=%]]46>EU0VH+=\$V!7O^=KU\B-M5M=M
MQ8#&B$^R-*3]ZKJS&)"9NC`.XOA2V2>Y&AK:VG#R#,B,7MV3;L&A+A.Z+=']
M;C>M--W6H';!@^C"W2:?QA/DSWA;A.K$C/QH<T.3W$VA;]F;`;5S;\K3+?PD
M@T-C',Z`]+!%01S-+@[;))=#8VS.@$Z/LN;AWLUZDK.A,=9F0.V2!]&E/<LD
M;_,ENC?M@W$SH+;\A8[[D[Q-H6^-FP&-$9_D;?X8;S,@/6ZA'WGS"S>Y/\G:
M%+I7]<&^R8!N3!N<+2:XBT+WA`</4@-J5WPX;?I`HO?K)=Z3'[C:TX);&=G!
M+M1S(K"H2A]'](5@I=J7;YF`8X3Z>H!C(X%-N^<`>,>8.%W(`T]]$-W\!P``
M__\#`%!+`P04``8`"````"$`RUBOJF\0``"XE0``&0```'AL+W=O<FMS:&5E
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M4K%EU_?_F,O-G=BEHIOC]EG1T]WJ2:R`^/OH^;$X-L0N6?R]^_?WX_WVQTVK
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M$O-P488JK+TH,ERLG;WO==_@[!MJ5L4]-/JJ#`Z)MBK#O=@O>;1O>%NR]A)/
M"F57ZKO)WYM]M^-]M_N&R;[A;3GZV@>'1%N5\%!TSK4?QW1O]DN.9,/N1+[;
M^['>D.@-J=Z0Z0TSV2#^?CUV],V9'Q)M<_)#H7?2*P_D]PMZZ^5$9.8U."+-
M2G"JAY%]/@I=Y&._E_K[AK<-ZNHK<WMHVNJ1;J*P#L7%F=J)?4@ZIRIQ)'F_
M5P[6UCTTVMH.4`P/A;XJHT.B+<8[%-V+<W6#_"ISI9KQH=&6-$$1H`@/A;[)
MTT.BK4AT*/1.8B8)DY1)QF1V2+0-FJ/(4?1Z=43)LAA;E2P7@V!'S(KJ,UV\
M2LFTWG"K-YAZ@Z4WV'J#(QO4Z&D)=AN800,S;&!&#8Q792[4=/D-S+C"7&JG
MIDF5>3ME[T:@H($)JXQV5$X;F*B!B1N8I(%)&YBL@9DU,/,&)F]@Q#7>+C;*
M`7WYMJ.57(JI_"=R6;Q*R:7><*LWF'J#I3?8>H,C&^3573')=/6&@=XPU!M&
M^X:W28"6;.]0="^T.;/?P(RKC+:L20,3-##AWNSG.M-]P]MF=B^UBX.H@8FK
MC#8=31J8M(')JHRVPV951IMHS!N8O,IHI\M>KQXIL1&W(Y38U`]CA1;#W;NI
M=?=2.\3ZTHA5>)M^JZ?S6Q0F"@N%C<)!X:(8H!BB&*'P4/@HQB@F*`(4(8HI
MB@A%C")!D:+(4,Q0S%'D*'J].J*D6=S&4M+<;'):O.JF)6;`KXGM7FH7.'UI
MZE*-PD1AH;!1."A<%`,40Q0C%!X*'\48Q01%@"*4XG)WL\XX+?^H9_4I]A*A
MB%$D*%(4&8H9BCF*'$6O5T>47(L[?)_(=?$J-=>=2VT.U)>F+M<H3!06"AN%
M@\)%,4`Q1#%"X:'P48Q13%`$*$(ISF6NSZISC;U$*&(4"8H4189BAF*.(D?1
MZ]41)=?%`V/]B0K?3"I>I>:Z>Z7=ZNA+4Y=K%"8*"X6-PD'AHAB@&*(8H?!0
M^"C&*"8H`A0ABJD4,OF7N^"KPWGT'K3EJ4$5\7LAN]`.PN2]V$\;U$Y2A91G
M()5D"NG(DY1*9I+4'.US%#F*7J^.*+F^TG)=?U5=:#W/VFW)OC0U6WB+PD1A
MH;!1."A<%`,40Q0C%!X*'\48Q01%@"*4XDP^+#?..]K5V11[B%#$*!(4*8H,
MQ0S%'$6.HM>K(TJ6#?%P1QFDZ\.\XVJ:._H=S'Z)ZN+,Q&1B,;&9.$Q<)@,F
M0R8C)AX3G\F8R81)P"0L23D+[U;/PKF?B$G,)&&2,LF8S)C,F>1,1)U&D>";
M5G7:U*R+1TU*UIO=0"O*V@Y&\+?G5+L'B_T25:_%CMPR,9E83.R2[`^Y\XH)
MH,/=N$P&3(9,1DP\)CZ3,9,)DX!)R&3*)&(2,TF8I$PR)C,F<R8Y$Q%YF<CJ
ML*F1+RH_WE^#P_`N"T64F^57V@/*?E&>^J\GG#+JDL@$7HCZ;O%'O:@QRUYJ
MB,4+LIDX3%PF`R9#)B,F'A.?R9C)A$G`)&0R91(QB9DD3%(F&9,9DSF3G(E(
M>EW6U*07U23OD]YP<)=%*&KB]=OH11TZ)5Z2_9A;F?CWY$+.!-63@L4+LIDX
M3%PF`R9#)B,F'A.?R9C)A$G`)&0R91(QB9DD3%(F&9,9DSF3G(E(?%W6U,2+
M\5])/(SM!5<OW;M76B%/OWC/""4=B<F]6$QL)@X3E\F`R9#)B(G'Q&<R9C)A
M$C`)F4R91$QB)@F3E$G&9%82.9"U+RH&LKE"KJI(KI"J"U`1=)FC<D':'%D-
M>E$A\XFA71;6J$.[5I77+][W1X%'8G(O%A.;B5.2<II1_4S7Y7X&3(9,1DP\
M)CZ3,9,)DX!)R&3*)&(2,TF8I$PR)C,F<R8Y$Y'YNBBIF2^J9SZ1>5ETHV9>
MJZ#M%^\'I<PC,;D7BXG-Q"G)>6?W@*ASO$_][M1\>MJQ_M!N1KK<Z8#)D,F(
MB<?$9S)F,F$2,`F93)E$3&(F"9.42<9DQF3.)&<B3@!UN5)/`$69S?L3`,SN
M956.&GR]>-VH*]TI[]PA,;D7BXG-Q*D@W2OMX;!;@;3SW8#)D,F(B<?$9S)F
M,F$2,`F93)E$3&(F"9.42<9DQF3.)&<BLEX7)37K1>G-![(N*W7>9UV,B>JM
MM'[Q:0LTR",QN1>K)/L[?]V.45SOJ&MC<S_.03\5EUXN]S-@,F0R8N(Q\9F,
MF4R8!$Q")E,F$9.82<(D99(QF3&9,\F9B+37A4E->U&<\S[MQ9WZKK@R@!%>
MUO2HJ=<+Z8RZPI]RA$=B<B\6$YN)P\1E,F`R9#)Z)<5GMAA&Y[A[<:9=6'BO
MYNW-1-IDPV<R9C)A$C`)F4R91$QB)@F3E$G&9,9DSB1G(B)?ER0E\FV]RJ[9
MP[G=R]1;]F>GVC'9+Y&XF_CZ!C?MF+QE8C*QF-A,'"8NDP&3(9-12<JIR\5I
MVVCKGZK@<3<^DS&3"9.`2<ADRB1B$C-)F*1,,B8S)G,F.1/Q02J-B^W:GRNV
MV[U,C[Q>@5.BVLC7E0CM)@(F]V(QL9DX)=D7>!NGVE-'E_L8,!DR&3'QF/A,
MQDPF3`(F(9,IDXA)S"1ADC+)F,R8S)GD3$3>ZV*D#O%B8GXPJ^=WNQ6?A2@N
MT]59O5Y_4Z+:O,M^:HC)O5A,;"9.2<J\7[;;VGU(E_L8,!DR&3'QF/A,QDPF
M3`(F(9,IDXA)S"1ADC+)F,R8S)GD3$3>ZV*DYKVHT]&OXAOD79;WJ'G7QL-^
M\1&G<.^N)'+JVFU75=.9#8S%B[*9.$Q<)@,F0R8C)AX3G\F8R81)P"1D,F42
M,8F9)$Q2)AF3&9,YDYR)R'Q=VM3,B^'U,YDO7J:/\7HA3ENBF@'\EHG)Q&)B
M,W&8N$P&3(8E*9_^GQV73_WW_QC6']K5T8@[]9CX3,9,)DP")B&3*9.(2<PD
M89(RR9C,F,R9Y$S$":`N>NH)H*C?^<2@+\M^U$%?NTG7+SZO7IPER@-=N[%_
M6_YOS>G!9&(QL9DX3%PF`R9#)B,F'A.?R9C)A$G`)&0R91(QB9DD3%(F&9,9
MDSF3G(D(NXQ9=9#4L!>U.I\(NRSQ4<.N70'WVW5U0/(Y'1.3B<7$9N(P<9D,
M2B*O6=J=J@]F&7(W(R8>$Y_)F,F$2<`D9#)E$C&)F21,4B89DQF3.9.<B8A\
M7=C4R!<E.^\C7_](OO@U(0<3>ZU`K5^BZA-.&?6Z2J'R9CT2BQ=D,W&8N"4I
M'YNUS[7W+NQ6>-`$#7EA(R8>$Y_)F,F$2<`D9#)E$C&)F21,4B89DQF3.9.<
MB4A[75+4M!<E.Q](NZSP409V0RMTZ[?KRH#*M",QN1>+B<W$8>(R&520,T.[
M@AE6(.T2:,3$8^(S&3.9,`F8A$RF3"(F,9.$2<HD8S)C,F>2,Q%9KXN2FO6B
M5N<#69>E/6K6#RIOZNI_RJPC,=M(+"8V$X>)6Y+R'L3IL=$5!??O_ZAEO8,/
M^B&OPHB)Q\1G,F8R81(P"9E,F41,8B8)DY1)QF3&9,XD9R+.`77Y4<X!Q=.Y
M#YP#=ER[;6]H-YO[):J;W3,QF5A,;"8.$[<D<G9?=8T^0#'DQ8R8>$Q\)N.2
MR.WI7%6\JV#"O01,0B93)A&3F$G")&62,9DQF3/)F8C?EM2X]*ZCE][57\7O
MN)YSO02G1+4YKZL5DE?QW(O%Q&;B,'&9#"K(X;R^`NGS>B8>$Y_)F,F$2<`D
M9#)E$C&)F21,4B89DQF3.9.<B<AZ7934,5U,T94QO5EE?:=XF9YYO0RG1+69
ME_W4$)-[L9C83!PF;DG*.W?=,_EYX]JDO@D:\L)&3#PF/I,QDPF3@$G(9,HD
M8A(S29BD3#(F,R9S)CD3D?JZ,*FI_USQ7:>B^,[0"W%*5!/I6R8F$XN)S<1A
MXI9$IOZL\FZ]0HS*WU0PY"6-F'A,?"9C)A,F`9.0R91)Q"1FDC!)F61,9DSF
M3'(F(O*-:^\Z(I"?&>B+E^D#O38_[>_Z_K>/T)8W\IB83"PF-A.'B5N2<J"O
M'N;EGJFY+A[R@D9,/"8^DS&3"9.`2<ADRB1B$C-)F*1,,B8S)G,F.1.1>'G8
MB;\KWJZJ#O*?*[;K5!3;&7K]38FJUZ),?%VA4'DYC\3B!=E,'"9N2<HX5P_R
M<G4EN:HB0U[0B(G'Q&<R9C(IB=RBJ@]B#!1A5-W]"WDY4R81DYA)PB1EDC&9
M,9DSR9F(P->%1`V\7G`']^TJ"NT,O?JF4U?[4P9=$GD0&:=7I\4O\U*OB<VR
MFSIC\:)LI9NVG(JK2W*X%U?IQ9"_>DSM9<!DR`L:,?&8^$S&3"9,`B8ADRF3
MB$G,)&&2,LF8S)C,F>1,1-;KTJ9FO:C2:?X\OB.+>L0-@M=9@TB/>M#W2U0[
MJ-<5!Y6#NB3RUP&?R5\.J"[(*A<D2?O"*.;7*K%Y71PF+I,!DR&3$1.O).5&
M5WVFL<]DS`N:,`F8A$RF3"(F,9.$2<HD8S)C,F>2,Q%)KPN23/K)YL=RN347
MV\77+\_+]??E[?+I:7-TM_KU(D)\)3[-];7U:+U\N&GUC.M>MW5RT&X:UY91
MT>X9UWY5>V1<9U7M_?9UOZK_V_;U;56[V;XVJ]JM]K55U6ZWK^U=^\GKAFV^
M?OFY^+[T%^OOCR^;HZ?E@]CTT^,+,2=:/WXOGE7(;[:KGS<M\=#CVVJ[73WO
MOORQ7-POUP40^&&UVNZ_$3OHY/=J_>=N]W[]OP````#__P,`4$L#!!0`!@`(
M````(0`_C"$OV@8``)8J```9````>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM
M;)S:6W.B6!`'\/>MVN]`\3XJ*+E5DJE1!$%0Q+T\$\5(C8H%))GY]MM'+N$T
MA#[N/(RQSX^6RQ^4R^/W7\>#]!XF:12?GF2E-Y"E\+2)M]'I]4G^^R_CVYTL
MI5EPV@:'^!0^R;_#5/[^_.<?CQ]Q\C/=AV$F08=3^B3OL^S\T.^GFWUX#-)>
M?`Y/,+*+DV.0P=ODM9^>DS#87B8Z'OKJ8'#3/P;12<X[/"0B/>+=+MJ$>KQY
M.X:G+&^2A(<@@_E/]]$Y+;L=-R+MCD'R\^W\;1,?S]#B)3I$V>]+4UDZ;AZL
MUU.<!"\'6.Y?RBC8E+TO;QKMC]$FB=-XE_6@73^?T>8RW_?O^]#I^7$;P1*P
MU2XEX>Y)_J$\K)61W']^O*R@?Z+P(ZW]+:7[^,-,HJT3G4)8V["=V!9XB>.?
MC%I;5H*)^XVIC<L6\!)I&^Z"MT/FQQ^S,'K=9["Y-5@BMF`/V]]ZF&Y@C4*;
MGJJQ3IOX`#,`_TO'B$4#UDCPZ_+Z$6VS_9,\O.EIMX.A`EQZ"=/,B%A+6=J\
MI5E\_#='2M$J;Z(63>"U:*)HO9&JW=Y=TV58=('7JHOP+(R*B6&FBXE5Y>KE
MN"F:W%9-%+6GWFF*=G/%VH!=Z[)*X;5<CKOKN]P77>"U[/(_YD6!0.7;]W.M
MJO<]932X9HD@P$67VNJ]N[I+N7J5SV42GI=^GMO+;J`'6?#\F,0?$AQ;()GI
M.6!'*N6!-2YW@#RNU2[QU1X!NP+K\H.UN32#L*>P&[\_:ZKRV'^'76]3F''3
M(#$I!=O/6%L]+T">JK9HDFDIRDD,7#!Q888+%B[8N##'!0<77%Q8X,(2%SQ<
M6.&"CPOK6J$/&[#:BG#DX+9B^^&KW%A,\QMK--30QFH:E1>3IM#4$6_TID%=
MIJ0P2&&28D8*BQ0V*>:D<$CADF)!BB4I/%*L2.&38MTEN/C"P?6*^#+-XEON
M\N.R\'F4T%24LXF`T=L,VB^F`L9H,[?\GF&VF3O>S-K,/6^L%C,<\,9N,^@X
M.A<PCH!Q!<Q"P"P%C-=FT/9:"1A?P*R[#9=F^+:_(LU,<VDN"_4T#_DM.A$P
MNH"9-LWP%B7,:!I-1?-C"IA9TS0^RVJ:QF?9;0;M[7,!XP@85\`L!,Q2P'@"
M9B5@?`&S[C9<FN$GZQ5I9II+,RY,<$$O"_6\W_!YG[89E$&C-.77@HD+L[)0
M_R34Q2I-V<4N"[6)ACAN`L9I,^CGDBM@%DW3V(V6`L9K&@TOUTK`^&T&+=>Z
MVW!Q@Y.<*^+&-!<W7)C@@HX+4UPP<,'$A1DN6+A@EX5::O!!<]YBABB.3HO!
M?=P6@_LL6@SNLVPQN(_78G"?58O!??P6@_NL6TRM#Y<:.$/D4L/.8H=P[MY]
M'L2F`E<[N]2&Z,@SS@T<+ZLS4/1+;D(*G1134ABD,$DQ(X5%"IL4<U(XI'!)
ML2#%DA0>*5:D\$FQ[A)<B-DUY?JEF.[P,OTDPRE6%4QMB*(YSDU7>$FAEX)=
MTT'?>]-R[',>T!P8I#!),2.%10J;%'-2.*1P2;$@Q9(4'BE6I/!)L>X27&SA
MHN$5L64:QQ:=]XYSTQ5;4NBDF.;B_G*Q<M!#YXT&.;U)BEG]$^#B\SWW#RVT
M1;:S23$GA4,*EQ0+4BQ)X9%B10J?%.LNP6687>>_(L07CE.,SIO'!>J*,4WT
MBK#CK])3!MP_=!5GRFD<Z6KPR\.U29-912XSA#[#JD:__`R;)G.:.#1Q:;*@
MR9(F'DU6-/%ILNXD?*#9G0+Q'Q-*?F.!^S4Q0I<1QP7J#'3>IX/H=)<I38R*
ML!2.>NA@:G+#@Q[:36;5\)<IM2K"/N`&=["KX2\[S&GBT,2ER8(F2YIX-%G1
MQ*?)NI/P(68W$.HA%CNM4_+[#GR8403&!>I(ZH0F.DVF-#%H8M)D1A.+)G9%
M6.[A'C5_(6[.#:.#O\,--J9UN6$T[8(;5&"'Z_J>6_(:':@\?E3%"['BQF_Q
M3S^?&X8G&-`Z6'/C]<GY\+([!O7P=I_.*?D-!CZTZ'QK7*#.T.9]1I>?M8K2
M0]<S=+K%E"8&34R:S&ABT<2FR9PF#DU<FBQHLJ2)1Y,537R:K#L)GV;(W#5I
M9AS]0!ZA:YMC]E@,H"_.P";%<$?8=9I,:6+0Q*3)C"8636R:S&GBT,2ER8(F
M2YIX-%G1Q*<)>TR0Q:D]+WF8\\<`\^>?CF'R&D["PR&5-O$;>\1/A6-F5<T?
M/]25!W@Z".X%H;K-'DMD]7XU`$\%GH/7T`V2U^B42H=P!RT'O5NX]Y'DSQ7F
M;[+XS.Y82"]Q!L\#7O[<P_.?(3SN!%<A9&D7QUGYAGU`]43I\W\```#__P,`
M4$L#!!0`!@`(````(0"Z_283:P8``,X;```8````>&PO=V]R:W-H965T<R]S
M:&5E=#(N>&ULE%G;CMLV$'TOT'\0]!Y;)'5=K#>(%*0MT`)%T<NSUI;70FS+
MD+39Y.\[U-`F9V1[I9=D+1Z-#F>&YU#BX\?OA[WWK6J[NCFN?+$(?*\ZKIM-
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M-C\^5]T:,@IA%C+2D=;-'@C`O]ZAUJT!&2F_#_^_U9M^M_)5O(B20`F`>\]5
MUW^I=4C?6[]V?7/X#T'"A,(@T@11P-Z,RX5,(Q'%[T=9(J-A@I_+OGQZ;)LW
M#[H&GMF=2MV#X@$BZYDIR,_UF<&4]#V?]$W#K8#NH!S?GF3ZN/P&&5P;2(Z0
MQ/<LA"**,4(%%\@2Z%TXPLSG<]0W,8[9)?PPC1PAR9!E/:_"N4`(0&)<`O>3
MH\&01&?F2K`'(R1T(`E%%/<0A!H$F4Y-@U<^S/)2%"7I@W.$I%A4&:5I1`$%
M`<2!#&T$0@P:>SHQ#6;$%'UNCI!X(";"P+;*4,L"AX'<96HVI817/(>7!C->
M(>.%$.2E$LE*7>#P!%ZP5*;G2X,9+U:G'"'(2R9!RO)9D'$AXQMEU!;FZ,/]
MUM=@1BMFZ4)(.)0Q4VRTH*,W*IC-H:3!C)(-BS*`$%/!2+'A@@S+R.:1M)4`
MT9R>J`'-:(T45$=<^::"H/%.B;#G312#2*,XL\U)R3&5OU]%@<I,9()+I\%@
M'>.0UY$,I\(N"DI+Z^WDYA*HSH06>VYN,)@1$8;*5LND#(,@(`W"6PG3^CN=
M&:JURRQD^I0+Q."#(Z78<BW(>)A%MU*FY7<Z,11K0LP&QNX7B#$I"]*$,2\H
M0*C(4J?5G*7X>OO$%J;C)(::J_DR4^FXSUR$$D%ZD]PLV1>HVE"RBYN$K)-R
M@[FN[*;9)HN_F*7^`YJJA]/()G>NOL=RO!#<<9&$D94?6M59!B#&#A#:=C',
M$'-NN"Q@'5F8(`B0D;0-29G-\@$Q-@+>3;G!&&:QX$Y@QJ^7G'"3L]Q@0+-Z
MLF?G!F.XR2BT]<)F(X!(RAO*)F=9P8!FS-B#<X-!9O!&DS&O*`A`U_/&5D-J
M;9ZL;0.:[K-#]N3<8*X7S*0-#>$ZA-9TEB?(L2=$MI%Q)1B,J6D8*<'\K*`(
M%4HG!B4'$YB1.XVF974,QY!##))+$R58<@M)`/`::A624IOE"_I5EE.S_6*H
M(08W'^[NPI24#MN<4EJS'$&BE+M.ZLS7T$+,>2&(B'M&8:*<$6$:V:E1<LP/
MIKV62]1T0M+*@"&)&*C=Q=H<SS0)O(NA1&?9@T3I=WTULN4Q!!'C$F1:6)@P
MUR&4'O,(G<?LW<\;<NP5$>.0&\QY[8IPG$6,8A`RC#(;@Y#4WUNFK]T!S=8N
MEV2#P4<G*HL<-\`2$T0L,AG;.E!RS"]T!D-88/=?(=3X%2)B^I$;#*[B#W+D
MMK?'*<%9KJ%0[MTE$G-9-AC,WH<T2Z%T]"VVH)`D3&)GK5-ZLUQ#C5TC9MNC
MW&`,/9'$3E^9XF(4@U"9`Z#<M(([ACM-992^BS8@?S/-#0897-VY$\2]G;O2
M:NZ0?*?Q4/M)?:TOH<(,$:&+'0FT*]-D\&PA5B4MA.9PEHTHM`A7`$>;%H.Y
M2P_#7(=0>LQ(WLG>V$!B;B`*,5A:D):,B4]!`+!/C6P$2FV6=2BT!5)8_F9A
M,-?38@I[SUTH/68=[V0.Q?Y^81%SE]X]"*$'QQTSEL6`9FO6E@67A<'@I]\$
M3IB8YI%Q\+N$KP@\/L'3A4/5OE1%M=]WWKIYU4<C$C[Y7:[BL4TN'G*IO[ZS
MZP4<YPS7EY<!.$TYE2_5'V7[4A\[;U]M(62P2&"=MG@>@S_ZYC1\]']N>CA'
M&?[<P;E9!5_W@P6`MTW3GW_H$Y_+2=S3_P```/__`P!02P,$%``&``@````A
M`,ZC"Z9\`@``/@8``!@```!X;"]W;W)K<VAE971S+W-H965T,RYX;6R,E-MN
MXR`0AN]7VG=`W-?X$#L'Q:F:5-VMM"NM5GNX)AC'*,980)KV[7>`-HF3JIL;
MQ\3__'PS`S._?98M>N+:"-65.(EBC'C'5"6Z38E__WJXF6!D+.TJVJJ.E_B%
M&WR[^/QIOE=Z:QK.+0*'SI2XL;:?$6)8PR4UD>IY!U]JI26UL-0;8GK-:>6#
M9$O2."Z(I*+#P6&FK_%0=2T8OU=L)WEG@XGF+;7`;QK1FS<WR:ZQDU1O=_T-
M4[('B[5HA7WQIAA)-GO<=$K3=0MY/R<CRMZ\_>+"7@JFE5&UC<".!-#+G*=D
M2L!I,:\$9.#*CC2O2WR7S%8Y)HNYK\\?P??FY!V91NV_:%%]$QV'8D.;7`/6
M2FV=]+%R?T$PN8A^\`WXH5'%:[IK[4^U_\K%IK'0[1P2<GG-JI=[;A@4%&RB
MU&,PU0(`/)$4[F1`0>BS_]V+RC8ESHHH'\=9`G*TYL8^"&>)$=L9J^3?($H<
MU,$D?37)@/[U>QJEDSS)B_^[D$#D$[RGEB[F6NT1'!K8T_34'<%D!LXNLPSJ
M\WYF0.-B[ER0#P6U@6X\+8IB3IZ@@NQ5LKR4I$/%ZE*1Q0<)`;P#(V1^RO@Q
MFQ.7&)Y'MO'!UN,O@V1T*ID,):L/)0,X*-KU<$Y\!C<=[KP,DL)7-1FG13&*
MDVRH60TT>9P5\30[:@9XD.7U>$X\Q!L?6Q)J%R1'O%$VS49G>`,-X(WB27[4
M#/#@^%^/Y\1G>,EPZV60!#R8D>.SZL*0<!;O?0]8802$&]+3#?].]49T!K6\
MAO,41V,PT&$`A(55O;\):V7AXOK7!N8TAVL21R"NE;)O"S=B#I-_\0\``/__
M`P!02P,$%``&``@````A`,=2[9Q';P``46@!`!0```!X;"]S:&%R9613=')I
M;F=S+GAM;-R=VVY<R96F[P>8=]@0Y"X*(%FD*)4D5Y4:%`]EME64++)<&,S,
MQ6;F)IFN9":=!TGTE1^B;PS,``7T_3R$'L5/,M^_5D3LV(<D*;O<W>ANPZ9R
MQX[#BG7XUR%B?_//'Z_&Q?MJ-A]-)]\^V-[<>E!4D\%T.)I<?/O@A]/#C></
MBOFBG`S+\712??O@IIH_^.>7__V_?3.?+PK>G<R_?7"Y6%S_^LLOYX/+ZJJ<
M;TZOJPE/SJ>SJW+!/V<77\ZO9U4YG%]6U>)J_.7CK:VOOKPJ1Y,'Q6"ZG"R^
M??!D9_NK!\5R,OKCLMKSGYX^WW[P\IOYZ.4WBY?[T\'RJIHL"N91'$P6H\5-
M<33Q`9CW-U\N7G[SI9IZ\Q?%]]/)XG).TV$U;#\]J:XWBYVM]>+QUO9.^^'Q
M]/UFL;7=__#-#+*4LYOBY+*<5?/VN[M7U6PT*"?%?G4]G8\6TY4MTWJR113_
M\_5H4A5'B^IJ_K_;77_1_B'U<'IS7;4??K&]M?&[]H_,;C(T(AZ.RXOVTR_.
MR_&\TU$:Y2TKFXKTPV*_7*QN=SB:#\IQ\3^J<E8<LFD=&GW11_0T3'@]C-;?
MP>\Z>W8Z*\6NQ<G-U=ETW%G9[O?OCML_!AYZ5UV,YHM9"6<=EU>=97VQ^_WN
MNZ/C8N_-N[?%V]=[_^N'WZ[H:`_FG+'P(QCN8_';ZJ;=[HLM_N_YBV=/GCQO
M/]I;SF;B[9QVJPC]Q<;&]N.-G>UV'V$]AZ-Q-2OVV*$+F*_=Z(O7Y>RB*G8'
M@XIF-!HR)G^UVX7.]J975]-)<;*8#GY:#RQ?O%DN3!M`[_9K>U,6/YG3*W_-
MI^/1T(9X58[+R:"B`X1_7JS]<+)?/'S4?OEH4IQ>3I=S!'R^CB(85_-Y,5U<
M5K,/HWE5S*^KP>A\U!7F_6J`,+N\/FYW&BF[.Y\S]*\[C\OYI6F4@?ZH_K@<
MO2_'[$2':=]5,,EH((*I:;L?""J5-2]FU:"BC[-QAY..)N_IF#U9+R;5HMW!
M?G5>P0/#8E%^+$I-MMWBC2A1#`*G6)/.+$^G"SCP]C9O9RCGV8)I7+,KKD^U
M\&LIAMZY^<B3Z63C]IZ/)AB)BQ%K]Q7T=G;ZYG3W=;%[<G)P>M)>8MRLUZ/R
M;#0>+495=\<2I:_+FSXR\WRVA(ZCR:)"02^*%>T2P6<5^[+L;%?LI_J(*9M7
M<^,2X\9B7$^OO8+F!MS2\/5T<K%Q6LVNBML6>_!Q<`E)*RVTF%>3T7163*:+
MKMVQ[ECP53&LSE:P#L;[8L/:W#(O7\`M#:021@OQBI-D@)E%$P`8V*UB[9C9
M%<\ZLOW%IY\__=PFEJF5R^EX"/3X`HMY/AJ,%ET1=1TT=QWTZ=^V-I]NL:FS
M`DE=5J8H1LR(+2^7B\OI;/2G:OAUL?WL\?I77SU9Q[X7H_D<CECWWY[LK+_8
M>5),:R56E(L"0(#1/4/`(BJ@BZ=;ZSM?;=$\ZT*_/=E:?_ZTTP5J*/2P0A7M
M#H>P]'2"A%Z7H^'&:((JN1XAL6W"G(*4YDN@@RWZ:U#*^M:S%\7<($?_=(T]
M[Y["`!"U')M2'CJ].V.;"K&!T]:L:FJB_/IH]]71ZZ/3HX.38O=XOS@Y?;/W
MV]^\>;U_\.Z$73TX/-H[.FV/\F,YD\EM_[P/QGA?+D;OJR1D'1,F5B].Q>K[
M/:Q^3POT%O`&/*P6@+7QHV+MNU=OBT__UF';8/\"[R6F:T_[T[\5<&7[U^;+
MSH2WM\F8LMVPR1+K@1?:K5:L_F3!CKO(3L^+-ZA_:(R!OI\EKCX.D`Z,-S0K
M,.CEYQCGG7OC\([IQE`-EX,%)M44=,?8A77`#0=!1_?H#@P`2[Z83H?S`D`R
M;%,,NPY0'3@(&#+2>&J&L-WNI!J/47/K!9H.\HU-WLKAU6ABZ%$LVW[%5:F,
M+=1FEM&2M-O5ZQA/YYU5KKWFQT?%!:Y2`11S>X!U*\[+4="!6B$ZM"TYZ./V
M4%AH-XIA+KT6VLW]6FCRB+$&TRL4;0]JT=R*\]GTJ@C+%%.=57AE57A->*8[
MCU<0\7RT\%?7KF?3]R,YGP4OQO'Z7SRN%D4?E6PB4-KEHL,'K\KY:&!;-AR-
ME]B*-F%^K$87EV9#\(-+$++KVDY']Q*P/;/9<VU2,&I_HZ"U9VD<U?XQJ!D3
MS\Z&9S;G;;`Y>_>Q.>U!0$/)<(0UM9N\PI&:3,3H$>YC5W-LWO%8NF^L03*G
M_".9N5O?/OA8S09R#.#^#VY.4&AU!^WY];5OM_D]@%$KH$MAQP#X3?TK,@'D
MN64`?-#)'!2OMYO"F:97A3D/G?,SF%4LIN9^+#KV[LXYM1<!CX9@#E(I/4^$
M!61.9$&H&#4TJ#'EI`],YI3RM7L_MZY^Y4OMZ9WBX)RY_,M=*L<";$X/&VSC
MK)0#B<X1\#9#U>[">#W`.ND,H/'L_6@@_+EZ_UU`^M[J="^H>8]IN/9C>(!$
M@?(A/-+N"B>^)1%YZ*EC\EK-L]4$U)>B5IU7N\+4$J![O-$:+Q>_SMLG(E*D
MIM@*%Y*0W#G1,5P!9"CKK$V5N]YMMV^1Q?%Z(L7.'<VSB;2IV'GU?OI=L8+#
M\?0#_-8?RMC;/?E-<?CZS8\GQ>&[-]\7;]X>O-L]/3K^KMC=.SWZO8'ECFW9
M'?YA.0^>%=J`2,(42N+X87C-Z$E'Z&^+52PE)-"]QA?E`!32[S03C:2[D0F3
M(Y>KZ6PQ^E.O=.%T*O*B0$20TZYTEJBT8=?:9+U*"^*#-P("[8W:;;67[UH,
MB1\JEN+F6K\(.EO\:#"==R,SF"./G#A.Z<<->Z;R1*\QKM4MWL7:=RC*1T[N
MOQMN^:@&!#Q>8VO*M'Z'!U*0J$.J&&`*X8SUH@R!C@@KK>\[`Q0"4'?R3WOP
M-CL?'?_^X.0N=GZ[!%:+UC!"'7H889N<R=N#Q/;$_,Y-F_3B\,[\O4,IG)K_
MVUVWYW]X=+Q[O'>'..)^#*H*M\'P;>)!)H=I4E34K)7!8LU8(>2YIF#VMH=/
MF_U%)*!7K:-@JXE\2L3_O@XCWOA;^\H7VX`+$M#/Z+2\<:=S2528T*4#3Y?`
MCNY(&VO>P!#E=I9;D]6;>WQP6JSM'^R].]@].7A4'!W[7_Q1V+XK)F%_'/SN
MAZ/?[[X^..X)/$I?]S5<+UX=?'=T?"Q>>7-8H,:/WNSWLE?_VP<,OOH]V1&%
M@HKA<B8.%HZX4=X$3-.C&MQW:X]^9.Y9O]H[5LQ6HV3<V0VI)N!JG-[C2=[4
MZ'3]3FC;GM\;PZ`>+,RBZ(X!?A"H;K]Q7"Z6.)#(P*OE'-B*,5+23TZ<*8>W
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MKXDO796#:FDQ.</_B:ZR<>`5C(DL^.@:D9D3;U9.Z5PI1J86B,A:2<$"=7`K
M:KB3!79,M9))*:]M)'#.M!A=2>E4:"BRN]/WY7Q`C'167.*<+"XWBS>3XE^6
MXYM//S_^RI+"C]<SDMU`(J5\F$)YK6[8.Y,CV^?-DTV2H*1-1<O]V?*BV,UB
M1M/)NCCM<'^7'J>15]1T3KC)N`FX,H2E/!+V>V9679=.2VBH_[SEOW#W%KOC
MT<5$,?%O'\R74&L^F(VN%P^^)"'^)__YV>93_7,P'3MW7Y'*W]8OLT/\0V]S
M.KJ"!8ZK#\6[Z54YT=/S\FH$QUG/UOQ+&W/Q\M/_ZTPD#K6]]4N.I!J#7\^O
MX8UO'UQ+]F?OJP<O<3#`@VPC<Z\6ES>$<;$P\R5IPV(-!0H;,.V?)M,/$XD%
M*>!B>VN;N(*T25$"MB=P.F0?CA!0_A<&7\)0>/T7XYL![MP0$5)$T`'<<#E6
M,HFDE%(?)NYSGJ*HUDZ_*SJD6&:4_V7)\?*?+A9?=\;[QY#^Y=.MK:N++X>O
M'Q675!G,<N)<C8@$?[@<$3RM-0AZCV#APMAH)F1N`@;-U<12Z0?(\)"PNY#2
M9G&:49N-@9KG%(Q$/7DV1G8VB\#WN",#4O2&OUS&V>#R?3D:6WZL5[<"(L0R
M)@R"9C3ZEW*RE()6&8(64+GZ=0UXX[VC61!"4L%B%OZZ]/2H:POF!T;[,)W]
M)&7R`S(>@@4?R)A4>HM5VVM*6:-#F(,K-TV&6"=*=^YJQ:>"9GGNY29-S6+*
MS*8BPW*^1"?4^JT8EW#PI:80Z=-+`<5'T)"1I-T]2*R4RF>DGON%+M/9XSFB
MXP%S6;8X!PVGO5X0VC%G5A-LBLTEL=9>,?NO+$@4/!4F2<89_S1>?(UH^2^/
M8,*I\3X%.%-9,NHK@`NB(W8*&`Q-J=<@,P97OMY_O;$7%!/R<XG]K`5*$,7$
MSDH)Z'1>7(T^\M;P9FYVLT)J([K!!_K-FW?9VYL4KQ2'U=DLDX^&:"_/0!06
M)B\P,M=C2RIA\&0PW+KQ8Y!M,VWSXV#;U`UV#L-6_63.6K25&?M&UNF9%R;X
MS6`Q)4$+>'$KC.S&3@F4D"*2!99B)Y>@LBM)BB8+*TJWOQ\QQVPQ?_WS7\@(
M,3VCKAYTAK6=TI.>/M\3.!T6+]3WXZ)4=H9,DT(VP`^/^24TP`K[N_=`IRDE
MEDZAG!24M!461HO!*C'X%34S4$Q;[23\,#(],)E+CUB3-*YW$0;LSGJ].%MZ
MIPK3C1%?`N@:%(@GZ!-<D/;,C4HVZAG3*3&+:%5-C0WU:?%&W'9QX'QY]H?*
MC6LI7J9R<"8H:7L@Q4A<`&6.XB4L`FS18HNWN9HV9OH!2P\[JEP)KQ,9>+O_
MPR%0B1RD>0?$)RWCCOH,I7P^&VOFK9B,)KI0U1.A);T8N4S<R.ZQ8_`QOTO%
MABD&`FK=-=D)2HT]+'U+<[9/-1KTNY!@VH!:,)/`M*DP$!).))?D]RVFM;@,
M^ZSYA*V]=49._-`Y$NO<I;>'4\S59+H(0)1EL_0.5^/&+(H/MIC+$M!;LJ4+
MT`[\``[&SXY0>B]Z/G^1[3&7C"T"!9D3EB7\M,`0]Z43A-'K'(HUA+TX5D'(
MB[_^^5]/EF=S@L2":P>JA)H_"DX!UB99GL7+>WEYIRQ,XWBM&7_5M6;U1*1$
M0]8;=VF\',)FV@84JRW<&/!Z!J"6L@PL'18-+L"?(Q]/40FK@6;P*B&XV=`V
MS="?_KVTXA?M.J%:^&@>\\-")A39455B7I-VHN7TG>/:0?9!6:SI*:ZFD$33
M^6R\PB/0*[2^7LX4$#70JE=GAGGU!#E6=0<B;7NDAR?5@.""2JGL78*['@IE
MH5?$>23]<?R3@SV-L5GL`?30:"RZUDO\4]W!7O1D_(TH>;"?3<]H'7O3QL]M
MSDG:ZRU#1J;!E`#`$`UX$JTA7;&`$Z'><.DJA='R:03\E(B:,RDK)[;H.P;9
M[V2+WEV]FZ`'>Z84@%3U>NX<"PAI(H?X`XQL^KQC/HBVP!A*0^?K,=:[ST)L
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M=UX&PVQWHYKCCZ@/W];Z<`W%]MWN[EO3!#-E"9EZ1@ZM_ZK\J2H070)GTB[2
M9#*05R%R:":R/#\W2,&\G4?@QL12O#`8"TM00EBK/WY0N;&ZRW(N]F\EF:@C
M6;(3;`XK%,32%JQZQV%31![:H5YR:2P][$R146(=DTT@96VRT*^_)!3F&^:[
MU+_3<6L7ES.,K(:E]`)TQDHX].!B3*K9BQH__1RK&JVE>-\X"/=4A4MC:H&-
M)X$.D2\5\HEN!2`A(*(XES@Z%&,[(865_)L&0;,K;!<`0[Z0(+T&_O!EQDLV
M&]>ZA@4XDPJMF+CWS9VU3I=R'2%POA-YNH)GGZF813M9J,`2O5-""AS'M.*8
MBY>GS$5`P(+`VKJ[55&@922'QA<11L,1@6G8OP><H$-*U*GBWQYP,?&@;4*/
ML;?H',#/2V8&]U/\%N9%3`O-X1V(Y2MPI@F<<VP=,F6&F1SHJ>HPYN=*PK@Z
M:\L3!$!!>+;'5+F0`BZ-X"!HQ1CH+`3S-X'Z`23C%#]IACP4YPX=Q/9B/L5#
MM0K"[\+HG!(H^D/&:*!A7*-VE?S!`$LD7T,;;().,;"+5B":N8*@))6$8A6)
M)\N)8:%:N59V9T`Y!#_BP+=$A(7369^9'^V\)*D;0[-!+?#C^0-;NOC$(E+^
M?CNF3D!]`=KKB'R3OI=@#[,0&MS^D$I&&DWTH/3#QX^?;K[X]#-!WS&;O4F7
M\)'B$B8!ST'R!Z'40Z*.D:Z#:^*;F!^9HJ\MJ<5:S,$RS*,XN@7>T(8R8%H8
MRU'*$V3G^=8`+L/F:/?-(?UHUH'7'VX_WMY\3%S#)_A-Z^27)#*\ZQN;>P<M
M2*)E!62``A#<@,^SXF.)8^W%/&7M/\9*,]$O_`.\E-Y\'<X&W%B@^8/"^'"A
M\M\%3I:7YP<#X$"\4]J?#?@5`ZK(&4BN586T;M]$E84P0.+^;K/\+"LKCGT8
MA,>/\`S]W`O+H;0XODF\.M6M22`74?2)L.#.3B?LR)D.)RP6`HALYNK>+-'M
M:VE1A'[!K_0X]E@N66?5'"^O3?,YI=2W!'@V'7L?T9<Q$IY4=CI"3,J>:1WV
MYR/`A4T0'Z\"?UFB2(Q[SG;$4#`Q)?)4R.2S&'0)A7.!(J$0WD?U$60O&ZEQ
M]`X=HF+-<QJ,9A1,RIU151IU,`0:R,.N1Y^OYX"@13AV]T_F]D<IQ7.&?Q4U
M;A):;Q*"!OE>$2$T_4S.$(-DX1Q9=I'B-LY9[^/.U:0=4H/$3J&&#;(2W^',
M!>A(S`T&&U$*[(ISS$%.\G3!D#1YJ]>,AK7`3>,14`"R`0;2LCNZ*@:DYLMS
M'1R1[H;*Y^R#O8@Z40Q*&PX(":!0VA;*J0;(`=VD^L@?B"E"[]BI,[43`E2&
M*QD@A[B<;M.1EV]:ZH>@E536042S[><29(B7`^^NT-T=SY`DL)H:E0N$+'^!
M:(1QWW<`=B'$?PA:ASH9NHCJ!%(2V?O'P'+@+5PA,O]"N#SC@\QM026DD"Z:
MDK-^>"-CJ_L'V`F':!I>HB4L-55R3.$_*1/VTP*Z,"P!@CG'A'3FR[6*9M[0
M*!+QA?SZ",C9>X*3PY&,;DP_3^'$-#O77==W,MYGA-0Z`3%Q#3.Z!].L%W]8
M#B\<+HHF!F=S;T]*^S:/+_$0VJL^C2>6];,BP<3ZT3W?_EDU-H?C,WG,\G1F
MZ#8<2!L,;X*JZ,VXRDHTMTDT%TIJ]'(Z)`-_8?SNV$,@B)_9KCA'%%E8"?\[
MF**`S`R(5+$)EG+ZP<S+.GJ7.(-8C?1L8#@=6?1)NJ<5<+NJY<(A5`5[1V3)
MY?1J"UJUF'7M)OV82>^IB%:D`SNE`#NG//0/PJR^G$H5`[AX&CC-U>`NI\E:
M1UT9H6[,UM9%@NZ]8UDC,E.>9;8TSG&63E:#4L,V_1GZ%CE4M02.R!*HCX!A
M&#HA!PFT&R.TQU0PIQ9-)VZ4/R;M*%XZV32->VLR.$0W1)*,$<X46#:A!DW>
MZ*&6S_036]N69)S=$7@)2%/<Y?<FUNM8L7<N&,6[FIWZ+%.DIORM><KIAO`V
MVVCAJA*9P_"@J29+.S/)M*_*/[#4+`&.T.&L!OQ+=VZ+54MD)R"SEK96.]V]
M(E5N)HFR%<,W'JX0--C7R:L1&2WTJ'8#10I")$^A?)85T,2<M(D3N(R#EYZ'
M%Z[7UF3!!U[!";)H'$R+5#CK>0T0,`1>R'+W;U,;?@\JSW@DI%2NZ2ZO.0".
MP6',(V'N,#=+N<IVYYD%*5+GK[`?YLCT:81KH1"!_Z!T185?4QGSZ-//XFGB
MZA2D46VP)'8`Q,%U1L%CB-SL()DZANEQ2>P4!%5>#CS4JHF0@A"_9B1?9Q0-
M,T1`WE?$,>5M3SDFI%/L]E!/PZ[Y<6XB2G;BPXT;"EY),+A(O:^-WON<H3(G
M.=3RW!+7[-*0]!Q(QRQBA[%/F5;DVH%E7U6Z8=`Q>>ZQ5$+L0?-&5D5P-52$
MU&48C1"%JD3T6APE:&2=6B&3%W?%HE:1X<1*\UNV5D!MW.A4U-,@D5+&LE(`
MB%R4:L82=YN:B"/9L%UIB+.*(#F;<X(H&BYP/0*<.H3@>@*C$FUVG43LWZ(O
MU\[U!OXC=R-ZVC_Y!*EG6WZ$(37A6--\2<5*QD40:4_`9[Z0';+P,E'')8*M
M4AG%FP:</.0<A"<SXQ:4@TMW$3+P[YJ>^B,-X=I`#J64P0HZ-K?52)7HE/:U
MM2C6T*9VTPZ%.!+;9G:N5J)Q2\(09AAK/J#J%Z_'SHX9]6=>\7=&MO)"N\31
M5=-8]]Z6KV.5!Y'F41WDMTW764?9&N<GO.7<`0JNL1IFK^;Q5O2@#N:&J$3:
M$R\(PK8[)T>@HD,;&BR\E555B1*<(O$=2[%\"3Z':B\1+S^VFS`+V5NH0*+6
M[/4<<"PIJNGJ^"YR67,\TSR&I)#;6Y6()!$P3L7T`&WH+,D?J"5B<3<-YC7.
M3PK0E)\"M*IKR-LQ1:L03;S0Y)@:/8KF`S3B2,5EI,.L]!G25?"[2-CF/!F4
MJ!QQ\CG.+AP3""+?V<H-$D\//9X2)PRLJ^LTV@%>3<5A4;`M!KG,$M?CU,C4
MR&LV*"(E1BEOV,.X25"`@([XP$\%B#V-5!HI[A7=4/YK)P)->R:SR898!M\%
MVU^YS4PT1?L*A2+T9BX5-#/["%X>*%GNE1\7,QUECO-()$RI1U=IO)LKKV"Y
M9.@2,,S4M;8K1#8;!]F;VY_F0>U`_R22"M*Z$W#"_8+@W#$EA&U"9DI/;:)(
M$C>C[L51<6/>PCX)@)QF;T13X^_T35[R1XX8^9=F2N9GQ=372EEU+F=2#+EV
M6$Q'(V>(]E3;.%1H'DYQ5,8ND/I+C"+S0H.(]8KS2J[-VAD]Q^E*50!")LF;
M05I5+:<^6.JL.E.>`T?)"')6#GX*CD4<5[*`C#&E[Q&_@<YD4"AR=:;<1>#\
MM8%M,S5)BDV)@LKA682I9ANWSP9HAHWYV=$UDV%L&7I+?5B('!&!JV+<4"DW
MY!7#!<OB6`G9UEY5L+_SEOY2N>9+#G%`Y-U$Y'!^A&?ZCZK$_S$5POUUHA:O
MCFP8KDS`)$(H(="^C8>)(P1)LM;1=Z)Z#W>PR^P(;.'^9>05"8:V"PZ#C'&#
M4[M(<TQ;Z7JE(2-AKMJ=3*9<=J,.$R[U0=.<&WW4*_=-1`J*Q[]*[.X6/>A#
M61H`ZLX6F)KU;.J\"\S!&K+AS1&(GJ2I'S&A1Y>:.L^9LT?V60]@PWJ=YY(G
MIG71,H$S$7=+;H7';I_%P4RG]\4[E8'Z#6%*^0'QHBQ%9+5$%8W[+B7U*Z^K
M-E^![6'E5"_&WXN7[Z)X[[7$F[UPM?*?2!A:T"*J&RPK-)@U]!C<8Y<JB6XQ
M5!$5&S<JEI-PQ`7F1BZ:#C*IFMEP@R@S51MOI00E`>)DB!WE+#H'X&._M<O$
M*R:%SL@=2-SH0D$E_C0^:*A%V_(@6MT1FW8NZNJ(#N]2R:`=T!?YLTP0NV,$
M""9[9!W#F7$@BVFY4=$-)5(F*ZQ4SH#BQ%7\U]!J<9A[KR?Z)/=8E%M\RWY%
M7SX:]9C3S/&I2V27.-%'UYIJ`[E!+9+@O%G58'9#`:]"SNB'K*WR*;1D#RYF
MY15,A-<OO)/7Y$W/PNT2"2T%S6]S;2A$L;*[^JL[<$%8B(&=^]#KS0)EM^H4
MMIL"C4#&XUD=[?`VN%+OW'G^SZ,*NM2QX)$QH'EH[$3PT)83DE@JDUY.KCVR
M=,8_HAQG)43;SS<LC14JB`"]\5*6.=0*U4'H$*0YV#7RK03GAAU?3SM5>27[
M*O=PQ:LN]FW?,8.<"NYXW9(JAD!BEHM%W.5Z6:D&2A(X)Q8-J=-KB@6L=/LJ
MUEA8'QS04B:/Z,$U+<V*P-Q+)5>65GP`WV+\W41'<FEEM6&.7IM;WQ(3^"'2
MZ<PO,HKO,6)PG9@7U,L9F_BLA67N57]1FVQ4%'WJ$BE<E.*/*NI5F9V\I,"U
M(>2S6>S[@L0=]ZKT<C3@]5>B3;?(!-[`08R5-6&531"A:AQ%=J+CU.?EM&9J
M(@G63RNPT$6+7.D<0H2(&NAS!XGXS:$7-(L;E?RE.+6E@!134!P+E6+A7>97
MAV@97)OK84;:XN/448>HZ*T+O,C`:,,<9N)83";5V*Q1K;D4F+W&DS?6:(ZG
MJ:@,Z6@2\P.\IFD0<IO+XVANA*W`3(&A518F'&TS$D=$,FK>C)9S)NHV966(
MZ_X$"O=)R7V#:'E;-%(6GJDI$.,N>5N'$O5$LEE8S$0W>MDEGB)ET#6])(.<
MR<U/6P"[8I2#0"A:;P7!D940BE8P7S+M=B/,:#9_%*U?;FGJ^390O4/73K?)
MVMU%=/D/T5SA'LNAB/,(@A?0&3O,3.T(.1$N!1QJ)K3W/)K:8P(U%X7(LX16
MBI3F*ZPM9;`=Q/X82.IW3M9&YYI#$B2>M&:F!I\8(<;@:Y:?<9TWZ@E>8;YC
M;O(8G5M]0Y0U%F#E>+"5#DE>PY-:81T%]0AF?-;6`VJ[]MXS!1YR4U:[O*"H
MU=QN\0Y6R#G=LDZFY&MGI&92S3/@$,0@DXJ.G5WE1[SAI1D2&1WT7\<K2\$4
M^L\_SHE^Z4,CJ3$VT(GE6+``NZF"M7:,@)\\.C:8`OEO*(U;C"Y0<_B.(?01
MV=%46T8;]3=(>1(VD?RJY61BJ$'Q)NPRN:.!(BRZ&B^WY-H_M8"-T4>\[2=!
M9-^17ZP/4^'-]JQ@.8.3#0_!]FEE6X&&G!D(DRZ)'%EHU'P4SM^P9!@U3-VZ
MD_85&5!T6G5=L\V$KY5X""HJ6Y._%[T@L!*C0"4*G>(%U!RTHDR-A+&=:(B.
MNJ%U#>)!@3!B6*D)1;^81EK46Y3+:B<OVI7:?#NCX+I3PK;9CG6)FJ+M[)_>
M9Z?$>MI>)IXV/[HL,9@`'6I:)TL8UYAK<B:"/2>,;P8)KY\SI624M;3N;"*3
MBIN0]7]W7VX%Y\5I97$Z^4WNE1J^A5JJY(O'$,-IEIT&6X?C(1Z)N2<A$H*1
M-:_WM-;MMF<U;ZL"'AT9)YRV+1:A^90M1R?OUBLA/3\9+B7&[C!#<@9+Q1V5
MZ&AY"?&L^01\/.0B"US!G/'@`4<D$97!1ATH8L"@EL%<W:FZ`E<%]<&U<I+B
MVL!DSDKN5]9J*Z9W&3*^U6!%4VFND>)SX4W`++>!DH9.-PC`WK=`1!-P/W1/
M5;3"Q=D"#)]8,6SD%C@C)OL-_V%%+9`2CNUGV":;MRV?G<2"-<`6Z\FO+7`&
MJZT@.T'@HY>R-C'%T*A`Z&A_H6[Q`Q(G+<GZ4^B#?QJ(V0`_Q+,'DMZ8B]+F
MGTU5]-LX[VM1UKZ)-&6BYFGC5?D+4,&7L9I0&77$6W!H-R77HI0#1[2]$JA0
MU>;7(&WB\Q[?K0<I^)&/<RS`](/X5&I.8<LKIL)-EA`46G(-GTQI@UA(B.@<
M*5SG0\PV,$,E%LC9V8<;!'F)DY-DEZ-?GNEV&E%?5+^7^R?83^OP.85'G=ND
M/O7<QVXI!(^BU!]2J3,*[2?O0MBU_7L6A6T_0L%_^AGJ>]2I_?2M4ZC]\SL/
MW+1_-LC4_O$H(:CVD^Q2VE3NP35(%'WOM)L^;/]`&7X?O9BOO!PD)>:Z$:"`
M?&,`QDW:N1>\F:?:[GP/^8.;OPPY!9V-`TF9H0Q'4H(3?W=7:]OK+YYVKMG%
M:6B/2<,GSY_T_/I\IW.-^=K3]<?/MMIM,W+VR$V[]2EL>XO(M$6C#OF;;*2"
MP2S0]8L(07/FND:@RPP-ZVY-.E>A!KY-DEU/OTV'=%=E:\7M=D=VTN'VT\%A
M%%/<-6LH4I]'C[P<MFFKA>;L(RUZ+=S*9Y?P2KL0@9CJIE#43JS<L#(,`PB^
MAYC^7WHG]D*12'U1NV57-<LV;0ZQ#_>H#FF_MJ=K\+1@^T-'F*BY!/)V"OA3
MP\Z)`Z*2JE02@?4,*A#=(0'/D3T5IN#P#&3(#.6<E9.08\[.1^CB&P!'.!F1
ME;+Z.[6OS3E8PGU^:']A2M^`IW8V.B;\_2*D"I6;P0R3,GR'7<5AL<W3>HGT
MR+`HL6ZK\0WG@>H%P_JY_:X:7K#=**\++GXA!LF)+Q6*V^V-MMIPJB4PCFI<
M=.M3.%D#"K*B/]-9Z=`>^0E*-4,!.^@#3TS8V<M;F(T*?V)<20<1IS?D;X.]
MK:V/%$<,;MFI9#F!7L(L$QD2-YAB+YURCE7)K=VZ9U6UJC!CTRQZ6P?X8FY5
MD6)DQE[4^4158B,$R7'B3:_9)L*;%S+3';1V%P?:625+?<:[CB4&3SBBXGSR
M(M]$97,Z7LF1%'`$D-RKGZU&VV>EHU"ZAM1],,;*%X<@FG<Z/0/@@!=4W*D+
M4J[,DYOE$33!$;_9%]9)G1%]ABF:^B%5PI&`$3QT9!+AAU<=6Q7I62@5->J)
MM_*I-0$?VLHOR=,!R'3!C/J,D!PSVKQESZ35<P,&$DT$/&B=E)8V+-(4ER4(
MA^'M2%/YU0:\+#OE0T-%N[^(BCNDY@>K(RLGQ>[;H_2[&"8V1O<AUW&B:A5'
M(F6NW**ARMBC1RK"A2.&L'%5"#8@AA(FT;/OBQ-1X3$?&OO51(E0VC(5@97U
M-V3B<,V]2Y1Q6!YO7.F;.]YX=^[R`N,9`:I@<X+F?:3MU*XG>Q(2)D8-?%55
M5^DFIK@*<S#%\779-=JPGC%LJ.Y$:^LB$IF-H`X`ATFZR:ZQ5S-UM%1@WZ!2
MBF'Y!MZ$NC/KQPH+6)@D>Y[?^!1)R!-%JXQ/Z%#MM,D9!W04TU%]M?6NKAFP
M6W';-B=KI,"^M'!M0KAWARLU<&DXMA]UK5T&BQ[6#%@6]3]^]"(<0!3[O"X_
M\AW&JG@=2O`SZ*FW=**Z41G&*YS`+KAF[Y+QZ3ML8RN/!E?J?D-:QVWV+9:`
MN53KK[B31G.;Y&@FW4I$TN]=L`T4W?PT"<14U-`B`='E(XDYKR@E"*%DN9D8
MK5+SVZ#*V,Y0C9#*4U8353]D"_)D.T4'FJDFT'S5537''8/LXMO)Z(2]MS,*
M(;]FYM!OR1!S)7T(@=#'GAZ4&97WJQIL6X8&[%^&,R1JG[`F>BH+.68#>1^J
M<H%"=81<3&W!2^6#=-KZ6%<F/</I8/G$3ST0KA'V[/AZ+`L1WY\OJ1,5@;.;
M>NHHD:<1IL3A/!JLF`<R*19W'LM+"+N\U6'Z!%_?^6F2-K^GYR&*(!01\4?4
MPHVK%!N.N-;3S5(J)XQ&4IF@2V;C'=UG)D40P+!J\N/89UP6*4;1IL7!8S[3
M,V`U'2*?,1:Q;G&ZI:&9>ZR[MEZ\)%ZLERKB:9(JX14,9`U!"S:="W,T.P1]
M5V6V8!^BAJ\/&63I(-/37")"::?(VVM-9)--WK/CKT9*!VN&%?O?#.K<M:Y,
MUXR+=Q%DW9.B/A/>(YPBLD3B`3#P5*6V1,"5$POQ$>!;7MJ(M5;045P>/P[R
MM0<#>XZ=18OS-9&_,^%*69F@S)DV?3CGASQ)7-#74K]6-R/()U3CE8$L*!Q;
M:QVD4T^M9%E^D["10YW&&R*B[9$%]0N!()8I/T5,L73H2:&8^=>N)R?G,\H7
M9D2%=!&-=9?3A#*&\!7$0'G-!Y\#9@^?<@@K:T5R5Y(^[9\N0[.]\U_8VB@A
M1D6EB`-<"Q!!]_NIL-]P;K#O7M'=9@(+RR$%:)@>")#4MFZ/I,>.1)SX11_K
M\8(A(U1^9S*!L#VQ85OW]`F'("!<%HH]K*OF)[L"79GK*BE)\[FS$^>BL(U:
MI[&TL3G$M717WZ['"W?\ED_)4QP)9C7<2E>9F%FN(GI9.;>HC0(8.3^&6#,]
M1*L./ZIA\PB4-*]^_5Z?NCV`9Z,Y%V/50%:I'UM8W*,X4_%E+V&Q<^'J`6X1
M=\L36-:QIWU35(ZJZB>L4KW]73--:TB!:^MB#CL\%N,4YG"'<80Q+1?"0L.-
MH<)$+\2/4DW82@+TR#W,#%G"?;9N=IBM[(@%RE&54GWQ"T12>CKGFKZ*UF%<
M"*4&?-VH>R=`LHOZIDI`@J)9=L#3(*Y&YZRO?0\I;$FX1TDOP@\.YZEHTMQK
M1ZQY:`_?V@^5-I)\^IJ+'9'ES5538$I!#E#@^LR:_/39S0:$@[S#7+66"Z_'
M9RKN-E<3%+O,K_1;&T^Q&97?WQ6.?.BP<SY_&6U*[775<^?0L!LB9,@33/&R
MU6'W&#%,#(X7GA,F`(+J#OR?N-]*#[AEAA]A`_`=J1\_9'*;%@DCBBG,`_;L
MY37@#,"&`4D!6RBJ_:'K6*5K^^Q?([4@#IN9+N=,FVPO16/'(`F9D6H+`1?U
M$^]\RZEO/"Z,K%V-W]*2%*]\%5*DI*)JSCP2DI`JVX*DD=+.)\7?/W&6J:WA
MW:)I:J`@3#W,2$V)`F'`7O/Q[D%YA1-)F@@IV*9)SHEZ,2V93*X))74)G(HE
MRD-,WA#N2FM0U&U1#2[]W#MBS0_0@U[V$%O[8,-?,$5^/!;!9G-<MNF>0>C>
ME#$"SJ%CA9*"8K1-C]\BC%+/6GMB4_NU6CJJ3Z6W.2IK5:?%^@3?U<XB^[X&
M+IH^*F&7"]ML)9),E4231:JTX?V*,_&8"BA-M5OP3)Z$-$=N[+@\7X&%D&.@
MUD88W#):_)J'*"56V4U"%JK2K@5ZN]XE%P@P98[0>TB>QU"J32`N.=Q(,ZR)
MUR4+N3.[CJE6A]*6Z%<*6!T4&CFR8(@<YPV6&H();6W*:YIJ\Z(XZ2"?K3-.
MLB!:J84.Y:J*0\OBU9@S0QLG`[O@'?H9<P*,!WI\-:4N-$;B-`ZW]@C022]H
MU,0</D[KZB.EX_VF0VI/_456WQH?MCP+1X,W/L1O5?JXLDSA4R::2[IG,GFJ
M;;WE+"/&,#@\'7O8!3&/:L&EDA!$XQ.C6HL^`.1<J1T1>Z:K#/Q:V;I70<J0
M'F.*=OUNUV@ZA1!(CM%`KK0%IA-"(ACU'<X@&CE#FZ#)X[6/Z`9,MC1;P@I]
M?#7F"Q$$2'TIM[9D#Y`BRHMUJ:3<'SQ-9MCMU)4'_*Z8.FE?+)"44TX[<1\_
M"_H31L8(04E"*;HRVY+'=G>6":>:`.K:C.,FL'/'EB\DV7OCF<AUB93B9JC2
ME"6\(/M6)<PG0M939VI\5C:;///.)G_*S"VBP>9Z6)J./;!KGD+\K%5S-S4%
M3<!4G''(O26YPS+VT46T57$B1=/6MJ_L0Z\ZMVCP1>U,Q%VAB,\L?BA>)TEO
M5Y6DQL'.)?&*20#7$:)K0P-ENC!/A[DBI5[;/S1K!T#_IKE0F[(4H%HYG_H+
MYO5HJQHW;H>SGNTZ",-DQF]83([[X`=&>(/4I79QW:;:PW$?!\BU0HZ?"#6]
M8-=*(`2#>,8V:E)QOKX,,4]?-P_I%5/HZ"-@X&(DH0"L84;JE`S7R([.-T*+
M:LAULBDQ<V2!![Z^B;<A@YFB.]K:)J"5.ZCX<ER1?<2R=^HN-G9CG`)T&XD8
M'E*6/`-&^!!4XI^:V42#N'U]CQ$')*X<=YA;E_WA<BDF8%&_-GO;\]J>N%K(
MU63T7GI@!#47RBLTX$\(TR88:.H]64D9<#^5FVD/Q%>;N!)/"$DA9P)8T=6#
M5/]!&`-JUM'/?V]0T=X\Z<Z]#)PVK@]T=I=!IHP9.^:,;D`TH(WDHV9&"2%T
MU>W((E/;B+*V*:$N<7R=@](CW^O$:Q8T!V(3C$+IF#)7JUB,E?2]@%T\*&%#
MY$_.L&L41JF(R>R*>NBLQ.>J"\"'C-=]KGTB!($I27WD9+,B,%,7]HD9&B4J
M*`"K(1NW?/IPG5EHE'CS`M9=-%>&"=9%\TFR'<.FI6*3=4?]0D=(]$D.'FMQ
M^!T@#MPF\RN#':UW**S5\Z[@17TE`->Q4;GG.Y$2#/WFO-Y()E9G5QBV(VZI
M)YF["`>TVQUU<\H*<M+&6A?%D1[[M`+>$0B.1?G:,7&IX%8/>"4N<'&!`D#E
M2]_`RHX,S7[:[9TQ]50?]ZIAED`<P8+(',,$YU9Q>-W".#C!#'6DZ=6EC=JO
MKH1(\.3*>_I=%&FW@>`1<V:#-3:$R@VS:6+&H.S<"`E).R((SIP3P]S-;)Q[
MZU>G0E3,-:B"#[2\?#%B<#]\\3>P2]Y1AVT.Y18H4&,NSF'Z",0MABOC-/<+
M*&XT!Q%H%%RE&EEGX:GZQTAOP6T#I#+0DA6!<XB>43,%"402.6F*==/$/WJ"
MCH+<CEF-0Q4EEIC`=S:RA3-T`X2(&G`RO!0G8(6=M+5#2PHMJ8F2&C![+(@(
M=1#7.CLMB;?;Q`2D"7(XHR2TO_GI9Z.G@_?LJ0H![>;:6IO4X0_U5"N1<(^+
MEYVRAD9@5$U'DVO0HA:4R)1L/L]QA#.:QX6*TC7^RLKW[,IY_S)>IZ[TM9)8
MQ3;)RR,?4]NTG.AS>YS2'*)CD3>R*MH5DP)+!RGVHXH==U6)]"@E*CWI67/B
M'/FD;#.UK*"[R-FY-LXNSZ+07N<^V74US,CJ7M@WK5M;?=J/ZVD'E[4U7T5<
MXBFJ%123]58%<%K2>D\?]0J[';862W^1-HGMD<XPB!(`MK6>\**%@F<YB=-+
ME`B1\3*'4\L066P)8O=(W1O*AC>K3?6*\1"&LW#N>G$S4H4;J4,26^M\;G&P
M^<A,<&2L&'<U!>G[ZZ8.`3$LP2!@4Z(85@9&((^4>CVA("]XOY2:Z]-=7"(W
M#AQ*P)ZY4M-5(6?%6FC:Z,QG$;\G5%>/^:[NL*L_3++1\DD'Q\C(D9M"UAZ^
M1A&0%+1J?I`B3*0AXZYAEL@3VQ;#0_V41NY/,Q8.>47C8WO==K6AR<ZT'WFB
MOWP?/GVH_8HI3,4>],E+T;*CN35B)LC&#-?L,_(F880OB,%*D9%6)=ZAF>=$
M6<'R2!]$ZLEW&XM$4,%'*+S>^C'](I=2#$$NVPK<8`-*FK)"&5!'8W*J0F;*
M3$##4',=W$QI<#L[K6E+G?I2/$JLB'*^GG3/E)1B#6C-N4LZLNJHMYY%ME7)
M$0(+2%0LO/W(^)'+QE?\WBDL#NUWVNUWI18[<]M3(DT(E+5K0V%[W/.*XX"N
M6]N]O*XOSNWT]:-[\%`F!<F2CNCTP^7V&ZB+<+E]%Q*V7S@D,:./U6I_J2.4
MO(?KUMHMN[S3;O&)<PQ?/=GLDC0L[J:S-,E`PMAN0XU_%=;BAJ@6$0D7#&HG
M&-0@F<E^#,C1.-T.=Z'\(J5D0*UBRC]=4-M>/)10G.+*!3AE5<).18\>=V0W
M;LE^O25Q!V_:5-E==$^EA:\6U\P=78-;P:TJ9I)X&"0"/SU\^F3S1>3R#"/T
M1LEK2?1XM0*?=N>MQ+161IE^#1>8DN7X:>.<D\!FA#3;K<W'3W\5CW77U=+&
M>SS>WGQNGT_'0H5;2KB?T^)\2FN8"8NGJ-]/95[&H1CLQ=-?V0:F\\_N8SIT
M1!EIIHK,:@X9E.AL$63O41`>I?U%Z+[S8O.K_Q"Z;]]*]BTC^V=379U*JW\N
MV=UR/MS):(']4U31[*[Q52=S$;D\"B?AS:59%S7WVTC"]2A^WKQG(Y.#&7+T
MY3QP:EDPF9VT,1;NA6V"XPL4Z&Y^S;U]*M;)8A?M/-S*>J:K05Z5$"-L`G2K
M1@L+Q[Y[882<`"^$J,ON+7'Z</MI-M2P^KLH>K_S.7X,,Q4]Y`3=1JDGBBH%
MJAC-JC5J#^]/T>SK,2"*)D5A))5Q_-T$?05H#1X:1@"H$QR*E)#%YE%<:.5@
M%*,OT"X]V5E-0VN[%S4#HFSS6A:^J'F?'S.M7GMY]]/@0F*&ID#/*K(`/RK[
MC\\#<V41#DT]PF1SPR7M3=6K)CG$A/IU3@'K#/QS^*\[?;C%C$4>N4)6":JE
MY$I]FER-W&?<WOJ5B-U0!XU)N,WM'=5SUVL/O]I\\;3I;//3#M\<\G,EP3!X
MB#6??8A-]IJ!1V+@NKZU3[_4IE*"8>#?C8<>I'QRK\+(/N@:%V].UL.GFWQE
MVO$HM#L)QY:=.ME+H=[5OB$$A&%X(AZJ`+I#ZJ):[9T4PM7>WQ6<3N%S]IF5
MN`+<O:B&YH\DJG9'CKEO^A??>0Y.HB\$1T8U[#RAI+SN#A=4!Z]P(=?LH-"C
M7!V;2W.K47\M'CP5O-U7=N9=G:X_]'1]&WR=ME@Z@EB/JO8%5"UK]6HT?0O_
M795@")`QFV#C'2Z1F:.CXC=4(N,,S3F_=D.2?[UXO<D=\>B']![@]=;`+#4^
M7!!`FF]U7#;;K3Q:AD^A^2#<P%V^O_4DL12?W[`P"U_\PX^,-\$0^U3\S,&U
MI1?5<5#>B)_A_2DG%75=O+$8ZPAETY%:R5W<L57F=^RK>TWCZ2\TC:!)?#)^
MX*@["X^\!F'/E:?Q9-?I$;6`ROW![!@!1XOVAS#-V>5A(S`>PADN""O<WW`>
M3/16&`)B9Y)`(*X3!EEA-<A0=F/P!H`Z.5V[)N"_0G6*H:"Z*C%%<T5,;N3.
MU(8YC/I9:16C2F9-?>/UM&V*>XEJ%2$=?EOIK66*MM\W`S@E'\'Q=6.B9DK,
M-&!J"5XIP&*K\)I"YQB_)\H:3.3%FH+RFRA1A+;Z&.I^@M,E;GV.G;'K_*)_
M%O+-7@\*'\87=C8QT'IC>WLS^EU^IV2PKN:H-<;8WMI\YN\\?L9?1K$>^[G*
MT;J39,_JSPG^\A2K<>FB3;N=S:=&B2>;3^Y'NQ>;+P+M'G\&[9X$VCW=?`[M
M3F',J,:RO!/?"360S1<@MYE.@`PVO8?/LA_``^*GU4C<H&4W:F206F]^YA=K
M]4TG78(D>#F^Z;C<AR&6M!=B26UCO$NZ5L<-T]=5I14UC68%?+S1R6.$7'IJ
M^1PR$#%&M5E\3RQM86=4/"DA%HZ`6C)"TH)/FA.\P5(:!!$T;H2YY`;`#3%3
M2(Q]VCL-2UMXUG!#D8M8*.#!^$W.ATUTR^>MLXEFY>^=B;L&28C35&3MB3Y+
M>UA)MP5.0WP88YX3QJ_&B7?$\A!X9P?&7=:"#^M>4CA1`&3+"/59<VAT%T?B
M>]6>L-:>>1%MJG!(`YG_U7;5W/E(9?^:._ZAG?:,=KC?DS,%5A?:;NH#Z7FN
MD$K9\,G,+`Z1%07&K'%/]6_3F?SE9IAK!A]>23CV`IFQS)RQ<V(!^!OT;P4<
M=J@*V>&J.-TE0*V`R+W(?<'TFO,2+T._\#&R=)RZ(T5M&4+UB[`X,O%#MUR8
M[K>XN/:/FLVN%M#1VMA#&K\][5#.JMPY,7M$WF&K#.'#)RCHZ#S=-7)>#WCW
MH)E-BK*B3R@!FJV@K(D<B`$EC=Q4X+"C5=:Z9Y2W<Q=.)APJN*.\2F?WS,5"
MUP@+ZL/YR_4@995UTD#)U;0-]2?&.RI:;%4/+=W;7%V=X\\KVS`C.*$>'\8/
M9"*WW&843OJTE?\GD@,_AEI$_=U^O@]Z:_^F=K6/]^GGHOO:"K_OT/5]N\.#
MC[[X]N\::"\F/OIFI]_T_Z?3!5?GQ7^UN\DNXFG=:]1-)]WAS_?P02>S(/E*
MAZ)^H?!C>TFGH>C"%(J75+6;K&UO[:P_?]ZYK"BC1I<U.P3Y_^R=:6Y=1Y;G
MM_)04$(R0%&<)$K=V09H2K*9;4LJ4<Y$=:,_4"0E,TV1;`Z6G>@/M8?>@-&Y
M$R^E5M*__QDBXL:][Y&4G5D])%!9%N^[-X839Y[BWNK&TLKFYFCPS:7UB:=K
MJTLK#Y_T+P\`XM+AUWH/^RGHUK2Z.9IX]]`NT#0-[<M#%1B>T94%_K53X[C]
M2*"H*3^WU,%L#N6$=3P6`BVYMHH[9UFB\QZ53I!94Q.A+GS%`P[FK1<)WU+/
M1HV/)3QR8>+AN4QDDMM<(=NV%Y[]B&/$W(POO81/NJ&Z3"AE+W/YX@/9-C@E
MT%8ME[*Z6BV8/.)1K\D(@DEN>:Q/6LVK\],3DE]I[:A8Z@B0ZIQA?260>?JO
M-(*/&2O4]Z1%-M^["]@=\)%G_KSD336S[G)C](&5VGUQRG_,]?%\:_<+5Y6D
MG.P=D`^*BAFCI+SC*!!88JZU3:F7W,DMJ^#5`.Q88W')LL7B]9WN`]TWARI6
M`7L&IA$QR"+[GTBGSNDC*CJQ4RO9.B%#):Y")*.`B"5XF1/(X][XOBO[SQHR
M4_GQY'4JE,/``K36N,&`<^#745M04?J'=A(P,=1J-+#^#'>Z%AX+?G<OH99-
M_R>'M&K/=(\KFJJWUD#FERI;V0:^?7(9(Y-$G0FRES(*5>V`0>#R448N_9!*
M>-K]OGZV8WZV;G0Y=AV(:FXN.]_T.^GA`'I>?8#*A'7H1J2T_<4R*_KW[FT^
M'+>46WLT8EQ;UN[?`N/L3VB;Q<E0:]<"*&GEZ=:0];RUWO6E=8S04`RH=HQA
MU`O2("S#I>J9S5RF_V<#&#$-M!D[,O.$*SO?ZW[J"E0,75M/!3(DU36![$FM
M:-Y17:/8O-[C-H(@H!$3^M/I^??2T"P#^V+T,PRF:936GU;NQ6KMPBD$"*YI
MI?7TMC'3X;')W^!UCBI$2.U?"4CJ?<GIX'MXG!HW].)(!UEG06Q^)/VT9!&=
MP&PTLIIVJ73$=$65,:72"FE^<,HJL#2&'+_+PB'?W`T2J#5:9\?))X[8"3;L
MQ0?,M6<DTW8G=QF+T&^3O3E2;_*%SHW^0</F7"XK4)ZCF#``X<Q);59X+;AK
MQ5@QHOVF)P5D,))WJ17;IN(/X@W%;?-UIL_T:/.F\E<S5YXL/5Y]M/1X[5'F
M2+/FYI9;K0.JOO#`6FLB31L/LBGV2LG3_2S!RK(RMJUL7D>4C0TD@IK/1NM5
MLU9T0)46K3GK*`-H1W)X]A3(];O;LH[>_5/TCG-4D\-??GZEZ<<_YP6;]#:=
M&'30AB!A#;J->AKT`[\L+0S(&7LD*W?ER9">`"_=^XPQS^YLKM10GP#E%^!1
MN.J19?/ATK&7'#%=]"N6*3$EM4541>B24`PHB^`U=GHRN_-HK4D(`%E5RV3,
M1OWH]+%2IFM'LD%&AO'7M^='<@><6"T7'%/57>X>XX]Q>\O1HJVQB7%:X.7I
M?,)N'?+DXDPY*"N,Y@ZAQ3QZM+SQR\_IU[RB&_,%F:RJ?=:_32<)L(!>YNN6
M^V#KZ>[L'BJL:)FD9("FIS`QM+=SW7F`3D8JK+`VA<\`25=6#%!^5S*8'7EU
M=AA<-B/E3%YS:QH_H)P57`\L!`AK"9I`_?L<$0<S$`7#6:.W%D#+8>_E1'#9
M-G6&2>)DK.ZN/;*E[(\1(-Q87OE[0W!E^<G?%8+B;Y<RN)N[S>/02@8-E#")
MOJ')@B.2!NL/E]<JM("RQ_XWEQ_6IU+HKV>*(^Z],V<!`TY35C-D&7&40\H%
MRG519;NF3BO_3O(3%&L;I_AF5I8?U>]&FS%%>4)M=<E9IHD5.51IAV,)R$8@
MHO/I/>D`XK(/A1^]#E_=-[($($OI?9VP!&\>(N[!UK'3/0/"MDA8;DA847]=
M7(9R69;XE1;U[3+$EC$#^.`7:M9*]NT9%B-<T8H=))E@+L6^*OLE,*9>Y'56
MOC#^8;+-XNE\Y&&67_XJ/D"8SAL"B"-H_A2K5K[Z;__Z/WV6(QC:Y-+9""U$
M8;RV;J@?KB2>\<M?5Q$9U&5P]_3)>]TQ)>2W&4BH$;^##ARJJL@==#48@LQQ
MK&Q1J`#3URGI7I!('F#+"^KZVCWAYL42%Y-]?QP-(\K8!V[QN;Y3NR9IC]Z6
M@1U$W-S[DY4O0RV+(CV37ZQS&&,?=!!(9^<X["0V,?1BFJ864^'*&$MW664E
MUF!';L*GND?2XV^H[SY#JY!IYI&6&\F'D(LP86X^S;?X?0M>^_$T`P4>%=#D
M::)##5<).C-I34,PL9[;+/`1UC2*0->-@],\EO/VO:B!ZS/"(YLT+-$YGX)]
MZ2=79"/8[>CE:[$-4_?=K,97?$3%J/$63TOS+S_LD7U]]:%AYXEHKI.686#9
MUNQ6*40!G@'O&2DG`M7ZHYJEZ&S-#TXVR%QPST4/U?5=$5TT3?8%%#A;&_%^
M&<C>T4H(O,6JCO7GYNQ/`=9>BQ2J;H<[+%AM6E,5EFYX3XT;$9<I3[]I-A/N
M!PZ9(&L9O%K5#1X![:##UNFO+=772W`C<#UV$;>U-"ZD0;VOQ7/X8HR/]\-?
M($974G]OE%JY-%M=6UE:@6T&9M13*-NT,&>EHX$F7532X*YY'HQ&S*;DN8X.
MVW+/8,]>6D%!1T*;DZ)"%PM_CS*KD_?]F6,YY)N41UA\K//=PMR-+5L06LI`
MJ>XU]E.2RM0=&6X&X<JIE"\Y:>4N<#TSFN6'E>^@I0NEL?E%&)K+BI=H6'IY
M!=.%IT0M!:-.%"RF1^@,R8M?-EQLG&J1R9+D=U976IO'!V4AB%,QFGU"O::Q
MN]!L5N]:0?E=F5^248R?8#,`.T7G-F5]VQBV4_@V26AUOU=G8H)*2JL:$<=;
M]HNS`^DJ!&_V[A.\LR:Z-$NB6EE7<=K0%HUVMX3V4A9OSKWF%:$0R2"#24OU
M7F2#(7BSLW!=,)M]@<O$^*KU#4S+ZAU<"+D?U?"S0[M^;4*-4R.0MW]&7TN=
MP>YG<RN-\MZXNP1'\^E'F$@U$V-@V%C9*(`%*2H$@&19L[(6XX90T-34`I!>
MMS!AR@HTU=S/`?Z#@:3XD0!1@0B[MF\,Y+E%7@`"&_]Q=D=93&DB2D/*-X1Y
M,A5Y4Y^?'/Y(Q;'Z*L<+:%X@XZ_YN,G3-=WLQC,;3LF45.P:G#3$$5:LHN>5
MS21H:.T`X>1K;.L;L)C-;SHJQJS#LR%:5(0W?("0?RZ.:0IB&`AUI&XJ5Y#K
M5J3EV3^7Y@HQ.;%^U^3PY>I4U*#-7%H",&(M6B4D;[]"&SV.\U;3XW8-.CQ;
M/V*G[J#,8[A54;5M]*!`&*57NKW!7#]*9O$D611I(D>U?TUY<ZDFAM>YDE]%
M\V'0`78I#1BD.2*_E$B.ME4_R!/@O]5G"=^*-Y@99'<VUHH]KNIU^PCR<'`Q
M<J$$>V+F4Z;_<-@(J-JIJ]!!AP7@CS-F5T(=&7*-G+)B:?V8`3$VVO"!J(X&
M@:9@)_0(#/6O(\M=<;H.A"06D_!UL3Q[9HK]W*1E,6UW]#B(*Z,L'1=QMY*_
MC)M'&-2F#:-KJ$<"/0ZUKB.4QQ1V#</]1[ZT6K.*\\GF/B=M^Q/RI87.9W;X
M<=MSJ-8X-C-[1PCO-(AB""L+:5HXV+6)YB/MZ0T4E\*[S<_E,932-]V;EQ6O
MA4!M+&\J(]KSTJ5EO#VB&;MWP0^Q/JI!FQI`KJ*&5`@ZY%(UJ)C&V(XXL*SC
ME'_5XL@#,G>'.?N*"FW6[O'%J3&+K.U>\*5OX>^>#.TQ7CN*T,Z<JO,8T9TB
M@#1M1)G<:Q*@/1.A\D7.4B"%,TLE,M8[?5AP-=3>D8N^-X__#LU>IHY_8F$(
MBR**:S*6>2+)WZ5TR6N`3%L0"%J(9CUCI`#C72S-'(>S3X+$8%X3U&R&0<IP
M*I9362?1'0=K<+Z:B8BN"<">1ZDSU%T1!)<NOUOX<;]7"]#=>;*\635FT08Z
M=(61>)WJP/5#:5%=1&=$[X:)R7"48VP5,PTT9=6S1:R1_<ESA\&G+GMMM&P\
ML.5H_P;+?M-@BB5VN'X0>:&9<V,T5;,;L/9*WZDJC@5,0:9FI12(9I=?J+LJ
M7&W+N$$?C%8?^J"KG3+,FYD6DE5%T5@H%6H`.+^-L+*2":85$A@H*>52[1`*
MJBL#<TT[3A,A-3A8C0*WY$O4Q4B65,S@B[$],]1'S0$HJ)7]%"OI]CB5RJG?
MB6F&F9V(B0UR?TSJ]@IQ=6)+'9:/NS$Q5IIHO3@F%BZ;&IJ5T6$EI5ESPM[8
M#E%?^7-H`,C$4T`G3UAP[.DUMFO!"$Y*L$#8&+2-4N<Z<SD*]>C)WF]5YDDW
MO/PH]5`G<).%8\<&EH_/*[0;-W4YY6+NMZJXV4)P-MUJ9;/B1.$:@%R>,-N-
MM2T4<CN:T@:]S*AR'5#4Z;'5S07#([P0&#O>?-9,!8;4]BH`\,Q87K_0TQ0R
M/U@H!$O%,THB-:(!23&/;F(=M>Z`].^K>E#GC3>H]-FQ2B`]0Q8/"WJ;F2?X
MB<5K`'$-90]'*(PG$S&:%/R;,6CI%?MRJH*ZB:(37_[AZH2L@<Q0-^3X1ADA
MM;AQQ)XP=TSXFE6X>WBBVX]?*'[^^ZYEU<[@2N#.O1>.7AD[C1.`$ZV&=9`:
MQT\9TN^*8\WF)=:M>:4F^>&OK:PS`X^$*NVJ7'MJGSAWB06`*-OD%2`O5.P2
M=U9)R9OMT-[C.]+)N>`($!HL06F[D$@PY<,,WP_WJ>O\^@'=)T:^*,4*]VE^
MQ/>EYL<Z`OE0OM8H,<&LXSH%!(!L\]AO[17J5$J.'H:L2)I$4,C0.MQ;142Y
M*+%=:>9)LG;+/77":L55617Y2Y,;D4%*TQ(OI`'@B%MSJ.%0*-R;4ZA)D)&>
M'P%#M33O%!&+;]BM@.T-'=C;VE;A&>G8:@_2*T,QG#V:-R@DA;CLHDEU.9+Q
M+K3(T"L8%4?'D9]:W0_>A1-21BQX-'5\/@",T/0&VUWV;6'GQZ=T_C+LVSOX
M0;X_=0%XT>:BA)`(4(-?EF+82`>F/SS_J"@MK/4=-TW:]H/\&=N<]Y:2Z+UZ
M.';*G#=J^LN(3M]TA.!Q"]UE9FI@83'&BX+(?OE9/D7E>RRE]0'J?3C:.SE!
M]C*G6"Z>Z#TOBJ[Y_`]MN9X;N6IY(:8=6>9(%1F<0[Z2+G\=,IJU=FU&54^^
MQ%*40N9^>GV_QTK.?\(L?Z@AUM<FZ+MSIX%#<4O@*"?YTO`B^M>&G)&SS2Y?
MJ1[5.BGI31)O2[_\W#U;@_MH+_WC31[C9+,`(JIE.@Z("_PN47J*X_5@"!N_
M;@6><'9\!9;L[Y^;P#0>8$[T<K*7I[@"K[``?XS>:VZJUD&:M.N6KHR>,HYA
M[-:PL^0X[A^=DW`+'@G300F06Q1!,L[3W2`#\<NW.'Q3@!O%"#[^R@+'87@+
M8<#9V3=74KHLK>(XWMA\N&:#F2_Z#I4/2ADH3MDJ.]J-H79=BA4+NBW72_U<
MD$,#$;M`-[;J-[T+SVH9+S2@[3#8@'_.S/4)9S_[[B?)$\HZ2]M\!WR[E.A>
M4%MCHZSG1@WD!E8P;86JCK7'*[;7Y=D7>W;3F;.C#`^Q;<(-@;[MOA9U^_`E
M34%LA'O>O(+5D:-AL/.L[YCP(L+4)4N+EXSA<LA*ZQ?1W=E8J_;WB%,UH1?E
MR!(RQ+@)QU`T,*J1&^/FX0M6LL9;I/.)6CPLP-&L^-;.5`L!(_.;802T@U.0
MF6-WC@MQ8!!9HC;1>R)[8`+M+H04\)QU:1BK#^\=T"O%#_]9:$/D@U!G+X^7
M93`:#)]M&TO0O]^<7Y'%0A&&:"!Z?RG77BE":7A0HWC0B*C^&)S1Q?&ZFZ>V
MO;@"1R$YDJ"X>4V,6ME#%`LJVQC]T[;$3A3F5713J\CI[411FTWRQ*X&F&J'
M>3C[\I@;/H[E[7;?"WHB#5%#`^#,'?Y:-5:EKJ[+9#X]<F5JU]*!R@CW`*87
M[\EK%CX>QUF0S6=!W<"`L#L1H#L-)5V31'>JF16H_4Q$+[7OM!,MA3P'>W%-
M@=`866-`R4%N_?(X?H`FC5Q'.U`?$!\%%RQ!*0+'RO$^)O]=T[,P>17`3L>+
MLL#\M5W&T&4(`6$-H0NT&0%B15I$ZB[MYQEW2<E-!M;*[UQT2U`7U\84<0_&
M:3/[9.29S#Y@(6%NF/WF#A6+RGE46GMMN0P>N&,A%4<`5>%SD'&<$6MA&APW
M+#NA.O-HKCK68$ES#FC$,][418#)?D\UFO+A(55/_#08LV)(41Y2CK?:J?CZ
MZ<D@OR_S4!P9BZ]#5TO9P2L$ASJ+FTF<@D0>]O=G=)4+[J=S.:*J#4<K^[K)
M^4C3]2VX;]=,R3EA'(3WY4X40$-#--[T`*AQCP\9N;24-C;8[W1Y]M(N^'3M
MLE-%5C>-[`LP]''1K,2HAU@IH`9`=5PNP,%3_HU1:4323^^:CCZ*ZX*8"\'T
MZY4>':NLH$_7>,J2M%'CI"`L>(DI<P;+#X_1F5VVA4&F)LHGW^LT91>(;=;L
MS'[7A=$D:S9&^/Z4(U+0DFHY21<XIR/1TBP53(>P\7##V?R>8V]4M`7`IX!D
M@.>F:#:?_E;@3_7Y5YS`&`[M'LNA=/L14ZET;FE5%V[X%]-XH)F)V9#J\WV:
MRU"T)>:(*><9`]U^S"EMPK)B01`L,,CQ`EF!:>Q9]7('+!AY>"2LR/%_P1<#
M9NI1[KJ_@8Z3J\+O,2-4UBYICAU4G$_L@'H&B<HY*PDHA,N!MQK=*H!&4@FH
MG")NH`6Z0P#`HU^(;DQTM&-,<O`AK#CNE/O761U#9:AQMNELAR$A/:EYH/#:
ML])O0#\-EL`^WU*YL;KVJ`9;7&?3JRQ.BF9(>*CK!I=ES)GYSMIZXYE6B!4=
MX)IK2:"8H<,P;K])%<'C.&]8:+E^03Y)H:OY-6(&G4Z?[H?<0ZJXPN8YRJ#^
M3>YFJ(T9"Z*!.:&ZQ&7GY;J/%M2RZU%OK(6YW#Q9>$I1(X+(E0.!I3U:#W-'
M0,Z.X2/HJ-L_R7/RB)7CQ<1:4E<:'3D;)3?GH7HVV=%.Q"A=,')'0+DS?AK`
M&CN!C-)<\"0N(@LB&L-:^R3GO30L]DU,O-<$=N2H@[&P?P@;\&7/'H:RZ_OX
MK]<,F4/=:MYT*8SQOG(GC.E\""`NA<O,U\@/Z'VYPJJ43_1ZR+LJ02TYKFDQ
M5B#"+B.@8G,-F(1)1CFYP#4A0'YDZ@WP>H=F`W;:G<^<!]4*U/)62`XG,IQN
M1C3QL&A$"S6/R`P@VJ5X,.H)6BW4+JO#-#A()Y<5!UJ(:3"VZ=*%V_B1YH>!
M&8OW<RV$$M<XA%C)Q`:DY/2$+-Q(&LT`0R'2>429Z-P2\3P:W+H%)0V0QRBA
MC=E)HNMA3:N05A77IJ-I7KF:'0!-S[(!-LS63,^[^`[T#\K"A6D-O@?(:2?L
M?9-BN"F*AS>Q'%RO32OB0;KV1)!E+DM)BFK,W_'!D"A)H59&#H'$L;'T./)8
M-2MVG@D?:=\]0V;`(P!:4Q>?1SG$OY05GF;DTBB(KV!X3#IB34HNK:YHUECF
MY57KO:30;33<RRVZ8"6]?+/97/G0F.G4HE/J&?WKK=OP@,%1?6*"1JEO"3%7
M2$@IK6V6['5']>3?Z:@:47.[HUJM,JK]\&]U5%N3&4-#,]4Z4H4//!%+^`T^
MSJ]:V"EQ!#.)HU9B==V'+L,4XUN6N<9<:W)9+"!C_G;X08F5C[1<2)P`8O4O
M;EN(FQ#?/C9\+V5?G_[$9<\>T/L&5PJ^,%*(7A+4]HK_T0>M6(;1RS#'J56[
M$9!3%8.8:13#M\YL(Q[4=M0_*!1"%TM%I)/:>GIFF=HE0>8"@BT-KT8UZ__V
MK_^KWTZS.A/.9'"HG/@,A_$'BK[IE",O.1(?1GX$E[((VM:K'>7M$_\'#EG.
MX7Z1%X0*U;;@E0VPA!-P?WEVCWLWXP>NW/P,)T%KK.-8L>*J&#`MV8'5B*!X
M>X@/CFNGAPY]`(E#0"[4&BXL7E.,`>(O?J-5Y#=S`C8/5[V$T6#>!7610)6Q
MT`+[A6M8%\9&L:G[+'E$*1JJ.,ZME#U$QV'#K6NU5\`*.($GF(3?)\!2QAJC
M1&WLT)Z#R,WRD3-MW`@(M$CG:4^=YF()TW+!K&ZAQ#F.B`AZ)>I&(JXX38&,
MJ3`RQ3FG`L%H!:MNN(VO+8\%%-[^#N\4>F6#/OE(^&/[^6)K]_GL'MHQ_G30
M\!E1N\O#_Y[9`;3GQHK64@*K0!N!-SM=B$9*IQV\0[9XPH/MXFV]KK>9U]@P
M"'<1E@PA!(V62UZ:[1[OG7SXCB$=[Y-P?`-&,_F&J3=$`AIH1!@%=FV.)F=$
M@_6#K68>*#1Y],XJ4G$LU<V(<]#;7G>1R.WH*X4\(5Z1!ABEUCNGYZ#)%464
M"F&;IAPQ1]OV\Z=;KGKEX>$OM7OG7*E6_,T4?[HO$!!Q`T`Y!J-[XGR13)UV
M07(L_R^J,-$F``T0$H#@IF((7;D/I^(:^IZNVZX5.J,)RCD#IW+P]#>_4K]_
MN;WC]`73_1*!L=X^=N33Q^$!]=J1P6L)Q+IOP7%L`^$L%F/-'7\B\R'AXTU#
M7W"S$]Q,P1G<R$`B0F_A#%:"%^=]^0Z[1T\%J04D/HRIZ>6DNTIS%7%]+>5O
M1[O$<P!MD3.Q'6/WYKFHF>XV>%24`E*MNGR:R]=Y*0GF5ELHG@E9XN:XM_":
MXH/`OR0PE-91FJ3%%4?.&>0@M`GV88ILKH^DFV!0%2HU]X,ZG<QAT!CLK1U=
M;&,"#74V689+Y'QPR%Y?\O[*(MY%&K1X[)+8UI@K(PPM!OGABO`4KUJ#EU0=
M0JIA6>GF$/WU=N]R'X($7*QMX-#E4`V,45TU?WI?LT1`PJP@ADQ9ZS!JQ)>:
MEJ#0(8$Y\JUK2JO<6*:-5T;N`4NOQ.9HL$J:BD5OCI(LL5"M6;E15MGJ_9H]
M`ONXHYO^6(D^D9V06<587F1N<;39E3;DI<XS@0*JPX<C<HRP;88M[S0@,'45
M%;CDD#>50P..M)2Q/H'K$PRB#WL'5JC@@D604[_U-I>_K1\6QB86%?P>YJDO
M)OQ0[ES$C@Z2Z>,XVKY``IQZ+*8B+MB48MB:?)B'<Y-3&:."+WMH_S53@F<U
M#(KV?UF9Q0<\_G#0T++B4F)L2E+*@IB2-Y@2[9I&BA^3FGMGB.=+2AB_51(9
MB`_K+@3RVQ]PTU%`YYFK0Q,X3L^$,G']\C(!_U(-_$S73UY@1Q*I<G)?3R'\
M2`O,W=%T8&5EPSL;R0S-Y*ZR91<67^_]>*"+<TM.)U09S[)B[DSHA$H.0F0N
M?<NA,UMM;;)`W=U2IE69(J>FH.!9-;F:B%.NA8E^^6O;8,?19CMDE1&3'5]^
M"^N&[:T9K91F@I+%.N,<M4YY[PYW%C3U%OT.4&_%2.!.)&^]MW9*%KC1,AA0
MGF._XL^>3OD.)_R$Y)ZTO2+%2&1"'ZL25&X?@$P.@0Q3R?S8:LFC-<F2.S%L
M:=YJ'&,#!U;K<E'_F>0WD;=P8UZ&V21GMAO!^JHL)"W/0!46<GAT9J$OOP1"
MA%?$/*?T[$J[+`JB5\P3_TI553(A<4QY+Z,70`VI(P#++/#0<#1-&)\O#IGB
M`K>!:LNG`3P-5,.AE0U,X_8`3'H[SI+362Q#3[]A@1;P3S2$S/4MFU";)1)6
MS@\SBLVZ$VCW"$#K-7K9HA9['(F?34WEO_:3T.+\PM*GAI0PN]=GMZY5#XXR
M"R:\J)]]ROE)SBMSJ3]!+<^R>]A\<YJ*X6.3L>WF--G-X#`GW[`4:_LR#]6C
M93<^SU]S8K<^BU;=Z4[B\?4'88C?'K0,\.KS<(@7@E&[=&YQ5GNGIAE%J%]F
MT78KH/]L\>;-Q84%[B?+2;)<#Q(Y3*R*'IL<^-;_P=7",J;0*UU;=6T-OJGX
M-!E^H((,(PZ5.X6$Z21.6213?TPCZDB6X5)`8O<KACE:,TJER?6_O4Q>KB;7
MR(3U(3FC:Y1&BV=7>`SWD6H13P-;22+=7/$&,<K`=;%C;"_"<46)E&RQKH*1
M#1_8RKXRB9GAB$@\*EW]3'^KE2R#'HPPCAB`K_I#76ON.<1FM93X`X_IP/:J
MYZML)-B^')W>E""D=0@5N`&(!KNS"&5I^L)V!CO=XT:&^\IR"Q;%&JL.P<>U
M$<CZTMK#AY99+*`5!1$9*@0HK70<FI%7KTQ,]@IV*%W60H;P\D%6F0GOLBFW
M[JICE4^)BM,UR3VY41)EI\(A1X8GZ6=4?%B[CV1$J`>D!WB04D?XS=;KG1?/
M&JXEURBI3F"Q([\5M=2,T1@QAP.,A@@OMK]Z^7HPBAI/G+$_:QH1!0_V;AR#
MJ:FOGSW]=OO9_9TW"!+:I*%FT3F*1NCJ)L@V6";E&7O'[JK0>J+J!3W]'/><
MG)12!C[203ATW"/E4'%0JKJ[&!'44T\[T9)O9,78Z%*MAF0454'KCQ_9L6L)
MZTNK*YM+3\C]-;D'&E27BVK#&N>G#EXK2,S0WR%031I"=U\BP]V6&]!)3>TH
M8:VY@T31FWMDL*ZJOB<XWA@"M3SS)@`#3N]MZ06QG2W&*C:72_:"07:PN>[-
M:A[>9M?F2$W:O+U1L_B\LWF6SGMUA7L;R+G??/1I!Y[]MC[UK//[_IBK`/SW
M.V;D<,4V`6O^.?-JU<NO.>C<\HBJ=_!<7;V7GTF3%0U0=#46@<GP][!*Q2MX
MB0[,J@MA>BL&`UF='$F$(R:NT-'KW6])M,#OCQ3(*!@!@N/3GU2#50V#D"S4
MAAEWDF5^=KRO5:S.=BVMG6@4=KW\@*]PV-O@]JO^T@Q(I_EI$>@FK,0XI\D#
MCO@=N@8+-BBS-J^RL!^#276,1QV2894FC)!!VMA,SZJG8<];_5A4#^!D<G.I
MX0-FQ91T'H7`56,:-IMMQVIAJ#IYTGO`I)V83OLIW\1DYJ_T.F!XNDM*6UJX
M620+T+#E_]!BV;#G'V2'!ZU3*02ZC',0G</;02*??20!P8^F?C*V<W3%0BW$
M@*\%X)FC$>?ZY=&E.IAQVJ@SD?9+:(2M\TC;L.3!T%=+?HBV:2>@>0(5)(Q9
M@"&4[RO'*]-E3S.-VZX'V2KSRC7=QF92]M(YE@G#-IL]/+EP3RKRE5@R922(
MXT0(J;'R;;WMBZWXP7'&US;.B?13`(FRG0M@86*M5?FX6H%1E(MHIB`[.A:2
MYG?C\=%G-B)NA,9J/TTE.E\M6"+G@N=U2U<R3=I7RB[/I)EK%.N%`6WDA+>U
M[QGD.'U26F'02$`WJ&2*ZUA*`!"X$9=YZ%RF%+KW/.9IPV,^6#\[8P1:4&S6
M"-\N5-'2GD)S^];M_._)?UCE;\9_9CF8,2#S&<&5Z=P0S<2]IL3/6]#)2`!8
M]JNX01=;OU`9DJRX0<YW-%5/*/_MN4,:#D8:U6'X%IXI[WDAYCGX_\G(#RK=
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M\F70?RH*[D_4(ICQ<`5BY+JCUL:/=5V\4/:1&WK5JJ=[O"EYLU=/OWV^-7M_
MRG[-#,Q=,9)2_F2<JH3UHS*&W=(6%/W*$(#FR4!:D?IE<743>*/-V:QXMN6A
ME#8NZR^=O%JLVI<I#Q>7@A+_KBCCE.*N(]3GFL,\!M=-81&!&'RDT+;8LX8P
M<^L._9NIO4N"%F=E)=B_&"EL5Y&('V7ZX@ZJ:8):4T$2M\YCHQ.G:!NV/73.
M9D%+WACA@%S=QP<?N8S$%V!>`)8&_`$$@]M1EN8_[X[>$5%GB7(ZZ6>!G!#$
M.T(/-)77UUA5.:1;%A_V_JST3`(?C$9P:%\3^S=IEBHZ<$'6!"&6\]-W5#LR
M#M$44(J;L[GLS/*OR/GC0X$@LYR,6JSUQ#@P,;1JY*12]HR:L'"VU*C9L1)L
MN\*3(6PM6[RS7N+ZP&$?!]A[/NOX2JT!2ECAK\#9PQ:](";2PU1)2#LO.TJ2
MK4C<]!PB/#OWI0<,TK+?'I[0<P*`BLF!C9F&&H5I;]CY=G@I-.`^;QK>R&%A
M<,G%LB:!*=)Z<3,!.;LD1)AGHQL!.S:YA19.)/+E/&$")J3-V#!3/>$7(_F3
M1')]+R(B<.771NI!;B*/0MF``(8+&P[B@)-G7%X=D$/)5G7ASJOS4SR>>.2V
MN`KDXD(8;*ZLW5=<@EFS<-[2+%.\TH%`3K'Q`QI0P>1)/[&[>RR?02O:QQ^D
M2^\8C^$T"Q!-SY2(4.LM=9W6\`6H)`\..%^PS"-6?G9Z1JS)**B$4[:VMU^^
M?GK_ZZ.S(\X4H&[M?'/_JYTOO\J(E`>D+BR@\Y$T!05V-*E'4_%/GA6&S3^(
M=T:`5.]\]6IW[?Z;KU[O_/'9<+@T_?62P!]!0M8K]"H]IM?BG.QXQ/<ZAP6J
MAP%$&:-0GZWKNY^(KY-8";-S2:<-<!L1;EV8R'V[)U.`.SB_HAS[B*HEH`S8
MV8ES.-\>S2J^%Y/IXW3P]Z@;8PPM^^CD_F64$Y_QEWX5:5\!L6YWB4ZP<F44
M@?&X<.V:)2@J';N``/<,S4K:5<\B#QK07USI"F5-(VC`-HBUJR&?YAKA`26!
MVJ6R8AQU"Q?OHH^V6TWMW?8CG7W^0M[J<HB9W!$?WC\X^'J*V$HST=HHW,.4
M<9.@-$K`"[:&XUA-4L3PSZX$57CJOFXOPF%N"$M?D0MR`XHJDB%M,%9;#Y(U
M3]V<2Z>#X#R9Y2F-?>C"<<F')*G806N8\IAEO4!*_X&DG$."F;N7.O?9[O<*
MU?Y0`NI]V$/T\P?BL&??S7:79_]E[_OSOQQ^O/C^:(GN/,NSU?7[^S_<?_3D
MX<;LWM/E%\M_6%;'59X[,R(2\H8EE(V2$23&+JP9Q/7<26AM?69&'RMH:7'3
M0UY\Y%W@>AWPP]&%0-S>&OE>4>A@(Q"B>SJQ[WAFS`0<2UTIF(J],M;EM'5!
ML":W()'4`,:E-$H-&4-V^38O@?VGFK5&PSD,YVU.LZ:>*0S.D+K6@203XX:\
M!)VB+HJ-Q;+1GGP.3=_B06U'-&P0!N]E&%7\2!MP,G7<@LFJR16(=T3+HNIE
MWO4;<53`\2P[,*FQ%5BR^F1]P_CFQ>'A]_JF7N--&.3P4BX"6IWLZ2A-;%Z"
M]2>'/UD9<VEH."%!(3%=0!%<#,R7%++\<?C_.U>\-*#I"3\<O3_EK@_UX[`?
MH:-0V044WT]'I.>?__[R<S2_0J</4R:*!!7.DS:3N/);T"D<V,I8@%I_5&1]
M<(@4W(3$LH2S0HQ#&MTE50*L(/:6-!S$^B\D12PE_5%8\X7RE1J2A-[LT23]
M+LU>?;V]7#[OR/</I]^=S)X;@9[3/5"#!DOX8GGVGP_)Y+_Z4(A\>^>/]S<?
M/UZ;W=M=%IW_2]!Y`'B:SBGNHZ6JV(L+N5]^]DPGCDG_]XK_=_3@\]]?_$4X
M\)_^:77EG_@+94.&`Y41ASS2D_/G1`7]E6UJ#;@45$_?[3$TD41]N:8',I90
M[NP!M2FGYWKXP&:Y_-RXW&CVO\?,O_R,-DK=T3R>%T'OQX:I:Q";+@8I/,_3
MD=>=H%.'^P?/,UW[_V^>!_$\N#@"[?D?^%V5/KNN4FB$+'EUBB$O%G\O__69
M$\$MOGRCS,>+\7=YU?6%^B%Z<6QP08P&2VQ^+04#17^+#@,?36J*R;S&%Z(;
MUK<Q#>'PK*Y?4O_]Z]HR4`,\153HBK3^LV=NNR,G>&E[[TQ99$=_@>%OJS$_
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MN$TK[W*C^P]8#G[-2ZN,P1$A=^6).O\H9^`</17<@LED?T-6?=B/<!W3_>3S
MH`IHT8%<-^\B,.V:Q^\@.ZN$5Q%5?K2YX8M*M^A?N;N^@AWPTXB+)9T<5#JI
M[8J:T`JF\)6WCP3H,M?OJU>K]7[NIVI([OJA)M>Z:KW.^W'O^N,9*:U.`:N/
M?[LM'2`5Z5U[,+.[(_JI/PE*/YS*2J0^'\_.!$9^J9+Z>U"+RF[,D:KKTGC6
M0!TZFSB8"3'\C7?]+;;HOC,M2WGJ-_.5>ZBRS8<:#*&>,7&DUXT&,<[7CS*\
M8K8EO[A"O?_@&R_C[1_OJE;=W+QV*PYFPO$1R3@R_8KH76)I^(8%R2G:OOMD
M&K>?(08/Y#)M,+*RK06B/?0"H(_D\B3'TNRE7W]L"P!DGB&?1>%D7+U@_).P
M1-Y<VP]QXW7._L=L#A3O;AC)7,PVDCC6-B:)X^YC?[%?0P.B:XAV25&E,S!V
M"JEO/@QL)/#-*&[$F&X%%.^;TN_I[GH`A>1HXQBC%Q)JU[&4YY3(H[57[PL/
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MT?ZA3+9Y?/+UX5ODZ`6M"A1S?+NWC\-S2T9F:$@C4AJ.[^K4ZT,DR<GH5<=N
M$`SDMF*!\U/RJ#Z,WKNAO7LMP,/>OEBH)^=DMO(>>*W5++NOF-37G;60&-<P
MY/'RW>QE":>;Y2UPQD`+5^99NMW7(V#=TE[OK/5K8?B\6/M+L_`"F*6^5.W^
M,=`4;4:_P)(&`A?W$0R'/P47&JW_!A/`&-NW=DX('\'VO\:=<CP;&5GMJW-6
MO'#`]=%^;N/!N!:@C?2NVE$_Y4A$8)Q9+\G^Q3H:`*D[7XA77^A.;PK?WG.E
MBC&2?E"LW@6_]LZ4Z\WL?OQ^A!LSON9#;"6YJ3*GHNVC3.`]FS+T,]]=?13J
MRG7:R/5.I&M/&C68,B;"[FI=U"P]*':159J.'?Q#UPB5^N;-QOMD&WR'Z^@5
M-+1PVM4)+E`\9%)7/G(UX*Q$Q'J(U_7),X.?LW^AJ`;BK_%':TRD$O33]7@V
MSYVSNM![4!80NDFTQ!PK)@0ATK4S^>,I#D'RJE:>X(72Y<16#8>?$!XX=]-5
M4_$2D=!7,E;6?V=+6+4@R'@)7YP?'6#=?LV-;/UW6RA!RH``L)8BI8BE.=OZ
M%RL_6<A"JO[\,;3`YCZ5?LQG/^IJ'I`$L.R/SA])B7P@S8+"_U3</"J+C6Q0
M/#NF8Z9GVIAOMA__5B.T59O]0`'`$^MWC54J=QBDB_;+']P@X%D*T?&2,/AX
M?5[NVX][JP5>3'H"*L#]=PN?>=D?]?DRC-WQ.1*OMYJ;':%6HJUXTG"_CZ3.
MRRG?U\-IF[=0EV,Z3::+Z14[V=\C4%]ZNP4^]5/_^J.Y9F\5P+&"M"+ZE3RU
M=HJEPXN&E;#\@;8%V?@IG#/FDK`$%TL_,B]O8Z7T`]]]@ZG631ZXU[50H"\N
M-7*%VW!%%.:`%B%/"AXOH+FW:%V>'7A&&X,C>6YD%\`:BM7HP>E:R6^0H^)5
M)F`QL>68(&>U7L%KX?P#;ODDO"U6SHE=*FGI#-.&]1S\^>H">6WEL`K]:K"R
M6<R?8S!`PSNKX(-+I0D9/IJHX1LW0M7SB()2Q;45@;)E[;<\Y+[3QA$*T>2B
MV0+=*=BWK9BFX60X">57EU<HPL73K4+BIXP=<*C9+G[&!)FXW$_N=Y^\+-J7
M:Z'ILK,]7CNA808G8UE@3,NP[%1YAC_Z7P(%9'I&Y>==Q7$J/UR696C).WD3
M;QGXX-3&]9Z=W.G&&<;Y'#IN,DW@GB53E@_%ON!HTL]Q]>FDM,9$4U9$%$L7
M&Y203G%5=<DEEY__*8-!Y=AZG,:XLIOS+/Z0;[6F>O]!&9+E7Q\=*MI1/\RV
MI95Q/C'>#/"\YC[PRX52+5\.H8Q4VGBPMOE@9;,?'NOM"`)0V.;IA-?Y[NJ#
MU<T'JQO]9^/Q-Q^LKSX82_*[/%^YT0"KO/9H:@3]\'!BB*>Z=."3E4#NU4H5
M:'6MW]YV$T#2-/WO%C>+T-C(R%J_V3W'_9CN:AXI%>TZ1U,%4HY$I8'F970.
MZB<JUY&C0HVW5A*L++DYB?$=/I.]X[R]FPI\<9T2BYWKL7D%,\I\:5$J[022
MU9QP#1&T?E5>&&U"`*%7C)?W]YO8)@^\?_8"))YZ;M"X8:QQRZXB1PN16TDL
MA&`#3"TOZ0P^6=*C^R4\]XN?LH%N]?*['CCWNZWL5`<++@0Y%;PPP[@(C.+U
MGF)RH[4-?)XW^<)B3@!UO[@-WMUZ#*Q%<B*)N+(QI0'VJVI);1BK160.KF:Z
M^9=*=.;LCG+JJ=##_'EU3\`4Z._JHN*;+V*1>CY_\J%6`KI))Y9,7W`Y[HFT
M_)LOS/NJ:%P`=!H%%D+R`S%4DC]R#<H.NOFP&<\"^$3HI@`X?]<+XW5_3/4H
MM&PQDG*'5X\D8B\OS.HI3?B3=DT%Z_>S5?N$#=!%,=83&T?`MPLY^T_G;P>R
MSW00U_O@(K63HD!M<OF\'S'9N1)^ZS5B^_VU7OUG0YZ@X8NB(QW,O;?]1R_8
M'/D04<C3.IUT>5?_]EWB@]-!,0_?R`<^@%\_P+?MO5O"L\Q3Z%\T9IT_*C!&
M'H>GF8@,CDY'0;3YQU#RH-R6M39'H,?4A4#]*N8/6G8YAY_M)-.)WQ7_G'MY
M#N4"^]1E'_?3CP<9`()-)(3Z+U&S[2;QLDRQ[T:;.>'8^V_*;$G"B?O]BZCV
M\Z]!N5X5ZX?+CJ/1V[?_60E-]\893:9[93/?_INM#^?<GDHI#_*6%!_]NW^%
MHYWT/V='Z_Y]=4GOGST?W_#0O[*+/_H[L+=__OS*^Y#N#+O*;GWS>G5E%`!X
MQ6EY'95G;,@RWHIJ@W&XX,LO7LWN_?+740[8PE%&$NVYU:?=:'F+\>&&&E=U
M5ZB\22I7ZD(CF?9489*XT,:*$61AJI?2B"F\OJ:S>G\JKZ*)E+5R<5U-?'3^
M4BI,K^FZV\^4!%I9-%0W)6G11"OKF\-LO`'I]90WSYV\TWK")51ICKPKKYWD
M]QY=DV_L'+\FK6VJMQH&Q@CA7R.0\)1(>]NU;[[U'F_JY##":YI:+,^BZ&Z$
MQK1HI#W\:`)_/.?M]?ZP,A]YN!BUV1DMQI:;[93C7%Y`O@O-=%/"/,*/5M-E
M-::#L5_4-1^YQB&MA1=O^>TBG?6E-[_T=F*<CTS#HN8@D;*K(S:;*VK]W#[`
M4OA.A/)S)+IA8#HMT5'2Z<XD%X84KDN-V(-WY<09Z#U;1YZ:A1^/DTQO/.^"
M]7X,OU(/B^N6.N^[Q:N<]Y63DK=+C'8O_8*:5Y84TD^GT)0>/W@7-/"V3OV(
M#2D[X&W^I?!(F6L.NY`*7*GLT;!CP1B#25F@E93U[[<O_5&Z+?+RU:36>#>2
MO?H1.HKW-6>.PPCCIM^^U19'S3)NPLW[CY9FT]G?%F3+'@G]5OM!KOM](2<C
MJYNF!:A<5QY:@IV!&?N8&$T[`-&[,F8F<I(MG426-Q8I%N3D6'6!#RXN+C__
MWP(```#__P,`4$L#!!0`!@`(````(0`DI+0]$0P``.MK```-````>&PO<W1Y
M;&5S+GAM;-Q=_V_BR!7_O5+_!\O;5G=2$\"8`+F0T\+&[4K;[>DV52OUJLJ`
M27SQ%VJ;W>1._=_[WOC;&\#V.!Z850_=!@SSWN=]GWD>VS??/_N>]MF)8C<,
M9OK@LJ]K3K`*UV[P,-/_=F]=3'0M3NQ@;7MAX,ST%R?6O[_][6]NXN3%<SX]
M.DZB`8D@GNF/2;*][O7BU:/CV_%EN'4"^&831KZ=P,?HH1=O(\=>QSC(]WI&
MOW_5\VTWT%,*U_Y*A(AO1T^[[<4J]+=VXBY=STU>&"U=\U?7[Q^",+*7'D!]
M'ICV*J?-/AR0]]U5%,;A)KD$<KUPLW%7SB'*:6_:`TJW-\'.M_PDUE;A+DAF
MNE$<TM)OWJ]G^I6NI2(OPC6`^,-_=F'RW>_2/V_^^.9-_]_??O?/'YWUOW[Z
MYO"[G[[5>SD;0A-L4$_SLE]+%KY.*?<R"6YO-F%0"C(T04VHK>NG(/P26/@=
M.`.(AS^[O8E_T3[;'AP9(+Q5Z(61EH"503YV)+!])_W%PO;<9>3BSS:V[WHO
MZ6$##S#'R'[GNV`F/-A+.9R7SQ+1Y#)-$`8GTQ"/4)E\$,G&@_4RV3\?D8GC
M-6KFU45_'"\F1;U<TG@=^L6!#KOP*FQ%^$0/RYEN69!#!OT^JI4:[$3,IHL^
M\#L;LZO1V20;6D-K+%4RSA</[88,AY9,538PM-Z.WYU-G?*954F7I>%S10`&
MG%PMNA"Z-?$]MO!U#C\Y<T$[C<4852[IL]`K<^.]ZSNQ]M'YHOT8^G:`BJ5%
MC?V:J\F<XYV&/+K`CKJ!?#8PPTW>>NY#D,Y'XMT6IKRKR-TFJ('<_\:7AP6Z
MJ_Y.+%@.G6384S@R%Z7RS9-+,45KU+FOG/FE@)V[,:)!(\#L54%)37(*'F>(
MRMSLC5'7S1HYFT&CXW;C0ZU^:E[4^J?CQ2I!#"7"];QBV0NKQ?3([0VLP!,G
M"BSX6LO>W[]L85D80+,`8[F'(QM__1#9+P.#>8'8@#CTW#6B>%BPQ6BV&%A<
MW5F+.\:7(!-%44'4LA;C$Q"]FT\7\I$NIBR%]B2*;UCPDHST[0A?DHE:\-]"
MFDZS*FK*`EG0TQ(7FT?]R_%T.IT,KB:3R=0<#DR3*7F9>;0;K)UG!_M)TM1T
MB&`$"*;#R?3*`"!]<\)8G17!$`",1Z/):#`U3/B?36-.CT"V3D>Z:JL2!(JL
M2A`HLBKK7\A(?5FD0"M7<:P2!(JL2A`HLNI8<@8>*[<J0:#(J@2!(JNRKKO$
M6(53)(ICE2!09%6"0)%5I4T^LPP\56Y5@D"150F"<ULU7U8M[NXLUH,]G)E5
MSX_92@[6CLLP6D.S+3]I.L#58WKL]L9S-@FL$B/WX1'_)N$6_EV&20)G8V]O
MUJ[]$`:V!V][^8C\;\U(.%\-IZ9G>O+HKIZ`&==/2O&F+$[%H<A$)L[PS;'9
M'YLCXRI=1$EB[3MK=^<?2E?P/NHKH$;4;;/@1(=!P21SA[(EWT,K9.83',%,
MS2PM.`!\(G<)P1$R9"Q/3XG*2$:(R4@&",I(1HC*"*%S++AR3:[#'6R5V#>P
M94WZ_?1,@"B?>H($^!&/.0Z"C#G49^.0(QIM'--65L@O![$Q-_#%9JQ')&T8
M<2AGPX`C4C:,$)61]YO<NASQHIV`Z?D(DCU]<S]_'0Q@E`[,\>PEP2P_X1G*
M]!RE<+H[+FXC>2(U4&A7KG(9]M1T*(,,)FTDR8$UCJDS8E:OH?RO',_[A`7Y
M'YMB#@"MKMN;YPW9X03;SG`+$&Z@PK?0-,[>IO4^_0`ZKAID5`[2[.W6>_FX
M\Y=.9+&]:(P%.XI]Z_+3G$U4RL_L?*'OL&:=GI+Y(0H39Y6PO7+L9$(5GF$%
MGD%&2`1/%_ZPH>NH$D%/POKHPA^:04?Y@UZ4\@?G$N8OTQ]P5V#FU&`"ZM1U
M>&0B@"5_C@",H`(![F+,=`#NJ0(!+*5R!."@)0*`4^,57>(`3LT5+,$'2I;`
M_U0L(<?D4G(L3RAE5?H%_C526ESZ[:1FDF_!T4LUPX<:`)U85J5852F&F!TB
MK50!?*A1@0555T[)&U3E?&4*(4D7,)0:@310IQ%Y7DER+O`L`=1K9"YQ'D*<
M`E.1:@@`1PD$8HB!HOH[H!@456#J#8I*,(7`U>`SQ@2U!%<A%6$`/$JBHIPG
M#+B*<48U$`BJ,B3Q!D-5BJ085.7(TA2&JA1)(*C*D-02JE(DQ:`J1Q)3J$J1
M!`)H1$F&I)90E2(I!E4YLC3%4%6*)!!494ABB>&)4V2/MDW3)BKIGU[A.=2J
MUB,8*%_^[]OJ>=/82!U4+9J`5CX\73VE*T>P!5M+D:4T7C=JX[46V#O5'L/(
M_046F7C]Z`H..)&.UQLG[HH>^1+9VWOG&9:BZ7FGYTTG`1LPE?RAN:YK;9A+
MUT\'+`*6;E!$H^1L4=_8F-_S#+ZYW>@AC2"PN:,:`^HZPR#=!22%"$:N:C5!
MD52.@9H*"F93,GQU-L,3O#27M<\EJ*VL(PZ@N1G.JW)M8R11U;1F7G?ZC?1?
MSRX)"B6DQ<H:]77G8&(T7*"*R6I!)L!BVK4`$.;8)%#&W%#I88;L25&K0"4Y
M;+B_+*Y+$Q9K9#>Z`*T^C2E-P^M24L^"=-`3G*8UP18#VD9IU&)-W+E($51:
M&RPT;O[?L5!G8MN96LZN28IYE:IJ:A0U`V2U[M66RBH>..S&*(>!0^:XXD"/
M3[0%4S^%W]%4TM79$<^K7*>A4E)U=;8VJ:J5A0UNMK2WKN(-.\].$S8F^%:Y
MBA0;Z5855UMS$V`@&^A7HZ77^'YK9>SG29I^A(FI3#_580.=N;I9T4G"ADXW
MI(1-&V\T2%]2"G.:ZO*6G11`N`5!BFVZ(J0E]NLI%A59C\:F^/Q()#@%)[M4
MVZ_)3@2T=/^465,`7+Z^;7(*L15+A[X"K6]-8$ZR@*%>1RI"`Y:OR.O$0?/S
MJCPH]DLD>D?67JW,N*=,<$WK[7/FM#0+-"$R9`>^G"($GGVJ(M2DD5-'=<=,
M7>G7#76[LK%*\60SB285&37[:NO,5HFAE=/4[&$]#7.X'+9(*RTB6'&>K4)=
M7]Y%0%>:D;K2*R8A!BD']2CY:E")IXU;4<-*84Z5T3@#:HPXV=WM#M,>W%Z2
MS\&D:*J-F7!3AU3F4LTTA$:/5'2-JF$7KV13'F&['`_R5F'$-K_`=A=R\2!_
MZ6"Q.4;#&YO"C=C[O]<NM+<K+#%%UPQK[7+G>G!;$-SU@IZUVL5P]?L\/9AM
M-:FC5;02L-M`:4'2;DNKF'5@D:6T8)+4EA:P3ZL1^@2A!==5MJ8%%2^CA5L-
M2WV9D!7:XH(A&2U>]R-!W9O'[,@VY9:X4&017)16:4?0')%Q""*WI57:$0Q'
M:8'(;6F5=@2$A)8)3-K2*NT(5J"TP-W:TBKL:&(.+G4_$M3]U5$[\KZ*R58$
M%Z55VI'WU:&@KU):I1UY7T61V^(J[0A4B;Y,^*(MK=*.?)XP!?,$E;&T(Z_[
MD:#N]S,J[_$XI1*1+J52V@[>$1UA0T&<2FDUWLN'@EZ>8BGMQ?NW*>C?*972
M4D"/2&3"%^(2%38:\MHU!;4[M]=YUN4=!NN,"`RXY^UJY\&C5$)\$`O;(8JG
MGHA`>#V`$*5'9_6D+>""_X(0'P]81D4(W3UO/3NPDS!ZT7!7:$&.-_I(D-R?
MPK#0$4\!^_8B@/X,CZV!)^)HH)=40[P/XX[`-F2*6.#5@Y>(M2$#HU,TO/_A
M:J,-&1B=DN&3*LZ?1,B\#[:[PD)\+L72+4+B@QL\.6O><W@-8U=`A-)'9Y=$
M=N%_?$AA/TJ("-XFHJ#!IXCT%M+Y/2VR^>='N"M$KD3<,4MB!^?0(CS_NDN(
M&G$4(6((YJ5[-X&[^>1!S)%`6"(X[D/8J5V0V,LH@C3^;D<!1@L7NGL^6B%1
MN>\=9O_KY_*6(4SO"3[8B=U,I%@/@*+6SL;>><E]\>5,+]__A=TG"YPI^]4/
M[N<P821F>OG^`]Z`#*(8ELJ0;C[$<%,K^*OM(G>F_WHW'T_?W5G&Q:0_GUR8
M0V=T,1W-WUV,S,7\W3MKVC?ZB_^"RO`I6-?P&*4.3YEB3\."G>\#\SKVX%E4
M429L!OY3>6RFDP\I?';7(8`-^[)R(7IQ\92NV_\!``#__P,`4$L#!!0`!@`(
M````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;
M-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7
M`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA
M0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD
M$4&P/I:;N.V%2B6;E8KT81C+RSPA,<Q-N(BP@E<15,8"'P'=B%76JM5F)<(T
M]E",(R![>S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;
M`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG
M6NO76U=V<OH&P-0RKM?K=7NUG)X!8-\'3:TL19KU_D:MD]$L@.SC,NUNM5&M
MN_@"_?4EF5N=3J?12F6Q1`W(/M:7\!O59GU[S<$;D,4WEO#USG:WVW3P!F3Q
MS25\_TJK67?Q!A0R&D^7T-JA_7Y*/8=,.-LMA6\`?*.:PA<HB(8\NC2+"8_5
MJEB+\'TN^@#00(85C9&:)V2"?8CB+HY&@F+-`&\27)BQ0[Y<&M*\D/0%353;
M^S#!D!$+>J^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;G
MUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M
M@4=%^)!&1*);Y`@=\`AT,X9Q)2<C<;X5PQ!39P4.@78)Z9X*'>"M.69EN`YQ
MC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#<N9B5L0=
M8'Q8QKN+8\>UO5D"53,+2L?VW9`X8NXS'"L<D)@HI.?XE)`2[>Y1ZMAUC_J"
M2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$
M'Q+FF/$ZGBD<E9$<XH@5#7X3J[!,R,%<^$5<3RKP=$`81[TQD;)LS6T!^A:<
M?@-#O2IU^QZ;1RY2*#HMHWD3<UY$[O!I-\114H8=T#@L8C^04PA1C/:Y*H/O
M<3=#]#OX`<<KW7V7$L?=IQ>".S1P1%H$B)Z9B1)?7B?<B=_!G$TP,54&2KI3
MJ2,:_UW99A3JMN7PKFRWO6W8Q,J29_=$L5Z%^P^6Z!T\B_<)9,7R%O6N0K^K
MT-Y;7Z%7Y?+%U^5%*88JK1L2VVN;SCM:V7A/*&,#-6?DIC2]MX0-:-R'0;W.
M'#I)?A!+0GC4F0P,'%P@L%F#!%<?414.0IQ`WU[S-)%`IJ0#B1(NX;QHADMI
M:SST_LJ>-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?7
M85;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&Q
MMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q<J2(EH/&PSZ['B*U0K<6IKL&W`[
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MX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0U
MG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO
M]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_
M7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`
MB\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?<DV'D@72#LX
M@L;)#MI@TJ2L:=/625LMVZPON-/-^9XPMI;L+/X^I['SYLQEY^3B11H[M;!C
M:SNVTM3@V9,I"D.3["!C'&.^E!4_9O'1?7#T#GPVF#$E33#!IRJ!H8<>F#R`
MY+<<S=*MOP```/__`P!02P,$%``&``@````A`+'U%*]F`@``#P8``!D```!X
M;"]W;W)K<VAE971S+W-H965T,S<N>&ULE%3;CML@$'VOU']`O*^QXS@WQ5EM
M%*5=J95652_/!.,8Q1@+R&7_O@,DV<39KM(78^PSY\R9&9@^'F2-=EP;H9H<
M)U&,$6^8*D2SSO&OG\N'$4;&TJ:@M6IXCE^YP8^SSY^F>Z4WIN+<(F!H3(XK
M:]L)(8957%(3J98W\*=46E(+6[TFIM6<%CY(UJ07QP,BJ6AP8)CH>SA460K&
M%XIM)6]L(-&\IA;R-Y5HS8E-LGOH)-6;;?O`E&R!8B5J85\]*4:239[7C=)T
M58/O0]*G[,3M-S?T4C"MC"IM!'0D)'KK>4S&!)AFTT*``U=VI'F9XZ=D,A]@
M,IOZ^OP6?&\NWI&IU/Z+%L4WT7`H-K3)-6"EU,9!GPOW"8+)3?32-^!%HX*7
M=%O;'VK_E8MU9:';&1AROB;%ZX(;!@4%FJB7.2:F:D@`GD@*-QE0$'KPZUX4
MMLIQ.HBR89PF`$<K;NQ2.$J,V-98)?\$4'*D"B2](PFL1Y(DB_J];#BZ@X6$
MC+S!!;5T-M5JCV!H0-.TU(U@,@%FYZS_3V=@R<4\N2`?"F@#W=C-LF$V)3LH
M(3MBYK>8?CHZ8PC(GW,`W<L<WJ_J2=N!K[7[:5?[%I,-!^]KI_^C[<`Y!O8+
MW\,SKZ_-/&#Z%Y@WQ)5K@-SOVH%A:BY8H>\=Y8"Y0QGZ>ZGL>I["F?BX[BZH
MZWW<R2!@!JD?B3AZ:\N5\<&U_,>R#MR1'<4=V8`9>=7T_"]HAC,=1KZE:_Z=
MZK5H#*IY";;C:`@YZW"BP\:JUH_72EDXB?ZU@HN7P]R#(XQ*I>QIX^Z,\U4^
M^PL``/__`P!02P,$%``&``@````A``'4X7>]"```>C@``!D```!X;"]W;W)K
M<VAE971S+W-H965T,S8N>&ULG)O;;NHX%(;O1YIW0-P/D$`(H+:C"3F?-!K-
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MD/^5?KC)_O4M9^[66(]XQU:[GV:2;=F(,C,CT8QM>F`-8+\'QSV7!AN1S8_B
M[\=^E[\]#J?SD:9/I@K#!\])EMM[;G(XV+YG>7K\3T`*;U1M1"V-L+^E$44;
MS51-7]QC95I:F5VMJ"-UH2G:_(ZVL%:+#K$FEXU1]9$RF]QC1*EZI+!&55;F
M]S=&87T1K;EV2IWW'IJQ<%;A>W.3;YX>+NG'@#U0K&_9><,?3V7%ZZB\+GQ4
MZ^`S&3#7<2M_<#.%,>;AC&GW^Y,VFSV,OS.];4O&:#-339>9M6#TX:"VH\B$
M61%<-;QJJTJX%IE-%W(ANV*J0HY(8+_K>K397"[D5H6N#&F+5Q&569\F!#0A
M%`GL=UVQ3L8I:B.DWKA--$=RS%Q;^Y?)K^7?*9L;;C_5E3MY*>I.31X>0S!-
M5TTU,N[K-J/*5LPVH9.*K'9C9OI2-F.W&6U&&*?-D,:XD/`@X4,B:!.TRV$;
M(4V-(!&WB:9_))&PJ4D22;<X.,W%4:G>$`EZG;"F"29-L"H;U\=`FY&YP.[!
M.#T8MP?C]6#\'DS0@PE[,%$/)K[!U$^%Y%XVK=_A7DY+[A4)#??2!),F6)6-
MIGO)W&#W8)P>C-N#\7HP?@\FZ,&$-QAM6CNF6+.B'DQ<,>PQD[S)MB5W>)/3
MDC=%0L.;-,&D"1:U8=,$AR:X54)#`-I$'@3O%D-6.O\60Z;"H`<35DPU9T4T
M(6XD2,,]OVNX.<TVOHWE7=/(^FX(AKGWN@601V8-"1,2%B1L2#B0<"'A0<*'
M1`")$!(1).(N0I($V_/<\01R^G'(5N/:W9I&MCB&8+HD`0D3$A8D;$@XD'`A
MX4'"AT0`B1`2$21B0<R+`XVJZ!/^4S^KDB9X%(2>H_`^FY>BVB#'$$,P7=J`
MA`D)"Q(V)!Q(N)#P(.%#(H!$"(D($K$@EN*P.[IZ39+%\DNRX*6H+,CNV!",
MJ%Y1E1%9%=<BOT,V)B0L2-B0<"#A0L*#A`^)`!(A)")(Q(*XY15)%@H[@7]A
MNBB*46&0?;510AV>7V/$Q(B%$1LC#D9<C'@8\3$28"3$2(21N$3$PC)5->W3
M=47AL9[FPM)]-B]PJA`2"#%*J%,A(L34@9C8BH41&R,.1ER,>!CQ,1)@),1(
MA)'X!C*=7Q]U>3;AH9ZF1G@0%V\^>&B:+C/SZ_:F.*D:)=0AA'6)E&)>S)M:
M+HR8,J%,]*5"3L06KL?&B(,1%R,>1GR,!!@),1)A).Y$9*'PD-$7A"(B3=(1
M9DY.Z@9_O\'4U"F4"N'O!R:-+5.IDF:V/B*SEH4KL#'B8,3%B(<1'R,!1D*,
M1!B).Q%9(<Q_7U$(+T:6G3G9D1K\]1)22(5\HI!FMCZZ3H>%@"Q<@8T1!R,N
M1CR,^!@),!)B),)(W(G("N&!LN8<`C8D(JXFSQUD\C?X:V:D#(&(149A7PUH
M',3+Z4,B)@OVQEB_GLI*A<"*;-P6!R,N1CR,^!@),!)B),)(W(G("N&!M*9"
M>FY'1/Q-5@J-G2I=0;K"Q^L:$7,(6:=,*5N9C_AVY?I#:*NFK]$[<A"W,>)@
MQ,6(AQ$?(P%&0HQ$&(D[$5DP/,SV!<&(Z)PL&!I956"0;UTCGPBFLL"SF6!(
M#59=O$,BE8E/$0=;<3'B8<3'2("1$",11N).1)8(C[8U)0)6'1&<DZ5!%@-#
M@3&^-49,C%@E(M:NF39;T/?]MD1HB]F,KFZ.1/!\<E!S<3L\C/@8"3`2EHCH
ML-9N;(1MQ)V(K`T>=+M#&R)&)VN#3.J&`D-]:XR8&+%*1"O"R#-55<BQQ\8V
M'-F&,I\2&RZVX6'$QTB`D1`C$4;B3D12ATI#K=TS1X'3DPPY:!@EQ$XC]3L]
M(J`U1DR,6!BQ,>)@Q*V18@VL7W$5.RJOS"P#/"H+5LJ`+P'+R7Q!MFU!;?[3
M`0LQ$M7(C4;&=>:M*F1%T)!JO_VI*D*B\KQ!GC2CA#J5@4.KV(J%$1LC#D;<
M&KDQZ%Y7IE]F"MDLIY,9>8P"&="G2P*$M?E;/BVT&6$D[D1D93#GWK&2J!PG
M<X5.G@VCA#H5(>QT(":V8F'$QHB#$;=&;BJBZLN-3%\N.2)A@$#*;KW1#.OL
M#C54M7^*Q)U69#7P>&3_?84JPI>L!?6BH.GD/&F44(>KUQ@Q,6)AQ,:(@Q$7
M(QY&?(P$&`DQ$MU`-)U$*N,;T'5]ES7"/'F/1CA.9PSR&!BJ@#HU`A$36[$P
M8F/$P8B+$0\C/D8"C(08B4ID(?;D_%L_\GXG[K0AZX,'')MS2,^]AHA3RG,)
MV509_"H+B)IBQ,2(A1$;(PY&7(QX&/$Q$F`DQ$A4(S?6.GY5ZW/O"(V(JUCB
M.LXQN;PFZ^1PR`;;])U?L^+[ICI57`%;*RMV_X5]AY6D6\J*77%II[O*BMU`
M::<;ZLHH;I(1.VMUM;Z5;JHK]JU@9F=<%V`WO\Z;UR3:7%[WIVQP2%Y8DR<C
MG?7Z(NZ.B0]Y>BXNDCRG.;OS5?S[QN[X)>SFSF3$X)<TS:L/O(+ZUN#3_P``
M`/__`P!02P,$%``&``@````A`)*&N:(1!```,`\``!@```!X;"]W;W)K<VAE
M971S+W-H965T,2YX;6R4E]N.HS@0AN]7VG=`W`]@$I).%#)J0+T[TJZTVN.U
M`TZ"&G`6.YWNMY\RQ<DFRM`W`<S'[[]<*1]V7]_+PGICM<AY%=K$\6R+52G/
M\NH4VO_\_?+ER;:$I%5&"UZQT/Y@POZZ__FGW8W7K^+,F+1`H1*A?9;RLG5=
MD9Y9287#+ZR"-T=>EU3"8WURQ:5F-&L^*@O7][R56]*\LE%A6\_1X,=CGK*$
MI]>251)%:E90"?[%.;^(3JU,Y\B5M'Z]7KZDO+R`Q"$O<OG1B-I6F6Z_G2I>
MTT,!<;^3)4T[[>9A(E_F:<T%/TH'Y%PT.HUYXVY<4-KOLAPB4,-NU>P8VL]D
MFY#`=O>[9H#^S=E-C.XM<>:W7^H\^RVO&(PVY$G2PU^L8*ED&63.ME1&#IR_
MJD^_09,'G8@&4)V(_[MNGA>J%[?O9GS?=?G2I.V/VLK8D5X+^2>__<KRTUE"
M3P$,@QJ-;?:1,)%"&J`OQV^\I[P`"?BURES]GV`8Z3NZRS-Y#NW%R@G6WH(`
M;AV8D"^YDK2M]"HD+_]#B"B#O8C?BL#UAN]]N)WY\:+]&*[MQR1PR-);?<+`
MLM6`:V=@Y2S]8/TT(PP7AZ09[81*NM_5_&;!?QV"%A>J*H=L0?G^D,(P*/99
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M?O,9]PHVW`^S`-8K(II[HZ3C*6*Z?T1H[@EL!^8/?D,;_HVNHY;1`C#J.K[#
M&#+)0T0/0:U&L_\_!->N\:Q#C$DE:IEQ"+Y1W?$=9A("=C66&1`]!+5LS0\!
M%[EQ"+XQLT0$F7'?OE'B\1UF\-<N]%.9`=%#4.O;_!!P-=1",,N8(*.%8-;Q
M'6;PUX8PE1D0/03HZA,A*%JO!=^L98*,%H)9S'>8P5\;PE1F0/00U&HWRH+:
M=B^@Q'^P1\0U4LO&T`%.2VKS#N&.0S&0N$56N&:LGH*E$:LZIB@1),C:)QM@
M!AD,!<\7N.,M67UB,2L*8:7\JLX+"U#O6_L#$)Y,C/98'8S4]M)HC_QMA">9
M_@4</2[TQ'ZG]2FOA%6P(W3E.6OP6^/A!1\DOS3[[P.7<.AH;L]P,F6P*?8<
M@(^<R^X!.G;[L^[^.P```/__`P!02P,$%``&``@````A`#K2EPZ,`@``TP8`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C0N>&ULE%5=;]HP%'V?M/]@^;UQ
M'$*@B%`54+=*FS1-^W@VB4,LDCBR36G__:YM2$GH*OH"<7SNR3GGWCCSN^>Z
M0D]<:2&;%-,@Q(@WF<Q%LTWQ[U\/-U.,M&%-SBK9\!2_<(WO%I\_S0]2[73)
MN4'`T.@4E\:T,T)T5O*:Z4"VO(&=0JJ:&5BJ+=&MXBQW175%HC!,2,U$@SW#
M3%W#(8M"9'PMLWW-&^-)%*^8`?VZ%*T^L=79-70U4[M]>Y/)N@6*C:B$>7&D
M&-79['';2,4V%?A^IC'+3MQN<4%?BTQ)+0L3`!WQ0B\]WY);`DR+>2[`@8T=
M*5ZD^)[.5@DFB[G+YX_@!WUVC70I#U^4R+^)AD/8T";;@(V4.PM]S.TM*"87
MU0^N`3\4RGG!]I7Y*0]?N=B6!KH]!D/6URQ_67.=0:!`$T1CRY3)"@3`+ZJ%
MG0P(A#V[_X/(39GB41*,)^&(`AQMN#8/PE)BE.VUD?5?#Z)'*D\2'4E&H/ZX
M/P[B:#R97L%"O")G<,T,6\R5/"`8&GBF;ID=03H#9NML!/F\[0PLV9I[6^1*
M`:VA&T^+.+R=DR>(,#MBEI>82=R'K"XAM$,0T->)!.L?%VF+^B*CH<8W()T`
MYW3U'J(G$;([E_A^?A8,.6/TFA\-^T]>>DQ\AIGT$:OW$#UM0'*]-@M.,?CN
MM$7AJ/_DI<=,7>>G\7![=;Y-DR@>=^4]63#ZU\NRX*&LP3PM/29QLFA"AWG]
M=[NG*OF(*@ONJXKIZPR[$5IZ#&32!3H4YA$^3CJ9)M$@+W\N^=>V95O^G:FM
M:#2J>`&<83`!9\J?2GYA9.LF?R,-G";NLH2/!X=W-PP`7$AI3@M[[G6?H\4_
M````__\#`%!+`P04``8`"````"$`5*!F/V8)```U.P``&0```'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6R<FUMOXS@2A=\7V/]@^-T777P+D@Q:(KD[P"RP
M6.S,/CNVDAAM6X:E=+K__9)BV5*5E"I;W4`N]L<C\O!VJ%B/O_T\[`<_LG.Q
MRX]/PV`\'0ZRXR;?[HYO3\,__VM&R^&@*-?'[7J?'[.GX:^L&/[V_/>_/7[F
MY^_%>Y:5`ZMP+)Z&[V5Y>IA,BLU[=E@7X_R4'>T[K_GYL"[MK^>W27$Z9^MM
M5>BPGX33Z7QR6.^.0Z_P<+Y%(W]]W6TRE6\^#MFQ]"+G;+\N;?V+]]VIN*@=
M-K?('=;G[Q^GT28_G*S$RVZ_*W]5HL/!8?/P^]LQ/Z]?]K;=/X-XO;EH5[^T
MY`^[S3DO\M=R;.4FOJ+M-J\FJXE5>G[<[FP+G.V#<_;Z-/P6/)A9.)P\/U8&
M_;7+/HO&SX/B/?_\QWFW_6-WS*S;MI]<#[SD^7>'_KYU+]G"DU9I4_7`O\^#
M;?:Z_MB7_\D__YGMWMY+V]TSVR+7L(?M+Y45&^NHE1F',Z>TR?>V`O;KX+!S
M0\,ZLOY9??_<;<OWIV$T'\\6TRBP^.`E*TJS<Y+#P>:C*//#_SP4@)07"4$D
MLK6']\-QN)P%L_D=*C&HV.^@$D;C.)PMEO?4Q=:Z:I#]7M?EW@;-0<1^O[\J
M$V]QU6-J7:Z?'\_YY\!.`VMB<5J[214\6.5+5WECKYWW5=_93G,BWYS*TW`Q
M'-AN*>R`^_$<S:/'R0\[2#;`)&UF$6,DO2!N2#A==7FAU@UP$7TA+D6,?\%^
M;52EOL[$-OO:=CM$FFWO'IZ7)CK8-?%RH<2_T+Q0B.N6MHG%#".JC1`1W2:H
MB&DCT?1Z'=1B.QF:+7:]'=GIS;?<%;(<<I2T(_&,G257UQ?7&E1=F8J$$@DM
M$H8CD!.VJDTG>`<<_#2T-E];%\WGN'V)9^91-?JGXRGIQ]2_;[]>-8A#2E#0
MHH+A"-1ZNQ#=WGH'T]:3NB>>85J7BH1J$]%\B5W6;8;4Q'`$\L"N=DT/;IL+
MKA#U8H7KF'B&\T(DE"=@-`5Z1!93+2H8I!".9U/T#TDB6^PB?K\MKA"Q95$O
M0=4"D'B&LT4D5)N(%G1':#-TB+2):%%/5^2&BZ1D>Y073%>(ND$Z,/$,YX9(
M*$]<EAP\"K58W'Q1'+5_U:?]KA!M?[T%^]'@&:[](J$\<6G_>$5'@JA@J$*]
MK2$7`KM'WC\,JE+4A_H*W@>`EM6V,0KBJ3VKD)F3(B:8Q[.XQ2C$A,%TMFHQ
M&C&C^=+^;T$&H.Z>P:ZXJ-68'/P>&OA@AC;1!=U$`5I5;LS'43TK?8B`][LK
M5R%*D-"RA&$1;(&+7@T+;MM$`A_8L!5DD4H`8IJ:RH@"Y#I'Z!21)0R+8#=<
M^FJX(0P(G]6P"V2_3P(NT,&8$!$EJV@9,8#,J\$9Q&[N-*8J=L)VVQU..)HN
M%#15!!YBQX.(*%E%RXAA$6R$BV.-(7'C!/$ASG;L-2Q'\];*R24]&!HBHMQ]
M">L]8ZN6$<,BV!"7R^XWQ*<Y-%>69)M(`C$4IC*B.I!HV5HVQ$N9#IUZB<.6
MN#QVOR4^Q6%+R'Z1!.VH5U<"QHB(*%E%RXAA$6R(2V;W&^+SG#!IQ%B8!B*B
M9$3+B&$1;(C+:?<;XM,=&B'TWDD20`2$11VOZ3!"/,(L$0JI+%P\:^P,E8H&
MA%$Q+((,"4D@Y7?:BB;[RY(>2`!BZI?*B)(1+2,&D,M.6]G9,!1;05+H;3M,
MV)%&E_2,`A!KB==A$"6K:!DQ@(`EE]/\]<R'+;%#OCE=A-'A:#(Z%C2'A1[R
MEU^X,TJC/_PT`82U0E31LHI!=>%S6.BRX=T+1U6*.+*D\0,@IKFIC"@9T3)B
M6`0/#5O?'H:X4M(MX-!#K"$BHF05+2.&1;`A+O_=/T)\:K3#N0ZHK1M>[L],
M?+1,941U(-&2G)MU!T1RCNE`HF4-85-ZA=2P*Z2V%A(Q.::@PPPD!4A]K`W)
M]-2RB&F)!+4(MJ-70`V[`BH]U0'$M#65$07(U8YPMH0]TW^C\5V6-"W)Q0))
MUDD;6]4KNH8^<J+IM*+'&X!8J^3H*JMH&3$L@@WI%5U#'SGY+`\0:X@<7645
M+2.&19`A[O;Y_0MN58ILR:T%%R#.$!E1'4C4NK7<`=5K:96'3`<2K;Z8-E&O
M$%N5(J8LZ8(+$&N*'&)!!5:8U=C=76[\F^E1W3)_WI&O:["H_9MI?2;!0\;%
MQKOWZ,B'3;2H+.GZ"Q#KCM=A$`4JU_4WF)*CA):O8]HB]8C"=I!0R\?[R-%D
MD*QJHZO.2@!BVIC*B)(1+2.&1;`1MKX]QH4K)879R$.L(2*B9!4M(X9%L"&]
MPFS4$6979``G`/D#8.S/G]?3IS\``L)XIF05+:L8%L&&]`JR44>07=79$*;,
M)<BZ3SN1@)6"`FL%4U[+Y0V+8!-ZQ=>H([ZNR+DC`0A&1;4AT$'A95@G//*U
MB(;+,"*&1;`=O2)JU!51ZP4:QH28/U/089JB9$3+B&$1;$BOB!K=$E$!8EJ;
MRHB2$2TCAD60(7&OB%J5(AMMZW8S0)PA,J(`86:,+&)8!/O1*YW&/E6B_+6B
MZ10@U@\YG<HJ6D8,BV!#7"2\.Y#&/DCRASJ`6$/D0"JK:!DQ+((-(9'TMIOP
M<5<TI0D=(-80K\,@"E3\C(&[YWBGTO*%#(M@0VQEFB.$S^BQH^G20?=:@"Z?
MC:&!)(7W61?\=;Z2T+*$81%L`0FC@@7M$-KZ!'GL&::%J8PH&=$R8E@$^]`K
M@\8^'@J+Q25#UK>A221)08?Q3,F(EA'#(M@0DD>%@='.H6%,PWC<C)#1BGPT
MQQ]/@&&=D&6T+&-0;6;Q$G]>#WM!PJC@13N$VK\UXW4LB>40*B-*1K2,&!;!
M1O0*H?$M(10@IN-3&5$RHF7$L`@R9-8KA%:ER$ZRHELJ0'XSC#HG"R",9PJI
MC()9U''\T[*.81%L2:\<.NO(H:U<#I"W9!1UM24%AO7$7\O+!''0:8F89PU[
M)6Q)1Q)U6Q._CMB'_VC>B*?D'D8"D/]D<K<A<A!%(J.@ZX,#&AC&5_>THJMP
M-^(-\4\C^F?;#MGY+4NS_;X8;/(/]Z2A>RSG^NKU*<AOU4.0Y/4D>$BK1PG)
MZRIXT-7KD^L;]J'%T_HM^]?Z_+8[%H-]]FHO-1TO;`><_6./_I<R/U5/VKWD
MI7U<L?KQW3Z>FME'W*9C"[_F>7GYQ3Y?-KD^\/K\?P```/__`P!02P,$%``&
M``@````A`'.45+X&"@``%S$``!D```!X;"]W;W)K<VAE971S+W-H965T,3$N
M>&ULK)M=<Z),%L?OMVJ_@^7]HX+O5I*G)BJ*@@*RN]>.(8DU45+J3&:^_9Z&
M/C3=?Y>)6S,7H_XX;_0Y?6@:<O?WS\-;[4=R.N_3XWW=:K3JM>2X2Y_VQY?[
M^K]BYZ]!O7:^;(]/V[?TF-S7?R7G^M\/__S'W4=Z^G9^39)+C2P<S_?UU\OE
M?=1LGG>OR6%[;J3OR9&./*>GP_9"/T\OS?/[*=D^94J'MZ;=:O6:A^W^6,\M
MC$Z?L9$^/^]WR23=?3\DQTMNY)2\;2\4__EU_WYF:X?=9\P=MJ=OW]__VJ6'
M=S+Q=?^VO_S*C-9KA]W(?3FFI^W7-SKOGU9GNV/;V0\P?]CO3NDY?;XTR%PS
M#Q3/>=@<-LG2P]W3GLY`#'OME#S?U[]8H]BVZ\V'NVR`_KU//LZE[[7S:_HQ
M.^V?O/TQH=&F/(D,?$W3;T+4?1*(E)N@[609"$ZUI^1Y^_WM$J4?\V3_\GJA
M='?IC,2)C9Y^39+SCD:4S#3LKK"T2]\H`/J_=MB+TJ`1V?[,/C_V3Y?7^WJ[
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M)IB:P#'!S`1S$[@F6)A@:0+/!+X)5B98FR`P06B"R`0;$\0ET*0$%EFDB?HG
MLBC,B"SR^#\R**752!E+L,K$!%,3.":8F6!N`M<$"Q,L3>"9P#?!R@1K$P0F
M"$T0F6!C@K@$M)11?_P3*1-F:.Y2SZR8>5*(FF,AU#?R6(@4B00R!>(`F0&9
M`W&!+(`L@7A`?"`K(&L@`9`02`1D`R0N$RVSE`LML]=7<=PYA7260![X1TE:
M61O]R^BBX^*HRF6YU6J14,)OB$1(ZY%(HK?UGE$YA1"?P`3(%(@#9`9D#L0%
ML@"R!.(!\8&L@*R!!$!"(!&0#9"X3+1\T0KDAGP):3U?.>EVB@8^!C(!,@7B
M`)D!F0-Q@2R`+(%X0'P@*R!K(`&0$$@$9`,D+A,M.30+;DB.D-:3DY-2;DPP
M,<'4!(X)9B:8F\`UP<($2Q-X)O!-L#+!V@2!"4(31";8F"`N`2T38ML#UZP-
M<8-Q>=WOOCVF^<WNE<;;IJ::KUB%$3U!.6G3>KRX2MI#\SI9"!7=#L@4B),3
ML=0O3%O]H=Y(9X6:$K*'`UUH7@BQ?Q?(`L@R)]7^O4*M[-\(TB^$V/\*R!I(
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MX$ID]_-D]0:=P<#H/0M64R$L&56&X"DI#L%GI$)8260/\A",\F`%Y3Q@5.D\
M5%+L/&*DG&\DX@18@ZY1S3$K90'H12)NR\L7I.J^8N5W\73/Q@$]2E3N+(Q4
M&4\DXCIN62U;'Z0I*ZE)Y#"B^]"J(LEC*@4P9T45@"N1;##]SJ#?QB*1EE0(
M2[94&8*GI'A8?$8JA!4CV50:QC19\W'E/F!4Z3Y44NP^8J3<;R3B%%A#VU@@
MQ*QTI9>(K8!RF>1[;3>N6\2FK'%98E1N,5)*5?A$2G&%7ZL>J:2FF*-,5U:/
M5%0!S%E1!>!*)%M,S^ZWS#FV8"T5P9)1Y23WE!1GSV>D(EA)Q!T&BP<&(&`K
ME>Y#)<7N(T;*_48BSL"UXBD'H/<8L=U0+I[?]!BY.U'N,1*I:AZ+37I12PI-
M$$T1.0I5E@68GTO%=O8\++N*N8@6RCP/YU*A"H^>DF)%'\VO$*U1,5"HPF.H
MI-ACA&B#*-:0GFIS`^G_ZQ.XL21V"2G=I28_9J2J=()HBLAA1`5;=5D!CW.I
MV%&5Z3+*U\S#@=4;V,8*;<$RO>*BN?Q4")Z2X@3Y;(N"4['#ZE5*=>5JNM'I
MZ!?;-9M1(07*6<FRN2(+E12'%#%2>=@@BC6DUXS84RJW![-FXO2=)OIO'^/(
MK2F5G$?Q2$WO$6-$$T131(Y"%<,S4U(\/'.)VFJH740+5%PJ5.'14U+LT4?S
M*T1K5`P4JO`8*BGV&"':((HUI)>`V+DJE\!OKA#Y1A>5%$?P*)Z`BE0/"C1&
M-$$T1>0@FB&:(W(1+1`M$7F(?$0K1&M$`:(0481H@RC6D)XQL<%U0\;R_3`M
M8SGJTD?1R=HM>*Q:2'&J)^+1-:6:%!E-$3F(9HCFB%Q$"T1+1!XB']$*T1I1
M@"A$%"':((HUI"=1[#:5DR@ZK]UM4-N\]1EZOF^EY5<B/;_&7=]8O'X@YJU*
MY@31%)&#:(9HCLA%M$"T1.0A\A&M$*T1!8A"1!&B#:)80WI^:>7_A_(K+%&:
MRAU7(CV_;7VA,1;[IF9^`4U1RD$T0S1'Y"):(%HB\A#YB%:(UH@"1"&B"-$&
M4:PA+;_BI9<_D]_,DIY?1GI^C87D6$EQ,YX@FB)R$,T0S1&YB!:(EH@\1#ZB
M%:(UH@!1B"A"M$$4:TC/K]B/*O?GZF61G6]?E2>I1,9%UMAX&BLIE<3<5ODB
MBU(.HAFB.2(7T0+1$I&'R$>T0K1&%"`*$46(-HAB#>E)%/LB-R11;J.4.BW=
M],H>6EXI&7>98R6EDE@H,IJBE(-HAFB.R$6T0+1$Y"'R$:T0K1$%B$)$$:(-
M(O&>M+I8Y4G,WWO.7SL\)*>79)R\O9UKN_2[>*>9+KT/=P7.7[A^M,4;U]G-
M,!RQ^5UL\TAO1`_O*4DFM^@`+<*O'>G3D6S5!#H#.I+=!\&1(1W)-CK-(W:+
M(LLVMLPC@Q$]$T;_L\&(GM4B]P8C>H:*/*2@KG%Z/?U+MF-J^J5!O#Z&%.@5
M^U_:9.?:@<?VB%YWPH`>NR-ZF85XL_!,KZ6_;U\2?WMZV1_/M;?DF5+<RO:X
M3_F+[?F/B]R/^)I>Z(5TJ@)Z]93^`"&AYZ$ML79^3M,+_Q`.BC]I>/@O````
M__\#`%!+`P04``8`"````"$`F#[SJQH&``"+&```&0```'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6RL6=N.HS@0?5]I_P'QWB%<<@$E&77"7;O2:C6[^TP3
MDJ`.(0)Z>N;OIWP%VPF=7LW+9')R?%P^KC*%>_7E>W76OA5-6]:7M6Y.IKI6
M7/)Z7UZ.:_V?K^'34M?:+KOLLW-]*=;ZCZ+5OVQ^_VWU7C>O[:DH.@T4+NU:
M/W7=U3.,-C\55=9.ZFMQ@5\.=5-E'7QMCD9[;8ILCP=59\.:3N=&E947G2AX
MS2,:]>%0YH5?YV]5<>F(2%.<LP[B;T_EM65J5?Z(7)4UKV_7I[RNKB#Q4I[+
M[@<6U;4J]Y+CI6ZRES.L^[OI9#G3QE\4^:K,F[JM#]T$Y`P2J+IFUW`-4-JL
M]B6L`-FN-<5AK3^;7FK.=6.SP@;]6Q;O[>#_6GNJWZ.FW/]17@IP&_8)[<!+
M7;\B:K)'$`PVE-$AWH&_&FU?'+*W<_=W_1X7Y?'4P7;/8$5H8=[^AU^T.3@*
M,A-KAI3R^@P!P+]:5:+4`$>R[_CSO=QWI[7N3F:+J6T"6WLIVBXLD:*NY6]M
M5U?_$8Y)E8B&135L")[\;L][D9&!#AT(GVSRT8D@)!PL?%*^M9@L9S-GOEP`
M-C+3G(Z$SX=F6E`^?%+^XJ$505GA".'SH7E<RH?/3Z[(A%0A.X=RAF[=+0\,
MLN,X@?RLRS:KIG[7H"IA4]MKAFK<])`:2QUB(T^F>[D$2814GI',6@>C($]:
M*(!O&].V5\8W2-J<<K8W.")CQQ@H0Y&L+P.!#(0R$,E`+`.)#*0#P`!;N#>0
MTK_"&R2#O&&KVC*@-\N2C&`,-L27@4`&0AF(9""6@40&T@$@&`$U_2N,0#*0
M9U#H(UE"25#)G+20W.$4;H^"!`H2*DBD(+&")`J2#A'!)5B7X-+MTY=5#&)C
M,]@BMA29XO)Y<J1%\U][7X8E)D0"Y@F1H**V9A-^.CY<UDA(#)(BPTJWW*D4
M*R>QM?D*$BA(J""1@L0*DBA(.D0$6^#<%VP9WR#$%M=.D)G#*WFG(+Z"!`H2
M*DBD(+&")`J2#A%AH;`[GU@H8HL+)<A@G3+@RT`@`Z$,1#(0RT`B`^D`$-:'
M^E;UH35!C__N5.:OVQH2'D[U&QML0W611Q82$9=-$;??7XX,BF[ABMGN$Y(#
MP?(3RYJ:(BG@)%82(==F2,217LB49XNY4$^RIM+S(^$DIIUR;4`$+Z'I$+R\
MX1ET@<PTQ!9-(X@#K4._>E=:_8Z0+'B^<)*R,I^2X'SM2?+1$M#I3'Q(.JXK
M-1DA%4&9P#L1V</HD7#B1\))A'"@!9V)VYY^$(ZP$ZC]^L168+JX%Q1RACY;
MKI0<.S808KOOD<]8I,M'W5A`(6N!S3<M<SX7EQNR0<,`E(V.&&LT@)BQ^@`2
M*8"9LY`2+66#[@4@&HX:O^$Y,I[[)ND3H7]A5;6ED)3]4D[N*.N#]&<LF\L'
M3)YDNVLM)>60C1E/=\:Z9PH^#V/&ZN=/&.3@#;<M:;M3]ON]Z46W87K!;?*J
M\<E3VT0J4M832,SZJ=PTLH&C2><S5I]T`86L)39A[D@I%[(AH^Y&C#4Z?<Q8
M_?1)/_V@6N4#-F4#+90\HNVH7_U$DM/V=ICD%.H38V=R:!"4?,SZE&7CRPN<
M9($*A;T6*ZNHAT;D8U4K4:&TUU*<D1OV_Y>0:B./WG`@1YVA803ZZ`B@+'"W
M/YF51R"3)Z>"M9BJQP+5N5>7>"\BJC,>4\Q8HS$E4DRF-9>>.BG3N1>3F+3`
M$I)6WIJO]14.@9L=WJ!;07=@\F%!H>'><&C@NIK,A&7C:SR:S`H4LAE[^:B'
M1N1CRAK()RJ4]EI*,J.7@6&9(\?L);KOHU=B#[_TP4VEXAJ%A![7E5]1V<#^
MJL-7H4"%0A6*5"A6H42%T#TKCAX'09**W)N2:Z^J:([%KCB?6RVOW]"=*+0,
MFQ6'R86MO_2@8P>/)3Q>>M!;JSA<\#[CHU?B;]'%[PW^UO+@LN6&CNT]PP+4
M'[:V!Q</-_"9!^^[-_"Y!Z^'-W`3?B`S&#Q6N`J^9L?BSZPYEI=6.Q<'L&6*
M'\P-N4PF7SI:="]U![?`N/Y.<.E?0&\X19<+A[KNV!>8VN!_1MC\!```__\#
M`%!+`P04``8`"````"$`?=^1%ET%``!P%```&````'AL+W=O<FMS:&5E=',O
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MFX].E#F>:2UFO4#_ENC<#OXWV@,^;YIR^T=9(U`;YHG,P#/&+\0TW1((G"W-
M.^YGX*_&V*)=_GKL_L;G!)7[0P?3'4!&)+%H^V.%V@(4!9J1&Q"F`A\A`/AK
M5"4I#5`D?^^?YW+;'8CWR'>#2>B`O?&,VBXN":=I%*]MAZO_F!7CHBPN8X$G
M8_'&HV!B>SW)#4>/.<*3.P:C,`C\<3B!X6]X^LP3GLS3'TT<>^I]X@>L?<+P
M9'[.?8YCY@A/YAB,'-\>$YENQ#EA;O!D;JYWES30H7V@\/Q2@E/F!\^O)>A`
M\=%:(%5(I_E6BA8MI;XR5WF7+V8-/AO0[E`K[2DGBX<3$5)>DU0E4:4?%2E4
M)V%Y)#1S$W2#\FNAL]X6;NC/K#?HAH+9+'4;1[9XXA:D]`GM2@76*A"KP$8%
M$A5(52`;`!;((K2!#OD5VA`:H@W/:LF!@5B*$-R"NZQ48*T"L0IL5"!1@50%
ML@$@"0$=_RN$(#109[`*W*@29@2-*HPFBCK"1,BC(6L-B35DHR&)AJ0:D@T1
M227(2U+I^K+..X98]V+P))8,L?OV>?"4I,6O%UV&+29%`N))D9"F=H.16/SN
M;FM")`?)$+G3`R568<1S6VG(6D-B#=EH2*(AJ89D0T22!78#29;;$T2LY=PI
M$OBBDY\T9*4A:PV)-62C(8F&I!J2#1$I49B=+R1*K.5$*3+(4P56*K!6@5@%
M-BJ0J$"J`MD`D/(C!V)]TQJ1TT1W*(N7)8:"AU7]R@1[T%UTRR(D<MH,F5[F
M5R"7IG,F4[G:5]3(AV#%BN7:RM:V%D:\)6+!S9&-AB3":TCMRN.GPH@394,B
M23@X9TC"71$(CDA<(6(M*T01'\X)EU3#L1S/$S5R83,11KIHS`@6TXO1U):9
MUFPXIU\1'6?L*D>*F+&0>>?G#FVHC8B'ZY/<,WCZV>#9)X-+PI.CE:0\/6=]
ML61[%GE&&.0/U79#=<?DCA#RQT*MN)4C&F#-(!<J2CBZ82C/4\P=AT$X4V57
MV'"K2W\E'+J,F%X?4>FYC#M^-*(L/CG@#=>+VV7OT/,@G%-XP2PYU'\<]LO'
MTP6Z**/5WHI9>?V'8>^XUJ'XPL5'W.A0HCNF.I1)CK(,()8DP_^K0<*BU""%
M_*$Z%/ID$7"8U>U5@%GY;!FPPXFR3L2<Y_8ZP*U<,:\)AVX&D"H!.%Z@E';&
M>3X*0)X'<H(<EJ,Z#]_Q"02^NGT-5F>XJ=`F@D'#B1#0S3*E5MY82+-F]`,H
MYB->Z#<ZE.B.J0Z1>Y8^^IZ+RD/O3>C7:86:/7I"QV-K%/B5W(E,81,0*+VO
M6841[*O0,@J>A!%LBCH.]SN/_>0K]DMR[W/%?NE&\$ETA<>+'B%^_8>E%\'G
MP14\B.!4>@4?1W"(`]P2$<%]SRG?HS_S9E_6K7%$.\C=[O>)AMX8T9>.U<@S
M[N"BIR^7`]SL(?AJMLE!?X=QQU_(`.*N</$3``#__P,`4$L#!!0`!@`(````
M(0#D;[YK%C0``)=``0`8````>&PO=V]R:W-H965T<R]S:&5E=#@N>&ULK)W9
MDAM'EFW?K]G]!QK?FTP@9YFDMF8",6">[S.+2I5H)8HRDC7]?6]'^`D?5C``
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M?]<`]/]???KHO*%+\OY?QY___/C+M]]^>CU\>',SO+U_&"C^U5^>OWXK/KJ<
MKU]]^/O7;Y\__;\FZOB1VBQ#GT4_?9;KNS>W]U?7ER2Y]DGTLR-)3^\WOJ%^
M^H8#7<>>!OI@QP^MGY?U=.<;ZN=Y/=W[!OKI&]R_>;B]O;E[N%?G/4/4!#T.
M43_/Z^G1-]!/^TS#-\.'V\'MG1.RIRMWL1H/./=Y>?LOX*"UC?YQV0<;F%?<
M/\[LS9PQ"-88GAB@>6(03/%XYN4P=[AI=.%G,W\,SC;(P!SB_N%[B^=.GV[F
MD<'9)AF82]P_+NO-7?"C2]P_SM-M:"YQ__!-AO?GJ3`TF[A_]';WMEG1C@OD
MZ/VW]S__^.7S/U_IMJ-.O_[YWMW$!C^X++8T-I>T72R_MU9JD719_L>E^>FU
MU-$J^%4K_#]^'MS=__CV'UJ4/_B8=QTQ:<231;@5V*4=Y6"<@R('90ZJ'-0Y
MF.1@FH-9#N8Y6.1@F8-5#M8YV.1@FX-=#O8Y.$3@K21N=9:T_PF=71JGLRGT
MSD`0?IB):A'69)2#<0Z*')0YJ')0YV"2@VD.9CF8YV"1@V4.5CE8YV"3@VT.
M=CG8Y^`0@414K?3_"5%=&LU_W01Z9J\/TG+?!F43_*D-::4&&8,4("5(!5*#
M3$"F(#.0.<@"9`FR`EF#;$"V(#N0/<@A)HGZTBM1OWLW:RNTBSZ*;.*\\^3J
MN%S_5SYMV_\:](Z7]&0D,L4%(W'1Z4@\T7Z@]=;@[B%;1]H@^P`CD#%(`5*"
M5"`UR`1D"C(#F8,L0)8@*Y`UR`9D"[(#V8,<8I)H*C$23=W&0&<TOT<^>V/@
MTJ1B>Y+N%1XSL=N@5FR0,4@!4H)4(#7(!&0*,@.9@RQ`EB`KD#7(!F0+L@/9
M@QQBDH@M,1*Q^Y<2%YUJZHGRAPE\?Y5IV@:UFH*,00J0$J0"J4$F(%.0&<@<
M9`&R!%F!K$$V(%N0'<@>Y!"31%.==Q)-W00>WK[1A+]P;^\2I7)[HJXCN0>9
MW&U0*S?(&*0`*4$JD!ID`C(%F8',018@2Y`5R!ID`[(%V8'L00XQ2>36615R
M7S^X>M:E>KM,J=Z>I'KG&X8VJ-4;9`Q2@)0@%4@-,@&9@LQ`YB`+D"7("F0-
ML@'9@NQ`]B"'F"1ZNX+4?TCP8ZI4<4.IY-?9%`]1K>9$8Z*"J"2JB&JB"=&4
M:$8T)UH0+8E61&NB#=&6:$>T)SHD*+6!._#'!9S^6[>K26:3V]!#>ZA_(AH1
MC8D*HI*H(JJ))D13HAG1G&A!M"1:$:V)-D1;HAW1GNB0H%17=^:/=7WQ[=N5
MD'/)&W2KHV5T`[_)9W<;%68WT-BG5RZ+*HA*HHJH)IH038EF1'.B!=&2:$6T
M)MH0;8EV1'NB0X)2%[C#_W_&!;Z,<-/*],X]*)`Q,A?<YBYHHTS?46AH:$Q4
M$)5$%5%--"&:$LV(YD0+HB71BFA-M"':$NV(]D2'!*4NR"L]+SR+NPI?OA(T
M*//`7>Z!-LH$'_E<T;0?$Q5$)5%%5!--B*9$,Z(YT8)H2;0B6A-MB+9$.Z(]
MT2%!J0=<H29?"5Y0CW'/ZW(/-"CS0%[<]0TCP4=$8Z*"J"2JB&JB"=&4:$8T
M)UH0+8E61&NB#=&6:$>T)]*;$+8L:[*E'G#UF]@#)_9ZOMP3+_EM!2B^\>>5
M5O=@UGDD/.89$8V)"J*2J"*JB29$4Z(9T9QH0;0D6A&MB39$6Z(=T9[HD*!4
M:E?6N4!J%YZ=X!IT&]1_<D_/%16A$=&8J"`JB2JBFFA"-"6:$<V)%D1+HA71
MFFA#M"7:$>V)#@E*=77UFPMT]>6>(.([]QZ#1`SD"60$,@8I0$J0"J0&F8!,
M068@<Y`%R!)D!;(&V8!L078@>Y!#3%()74GF`@E]!2<(]LZ]5R()K\/Z^A10
MO#!G3T5&%B4+A'/;0U9G'X<HVZT5AD*/)5%E*$V?U?GJ$&7I)X9"^BG1S%":
M/CMOS$.4I5\8"NF7`457XCZ[7BN+2GO,=C;K$&4];@R%'K=$.T-Q^L?L%+T/
M09;]8.B8/?&6>VWH`F\=P]-EWZ/86T0C0_'(!P]9!7\<HFSHA:%P84JBRE":
M/JL>UB'*TD\,A?13HIFA-'UV:)F'*$N_,!32+XE6AM+TV29I':(L_<902+\E
MVAD*];8]T<'0,5?JD;SBYTZ#@]LW[EW);[]]_/"W=Y\=Z'QCZUK/^IL7MH8L
M!'J46*>)BM#(HA[;0L*8J#`4+D5)5!G2>ABM9]D,JD.47>F)H9!^2C0S%(8Z
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MH*$*$Y'-LIWIT]`W3&XG-+:/:GXYPZUT8]]P>']\%6[X<)U-F<(R]RI96E18
MURM#H;,ZZ^QFD.TL)M:FM[.I187.9H9"9W/K[.'XR>ZS*[:P%KU=+2VJ][JN
M+"KTOK;>_76]RC_JQMKT]K^UJ/!1=X9"9_NTL_OKFVR??[`VW^LL=:^KPL7W
MV*-[[X[O4URPRVIJ>2KKVM;EG7LA0^X>)A?S,=L;/UG4]\;:O!YO4>'9V]B0
M3![-E&Q+55B4VS*V+^P_9D>QTJ+"TE$9"CW6AM(>L]WXQ*)Z>YQ:5.AQ9BCT
M.#>4]IC==!86%=;"I:'>J[JRJ-#CVE#:8V:PC47U?L:M187/N#,4>MP;2GO,
MEHJ#17VOQ]32KJP;6_K$,NRKP+%W/0KC?')+LENLDWL)U]PFZOKX:WI'[XY]
MPP@5(9?-EI*H8L.::,*&4Z(9&\Z)%FRX#"B:0/G'7C'7FF@3<MG'WA+MV'!/
M=$@:INKG%>67'1M9:-9=TSG@6D?%:"W)[J!//LJ5/D)4?L%&EBN9H-QT^A[=
M:?8?/S\\9+.BL"S)W,G[*L.([+)7UK"W^]JBFNX?K[/%=6+_O;?[*;N?6</>
M[N<6U73/6[J_.+V]+T/O/7*LK*O>`:TMJAG0X"&[EVWLO_>.:!M&9'+LK&%O
M]WN+NFTV;U?WV;)\L(#O]9].$U5]DD4RGR:[SW]^K[JBU;@MK[@TV1[6HWCQ
M;%&/"J-A$W5]UVXBQD2%1UJ([?J51!4;UD03-IP2S=AP3K1@PV5`/1][Q5QK
MHDW(91][2[1CPSW1(6F8ND++5N**$[=.%YZI[U&H^CVY+:"+"FA$-"8JB$JB
MBJ@FFA!-B69$<Z(%T9)H1;0FVA!MB79$>Z)#@A)=M?NX1-=C>*JK(:VZ[7U-
M7^^0O4`3HLRE(Z(Q44%4$E5$-=&$:$HT(YH3+8B61"NB-=&&:$NT(]H3'1*4
M2NU*V>?O?MUV)IO"'D6/SY^(1D1CHH*H)*J(:J()T91H1C0G6A`MB59$:Z(-
MT99H1[0G.B0HU56[@TMT=>'9%&Y0..<\7>=D!#(&*4!*D`JD!IG$)/VH.F0E
M'S7?FYSUY.?:9<FN@$>AP/)D4;I'M>O:(-]#CWS43;KZ92?Q<8BRU:\(Z0V5
M`?7T6(5<(6IXE=6UZA!EZ2<AO5!Z6;4Q3"YK_\W]VH5GUZ]!-W'=?7B5[8.?
M?$/W`*#ODC:Y7%TU1.$(Y'/=#(Z;WL'=\"8KWA366U(:R`4L+:IW3)5%]8ZI
MMBA]@&CDF1DF%L6"\;6&FNCP,GN[+)D\#;J)/^3P*CNV/1V[5\,3CO?I0^%Q
M[!OJF-%\[\4@.X`4ECGN'W.IM*C>_BN+"OW7UK^."7W7W0_\6'9*_>^*,Q?<
M&7W%)ZR7[W0T.5[S</9X"B@:5&Z_D8_27=OFZ9BH"+DLJ@RH)WW%7#71).3"
MRN#.TO&5>9DCFQ-Y7`36`W5WP6[B"]:@4ZN#;YC.L6R[.;;TS9%X</]PERV0
MA45(N."97)[21_6/J;*H$ZN#_WSIR+$Z^*B.U<&=@ONT..]@?NV/W+%[/8K%
M:%'/Y1GY7/*/^7),5%B/(7T94$_ZBKEJHDG(!?>Z\V5\Q4[<UUQXMG!Z)%%:
MEPROLCO-TW4;99=A1#0F*HA*HHJH)IH038EF1'.B!=&2:$6T)MH0;8EV1'NB
M0X*2)=SM/"Z0^AB>2NU1?+@A&A&-B0JBDJ@BJHDF1%.B&=&<:$&T)%H1K8DV
M1%NB'=&>Z)"@5-?+#JW:#N93V*.PW#V!C$#&(`5("5*!U""3F*0?5;NCQ,(O
MNM>Z/5ZVB!F*#C<!A74-&[*1CSIQN`E1MOH5(;VA,J">'JN0*T3Q<!.B+/TD
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M:2[%>2<;=Y_*%P>/8BU:%`TVOSPCGRL^V1`5UF-(7P;4D[YBKIIH$G+ABKGC
M67S%^D\V-_XT%T]KCV*7#*^R%PF>K&$XX(V(QD0%44E4$=5$$Z(IT8QH3K0@
M6A*MB-9$&Z(MT8YH3W1(4+I_<8?+"Z3V9]%8ZO9X&BPYO,K?3[EIHVS9&A&-
MB0JBDJ@BJHDF1%.B&=&<:$&T)%H1K8DV1%NB'=&>Z)"@1.K;RPZQQ_!T,V0H
MGM6#ZVSW^!2B6JF)QD0%44E4$=5$$Z(IT8QH3K0@6A*MB-9$&Z(MT8YH3W1(
M4"IU?JYUM[R7?5N9^PZ$[+9G2+>Z]H8\'&1%TJ<0%6S@<X5?WQDSJB`JB2JB
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M6A-MB+9$.Z(]T2%!J=2N?!0OX"^_C;M,F0L\2B=\_J3AMHT*+@`:,ZH@*HDJ
MHIIH0C0EFA'-B19$2Z(5T9IH0[0EVA'MB0X)2EUP6?WMEO4W0^'=]R>B$=&8
MJ"`JB2JBFFA"-"6:$<V)%D1+HA71FFA#M"7:$>V)#@E*=;VLV';+8INA="'/
M'T>%J#"%?:ZP%QLSJB`JB2JBFFA"-"6:$<V)%D1+HA71FFA#M"7:$>V)#@E*
MI+[+BVTO7LB/F=*%W%"ZD.?5]1#5NH!H3%00E40544TT(9H2S8CF1`NB)=&*
M:$VT(=H2[8CV1(<$I2[(ZW#]Y[$[UMH,I1,^KZZ'J""USQ5->$851"511503
M38BF1#.B.=&":$FT(EH3;8BV1#NB/=$A0:G4E]7:[EAK,Y3,ZF%>5@U106J?
M*SJ/,:H@*HDJHIIH0C0EFA'-B19$2Z(5T9IH0[0EVA'MB0X)2J7^C]7:[EAK
M,Y2Z(*^XAJC@@K9(9VC,J(*H)*J(:J()T91H1C0G6A`MB59$:Z(-T99H1[0G
M.B0H=8$K>,5'M1-KNZ^/14].[]J26?0<99B754.4Z3HB&A,51"51150338BF
M1#.B.=&":$FT(EH3;8BV1#NB/=$A0:G4>:WMY9LYEN'NVFI:[(*\XAJB@@O:
MAH;&C"J(2J**J"::$$V)9D1SH@71DFA%M";:$&V)=D1[HD."4A>X6E@\X5_N
M`E]5B]<"C])E/R_&WK51)OF(:$Q4$)5$%5%--"&:$LV(YD0+HB71BFA-M"':
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MK8C61!NB+=&.:$]T2%`J=5Z9>_':?L^BG:'4!7G1+D0%%_A<426'40512501
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M*)4ZK[C>MU&FZXAH3%00E40544TT(9H2S8CF1`NB)=&*:$VT(=H2[8CV1(<$
MI5)+H4ND=N&9U!ZE4N=EU?LV*D@--&940502540UT81H2C0CFA,MB)9$*Z(U
MT89H2[0CVA,=$I1*G=?:3LQJ%M3NV[I8O-W.RZHA*DC=-C0T9E1!5!)51#71
MA&A*-".:$RV(ED0KHC71AFA+M"/:$QT2E$I]64'MG@4U0^FLSFNG(<IT'1&-
MB0JBDJ@BJHDF1%.B&=&<:$&T)%H1K8DV1%NB'=&>Z)"@1.J'RPIJQ_!T`?=(
MOP=A(CX1C8C&1`512501U403HBG1C&A.M"!:$JV(UD0;HBW1CFA/=$A0JFM>
M/>M?K1]8(O,HEK4)"F2$F#%(`5*"5"`UR`1D"C(#F8,L0)8@*Y`UR"8FZ:7O
M*EE=_.<)'UBN,A1]CU-`X9:*[Y49^2CW[6GA2=9U]GAC'*)L(A=$)5%%5!--
MB*9$,Z(YT8)H2;0B6A-M/-*WGNICIT+F52=7>[Q<2!:C'AKDO@@@TB-_!N&C
M3GP=JX]ROVG>YLK_!.LX!`5I_;""F<JS.JQ"KM#A,/][876(LAXG(;VA:4`A
M%^P["[E"U/`F*]/.0Y2E7X3TAI8!A5SH<15RA:AA_M5/ZQ!EZ3<AO5!JILM*
M70\L=7F4_&W#X4U>_[`H+1^M'_`!1Q85OFEJ3%00E89ZTU<6%=+71!.BJ:'>
M]#.+"NGG1`NBI:'>]"N+"NG71)L$I5+GI:Z7K1NL@#TT*/VJLYN\+.*C3JT;
M/KWNZ<$G^3<[C7TN_^UG@\'UF^RX5EAOO9>TM*AXQ8,K*XOJ'5-]<DP3R],[
MIJE%]8YI9E&]8YJ',<57,RM#+RQ7^,-G2T.]@UA95.\@UF<-8F.Y^%UQ#WG=
M+O?M>5_#=4R3G1%\I2Y\3]:31>DV%/R'K^'R4?'7<!$5(9<MQ&5`/>DKYJJ)
M)B&7I9\&U)-^QEQSHD7(9>F7`?6D7S'7FF@3<N&6Y"IHY]=I'WS!+>S_WWD4
MR),%';_DK?D;C41CHH*H)*J(:J()T91H1C0G6A`MB59$:Z)-@M);QF7%M0<6
MUSS*=@=Y'=6B>E?&D46%&^"8J"`J#?6FKRPJI*^))D130[WI9Q85TL^)%D1+
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M)KM3%Y:E5X/2HGI'5%E4[XCJ,*)>S_J+%Q:SJ:7O'<3,HGH',3]K$`O+%0:Q
M--0[B)5%]0YB'0;A5E1HL[$LW],F]:RB>CU[WJGJT:7)3.M1=*JRJ&1.XE3E
MH^)3%5$1<MFYI`PHLDB>OF*NFF@2<EGZ:4`]Z6?,-2=:A%R6?AE03_H5<ZV)
M-B%7?JIZU+5/].Y_\G(,SW1U&7YZ'3]1\U$1&A&-B0JBDJ@BJHDF1%.B&=&<
M:$&T)%H1K8DV1%NB'=&>Z)"@=!Y?5L!]9`'7H^BT##("&8,4("5(!5*#3$"F
M(#.0.<@"9`FR`EF#;&*27GI7JXP+%2^[[?N*9[C^[QX]"@]!G@+J621&/BI]
MHG:3/<$9ARA;@PJBDJ@BJHDF1%.B&=&<:$&T)%H1K8DV'G4\47L\56$\;__F
MJXFQD`TZ\43MV+W6VMX]PLA']3]1"T%!6C^L8*;RK`ZKD"M8CD_40I3U.`GI
M#4T#"KE0:)^%7"&*3]1"E*5?A/2&E@&%7.AQ%7*%*#Y1"U&6?A/2"Z6KPF7E
MRT>6+SW*:F;9Z?')HKZWVVNJG!85RD)CHH*H--2;OK*HD+XFFA!-#?6FGUE4
M2#\G6A`M#?6F7UE42+\FVB0HE3HOC[[L!L"JZ6.#LG-?_D3-1YU:-WSZWK/%
MV.?2N2^>"-EOGA768^]E+2VJ=SVK+*IW7/59XYI8KMYQ32VJ=UPSB^H=U[QK
M7(.\DK*P7/&!T,O1.XB5->P=Q/JL06PLUW$0J7\UB-X-S)EG0)<F.RMX%)\!
M6Q0<A@5Y]-A$)6=`H,)'17_\J0RH)WW%]#71).2R]7X:4$_Z&7/-B18AEZ5?
M!M23?L5<:Z)-R)7?F@97EU51F_A466-AE_-D:!!J=:,.-NY@10<K.UC5P>H.
M-NE@TPXVZV#S#K;H8,L.MNI@ZPZV25DR&P=7FNW)=.P_HC?QN3HNA[[`/W[O
M:GB;O90DQ7Q8[X(I$7U8N$%*1#")""81S^E"NJ*I=`63KF#2]9PN)#6:2FHP
M20TFJ<_I0NJCJ=0'D_HQR]27%A>I[^)S]1N6[1OR1W"#*]]4"VMX#)#7RZ2^
M#].80QB><EB8+QG?WKS)=PT6,5"^D"CO3XXY9UARS#G#DHF:L&1'@SNT?.6S
MA5NT?'7.0.2K<P8BJYTS$+D/`Y'[SAF(W'?.0&3(=B"N?DRA9,]V#-U"98[-
M2XHOVOX.KIJZ8OQGV(V=>%AG82>>UK5AZBCXK\/(S4"&S3.AP0T>)[>)OO=4
MZ'CFDI%](EW-T%_N=QG9A_4.2T9NAQ5ER[>:,K(/"S=A&=FSWH'(R#Y,/\)X
M\^LC(_NP_@=W;5@8B(Q\SD!DY',&(B.W`W%&IE`RLH_XGE"9D?,::F[D\_;!
M@RL65UL6[80C%EWOW!]:?YMT\5ZX@^GNZ[L-7<B"+>OI0A9$%_(;F,S5IK,M
MJ\S5LIXN9"ZDDY/`M/ZUZ:P+V:9E/5W(-D@GCX#)%6TZ[HQ=R36NY9[:>_D2
M;=@&OQM<>::*3CN-AK?9VY;:>[5A]D$E-9@V6F"2&DQ2@TE7,.D*)EW!I"N8
M1`23B&`2$4PB@DDQ,"D&)L7`MAULU\'V'>R0LFP1R(O`IQS`<N_@RC/]B!R0
M5^ZBL,@!;5-C<@"8'``F!X#)`6!R`)@<`"8'@,D!8'(`F!P`)@>`R0%@<@"8
M'``F!X#)`6!R`)@<$+/,`9=5;@=7+-VV+%T#\LI=%&9J:PWPZ:+O<.I@<@#B
MY``P.0!,#@"3`\#D`#`Y`$P.`),#P.0`,#D`3`X`DP/`Y``P.0!,#@"3`V*6
M.<`5Y^*[@-L(N#^3^.'O7[]]_E0]?_SK<6OP^M6IQ<%7^9+;@V?J/EH<LA=L
M='MHPR)K@&EQ`),UP&0-,%D#3-8`DS7`9`TP60-,U@"3-<!D#3!9`TS6`),U
MP&0-,%D#3-8`DS5BEEG#52%C:YQR0%.U3$\UGD7?]C2X`M-*`":YP20WF.0&
MD]Q@DAM,<H-);C#)#2:YP20WF.0&D]Q@DAM,<H-);C#)#2:YP21WS%*Y!Q=6
M2H_Q637&F.XXT81'-2:$A0E/-AZ0%1VL[&!5!ZL[V*2#33O8K(/-.]BB@RT[
MV*J#K3O8IH-M.]BN@^T[V"%EF0-<J2Z>\"^]%PR:FE^R$AA+[P7YR\B#$!99
MPZ>+MPF,DS40)VN`R1I@L@:8K`$F:X#)&F"R!IBL`29K@,D:8.L.)FL@3M8`
MDS7`9`TP62-FF35<F2RVQHE[@2M\YJ5:8^GBD+_:.PAAD0-\NN@O]'3$R0&(
MDP/`Y``P.0!,#@"3`\#D`#`Y`$P.`),#P.0`L'4'DP,0)P>`R0%@<@"8'!"S
MS`&NOA0[P"T.+_L[Z?KMU0YW>):N#]F+7$]MT[`6C#J8;AUM.G.1W`$F=X#)
M'6!R!YC<`29W@,D=8'('F-P!)G>`R1U@<@>8W`$F=X#)'6!R!YC<$;/,':[.
M%+OCU/K@ZU+Q:4&WB^.:D3H@>[0B![1AIJP<`"8'@,D!8'(`F!P`)@>`R0%@
M<@"8'``F!X#)`6!R`)@<`"8'@,D!8'(`F!P`)@>`R0$QRQS@ZE:7.,#7N1('
M-"QZN5IR@TEN,,D-)KG!)#>8Y`:3W&"2&TQR@TEN,,D-)KG!)#>8Y`:3W&"2
M&TQR@TEN,,D-)KECELGMBDJ7R.V+4(G<#0M(:N=(8N=(6N=(4N=(2N=(0N=(
M.N=(,N=(*N=((N=(&N=($N=("N=(`N=(^N9(\D8H4T-KYD5JN/C\[-:PZW!G
ME1PM"^<YOL%D8;?:/81CWUWV"H9D:[(IS%9NZ=;V8$S"@4FYMFW<159GEIIM
MF*63G$@G/<$D:-LV[B([O$KD-LRZD,I()YE;%M+AVDGZ-ET(&]YE^Q[9H0VS
M7N6'M@>QS!"NK'/)]/1EH#`7WPT&#4L-`:8)VC#)ZIY-#J^NLENVA&\C;/`2
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MK_DXE^4W#6/A'1R9TL>I4!`$S*^'%IPF+'G-ATR.:].9E60O,-D+^>0E,"TX
M:"OC@,DX:"N7@,D2:"M+M*SG$L@22"?]P:1WFTZ7(!/7E6-B<4_=(7SY)EEL
M&A:0-/1AR1T"3$L&F`0#DV!@$@Q,@H%),#`)!B;!P"08F`0#DV!@4@=,ZH!)
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MX2EVPO`^*[[(,+[IJ=7'AP7]9)B&)6O!\#X[Y<LUOFD\D,%C5J*1:]J!F.GE
M&O0JUW3TVO$+$]8TF%!&0A<R$KJ0D<[I0M[R34,7\E;;1;?\QU59WD*O\E9'
MK[B<,EC;:]1#=#DS@[ER4VRP4TM/4YY*G>19F`BR3<NB471L&INPZZMV)9-M
MP.21-IV)+T.`R1!H*T.`:1E!6ZD/)O715NJ#26JTE=0MZ[D$DAKI)#68=&W3
MZ1)D(KH"TR4B-@6I5,2&A5N*-/1AR:813(*!23`P"08FP<`D&)@$`Y-@8!(,
M3(*!23`P"08F=<"D#IC4B5FFCJL'Q>J\K,8W;,I*J6@-2\L*]UEA34+ZL&2%
M[9B,3=C)LH(/:TZTCU>/=US2?8B6HLZ;G/\%HS`NF]4RQ#F#D$>:L)-5A78@
MUH-LTS!M@8S)-N?T*B>=TZO,A5YEKK;7GDLBOYTS$%G0AWU7`SFR'41WAZE)
MM0+WF_3,HL(Q3U:Q-!;?'P+K'MW1(:.!#TN*"F2%Q>EE!M.T[&"5L2A?W<$F
MQJ)\TPXV,Q;EFW>PA;$HWS)B/9=@96%1%^L.MC'6=)&)Z^I+\0ITXB9_W=2C
MDJ7&L^0Q/ID4:]I&<>,.)L40)\7`I!B8%`.38F!2#$R*@4DQ,"D&)L7`)`^8
MY`&3/&#;#K;K8/L.=DA9)K?6^8OD=O'YG&U8O!VXSI'$SI&TSI&DSI&4SI&$
MSI%TSI%DSI%4SI%$SI$TSI$DSI$4SI$$SI'TS9'DC5"FABLG73+Y?/DI7/IW
M@^N&)<_R`NM9/B11T_348_P09@NH=$.O$@Y,RG5VD9TDI68;9EU(3J23GF`2
MM&T;/NSP+CLC2N0VS+J0RD@GF5L6TG4\Q@_I0EC'8_P09KW*#VT/8IDA7)GH
M$D/XLE)BB(:EA@"3^@WK>8P?(FSP$AZ9)#R8A&^SQ]<GVPU*^#;,NI#P2"?A
MP21\VS;N(JMB2O@VS+J0\$@GX<$TP=%6,QQ,DL9M,TE=42>6]&5;_.NF-I3>
M=QN6*@TFI1MVZC%^"+,+);F13G*#2>[.+K+3AN1NPZP+R8UTDAM,<K=M8[GQ
M&#^$61>2&^DD-YCD;KNPMI(;3'+';3.Y78DEEOO4?LJ79)(9W+"`G@;:XAWO
MP_%YFTRW6,1)0S!I""8-P208F`0#DV!@$@Q,DQ%,ZH!)'3"I`R9UP*1.S#)U
M7*$D5N>%D]'76X)"[P::A4ZAY+P]>,!C?`O3GN#[QU]-V2;;J?.VA35GO=N;
MA]MLRDE]GTD7Y?L=RA!^^.'D*T.<,PAYQ(?YQ]@WM_?9I)1ESAF$7(1!R$7G
M#$+&:L+Z#_WR6CL0F^'R6MMKSQ62_<X9B!SIPYJK<?=X<YT]:)%!VT%T=YAY
MUI6/^CQ[[O';EZ$2TWH6SL9::EK6/3H[?C=AFFQV);7Z@,E_;3J+D]G`9#:T
ME;/`9"6TE6_`Y!NTE4G`Y`BTE2-:UG,)Y`BDD_Q@TKM-ITN0B>LJ,;&XIVX7
M3>4FW0;X:DXKA#3T8<GM`DR"@4DP,`D&)L'`)!B8!`.38&`2#$R"@4DP,`D&
M)G7`I`Z8U(E9JHY[8IJH<_8S_6/+[-SL6?),7V?U]*G[T\"::EC?7[!';5C\
M5,TW=07GMNGP/CL*%6W3Y!X4/0;R)=@P$)NY5=LT]%H;RWK-]N$3"W._<M8.
M#L_RIFU8^#+G6<M"KW-CZM6]A7R=#W]A`6E_>65[V8;U7NY5&Q:&L#:6??#L
MYK>QL'0@T7@SS[EB4+PB.,^=]^Q?CY91K/',:=E>]>%]]KJY3-<T/?7LW\+"
M_6+<-M41*.HAV_C(=+X';9W;,,A?MF'Q/L2:AFLOT_ET@<EA8+)3^\',Q+(3
MXF0G,#D(3'9I\T4?(W>5[.+#PH6273SKO5"RBP_[WH7*[.**2[E=+G\+P"U*
M>9W/LV2]ZG@+P)KV3B"M5[Z'()BLT[!D`N%YO*SCFP9/R">>A65"BQ.ZD$_.
MZ4+601>R#KJ0=="%K'-.%W(3NI";VB[ZW81>Y:9S>I6;XEXSZ[@Z5&R=$WN/
MFZ9NE>P]C`6?:RWQ<?H19GH^162()DR/;&QFRA!@4K]-9W%2'TSJHZW4!Y/4
M:"NIP20UVDIJ,.F*MM*U93V70*L$TDE7,(G8IM,ER$1TE:=+1&PJ5:F(#0L'
M`VGHP^(-))D$0YP$`Y-@8!(,3(*!23`P"08FP<`D&)@$`Y-@8%('3.J`29V8
M9>JX0E&LSLOJ#7I-GZMSP])ZPV-VVY60/DS+0.]D;,+<1PEA_+4!G\W_VH`V
M78_93D+J^TPGZ@UA7#:K98AS!B&/^+#FA'VO7T!+M]!RS#ECD(F:L.1IOS7M
MO1#R5=-4Y8;O[3[/&8)\UPXANN[Y6BDK^FR]HY([?5AS96[N!X]9P5UF/3&N
MS+^NE-;GWS-K#S>^)!>6F'<#8\FMP\=IO0LVS"^';AU-6%)[(),7VW1F,JU$
M8#(>\LEE8/(5VLI$8%J)T%:.`=-*A+9R1,MZ+H$<@722'TQZM^EXZW!EJ%C<
M?PUNWG_XX9=_CYZ_?GC^0P)<O=$KJ?YU\/\9N.<'V"-Z%G_?E\4%)L40IWL'
MF!0#DV)@4@Q,BH%),3`I!B;%P*08F!0#DV)@D@=,\H!)'K!M!]MUL'T'.Z0L
MF\NN"G6)W+YJE<Q9SV2J=GX.'[+U5S>=-LSFG1P`)@>`R0%@<@"8'``F!X#)
M`6!R`)@<`"8'@,D!8'(`F!P`)@>`R0%@<@"8'``F!X#)`3'+'.`J79<XP,7G
M12S/Y-O(`2QBM6&1`\#D`#`Y`$P.`),#P.0`,#D`3`X`DP/`Y``P.0!,#@"3
M`\#D`#`Y`$P.`),#P.0`,#D@9JD#W)]6N\0!Q_C,`<;2-2![I>-I$,*"`\C&
M'7%%!RL[6-7!Z@XVZ6#3#C;K8/,.MNA@RPZVZF#K#K;I8-L.MNM@^PYV2%GF
M`%==NF`-<`_4\C7`6+H&9%M-.<`W#5\P,NI@<@#BY``P.0!,#@"3`\#D`#`Y
M`$P.`),#P.0`,#D`3`X`DP/`Y``P.0!,#@"3`\#D@)@U#GC[];?GYV^C]]_>
M__SCI^<O?WU^>O[]]Z^O/GS^N]OJ#1[<;Z^U_-67YU]_^E^ZSFBW;2.(HK\2
MY`<BB>2N1!0!+$N*9,NV9+=^=U$G+5I4@1.@O]]S*;0/XLD+D?AH=V?OSHY$
M<CA\OZ2??NB,/3QBTPY&R2!C3=J1UVBLK3!^^"B;APV_'$?CM8NPX8+?B'43
M&.'%^IRD'850C4W3CK*CRC(':B0JFX4-%R1'MDR;L.&T9LS:L.$GU26;8\I<
M+5G0(:_'-3LF60-*R"LK8</]V<NQJ!`=YFLPR1I0)UCZK)A?U?J*(50FL3:8
M4=6*BA%5;:B84-T"%K/J6A;:%&U3:%.T347SJII7%K_JVE>6ONK*5]:IZCH5
MVA1M4VA3O`U:%]6ZH'51K0M:%]6ZH'51K3O:=-JFHTWG;="Z4ZT[M.Y4ZX+6
M1;4N:%U4ZVQKW]4)3`0Y\;<.K<\EIRZ]OD/K3K7NT/J<ECYJ@]:=:CUCICQ(
M(18T6'V^K'W96\*B1\6&WK@3+;VU],;M.R.LP@]B9<*3^ML0G%2#:4*3^ML0
MZ%6#:4*,^LXT`49])RYJLTDPL+\S2?4T!%.]AI"N>DU17^,Y9ZQMO\F%W+'*
MG'NT/2<1QCB/:'M."(QQ3M#V_+@W=C7MKWQU,%!L6+*<]OFKIK_*5_W8ZB6N
MKJL<=Y;/DP;18"V)C>.^DGV(.N>K;1<>G4Q"U%&6K$#4498,OXQGGI#TE8QG
MJYM4E(QG+&DE&<]84D0RGC%23YJ>7!/3"]:&V2K"NC#3##.:V&(,6YJ>@S'2
M5IJ>/!5CS+WI.1@C':?IR;^Q.<#:,)L#K`NS/I&YB=;&T+KI.1C+TZ&L'W=U
MQ[Z4)SWI4UF>VD0S97D"D_53MHPM'-P6&`YE+`]`].1`F69)CP\SS9)0'69]
MXK9-?-=8"O@Q!VJ`C75!LTDTL[B%9I-H9@S-)M',&)I-HIDQQHN=U#,9V\)X
M67=EC!>_5L9XB2'*4FV1O:+?""G(%V;^DNIM8:99RC!BB[*48V2/*4L-1O:8
MLA2C9(\I2U%*]HK.(74+PVP.*7(79G-(M4JT5I:JE>PQ9;Q$)?["VVYM_6"\
MZL(8;[N(ORCCS17Q%V7+V,+!YI"RH>PQ9=00K.P5U2R5),-,L]0>#+/Q-NF3
M@['K.8A365$%<J/D%G*OY`'RJ&2UZ/KCPG;Y:E'Z]<*^U[:0G9(]Y$[)`7)4
MLDKPTMBUA>R4K-I9OR8C9*S.%K)3LIK/^N/<VJSF6#"W"+*%[)3L(7=*#I"C
MDF5._/6\_Q$G>:1"VG@^3Y`G)3]#?E'R#'E6<CV;]9OS;>++WS^0&R6WD'LE
M#Y!')4^09R5[;+M3C]\3Y.\TQN]G4XBI<T]O]TH>(`]*#I"C6G#`@J-:<,""
MH_;VB=X^*=E"=CK.EG%V.LZ6<7;:VPV]W2BYA=PJ64*62JXAUTI6D+5:O<+J
MM5J]PNJU]K:AM\V9?/C?X;Y]_.GKRY?7NY>W+W_\_>W=7Z^?ASNT*0?[=GYI
MU^1<&_;TE<MY[]_]>OK."[V&?_[^^O+;ZUONY_+ASZ?3]__^P\;Y\,_I[<_A
MTN#'?P$``/__`P!02P,$%``&``@````A`%=9Y-_D`P``P@T``!@```!X;"]W
M;W)K<VAE971S+W-H965T-RYX;6RLEUUOZC@0AN]7VO\0Y;[DBP2(@`JHNGND
M/=)J=3ZNT\2`U22.;%/:?[\S3F*PDU,=JMX`&8]?/YZQ)\/R_K4JG1?"!67U
MR@TFONN0.F<%K0\K]_NWQ[NYZPB9U456LIJLW#<BW/OUGW\LSXP_BR,AT@&%
M6JS<HY1-ZGDB/Y(J$Q/6D!I&]HQ7F81'?O!$PTE6J$E5Z86^GWA51FNW54CY
M[VBP_9[FY('EIXK4LA7AI,PD\(LC;42O5N6_(U=E_/G4W.6L:D#BB994OBE1
MUZGR],NA9CQ[*F'?K\$TRWMM]3"0KVC.F6![.0$YKP4=[GGA+3Q06B\+"CO`
ML#N<[%?N)DAW0>QZZZ4*T`]*SN+JMR..[/P7I\4_M"80;<@39N")L6=T_5*@
M"29[@]F/*@/_<J<@^^Q4RO_8^6]"#T<)Z8YA1[BQM'A[("*'B(+,)%08.2L!
M`#Z=BN+1@(ADK^K[3`MY7+E1,HEG?A2`N_-$A'RD*.DZ^4E(5OULG0*$TB)A
M)P+?G4AXT7AG7M3-@^^;%_?:C:BX/&0R6R\Y.SMPV`!5-!D>W2`%X3X@+88.
MT:\B!+M"D0VJK-R9Z\#F!:3U91W$R=)[@53DG<]VQ,?TV/4>F$'`TXP0J$]@
M1!5DQ%0@]+8W7*!#"ZCWL($@4)\`A"H0]NF[4>N<X'3IT,XL2NUB8X*RC1G&
MDU\>]SZ9.$UQZ4AU%E]E]BZPUM>C%\3K[!NIA,6OD<;O70^"SB9(9TFNHA'$
M=CRTDQT/F':]N#KK/N3XQL..,B969S'/_]P*DW:RL6":C14FL\D,]G$C&2J9
M9)W%)%M89-K))L/7GE4<HD6,I?%6,E0RR3J+09;X%IEVLLD6)MG[YPB=S<4[
M"Z1$WZH@L<^U=K(7#^"]8\=EZB\F('=CPI22B=:;S,#8E>GB-8`;J^BS.5[[
M6^':>@P%"M9H2V;0F4RXR,K:Q6L`AQ7UZD2]G[>@K;\&0&>::Z9=[Z5,1K$)
M1NIT$GWD8BDE*T]=V35#,;5#H;T&H1BMSA_(TK!<XRL%#[R)%MMHVFN`!A37
M6<)"&<T_<NVQM[*N7F\RX:QF`9O`;@L:KFWJVN:E(OQ`=J0LA9.S$S9L00(O
M)VUNN\EMX$,[J3K"P0@VFJHM&XR$,!+B\1J,1#`2C8Y,841=D\&<&$94)VF-
M0*>[&5\%)HRM`5AC_ILHW8PNL`7:45@@&@/:)NDN&5MXENY4TV1M8#M/=^K*
MV?9%NEN@CJ<'H(-NL@/YFO$#K853DCTDS%?WD+<]>/L@60.)A#Z:2>B=U<\C
M_%<BT*SY6+_VC,G^`1?0_[[6_P,``/__`P!02P,$%``&``@````A`*X4/*5"
M!P``3B$``!@```!X;"]W;W)K<VAE971S+W-H965T-BYX;6R<6MN.VS80?2_0
M?S#TOK9(ZN;%>H-(0=H"+5`4O3QK;7DMQ+8,29M-_KY##65R1K)LYV43+P]'
MAV>&<RASGSY\.^QG7XNZ*:OCRA-SWYL5QW6U*8^O*^^?OS\_)-ZL:?/C)M]7
MQV+E?2\:[\/SSS\]O5?UEV97%.T,(AR;E;=KV]/C8M&L=\4A;^;5J3C"R+:J
M#WD+'^O717.JBWS333KL%]+WH\4A+X\>1GBL;XE1;;?ENOA4K=\.Q;'%('6Q
MSUO@W^S*4]-'.ZQO"7?(ZR]OIX=U=3A!B)=R7[;?NZ#>[+!^_.WU6-7YRQ[6
M_4T$^;J/W7T8A#^4Z[IJJFT[AW`+)#I<\W*Q7$"DYZ=-"2O0LL_J8KOR/HK'
M+$B\Q?-3)]"_9?'>./^?-;OJ_9>ZW/Q>'@M0&_*D,_!255\T]+>-_A5,7@QF
M?^XR\&<]VQ3;_&W?_E6]_UJ4K[L6TAW"BO3"'C??/Q7-&A2%,',9ZDCK:@\$
MX.?L4.K2`$7R;]V_[^6FW:T\%<W#V%<"X+.7HFD_ESJD-UN_-6UU^`]!PH3"
M(-($4<#>C,NY3$(11M>C+)!1M\!/>9L_/]75^PRJ!I[9G')=@^(1(O<K0Q[G
MM5Y:*JQ1!_FHHW2Q8!4-Y.?KLY#R:?$5-%T;3(J8V)M9#$5D/4*G`NB=.<+*
M.4<%.1Q7OZ>D)U%*<DF?EXY`*"(;(N+P#"$<0;O[.>I)4`NN)%*=XW?2IH@)
M'$Q,$=D4@G"$("[':?TT>.6!`.=T)0E]<(J0I,OW@PC]1$04D5%$E$3"DB?4
M8!NXU'097D^QGL3E"RB#%#'`X[P,RZ`3.)M"$(X1Y3@MGP93^6"O,VZ("7"_
MQ*PZ,S+JE`7A!-O)U6V:DP8S3D(P3HA!3I)+10:MTH21]CS64*YG4D]BS"2K
MI10QR.QA&;'A#(<C4XR^\"V`\%M2?M.*:3#E%?`D(@2?FZB$Z9FYP\)?7A!-
M0#MS59MFU:$I+<%SE1H0ZA4DC'9&AH5OMS812XS8P_5L=K,X/_L$[&L&A,()
M)17SBXP`EBJR*Z`4=8]V"NZ*=-C1W;8F!KX@$&1J*5()WYH&,-Y5*#O=G&]G
MAZV<L%,^VZ&B[_?:9IE;9&3P(;RDF>[+#JO;VJW`;D[9L7I/#<AH)X4?#L3#
M,(@`2T@N;%1]P'))7DGLB!GPDDJ[D"MO/&_H!I,0FMJ[_$`,#4&QY*4&8[03
M@<]2GQG`.']*[BYC$$-G4+93F?V*&$-.Q9)E/C-!;B''/.)*9D?,82@=:?]A
M,F1'`,G2V=-4N+O\00P-0C'33`W&&)=,6-8S,][O&!E;`&$F[_*(#DU[<,#*
M*348PTPE+.69&>_K,5:7^HG\(9OH9E&*8E!V!G3F(`8D\:T!`4KYEP[H4C=U
MI^=-%UV'YMQL-\4M84`]MS"6CD#83B@D3D)EVR'-+C.*VUJR1"^`G^?CK5"V
MGQJ:O6%8$*O1S,2Y8>]*P-PAHT9S&=G#TR[D=%<VD%YIJ>QI@JIXEV?HU^8!
M.QO9J(<@LTF&Y4>&@]@NCA*[RRSDT"R$4SB&&((N$L/A7K)8V.JES)A3W%AX
MZ`:D\(;]!4'C567VQQ2$\F2F<2//$?,(F'.ETO4&(85TWAT,342,KX329/YQ
M(\VACXB`'8A3B2!,>,0/_)D9QH3'B=-)"4%]?'<W\&T$NUEL(P?6J+`B#0@)
M@HKTX)J9820HHM!YPZ,,?\A-%/H`.9TZ3S`,$80,A^^0)H9A>/D=4C$OT1H&
MT`BF/:6;Q35D=I8:T'BE83$:B&$9!,KYVH4*J1O_S9:GT":(@(.W70,R3<<V
M.\.L=QK]:O+@%`"EI4W!H75C!>I97#UN=0I!1AHIEX)MHHPBXB2.+(*RU(W]
M?I9H!U1$)E.J$(0L'U2@0H;("&*9P%=KY[U$23);N5'*$7L)[!/,5G']0T:^
MY/TH4RY"B`@P%UC^D,4HM`8JI3T]&98(0BFE#)/!%QTFC$&(4`C;EZB6S&"N
M;&9T!&*`H8ULV$W9AMDR4Q#*CSG+%7XCCA)RXU,(0FU"R?EG9%S&PC9\PBQ@
MEC+-K$.SC1S:RD'E#`B9P=G''EY0-C-NO'!I]P\EQISD"C$T!YI2NV1#K'>0
MRX?I8`I"^8WXB';)*SSU+"X@]Y$`05,^8B!&8U^Y>X?2U&W=:857Z*$)D'W+
MWXO2`$&3]*8@E)_N^@Z_V[I@@%X!3['O3G(@(X(F>4Y!*$]F*5=T'+$2;F>I
M/G5`+9@<!B)F+2BC`*4"NT+*C3G)%6Y#!XD&.P4QD])-02B]'[*0`-WA2HH1
M-,ES"D)YWF4B<&<]V,G#%".HOV83@XLB$P4!RG>^@$)J>*V-M[Z'HGXMLF*_
M;V;KZDU?60NX,3G_%J_34[A.[^Z>%^<!N,T^Y:_%'WG]6AZ;V;[8PE1_'D/Y
MU7@?CA_:ZM1=NKY4+=QC=__=P=\M%'!)[,\!O*VJMO^@KWG/?PGQ_#\```#_
M_P,`4$L#!!0`!@`(````(0`)7FE7+0@``$0I```8````>&PO=V]R:W-H965T
M<R]S:&5E=#4N>&ULE)I=CZ.X$H;O5SK_(<I]$HSYC+I[M8`Y9Z5=:75T/J[I
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MG1KHU.=X%^_`TM/#L0(/I.RKIGQY7/_&]CD/UKNGAUZ@_U7E1SOZ>]6^U1__
M;*KC']6E!+5AGN0,/-?U-XG^?I27H/-NTCOO9^"O9G4L7XKW4_?O^N-?9?7Z
MUL%T^^"1=&Q__)F5[0$4!3-;UY>6#O4)!@#_K\Z5#`U0I/C1?WY4Q^[M<<V#
MK1\ZG`&^>B[;+J^DR?7J\-YV]?G_"F+:E#+B:B/PJ8TP9\L\)[C#!M<VX'.P
MX6\]UP^C>T;B:2OPJ:VX\.="-\#A7@OX'(;`MR%S8AXNUR+01N!S,!(OU&*G
MYJ:?ZJSHBJ>'IOY8P?H!]=MK(5<CVX-=.<<<(F5^CF%R99_?9*>^*]`M!.;W
MI]A]V'V'6#IH)%%(N%Y](AY&TAG$QT@V@P08$3-(B)%\!HENR`Z$N*D!4396
MPZR"A(D*_&:V%RI12-A'M%0NI1<R>D'0"_GH`AHK1//RL4KX<0VF/J<C)F-5
M2-1/Y\:/`S*CZ;B=,<Y=A@UD8\#S8AX3-<08V+B,3A-J]H/(\S^'B#R'93?V
M?%G,RDY8`>8XV(-$,?#_324RQE0102\2XW[$7=\C0F56*\)*Y"8":0'98ZR%
M.6(E3#4@LY@H1GOH1)`B0[+D4CN2*02\^$I)825R$X$T@+RU7`,)4PW(#":*
MT1H$ODL%&+='GD.")$/-C'U&<9\4A&HV:).;".0YY->QY\M6@NQ$%2!+-5&,
M88RI(I1&<<CCSXS:>YE9+0@KD9L(I(,L.>_>Q60GJ@/9HQ+%#*N!1Q'9H5(%
M&(3*;":$U41N(I`.,=;!G`TD3/TG[B6*,;B7#H2L`FBFR,:-&]HJAM8ODT1N
M(I#C#&J6^R.@[T4E((L]T9"*`=>-:*2G&C"(E-EL"+N-W(A@,63!,UH.YC!@
MJCP:UP:,IK1$0TH$#NTQ(RDCM2.91@Q*"3N2&Q$LA*R=E@NA*BTL!$EK"5.0
M$B*,.$D8*6IW/4Z2?X;:?1Z3!2=TNT&BW(A@_V5)-?)_V?[`5"&&=2!^)!H:
M,B-SR+))-6!P)+/9$'8;N1'!8L!0QF)85H6D26I@M%YD"C+XF&IDR!ZT)L[L
M)H0=R8T(5D%65:.0L*B@:C`4"HQ6C/*=`$CE]46Q.UD0XU;2-<-=2481M]:O
M-P@C@AV71=5RQU4)AAVG92)3D%X#G'L3WTV%G"J3;#:$!@PQEAL1+(*LJ):+
MH.HO+`*9I(0I2(FP84$4T`>[5",&%S([(NQ(;AP+%D*65,N%4`48%H),=L*&
M*DU60ISL&ZENU;'B>BX-E@P1`>-.1)XK!+K#S`,TLK`)>>B,2B[LOBRL1NXO
MW!A4.89E(!M8PDPU6Q_SJ4:T%EX<N\QSR>+*[':$'<F-")+$)16D.3'V--T>
MR!:8:$@O#1['9$)3!#`77G@0(D-$P&(W(#<1FE#9=R8HD(5-Z(6!][F$L0*D
M;%P6%.Y,^4@S0*(A0P9(-:*#PG=X`"]'/T>JLJ7=CK`CN1'!DD"LW[].7-F+
M!@=)"(F&C)(H.TH2>%_FR'_XE55F-R/L2&Y$L"*DI+0LDYE2DKX/25P%Z9EW
MF3NI)3$1>`ZM(S#@>)%#TI+0A$'NW(A@$<#,."PL(DB:A`/U()&_)0`TB#"=
MZ=1*9)HP^"CL2&Y$L`QWU9+R!YN)#"3K)QI2V0PB`4=[BIKC212,2TV7/+&(
M6]^OJTDC@ETGU>3"7#E353HDQR6NM6A,-:*")>80[UBGS&Y#V)'<B&`Y[JHK
MW9FZDB[81$.&8$YO2/_N:1(-ZBYZ8PQ)L[AU-H3#8&$.P?[?54ZZ,^7DY(V+
MAM0<\RB8I/[42F2:,&@H[$AN1+`,I*RTY,69<M(AD9RX0SDIYSAP27V4HF:7
M_@J9H6;.)YO"8'QN@ON*([]9F$.0\_)GT_&FL"PE]+WHYD!25Z(A%<HQ+0'3
M6_/<&%7A=$.DC!,+XM;\I87<B&`A2!UIC@(^5S^2O)]HR!#(J4;4>O$<3G:6
MS&Y"V)'<B&`52.EH46&N9"0I*^$*4F$P60JHE6PJ&6JD[VC$K=4P_<.]YQ#L
M^%T5(I^K$,G<)1K2Q9$'E3#>[U(-&.(CL]D0=ANY$<$BP%#&R<`R^Y(F28"^
M7T^X@I0(&^8[$2//@JE&C#(H*P9$V*WDQK%@(>ZJ$?E,C4B+P$1#^J0""P/Z
MU)PB@GG,\TGFSQ`!OU[ZTS6AAJ+O,G-:`;7#KT)?'E>`,UHH%A9N##.U(CUR
MD?2FY:O7N56I7K9H1*^=$%X@P./3)#U8:TYAOY4\C";#>'XT*BK483-U`NE<
M-J]E6IY.[>I0O\N#9#Z\0KY=58?<$K9/7'E^AEQ/V3Z=NYZQ/9RIF?*"[>%H
MS?1Z#H?H^NN[VPW@#-NU>"W_+)K7ZM*N3N4+#,W9RH-:C3H%I[YT];4__O-<
M=W!ZK?_S#4XKEG#.Q]D"_%+7W?`%;KR[G7]\^AL``/__`P!02P,$%``&``@`
M```A`))1(QN[`P``E0\``!D```!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
MG%==;YLP%'V?M/^`>&_`0`*)DDRKJFZ3-FF:]O'L@)-8!8RPV[3_?M>^A`1(
M"N2E">FY]Q[?>WRPEY]>L]1Z8:7D(E_99.+:%LMCD?!\M[+__'Z\BVQ+*IHG
M-!4Y6]EO3-J?UA\_+`^B?))[QI0%&7*YLO=*%0O'D?&>951.1,%R^,]6E!E5
M\%CN'%F4C"8F*$L=SW5G3D9Y;F.&13DDA]AN><P>1/R<L5QADI*E5`%_N>>%
M/&;+XB'I,EH^/1=WL<@*2+'A*5=O)JEM9?'BVRX7)=VDL.Y7$M#XF-L\=-)G
M/"Z%%%LU@70.$NVN>>[,'<BT7B8<5J#;;I5LN[(_D\6]-[6=]=(TZ"]G!WGV
MW9)[<?A2\N0[SQET&^:D)[`1XDE#OR7Z)PAV.M&/9@(_2RMA6_J<JE_B\)7Q
MW5[!N*>P(KVP1?+VP&0,'84T$Z01BQ0(P%\KXUH:T!'Z:CX//%'[E>W/)M/0
M]0G`K0V3ZI'KE+85/TLELG\((II4G<2KDL!GE81,)X$W#:,!61QD9!;X0!5=
M+TMQL$`U4%,65&N0+""S7EEP=67`1L=\UD$F%-`2QO&R#EQOZ;Q`"^,*<]_%
MD!KA0/&:`51M,_!A0I=[>V2@@YH,O'F=WI"\OP"I$0T"_BT$=!",T;;.6N#7
M^9$!8H(S3%@C&@P`,KX%.FAEPRIK!F3>'@)B(C.BT`^NE(=YCR^O@]KEVPU`
MS,R4OYMZH7MY^;-F_?<GK\'-NH$;U'FQ\8C!NIX;7EEV.*:L!K?+3EME$3-@
MWOJ]T-IT_9+707V*0\P`!O-;&.B@9@^ZBD-,U?K(/VW*AN`);/#Q'3!1;0)M
MS56@2G1D/KUB.Z3E?.^KSJ";I;NRJT"!T7L41;4\FFMO&5Y/8;2Q\VT>N+,Z
M,^J=(&C`W,E-9F>B^K17@8:0`,P-T]=1S1%TY4<05.DO(-=F<)/EZ5=^AT%'
M?PW3(T%T,J>F#$:Y'AEB>Q4(]3?WKQ4>Y7ODDO&=#+72WV#G(S=9GXGJU=]@
M\R,WN9^)ZM4?^A^.(#R]CANC]UKN][X#&'2S;M=Z*E!/W5&6Y^$)KND\I_V$
MDZ]``S:]ISUJ]$O/1/5-O@(-(7&3_7EXD#OO1-=Y*M#QT''->3QM4./;@+;6
M9-!V'I-Z91_??)%_.I\TY=<ROQ[Y=4WO@OP0A`=-$IV886&\6.&]HZ`[]H.6
M.YY+*V5;.+RZDQ#"2[Q6X8,2A3G=;X2"ZY#YNH?K+X/+ASL!\%8(=7S0%[?Z
M0KW^#P``__\#`%!+`P04``8`"````"$`J%*7I0($``"2#@``&0```'AL+W=O
M<FMS:&5E=',O<VAE970Q,BYX;6RLE]]OHS@0Q]]/NO\!\5[`$/(#)5DEJ7JW
MTJVT.MWN/E-P$E3`"#M-^]_?C`U.;-BJJ?K2E/'XZX]GS#!>?GFI2N>9MKQ@
M]<HE7N`ZM,Y87M2'E?OCOX>[N>MPD=9Y6K*:KMQ7RMTOZS__6)Y9^\2/E`H'
M%&J^<H]"-(GO\^Q(JY1[K*$UC.Q96Z4"'MN#SYN6IKF<5)5^&`13OTJ+VE4*
M2?L>#;;?%QF]9]FIHK50(BTM4P'\_%@TO%>KLO?(56G[=&KN,E8U(/%8E(5X
ME:*N4V7)UT/-VO2QA'V_D$F:]=KR82!?%5G+.-L+#^1\!3K<\\)?^*"T7N8%
M[`##[K1TOW(W)-F1J>NOES)`/PMZYE?_._S(SG^U1?Y/45.(-N0),_#(V!.Z
M?LW1!)/]P>P'F8'OK9/3?7HJQ;_L_#<M#D<!Z8YA1[BQ)'^]ISR#B(*,%\:H
ME+$2`."O4Q5X-"`BZ8O\/1>Y.*[<V`OG,8FGX.X\4BX>"I1TG>S$!:M^*2?2
M22F1L!.!WTZ$1!Z9!%+CC7E1-P]^NWEAY,6S("*X^'"BK^!E+.Y3D:Z7+3L[
M<,``CS<I'E>2@%@?!*6@P_*[J$`X4&2#*BMWYCJP80ZI?%Z'TW#I/T/XL\YG
M._0AIL>N]\"L`9YFA.!\`B.J("-F$J&WO>$*V@+J/6P@"-0G`*$*A'WR9M0Z
M)TBJ#NW,HM0N-B8H7V..'^P^A>@L:71\.DL@\WDWM5;5HQ>PZYP;"03Z]X.@
MLPFB+/'U\8H".PK:R8["U%P<3_@D6'A@OO&0HY`)UEE,L+D5*.UD@\&TZZA\
M'`R%3+#.8H(M+##M9(/A%\ZJ"1%&_\9XH8R)U5D,+!)86-K)QEJ86&\?9W0V
M%U<6\Q01NP1I)WMQ`M\7.RCA=.;-X-S=&!<I9;+U)C,R5@7=7;P&="-E/)I,
M\,-U,YVJPE"68!%5*$EG,NDB*V\7KP'=2`&/@MM?0*+JL8'6F4RTB8VFO09H
M(Z7\8]6!Z')^B5MG,N%B&TY[#>"L`HX5XJ-G;EC>\<.#KXA)9Y?YB]>`#BNN
M528^&#I5NXV\=B83SJ[YV*ZI+0S@L.I:<&'L@?^M+VM7OJ]?!UW1+Y^^B-AE
M'UI7FTVUHJK]JFA[H#M:EMS)V`G;3$C$>JG-J@?>DFG?!`]&`AB1'>Y@!!MG
MV68.1D(8"?'%'HQ$,!*-CDQ@1.Y^,">&$=D96R/0N6_&5X$)8VL`UIC_)DHV
MZ@9@+;`%VE%8(!H#VD(4Y4W"UIDE.]D0VO9YLIN/@2Z2W0+MOIX`-X(F/=!O
M:7LH:NZ4=`^I#.1GH55W"O4@6`,IAGL!$W`7D/\>X>Y'H1$-\%CN&1/]`RZ@
M;Y/K_P$``/__`P!02P,$%``&``@````A`,2X0_9C`P``'@L``!D```!X;"]W
M;W)K<VAE971S+W-H965T,30N>&ULK%;;;J,P$'U?:?\!\5ZNS0TEJ1*J[E;:
ME5:KO3P[8()5P,AVFO;O=VS`C4VV:JJ^A#"<.1R?,>-9WCS5E?.(&2>T6;FA
M%[@.;C*:DV:_<G__NKN:NPX7J,E111N\<I\Q=V_6GS\MCY0]\!)CX0!#PU=N
M*42;^#[/2EPC[M$6-_"DH*Q&`F[9WN<MPRA7277E1T$P]6M$&K=C2-A;.&A1
MD`S?TNQ0XT9T)`Q72(!^7I*6#VQU]A:Z&K&'0WN5T;H%BAVIB'A6I*Y39\G]
MOJ$,[2I8]U-XC;*!6]V,Z&N2,<II(3R@\SNAXS4O_(4/3.ME3F`%TG:'X6+E
M;L(D#4/77R^507\(/O*3_PXOZ?$+(_DWTF!P&^HD*["C]$%"[W,9@F1_E'VG
M*O"#.3DNT*$2/^GQ*R;[4D"Y)[`BN;`D?[[%/`-'@<:+)I(IHQ4(@%^G)G)K
M@"/H25V/)!?ERIUZDUD0AX!V=IB+.R(972<[<$'KOQU&+4AS1#T'7'N.<.9=
M1Y/97+&\DAGWF7#M,^.3UX\3_4Z],N,6";1>,GIT8(>!0-XBN5_#!,@&%SH&
M[<O_;`$_),E&LJS<F>O`DCG4\G$=1[.E_PC^9SUF.\:$)B(=$+)L($]K!'L^
M0*-DD1IE*:7H[1!X$1U9@@:$+0B,^@!!D@5LOW[5M1X$>TI;:QF;:H@M$YA/
M99[?V4,))5BIT?[TD4#5\VIN>:.?O@@[K;E10%#_=B$2;`KI(A-S>]EZ-,AV
M86J^7.WPZ<2;0<*%NUPRF<KZB*EL83FE0;8R2#NU12E;A++=7*I,,IG*^HBA
M+`XL91ID*Y.'G-45HG#Z'L\DDZFLCYC*[%:@0;:RQ5A9.($OX,)22AI35A\Q
M9=D-08-L62&</R/'`OA&+M2E>$QA0\A4%ENE?$&-I)UI\>\L)IS'MFU#R%1W
M;:OK$U7W[5I#=S!W9U&-V1ZGN*JXD]&#/'3#"+J.#G<3P38,8"10I_KHB1X6
MK"<P16PBV?*M^%8FG(M'27H.OXF333>-V$1Q`@WXS`LF2:K&!AL_3=+I.?PL
M294[-GZ>I/-S^$62+F3<UPDPG;1HC[\CMB<-=RI<@)&!^FA9-]]T-X*V8#`,
M*53`8*+^EC"'8C@3`P]Z3T&I&&[D"_1DN_X'``#__P,`4$L#!!0`!@`(````
M(0!8$1)1+`,``*8)```9````>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;)26
MVXZ;,!"&[ROU'9#OEV,@V2ADM0FAK=1*5=7#M0,F6`L8V<YF]^T[QH%RV$W2
M&Q+,YY^9?P:&U<-+61C/A`O*JA`YIHT,4B4LI=4A1+]^QG<+9`B)JQ07K"(A
M>B4"/:P_?EB=&'\2.2'2`(5*A"B7LEY:EDAR4F)ALII4<"5CO,023OG!$C4G
M.&TVE87EVG9@E9A62"LL^2T:+,MH0B*6'$M222W"28$EQ"]R6HM6K4QND2LQ
M?SK6=PDK:Y#8TX+*UT84&66R_'*H&,?[`O)^<68X:;6;DXE\21/.!,ND"7*6
M#G2:\[UU;X'2>I52R$#9;G"2A>C16<8!LM:KQI_?E)Q$[[\A<G;ZQ&GZE58$
MS(8RJ0+L&7M2Z)=4+<%F:[([;@KPG1LIR?"QD#_8Z3.AAUQ"M7U(2.6U3%\C
M(A(P%&1,UU=*"2L@`#@:)56=`8;@E^;W1%.9A\@+3']N>P[@QIX(&5,EB8SD
M*"0K_VC(.4MI$?<LXD'TY^N^.7/]^>)_5&9GE>"?BGMK*)9.JW$IPA*O5YR=
M#.@\"%S46/6QLP1A98\')NMD.L/>\PN,4B*/2B5$<V3`=@$U?EY[?K"RGJ$P
MR9G9:`:./68^9+93QAD244NH2JE;[\8+<6_!@B2[3*$(_4S?;H`V(06KA-K;
M;/0":/>B7PQCVTX9=TA$4\*SA\ANBLS](1)/$<^_[YA!TM!Q_:15>6?O=G^;
MO-H$;=#/-1B%N=$,M&3GQ[B65XGH*K&[2L27B($3$&K?B<OE5W"(P.<N.V]4
MRHU&+AF@B47S.+BNOUCXMCVR,1HP@>W.8#J,F-V`<7S'`63$Q'W&<0)0ZC,#
M(Z#\MQNAX)$1P>B1W&A&Y^FXCKKS.+ZM9B#*SM!1NT17B=U5(KY$##R`-UW?
M@_:M=[DIU*:Q%^.NT,R%/+>:\)NNF+ES?]8]N,W[++JJL+M*P#Q5D;X=A?9!
MSTL]"4K"#V1+BD(8"3NJ6>A`=-UJ-Z8?W6;2=A=@3-;X0+YA?J"5,`J2P5;;
MG$,5N!ZT^D2RNIDS>R9A0#9_<_@>(O#VMDV`,\9D>Z)&>?>%M?X+``#__P,`
M4$L#!!0`!@`(````(0!RJ)L5ZP<``,\B```9````>&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;*R:67/B1A"`WU.5_T#Q'D`"<97MU'*(^R;)LPRR42T@2I+7
MN_\^/9KI&:G;T9JM[,."/_I2=T]K-/#PY_?+N?3-C^(@O#Z6K4JM7/*OA_`8
M7%\?RW_MW3_:Y5*<>->C=PZO_F/YAQ^7_WSZ_;>']S#Z&I]\/RF!A6O\6#XE
MR:U;K<:'DW_QXDIX\Z_PR4L87;P$_HQ>J_$M\KUCJG0Y5^U:K5F]>,&U+"UT
MH\_8"%]>@H,_"`]O%_^:2".1?_82B#\^!;<8K5T.GS%W\:*O;[<_#N'E!B:>
M@W.0_$B-EDN70W?R>@TC[_D,U_W=:G@'M)W^P<Q?@D,4QN%+4@%S51DHO^9.
MM5,%2T\/QP"N0*2]%/DOC^4O5G=O-<K5IX<T07\'_GN<>5^*3^'[*`J.\^#J
M0[:A3J("SV'X58A.C@*!<I5INVD%UE'IZ+]X;^=D&[Z/_>#UE$"Y';@B<6'=
MXX^!'Q\@HV"F8CO"TB$\0P#P?^D2B-:`C'C?T]?WX)B<'LOU9L5IU>H6B)>>
M_3AQ`V&R7#J\Q4EX^4<*6<J4-&(K(W6(7G[>J31LI]5.C10H-I0BO&I%N^U8
M3E-X+U"$3].PX54K?LIC4RG"JU*TS.46.&PI/5@W]SGL*$5XU8I6H_:S"[2@
M$V1A1$O<E51+UQ3>W'61%A92O+G3*=1>QFN:`(P49!16A=(PU7<JGTD-%E_T
M^9U18OFM>^MO80-8=W>`A2T@WNAX/]7F-G:!>*-5BQJ]*M=W.BX&7N(]/43A
M>PEF,/1"?//$1+>ZPAH."EDA/3K^:W+`R!!6O@@SCV5(!@R%&,;=MZ>ZTWBH
M?H,1=5`R/2YCY27Z*"'FD3`[H&!(@4O!B((Q!1,*IA3,*)A3L*!@2<&*@C4%
M&PJV%.PHV&=`%0JHJPA+ZO^HHC`CJHCY[R$P9;5)R5`"5084#"EP*1A1,*9@
M0L&4@AD%<PH6%"PI6%&PIF!#P9:"'07[#,B5#.;A_U$R80;6+LS*S,IS\D7J
M*2&8BUJHE1?I:Q%=2$:&C+B,C!@9,S)A9,K(C)$Y(PM&EHRL&%DSLF%DR\B.
MD7V6Y"H+M<A5]N,]%TY.(9T6$!/?4R0[3.U.D]1+"Z':@)$A(RXC(T;&C$P8
MF3(R8V3.R(*1)2,K1M:,;!C9,K)C9)\EN7K!LKBC7D(Z7R])G'0WG]ZV^HP,
M&!DRXC(R8F3,R(21*2,S1N:,+!A9,K)B9,W(AI$M(SM&]EF2*PYLR.XHCI#.
M%T>23&TH&%`PI,"E8$3!F(()!5,*9A3,*5A0L*1@1<&:@@T%6PIV%.PS(%<)
MF$>Y2LB=8J4%I4M.P>%K+Y0/A!^,NSKL".4^41C)%TB2.NR!];W)[M"[DQ;2
MTXZ1(2.N)&)[K4U;K4Y^D(ZTFA&R.^V\T%@+H?\)(U-&9I(4^Y]KM:Q_$N1"
M"Z'_)2,K1M:2%/O?:#7COUZKY:]_JX70_XZ1?9;D&D><*64?,3YH$'BLQPX1
MTOD.D<2V];:TKTA=DX$DCC`#CQX=JT,R.%0J\JQ#/%NXVJRY<-X=6@@O?*R(
M\3V1I&&EOJV60[,W52K&]TR;+?`]UT+H>Z$([#Q,0W=(K99*J*'"J;0[N7_Y
MRJZ4M(EMK=UFG-!5L]%"&-M6$9.7G22J)@VKZ9`]S%ZII+YS'0,K]HZ.$=+Y
MCE&DH_NCKX@\GTH?+25QFFF:&K6:33;-0Z5BVL[59@LR,])"F)FQ(L;W1!*[
M)4O4;#?:;3)QIDK)>)]IPP7>YUH(O2\4,=Z7DMAMZ9WT@Q(W?M?:9('?C19"
MOUM%C-^=))AQJ^V0SMTKE=1WKA_$J=<=#9&*YSM"H>P0060Z=J`0MFS-JI''
MW2$JF?7B(H('/;,JZ8(9&2G,T!B1"6"BD)HEK4:[56>=@6HFA!FBPA#F1@I#
M6"`R(2P1J?E1(<MBA9\;]VM$A>XW1@K=;Q$9]SN%L`16QR9[@3TJ\;$A3CAS
M;?)+6Y34"ND>>>X"=U(,O8]2IK\'"F&#?]0]RHY972[:@=XOZAX6P!@530`3
MA=1<:=JM&EUB4]0R$<P0%48P-U*8@@4B$\%2(9PMO'E8`M9HI=#]QDBA^RTB
MXWZG$%;@H^;)!I"?,>*@YO/;%'$43NXZB$PW]SD:<#3DR#6HL"U4$,;C6"G6
MTZ^'TCWWA*.I,8_IG!E4X'%NI%!QP<TO.5IQQ;5!!1XW1@H];CG:<;3/H7RI
MQ=%-MM2_-B?4`9!YMNQ9$N7N,@J9+AV@E$%#CEQ$A4-U9*0P.V.%&B:N"2*Y
M/>ZTK6;;)INQ*<HT]8R;&>,%!9H;*0QA@;;@R,4,-;9155*.VCA7&N0+@Q6:
M,2&MC;.,97JSW1@I#&F+R"1]Q]$^A_(](XZ/BGIF'][@IO'3[TG4*90I3D^<
MW8I)8A9QGZ,!1T..7(,*TC,R4IB>L4)UD^H)1U.N.#.HP./<2*''!3>_Y&C%
M%=<&%7C<&"GTN.5HQY'X5MZ40[:`_)9=?FUV\:-7O^^?SW'I$+Z);]#AIO/T
MH+'\>K_G=.%("SQ3WNK".07GHU87S@\XG[>Z\%S/^:;5A>=MSN%G!5_26SOU
M*WYN\(%\S^["%Q0?V*EWOT`B^`>]>A<.OC_@C2X<L`*O:L_P<X*;]^HOO.@U
MN,:EL_\"R:JEYT61_$&"_"-1"^<Y3."'!.D:.L$/1WQX1J]5X'#I)0P3_$,X
MT#]%>?H7``#__P,`4$L#!!0`!@`(````(0"+!R)B^`,``*@-```9````>&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;*Q7WV^C.!!^7^G^!\1[PZ^2-"C)*@GT
M;J4]Z;3:W7NFX"2H@!%VFO:_WQD;`P::YD[[4LK'S/B;;^SQ9/7YM<B-%U*S
MC)9KTYG9ID'*A*99>5R;/[X_WCV8!N-QF<8Y+<G:?"/,_+SYX]/J0NMG=B*$
M&Q"A9&OSQ'D56!9+3J2(V8Q6I(0O!UH7,8?7^FBQJB9Q*IR*W')M>VX5<5::
M,D)0WQ*#'@Y90D*:G`M2<AFD)GG,@3\[9153T8KDEG!%7#^?J[N$%A6$>,KR
MC+^)H*91),&78TGK^"F'O%^=^SA1L<7+*'R1)35E],!G$,Z21,<Y+ZVE!9$V
MJS2##%!VHR:'M;EU@LCQ3&NS$@+]S,B%]?XWV(E>_JRS]&M6$E`;ZH05>*+T
M&4V_I`B!LS7R?A05^*<V4G*(SSG_1B]_D>QXXE!N'S+"Q(+T+20L`44AS,SU
M,5)"<R``?XTBPZT!BL2OXGG)4GY:FQY`3X3QQPQ#F49R9IP6_\J/3A-".KN-
M,SP;9W?F+VS/@:6N^7F-'SR5WV+F/OB./__`$^(*NO!4=.?=DM=I6S)UH608
M\WBSJNG%@.T)2;(JQLWN!!!822@3;T5]3U,0$X-L,<K:7)@&R,9@([QL/&>Y
MLEZ@>$ECLQO;.+K%7EE@I3!L.`2B'F!!`FT64(3?D`5&P2S4^CL%=&FY`\K*
M0KF$0R#J`1IEJ/]OH(Q1H'3W5Y5OC*"\;7D6@SQ:DS:1$1+U$2T56+V?RO3Q
M4UL%C05CM=*N06RQ;^Z&S-JO'?G^WM*(0(:W$T%CG8A$?&T;N_9`J=9(\0]'
M2-1'-()SG2">-M>?@?E_/&\81^?>(#KWX0%KC5KN(R3J(QIW"'V[N&BL$Y3(
M7'1T<;KW(R0<(5$?T=C@'3[L6XL'E/+Z]D,_G5B#+-MCOY>(#X_VO'CNX.2'
MC5'G%DVZ>>WVT>@O=?K7.:.QSEDB?3%'2#A"HCZBL7'@ZAVJ>6\O/U93..K4
M%-0)LV^@#P155IUCI""]$O?3DCIX.?2VQ'5-A?6`N;Q=^JHV5CTH'$.1!NG"
M8O?O<<(#?YNP\MJ`QJZ.ZLYIH$Z??0-])*QT]#O':-K1?T=8;/R#)/Y7UX)9
M<+B1%03GO'?6YBT1V2DZ*Z5&.(9PU!3AQ04NRR!'1SGP%*0^DCW)<V8D](QC
M(=1MLVIA.;/N'$\-K8,O,,UN72S'`-_AE#N%NP%<_F/[K1=L@>KXPPY6GL3]
M`&Z4"?MY`-UZ`E\$T#<G\&4`+6`"=S`#D8+5Y@9S<A4?R=]Q?<Q*9N3D`(+9
MLP4TV%I.VO*%TPJ$A*F9<IB4Q;\G^$5$8'RSL7\<*.7J!9:VVM]8FU\```#_
M_P,`4$L#!!0`!@`(````(0"^2&#^T04``-T6```9````>&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;*Q878^C-A1]K]3_@'C?\)ED0)-934((H%:JJFW[S!`G
M01/B")BO?]_K+\!VPF3:?5EOSAP?^QY?7QO??W^OCL8KJIL2GQ:F,[%-`YT*
MO"U/^X7YUX_XVYUI-&U^VN9'?$(+\P,UYO>'7W^Y?\/U<W-`J#5`X=0LS$/;
MGD/+:HH#JO)F@L_H!'_9X;K*6_A9[ZWF7*-\2SM51\NU[9E5Y>7)9`IA?8L&
MWNW*`D6X>*G0J64B-3KF+<R_.93G1JA5Q2UR55X_OYR_%;@Z@\13>2S;#RIJ
M&E41IOL3KO.G(\3][OAY(;3I#TV^*HL:-WC73D#.8A/58PZLP`*EA_MM"1$0
MVXT:[1;FHQ-FCF]:#_?4H+]+]-8,_F\T!_RVJ<OM;^4)@=NP3F0%GC!^)M1T
M2R#H;&F]8[H"?]3&%NWREV/[)WY+4+D_M+#<4XB(!!9N/R+4%.`HR$S<*5$J
M\!$F`/\:54E2`QS)WVG[5F[;P\)T[<G<L0-O#BI/J&GCDDB:1O'2M+CZAY$<
M+L5$7"X"+1?Q9I/IW/8<&'.LH\<[0BM&'^7[G`\MY\/_1B8&H]/HH.5\Q^VC
M&^DXXQVA%1.;^.YT?O=91'/>$5K1<72&L`_I#*'E?.^F"0:\'[1]9(YOSSYQ
MW($,8PM.4HVO^&AH%LL8FH!1WN8/]S5^,V!70TXTYYS4""<DLB+UF*U=,E[+
M14A"HO)(9!8F^`5IUL`&>GWPILZ]]0I)7W#.4N<HC)5@D`PGLI$*K%4@5H&-
M"B0JD*I`-@`LL*7S!G;"S_"&R!!O1%1+`?1FN;)5*\$072(56*M`K`(;%4A4
M(%6!;`!(1L#._AE&$!G(,]CM@RQ10E]R$FSVCC17W.DHG3T:LM:06$,V&I)H
M2*HAV1"17(*X))<N5V^Q8PB;FB&"6')$WD2>$GM'$MTB#5EK2*PA&PU)-"35
MD&R(2+'#<GTA=L*68V?(E)ZQ=.NO-"32D+6&Q!JRT9!$0U(-R8:(%"B<)5\(
ME+#E0!DRB%,%(A58JT"L`AL52%0@58%L`$CQ0?9)\;'S8$+N$>VA+)Z7F%TD
M+B2W!W6?G09$1`Z;(T%7!%<=TN]S9Q[(V1XQD@]-5PQ<6SDUUAU);(FXTQ;(
MID-Z(6VTI!/J2:ZMU*>T(PGMK-,&1/*27,^'9^L%S^"@%Z81MFP:0WPXE?OH
M`R7Z%2.Y4+H[DA99Q$E0NGI28,MFK_EP#CV^_2!02D_,14@FB$->&VESRW22
M6Z:32M.9^K.I/-WLD^E(*P$7K"^L!&'+*\$0?VBR&RB9L>+=H+GN3\1)[.I-
M[CAKAKAS:KOC.K.9'&C,NPP'UWWG)&BN#YYP4C]XRA`Q^-2?*^F5\2[7!I=<
M)O?'+]A,Z;+/'%)27DG$%6=]DO."Y74U9RWD68H'[IVB'(L^XSDN6-=,H44P
M$:Q^_%1`/EUKSU56.A-_OS:\[#:YM@[+RW\JU0Z[_+*O6SKQ)8?D;+?52YCH
M.)IQD6#U*;?FD'M'39CY2L;%HLNHNQO!&AT^$:Q^^+0??K!3U*J:B8XN21[9
M=IB79/MX57<(74ER#O6)L1(LJ4!KIR%G>?0Q@:[56H?B7DN<4)L>&L2LRB>Z
M5JI#6:^E.4-NQO\_(?G]NK\B+1T&^4/#&/19">`L:/JJJ)U[0IY5!7=NZV6!
MZUS;EW0M-EQG?$Z)8(W.*57FY+@SY;3)A,ZU.<E)2R[N8TOS`Y\A23_]RN?W
M_^':<&BX-ATT<%W-MHA\!L+&\&:#\JQ!,6=!L'TRWR*?Z/*I#I%'/;H[J3QS
MC#W2L3>2"M5[M$+'8V,4^(4\P`50M#J4/0Y&\Q"NH#`]!4_F(5P6=1P>$Q]I
M65'X2_+(>(&_=$/X,+^@XX6/,'_]#TLOA(_4"[@?P@?<!7P:PO<.X%8W(WA<
M/.=[]'M>[\M38QS1#F*')T5(MIH]3[(?+4^;)]S"LR+-H`,\(R.XU]@3(.\P
M;L4/,D#W,/WP+P```/__`P!02P,$%``&``@````A``"9S*:\(P``6,\``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,3<N>&ULK)U;;QO'EH7?!YC_8/A];).4
M1(F(?6"Q[_=N29QGQ59B(;9E2$IRSK^?7>S:W%5[-8N4)SC`L?+5JE75=;^0
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MN5B^?OOAEVT!;>[O_GYR_G[U].7A[_3Q_G-U__V.2IOJR=3`KP\/?QAI_MD@
MBOP68B?;&N@>7WV^^^WVSZ_/P\/?V=W][U^>J;I/Z8G,@ZT^_R>Z>_I$)4HV
M;^:GQNG3PU?*`/W_JV_WIFE0B=S^^_WK.25\__GYR_O7B[,WI\MWBQG)7_UZ
M]_2<W!O+UZ\^_?GT_/#M?T?1S%J-)@MK0O]:DY,W\_/3V>F9,0E$/+$1Z5\;
M\?2XB&2[S3;]:R/.W[TY/ST].3M?AI,\LS'IWY<EN;01Z=^7/21UM6U>Z=^7
MI7AA(]*_-N*,/`+%.:/FLTW*_/&RM&;<$,P?+WN^&;6=,55I1$=6XXQ;COF#
MGS'<UF;<9LP?_(SA4N'&8OK%"Q^-6\OLQ<UEQNW%_&%3/;:-FFH>2_3%;6;&
MC<;\P<F>'M<UYMQ\S!]<M,?UQSDW'_.'C3H[?3,[>7=H")ASZS%_')7HVW$(
MVXZ(T>WS[8=?'A_^?D73#"7]]./63%JSE7'CL7#L,;O1<=_@2*.B<?EH;-Z_
MIEJC<>^)1O2_/BQ.YK^\_8M&X4]6<XF:F:]8L\(,N<8VTB#6(-$@U2#3(->@
MT*#4H-*@UJ#1H-6@TZ#78-#@2H-K#6XTV#C@+57QKIZI:O^)>C8VIIZYABX9
M2,6K:E^S@J-$&L0:)!JD&F0:Y!H4&I0:5!K4&C0:M!IT&O0:#!I<:7"MP8T&
M&P=XE4H3P#]1J<:&^C_-#4[O7?A]\]**:#K8B9:^9+V3[*H:2`PD`9("R8#D
M0`H@)9`*2`VD`=("Z8#T0`8@5T"N@=P`V;C$JWVJ+Z_VIY>O/$(;];:2N7(N
M+7$'[=GR7-7I3L31(B`QD`1("B0#D@,I@)1`*B`UD`9("Z0#T@,9@%P!N09R
M`V3C$J].J7N]H$Z-VJ_3D9R>[`;H-9`(2`PD`9("R8#D0`H@)9`*2`VD`=("
MZ8#T0`8@5T"N@=P`V;C$JT!:\[Z@`HW:K\"1./6G0:1!K$&B0:I!ID&N0:%!
MJ4&E0:U!HT&K0:=!K\&@P94&UQK<:+!Q@%=7-/*]H*Z,VJ^KD2QD-;3>$9DD
M9\L+?TB-K(BV*;N9=';^SA?%.Q&/N\G.FTD*)-O%<JW5@BS?B=BH`*,22+6+
MY5J?^KFN=R*V;L"HW1''2)=1MS-R1.=JO='O1)S:L/-F<@7D>A=+K"]._.>X
MV6G89^/Z>(V(JO$%C<BH_48T$K<1`8DLH7^<%J,V3_%.Q'E.P"@%DNUBN=9J
M[9?O1&Q=@%$)I-K%<JW/_)*N=R*V;L"H!=+M8KG6:NG2[T1L/8#1%9!KB'4#
M9./&\AH#G1]XC6'<3;\QQVO/7^X__7'Y0!5(6[2)I=J"=LWC7MJ8^&UD)&X;
M`1)9<K&;^6,@"<1*@62[6&[1JOZ1[T1<M`48E4`JB%4#:2!6"Z2#6#V0`6)=
M`;F&6#=`-FXLKZK-<:%7UQ-U2B>Y7*E;N5^K%CES/8O&0^?Q!,0D0_$$Q:A*
M$*6(,D0YH@)1B:A"5"-J$+6(.D0]H@'1%:)K1#>(-A[RJ]4<H+@'8@>J=3QO
MH;TS]X1+<QA,-6;.`YW16BT"UJRBK;VH]#08L8KV@**ZT&L%5M&NPE&I^2%A
ME;2DE-%\E_N,43#%G%7!%`M628HE(TFQ8A1,L695,,6&59)BRRA8T!VK@IGH
M617,Q,`JR<05(WGL:T;!%&]8%4QQPZIMBGYS-D=';G,V,]+\]`U-2`<:]GCF
MY#7L$<UI.>TT,[6Z7)N;#3-@T<`I*FS85C7>B9F1+K81Y\OM\?'\?*&Z3,+.
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MR>M&,:(%K3V=L43-H&N.Z`U[NL`BJUIX'107G39%LV_]Z\/YN>H5";M0HY,<
MZ;12R1$7>\81@\GGK!J3OUBHP;7@\&#R)29?<<1@\C6KQN1Q2K>%$TR]E=0#
M1=1Q4L$,]:P:,S0[5W/9P.'!'%U)CK@ZKCEB,/D;5ID-[U\?YN^6:EC>L&!?
M^GXW,2>V>M5*'XW8G:-</_R@X>[@&G8\^*7NR$]S:3Z3,HZ4C-:"`K406=7B
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M+9*:7@.)@,1`$B`ID`Q(#J1PB?^HYFS8':U^:OT_'T^8W9;-2$YGUH)D7,/+
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MG`H*V&?HE2,JQ`M&!K,1__\/N.-VWAMP1W3B%MB(3/>06L0"LQ&I=$6%HX-5
MC?MI^ECFF1H@$W,&3I5XXMW&Z-12JPKG*6,5-;#]><I9Y><<1@=;"A.CPS^S
MJS?W3[KUXJZ>5=XCZ>*)K,K=U2-*Q$M:[RY%I\2T?89>.:+"L_?[M=F#8NM]
M\8Z7!C9;9)+;A9YO+EE%%;AK!6H@7(N&BR)"%"-*$*6(,D0YH@)1B:A"5"-J
M$+6(.D0]H@'1%:)K1#>(-A[R&X79B;J-XL!@;S>NLCB^G._VLE+1\W=J^;$6
ME53U+B*C&%4)HA11ABA'5"`J$56(:D0-HA91AZA'-""Z0G2-Z`;1QD-^59O-
MZ0NJ>MS+>M/4B)SM[=I<>M+XZ:`(48PH090BRA#EB`I$):(*48VH0=0BZA#U
MB`9$5XBN$=T@VGC(JU=:+;VD7K=R?[UFD73J-9`(2`PD`9("R8#D0`J7^(_Z
MC^QXS;V6FO,9.3M>03*NP2H]LJH#.UY1\5"7B#VC5%`@Q4R\1(4[7E&Q?2'V
MA/QBI47F"T8&<Y>GRV]$:L>K/C&PMA'#Z\>(5=YB"]:T5G4R[GB7YS.UO4[8
MQEV`0/VEK`HNLS-6!;.4LRJ\I&45+FD79.]5PT]M>+<NJG\;8UK=NP])MVKJ
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M;)%);A<G:FJ[9)7;"F"`M4[R\;5(HG'IQ(@21"FB#%&.J$!4(JH0U8@:1"VB
M#E&/:$!TA>@:T0VBC8?\E8[9<^IN-'Z"^87OJ%C8W:LLFB\9437O^OA\H5K*
M6E1<Y1&B&%&"*$64(<H1%8A*1!6B&E&#J$74(>H1#8BN$%TCND&T\9#?"LRF
MU6T%X4./Q;C']2:P$3G;WK55.2A"%"-*$*6(,D0YH@)1B:A"5"-J$+6(.D0]
MH@'1%:)K1#>(-A[RZM5L/UY0KUNYOY*S2#KU&D@$)`:2`$F!9$!R(`60$D@%
MI`;2`&F!=$!Z((-+_*+_1W;FM)O3RQ-&SLY<D(RSL)^(K,JT%F<T5G-R+"H>
MC1-$*:(,48ZH0%0BJA#5B!I$+:(.48]HL(@N-_6RR6P2O3[T4VO^K8OJ6L:8
M-J%^?:@/^JXYHJN:J-O1Z]2]8-=?NXZM%8FD:L=XXV-O/[2>'I5@)EYN8U*?
MB,Y%Q2D68L^H%"1>\(B5>(EJ?J)V.K6HV+X1>T:M(/&"%#OQ$M5<;^9[4;']
M(/:$_%%!GVB$)UK:#T+W'Y'Y#(ST8OTRL+6->&#SR"HY.X@1)8A21M1Z=IF`
M\LM8)?8YH@)1R2AH7[%*[&M$#:*64="^8Y78]X@&#_E5K4]1?F[<L"<I,@%?
MGHS(-+)=X<]/U&G?VJH.?%J#533-[+QF>J\>6Y4]SYK-%F_4;5;"/FZ>H$&D
MK`J.91FK@GG*#^:I8)]@GDI6!?-4L2J8IUKRY):F.M-HV$N^'-4R"F:B8U4P
M$_U1F1C8"T__3LR)DKL7T.WVN(.5K8V:\,:S*O=4D%7A@Q6KHJ,-'F)C1(EX
ML2H5Y%0('*R@5XZH$"^V+P4%["OTJA$UXL7VK:"`?8=>/:)!O,C>'Z?,L9);
MWP>F)'LZY@Y((Q*R-A^;,>>_SL$.HAA1@BA%E"'*$16(2D05HAI1@ZA%U"'J
M$0T>\JM"G]`=J(K=01PWF4MS[48%KU8'ZK1WS:K@R!BQ2B;`&%&"*&44M,]8
M)?8YH@)1R2AH7[%*[&M$#:*64="^8Y78]X@&#_E5K<_=#E0U'JZ=C$@M`]3$
MO+:J0\L`:Q^<66+K99<!BXLWZB0OX<2"19>R*CC99:P*9BF7+#E#)%QUL9?,
MN"6C8"8J5@4S41^5B8:])!,MHV`F.E8%,]%+)K:O!X;*&=AF7^7XS9.R])))
MP<C59#\B<SZR6UG.]2W!VFQ^S7BU+U/C.P!8Y:T2<)5JO4ZVMZ[+-_HCG>SB
MWDA,K%&/R5'&7L$<Y:SR+^?4>K!@E4R6):-@L52L"F:B9E4P$PVK)!,MHV`F
M.E8%,]&S:D_=#!R^KVZ\QFE..;S&J5>H1[T';.OBMUF+U)"J3LC6')$:RJYE
M0SN*6!7LM;%5V2'UW1LU4R?L$JR#E%7!'&6L"N8HEQPY3P<C*GO)8%8R"F:B
M8E4P$_51F6C82S+1,@IFHF-5,!.]9,*,J%`W`[OLJQN_S5):P39[W*[JU-BH
M1FN1\UD+5GE]4F][(JMR=U6($O'B168JR&DBVCY#KQQ1(5YL7PH*V%?H52-J
MQ(OM6T$!^PZ]>D2#>)&]7]_4*KSZ#J_O3HU<U>N(G.NSM54Y*$(4(TH0I8@R
M1#FB`E&)J$)4(VH0M8@Z1#VB`=$5HFM$-X@V'O+KE?K42^K5R%6]CLC9+9]J
M$@&)@21`4B`9D!Q(`:0$4@&I@31`6B`=D![(X!*_Z,VYIWM0\7/3_GAZZMY=
M4W_:5I)SHR8H,$A$5N7?J)VH&YQ85#P&)8A21!FB'%&!J$14(:H1-8A:1!VB
M'M%@T<2-VNFA$\;CUF_V-%$ZTN76^."-FE4=V!);E9GD=ZL\N%$3D52MS98T
MIO2H!#/QD@3G^BU]N:@XQ4+L&96"Q`N6J)5XB0IOU$3%]HW8,VH%B1>DV(F7
MJ/!&351L/X@](7]4>-GQY2D>7UJDSLS4[G'-JGVKO7&GRBHY%HH1)8A21D'[
MC%5BGR,J$)6,@O85J\2^1M0@:AD%[3M6B7V/:/"07]7Z>/3G)@`\-3T=D=KW
MZ1LUJSHT;EC[X-XBMEZT[W,[@KH^3SC%8+&FK`KN>3)6!?.5'Y6O@KV"^2I9
M%<Q7Q:I@ONJI?,%7YQOV<C>$MCJ"F>@X8C`3_5&9&-AKFPF__9I3UM`"YL@]
MH#VL=2<^B]P]X`Y)"X,!.3H=5=X>$%!B5<[%72HH8)^A?8ZH$"\>[TM!`?L*
MO6I$C7BQ?2LH8-^A5X]H$"^8FJC1>?5]8`]HY&JO,"*IZ?6I%<DY780H1I0@
M2A%EB')$!:(2486H1M0@:A%UB'I$@X>\KG>FCPS#5;&5^U5AD;]*.%4?/UJS
M*C@R1JR2B3!&E"!*&07M,U:)?8ZH0%0R"MI7K!+[&E&#J&44M.]8)?8]HL%#
M?E73(/Z"7G=FY*JJ1Z26`_IFC2-2A]QM$'"`955P9HFMRAX#GYZ\T2L!M@D6
M7<JJ8)8R5@6SE$N6G,>#<V#VDAFW9!3,1,6J8";JHS+1L)=DHF44S$3'JF`F
M>LF$.0?&RAG89E_E^,V35%[S_*E%[)EQ4:UV1`<NW&S$`Q=NK**#*6G;<.'&
MJO%29W8"]\$LV'>K,W[@E%7[BF^KRE@5S%+.JN!E5\$JF41+1L%,5*P*9J)F
M53`3#:LD$RVC8"8Z5@4ST;-J7^4,+-A7.7ZKI<2"K?:XI>N9L5'-UB)GZ<HJ
M[P'U_4)D5>[2%5$B7KSX2P4YC5O;9^B5(RK$B^U+00'["KUJ1(UXL7TK*&#?
MH5>/:!`OO70],T>BN%5Y\:MQMC[;"I?<PJ\67++*;8KZUE4T7!01HAA1@BA%
ME"'*$16(2D05HAI1@ZA%U"'J$0V(KA!=([I!M/&0/PB8HTVW41Q81!NYZNP6
MT:9\-Z_,3]5B9WVV4TE5`XI1E2!*$66(<D0%HA)1A:A&U"!J$76(>D0#HBM$
MUXAN$&T\Y%?URTY5S_!4U2*Z!>!*7".*$,6($D0IH@Q1CJA`5"*J$-6(&D0M
MH@Y1CVA`=(7H&M$-HHV'_'HUQV$OZ,+V]$PJ\?)L1$+60"(@,9`$2`HD`Y(#
M*8"40"H@-9`&2`ND`](#&5SB%[TY5WM!T=OS.RGHRS-[,B<OR5X+D@%U8A,Z
M1C2WVC+LGJFSB]AZD8I[;"+VC%)$F41T[=4%2BXJ]BK0JT1424377FW':U&Q
M?8->K2#Q@O+JQ$M4\S-UK]N+BE,<Q)Z07_NT$WU)[1NYFCM'1%_EY^369X`B
MBZ@2S6:57K2N)M=8!&R3H$V**).(;J&H2Y)<5&Q?H%>)J)*(KKWZA'$M*K9O
MT*M%U&'$'M'@1?3J;ZD/$']JV[YU\:O5(K=:$446F<^3.SU8?9(T%A673H)>
M*:),(KKVZL.(N:C8OD"O$E$E$5U[M<*O1<7V#7JUB#J,V",:O(A^W=+YSPOZ
MYM+(526.2,;J-8MD=Q\ABA$EB%)$&:(<48&H1%0AJA$UB%I$':(>T>`AORIH
MBO*JXN>ZF7%1-30B__C^3`V.ZZ55T3^[;@;30V15YBMTHH+3,5;9=PS/%[.Y
MFK,2EM#J68ST240JF>)^D7'$8`YRJS(?4A1[.,)E+_ER78DI5JP*IE@?E6+#
M7I)B*RDZ6=4ET7'$8"9Z5NTO^($E^PK>;Y/_S-G7$L^^&#EG7X("!1%9E7OV
MA2@1+VXX*:(,(^:("HQ8(JHP8HVHP8BMH,!C=^C5(QK$BQ[;KTEJ.-[H$C[`
M6!JY&D9&Y`[T5N0.](!BMA)5@BA%E"'*$16(2D05HAI1@ZA%U"'J$0T>\JO"
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M2WO4Y3[?7/\8Y=JJ#GPLD%52R+%%_F<`EVI#G7!$-Q/X,\:LDLZ?,9(4\ZD4
MX5-T!4>4)E(R$ON*D=C71]DW'%'L6T8'QA9;0Y)B/Y7B7!?AP/;[BM!O3>:L
MS)V8#@PJX]&:^W6"I472X->"`OT\LBKWY;>($O&251VDF&'$'%&!7B6B"B/6
MB!J,V`H*/':'7CVB0;Q@56=.P5Y08T:N5G4C<E=U5B3KM6@)*$:4($H198AR
M1`6B$E&%J$;4(&H1=8AZ1(.'O,YS_H^<DFU=_!JRR-^^+]4!U9I57D?7TVED
M50>V[ZP:=Y$7[R[.],C,BGV;R/'3+9(G[JX91Z1M@LSZ^OP@MZH#NW?VDKUT
MB2E6K`JF6!^58L->DF(K*3H/I,N]XXC!3/2LVEON`ROVE;O?(O79GEX<'/?!
ME7,\\V/D#/."`N40696[>4>4B!>WFQ11AA%S1`5&+!%5&+%&U&#$5E#@L3OT
MZA$-XJ6'^7/JU2\8YK=R-8@8!^^G6=96Y=Q21XAB1`FB%%&&*$=4("H158AJ
M1`VB%E&'J$<T(+I"=(WH!M'&0WX/U<=KX077.1ZC6>1,WT`B(#&0!$@*)`.2
M`RF`E$`J(#60!D@+I`/2`QE<XA>].:@Z?N5T;N2J2XW(O;VR*O/*<9G=]&00
M6=6!*VE1\2"8B#VC%%$F$243<_TC?[FHV*M`KQ)1)1%=>W6\7XN*[1OT:@6)
M%]PY=.(E*KR2%A6G.(@](;_VS1G2"VK?'CE)-[L\'Y%7^X`BJ]I_)2T"SG6"
MSBFB3"*ZA:+6:;FHV+Y`KQ)1)1%=>W7X5XN*[1OT:A%U&+%'-'@1_?HSAU=N
M_>FES5%?HSX?C\#<#:Q%7K6.*@=%5G7@2EI47#H)VJ>(,HGH%KY:\>>B8OL"
MO4I$E41T[=7Y7"TJMF_0JT748<0>T>!%].O6G'6X=7M@4K1'(V[?')&0];D5
M.7M:1#&B!%&**$.4(RH0E8@J1#6B!E&+J$/4(QH\Y%>%/A#ZN6Z&YT3G(_+V
MM+-S?27-J@-[VM'KT)[6JL:]U>G).?P.D$W-O*)R_^2=2IZX6V0<,;BYRUEE
MKV9/3I>JQQ6L"&:@Q`Q4'#&8@=JJPIOJAKW<+:ZMK&`U=!PQF(F>56,IG%V<
M+-2-P\"*?:7@-U!S,.6.%;J!'KG%M>=;,F)<GEOD;G%W*-!`(AO1V^*.$1V4
MH'V**$.O'%&!$4M$%4:L$348L144>.P.O7I$@WA1[_%J\D(?GX5'_:W<7X];
M)'6X9I$SZB.*$26(4D09HAQ1@:A$5"&J$36(6D0=HA[1X"&_*J;.C8ZYG[[`
MDR*+O/OIF>[S:XY(_63_T!NQ2BY!8HO4/9+:C"0<T1O`+I0J995<]&2,),5\
M.D6U,"XX8C#%DE628L5(4JPEQ>V-H<YWPU&\M/2FLV55L(@[5DGRO20O=3/7
M<]?`$;U,.%GU&QBI8-0^ZA[[PL14W7Y$ZAY;?6!Y;2,>N,=FE0SZ,2-W6IOK
MTDU813M`:<#.XX_GX:R2Z[^,D11XCJA`5#(2KXJ1>-6(&D0M(Z_R]#-VK)+"
MZ1D%"V=@U;["\=N&/A+3,_I1.[L+/"FSR!N)\$:;(P:[2<0J*>G8(F\D@OOE
MA"-*K:6,9!#(&(E]?I1]P1'%OF0D]A4CL:^/LF\XHMBWC(+EU;%*4NR/2G'@
MB-L4_79";<X;0PZL%XQ<#1P627M>7^R0TXUU1XBLRKVK1I2(%V\44D091LP1
M%1BQ1%1AQ!I1@Q%;08''[M"K1S2(%ZSPS/&8NU8_4&/C:9I[.',Q(G>%9T7N
M"@]0;.,Y/\F0($H198AR1`6B$E&%J$;4(&H1=8AZ1(.'_,YCCK3<JOBY0=:X
MJ#XU(G]??Z'W]1=6%9QO(JLZL*]GU;BA7%R<7JBI/V$%)2ISL^[4J>2)NVO&
M$6E0D(AP5\VJ,0-+^MJ1_PG)@@7!]$M,O^*(P?1KJZ)M_9[EX5C8X6.-5I)W
MGE474G=4CGI6C25RLIQ=J&/I@17[BL1OK.YYX(S.(G1C/6Z/?X'GA(S<&<"J
M:/T@=:[+(;(1G0U]C"A!^Q11AA%S1`5&+!%5&+%&U&#$5E#@L3OTZA$-XK6;
M`=X^?;F[>XYNGV\__/+M[O'WN_7=UZ]/KSX]_/F=2GE&/\[J\%>/=[^]?_UQ
ML5Q]I)<TD,<NQAA"/Z^\,K_J.Q5R3B'GDR$7%+)=`VFWT_G*O/,8W3Z>G:P^
MTL-@"+VT867>%3`5<DHAV]E(IW-V1B';4S4=<DXYH#OB"3<RF_+Z.*.RF4]Z
M4<AF-IGG&94-]9Z)5&94-N.K:E7./LXIG;&1JY!+"MG0I\(GW.:4#JV"IT(H
MG?E4':PO3E=F1L8X-"FOS/R*(33%KLQLB2$T8:[,W(<A'V=4;!/\<D8%,,6I
M8J;T'Q>KC[/)XE]0*YLRHO8RU5SHAG)E;D(PJW1CL3*7#QA"]P\K<Y6`(72;
ML#(7`QA"=P.4SE0(G9%1T6]_%5-5,9UX4=%/A=#Y%17]5`B=1E'13X70M?'*
M7`ICWNBJD4*FJHLNJBADJG3H+IF>="J$KI17YE(*TZ%KY)6YB,(0ND1?F6LX
M#*&[])6Y*9\*.:60J5S3[1V%3+G1!3O5W%0(W;.OS$T=IK->7JS,!RLQA#Y;
MN3(?D\00^J3DRGSH$4/H<X\K\Q%&#+FD'%Q.YX!"UI,A]$&&53Q9.G3O32%3
MI4-7IQ0R]:3TZ09J\5,A]-5RRO54JZ*OFE+I3'5=^N(HE<Y4"'T-E$IG*H2^
MU$GI3(6LEY0W^D(/EAM];XG2F0JA;R%1.E,A])TB2F<JA+[OOS+?YL=TZ#OB
M%#)5<_0-XY7Y_C#&H9<`4`ZF0NA=`"OS;6*,0]__7YEO$&,(O?U@9;X_C2'T
M$H25><7!5,@%A4SEFKYVO3)?JL8X]&8$*M&I$'I!PLI\Q1KCT*M!5^8MGQA"
M+_I<F7=V8@B]MG-EWL")(?02SI5YGR:&7%(.+J=S0"'KR9"(0LS[)="-7EA`
M(5/IT'?>5^8;[1B'7DM!+7$JA'YX<&5^0Q#CT,\(KLPO`F((_2C@ROR^'X;0
M3_RMS*_U80B]^7]EWGD_%4*]GMY6CB'T@O>5>7T[AM"+V%?U9`B],)W2F8H3
MS6>K>#[53S,*R2=#H@7%64S&H9!\,H1^-7QE?B\;<QV=S%?F)Z4QA'X<>F5^
M^AE#Z$><5^8GFC&$?FR9TID*&6C:GFH?5\O5U12_7JYNIOB&5FM3?#VCV7\V
MU9I2"BDF0TH*:29#6@H9)D.N*&0S&5(M:?":*).*!L*I/E/1,#CU)`TM?:9X
MNURU4[Q;TC`WD6Y'P]]4NMW%JI_R29>K=(IG2QK>)OPS&BJG_#,:**=\"EKL
M3?%RN2JG^.5R=3G%U\O5>HI'2QIH)O(9T:`UE<^(AJPIGX26JUO^=K>,?/KP
MRX_;W^_JV\??[[\_O?IZ]QOM]=Z],=]X?+S_W6SBQ_]X?OA!>\#7KWY]>'Y^
M^+;]\\O=[>>[1R,@\6\/#\_\']1YWO[]\/C'=C_YX?\$````__\#`%!+`P04
M``8`"````"$`"NK3W[8#``!Q#```&0```'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6RL5U%OHS@0?C_I_@/BO8`A(0E*LDI2]6ZE6VEUNMU]=L%)K`)&V&G:
M?W\S-E`P;-6L]J6$\<SGS]\,X^GZTTN1.\^LEER4&Y=X@>NP,A49+T\;]]M_
M#W=+UY&*EAG-1<DV[BN3[J?MGW^LKZ)^DF?&E`,(I=RX9Z6JQ/=E>F8%E9ZH
M6`DK1U$75,%K??)E53.:Z:`B]\,@B/V"\M(U"$G]$0QQ//*4W8OT4K!2&9":
MY50!?WGFE6S1BO0C<`6MGR[572J*"B`>><[5JP9UG2)-/I]*4=/'',[]0F8T
M;;'URPB^X&DMI#@J#^!\0W1\YI6_\@%IN\XXG`!E=VIVW+@[DAS(S/6W:RW0
M=\ZNLO?;D6=Q_:OFV3^\9*`VY`DS\"C$$[I^SM`$P?XH^D%GX&OM9.Q(+[GZ
M5US_9OQT5I#N.9P(#Y9DK_=,IJ`HP'CA')%2D0,!^.L4'$L#%*$O^GGEF3K#
MKZ5'9D$,WLXCD^J!(Z+KI!>I1/&C\6F0#$;88,"SP5AXLW"^6!($>2<P:@+A
MV01&L3=?!-%/`GU#7FMQ3Q7=KFMQ=:#`@)^L*)8K20"L%<%LW<GR,U5`#@39
M(<K&7;@.G%A"*I^W431?^\\@?]KX[,<^9.AQ:#TP:T"OXPCJ_`:.B((<,9-(
M>M\:WDB'%J'6PR8$0OT&0H@"LL_>5:UQ@FKHI%U8+#L7FR8@]VE.%W:;0G36
M;#I]C"4F.I]W*VO7;O6-6#_G@P0"^SX14V1`^\8J0Y@A16.)(4^=.E$46TP[
M)UN?>$CK?7W0>;AY8S&]`2OJT+<,!(`O8R3`BF!?N54#1!K2,!9+`[M&.B=;
M`[S->M__^QJ@\W#SQM+3H&\9:+`:[H1%$)+86]RN`2(-:1B+I<'2JH/.R=:`
MP-WQ<1&T]W#[UM2386`:Z$`F6FX8KKS;==!(%A/30RTE[&^W"02OD138\CY<
M#\0T2'-+FZ;:FOI2-%[:-)0"6U=O-UT3\U\0HFF!>EIH>!C34(A98)4$Z;Q&
M0MS4/+&)6R79FOI"-%X](<QT8F[D@M4G=F!Y+IU47'#R@'%DN^[,9BS:DP#F
M(CW:C%9P8B*8T]%*""LZVZ.5"%:BR9@9K&A%K1@8S';36!`PA02;3_GOHF0W
MN<$>.$U2FB<'K9U%:!\GT'HGCKU(#OJ^M_V7R6$YY;]*#BNT^UT`#'P5/;$O
MM#[Q4CHY.T):`MVT:C,RFA<E*D@7S'U"P:RG?YYAM&=P*P3X91^%4.T+;M#]
ML[#]'P``__\#`%!+`P04``8`"````"$`F4(@^+$Y```G8@$`&0```'AL+W=O
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M_O[K=^E]JTNJK^POO_SO\..W#[JE2O.V?UMG^O#E-PU`__^'SY]J;^B6O/_/
M3V_ZZOC3+]]__>G-]=W;V_NKZY["?_CKQV_?BT]URC<_?/CGM^]?/O^_)J@7
M4C5)KD,2_0Q)>E=O>S=7=W6.CG8WH9U^6KO^VX?;VYN[A_ONEOJOQV'KYXEA
M=W1Y%QKJYX5=WH>6^FDMS[I(/6K'H>JGM3OS(A]#2_V\[")[LM&QS_H?%W;:
M,T?4_["V9UUH3QYJ>HUFZIUYJ3VS4/V/T&O_]CPO],Q&]3]LQ!I"APOJ)Z09
M:C30>9;MF8'J?[2=G3E0LU`O>BA]VKH&;"[J76ZCGOFH_D<8\IG=]LU(]3\N
MO-J^&:G^AW5[>\ZTT#<CU?\XK]=WS;1VG"6'[[^___G'KU_^_8/6'O7][8_W
M]4K6^TN=SN;'YEZW,^9S$Z9FRCK+_]1I?GHCV307?M,T_Z^?KV]Z/[[[EV;F
M#R'FB3$N8F`1]31<IQUZ,/*@\&#L0>E!Y<'$@ZD',P_F'BP\6'JP\F#MP<:#
MK0<[#_8>'!+P3A*W.DO:/T/G.DVMLRGT9"`*W\]E'UB$-1EZ,/*@\&#L0>E!
MY<'$@ZD',P_F'BP\6'JP\F#MP<:#K0<[#_8>'!*0B:JUX,\0M4ZCYU^K0_OT
M]NX><AF?0I#6@S;H/@\9M"&MU"`CD`)D#%*"5"`3D"G(#&0.L@!9@JQ`UB`;
MD"W(#F0/<DA)IK[TRM0_O:6U&;J./HILXCP%HG6Z512R#]H@:S8$&8$4(&.0
M$J0"F8!,068@<Y`%R!)D!;(&V8!L078@>Y!#2C)-]7AEFM;+\:WF]`N7XSI-
M+G8@Z0K=NWMT#W`;U(H-,@(I0,8@)4@%,@&9@LQ`YB`+D"7("F0-L@'9@NQ`
M]B"'E&1BZ\F#V/7.^T*QZS1^^KZ_RJ5]"D'*WC[L?OIN0UKU048@!<@8I`2I
M0"8@4Y`9R!QD`;($68&L038@6Y`=R![DD)),?3V*F?K=TW<=G3_1@2A_JVC/
MRSYH@UI-048@!<@8I`2I0"8@4Y`9R!QD`;($68&L038@6Y`=R![DD)),4QT^
M,TWKZ5O'],N?Z3I1+G<@ZCJ1VQ^@VJ!6;I`12`$R!BE!*I`)R!1D!C('68`L
M058@:Y`-R!9D![('.:0DDUOU@C]'[CI1+G<@N=S^:-4&M7*#C$`*D#%("5*!
M3$"F(#.0.<@"9`FR`EF#;$"V(#N0/<@A)9G<=;40>E\_U(7C2]?L8ZI<<4.Y
MY-?Y.CZ(4:WF1".B@FA,5!)51!.B*=&,:$ZT(%H2K8C61!NB+=&.:$]TR%!N
M@[K&DM;,NE?NND[L'FY##VT=94`T)!H1%41CHI*H(IH038EF1'.B!=&2:$6T
M)MH0;8EV1'NB0X9R7>LR2ZKKJU?ONM+O)6_0K4[SR?I]XY_N-BH^W4"CD%ZY
M+*H@&A.51!71A&A*-".:$RV(ED0KHC71AFA+M"/:$QTRE+N@KK?\.2X(E9OC
MV\UC/?NI?GLC8S@7W'H7M%&F[S`V-#0B*HC&1"51130AFA+-B.9$"Z(ET8IH
M3;0AVA+MB/9$APSE+J@K--X%KRC$U$55/Q,TR'G@SGN@C3+!AR%7\MB/B`JB
M,5%)5!%-B*9$,Z(YT8)H2;0B6A-MB+9$.Z(]T2%#N0>TK?M3/%#G<7N]!CD/
M^(),70MJ9HOH`:`1HPJB,5%)5!%-B*9$,Z(YT8)H2;0B6A-MB+9$.Z(]T2%#
MN0?J\DTZ#[RPUPO5GG3*#RC?UKNW*X/Z;7GMD?AF;4@T(BJ(QD0E444T(9H2
MS8CF1`NB)=&*:$VT(=H2[8CV1/JP47*C<ZFET"52U^'NJ6[0;51_4'^2H7Z$
M(QH2C8@*HC%1250138BF1#.B.=&":$FT(EH3;8BV1#NB/=$A0[FN=?GF@D<X
M5'NB8D_U9THD8B0#D"'("*0`&8.4(!7(!&0*,@.9@RQ`EB`KD#7(!F0+L@/9
M@QQ2DDM8EV0ND#!4<*)@3_5'>R3A=9Q?!Q&E)S+W2FQH4;)`/+<]N+<KHQAE
M*W5A*/8X)BH-Y>E=G:^*499^8BBFGQ+-#.7IW7EC'J,L_<)03+^,*+D3]^Y^
MK2PJ[]'M;-8QRGK<&(H];HEVAM+TC^X4O8]!EOU@Z)@]\U;]R:T+O'4,SZ?]
M@%)O$0T-I2/O/;@"_BA&V=`+0_'&C(E*0WEZ5SVL8I2EGQB*Z:=$,T-Y>G=H
MF<<H2[\P%-,OB5:&\O1ND[2.499^8RBFWQ+M#,5ZVY[H8.B8*_>(K_@UGY)[
M6W\(]_NOGS[\X^F+)@<%G=@=7NO3<,UGY/HL!`:46:>)2M#0HA[;>L^(J#`4
M;\68J#2D^3"9S]P35,4HN],30S']E&AF*`YU3K0P%',MB5:&8JXUT<90S+4E
MVAF*N?9$!T/'7+D#ZBK<^2M0_4E*MSD,**Y)`PMJ/G9^_+PCT8BH(!H3E405
MT81H2C0CFA,MB)9$*Z(UT89H2[0CVA,=,I3+ZHM])QY@O=UIGV!6]/H-JN>.
MY'ERJ^+`HF2+&.77SJ%%*66,>O1[#8M2@2B)<@M)85'17&-#_78:*0UU]EA9
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M>W1'L;%%Q:FC-!1[K`SE/;K=^,2B.GN<6E3L<68H]C@WE/?H%IV%1<6Y<&FH
M\ZZN+"KVN#:4]^@,MK&HSFO<6E2\QIVAV./>4-ZCFRH.%O5<C[FEZVIC:ND7
MIN%0G$R]&U`<YZ">DNO).EM+..<V4=?'7X\\>G<4&B:HB+GL:1D3E6Q8$4W8
M<$HT8\,YT8(-EQ$E#Y"_[!5SK8DV,9==]I9HQX9[HD/6,%??5Y1?=VQDH5FK
M9NV`:QT5D[G$K:"#$%67/F*4OV%#RY4]H-QTAA[KT^R_?GYX<$]%85FR9\?W
M-8XCLMM>6L/.[BN+:KI_O':3Z\3^>V?W4W8_LX:=W<\MJNF>2WJX.9V]+V/O
M'7*LK*O.`:TMJAE0[\&M91O[[YTCVL81F1P[:]C9_=ZBZI/1OW[N7]V[:?E@
M`<_UGS\FJOIDDZ1_3'9?_GBNNJ+9N#V<U6G<'C:@=/)L48<*PWX3=7W7;B)&
M1$5`FHCM_HV)2C:LB"9L."6:L>&<:,&&RX@Z+GO%7&NB3<QEE[TEVK'AGNB0
M-<Q=H6DK<\4+2V<=[M0/*%;]!O46L(Z*:$@T(BJ(QD0E444T(9H2S8CF1`NB
M)=&*:$VT(=H2[8CV1(<,9;IJ]W&)KL?P7%=#FG7;=4U?J^$^0!.CS*5#HA%1
M030F*HDJH@G1E&A&-"=:$"V)5D1KH@W1EFA'M"<Z9"B7NBYEG[_[K;<S[A$.
M*'E]/B`:$HV("J(Q44E4$4V(ID0SHCG1@FA)M"):$VV(MD0[HCW1(4.YKMH=
M7*)K'>X>X0;%<\[@VI,AR`BD`!F#E"`5R"0E^:7JD)5=JM^;G/7FY[K.XNY`
M0+'`,K`HK5'MO-;S>^AAB+K)9S]W$A_%*)O]BIC>T#BBCA[+F"M&]:]<7:N*
M499^$M,+Y;=5&\/LMG8O[M=UN+M_#;I)Z^[]*[</'H2&]0N`KEO:Y*KKJC$*
M1Z"0ZZ9WW/3V[OHWKGA36&]9:<`+.+:HSC&5%M4YILJB=`')R)T9)A;%@O&U
MAIKI\#I[UUF</`VZ22^R?^6.;8-C]VKX@N-#^EAX'(6&.F;4!Y#>7<\=0`K+
MG/:/9VEL49W]EQ85^Z^L?QT3NNY[&/BQ[)3[OR[.7+`RAHI/G"^?=#0YWO-X
M]AA$E`S*VV\8HK1JVW,Z(BIB+HL:1]21OF2NBF@2<V%FJ,_2Z9UYG2.;$WE:
M!-8+]?J&W:0WK$$OS0ZA8?Z,N>WFR-(W1^+>_<.=FR`+BY!PT3->GG&(ZAY3
M:5$OS`[A^O*18W8(42=FA_H4W*7%>0?SZW#D3MT;4"I&BSINSS#DDG_,ER.B
MPGJ,Z<<1=:0OF:LBFL1<<&]]ODSOV`OK6AWN)LZ`)$KKDOZ56VD&UVV4W88A
MT8BH(!H3E405T81H2C0CFA,MB)9$*Z(UT89H2[0CVA,=,I1-X?7.XP*IC^&Y
MU`&EAQNB(=&(J"`:$Y5$%=&$:$HT(YH3+8B61"NB-=&&:$NT(]H3'3*4ZWK9
MH57;0?\(!Q2GNP'($&0$4H",04J0"F22DOQ2M3O*+/RJM;;>X[E)S%!RN(DH
MSFO8D`U#U`N'FQAELU\1TQL:1]318QESQ2@>;F*4I9_$]$+Y;:V/=N<O`MJ1
MX/XUJ#9IL@BX][N#T+![JS"TJ,ZMPBA$R2KUAOK^H>=.4H6ET9:V'1+T&UM4
MY[:[M*C.(546U;U[L2CN7F[4,)/A=>ZNL[AYNT&U`=I;H7<@KOYX[/[%LXU%
MQ;/%*"!5QFLI[OS7*!;6).W^A!)AW-HHM(-$5&FY8O=5[#YI^.@WC=:01YN;
M^M!S@?O#&2G.ED_'#+IS<?<VB"@9E-\[#T-4>K0A*F(N>Y;'$76D+YFK(IK$
M7)@7_*'O=8;D6?"F07H4[(H&`;TT-X2&\DHT"0H?EKXYVCS<W+IC?&$!RA;3
M>'7&9PVIM*ALGO%#JJQ'G1EBCS1I<WEZ1P@IZC-/:E(OQ7DGFWJ=\I-#0*D6
M+4H&ZV_/,.1*3S9$A?48TX\CZDA?,E=%-(FY<,?JXQGOV,5??'(3CGFIY?I7
M[N,$3Q:5N@`3;,AT5+?Y<%9L9@_"B*@@&A.51!71A&A*-".:$RV(ED0KHC71
MAFA+M"/:$QTRE.]TZF-H:HKNX^Y-.+6F<WU`Z=0!.PRL83SU#XE&1`71F*@D
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M^YJ[^@M.O`T"RI:!GGN=,K"&\;?ZAD0CHH)H3%025403HBG1C&A.M"!:$JV(
MUD0;HBW1CFA/=,A0;H.Z@N!M4']3RH5?3ZSZ-I:!?L\5%)XLJG,9")GBG#^,
MS6QE&!$51&.BDJ@BFA!-B69$<Z(%T9)H1;0FVA!MB79$>Z)#AG)32)_,%-T[
M_MLZW"T#`:7+`.PPL(;I,M`VC%(#%6PX)BJ)*J()T91H1C0G6A`MB59$:Z(-
MT99H1[0G.F0HE[JNGOCG_U5?9GQ;9W(N""A?!=PK\X$U3%>!MF%T`5#!AF.B
MDJ@BFA!-B69$<Z(%T9)H1;0FVA!MB79$>Z)#AG(7U,4K[X+7K`)UGJ,'XF&@
M[]\R/-V&*#W7[1G1UWUBC#E@2#0B*HC&1"51130AFA+-B.9$"Z(ET8IH3;0A
MVA+MB/9$APSEIO#%P!=6@;;F9XH]W0:D1[<5&G88Q"AK."0:$15$8Z*2J"*:
M$$V)9D1SH@71DFA%M";:$&V)=D1[HD.&<JDO*_'=LL1G*)_JW3N$08R*4H=<
M<?8?,:H@&A.51!71A&A*-".:$RV(ED0KHC71AFA+M"/:$QTRE$E]YTM\KZS[
M'/-@JG<?87JRJ*ZI/L:TIB`:$15$8Z*2J"*:$$V)9D1SH@71DFA%M";:$&V)
M=D1[HD.&<E/X8F#W5'_7UOQ,L2=#^53O[#"(4=9P2#0B*HC&1"51130AFA+-
MB.9$"Z(ET8IH3;0AVA+MB/9$APSE4OL27_W\OVK#?\?JGZ%\%?`?:8E1T04A
M5[(*,*H@&A.51!71A&A*-".:$RV(ED0KHC71AFA+M"/:$QTRE+O@5/7O%1O^
MN[;TE^[PW&;^R:(Z5X&0*2G[Q&;FDQ%1030F*HDJH@G1E&A&-"=:$"V)5D1K
MH@W1EFA'M"<Z9"@WA:\%OK`*M"4_D^=)?^/[>/[+5P%GAT&,LH9#HA%1030F
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MS8CF1`NB)=&*:$VT(=H2[8CV1(<,95+?_TD5OF,>OZKWW=N[)XOJ6M5C3&L*
MHA%1030F*HDJH@G1E&A&-"=:$"V)5D1KH@W1EFA'M"<Z9"@WQ645OGM6^`QE
MJ[JWPR!&1:E#KOB6?\2H@FA,5!)51!.B*=&,:$ZT(%H2K8C61!NB+=&.:$]T
MR%`N]9]6X;MGA<]0O@JXCWL.8E1T`2M\C"J(QD0E444T(9H2S8CF1`NB)=&*
M:$VT(=H2[8CV1(<,Y2[P%;[N;?Q]6\@SQ9X,Y5+[5WHQRAH.B49$!=&8J"2J
MB"9$4Z(9T9QH0;0D6A&MB39$6Z(=T9[HD*%<:E^W>^4KO?NVH)=NYMT[G">+
MZESP0Z:DF!N;F4]&1`71F*@DJH@F1%.B&=&<:$&T)%H1K8DV1%NB'=&>Z)"A
MW!1U+>W\8WS]1T[<,=Y0ON`[.PQBE.DZ)!H1%41CHI*H(IH038EF1'.B!=&2
M:$6T)MH0;8EV1'NB0X9RJ>NB62KUJU_IW=>9\F*.H7P5\*_T8E1T0<B5G/`9
M51"-B4JBBFA"-"6:$<V)%D1+HA71FFA#M"7:$>V)#AG*72"%X()7%'/OZSPX
M]KE"[9-%=:X"(5.Z"@"-8B:S3D$T)BJ)*J()T91H1C0G6A`MB59$:Z(-T99H
M1[0G.F0H-\5E%;Y[5O@,Y:N`L\,@1IF(0Z(144$T)BJ)*J()T91H1C0G6A`M
MB59$:Z(-T99H1[0G.F0HE_JR"M\]*WR&](PFQ5S_WBY&1:E9X6-4030F*HDJ
MH@G1E&A&-"=:$"V)5D1KH@W1EFA'M"<Z9"B3^N%4A>]5;V^/F?(%WU#N`O_V
M)D:U+B`:$15$8Z*2J"*:$$V)9D1SH@71DFA%M";:$&V)=D1[HD.&<A?XDMZK
MMWT/K/89REQP[5_LQ*CH@I`KV?8QJB`:$Y5$%=&$:$HT(YH3+8B61"NB-=&&
M:$NT(]H3'3*4N^!4M>\5V[Z'MM:73/[7[O7.DT5U;?MB3#1%2!YW@B-&%41C
MHI*H(IH038EF1'.B!=&2:$6T)MH0;8EV1'NB0X9R4UQ6_'M@\<]0MNWS=AC$
MJ"AUR)54^QE5$(V)2J**:$(T)9H1S8D61$NB%=&::$.T)=H1[8D.&<JE]L6_
M[CKO0UOC,\6>#.53O7O/-XA1UG!(-"(JB,9$)5%%-"&:$LV(YD0+HB71BFA-
MM"':$NV(]D2'#.527U;2>V!)SU`NM7][$Z.BU"%7NJH#%6PX)BJ)*J()T91H
M1C0G6A`MB59$:Z(-T99H1[0G.F0HE[HNGJ4EO1>>ZE!K2[YSZ2&@7&K_]B9&
M1:G;AH9&C"J(QD0E444T(9H2S8CF1`NB)=&*:$VT(=H2[8CV1(<,Y5)+H4ND
MKL/=B2V@7&I?J']HHTS7(=&(J"`:$Y5$%=&$:$HT(YH3+8B61"NB-=&&:$NT
M(]H3'3*42WU9->Z!U3A#N=2^&A^CHM0A5SJ!`Q5L."8JB2JB"=&4:$8T)UH0
M+8E61&NB#=&6:$>T)SID*)?ZLFK<`ZMQ`>E;.DS$`=&0:$14$(V)2J**:$(T
M)9H1S8D61$NB%=&::$.T)=H1[8D.&<IT??2EM^Z%^1B>S]8!);*"#$%&(`7(
M&*0$J4`F(%.0&<@<9`&R!%F!K$$V*<EO_:EZ5^_V;?UB]/R_'/W(6I>AY(O,
M(XK5$'RQ\C!$U7\^(!;,K]V[D5&,L@>Y(!H3E405T81H2C0CFA,MB)9$*Z(U
MT28@_=D?778NY.F2U:5"M@4KNZU/CPVJO]\RT<._P`A1+_P]HA!5?X%BF^O1
M;9]',<C&4,3LAL81Q50P4QESQ:C^M:N[5S'*TD]B>D/3B&(N]#B+N6)4_\;5
M>.<QRM(O8GI#RXAB+O2XBKEB5-]_]_DZ1EGZ34POE)OILE+7(TM=`?53I?LW
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MLO33B#K2SYAK3K2(N2S],J*.]"OF6A-M8BXL29<5[QY9O`LH/2.$H/@&;6CM
M(AH1%41CHI*H(IH038EF1'.B!=&2:$6T)MID*%\RZJ)7^NB]<%P+-;)XXY\>
M&^1V!VXC.+"HSIEQ:%%Q`1P1%41C0YWI2XN*Z2NB"='44&?ZF47%]'.B!='2
M4&?ZE47%]&NB389RJ2\KKCVRN!:0VP:XA7E@#3M7EJ%%=:XLHQ`5M@'7CV]=
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M0.86UCV0A84E`UFVK',@JS:L<R!K"WM.IXT%/*N3L[&ZRR99;^/S3EJ]JSJ/
M]W%@R5FKC<L>56^/H86EIZT33*9$%W)@RQ+/^"[DP"8LZ4)V`YL82_[LGKQU
M3A?R%M+)2&!R39O.["O7M*SC*N0:I)-%P.2*-IT_>_6N]$1G%NC>\3?Q7NHZ
MQT]OTE=O%I<PZ8HXS3Q@TA5,NH))1#")""81P20BF!0#DV)@4@Q,BH%)'C#)
M`R9YP+8GV.X$VY]@AYRY)UZ/WD5RU_%>[H;%0Y]6(X\DMD?2VB-)[9&4]DA"
M>R2=/9+,'DEECR2R1]+8(TGLD13V2`)[)'T]DKP)<FK4Q<_TN.WGWS.W$:&&
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M*@&3(<!DB'.ZD"'05.J#2?V4.?5]H?:5*P<+N+VKAKD#J'^[9V$OSBZA!^U`
MXXD0E1/+EIVP^C?N;;ZL$[)IPQ2S^=V]W!3".F<^N>F<L<E@35CWV.2Y<\8F
M&YXS-MGPG+')F2?&UO-'9)FU'9O-+3+K.0.16<\9B/Q[SD!DZ70@SM*^(.TM
M?>YAE)7JWE5@V6&T91U>TO+8A"4G1<UJ8+)FF\YNL7S8LHXNY$.DD^G`Y+`V
MG74A.[6LHPO9">GD'3`9I4UG7<@H+>OH0D9!.KD"3!9HTZD+9P$]L-E^^*7#
M:!WO3R<-B_LEK5\A+)86)2N89`63K&"2%4P:@DE#,&D()@W!)!B8!`.38&`2
M#$SJ@$D=,*F3LER=GB]ZOJ#.,=ZI$UB^X[AUGZ$:]"RL<YX?MF%Q=S$ZP8H3
M;-RRSB[*-BQV49U@DQ-LVK+.+F9M6.QB?H(M3K!ERSJ[6+5AL8OU";;)F5._
MKB&E9]67U`\UI_@@/O5Z#7-;"__&T,)>VEJ$;/6/N!G@UB*$A9KI[<U;["HL
M4>=-E&/"%>D)B?WYS8<<$\(ZAR43-6'9K@(KMWP5LJ7%;6.=`Y&OSAF(K';.
M0.0^#$3N"ZQS('+?.0-96]BS0LF>[1A.*^`<*STSQ_H-Q7DG\+J6[A>9P%YX
MM]@+82\=G"Q,=:)HK!-&;@;2;UYA]6[P]KOM3Z?&F,@[5$8.B?3C^3`9.81U
M#DM&;H>59/-;4!DYA,5%6!-D8/KQ_$!DY!#6.1`9.82I)A.S^8'(R"$L#D1&
M#DP_8E-_XV3D$-8Y$!DYA#TGE(P<(IX3RAE9_74:^<R=L=YBT,F!I3MCB\LN
MT]\-K;Y-TVQG3*;5%UW(@BWKN.&R(+J0W\!DKC:=;5MEKI9U="%S(9V<!";;
MM.FL"]FF91U=R#9()X^`R15M.NR,>W6A\9+5-Q0FL]4W,!W!6I/W;UT=2GNO
M-LPN5%*#::,%)JG!)#68=`63KF#2%4RZ@DE$,(D()A'!)"*8%`.38F!2#&Q[
M@NU.L/T)=LB9FP3J4F#J@&8UN_@OC_?J+SMIUK/4!FX3]M2&I5,4/H5@N>)<
M*J^$_)')*V#R"IB\`B:O@,DK8/(*F+P")J^`R2M@\@J8O`(FKX#)*V#R"IB\
M`B:O@,DK8/)*RIQ7ZL)AZI67]NI-H5%NMD=>^@>F'\ELX6RBV:(-LZ9R`)@<
M`"8'@,D!8'(`F!P`)@>`R0%@<@"8'``F!X#)`6!R`)@<`"8'@,D!8'(`F!P`
M)@>DS#F@KK.E#JAGBUMMGS_\\]OW+Y_+CY_^?IP_WOSPDC5"P2ZS1F#Y0N(_
M6=?KM6&)-<!D#3!9`TS6`),UP&0-,%D#3-8`DS7`9`TP60-,U@"3-<!D#3!9
M`TS6`),UP&0-,%DC9<X:=?W-6Z.>3"ZV1BCD:0U,9@BW1F@B"6'JH0US09I&
MVJ#$*V#R"IB\`B:O@,DK8/(*F+P")J^`R2M@\@J8O`(FKX#)*V#R"IB\`B:O
M@,DK8/(*F+R2,N>5NAJ8>N6EV:*.]R6_P#19M?KW;^F`-BQQ`)@<`"8'@,D!
M8'(`F!P`)@>`R0%@<@"8'``F!X#)`6!R`)@<`"8'@,D!8'(`F!P`)@>D+'=`
M7:G-'%`O&]</;_NOF#".N9P[C&F^2MSA/FPRZ,6PZ`ZRT8FXX@0;GV#E"5:=
M8),3;'J"S4ZP^0FV.,&6)]CJ!%N?8)L3;'N"[4ZP_0EVR)ES1UV0NV!^Z(<"
M7KJ;,)8[P!5IY8#0-'XCR_`$DP,0)P>`R0%@<@"8'``F!X#)`6!R`)@<`"8'
M@,D!8'(`F!P`)@>`R0%@<@"8'``F!Z3,.:"N9%WB@*;RE1TUZOJH5HWDLZ*2
M&TQR@TEN,,D-)KG!)#>8Y`:3W&"2&TQR@TEN,,D-)KG!)#>8Y`:3W&"2&TQR
M@TEN,,F=,B=W7:*Z1.Y0TLH>^(9%)+4]DM@>26N/)+5'4MHC">V1=/9(,GLD
ME3V2R!Y)8X\DL4=2V",)[)'T]4CR)LBI49>?+E$CE*OBK7_JZ75"_?!=QWE5
M<K0L+LKX-7E)U(3=RBYQ[;YS+W,E6QMF:[=T:WLP)N'`I%S;-NW"?4)-:K9A
MEDYR(IWT!).@;=NT"U?HD,AMF'4AE9%.,K<LIL.]D_1MNAC6OW/['MFA#;->
MY8>V!S%GB+HF=(DAZGB_(VM8;@@PJ=\PJ5__OE__ZLHMV1*^C;#!2WADDO!@
M$KYMF]X?]RDT"=^&61<2'NDD/)B$;]NF7;@RAH1OPZP+"8]T$AY,*J.M)`63
MI&E;)VE=Y$DE;>J^%WZ+1Z\?:D79H]^P7&DP*=VPFVR'=N=>'$CN-LQNE.1&
M.LD-)KG;MJD6[M?0)'<;9EU(;J23W&"2NVV;=N'.H9*[#;,N)#?226XPR8VV
MDAM,<J=MG=QUX2:5^X43=[^.]T]PPZ+4FM%#6"S*2U8P:0@F#<&D(9@T!)-@
M8!(,3(*!23`PJ0,F=<"D#IC4`9,Z8%(G94Z=NE22JO/*AS%47*)"3[WZ@R`2
MLC[4)HNIFU,E9`A+UUPL+]*V";O14M%FZ_$C!19VV_PN<O]:,]&/[_ZE9>7#
MSS\>?]%8\H=4\FQ,Y=\&RQ'MP.RYD2/.&85,TH35Y>G8@W]Q+]^T`[$>Y!OT
M*M^<TZNL=$ZO<A=ZE;O:7I,!^ULBPYTS$'DPA#TO@CS9CN)TC\ZF=3VGRZ9G
M?F"@'^I"F4\#2S\P8'':J$8!_?V0*9NFV0<&R.0X="%[@<E>R"<O@<DX:"OC
M@,DX:"N7@,D2:"M+M*SC%L@22"?]P:1WFTY>S\6]]A6Y%U:(8[Q;(0*+N@YZ
M%I:N$&2C$W'%"38^P<H3K#K!)B?8]`2;G6#S$VQQ@BU/L-4)MC[!-CESZM2E
M$O_H-7]KZ"6=0I$EBO+4NVY8_H')>W?"DG:AJ4S3]?Q96/P4J.1LFFK-JW?Q
M=P_Z/[\`6+/.)4>"MX.PZ5F"!Q9[E."A1\UH<;"<[:UI^L%'8_$7SN0!="$/
MG-.%;!&:QBYDB\`Z;Z6<@E[EE-#KL[=2QFE[3*X]F2B=E^HZC/=2J+V_9*:Z
MJ7_H&Y9_:/'>;>-EIB:L+@)%?9(Q'K<%PS8LK@,R4^BA=S33]97_;E?-%"&Y
MSCO/)Y>7VC$D7@HL\Q*8)@\P31[()^,@3L8!DTO`Y)(V7\=ER"4A+-XCN:1A
M-\_=(YDDM'KN'CF3U-4A;Y*+O^:W=]T4F;*Z;&!N]G'%%QDF-.U\9&28$!;U
MDV$:5N]N6COT[]TI7ZX)375CVK#>H]NIRC7M0!+7H%?-0"=Z/?'1:TL7IP<9
M"5W(2.A"1CJG"WDK-(U=R%MM%\G%^N=/WD*O\M:)7G$[9;"VUZ2'Y'8Z@]7E
MIM1@+TT]37DJ=U)@\4&0;5J6C,)?IVS3A&DK8J+*-F#R2)O.XF0(,"U):"M#
M@&D:05NI#R;UT5;J@TEJM)74+>NX!9(:Z20UF'1MT^D6.!'K`M,E(C8%J5S$
MAL7]B30,8=FF$4R"@4DP,`D&)L'`)!B8!`.38&`2#$R"@4DP,`D&)G7`I`Z8
MU$F94Z>N!Z7JO*ZLH(,5%_V&Y66%>U=8DY`A+)MA3SR,3=A+9860[:8YT3Y>
M/=YQ2@^9]"-.Z;Y#&:(=ESW5,L0Y@Y!'FK"7J@J6+?X!-MD&O<HVY_0J)YW3
MJ\P5LL5>9:ZVUXY;(K^=,Q!9,(0]JX$<V0[B=(?.I'59K,ND9Q855&ZF2P/+
MUH>6G1Z=[4.;,%V+.433#9BFFS:=Q<E=8'(7VLI*8)INT%:^`9-OT%8F`9,C
MT%:.:%G'+9`CD$[R@TGO-AW7A[J^E(K[TB+?U*/R]:%AV6O\:S"MZ&!2#$R*
M@4DQ,"D&)L7`I!B8%`.38F!2#$R*@4DQ,,D#)GG`)`_8]@3;G6#[$^R0,_<L
MU^6E2^2NX_UQLF'9=L`CB>V1M/9(4GLDI3V2T!Y)9X\DLT=2V2.)[)$T]D@2
M>R2%/9+`'DE?CR1O@G(UZA/Y)6H<XYT:@>D1M^EMT(NL8_H86MA+K_%#-H59
M#X4U37H=GV"E,=>%.TE629AU,3&6=#$]P6;&7!?NC#A/PJR+A;&DBV7".N[=
MRL)<KWB-SWNWL:9-K\X0=9GH@L=3Q00\GH$E%R5#-'$)D_H-TQ4\]QH_1M@M
MD_#().'!)'R;/=[&OM\-2O@VS+J0\$@GX<$D?-LV[<)5,25\&V9=2'BDD_!@
M4AEMUR>8)$W;.DGKHDXJZ>NV^'4MQD_$@26J2NDF+F%2NF$OO<:/87:C)#?2
M26XPR7VR"W?:D-QMF'4AN9%.<H-)[K9M*C=>X\<PZT)R(YWD!I/<;1?65G*#
M2>ZTK9.[+K&D<K^PG[H))9FXFC[U`HM(LH:P]+Q--CH1)PW15AJ"24,P"08F
MP<`D&)@$`]/#""9UP*0.F-0!DSI@4B=E3IVZ4)*J\\J',=1;HD(2K6'9>;OW
M@-?X%B8'/7_\U2/;9'OIO&UAS5GO]N;AUCUR4C]DTI'O^0YEB##\N,C+$.<,
M0AX)8>$U]LWMO7LH99ES!B$781!RT3F#D+&:L.Y#O[S6#L2><'FM[;7C#LE^
MYPQ$C@QAS=VX>[SQ?PQ>!FT'<;I#Y]FZ?-3EV3./WRK*<`4)+#U^6YR>HN<-
M(X<V3;/C-YG\ARYD-C"9#?GD+#!9"6WE&S#Y!FUE$C`Y`FWEB)9UW`(Y`NDD
M/YCT;M/)=$[<NA*3BOO2<M%4;K+C]TVHYK3;<RT7(2Q;+L"T7(!),#`)!B;!
MP"08F`0#DV!@$@Q,@H%),#`)!B9UP*0.F-1)F5.GKINDZM3+Q5GO].N]%K9K
M#:LW#_'!\K.#M`M-=6J,8;Y`JN<OA*5OU0)S;]7<44@*AZ;90)+70,<"FT1O
M!V)SI41'KQ*]8:Y7MP^7#\[I5=9`K[(&>I4UVEZ;OSKBKE(^.=6?OX^R3MM?
MQ^V6FS`$N:D=0FS:]XN?#'9J(,GM=IZKBT'><^>]^[]IZDCYY-"P^AS:NJE_
M[\ZI,ET3]M*[?PN+ZX7FD-!4BUK2@]OXR'0A3'-A&W;B5:Z%9?N0T#1:7:8#
MD\/`9*?`8C[9"7&R$Y@<!":[M/F2R_"NDEU"6+Q1LDM@G3=*=@EAS]TH9Y>Z
MN.3M<OFG`.JOE,9\%>I6Z331OW>U&UDG--6/**R_(YJO0E@44=9I6#9SX'V\
MK!.:1@TU.046/Q&DR0E=R"?G="'KH`M9!UW(.NA"UCFG"[D)7<A-;1<=]TYN
M0J]RTSF]RDUIK[EUZB_^SJSSPM[C&.^JC\:BSP>]R#HN:FAAV?O]T#1AA<7I
M.Y)L&1J?8*6QI&UU@DV,)?FF)]C,6))O?H(MC"7YE@GKN`4K"TNZ6)]@&V/_
MG[-S6V[;AJ+HKV3R`R$E\2)-FQG*LBW?;XG>W59).TWKCN-.?[_KB!0%<>_8
M<5X\R=X@<(BS")`01+5-#)(8*T_I]?]2$MN5JKTY(AZ:N/AW3[/DL"N6WD"J
M=FC*D3`YEH2)1L)$(V&BD3#12)AH)$PT$B8:"1.-A(E&=D0C.Z*1G50;9(>Q
M<R\[/[;>$*O,P]&YT_;7&Z:#:9=$MH>^-+%WQ>+)=#>(Z]<&ML7:A]OQM)@.
M[B3(?MM@W%7O:AI.!P#1Q[6]J@&B._39(&"D*]8&4?$%M/V-JQ#S/3$`D<0`
M1-\3`URUQ4C]-^X^M_4\VPUPUX?P3&^!XO=$!9U=L;9G)E4^'6R_`-:NR+?B
M&O`;2VGIZ#+D]SO7'HIN26XWQ,SSK;8;UZ&U*_?"VD-7;&_M0358[*O;0@9X
MH@%>JR7U09EH<"7'`I%H0"3'0HQHC$1R+$3TVO-$2'6D7S3RW5='%PR2RW5F
MDOOZ]P'QP7\W/.U"'M6#JY*$=\72&]O!2B$$](6V*>-.030F'M%(MVBD6S32
M+1KI%HUTBT:Z12/=HI%NT4BW:*1;-*YVT<BM:.16M#NC?3#:1Z.M]K4!*[&$
ME0X$+]UF1/GAO6*GI4./8`(!?;&$`-$@0#0($`T"1(,`T2!`-`@0#0)$@P#1
M($`T"!`-`D2#`-$@0#0($`T"1(,`T2!`-`A(M0$!I.U5!$3Y(0&=QH)(?V\P
MJN6+"$5?+"%`-`@0#0)$@P#1($`T"!`-`D2#`-$@0#0($`T"1(,`T2!`-`@0
M#0)$@P#1($`T"!`-`E)M0$"L8Z5C0'LS\`/S1;<@QO"58#!86&"^Z(K!9%],
MYXN^4,**:+`B&JR(!BNBP8IHL"(:K(@&*Z+!BFBP(AJLB`8KHL&*:+`B&JR(
M!BNBP8IHL"(:K*3:@)58Q$I9>6F^:!>]]A]+.PTB^_R/Z@$FS!=]L80`T2!`
M-`@0#0)$@P#1($`T"!`-`D2#`-$@0#0($`T"1(,`T2!`-`@0#0)$@P#1($`T
M"$BU`0&Q\/0:`KJ%JKU'A$Z#LX2`P3,-!/3%$@)$@P#1($`T"!`-`D2#`-$@
M0#0($`T"1(,`T2!`-`@0#0)$@P#1($`T"!`-`D2#`-$@(-7V"2B'ZXL_.E]L
M*N*#MX2"X4ZR>=X5BO>9]JS(;+$KM"-%M<.DLFVY(Z,=&VUIM!.CG1KMS&CG
M1KLPVJ71KHQV;;0;H]T:[<YH'XSVT6BK?6U`2JR@I6/%#Y/2+<7MW5F,!E,&
MK/0K=L^QTA?:,K!(#MQJL"+E8$4T6!$-5D2#%=%@1318$0U61(,5T6!%-%@1
M#59$@Q718$4T6!$-5D2#%=%@)=4&K,0"5LK*"W<69;O@M7=GL=7V[BR*`28'
M^:[8-ML0T%67?NM$-0B0<A`@&@2(!@&B08!H$"`:!(@&`:)!@&@0(!H$B`8!
MHD&`:!`@&@2(!@&B04"J#0B():W7$-`M@:5W%F6G[=U9%')GL2N6$-`?NM48
M`T2#`-$@0#0($`T"1(,`T2!`-`@0#0)$@P#1($`T"!`-`D2#`-$@0#0($`T"
M1(.`5!L0$`M?*0$Q7\3',*]]DWG9K:#MH=%I^V@,]E4R./3%MA@P.(@&&J*!
MAFB@(1IHB`8:HH&&:*`A&FB(!AJB@89HH"$::(@&&J*!AFB@(1IHB`8:HH%&
MJK5HO/OZ^WK]M+A_NG__TU_KQ\_K@_67+U_?_/KP[]^P,>)5YXG^YG']Z>>W
M#0^P,_YLMA#TQ[1>K#[,N+O=?*M&O3J\.CZ05F\:GJ^SS/"XW]3C&J8\8N'$
MU)N'QW&;G1/27CD*;[,U0KUQ>)L/6-2;A.?;&T6=?&3H8AG'N?.--?7HRDGT
MYV9JE/;PZ!??7E&$M_FL68\KP_-UYE%G.[,/CFORO"`6?@U!X^27":(]GA2L
M%^WQ`QO6"R9LG315Q[G[OL;C.-=GQ!*\\!YVU]XH>.$37NL%$[R?6;VF'L6I
MVZ[&6M4VL36LU#;\FEZN?6WT8VV[L:87:]N)-7U8V[34]%)M.ZFFCVK?15F@
MFKDS:BJN[MIUT!QG5=D8*F*H;`P5,50VAIHLU39)-3FR$315-FLJV]LXJ\K6
M5E%;Y<^'3JA<'\PKLFK;:2JNU<IF"&=5V7Q7Y+NR^:[(MZVM*<>SIK3'X*S\
MX%02@1^:2B*PM35E23LV/SBKTIYI"0>EY:"$@])R4,*!;:>)V<0/_#&7^*FD
MH!T_D12T8VMKF$4:/^#'_&*GEWG,('X"B?G#UM84S$A^0,-9<;NE0\^\H#:V
M&#B';-O:FI@U_``?<X:?,F+&\!-&0;9];6.BYCU<)K8Q?<VW=(TSH4?9.ZM.
M,V&\9[N:.G.<%9LXG4,[;,@S3D$[OK;-'&>OQLTL9J^LG#[XQA0&B78"FX^(
MC9</FMC&Q-9N41M,LO-(@CFBX5)DT[.I*JY$I\=X['1ZTG8DL=I0<T+E)Z1-
MRSG)YU=DG1,SB$4V!]EVS]W@Q%ERSF='L?%+ZV/Y.)^Q#NP\EH+S&6NZSF-9
M-Y^Q/NN\ABO11TB`)H8YI^3*-XS%+F%S3M1.1EQ_#CVVE6;$RC<9]/S9$#RF
M;_@2GGILVQW3-]9CO^V8OK$>&V7'T9ZKD_;*:,]Q%5]<B?:<1WMEM.<\VBNC
M/>>Q!SB;L>G748:7A^=R@C<*S_498601B_.()9OQQWGL#,YF;`5V'N>>S?CC
MO&5X[(UVYX"7A^?.`6\4GJN3;LZBKYU'7V<S_C@OWB5%_GA)DN,%;_.")_5X
MN4-!G]GC>%E#0?ZL-X]8^.-CP0,HY[&#/9NQ9=WU&5X>GNLSO%%XKDZPS8)=
MY_$JV`GGP!O#]=SCM=X<Q[L[U8M7=--GUHO7;=-GUHM79T=[KDYR%'':28`7
M=D3>K4>.@FOKD:,80ZS'&WDG7"O\WH&>'UX1GN,%KPS/]1FG/8ES=Q[G/N$:
MLQZO[IUPC5F/OIYPC5F/MQ1/N%;L.>`5X;ESP"O#<W&2UDGDUGGD=L(U9KV#
M/)N2O\S-F<?AG7KO++Q+[UV%=^N]><3"'Q<G[$ZXQJS'FZ(G7"NVS_"*\%R?
MX97AN?:X3"9QK3CO8,K4,77.,<ZI=<YP+JUSA7-KG46>!4.9XQDOSBMSY[4,
M[\1[Y^%=>.\Z/-IS=2[&X]DA+X+4*VN)<V*=10QA=I1:QH1@G<4TG]U,[8@X
MI;:I&_.6."?6.<>YL,XUSHUU;EE:N;4K)'<X=];Y@//1.JM8J+'.`<ME1W:U
M[!CGU#IG.)?6N<*YM<X=SLHZY\1V8=>0SEE"NK`K2.<C;E7L^5Q2VZ5UKG"N
MK'.-<V,CN":"&QO!-1'<V-J.J>W8.DN<$]O.DG9.;#M+VCFQM9U2VZEUSG#.
MK#/'F5OG`.?`.@N<0QOU@J@/;=0+HCZTM1U1VU'KO.L?3+Z^_^F?^\_KB_O'
MSW_\_?7-E_4GEKVSS8_%/+8_^=O^Y^GA'S9EOGWSR\,3/P>\^>?OZ_O?UH]1
MFKT3GQX>GK;_88AX]]_#XY^;I?7W_P,``/__`P!02P,$%``&``@````A`$C:
M!E,U!0``MA,``!D```!X;"]W;W)K<VAE971S+W-H965T,3@N>&ULK%C;;N,V
M$'TOT'\0]+[6U3?!]B*.K!M:H"BV[;,BT[80230D)<[^?8<B*8FD8WL7^Q+&
MQS.'G#,S),W5UX^RT-Y1W>2X6NO6Q-0U5&5XGU?'M?[/M^#+0M>:-JWV:8$K
MM-:_HT;_NOG]M]4%UZ_-":%6`X:J6>NGMCU[AM%D)U2FS02?407?''!=IBU\
MK(]&<ZY1NN^<RL*P37-FE&E>Z93!JQ_AP(=#GB$?9V\EJEI*4J,B;6']S2D_
M-YRMS!ZA*]/Z]>W\)</E&2A>\B)OOW>DNE9F7GRL<)V^%!#WA^6F&>?N/BCT
M99[5N,&'=@)T!EVH&O/26!K`M%GM<XB`R*[5Z+#6GRPOL6S=V*PZ@?[-T:49
M_:\U)WP)ZWS_1UXA4!OR1#+P@O$K,8WW!`)G0_$.N@S\56M[=$C?BO9O?(E0
M?CRUD.XI1$0"\_;??=1DH"C03.PI8<IP`0N`OUJ9D](`1=*/;KSD^_:TUIW9
M9#HW'0O,M1?4M$%.*'4M>VM:7/Y'C2Q&14EL1@(C)[$G<\M<.G,@N>'H,$<8
MF:,]L5QS1N:^X>8R-QB9&_QWPQ[8NB!A9/;68^N;,4<8^_4MIE-WMK@3V)PY
MPLAG=!Z)#-JR6RF,S,]Y2,@E\X.1S_>0DA84',T_J3R:6WMR*T2#%E!7CW[:
MIIM5C2\:-#F42'-.R99A>8265R+-2U^;GY4FU"1A>2(T:QUT@ZIKH)_>-XZ[
M6!GOT`,9L]FJ-I9H\<PM2,$36E\&=C(0R$`H`Y$,Q#*0C``#9.FU@<;X%=H0
M&J(-CVK+@4$L6Q*"6W`77P9V,A#(0"@#D0S$,I",`$$(:/1?(02A@3J#KA]5
MR5(,?<N,H.E[H[EH\MR;]/(HR$Y!`@4)%212D%A!DC$BJ`1Q"2I=W\QYQQ#K
M3@P>Q)8A0A--32GVWHB[^0JR4Y!`04(%B10D5I!DC`BQ0[I^('9B+<9.D:G;
M-\FS@O@*LE.00$%"!8D4)%:09(P(@<*9\@.!$FLQ4(J,XI0!7P9V,A#(0"@#
MD0S$,I",`"$^J#XA/GH>3,C!V9[R['6+Z;WB2G$[L._3TX"0B&$S9#GDMT>&
M/K?FTF;@4R,7AGXSL$WIU-CU1KPE@IZ;(Z&"1+W7F%K:A^/>B!,E8R)!.'(U
M'Q^D5P2"^Q%7B%B+"E'$A2-X"'4QD[J?&MFP3_=&JFC,"/:IP6@I[2,[-IW5
MG=66-;-=<:J`L9"\\R-=F2KLU\/UB1Z9/+XW>7)G<D%XN#P)PO]4Q1(2,1\4
M<<=2VPOY)&)N,'PNDL^,Z.6;7&MV%+$ARM[-7DC7I8"YC1=@+:=BED)F-/15
MI,P67YU-ZK3DSFR"XN2>*$A^N]8[<U%<#CG#?C!`@RA*P?G,RNE^7G6;S4Z%
M@H&+UV6H0I'J&*M0(CB*,I![X[CE?ZKR+'K[A%L17^N60>Y8'6IUI_.9HWV[
M]3D]ZWUS,9<VAX#SW&Y^;M7]3NYR$7'HY@)B:0&6,Y7*.N$\GRU`S`.YMM[*
MPS=\AO*[^Q.&T$AERJ!Q(GKH9IE2*V?6)W4'SPF$?@0%#+(&^E"%(M4Q5B'R
M6M&MON.B\M#7!_IKKT3U$3VCHFBT#+^1EX4E[/P]2E\]_+D'ARF4H81'<P].
M0A6'5Y*G+OF2_9:\GERQW]H>_,2XPN-X3[!^]8NMX\%U^PKN>G`5O8)//;BY
M`6[T*X)7DW-Z1'^F]3&O&JU`!XC=[.XS-7UWH1]:5B,ON(7WDJY<3O`^AF"[
M-B=0A@>,6_Z!3-"_N&W^!P``__\#`%!+`P04``8`"````"$`[B\_63(!``!`
M`@``$0`(`61O8U!R;W!S+V-O<F4N>&UL(*($`2B@``$`````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````G)%=3\,@%(;O3?P/#?<MI8T?(2U+U.S*)2;.
M:+Q#.%N)A1)`V_U[6=?5&;WRDKPO#\\Y5(M!M\DG.*\Z4R.2Y2@!(SJIS+9&
M3^ME>HT2'[B1O.T,U&@''BW8^5DE+!6=@P?767!!@4\BR7@J;(V:$"S%V(L&
M-/=9;)@8;CJG>8A'M\66BW>^!5SD^276$+CD@>,],+4S$4U(*6:D_7#M")`"
M0PL:3/"89`1_=P,X[?^\,"8G3:W"SL:9)MU3MA2'<&X/7LW%ON^SOAPUHC_!
M+ZO[QW'45)G]K@0@MM]/RWU8Q55N%,B;'1O>7)MXWU3X=U9),=I1X8`'D$E\
MCQ[LCLES>7NW7B)6Y*1,"4GSJW5!:%'2"_):X6-KNL]FH)X$_DT\`MCH_?//
MV1<```#__P,`4$L#!!0`!@`(````(0`)5P'7,P,``,<)```0``@!9&]C4')O
M<',O87!P+GAM;""B!`$HH``!````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````)Q6P4[C,!"]K[3_4.4.*10M*Y0&E;8()-BMM@6.ENM,&PO'#K83M7S]
MCFO:IF`BP2F./6_\/)YYX^1R58A.#=IP)?O1R7$WZH!D*N-RV8\>9M='OZ..
ML51F5"@)_6@-)KI,?_Y()EJ5H"T'TT$7TO2CW-KR(HX-RZ&@YAB7):XLE"ZH
MQ5^]C-5BP1F,%*L*D#8^[79_Q;"R(#/(CLJ=P\A[O*CM=YUFBCE^YG&V+I%P
MF@S*4G!&+9XRO>=,*Z,6MC->,1!)W%Q,D-T46*6Y7:?=)&[^)E-&!0S1<;J@
MPD`2[R>2&Z`N:!/*M4F3VE[4P*S2'<-?,6RG46=.#3@Z_:BFFE-ID98S\S^;
ML2B-U>F3TL\F![`FB='`3VZ&3=OFF)^EO?.-!8X.+9T'SP07#CG.N!5@_BXF
M5-L`Y=YYD_.&A6?L"6UOD6!ND+&T&"]R*_UM<]5DOCO#4.%%2P,9P9%1@F?4
MXL\5%50RC.;.T,7%[](..?D*9FIQM^)+V[Q!OK/-:9#:'VHK#40MR%5EN`1C
M-N&[HH8;$@[:E"\EQ[+!A"$#QE2%H99+,L'P,1X^S:W$@EWRN0`R,`9LD,JM
MK+$&E5X'5Y^HUKBCI_?V0T:@>8TU5`<A(YB'=QJJHN#65;QWAW?JCH`R@^(1
M=#5^J3"=@DO3:F[@I4)G9.P.$';0'K3P?;9CPO?Y/M)D1C'J84Z[@+<9M<<]
M3+P]J<*8]L/V/@E]4:!8O8+!1,0L<!6/F6QS("BV00C.9Q6SY!_@756`7Z8P
MG5^QZE$V@I`A+;FE8FM#QBOL(TXS1F`I#T(V2>YSZX[3.1>.V3U0@[66D2!D
MF&.%`.&27*-@DT<JD!T>YII+U*(@Y,-=#[*,NX9"!0I?$#+$*EJ[:MWY;SH)
M0O99LCDO=J>=%NY5<6]TP.%-?(.0]L0*9_<.8Q695)KEV,%0NHM"23+-@]LX
M$2`A4@@9A=6J51["M^?UX;-]@L0^Z,8!N@DYZ)CO>N0=E\_FH9RI$?:2[2/@
M<#*9YA33#MOC=GT_D=Q@_]?".?$)F&UM/BZX)\NC?Y>E)V?'W5X77R.-N21V
M+QS_`DO_`P``__\#`%!+`0(M`!0`!@`(````(0"I^C`/Y@$``,P7```3````
M``````````````````!;0V]N=&5N=%]4>7!E<UTN>&UL4$L!`BT`%``&``@`
M```A`+55,"/U````3`(```L`````````````````'P0``%]R96QS+RYR96QS
M4$L!`BT`%``&``@````A`/"@[F3T`0``R18``!H`````````````````10<`
M`'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!`BT`%``&``@````A`.@L
M)__.`P``P@L```\`````````````````>0H``'AL+W=O<FMB;V]K+GAM;%!+
M`0(M`!0`!@`(````(0#"IR0*1@4``!<4```8`````````````````'0.``!X
M;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"+0`4``8`"````"$`.['LA/P'
M``#$,0``&0````````````````#P$P``>&PO=V]R:W-H965T<R]S:&5E=#,R
M+GAM;%!+`0(M`!0`!@`(````(0#PAKG36P(``#X%```9````````````````
M`",<``!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L!`BT`%``&``@````A
M`$J6E4KZ`@``+P@``!D`````````````````M1X``'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"+0`4``8`"````"$`1+[V([,"```*!P``&0``````
M``````````#F(0``>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+`0(M`!0`
M!@`(````(0##1NC?9`(``&,%```9`````````````````-`D``!X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L!`BT`%``&``@````A`$V^A?MO!@``:B$`
M`!D`````````````````:R<``'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"+0`4``8`"````"$`J4QI'&P$``!V%```&0`````````````````1+@``
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+`0(M`!0`!@`(````(0#7XBW5
MDP(``-\&```9`````````````````+0R``!X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L!`BT`%``&``@````A`(AL#:F=`P``S0X``!D`````````````
M````?C4``'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"+0`4``8`"```
M`"$`RUBOJF\0``"XE0``&0````````````````!2.0``>&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+`0(M`!0`!@`(````(0`_C"$OV@8``)8J```9````
M`````````````/A)``!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L!`BT`
M%``&``@````A`+K])A-K!@``SAL``!@`````````````````"5$``'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+`0(M`!0`!@`(````(0#.HPNF?`(``#X&
M```8`````````````````*I7``!X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"+0`4``8`"````"$`QU+MG$=O``!1:`$`%`````````````````!<6@``
M>&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"+0`4``8`"````"$`)*2T/1$,``#K
M:P``#0````````````````#5R0``>&PO<W1Y;&5S+GAM;%!+`0(M`!0`!@`(
M````(0#[8J5ME`8``*<;```3`````````````````!'6``!X;"]T:&5M92]T
M:&5M93$N>&UL4$L!`BT`%``&``@````A`+'U%*]F`@``#P8``!D`````````
M````````UMP``'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"+0`4``8`
M"````"$``=3A=[T(``!Z.```&0````````````````!SWP``>&PO=V]R:W-H
M965T<R]S:&5E=#,V+GAM;%!+`0(M`!0`!@`(````(0"2AKFB$00``#`/```8
M`````````````````&?H``!X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"
M+0`4``8`"````"$`.M*7#HP"``#3!@``&0````````````````"N[```>&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+`0(M`!0`!@`(````(0!4H&8_9@D`
M`#4[```9`````````````````''O``!X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L!`BT`%``&``@````A`'.45+X&"@``%S$``!D`````````````````
M#OD``'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"+0`4``8`"````"$`
MF#[SJQH&``"+&```&0````````````````!+`P$`>&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+`0(M`!0`!@`(````(0!]WY$6704``'`4```8````````
M`````````)P)`0!X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"+0`4``8`
M"````"$`Y&^^:Q8T``"70`$`&``````````````````O#P$`>&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L!`BT`%``&``@````A`%=9Y-_D`P``P@T``!@`
M````````````````>T,!`'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+`0(M
M`!0`!@`(````(0"N%#RE0@<``$XA```8`````````````````)5'`0!X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"+0`4``8`"````"$`"5YI5RT(``!$
M*0``&``````````````````-3P$`>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L!`BT`%``&``@````A`))1(QN[`P``E0\``!D`````````````````<%<!
M`'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"+0`4``8`"````"$`J%*7
MI0($``"2#@``&0````````````````!B6P$`>&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+`0(M`!0`!@`(````(0#$N$/V8P,``!X+```9````````````
M`````)M?`0!X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!`BT`%``&``@`
M```A`%@1$E$L`P``I@D``!D`````````````````-6,!`'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"+0`4``8`"````"$`<JB;%>L'``#/(@``&0``
M``````````````"89@$`>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+`0(M
M`!0`!@`(````(0"+!R)B^`,``*@-```9`````````````````+IN`0!X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L!`BT`%``&``@````A`+Y(8/[1!0``
MW18``!D`````````````````Z7(!`'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"+0`4``8`"````"$``)G,IKPC``!8SP``&0````````````````#Q
M>`$`>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+`0(M`!0`!@`(````(0`*
MZM/?M@,``'$,```9`````````````````.2<`0!X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L!`BT`%``&``@````A`)E"(/BQ.0``)V(!`!D`````````
M````````T:`!`'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"+0`4``8`
M"````"$`2-H&4S4%``"V$P``&0````````````````"YV@$`>&PO=V]R:W-H
M965T<R]S:&5E=#$X+GAM;%!+`0(M`!0`!@`(````(0#N+S]9,@$``$`"```1
M`````````````````"7@`0!D;V-0<F]P<R]C;W)E+GAM;%!+`0(M`!0`!@`(
M````(0`)5P'7,P,``,<)```0`````````````````([B`0!D;V-0<F]P<R]A
<<'`N>&UL4$L%!@`````N`"X`=`P``/?F`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EMFAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
        <td class="nump">$ 8,403<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 16,245<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
        <td class="nump">3,682<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,813<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">16,821<span></span></td>
        <td class="nump">20,913<span></span></td>
        <td class="nump">56,148<span></span></td>
        <td class="nump">39,735<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
        <td class="nump">28,274<span></span></td>
        <td class="nump">13,397<span></span></td>
        <td class="nump">101,502<span></span></td>
        <td class="nump">41,059<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">48,777<span></span></td>
        <td class="nump">34,310<span></span></td>
        <td class="nump">165,463<span></span></td>
        <td class="nump">80,794<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
        <td class="num">(40,374)<span></span></td>
        <td class="num">(34,310)<span></span></td>
        <td class="num">(149,218)<span></span></td>
        <td class="num">(80,794)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">(Loss) gain on change in fair value of derivative liabilities</a></td>
        <td class="num">(1,402)<span></span></td>
        <td class="nump">16,454<span></span></td>
        <td class="nump">21,059<span></span></td>
        <td class="num">(68,686)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
        <td class="num">(8,441)<span></span></td>
        <td class="num">(4,570)<span></span></td>
        <td class="num">(26,646)<span></span></td>
        <td class="num">(12,838)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
        <td class="num">(302)<span></span></td>
        <td class="num">(427)<span></span></td>
        <td class="num">(838)<span></span></td>
        <td class="num">(411)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss from operations before income taxes</a></td>
        <td class="num">(50,519)<span></span></td>
        <td class="num">(22,853)<span></span></td>
        <td class="num">(155,643)<span></span></td>
        <td class="num">(162,729)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from (provision for) income taxes</a></td>
        <td class="nump">1,635<span></span></td>
        <td class="num">(3,573)<span></span></td>
        <td class="nump">4,827<span></span></td>
        <td class="num">(5,888)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (48,884)<span></span></td>
        <td class="num">$ (26,426)<span></span></td>
        <td class="num">$ (150,816)<span></span></td>
        <td class="num">$ (168,617)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
        <td class="num">$ (0.29)<span></span></td>
        <td class="num">$ (0.18)<span></span></td>
        <td class="num">$ (0.96)<span></span></td>
        <td class="num">$ (1.19)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract', window );"><strong>Weighted average shares:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_WeightedAverageNumberBasicDilutedSharesOutstanding', window );">Basic and diluted</a></td>
        <td class="nump">170,187<span></span></td>
        <td class="nump">149,200<span></span></td>
        <td class="nump">157,105<span></span></td>
        <td class="nump">141,947<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_WeightedAverageNumberBasicDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted Average Number Basic Diluted Shares Outstanding</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_WeightedAverageNumberBasicDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to goods produced and sold during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfGoodsSold</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of nonoperating interest income (expense).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestIncomeExpenseNonoperatingNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386349&amp;loc=d3e3636-108311<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingGeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrealizedGainLossOnDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Inventory<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
        <td class="text"><div>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(4)</b></font></td>
 <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Inventory</b></font></td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">After approval of Vascepa
 on July&#xA0;26, 2012 by the FDA, the Company began capitalizing
 its purchases of saleable inventory of Vascepa from suppliers that
 have been qualified by the FDA. Inventories consist of the
 following at September&#xA0;30, 2013 and December&#xA0;31, 2012 (in
 thousands):</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>September&#xA0;30,&#xA0;2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Raw materials</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,993</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,465</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Work in process</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12,166</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,471</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Finished goods</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9,283</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">326</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Finished goods inventory
 held by others</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">641</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,083</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21,262</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Inventory is valued at
 lower of cost or market value. During the three months ended
 September&#xA0;30, 2013, the Company recorded an inventory reserve
 of $1.8 million related to certain inventories that are not
 recoverable in their current form. The materials are currently
 under investigation by the supplier and the Company. The reserve
 was recorded within research and development expense in the
 statement of operations as this supplier has yet to produce
 material qualified for commercial sale.</font></p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EIDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Product Revenue Recognized and Deferred (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_RevenuesLineItems', window );"><strong>Revenues [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenue recognized</a></td>
        <td class="nump">$ 8,403<span></span></td>
        <td class="nump">$ 16,245<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred product revenue</a></td>
        <td class="nump">1,617<span></span></td>
        <td class="nump">1,617<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ProductSales', window );">Product Sales</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 17,862<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ProductSales">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Product Sales</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_ProductSales</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_RevenuesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_RevenuesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Asset (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Carrying Value of Intangible Asset</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The carrying value as of
 September&#xA0;30, 2013 and December&#xA0;31, 2012 is as follows
 (in thousands):</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>September&#xA0;30,&#xA0;2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Technology
 rights</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,624</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,624</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Accumulated
 amortization</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(754</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(269</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,870</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,355</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3VBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Change in Fair Value of Financial Instruments (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="7">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="4">9 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Derivative Instrument</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Derivative Instrument</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Warrant</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Warrant</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Warrants Issued October 2009</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Warrants Issued October 2009</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Warrants Issued October 2009</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Warrants Issued October 2009

</div>
          <div>Derivative Instrument</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Warrants Issued October 2009

</div>
          <div>Derivative Instrument</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Warrants Issued October 2009

</div>
          <div>Warrant</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Warrants Issued October 2009

</div>
          <div>Warrant</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Embedded Derivative Financial Instruments</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Embedded Derivative Financial Instruments</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Embedded Derivative Financial Instruments

</div>
          <div>Derivative Instrument</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Foreign Exchange Contract</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Foreign Exchange Contract

</div>
          <div>Derivative Instrument</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Beginning Balance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 69,431<span></span></td>
        <td class="nump">$ 123,125<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 123,125<span></span></td>
        <td class="nump">$ 39,598<span></span></td>
        <td class="nump">$ 54,854<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 14,577<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 395<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">(Gain) loss on change in fair value of derivative liabilities</a></td>
        <td class="nump">1,402<span></span></td>
        <td class="num">(16,454)<span></span></td>
        <td class="num">(21,059)<span></span></td>
        <td class="nump">68,686<span></span></td>
        <td class="num">(21,059)<span></span></td>
        <td class="nump">68,686<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(14,077)<span></span></td>
        <td class="nump">68,686<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,400)<span></span></td>
        <td class="num">(7,400)<span></span></td>
        <td class="num">(7,377)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">395<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation expense (income) for change in fair value of warrants issued to former employees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,179)<span></span></td>
        <td class="nump">3,037<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,179)<span></span></td>
        <td class="nump">3,037<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DerivativeLiabilitiesTransferredToStockholdersEquity', window );">Transfers to equity</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(103,885)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(103,885)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Ending Balance</a></td>
        <td class="nump">$ 47,193<span></span></td>
        <td class="nump">$ 90,963<span></span></td>
        <td class="nump">$ 47,193<span></span></td>
        <td class="nump">$ 90,963<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 90,963<span></span></td>
        <td class="nump">$ 39,598<span></span></td>
        <td class="nump">$ 54,854<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 7,200<span></span></td>
        <td class="nump">$ 7,200<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 395<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_DerivativeLiabilitiesTransferredToStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative Liabilities Transferred to Stockholders' Equity</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_DerivativeLiabilitiesTransferredToStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20225523&amp;loc=SL20225862-175312<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28370219&amp;loc=SL20226008-175313<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativesFairValueLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrealizedGainLossOnDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EOQAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Assets and Liability Measured at Fair Value on Recurring Basis (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant derivative liability</a></td>
        <td class="nump">$ 47,193,000<span></span></td>
        <td class="nump">$ 69,431,000<span></span></td>
        <td class="nump">$ 90,963,000<span></span></td>
        <td class="nump">$ 123,125,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Long-term debt redemption feature</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Measurements, Recurring</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Asset:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents-money markets</a></td>
        <td class="nump">113,500,000<span></span></td>
        <td class="nump">64,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant derivative liability</a></td>
        <td class="nump">39,600,000<span></span></td>
        <td class="nump">54,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Long-term debt redemption feature</a></td>
        <td class="nump">7,200,000<span></span></td>
        <td class="nump">14,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency contracts</a></td>
        <td class="nump">400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Asset:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents-money markets</a></td>
        <td class="nump">113,500,000<span></span></td>
        <td class="nump">64,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant derivative liability</a></td>
        <td class="nump">39,600,000<span></span></td>
        <td class="nump">54,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Long-term debt redemption feature</a></td>
        <td class="nump">7,200,000<span></span></td>
        <td class="nump">14,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency contracts</a></td>
        <td class="nump">$ 400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20225523&amp;loc=SL20225862-175312<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28370219&amp;loc=SL20226008-175313<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624163-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesFairValueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EOIBM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Debt - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="5"></th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2012

</div>
          <div>Convertible Debt</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Convertible Debt</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Convertible Debt</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Convertible Debt</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Convertible Debt

</div>
          <div>American Depository Shares</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2013

</div>
          <div>3.5% exchangeable senior notes due 2032

</div>
          <div>Finance</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2013

</div>
          <div>3.5% exchangeable senior notes due 2032

</div>
          <div>Finance</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Proceeds

</div>
          <div>Convertible Debt</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Debt Offering

</div>
          <div>Convertible Debt</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Debt Offering

</div>
          <div>Convertible Debt</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>BioPharma Debt</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>BioPharma Debt

</div>
          <div>November 2013 for the fiscal quarter ended September 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>BioPharma Debt

</div>
          <div>November 2013 for the fiscal quarter ended September 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>BioPharma Debt

</div>
          <div>Per quarter in each of the next four quarters</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>BioPharma Debt

</div>
          <div>Per quarter in each of the next four quarters</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>BioPharma Debt

</div>
          <div>Per quarter in each of the next four quarters</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>BioPharma Debt

</div>
          <div>Final payment</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>BioPharma Debt

</div>
          <div>Cash</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>BioPharma Debt

</div>
          <div>Cash</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>BioPharma Debt

</div>
          <div>Non Cash</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>BioPharma Debt

</div>
          <div>Non Cash</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Amount received at the closing of the agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 100,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Maximum repayment of future revenue and receivables</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_FutureMinimumGuaranteePayments', window );">Future minimum repayment under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">800,000<span></span></td>
        <td class="nump">2,500,000<span></span></td>
        <td class="nump">8,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">15,000,000<span></span></td>
        <td class="nump">13,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_AgreementExpirationDate', window );">Agreement expiration date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Dec. 31,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ChangeInControlObligations', window );">Change of control obligation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">140,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of Embedded derivative liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of derivative liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,200,000<span></span></td>
        <td class="nump">7,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOnDerivativeInstrumentsPretax', window );">Gain on change in fair value of derivative liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,400,000<span></span></td>
        <td class="nump">7,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,700,000<span></span></td>
        <td class="nump">9,700,000<span></span></td>
        <td class="nump">600,000<span></span></td>
        <td class="nump">2,200,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible senior notes, principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible senior notes, stated interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtInstrumentMaturityDateYear', window );">Convertible senior notes, due date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2032<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Convertible senior notes, net proceeds</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">144,316,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">144,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Convertible senior notes, exchange rate of ADS per $1,000 principal amount of notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">113.4752<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible senior notes, total ADS into which the debt is exchangeable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,021,280<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1', window );">Convertible senior notes, payment start date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jul. 15,
				 2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Convertible senior notes, maturity date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jan. 15,
				 2032<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ExcessFairValueOverPrincipalValue', window );">Value of shares in excess of principal amount of Notes based on closing price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">42,400,000<span></span></td>
        <td class="nump">42,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_AdditionalPercentageInterestRatePenalty', window );">Additional interest rate on notes per annum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Convertible senior notes, repurchase price at option of the issuer</a></td>
        <td class="nump">100.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds allocated to conversion option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">23,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of the liability component</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">126,200,000<span></span></td>
        <td class="nump">126,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Note, estimated remaining life</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">24 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14.50%<span></span></td>
        <td class="nump">14.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">800,000<span></span></td>
        <td class="nump">800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Debt discount amortization period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">24 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible senior notes, carrying amount net of unamortized discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">145,300,000<span></span></td>
        <td class="nump">145,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Convertible senior notes, interest expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,200,000<span></span></td>
        <td class="nump">15,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest expense, contractual coupon interest accrual</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,300,000<span></span></td>
        <td class="nump">3,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Interest expense, amortization of discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,200,000<span></span></td>
        <td class="nump">9,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">700,000<span></span></td>
        <td class="nump">1,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest on convertible note</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,901,000<span></span></td>
        <td class="nump">10,901,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,520,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,100,000<span></span></td>
        <td class="nump">1,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest payment on notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,250,000<span></span></td>
        <td class="nump">$ 2,713,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2,600,000<span></span></td>
        <td class="nump">$ 2,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_AdditionalPercentageInterestRatePenalty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional Percentage Interest Rate Penalty</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_AdditionalPercentageInterestRatePenalty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_AgreementExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreement Expiration Date</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_AgreementExpirationDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ChangeInControlObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change In Control Obligations</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_ChangeInControlObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_DebtDisclosureLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_DebtDisclosureLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_DebtInstrumentMaturityDateYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt Instrument Maturity Date Year</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_DebtInstrumentMaturityDateYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ExcessFairValueOverPrincipalValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess Fair Value over Principal Value</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_ExcessFairValueOverPrincipalValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_FutureMinimumGuaranteePayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Future Minimum Guarantee Payments</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_FutureMinimumGuaranteePayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentSharesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Conversion Rate<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509012<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleConversionRatio1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date the debt agreement requires the first payment to be made, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 470<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentDateOfFirstRequiredPayment1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13476-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateEffectivePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentMaturityDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 470<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph e<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentRedemptionPricePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentUnamortizedDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28370219&amp;loc=SL20226000-175313<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20225523&amp;loc=SL20225862-175312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624163-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeFairValueOfDerivativeLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624163-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnDerivativeInstrumentsPretax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5618551-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainOnDerivativeInstrumentsPretax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpenseDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpenseDebtExcludingAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherCommitment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromDebtNetOfIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from other financing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3095-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3098-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Inventory - Additional Information (Detail) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserve</a></td>
        <td class="nump">$ 1.8<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of valuation reserve for inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SX 210.12-09)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 09<br><br> -Article 12<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryValuationReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001193125-13-432814-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-13-432814-xbrl.zip
M4$L#!!0````(`&:!9T/C4S;Y+00!`,D("P`1`!P`86UR;BTR,#$S,#DS,"YX
M;6Q55`D``^\!?%+O`7Q2=7@+``$$)0X```0Y`0``W%U;;]M(EGY?8/^#U@^+
M76#+9MVKC$X&O`8!NA.OTSW3NR\&(S$.,;+D(:7$WE^_IXJ2+%&415$D)4^C
MT4E;I%S?J7.M.I=?_O+T,![\2+(\G4[>7>!+YV*03(;343JY?W<QSU&<#]/T
M8I#/XLDH'D\GR;N+YR2_^,O[?_V77_X-H<'M[2"83B;)>)P\#_X<)N,DBV?)
MX./$O#%,X,/A_"&9S/YK\#7.D]%@.AG\Z=W^.B"7>##X/IL]7E]=_?SY\S(9
MW<<9FD[&Z22Y'$X?K@8(+7_'7XOE70\&XI+`$M<^NIW.)Z/K`5_[D9\E\0P>
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MAFH^,<O`F\L8`EO/LN?J=Q8?5JQ^.,\RD-Y=[RT^-2^2S1>3I^'WZI?,)Q6_
M*9W\2/)9]2O%9Q4O3>8/U6PXFF579D>NX(DD2X>K%T#^]K\SG:#2>_-9MI/?
M]15\>@&2.AA861U?YY:C;Y-O`RLXU^9;WUWDZ</CV+"W_5F<#;/I.*DGHO:-
M[UGR[=V%85JTY,S+IWS40(+K*X>K`M9"Y*Z#Y.O,*.+,:N"/DUF2P<;<@EK\
M,H/_C&Z2;`@?Q/?)8#B%3Y]FMV;-R71\=Q,RH:E""&&*'?3?(/S.W9??@SOG
MSG`/`,+P5XD9E>H)_B",7`SFD[3XAL=Y!JL9)</T(1Z#`-*+03IZ=Y&.[@C7
M4F-\YROL<A$1Y+N^0"RB#"G.7<1<*K@7!-*)W#OL..0.7[QW+AW*?[DZ'-9K
MY(CB8>(^&%%J&?Q"G=[]\258IP'B1Q#!N7B/N5/\LXL0+X`*V*!%K\/)+)T]
M@]5ZF$Z^S*;#OW_Y'@.Q/L]GUJ"#D3\0/,78*<!CK,63(@YUUL'G]OO7<7_\
M%&T!E\R7A"B*N"L#Q!Q*D9(A0VXHPBCP74(COP!N08N+]TPHSL0O5_5`]4D`
M>)9V0P"R(H""[9<$:R"!/(P&2U;Y//N>9.YPF,V3T:]I_#4=I[,TR3]-)X55
M.%P()!&&#)0[G#])YG`J&PF!ZWD,.RY%OHX<Q##UD<>UAXC+@"+<#73(#2^P
M.P)4P*(D`WN!;=*A(-/'/(?';\!B)*`L[,\.90-'8O(*&ZSAOWM,LKMMMB!;
ME,"!P%&H'.1RS1!CKD2NIAQAWQ.!"&0@:&28`AN=R"_%&A5VPBK0&RMT_?G1
M>,7YARP&H*-@#K[3/3R63D<M8Z\G`O71THOWE'!NMWT/DLW-]L=QGG_^]K<X
M,T]^SJS'_FG^\#7)/G_[D@"#6%[Q8W#Q1][SXKE\\6!^&%D<#8K!BH2CN`"R
M@,)F!9$D!BLAI";&9D@IGZ0"+:+NS`\%-<(CE7J5@'A;@R@<.,H/$'<$V`XW
MI,CSB!$;S^.>(R(5\3MJ#2@U%G3-?AY)EAHT#I_`!*=Y8EEQ]>'I"5N62KN<
MUX7R`#HST$^7W-E#Z#VT61/8RM=_3[*'ONG7G"2@LF_X_RS$=B>><Y3:7N64
M&6+)?U(Q/:5@6L*J-R:7+4NBI8%H((B;X84_A;`^FZ5?QTGQ5W,D9XF%F^+>
MK8&.]*1JT:6(+FUXJ7<&5:^@WL<1A3?6G#9"DB?I:*[83MILTZ+"P9:1DBK4
M(0I4&(*#[7D(/N"($4I@"0%SF3*_FAJW4B_<ZWVP.@;?3/M6@:_#"<)R`@<W
MDY.#\*_<;Q.!?9^.1\`?X3_F$)D='$YIZD"4OS^`VCY*84[`F(\EBDCD(<:9
MAUP1:@2!.?,$?#67V)AC<6<VEX`FH&HCA-I>?5D/9.F/>);^2-8"K!X!4D*U
M]@&1'U(-;!L&2(4!0=RG/`26\10)#4!VQPT#:T%+IR05RR]9QSC_[DY&Y@]#
M@!_Q&$0_=V<^[/PS!!=_C<?SP\_(FB/VL-0>CP*$/>XC"/I=I)6"OP61SR*J
M?`U*P7I8%+:38`Z"LH&Y%J!N>!C,F1;<>3)63=8Y%VO.T:`8%QR-X(L/XNG6
MT8*F<KI%2XV>LF@%A.#J0+Q''GMMP:7P[\$Q?UVHYLD"*F9:$\P(*9]U[#SI
M:G]G2U#;WUEL3_DL7,((8R?F9$Y4MY:(WZFEW$HJ'2E.98[`M^""DE?CD9:,
M$VYNG,J'O$U\J^(":L,<U1/9*(JDQ[&'`JHQ8DJ&R"4T0&$@/$HB%6!7W!DR
MV"-J(1C\JC4[5+WVOF/3"O0-(LX@""4F"AQI*ES$M$O-=0U'7$`<HQ0GH7#N
M[.$LOF2LC7!S0^79)UO'72><8I%/S9$LXIH!CPM&D78];>XUA<9<8P'.I;VI
M$Y>TK*GMLC?A_)XE<3[/GM?XXLRXV7A5CB/U"Y:*->\4TYLX^YP5=Y'6T6I\
MQ[!K\SYX-SLVKS%HJZ*HC88WCDKVHZHAS$=<MS7<Z)JRZH!.5E@H(O:(ZTYW
MH\VKQ8Z9FA8JFE%-V2LJ>B?4Y4W[3?P<F_.01A>'KVJD/;:V)E`L`:BC';QA
M::M7OXG0\+7-'7/'X^E/D]Z40Q2UR/#*O7AL4]KZ`RQ]'>)(!,B)P@@<*H^#
MXG4TPJ&6*@I]SK4H'"IF%);<C`EJH=GFYG3V8(-%"!\!*'!!,AD>[F'M@?V4
MI]>3=/SN8I;-DZ8;351%RLO2GXKB-+-ZZO.W;2?K4!^Y_B969'E0"?^0"&&7
M$,0<UT=*8XT4^(D!(U[`?;&X+KEX+TGI?KLNH$TRK#F39RNF!)0OQ43K#;S;
M*R^Y0LDDG6:_3B?WYL#ZTW36-F>V`LVH6L8I+D4VVVLO;=OB(W,&W3@UHP]\
MH&Z4I+BT=96KWT2XG:D!>L;F<#0/YOHP*=K$YIQM'IS6`K.%WV1HY6=O0\TQ
M$Z&TC+=B\16)1FUD&/7!Q@!2X4TW8??Z6SYVZ0$?51?O$99"'W96Z(Y&J7$;
MXO%-G(X^3OSX,9W%XS5'\0RA@D:25'.R>7BV'TK[9TO'H&61I[3'-8JX`E\A
M4!II2@1B,E">2R4+!5]==3")]<&G2;?)+$XGR2B,LPGX=CG(]/QA/C9179!\
M2X?I&<HI!8<>?";%^*;!V8^EO+O?$A!E<(%_))/Y&2M?D[$@2C<:U8O?Z?:=
M'RHBC;^'.:.['+Y-,%$*2P%&_I&`X$)`>F\NX=T\3V;K&^T^3+-9^G]%Q4^/
MD9G'&`LQ0P00@:!R'WE8^DA[-'!%Y!,<1<59H.2;*NEP6#L/')I<2_8AKB9;
MG8'_RS?O)$L+W\FZX$2]">L*/B&!%3"QBY\K@93/5$":9]/L>16L+^/S'B-4
M`:K5E5@@HKT(`5^'2`F?H<!W`M=78&8<OS@LPZH4GNY>?U7^N>7R<_8(33H0
MIY1ONX3EM9>M:C[+TB$(;A>I!'TPLQ'9TMX>"*HZT+E-A@F\`#KN4S([6XL+
MWB.5!%=&.U4(=@@Q/'!^V,!3)-)1M%IN8<D[P!A#E7]/1A^FTU$.CWW^UKEJ
MJG"(M?`#`LA\(L#.NMQ#FFCPBDGD8=_Q0B\P=I9<O-=D%\3=0*K=P]_CIX6T
MGS''0NBJJ:CT$"O6OV.+;^.?OX&WD:6PF#/?83`^3.L=.[P3QROWCN>JB(VX
MEES_[75OXKK)IH])-GN^&<>3&>AIHZ,?S2'^6>HC<)M$R6=Z#<!^&3UKA\+Z
MPHR6X_374)0,J7W@#)'12O>W6&[WZ95]!*P`D'"E2F',X;[0*R'?64JH*=O!
M189AO<!U2TS77.:SM:#F.()3N<O5?]UR_FV:_?WC!/36,,G/W72:A"2"A:BV
MG;N1U&;B#]DT[Q-WS<,7Q]8+D]K'+Q9&!1^O2+7R,;[,'Q_'18#_6Y(-OYML
MB3SY8P)1OC^=Y.G]Y*%?EM?45X03BC1W)&)<:.1)&2&/,I]$U)&.E*;@Q3*#
M8!57'DU!5AFKLQ5Y!1I=$"Y(A<G:D/>B_`-4?)#F-@I<])0X&E*Y,T9%%3AE
M&FOMHTA%`0BUBV$K*4<1<2,WQ,KQ""FVTK&=,<BR6&5[M6M8PB<CWB\I!#^2
M[,8TSTD?XW&WYG?[N$D%#O6=D")'B,@D1'C(U9PBK$(613H0(F!WU,3DC"S/
M).J!6`,<S6=`ZM]`VA_F#Q_FL:T53V[B9YO<T@SM'8@1D>I)$2*ENI.<@V<'
M_Z=!#S5+#0D"'UP,BKR`4:"$IY!+X3^@X$*AHM!SE%CMM5HGQ>OP2H=3T^=X
M/'M>/96O9_DTZ8#R0@ZE)'V2$'@S4Z2&N4-,.1_&9&]CB`_>31N-(<BBN!%O
M-4?9C_H-4*FE]AFVC8*PETIOA$KK=+F38+&T\R2E%HQUQTLV!PO";_Y66.D@
M(K7$2LM2!O66.0E4-D#NCI-LR35[XYRTDT@M<1*S=5XM<-*QU1$OQ&"*B3YJ
M)98]O<2E7FOXL*M<8K,B_8])7-P-)Z.ENW<<;'-LKE0+[<RTPF'D1QI1US6)
MK@[$'U[@(\J8<CTF`RUQ88K,=8LN[?I>E/U*AJ),:G4:0\27R<#\S-5'(R*U
MI#[X(IK%Y-PMT6M4ZMH2B86F>=.LU+4E$HL(ZWA6:BMOI:\B>KDLHC>G^?T7
MT9?1=EQ$+Y=%]`9M1;9HUT7T6W"[*Z*7RR)Z3"L+<[LNHM\'M?V=+8KH+=SM
MW+/^.;G;(GJY+**W<EN1&KL/<(>5;H8&$F/3N\CAW=:]%?&#VJS*:%#VU@<U
M0`)8'1O6G!KVR%22-T`,11BK%60T)P8SQ,"EE*!SI087JEMJV-,(3=FQU*@L
M,#@V_P)"3P=(8)4FX1W>_QB%`;_@M2++&I4_7=.`JSJ7"0UI8,-O0DS\S;5J
M3H1>FW2N$6GC\+S%-G$>XUBX$:)8^XB%?H"\0!'$I1]I-PH%<9W510S=.D7O
MOE5G"TYG_QT%;0I-N6'W8>T56BS(`LR$,R-BYHJU430I0^K"M_DHE`XS"1?`
M)D`))$+'W&4Z`?9)D4Q-=1EWC=JL:)HEZ?W$7\SI,.7W63R<Y:LB[]75ISD3
M&T_S>=.>(OW1PM2IE2C1!.8FH4*0K-'(5'E5%,=O?WADU7]_Q&(5MJDIUCHI
M>&^0G\R)'Z;ETZS:\$Y(%=-L3'+0N8X$(]4=C4B[-.I,`Z_H`7_H.LW7&M*#
MO3E]W!]E_NFT<W^DZU!7]]8/#ZA%J=9/DG#%=T1>=;OCN3R*/$Q=Q%4`3J$O
M!/(\"<XT#37SE70YUB]S7%KJQ]ZYSUQ-GGH'M?4I8I(RB73VTF3+3=[=ICI\
M>DPS&]T'9AYC*_@;XS.'LLX5YE>8O=9:>W/-)Q<*+27?<8'9ME"00BCVQDGG
M)!1E\K0K%(47(Q132IVI5"P(T!B@N82ZHLZ;$@HSI(+O.)]J6RCL\0&6&],9
MSETJMNC3KE04\8^YS#]/F5C";PS/6(HK+-^63!!,:$^&@KX][VF+/.V*A!U;
M(IF2]%P-Q9(`C0&VX#[MGID:?ON6#$TTTG@:[`O<IM-@:V4.TH5^<"XQJS4-
MM@)9=PUM6\B?%)X?AEPX2"@M@`TX1?#5`?(Q%=PAG@_:M:"":7!;OH.HT]]V
M;9J1(=L;0$J*1IKEHZQ-'*^/^5T$X"<#6Y^Y;3:CV+Z<K,334XYPCWN-7VJ<
M&B8%=V;(>I]'16T'SJVLS5->GA63,D#MR&;WTW5[&U)S*DDU/_2TMA.T8+D;
M)B361&LKCNHE))SXE/4PBFRS/HDHX<)SD.<S#YG$7N3Q0**`,:J`6)IR563N
MD,Z.5E\>L$6_GZ9%<]#C$IB7E!&Z5N9&A5(`71*&3"()7VFF@4=($X:1U&8.
M<N`'2BPR-TP7G+).>!73JQ<:+V_F[HMA:=R2HE=*D+TW%SO1K?G^RQR-TJOP
MOS_C;+2Z^VC#A%239ODK]@Z,KTT8XT0LHH3#T76O49M/6JJK4?'"?M1);^HG
MLZOP%^IF=E44S,-^AYY0"&/)07,RC5SIFCX/+"`!4UQ$=*4?:MYT=M;7VA@(
MW.4H2[P<96D&;B.N2]T<^A@?=@S&6@/#EK="YO>0@SVA+OHM'0.YUCA+6PYJ
MNI]ATZIF<T]/,<YR`;BO2AR\JL1AIZC$*:/MN!('KRIQ3)</IFFILU_7E3A;
M<+NKQ,&K2AR3D`X^+GC!K,=QEON@MK^SBTH<9K.0:*FK:O^<W&TE#EY5XEAK
M)`ZNQ&G1'O4USG)U$=7,.K4RSY)LV:,6AZ618IXE=Z@`)^[0>9;'CS?L&MQ9
MC#?<!MGM>$/2RGC#]L;]=;W)M.!@!H[+Z<;][=[DM@I:[+@_PDF3VY"VAMWM
M0=G"L#M2->SNZ"EO/>R.F?)F=F?3H>]^REL?T(R$468M8.]3WOK`9XIK.>:E
M>2TGFO+6AR;1%^\Y*8^0.M&0MS[PFI9PDO&MJ7;]37GK@XWME+?-[K>]37GK
M`9^=\@9>^XF'O/6!%!22P)J46AF?8LC;,6AK'62O\L(UH_C0$*OU(6]];*X9
M\B:9%*7Y8(<.>>OI7K0^11I.!"XZ$K'R87X[]Z!G;8:+07%,\9T^8\^#XH[!
M7*M7N4UV)V+SX.C$@^+Z$'G;<XOQDNGJ=5!<'S"UX6<(P_DN?JXQ**Z-`6I]
MN)38S.GA>-O;>GV`VA$CM'I`96?RD-)%8Y\CM(YR-^I,B;`%2."$5"/L?X)6
M#YMJ)VA5SUCM?X)6#QL,RI8SP:MWN*\)6GVHV]-.T.H!H=X>6WZB"5I]6!0[
M^H"QO8+:Z@"M/H#12K>@KP%:?3CRQJEU"#LZF:/5`5I];"TI.G#PN@Y]^P.T
M>D!IPC12.AWN?X!6#Y;37'5S)G&UZ3S1`*T>@M(6!FB=.0N;@5"*"\TJ5/#N
M@^^7B\-FB#;G"-7`)[93Z@1VM.L["&N?`#[3L,ZT*_$<Z0>.HD'@K.5I+.90
ME.7T!<=Z.>1WV-/DX\2F!T_'G[^.TWM[NM"007L%JU9CK%>3DG;CZ6I:5"7P
MY;0H23G3S0HH:I%A626I-HA09UQ4WX209NQ$=X18CA?!SME30@NJZO0];4@)
M.RG!7/71<Z>$`EO#=TQ@:8,28E$=@/GY4Z+Q4+E:E)"+&AK"#R5$VU>C?258
M\V6"M8-/D6!=1MMQ@C5?)E@;M!5WIETG6&_![2[!FB\3K!U<F;/9=8+U/JCM
M[VR18&WA;M^>],_)W298\V6"M97;B@OB1@G6QYYX]=BSG-B>Y9AQ63ZL/EG3
M\FTB=-VTG-BFY9PI7CX(/)8(C:$?V_"6*E=**3@*?.4@)K&+%/,X\K'G"I>Z
M6$=NT4P:(H:SK0_OG1ZLNZR(KMH!]TZCU9#O,^Z17$F4%GHDUR(1:95$G>F5
M%KK9UB('>Y-:IC_J=*!S;+RUEKFX:E&UWL'J)IF8\7.-B56O']=V:S*($97B
M#D8AID`6#VL$L62`M"`>H=KE5,OU&?2V<^TAB#HY5#VP0\GV.6/=#B7DD$/5
M;I1$+^UI5FU8Z_F>)]8,??6G^7_V_K2Y;219%(:_=X3_`\+'?<..(&B"!#?W
M=$=0(MFCN6[;QU;/><Z--\(!`D41;1!@8Y&L^?5O9E854`!!BMI)NNXR+4M`
M(2OWK;)X2?I1],'#Y]Z?4"9:M\^]/Z9L//*@$5E;V3$D>9IH[':#1M9WW@5[
M.`23"@'Y">Y\TC<A"H/_:5F=D]/6N->;%-<@W3,8HX(I\Y)I'"WQ%"U>-O8Q
M_@(N%TC++?,25IL/7`'WX(XMV?;IR7@TFDS-81=3$:>MMCF:GG;,[J`S[DY.
MK.[$FHA*,*"[(ODW;Z4F!<-/#H^SV`\OP%;ZD<<351_8%?WI%OQ?VCY>]&0-
M>]\';7CX]BDW:]RSIA-PAD;=H6W:]JAOCD#&3>OTI(?WFH][G6G.`CR+NI:,
MN7%K3\0)&U&Q.U_LCH[VO5B#U.7'%>E&,;L7#U]Q[#W0]N^\-7!_/W5:8Z'4
M-T%9/8*"4QO=E)B`KA6D=O73*,DO1OL4)3Y?*O"7?HA_YBL)UW'W;;?YMJU6
MFV^[U6]C8M+N]?I;_-[U*<SC=F\PZ?1L<SIM]4V[/9J8HW%O8';LZ7#8LJQN
MV[(4OU<]2?X`^]T9@9/O*^:*GQ\:2;M[!KLC"[1FI^HK[[@]CA./^>_.8P>3
M]U^NE[,HN,6N^QUE&-=Z)XQ]VF^W!Z#H1_TQSE7KF(/^Q#9'D]YD.CX=M3O3
MTZ^BO``T'_WQ^<,_WJZ!4T`Y"5.0Z<_LPH?M.6'ZP5G>(C'R@,!:".SH\]D'
MX_3CYT_&I_>G_[\__R\'O0[&8@<C"%T\FC0;.+>H^MP`.H2,TTEWV#,GK<FI
M:0_LH7EB([.<P((3G(DZ$(FK.?`;XX"60*GB>.H'$&P!SUQ$\2T,Q`.B&-3B
M>R>^8,;(=1D`@_QK$%@JGDMP%IL81RZ?Y^LGKA/\+W/B*?SF%D;_81#>P4D@
M>#'X%IC6@3Z_7CT<5^\(*887L&H94@1D'3RN52>A=[O9[0\#9YMCU&QA':L,
M;0FN*C^?,AS'&)R%'OO^?]GS<#3`CO\9#/NV/5"9N`)<`;MHDBLXYJ&Q?AOP
M\2YTTVJ;'8O#O@FX35+(Z?,L<@BZY+]KI5"!:6T\2ZGY4NG+_!0%OOMP'#3J
MV2?C$[MKG@QMK-$-<`MT\:L][HY/.O"W/A?0_Q.DOWC^Y?^Y2'\!6/%?*R-)
MKP/VZTNP1;^??3#//WYZ9UB#U?=?#/&;DX_GYQ__>&>TE-^]GTS/WQGMGU\J
M*\UA-W*QZ<</Y^9T],?9^_]]9YS[2PB6(+8P/D=+)WQI)/Y_&'IW^#*^.9,_
M^/*'#'\H$&@0!AM&R%+\Z]M,/O<V?^-MOLA;!"3_Q^JFO?;JMYH#=[=M*;`[
M^?&&!.PY@!+-#<=8@M5)TBADQHIW[\!_?<]((R-=,&,>Q4L6&Q01BLHYOO;>
M^>Y!9`)KO`<'%:U9S+TR^1Y$-[;AN!"W<$\67XJRV(CY+2KPU+^=Q&4KIP%K
M7"U\=V'X";T)T5\6I/B\>`)^XS+_$CM+ED[\C>'L'<-9K>+HT@D00'P-5IG[
M,3BY?NCY+C^ZZX0>+II/@C>B2]B*#Y^'#8.WBN!F"9MG@1'X<V9$(:SB&.CJ
M()1FX`-29@X@JVF<`V2GT7+EA"0M;I!YN-F%D^(2""T'HOSRDJ4+",JNG(0#
MO(I]U'@.W^G2^2N*,6:%MUTG61CS(+I*$(:8&4RXMHBJ&3,N6"C<!OA?B*2N
M^69PF=K-X"JP_3`"S_P"'%!'$@'?*#XF5@$&0DR)[$MP36^GONNO<-VF\84Q
M`\?3&/W_XRQ7O_S7=]`!]B_*5"3Z6'DN$A`&B9+%F.H&LB`G<2AB=N'$U"D4
MT=\B)7E99B.$H\Q#@O$DVS6WR]E;H6)*TYZVZ\+URQ+X[\]!/YX$MQIV<8.R
M[/8'=L^>C,QANS<R[6F_8XXZUMCLM5O=P:0]&8&V/$!EB2B#M8N[&)(#T91T
MSXE?@(UB"%`@@_A.`!('>BB*4>Q!Z.>.'QN7F+%O&%=^N@"NR%;`HKZH8*%`
M(/>JHP2`?3WZALCN&)ZXFB*AI2]"4E)^2#*:X'PYA(/K:3RS)T0$M$?^%=02
M(>@?@(@YH$-7/`L$P1`J59"3)',7M(G2MD`5YSUN3>.,:P6IWGR>4^1)0!!$
M>!T!75``@P\&LA[1H'_2G@H91D4"9J+8$,>$2T?U85LH0J@MG+S^1P;'A'V[
M?!P+0:@L$(5"%^2((ST6P;XYD#=H@7IA:3\*$REVHE"5PU]0J[/O+A4Y,`\&
MBED.*G-@XP[^!)HX(3:AK%EA%%V\R<.?^XP8"HP7)0.Y22K84.KV0*F.+8$C
MT:"+/WE<,@M>(,,$#)V1H9G'T9*>$QQOK$1&$I6QQX#CEFC3."G4OX%Y`OF(
M7-7^K^V'P\M$<8L8HKIC'QD;PH9BE3I,%BP$BZ0QHZ_F:!',`F8[($Y)%HRE
M_-MU'T2R(/IH$709C+\S)X:M@KB3Y2_OW9^#^P``^$$`MAV=*8X-%\PXGH@6
MV!"@%(03F_^.Y[X`=7Z(EC5`[9`1>7`GN21)N^Z*4XZ;Z%MR;4A,U]1"OA9N
M0&6#PY"8,3A^F!`UL'3%L3/W0Z`K>8`7,6-Y$P!($:`#M(;'ED1<]#V`-[#;
M*`6G\P(0`P[2BFC,Y9#<+EYN;`AI6P`?S1C#EPOB(7,Y8<ZZJ-Q$[6J##*+"
MS)\A&2LLAP`2)`X94#K9-2N@@D"/'+5%_7>`_E?\=A_U<SE_D+Z$;RWI/#NW
M6F0C8K9"K@$4<FLA#1@A!450^1(LLL4TE0T3AU+:M&+/Q)KXGKHEA&W&B(X*
M#V_F8%Q"X>$2=F[K`]8X=>M>7]'!]?">7Z\[F8[;(\L<M'JV:4_@?P;]_HG9
MG[:[DW9K>CH>#3=Y?BEA3TC9R<?/X\EG\_3C^_>C3U\F[^0/+XT9XC[^]25\
MW&5!L$)K&U[D_TY6CBO_?>5[Z>+7EU:K57(,TUC]AR<?LW]^B:SA7X2_ODRC
MU4M#_!RP>5JK"?!G<^Y`F'G];C>?\G7OS3;W,/7*@*D`E$![&&B0&78&YVT)
M:V^)6'5Z%0+9"S\T`<IWZ,R*?\ZB-(V6[\AE%[_"7;W;[+'?:CME/QVG<Y),
MD;J"/2J175GQ3J7.W>C(WVQ(;MKP_8CU,<QMA=C&J/5+KT'@-X3VD>XM(Q6#
MR@ST#>CUPHZ0&CSQHT_@5"Z=IO$G.",Q*5ITO.1CC=)J%W3PB717_B;F$!C$
MTF2DI4+SR2+1J2F1T$#>0&\^B5R?_`_Z/BXN$Q\8?:,FY3D36D$ZD93W>`4R
MVVQA!B?@<34NRS4].1"@ORC*EC9%V0.W=_D3+H7^I.%+M"\G/L`\RE5HQV!)
MG&MEW]D*?_O*ZK8**DC@`(A\]Y<LS&2&0L&%,'.4QH%X`ZQD0(DEF9?*!#U8
ML1%NY!SE(?C.JW:S6PM`3@P/;"AWU42N"]8IM@%(^`!V1R*A(W-,`!KF6:6+
MB%$6>;)?V"JM\%ZG1<S7:4``-ON+N:DT]5C/37F<Y+$$_$9P*@".(+IJPDI%
M3Z3BA^9[XZ%;@1EU!PO8F#.'%\@--!P7C2]YP#E7S2-PTJ^0W'*)=X0JHP9#
M?)4T)X?<,CQ""L)X-5`8#UR`_`EXC;R,W*D-P6+"M[/\D:2!C'OCZ](/JGV]
MN]/K]#**G?HZ#S[)D0P,E6NLCK)H@66>QY(/P@?^`)X')/0YN];2*5W$47;!
MT0[Z(T8N45"8,PPA$U\$G//5!8-&80`1WG_+M0L`(%Z+T/L!RE_X(1="\"9Y
M8%Y$%C+\`4?,#V1^-,)<7)64M(M$W4>9VPKV=8I-P%.P199@1EA&,5?(@K/K
M!@9)X&([@9N)5)Y\$C4Q!%4\TBI6*M*\I!>`OB#2N$4@I`^_\[C&_7L=&84S
M&?)4K-R;BWH]W1Q"LH"Y(DB8,8%!Z0?S'+3TT#$(\SD7X$UH]$B4*91:8P]'
MZCGN77,N4?B,,LCE57FB")$(.U<PGH"R"!S$41TZ"X;+WT\*_%:P:@3PWP!4
M[`2"T%6Z%@GQ@!QC(=S#".RS'S;*NA8XCW'",+P^6C(7JGLI-K"*#*$(.M\K
MK"A3S<_F0(SSJK0X5U$6>)Q&$%/'7.FAT7EEV?E7&["Y)"'$@B!=^E&6$)=P
M"`1JB"_)*E:_R:U?@D@#/3]C0!2F!)^*4K>D4H?G5("X'50148!$N1()U,X@
M(=%2`1A2%S7[%H@J]0G@_A6'29J$CVX:E=[,MX*2PGD/-@2:0QCP7!'NL(]=
MDPF*#TBYA`=V`E44Y"D;3S!4D1C(TP*;>%"FM$(U6Z5$V)SR:$=G_CR+>;%I
M4SJN?@G,"2@B/2L`QF5K4P(R>Y?K*`&W'^9P8T7,I_R6+PM49.N"),KUELA7
M;7Y71O'S.<,K(!F@(KU">29;=A419+`$P9:HP(EL8H%X0N.F_$9-.J5!X!)9
MA&-:]K6++$H9FT5*C,RXW>SEW%N?;\'L`5?:6[,KM9\HY510-.^052GG5(2?
MM#6K4L<.$CAXOP`/P-GBCA*)7O6;[0)!H5=1N6KFWKC`[#32(V>8,B0;H"`Z
M-.W25^"SQ2^D1XW&C/%*)?`,K+$$?I1EC(1[V-O]:S"&6"@%"-!CFN;5X)#J
MK[C:3LO4\1FL\FK8[*^'$K2=MH)%6<#E)=?0I'\HOK3(9I6AK9;,BP"$,K1R
M+QQ'$C7WVDQ[XV9:BLP\RF84Y4Q*+`@$D7V7:FLR"R_<KZ4C5*&2\RL<$9'[
M1_4*:HH@*!PR6IL\!D7#JL4QZ2*5\P)E!W%)_;+BC(4LL",@N<^UAT9/+=]+
MF!/N&&/30[U'R/'%(PICX4/0PD*,77@$2'B37C5ZI-D*U9P2;Y<2'Z7(LS!6
MY4@AD:%EL8B,MN[#]#)\,*Z`#WA(+:U=Q*\O)O>F&K9@@93CR.%LKX:$K>8`
M81""@28A8^OI@9C-*9X0IEMA.UYG<@+N@`@C)#X,FC@"9":EFED-G`4\7(3S
M>+UIG-4'^ILR6HU2`%>8^*1DXVO`+X!7(@UA.6JH6#Q"V9Y-H31%L"3ELJX`
MJ@H6+0>H$&:/@+>)3)Z8Y2I\>Q&F$@-SE:$&3RYUH^!U@<YJ%<B>H-S_*!#A
M,C!:'`H).)(9)`B\`QIFC0Y:&36D.R2%=HAIFTIJ)[B640[ZTPE5A9*,.Z>)
M<>VS@'P<;*G'6<1,HD=59U+MJ44_;`\2W5-R.Z4UUFHK'G74"S7(+?&NXH;<
MB_5E)U9[=6K6^%<6LKK7@<Y_.+&[*,4RL`1%,W=0K8-GRJ)/U*(^O\^+.J4V
M-[T\=ZX<E,:_G!`X]9JGQU4C*'HL@&X8`RKI,#^L*UL;G6;WYU)?`RR0<"3P
M!@<4I':KTZ:0&3^DHHA[!>IO2'<70(#8G49Q`K*+N7K1\D4AZUD,@LF3J70?
M*#>`U"L6TXN83*4D!H*N[K=9LR3/(5^!,`?79G05DGR#*DE\S\?W8*=\,0XQ
M[\4+&D864IX?81*[5EK97O`^OGF&[@T%-B&JMUP)&!=R:AIM5$`[@QB-C/&U
M"+JC^68O)0?11V36[`N3,6%$;2/8[-90X@K%8$9QJ2.0>O+`(H:BQT9X=BC?
MW$[)-AR@A(<A*_8\Y@V7I4Q\07%XF].\$/AS3!@2CD),=4',,2?P48>EL>]R
M?2CZ.8K(HJ`L@!/-J']FGH40+5`#2QUU128[XKXD[A4#2/_2]T!)`2:"R$&$
M`!X<[Q)WIH*)8Z/5;A>%&HT\-:/LF:H45[%/2GC.&+>40N?"5\@]H6[0[^2A
MD;L&4:O=[.26?7]\RY)T+AQPM#'XIEC5JY@>H0\*S&%B_IHY<2//TR9LZ3LA
M""/R/T6^#MASAR??A)0J.:HNH>Y?65#^)7R(_%)<N_`B4%;"M8=%#9#3@(^G
MHP1#51>I@H4N'Z:(1#M1#5P-4FHU^JN<,N=^2@9F#DVP<"*DMR[RTZ(520A+
MWF*M5E'6`1C2MOJ-XE<;GFGSK6]>I-UO&.3[@GIW69$#Q&X`"52N^8L\=4FV
MQ=YYOJ?8,&C%59`EZ*+&6=X'F(64.<Q9)XT:I/3`B@29E^=\%+QYP%PJJJ4J
M$6W2BOWE!4*7Q:047#]VLR6V.;J4@$&?$$2_88S&7Q(4791WM!TS/&%9C7SI
MH9V*"`T9Z#AAWCJ7EVFE9%C@UMC];IO6I9+5*ZO1:K4V(+=L)L]2V1Q?"XB,
M4Q&GH?#2,59C:1I00(U]-$J/-75:)HNUQD_:$"GZU>(:E6@@UBC*WF5C3<GY
MHC]VQEY4NAP)Z<"GK;;5:`]:M/FF<2+]9;5(S?DOKQINZ_S;FN)JW(9E^0ZP
M+X\GBLLI-M$!ZXOBR"7PE80;8$"V1)E^9;>+Q-:>:&ZECNQ"J!J".4PH5*"T
M\#OCM?^FP%Q1DB:](ZI7V(DY@_V&F/\O"19B0Q6M!BRGKD?1!$`''#'GD14F
M"L51I40Z"5%,((&4HS-!$=L7+D^*BNJ@C%K=U]X;21/I;QLC5X2W@+.%8)HO
MD],\+#V/LP1\*Z[Y`4`50@P54Z=(MJ=X0"+OFJMAE')]A5+`1?4'SW]@=S,>
M<D<Y(*WO)(!]%`$(U7"K5+<"+P)1BQ!)$$130)*6&C5*3"H$Y?<@F@$]<P3\
M06=AA$>'O8VRSD:^*_Q6U`+$=KC'S*_KS-=XC2XK^7M*UI>D3&TUH;3^G'+Z
M`F`Z"X)'_$+DE3<H;A'EA];,+P_IVKFN6;.6Z.S.(6S$DC*1(4":\;2].`A$
M"%5<0I5G_FQ^:<IN&SQU$CA7,M3`W&%2X#0'MRX4*>=,0?`#Z@U0FM352+O&
M?Y"60NI[//)?<870\5D6&JXNGBK371FIB_ER<@@\!_F+1^X\*2*RFO@$;^K9
MJ#[GCA]0/VR$@LE$L3;O_1''I43>A/@QKBQ;I=Z+G^KHMR=*4!79)=`2(<4R
M(%M*=:'NIF#AC=Z6&AIQ-1B%(==9HM@C/8^BZ$.,Z'SG?#DGK@[8)3&O\YU[
MK7\!,1//%Q4J-"V<\^E]Y91$7N('45TB>3"XQN]R^5B)O%?1OA%Z;V%+'@M\
M,%U^H4G*FNTCEKWS0&;C[HD]<B3A,KF/C):P6KA'A'-D$PMQMPJ$*L)8*:ZW
MQNB'EDNUNSBE9?M>59[2*45(ZCS2.G\4NT+J/-(<K-PCC1GO51'E=MZ3PN?6
M<?\27)MO)+\982_"D-/+JU\5+Z_DC9&K#!K]`ILN'%K`P?71I!-[-?)@@>.:
M#%))C54#D"V$\.,-I,A??CA2;(D/JM0@1[8V/EC'1VW(4(7!*:.HXE[R)_.L
M3C6;@XZ+$WZ3SX%T4F<F;E>IAFQ6O^18D1U17"M>GDDP00`[QMX*B!\C/!XI
M0NRZC]0I,(IPB3R;`2L$M`XT9>>U(*("32*>&LLAW!`$YQEJV-!?615?2A4`
MC1'_>OVW.4+9]U1)*<FC";(PR,\U<R]`FD5UE3TR2#46=-<0MMKD4ZI%W/(H
MV+I@4A*JW2N*VHW<E1;GEK9+N^Q/R8\<;?CZJW:G.<CSRG0RNG)V[$7=V;!J
M74.>,A$FK2@RR[_@*N)P&.4%Q5=XJ%G.YM6>1*/#*2]^NN%X2I;(&**F$LU/
M?ZLXV91Q4LYP%[5O/,8M&[6OJ/-:[0+D/4K2^T,:7`&&KTWJ=>4E&''J;&.M
MJ(X78.>6W>S^W#1&"1?4&V/M+"QPE-.EA'M.5$F!(B:YF1#4K])I#HLJ[*:S
M?&H9&_/BH`JI%E[IUH$(`<\]X!G:-"\1$@!XGH]#(0_SD=--1_E>%.?!1+O7
M_FB4/)^(;5Z5%JE96E"$^A2I4+V>Z<ASUH#32B:T.*.,ZB#"FC&_XR-)L:II
M4-=30=+R-Y'ZTI'ARY?MSK;%UW2#;/G@AROQA1H5DZLIP<[H0T82QGR-G/%*
MNH<"K'PET;B[OCT%*9R]-V%OZ_8*@2@:`.I49LTY.>4`>-&.4S</HJQ+:N6=
MAZ,UJH/$_U;"O\9Q)+PM1=LC%M:/0WK@M[IIJ45"0"I[BOBYV,T'>\5!V1<_
ME;E:1/8A2PL^7U=5#0ZG97>;'57-\*&4=ZB-5T.A4K-?]7@C&,2NTDBV-OY"
M[`&>XX8`E*'ZM#@XD*P-&JAC5JF3>>-K21MOUL1HODC#XK&+HD2E?EOM6ZF,
M09#5!V"#?MVKY+[5@5X2,(Z*.VF1$AW5'L,[-=)Q,KZH.VD]KYQ*J?3#5>CX
M@EH+;T7)-3HB2FY#R8*.8%"5COU;4!)98%@#M%"K.U%R(QUO-C8W)_X5L5LX
M7AY:%ID[:DRU]BQ=K[1DR((GWY+`:PY^<0B(:[E7;:5ODPK+O"T?<9FW7=WI
M?'3-\>?JT%'J'OC,I0(I_EAS<JSQ2=\:C+KF8'+2-^W!Q#)/IBV<F#,9V/V3
M[DD7!X<>W)P<@4!#P>"!#,I1O<X$#Y/+=C<,ZV5TB/G@"*R[[-$):;0M,BV-
MO:)N&Y8X`1WH<[#S!_QWSKBB#HESHGCF4WF6!`1SG3Y==[&BQD;W6N;68FKC
MH`@R"&0"HD'MKV/L4_%G61K%E.YWZ+16FL447.+79=.>R)M!!![(#XB!5DID
M@2_A("K*N*9^7MI:,`!L@3Z)&)/"P6H:G_*GXO)Q)MY5@2E$/`\J`E!,RE(]
M)^)%,I[7$A#6=G[^/AI]*EFLJG*5?;]QP7#@WM+\/P$.3_54RH.I2',B'`P+
M+PD&N8R:9^C<(>8*0X,F45SPME/VW4_2<E=ID=64606%'M4*HDA97Y?J$Z@,
M*W4\0>32T0Q1>+NFIDI9UGCM7Y9WQ#G5I?3MW,>),Y0IYV=7;E/#>-H!*;S.
M"&CWD*5?_*34'8W`R4+*>Q%V_PQ)ZKZDCB@AKB7VVP-Q=@R6^23S^MO<'LQS
M2QXB8UY(/4I"LH4K\V.HZE%R[C+D95>*3S$"PM,`LN,>I!`$E$(1*9WTZ36!
M5OA;.0`@(<\[='E408*K+IF?&@%)PY9L^N`<[2JFB[C@E@0T:8CC$6FQ-B$!
MUL@=G2(/SU.2*L#8KD=C&/,V;3_T,O@[/V@'/IB/#791Z)9S^N),+/;^S>>^
M2X`M8!F<;%RTLON4_G+"S1@M$UFT4`M\*2?TRYNC%%@%\Y6LI#R"P'NU$1W5
M8P>J^BGX@CEQX'/[(`)TC`7S+!R@'CNMD5`[D^@7(R<K'5@MN:5Y@ISCPW@-
MJBJXS(,\7@Q;>]E3TF8"Q#=E!%`6AN]=O"X#`71BA8-.6^,8%2,00&823K^\
M=QX54TCMY[#(183'H?P0CX4BJ1<LH*Y1JD@F`H\%AO/00XQ_*W_35^?-[:FB
M6SA%-()<Q$4DI3KM$AUEE0<)B[G1$,=YKQ9@>E`Y*4_*$1E)84G5C\I#2,58
M+^;YZ14$-0L_%"EP.5Z@*@?E06'P<:1,H942$L>R5J+X2H)=FA21`+LE<T<>
MN1`<)SLUR%93'$`]J^);)<&JM*C,^$RJP+FF1A'.+(")5:E&Q-<*2P(("V7P
M.'$*-5'D?DD^!I6K'%$:V&)2UTK$H.XHB3WC;E3)Z\A3W83HBSBBP6D$DXK4
M7-?F^FF-+\JN1>$@O"@.2=$W0M[G2[LNCFW4EEP$0(I@Y0"5+$WNMY:FF)(B
MD#A3\,$G+";KG(5:KYY?Y2$OS$ALV`(_7$R)-:Q#2^.Y$:.O'=53BAV/#_>[
M$JU>7$>1*HK\T@A+<;@'/K#*`U4NF(K\83\T>'LSY1M%NO("4YBA'&C`VPTN
M'3[HBV1WYE`2A2-JYKC?$OD!#D,.'KS_!\.CA3YJ5W\Y`X4@)>:U6V*'A,67
MPKG/1^ZJ:.'^!S&25PLU3U;3[!2\FH.T"V4N9-):%O-P,C%F.L%(@KU>4JS"
M._(4$W:G698;PKQ?#-*]7\[^WP1TME#/N$Z^B]V6IZ7.)__?N7GV83SY`*&Q
M_?,.\;/]0/$SA<%XB08*RRCGQ7=%C%P2"G$Z(\ACPCIF);4J/9.-O@WW-]8Y
M&GY.B)71VT,M)]^AR3'8>5>2%3H$0,T7@A/`C7!(`Y2M4R(AKK01E$>(\+8V
M"D8%W-55"@R(AD^(+ML_*YFXJ#BP@':5>IDZRLPF#_97:=.M;1OX*_,N<J2@
M],0^!B=K$[=(KFH4&]5<8OI`PLK)/\0LZ0INVE$<$]'X$50JS]57!;YYZ6E-
MUQ6:CF8CN,4`7C&&2G;RT5!LX3\5[Y0FT]Y95I]9F#X+38K&IZ)+QQ*3F\0K
M=\JX2R;5+/73DQM2:''#D;/`<>5+)\;A(;E2C^(+)Q3)XOJLS3E.3C*Q2^G:
M^(0F`&4JXJ93RJX,]L"+HJG>0B*50Q<-V>J$03*:H(QB'<4H$*\T)*W7O[K!
MZ(I@<MTH">M5,*4O3J4KXKW^%973N0`E:BU/Q@7U%ESAT()[A1AN8MX==O7B
MI\W&5D::V[:&J06^.>X7D<=;S2YM.-10YC-"1RUUZMK/"QXT00H\7D24@"-Y
M^(E@X7@J3V-;&7<`+F)GR==6%U?&V"/#T^DSI<NA?BM5EY0269?UJU;6E!VG
ML&G.PPQ5E1B?+XO9Y!TM_>\E1_%`5=.GW/7ZS%VO#7IH"X8IGUK$^#*;BU%^
M%D8K%E(,)%(%.'Y/ZA*OJ!1:`U.=1(*9D/RT>@*8%FF"4C]LX,P8GG*OY@LX
MQ<7ALPUIADTORR;&ZIH*I?G1("Q07]-).KXFR*4ZS#@_O2*.0:T2/*>/7-<H
MW[X1.#A\,64KD4C$<JD39AB+<NQ0?3$I!26D%PJG0\;?Y%E@ZRJ[*HJN?+R6
M"KL(@'F@6LXL[=R"I-;\"C^$'Z+'$ZH0:KZ@(_]T19&:A1$._EJ9N%0DW@4$
MT8CEA^M=^,@[3L@K&Y2NDE>?E'-PCIAZ)[22DLJ6RKD4</+`!,G@</W+,SR8
M)JN&P;.L&FM2;\WF#]5^ICC^PQU/)8&:1[WRO4R,M9B3;>"A#4&OY.>,\KBH
MV;62WRKL'F]TRYFQY&ICWV3(`E%2D#KR6AXOXG16OHC.`0"$MN\L!+[^QBGN
MTQ168.KU\:ZTCY+!0M^]*.Q4)]73+JIN[NLBRKMB[)N<32?&10&0ZM.E!J(B
M1[B6^JLZ_62-"ZA*R5W08W@82)9)PKR[I!:;2NVIE-'B\Q51@OSBI+[DM_5R
M&57PR7SE1;`WHH:SP?1MPBE90OX!Q'S^B37K3''5%LHXAAS&R?E$?5X><Q$N
M*(=_E?$)($FY.H?O-8275V.A&Q7SSO/S=)Y2)OF-LB-1W(@C#%5,KA@%>7P&
MI-PV`UJY3B[OY**]KA2W:CO`8!?!/.\#RR<,J_,2DX6_6HF*69'(Y]UG\F\U
M&3:"H%R6*[I(\EDTO&<M%(2AJK#L&<GO0"B87!Z/*V:O;+HB0#48!^KS?!2I
MXK,\@?2NDJ(I'E.S3'G>5;(XI9T2>1=$-=N49P/<R,2S;4`!>66+\/<+V2']
M4JEAJ6<<\1(1JJ[FM>^KA:ADXX'3V.$3JI4D"_7^+5!1)!@GX*R>M)A/M4(M
MDZY#QC4M^>+-S>[?^H;$2_Q*D50:\6):+I\'AN)*=UPI";CRRN7V3[(?-`N=
M9B(E*RSA":VJ^$.5)<HG:,0@76IAH-LE/%`X(-]BE*;(NN0S"M1#C/FNN-#5
M7ZDET54^;22U2-XY42C2-8U2SMV4XD)'D)8C'+VZ`N75N5`K?E6QPV=KYGPB
MHT:1%.)4*2B13SO**:A8HWPD$]E8:NYR`IF$V\S5E11275@MR[:[!=9K8?6+
MGS8%UC<QJH119(PY.LC%I[!:3-J-ZN;;UP]_=;R_,MY>K.+H!@SE_IMZ.5Y2
M,DQIN1E:3.B1"^14S=E%]N._^$D]@,=[!,291NK[H6OG4$-A4:\23U%#`UF&
M$%2H%V<7%>[,>5QF5NL*<^*(9"&YJ@J-Q"!M.O2L^.8E4%YL.#:UWGVAF-82
MXY*V))6JYJZH%=KQ?.Q6N03O1GKDJM>\YL&2:N"?:QI?^%&G?#_4`XC#P_,2
M!"I#H8$2:67YC`H!LN+3*=`3/KCU+2&3_']EGI+@OFI"MA;9PF7,N[^K`U'6
M9K46$XI":I"*S)A[W_QJIOQ0M%"/V(X9L/($;<1/'3!-RB75ZSEL:,(3DG(S
M&Q&&>KS`T\;J='D"58<3270TD*%=ZPXIN&]+W+EGE?OB>H%43@++ECBHZ3^H
M(S&IRX./$LDJ6K8H-0H;)^ISALMOQ48F+:Y-<&;@:N2':6\9M6-49N!,Y`2^
ME+QY=P=DMG8IN[5WJKMMO=6'8A)GE;"U:WW4:WRJU_RHU_K(.W)<NOQDAUM^
M>N(NH-H+=^0=.[S].?]2=_,K#_5[_>D?Y=/EBY2J7%J!JJR\2"]9_)=EB=MZ
MC=0=UKS%ZF71EMKBOUKT?[`XCYD4WWNYAG"0?9#R$#5MC13?165;Y<YTJJS3
MOV+CK0"ZJ+)O:S]_``P^RYK[2PM9F*V00RG25OX"MJO8>5Z[U41[2J*)DE6%
M,J)\=8"D.`JB4+*L0I(BOW:`5#E@6IQ'J1,\*\JW>Q,+AH7B7U\.-KN\Q2,%
MNNPC?+R**&-V`>]$$''\U^GI9#*=OJRGE+QNLQHNE3+KIL66E3PZ_.:>H6?.
M92?B8#AUU:V/L>)1WS8N+!V*?%H]NG7UVV+DU:V_)\6>&B;N2P_E&M$'0881
M1E>QL_KU)?_OPX#W;%I:4UI36E/ZH"BM:?[CT5Q3^O`HO5O*\*Z>:N?>GNJG
M_'K&XH`F0"&GMXL&0EZLYO<<\?ZOX_54[\-C#R@`[<:@,]P?+C\FS;8W%+:M
M@:;P$5.XW_Y1R/N#$[K=:&E1/FH*]QL=NW]X%'[JU.G]'=)3&F^1O,VGRBWQ
MM#]OV]5>Z7.+P6NK,>Q:SRP';[2">Q3*V@-;4_;X*'LLJ12ML.\FUH-.5XOU
M$5*VVVCW6P=#V35/5/W6^C2@K73;B;Z;5,`.[U:]7M&^0OW5Z[TK-3QQ6Z_S
M43]8\_CM\+</F]!8^S&PIO&GN>[!L?:X1;C':A?;<DZ(-C7+S>%Q9CPD4EYM
MV^U3QE$2H,%@<!^0'C9ZDD!MI-C=H-Q#MWMO^6'8L34_:'[(`1)EOQ^='31C
M5`&R!ELM]P_#&9H?.$#M1JO?/S*..+8\3P>"$B_*9@%[JC#H[E^L>?S9HD>-
M-XTW+;&:\YX';V4K])8FF=1!M<L8F@>]L>#II]Q4I]DH=[V4&FB\.U])^J-,
MK>GW[C*TIG/[H366_7Q#5![_VWJ*2LT9]XHG_SAGWNMEN/C'3:GE9P_]?B!:
MU8Y6+)'J/EFF^Y/J\`[E?RH;PA?J>,SM)NN0LV'/>XS/ZC7:]G.W'QW]*0A]
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M^%@CXWW37U,_Q,N1/:'`\MM[`1)Q236_'5G/BGILCN_9SSTHZNA5VIY0^EAU
MVZ%G_8ZGY*/QITMF#U()VKN2V:!A=_7Q\7TR%W>($S;D.K1M/5[;>DSU((W!
MA[6O:Q6UMYY_B?_\Q]LL,2\<9_7N,R]2?2[J69_`[KO7Y^Q[>A)$[K??X%7C
M'_+QJ>/'_W:"C(V2)%NN\/ED\GW%W)1Y_XX")_4#/[W^[*0,RVDI+/*9S7]]
MR:+@ZZ>)W1MV!J9I6AVK9?YWJV6UOGXY'W]M]SM?,9?=&G9:7ULOC0S@H+=6
M6<Q>&AYS_:43))3,];U?7_K>UW9WV!]:UM>!W>I,3GH#T[+Z7=.V[*$YZH_Z
M)IBR<7ML#[J]:>>K]=5^^5NK.;2*7>^^C?+VO[@0T6<!^SC_@E?;+Z+`@PA^
M\G<&3W^(4O8_3AP[89I\C#^CRDUR+-X=&Y4=3_I3NW?:;9LGX^'`M`?#4W,X
M/>V8@]ZX-QCW^VVK-8(=MU[^AO06Y-Y6R^L]VFE`6>]<.)XQ;`RL7F/0[@$H
M5P))1AH90&)WX23(+<ME%!K)PHEAU2A+D]0)L:1WXPPJ>,!PC"NZQY%YIG/)
M8N>"&>P[BUT?5E[%OLN,:`ZKO+*:MHV5U.)<HF?0F<&ULXM'6Q8=V+<IBPH(
M_N=L?/Y/`+Z_2C<:O]O^_C9K;RI_MK<=:JRL;S\B[-O6?@#8VX\(^]:U'P+V
M1^29+6MO3P_?O[!H/U(A\0P,$C:+C,'V[$^<L[_X&BWQ4G>-J9LQ-1$&L=C-
M)[2,&G6[H&[EQPYZB<5^;B6@=TU[[>\LJ_U(^-MOV_VWK3TZ$?7,(J3Y9L=S
M=/U&M_7<,^LUVQQ(RX35;PXULQP,L^R+CGEK]=]:SWV3T0/WTVBBW]!`][9C
MO6WMT7VY6ED<!-]8C=[`;LB![IIS-.?LS#E-[<AJIKF]F6H=L&^BTR</I#N`
M"7K:7=&,<_MS(O:@W^AH=T5SSJW=E:YV5S33W-Y.=0_87]%4U]Z)5A=/QCB]
M=K_1TF9&\XWV3333:-_DD<X_W+Z/_[F>N\?Y`7V>[TZ4UA@_:HP__G-[G/%]
MKN=^&+L>K!_]Q(_.\L\_EZG/(<M/L]P'L$<_+WMWV'Y8EMN[4]EX8$DSV9XQ
MV1.;/NV@/[F[>$Q'@C7.?TR</[6FVN&P^9V/3V\ZA7TFIZJ=9G$,/YTC"`]_
MZ+HSL(?=SG1J#H8MR[2MKFV>V)T3LVN-VNU>:WPR;9WNP:%KB0T?'H&M)SZ?
MH,FG3Q?GFYUT^W'JT#-JQYGBG]MZ?G1]4>\^\Z/;SS@_^M&_O6>UT#TXI:CG
M1VM:Z?G1CSU_];-S92P=()'O!$<\8_5Y3\;9C>%0SXL^:A)W&W;O`"_.W??Q
MT/\3Q=]P]-`JCER6'+&"VI<R?;MA]7J'Q\>:V'<A-BBM_@$._3X\+ZL\Y5YK
ML4=F[&&C/=#^UH]!ZT[[`,W5OKM=^E:.?6%O?2O'CT)I`8:>'/Z$9?%=RI^Z
M)U+C[V'BCD-7E,^;8</32MJK/W(:6XUVKWUX-#XVFZ>;C#0&-W'WK1J8MG<>
M;>I7&K/8OW12_Y*]]YT97C+ALV24YM=1/%+_DC4X/>U8@ZEIC4]/3'LP;9G#
M[FG;M*8GXW9W?#KLC-NWZE_"YIQ'NC7"73CA!<MO90#,`""7B!SL99K[H1.Z
MOA/``TD:9TN&%TGX"=[IP#N<DA^G0VG8OD.'4G=X^PZEWO,U*.E/ZZZL'58_
MG$Z?CVX:8:,/[F*6[T?=W"PVWBJ[N^?WVBTQ0>,I/E9'/-G4NY&P]8#M:_O9
M$;'BF,VVW9SQ^*SQF7F,W[Y5_*YJ2I\"MBESTBQ^[*LP-#=N)T(4,UCVR8@^
M^<Y=S6>5@%-8,G;<H]&.1\F9M?NK^>D\2K'7=,>GGY6ZV_V_!5VF]^O+P>9(
MH7A$O7[G`!X_O!Z;G`]/G`""7\9O1/R7$V9.?%U07!S0V<961U/"#O;VO':[
MT[#:W?N`=33W:&N>**%^>_U[7YE%LXAFD:,8`7$\S'*<-D97&O>W3J;'0&B\
M[17>-`9OP*".[[=7MIXOFG\?)8D1A4J=NUKC]O(F`2,070+7Z\;S:&+Y_6A2
M[@T:O<$!'K@XB+AK/TA\+'WHFN2:Y%JE'Z]*/[P*Q6FT7+$P<;"2;[#O^#,S
MYA%Z-64WIW!RKD17B.$G2<8\(XWPA27#=]AR%437C.E#>(\M(IU&J],_/`EY
M6@OX7,_]*'O1,GB(,KCO<?8YF)=DSN($3`O:%!HRJ@W*(S/S:ZO5:0P&SSTP
MZLV>FI*#INV/'4QIDO]P)/_!B7]PNOS82LC',V#@*0NA&FL::UI6[XX_73H^
MG,0KOCG#'TJMX9MO=]#=X<_B14N`AJW&L'>?F?O[V+AW$.'4WK*$[OS5+*)9
M1)L8;6)^H,#^F#I-=8^SQMM>X4UC\`8,WC#U[$>;AS70\[#TI_4\K.<:KJ'G
M81U*1'WT$XCT/"P]#VM_N%'/PSH"[7B4G%F[OYJ?]#RL`WC\6(J>&^9A;4V%
MZHKG8Z>CNW9CT+7O`]4>IJ-U.>M>XVOL1K??URRA6:**>EWAU";E9H!ZPX;=
ML?::)72%\YCJ);I2I_&V5WC3&+P!@SJ:WU['>K[8_?7OCA^^,8+J$"R`I#P?
MHF8(EJ\'0CRZE_4:HK-6_[F/H^OCNX]!VGZCHRE[C)3M#)_[C.8C*%"MGNMD
MN&TU6MWAP0CQX1472J.L_-"-EGJ2U4%(AM6P^H<C&$]KW9[KN1]E+UKV#DGV
M]CU&UI.KGH.)=ZI![86'O4^619-<DUR3_%!(KHE_%,0_MF+Q\<S.><J2I\::
MQIJ6U;OC3Q>)#R<KBV_.\(<=YUSIKN]G\:\D0)UAHSL<W`>J/6S1.X@H:V]9
MHM]HMUJ:(S1'*$KBV*ZPU>;C80"R^PUKJ&=8[7?0?DS]HKI36>-MK_"F,7@#
M!F^88?76\R_QG_]XFR7FA>.LWGUQ%\S+`O9Q/LX[B]\7C<6C=.KX\;^QI^<<
MUSIGW].3('*__08K&O^0JQ3OGH5)&F=+%J;)*/3^R;P+/[P8N?`G6F_L)VX0
M)5E<K`1Q>9C"/SZS^:\O611\_32Q>\/.P#1-JV.US/]NM:S6UR_GXZ_M?N<K
M!K&M8:?UM?72\+U?7_K>UW9WV!]:UM=1KVNUQ\.Q:8UZMFE/.F-ST.U;YFC4
M[8['XT&[.[:_6O#B;X@*@0F)V4<;OF6U6C^7K->6NKI\QR[F=05L_F#^P^ON
MF[LX#P39(X`C!_X83N@9XA_P]8*7C/>E:YYO[TWL-L.M5S_#[9[;/%\P`YOF
MG/#:6#B>,6P,K%YCT.X!*'EK7!H9JRQV%T["@,F6RR@TDH43PZI1EB8I(`:X
MZ<:D#CQ@.,859;J89SJ7+'8NF,&^L]CU8>55[+O8D@>KO+*:MMTPG,1(LN72
MB0%@#UOWT@6V\P5!=(4?)+2]6T?UZB94'L0XO(%]FW%X`H+_.1N?_Q.`[Z\*
M_J]5SK?X_6W67G/EQ6;:G2UC^BKKVX\(^[:U'P#V]B/"OG7MAX#]$7EFR]K;
M\_CWGZIC/](4G3-L%T8[X*2//6GK%BF&_<77:!EEX;;Y;!I3^20O;A"+W7Q"
MRZA1MPOJ5G[LE"?PW4I`[UI;V]\$\G[T[MAOV_VWK><^OG8@_5F:;W(PK'ZC
M*PI/FFT.@&U>/3.W-(>:60Z&6?9%Q[RU^F\M^U#X9L]FG1\HT?MO.];;UG.?
M>M+*XM#XQFKT!G9C,!AHSM&<<SO.:6I'5C/-[<U4ZX!]$YT^>2#=`4S0T^Z*
M9IQ;ZX^&/>@W.MI=T9QS:W>EJ]T5S32WMU/=`_97--6U=Z+5Q9,Q3J_=;[2T
MF=%\HWT3S33:-WFD$T>W/\GP7,_=XP2%'I=P)TIKC!\UQA__N3W.^#[7<S^,
M70\>\C:M1SF*G)]FN0]@^@JR_6.YO3OTC@>6-)/M&9,]L>G3#OJ3NXO'="A:
MX_S'Q/E3:ZK=CAM;@UT.R>YT1O9V9W!+L^?:I4/I=[>&OOPAPQ\^NFDTHQL^
MVJW64![JKKNTC!_ISG*TYNO<\L3QXQS>_A@:8BL%]L'?I5TU`)Q4.=SMPG\#
MEC+/<(Q7_5:S92S](,!K4E:T:V:L`L=E.!+!N/+3A0$<M8`UV'<_2>EX=^@9
M(<#AAY<L2:,X,6*69`']S0^-5[UVLY.O";\(&9X'7\61RYC'3\\[H8'GG/%\
MEA,8KSK-7O["/(Z6QBSVO0L&OE`*>W8C^%`,`,,JL!S\\Z\L=.EB%X(/-[<&
M>M,XHT<3'XC);X&91S$^"ZO4@6BX3K(HH!SA8?-0W@73ZS7M`K/B15@H"_TT
M:1C,<1?T,_\B1U,T-U[[RFT&4<B,T?B+\3IF*T`8P$A/A0A0%'M^Z,37_#3]
M&WY`/C]I+\_#XVEX4(*(P->^NK3S(C^CSU'B&'-DWFOFP)99O"P=W&\UN[@8
MT`#!P4^%1-[*Z7O\6K=EK%B,SVW%)Z=0@K_$]U1RPK\%_7P\'Z\2MB&0C&3E
M:+:;K34LWQ;'L%HMEG?&<:LY;,$B-5B^"XX%.(3EFW&,0QC2*`69"#.<G<"'
M(%1O)MHD!'/87XC3!."-!-[K=)OM=7SB54<+'Y#9;W;7_PJHN=4LA^8=="!.
M5'@$)7A6CQ:`1.A&KN1S+#5*:E'@MJ29X%7@AG4DJ?,PTD7,F+@I"G`[!\*"
M1I1(IA5Z.Z"97MF&9^2-C;P0L@HKU.^8BVKJ^"%I?^1"_/@E2*&P<L:<.6D&
MP'$6`75X"0+OD:P3,_NA&S/D<-KZVM`.?RY^*V[9BE$ISUAZQ5@HB/%G$QC=
MPWD8,0G920S81M4;96@9O+^R),5Q'R[N!.0&U\MW[499@'9@5GS9$Y),WP]8
MDN!K?$*(1&/G%Y3'E:/<]B45%Y]ADN)<'_$T8OL7_FD?]$[MCN!?8"7@T[@9
M-"@=5,PHQL4G05?#PBP.`,5-8YSE*%N!\@.U!$+.$0]J,22DHR&8UV"U4<8!
M\@XHT%P;\[O*9HRHX\&KGOR2X.UB8\-?DM*>F\;(=4DQ7@37#8&4_$->1-_Y
M.P/7<GXM]3UM?D7L!I]Q`R=)\*\JB+@(<"+P)K_TAMM\`%L\[2/18".*HP6O
MY*[6'ND45,CE:^)@6XEB;NM<1>`;<(F6("99S-F3C!=8I"A.N1@"J_B1U^`"
MRSDKJ5Q)%S,WN@C5@3>@+5+NEY%9B%;"$B=-X\]55)@7SB]5L!4.RD6'3&\)
M5B`4?+@@$[EC<K/%#H'R)36Y<GS/1%WDK'PP7\!70;J(LHM%57Q)^Q2Z!UZM
MT3Y\`[D)+"L]$A@`&=9)0+4!NZ,$`J%B!APJWETZW_UEME36*(\KRA<B-N3^
M:R%^)>VY[A4#RCJ]IB5]'&ZV.1&YB[H1]1O9Q?,3-TL2HC6L\0%4A-&^DQQL
MC-:>()SZ5Q9<$]*$_S0"W`7XB[X,K9*]#J/.U_T!L.;(L27+&QKY1BO;!+Z_
MR9`+U(R96WW`H@?:R"^)(C,+YQ)-*-C/DO9\(6\4`WCR$7:T=/$"&.L@\PH%
M4F</N$]`A4\'@\*9F,R>+!A+I1I7@C4AZ::4='A_G,4TA0ME%EP+`^0L78"6
M"?'36U#1`*W=:F!>A_09OE\@-M__%0BV8NQ+L68>KG&#!XM(\G%/OI#1[3RV
M/F?P/A,"R[,&\X&$(^"H)1G.9/)]!1X;\\8^NE>A]QD5S)WG"F)41&]!^,%>
M@HYQ_:43)+^^-'MK0P<'=JLS.>D-3,OJ=TW;LH?FJ#_JFW;7'K?']J#;FW:^
M6E\[+W]K%<C8=0N;ABPF$V``#[A!^=6#C5'LG71ZD]/IR.SU1Y9I3[LM\\2>
MVF:KUSJ9VNU1QSJU-HU1W(.$U*Q>E;Z/R#B>8V`Y9K/4^`S^)D>],>56<J,J
MW5#=>7ZE6E4\4@ERO5>$K\X%Q%1%`NK$CSZ!V5XZH$Q<<E,((U.(%V"1LS/C
MGU&`+FQBG#K7\/V&\;[YJ0$!?_%F0[H>W-Q+5,+K1<`#>F8&3G"&KI0CKPGF
M^8LTCH)RN'B%@0AWNF/4P\(+7SG7$-/;>4ZMP2,2?&,5LTL_RA)0<.`)@A8U
M')J$A2&&T'YKWS0B%S8,)B7$W<S(P=EL.CH-2B65`,)/(4C=G4!"XY0#M0$D
M=DD>*`?,F:>4/MT,$_>.)-H\AJD2BC_1D:XG!44SE"\1:D-QFQHB,H5W7;`0
M/O>OT>$B5Q)=+K2!^.=2K/$>P`Z,3CX[LO#0%CZXT;&[`.!HCIN(G;*$=IWX
MX(-#4(_.6Q9&LX3%E^0X^N$*XO=FL>%RJ*#$<NN;P/P,@!^X64`V-TN(ZWF6
M=";<0E,.R`1[Z@'L>(EU#!&$0\8/V-RYX#+"DA3T/69*^07717Q97'6=\S`B
M9U;00=KMDL<JN-%#(>.I+G@)?XBR5&6*8EV>*$C$7=OD<PBG'#S;^1PD"UT*
M)0]@I%>1\M%$(HM_D[P;E56((>J#FAKT@A>6;N/)]J8`J4RA.AA`MHOD)L>F
M"C9?#C',DPLKASPC^C,YE`GG*5C`B?D#(?@0',NE3"9^-^&TD&BSFP/ZX*#9
MHJQCTJ@D*-V(=%=,O`#?D2]VFJV?A=MI6<WNSS*WJ;Z[=.)OX.]=^RSP2B];
MK6:?O]'NPT](UE&ZW:N[,W+[S?8NN"TP2ZO<&K<\>"367\=RI]FE3]M-^W98
M'C:'.9;;=\"R+;#<;0Y^EL(CU::2"W","XR@>>[8SO/L^"K@K_@%:=2RL*XG
M,NKC49GHH=2FV-+M''NRB@DZB+!R<%-"9YOW7><ZEMW,,]"+2W;N?/\$,8Q[
M_?!SNB>]3GLP'=CFJ=4:@:/<LLQAIS\UA_AG>]2S!IW>K1S,)X[1-WB8'&_(
M:,YWMCDNWR]G<LS`F)!KXWP'LYXP'O,JV4,4>4PU*B(C^7F><?<"7L60%[PD
M-$M"_@L[E90,%7H9UV2>R3'B(38N,7,2K@`X&$).2F#`OT62#MZ'()'[+-<F
M``3AK:B%1O`5--M.FL;^+$.MPOT!%CH88`E-PT2\)70EYE8!8#=%QQ4AC1)6
MV04X=RQ.P!IBZ,9+=@Y.S';HKXBC/+WOH$Y)4E*GZPBF7+C,.B_1!0W\;R#6
M/-&.OY3YYY@Y`:)\SS*X4HV*_29</8$GQWTFQ6,"9YDG4E!!`@9@8YB?!!^9
M(R0#1,=$7>YJ>Q$L@1C(V8WS!@O9W$^1!MS#@W6R4.22\`ERTQ+*J2A<(.Q8
M$T6R6`,AW/(RD`-9T3,H;)%&E=.;RE",EG94P-`T.-^`;V;7Y2(8^&\IW^K<
M#RBD(O3(CX'%4.A/!D;E@)S^.+$]R9;<NQ0U''!14]QB:(#<):)<%02\F(,Y
M"X^R3V(G!`9S%R&XWH&Q!.6?)J50HAI+KDC[(X04]6!5`[X%7X1O$897($\!
MR:6(`0J?E?O-/BE$W#R0X+86:Y,5*MNJ+RQ`K/X.5(B=8!1Z(P^=\"2-R;)A
M3@7T4O)8EJP[ZL)?1J=F>SH>F_9PTC,'G6'/'-N=X:C?GO9.3SN'ERH12&T8
M`JT\)UM"+"4&DRW9Y_VR<JK.`O<MQN)0XD#8CH[5A;)+I[1+X).$%Z6+TA#&
MOL#8&>KT)I7R!;)N7$8$<N)?9",!!E"&V+D!LG,1.TNNN_QP'CN8)'7)OH80
M=R4)=EI(PRN^Q5/-'CPF8X+:`N4,S1^LT!`@R!A59,^QD(/)8(`]<$`O+G"Q
M?SN)RU:.%.T_0Q^U[I=4AL7T6Z#3V8<)+Y."6DFI=G,F<^2`*`@J"+3D9B01
M((2F1*:J3:GL&1=C7CL+(\R5)VM5OCQ=L1X>%9XX:-$(=HJ+4AA3J?[S:E.I
M6@7$K^E%$-U,>>J$ZT=91\!8"0#F)D-HP==B$V]NK0GOIN,J.7,?"?@>'O?.
MPA3PALU#(_1&_DS8/`O>^_-[Y,LK6K$][K7:76MLGDXF0TP@#\"_[YZ8H]%X
M?#IM#T<GXQ.N%3]9O?\=_F$-QDIJ?`=(-]<#&-44E/N+_A"%V(_A9TQU8HP+
M#WR(PEC^\\1)_*1\M]&#8<*&/_1/6B?F=-(;F/;IJ&4.N^.6.6H-)VUX97#2
M;]TNTGG$JGSY]A?*G5&_%TH8BH#P>&<R:56K:S:'$#?5\397\5[\).MXPFU6
M.P'4&#RD7+2@*[H^OH1$*"B6;$Y6"K5QF?OVW%M"WZI2"LM2GYPRU`UYSH4W
MV!0K'^WM.;W!;6[/$2]UAUMN2ZF>V)$?VOS*0_U>?UK]])8;;1[]$WLV+V@/
M;O*P'NLJCWH=S)7L?2Z7O3]5[L$$=\9&'OZ<A3+5F^P6RQP:0[77SD(^#G^=
M8[_UL_*1)D9.#"K3*F=8-%WVDBYM39>]I,M^V<-=1X#@A:UUL<;YY/\[-\\^
MC"<?SM\9IL66E;PB_.:ASL=3+/YN&_9N>YSU`=EQGPY^ZUWI73W+8>5M]U`_
MC_(X=1(Z%_MWY@,PF'DJ<DOV+\LH9-<&;_A(#D&=W`T)SWS/E]5I=F\/P6/-
M\=L;!T:36)/X<$BLJLT'0<8/.>%5T_R@A[/N2N][3*2INDAZIH_&H,:@QN!^
M8W![&+B@0S*_OAQLUJ+%(^J]\P?P^`'GTY26%IU5T[O2N]J;7>U[5FU]!M\+
M933,(6B00PS'.L-F[_8`Z"3+X5#X6`)N37--<TWS8]/DAQ?JX(`6D^9^T@GT
MND$6VEEY'!;O-]N'Q^&:P-IN:9IKFFN:'[@BW_<$RC2*&8!@T)G?T.63B,(T
M=ES=A_18C-QJ[M%MHEI3:>ND::YIKFG^@RARW8.TO]T+&H,:@QJ#AX[!N]R;
MIZ=CD'%\_CD1/^:G]72,AW-P]W@ZQK8)1+276;ZKAT;@[9S21PD9]'`,/1SC
MQR&&'HYQ$'31PS'VDRYZ.(8>CJ%;P_6NCF)7^UZ%UL,Q+IZ[EE&'@)[=M&X/
MU',7.#35-=4UU76M6M/\&&FNR]?[6_C2&-08U!@\=`SJ$1H'F'63(S2N=>9-
M[TKO:F]VM>^9-SU`8]?O/60PUK6;P]L#H%,LAT/A8PFW-<TUS37-CTV3'UZ@
MHP=H/!N+6_8ASHC1%-:&2]-<TUS3_-`UN:[X[6^M0&-08U!C\-`Q>,.!U;>>
M?XG__,?;+#$O'&?U;NKX\;_Q(GAJ]DY&H:>,</]#7&#_,?PLKZN'!SY$87Y[
M_0E>7G^.7SEGW].3('*__0;?,OXAUS\++UF81O'UV$_<(,+E\B=I/A'\XS.;
M__J21<'73Q.[-^P,3-.T.E;+_.]6RVI]_7(^_MKN=[[BM<^M8:?UM?72\+U?
M7_K>UW9WV!]:UM=.:]#K6.VQ.1A:/=.>GO;,$2QE6F-XI3,:]SHGPZ\6O/@;
M(D'@0.+TT<[86JW6SR5;MJ5D(-^QBV.Y`9O?VS,,1$WQM?V&R+^AF+B)K0FR
M1P`G9XJ=@;K+0>Q>_4'L>VYB-$]9;#BK51P!FHQH;OS;25RV<@"4*#3^E077
MRI&@7H-.9!JS:R-=,&,Z'C7HA]-HN7+":V/&+IS0<)V5GP*>_P,<!,OX:6*L
MLMA=.`G``5](G(`1F_H2<<IWC7D<+8TD6ZT"G\4)+.^DL,C"N62P/`N-OS-8
M>NXS3X&B:4@:@)BC'((8I[@H_!WS,,#VT15`8SBI47\1.UW#;CBA9]0>1>7;
M?NUC5B==1%D"3R9OWJV3>743&0_B/'V_=X?S]#W[]N?IK?;S'2U__&_K`^3/
M=6:N7L@530;2?A<3HFGU\+2J5;@E4NW7"(#]KTE\=JZ,I0,D\IU`GTMZI)R5
MW1@..[>'X+F35IK$MZBA-NS>`5[:N_>M75'\#7Q_`V(.ER5'K*#N4[1XR.QZ
MNV'U#C"_KHE]%V*#TNH?X#')P_.RIG[H)POF&1=1Y&DM]MB,/6RT!]K?^C%H
MW6D?H+G:=[>KK*^*Y"MF5UE`Z=0H7;!8J[+'9N^>?8`&6E/Z!VYF.K96ER+_
M68.&QZB1W_F#-8]K_#U:B\'MXXY#5Y3/FV%K]QLM[=4?.8VM1KMW!#>D';K-
M.Z;&,(W!A[5[N[4@85_*(_0@Y?U3AI\@HC*(4:GI)XBN6(QM/&Z$[3RQ&+7(
MGVD:XPQ[]J@'*%W$C!E+^/PB,5CH,0]>W]+I4VY;BIF++3+PU5#I28I9PF(Z
M=@X0O+*:`SF,'?X2."D\GD:&R^+4\8O7L/\(6Y8,)V:@P7`7N/HEBT7'$W[8
MC\6UAJDQC^)ETS@'8/*"+;TJ_AY@=)[!?F+Z0I+Z%PX>+I.]3[)/BCJ7E"WQ
M)8L=7#E)L<LK/UWX(?W5B=T%O>OAD.%HM428V/<5"Q,)++R=I``;_0DP$:U@
M+P@#`(I[!9KE4"S@-]=`($#,*HZ\S,6WY<:4SBW8-=!TN62QBW_`AK#FNC8N
ML?=:J^>V5LQRT^:7%'ZUB`+`8C+Y._/3ZP]1RAZS@W,R.IWT[&X+7IN,3'O<
M:9D#:VR9K4GK=-`;6=/6R>F=.CCE#VM-76H35[7):\<&3J5G\U8=D_BS.7=`
M.*[?[=B_.;A5_Z8*0*W_?3]H.$OL#-"NBA-TU84?F@#G.VS=%/_D^O\==?R)
M7^&^WK5+I+GSAO(;(C+\`93!D@ZB)B@!!&Z6;\JOWVMM`^-->[D?)3Y6^TRM
MMJ*E`1:IIT%EK`*&FM<Q5F`4?1<4TIR1%0#-!(YFO]5JH-T<C;\DI`.E^KR*
M_13;264C*M>6^!AO.!W!GD#?H>(&U>6[C)1^M]EK&:#O8!5XM($J,PM2_!P\
M&X*BHQ(V\Q+4>&()>(_::;_[J/B":S`=;:O91D7(S4?#<*CI%E1QYM)BJ->7
M9%'R[0@=#``[UZ00N,(OD-',00Z2R+C`62EB4Z7].@;H'L^Y!K5-=B.-8`F)
M!+1WJ#?P+Z"&.XUVMYNCKV%<+7RP#F@ZP)`!1*BM`7,2KV05/"-+"%<Y)@`D
M4*,A<^E[:&NXD<BW!C8=OIR\D'VYR3O$.&X&D(4F%?C&#S-&FU&L1.!D(<!3
M:E%VG150A"7"5J%O<O9A`O_R?)>,5`/6AD?ABVAST-(5*Y)Q%:O*[F.QSNC#
MZ3\_?BZMXPNZ7C(/*.A=.J'+RB0IDGW#7Q+C\V3\Y^G$/#L'(&//CR[A"UG@
M@#^3I0`#^@EH%1L$%``'ZURP$&QK`"#&JPB,+*._747Q-\2;:*M&ZJTB8(T;
M+&:=\)(#]\#2JWAAH1_>Q@FCW6%[7]D;\Y,$/<#.H$>\"`_!,IV&U>HWAO!2
ML@!J)B2+*V0R\%NN&^B*.$(\1=]WSK#P;ZD"A12`:O@]CI*$`"B)<2'@I!74
M9;@?6%K&<)91%@I/\%6KV<L]1&2V.V"D:4SO]")@\((VE&^D!%F_.920P3)K
MFZX\J_JY56S`ZPI:JT@]*]1)P_!J^0(7P.W<G2^L-JEXL1&KU1@,K$:[W[LK
M8USQ05-WXHGR"E5VL/:4':Q>P:DW\@,\W-V=(7)D[H=N`H8<91<9!(^XR1QA
MG&SK<:"TH@[L/.6G86R;E!!L'+2UBW_D/)^%?HK,_+I0^J>_?/[RIW(_P/B7
M-XC!A%V24F?@NT37#(#E\1R9&3+A9$&XQD<DKP(78;,,BEM`J+#=&KC9^!2`
MO2Y]$!^#M_$/I>^"<T`G;;9&P&%D`,!EHX6VF0QS/&<^H0*9(Q*RQ4VWD,.*
M8%%P&EZ0<T#*$I%!OS6R5<2MJN,N?,"&C"1E[)Q'E(`EH"F\$H4L$9P)CI`/
M'X45-A[,Z:!M#N$=*>#%(AA+XT+\PU3C3C(P]QX85QXC$YA7P-_&C*%9-N89
M.`8$.#HW"#HY&@LGO&`\%Q&F<13(;^7NV)_XJ,`"_I'!1W%UZ<2"$Y+ZKK_"
MH7:`3OJ@@91-`RYJ#OIZ/`#'2!E_A1^8.[Y,?,`JE/J@,!RV2U3!?PA7T"5_
MGW,HWYU<47Z0X/`]N;8*$[[O)(L&YEG`#:;L0@2.IP=Q<LR(,_,#5;AI<$\Y
MOV*4X:<IHX2!8!1<`\&9^:$C7\75#?)S^$,<0MI>OJLTIPBPE\=PK@YH/L\0
M#(1DX\)+HMJ0#ET!C,Q=*"F:?$V?YT`N0M`0J$`CX<'E#^=\@X]Z#!C50ZTX
M0P><0UO-&,$J(!WRH_4F[V:#1TFB$KP*'Z4H3[2!_5&J&*Y1Q%55H9(R927:
MY4K48Q`!Q&456M9GXZH"A?4`(TO"6U(1N;+F.HG`R\8GQJ`NW#2*%3V+X1N7
MD&?2L^/'T;.PPMK*I'$QWX@$H*SH-8.@`U2L'_'0#=\IJ3P$9%WI[:CRD$(D
MI;F<8\X1`VC!RN+I!E>(DCJJ1KJ=$JQ1@=PUKU&",H8ER?\[\V/^D1EF6SU%
M7TELKB6$=Y'L&X(<S"/8?>%%;!5R3LY]$G,GS)SX>JN8VR#<@WZ7:]@;W!V2
M-A0BE!M.M*V2TVDWNH`V;A`8C^%+\I+;DMT]DQJ_I'`0=O-,RGX)*A?R,94=
MT`:ZV]V2-:<$%KJ=6U(KH2B/.[LEM4[)HTIDO5NB.B455VEGMZ3DE'!9OHU;
MLN:4J,[6;FZ)XI2@QW@GMR1W2A2?X/9N"1>-'\XMF;)9+!56NYH\E@JK.[`;
MMM0J.R@L8?=W,O6*SS-L-7H#N]!=JK7?K(HV*"*BQ$4&M,#")-7Z`!7FC!+9
MA5K9ICJ0G>]@WA62(T?=J#QN4!U".VU7'MM4!VF'S<IC%]6!>G:K\MA)=7`-
M5U4>VY*A&UA'9"*V)[V&G4;+'M`SPWZC,QS(;!=QQ@WYKGJI/3A%]^")YC4O
MCWC\5:O9R1->^.(KJ]DN:C=E;-?K1\X;.VO(]=KVSA7K<J%;G7Z4\2FTR6<_
M^3:%,.`,C^P#>)^1A'>N<V/,1F^M`(J70"/77SI!\NO+SEH-?&"W.I.3WL"T
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MU1>FIJG71K&I7D9!>#1#JY>X#.!K@`I?XAX`(6"2T5;[O'J*BR6),/-B00`7
M8/?*6I,\"ZXZN:7!%B-9X2#;BH5>_!C`GU[AR":"%E5IF085SY7Y&`Q-QR-$
MJ!Q(A>O*VNSF>52X-B^J$U;13,$BZ].H%`S63Z3B74LIE3=R,#!C)>=1@5<$
M2`NP<C[Z=%9T/@'=E>HP8*BH4>-S1=N!&&\%?I3ZKA^Z0>;)V!4M*EA!<@&Y
M@=_:J"4\M>3#>%2:Y(7>&FZBJ/#+3Y8IFF.(82O7+`%G#5>7:`?XE9Z!I&X'
MCG*<K&E\4E%;7B4GLPBA$7R0.P9D9GQ-U<\5>R'/@??2%>`%*MP>SP0CWFF1
M`EAT)X'1T5]!$9?EK@CENJ81#3=T#58.24PKH9_-^]P81S"OU)=Z[XCG1+^;
MZ"L!DBL<<??>MHHQ*YN\,9NE9V&2QAERPRGL?@R,/W%B@`H$[J$,7Z]OC[J=
MUL"<=,8GIMT:CLQ!MS4V)]UI>]#N].S>>,(-'RS2-UN6:0V+K6P'LKPAO&U[
M%'KXGTEQX_9C&?3!=-#NG0PG9G<R[IGVR>G0/!F-1V"&)L/VR0GX*JW^`1IT
M<64YLCG^:"B8/!`33V!390=_4.Y>IV`CG^W'8SN/K:($"PETAA5-*FH!:CN:
M.>$WGJQ+%E&<4IX:EECX%PL0\L"'A3W06Y(W$_Y6##;/#]%8+/'V!FX@A5-1
MU)_R%BH*]0N3Y#G7%"N"P05;\;DH&]->8K9"98[?<@LR5;=IK"!^ON!1Q077
M70PC*AGXEO(">:,8SW2CZS##N)4:B+F"FZ$+@\8]C<&%"41^(V\R0JS"HWY*
MC4I)?A@X3XC<6GWM),=ET?_`4GS\$^A+'^S@R?6?H)[/PH\\`1M>C##DXK2X
M?_#B)Y'=MOI?__PR5F,8<SV(.;'ZPY/N=&Q:)]U3T^[U1^9P,("?QM-3>]H9
MG`X'-NB(-D0QIM7MM[O=5JM5(&+W7=5T+)]1Z,^CWD]4OOE",3_]\2./BR:R
M*>\!L,(S"BI"SCY,US!B=7N=T:C;-J?3\=2TI_V..3J=6*8]''5/>Y-!U[8M
MKC4[@UX)&;??5#7"2YWPP@<WC0_W?<P&[FZ[-^GW.J?FZ?04;-YPTC-'G:%M
MCELGXY.I;8U/!J,?>P1O9\]&\$K>0(<;V>/!^[D?W^X5FP"/$[8@C9THE:7,
M7811$%U`M(3'\I)2<(2&A(;D0F12]!/GQ@R6`(=WG@5@]^9DM:Q><T"U89$*
M!.4?7Z/9X\&C(V+!>XS+]>F$B&CRQ5XI:J[5PW/K3EW<:7ANYQF'YS[ZM_7P
M7#T\]VG7/!P*Z9&Y#ST<Z3PWKIBE(O-Z0]2CYP'<=4*AU>BU[=N#\-SS`)Y#
MDVG*ZLEMZ2\CU\V6&56:,66TC.+4_P_5VX]71^W)`*_7_>YS,_2;H])0^T+7
M=N^YKT?>G:['-HGF>*:'W8B_?=C$WF%-SUQ[5B^MU1CT6X?GI1V"=7MV_[O3
M/8(+*P[=OAW3G+"GM'#'A+=;7UVZ0WFS4B1F%]@.\)FM,!X,+WA]_;&Z97I]
M:])K3Z>F?3)MFW:KU35'8VMLMD9VQ^YWQKU!9V-%]':UG*=LEA$XI$K6[RRZ
M`/6W\%TG@.^=A3B;K8BR][]O1@Z+X,<^J<_-#VD"VXX'?C;TR2]H6$],?`8+
M8+--WE)"_8K8(1LP\026$!..ULJQRO)!53SH,J=F@P0[[9?.-^Q+O%I$6#>D
MS],#D^_,S;#='M;Y.)_[+C[%FP3CX-I@6*W$+N`2Q/R`2Q22]RK2)C.\V_?V
MG?B["%E%+MT%\[*`?9SCQ/V4O<>&QZITER\9?C`I'5JCOCT9#\S3"7:I3$9M
M\Z33:YN3X:#5.^E:TU9WX^"Y)V[BUO5F76_>IV_K>K.N-^MZLZXWZWKS\65%
M#K(JJ?-=QTI976_>/QVU+W5)76\^3KKJ>O.6YW2]>0^S\<>#-5UO?E8O3=>;
MCY6RNMZ\%_;MF.JFNM[\1/7F.Y2I*G4N0(`_]UTG3"%@Q)'QLC[FL^3A2UNM
MSK0U'O6'YM@:]4R[==(V1W9W:/8F]NFD,QJ/.JV[W:ET-$=RVWMU)%=A#Z/@
M#_B^9)&=@7W`$[I/VUWPIYPI-Q$'<@]E`@?-:*5[<YSUP>_KE7RET&[,_=`)
M^3`=>6N<O!,(^RG\%!/>-&C#R9D"[_^!=U9XD8^X`R>XQK]C8<B3=_+\&=+D
MWR]RZ!=-B60Q<!A->/Q]-/K4D&.>$W7H%DX0=[ZQ_%AT(@87.L5\.7%GWWS.
MW%2,A!?=#OPR#!IE1(>RY<N![\S\@&8W-&B>)._5D?,T85?45Y*_HKX@QHF\
M^"D?J$A#,6LPU\@O]JL!""L'[)*%63&2F(\"40:^%CT9<@)X2185E`#L^?RS
MA9_@*#(7QZ)^QQ=IG!=^(X)%8V/N\`GKB#5$9,SX6750GG3HW$FBD%1N,4K5
M]6,W6\+.8*4$H:`):WQ0)1_LD@6>&!XF;Q>)$H5H8G+P;;C2X^.E=N%/W(6+
M,\UHBAOQ)S+4;OR$4SC_RKP+OAA-HJJR%LYEV<Y>G"$9TKS$6[4DYGPAIT\6
M[,?%XD8&;!H?<;8ED-J\B)`YJ#FF.C&WZ*W!EI^2]%2VRX?A83G+Y]C@\\PX
M$T;E<:!B/W(4:"K';(I'7BC3]``B-P#G!/F0+LM2]D_C-@D^P0KY`#+Z/NS`
MC_/6+C6%S9^5;@ZL1'-/^"S=%^5II@W<!T[039WO+"EM2OUX,?V/#P?+[SF`
MUW*:KL&:I`7^0$C\2T=T.2D3B<HS\F8TT:Q,BY*POOAI35Q#^##(?98(R5W7
M>2CW+."3R&DV/JD5*<$-P:XDIG3##XT90E5.?R'&H4$4(!)<IRBL,8LRSN_E
M9I^*-BUQ)BQ0U@TD.F6]P$IZX0Y6<S\F=7T6DO"YD(0#\@_R(9SH*"OC#H4M
M)Q-.,Z`#?TF&.\S$W4M`T;^`8:X6.);2"5B<T-CB*UB(WPL(2_+YDS&[X(,+
ME6?Y0*\50QV>7ALKD-ZEXU[C`#X<LH2+D12B5U\,ZD6I&?LXC6N6H>EJ<.Y'
MUR*+^5VXQ=!&/J@Z9JGC!_(#:+:1S94!B3%!1)?=@NSFPKQ@`-@"69ZF54NP
MFL:G_*F8E>ZCX'-;T+8E;NSSBQKQ]H&8C&?IQD8!(;]KK<9@E3HW2P:Q\!9*
MJG=%K8R%G4.TO#->^TJU`!4'X\-20;DD&8@\P,MP6WR&,ZH1``>O_A(FDGW'
MN37Y`-#RU1'2I5'HT8`OJI_T0"-=LIAZ3XW(Y</,4+'#8^IS@LA<?5SS"=-"
M=5V3KHO%K,G7_F5Y1YQ3^<36N?\=_9XX'\]*$U?OHE<>YX)L5=QH6F7H\CY<
M;J\J%V36N<LT.Y7?YJ&T[0S$-7,8E(&10%[;<#NVF-D=%N:;5'$A]2@)R1:N
MY",U*UW%?*HNI]V+G[AS@+8`^WJ%>D<I!`$MC1*E3Z\)M,+?8OB]"GGNV@IS
MAH*K+IF/KY6W:^)?YSCT&UUG+K@E`14N&(WIE6L3$F"-_)Y`N5>\9B"CVV\*
M@'$&,8UWPI4)4W[H9?#W:V)-\+!]G->;7U(EUQ(W!."H5FR')L"X"R#N-N.*
M#?URB+TW8W3#5%_"E\3DBY\JF\.=5#%?=E+RB\NY&X3HD$BN4S\%7S`:"1K+
M:$A.XITQ[E4`ZJ.`SS/<F42_&#E9Z;H6-6S@35?X#XX/XS6HJN`R'RLOQPE7
M7E8#-@'BFS("Z#Y>OO?*>'L^B7J>;XUCE/N^*#,)IY\,";"7&9Q?G",-BUQ$
MD:=,V<VG-));EP@\%AC.W6UQLTSYFZ5)_'NJZ%`_T,T4(`F)S!D@[_'+@J]+
M/"B\:&$TR&`D?/@V*B?E23F!."DLJ?K1TG&"%W(PYA5$#PM^WD'>H(-.?$4.
M$-OY?&_\.%)&C=%1',M:B:[BD&`WT+?XBR)$(!NP6X)A=G[5!'(<]^&%K18)
M`O*DF/A#(5AK5UY18!(XU_A9P2R`B17G2#E9-.9(4P40%LK@<>*4%W@L)O=+
MD#PTMIJK'/[2-I-:#3"7>#/G#$T`=Z-*7@?$,R[U(!&B\_M,$285J;FNS?73
M&E^478O"05#R'_0-<0DJ[5JN7U%N$B8!D")8.4`E2Y/[K:"V@1@)IPTI`HDS
M!1_@XL47(L0K[4(9]%?A5QD%8=RX80NH)8J[QG/CN1&CKQW54XKQHC0U(N<Z
MBE11A,3&Y`-76#SZA14AP,Q9B@13D;\YPT5>SY1O%.,*+_#BNA#?$V[BBN)B
MNC"*9'=&Z1:!J)GCBOF^.0PY>/#^'PPO[_91N_K+&2@$*3&OW1([T`![CN-\
M\+V*%NY_$"-YM5`C.1,>UHLK!,5MYR1ZJ$7$=6)XG3A>?P=&$NSUDF*5(JD@
M@XB[Z..-Z>X-)<W-=:?-YV!*?8?VSSO$S_8#Q<\4!I\C)V)V(.?%=T6,7!**
M(H4L@J\Z9B6U*CV3C;X-]S?6.7J%8YZ1E5_0M4X%AZ-XBPL0%5G!)_FL><$)
MX$8X,GM:^IZ`N')Y8OG6-%2H(A@5<%=7*3`@+A:`Z++]<[Y[OBNQ&MI5RG]V
M*F.LF\:)JLIJDZPRUY,G)WGN"9UQU;OD<E6CV&";X/>%(J=34(?GV+FNX*8=
MQ9$'#'B=E7"2BFMV2J\*?/,['-9T73FC*JH0B7`,R!0)8T:S_X7_5+P3LWOZ
M3KT]$*;/0I.B\:GHTK'$Y";QRITR[I))-8MK<?^DT.*&`YQ(J1-<668BI5*/
MX@LG%%G9^JS-^<*//1/O]+HV/J$)0)F*N.F4LBN#/?"BY`!@$23PC,GLFGPD
MNA@,[\6(.0.5C`+Q2D/2>OVK&XRN"";7C9*P7@53^BF'4Q'O]:^HG,X%2,ES
M%J6">@NN<&C!O4(,-S'O#KMZ\=-F8RLCS6U;P]0"WQSWB\CCK6:7-A9P5#Y+
MQ16I=3Q1]O!PQ8('3;S")B^3$.`OZ&:7`-A6.)[*T_.,3DG#;BYB9\G75A?W
MBV/AR/`S5.?R6I>-6ZFZI)3(NJQ?M;(F%ZD4-\UYF*&JNG!BC\?%_-([](Z6
M_O>2HWB@JNE3[GI]YJ[7!CVT!<.43RUB?)G-Q2@_"Z,5"RD&$JF"&?Q#ZA*E
M<&H-3,H$B+KI"[I.R`_I8H@$,"W2!"N9-Z,[IYP9"YBWEB_@%&<AKQW5IQDV
MO2S/T%?75&=_TX%Y>=6S7!/D$D/H&6,AZ=406)Q7TS%R<U9)%M`J2^629`Y'
M@N1C*Y%(?(&W2H49QJ(<.R`:=%54=?IXX73(^)L\"W`]YNSJ13Z%0%SVH\`N
M`F`>J)8S2Z.;3X579Q6H?@C>4.4QB#Y]"#5A&7'EU;6:A1$._GWN%Q3781*C
M(-8X/E6PZ"HJ7MF@=)78?24'Y]`U1WDXK*2RI7(N!9P\,$$R.%S_\@P/ILFJ
M8?`LJ\::^+$M'ZK]3''K"'<\E01J'O7*]^AZ)5A[3K:!AS8$O9*?,\J73,ZN
ME?Q68??XA=TY,Y9<;;S$-&2!*"E('7DMZNL)I[/R170.`""T?6>A*%GBBPF5
M(Y,$34"9*+2/DL%"W[TH['@55YUV475S7Q=1WA5CWRCU4'1FT*7UQ=.J8E-R
MA&NIOZK3+Z^A$E"5DKN@QR[]Q)=EDC"_:KD6FTKMJ931@O652^/$K;:2W];+
M946_2%X$>R-J.!M,WR:<DB7D'T#,YY]8L\X45VVAC,.YY,5/@D_4YV,AM\(%
MY?"O,GZ57U*NSN%[#>'EU5CH1L6\*_TT,LEOE!V)W*1+0Q63*T9!GK_T`R>6
MVV9`*UQ("!JY:*\KQ:VZ&R`,V$4PSZ]_D((+V[I$KYQX,EGXJY6HF!6)?$K!
MYW^KR;`1!.6R''?=L(SO7,0L;[-)^0P:6(.JPKP`)$.Y%S\I3(Y0"S\(Z+:E
MJ%DR&`?J\WP4J>*S/('TKI*B*1Y3LTQYWC4??#/G=8>(<%G--N79`#<"!QIP
M#()\P25/^/N%[)!^J=2PBEHC919X=36O?>/H'O*\W$A<E,D3@JJ/@,^`'&&<
M@%<KIR+>0,6%6B9=AXQK6O+%FYO=O_4-B9?XY8JI-.*DI_">/I[%SV^+3I4$
M7'EE4M)JLUG10(97`6,)3VA5Q1^J+"%#49X=QZ8(E#5L89C[&)=@_W$LY$!F
M7?(;P7FVIR@YT:ZXT*FJLU`@$ET%+54MDG=.%(IT3:.4<S>EN+"X`Q41CEY=
M@?*\<"7J^T!2Y%2'WS*>\XF,&D52B%.EH(0T]04%%6N4WZU*-M9QW1A4C$S"
M;>;J2@JI+JR69=O=`NNUL)I4>&U@?1.C2AA%QIBC@UQ\"JO)[V?H66V<?-2I
M%""]OS)^:9"*HQLPE/MOI?:RDF$BFA32(&XFEPOD5,W9A<#GUW92U8M?Z,U[
M!,25I-3W`Q+*-106]2KQ%#4TD&4(085Z<791X<Z<QV5FM:XPA_Y/27)5%1KQ
MP([?,:_XYB507FQL,JUV7RBFM<2XH6C/+.>N'&I8\7SL5KD$[T9ZY*K7O.;!
MDFK@GVL:7S)J^<CW@UX9T#&XSDL0J`R5&UE);_BI`K+BTRG0$SZX]2TAD_Q_
MT4NB<%\U(5N+;.$RYA>OERV[O+N>2E6H_:)"Q&BB&Q#;C+GW7?0=RG(L=2-&
M:1I0:T112$7\U`'3I%Q2O9[#AJ8@*#:S$6&HQPL\;:Q.^V$)8YQ(HJ.!#.U:
M=TC!?5OBSCVKW//):Z0J')Z(3;(E((,N%G;X58?7=->T0K**EE6::;F-DQ=,
MNT":"WX]MI?G;9Q95-P]?=NH_4>9#T='E&X_(*YU^P%QW>>;#Z<_?6R?UO/X
M:J:]/<IT-ZJLT[]BXZT`NJBR;VL_?_;S\L\Y>>]1:"$+LQ5R*$7:RE_`=A4[
MSVNWFFA/2311LJI01I2O#I`41T$42I952%+DUPZ0*@=,B_,H=8)G1?EV;V+!
ML%#\Z\O!9I>W>*1`EWV$CQ_>*-6<RTZ<@`>.:9&A*!A$Y,JV<>&QS#)\WJE`
M18;,?AAD/-J\H/W3_)K2FM*:TOM&:4WS'X_FFM*'1^G'G:O=N;>G^@F+E0DO
MN\H#F@"%Z+21#82\6"U&B%#_U_%ZJGLRG;G=&'2>>SSSD4XHW1L*V]9`4_B(
M*=QO_RCD_<$)W6ZTM"@?-87[C8[=/SP*/W7J]/X.Z2F-MTC>BK/`.&O-DVV[
MVBM];C%X;36&7>N9Y4#?!O,XE+4'^IZ?(Z3LL:12M,*^FU@/.L]]'X86Z\>@
M;+?1?O8[;/0%7H=_%96^P$MC;6^PIO&GN>[1+]NKAW;?VL6VG!.B3<UR<WB<
M&0^)E%?;=ON4<90$:#`8W`>DAXV>)%`;*78W*/?0[=Y;?AAV;,T/FA]R@$39
M[T=G!\T858"LP5;+_<-PAN8'#E"[T>KWCXPCCBW/<TP7LCYE]*CQIO&F)59S
MWO/@[2[W\VX:0_.@-Q8\_92;ZC0;Y:Z74@.-5YXU^^*GTMP:/;7FUY?]WEV&
MUG1N/[3&LI]OB,KC?UM/4:DYXU[QY!_GS'N]#!?_N"FU_.RAWP]$J]K1BB52
MW2?+=']2'=ZA_$]E0_A"'8^YW60=<C;L>8_Q6;U&VW[N]J.C/P6ACVKN_U'-
M^^NOL?34UR[(.U[MM2>]=E:C9QW@Z0]-:ZW.CB81?SSM2!I_#]O.==O0X^`5
M9;"O!4VKWQCT=/>#C@6T\=POXWE,M1V-P8<UH/>KCMU3(L_PZOGPKRSD]VO(
M:U5?;+C<1&3L^-T^>?7*"<JW)_(+.AJ5ZP7Q<I\PD5>).2L_!;K\1]Q+YR1)
MY/KYW>FXWD44>7C7,[_+!RML\"]ORXV,-]7(7ORDJV2;JF1;JDZZ2J:K9+I*
MIFFEJV1/D64^5:T?W:3ZXJ?<=&ZW63ILNOMTH8'0*7L1&^V-(CHB$A]K9+QO
M^FOJAW@YLB<46'Y[+T`B+JGFMR/K65&/S?$]^[D'11V]2ML32A^K;COTK-_Q
ME'PT_G3)[$$J07M7,ALT[*X^/KY/YN(.<<*&7(>VK<=K6X^I'J0Q^+#V=<>*
MVF!3.:<4$K=_5O=W7[4./_CRAPQ_.'62Q0NZL]7`'XW)WYD/Z&7RQM8L%[K\
MO5TF#]7NN/<H)40"F]?TX`=6P`^@N%&8^#RAB7]M&!Y;18F?)CP9X*3PZR#@
M9<>9$WY+:*%D$<6ID;)XB5D#4.+!M1'XL+!G^&&2QAF?3$UOQ6SI^"'6!)=.
MFL5^BM?!P[I8(?2<E,&G89%5%KL+)\%_&<-6P4F><YT846P$+$F:QF<&B_LN
M%2%Q+S%;X5WS^"VW(%-UF\8J8-X%W=QB7&1.[(0IPV-^8H(V[9W%J4,%2)')
M!>`7OKL`F*^-&8-=T6AMC^ZMGV6)'P(\1AH[ERPPLM!C,6`R7D4Q;`BQ2C.Z
M`9#82_*L"ENN@NB:L:1Y!\[8#UDXD\FB`^%\//LIJ]M)BI<T`PPRXZ7P81!=
M`061#RBY'P/9XV\L136:L:9!*7\?W_48,CU0'RCJ8*D<R^QNFCD!?Q4Y@Q>_
M@3-BYX+Q7R]9NHB\IC%"#G/D-=VPI`$,#:J0)^2N%BR$+X?P&O%E_C'@M`5*
M8LZDZA:00\,H12[%$>^H6)O&V;Q(['$0V'>7,>!&Y&\4(%A%W:3AP?\'^8AF
M$%ZQQ&4`'R@#9XE[`(3\G8'4<-GU0UH,^)\D5RX(X`+L'C45Y$B_\D%Y8$]"
M#+K$0%F-+VE8O6@]\/SYG,7X,8`_O6(LY-"B&)=IH)(2%F3^)7QR.AXA0E>K
M.(+':-U_.P#\RD'"_"L+E+M$VSUJ-&C3VLX<4,NQZG&1G;$+)RRZ'I",!0:E
M=L(MYUC.^RGF<;3,P<!)^]EJ%?@L!H7U)R`M@"\:HT]G^>^1[O+A!K*#!!H6
MP>?DUSQ:&5X#/:2^"\HHR+"=PH%U`%_+511R/?;B)\*Q`^^+[@_03]&*N$DH
M-H`)'C>2#^-1@3C8%7-<TI^>1\TC\$OYR3)%B[Z0!)Z8):!G<76)=H!?T>9)
MW0X<)>G<-#ZIJ"VODI,9MY(WI\P8D)GQ-6-VD04.D4CN)4$,@3R\^$D!+U#A
M1IPC"P0!7Z0`UH%U_^8&`D5<F!,4KBP1NA^PO62QZTO\7(/V1Q+32BGH(MP>
MXHL0S&]EH'_*W1//<<X1G35(<H4C#MDZI$YXX:-HC)*$I0TC9.F!6`H%=@=A
M3Z1G!*``8SK&T@>UF(*@&=)M6#D^N10I#1B(@2W`+P(66D0!^`/$S^^=[YY#
M\P;>^TL?E61QB1R]UVZU;#`@X*LDO&<+7HJRV*#`.,&GA$@T8`WND?B<OT#.
MLR!5A8:+"W>T4'/B3R75R%7NW(_1FH6>[SIYFQCRWQ)\.FKW`BX$/9.2<?*7
M!"[P_SP+P,>;@S4@(P8HCAV$T@RPS0NLH9^4M30@4.@IXOF,.W<<B/++W#P:
M5XZ0@E6,C692DI;.7V#ITFOIHQIS[#1#&$!<<^L#J`(+>,%"%A/$\+^@I*_Y
M9G"9VLWD(@ZJ\B)V/$<2`=\H/B960?$&3(E;5H)K>COU77^%ZS:-+^!6?H@`
M\KZ:E`!\`.VY1TQ11(3J!2!UT9IR%3'/8JRY`5F0DS@4H-S`?T0J4CT.3#/$
M=/2GI,)&"$>9AP3C2;8[7)V2G^G[K)SDVW]UDH-=#!61D0J:1^$X)`M_Q?D"
MZ#CV,;:996#-B"N$N*NV=^$(_S7RI?$HO07_(6NE3#"1WY\QUT$)Y-PB`4")
MXR]`Z**H)?E!^//"(94R0]<,=@"Z3;%J8#HA6B2YGH.GAP_B-MW87W$^16Z,
MA<E^L75B[^&RZ&?5XQHK'A>&#8>2(R@I;K!B%Q0J;70FT4DGKHU6J&^)UN37
M\3"9(G5Z4RC8&D>4NUOHO<8^15)SL6H>:T/,7&Y0AL@#/H<:$CEM(W`0D($=
MQ%BE0>*"5@A?`,?=04\Q1"<R9',P<;\`IB+WF\F#.00&0./J5X")M`B<&4;V
MZ&8*/XYK<JZ7/1_DK=C6+VCXP+Q15(BF#D(>$->DH4#B@JB`^0T,D%TGH+56
M@/2EX[(LI3\H^Z$L39+2PE7G$QWIA&P+(@=MMA=GL#ZLZ&-@`R_!CX2%>>Q@
M9@;`BGE46H)H[KA^P.,[3@6.5)!F;/KV(R4U`M%EF,<)C9MX1`0K@I+\=THO
MNMA'[NJ+>$$$4#PD%JX^/+%"9'"V*)@")SCYZ-Y$=?&`XG.(51]6TSSJZ*NG
M561?&*GPAO$[>5&<+T?>$AN&4I3R2RZ,!ZW5^#UXJ!@NE%TZI5W>J-[(E`ED
MW;B,E`#)^\B*J(E0/Z$<@-^YY/)6$=*0898%59;PWN6W>-Z6Y$>XJK5G062>
M4I5S'G18'5HBUR:!DX4@8THP00/+F/%G2%'+%\J=Y6``G<X^3$BKR"@"E4*1
ME5@Y,8&6W(RD7"F`'%\Y,<;>IO1NA<+A2B&,0I,\<B!D>,'S4'/'1U>$9[`$
M*B#V\B\Y_@/?F:%6NU9/KU!26GP)OYIDC"M(XZ.;1N";8%`V1.*+H"Z:ST%_
M\X!NA$/CPB(2XZDMVC3':&$_`.<1Q`NOQ2;>'*Z#<T8[@=7/G>_L4$0_]\!3
MY[L,Z;DIE%SA"Q=$\98E@\\S$D!\%=,`E$1RF1#>(F>9Y$E+'B[&\34%W<LH
MD\$>+C&3Z2T.AG")2F"@,\%5#;P?1$G"5S,!H"LJ(N3N!KZ=<I<?7N3Y9A8Z
MKHAY65(-B3%="P"CM[\@2,%AK^P"@X08#?N_09!$4D`FJ3F.T);ZQ.<7#E9X
M*!6^CF`*]/%Y#"J6F*8+_&\L0(/MA/1+@HD\2YZ+NY-4/,Y).]58B/U*'SB^
M%-IO!=$]1.^@R?+K5U'M``9@8Y>@&Z(LX0C)`-&\V(49)/`2(Y:4@S/.&\(1
M52-ZT,4\TX]/8+06\<!>=3I);V'"15T#(=SR<LR4HD5>7<A3'L`>M+2C`H:!
MGO,-^*;J=7%O$Y^$R`^8D*ITQ<=`-RKTIW!1Y8"<_GA\,,F6W#2):LP2&)QR
M(0;(72*./08!)>D!;)<8,=\)@<'<!7>H06'#+TJ)J))1)(P$ODM^(WF,5)OP
M\<P-$X4'T-=.($L=%.8B-R0(!P]]A6I/41T>KEH?%X;RK"C:'HQZSX&?`P^'
MZ,9LT.W</J?D+'!7H<&=`%)E7!>#QF4\I>B31J54?]G/$%Z&8BT$=U!A<9D7
M8%27,:6RBKR.F858X_,#4;Q0*^4.I4>B+(7%0G34J(17#G-0X'F&F3C7\Q/N
MTHKP)G=V&E4W*$>0XA`!]\,3I4FWPB7$XA#&Q,)7R\M!F.XV_;Q$5C6=42C@
M0$"INDG^&&:'.,Q<)G/'"U\GC'K"B&'UZR1P(!C_XBZP!@F8)-F'Z,ZEK';D
ML4#6*>E\L4-6.@_P"H3R;P41:A50<K#5&2I>CRWYDG/&7P4LK,$`PCX36#*O
M&":IX<_\VRCWO,C/L^QYI5;FEF4ZMS`3G(F052@K$`6\^`3:5.I?Z94K/$9\
MQ(D(<!.OXDOX`[`(=S:JZQ9**L]Y[)5U%>R,>R:;*1F!FP9,7_B(,,H%_)WY
M,;&U?$H8#3<`8^'/?5GZ+'B<ZAKK7$YGM'>4!UYP++Z`F*:\9O5A;A@`(H03
M8XN4;%`Y%@F+XG+3&'&:.9A_</FY<I:F@:CRPR,0H:TS,9<1_B0I&RY'C;*S
MJ<8^6"-2Y:LJX=BP$B;2;5,W`"\#]Y6V0+_-MW`NZR'`9KR1H)RR8=\QE$RD
MCUP"(U?"Q*TW:AC40US''*YM?0\&!?4`N#%?D&H'8E5/G,1WL6K+8Y"5+&FN
M-[^`_O+!0T8.S!\7+F*N-&4+C+!9Q!@E^BOV3IT;P<UETQC[08;KJ/!@\D1`
MM`L\GEA"PH0FO@*5:G/'E<<K#Y.*F`<02_'*)*V.&H4'6"3%8*L;E."4)B"X
MSI]3]B]$F1P!)ZF@955X^[D@@7/K9A0BP"I%FU$*CG2286*:7A655.J"BT(`
M/J62-OC=>;#(]43A%)_^XL]-\3#SBM^/?\G;ELY"09.\I4^4BP#5A<<C(E?<
M%O96W+PEKJ)`"WJBD&KF".7M%*A^9IM8DM+-!8>@!U1Y`,O#?V>'K$;&8/]A
M[4-TSV=IC8.K&ODMCKD;92O*H!5!&7((;U#(XU5RCG)O$]UAGG;9XJ'S9HYJ
M4E=\168;MWKM-1;Z-EX[)5X4OWW=:X<]%87^YW#3]\=EW!+#L^_<`78*[89^
M,*8]'*'Y*%X7(42>KRW\.V2H1'A`W+TI.>!EXI2:[')"E7B!:NG`T!FEWL@G
MPN<$QQ=N$T9NTFX5U?C\;^#E8NK-59N$UO;#X<5"NN<QSA#5'5.;H`=>6;6F
M7RX1Y"R$;CB8DI2[UL(QY,P"*IA?NILL&!.A5=T'D2R7E$"4*2;LI8.M@KA3
M>U!Y[V`K?60*[!!=,IX]Y+W3/CSB.P(;`I2"<&+SO`,58L,0VV\"D72MA$YY
M\T^MNUP.AXO^)Q+3-;60KT41I<(&AR$Q<A`,[X$E[(C0!N/>BY@Q4;0E*4JH
M6U?&RQA=B8@YC?V+"X;Q`ZEH1P:B5+T7`2Z7MH634-<(DK0<MX4YZRI1V089
M)+<SC]Q0QI22"P<RXY/19"=>S0JH(#!ARWNCZ[Y3%)]JZT>D+_$D`SE;W&J1
MC>">$/6]D+60!JPN=?3BIQN21XIAXE!*FU;LF5B3<A_*EA"V&1.5AYR'-W,P
M+J'P<`D[NC9>[XE->6C\;\DRTSPM<'C.V89"!W(;N-`BI5;D/8KBV89DB*SZ
M4.`>QW[5JRMR]3R9[KN,OW,597@TAN6Y!`QMJ#L=>Q>Q8!;RKU-M0;;;BAP&
M"+^BO[&-U:!1?+S:@`\Y7#'(&ITX3X"U:6K9)/]-5!RX7`L7D3(>!9=.BXTH
MSR7R:)"BW-1]<H>5FR3L1/^+\:ZD]5HT=Q-6&>\XR-$FNVZXE"9,I8.*_2(6
M5&XY6X`^QX@(VW&2NTQ2?"0#]1X!,BRU/?:,;YWS3Q8ZWE]9@KCY.XM2NLL!
MFZ>(P"XI94Y&7NP"S@UYOY1`#F5?UWBSTD/)DW&"<P#ECDN^!'\0WE>H+'AA
MS_#77L=?D?2M(`[1E/A+/W#B31R4X_:%/!,$(?SZ*@6RUY=<P[L?YH0J%87Y
MAQJ2X7DQ$VN#\'[YD_EKT0P+L&3H9'T^5PJ%!GCM-UFSH3IN5`UO&-<^GK]S
M,ZSA-@R6NLTWHMF&BYS\#-E]4D&Y4PF.*SGR=.XCCB/J`N39)@4HH5>`4QSX
M"WGC,55S?=[]RO<(3`5>U6OQ<&DY#LG=&D0>D\TZ*IO]&19;)BP7V!,YL<U1
M1E$>R5TRJOJ*I!`M4J>=N7W`MF6_*`/E].=U]9P#%(VM&CC1D9@()2K@KFCJ
M&:,C$47OO7/I`'O#5M7>*<SR1U<A47J/B'5>>\%E?C"VM*V9K!_5TFESFPQ1
M;MOT7M[[7#-K$E:BB".7,]6'5MWPD+QY;+"C?G,*&&7O*G69L:3JX"]\\)=C
M=W$M7=G<;HJ.`.P?J/009Q!P2@^Y"$8IWUBL?+2SAWN#.\P>[@YO/WNX]WRC
MAW_,3V^Y1?71/Z%',5?'^UKVD\Y>YDKV>8<NWX,)[HR-/$X_"_&`9H#NQ&ZA
M]Z$QU%/-BSZ/4B=X5C[2Q,B)06YXL35+TV4OZ?*\$]0U73;19;_LX?Y/ML_Q
M2-,;WFW#WOY-@GZNY_2N]*Z>XKE]'RLOQN0I8]?4[.$R"MFUS`@?@CIYLLFH
M#S@)U;(Z37V5O":Q)O$AD_A8YAEKFO]X--<SK)_OBS6/:PQJ#&H,'A4&MX>!
M"SJW].O+P68M6CQ2Y.?L0WC\@/-I[XM6"IU5T[O2N]J;7>U[5NU_U@XEO%`F
M/1R"!CG$<*PS;/9N#X!.LAP.A8\EX-8TUS37-#\V37YXH<[[*+PPZT8MO<B/
MCFIGY7%8O-]L'QZ':P)KNZ5IKFFN:7[@BGS?$RC3*&8`@KBSQ^7',_GU#+H/
MZ9$8N=6T#X^1-8&U==(TUS37-#]P1:Y[D/:W>T%C4&-08_#0,5C6L&]I6D4=
M5'HZQIIQ?/XY$3_FI_5TC(=S</=X.L:V"42TEUF^JX=&X.V<TD<)&?1P##T<
MX\<AAAZ.<1!TT<,Q]I,N>CB&'HZA6\/UKHYB5_M>A=;#,2Z>NY91AX">W;1N
M#]1S%S@TU375-=5UK5K3_!AIKLO7^UOXTAC4&-08/'0,ZA$:!YAUDR,TKG7F
M3>]*[VIO=K7OF3<]0&/7[SUD,-:UF\/;`Z!3+(=#X6,)MS7--<TUS8]-DQ]>
MH*,':#P;BUOV(<Z(T136ADO37--<T_S0-;FN^.UOK4!C4&-08_#0,7B7`ZMX
M&+7NQ.H][</Y@AFN$\?7>,F]LXRR,$V,:`Z0N$ZR:-#_JGVB#<-Q7?Y4S%P&
MOP;8E5^NG&LZ#NN$'JP!OXXSYN4);A\`<5:K./KN+YV4*3?<&S/F.EG"X-M&
MNF!^#&\GBRA.>1`:4L39W!YRUN-ML.FD;REB;O^L\L4]BX/X0WZH+<,?9-I_
MG*?]C?>EI'^6[^C&TW`W;KGW*)PR0NAKCC/2848\U`AD4PG*"6E<K14\BG('
M_#&!/R"%_9`APZ01,(+Q"K,\\HR@D27(F[C62>"XW\PO[B(*`,Z(\A'T-8=^
M6D8>"Y#K5JO@6KXSCX(@NB+N3I*,YS"2=\9K_TVQB]A/OIGSF#$C1JXD]F\U
MV]V?&_!<Z4&V=/R0ED:NA"U:S8%QS9PXH4?59\,(5O'\2]]CH6=<^RSP\)E+
MY9'+*`#("1.PU+#[,XJ-\5I]!+>0I)'[#19;Q;X+T(6T+X]#:BR9DX!H+$$X
M[R0>CZ-6@%GJ;X:G>^$?F%MPJ.ZS<XNU$[.TB%EJ>"7G%%AL%U[!SVUFEIQ5
M!*)KF25_#6W`JXZ"0S]T8WB2P0\YG6"E6DH5Y/&R6*(Q72!ZEL`ZB\2`31&U
MMC`$D1;L2701`A-Y@/P*SAT$L",!Q))IE"0H"N[""2\(T'5F*@A0QTY(>D1@
MB1"O6L57<%$W6JY8F'".8=_Q9V22N/@NYD-+7Q:(20P?.`CV`DP*+RQ9;+#E
M*HBN&4N:!J'<ZC8[\+K\G,?6L;X;S@658:MEI-\2Y;!,%>D0P5HY@!>`S1MP
M#DMLQWH=SJUF6\$YNAXJUH$9HV4%Z3>B'*FRAO23*%WD/HX3XT)ND"&>!,9=
M$'8\'0G2@@R;I/`#R@I^(UJQF`!*")1:?&]G\HK$57'G)W(?:D<`;$G1>3MK
M-V0KU&^$;E@"WH@9P`WZ`1#K$TV`,3E"$[E_?N1'*`_NP975#CYT"L1QPNLB
MGS7\)4&*`2*$\@$4`Y`1?I.DPTVC.%%V?\:_QBX%:AUC<;W"QU/?=0+#:OU<
MU4"X'16V74!9`(43X_6K7G/8-6:PEE?H0_AEI[W[DF);Z7;ZOD'9N%KX[H)6
MVO*DT*6<OU$.";P&O582^'HS&&4!DF;A7+(<49XQNP:_"0R,D"0%WU\R`"G'
M*+W.7YXQ%I+$S@/FIJ0$@!B[J-:"4VM!%/RT`9F%5,'[A5PUC2\0IOES8`+X
MHX072"@58_*&+^PCPZZRE"L+/R$614S2SH#J68!_@ZTDQ8+!M;'P+X`EC==@
MX5G\1MD5F@(\17MO9VICK+$A=[8YI+S=T**G#&6P,@AKGZ-/,\;:X.>\-FA,
ME<K@_D<TYQM8%""1D0X%-\;<#YW0):_P`AP;8MXK'XS)B1]]`CVS=$#:7=BX
MQS$RS4AWGIT9_XP"'.J4&*?.-7R_8;QO?FH88#_R-QLT_Q<L)HI>79D55`KH
M[MEUP\A6$3*UD$N01)H<'`4-5=B$%,RX*8;`/>8^"`3F:,YS_=`PP&[`-^&-
M5<PN_2A+0$1BMG)\3QC)AN'/A<)<^Z81N;!ATA.PFQFW+1OC0_+XX3D5(/P4
M@M3="204T1RH#2`)@\(!<^8IF9_-,'$O3*)-,;*D86I)P0,.!UQ!6-)#SZ%0
M?PVA^^%=3*CXJ$[3LNLLC+$;@+8!M<05+LU!,#HU7M_"!]48NPMT\Q@/=_`)
MD251=)N1A=$L83$E8[AN3#9Z&T@)CL&:39`U`B/L9@$Z0<+?<"CXC&9"O9M7
MU.,-?^8^!GIH\2I"-0X/`YL[%UQ&6))2GH=<)EPC2N'7/MCXPK;D/(S(F15T
MR",RU?;(<`:%C`007\(?(K`&"E,4ZR+<EWXB'$GR]IJHO7`5?SYG.(0;#6%Z
M!;:0QRY7D?+1I##%^$TG(9-7L`HQ1+VW7H/>IC%*M_%DN[%AK3*%ZF!`5[U7
M2!(B1@6;+X<8%OZU$W,7'?Y,7G/">0H6<&+^0(C9.L)R*2K`[XH4H42;W1S0
M!P<BODVJH;`;D>Z*B1?@._+%3K/ULXC#+*LI\Q_EV%AX:104EUZV6LT^?Z/=
MAY^0K#>D'>Z.W'X1HFS#;8%96N76N"VG#"I8[C2[]&F[:=\.R\/F,,=R^PY8
MM@66N\W!SU)XI-I4(T@1(,Z!%P%$&='AJX"_XA>Y%[[9P:2@I\:OE)$7Y1?$
MEFX5]3;(*B8K<'=AY>#Z<#/*\B*!4W&1P('X7*,@,))LEOB>#W("SZ$UXQ'>
MGZ&/-N5+2OSKX=S,&`TD"6T6NFB+T72(#3>-/Z*0I4Y\S9WW1/"#6FOP6!B!
M'),IHX!@7KE^@=(`Z/"3WX]>AA^"R->!DJ`YAV#%CSP3,[KLN^!?DC>4BP]1
M:"[+,*U!)%V#6FAP!R5XMD'#37,N[!(<,M7LTH$/PI_!=X10&.,_`0\(D`H.
M!$(@<C/T/S$^C@D!!([']9S(>?%\R04+P2,)R"G+02S#`0ODB*F%H[2@_%;3
M^)U[P.0W8P"*/D,<+64>KXC+UA(WE&<P7HMUW_`=1$OPQX`2=9F=(@)-RHF=
MIC$E#*00VB:.RY,]@+4T0"->9#<Q8PQ^%_I:G!\:I/D$L0EX0<DM<-X$I9I_
M6H-3U<`<!,R<`%VRA#M;R%8J*>!7$+)[Q5TC:-@6S(,_.01[JN:"%%Z*I?L&
MOT?W.@+67F7@E%)H7I&O*C^#NY.0NZGD(J1N-LI66>YF`?8'+`3+UU)@J6Y"
MN(!&&`G5P",$LD`V&$N9"=D="G`C`>DAAFP[`5!KI!8.VD(D:]FLO0)+6J1[
MRT3,&85L'SY9V$\,#-%I`*S(I,DFRUD##Y5<0X4#.7'4)",]LM5SVJ/*TGG)
M<:BK3HAHW<'`)$GCC$L0H-5)1'TG`>^'.R$08@)RDC?O[K#!@Q@A/6SK$=+Z
MTW?ZO9X3_5RC,3^Z:81Z>+/[/HN-M_>(+BK?:[=:PR?[6!WQ1'M,LI&P&X*8
M!V"@9UGS<%@1\]G/RAI%=:'X7=64/@5L:FE#<^,S<:-(>CP9T2?"]W]6"3B5
M,=N1:,>CY,S:_=7\1"/[ZRFY;]35<XD.Y[ANSH<G3N!@18N:5?[EA)D37Q<4
M%U6F;6QU+&=X<XR\NH<0/>@!0`F0U>XTK';W/F`][!&QK3ILG^W+\?#$3J=#
M]Y59-(MH%GE6%M',\F/8&'TR>7_/--Z(P;W8A<;;#X,WC<$;,*CC^^V5K><<
MOE5W`D.M<=<U'JP;SZ.)Y>_^X8?TKGJ#1F]P@`-=#B+NV@\2[Q1D[07Q-<DU
MR;5*_U%5^N%5*$XWG*1_L;F;<>-)>G@G/]:MO9Y'%I%.H]7I'YZ$/*T%?*[G
M?I2]:!D\1!G<]SC['`]ZS%F<\(DA>#A9A]&/SLROK5:G,1ATGYF?W^RI*3EH
MVO[8P90F^0]'\A^<^`>GRX^MA%STP-9PQ6/4H^[\P9K'GZT0JK&FL:9E]>[X
MTZ7CPTF\XILS_*'4&K[YL+?N#G\6+UH"-&PUAKW.?:#:P\:]@PBG]I8E=.>O
M9A'-(MK$:!/S`P7VQ]1IJGN<-=[V"F\:@S=@\"XW5!WQ/*R!GH>E/ZWG83W7
M<`T]#^M0(NJCGT"DYV'I>5C[PXUZ'M81:,>CY,S:_=7\I.=A'<#CQU+TW#`/
M:VLJ5%<\'SL=W;4;@ZY]'ZCV,!VMRUGW&E]C-[K]OF8)S1)5U.L*IS8I-P/4
M&S;LCK77+*$KG,=4+]&5.HVWO<*;QN`-&-31_/8ZUO/%[J_Q+K@WZ]>0O_AI
MI]NNUJWHT83P^W+FRVZT^L]]'%T?WWT,TO8;'4W98Z1L9_C<9S0?08%J]5PG
MPVVKT>H.#T:(#Z^X4!IEQ:]QU9.L#D$RK(;5/QS!>%KK]ES/_2A[T;)W2+*W
M[S&RGESU'$R\4PUJ+SSL?;(LFN2:Y)KDAT)R3?RC(/ZQ%8N/9W;.4Y8\-=8T
MUK2LWAU_NDA\.%E9?'.&/^PXYTIW?3^+?R4!Z@P;W>'@/E#M88O>0419>\L2
M_4:[U=(<H3E"41+'=H6M-A\/`Y#=;UA#/<-JOX/V8^H7U9W*&F][A3>-P1LP
M>)<95M9@ER%6.\VPNMV,K%(PW/Y91=]]+1+\X,L?,OSA"[M8,EC3"3WC=Q9=
M@/E;^*X3P/?.0NQ+HLXFVE"6FY-\B5U"YMJ]]^KW?D_+.XUB(UTP^/\Q8[2E
MT`\9P+&$Y1:)P4*/>=O2`/0.SKUNT#K8W.6$U\;"26"1F*VB.(4%_#0Q9ED"
M2R>)X<#_`R#"BX"))^!G(^%H;1KG"_R^6*@H*`Q_20QWX3-L7'?]!)O'ELXW
M%C>,JT5D^`G_/#TP^<[<#!O;89V/\[GOXE,QN\@")PZN#8:-94[*DA+$L)YC
MN%%(F3#XJP<OSYS$3YIW(-9F07A*3OW,<"H%K#YRW2@+"<V?XBB$GUV&R$X.
MA4OC:&FD\`2V_N%_&T;(K@`.I]C8JK0QPXF9;!><71.AIW[HA*[O!`HZ,,65
M`@<[L9<8)Q'\IV&`1$Q'7TX:Q-FXC.-%J[181S(,L'$TQ]_`(LD*>'+NPT-L
M/F<N':I`)B)NSM^8L<!GE\1W3DIK^?`'-X5U2%B06L"?$NPL!2\[-:Y9FH.P
M>;]7?H`:"%]8./!U!Z0C93%N5WXD++&W,<_QL8H2'W56@Z!(LB"EK44K%I,N
M2S@N7"=9&/,@NDH(25Y$7W-6*X`9Z;)9;HN5;A"FMYY_B?_\Q]LL,2\<9_7N
M"UA%P*SKA&E!MD^P"==GR3G[GIX$D?OM-WC?^(=\9YR?;$GHR>O\.<1`"O_X
MS.:_OF11\/73Q.X-.P/3-*V.U3+_N]6R6E^_G(^_MON=KZC?6L-.ZVOKI>%[
MO[[TO:_M[K`_M*ROXTG7[O>[0W,T')Z8]F0Z,D?CULBTQJ>MD];0&IZTIE\M
M>/$WW);8U?YKC`)S8,N2-,X.24LHP.>\#5`HAYM(G$'.<.XE"%.J]!F#&?'3
MA7'A^&%"W(X'J!@:,2?VT5AAR['H4$XJ+<JX(G#I?]#0A23720HB1EX"B7;!
M__A1YK@+`W[C1Q[:5[!?/H[KS."W?H%TA!5?S=($-11`T#3.YB4-1(HB,9(%
M/(JM;(;G)P!A?,&$,,JM7W/C[-4@J'@&;2@\4>P%O@IKN-$2?`'8$8H/J43/
M(VV!BL/Q/1.V[#HK/X5_2_2*!:)0P(&`4E&!%&:4,`$S5X]Y>S>^3ACUC(Q0
M[L"[)X'C?C._N(LH8*A)J&U\%?LXJA2\%(\%AI<QH8",D,:J%8JY0"C_5A#!
M6Z`7E[#560K`RG%PQIQ/9$,LK,$`NG8FL&1>41D(_LR_C0WL,?@P#BEEX$GG
M@A.>)6"HR,O@S>VK*(5?(\:+-G?41G$4</4*YL5C")H?XE*XFU(;/*S!B0AP
M$Z_B2_@#L`C]96U=A/N27"7"A!MDP/9W<F?:CR*P@IUQSXG:YT\[!4$!1"#"
MP+S$V*(9$UO+IY#B,]ATX"0)-[WD5Q8\#JO4<3G-OMU1'KA5+KZ`F`8XUQ_V
M22<`1+R5%*4<75ZD'ZPA*!CR77&_8,1IAM83C!O-ZV5I&G#>P4<:AK_.Q%Q&
M^).D;+@<\>VX@)AK9)W\X`1_O21?50DW4M$+&_.#%<4&X&7@OM(6Z+?Y%L[I
MF^`3`)NYC($'A2X,8!-\"W38V'<6@Z>.4CNO@I$K8>+6&S4,ZB&N8V[M0&QV
M!LI.@Q@&>)H!)D)X"M$";A,J[5'HT3\#KL,?RZ?HG-CMUDE[;/8'_;YI]Z8M
M<S2:=,SI=-IOM3J34_C_!^A3",0:$K,'XDV,@@!L\BSQ/1\\`'@N2Z19_1/T
M$D;%*:EW#^=IQZA]2&6#2RYXUQ4;;AI_1"%+G1AC!I!=<BK0PU"4A\?""!0_
M.>8^1J)S@36YB)":)7,2L%(>:040USI0R,G@_H6)_@438R>-&!]JPJL?HM!<
MEF%:@PBUB;\)&G*+5'BV0</M*'T<E9($A^PJQ.+P0?CSU8*%W`<2\("WI8)S
MQ="LSU+PSU`1Q]RB(3@>-Y_L.YXJ$S[>!0O!X^*6(P>Q#`<LD".F%H[2@O);
M3>-WZ2&B?T4^(M=V2/S\8SQ!Q-\CJXMHC."1V'@MUGW#=Q#Q8#:5GF,I1,O=
MR$H\UC2FA(%445*Y5?"R6/H/BG7A_-"H=W"WPGD3E!C^;H13#7\Y")@J`[ID
M"?>,D*U44L"OP%!XW(7!,:5HE!;,@S\Y!'NJ.N$*+\72UX+?7P(H$;#V*HOA
M[\FZ?%7Y&>PQ8B*:%PFN/.=ER%17)</%`O1P6;Z6`DMU$\)?PWB9JP9GB9$L
M(NN5W>P:2PC>X0^W@$()"W8"H&;8`R;I/`2*I97SEJ]:31M3@!(JE8@YHZ0+
M\)3Q2?D<][^`55:`%1GY;#K263]\@O@RYT!.G+0:PJ7;TI%[Y-V>EUQRZ<X7
M[J#J1ZH>GD\9TCDHS^@J,5Z3\X-.?@+(2=Z\N\,&C_AJB:&^6D)_6E\M\5QS
MJO75$H?2U7;TP_SUU1+Z:HG]X49]M<01:,>CY,S:_=7\I*^6.(#'C^6<T8:K
M)=K;V$H?,GKL+G&KW6E8;7V&0//$&NKU10*:132+:!NC;<QN?ID^BK0W!QOT
MD1J-M[W"F\;@#1C4\?WVRM;S1?/OJ[=,K-6XZQH/UHWGT<3R=__P0WI7O4&C
M-^@]MR?U\.38B[AK/TB\4Y"U%\37)-<DURK]1U7IAU>A*-U/(9I@]045!R`B
MG4:K\]RW+^V]T_-<S_TH>]$R>(@RN.]QMKZPXCF8^;75ZC0&@^>^^FU?[SPZ
M:-K^V,&4)OD/1_(?G/@'I\N/K81\/&/MG[(0JK&FL:9E]>[XTZ7CPTF\XILS
M_&''*RAT=_BS>-$2H&&K,>P=VPSQ@PBG]I8E=.>O9A'-(MK$:!/S`P7VQ]1I
MJGN<-=[V"F\:@S=@\"[75!SQ/*R!GH>E/ZWG83W7<`T]#^M0(NJCGT"DYV'I
M>5C[PXUZ'M81:,>CY,S:_=7\I.=A'<#CQU+TW#`/:VLJ5%<\'SL=W;4;@ZY]
M'ZCV,!VMRUGW&E]C-[K]OF8)S1)5U.L*IS8I-P/4&S;LCK77+*$KG,=4+]&5
M.HVWO<*;QN`-&-31_/8ZUO/%[J_Q+K@W=)%::0@60+++;5?K5O1H0OA].?-E
M-UK]YSZ.KH_O/@9I^XV.INPQ4K8S?.XSFH^@0+5ZKI/AMM5H=8<'(\2'5UPH
MC;+BU[CJ25:'(!E6P^H?CF`\K75[KN=^E+UHV3LDV=OW&%E/KGH.)MZI!K47
M'O8^619-<DUR3?)#(;DF_E$0_]B*Q<<S.^<I2YX::QIK6E;OCC]=)#Z<K"R^
M.<,?=IQSI;N^G\6_D@!UAHWN<'`?J/:P1>\@HJR]98E^H]UJ:8[0'*$HB6.[
MPE:;CX<!R.XWK*&>8;7?0?LQ]8OJ3F6-M[W"F\;@#1B\88;56\^_Q'_^XVV6
MF!>.LWHGIBF<9G',0O>::JR.BUT^R2CTZ)\!-?TDGZ+`AP?8]_0DB-QOO\&2
MQC_D,G\F[.-\DJ3^TDG!8KB@[N'!SVS^ZTL6!5\_3>S>L#,P3=/J6"WSOULM
MJ_7UR_GX:[O?^8IQ:6O8:7UMO31\[]>7OO>UW1WVAY;UM=OIV!.[W3%'DYYE
MVB<G8_/$[O7,X:`]L5LGG4YK-/UJP8N_X>[$YJH44.=U]3;-ZRH%YNV?55+>
MUSK"#[[\(<,?`%E&-(?5<X01;;+<C.6/[Q*JWV:?][3XYPMFK&*V<F+>!Q;-
MC73!``[L#G-"><@<"#K\A9B`$E2P0<^8^Z$3NKX3P%?A%TM&G6$A/H1=87YZ
M#<M<^>G"<%PWRL+4#R_@6SZ\LPH`H@L6LM@)@FO\.^8W/'P;OF[\&?KXKR^X
M;`*+`%"C)8M]UVD846S\/AI]:A@Q=@O$L`[LR;F@SV-#VM+YQ@R6LZT3>K"`
MDR09GS:3P`><U'#F<^:F]#'8?!3CYYPE`IG@U^!YELJ7E:;\AN'YB1M$2193
M0QP*!>P*/UV\HKY@.*G`)^),8+<6<PUZ=0-`\'[,+EF8\1W)BR<3P\MBQ&KQ
M&N$84!5Y36.4HQW>5U`"L,^<!#X`]%[X21HA9@-:-/89Y9S@&Q$L&AMST!Q1
MS+&&B(1WD0E\C\6P0,R<)`IIRET6PJ\($->/W6P).X.5$H0BS6!UH%06I$A-
M`"KP`)%``E@_CI;P5I0H1&L:M^9*#]'A[<2?N`M`3.Q1=HWX$QEJ-WYJP-M_
M9=X%7PS1M,9:2^?Z!O;B#,F0YB7>JB4QYXN8!;2G@OVX6-S(@$WC8PB_`U*;
M%Q$R!U#>AT5+Z#08MG@2<_BP1$EZ*MM=,B"6%P71A<^Q`>(<9!YG0J2BA!10
M)_8#_W6C"Q!II*2R&41#$$17Q"<-PPW\D/@PC7W!C7S_B$4.GV`%/X1U@2NO
MZ?NP`S\F:A$YEB@$_U&>!3Z\\(%#8:5D`?QK$N\3'Q;]KPW9`)LZWQ$+RJ;4
MC^?PBD99CP$/HR#`:SE-UV!-T@)_Q6$?PEV2QAG]D?.\I`>"6*5%25A1H"OB
M&L*'0>ZS1$CNNLY#N6>!#U0A\LP8J14IP0W!KB2FU.V[\-T%-?C27XAQ\)\H
M$ERG**PQBS+.[ZX3Q]>(.>H:KFC3$F?"`F7=0*)3U@NLI!>V6\UU3ZCLPI3=
MFX_QA1,*1CG-U0;\`WRD3P`0;(O^^7$^E7KD2ZY&QKD8YL[3@SE(H^EH<-J?
MG)C3R?#$M/OMH3EH36USTN[VAD-[-!BU.YL<I,<;.&JU6B4/:ELOH7S'+F:4
M!FS^8#F3U]:;NR1,"+)'`.<##9!#/C_)$C]DB?0;3DA@X/<J.]TQB;+;Z-J]
M<(4Y/KAYDA@Y$&=XM`0-&H(6CL%F<Q6^"ERT,H7#<2J>*GXS_@6=4M1]ZE-K
MGLKX%S`RP!O&"J)$WR7'<DE^KBNT/ODBJ/3!289O7,,&4+'`C]]8"D\GY-V5
M?&0L#:;2/."O/XR^C$?_;?P>1#-0K'_0J^"#\8U=.?!<[%^`0@.WFQMOL5?N
M?$_"BX`[-0@G62JV!F:$+A2L["Z*L-5J&-9P,%2\0+Y_=(%!R>,?N]*3,6-V
M`7M!!Y)`J'R5L%/ST;5/#I$PUG#8N<$NY`ST:30>GWWXO58TB*MPK/-&MKJ7
MO`@"(/UAG9D?K<`563HNRU+R>4HL0)8]]1,Z@1/X*]\S$I=;^GGD9MQ[$?2&
M%R$R0NLDG1[N95RR(%J15\1]Y]A9T;>PTQI]IC@B#P2LM>='ET[B9H$3&POF
M!.F"?,9_98$R8:S=XY<J-13:7J-CQ\"3(4]NA4O"3J3A-OYL?FD:TRCR"*)Q
MG%T8(V\)/A[X/,+G`K&9CD<-WOPMV!P?3L`&D2`$S/&`#R,O`Q[Z-T`)(<%=
MB%!,]4NR@AT^?CD[/_OXX1UW2&$COQ@YT9L#!JSP[\GG\[/3T7MS]/[L=W@0
M_3)P4\LYG@EG.5AY39G!ME[[;I0`\@%@<)VO@S>`\Q6X.P#F:WYX"@+@;V%T
M%2+_C_[X;%@MZPW)`H4JWE]9Z%(DXODLY6XUH(.AFWP17+O@`WH@HTAPBKX=
M#UPI8P7[04=%1N`)_!V,U.OSWXU<41/\$F+Z3;?56EZ\]=Z_,1;7R(+*%Y8^
MQ-[D$<*2*@\DX#6GA/68B4Y^!!X?`4$Z^S`!H#S@<:0XNGSGRJ(\%IT[/&]`
M3F808>0J2`TNJNLL528GK>5<.GY`GDY=OL"876/LF+BQOQ)'V^3$/.J70*UQ
MM6!A:1?T!1`PX#TG$(%/LO!7W+M%D8'_A"R]BN)O/()#]N:A!*P6P3OP7BQ>
M7#&$-04XN)0C0-$EQLP4C[VH&>'7'O!NCL8&L/#[\RP(%%R@!7&`.18HXA)C
MM1A!ISU+<G1QNI#NS2ES!QN\55L^B*H,DDBJ,AYPR%W.A<%-(7Q)I9:3/,\Y
M?N%?+.ID!$5RNQ2T6RV#Q("(27\/2#8,(1Q`;V)<@@\8#-,+E%?@>O::P&/P
M.3*K[\?OS5/Q<8SR_$3!.VXSSH/(B#(#QM+_CJ'^=4*Z'T5/.ABC#Z?__/A9
MI9MQ%AI3-HM+[%V2SVP&EI02$/#S:A50!`.*&M'/M3+\4BQ'*CGY`#H95XEH
M(=#0H#X8AGR%EE<X;KX1-E@##(F<>EX8[I[*ZK@\A$X0T2.(J+\N_01B>V)T
M!)QQO,3LT@>(E:V5DT`(]6989'*--.K:!RXCQ,\0=]PVG`L'XW+*6J#T>96-
M"_RN?R+/J?F4_Q3^(_?]<6\R$[AD#!TY'O'C]J]\DFN>51-1N/BVFO[*(>>Y
M"PY[PYB)P!O370&(B^LG^`XX66C;10I#)1R'@O!%7YXQL+T@'Z`W!4$X:$[!
M%\BFP$A_,6Z)T(?!_)X'7Y"$000O@'EGC*$E2R#.(I[[I*IBXC>(RL'N,\;C
M?V*Y3^,_I^`'R!SI&/R*<K-;6S2[<<CH<?ZTGPAZI$Y\`?:1?BG9`)$+X*)S
M%3!\.$TDN`*EB`5:$U;AG(BYR1M>0,\8OX#R`8BA3_*0#Q4`ID!"1&H840XF
MIGP196#2,L'K/B)V0Y\A@H@/@*#/\_>]"-1G&*6"K$QAR))6AX`C-:YH2PL'
M'G,,3(10>@W39D#,*-PH4;#2/*/05LD)1>`6\-H1$;Q(L6(.EF?X7H.R,#Z`
M1,$"0_4<PI=LEK"_,]36$TS@)6_N9'4&^Q#D4FS/8]RUZ'[_X]QS"ASJDN9(
M]/JT.29$&3;?Q@RL,[$3B3I/T\-?N/HHDLH-LL.8%G0R8(T&.:>5Q'MM80B6
MV+$TI!2&C-?\XVH(CB[:36%Z:3WUX3?$X*LL3C(G3`MS&&?2/P0-FXE"JM0.
M7YB;Q:+P`T_(.?,<*4L_(<W\N@K#E\EIZ<M-XQ2<;\<O6Q*.`%@*!)\E$IQ:
M:JU]`<6QLCO0U1B)(@D+5@`$1<);N")5!OH#]#[J^I2\;\/+N%$@,I4-'7FX
M.:%JC33F_1/!$"('?T/!II9M2G0@WV"=$I-3TNO))DXOOL:-F<1=LB!].4.U
MYWBBGDDQ&.XR__P&C2EVMD,A"OF#4S*7+20XA6RC,,2T^&<J':&.GF(2WFJ9
M_S<W;7,_P;S!-8.H'?P$0N:ZV>Q8,FR?^P$258(/Z%GG$GR2/H5Y%?A8A2G/
MJ0C`F]*3!<-8792TP+1M_C;/\9`AX[4PXPHYBPHAB!R9+ZAE&(E/L=`N];T"
MF;AJOB?:$06@&Y5?_8K@G@?H]P#[BWA<UG/0IC?DAS!$$;Y:44!L4)P0`FZ2
M!!UT\F2%2TBS58+KS7LOH%E%B<_M>6&*T?B4C;'K)`MC'D172<XEO!*<!QS,
MD[Y.I;AZ<RF?LPYJ5'C[]UP]CZ1Z+FK-8!#S$O]KE;VPREIB*9+<'8OXFTKX
MPE]:J[(20@+T0^?"&=I2BD*ZAMX=:_O2:Q60;!3V3;T&:M57E/5N+NV?+S:Y
M9;PP21[Q(F:\-ACZ(?CXL)]%PI7%MO,D]`8I#:(/)C,P-Q9<"V8&MU,RM`\<
M(+W-R[R[0<(EF!#W!)B,RSH+_H;1J?`PU6W)P!6#"5F71L0DA?O(R'WDJF/;
M3@`#47:QJ*$2#C`B1<9AWL%**.04[((`"I;!O-$:>"`_:'>-X1XE5RBN<T6V
MF>=4;M:`@JZ2,)3B@MWZG@\L0-)3XPYBS"UJQKR03`+,DB(2.LUSWJ19N;QE
MC)<!>+,"_,YE<2@RC[S$"E$3*07.:D7>6^FKR.4-B_O)G#>_X39*TAMZ(HS.
MU9WTK\"GP8@&?#]BD)FH8C51M?'`K]UJV>54'=96\B7D&_@V)K,IA8"XN:0"
M?7W^'S2"5^18D;M@$5?@%1E-(*@L)Y56&&KZ2WF=@`?'MRD4B)R.Q/?6_#X&
MHK!A,K`4"P)F^&NU&<P\PT^X"&6BE:^P<PEG%Q$IW]2YTT6=M[D(]+[IS72;
MRJIF[Q:.L.NY@4>#"720@OFJW>XVA\5"2Q`FD7O[PD2*DK300`W%)S1HATCF
M``\4"1HTD;($%V$CAM01/%=!;A56AKA^Y9I>%"5#<`B!1US&O#PZD=O@LHDL
M])U,.BSPRFI;S;8AX=TO%;G!NR^IRHHKC(@6SF>R8:0OIIYE<L3HJO20%R42
MF<4_P*7.%WDO%KG&PA#6+[!`!@HBB-!#8.#=>FR6BKXQ'G/R3A`6HL+B<8::
MF.FI7\?+`(5_+R;\U6W@6GK"7/6B]PH+Y;,!(="GE"!R0SXG$-@`(F@`*&&\
M^2HI$I`;6OF62\JH1^XWD2POON]2'QOPS@QWEJ8!\2.Z!NK2&]+#<D5619I/
MJ32JA0:\J@0H!`DULA79L&(8(BK@.`KX*A,5SU\(S[#&!XYIJL3CCV^HIXF"
M28^!.26[B%(W!P!J+G(:DAKHH[2D(JQ0,\"+*.!%I'/Y`?+)2C2G$CQN1^00
M2NV8V`\7D2)IR,Q)"(Q&`0;FQ+\0)C$GBV'H^`O]B$B(EC-P#20LN4KBCY0-
M>E5J&#(-U2I&%,<#AZ`SF=[`;HV"4"]^*OB[!N\"$UY$SJD,KQP,Y2':%`M`
M,.`OI3$,?%"`GO06RGRSGZI(=NXE(D6PV2C(G'Z2S2'T\45$-0>V$+TE$:;Q
M>0]!*6Q`,@;,23@Q0_8=?@!%<RE#AUNWWSUTBUVY@6_BQ!#77"2?6$Q<6SG,
M\&#]>)-6_Z37FK3,5F_4->V>/39'K5[/[(V'X]:@>S+NM(>W.K"P'QGL]U&"
M?`0<P(7^0%+7F'AWR=>@P?H(/FE_[NMZ#*7=#WDZ&FCADSW*'Q<EKBN:((%A
M^"4(P(5BFT1I39J@DE53`G(9KX[](,-U5'BD/4+#L@,\GEA"PD3]#66H"AB*
M+V[8`H7LBI6FU5&M,LJ6-`Q_;E!N'NOEH#7SM*YX3MF_L`1)1K%;!2VK(NV4
M&WNPG]A%Q/>``=!%7J,',<Z[V:B!7$1?X24V.J$FYRY*_E8ED^_/3?$P\TH9
M?;X:5<%EKHL257FB!5!=*#I8&]%.3?6BE6+[EAQ*5*+=II@_]<T<H807BF5G
MFUB2YY1R#L%^C<H#:+O_SIS@UJKU!N57UI13<-7^C7Z:HFC/BM9S_NZ#Z<O!
MH-,[M4:VV9Z.)Z8]&5KFH-T?FJ.3;G_2'PTFTUOJRPUQV-.JRREW=_\MW=T<
MD8:"R0/1H:I;(<HVI#Q+Z<\B$Z3D5(I?JID4>;J`W)(X]GFS@S(Z/.^,(-T)
M3J>HAU\5I98\T4!>-^8&*!8-^=?1"5TY/AU;2,7,6'#PBM#`YX=<L*N=6L32
MXM`CK`]N#`ME@^'*`97C^BM'5"X0IB6I*'(\7O"C6LW"*9\6&U&>2Z1G+[/,
M%!(6^T2%04E>R@'QW@G0_P`K/!X!#E.U'N.'JXS'2SG:R#7B)6:>H=R0A2XT
M[3S"XRG\7S'U5_"NHW?[X]&^1X`,2XT^S_C6.?]D(2^P`&[^SJ@KA]B%=S92
M'EJ0D7NLP+DA3Z!)5QZ%=(TWRQD5;ADEYV`[B^M2UW[1H)-36?#"GN&OO8Z_
M%_(D%JL@#M&4^$L?VWLW<%".VSQ'!P9R?94"V>M+KN'=#W-"Y8>/J&.%/M20
M#,^/*L$3R.GE3^:O1;.$Q9<4[\FZ5JX4"@WPVF^R)C^0AJWEV,!%!_:,:Y]A
M2T\67^*_6.HV>6E?BIS\C"A(4G&,"ECD&%&Z$SX$@6L<S42G/+AM"E!"KP"G
M./`7\J!BWE',8WV^1V`J\"Y>BX=+RW%([M8-\YALUE'9[,^PV#)AN<">K)!N
M3+XHA]AD]J?FV.2Z=N;V072N(EOD[6Q(?]2-"@<H&ELU<"+#G0@E*N"N:.H9
M\HO:S9"W&#>4LX`8/F.?-E)ZCXAU7E;]@D`B#9*4MY4?TZNOMF\X]HS^/U#N
MIJ)A;0\`K$0E@ES.A':M^@B4:XNQ?R;.CZD*2&3UND@\BG<6/KCUL;NXEBF<
MXNAERMQ%Z/^=\9>*=*,!WGL`R"-7(@_/N#=?K'P7B[G1356K$>V=RA&/=XRO
M-RC.Y+G8EQIO.]0G7NH.?]YY'D_^H<VO/-3O]:?53W<>[M.W_L1NUTP\V>"X
M>P\?*TN>%.;U,:UKB,KGD5IVG9C=1<=;Y<BT7@=S)7N?.6+WI\H]F.#.V,CC
M]+-05A*3W4+O0V.H]MJDM\?AK_,H=8)GY2--C)P8Y(8KU4%-E[VD2UO392_I
MLE_V\(!&CX\P#GRW#7O[-UC\."_+T[O2N[J->_V,M\DZ";:M*ITH:O9P&87L
M6F:$#T&=W`T)KV[]O8><*FU9G::^'EN36)/XD$FLJLT'08:^MT_3_(EHKB?_
M/]\7:Q[7&-08U!@\*@SJJ_P.,)_VOFBET%DUO2N]J[W9U;YGU?YG[8#<BZ(S
MZ_H0-,@AAF.=8;-W>P!TDN5P*'PL`;>FN::YIOFQ:?+#"W7>1^&%6<Q4P&D'
MO+L?0)DSNA%".RN/P^+]9OOP.%P36-LM37--<TWS`U?D^YY`$9?ABL%X+C^>
M&::QX^H^I,=BY%;3/CQ&U@36UDG37--<T_S`%;GN0=K?[@6-08U!C<%#Q^!=
MKB;6TS'(.#[_G(@?\]-Z.L;#.;A[/!UCVP0BVLLLW]5#(_!V3NFCA`QZ.(8>
MCO'C$$,/QS@(NNCA&/M)%ST<0P_'T*WA>E='L:M]KT+KX1@7SUW+J$-`SVY:
MMP?JN0L<FNJ:ZIKJNE:M:7Z,--?EZ_TM?&D,:@QJ#!XZ!O4(C0/,NN4W(.O,
MF]Z5WM7>[&K?,V]Z@,:NWWO(8*QK-X>W!T"G6`Z'PL<2;FN::YIKFA^;)C^\
M0$</T'@V%K?L0YP1HRFL#9>FN::YIOFA:W)=\=O?6H'&H,:@QN"A8_`N!U;Q
M,&K=B=5[VH?S!3-<)XZO\9)[9QEE89H8T1P@<9UDT:#_5?M$&X;CNORIF+D,
M?@VP*[]<.==T'-8)/5@#?AUGS,L3W#X`XJQ6<?3=7SHI4VZX-V;,=;*$P;>-
M=,'\&-Y.%E&<\B`TI(BS>4/(Z?F7^,]_O,T2\\)Q5N^FL/Z_<?F/\ZD?.J'K
M.\%9F*1QML3-?(H"W[W^#5XW_B%?F3AQ"+A(/K'XR\*)V8F3^.XH],9^D*6P
M%9S6Q+ZGG]G\UY<L"KY^FMB]86=@FJ;5L5KF?[=:5NOKE_/QUW:_\Q4OP6X-
M.ZVOK9=&%OK\+3^)[+;5__KGE_'7%8N_)OB9Y"4$VBY@)4CH"(;OP8/>UW9W
MV!]:UM>6W9M,!I.>V;'MGFE;O9$YZK3ZYOC$GMA=^^1D-.A_[7RU[)>_F:WF
ML%>@X(;]E#?_)9LE0&S`S>02$70..ST)(O?;W;==V<ADVAK9TZYMCFQ["!L9
M3<WA8-(U3TZ&D]YT..I8@]97V._+WY"B@J#WDHO-9[4IBW+^>?3AR_3C9W@K
MC$+VBU'*K="1\/>3\W-0#E\^C4[//OR.S\5`IU^,C6>]Q2ER*8#_QUE%R2\5
M,>2__,7X'UBD6)J^9UZQV3<?.?][:@*S1M^828=Z^<;N<)#<:K5^+CEL6^IB
M\AV[.'L>L/D.KO"6;6XHHK\>OB$*;:B>;]+C!.4C@U9(`GR?"\/.H.ZJWNOY
M3V7N'K+#[@R)>WYG+)GG9\L;N.Z?9^<36F!2O%XW#@&8^^/G=T9\,7O=:L#_
M?7,7CE4VKP2)[0>DV\?0^.BF4>FHM=5KX$'K3@,-BG$:+5=.>`V&*01+Y8(F
M3Q=."O]$,^5=@E*.KT&`ETL_31DSTHC>FHY'QF6$>G^(OVH;SH7C@P%!XP?/
MLA`E#5=`HP;\*<R7(2S9OYW$92L'K.@JR0+8Q#R*Z>^C#Z?__/C9\.%]UQ%I
MU9F3P'>B$'X[1XK@KXT5F`8\=N<9`"R^60/KDK$4P&C"&N<"9C\Q$G?!//BH
MAX`OG6_,\,$^HY%)<&'X?U<+!BO&^'<./\,OP"H"NN0#K`3/X6?73[*W6QR]
MQJ?QG].1<1'![CTRZGR/'"N!V%_#6$17[)+%C1ROX#$$:$^7JX"E'+J87?I`
M9H%$_#ZLLHK]*.8$@6W1)\"[P"=B]%U"<!V`A0TG2;(83#SCA)5?N?*#`+V9
M[9\Q9M?%\C5NQD:?XQ;"S"V5EN:[27.[+:79#X'^!IL#GZ7(%C&P.5`]`E_*
M2;DXLN\K%B8D;T$07:%OBY3.A9;+EJ!_K?3#(H*#RNK#1S9:"HDTKJ(X\``U
MC`-!JP)X`!D"-)>*@7N[P;4Q]^?IM0&`XE%:_#YR8Y(Z\[D!6/#Q_:18M(GB
M#&LLG;^BV(<7X05XE+GX<?[6DH02G&H0A<1!#0.?F[,$11Q<21#QR%@XU&22
M9*L58(P4'X@!>*/@#-.>`1S\,7!`+RX4M47?ESM'K"8I;23A$N:G)%RPE)O%
ME8V^ZL@1#X@/%QS/"Y;`$C$+G)2K)$Z0*M8@E`A(BUXM?``&U@XR#[[HBA-K
M2%C/QV"`*U.0,A.@`I)!F``N/BTV8R&;(VI13X!>B&!_\%52`TF:E/9%2[KP
M+'&2"ZX5029`1KCPG_,HBU,$X._,`1S&""$I/_P"*5>^';X["((HON!:A1D`
MLF`VK)[Y,=B/\CJV5CG[J'*&J@.!QB2,4G_N"Q&2#"2$`>!;.&A;$O#&/?&,
MM*1IYET;7X#14-`^Q5$:0:Q@X-'M)$%6:1C`RX`2'`[C7,2,5$P>$W,FQ%`9
MS98#HCP#\0])@.%K\"A`Y8+13S)&<HHN`_X1>-IC7#*D#F2D0'SP:.$QU4?A
M'T%%`<#B'E?1*@NX0,WC:,GW<WJ*Q'OOKWR/>']T]H?YS[/?_VE$60JZ!-]/
M8_@T)@I`_4`X@O_%5U?9#)P!T`V%2P,_9`&(B5P>7O[GIR]M\_R?G\_^/9%+
M\@4;0B-(4@`"<`F`&@0=7MQ(/2*:FWMT@FH-S#T0@H1>%-]?7*\B^"GQA9)S
M\.L7P;7+8M#()A@3^`%0Z<79!3#018B8!U+`OK@=2H3EB/WD&VDHUXD]'WS#
MQ`5LQ@:C6`)3+;`*;L(/S31F0F^D2,R$>W)9TJCN5NI=<'<">!_T!\3E"0"&
M)@!U%OP.49*P.%MR4N2P&P$.7$B0'$DV!ZCQ4X@`4.L0H?C)HI8_D"'Y;GV@
M&6?LW.96]D9[QL]GL[](IU[YI#0)G%I@9@PP:G1;+6-Y\=9[K]7@\ZO!#Q`'
MH%-A6%+[.2"[L?`=_/`2^"4BPS5:.C':;1^##`<]]2REEE;##<#J&@XW[8%S
ME63`M#)T$J\)'QY>$R)95$B'OR3&Z<)G<V/RG;D9+?D161:@$@;YS^:7IC'V
M`4>^F\(*8)[1MHKP*O\#0(G[_1<("`.9_Y*B^!E?OB&W7C8E**<1;D_&8:O`
M)>#^%25LM3#@.__/^1;_AUTEW_P&H*=I6!W3O31[PZYMO!XW/S3_U42L-27&
MWLA(+-]Y$+`+X38U#"^+I3(&3]"/X$L9J`]25RT(,Q=QE%TL"I5F6-VZ0';I
M)X%"$+0\%RB.?&EX'?1&&:7HK<&?2;"5F$\8@/*SW'#!*D6(*BD&AB$5]@4<
M'G9),1<@&KQJI[`4H)XB[HQ_GHS_/)V89^=<D7-%C*I5Q,P-'LJ!KP0N$:I3
M>`CP`5%P(/UY^FKLNS(]7,\R"?!*3$GFIG$B@VE4YA2+(@UH'T*M<LJ`J8Q!
M40'#^LO$R$"_<0[ZDJ\%/,@5*P;&G*6L8<<F;"2,?<.W$K3LY!C@[(34@6#"
M<Y8.TEPDPE,@4<BN$Q5B8\[X`W5N*6A&'YBU\+7!N8"%,`?F@5&?\_@&7R8G
M_-*_B(!O$D`<_='+Q8TS`]^@UJ][I%^[CZ]?06&F\,LB^*B5FXBKUF2+;E62
M.E_`+0-Y#=>4[/]&\;>&U)HC$$%4+HHB_9?XU26JQW7-VS`^O3]M-C:HW7]%
MB]"8DHC$44-(E5#G)TWC_[+4763+7#V?GOW;[`\&;>/UER9JZ/\5&KHK-;0(
MK2L:N@'$@KC5$>DF5B[BT9Q"LATD+'ZYS`<1*FML4O&XX^PB`^H,"((V*(T4
M_,]<Q=?F*JLJG@)H1<G?2\47>;X[JGA80"CY.ZIXLBY"R=]#Q7/[`&'2G54\
MIOB%DO^A5/QZP71C`;!<)_P,Z'9B=X%U1'3DHQ7&JQ.>=>-5U0>K&$Z'0_MD
M?&J!/`\GIFV!=`_;PZG9;D]Z=KO=;@U/VK>K&`XVS7XN]5"W?UZW!W<^+IJK
M#_PAPQ\D"HF^"A*!.Q)1:\IRHMTX(;76<*]5DAZE>T!RLYKD4[;F*5LC&4#E
M('*UF.UT$IY`A(BR:4BDH#A5WLU3NICJQ&P^!)N,TFI\5;F(R+D5M@ZM&GP.
M2RJH9S8"A];TDM1!@Q03)A[QA<0)4-CQ<9E7_`4P!3)A\HH-`@.@<04JP/R%
M;,L,31MFEC''$/A"F",JNGA^#"%ROJU?\FN@,B?@(?,E*,.DH4#B@FH'11T(
M)8MKK0#I2\=E$"/A'Y3]R&3G+VJ*E^"X%@:%=LWS)SS`=V%%'PL@\!+7::">
M8P?;)5S,N/(%58CFCBO;.C@5.%)7,2:Z1#@E=M@TSL"\>)[/;?T-/"+ROE*S
MT>^`U&!-,&$L]\$[4(`$9)($DF/,>C-,0L#J],0*D2%2L3E3)$5="6PJ)KJ0
M4)4ZGDB;XZJW[CW904>6E6K>K#)*DHP?MD@FE)QFWCDVP3R41AW8K<[DI#<P
M+:O?!8UJ#\U1?]0W[:X];H_M0;<W[8!&;;_\[9/UOS7--!O@*^_FE(HIE`8'
M#)P"Z,`P+'2!5\!Q=(,H`8YZ^/Z2:;]OVV.P$9U>IV?:_9%E0I@^,4>CTY9E
M=ZWI2?=DD[78.LA?_K#6?J&V6U3;,79LOU`Z+F[5XX`_FW,'/-;K=[O9H=?]
M6W5<J`"L'4JZ/S0*CPB%4^*3!V^X@)CC`M.MT>H=VD/Q3]X6^(X\`/$KW/"[
MS0[`K79:,?O1M1.DU\+`_0&A'9B2D!D?9X!<;A(WVOZ;+?Y-&[P?W<XK^A-\
M^6M>*I5QYC+?#^XNYGLUHF)OPOU.L!,`M*S0Y[!"R1++`@@O(O`:;O)N1QS0
M=A!L%06(D=9&C.`2F[L[GULM='^ND.V.@Z?%<NW'TS(R\&FW=P?'^GF;9KGC
M5K?JK9QA'FSCYYO"5?(I6=5+`S8`1]679;_1I[.&=#2NE>H?%D^,#WZ2+$"R
M/M$2#7"BW*;QNOC*Z2_BB>)7XU_>-*AM)KKTL5R#J1LL`"ZSI?S(*@/'Q,$>
M)44TJ7"^<(+Y6KJ(JD0AB8'(VU!+D1^2T+/OX*LEZ#M?<YBQD4;QG!H\JQ!A
MX0^#2B6YH!;M93>&W+_:$977ZD4'@I=O*-])C$W*,5<;36,D2E=?V"JMWL#1
M4E,M@'SXY`6F55*VMBJF.-:4%_4)K5%KX6!\`'ZGXRXPJO=$\P$E[GBALYS<
MP6)Q&!GSC%SKM?T4WR7O%A81A+[)$;V39=1*4RO-)U::$`Z"&%IEH:`;!BCE
MB=G+W`\0>N4*?0T90\IP%B.^AG&Z8$M,H==I2/FWDHH4#N?)Z,O4>(W)`1:#
M/$_^SD`/_&V\]\$Q9=Z;O*(HY!VS\J`Q4`=1EP/^'5;)&Z;XIMJ5EE/<!^]Y
M`GTG-N.(GB)<KZ0LOP1.N%S`9S^5K`;?&.\3$4]0-I$7MPI,R<A9U8?E75"(
M#,#`5@-_?IT?MR@VA9I+">TYO+R7$Z5:C9>S=!'E2=0B,2"2T^5\)W:LN/Z*
M.LAXNH:R&L)WI"`?]Y+W:TEKP@2H,DFM)`+X?_.L3Z)&[)1;\ECBQOX,G\!6
M`Z(0`Q5M\'1]T1]8^@3J_7D)8SD*@8^SN</S(8(;J,M#2;(X`6L42>EUTCAA
MF*'S*U6]Z(6H,;)$E4UFEK8!EF7%^S4VVEOT!7:RN)7TM(_V*2U,(&?AE4,9
M-3H7A$_1(9VY0WV`'$';;2C\.LD<WGE"0B*$DX`F::S`4^J(HHWG$H))`\R`
M8P4-O1UJ;.:,+YFPZ%X4L.<ORTT@]>ZP$=F/1*GY&:-&I;QWQLA6HF\Z3RAQ
M1:%RC\A(87L/4$(H&,ID%0*^AAU8XPK[GD5EQU-7(:>L6'\#:\+VL/2SBOV`
M_*`RT=$KF8%\DXN7<^A:"A%[+1!2"5^3DVZ)%:Z\U5H(J6`U*FN(_DPG=1>D
M,68,(&0E;2D0>N'?`()D#C0B:^Y8(6RNDF.0,JRXM?.,S,!K_TUA*M58E.HW
MV8J*:8#=[\01L)M7K6:W>$/TNM)"ZDI2I>;;H"PF7^Y5M]G*FV3GQ)"\)3=V
MKE1M+!F-'\Z3Z#%<#"&H"UD4@80CR<U)\3UD'`!*A<K!3QAKL"FHXL[S*ZMI
MK>VQ:?PI*V@E[58J>H9^R+!.EBZ0R+QK[$97/*]Z.D"VO(46<6TW!X@1@2O<
M$:#?RG\!R%R3DX:B&0M>V:1(1*S$.62-_`7)VLU.!1"GC#7YH*40MZ(I,%VR
MF7;K9!%:N;0DY<3SSP*0J*Q=F3M+"_6SS+">$.0^"/Z!Y^2=,!&"*;%0:0`B
M6*0V(4/MH#>>7@L.(`L'G\UQNHD#MM*?"_"-'-`KDSLGG.BXYNH=^QAIC"(W
M@,Q=\'*)4#><7AX5LRG:K9<8'5_I^.H8XJM<36-;H6W0*6.0EUS;5W3A>^>[
MA]Z!B'Q0,$&^Q&\;7*.HU3'9-JYZ,2%U,BHMV#UYV6E9OJ^H3Y[BD^)TFJ-D
MCX7L<P]80@8?E4MW?NG7F-^R)T-*A#247(T<'VJ^H88,9^6G@.W_4%\U/":_
M4X#Q^I5E-7NYXB'5N;9#6O$-97KP&$OJA!<^G8#'>]D0)%@ZR*>IT6\-G_L^
MXLQ]G!(0X,YQ>A59KBQA\RPP(##)VV*P"SL(F*P3`T%6C/+P:J#E"MR2CR;W
M)7M["I<8S[M<A/1Q`4:IB"W]G!P!%?V.IO!F#2^<S%&01$KSC0!*M<F"R43)
M%C_.KZ`B+$G.`Z]PDN&>E8XT?J)&Z6+"/TG^?`T_KSV`!ZG":Z7\("()_)0(
MOCXP^`P=KG#+2"]07D*SPJA^2"+WIF+4T#?FG!XJ*4?J)##HG`"=<"I87QP\
MPLP$E]Y%%%"G/T`O/_5:G'1,(A2051&[4G`H8UB$/4[>W"Q!L)YZC(M\P+9B
M>N%K6XC\YFY4=C;0.6]%I,A)H;H#ECNF)HHR24LD7WN"XP4IP1LP9`H!8NH=
MJ*Z(VAWH*JF*`<(ZQ7:C5WVX43EV-]B=6(1*\5F>K<`$FY(JX%3)29)`&-%D
M304BJU4'D@B2*%-5@<[J[0*><`G?/(HCIKA>U+7\B"52D>#/,Q,O?LIS#8+0
M:E[$F6&C)O"BR\-A.8L%K3;SB6-Y-@;6FY'SA^0C2T'69BNQ;]V\<KONC<H0
M$>3\,SR+YHW)8'RB%EAJ'0&TT5^2AYVCH@Y/,3MK32%V:VS;IU;?G+:G)]CF
M<F*.>I.AV6FU[9.>U6YU^];78:O5P_]IM3HO?[/:\-L>_*RT1NZRK3(F/HD0
MYCP:<5/Q2:B03Q"_I(#8"?Q6MCT]'3I.K/[PI#L=F]9)]]2T>_V1.1P,X*?Q
M]-2>=@:GPX&-_3\VX,$NX6#W#941<19"R`M.YYCQ_YZ%GQEO'F<>WD6YC]NW
MNF+[*@)NVDAYVW^&\!!YF+^#<_$^2I*/X3@?_/^T,K#C!*'^R]_:5JL[+.WZ
MAGWL+O[TMX^R=0S3><E#CU1Z6%4`Z.BU^SOK@=K]K8E"M&3GSG>6?'+\I]W\
MCIQOMX#S.\-NE?-5N,N;^HCVZ4,4YC,8^-.BV7$?^7SX\C=ST!F4MKA]%U4R
M8J$R24N/J.]^8$^KU'?<]P#VW>[U[%Z%N#?OIC(F[;O+D@38X83W1$\A!)+S
MQ4`5*BW1'^4:H[S!>A^9'B1]V"MCY5Y[O,D`$K.=8LLZ&$Y,"NPE5BS@E_:@
M<X,-7-]+>?>H&PE/(ZRV4OX5?`5LD([!?)S2P0'O/,*3#^A#/(/6Z)\.)]:T
M-S9;T\D4S,))UQR.6D/3F@S[@^GDM-L=]KZ"0NQB5W2_8Y=-PIWV5Z]/]M4F
M=$!A=MO=JC=4`%UGY=!30*'A\4,&\O$Q/_AQ0I4_Q:K\X8<TY48N"I@JKX*^
M97K]!TL7$?Q%GF#82R_*`@MJ6MUNSUX3G:="RTWZ9R0F=G[.IWCN(]M9O9>_
M=?K@D6Y70.N;J9Y7NV3A4T>=._(*.EN]MEWVMB3`.UD1,-3NWAL2T!^=@;V+
M(:ENI^)JEITSE()]I&H/%8`];%L5%W,=^O+V,,!2@RMU6FW,4N?[(VZVN[;9
MTTX?_D][:EJC=MNT6Z-3<S"TAN9@,!F/[?;)N'O:^]HFFUB-E&_<2'G?(^^O
M3&BN\VB4M_BA93D+3WFI!O3AA#IL-CMB^QQ+#M8]S`?:=1F5X*OOMVQ8;;*.
MK8%5QD8)\*H"E^T`'^=X-1&>-Q/X>8^J0SD^LX_:KX,24E'P.V_H)AN`1C],
MP4G8S\#*@LBJ.[C1A"N[N+UF(+&85<7B,Y:8$S]E7_AA6IZH^<R+GO@`Y6SV
M6&58%J8@K7[KUDKC/@BIGN-,TH_SWZ/(2[Y$P=/&)COJ$Q2N@57VM"M@E_<T
M9G.&9\5S-UN$9"+.WTLI`E8P>YU!.3%[PT8J@J24^/-Y^.$%S1N@@?")F.&_
MC]NGE&2[TRY+PHX[6K./F*K_),Y'G5S_F2`&\]?W.T_5H>I4>VBUJ[9SQTU5
M2E1QY#+F)927V)#N6M,C>XF7UKI[=:?-555%,<P`EE$Y;B^Q`,S1K^J(C3NH
M:'K@'RSVPG\FQ84?W$94[?5>[ATOO^C8G6[9T[K-MG9-FGSBMYS`LA2QYE'=
M>^6>DSW$4)O24GWKIC#\%MN\V3F5*4):ZJFK(CLB!D*S06=PLXM:W<N&U,1$
MSJK90V<)J]J]KMWKU.<E).B5FBZCL6*_@^Z,G0"UB(>G8R"BI]A^C^M\V,/0
M@EBS;"UWV\^&PNTS.HN[!MCH+-J#2N%Z)R=1FDRTC__CQ+&#(VMX(7L_5=H0
MW:%6K=FOV\-M"E-C.9W^:7>^>RVJ@S692G2XZY8VDQU[&_"]CW/L`HM":FK8
M2]KW:QNU;MS+YJT_?W_*KEL?K#>FW+B1;>'@6=ZXOK\U!!!U>]#=$@%6-U%Q
MY6GB6F[I*$I\TFT..Z>#=K?=,8?=%D[;Z@W-DWY_:IYT[-/V%/1XJ]_G<[<&
MH,S+3GP-[#M%M;PBN/=1;;M+]9)=0MJ:'=UB..4^FFM4XSW+'E02Q%MV4?%,
M<B5'8@]O"*N73*-8I/J2C_$I'X"ZA]3OO?RMZJO<9DL<&\XR#M_]#\-KFYDW
MPOE2%^Q#AOW0=.6AN.^08O[D8Y;B!1I\JN*]\;%^@>/Z7+I=/3=`A=7M6ZWN
M/][><4,*-C[Q(PY?Z&*@IZ3[=-(:3D].1V9O..F:J+3-86LX,MMV=]3J=$Z'
MW=&0:SJK/^AQWWP-8F4C6-</4Q&68LME'/%;W)1K/!]^EF!_`.Z6/6Z9G>&)
M;=J@O<U1[]0V,4ZT3T]@%WW[("?/NOPH2H%/HXS0`YD^.Z5!U'3Y4T3_;1@A
MP[/S3K&Q56EC=)J"KLDI!B?(>V$5=+S`T>(@34[L)<9)!/^ATRS3T9<3/EP#
MEW&\:)46Z^1G[Q)E=F@^,[J8#$$7S&T9`TUG_.`/KCB$'Q.U<&BK`#O#ZU]2
MXQJ/Y@@0-N]7W'Z'+^`U8'362IPOEQ^A/&82T7`&/,N6XT/>2-9X\5-^4P]L
MK9C=VQ#G*'&(!D[H(R1Y$7W-H7D,_!#;BTUSY_.5=CZ?<GMMH&@162T1S36/
MI38FTQ8H]9.V:0U/.J;=!Z5_<GIJF8->K]L?=_J6-3H]0+4AL6<(]!V(DLC!
MCCG8>`2:7T"5\,-4?*#P@A];H2D\_&(#$#2\506/;!4W3REGNU[@O*/+R'?%
M55^EMZ24*B=LY??EI5Y<,"0`5W18#%^0E_1%5;4"`HP23D/F8`=8C.5#96AT
M/MX@P8_LSOD=`'3/EAO[JWRZ'^R$SUMYL74PWNV$<;M0E6PX;VD[Q]SIPTM=
M;SS!CJ2IV1GU0>HF-H19I].1:9_VVIU1=]B9PD.WD;K6HTU,5RZE1%R@H<B6
M>/[T/_S^1F*(@EV+,]HAOQ:`V/GN9[&-UW2X-LH26#!YL^M<U1UP(^Z]_G+V
M_R;\4IC[#K+(;]2^RZ77_5YQ@[5+@^5VF&O1ZQ2#+39>0,U/BQ8C,^S-[SS4
M[Y_OV^63M9MN#A=@/<B@C#NL>8O5RZPFN?>_J'VQ95BK[P8Y0R_7,`Z\"%P7
MHB2#JKZ*G=6O+_E_Z]CL+BK"JMQ!7BO#Z@W,5F>;Q7T`O&I:[4BK]?NQ.U:9
M5.UG)555BHW9!>`H`H7Z7Z>GD\ET^K(>@+7Y-.JE8/*R+]-BRXHS"K^YIZ7\
M5#:$I7$EMYD,\.A,NG7UV^[ZU:V_)_DYQD31/;]N]1IMNWM[$"HB=C\@'H$*
MFL8U`[$L^V&0\6C4OYU&VS?]E0>>Q92A6(F<CU)[W8>+'E*--7I6?W_X^#BU
MV)[0^EC56>E3(J(N7U&ZF:`[$7X3KG9XMZI,A7].J8%UY[P&#;?5=X_ZP9K'
M-?X>$'_W#3T.7E'*&/'5/2+`!U69$B"KWQCT[A.7/K"NE'!M)-KC1<\Z%M#&
M<W^,9P=TL1=ELX`]E?:_^Q?WTWP>$P9OF&VY5AVOJ[,IA;@O5&RZ_CBO:15^
MI.+<H-.Q[?&X:[9.>FW3MGL=<]"Q+/.T/^ZT)KW)],3JWJXDWGZ>ZIRX))BN
M0%%'ME:K=H[$J+AF*.;]UX;KI.R"']4N;J;AHS_EY11KD_.W5VM_E&H>S:6_
M?3FO=?MR7O?YJGGZT\?V:5T]K:G(/4H%[CQV/$JMSF+CK0"Z,&R/'#X\RYK[
M2XO/;(:WO#4JY."3\&:.^RVI_`5L5['S_-R^)MI3$DT47"N4^<S2+`X/D11'
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M[8&M*7M\E#V65(I6V'<3ZT'GN0^!:[%^#,IV&^U^ZV`H>VRG.H[G2-^-^-N'
M36BL_1A8T_C37/?HAY;KH=VW=K$MYX1H4[/<'!YGQB/8UY/6@\'@/B`=S3%K
MS0\<H&''UOR@^2$'J*^G,&C#43NB8W"?$9_'PQF:'SA`[4:KWS\RCCBV/,\Q
MS9YXRNA1XTWC34NLYKQ#F+*S^Q`==?(.WF5V1O?XC.GZ!GX+-;_"B_XH;SE[
MR,LGUZ\G._LP71O18W5[G=&HVS:GT_'4M*?]CCDZG5BF/1QU3WN30=>V+7'!
MN+AN]:Y;4A'B+IB7!70]9Y)^G(O918\TA6@\[(Y/!X.Q.3D=#F"+=LL\Z9YV
MS4ZO:YT.>NU>KS79ARE$9W0ETU]92#>U&E=^NMAVC9(8BT[/%OU-3H"SB2IS
MB9)&>2&#\?L$/7&3T\I/02S_(VZT<9(DPHOCB0L3O(_*N(@B#^]]PMMO^*`D
M^%?E*I);743RXJ<?87C1W:XBV7*UQYI;KZ\BV9<!![=8_4%&'>BK2#2M2K32
M5Y$\=+'M5+5^2&><R2=-YW:;=<A9T><]SMEO#(1.V8M&P[U11$=$XF-I,]WW
M9H&I'_H)1%I"@?DA!`-I%%\#)`L6T!6V$<Z9TH<A'IOC>_9SGX0X>I6V)Y0^
M5MUVZ,69XVE1T_C3]Y(\2/%V[XK<@X;=U?U1^V0N[A`G;,AU:-MZO+;UF,J!
M&H,/:U]O+*CN4@I42H>?XLAES$NF<;2D.N/'%5;`9)5Q%'HT.OD!ZJ=^$MEM
MJ__USR]CM8AJ=N]:0VV__*W74FJH.VY%K9L"I?VY[SIA.DJ2;$G/)V?A'T[\
MC:6?8M\%/-)2#[#_518S=>/MM7W;T]/.N#?NF]VA/33MGMTQAZ.3H0G+]896
M=VCU6CU>.VXUK;QRO/,>;JZ@BP<!4[+:/(WB+RR^A$62C_%IX/C+Y!%9H;..
MDM;8MD^MOCEM3T],<&=.S%%O,C0[K;9]TK/:K6[?^CIL`5[@?^"[+W]K]V^L
MJN^T305;ITZRD,/TS\++"!X[9_%],%%E^(X]M(;#4W,ZF(Y->S2RS)-^IPN;
M'DU'$VO0.FFW@?#6R]\^=5ICL;E-4&T0;BD&8O-<-A(%!_LHXMV7OUF;1/S&
M#=W,[]ATPAZM8>2QN+QE[]8\LF5W-QN`XMG?XRC92^:P=M/_E9ULV+I`D7PV
MV=M=VUM$HG83RH;/0C=F3L+&C/_W+'R/__G,YT^^]YV9'_@IWJKUE-Q_8O6'
M)UU0?-9)]Q3,7G]D#@<#^&D\/;6GG<'I<&`CN<'>=XI][[P7OO\L,2\<9P6O
MI2QF">"(RHYWW>C7?JO?[@^^#]KM?G\`_QH,^IWO?<MJ#X9WHOYIIP__ISTU
MK5&[;=JMT:DY`)M@#@:3\=ANGXR!![X"X=MH_H=]P0$;=O646Q[VAOWVXVVY
MC5L&GF^W;[/ET3**4_\_U%#X<3YFLU1:RD\Q6_K9\AY(X-ONMH`(7_N6W0&4
MP'_:]MV0T#LYG4RZO9;9&PQ[IMWI@L\'-MX\M3J];JM]<CK`*_T`FJ\]$/QA
M!0DW[K.,EJU=AI\!F>`M@O!P[^C*B;T/#$((<([FS$_!?;VS7BC0-AQ80T!;
MQ[*Z@+;NH&/COP;]X?=^;]!J=6[=<#EIM2;C-J"M==H>@=H<#,QAOPNFM-L>
M#-H3>]CM3G/!45!W;UQ44(OOG8`"\K`G$#B2-[.B/KY@.$[MY+IXY!.?L$;+
M3O[._/3Z+(0/9C1VC8*4\X43"O,E/LF\LY"#>-!$0"7>[JH\_(28*Y.L0N3[
MJ\?;8W>3GNC=`\-VB<WK-UDU$%53.@9T73IX-](#.`4Y9@;VP.[=24ON%AFC
ME@3^ZK;63,5.^]LS73EH#8;@]C^DF-J#3MOJC%MH9X&)3H<M<]CJVV:O,SQM
M#4:#P7@XT+IR;XC0+A/AN/3DK3"[NY[<';NWUY//KQ*L3K_;>U!N[`,=NM-A
MU^Q:PQ/3MD=]<S2=V.;)27\Z:7>Z_7YGD&M6`,8>:+7PS(2P@!"MWL`^7M5P
M&^SN[D3LCN$.SS2T'D8_4![N`[NBO]Q'!PPA(@1TM`:M76+-NZ<9.U\IKX9G
MU$#>6]T2(G;:Y.YXJ4W4'0Z.^L`IG=T15+O;2NK"^RM+4A+&\VCD>70@S0D^
M.3[(X"D_6G;N?)_,Y\Q-*=59*_R'@\(!J+->KYS6>!@<[,Z%CVR\GQBCO9>_
MF7UK9Z:\O:7>A3Y$DEF5))\96)P$#(HHMW$P/A='+PFB@T&U!;;8LJU^Z];L
M>Q_T/',A]^FQC&5=^\'+ND]7%'QZ%8`9\^']*X0[>?H/Z-ITX/_=/J#>$37X
M)/P?B&/:5K6`LML&]R<<?$)\=1\][KMQ]L'#^X=/@3CT#0>]W=EL!^?PB2*,
M"G8>7DM97[LRPNC9K=U=E?T),)X*17U4Y.V'##">WP]^*MR!'_PH;O#-$UNV
MNB)/H+W66\QNJ;N&+W^S6YWV+M-IMN[U>:;V/*V>W[$=:]=9/L_JT3^1:*)'
MWSD*A_ZI=!DPV=!Z.(<>%-M9Z$9+]OX>;6X%%KKMP>-V/G:_#I!MP'<WK6YK
M8)7=JM)NRANMF2L&_`2Z'MB():<@DQ?,.X^P61Y^?_\$]K!O6=_A/ZWNW1#2
M/QU.K&EO;+:FDRD@Y*1K#D>MH6E-AOW!='+:[0Y[R!%4CVD/.L,2(NZTV]L@
M;,QP#A9Z%P>!(W0PAUWK%C@J-K@/?`3JQ=ZEG_#N..H@'_7;3\M%CX2N0=NV
M=VK#NSNZ;!*[EC4X5+%[$ARAV`TJ99$#$KM!N]L;/"Z.J+FC;1\R'ST!CI"/
M[(']`'R$K;%%F?LT"B]9G/JS@/$?$\R]XZK6W?%B6=:P!WB!ISL;&X.KA\#L
M->P,QJW.:6O2,5N]WA2[HL$C&G8[IC68V-/I<-SKC6U>I08?VK(Z3;O?;1?H
MV7FCZ_@IGA"O8=5?KL2C%^YQ/C:2=HO2=D<4%FGZK;8%3FH94;OON(RM/\.8
M\0&?OSM^B$[G1Z6E\!ZR95EV#\Q^9PA/W\V?GIX,AB?=H3GM#MJF/1X,S6&G
MW3/M_GAP,@)O8M+K8H6`VS&KU2W[CS=L[!FP`/_J]CIM+)VT^M:CXH1<(;,S
M[!X,2JQVYX[5I!U10F:JW^GW#P4E=JL_>%S)H<#+@N_<`R=3QX\I5%=.[*(U
MQ^0CGN&\#U*Z+>(,JS>L\DEEP^UI!VSX2<L\.86HV[:&.,9YW#<A(.\,`!?#
M3I?:H3I?+3IX^K^]/XKMWK0#)2M3]RC-38[Q3/K_^BP`E^8/)\UB/[U^G)UO
M-+_K;'`+K'3Y.6Q;I&1NM<\Z_)R%JRR%5[(5V>A[N+%/CPLZD]X:#JNXJ.Y)
MV;=$!<]<_9F09QLX2>+/K\_`&HL.BOMCH0<[7]M;J]?N=SNG/=/J4N()9'XT
M'9^:T^F)==H^M7O]P21WLSX-\U/7.T+]U/*.>WP(>6\3-4'#?;+_U_ZC;8\/
M0>3K-O_0;,X1TT,V;W<'^ROR3X<+F]1?N[N;R$LN>A^%%\@MG[+873@)A"7+
MI4\R,UKBN<6'PD"GV^IVO_<'W<YP%Z^QYF!FK]\YL4<=<`#P?UK#B0G1Q<2T
MAX/1$+1#=VR);N$^^`-K9XYNVJ?"#6-VR8)HA7^;,I;P)]/[%">>#14@'VW9
M.;UU;\_)%`/@ZIW\YCMBHKWI'-K>\<238,*2F+@52SQT5W-^EJ`[N%L4N=N4
M`JK789$*GBYW'NS2H?R(>WZJ"*DORBYWQ,"VTOEDN0JB:R9Z7*Y"%B<+?_4I
M<.Z/HLZ@UVO?\P#/<-)OM]J3,?`&2H0-SN3H9`1N9;<_/1UU[>EH:-6=/+OC
MGA_H[!3]S[_!;<T_?)_LWA9LWAE;//A\@,-.-5L]P`-HS\*QG?TXB3JF*YDV
M?O9__'1Q%GK^I>]E3H#U`1=GP=2#>^]:T4Z$V/W@ZN[$`-?"YOW+9??B$;#S
M)/;);MEW;(K?R2:3$V+7G=/8Q2(I.;Q/4>"[U_>^3PWWW1D.<U^D.NAAVAH-
MA_;([+5ZL).3P=@<C'H0@76[O<FXUYF>3&YYN]I@T]5>I>L1VC^KLR[O.^(7
M?O#E#QG^(/J1C`*?AAR]<$UC++-\`FO^XJ:!P#=>9M9[E/OD1@A]S9U`>`E;
MN_'B)[JY;0YA,,X0S1C>=(._N1([]XJ=!W+G\,<$_I!"4."'#*_#22-CQHQ7
M7;LY-)9^$*"`98F\%^XD<-QOYA=W$04`9T1*D[[&)7$9>2R`19S5*KB6[_#[
MY?!?3I&E>&>\]M\4NXC]Y)LYCQDS8LQ"1'-8!!,=/S?@N=*#;.GX(2V->2O8
MHM4<&-?,B1-Z5'TVC&`5TC<L](QKS(;@,Y?*(Y=1`)`3)F"I8?=GND#OM?H(
M;B%![P<66^$T2P,VBK_T.*3&DCE)%I.*:]Z!5Q[I\D%@EBU7]CTPMW2&S=ZS
M<XNU$[.TB%EJ>"7G%%AL%U[!SVUFEIQ5!*)KF25_[7R!2%1PZ(N),?!#3B=8
MJ992!7F4"QS3!:)'O<$17M]VAR.25MQ`B?=&.E6<.PA@1P((BP78N(G6=X$&
M'@%=9Z:"`'7LA*1'!)8(\:I5?`47=55++^[J`B:)B^_",N4O7\F!HCX%-<BD
M\,*2Q083T4S2-`CE5K?9@=?EYSRVCO7=<"ZH?+MK,]=1#LM4D6[932L'\`*P
M>0/.88GM6*_#N=5L*SB')4I8]ZFUM8ST&U&.5%E#^DF4+@R'<DV)`;X/+AUD
MB">!<7!IZ(X(=`QAA22%'U!6\!O1BL4.[QU"4&KQO9W)*Q)7Q9V?R'T@>^?X
M\E6=M[-V0[9"_4;HAB4PT&``-^@'0*Q/-`'&Y`A-Y/Z7-#19*`^'=%%9[>!#
MM;?'`HD`$4+Y`(H!2+H+BJ3#3:,X479_QK^&H[D)M8ZQN%[AXZGO.H%AM7ZN
M:B#<C@K;+J!0#&B\?M5K#KL&'34N]"'\LM/>?4FQK70[?=^@;%PM?)?NV=WV
MI-"EG+]1#@D\NE6W+/#U9C#*Z.K`A7/)<D31]5NONF!@A"0I^/Z2`4@Y1NEU
M_O*,L9`D=AY0'0N4`!!C%]5:<&HMB(*?-B"SD"IXOY"KIJ$,\\[A!1)*Q9B\
MX0O[R+"K+.7*`N*E0&"2=@94SP+\&VPE*18,KHV%?X&SW%^#A6?Q&V57:`J2
M!%AA=V>JF#M_<ZBTK1?OGO7/4@=9-:0>6)/IZ71H=D8C'##:FIHG)Q!7=VQ[
M,#JQ^V,<0"5G&WUJVW]L:J,KRILWMME]ELI?#N)41W3>/\&V;;L[C1)MRY+V
MENW><CM;I\WBR@^UW\<:K]J61P5J)@>N;>;)!LT^X=[QB'=UONXM1\O68&KR
M'9T+X!UUJ8/`A_WRMTYUU.ZN&RRC19W.C:_0@5),]F/C,O9QWZ>_Y;X(V5T_
MX@".SJ""D9OW5L;%!'P!#YS$PDZ,6>+&_HJSV#_A#=`\:0SNTGV0TN_WO_<'
MEM7"KL!>O]?):U[5/O3IH#^8#"?F>#"9F+9U<F+"'[JFW<81@M;8'MF#?/OG
MA<W/O6P*C\*0N=SX^BGW>SZ"NP=>#S@ZK:$Q]T-`!_JLN"6'?%@''2[\U:43
MYQ[#G&&?"!/^TRJ.,!KVR-5VE(`4?%9R'<6Q/NZ[^7/Q2^&Q4%@^8^D5N#?T
MES^;7YJ&!Z&]$Y-#?!*#!YS`9T">`1Z:5P..24:>FY.FZF;__^Q=[7.;2-+_
M5U+Y?"0P,`Q<Y5*%WO;V>9+896?OJ7V^I(B$'6IE28NDQ/[OKWL`"1"2!@2C
MD<75UM[&P1+=_9N>?N\Q-RJ^;[\3?F$%ID5L-8+MC<:U'W^/_HZ^6?AY4REG
M&6O\\X&!_WA3^M+P)X`4?`5_8W!Y=?T-V$<8.%C"^9L"U]Z]&:PW?`"K&2ZL
M$(SFF)=3<$IB/LX?2AC%+<P-9>@!S>8<;$M@=A3[JM_1XIO`[TW2+]E8<8OY
MLF#JO_/&XWF$.F#Z\H\W.;Y-YOS#_U[[T_#A9>,S(86QKX+N1U(YEGLM!!)`
M*^#)$BXN?-'DT3`U4LO,SG?;PUGAL,FJUZU6M+RKKH1JDTRL37+??F1605LI
M4K2<,,%VXY2\Z_(F8K%R_Y*1AD#F<&@QC<$7@`8W1YI++$-CKCU@@T%_X-CV
M9J2AHAS)J>@:/'"`[&'/=K#B`)2W8;F:QSR&S<0#,K`<:H_,[01]RSB%"XUG
MP.01S[`FHVCDB63`6I\.+I$)O#2'%F=[UIH/?FCORJF\`()<4G-2>L^SJ3'J
M:0,/+#ELGM-Z(YUJHZ'=[U/;'=*>L>V*.F#1%6G*[L/"J^CF(7GB)KK#792;
M00,-E#B4,T%P>(<P`_3"W`XQLO9-0AS-HV;\G*1<T]*IR6I!P.OU0,MYIM9W
M1SH<![,/]Z3;TXAGL:%%O0'P("[;-[>E>4<)*J`_KNK`@HVTFO'F@5=S>!A'
M6IX0XTCH9SIA5GNEB6:B#G:.P#'"I/.!TKK^K@@?K,3?M7:\.]48X1@N;9$1
M?%Z$\_:C?2(BVJMEEE.S:Z?!L"(?*E0O?UECV/_FP7N,@N#$+IX]5*?.R^&I
M5^(48X0CN0=VWWYG=@[N7KQ-7/3>RQ_\>KB)X_BS1V\,AD-EFP@+E>`Z:GF-
M&OE&#)P.C,T`Q1$Z@D3)'-ZXAREBEH#00CV"DH>OA=\PFYO3./0C#)HOX==2
M$SL<>[/)()RN*U;Q'\?%-Y#1MUV6E/2\6?9PZ`QM#/#98!C8GN:9.CC0/6N(
MHY=ZGL.^6;RS1S/>&6XFFG"8GNK3H2LO%3[Y>`A-FK(VFV315]1-QZ%[K*,C
MI)5?CO`[X[_7813`,0.AK5ZPD)N/\H"?\HX()34&F@>%=F=QBEH+(YQ,ON!Q
M0,?9=NS")-=*88,=;N%=BB4--?M<I4D>[8`X\']`]"7$2!S/*ELQ@(G('#,_
MD^;$B:SQ[+JO_G.P1$VB(A(LN"5MEQ7#)MG7SM/$M>"7^6R>&A#QTS6J[F6=
M<Q?.N67D9\4=IJ(\`YI[)/N[8&*I2+?#`X-.X92+4%.P>9['P7()<.@%L^`A
M/+"7XT(L9>SKA6_-Z_V3J#P66.5PZZ^C")TJ[ERJR!=4@03<M",QU%UBRL^+
MJBK/!(5`F%$D<_O294H<#0&$!+JGX6P-TK_9E'?U>/UA1FM^#F?SB#=$Q1\*
M9E/^4^)^J<_!ZL=\<BY30=1IT%&-V(01M^22D,(6H=,%*FRL_`%S<6"92:G(
M"2L25+B&\Q=7U6F_LM"#&XL<\,'S9E7)RU?W-&.PH&*>S^#!FX=,=5O5XC39
MMB8._R>.ZU3V08\1??:58[(YZ9;=Y:VL&:L]65N:IN9#M,&?-5@Q`KCOG-T%
MB\3INWE(P\`)?SZA*KKY/@T?_<IS1:7=Y'QF;X[8"A0=NU;P!IJMX,92TXI%
M)0(J9.=6WD^%NKO>)&L-#'P9)IRFREKC].UNY66XH[2:D)=7\@!L7).K)O1T
M7!UE%T*H@@0)Y5PVOZZV)VEB'(TYS"8B.9<2HLI+3_@,Z#WNZ`[XE.2+7G8M
MUR*OV)ZQB.#]XA$(LTG=P@QI?.!AUL(PA[T4Y$E%!,$#^']H]?WTIZB98M52
M5/-*THZ;31RJYXW<*E0=NZ"Q1!<URJW_@@7"\+'<<=IX%S6+V*0%X3%!"7;<
M,6^P`IG'39HTRL$_2G;@4I`Q#BJ/@LLH0LL>#SF)<2IILU.PX?:[Q^F;%[(N
MP13+Y7\#S1GY4]0ADZ=P%BY7$4]1*1R)QWSCSFAR,7+VUVB>T^T7585\F[!E
M&N7W80D5>_)("3.22U-%$>-(:>HXQ9Q#Z?NW4W<K37UCZ,&F9+],RRMMRYX\
M?[)4E.BR+.E12@YY/J#&_=DCXE[=N"T/,CD'O)TB$4(^3ASA5M['(;RVGAE4
MQ,4IH:D8<5H&?C1&&S`S+U3A.\O$EE%6V'ETD(J"[D[Z)AO?\RA+_O9F1WLM
MDC+5H_\78.%],/'@IO,?@[@<DU><)>5FR=[1]6H)QVF2]E8V75*X6TTJ>K?%
M?4:NQ9*"TNH$Y28!E[2B?`4V+N-I?U_GG+L_YM-)$"WCP+]4?)C$=-W^T-7Z
M0]/5+!QAZ`P'1*-]DP[!N^\Y9!BO!;-R-76UJ9.W4U9&^:G)+PW'(,QN9'_L
MGELV?31U"UN$R&[AN2`K<-=,VH90A98S;,^5'8DV-]JUR86Y6?ZF3$T^(['-
M,A^E(F(HMZWW0>8H2=)V!\M.=]*LSW'2PN!#YW#[[&]1N\G.V@`!-Y.Y`BJE
M0,H>VHN>FK)DXTUKV_OH+B4C0_)=D`X;&&_&OY1=T_NR7RJ:IQ;9-3Y.I3/#
MLMVX(T\CWP53'*6G>(295P30#&.$J:G0"P2^T"H*<<A:?$?A/'`^,2:9^;V.
MZC/G&P,+BIG/CF$R:F<6'SBF=>*,=#!('#IRJ48-%Q2OY3'-&PTMK==CHR$Q
M*6.FLQG+#0Z@ZPAV$8GP8\<GSO[&B<YP+9Y5F$PAS#<S;</..\XEI$IN,]JN
MM]>=F@/*1:]M$YL0&VXZDM9U(9]/SMN/M+BG\\0>C'.6$LIGX'44%LKGJ[PR
MPT-P;_FJE<O3N%_9%C[KU>]552O<Y+/ZC/5N9XO>R.>RF2S):S:6(R^`(5^M
M8OF#8;BG1S-4\%02WIGP3_7A1H)\X__2L7*H79=$WO0'J8Q#`[/QF1!GL,<+
MK&K^?!J8V.'L(E9AH,B)]OCY[1M)S$/[IA7SYG@NZ>`5(^&@[F98*^HW[.L@
MKBF2-SM(ZWDRBG)5&FTXSWA>6TW6X33C"7&7;ZK)N@K05+-TUIRIUD@_W98/
ME#CM9N#H-XRJQ-50E9KL6AJ-@YN?+=MX!CM0;,IPS0H/&RL\R.FS<J2PH8%M
MR*),,9I@2M-Q,6G;L'F*WM3-_"F0LPQ[/\FRQ)\NPU:)`>UO6XW3SSMQI$,T
M2Z]TDX4`FHQ7;:[N[3`[FUC"_!N_CFN,<79C!H-)GCMPDI*P!,-%.K85(/!D
M;*O.,ZI"9.1+\(O_587;S#200!=P9,27F<$,W"/`7))?>G*0N:6)6F.@._V!
M1G7;UBQO:`);"4Z+[O5H3[='SHC&\[+==(6`Z/+Z#9F[N[/BM-$2BRZB\#&<
M^5/\:3Q(ML*HX#I<J9+#%F4-7/&F76#-43(SJL][`K:-?3``%O-EN)I',227
MH`;BR!QBMEVV+-91<-@Y%V<'-GX;B:83(DWNV6G[M*3[Q&R[N'*CSG%)U%!2
M3)].8*TZ3%J,!W6FRHJS!$,0[W+#U`Z0)AX.;`T1#6N*=/4>TP6U:)ZZ_6UA
MVT:+6VY5!+=3?QQ4&R=[/HX8<%!(<26'&'GR-&BK.C/=.7>"RLPO<+P+)D&\
MNOLVBO.N8_BI_U@A%<T98.`@=B-7?%@D>5<?#'K$]?HZTPRK#W:Q/<"%34`R
M(_V^J7O.0-='W^+M&^^*]Z4`"8?H_HRKOT"C#'"56#U2C^S8A+<W^SI($<0Y
MTBS=ZVF>2TW-<(;6:.0.;'N0^$"8Y=5-HNF&9M!]5&9?^!!A^/<X+"5:KGA2
M/=I8JE6-I<;IY+.5#*"3':#SP/NWT+%]D-`:NJSO&!ZU1T3K>WTXQ"/3TAQ*
M/3C.IDU[@P'31]YFRQ8V<!]09J7U4HE+N`\9?P9^A2+&*F(6IXS$<-ZXKX?>
MM8DYGS$59DJ%[IC$>'9`'U.VI<FV+)'PU:Y$Z9!:!L'=<?K``H?2,#0/P*SU
M+*]/F6V,#)=L-U\6+?O]0T#K^YK/BS">AUE'=VW8=,CG+K!@J.O#`8$CK?<)
M"'SD.)K+*--&E#@.&5HNI:/-!0W?037=T72S";\Z1ZOJ48T*'*X8U1"7`(#0
MHI;#Z+FC&J>=97;6LTPJGN61'T;<`O?`_GQ*BQ46?$_\?_C&=5RY>5?MN-HV
M5\X&J6Q64=/Q8GB0'M&LP9!I/9/`OX"SO;X.-_)0_\;-2/V=FP&*.!GBY`]"
M[.:?35HBONRP")(/%[`N1GN6AN.4WX7+OT91$*1P:8ERJR[=!HH=TXZ'B2\C
M0USL."2S/M'U"`.[X];XT_UL.`,QN>)+[K<I,\N\N-X[:8!@GD)0;(R`*G,(
M8:R>T]RS#1U])\UP^\`3]!M[3+>`)ZP/;J0Y&.C#C2HS])TX0D5*L^YSNNNJ
MMB%RD!>UZ63<]@"_@VCFQCTN?U<Y.,9H*M7Y'F/#=HM;C>ML+$X=AUNK'LPY
M3\H>Y6NK(QQZ]F<83"=?YZF=W@[M>Y7:KNTISA>&>LW0TTD:E<@L8\_OL\5Z
M!;^R7LQGI^CP,[""<A5OZD56%$F2?0YL(+J)<Y!&P6Z=/R_A")21W;3<.4L<
ME#NH476/@#16V%P;8)BIRA&0[I3;1GZ=L;A3;J%K9`YTS7$-<`G[P`I79Y9F
MFVY?=SS'&;A.UBG?7(Q7YI17X'#5JEIA":!3+E+ATK9/WMBN29=(7C5)XE63
M<*0S'2J55DTV5BPH0'L3<^+BI5(V_+E^+6!3F]6DD<P7JY%\`=SY%JM)(QOW
MJEF4E8>;Q->J*;E72AH3^5HI0ARZLVWL/%NE3MJG)(UKN$[)M$PCC[VCZY1J
MEMK+`P-64A/;*LS2/5!3?\)P;VE488'T?EG)F>TMC=BX,KBP2+3.:.^39UW+
M0RV8ZB;=79=X?-1U0T-PI5'*2Q[<PL9$@1FXK4]]W<>!QH:^DF3HJTLV%=YU
MA[ZV9-:;\LQZ(S7K2=T-\@V;]0=I;P+Z/$ZI&99.5#'K)9",9KU9H/C<9KT$
MLM&L=RS+>+UFO00F<K.>ZM109%GL'=Q,LTH5Q-)8I?.&VN*=&K]NX[Z)!'K0
M-P%Z6,55KZA!L]HS$RR[C8*5_]P>J24%@2:#_Y&19GB$8'5D'\.%KN8XP\'`
M(KT![=O?3,Q=&\4.@*-T-.B2R3C(Z))9CN-8HBX9+OJ[>?AM/I\L[^?39NV8
M9FCBS3Q._F(KO'7#7J8$HL#+M!P`[?F]3`G$@OE)'%)0,6?T,F4<1(,/'#!W
MML1)=C,ED(I%UG`^#47=S%T.-.9F&K&;R73#.76W2-%R/4W<^7J?=+0PYH(=
MM[T;UL".7PPZL#U%G0?]CE8H=FV7U6PR$*&8]SB#=MM7Q5H^*#FW@PI+]],E
MNV!Q/(7K"C4@11;$1%/=94WT6=B]_G!(;5VS'1?.@$E-#;YHH/4-7"),>GW'
MH'%9F)UVT>W;M%5"I>HY[0)ODYRVZ=@V.3&G[0X9T7$^@65[IF99@[[F]3RB
M>92-^AZU1IYK;+H=J`HY[0*>J[7_%!DI!99ISQ<MCC(O(476\91(.28QBI17
M/)$EC!H^CZ=KO+/J+7`^'SMXFN,X$$KIDQ$*W5NM)<X,H:HM$^=AN25N\'E&
M0A5Y8#/;%!\!L\L##,P,>[:C&0:CP`/+U3SF,9P.-B`#RZ'VR-Q<6)I91(34
M$5#GHYWA`"1=X%8YMI:Z=&C.)7"`EHP'$20OYDE"(W^#VC3RCX(/@\LX+0WE
M?\8VF%7X$`;1F^7X!USJ_WK[8[5:_//]^U^_?KU;!N-WC_.?[_N__^_;CTB"
MXS++<CZ\W_[:]J.6P2/OR__P_#V:3L)_!L^+:3@.5Y\#=$O>3$+X6YR&\J^W
MF\`*;N"Y>4B&`-Y$=^C.>,_A\NW'V+])I@/&TQ%NQJLY?-#77_`E+_\?1/,O
MX2R(/_S#^]+O_/CA??I2"?GO<_1_6&S-CYB$E1_Q?N6XOA)<,-V`S]C\=/-@
M`)[F]C$<!(@?/<D\].%]YL,_O$^$>*)$LWI;28F6Q3:Q[R@6ZB8?"+\^F023
M[=-)@XH_S=B,UR7:K'VBI&@_S6>/8,0\H>WR]641Y$5::&V_+MGM]]:4E"1W
MT;8B3)KZX]ES?!K-'W`?+@?W?QP[@L+?>#OU9U_\I^P7QF-O9CC8`\X_/A`K
M]N$4\UM7A9\#D10E\=.D)A#^TOL5"`%?]!X@XX,(<N#]OKIY``"#-W5=R-D?
MAE02.1LA]M9+,-Z6R_OX(Y898?;"^0(\A"=_'*Q7X=B?RD#0E_D,5]5WX(FC
M]AUX!,&S47K7!9[6`7*9W"$J<H>(<8>TR!WQCCTE%4_!7LYDG;/;6+C1?'?_
MQRNUF9TSG[`*_<=*@DAB9$3XG>XPCY=_@<_^<_BT?FH12WPJHH@^2KJ;)6*I
M9)Q#AZ43L!3.K@]+N=DW2J*G#3OZ50E1.?OM[.P1GN&G).`/QZN^S%?!\M9_
MP0DJO$PE^>_&-.-],,9Y+&&PW(SAXLL^_#&OIMD>NOBOU4AIL;:Q='RDII)8
MZGP!4TP?\<?D8*C31Q>LC]3`4OG$[`M$C[P\K+!=(DEV%VJUM<R=/6LLE$3V
M_?K[,IR$?O1R[X/N2Q:K;O51:0%0<2U(>XC770WX>U2F\6.29+I_N9.2$LZO
MQ>J]@)WT]QH4U7(<A8OM[9,^WHO"R6/P:>X?LV<ZB#4',?%-?DI"K#/0X4XA
M8E</T7!*1QL8.K1O4TG8'`ZI*E"-*FY0M):".;A45DFIEE6Z\7.9M"%YLTF9
M8KA*,98M1[X$H:8_3HYG4QJ]4PBG(>D58N>U2<NP;'`>3!>>OH1SG]\[EBO_
MW#VJG1I0`UBO'TJO3'BZ:U,==3AQV@^IU0L3I?GKN,L<FPCGLVW^>NOQK7PX
M>I-T^.!UBM&$?RY:C/#SI_F,V^;7*4'=4=6[$I2@-YF$Z&WY4]RS]_NL[R_"
ME1H5)1*ER<OK'3B/U.Z":N<)JC72*?);-%\OS&L"[Z4FUEIDCYFK9S>I3BF<
M;5=7K6"4(S8S4&`TC_`^#5?%>C_O*;J9!?]>SR81N#!MM]4+YOPE"Y"!!.FE
M"O!^O8#/P!E+47"=TF.4JE:R45EZUWKRF`Y7SH7+[NNO^57*SM*IR2Y4=I_\
MYXD_#3Z%\'?!Y+K$%X\'<BS=);9:XJLW'NA_UM,7F;.!U)2GR@%\Y<<]*2?2
MI!/-=N/,K.ORD)ZR8?6>/\6"X?L?0;#Z-!_[NQ5=O*"YOXXB^.",@I:3K4F?
M@NL@"!]GP^?Q#VQ:@S]B>.,ZH=4U.;Y"V6;J0+M[X375AZJ)MJYCXG*%9YJN
MJW3%SE:Q]UZ^X&9[Z:4[2HJMJ[Q\/6+L!D=>1%V]N@#J2G<OJV9/<22]0NR\
M-FGEAE]=7_Y9[0E7%P(8YE#35>RP5\ZZ#3JDM(F4+DS88:D9+*F)GDY2>4EU
M$Q`O;`*BDECJ^LHZ'U46L)164LH!JTN;5H67KC/%?*0+@%>APJ(/(HG\\=4%
M:;HVV`L6GN':SPZ!I\UKRW%7[Y-**CB*U1+>$PAF[,\&P6*^#%?S*%X7?67W
MBNX"F@!*U'84!<]__.DZ+M:;3N>_L(0OR<\&T<]@64CXW07?@6'+/DCR$?YS
M_!<^FRYWOE+16I:J>J&2:'EUYC:U&LT?(__I*D6*C?.6HGNP1$6Z29RECX%5
MAE5MR[M@M8YFURE7W=6IHG,M3I'KU\B?!'?!.`"S36!6]*N3;3>SY!6)L9M9
M<ND2[&:6O`II=C-+SEZP>!DS2]0%+X+*Z,![Z>`UKA&\S+$<2]'>[$,22W]T
M==,L$K%1US'<3N=<NLXAUPE>W657U]77"&CP>VX>'D`RL\<K@TYFY^D&2*[M
M,D6A<]_"!M1&(/1E#I[F\D>''BSK<12-OZN(GHW:NS+TJ#6;4@7V$,X=0X?_
MP&L<#A<&Y"S;5FQ&5W;B0O#W&B-R8-R5W.2%!UI%M\CRK?@Q0EH1GT&23<L&
M*5:A*"H^)4M`A)<<&Q+$J)R..C=W],RN]<U\&H4[3P_,IVFU"S6<@8S@:9+9
M[I[^K#UQ7$"]OGJE\^<4E=(5\*H6HY]'8%<55+D(B1!JV7B$3(OWO3'*\"IB
MKJ*Z;^2'$=8)!;V7S7_^&S[3C\8_7CX%/X-IH1`_?>CWV6*]6O(GCB4"Z[S,
MY\!?KB-N"(XB;JV/7_:\2>;1Y1VNHF\^7J8.E'0&-^GKA=*QM%P'I9.AI#QX
M.GDQ0R?45MJ%^1TN[B4?HB%I@LYYY4`(O3PYH.WU-;&]7H$PNJ)<]6735=HJ
M*9:N?%9U$>D.53ZY?5A$7R-NC+V\FK.3RR)3:EDF_,DEAF(6&8]/WG+J,P'+
M^`<-#KYK(TE]N3"P=*I8'>4A&(SFZZC#0?,X8*YM.HHY!@=Q$/[L]$$;.&`@
M/<4"O(=P(++3L0-"'2"8U'(5,^,.`N'HBL$.!A5@H);@KULR9R^2D4FST15;
M-`1/0YJHNG"F^K+IPIE*BJ4+9ZHNHBZ<J99@5+*&6J>YN,%8X32Z`I7`F^:1
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MB.8__6D#8SGX-WP*_>_A%$YLL`1;!'5JN"J^Q2?_>0(6Y:<0_BXX5OE:':PE
M.T=&8;1<_3Z;A&-N5<&;>4\1D(SAK]=1.G$<LXRYMJ586<5IF&V@5;S#K`*8
MQ4D5UU:HV`A$;J/Y.`@FK\*-Z+9!*B<+4[>LSOYY%7?).HHCKZ_^-CF$VLX"
MZE"K-FKS9199#"N(VO.!1D(1Q;7#LILTJNZ\*EDP4&E"0^LTDVXD0&/CU&2)
MJLL+JB^;+B^HI%BZO*#J(NKR@FH)1B5KJ&V:==?0#;N;0/%Z"_$!/R!UPY8!
MH:[MJ(-.7>@8#,MJ;>:22X`.)O[B/"#^O/?RQRS\>QT,@N4X"A>\GC.'FEX4
M3AZ#3W-_U@&G6>"`\63;?*J'U5UBIP!J.`NBQ_^V<W4M",)0]!>);@:CD*`0
M>JL@>A9)(1_\0#'HWW?=_&)SH-7*:&^Z=4_W[MQSIRONO??=FQBXNOB)&V9I
M`4_<D&E7/]>;IMH$EM9!G<Z3TNOK!5KKZ9-Z0K9%$*Z?)):@)PR?G?MQ5"T7
MGBDN4=(Z493^^8<8"*M\L2:8%KM_^Z'SI<,.8F"5@H%-!6G!/"D8A`Q+91=Q
MGAS+GOTIKH2<0QY$B?_[E%!6=)_-214,36RU7R81HR,K\[!=VYAUZ5E7@X[9
MW#'SRH*SC8IT@1'QSB=7@*CG5C`W`JF@*2N`L.%IGG@0M,?A!=$-^.[6KK+;
MEU#+?"AA[?`8[]FZ#MM36#=,TAAD*`$>BJC#%(T=L^?[J-#IF\`,(V?-!2KG
M5$2_VQ[?2CS@_0KQX*I4?4(8@TA-=V\!AG+6S$J`6#V#BP=02P,$%`````@`
M9H%G0Y0X(BW'"P``)9L``!4`'`!A;7)N+3(P,3,P.3,P7V-A;"YX;6Q55`D`
M`^\!?%+O`7Q2=7@+``$$)0X```0Y`0``[5UM;^,V$OY>H/]!YP*''G".XZ3[
MDF#3PGG9/0-);#C9=G%?"D:B;6)ETB6I)-Y??T-9MJQ8E&A+6DKI?<F+37*>
M9S@:#LD1^>&WYYGO/&(N"*-GK>[!8<O!U&4>H9.SUN>[=N_NHM]O_?;KCS]\
M^$>[[8Q&SB6C%/L^7CA?7.QCCB1V[M$SHVRV<"Z0[P8^DM":<TWHUP<D\+\=
M]=-SX*,OYZ-KY^B@ZSA3*>>GG<[3T],!]B:(MQGU"<4'+IMUG'9[)>_W);)3
MY^W!$8#;^&;$`NJ=.F\V/KK@>"G9`TRGSM%A][C=[;8/W]UWWYYVWYW^\OZ_
MFZ79?,')9"J=G]U_0>'#-VU5PQD=C`XV2/[3N6-40.G9'-&%T_-]9Z1J"6>$
M!>:/V#N(&O4CO@ZHE(JSU@;%YP?N'S`^Z8"8X\ZJ8.O''YQEX=-G01(5GHY7
MQ;N=+S?7=^X4SU";4"$1=1,556-I5;LG)R>=\-ME:4%.1=C*-7-#+1D`=+0E
MU'_M5;&V^JC=/6H?=P^>A=?Z50G\P)F/1WCLA!A.Y6*.SUJ"S.8^;D6?33D>
MG[70C--0\X<GQX>J_D^7S`UFF`)5[XI*(A=].F9\%J)N.:K=SZ-^`CZ:(4[`
M;/D\-"`9F6-'E>UD-M<I"G8$-?^\DV!Q2L9@_)%0Z"*"_"$31(FX\)$09$RP
MMP=VPX:_)XLAXGB?;MBA=3G%DKC(+Y]7']#-<,^7F%,P@$=<C,AV<^4@=DE[
M0\K=%)0R9;X'SO#JKP`LN$>]`2B)*Z\$7V$J0/823#%"NXDJO7LND)A^]-F3
MZ%./<.S*8FRVFRN,^)((UV<BX/@62?@Y&)\'`@8N(4!1YT@0,1@/.8P,X&^4
M9?<\+[1PY!=T8J7(+9'^'9E0>&)=1&7/=6$PEA`R#)E/7()%^:SW$%<FV6"F
M8'X#42X\YO!8#,;W4SSDS`M<.<*/F`;@!L#4U/`,/1+%!A=@BA/&`6(Q\L7%
MEZB,I-@1=AETS3?L@=Q+/,:<[S72[=9^B70NT)Q(Y$<2KI[GX.(*,M`T62+H
MGA!8JD?_FJ`'XH-%W&"DOO!Z\B,B_'?D!WA`07D!!\23T$,4XK2?Q#+[:8KH
M!$:>6%@<1_0A,.9AD%>,I*F,$FGU56`Z(0_^4L/E>TXC`:4^3YPOP``B_;T0
M7_"YRFRZU%X!YR,97Q14_:J5*J!582J939=(X@_H21C*E3^)_KS$G#R&,?3:
MP91/L(#8"LC?LV'`W2G,H"&XGC$:!M]B$$@URU<K,*5PS9=2(K5+_%"!"].W
M6J;?`NT0&?IW,(\+%D:8F%83SNXLK$2BT;RN=$Y9[98:BS\(_%<`JKMZ#/57
M_ES#2$(YD]];)C$\HNLH8SU[%0,^01#WAL+`0`3,=;SEU(YZFS.]C1`EKAR3
MN<?/\MQG[M<]5/(=P56MS<SY8S4Z,A19#^:K#RQH8"VZ'IJX1Q!0VM!#)+AJ
M+;R(FBMW%2;R:L"Y@FXWEUH]_RBPK[ZS,P399%E)]^:*JYIQ/'O96)V`(?@_
MV)N`BXE6"\')5-WOA8#464L5V$T)<*K7V(.LWF32953-+6/J537E'457'@])
MD)+8[%-EJU:"N=3*^;^8YU7$5RLEXN?&.3,J92;!$\IBZJGMB.6G2E9)F0]+
MX9T7TJN&9)C0$,(`(*"GA'!?):\PGNSX2':8H3)&XB%,4PE$>X+0O*,,HH-]
M*5:?A";2/NQ&V2H_11__&47F8H@6RLE>!%QE(JPD^>@!^V>MG,(=B[A'V,4P
MK@":6RS-T*=6L<2!!WB]M:16P:*T@XV/]&0,ZEIAM5XW&B+B]6FT+1@MP\K0
MT:13RJ]HA4\XB]%A7GYI#U>.R2?*V$"IDE'4J`^_U+#WB/PP#I")32T->K.Z
M5EC%-IE)X&4Q&UA7V0-19D&VP6@*V\1]CYZ79ISKX+-JU(7!+:/NSB0V*MG@
M`2$+D?@:IF[>R\6=6ZSCD5/)!@_`@3D6TBC6T12V@SM:<M%K.U'$!L;\B,5V
M7)(,E;;G8_FPTZM9YI)MQ2D%;>`-`U.3@"6EH&6\N0X[O:P-U$/.YIC+Q=!7
M6RXP^P4#G:M9I]YO9%:QP6$$+I<35V*O2.2X:RMVF$I$*/:N$*<`1,",+IBI
MY0>L$CZ)2W1]9E#1!A]CCUH3'WK/PTS.16X4GU)PC7=CR:C'D]`1=U<-PI];
MZT7)-XNB$AVA<IY5:VT(GF:K^F/.9EMSSI4PIION.8R#BL/7V]X='K:<)ZS>
MX`K_A__FG#`.NC]K';6<0``X-E_.ONO*+MN]Q63?OP:R>7.'F.[):Z"K&7#7
M++N'KX%EWD0JIMMM&MT78=TF:\.!/+;HUT1^YW@F5L/1*U)#]G)]S/GX%7%.
M3MMCCK^\(HZ9BW0QY3>OB'+:7#9F^K8Y3$T71#;))Y9YUJR/&C0Z[\,ZK51,
MOD'&K5\W2G/6+]=)X_"D04.3&67=TG!,N4$CDQEEW;Y03+E!`Y6Q89MLN,<:
M:-"C;>;)MC<N8S_6H+#;C*Q))D),OT$^S8Q^V@)73#?AS]JO@:_)@FK,?Q_G
M5M.\L>3I,=:1;A\/8R5#0P"43XQYX@X,1YN@D2QE9W=7J>N:"?$1C'Z9'AN`
M_0[FZI0QZ"EQCL>,1Z?/P$0+BQM"0T-=12TPBB5;63XD-UA.F:>FH4)&IP1H
M-H^_'P)[&@;<T9D4YYB"/]!OI:>7MIFQL,04`;J%QV[9,W22E1%@4-4&)Y`;
MFXH&?+*,E1W@E9HBS>F0;I>SBC97LVDEK>VP;YICPDZSMMKUE2SM5V,(9:;A
M,3V/V&?ACE0VC>PZ=EB$<T"=T:R_MK*OC'UH<_()W#!'/NBLY\T()4+R,+C(
M5K5A91N\/E.(S\/3DCY!V*H>Q`&-7Y+2=45>+:MQNH50)K$RF^8%&[DT:UF1
MN:;9R,P"RTHUB^4:F<9@^[G/B24:F2N1&B8G[>D[*KV1B1B&*DR9&&H2,6J^
M3*:=LR17@%\LC#0RX<"(:DYLWLBL`R/BIB%S(W,2,N:ZR<Y?36D:F5ADR#+%
M'#19%Z:^R^;*\6[G<%N'NWW0=FU>L!Q"M*Z&<%?M`>%+O/RM6P7?I0E+2X8*
MW)"S1P(==[[X+%0&9;0ELGEXB'X]T;2!&O%;1F`%^*4U4"-^:^>U+[^T!JR\
M>(,689Q\SWHN/$`<W#6=0(@]R]][,:I:"T[:]'M39OH&++TLY6+LB?"H<A<+
M`=.`*/Y7,Z%P*`IO\%%##XP[T0&;Z53W:LLFZVC*^`C]H7+0U:E$.=S2:MAF
MT!<B4&?_PU"<>[I$?CW;;$(4@S`:$U?/F+M$8-W&=7X]VVRB@YA7@+3^+ZN*
MG:V0>>2X!F/EB^_!%T>)0]<J`!H\^&2R7%_1[I:8MV!UCK%/Z+@Y^=AE6(]7
M5!JT8ER1@E+CND8F4U>DH-3`/E90@RQH]YG+BS<>\\:Z1J9OEJ<5S9C9R*S.
M\K2R/?9J\C[_#@K9,<`OEB'::$VE3@H:^9Y+,7WL%`+&^GG;H*VBW5><$@9C
MM-X1AWSO_[Z:R5@UB?5STHB%^G(N8[2-?8\K%:U#+GX1HFT*)K<;VL:HN;_0
M-JS]KB"TC=KT3D';.(WN";0-,N<&P'H=";GQVE5OQB"4_):U=+Y'0S4[`O,3
MUV?;YU:K&9?BQWG:"-G,"!D>Q!-U9R.31DI5A/8YUB2,-2!NC6\FM7F*J]*Y
MF&(OS,&#?AF,HWA-_WY>?LW_GTN;@W&$GF[`ECG$'[LI75_1*I\_&/_:I^'2
MC=B-4$9-:V^"K<&M57T7S.?^\H2&&ZQN<J4>$?@SN`&NKEZ$65Q&[D&Q-BWG
MTF\_5*FG2F48=",'+V/B69;?R&1F8^99(T<CLYGSF!?T#<7RF^L0J-1S/EK@
M0O&Z0,^_']PV4OWUW[:1[7R-MVW`67=TV\9F=NVV'93?\2;LNA$TO,:ZF;#7
M=T\W$WYT'6C=P)M<^=Q`S+75=L:=RTT"6U/]%KK;^#61J6W_I%\D7#><.][^
M6S?XYO?VU@ZY]@9>+=(/'85`)<7!/_\#4$L#!!0````(`&:!9T-E$XH>ASD`
M`/0D!``5`!P`86UR;BTR,#$S,#DS,%]D968N>&UL550)``/O`7Q2[P%\4G5X
M"P`!!"4.```$.0$``.U]67/D.)+F^YC-?]#FF*W-FFW>5=7395TSIK-*NYD*
MK:3LZZ6,"B)"G&*043R4BOKU"Y",X(7#08+A(),OW5D*`/3/<;D[_/C+?[UL
M_)-G$L5>&/STZOV;=Z].2+`,72]8__3JR_WKT_OSZ^M7__6?__HO?_D?KU^?
MW-V=7(1!0'R?[$[^OB0^B9R$G#PX+V$0;G8G%V3E!5Y"!SOYY`6_/3HQ^=\G
M['_=$_JGOY_=?3KY\.;]R<E3DFQ_?/OVZ]>O;XB[=J+78>![`7FS##=O3UZ_
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M%-`%\$SZ`6D/9X;BI?>Z\I7[)\J4I]!WZ=%Y^7M*5_!IX"XHDR)VAM&?2!#3
M;^?$]`.D]RGCTW/NQ$]7?O@UO@Y<+R++I!^:]G"]*;[PXJ4?QFE$;IR$_N]B
M=9;&])J+8\JH,R?VXL7J-J+W"#UOV,H^==ULA3M^ST/,R'<-PK_WU@'=L4LG
M2$Z72WIU)U2^N`U];^F1V#SJ#I\S"3;=,#+_H)]:TFU.M\5B]?!$;J/039?)
M'7DF04J/`;K4V&5.9Z20),[I4ER'$26Q'_C^GS?(C/IG[\@RI%/S!W'I=ZFL
M2**HTTVG-[Y!..?.UDL<O_C"Y<N6'G$]$0B&-$CT:1R3A&W]3Y[SZ/ET17PF
M#OO!/4VN'"_ZJ^.G9!%0YJ41I7B=G1"],'7[HLEY>G*"-;UYRH^5<L0U%:.C
M3,CK!Q+Z#8.PKIE@NO8>_9S#YD].T`>,[J<HVM$%4/"O\?F>^THZM-%9H8=/
M$D:[GJS?CS($:4,L%>G0!D'\C<XDO<K9>5+\\X)$WG,F0Q\.&/,`>WQV`/`/
MX6T:+9^H!DV%ZTT89,)WO$@39A-@YAHC6-5?,0CM@CP.<(2)1S5Y;E'N>$EV
MOM/E<1YF$B8)AA%GM3]F$&BAUQG')!O7J"S^&)/?4\JZR^>,?^9U#=`7S"B_
M-V%"Z!8]2!D'[35>1&N'RKW9Q^@"B:FNX^:J7>!6-;V*B%)V+L$\D)?DS`^7
MOW5@R1&)&YJ;4OUQ&!X!/VD'\OT?$#AP^+0=G'APJ$")P8?BPT-SH2$U#WY4
M0+YG`>8!IAW^U>'Q%X+]\),M^1`FRD&F5_FYH1&7VDO%.D&OX%^(NZ9'3&$M
MI(?,T//>BQ";N33`NC%`SO`<>TR&7S+\;PR-3:)Z#0U9\].#RT,)_4KML8^U
M'9H)\*\.CK^AYPV$5_B5`I\3+:$0!?X8>T\/YHCQ?8;<\?U7)\7`51R'7EZ0
MO'6]S=NBS5O684!ZZ*?8RW$8O';)RDG]1(^Z=O?CT!IN'"_H3&K>>TA*LR^\
MWI#-(XDTR:QU'9#&)SI$M$P?R>L#9_0HY0U0T.L>7-.89UJ-9KK)2."R=[S\
MKVPH0RY#V;?IU^D>KGW29XY58<3E4X8N)LLWZ_#YK4N\M^R<8O_(#JS7[]X7
MOE/_1O_TZRG]M,L^?^4[Z_UPOO-(_)]>M7]_JT5/^Y!D?V%#1DP_O2!;YI)#
MA=K<3/RY6%HU&B`]]*BJ<FGEQ(_90DCCUVO'V>:L(GX2[__2Y%GQYU\S+Z+%
M*KM@+HJM6R-<TK`[O=!9/4\CYMIT12\ZQ_\'<:++P+V@EP1G@H5-AZ=RO_+S
M;]_2.0[=*_JWF$.FN.VQZ60\@E%9MCP>C97#@YY3Y)H*!C)"N<V/1VT^C^+%
MR6]W//H>Z+`2LK*?AZ<FNQ:8]8XI9!QRZK\?B9[=.65`Q)XI7/+R?\E.1%>K
MW='HRU\@V;G+>>P4$2OK="S*N?=)Z^=C47/E^20JO+O$LUQO=2S:[LC:BQ/V
M]'SC;(1;H]EL>.H^D;7CY]\^??%X!W"SA1'):A'1=>JHY2EN.PPIZJ"Y5J4D
M#L?4[8>?TX?(8:?`_6[S&/J<&:W_?J"GU!M.HSIE5.G8#U/H'[JJ5-%[%84;
MJ<"Y_VPHF_^3,'))Q()XZ+)Z]^ID2Z_<B"[/GUY]>'62QI2X<)N_3-L-3J5>
ME#"_PX&9V4NJX*#R&X/(D0?V@-Z]>_/N'8.4J\4_,AL7<7]ZE40I*?\8!@G5
M5R_];!M1?9NLV3\LFVY=CM3EM<,,OWMOW4+61=;0STMH'T8/3:`$E!#M.X:Z
M0FQICB5(I$-H,)`U-;Z$^?WH83;N_Q+:#Z.'QA>F2X1_F@C"ELI:0OR/T4,4
MV_Q*E'\>/4JN3EJ*=.\F`E!NO"CQ(@DXW(>6)FJNV6H/LZ4AEXL4:0[[80)H
MM`7"#V@(VX^-37@"NT5];>[U+O09D^,!VQBJT\?3+W5Q_N5M_:UPX/=#8-@^
M@G6G\#^-;YT=VR[%!24P[0@:8UBE]J3<D27QGADU-R2!4<_M@H2!JOV'`$H6
MZU$$UU?^)`8#Z(N"ZA`=<>MX[G50!+]6;DL1)'5'%#R9KZZ(YOQ'/+I.'YDZ
ML!2N^7HC/#H56[/6!IU*$%.;;5$\')SXB7D.TO]CKG//CI_Y$B:UP%B1TP.H
M+PHJL5ND"(ND!Q:"XLR23D&S&0:M^QP*17X%^485-,:D^\%YR3>D4@"0];`%
MP4T8++5!5#KAX&C&3--]!P`B[S65E_SN?+UBR@CESC-QFZ%#-T3$5D4G#!R4
M#A*1.`'I&(+&.'07`3UB;M>:8-$8)_MW-<FS/*<A/KW[A$1YX##7&4*CX\3P
M_/IA`EXP9KBLUH>QM=ZZ(MZ.:5&3S>]F(Q:%>@3NCHQ-?@]Q&MI!+YS[-FBH
M7-D.#H'3!P5%&*P?2+1A,8K24YW3$)M>I2`N:(Q!=V;`A!B,.`V1Z56RF=\6
MC6H=54W2`8/^VRC<DBC9W?HL@4;@LFMERR0IL9PN[8*!X8X*?Y&W3(C;QX:G
M.PH.TH0JT,2]=**`$A*?+I?I)O6IP,O2=WI+3S1G@(XH_M`D\,)H?VAF<;X"
M`+R6J![<GP311I*&J/3R@FD$C7#H!$KYELCUVI*\9;+[0Y1EF-TI[>J<AACT
M%AD7I0)CO0V>TS[_-;'J=B%X(3MX7GRTSQ48#DXN4I08[?,$AF-4/3>4*.US
M!(:C%(CD)3C[7('AX%0O`B5*^]R!=4^:*AK[/'\5IV(;%%#,1X]\,HE96\DI
MT=M^!`'0RUW42JBV'T@`J/67LA*:[:<0`)K4S:!$.H$3BF=\*P':%Y:@OR$%
MV#[@^T;ODV#Q\(F?>)M;4/40.1)O<%.`?_U@`V3U`H:_(5?Q-[3+<C7;>^AV
M`\I[?"G18AV\4XO34,^>[K-P;0XESYCE7-H7"FX8.^\)M(1O7[BX8?A5L/9:
MB_J`E;HNE^#MU>WZ@)>U+K';J]D96N4"_Y^2`_8J?&IO$YZ"V_3KM#D!1C>D
M(@]6F_-@=$,JB@:P.1E&Y]4+B;ZS.3U&-^`\%SB;,V5HN9+5U[(B+J$\DNVU
M;FBCYOHGE*;T4>@7,*0B+[<2["@4"AA8F=-6"1CIPFVE2U.[GG`3,DPW6YH>
M0YIO9#:G^=%#!I>QT?/^*).-R/V51IQ%10U,9JK%SZ$"6:RZ6GT]G-?F=$W=
M,$+2-MB<PZD;:IY+&7KF)N,H(2ZX)6I[E?:^YBC]_+E6Y@FZ=9C8]T02;TD)
MQ4UO0&E91!G9;K9];DF4)4/;?U:<\4#8$SEA0Y[+[3J.TW(6Q2AJK:V@7)Q"
M']1E*F'W`U`S!^3.(07'=''/-Z>`6%Y+'#^5$3YVFWR\M\++9#;`F#53@"2<
M,;QS:<.MBS]C>.#J")&?K=?BYRT83NX-@OZ(98LM#4^?NZ9M-N343T@49&]2
M.(I;3$GY.0S=^)XJQD+]H-X*0Q#:FRKVIZTB4E'8W`;:SYS86YX&[H7GIXE0
MJ53ULDH50LJUQ+;0IS".K^B9D3M7I91E"WJV9#ZD\1E9A1')VSTX+R3^[`79
M@;!WX*#\K(^2&X8^D^0I=$MCMCB)UO$HP.,PI?OR94M/:7)&`GHTBI.?\5MC
MYIC+:2H(NJ%'<3XSP5J6PPW0=5;\<V917I3+5\#0>AN4#"?[J2MF4T1INYT5
MU"HN.W%[5.J5ZX+7$BW_376#UW:^B'AY)Z0<,H0*V"RP\H(\$S_,(M;E,.1]
M<%!DGH:B17/X&2?7BT_'7/],+[;(\2G/3MT-U138;F,BO)S5P,ZS^78ZYMLO
M`=6^?>\/XOY,A61VP"V"T@M1Q&15+STD@KJS?R/>^HGJ$:?/=#6NR4W*#`T-
M':-E&!%<1`8&'!B3Z/MZ0(2CX!F!5'IQU12DU$/QK7O?7A2=4MBK&RT;]IHQ
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M;U&O(^S!,LCHR`%&TA.QW6[V6&L<BEQ"Y6U'2?4<*#4R?ZEF@+!THPL:H_@%
M`",>388Y&O!B:&R:6%*V5=YG]AV9CN_(\:H)";PILG'SP)^+E&IVZUP\HPH<
M^X'J;$7&X?@JC`H!+EY$Y[[CM99`__'09J!-<'YXW)"OV4_BU0[J/.1,%:><
MC+\:\P09S;I9*BM.Y&1_=2*77J^+%:5Z1;PD%0?4]A_7.FYD/RXR.U!\^4*B
MI1<+PT\Z##3\6LY^W"\\$8+.PU@T7YGBV_&(:?2U#97Y+0D?UC9>&-B0DG&&
MW(_E9_ML1]DHZ.D6I$H/KR6B%ZA,0Q=$/;=+)]C[[@G&IS#=CR&W/A@K=[&.
M(:$^&*'(#(&?.']J?LJPRD,@@T7MP9X_TS;AE=0=,@-WS@<S0<]6Z0.\O7<+
M=+8EB1)'G_@%:M69CLLR4,<<O_MR=P/"^'V;.RMKT_%U-F`)G(XCM(:KRW1\
MHOO;G:;CZ&S&_VLZ7M%=+./3<9WN8(4<OT^U<6<N=`?K(XA(BO?",40<=V<!
M\'%[#&'(YK9&/Y_1,40N]XRKF0O26`<,:,/3K4V#%S5Q[L1/5W[X-;X.7"^B
M]Q1.9$3EM&!;/5AZ/JGMBX>047H;A<\>A7VV^T*/C>O@$%!\NDR\Y[S<DSRI
MV2"?0O$DWX14H,Z+FA_*>`1KELHCSH*#XKQJJH@/T.[XV*Z#Q`G63'?(ZY6!
M$+4ZH>!@RF!9L8I/=JT-BN<]7>VLBC3]/W::/3M^=I`EYU14V=$U(0O2@/6U
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MHJBX3#<#=;4(4Z56>@=8K=YV("M?*IF<#(;4Z(99=4$J(%2:H-`8QRE5C4B7
M.+9N8\RQSP?[.<]@QU%5!6S7&,!N?(K[I<-`%N$MS1`=YY,W@-WXNLVG;""+
M\,*56HT![,;7;3YM>WD81ZX)JG[MGY^7OZ=>1"D)UE1&V*C+;X&Z6H&)+A6Z
M.)+=K4^%!"HN,#/U-O>"AR$3#X""+PJ7A+CL`4IHR&HY#(B@=AH+$W61;Q60
M*$W6`QM!*<-6@@(!./C]L-'H1-*J^V&C*;2)/4'"\T_6Q8@5Z(XL?2>.O96W
M+-YKRSS9%3..T'6(9QSJ/29.1J1M<20O5NR6>:"W3$%/9MI://K>.D^[+)@L
MG1'0<B=!$]A9E(^.3\HIVPWKS'<F/MN5;8J+-7O,+U_T`Y?=JS?.ADB3FPWR
MJ3EGDPTYFV39#XKK@4Y=(X;@2^`E_-QHFIU1>)INMWE(IN/O'0FN@U48;?)5
M+5>!H+V_U:IK9I`4E[HT$T6]#9X/[9"^@56/3JEWPQCB^([%*&40@\4!?\?B
MD>9CP!C"`X_%NIY>,6,(.CS:*@2Y-8PA-/%8'%,Y'H\A;!&'5S(']#&$.QY/
MS%"X@XXA/')H9NEZ"HTA?O)8"PQ>A,[B2$N\&U+LLH4?G`G*+L6-.5'+[WT-
M6^C!?8!592I<XG!$]3=CERGG[-N,.E$8O-J0N;?6`>%W]IW-W1$V?-9+D/9-
M8Y>S#G)2-MT)RZ5LK^9EF@<\U_<#'S[:>Q*:YD/-M;QD@+U*DFD&\#RA2S[8
MJ_8,PH>V]W3)"GN5FJ'.!E!P4,F@.?7LL2:\NU]M=>(!OB_EY-HK'9AGABK]
MTT=[GU+,,Z/M>5/RP=[G$K-\T/3J*QED[Z.(^84BSI3WT5ZQV@P;M'RA2HUK
MZA>,3GA+R15[1>_NX0^U/0-R[RYUTM%=-GWY(7$-+[DRNJM'DRLZH40E5T9W
MWVA:O44)YRS.P6X&^##/"F/(Z&YLX8`CN4:1]GU`']]Z2E"8KV=Y?=MK,1J:
M9P(?Q9(U2(?47.K$>-;3[B?M%'*^:HLWZ(EAAT8O58Q*]/;JP3#T>ID)2['4
M7D6W#^Y6GLDQ%`X$GOG04(@Q5->#SW$_%POT(GQS^FMU^NN&DY%NNFN4]:L7
MEW00WY7N(;H%VHZ<Z[O<8S<.*T:S6)VE,=W",5-&J(SNQ8O5;41BQIB,$0=7
MI0IW,)*"3S,M,3/J7P=T[:1L*9Y3K>*";K9+)_+I>2C.!BOM-)54JK:DI1($
M;2ZBM1,4#N_G5)D/?<_=AXM5=]#!&=[Q#R=IY:IKW9_5V$[CW[`).2_*UOSX
MV$D6#DX`T3T]=A:K?:E+[LX&=)P=/KK99P;=LP?QP.S6F*!5:/!IZ*I>6EA/
M]VB\@IQ7-C\+'8U1*G$-_>U'J=0-=H$;4W31%*)[;QUDL1M!4CAK,@V/\F;)
M+(^VZ$%GCL^VY_T3(<FG,`\TD=23$3;'D(MXQ$A3X4@ZC)S^7S^8*XNRCZV]
M#IY#;TF8HQ17FQ"V-4[)+3V$VFD'A<W,?/^)/3E>LP,MH3M;G"I+U1JE=`\+
M'%NLBE?.173GK9\2R;86M[>&>NG&D/48/0+MO6W*EK0/-LSB+&["_+XZW;"M
M)C0ER?K@HLBVIK-,F&%9.A72+K@82F'QSHM_DVQH:1=<#)7(E#*41PF#WPNE
ML!)5&%PJ'Y:T73E>E.E_5+UI_;@G7&2CZ3R<)=CW$GVYSOC)Y3H-,6;;LT"N
M.,PN/2'33>ZXQ7R=G(BI/__PB.\^A)_98TI[S708`&.5\"ADB4B86]J%QYPR
M`O>.ZG^"%0+N;ALV)OUVP)1ULPW+7T.?;DYVT'2<J<8`MN!CE^!51,@^C8`F
M.FYWL^?"=;!-$[JCTVT8<*A3-$;A<Q@1;QWD`<K+724?S&ERH%1<Y`S<'1';
MY<LRT_#H?S+G!.D-)^UB1[$FKEPE@`/M/=F7V?U=FGMG,&?"A_`\S\RR$Y=[
MT.J*L2H^.R_>)MU(EW*]#0J57J"FLM;&R)S?I&RLQ:IQ-A5[>:\7Q@MZ^"9.
MX'K!FC?]'4;!X'&>7B+<;+Q$4MVCV0J/TESYJYP]TM4A[X.2EI]="Q+EO?P=
MC3HI1ZLMS"0L7Y+`H2?D(N!_6-`()0%Y0<67(*9RKK?RJ$XBS;XO;&]/V0$1
MZ9:52[B-O*4PC7[9P,R*E#W>M=YT:\L4UG-X*H7^4(!>QJDK-:CKX+,3_4:2
M;+**#-8J*A6]48L[[#>XY#SGMYV+#"`5&>BSIO>)UIE;"W$7RR2D0S]\I7.[
M^R>)PAM/=H/!.P_OE4=63NH?1+VZ,[O*)Z#JPB)[PT;WVH/E-#4#]]</-@!6
M1RJHG0ZJ>!4"-WZN!]B*5KZ'UUS]9(^W^%,,6M.F`(]E50,>W"'AWUA18>80
MZMY28\A+`GG#KQ7YT'JE'$,6'UT.R*W6^#ED06<8Q.VA[DTK8Q+^*3:QD`C8
M)+9L7;6<;%53$SX@]3[DV,:J>!HF]3$$7JL0U<WO8\C"K;30E;ESVF9'](SY
M_$`C/7-4"1!@'YIJ4%!'EG'=CJV/ZC$`MN[M;7UX3D?$X+=<]-`;\PP`NV+:
MG%RM)W:X2Y#-13D'8$+=A\WF:IL#@J\[)]I<-W-`)C0]_VRN>=F3#6#'*)NK
M6/;D@49%-_LR9O7$KBPV;&%)21.0BY=TFXM!FE)[5`_/-A=W["7:2\(7;:[1
MV'-YMUS9\.LJ#H:U>R"2S9E.^RQZB0^]S>E-C4"&A1/9G.?4F%K+C5>U.=-I
MGP70Q5/9YB2H?34;<"Q*R00D(0^67`7NXS?BW*`=D`(\'=`3APZ)6^"`6&#^
M.$G,\A?A`OIWDX0N=E(K8'\_2=B5Y^,"YP^6/WA+'8-K&UC\3CF>'%?IAC7\
M@]ZN>=KMW6+U\,2J0[GI,KDCSR2@DJGOAU_9XLWKDY#HF9Q3'JWS@KX(OL,'
M@JBPP++2Q7>$RL>!/(Q(T0G#![I*TD/DN*0L%`W'(N@XYLP+(XHMS>P5UP%[
M9J:W&MTWZ\C9\"=/W=X(17?DD6[.^/S)B=;TG\O?6";O_2.QA#)0/XQ=PB3^
M_+K<K_JX/(CBXEX5;!187_M0Y;/`WK;#."O/]\*LV]U0BL:R#_4%8;>.UT[1
MIMW=0FRR($-0UPEB0LJ,)B>M+%S1`=>A,RZNP/U_J>-[JUU64"4_PM4YYKN/
M8S-:7AQEMS%FQV)3/IXZYTJML@Q`8K;9\:<K?@W)SF;7'Y/3SU/\;/;XZ37U
M<C4#W\,'%L6G=^]6)Q[&-/R3#V1A&I8-5D3\"<NA=A91^&P`W?P3])`?B)U2
M!=MF)_HC\D.HFMOL<G]$_E25>'0G?'!1PT[*Q(@?;'OCUKW,=-]RT9Y$ZF\?
M5+\(UP'SKF6R-EF1***?0,F_G7^[H.M<D7:;VWA^$SC*FT"Q@C(%A6=IK_V.
MDB$N7Q;"]'7[GPV]1^2CB8Q.@D:&\M(]T=N(E:W:?T"<5$O0=+;Y]`A[%<Y]
M)817,$,3%-K5+&EOT')B+?7T`^$175XVJQ3`!5P_[-%U`*`OC_Q<''_MMG-G
MZR5Y5%2IHFG*;:*Z4N%F&P9T^2Y6"\IKA[E!U55!Z4VGT]U,'2SE!X5W(K0K
M2H4F2L=B]7,8NO%]Z+L"4:;9"J5RCA>195)CH+#J#Z_I++6;E=H-9K)F&0<"
M^H'=9R<AD>?X\7VZW;+BGW2+?*8'\1/SV(_)%WJF1:RRIK<.5!FZ.X]Y5,FN
MPRE8AK9!3Z2IRH`=F2<\^JP7$GL"[KG7K)<R>[*'?\&,1!35%$_L-;DB:_1H
MHG86K,?VX"$^]3-QV`]N)6!K$=P1EIZ&3NZ9$WLX7N,9H0>2*@@>XRS&3G`K
MJ_NAR+_<>O8<*D62,;@_BLRL4=_(=#6C;[FRI%T:@YG*<?73*4M^G9]/E4.)
M-K@)@ZAV1HG4^&&^,58NR;PKS8V/RIVSW>&?OWA41*&BYNX3>2:^Q$L8V!D9
M5S$'3$R^BLCO*8NXAH$2]D1%E*>-R-C[7E[B3]+#%@0?M1%\M`$!;V5(`P4@
M/2>'""GR@4=9W#Z@M-&)Q_@F4-HTFX?;%'9\R+JB8*KG_SCD/SE(MW`5I]-0
MLWT[9UY%4M-7F8&=\?P@P;:`FMT5KG*C.SX*';`'T8Q$J4E[*A43M/\?;1H`
M*WP,@5*#\PEZSJ&'58%=>HUK]?;:W'%YHJ50VY_+ZMB\DAI5T--@`4/:](Q$
M7$[`E!3TO0:+;3L2/ZP(<M-?(BI[FXH?+?.#33R`K0K#++!C(6C(,6ICDG)3
MM#1\F^M]]++)<%G!,_+:[.(Q*`<^MCF`%7TXL8@&P(SJV4B4)7S&D;^@.V@#
M^<XM+&'2GR_=3)ZZ)4WP?/&+2@:5R>:5<T5Q"6(IMA7YGNIM<)QA'I.241)2
M.0WQZ;UQ-D3ZTB)L/F+:D1Z$(&6&A=Y3G"X3P*`]$X(P&E[J:G$R34EK7)Z*
M*S$+><KI\BVX!"K7067HA\@)XCS$\2',"A,]A3Z]GF/V3M3R[^L^#B[?2[FF
M95$7\I_7QQ+73$E)>2XHK2'&[((I6/FE73AP>:>#.+8>V!/1W>#R99E)J?O[
M0^X[(>TS.Q#D7!+5YN.R5-#8'KI/6762=6ZS.=N5;6Z=729K,R6AU!0"]]9W
M`J7T.,BG9IYI?PI)6E=6[N0R0-4+`TE1O$=Z:M;;&+F1BB'CZSA.B;M8)B$=
M^N$KG?#=/TD4WE")0RRBPSOC/A]Q;13J(JA]-Q^^_17TLH3"'3L>G6#+1VP\
MJMNC168/FW!*UD$_F'9,J-K&K+).'4+L9=8*=$\F$%"U$>@`5N,:&,,#"Q1[
M-]5V#$\INAQ0*''XQ=^A1[7:2L=_1.2Q"?\\`Q[<YD!;<8P+/:]!AC1.76"Y
MM67"/M)@AH%?U>UU#M'&JE0>\1U"!D`M,BJAQUN8!-OCG0'=$PR6]$7/E#QB
M__..:&&7H_TNY3WA-Y1[=)_PX:>[K<2B%T7^!OWZAC1G5^>[838M]118&C<T
MCZ[K(*&<\.@JSD)$3EW7RPF[#E9AM,GOY!$_@!IZ6F330&_O9^(V&/8E)JO4
M_^2MA)'+D*Y&3.B-X0%%`L'=!J9/^-JLZF+U`^TQ<G=JS/E!'%7.PP3UT"[,
MTMO\Z)HI3*(!;D)[Y?1O-3?C.14P6#V?PNVZ,8_S%2W>I?'I<IEN4M])B'NZ
M":/$^T/FO])A(,OP_AR%L3#OEZJ;95A$HHM65\LPW1!1LA5%)ZO%G6/Z*!UJ
M7D@8)LMFJ#'`T9.Z:.R%FCE5@R<3%/#ZLD]]G*(+>#CHA9?G&!XE!N!'=GCC
MOU%,S)('SFBB?_2/OP+2H5S"+.4?6%'4'9-=\ORVJ%2S-1O3!9P5_*`G"2O:
ME5=756&0]$1%I)+/.0U1Z17+WK4FJ#3>.5\/A5&T%HFX(RJ>OX71;]?!;10N
M2:P'2-)SUH5R7GTSQ:O`(H+TCK#7L"G4",5G;55D%:">L*JGR1?)J3H&U4X3
MK>S,'8/FI@E7)ECA*VNFX!HKGF9O;C'->6]HXUC);[_1-ZG#-,QN(U/45L>F
MV[&GT6SE0=6+=@>KM8I9GI[E:7NN7LYNPY>CO]&+>!\V227`XI^<W(L&+FF!
M9]_IAGYMZ0079!O&7N)$N4NM.&!?WL&(MV'C$V'QB?@AS/__CL$'T";HB''1
MG46>NR:?0B>09F=H-<.@]=QWXGBQ*E;C(KKSUD^R?(?B]M90+\UE(NMA9#US
M/W#Y0J]PJNNY5-6GJS9T>0L:V-,:/N])NZ7;D!Q^C(M?M1:0:JCA9B8/8`=/
M1]'<FCFX2=G)L5C=L_SD6;S:.96GB'NVZS,=&J-:PXE%FL0)LZ@$:QVHU6[#
MK;('$FW`:RQKC)6(]3RD<F/$1+.SW9?`^STE%R1>1EXF0"GRX*K[XJ,"I9?E
M-A\Q[6BI<:OD+")O[5&AEOWU=!.F0?(>!(/7#S]-<4Y?PGQ92E*SZTN&"M8?
M.]4K--$HKCFII$-FKFNVLB,1:N5<7*Q^">-DGUA#@$)G!!2$`8G6LC+6E09X
M]$G/SEJ3$=#8ZTR?BN$^S\'`A'(G6!*J(&6J?WY+B'@HZV*U6?F(?/WLO'B;
M=",U7]3;&)&=N7G$;K,CC]SZSI+(,\#K=$=Q`5JMZ/T>2;E:;X-!9>:+0-SX
M*@HW^VVR6#79*"`?V!D;5Z%P[<T.HEM+V@4#PQW+AB"Y9LO?T:B3KNYJ"Q0*
M218@<>M$@EM-TG!D]"+I?%5"LM1)5"2E,FI\MJO^(EO"\`%00MH<%M.0Y8%B
M^O5B5:%1GD1;W7%B>)!68$92;J>]2%G)QMQNGC\*W9"OV4^BU0?L;!&N+,Z\
M(ZQ&7Q14Z6/LN1Y[62P7E.1X$+<?(+WY_TG]7;?<YL*><Q)V8))2Y<-DU=E!
M^@Z([N$"\.D`/&3VRKW\88K0Q=NSQ(U?F565*1[\XM),6\=_&,!?[>#D\4:1
M6Y&(&)A/7O:D4\7:=B0I\]4A)5,'I%IN/2#PTVM.WU$/R!+U<S:^O]ZP8)6>
M)&.(A`$R`"C&CR$8!H@8:E`<0]@+^)13OGSC!\,,O:1;&O>XJJ!P(>NXK(ZK
M\(ETAN7O;..J;R*>5XGK%GX]DV%O8!T_0MV<R1;S0L.GIT0]6AE,[05;@AR]
MG*7E=%/B'JVTI>5\7N(=O:@E?]8M@2))6>#H/8$[F[UQ>R:0`5X![*^XH8%3
M8M2VO]*&!DZ@=0^]T(9)S#HOWP7P[Z<!O'1**7#],`E<5:?6`MB?;+"JRQX4
MVHZX;40C>RF`0QK+$P#/TU=D7&C&Z)8"#9:N/;&,IK!%V'*\:QV`[6*O]BY`
MCJ->%4_#^[=\3+57\Q4[RM7R,M4=<$M@6(8,V*&N[U,GDDO&MNL,`Q_+!0%W
MRCM<&UJN\^4E@F6(ARU\I7-838<$,`U_\D'KWC#N+LL>/47*0WB;LAQY,3D/
M-YLPR)]6JL_BMD2>3R(/PN7+UHNR3#,7],1HT`SN9DTV@);)$,+]3ZCQK'9D
M-1@0BRQ,5](!-[;X;'?C)/18DJ8^X#;&I1N0*X#3=(0T3R@.UI884KG7^568
M\D,8!8U,?GL!<&Q?#.)K_T`;J;]=;67TZU]#];</;8[M^@F[@97O(--W"#7$
M*(%OJ+U^9(9P:[B)VNM@!N<%7%A']S0#/[NH!<,)/'C#0*ID3?2';W`,BTQ6
MYB,=9<!*'YACL3S*A/%F%-:"$V\UB@`%-;2*O#6NT`,`M*H@.ZXH`S6XJFZ"
M'T[PC2:YSL(<ALMA?1CYEM[&5-9WUN2:*@$1B9,[]MA!Z$_)CJ<H0;N:R6N]
MION,Z2)JRZJHZ:#YM<%)OYL],&Q$U8JVBQ5;8&RYL>B#VXALO+297!7>SPB/
MS[QP2UFT<98D32CK?#%S14U1K+1._"1-UU-I8.;EX8DY'EP'F>-UZ"\>?6^=
MS4W3AJ5JC6C3SA[:("G&JPU'1B]2YI9*_`7;JB)R&ZTLH%2^B;AM\?/Q%G2Q
ML(!]`$Q^SN?!(+#DO,I!C)P;^X,[ER]:QI+JH2%J.@`=O/<L83-+,Q9GH8H]
M,A87_:U"=T?8&>8%Z_U=7Y4"\@@8;<2@,?&YP,1&5G$]H@(M^3WU(N;^M&._
MP!#+^N.CNZ)"DS2WJ["Y#;1[41;C#R1]WQJ?\JJ&=+E:D253Q4L%"H1'-89=
M*.^3S&^P.\36`/CX/C.3);,FM'500`=CMR=__'\0AZLL*7K@<_6.N&23F5VR
M-RG-)2/NC8^,4[%$TA"?WB^!D]_(Q-U?T2#R>?V,K?8%/>I8/@RQ.8#3"M<'
MYW#S,'-)JS2=TB]'T=V.Z@L5(ML_JK!V'F[,7DJ"-7[YPJJ6E_BIM'S++,3>
MUO%YP@ZPDQ':KKR`Y2H1;[UZ`S/?3-F[X&>J*&S2S<^IPYXD""DD:*ZZJNB!
ML5]^ILMC$90KN#PKX]N(),Z+8&.H^V&@V8MEER];$L3BHL[U5A90*K&`\5I:
M0C'=W'[*').J^C$<!K\[)K9;QVM6!^0VP:5QQVQ,10%D);6UQN/W5C7#RT]A
ML*8,VK!5^$`_)O'WYC:U@6:IE5_0>*1T:[]0"&[LFS`0OH)Q&F!PZR9,2%SL
MVD7R1*6E_-_\%UQH+Y3Z-XP.%LWE)9(2,LU61N8Y-]%R-G7S5X-?XR[K]N]'
M_Z*IO9./>45%/?'V:;4Q^65I($*KC<$O2\,0FDT,?E<1A-!N9/+;LA"$9A.,
MTZ6:"`SVDBSK@8V`$7%#DL5JGW3S/(R%L:2`CMAX]BKM51AE!WRN?3-)G[T%
M9!DG`>`@HYA9\\5')4N^W@*#O_=+$CATXWT)XBU9>BN/\&\`=7L4Z@^I1@^S
M6(E<EY6`47>T#X]2S@5WGS`VK(I1>="8`D*US2BH1*N_Y229-^M9&GL!B>."
MJ%BVI:5]4%%4O>,@"%KM4:G?'_D0RFMMT0/D.'Z+R@3L+=?_C[9428&XL1W@
M<=W,)A@6"V5*9WG2YK`D7?`MXXG-@4E:RUWU:F9SD)(64&%("'ZHDB&$,@=_
MFP/5=3=C=Y\"FT/4=;D`]QI!#U`WB!KP/FYS011=N*T'=)M+H>BO8)%_L<U%
M3OJAE'NZVESF1%N(EGF;VESJI(]@W#)]VUS;I-]*ED:TV%SBI`MLG<`M]*HG
M@TVY-,`%/ZWM4+#KWOOH16!-G=$`_U'\?/>FE#]HW@*;:W;W6\62:`G\5.S#
MW,:B9UR;<^KW%:(/@6[X5=B'`MDH"OEA:I*5,N:OA#X-Z4H12%3"G9I`I1TW
M7;)B_$*66%?Z,%[)2AI/4`(<KSBE'WY0O@>.7Z0"I$(JX8Y?F!+%.)08QR]`
MU6--2F1(4I,RSZDJ%\J(4[A"H`$=7=#SMPX#MNY18G_54AV0_"`@^ZN40C"V
MPB#LKT'::7VV_;7L+TJJ!13@-FM3M=*I%8F4I<*6!1'*SAD;<4I28?>#.994
MV/(H18D:V?9"M$]3U@>I#$,\P/T.2R*7;U)!'&#C;AS)5M0!8_N&$P8P-M#P
M\LU_M-3\"(##RS'_W7AGAY]7_CM++?\`0-Q<\M^-=[U5`W5+//9>3<KHMMH5
M7`GB+P\'^XSU6N!X&0K*F;//MJ</KAEF6:*S[T5-'QTO!5R)$&MQ`DLO@Z,S
MX<KI"%6=8=E@NV36-?RS#.VH)V$K3V;[7I^D898'0,)*#R4TK),+N*\AT9GU
MM5SC!_YRA>W;7C#MV)>:$RH*5.645:S%5MH$%#*CW7#:-J40I+S@W=J:%4LB
MHRD6548TQJ>!R^+&Z.5"Z!5#8@,UI`Q5'W+_.XTS&J_"")#84-S>2&Z2TTVT
M",@O:>!&1)Z*2-#2"!7[@_6"/!,_W`I3$R@:6T2+J;Q8G`_P<A_(VQJA1+*Y
M@.54-$<X'M7"XBL:O0WE^3[,W!4A<?[YA#23ALK;3C`W=!:C<1VX5$AF1U]V
M$K+3Z)\D"J6'%JRCH7S-$7O)Z$0EL*L1.C\Y+Z[CTWU&EPMQQ41QVXT_PZN(
M*T5\,5-+PZBZ[P6'K;S#L#2)[R-5%TOI0LHNQ!XLF??];1HMGYRX(C]**P,I
MNV%@^>R\L)07TCRN]39F<MZF;*S%ZI".@KM9.*W0<L:>+I=12MS*BKP)@Z4T
MW;6Z'TI&Q#)KS7XE+E8YJ7%,DEA4I4O=STS6PY`J=8GG^)^=Z#?"!*?3[38*
MGQU?GO$4T&U@^N3920'=,%;#'4N6(LG,5?Z.1IWT;*JVL)Y"I/OJ+MRQL,Y#
M6J.X*G;(;BQ`QSGG*!KUV+D5^^?UZW,.WZ?;K>^1Z$)\YC:;&/VN]#9J-S+Z
M;44.;EXSL]^7W73M1DC^*$J+7.D"`)$YK,_&8P(OSR$,+7D)P)=29><L'TW%
MS+'\2<803BL>G_@Y2;N9B,N$?QJVVJEF,.W)0IXZ;GWBTIZ8Q49SZ[.:=D<.
M-V%9G_&T/Q,`EA#KLZ+VYP)$.[0^;VI_-@",?-;G3>W/!8F;`7K^5%@(H_[+
M[=A#Q;LAA@55VQXYW@T[Y.EN)%'E_2:_8OT=281YCPD7ZU#H8>C?6*PR_.E<
MO5MMQ"S2XHU"MD*A5TDDP#?_$C/7R\3Z=-^Z,$7ND]8GA-8%RK&66Y\8N"M&
MKNW44DVA*\:+-D)+L]1UGD5N##%:YE]8`$;K%;\EY+40V7E-Z@*R_1*4N`E4
M$36\L&RNW:$?@@KV<+6Y[D,'V##G8_S2")HQ7D>,"!IM\%.78PDM_.GR]Y1I
ME?TCG82Q0O)*B?D0]9@A:0\,KY?3KT[D-A---6.N:FTPJ!37K6R0RFF(0>\%
M69&(JD!4/&/Y<YU\GT?LLF3[[V]>\L1.T&?/31W_U,\H(6ZV&,Z<N-[O4!R*
M"WB(+QF*W<D)RZ;B"]WJ\<7]%\G>D+:?8`S/SU&8;M^+^5'[W=P7/RB^^,'X
M%S\JOOCQ:'.,%$NSR.[#^/*%1$LO9B;</&D0CR/"MB8I^3E[$'4O4I8\14D+
MKS6*?[_O!#?.1G91U9I@TBB]HQJ-1D*GJ0C>:@678IF3XL(N%MQIX/[-85<8
M/WA&;P`4[E8HW->F643WCL\*F&9"J8CCZH[&YZ#"N#TW*?\RKP$5]V5=AZ1S
M?SP2EUX@L7*12'H:I[)8=_O/Q"`"^9U0(BI(G%`-)2G$,+GH*6AL`=V9^'AW
M_T4>OR+M,^H("ASJN3I%11<YVY5-"A>U3+/,_N>O=#8.\H4H5,_H)T;%H_ST
MKY1#SD[9AR<G*`ZVJS!:$2\K7,F5Z#`HF!:',SDX1F-OX_/CXNW+UHNRQGF1
M3<.LJX]N)6=BZ<F4V=8"%R25#_(I-)X5=77W-2NSO\F`<]NC1@N*4J:)(@9;
M[;_E6$?&A*?0=TD4YP<@RX3_298T2=5E0+J$:9%DS<W1<QVP"I&L5B3=NP]?
MZ;]WESYY)H$D9!'2#V?],<*RK5RU*^5;_'*S]<,=(;G>]C6@7'WRMHQZX0KM
M-IIUR&_(U^PG\58$=;8.5T/5RBZBK')O(3.F43?(H'&MXP;7'M$%/G\@@R>.
M[+M["YL(0>=A4)_(N<^AM:?Q020]?`<"M8>(^`VVXOXI?Q''KT3^;?FCRYY.
M:@&#UBU'T&;5@S46ESJ^%ECZ<X)D09O+P^N[G-7?RFTN#=\1VX<V-ON<R#MB
M^]C&9I_S^#$,.3577_F#1<DJBSU&!V85P(NH9!-^*I?ATNO;<&U9FUS_2*E<
M@):J^BTMLB!--5F+!I-TS2'6)VWI@EUL`+<^4TL'N!"O&.N3L^B>`S*/.^MS
ML'0$RW%TM#[/BNFC2V#CLS[3BNZ40SVTT).L'`EXVX7.YIBW[J*-KFG8^DCW
M/O,O</JS/K%F'\P`UUV;PQY[R6Q'<2^R/F7"4;G7<"#"#RZUB3D=?`/QD^`>
M62"#/4%;G\.C`UM$/MW6Y_(XYA[B^B!;GPND`X<&B4S%3R=RY--$YJ)4&J6M
M3C@'\'$;>P))($2`F7XD62,U`=??ST>2&%(38\.A9R39(+NN7&ZN4W#Z1[1,
M'??I8TQ^3RF`R^<L;:#9ZL3X.0!LC%8W&'F7+I/LBJ3J_QWQF<!P'L8)$P^6
MQ;\%[HW0WI8AVY<5N&5>;IFYT_<V7L!^SJ4$^K]+(BX_96!D%*_6^C9MB4]-
MWU51<PMHET:&\MM:0#4O`D':U`::Y;F%1*TMH5P>BB5L/VKJJYD>9O=;+5\1
MZ$E9$]ZX>WR"/B)=F&/D$K;9><0P4^HR%[H;B5+;@5QT(S9#0.$I[TYT`P0T
MFZ;\\E=@M>9@!_H[&@`[EJ@$I70A0=M._PM[M3NR/8*96.*'\(K>(<'2<_R#
M525>1&LG*`H&G=.;)O0]-[><!^YM1&+:)OO/Q8K3N5*^@])W1B7`WV93AHVF
M#..SS)>[C7\&-8&`T@C0;HA*KU2%KC>:E:">2I!PC7!MU]^`X@-BB/EC"%W_
M@<O)W&UJ3`&P1J"X]]:!MV*ATLGI<LEJ4;('9CK3K-[7+"98+28`YTYPQ<`Z
MSU?Z?*7/5_IDKG3HD3%?U..\J/=_Z'YA]RB-X<1/K&(H_3_F*?+L^(SNC**=
MZC:"]<4IH/&8P##P6AHM8'''\FJD1$X-I`<.'R,ZK2Q3R-GNQF%>SI*W6$%C
M7+J5"3&Y37%ICB_IC>'2XZCR)R7UW$[(.*!;4-@!@_Y+)PKH*1WOPZEA(%2]
MQER"Q@Q?KQPO^JOCIZ1B>:A$G>0,$W`7UA<%51@1>LF?I_3D#NB$1TX0.\M]
M-%OVGWYF;P%NAN[C8:"_IB+1ACPX+S!PPN8XM"=.L/:H_'D:QR2)KYAP2#[1
M8\B5KD5U/QPT[*DLC';0F1`T'[^91B"/W1'FS5&1PB,JP:?!DFS4`F^'`9!<
M3@E5Q9A,?D%E2#_<,M**,!OIFH;TQ$&4B<*4]>$Z5]U@RUO=#\7DE-LB[L@V
MC`Z*('##POKBH/+IF.N?24`BQZ<KZ-3=T".17LZ93%<L(N#UUW&PV>`YL,'S
MB'1^85D!+N/$VU!21#QM-,*@L\A4('4%K[=!]3:2J_+U&$^>\HQN50:84V5J
M?Q5A8^K0[:;S`\#\`"!C2/-(1'?,-88,(.#9G-1-#RS0UFYS8C<]P&*EU.:,
M;KH8E68$F].VP<""7C1L3M*F>RH!%&F;,[-IWK<=-3B;L[+I;F*1'=/F+&QZ
M&&7O,C;G6M-#J7R]L3DQFNZ$<AZY;4YMI@</^%YD<RJRSAN4^P!L<W8QS:GM
M_FAF<]HQW5L79`VV.8N8AO"H^?R"GA+,%E<V&X&I3(JZT:8C<]?+^-'#66]R
M#AVYXDM/[D^>\^CY=,Y8S3:'A9&XBX#N?'K.YZ'F-V$0[?_SS(F]...ETB?"
M_(<F_,R=*>=RQLI:FJG_N'PB;LI*,[!,`HM5\2TU4;".*,]G!\K*8Z^R#$^3
MPRH%K>G.P\U/G38\=8K6?;JA-\]NL6(SET?=^7[XE=4J`>Q(C=[S0]3\$'5L
M$5YG<>,_J1K26OBWZ?@?X'2NZ>F\P`TALD[GN:Z[B(/^G&>+NFZ-*MM\EIQP
M&AES+N#P+"R0GN/7,6?M88X,G^5QBV]LT`&&+HO/E[/^Y3PM(_/$+K2#G%QQ
M]FK.J:85$#[2?(7/5_A\A4_F"N]TF,Q7NGU7>N'J/"O:LNAD'0U;TF661.9[
M>;Z7YWOY&+$KLTX]^@MX5J8MOL(.\N]A!G._X$13@U9TGZ_G^7J>K^?)7,_P
M8V.^JFV[JDOO@DH\SVG@_D+<-7.Z6-*?,H\#H[JTB8R&'>CE'Z*]AIQ*+L&)
M"3+S93]?]O-E/VQD9)<#>!8`IB0`S+J\Q5?@02B_3^A4/84^7:`QRW63[-AJ
M*/)NQ8OHSEL_)>IR)YW'FP6`60"8!8#)"``]#I;Y]K?O]G],K-'L^:2(E'9^
MZUD?MU(8F:_C^3J>K^.A,D_-JO8H+MOS<+/QDKV"?1YF*4U(L+3'NJY)(?]<
MU!QDOK'G&WN^L><;^YNYL74/V?DBM^TBYQL^)NQM/M]MH[W;CDHG=%N(($#[
MSS?W?'-CF+[A"WR^M*V[M-/'F/R>TG]>,B?%>+ZDYTOZ6[RDA=M`0+*P_7P)
MSY<PQB4L7L#SI2N^=/_REGWBT8D)_8__#U!+`P04````"`!F@6=#DI5&GXQU
M```.'`8`%0`<`&%M<FXM,C`Q,S`Y,S!?;&%B+GAM;%54"0`#[P%\4N\!?%)U
M>`L``00E#@``!#D!``#=O7MSY#B2)_C_F=UWP-7<[E2;*:OB_:B9WC6EI*S6
M;E9**ZFZ9Z?MK(V*0$C<"A'1)$.9ZD]_>)`15`0!N`,D&-5F;5U*":3[S^D_
MQ\OA^/?__NUE35YIFL4L^>-W_1]ZWQ&:+-@R3I[^^-VO]Q_.[R^NK[\C61XE
MRVC-$OK'[Q+V'?GO_^W__K_^_?_Y\('<W9%+EB1TO:9OY#\6=$W3**?D(?K&
M$O;R1CY'CW2=D<]Q\MMCE-$S(OY_25A"_N/CW6<R^*%/R'.>;W[Z\<>O7[_^
M0)=/4?J!)>LXH3\LV,N/Y,.'4M2?E98_D<D/`ZYHY2]W;)LL?R+CRJ\N4AKE
MO#59<G5^(H->?_BAW__0FS[T)S_UIS^-9O]9;<TV;VG\])R3[Q=_X(U[XP_B
M"7+WP]T/%7S_E=RS)..M7S91\D;.UVMR)Y[*R!W-:/I*ES\4+UT7>`DW;Y+]
M\;L*Q&^/Z?H'EC[]R,4,?RP;?J=:_O1-_.)=^Z]#V;H_G\]_E'_=-<WBNH;\
MM?T?_^.7S_>+9_H2?8@3\>T60D`6_Y3)7WYF"VD<@%Y$VT+\ZT/9[(/XU8?^
MX,.P_\.W;/D=MP$A_YZR-;VC*R+^^^O=M5;<_$?1XL>$/O&/M90NP]45[_[I
M.:6K^N?6:?KN,:'"7*C0GP@5_J7N;?G;ACMP%K]LUO2['Y62:]%`^&?11KS3
M8!@ILO@,E7?2;SE-EK1`+E[+%G40Y,M64?8HW[C-/CQ%T>9'X6P_TG6>E;^1
M[O>AUR_L^2_%K_]VOEAP7\\Y.V_9.E[$-#M_S/(T6N2E.A+.'[^#/Z#T7PN7
M8&EAE-(L)%[^\;MX^;?!>#Z=]_M_F_:'O?'P;_V_]='B_K9^W'T&D(F/OUM*
M,[9-%XHK7+((433Y\.O]=_]M+Y>4@LE?2]'_W[^KMT&@#0)`RWD@HS5^V2B^
M\[3TORA=6+0J6ORX8#Q0;/(/[VR_2MD+RI\8UF8*/5>BXGUMLB>[C=ZBQS6]
MV*8I32S,T33&L68V&,WLK#D0%80Q&2F$DD(JC"L2D)4KGH#<>9*1C9(<GADZ
M?SEFA<$ZP1EQ1Q<T?A7:?*$YC!>F1U#L&/1G\Q&`'74"`W%D+YIPV2BJ*'1V
MJC2!SH<PZ4Y^!YPQ^E(-<VS&"LF?=,L'F7'T&*_C7'1PR?(F?Z9IY5?Z+P]_
M%MO?]`9F1MDEMTXMH0*I""1<"2*UJ/X6VA]QP$:2-0_8C6T2-?VVH4G&(?-9
M-6$2\MH,N3T"(GR0>5@T'"67RUA,;J/U;10OKY.+:!/GT9I/VE]8<I^SQ6\Z
M)P$_B"3C=&J<,EG%MLS$G7PB%"#7"2E4($H'(I4`\E!@-?"P<:PN)-P#WG`M
M/L0)62@]0A(/[FS,U7Y=4^X7^O)(4YPKO'\&1[3>S-SKF21VQK&_*OG`-0H)
M$<TO-XA^U+HMJ'5Q*M0Z\"P[JXZM!B!4])(FDB:]^;`G22)^4Q5!N>F2/'JB
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MKF;D@1'#"%OI27:*DIL5J:A*A*ZPT;<T&H3>X8SF$`F41)%*0=A&A@/.WSR*
M$[KD72Z/#8MGWIS*U6[9XW82)AH@1&U$:>;3G%3PD<MN'C[Y[GE<&)GVQWW/
M,"*EGTJLD,K`@H&$[A<,G*`[,/XAC9)LQ8?-;$5649R2UVB]I>)?7Z.4_XV;
MA7[C0]18I&8)0E97HTG.")74.+$X\-YMD60_,OU),?K^.4JIS)03X8@/U>3H
MYTY\ABS.Z3U-7^,%GS^D,5O>T05[2N1;_BP^JX<_-B$6-P_H32>P>4`[2I]*
MV-EC(%409(>"%#"(PD$J0(A$`IN?2'/[Q:R0YG8(=7(1_(,RY:*BX(G%KD:8
MA@QY37VYDXJ4#]&WJ]6*+O)/_!M(A!\/$7HX.^+MR+@W',T]XQY`MU,);UQ5
MHG0E0ED5[LC'HW@'#&+"=GY!K`7;N0S+N%D>:4)7L<R_B=;Q/\KQ5_;["&,8
M?B"C%?(3=1.41)A,%K%,0[I.^(>BGUG&?W\19<^W*7N-EW3Y\>U7KO=U<K,1
M1R/BY.E\D<>O*F7"DKO=HBC<-&\\Z(^AX:HA18/&KIW.,KU/:4V$VN*/0G%2
M:DX^OA&ANPAO.^W)7GUTUKDT+3":=61:IUV<O7WY_#'=V3?A]ET+P_+?BI\7
MPKC;3"T]L9U!HYW2/W45\IHFG"[^M?!1/?:IGU)*A6)7WS9Q*J/L990?SBDA
M37'[T(/>?*S=AZX7%&C?N11.]M*)$`_;<Y6X=+O,S>!"!KX&\.CVD)O!XQ)M
M=J#H'M12`ZJ5'6(+%QC<1.$&,NLU^RI.!GYBZ7VTIMD=S;=IDIFSMD`/(8^4
M3<US(:/(EME2RI;[P5(Z*<0C$[<D2$,WWRA(%PKMD*X.D8;L@&'NQ5P,UPFQ
M'M)H2?>G%>#D,C^((EAOWAOW@`2K%QN29%*#RH$;)-$46!C1F@'K3;8CQ!T1
MSN)R&M+9C8@D7D87/SRQUQ^7-%:<XS\<4HW_ZF_GO!]=RAR1=?1T\+6U?\<1
M9SR?UR44'[V]97Z4HHB0!6.!U/R8!=Z:.R4>V=1OV+?U'Y]9+.`Q;WJA:;R(
MDDNZ85F<1^F;7+*J#??P!U!SJ/ZX-^IIYU`F<8%F4H4*9*^#6@@&S3P4.MU,
MJDET:'+6HT)U6P4\W<2J27AN#(9_N5:F5R"R,*RY&J,[*T34#^\03Z`(/YC,
MAT,@X0_D=<-X5OH-;DQ7`(5QWQ.H'_G]`,+8[PFP`?KO47;$?QUY-`'`8+'F
M(\`#4_^]$U3!?,[:!W'Q8#P9#+#QX)W8SL-"SLJ?I#XP\DC8R.C@!;NQ(/'@
M#!<9*[S@.H2,+UO!-)%@F!4?]CG*"8T6S^3\\IZD=,-_*;8_NHX@]:RS!1*M
M.<.M,54.1=RL1';R99S)VABW*7V)MR^ZY0_H<\CC/,.),0W8)K5M!E:.OMRL
M9,(_*34@A0K``SX"J&%UJ6F@#MS;G1`L#OF<D:B*GW-R6>@4<IT)['?,T9H=
M4>]3G$3)(DZ>+EB6BQH8I8K:JB_(QY&EE$9SXU(O4'A8/N[T(%(160=FIPJP
MR)+`#>5E<[A]S^$),HI@5#)2UH.1OXFS;"M7B!="Q\Z8"O!/+6%A9NZ(MSQ*
M\J\BCO:<9QD%LE7W$(ZCPZDYF<HH,BPS]]*)$@]CHT0(9:,OP@8X&.]A1D*'
MSNBF=3`MR4S6\YG=IC<)_=,V6:9TR7\RK6N96N(6L.>]H6'^6B<GU(0U)5PD
M*:3+GW&KNQ*9=HK:!#(LSQM!I)V%-H'(B=='L,)-,(T\8&#3A.L/C?V>1_\V
MF,R,9[I"]&.(SDJJ.VE8W9SET1KGO`\W#^>?R?G]_=7#?<@.2-_1N'0H3?JF
M+3V^MA$N]VPP'M15`:H7$<)GT?GC$H%AK.6%P"4&=^/`QG1KK0T".[2EL')=
M&USHY;-@XSI<54(0;T952I;:VR*Q:VEDAX`L'B$+)4]-#().Q&O=X<BM.ZU^
M7-4`%*TU;7%I6;.^.6&X3E)(;\?&<`7(%L,]`;D4BBG@*/E!#^(8G47'@1.(
M\)^B.)4'IL5:UYIEVY2">`%X#C>PZ0^F]D&X06H0O@CYJGP!V6N`'@%)J#;V
M-`C595`D=`A/((A7'9$):*EPQ/H:I<L'+NW\6ZR=KM:U09Y"Z9M79:L26B:'
M$$6$+$X%+@UZPJ1O7G3U`>#B\A`4;7E_K3LP@#&">?7':"VV=^Z?*<W+Z]@,
M#FYKCCS./3?N$NJ$M>OVA50BQ9)2+HH"$I>>`DWA<F`#&EQ+S+#Z$<.9JU.^
M7+*7*-:5=[$_@!Q0S0:F@IEZ<=VP1LF&CJ`$-AQOW+`UR!P#P(#<.?`H"WN.
MC>:^1?<Q9IOG*'V)%G2;QPO-;0N0IK@DT\&4C[8UFW0:06%VZ8Z$(W.P)3#-
M'EU#P)#4;@*09HNN(4`N?([9K92LK;O;QO:<C0(,;I=P75X:+Y_H9Q8EQE/#
MNF:X[FTRK3WJJ!/2LN=+:42(0QZSES`,/9DG#!=_WV,)V5?IG(+!C.'1+VVS
M.*%9=DE?Z9IM1!RO':?!&N.JR,P&8WW?I!,5J'<JQ).*?-0HK4"GZZ":0H<D
M:D.H=+U44ZA<>(N%UDJW9>4'PYBJ459G-<L5H+:HCFDRZL^UIYIUDKJC=(99
MKU#8X(QVPN9/:`=,<#X[86J(SL%.'UD986#QD8&"C3]%`;KS9"G^(ZY&>(W6
M4IW\(DK3MSAY,E4;1SV+3"^;SDP+]2#)[9)(%HP4AQCD#Q4MR'E.2CTP9;LE
MY%%8R!M9!_HJ62+WC,_O_T3.OUP2^</5__KU^L_GGZ^^/-R?D2O^VYM/Y/;J
M[OKF$@%\W`7P^SQ*\\:@?[SZ^?K+E^LO/SL90#^?:<4`+ID"PM'%V159SI/N
M50DXY<&%'.9AQ(XC<,T&+<H]#,]C$WVGIC4#L/2NHG%M^@$T:7AJ6F=H#;HK
M-RN4_/#"$OI&7J+TM[`);7AOM)+48M&.B:JN4KA.%BF-,GI)U7]1+F-^!?)L
MZ'0^0M.U7H&N&%O<?E*J0TI]@(=$A0'T^:5M&L`A_?3+U0/Y_O+JXN[J_/[J
M#^3ZB_J)_T"T(XW.V6SQ5RNA[=;NFM-L'2_>'NBW_..Z<DD[S)7JGT6>6)B.
M3<FO(,F=T5>J0?XJ%"%2$^@A!P$:V]UZ@O89!A\B[YZ7&M>S$U)O1/?51"&C
M/`Q^G;RR>$$?:/I2NYIH:XL[8CJ:<T?2K";J)(59390NLRM*4L@G4@'8B4P)
M3;.8V!0TAT#@#4FSEM@4))<[QF1U[%W-!OZ&8%>16]G`$.9IAL#%W>:V;W30
M#$7;WF`TF$!H6PCI@K&%:)!C*SP`KCKB\:$I'@>`H(XX_+FY48*CIV`'P4T^
M7T?.&M,$'>)^6K.O7S@F_B./$S23M\LDRUWQEOU-,^`C+4V]%G<J;#KNF4Z\
M^"H5@(-"/5+H1W8*RJ'TOD12Y:HI]S,SRECF`75(8[F4&&3)!VFH7%QN+.Z+
M8DG0,VJ->3EKQ^Y!HX@Q0^VX`?8LV\PVY0V1E28YBDM'DYJ;:18L$4T("TP/
M?>Y9/7*_`:FX/O)RFW**J%6D3RS5=%281U"N.NV-YMH21A:!`0>M\GY6I4:Y
MI"JN7D%V(@JL813;(%@'IC8)TC#$;1"DZXK31B!=*J3Y,R5O-$K%S3(A>D,4
ME1C>;AXAX9D;BEXG%RS).8J;QW7\)+E2O\QD;8T*!//>O*\/!%I9@6*`E"\O
M:%8:D(H*(%8H>#KJ-P8/R?J&8.G(WA@L%YXK;&Q%%@4VMI,?C.5VBC"4K<*-
M4-=1EMVL[L6EVL9#@_J&N!%K;]8S';`]%M,R,X0\4<]32D0>#I18#&-8;RPN
M=)"`&`106\-;O:<PJ'%"^_]?HI3/E?.;]"Y^>LX-I\VM[;%GBR:FH[-::8%(
M40@F-RF1HE%'SB4V*SO\L?F0I`3("H#A:6+PI&.VF(W5+6D@O8?I"61-DE[M
M-@%`7F?4074M$A^2/.'[F$/Z=-C=&%W+QJ0FSP/5"KCZ1M-%+"^J5W.ZVF$T
MZDD47\;]R5Q[_@\F-]`$3.=:9V2G$8F38MD"Q"6%73<C:P5[4S%C#_G:`;)N
MMM8*9(<P4FB0$5H*#S9?PS&-.5NNVRZY5.TVC1=T]\>L^"MJB`M\%7+WHC\%
MS`51BG3-5"+UJC3)=FU@"RW**,B>OV&C.'#Y/?ZNNW^HM]K&!0B[-CY@V,2I
MJHP3Y8>)\=C'4*P<S<?#$7*H4!5Z`N.$4ATB]`&Q3H'&C1%\0#<7=ERQX@8'
M/EB=HHD55L!A02VE+&,"G<$:#A/76;:E\,G$^^:X;9O98-9'A04EK/-PH-2`
M;7)(C)@HX(:Q*?:CH6%([P;-ZT;4K^60*=8""T;[`ZH8Z7YLJF['_9_CA%[G
M].C4`.XAW%A^-!ZC5[)W(CM;DQ,:$*D"<%U.PD2.SIUA-KLT9\$:<GQ^[&NV
MD7BM#;MEF8I;-ZM[NMBF,NOP(EJOZ?+CF\]$&_]67"[PO#\Q9@SZZ=05D8L^
M1.SC[G0D2DGR\<UU+JZ,A61[>\;R66)3/>H920ZO'U\H(SV^R?RHH@?N.CXX
MD,`60-P^2[<1YF:;9WF4+./D">.!-8\ABZ`/9\;C\!:A706!B@K`HN@")Y+>
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M(G5;0AYOP-6IF?2&^NUCE/Q`8V6PGR+WD`I3Z$;0K9JBK9#E9@+=:+M5$[0:
MLL)NL?EPEWD;N^6`5;>$Y?@T:D@Q&P^F^H):8-FG%J00:U[*`C[Q*<3R'C@V
MH9'[A*5@2W\-?/C.HM'1LJ"'?4]K0F0M?NOT$N24:#YQ7(&H4>%D2(PMBRNM
MX#DK"EH?UT3H4YL`F8OE.ILV*)=9(H^>FZMSZ=HASZKR_UD8^4Y*^Z1C25D>
M`%6S2P(QD\H+B"-O!!J9S!*8)_6NP8`&Z<+;;Z/T)KWG@TRZE'=#W-)46L[^
M06U/(I-%9_VZ&3!";D".<!7$AI)2HK@4A:NA?`Z8-2KP@HC3%%YW*F5"C3.R
MX:A?=?=PM4\JJ[_5TPQBOBZ(I^)3[6D-8&MDQ=?I9`HC6%560%(IL9@3#`H3
MB$0^F+R)$^SL`M1QZIFBLU%W[`!D.P(>04Z6QA/C"62#P/!D0><W2G0(QH3-
M;7Q/FX[2`"$>92)0Y^E_>X6,EXYJFN&NR>J->\:S`P="`C($<6.H!`$B1;`K
M(M\1X;_^R[?SX;_U?ACW]F.P,[)-UC&?5O,!:+3-GUD:_X,N_XWTIX.SR61T
MQGUCE^$O?S<:GLV'HRJI2)23>\X&.0\AP]X9$1[%7S'NG0TG/=Z\\@KQNU'O
M;#8^>L4E711OZ,LW#+HAJ_[&2L/G\]JQV+"$)OG-ZF9#Q<G>Y.F"9?EYLKSZ
MMJ%)9MU?Q3Z.S#D<&8[LPX4'V[10"HF,O9U*1.@D5P$+K?"'\Y09]!L7;9D!
M';?:A*_?O6@+OEO$:\0&+6UAH,G*_*S<9F`R[:-B'L45>Y_-YZ9L#XC@$PM&
MB&U$A=XY#H79/6T)M7/X";ASZ@N]FZBCW37%&C;@W"1YI6D><_F7]%&?)5K;
M"IEV/>B;Y_'O9+1-KITP(J0!LZL%`M.TQ`N!$U'V,#*:Q"PE"<MI=D86Q>WO
M))*G$TE"<W&H9)OP?_,'^,QD=\M8T-E!O1\QD!&[(H5E_]'0%KGC,K"<2ZB1
M%)8FR+U("0C,EX#[D7;RAR&`:5O28IN`9,AXQ_4S8\OLGJWU.R.UK7!K5_W>
MW+PC\DY&VZZ?R>&'%$>$/.`M[0*#R>>],#AY>R9#_Y,$DN&`F(ZJ^R%Q.IE^
MC(50-8(*NYE3[^L,9!PD<3.Z^.&)O?ZXI+'B+/_AD*K\5W^[V*8I'V)^XIUZ
MM/[?-$JODF5-64I(4]PVYJ0WJEMP-@EJF;E**E%BB9!+N&!X\44%Z=CSFX3D
M0F0DKH:]'^0Y#&ZE8!V8Z#]5=YK%+/GX]FL2_WW+>]5LD<8;L1!AN$H$]2RZ
ML+(IOP8DN5TBR1'?7@=1I$EI02IJH*X;D9CU74HKF!V8=@C\L0YXP`X'YX7,
MPZ`=D;(8[8KZ[%F>RB7":NX#S%^@+T$FAH[[IDM,<"J$Y>M.&[)7YWU2#^D#
MDTJ%$:"\;=H(C:Z+Y"SG?>?YY3V)DYR1K\_QXEE655L*X\7BGH.%O/U-K,AU
M1G&P*VNYCOD('9'^2_1"C1<2V9IC:R#5UD2Q"0M+62$7>0N1Q`7EICLN_V[T
MS(XN"+EJ'$E+HWI[=428FS1^BI-H+7ZKBL[!/KKA.>P*_MRT@F^5&I9+I0)J
MY5*I`.WP)%(HJ1I`ZL"NCVF\?**J7Q.E5(JN/D[$/_[/-EG(T?G7.%?]VR:-
M7_D,C&S6T8**[N"LV!KHC(<FM]02TF+KH,P$%UDQ-T9V8[.^J9I*O:@`Q/.H
MCB(AF<G621D4'*X6.0,K:V*WDWL.R_MW?S8ETEF:HKQ]..G/IKH<%8V@,#DI
M1[[Q&9D)IJ!I$E`:@N9)8S=(FNR2AB`U06,+KC921VRD8'`K-45B;=*9H1GN
M-IK>?*)-,*L1TA%Q$>E3"A&(LP$2Q/R1@*@:*ND+`:=]AM8G<ED,T]'@TU;0
MPM(:>6AQ/C)5DM;("DT$9"4*A0HZ`@U9<B)P>HK-5;2CS6YK10A=]NN<ENV\
M^H;(O;M1;3^@%Q.``)4U?M26W*BV(V@.BFM7`,+3(@\T?L*@MNG(^\6-*6*K
M_2I*US'-3$L2]H>02Q.3@>GHH5ED6(8(Z3)Q@I3R@4L5`B*4+;X0&]WXHH42
M)*5+^J*V[I=A,D>0/J=EF,F>7;%M;^_]&J6\B1CH(O;GD>.ST0C>,QFD!Z9C
MQ6TK*_CJGF[8DKU"#J9F<\@[6;K?2,ML:*JN".N.Q`#_U?,9]A%.B=IW8K'!
MP\7>/X^D=G]NV\`&23\):DM5P-06R+VH[8:\V0ZX2"PAJ>`R6\DD%,'@_[=_
MUNOU!*631;R)UN61'=Y$/GI:Y#[P8!RYCS]#]^2^HV)[/TZ>+HOS4.?JA)1<
M5KRE:<R,^6?>[T2FH_6,Y3V\-.HN,.RT(Z5ZI*H?40J"L]5ZQNHA06WD.OLM
M#^>1J&J'C53B%`("RL,A00)K_(X"AYA_W*P^Q6F6W]&_;V,^F[J-WL1?8.X&
M>!Y9'6LVL^4#@*2');^<>M^LB%2%E+J00ADHT25V*-$;Q-[HN&!38,[R*,V[
MG9)#G%/+9:!].^+M)SYU4OE"(&<Y;HYCY7PP@;-R+RPL"85<@KF]5J*"\LT=
M5;/T.AA6=T:N&I?2<JG>=IU1)TY-=>LLK9'$F1JK#FMDA>9-G"*JV2E,<-HX
M8G)@C00BB]>)R:98:EK'T6.\CO,WLBB+EG1(F$-/,O"EQF@=T>4ZX5^"\DY0
MK%2O5G21QZ^BQO%"I*H\P4@$?`=N_6@^&IM.UZ,T"$NX4AFQ:D3)3AVRUP>V
MCB0M`"5BPQ9PH.<>:%P:(.UR>`CU2BU-$28]`?*J$N4>S-6]`$?;67W!1+SX
M+CE;%.;'$G967RVQ?>R-#D$S!?[T2*QU4!"#33;NB+Z_1/DVY:.7FL(7\`>P
MJ4`]>*]:%1>6CJ5D>!4,A0Q*/A]DC9+MI03:Z4I*K5]I6:4SGE^J=_W[136.
M@R^*>`+#C5FOU^\-3`G@>GD!<\%U))$%5F`WI4J<AK3PYG`V&`2P^`S)XLWA
M:S04+/F\-E`4P%"(H2W746\*.J!O:HXM?V@]75PG+"R%'`[HC^QGB9O`Y9]G
MV^T!?:,C:;O.$SB@OU?F;I=:*;.8D%-'Z]/(@>F\!Y\W:F6'9==>C2+W#SEA
M5*"A7&L,=*.]5DHW_)GG**-%EE^4$Z9L4BS2RBM`:KON(/2T^ZF6K2"+=T3>
M!YJ^@-RFVA"YE-.SEGQ[+R8L^X1$X+I,SUK'S0^(`Z.^</J<$9KE\8M<;DEW
M.47K>-7=3/"=MVB)<6BCCCCPZ[X\>)F&`_K$AN=P%8!'_3&<(352PQ*FHL`N
M<0U67%?BA!*H`9P.?*J"6U93TCJCDLG+M,RR&,]OB>5FM:(I#S&U%>(MK7"W
M1_7FTYYI*>6]C(#+)Z5@7&EXA<>P9.*'QX'6/C@,2R-^.%SG=*74D"L?&B]G
M(&,$[>]NV3I>O$&.S6M:(L]M3.>F:QUJY`1P=R71Y:B\0&/NN3S1^"]DA#XR
MH7,3!K9+0/_G%$SI4MQ)1)-,!OSS-!4'4X3E_A+GS]?),GZ-E]MH?;Z6/DZ7
MLG3H1SXE??=<<7F1UA-:DX0<4_(?C?QK7,^V^:L4)E7)I*(R$3J3O=)DI[6J
M_DNDWN\?+S0'CEZ%14TQH'.+.L60PJSJMMIM$N?966F7L!&E/>*P8%\I>$2[
M3A;LA3Y$WPIE/M*$KF+]_!7T%/+^FO[8O.1JE!DH:BCIA(O?W:-7*`"\%T:`
MM)._(9`^1(X5TCSZU@E_;:Y5PT6`T8+SZHZ^TF1+BRL]+%^]OC$R!;P_'@)8
M]%Y4(/(40DDA%9C_+0#9&>,'R(<HFY0MMPM1&D1J@$!EN!^J&5A.UT3M@!D`
MM4Q^#1%J.*^WC\_:U+MWFR>\B"=01)[.)D-#_4>3O%#K5^]9?>8\*U90M<M9
M34+U#%Q^"+4+74TB](ED=\$(CV$-0]O)G_IR%O.KF,1<WO^:F1:H[>UQ-9MG
MDXDAZT\O+3#IU31/ZD`NR3WY-<,M_2J<%LXW@=.1\<W@LS"^"7S^<W4%\GNA
MPA]"4]_(FT/BV\P5?'#/IQKG64;S[`O-82-\PQ.XR?*@/FD6("\0@<0,68DF
M7#9JR*_`V<?&#8#S80^?&9-(R.]@@&SRHYI1LL52G1+G"T>-YL[Q0TCZ3"RY
M1":1W3!H+Q](HHDERZA)B/\,/*KQ*0N5ZNT5D$V;E"YBM?:<+*LE?[0?W?H$
M<LUV.C9W0UIY;9-H+YAPR>\*8@%7:@4T$W\:@^9$G@J^B..++/A:XY'=H1C:
M:`$9)(N#QJ]4<OH+$YI$:TNI&\`SR,S6B66/U2"Q;1Z5HE571$KAF,HW"I^)
M2@WB<\M]59A4C9OLC*Q82N.G9%]UDO_B:Y0N1859>2]4V!T1B,,Q!WMVP+./
M;U_$42UJO&;`U!A9\'$XAS&K*BH8I3Z^$245=>>`Q`1ADP\FISZI%'PF[OQ6
MLCOA2:W?U!)$9Z(.F'%1A)8'+MIR;M#^"/+J@:&E-K)>8#"NE**)D(V]Y'=H
MJ8#<'#XOWNQ!=G**$.!6M20R6ZT#*NT*6MVL]K_\7!;GLGH!['$<Q::CGKFD
M(4QX,+KMJ[2)0J.5/^Q4`5X%+'!#J-<L;N]R;LL]XK4)<>MD!#IC+3'A-O79
M,2M?7#F-;]@OL[7&[9;-Y\.9?K=,)RO47MG.A:JW,:%VD20^[2Y94_B<HX0?
M+NWN6%.X_#KCO?1PNV)6=C"4D3KH>RO'E>/L-]`T3_\(KH\=3X;FQ4B]P"X8
M(V2C)GX2'Z0O]<?7%'.ZN'P.X%:UO:79:IU2*3M/EG^BRZ<X>3H791_C/*:9
M_EYS@&,@WXA<SYS-S9G<SOITP--,[A\4NI&]<O"[[34&PC&Y)0,U1?1,[D+X
M6"E@/,`ZOR5<.'R:4XXF]J.=_J_$=>R]_A0V><8K=*H!!9MAJFS4:$@)F8+Z
METB<G2JB2/$/\*K#Z40.RR'69CY!![&C-#]7SNI?-6UQ;)_QR2&([15)P6A<
MD0GCI40S:A>-NMCJ*EGB2,<?$!'H8\1_NP">6Y%PQB'@W(L;?7"`/E).I,0-
M$R1T>F!RCXFGLQ19Q^S:^*:Q4[>!"Y!G"'H*ER#5&PW,!:Z-,KL(:^A$0PD1
M29_`F88P`NF^7C!L3L?U3CE,V%(JP=9K8G^B(N2!6RPK\CF9/%;PS-;<@-G5
MW[?'.X3>[\$5JQI/9G/[G@9<B^"['=5@4M&-Y(Q4M?M7HO2#E8J25K'NA+1G
ME49":]4:#^^MX6",XU%E^]:8*VLD]$G4L\!%JE*'3'@"U<)M=V?%@;W'>RYN
MANUD_)/0ZYR^0*9M!RUQD[:)K3CKD9Q@!/RK$$FD3.!:RL16H-4;C-\HQH8H
M0!=_Z"R:;KW&/!VP`%"*7]\4F7!:?ZS5)"@8$1RJ[P_K3[$V"<<ST[2[HOL&
MEZEE0^?%]DM%LJN71[I<TF7E5]8/;'H(N9K/_PNB2)W(4&3AX[%">&49&KCD
M)P%"2-,$0`?Z?&;)DRQ73F3EQ\JU`9]H=TG;1@>K)93-?%U0:Y=R!Q]Y&9[!
MWEG1G\"(=2PQ'*\JF:7XD9F$"**6/T2OCBD[PP!MGUP&'ZOGEME^75`+6GC8
M]@".5*/Q`-A;!2Y-M&>4:U4BA0W$IBZ*$M5MG7=#'E"%8HBM.J#-0_2XUA<9
MKFV%G/$,@"<;I(QPLWXI#CK-&0!/*3AA\)SLZX&T[OGOW:+6W8\LXK-4_TK7
M;".OI*<TNV`O+W&>TV7](J>Y+<J')[-QS[#D7B\IU++Z3CH1XLE./LBS%3+M
MLGDSR+`<;0"1]NA`,XB<&+N'M1*P%B98[:QQ6RC!$%8*UU/%*5WD-QN:<F(D
M3Q<LR[53)D-3W*[\<&HNN%`CJ&522(ED)Y)(F;!-:@G&T'DU`,:%#V!$;?5B
M)F]A</MX]&=%Q#]/EE=)'N=OU\F*I2^R`]"D[*.?0QZ7FPSU]R`!I`;J\XJG
M9)ZLTH54E,%FVRO4NCZP!=1(ZK>!5M<_MH#6)39X06ZE[\10CCE:$]FG9G3Q
MPQ-[_7%)8]6=\A\.>U'^JYT:G^)L$:UO9?+D)_Z[PVX4U!9WT&?2F]0=]#%*
M"L0F)9<HP41*AIW-D9B.^=,H)A_.`($US!*8\S"$G8*P0=P%#^/"44LL$_IU
M(TJ#G+`\$&)Q+.C7#2H;Q-,`!\R@6F?`L<O4^G^MA5KV_DI/I-N(@C;'\6`\
MG]AX4"<L$!G>#3*PFT\*FYD336#S(08&8(O\,/H3PYFL9:;<EF=G+J/\<)W<
MV@[;1PQMHZ5W4@*1HAA)<*%$2(7V#T/;*,D+BP\)`(!:]/UZ1V%`V[3L[:)$
ME^&35?^,]>V!+>Z+EP=R:2$*ZL<#6TQWT=O'?77*M^BS[[X[,\,/MC)\%:7B
M+%_&N2+O3;14N;`U1]:2F<Y,>9PZ8>WZ=RE51+CB,E+DZI#"I5\L;@J74U9:
MEI$-!Y8)P3\%7"FV>@[#&:@SAGR,LGAQSCN5>+T]WC=%/H7D2W]NR@*PR`Q.
M&RE?+C\6&@#9(U#"V>.)TH%$"I<HHK#4XPI$(YU?&=AD,%AGI(*EG0&?0N:>
MS2>FP\,6F<%)Y9Z')G#":14^&6W7-TGY'7(*D(F&L%8X3ATE:E_2;)'&,NO\
M9O4GEN5E$6&=#^#?@)O`S.<#4_(T0G[+O#L^ED`JJHAJO4*972EIV#1(HC<P
ML#WT3JDV>[AL139IO!`)!J]16IY[)RMUD$'VA(MUE&7Q*EY$Y1-?BVI#(8GL
MX+_,^P-T2/!*[>'C/]IJ<?N^#M?-S@?SNOP`7V7"QX'W1;OK6B"K=TO+##%Q
MH1W3;%@6RQ<@>^WDZ4,NSCDMQ3FG='_.::4_YZ0Q0O<V\"YIOO,':*40'5.Z
MMX53H11Y[`WK#L&Z`V2`,_8->*-WV5'$290LXFA=.>916T#>YQ7(@W0#8R%I
MC`(==`*E+N]*3J+*LRL#H&C>F`$<PAS8"MT2W.ZD9E*#3!R.R`E-G]X,]=V/
M&R"+2(\GQ@G9[O4M4TS*P=1I5YH;V..LN0,W@EYB8/CTS(8_L.,:RX'4-4$N
MA_.?K,X;HOQ'Z;ZHJA]2>YL#!ZOV`8#0JA_K:WOH#-'2)KY,,A8EIVJ.=&K_
MCDW?JIT*'[V];:=5HE"'.)7N]5OY7KH[N:P=0`O;^?4.P"PV:--;WRZH6)7B
M8Y8E_?8_Z>%ZC[4=-@EE5#=NUTH)X,5OI)!)I%#"I4(34T9U0_#&L+AZ-1!0
M6]ZM=10&M$V[WLY>7E@BJP#*O9?L9IMG>23K;.L_).`A+`]F=:,/F,@PI)`*
MJ`*8:E,M(Q4=H!29U0U3VH'IP9<*UC,@V/;H`W$VYF+$5HE5.US7_1E]<J/N
M\MO#EP>A!6J8KC0W^7_`(;I5_=8\^GAX;C)`JU[Z*5[3]"+*Z1-+]4.=VE98
MG^T9A^GO901Q72F1E"*A#MPSCMC]8+C[L1U+:]Y<[QP,9)16??N./L4BU3')
M11U+[1>K;X:=A-;FWNJ$!''OO4A9<10Z(ZU-MFT*B+N#`]"TYN$:#V$PNX1;
M)I3ENVTYY[6-D.50QS/3=4?O1;3LZU(6.J=<(C`L%WHA<'%R"(RVE@SK/8)!
MS!'8M_G`?L,2/E,VKX6;VB)3[(8`3S^0%,3A=S*1`W`)R.;XGH#<_1^&JE4>
MZ-SFB`X&(P5FQ766;<758;L#'B]LJ[TR"O((-N6[;SQ'81`8A"JEZ$K:MY(.
MS?3N&P]0-`C/@3C%2DTF5Z5BK@5=DFVRY$@W<A>>DLTZ6E"QFWHFTT[I_L!2
M<&Y9O.Z(8G:KNE>ZNOJVH-F^9/#-*TUOTSA9Q)MH+7]S\+UQ#V$8-!L,A].Q
MKL:55628`E=*C6JZ)N.:D)TJZI<01A5P-<6M&H>+#!E',&_\8&JJ6C4.TR%T
M_+G,LLS4^FZ<$*K@JPSU`G$D22=^]X7EO-ECE/$8PV..N/!5)+'+J!*JZA6<
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M+$G+?XK#\=EGR[5"K<A`+F@/:DLAMJ)AN'@@E97TJ%[H6NI+;A*RTUBVJNHL
MRTUD#M<=25/JETLZ-:57G#DK#1KI#,JJ!HW<#-K26*D=CK$`W_5W%>I,-]<T
M_GYDB!N.V@YQ@8<[380WS(T[TH+M1K8.1D^%9G*<<6:*7^$O]6F>,0T'K-_W
MN$QJ;RL2U)X@Y/G6Z3!(^`I4BJCA."95=ZAB)*T:(*2%+'Q4,TI[VULSRM_M
M820DJEA7*OQ[#'#&ZDKM?L4FUKJR;*O*&HB+G391*H3][YBNEP_L%U'FX+CJ
MBOL+4&%G/!N/!O:5+X#X\`M@>Z7.R%XM(O4B.2.E9J!(H0QA70=KP1`^<;54
MYAC_@Q-^ZZ)8"_C];F+<%4LAJWUAE:CJ&B]1^AO-R9O0,D3L\V#N\7H9TMZ=
M#,]*#:^^;>@BI\O+^#5>TF1Y=UR\W?5QY$QP,C15*8`*[X3(I2*DU(3<0>N_
M*]RPP4Z3N!T(_!=5[*VVZI&6R,O2(I+*'8UB0-ZJ&9M`C7X2+'Z@Z8N#(U4?
MP[%V,AV9=MIM0KMEJ]``1E()TXVD+C#;[EUS#?`.J/C.]8`4/#3I25#OSVS-
MS2_,[MB%UK\`6>IG-C8EAL/%=TO,O2[PCE1A=^.H'_907>GKWBIIF-M8/-P6
M2&6]Y3LE]5V<_?8II?0ZX1^79CF2TJ;'<?WK8&+,8H<*[X3.0A$B-"&E*HAA
ML02.8W,3P$-Q.>6Z?E@)VYP`E8WN:B&RS>CA:?SQ;??CGV*:<M'/;Y_%1>V&
M$GNXA[$7X(Q-%<Q@HH,1^.-;=25ZIPB1FF"*]RG<``8WBMLSEV*G0!>,A/E>
M'1_!)NR"C96M7!XH_KZER<)4[1+Q)+(K'8]`"TQZN2%)6-&![)1`\4_B!?&O
M*;Q^6_Z/&M#=4-'J>_4\A)@R/`DOXTP<B^&*999S^)!'<+0;SJ:@$6R-P&!\
MJ\A&G]F7^``T:P"?'[_@(-MFE\FWZFAE,5T#>[W7R6:;9Q=LNV%)S5P/UAAU
MNK+7&\^'UCW<0U'!]VN5`D1I`)Z^%>AL&[.^Z)SY[H7*MMWJBZK5Q=\SLE"@
M`TT[@<PYVD,U&3%\_ZFTD2/JOO%&!<`3N`7=Z71DNE''("\TF=0$L8^['T'A
M`_2>_O@\9X9*@;,29A?=IL&GZGI-L\DZ)=$03:*ASRTDXZGQ2E6#O&Y(-$1>
M,B+QX4CDB*]1$@T[)M&A3UE(5&.R\"2JFU\:JTXAGD36H#+?*@*0&XQ<FK44
M7(4J\U4D+<#UY!H>=-O4`WA@'05A%NV4BOLZ'KOE5S0IK>]`+KN,)J`^#Z)!
M%T3-ZK<A<->O2"/@2-N8$?P6:V"(`S+6[IX6[H(,VRV+=V<-8,-3P*/(TT3`
MPY`&P=U0=7]6!7D['O#L8H.`F^M5J^<2NR:GSOULG#08,SP5;U9U-_.I6]=M
M'@)Y%CEI[/5`':A)<C`VWJPTMU4J/8#32($8P,8F$?OUDDP#NPLZ@CRPCH]0
M<WIL<\CWT]I>3=\`M9W1[PW'^F),U=<'VL)0(E']40%"MVOA`P));'?E=9L3
M/LJ[<%3)"[;!4.N_S`8^7!<7)W%./\>O='G-/3EYBA_7Y;G7!7?O[5H4OSM_
M86D>_^.=HQ_&8.<7H3J_06\T,>:LH=5HG3!<'R(5(GN-=H?8]SJ1JE*@;K&P
MA;Y.8HO&\"F.6`4=64"WU3>Z>RMKRKZGP/&?4Y9IT]V`C^'X.ZKOR*!".V6K
MU`!&S5%]E]<63(>.\($NGA.V9D]O)(V?GL,.3:&N!2/;D<E.@5J?;57\$(\B
M3SZ.:N]6P@CNE&;X&GH2L1/;G!&[#3VY&A]<88?GXK$?POA8:]13X.07JLTN
M!3V$Z^KX7+>N;#],9*<,Y/)AW9R$Z$0\!X@.E*M`BX38,Y*@H$U"06-YM&X)
M6OBX464,+&(<F.P$8L6O&5UMUY_CE?9T)>)1Y&9+?^06-_:".XP>1&E!A!K`
MO1:!UR6(N.-M()1DA&9Y_")GL2D5VX5BEVFKP*\UX(-SL<8708RL-ZW/0F^:
MY=?),E[(>?`GEIZ_I#<)_4^:,OX?TP(PXD'4PO!P))+3M`O#`+&A%HRY*F2O
M"UFQE)S_<M?OX5):"\#:1>06`&/#R@'03P+H2TJX?"+TD#\X0-8N/;<`V6E>
MH/W`X9:I,2QCK@8,UZ^SE,9/R<4V3452U@5+Y-F<;%?@LN8$CZ[[\7@5KM^?
M]_K&I3$'15HFK-*(E"J1G4Z52J*UY[Q@`P-I$,/`((!!7.A<6&516F51*A9R
M1.#CM:PY&W?%^/VYH^P\W^EHF/\C'\>M!/3G?6/Q(Z#PP&RNZ$'.WY4!!J\/
M2.!@!C<&W(&U7$KE7-J9Z(.E->BWQ3-O1\4OQ(5=I\!FNW?J&0RR<5>L?4BC
M)..V%>5;SI.E_.=:CBV*K!-K]77?]^%Z[-',7&3=59O`1*\J)BNF5U4K$K4<
MBJ5+ZX#)WYYU//KP4KGNN.[@PGKRN]DX=#2X*D)N.=@PYSQ#GD'6^^U-C95#
M31+#,+>4O1MP([.;)4(K,YM!Z,&^(YCA:6CQJV.JV8W6%9T^J0$,ADVUCR`W
MH^<S!)G>"0S,I4(VDDH2'YA*7OB:8%*A0'=$JG<I/8^T%O-8B]ZF^3--G5:C
M<8^BJ#(;]D8C[7HT3'"@%6FE3`-KT@5HW9IT.Z"1<>(8K/>Z=`%;MR[=#FR7
M\&'ZT,'6II&<8^YF](DI^3:EO\1)_+)]^7D;B;JKE-Y&;_+(1/U7ACR!VM$:
M3,>&HPY&>:$"A]"!%$J0G1:D5`.TJ:-@:F-&DS"QH:(Y>-K8T"0\IY`@,;X4
M&%.Z4;+)-EGR2!$]I50>X`L7'4`T8FC[!1NF_QS%R4U2>X_U;4KSZ)MF:`E^
M#KD+9:Z*:)7:+L6$>''#G^;^<J4"<'?)7!ZQ<:`.9)-H>:=;#-[Y/RJET]BJ
MMK!WP*$]W`.9HUW#D9"QY==XO3Y/CG+3]AM;E@JE3N]`+DWUIZ;4,)0&+1.U
M4$6N)Q]GF.[509<UE38P\+9-&[APN#1$Y&>(MCCLY+2L`7N[#[9_3MEV4U_N
M4/MW7`G4V7S:UPVDJV\/,VR6$I$%#`L,FE&R#P9D''#773,$]M'=A;\*0*CQ
M;*WO,@MT3RH-+%0:>*QJC>>S_MQ(I4%X*@UPJS4*@XE*CAA<J.2DNXE*CKH[
M4VD0E$J'OLLLT#VI5%\_5/MW7"6+X70\,5+)L7:F#Y5P%4$+#"8J!:EOZJ&[
MB4KA:I<6`()2J:8JJ1%ZL,G;=;)@+_0SR[)/7&6Q\QHGVSAYNMG05&4W?*0B
MGTNU>XB^T>R7.&'BMN/R<B@Y>JV^Y>KO6_[G7VC^S/A?7GF3NI7<#C5`KNKT
M!Z;<XH#ZMTMLI0(1.A"A!-EC(7LP1*$A16N)AY2`]G?"J:GKP0L5+*)PD0HP
MX*J3^!#Z8X4G_"$<SBA*JXDP0MC>]H_*]K$R;"X@!)SO=L%4UOGW#1R*[_E0
M0NX"6%;,+*V199_GQK)X&EE!PM%.*G:Q2X'2+W8U!,KI."0*6:MLUCO0$?.,
MI@K,$LGNVRA>&C_N42M<QS^=SDQ'#PYD!&&#ZFZ%.%B7*2'8..`,P=WWN^FZ
MCOWAR,EK;1'>N<5-RDE&/]*$KF)S%Z!MC3MG,QC5)A-99(5R>E*()85<V!$:
MA4E?Y,T7E$\EMT*6&N)]OTG9:YP524)_Z':`IW>H.K;H31>>-;"#+K;FR&W%
MZ=Q4,4HG+!AQG(^@2&"`KB/\"9-J7]@%.P"'1R#6"<F/E$89O:3JO]?)^6+!
MMB)K('J+Q)9CLKP1^7[%3"IY*H^HQM2P:N/_3F0/U1N;TN&]-&J=CE(E4NI&
MKA-2:D<*]>22B520[#0D%16!79XPDI&UX8SD0.V=439*G3,2+1;IEBX)5?U,
M)G,!F#33VFR<]L)``Y[/6O@F)Q!0[NB"QJ]":;0#'C^*7:8=699IK8*[C`)[
M+:"+H2-C`>-&\7J6+%8(4R/"X&RM\3<0*>O-UR'W]OF`+MVV\6EDT<9QWW1Y
M'%!V!R2L9,2B.UP)&M/A-@+:;=2L`']?ZB+FF81W+`>9L5^C5*1V=YTABW55
M(WFM1N^0O^7F1-';ZPNM8!Y%#JT',U,Q!HC@#FB[VVPL1]#@VBH2+X:T_GC=
M!L-RZ!N7.(M!<:<D-+B<D8%F"W9*OU>:<))@.LV:9Y!7<8RGEM56O<1.F+:3
M#KQ>0^+#C$Y=`/H,2TMYW79I=8YDH5&MF=Q3[XY%?!;_N:/R`@[]B-+M8532
MWF@ZZVG/9()%A\GHJQM=<>)(G4BA%'9P61A`D_'7F@$:B!=-P-8D"[8&VZ&#
MOMB=+5M+P"&'R8[\8SYF[+"7WJU]742;.(_6]NP8Y`MP"3.SR<!TF`PNO@-R
M[E>7"UW0F342/6;XW!1Z9XYF@J1%[7&Q@%Q9.OZITP&`U2V-HP&(7;LDK5BU
M5@74<G6L#>XQVD=QJ\*SJ2VMP2JX"XK*_8U"B^*X(VQ96.'%#+P]`/N,OQ7$
M10$QTD(,QT2]QYDY:+1?U^S[PDWA3D#=T\B=F<G$@8.'LCNCX5X1%!,5:C03
MG6'[DS%AR8=3(Z36`^V<-%FR0UK>4=Y'QPO^C2ZB[!GL'/6/(1-:AP/<!LU[
MH1TP<*\`$1H`DUXE3`SS'''Z4*Z";*%!%HQI&M\R4DQO,I^U*%T1A,^:&R&Q
MCZ'X,AKUQ]I2!@"AH5:>3'4Q/B/O@U28M4M.C6/&QHCFL6K7F1K'ZG=S%AYP
M.RM.<*XQ-U.V$3\>:E*2,(_@2J#,![,>/FX\N*0@M1$SI"+`:B,2*CI<.$%M
M,E2@(:*CA!/$QB.$'F?8X/!PF&>%M5[``;M6)^NY`O"3N&'[<&:\`@<@MU.J
M80\>2+BFU>7&X39`NZ#C=[B?,6>[=4:XRL6:ZO`$T`^TS^%V=J;#B?D\CT5J
M:*J]NU!6J0#;Q)%`X33S!MH`R4+?TPQW,0//C(8+R3*9?E4<U]-_]+I6R&3"
M^<R\RO1.1NM\4:ESA31@>J!`8*2&#P(W(B@85`^C/0[4N@0#V:,K_[ZDC_K4
M`&U+;-+LW#(L.Y03UM>)$`G-AYU;AER^4%QV[EGR2M-<AO^,)C$3.Q0YS<[V
M";&=T^&=]^@I<6BQ+FEQ]6VQWB[CY.G\A7'K_N/=RH']PQL?1YX7&4[,)[9@
MPCM@%=DI0JJ:`$^,"-@HLC4"NX%NYVQW@^<V6O.?MQN6[,DH3VI&ZV[):'9/
M,T.M9@Y.6W6,O%#Q"TM8F>]C.B0"?Q292C/IF7/>[((#4;4H$%`RMJH$^(R(
M@FNG:9-P&Z%H\"D2W-UJZ`<U7W#J&8M+'3=!4FD^MBPR[`0$H@R\I)34W<Z+
M8/6DE#B$[OUVE.=CU4?F3-_R*B#>H<I!;@<4UA?&JC=*!Y241\>*7#OK)ZQK
MC,R7Z??,QR+K1`4CK#KS6$@%9L8(0!#W]P'4Q$E'<7%/9?HG*(%`"&*X#T0G
MKI_$<4XC.6I)K[-30/H7)_4*)>KV\D%MD1L!\Y%Y&;-&4MO<+T3N,L,1^]@%
M(!,S&@#DU(,7<L\@L%HCALEO&,)*X6D!OF0+\`1R8[H_!5$D]`5:>Z)XW)4E
MP0'HTLG-6`X(VV8.[,HKH-FZ9)$]S\/^"(Y'@][8?$!"+[`+(J$S.B0^%)7"
MIG)T40D`X$-FVG2=M5$H)+:WLV>Z%'?995]H?K.ZHQE-7PW5-,!/8NM#6LI/
M6>6&(E.I`9$JB"5)<K,BI1;00H^6NE.-HW6Y\;@$^B2D=\$O@)/5T0QFM?!L
M^ZPY!V%OB*QJ/!^:5SX.Q82B#CK)7T$!$,49BM?P+7`./\!/ZNA0:YOPWF_:
M]3IN@NL]^K8K4/8"0ODZN)Q9WW;3B;ON?A-ZS5Z4!H'I:B</!/B[E^P(VJ:E
M=M>LW@[AJ0@MM6]NCIPF308@B@8NM5_2U;G2OL0%H&\7E?8[G!J!RNS;31.>
M&W?1UU\B;NTX6N-F1-8'D1.B_M2\RVP3&XHY7`&RT\!Q.B2P`CC4&%8'-@F8
M+Z7P+AAE]Z\Z;H%,%IYE?X[66YFA!667]@%DZ<[)T)RUJ!,7BDT[P4@*26``
M"GD#\YHPI4IH%_31.U`=;8QF"D^7O[#TM^OD-F4+FN%Z)?N3R+3?R;#NR#!"
M;B@F"0U$%9)"![>>2<(%T*HYN`[\DDCCA&R4^"[8!7"S.IK!S!:4;^H2V0<N
M\OQ;;*)7?4/D2MV@]E)XO9CVR:/D$2&0_%6(A*[4#6KOB&\.BF/'`\/3(C\T
M?L*@MNG(^R_XJ/&)I44BO;KD'O1M30\BV3&SU&FUB0W+EO<:D+\J':#TF5FJ
MLC:-U8M.&?GK)7N)XJ0[,AG=3$LNF^7"D2W+MA&'?+.ZS]GBM_-D^1=U<TOV
MB:7WO`N,>9=XDUZLHUB_7^3R#MQP;S2;&H=[&`U:9F.ABACC267DE7RE.H3K
M0TJ%R$U*E$JP0:`T@H&;;1K!@:;WSU$J:B9SM>A27$E+LD*)D&1U\DW6@%7=
M*U!]CKXMHS7]'+_$.5W6=GG6=K@:=;WQ4'M'0IV4,`6F"LFD$(WKR10F35&I
M)C#APD(#6#35HYK`XL#N`T"AJD,9?9X!38+L73.Z^.&)O?ZXI+'J6/D/A_TI
M_]7?/M.G:'V5Y''^5C-G,[3`Y92/Y_.ZM(J:][?LTD(84=(P4S0%X-B;&P#@
MXL<P%`W[LLD9F-44P4:']KL@O>][[`WZII7P8%?0H.]LE(KK1V-A+Y%Y$/D)
M'=UE;+E'L>MK8"KR^>!-#N*>V7K);7SU]RTGE_W[&1_#[OOT3+NI-J'!*"`G
M+57Y1"D`W03B*/6).$VC=$C.>;AY./],/E^??[S^?/UP?75/SK]<DON'FXO_
M^:>;SY=7=_?_2BZO/EU?7#]TPR2SS]73RVK,D^&<Y8P1]G'<^&DV,JXE0(5W
MSD7\C4LCX_I!6\!=!F6_,V*:#BNYF+4+HII/Q.L;(D_#CR>FG/!C,>%HACL$
M+W"`NCC7`_`.G9H<!):7KW0^&#0<##>;IT/OAW=,F@=P;!A/C6?V].*"LP)]
M\E5"`W4VGM!<B@(6F"I*A+S`#^!%1JZ<2H_Q*8I3D:!$P8?'<0^CSY$#IU8&
MT>%X)92067;4\WRY*6.U'=`N`[K.F0;QMWK6`2WGL=]3D<72"_;R$JO=[9I5
M9/@#*/8,Q[WQ6+L#9!(7:"NHRAR6DHH2F*5G!5.W*=0D3(_`X`M/MT_4)#R_
M$(#`V,H>$H@^#&NW%@*`2FY!?<WWCV""P*P_G,UGZ""@!)Y`&#!D`FF@8@.!
M&]0&0P$>(C88N$%L.AR$2^I"D<D:$HZMU\6XO')G*7@XKG\&-PH?#2?`Q=5C
MB>&(5;F-%SOBE@!!(VY_@"ZT8LG3AP>:OIS`Y-;@4_4C;;/%PE&)VU"84)3S
M-B8<ZQLBEX$&Q@3C8S$M,X7+(]*'9)EZ7`*QQ&+@AS<61U+L`84D@]Y!&-0F
MG;C]GHF`[WC<&+DG,)N9CN37BPI*@;U8X.Z`0`0C@3LBU]XA%["6W1&AQETT
M9*BW35!"Y(4JEH-8IJ;8`=341H9#0>U3(=\Q`7T>2^(Q4\$7CQ<1A."SCHYE
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MA>6=A+9Y)44AU_ZD_OJ.V$M_!Y(4\@)VKO4^P``F".?*<6)WY;HV.%?N]XUY
MON\DM.S*2A32E:7^!E?VT=_%E96\D*Y<ZP,,8()@KOR%YA=1]GR;LM=X29<?
MWT2G<9U\BI,H68@;6!=Y_&HZO(A_`>ZT5W_<,YUMA(MOER&B(IE0A)2:D(]O
M:B1UG9"=-F2O#K`<LT"O3Y%O#[U#ZKPPP4*88%.:X/&-K';0(R/TEACHX)W,
MU[PGR%U+#H/[BY"GQB8ST]@,K\:)<1I_FDP81-]#MF\0E\3_\_L_D4^?;_YR
M3S[=W?Q"/EU_.?]R<?WE9W)^\7#]9WG@+&2RA(?S.E&]T[0*C9IJ;N?171M>
M@"PRU1^;QJQP\1U2>Z<-NKN6Z-'==0/H?;KK;2;O0N7_*V&?4E=M\DP[?RVF
M/4'>NG75@!<ANVJG8;=!C1/C,[ZK%@9!=]4-&J2!KOKZRY^O[A].KJN&.*\3
MU4^QJ[[9T#3RZ:H-+\`M+PWF/5/!8KCX#JF]TP;;52OT:#XW@-Z!QT==-=O!
M/J6NVN29=OY:3'N"O'7KJ@$O0A[:Y3\TPN,3Z*KK^(P_T"L,T@2U.^RJ;VZO
M[LY/KZN&.*\3U;ONJJ^3!7NAGUEFZ(V/VR`+EXV,YWK>26B?@TH6$<*`%<E&
MQE,[7NH[I=AEF:R(G#]3LI$;W@@<QDFZ!PZW>?@:]Q'Z+7V%5YH^,I?!B4[_
M]H)3#1<9P`KNF55?6")"F;Z2=&T#5("83^;3@2Y+ZMWKP^1"<9&JIT9M^RH4
MFH0G+Q3(&.>AO29WR4M[EW%_`2%4VE&]"S,;^G#]-,MI=AN]18]K>L/#?EK\
MG!DS,8!/(=.,1J.^J2\WRVS;\[EP4D@D4GSYKPR;C21@&GJ;9F$Z4&3XP_B_
M$/IM\<Q_227>C"8Q'Q4DT@C++26#WG`0LG,"NAMS,J-'![85[[I9G3^EE&JS
M@/6M<+5PIN/12-N5'<D(U)])N82MR%XRK":,1*/KTKS1(-FM4-PXHM!U;=XH
M7/JWW0?)XJ>$+DED1-1*EZ?W=P8RC3\A/[&4<OBJ,-WBC?_S:Y0N+U@B)\39
MS3;/\BA9\NFRZ</AWX*J:S,8CF<]&Z'A.@0E/*=*H1DI52.%;F2G'*EH!ZH-
MHRQB"0KM6<0U:+1F"4M@:<\27H%G59BC'$*(7TAS+`K-0@<B!QX?!BHW4[L'
MLIM%SKC@AZ^<H&__25/V)4[H;1J_1CF]74<+&33U$V>'QU%CD5F_W].6Y$((
M#Q.S"H7XJ+4W)X4B9*<);OBND&M"5(O(<;&I1*PT(4(5(G1I!KTF++6(WB$>
MF3]ZJ!#D0D3F9\]@2P<WJU6\H*EQH:"V#2YM9CZ>F8I1OY/0,JN4*!QEE/[Z
M^;Z7_BZW89=7/A87(.:,Y-PK9"_](CMPJ4_(M>=Z)V$`&X7S]7)[[>K;AB:9
M-L%$VPZWK348U):!U$IIV>]W.\BE/-C&BD2AWQ7R1N%\%\$^UX,:`+7E[5H7
M84#;=.?UEO0,:WMDY)]/3`F36FFAV8!.?)3`#%U"4\!<ADU'Z$*F2-@=R,21
M3A,>=MI8TQX,+9%U5"9S4[9AC9Q0S,`F0B@H@*XB:!K!'D_@S7B3A]01H.F-
M^9N-F%]G5]]HNH@SL6VBJA_4SOHL;7%%34:CL7:[7B<IT"*"DDXJXHOJ'K`"
M'A*9;MV@(618NC:`2+<6T!`BIQY,B#ZC%53Z5*96YOPV1C"$D;Q)_+.8[='E
MY3;E@<)*8T-KW&;E;#K27MVNEQ66RH4"1&F`\7T%S\SF!N"Y\=D7EIG2#<!R
M)G5&G@IL(DEQ5[",K4BT7,:B!9_<9<]1&F1"!^4-0QG0@_#I,DZB].U>&L"P
M.6!HA]O`[`U[^MZZ1DH@>A>2R;W6$S10=(1N``J2RN\AH%8<"RPZ%C>`Q86_
M]F_2"CM-KLZ`)@DWA4R?HB3^A_3V"QXIV#I>RG^<)\M;KEK)A)M5<88^6M_S
MWZ@$"MO23)/O1B[CS&9#TS2U"<W:IN->1?).1WD)<E5+F0]0ZDGVBN+7B(35
M#&M$75C-B?A[/<\.;!<=VHXYV:ZM27BCC&$M?CJ?(8.'*OM[!S_'";WFOZU-
M?VQ+!FJH,NJ/^Q/]4*59#4,-<QI@5O6.3Z$_D0!@XPQE4^V8J5N;A@_P_J;4
M#MFZ-65741]AT';&CBW%+1;@NW;>)3R(Y:P6O?G=^Y&Y:].!-NVV2>U^I]V`
MU!V:#B9,V6X/X&3*;J,_VH+M!GXG"YY"T-?;\83C_?O`U'"L/_J4OX^UB0H`
M^BW_R#7\K8UIK4$,;F-]-!\8TZ\:5O)W%MVXVD3J#;UJ2UBSI96,!JSI<M9!
MW`D@]QT^;C,^_,HR&>`^1EF<B=]6U?Z]K%B8R-/4XH7E:X4+9N)`Z/EBD6[I
MLO:>5YVK0I]#YO%,AZ9J0U:I+<</>=BYD$_JKRL&)OD(G(9`T#1.!V:7,->%
M_#>R4>>&0](8[&7,T7B!B99E-,\N`,RJ:XA+G!Z.C?<['(L)PATIL#@>"..*
M`F+CB@\0EP&^1%/>4!Y)Z<%Y4>LC1T306:8+SP=V*YJVR'I8LP'0_P-W'XH"
MR!Y#P0&Q(&@OH3`E+/EP"F2`=`P&&X6EQ/Z./M,W/6Z%&U'-^C-C9O1[&2$(
M<&&\5%&#P.+Y[@C<;ZTB*>4C(GER5!SUWLJ)4$I?:;*E<A*4T@6-7V6IE=!T
MJ/&:0R+4FRPP!10'*Z,T\Q%*R#/8\J9#X_J&26(0LA11M3K9P!59D@AM]&D(
MH7,'4@,S.&5L?G5$((#1/#:?A(AKKGJ2QZ_T-F5/:?1B2F4$M,>E-(Y&(WU*
MHT%:H,T>Z3<[%4BI`S)!4(+4;=LT"-*%^\V`T^VH-`C.F?;'"(-M<4#HPI"V
M"MMYBBL)$D[DMU^*>ZNS^^UFLQ;ECI/E+U1DA"?+.*._)DO1VR>B"I9MM.G[
M3N1U/K/:PF>-:!2&H(5N9*<<*;63.PH5_8A4D%0T!%[Z,ZLMJ]:)C1QX_BE.
MXNR9+LD38\M,W@*D+/9,U_(*/R8`!._LO?W\<##0Q"<(&S[0J_T-+O//)B/K
MI+2S]7V?=7T)S,+6KA;T%;HU2YX^R&O)U]V-M7%K^2>VB,]U8.^/&Q>G[DT?
MW?H0DD!C8[%_L\@0)*H*+\_`%^*!3!H;[P-H%J$SF[XOJJ;\@?=L0OX926B(
MBEI(WSID%,APP5AUJU;1LD\LO2T.,MZL*HNU.A\`/X?CUG0R-2T)6:6V2Z]2
MO*BL24H%1+;*N]V%/HQD$JJ>9(U#=>!9H0-YB9:4;.486ES)$;26+][AF*,1
M@W/N@9TO_KZ-4_J9CPO$L$!==%=7P=OE42SS^J8;G"&"`Y'O@9%"!U(J02I:
M0-DGX(["X)TKO`E]XA.4)9*#E>/E^_%CO-.B`PJ"G*^&A5!;=D?$VU1TS?G;
M+?\$.9\\7O'?;@SK-O@7($DYJ*W6@A<?GIJE*D3J(E=D=MH`*2K!(RCJC[X)
MHLK42VJ"&HJ>=F<TD11D3?<]%E5RXOQ;7'M:\_BO*.*,QZ/14+=_LG]WF-T2
M)8_\54B$[1LJ]34[(^[J(TGMJ+9FS\-=;9>!:]!*2S7.RHRH?5ESR5ZB.-%;
M^?W?<:7/>G/]SF/U[6&YHV3"W%!!,++'#8(;?_"J&QGDIKHSAXSZMT>F`P]F
M%A/X$NI3_$KUV_NZ-BABS2?#V=A,K+V$H.0:8^_1$T",]'('XD0Q(<X%@Y%G
M[AC<=NJB-2DRVL(RK<:M&<`0WHSCIK`R[J@-,HFF-]86VSB4$)1Q(VPNB0!B
M9IPS$#?&\;^[8#`SSAF#6^]&_KZ-4OXHB1-"H\6SF+>)Y<U$G"Q<"81%@V")
M,5JW9P!#^3+R)K%V@4=-<'R<#_A_C'S<"0A*QS[2E24.(QV=<3BQD4MS06`D
MHS,"I\MP7Z4H(EQS=_'W*LX6O%,L24J3)5V2>TX?U7;8.Y/MPW+SF`',;C9?
M9CZ(BU%LW*QIA!J?3GN]F?8NK2,10?DYQ`WN%!(C/SV0.#%4RG-!8>2H!XI_
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M\CZ6QRBCRPOV(@YJO*/BX2#2YUVX`[S]:<]T@-=)DY:Y6JBDDD&E4H1K10JU
MB-"+[!4C5<U@!W:E30Q#_!`V<>!T88N<V^*QL(7@&LERMOCM@S)&]#5*ET$/
M7'BY,FO0ZL$C@5#K@B6O-,WCQS6]I(_:!'#[$SA6#T8CT^%"@[Q`W)4DK8@F
M0C;P(G:!S<[.!K`Y<+`**:-)S$1EM9QF\E0AV12Z(8#V@R#ESSXR]!BB_)@R
MRL19MHUX.)!YZ]_$8?DG*N\K77)]%'RQLIQ&G)H+69]YP;*P9[\`+*L).!;S
M=A)6A!)?:'ZSNBZL?B%L"?`3\X/(\J23L>E&>[O8D+%&:$"X"N*<9:D$N=!Y
MH`8LC(O-@'49U)>(H[7\AKR_SQFGF?#=3-Y3L`E<Q!OA>AKFV8WIL2A0D5/<
M6TQO5O=BN%1<;\H'&W^)4G'':?WY$I<7H-86AZ/>4'N_"TI\H"6#=Z0KE1*D
MDVJ1\NI;,78O-0,MPRE#Z-8/VC2$3]1IW`"Z184V#>"2BU49[*CA`2TMP0<!
M7PVX6UEF<*(I\[5M)R.#,DS>K$1U4)9(/0&=EO$YY+B@9ZQL8I4:DJ"[H0`G
MJ%)!\10X*.@9*YPTCM1G3'`T2%\HN')UX.3&YV9WU(P5K#;NF)&W:?S*1V6W
MZVA!3<?!40\CE_MZ4SPW#T5W1=!"#[)3!+B<)S!C6>J+V6GM8$](R50^?E?E
M4C8%\$VIC7TY(2A'M;YI):K)S-VR-;V/UEQ!<5X]?\.X3NV#V*J:$V/](JO8
M;AB:$J&#8*K2`EH><V*L8-0X6)>;="[O2T;&"=EL']?Q@G>7*YK&R9/+VI[Z
MPB%1.RWQ'8_C#[!W'7KJR68+.UI#=A)R*N6E9%&IXJZQY.F<C\->9=%$@)<@
MWH(<,@QF=54D''4(&9G>%5I3Q=5V&I&]2L!1A#`#C+`MF,$E9KVP;9(75UB(
MK;]<YG6+.^L$_B+->U>%K2,F8]Q60VNDN9M9+ZS,_\M%@?-D*>7;%F@`CZ+6
M"'OC7D^??P@3W,7J8'5!;+]2)A;&I$J@53&%';`LV"!VGY#4'&;`2F"#F!M?
M`U2S'+4AT<E"((2%=4N`0*-V,I*H+DJ6RBT!'9;Q.>3BWW``'2W42NV*C-F.
MC;4%GS1`8>.!1H!ZK_UIV7=RBW]F=]2,`JQ&;KS?WXOY.669=8/0_B2JUQ]-
M>WU]71*0W,"=_LK`.2(5`G5_"CBNR_<$WD*000/&]?>>@!V"C93S.^GP=?RS
M]/<&HW;2W1>;CJ56D%4"W2/(]$)+?76#P)#4*V3O2`?-N[.45&\0G7NGCMM5
MUWW","@;R"ZL`WIRXQ8MN31#%I-=FQFM'$H`#52,#R''*/V^_IB33607PY.C
MD('JIP5:P,"D$;2-!D8T2L!HI!&4+0Q$NLP^,E.K;OAAM:)_H#`<?ZQM@4M@
M-!:$>O?^P'Q'G0(>&JM!><%P)+*#^A;2ACM\&"YOP>3&AW1K]+QQRI;;12[V
M&77][='?46/PR6!@*$M:>7LP5@F),@$`-@)5`/2,<@:`YI.3XGHN.2ONQB2S
M]BW1Z=AWF<4`(2?(]1=.?*&&A#OK(]CS=U-CG1N#P-;=77N?BC@>`SV9-C76
MP&D0GALII/@SD2_'844<Y.XFE=#7^X%\B^%M%XQ/=^(@GZ',V='?<16A^N.>
MZ6ZBW=O;I844@RIN)O764\!9;P=_E[("NO3Q%V<6X&&=M78^8VB!+<I7.Q&H
M>7\0E\74)5&Z6YPVV"R@`!"^:%F="QQZ<)-S@3OZ&.4TNWB.TB?^X^(W<6#H
M,LX6(C_+,/O&/(<K6#:>S+3E8"%2P\PI"DU(114Y8-DI@RSD)5%K)AQMH$;R
MN0VTFEE*&VA=(H`-<J@9#8IIS-&(/@%DP<ESOI!OCI,G/D9,^(_JQ$1VR];Q
MXNV!?LL_KH_/^KF_`+<<,9N.M,M\*/&A8HM0B40[G<2"<44I<D:47N2O0C,B
M58/ULLH4VCC3HBFP`4>:8*\+>:^,IP&TH:=%`SC%(+,5PH4@%XHR7ZMZ!:5U
ME&7Q*EY(ZMVL+JD\S!6_TL]Q]!BO9>;U`SM?+F/1(%K?1O'R.KF(-G$>K37.
MT<@[L9N4<U/H\M(H6#1[IZ4X@K77DU04E7?K[E0E0E=RG9!"6^@&X-P4WX+:
M"QWR0MM)'P:#VLDA,CZ(K(H53=4.ZG)OIG6AWYNH+D/E&:HSLHKBE+Q&Z^V[
M/=;=QFNP6U0;"R&LA2\5;AV$KD7YG]LHS=^,1=WU#7&K(KWAT+@J<B2F;:)+
M>40*1!9XEU`,BR3>4)Q&*5`\;:V9Z/V$06W3B?<_['/#LH]OU;^8UK31+T`N
M>D^FQD5OL/B0+*IJ0CZ^D0.?Q*R="_@PAC4+WYMY577.R..!$3KB(]!#-3R%
M6S@@?XL[;+.;U6>6/#W0]*7H33_3**,WC^OX27;&>@*CWX#;X.V-AV8&@^6W
M3>%2$3'6%:H0H4LYD"52&U)1![8!K."/@N*?*_P)?1(>BMP2+HV@ZJDL"O1K
MH4O(;&$7OV3>9@U(W(QR,<]B(92^TC63.]=7WT0]9JIU%<`SR/(I@ZFIIKE1
M8MMT5*+5,O=>."FD`XN'"'RF_K-!?$Y=9@%2)%XL]QH$Y1G$J9B#S4Z#2VI%
MS^7[OW\2-VP=ST:FL[T`N=VRJUC1A@U2)5A'DKF!]:5:%;&VLG$7A#OP.2CM
MCJT8DGQY&B_X..,BRH1VXC\B%>LU6HON]SR_B-+T+4Z>_BR6O/0^XO(6Y$AT
M9BS/@]2A=8(6RA"AAN2I_*&B$#GGWENH1*1.P"'IS%B?IV4[N'&W-,:"ZQ*6
MK$Y^R1HQ9P<DEF=XK<-00V-DQ:R1L7Q?O:A@S%,'TE$#3@D(PBT?0'X44JBV
M22S.A18:!.X`3?Y32QV=M;IBR*_">G?WOYH3*"'/8,>50\M\32\Q,&VD<')'
M[LFOR-Q+"1+,(3^035!)(?V>ZY#]H3L>:=Q+3R>]X<*R:KO(MZ)`)N\:BS55
M,2079%\4/YL<`?XTMG!#W]HSV64'X%RIA!PBEHOL0C8I%9'_@M8ZZ%N[K^91
M.U6`Y@"76RHVUK,\6JU(2L5I*I&J$"=DQ?ACH;F(<,5#5N)L>@K\_+(54>-F
M=<NR6%5\6<<O<2*W1&@:,_'_"WWE]@;?C.M!1SUC098&].J4\TI)60*^5)/L
M]21*45)H"KS&O6<L\M*!Q1SBQ;TF1IR12-R)^BU^D57CE3Y1V$-"#5(!%E=<
MODO`F)-'<4*75U&:<,VS\\5B^[*5NE_25;R(]2$%^B`N8LS[M=<QP\6V'1"4
M?%(J0"H:D$(%&-,E4A/3FT;J4JNY`FZI!]<:5\$^QEP-UQG3+)-94V/D+'8P
M,UVM4B\J-(N0<U8!"4Z=8)-58"P(1!?3W-1FH("T>*7)EM[1!7M*9/]H/C>$
M?@Y%EMYL..H;R6*1VC9OI'A2D>]\&D9!-9&H8:A.BS]'>(/R">IBS-%LH5FF
M3TM[_V?DD&UHV>E3+P]"#5B>F%+9ZOLA*^6DA:NGRG'^`2SW71B_>2BNM3&K
M8,+N<QRX\#$G&RI/5[[M,^]!KW/Z4EM'2]L(5Z1N-)EHBVD=B0AUIDN))7\5
M@HF4#"SV)M%H#VAYHG$+%ZXHM,>G/%&X=Y)V*.T<:]+Y.8.8Q)^%#]'CFEH.
MF9M:HKJZV7PT']KX^%Y.8%)*X?C!H`)FH:8?,$=^>@&RL-0/D$=G?S"N_8>X
M!4LFRJUHFH8\DVADQB&#]>8*-XYE;]$Z?_MY&XECG)1FXF[2.)>IY^I>,=TP
M"/P@<NP[&AKGBU:Q+=-(R2=[!4A%`Z)4``XT!5+#.+-QI"[\8CF7%T=K$CT]
MI?)`1GF_0RJ3V4AQ3B'DP!3N><S5G,'XI^ZGE`D-7Z(7_F/EE);Q/"_\0>0&
MX\1XI[M=;+O\*^^=5:DK0@7QKXH2R#/`$JZ>A,W#==G\$YA9@?E,@69PT"W1
M$.&`S-6@[J/9^P5-HC1F-TE]E4!S(]P8=C0;:>>41R+"#%]+L:2/VPA06#3#
M5F\L2*J7&+@\%Q2:L:HW"@<&7ZU6="%O,(G(\]N&Y<\TCQ>\5^WW_@N)DT4J
M#V?&B;RH]25*?Y,W*L8+R?-%<5O\<Y2&*_VLIP:#V#%<_UEH\6N2;>@B7L5T
M:>XV;>V1-4+G$]-H52LM$',J<I']H@1FZ!>;`N;2'1:RS\#PVNH!K;[$D!;S
MZ>^>Z7(K^E:1(7.S*J:8]L4<U(,H<LR'XX&A7P2(#=57*E5$K)5):/R_Y7K"
M7]5J"7:Q1$'7=J,M0,<&B`+R30'Y9@_9<7U(0=;VN2U`=NF'U1$,M3A4G*>7
MBT7E=_^9L7"WE>"HQUQM&;`O+C6K+9QUGG^*XE2>$C.&I:9>A\M3F$^G4V-/
M[J9,.!YKRMN=YT2HI@Y8NI);6<<T'`AC'9=,^V=9?9R/K2MFX$S_%"=1LA`K
M6]>)R#0-50.T,>]FS9J_@RC!/T&<<T5?Z?*:=]K)4\R5.\\RFJN5<:NS05^`
M'-/W:JM>XL6'X[[2A$A5R%X7HI0I1C'0D7^OMIAE^_"=I@+[H9M2YX.##5IG
M.-A/:SF-L?,)LAC>S:/?A)VK3XTKVW@]3H;@CMVZ,DD37`_9H[^;K[VK'R%^
M<VB<DR0\L#=WLGH'(>`ZX5,03L&WBVV:\I^0O(<]CAS.3_JF>]F@PL,Q?*<'
M*11Q'ZL+Z!!2-PO=D\D[93HA+-`%:UD*-V,3RWOO<D?,:RVU35'IDKWY?#JV
M+^&]$Q1XT6Z_<H4:YQ;0K$MT7M#<HX$').L2G!<D'Y8#<;6[U%9/BN/%-:V5
M.NA?Y7;Y,ULON?&O9!G^+RRGQ87AV4UZ%S\]\R$!N,-U?!^R!^Z-3>=.G;4)
M1\*J8D1I1H1JI-2-W*1$:>?230O[0+KIENWCP.@=_IR16][F6>Q>7ZAMZGNY
M34UNMGG&1ZQ+/C;OI$-W=?':'M[C"X2+%G2Q3>5R7[&RF3Q54FL,)?#A#V(/
M_@V,6^-6L2T3?2>?[!1XGU(%KW.OL!JXW#A6EV[8'7!;;(5['G,UYHGP[X&K
M8<Y+03Z.3.H<#HQ],5!XQXP4BF#3.P5P5V*Z`V^%GATDN&"=$DS3>M,&).N3
MF'):&%G3!EDHHF<L3_].0MO<DJ*0[)'ZF]CCH;\319[4*8M.J%#G#0Q@C-!.
M?4<W+)570\IC\K#B#ZAGL=LNH[IU%I3D,.38Z5"6@'"M!*$P6XG3+&9W0LEL
MJ)\I>TJCS;-,2[Y.5BQ]B0*7A\`YX3'WX/8,R,DU?^?3SS2A:;0^3Y;GRY<X
MB;,\E4D:YDK5N(>1]4%'QFN-8*+;IJ74@11*R&*![]7`U;:6D$VD;`.R$RNE
M(F?DJ0`NZ!F]4R8H*5%.R'P,>F*TM%RXWLS+<)UI;SXV=Z8NJIP*C=TO(E=V
M\>5V!Y>2[[C^<X7K!]8)?<.+IS^C(X#GK>5-180D9FEYU9I8WM6OEVI;XK@\
MG<[G1BX?R6F;J$)@Y>I`*1/&/XG%Q#]O+$[9_@N9_"OS*#*%+M%A:HU,>F]A
M8`.%HX'8O?D89:+0[HM@Y[M=^<.O:FR,O$EE,C%V;+6B6N:#D$FD4%*5"KQ)
M10`R,*(10$Z5Y_?B""VN2_L^3A;LA?Y!%)4FBUW&O.:J]SC+MMPF.1/-7VA*
MZ,MFS=XH,%@4W[IMVSC56Y,[?1\>Y3=?6+YY6Q'#S"J&L5/'<>-<.,P3%7/S
MCV_[)L4=K>?<H9;R__Y,,SEME\6[<5[A)P+780_ZQCLUFE2PF\A&*LJ*B[^K
M[0J%B52V^/]"Y[(L?Q\V5I!FQ+(_C!F=*O/OKZ-Z;X_.8X8G-ZR1QO^;G'Y\
M4ND>E2-B-_DS31]X%WFSD7</?&+IBL:YR-!6`)MV:W<-<-%M,NCC1V"MZ'_J
MP:](!:M`(A(3$:!(@8KL8/&&AHB@^1`MQ,?V/X1G^!3#2:7`[R%T>O"RB<CJ
M]S7_"0+OSW(RTEG4K1>/#+FCGG$3)I#R_QSQ5F%"!UOQ";H(MGZ?P"_2DB=9
M`_&?(\QJB!@DQNH_XN\@P'[;Q*EL?!GEVBWH9M^.3)^:SXSI4\WH=O+1;Z<M
M$>H",[>$Z=H(:UZF\QT?5DRQU)CBY,)7/0\:B4[:;W$ZP2<S+@R(+-#S9'G+
MO[@H!FI.QVQ1%'(9<&*N(]""HMW'J`RR'B@3M,7^OM!>U:G%)9Q*TWJ$K0"F
M==F'5.-79:,N<E?;I`XFDGE^GK!A[5;47S4YXKL&V!`RM(80^?H0Q)>"H/P<
M6OGII+<#JW[1E,D5`X;0Y'KO"H>4.+)(6$?.KN5^K=2"3U3D[TP?T-0>Z>9#
M<W5<G;0`7I\1)5=YOU@R4+T;D`=#<W7<IH"YW)AY>5]NT,<)V6P?U_&"TV-%
M4YEGINBRX7!YP]`T,7K6(6ML]@M,HLJ!9N-7KVF'7!2<F,O/'4H)0A;+<6X-
MBE%[*#9RQ>4J62*'8E(8'\+RWRYDWDM15_T/"%CCMF'=YU&:XX!]I$]QDB"P
MM<KS.A(<\5MC)H\B.?%3$J_B1<1'E8N%N-*E/`L26RX7Q#V)XO.(J]G7EM`!
MR0U446>O"]DK0TIMT/?Z%<AU%79:08Z,;>T@UA7@:06QRY*:)^Q6ZO/@",B<
M;=I2=-%7XP(_A8HJX]Y\/G"**B%K=-D<#5&65@%V"28A*G<U#M0EA@2KY^6.
M-GCHT%3Y0IDQW$3#J);M%!KJ863YD/[8>%(%)+IK"F*/E$G0ACE^*Z";IV/(
ML3_.!9F/,9OIQ[-L^Z)V\J\3M9XHEQN*BE^V"`Q[&EMP<]:#].MFV1WT[WN%
MQ+I3L3BK%M?*4GK0(I:SNK7QEBW@$6TJR*_]D0-Z_F:1.X2</U6OL*M>7W<:
M5]?A*5HW,(!;.=P`@1-4I01L,SZYR;*R(HZIO!_D&5QEO^E@:ERA-$ELF9>E
M:%+*)ONB08AZ?A*AH>]O$J%7(:3@)?M`WL0<3!6>1!?K*,L*.D,(I&N/&TOW
M^W-C87J=M%#$D7+W-RPC6*.@`5CC"\WEU*M$Q>RHVN:-UHGJ.&,R5'B^J#06
MD=K!$FBG8WH&>Z'#V)@R89(8BCM%HL]>.*K3D0@!]&D"H5,F9B'_[!AG%TPR
MNE8=FVQV"\\HW9Z4O2&RSYD,C4?[CL2$(@QZAT5!`9`DZ(8*&$_;G*C=*8'9
M)KSWWZPNHNSYTYI]S<X?14V@16[[JH9'L'6TIL:35P:!H;@AKN;ELHD4SCN2
M0CRX(-;4>*ZI08!>C&$(E&VSQ^1==3RRV*X+1NUN-;UE62RS;\',LCZ*+/\_
MK;U>!R,X(-/VM\&62F`9IP"#&-<88%_FH5&WST"[%]8S$633+AAY?'<(G)+V
M9Y'CP*'Y2AZ(Y("DK+M_!]L/2L@@5C8'V9>654W^%0:\?6("?+&>F3"[AJ?F
M_8(F41HSR#)&75MD=SB;#B'4JTH*1;52)N[*&P$(0"P?0'ZK%*7D+OA2ZS!U
M_-"9)SP?C%>NUS9"=CZS(6CA.T2^UG["CKD972(`N'RP1"P(C+8]77^!N=8<
M`7W[L.O1?CI=0YR/SZ;F*J9'8MKV\Z,!%,S3)0[#Z0UO'(T<WT!@,1S9:`A+
M$V<V$(`F+0+*61ZM<5`>Q"/J[.5NX+JDJW@1![V`74]C!C50A\').C%L=#;8
MF_;GYAVUKJ:`WK,^!<W44W<ZU:N2Y%*1Y*=.66*>R9W8]*WN*M;+.%NL6;9-
MC^]LMWYZR_/8$L&UIQ30TL-33%YLO-?$(6%:8L>0KB'LSA4Y.N6<S>V,%`18
MSB-!NE;<T=9B\7DQCZ!2H?NCT62D384V"PR4_ZRC$79;N\"J2WIN%FM#H<(1
MHRZ]N5F,GMTR"F@K*<Q`/C&\^9J."_J3C_;FJ+YU.AX-I[AX$/*LH]9]$"M,
M"B(J#`19+6L,&HK]X9;1\/C"D5YS@A%F,4^R7W.%$W%3EZC)]?"5__QVM::O
M-/F%OCS25/LI@<^AZ#^9<5L:Z6^1&C`.D)TJJA(>-V^?_%6I`:.+0FN*!`VC
M=0@)ARB5$D1IX0+7%!T:ANM<B;3FRP:-#U!J,4?C^48,6;/I<ION[OLHT]>3
MY5^*^Z,^L?2>IJ_Q@F8WZ<4ZB@US"L_WX28<O>%\8HXP;MJ$B3Q_+N_IXFWR
M-%Z(FR?D@BQA:?E#<4RQ*/\M;O!*6+*[O8M$&=D493W%16!9@8._,>$=#7^`
M_S):_):PKVNZ?!)79$E\/\#&_]*\QI`6QKQ.H4Y55%.ZE?<=[0[)B)*GI8+B
MW@]2JDAN4J*41)C(&`;#F,@E/*I"847IN:K[A(V/G@&#-6SML`NCQPJKSW)5
M4%PVNOF:\,_['&]$;V!:K'-_&S(9>SHPGR=UTJ6SL%`PH=2LB!$[W>3``9C$
M+0QC65%MWS`.P>"2KF@J.HQWY=N+V,![F4AT4MNUS'9[5;>#A5Z,]7#NPZ59
MOT]P&A'B"_TJ_Z1/A<,\C,P,ZLV,Y65`HKNF.U=$_1UX8[($/70DMS/JC<R.
M?G6:^NRKRE*U2+)2.=?<%.@ZFA)]:/#-5]--MF+^A(!LNO6V%<Q.M^!>5$II
ME_"W8@H@*GN\1CDEFW6T*-(L@Q7W<`Q%T&A=:^+&I\-%Z5/3,!(Q^$>\#;G8
M-A[KRQ`YZQ)T"<X0J^T3-^"JU;CV3'I@*S7=DS5J'=QDM@7KN$YEZV:R@6LJ
M-\5\RYP6:?33&*_>[1:YE-KB`I$O5!P$4]=>;E.WH2SFO=C+$/K6U"`?K;H.
M&WL=R_`A[[OA:LH#EGM%H5<L]*W91"'-Y1!'[@X78M4\&#T-UOG2"5G':9A9
M7I=>MV:M[JGLJ(9]8P$".O;$?I+3B,%J74/M*5Q]H^DBSJCV(E[G%^&B['`Z
M=%Y+K%6CZ[!:K!X6.S<[M6!Q0EK#,4PT8@V7W,Q"E@@+[[>MT*L,RAFZQ.\4
M%]]MI9P1JC/(J81$,WVA,=!J[Y;FXO*/Y9A7%\9\7X,*8O-A?SQSFGW7*Q%F
MVOU%KH5))WVW%;A442U_EM=.B<AV,/(1?ZGZ^-="?]"V<F$LETEX,\9J)][O
MIMVX@*^,X3+G;L88GN&^_/+H2%\X07?`FX[SI25.8I7!$MI`RPMV,W<]II7Y
M,X[;8/7/XD:NTX&EP"5`<F?!2R4?8??`)&3T\,P/LDOQ6,QVR*O0#@$?/SSU
MP^\6J2P;@-V/1#4,M`\^]=8\B8#4_#HG^K6H,#;HC>;6$@@>2G4<X9I=Y%3&
M<@L`)[+&:5W#.Y'0T/"RG=,G.(F`TL"BG?T]R)'/=&"NC874HN,8X;5B)VWA
M%A%.;L'N1*CONSP%,V[CJU-[L3Z+4X"WH`Y)#.?]*38SQ*!#R*,1[\;O[:Y*
M%6;"K4HU:*96(IK;FE1A"MS23(.F:&A)JN.%&`B-+>LP0)MZQK$B1)XGRX/1
MT:]B,&@Y-XIY&#7$&/5&/?UUN5#1(=/7RN&#R,$ZFG1(G7`G+)4%3`&I#0NX
MQ*%VD)OB3QO('<)."3S2`@\:A%!D9#[V##<OVCYF].];<1?,*^3Z%4MSY"RG
M9U[?U0AKF7([J42*=;B11>(RS%@:PN62QXD%U];DQ.9'#&>NKOA2VWN#VN*8
M,II,ZJJ@&"6%I@FF!U*`P!0)5]'@`%5WE#CN3<"VZ8H,UCN++,V1M3JG4^/-
M#1IA85F!OJ5(P0(3(^@-14AL87ABOI<(8*W.V&*MRVEKC^M"QJ.9L=B\3EIP
MPJ"K;$ID<,J$K*IY!*]#HI@+:D*,U!55C/<P&)IB\Z1GQCV7&D&AAUB8JQDD
M'#`K@E660V`*PPO];0T6"W7&!B[7=$./N36Z#@EBAE[*"DP+(19U*[=$!:>&
M(ZHFV"%D=TB-0]\QL*/&2%T2Y)*]1+&VE(^M/7)D-1LA2:*D=4(3)1HZLA+(
M4$1Q0]8458SPPG'FP)G,K#FV6%#>Q,LX2M_NHS4MCSN;NQ9C>^2B%I_K6GA3
M*ZU]WBBQ1,C=G_W']#`2FIDXC4!S)(Z2?:8`EM<K!N:,V9$8TE@>>[3;EQ?^
M[IN5V`V6^Y+GZS7[*BX?RN283S=/=WP:=^ZI-QWI*WR#90?:IE7Z",;L-")[
ME8C4"3^_5S;0[=.V9@-LU&@1NVZGMC7L3F%%*!/_@V,]7^3QJTB&+W*&;E.V
MW"YR<B?JZV[IWBSEOBY-7RFYB'+ZQ-(X8'5,/'>9E^D#=NR;S5J>OHC6Y87L
MU\F*I2\1Y`9TW-/(598Q_X^ITP?);IO,>R6(T(((-4A%#_2ERQ*V:4#0"FPG
M'E>P+_>7'W$N+X0E5L(2\5ZUH-=T(1V3>1G89TC!A<4TO30D=]4W07%I-A[.
M^_K!P3L!H48`2BBYQ&T'*R3:+MX+B0/UG1%H.VHO!`XL_L3_D#^3\]MKDA7"
MP_6J]9[-[,;P9]Q-0NV<.VJ$8MUT/![I$R</103F'9>+\UN%QL(\9S2.W'-$
M86&?,PJ7\['/]&7#TA#Y(Q;7/J1=K17\B??`6P&H5],,U^7UYV,K^2I"`M-/
M2D9V'!*1A8`>B!PIZ(S$0D(/)"Z#6?ZOYQ<6O.^K<_-#(FHLT0`5OS(`$0\;
MX?K`WF"JOXCR4$1H$GYER-Y#HK%1T!6-*P'=4-CHYXK"@7P?S^\_!2?>D5L?
MT:[.`LB%F8PN?GABKS\N::S69/@/ATLQ_%=_>TBC99P\W;^]/++UP6?1_AV7
M!<E_J.L]CM[>KM<6HHB2!4MTE)H?NZNWY@Z>:E>_89_5?WQFL4"P)<2'E$;9
M-GV3NRW&-'=#2YPOS\:UOFR0T[97*X'E_A\F&BLP^@6_!L`X.7J!*`N\X6?R
M$0:V2C?.KZIU0;[C^Y;(=?%9WY2>6R,GJ//?:Z^TT$`!NKX;%&_7[^".#I.G
MZ"AP;)UN*"`/2D,^Y[N&N"I)@Z$QU?!83%#__S.XAED!9-0&DKE"DM"G**=+
M'P+\&QGTSGK3>5F9-,K)/7=@&7+)L'<FKG$=ROW92[HH?MN7OQUTQ9GWOJ6C
MS)%!@S'FUX3KL8[_09<_1W'RF67937))93F\^%7;@0"?0AZL'4U,J>P6F>T2
M:R^<".E$B"<W":DH`#QE*T#JNYF&03IT.=\+H7\@3P(E2\CBF?^1BEJ!JRA.
M555$L:VZW"E%UG'T&*_C7),$H?O0P8S@5"E1?N7OU](6K9I!'W*;,H-/_/U>
MB/X#$79HQ@PMQ5QH0&).Y@T7C3-ZL[K*\OB%?RIM\*UMA,QBG0],U1W?BV@Y
MM&8R774G#9BK*@`80H@7`(>P^:LJ,V1$T9;OU_L#@U@CF&?7I)RINB(BC2[[
M&*W%KS0?$_4L<LS1GYFN&0%);I<>M8F9Y_L4Q(P4:@`['0%8W^>T`E@59KM*
MD'U/(:U^E(]`.^X"[7T>I;DSWO\1)5N1F-O7@VTIF."XQCQL>2*AYX)/)9_H
M\H%=L"SGO[_ZMJ%)YA:*+._"A:;9U%B`V4F3KD-5H19Y8$0H)O]8J`8CM#2*
MOML/8A2'T<%MRE[C3%@FI6LQ"B<Y(XMMFHHS8&7=2FZ+97G?>A:M@XXA_/P:
M'`8`7^!$PL(E%=G_HOR9DZL=/XY<5YP/3`OK4.%=\WVO"7`54L)V'9XXX/:9
M&U]PHL;<SS;1VXLL`O(2+:F\9_;WP^P:/P63N=[<I\)?TU%JS*/(W>#>V'0Z
M%"*X:\ZB#ELKP*X=<K!SU[6H(RCJ;IBI/8Z-M>F),-)2`03W,(Z5\ZGQ^!9,
M=->\Q!8,4:A=J1FP?HB=G!;HG?#35&8$;]H..)HL_]<V6L>KMSAY.E\LV-9>
M"Q'W,')%F@_^0!PUB0[&4>Z=>RU(J0;Z@*4$#:%HDZ"]*!HY(6^=H2!_K&4H
MU+(GPM#+W>'6SY:JU\[OP58T!?:M0"VZIO!>)7P-;64,5SXW8(Q6J(VP2"<\
M-[DRF/(6XY\<^TW5)9W>@63]9-0$ZP/4H\0Q'E&K4MG`G^RABECBB!Z\P*6;
MTSKPVZ4DIN;P6G$!CSBWKC^\IFV$6Q$>S\9CW>&U(Q%A#J\58LD(=\I`0=&<
M7/.&@HL.)00ASP6%YN2:-PH'?I=0BHO1.,_[O1_[DQ][\U#GV?2>SB!V"=;'
M%EH8SP?5MD%6V!S/3'WD.PEAO!QWVX747]^_>>GO[M\!NZ1Z'V``$WAW*<:2
M(+HV&/><]<>]L;8.SZ&$L/U)'^6H!1)S?Q*H&$B)`%L+I,!@[DU"E@(Y[DQ&
M/PZF/_:F@?L2?6D0DU&\Z9>I:Q?_QW;]]O"5^_';?]*4?8D!I`0^B:+JJ">V
MQ<U4M<@-2N"LO(-4:$/$+CN.#`JOF=`-XW6B^7N<2@TB]"!"$1?,Y@#0,&;W
ML'#\@0.'!2C+F+,!FPHA-XN</8H"#BY1!/`P:D@ZZDUG,U@@,8CN)I84"N'#
M28$:%$X:1.T744JT7D&E0`X**@TB;R"N5#]V-Z$%0KWZZ`*TI'>`L10OT[="
MC3T&_<%06S3I6$;8B<(0U\<J+.9`$*QH68D!7[.LP&&F==B292>S]F2J86:V
MC#\?317,=&UP=?6GT[&5BV'KEY4??H#KF!02"Q/#U"[;\1!;NDQAL+`P8.6R
M8PY.?QSV.Z"@MIJ9R2@>]*/QTW-.E^>O-(V>Z)>M>/7'*(L7Y\GR,EYOQ:WE
MLE[$S3;/\B@1-:HTB4[-O1#5R0['P]%02VP?=0)%@4)%4NA(E))$:BGW70L]
MSXJ2/*2B*C)IJC"6+G:$-!8RT$"-U)B-=+$II(U<`EEIJ*@PE*KV$J)F?X/\
M9TU;NXT(J9./<QO;6U"#G&&_/^WA8Z%.AU,(@'I>@P8:RB+H@->419J,<HU8
M`AW6FK*$2SE9"5L>`%-*=!_$K&RU1RZ(00_#50'\,_\;_S?_%__A,<HH_\?_
M#U!+`P04````"`!F@6=#P,Q7/Q\[``!4P00`%0`<`&%M<FXM,C`Q,S`Y,S!?
M<')E+GAM;%54"0`#[P%\4N\!?%)U>`L``00E#@``!#D!``#M?5ESY$:2YON8
MS7_@UIBMS9IMJ2YU]TC6FK'D5>(NB\E-LM3'BPP$(I,8(8$4`F`Q]>LW`D?B
MBA-'!M*!EU8U,P[W#W&X>_CQU_]ZW7IG+RC$;N#_].;#=^_?G"'?#AS7W_ST
MYNO#V\7#Q<W-F__ZSW_]E[_^C[=OSU:KL\O`]Y'GH?W9WVWDH="*T-FC]1KX
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MYA_>_?W+[8/]C+;66]?'D>7;E8YT,%;7#S_\\,.[Y->T-79_Q,DHMX&=H*1`
MX!FW!?U_;_-F;^F?WG[X^/;3A^]>L?/F/^F$?PT##ZW0^BRAX<=HOT,_O<'N
M=N>A-]G?GD.T_NF-M0W]!/GW/WQZ3_O_VV5@QUNZC'SGRH_<:'_CKX-PFU#]
MYHR.^W5U4R'?VEJA2]9MN$L64)2MQW>T[3OA<.^Z$KLB/7]]($L>T3F6ZVO7
M)Y_(M;S[`+MTB@O/PMA=N\AI0;OBP,?DXMX*49O/H#%Z](PBU[:\_OFZ(=1M
MT<*+4.B3!?""NC'2'*X?BFWW;6F6AV<"RG/@.>0PO/H])BMXX3M+`E)(3R7R
M$_(QF3LEIAM#>E/U_GDN+/Q\[07?\(WON"&RHV[<-(?K3/&EBVTOP'&([JR(
M_.]R?1YC<G%A3(`ZM["+E^OR+;APG&2%6U['0ZR7>7MD_\'=^&3'VI8?+6R;
M7,81D1GN`\^U783[Y[K%='TR&V\IF7^0J6RRS<FV6*X?G]%]&#BQ':W0"_)C
M<@R0I4:O9_)%,MG@@BS%31`2$KLQWWWZ'L&H3KM"=D`^S1_((?->HC4*PU8W
MG=[X/;)S8>W<R/*R&:Y>=^2(Z\@!9\@>B5Y@C"*Z]6]=Z\GUR(KX@BSZ@[.(
MKBTW_,7R8K3T"7AQ2"C>)"=$)Y[:S=CG=WJV_`VY>8K)"CGBA@C&82+D=6-2
M=8X>V;JA@NG&??)2A/L_.94FZ'4_A>&>+(`,O]KT'?>5<.A>OPHY?*(@W'>$
M/A]E"-*&6"K"H7MDXF_D2Y*KG)XGV3\O4>B^)#+TX8#IG\$.TP[`_&-P'X?V
M,]&@B7"]#?Q$^,;+.*):/C7!],*K?)8>6;M$3P,<8?Q1^SRW"#INE)SO9'E<
M!(F$B?QAQ%GMR7ID--/K>N=)-&ZOLO@31K_'!+JKEP2__G4-I1GZ47[O@@B1
M+7J0,@[:*UZ&&XO(O<ED9(%@HNLXJ6KG.V5-KR2B%)T+9A[1:W3N!?9O+2`Y
M(G%#HRG4'X?!2''*<7">_\$``H>IQX'$HT4$2A,X9!,/C4)-:A[\J%"9;P0\
M#_#9U6<=GO],L!_^8PLF,LGE()]7.MW0'!?:2\DZ0:[@GY&S(4=,9BTDA\S0
MW[T3(6-&:8!UTP,YPR/V%`V_9-AS#,V;0/4:FF7-J0>7AR(R2^6QC[8=&@3U
M60?GOZ;G#<0O=Y:,OUU)7Z(^,Q5&26/D._0](OTKG:PGUX=D=C(_H:4RI4<=
M1(*P"FXV8^(%@I']W29X>><@]QW%F_XC`?[M^P^9#\B_D3_]NB!3.W3Z:\_:
MY,-YUA/R?GK3_/V=%CW-CTW_0H<,J9Q]B7;4M8!<SJFYZPO:/J&P1H-*#SVJ
MRBBM+?R4.,S$^.W&LG8I5,B+</Z7.F;9GW]-O"&6ZV2C7`9;R_5KA`L:MJ=7
M]:M>Q"%UT;@F&];R_H&L\,IW+LEB9WQ@;M->OG6^N!>,Q;UX(C>K1?T'FE]<
MJ=_P..9DI.C<DU48.-?D;Y@!)+_ML>FD7U&-RJ+E\6@L?4ERDJ(;<@2+"&4V
M/QZUZ7?D;Q]VN^/1]TB&%9"5_#P\-<D>I782*OHRR*G^?B1Z]A<$@)`:A!WT
M^G_1GD=7H]W1Z$O?>NC-P'A6XA$KZG0LRIDW7N/G8U%S[7HHS/QH^%^YVNI8
MM*W0QJ77E1_=65ONUJ@W&YZZ6[2QO'3NQ:O+.H#K+7J1!Y8A6:>67.)CMC,A
MYQUTA+(<QT!,WG[X;_H86O04>-AOGP*/\46KOQ_H*>LVB[!*FQ7:^4#DGPW%
MINIPGK5XMTO\@]_:SZYWT(G68;`5"L7YM(%H!9P%(5%):1`$65COWYP1TE-G
ML]N42RYI"5T1T691TI+V=(.0+.V?WGQ\<Q9CPE:P2]\/QPZ,3'TJ(/H>%$3:
M^@1%C"&<'/!Y_QX4/JHR=@Y+58(L4/DP:51J]I`"EH^3AH6C#A7PP#J.V\+3
MT+\+@&`=QMT`JAA2"HC^-&F(:M);`<N?)PT+6XTJT/G+C$[3T%'`\Q^3AH=O
M!R\0^F'2"#$M*(4*,6T16<5,5V`%3W!FFG5S<!H6),B*%1<)!3M1ALO'2>$B
MWVKY<GG_'B(P'/MJ]63)+3Q0=XZR$;6\DU@FL.,!]-=W=5>/P1U`%/-'&#!^
M9X[0^-[:T_V=25,<RS>GL0FC?4[*"MG(?:'4W*%(C7IF%T,\A#$Z1/+2H*,L
MRT/I3WQF%/H:X>H0IG-ON<Z-GT5AET0L'DORCD;X29S&>32G/YJCB^-APVED
MCD[)UJRT,4ZE$JCUMD9<U"S\3%U8R7^H#^>+Y5'7QD54B=#F>:TI]37"%=\_
ME\>+H(<I#K(S2_@)ZLU,T)HG\\@2?8@W*J>Q2;H?K==T0TH%`%&/L7!P%_BV
M-A.E3F;XJ`?ODWVGP(BX%Q1'I_:X$E7!C0@Z+\BIQ[#=(1ZLDDXF^"!T(*);
M14HZ!J>Q&;JSR#(^VI4FIFC$4?[(+_!:8C0T3V^>&2N-8&?ZBFET/'V7NGXP
MEFN/IG7$JMK:#$62D\WN-D9>),J$<G?#O(E/;4;#<="KCOX8]#FF)*3.`J./
M$2X"?_.(PBT-+16>Z8R&INF5BJV<QB;H3LQ]*N851D/#]$IA9K<U1K6.8B/H
M8(+^^S#8H3#:WWM6ZE1+KI4=E:/X4JVPBPD>5D3T"UT[0DX7BY?N*&8XC8BZ
MB9PK*_0)(7AAV_$V]HBX2[.NNK;+^V8*'8T$5R#?#<+\T$S"LSD,L%H:#0>Y
MY80N"AH:I9?QMB@1'92Z&N6)%6W(:62&3D7-922ZBK9V,C)]Y#%,DAWOI99U
M1D,3]&;)/X5"<+6-21\.]HMBV7&#\TIV\-WX!"M&0!T8L9!5X`,K1$`=']E3
M1X$0K`@!=80XRE$!#*P8`75@9*\@!4*PX@1T3^4R$FU"`H+(\DX!"8YAK^)?
MJ*8D0@VCU<9+6[TND(-\7"L@)W9#+&""?'@KP%1]22U@@7QB*\`B=&$I4((5
MX*6-$LO,78`#*[9+_P#BX/*QC1?]^$4`OKM#_;B1.1E`#\A0=[0H(U<S6!3+
M">9)W0XDUOMF@12LTWH.=*HM&5UWC\K"$;@G%`L(5I!IS[BQW"(*Z&!E<.D9
MNC)0,.VT78`2!AT4P,&T%'0!3M2ZP`VFG:"GG<GQ@2S0:V,^&+\P+_?68YE:
MZE[D4/-WM4.)YVO?*8W7"PJ?`E@X\:*>.F7S`HB38HPRU`Q?[4!CN4UW2_9U
M4H<YWW6YN@,E46/%]0?3QJ>-&-.7KGCT`Z]OJZ'$\^8N@`*O8*L!)7)L+L""
M*53QG3R;QG6&.@,L):$>*NI*#]0<A6U<;YF9Q(#GJQ:[\TXNRYP<#M$SUR&9
MVG1A89U/<'/,J3MMU^V8U=0C4/.@ML-')3T5U.2H[1!C.=VW2XGZ0XJ03P[\
M*&L+!".5L*T",Z@R=;=G@ZZE7W1L)*/-`7F?P/R,(M<FQ)I-745H688)V4ZR
M[>]1F&1'SJ?E9[/B]C2<C"M-[GR#<5Q\13X7E=:CH)Q?/4ZI"Y242K#2M<P!
MIW/`::L`R'2#<XAEM9P=R$8A)JD8V92N8>A/W]I05>]WJ*6K.L+#KFT!K'J5
M'D;,8Q7ZF_9LO9ZMUR#-M&:5^QO29HL6'B'93]P;S&CQF)#R.0@<_!!X?%VW
MVLJ$1)M;S'*I1J)!<)N/@?9S"[OVPG<N72^.N!8&62\H6GJ7)+%T"]T&&%^3
MHR?UQ8X)9,L="I/=B\_1.@A1VN[1>D7XB^LGAT+N_TCPK(Z2VAB_H.@Y<(KG
M-7ZVW.-18`[APZDEV72\UN8H)XA?O>Z0C]$Y\M&:FQ6-U]ID&NR4IHR@.W*)
MI&O*WXC23"MTG>UI*5@$BV+C<0"MMC&25C+_=-G7Y%':;#<*:B4G!K^]4>JE
MZX+5TEC2T?(&K^Q\'O'B3H82=R*B6M"<(I?H!7E!DA1+S(:XCQDNDB`!WJ(Y
M_&PFP:9'QMQ\)A=;:'D$LX6S=?VDDC)5/L10*W:>7T7@O"!\]4-D>>X?R/E,
MQ'MZP"W]PA6?![*LEQXGUC;T$_K>__#I?4(=_<NO?T/NYIEH0(L7LAHWZ"ZF
MH?4U[:AAPN1<1#T,.#!/O/GU&.&.8M)$)-/IR\8BJ0X-W8HO4<6F:'F=WPQK
M:T0J?E<??&JV/^C9VK30D4BDT%.V:6&E*EM"3^BF!1I#L>^6RFW\L9]JCZR%
M%@4_R%H-$<&ZFLSCLQI`9<,-]$AJ-6BD>MP<K*AN=)],H*)XMTF,CO`#B=16
MU!$?)[M%(D$YZ[AO?E,(0U(!J/;DU2W2",JJX5NANL49G?I!UH>M%7KJ_-GG
M[\1\_HZ+2W_/%0H;DO]04"R[H5/:F'6I3%BO1I9F2<@N@BTAX9D(!43I2:]`
M$^Z6G*!R8=TO<1\33X,+Y[_C3/)\##CDI?!3V`,_^39$`"8K-J)%>6C&)2ZS
M/0P]5DR2E=B!\;3_6+E+-M^3A9%#/PW9:<EF7R'RM;`;H0<4OK@V#4IR`V>%
M[&#C)Z.(JO,-/NU8L:0JS'J-[(@J??ES9Y7##I"IC&XXC%EX(C;;S:[0M4.1
M2:BX[>P6>DINH?5$(L(-PVELQ/U),3]!GTD)#%#[ZT>SSF6U+8X9^TVMS^S2
MIY7HH$7A9)6^LZ,BY-K:RO1JGRH<9\-DY#3Z_3(FFO4F%8^S)4ATYJR\$[X.
MPDR`QLOPPK/<QE;L/IZQ;]`D.#W&[]"WY"?^J:/4><@OE=TW(GPUOI/*:*/[
M2D4MTI3L;U;H$+%LN294KY$;Q?R4)]W''1T:R8_+Q!:'KUY1:+N8&U?:8J#A
MUW+R8[[P>!RT'F9$WRLQ/+0\8FI]Q\95_UM2?=BQ8='#AA2,,^1^+*;MLAU%
MHQA/B"54EEDMC09)B"P[G`0^S6J3,&L9*&,C>7B!7AE0&2?F-H%>#E`9'9[1
M#6K9OSF^AN??(+*O57R+V$MK,C@U+'@57Q"1IT*+@WB7*@*1%48@X!%EOFX3
MY`@1'P4C3J<HDEV2Z.X%QGY3TT@[A90`B+II;ZSH%G%RZL=Z:Z5RCD#IR=K9
M*3P%P,YMX8PUQZKT8]6#7PJGKX4G]XQL%ZT"#<LV[QWP2^=TW<U2X&":>/K;
MODJNF9,)>VDI0$M>KJ$G(FD/GZ*+!O3L)/UMYVY>Z]`3FG2,*IURD#S+);0$
M30MM(S7?7?D@(I&9SFVEAY066L2IX:/B+3K%K&YB!]0YME8>6\M^G<H`^C@#
M-,V"(Q<6?K[V@F_XAMQ'(=%@S$3`EF0R*E#YMNNAB@3Q&%!*[\/@Q25LG^^_
M$N'LQC^D>%K8D?M"A#!I;O%!IC(2,;@-PLC](UD>AQI,_H;F;\1)"#FV@YA?
MHT*YNWG>;L@F\#?4$K;`&"ERU.ADA`]J%GTDLP@B;:IMC$18DM5./CG]#[TC
M7BPON1ZB"Z),[LF:$`7CJO4%R96A:"XV;:DN2LXPZJJ%+E'Z7RWV.$.8XI%>
M2G?D=";_3)-:T:/7=PXG57$,T[/*"W`L+?_4>=A>/&R3R\5R*Q:<ZR`4I2*7
M=3'QC2XS@4BOI(ZLEQE.B*AENZE4ZCOE>X3+!;_'''5^]6HC(D59K]E'Y=O$
M&3(5!_%N8QHM-84PW;H<ONJM#%%:.?)O_(6="G_WUIYJ37F^G`.TMZ[UY'JB
M[]5MS'&A0+0$1"Y)?KRK4M=Q\)0GD<R^@JAHF$+7L?#T0N07HF1KK,9RGUYN
M]>84M_0_*^0E:2*Y&T:S\S@0/VS:[+U$7@%0=8"1\)=D!XM#:EP2ZIQ*74?$
M$Y5\V[/5Z#T.S@I?)"HG*[-4ZV:RJ*-00"@U,4(CQC%1C5";/`#MQIAS#AU>
M4%F&2(:JRH%=8X!Q\R>Y7UH,-")^"S-$R^_)&F#<_+7[GJ*!1L2ONE*K,<"X
M^6OW/<?VHG(:.=Z(^I4[+]F_QVY(*/$W1$;8RNN2*W4=!4]DJ9#%$>WO/2(D
M$'&!FJF34ENJG/$',,)?&-@(.?1AC6O(:KB;\5AM-99)KK-*%PJ)?D4]3'-0
MR+"EE`H*?+#[F>9&)Q.)O)]I;C)M(B>(>_Z)NO1B!5HAV[,P=M>NG;U#%U65
M2F8<KN,IRSC4>4PSF4AWV9&\7--;YI'<,AD]B6EK^>2YF[3@#>=CZ8Q@+`NH
M:@+F$>539I.RH+MAD_@$X?-]T2:[6!,GA<)3P7?HO7IG;9$PI?`@4\VY1[5R
MCQ[\N]13CC:[P,PT*LJ`E5UQ9/G5(AV_^F[$SJNLV=D(IO%NYR5X65[^E6_\
M=1!NTYTI62**O4UP-H;"]/UPD@DFPFQDU38FW6N']-PL.^D*?32@9U@X%LC2
MP,4VJ1A.(H/`L1#6?$R!7EGT6+!W]$AJEP[BE`I%'FW]*SFD0$\;<2RT96[T
MT%-*F,%9%(H!/17%\<1!B?,Q]-050P.MZ],&/;?%L1:V5(]MEP5CED549!&^
M6R/TU!G,0#6Y:MC5:@P].KNO.*;#B=S]?:E(I@`KBXY.:%7U%"B[8![0^1[6
M-=8>G5H02P$0K.73YE)0N5+JOLG%]H-J2N@;0584S@'%3SKWQI11K,3(%/#I
MZ/U3AH\5$%*@J*/+3Q[%9@A*`:2.KCYE(+7B,PMX8<DT<QV2VBIK'T]17FT*
M/H_%BH(I!/8/I"S![B>89H7^@6QZ>A880GV<[A=%31_T`EZ83]#]+U%^YO9/
M+?)[3FB%:OD,%X8(J"I@/Z#J!)$6F+9Y#P[H=SI%1!4"%"M[72D`JS#TZ%SM
M`-9G5S0%H5\%ICI7_?0PU0DT+C!M<[^?[)[7?"OD)3-O4W#OE&]T7<>809YR
M.Y7N.UV15'_)*D>G=RKN=P*(#AGS5"W.H18W4@A:,-W`AL:;$RM1P`K3Z4NY
M\$;[(W7J)4NTI:^YKDE;7;53V1,PR.FE<^Y4"N4$I/4NF#52>Q=@M3!G`"N+
MK9K1O`1:"]'DU(KM""%3#I8M()NRV-'=U['`$:9>IQ*5/Y=V0G-I)QD<'*_M
M0]&BZ2)BNI:3(5STTCH<+!92A^!BBPUMIS!0!*NX@NXL6J]\N3Z/,5DVF%IO
MSBWLXN7ZOOPQ#R[U)6Q-5,N"6:^'OI7?^&3EQ70A7UB>=TGV\I45>D1<X)<3
M$7:"4HL#5E[C9;BQ_"Q<]B+P<>"Y3I[8H[SA#J&TEG<XUV5IC/H9NY<\0IU(
M*0ZGAM!=3C?4^QQCXIR5^*G_\4WG+CSX6(8/Y#!>KM,RG9SEK=!Q=L4=@436
MZQ%WD-?ZW5=0O\&@AV\7,^3@0C10G%5.2[@>&4>#62:`0W6[&$QDF9SE:E`D
M!]H'P"M]%SP_N!L_R1O@1UGX&+7Y$`!M^BH[%ML&@S1)/6]^!Q.2_;GET>OI
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MQ^`+?5ILKID6`YA8)2P*::9-ZM5^Z5)73]]9$?6*LT*4NX^--RHYMN`IZ38V
M7GX)/+(YZ4'3\DO5!A@+?_02O`X1RA.X:7+'[-[ON7#C[^*([.AX%_@,ZB2-
MC>`<A,C=^&FB(WM?2CRZB`Z4\FO&*W<WR-O5JYUH1^3_4N\IX0TG[#*.VM=,
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MG0X:4FMMH<HV3="@:][I&3@KN1\:'LV@0]5Z`*KJA-XIY@PH6LI/[*"CR?3!
M4_:N[92J=_R!CNV14_<1*R"$I;8-`&#5(;(`#I:Q;D#@JEZR!8"PS"T#`EAW
M7RT@A"7H=H10V3.PR+H+2XGLB)_T/;7`K44R6<CW+L\3I0!LUB7J<&4.,`5$
MLP+!>HF6^9H4^,TZQ$%=%40*%WC-=I#&$W7):[;`:580Q(]CBO&2G<I+0+P\
M98%"4*M*]`*76KPEU/(2O1F8F,D`NA68`(=:ZQ"23K4GX.&H'V#8J0[%20,X
MYQ#3Q$?!UPYL:OP.<'$<WW.HYI6EZMJ3(_9Q1DS!F3I'Z].,%LL'*(?G^QD>
M/6%C`F4^1)%*E9.=[RQS/+'!;+++>$L;_D'DRK3DU'ZY?GRFM<6=V(Y6Z`7Y
M1(_TO.`;/:72:JTH?$$7!.$-X0MA(\DO<X*(F$S3&^,5(MJL+XZ*EG0R$=)5
M)NDQM!RT0C8B%RC9WNJ\<#J><B*I$TJ5D=A$;WSJ%D:D'K)O-J&U97\\>?M>
M*%JA)[(Y\<6S%6[(/^W?:)F>W#%+0)E2/Q.[A.JZZ?61KWI<'$0X$Z`X&T6M
M+TBN?OTX0K[2U45]W0(<D;]3[P4?M^.3-];XN+Y$]#9E9*'5[CY"WD2Y()2Z
MCH^GHE1@"ZX.G<WRY3O_+[8\=[U/RHFFA[@D1;ABY_'Q)2\"U7Z<,7/+2GC1
M;HPYPFD$>JO.05LI;ZJ@1D#UY6V+G8:H#-6;M\]EQ]+"H3KQ=EIR8GT1JM-N
M.[&KO-C4P)[.#:$BWK'Q4Q(II@VD8B$P116^4[#@+HD/>XBL,)H\HESC`=0`
MPR-B6S91M`LY_"&%TR<2?92UG3*@A16N6RAB>@!<^4`0G;;33F>T=`4IL/X\
M`R"I?!1,IA1B]1EXA>Q@X]/0+ZHE9QS/M0_;5(9*L<MPO9`4A&(VGI]WC_*\
MF^V`Q+S!>C2M_&XD=WFZ++B)U?.?>WI:3D?C6=DYC7K*F/Y,1%1:RCJ?@)_N
MF=/T5'+,\CB%*A7-#P%EUS_N)JLX0AZV?8$%P``*)2QXURGH)$U"9!A7%U03
MB<K=,#DU4Q44WDJ:C()S8>W<*$UG4=@3)Z;3\"II!]M=X),OL%PO=RBTZ$Q5
MNZM0"M3I?B1ZN?*B:E<C5;4)'<OUYR!P\$-0[//:8JBW,J+5NB&RHPJ`W%K-
MK*:S1MNO1MO/5\W>J\D502;8?['(V>Y:'GZ(=SO/38R.7U!(TU@[+D9?R9D<
M7@0^=C>^K*Y:ZS%/1(M3/H]`"R$M;I%*I&K]].ND[8P_049'N#IN5M`*4T=H
MV;<;:*U*4Z*:II;5`B3]Y0@W9'/$IC^CBFF2<X8>V(?D4%^017]P2OD_EOX*
MT7S'9.F<6]@U$XIYXF]Q*=`'2$M?0,*&M)\1;='"SV31T/]<_1Z[+Y9'5BJ+
M2IX>J=S?S+NI>@WWOBNVMZ>Z?38X)F.MAX.B7[?_$N7$:-73-2FTEYZOI4.5
M-+@+_+!RQO*,7L/,<:HHB0*3^AO?*#KG^\,_?W:)`$?TJOTM>D&>('!0L;-A
MOK)O0'7"ZQ#]'M,$9&I,<7L:Y2C-&IG`^T&854'48RP<?-+FX-,8.&"M#&'D
ML$K/L7"$FYM9FS?^&*/A\G`BJRU!45<C/%53*A[241XD)'4QN=50\XM""E[I
MMM=7NQ0[C_^-8`!I"ZJ=35M5K[P@J&O$4"MM#:K^5`*"Y1\(>ACZX!BKGI[0
M@]9[UU(G]WPQ*))::B7X(*5C02RT2(#-5WQ<E/LYV.&^Z+4SE#&A5E.Q)W,^
MRRUS,A0;II?)8">W/TE78,/\T2FL^T3!DYJZF#"R++!0G8T&1>]3$SU8CD<C
M]@<QLXSTK&72"MGPLW*U!ZR'LFUMTG;M`NPFXP&%M9W=_7CE=\T&(&55*$LK
M[=KU+=]V+:\HH6+&LXL6[9)DPJVV,>,3]!050`E(930T3^^=M47"IT)N<[/^
M5_DFII]>0K^@2R]Q7ZR20_PD]X+69A%EU4N2(,KH,GOE'8UJ[?3ZTO5;&OPQ
MM'R<7GB/05+$^3GPR(6(Z1M6PS6P_3AFD2\DB<:3!_<+L/J,Q*N3<6\+/26T
MACAE[TW.RB],JK[#.M7X"5X4>QKUG"ED/)E'O+"+04^9JU<[D4[SFUOL]B/L
M,_N^I"@]/!-%Z]S"R*'Q/\C'B7;!@933>#QT+VC]T$UJV3K?%VWNK7TB8U/E
MH-`0?.?>LWRIQ#O(5"8P^^J'*$TM\9F0<!M@O/1+]QB'?5DO$YQDA6*%^[_:
MII?[(1L2WV`<(V=I1P$9^O$;^=S[?Z(PN"/W/U_05^]LU*6)I6-7*A0.LO&@
M&TWY1H&J@92GBD\+G^:1?(A2%2G7T#V,5*P=!Z`TSBKH!GA5W-II4M`K9.BB
M)Y'5CV=&-PT7WX#&?A1CP0O_W%<PO6B](4*N:*&-EE3B;_=J?TJ%%;0QXVG$
MT)WQE8'J8"1NYZ`$>KGQ3/G=`A-&7J.CA;5U<M[P+3%2DT/`.KAW1*UF_@#K
MH=YY<37-&3E6'V>L.!N1>2-,R.]>\`!UD"M4<89ZZL_NIK75,^1#3WF;UIX4
M"C/%T$4,C'K[W9`)_(U+ME021;1P'#<E[L9?!^$V57U.^*&_I^=GUW<C<FB_
M(*<&V%>,UK%WZZZYB1E4NIK@B::P_>9Z'MD<-<*P<NX#O3%Z>8+CS]/0LLJ/
M;RK=!J:/ZSLBZS)J5P4#-T*KE7L0,*0?".J%JKM]*C9]I0,0:@"5SL:>IIE"
M`QSU90A7,QJQD&^X^$T8TEJG6=Q);97,<BC_&,8+VXZWL4<-Y(MM$$;N'R)'
MOA8#C8S?SV&`N?D?9=U&Q@M/<M7J.C*>[A#7N5C<:=:%C,OTQW3C/92$$RP+
M4>Y>C0&,VD`U=K^:X)V?@%"%[@&1X]Z5\+TA!D`S.>F[.4<$D>6-&[?6-H<V
M!QU457'$:H^AMPWMVV]RYH5N4.D=>Y,I,GLHR#:KU`<HLB+=(EF3W=8HU<KJ
MB:B'40[HUL1D;R<E%8DL08M#8Q3RX]%4>AKE2*;.,QH:I9>OJE>:&*5Q97T[
M%(_46B3\CD;Y^5L0_G;CWX>!C;`>0X*>LU$AQ6JN$%R6G(0WW&3E22DJHF,=
M[LN4AH#!!*F*YF06D=!VHG*)0;?B:2(ENAZA)AIM"95(?H8>LJ0&56\UR&$F
M5=9<;S5S;YNB*>,U]X[80CD.@]'L(#Q;D<9H13HUFPOU<$KVCJK:W^PP:FU_
MC!K=K.?.>NZLYQY!1&0<;E#UVUE@9`N,>?8IHEQE_V24*>A!F.1$X2RV9#;;
M\B]14LO`"M,007YR/G&'7B*#:E,$V13X,4C_NZ+L*]#&Z6A"G#D/76>#;@/+
M%V9B;#0S0>N%9V&\7&>K<1FNW,VS*#L_O_UHJ!=F+17UZ&4],R>X>D6A[6+J
M9G&?I"!A+6C%GJ/!.2?MGFQ#=/@19[]J+2#94,-]F30/H/+GR)J/YAO<Q?3D
M6*X?:,VS)$?.A>5YR#G?=_D<&J..!HEE'.&(&BO]C0ZKY6[#K;)'%&Z5UUC2
MV%3)DXN`B*LA)A+'^?ZK[_X>HTN$[=!-A"A)U19Y7_-<*15R838W3_LR=#<N
M$0OI7Q=;6KO^@Q(3K'[F2^JD]$74Y;`@-;D`1%RI]1]+B1@JZ/^,G`VM,VN3
MGY*S5-FLV&5$TZ5:5,N$F#4\%G2(3-/U5N,H8U(Z6Y?KGP,<Y8E2.5SHC&"$
M0Q^%&Y9%E='`''W"NZ/2Y)0+P?2$6)+>DHK,EF\CHKXDBGEZ`_$0%'49M6G_
MB+A^L5[=;;P5&A>J;7J1;)G)TN^3PP3=>Y:-Q!7==+H;<8]<KXGL$`I1K;8Q
M067B_(,<?!T&VWR;+-=U&#GD*W8VS5>F#N5&`=Y](.QB@H<5S;TFN,"*WXU1
M)US=Y19&*$1)\.F]%7)N-4%#T_0F.9Z)Z$1D*7R^+_\B6A#J`QB)0K=H8%F2
ML)KJP<MUB49Q:2AY1R/\4()2"]YE'!(-*K6HIL\%=^A;\A/O6REV'A%?2;J8
MEFS5^AKA*G["KN/2-Z=B.0DV$[_]`$6N_D_L[=M5N.+VG$MQJ;VZ2U^LRH_O
MP@<BZ/X)"J]CG>HB?9QA4ST5"LQ@>N=K/1W44Z:SK?/0=Z?L7:*,4M.CH$C$
M#+TX66MK.CO;_$1\TP2V>.G]6'E*[>2B1A;W4P`9*JD/!/2P+$7P%%44Z)%9
MBFBI&OF@QV`IPJ7P2MXM,@L,4JH6D$XE8R$<^CJNJ=.I$RM<6^+7ONF4@^6O
M)X%KV'3*O^K+6#H^CL>K3S-J'#4\K0K$8(6@=-Z8N6=P`="D)7@M!Z0"LTG*
M\5J!``56DQ;BQ0X`!4C0Y?<Y/E>"A\+[(-@RKAKP")[)P)9OU8!'\<$";/56
M#:ATW%QRO#Y-&:_"#2R'X_L)PU'VZ\[Q^-.$\6#*0_!32C3=^YN+9"I/OZQ0
M`I[5L1ZD7TC"L`QI(TX986:1-+R)&W=,8TE`1J+JME;&HA8.4;C:P#1H\;VD
M*]D=J]$,!2@P[:+ZKM@\"7<JQXNZ<_?A9M(*`"KNJ19/B*>`G\P]N6*K4`![
M8BF0'H/[F*:7Q>@BV&X#/WU2+;L>C26S!(@\)U>O.S=,ONPEV:TL[V^5;J/)
M]M$P):N@?VLTUGP<64L&Y$440B_H8#;N_WQ_9T74>524VH39>,XQ818!A4PN
MC*90HO+'$M$NCD.Z#F)V0#6G49]S+Q5"G9:#1%\]DD;RN<NM>IW]6R"?^]!F
M=($VPD=B'7=UF`_%/6&FX;<.4WU3QU%=IH;N""J7^B;KKZ`&C4S\!.^WH`>3
M;(_"?S03ZRGL)36M&,I>HP1%RW,Z4+)#43FB-=0,]FU@*4G>TPG[4X"EK`Y-
M)\)/#DQ9.X8:RC?B9WVCSR!)=.)PA1X.(]\3/8\RLR$W)$$'X6A%7^L0^2G:
MLRP$JEW[*?ZP(4<#O;3ESQ.\IH,6H5"NC%'O8<(TNM@&8>3^8:4!&72!T>5&
MP^_N0[1UXWH&<O5^O6!\[@8[`M'6LE$<$>@\/KB\ID:>.BS\+,R:5VK0S_/=
M,W5WN?&3:)K`6SYY[B;Y-G7CK:RUP8>AY*5;I0Y'N:$1>HO0.+KP><366HV`
M4O&29+8UG\`^HXM&/^7:6GIJIK%V:MGLI8.8XE/CS8W9N)?3HSIVPZ!9/CIX
M30>@@_4TS&TVTM($2;1_A]($6?]1<;="].1U_4U^XY=E@31`49MCI3'-HT"%
MQ^7ZV@V)6(M^C]V0^O_MZ2]J'(OZF^?NFHA.PD3KW.9CH-T-D\1`BJ3GK<U3
M7M:3KM9K1,V/J%"CE/B1C3$N+A^BQ'&V/8N-`<SS]X4:VJE%HJF)*G3H[?9D
MC_\/9#%5)DD/\ZBND(.VB0$F>7/67#+\WN8Y8Q3W$C0T3^]7WTIO9.3D5[02
M^:Q^O:WV)3GJ:$(JOE&`T<JL`]KAYJ%&DT855ZE3FJ3[.(H,E8AL_BCCM?5P
MI^RDQUGC5Z\VPKC@GTC+]]1.[.XLCR7L*';JA;9KUZ<IN_A;K]J@GSEC^IK]
MA2@*VWC[.;;H>PA"F03-5%<E/4SLE\]D>2Q]YB/T?8@BZY6S,>3]3'"3BV57
MKSOD8]Z]7&\U`DH%ECM6RY%03#:W%U.GQ;)^K,X&N[M)WNXMMUY(E]G$+(U[
M:F.ZB$/Z8"FEMM+X])VU^\'R-O`W!*`M786/9#)!Z`2SZ1AH%KY-<!KW<N_=
M!3[W18G1P`16=T&$<+;VE]$SD3G2?[-?0U5[&2GI1NF@X85N)*B*5F_5RW=.
M#9V,K5'_M<?9F(NZ^7N/,UX3X86_E!MM^IQ9&%G2:-/CS,*XDGJ3'N>51)4T
M&_4YMRBFI-[$=/E`M3==40_3'%`B[E"T7.?9E"\"S`TT5NAHFI]<2;L.PN2P
M3?7)BH.N`G,JH_2SYK-)!4N^VL)(>30;^1;9>%]]O$.VNW81^_R7MS="_2&7
M\^$KEE(BB*J\R3N.CQ^IQ*G<W0QOF^3!4\Q`N8T1*NE#$J7A/,:NCS#.2,*B
MQ23L8Y2+LG^4"@>-]D:ISP\;%<HK;4<0G,3P79-6A&AX<7^"&0$H=G,ZP,1T
M_H$:0*/B=L5+=*TD&$$-L=$%KJ'-0PVR405&Z2$%:L"-%DC<.`.H83=:Z(@\
MSJ'F4]`]?-H_C4/-I*"+H+KC!-0\"KJ(*3PO0RVKI0M5X^T::D$M_5W'<PN&
M6BJK&T)BYU:HQ;*TQ`69<RK4@EE=%+W&FP34"EG==I\P\`9JH:PVD.G$U$&M
MG=5MJ0GC?Z`FK^X&634PHL!HFE*ZJELOU((=>@88U8041:&"66Y7"IZ!6MFA
MB[3%\Y^`6AJDJU)XB+<L`)JVZ,X*\"JPF25VC9#7`K99:I?$X!50S8)ZAW0%
M!8S3%M[Y-H>/TY38A>%#!3C3%-/U(Y4*9Y=IB^H*>=<*J*8MI//"L`I\IBV8
M5T/I"E1:2./DZ'\*3@B7:>>15P%$T=,5;!+Y5AA5/5%S;":]?MCQFV`KW:M`
MTPC9`UO'OM4F:CJC@RULKX6/0A`+V(KWRMN**_[`+=\QXJ3G9N(&1"D#1%?3
M5/'AU_7FI`$N5`58-B]]@*39"PY0?0]0UVRF':B)-]!W%#<=0@T'5@F;3P!?
M*!2@8)6M^7Z:JX)=JN9[@(^A"F`PR]-\/\T]4DYT4F`!\ZZ59A:HR".E9$;%
M00KK_5(+&%:6IV+%P#+_ZP-33ZU1(`/+J4(?&582W`(=H!M*.0N(NMEE2FJC
M;M:1(FBXFO&U.+AAO7T+,Y@<P.`6IBI@`7HXJ:1,J>Z\"H[@MY<L&0NC=FPE
M>\AD`&+E>ZDL'/XU.)%ZCT7>"EJ?F$;:D\,:D2,;X1[*0/:3OF?A_'>,$QJO
M@U`A*S&_?4]%&<.ECWZ.?8<L!V'614[+?LH69F?C)7I!7K#C9L*2-!Z*%E9Z
M*W%;,\7KN*M?N6J:WAC]E&)4F?*V[M!3_@J:(QR/:FY%-HW>/17_.*S/:X1P
M.GU4'+AEVKAM`1:,2"(3;WR'"*3T2$U.6'K*_1.%@?`P5.O84Q&'D+ZPM*)2
ML6LO=-Y:KX[ED7U&E@MR^$0QVYU^VG<>*EG&%:H^!F%YWW.N%'&'86GBW[FR
M+J;2S=.HH?LXM)\M7)+^A$7YI-U,\/+%>J6IQ83)WZMM^DF4'].QENM#ZB[F
MDF2T,I9H?F';84P4EV(]W@6^+:PT(>]G)'5SD94P7XG+=4HJQBC"O`*9\G[]
MI&<.B$H6N9;WQ0I_0U0\6>QV8?!B>>+4[`K=!J9/G$9=H9N)U;"BR>$$B5R+
MWXU1)SR;RBV,4!CL:6C[(34C+E^<HMM`H>.<>-Q@BN(N9\1#O-MY+@HO^>=!
MO4FO\PI/RF:C7N>6%+)@->MW?M$IW&QDS"U!:GDJ7E55;D30^=[ZP(KE!P4Q
MU93,BE@\C/%!A?ZRT<I@6234U;#`046R@P&U<*-AZ("@LZ%WQ(MO2P6=*KT]
M:NKV&M!IU+L#J&`R`)UJO3N"*FHBZ&3LW2%4L,*!3L;>'4&!!P#HI.SZ3Z;3
MS%#0#B?%H'QP8:`=(%-YH(.=S*#;4BL9K6$G-NBPO/AV`-C9#SI`IGO#SB'N
MX$/<U5TIY.?ZM+'B&&S9SCN@Z[OH0L3SE`5=B4,7),;3%^C*"&WQ83Z#`-26
MV^)SV40'H$;<>O4P(^B!E3[@NL8T5)`&$L!N=($;3AF+F@\AU*IU^E&_RA[4
M4"N/M8!,S3$>:H&M.?9.._;NZO>8JJC=P^RX@6KBJO!-+R-)#Q..<8MO5NC4
M<[/5`_XJ;8P$DC&B;)FD,AJ:H/<RVU%$@*+IU+,#(J2W)=V[?W.C9WJ4O;A.
M;'D++Z$$.<EB.+=PM=^AMBF3X2%FZBG`*R4L^11??9>(D`]?!7M#V/Z4`[WZ
M65'982:.E:PUZN4[?@Z#>/>!_]TJO_<WXT?)C!][G_&39,9/1UN+A@+#ELG=
MC:]>46B[F!K"TR18+$2X;?NDY'/B$N%<QC0YCI065FLC832>Y=]96]&%6FEB
MDD;A75IKU$^03*E<6[9X4'9=9Y]QX3M_L^@%QH[\TAO`"+8E"O-"=,OPP?((
MG>D!S<-;WK'W;U`"+D>3X)=XU,C0%W4=DL[\T$$..9:Q=)$(>O9.9;;N\FFP
M$H'L3D9"EA`1'%P[RH0PL>#):3P"NA/A<?7P51P>)NPS!UAI4\_4*$J:R/F^
M:)*YC29Z9?(_OY"O<;BU>7&FO4YQ4ABEIW]1&P\GI^SCL^5G!]MU$*Z1FU0#
M9\I))BB`A7`B76)C\-:F/RUL7W=NF#1.*XCW#%UU]%$B@X4G4V)9\QTEF7R0
MJ8QAAJF82\C,BELG?Q,QSFQO-)R8ER*0%U+<:#_E8&@*PG/@.2C$Z0%(BSC<
MBO)JR;H,2!<W<Y:H>7_TW/BTM#(MLDSV[N,W\N_]E8=>D"^(:5;I9V;]4<*2
MK5RVUJ1;_&J[\X(]0JG>]LTGJ#Z[.TH]=X6V&VUTG-^A;\E/_*VHU'ET?-54
MK>0BND/1<IW)C''8CF6E<4>'!M,>T89]]D`]GCBB>7,+&X^#UL.8?%MGOH56
MWM0'$?2@.PGQ'V]+GJSBI_2B2C>L)!;BU[W"RTXDD4!=/G.H06V1L!Z6*L'8
M$SM7V`IS==-(Q>;B9('E*Z_O8%=]Z"]P`>I'IX?+QR8NL&('6N+RJ8D+K)B!
M8]CX*N[CXK>L`F:@_L`#PZS@FE9`#"MAB;+M<BYO<DHNU@:"A!0-M]4<$&J&
M+]!IOMK@QG\F`9W;JP54*GY7H--Y:6`F];($G;6K)5`,QUC0F;GZ/N8YEN].
MN;E>4/@40$%1R^L1=&*NGD!KNK1"#4%MA5JK9YY.&3A@;U>.^R_H#-Q=\%((
M`(`:_]Q)'SB*@R/H)#)'1;[F_@@U0GU\2YKA%0TZPW_?`KN:XP[H;$HM(.5%
MT8#.JG3,?<^,&`&=E:D%NH-D((":V&F0TU/DR%J\,4WF>6!.HZT*C,)#'>S<
MV9HX5?VB8*?'UH2FYM$*.R=VV^W%3DL/,PFV(D9J%^(QTUP;S23V$#]A]'M,
MYKEZH8IF#SG%QINC:"Q9:GK,#1#;42*>+7QGA3PJZ%X$.*)BK9W]FQ.`H=I[
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M3Z(B"CI`20(.R\#6^RIEKXO>IS&:>$MJFFHV-$JOT#A2;60T@8OTM&$^``'7
M!6;C!2_`4ZAE]W^P@;=A,(^+Z:J97#A$"Q'XHRI?W'UP-[Z[IEF@HN8Y/@NQ
MLQ`[I*"CMO8X`I!:YUG@G`7.6>"<!4Z^-['B(32+D;,8.8N1W<3(_`_3%2<[
M%..T\#/1@>E_J%OHB^51W!/2]C)92:VOF9*=3Y$:#ZR6O9;,7-$$E3$24Z/2
MPPR.(?FL-.7F^?[.HC&"`@\E3F.S=$N+<#";FJ497VV?D$..T]*?I-0S.QGF
M0W4+<CL8*<YJA3XYG7&>G$N-"5DO**:"]KA>6V[XB^7%J&1C+<5[IX!QT%7K
M:X2K($1$2+F(R<GMDP\>6CXF=WF6^R+YOUXB,RENAO;CF>#^AHAT6_1HO:HQ
MQVUNAO;(\C<N$<,7&*,(DX7ETHB8%^0(UZ*\GQENJ)-%$.Y5OP2G^>D;$3GR
MV`I1W].2]!T2#23V;;25"[PM!C`41(*(*DIE\DLB0WK!CI*6!7P+U[1*3S,<
M):(P@3X@BB`]]M26M[R?$8,HVE!85V@7A`<%4''#JO4UPY5'QMQ\1CX*+8^L
MH(6S)4<BU6FI3)<M(L7KK^5@LSE^8'/\$>G\2G.(7>'(W1)2>)C6&IF@,\MK
M)@SNJK:9'S?&:I85VSFJJ5A8EH7IX",N>%#;$U`?-^8WL59O8O63'7Q$DQ(J
M"C(NU$SG>D`I/E5`S7:N!Q;?'@`US;DN/E+K3Z=<YB</E-(C%M2\Y;HGN(+=
M!6JR<DVWF);&@DZ)RL&@QS>W0TU+KH>/Z.D1:O)Q/82DCYM0,X7K+B2&_PC4
M7-]ZT"@^XT+-S=WZ0&+Z=$!-MZVYI-J_H4/-PZTK52D]+$%-JZVAT&B^`D/-
MD3U[9VO"(7LHR)`!EXMW]EL?T&\]P7+"7NO@/!M34R*166Y=Z\GUW(C@]`59
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M&=%L:9H67ZPW".`5A0$FJ<_2[)&22;<^AV9I=Y9VM5-PM3GS9PEXEH!G"7@(
M"=A<\ALH<O`L`Q[#6OL0D<7Z''ADBV.:=C[:T_V0%;K`RW#E;IXCK&Z^U1UO
MEH!G"7B6@&<)N`][K_99-HN_L_@[B[]\\?<I&HUMMTR*5%QE-C9CD65#J$+X
M;$<=N0P]2Y$#2Y&B/3\+B+.`J%'M8K9^SN+?+/YIB7\7P7;K1KGN?A$DF4"1
M;X_GQ5^)0HFPJ#>&B7M;\SMT8'.6.&>)<\H29ZOS9!9$9T%4M<*OYDD^RZ>S
M?#K+I]PB-$QK_QP:S[B(4W@DDG"MT2QT35#H.BJ=JMN7QX)J?Y-G.GOGS3+C
M+#.JOFZK;Y-97)S%Q5E<Y(J+\1-&O\?DGU<T*A"#$P]GL6L6NQ3HK&T#B5+`
M;3X&VJ4B(K?]+`"-Z0(3"T#\CSX+/+/`,RJ!QQ`NDB-]'-HF4QC\ZSM*X9.%
M$?D__Q]02P,$%`````@`9H%G0T\TKG^<$```Z+$``!$`'`!A;7)N+3(P,3,P
M.3,P+GAS9%54"0`#[P%\4N\!?%)U>`L``00E#@``!#D!``#M7=UOXS82?S^@
M_P//#X<6J.,XZ>YV@TV+;)RT/F37@9/MM7TI:(FVB95)E:22N'_]D91D?5&T
M9#N[#*"71!9GAC/\#;]&U.C=ST^K`#P@QC$EY[WAT7$/(.)1'Y/%>>_37?_B
M[G(\[OW\TS?_>O?O?A],IV!$"4%!@-;@=P\%B$&!P#U\HH2NUN#.6Z(5_![,
M($<^H`3\_GYZ`TZ.A@`LA0C/!H/'Q\<CY"\@ZU,28(*./+H:@'X_K>&W6)<S
M\/KH1*J3*YG2B/AGX%7NUB5#4$AJX$LMSL#)\?"T/QSVC]_<#U^?#=^<_?#C
MGWEJ&JX97BP%^-;[3A(?O^HK#C`]FA[ES/H/N*.$2^I5",D:7`0!F"HN#J:(
M(_:`_*-$*-?6`MF$A)_W<@8^GAY1MAC(*H:#WS_<Q*W2^^9?(*8]>YJQ`!<X
MU)V4YW2`"1>0>"C'(MOJLX5#%:M&SU=284G4&KY]^W:@2W/4$>\O(`PW]'/(
M9YHZ*1CHQCT>]D^'12ZQ#A$WLND2,Q]<,5)0#:X@P]+Q6*@=0C$=OST]SK$0
M"5"T,C>!+]A`U3:01'U)A1CV\JS;^2H\BL87&[9\:[\:Q(4Y:D_ZIF#K(CE'
MWM&"/@R20G-+>!%CLL?5L2:EBO>DPNLC;&:3!>;:T).W-+.H$C,/)@^("S-7
M7&;FXR)D9BY5HGB&.1X!V0*)CW"%>`@]U-@YY!"T0D1<4[8:H3F,`JGIWQ$,
M\!PCOP>@$`S/(H$*!!')2'Y24MY!0JC08XG^K>Z$(29SFOR4-U2'.6,T0/?2
M8X"Z^#0=V_04R:@X4+2#$?4BI2DD_A416*S'4CI;Z3I[`/OG/2O%1H]4$Q_-
M,<%:X^'Q$/1!RIZ_E*)`+`ODA+T;E"64A4=R^)Z0G_2U!P,O"C3CC?R=,"<4
M-L:0R?&2B!TX,\WJ^9*[*2`'P^E.*JQ=:C*_QD2.PA@&MY1K;2X#R'GB60JQ
MJ63XJR&#'<!3B=I&$%!S%?$149.HO.(TP&J&\\%[&*AY`=PM$1*\PW%O'&^A
M'%_%$@DLFZ<UJ)I["[(_[((L^+:@V'<=TLV0'DN:%;H(!&)$6O&`S)!6R>P8
MOFJ&X8:$`SH'DU`MCJ6`KI\V1.]N*9U^20-?[@&N_H[DK'5!_(GL!$PMQF61
M;',)5HQ>#ED/]W>68@?^]2[`7RXA62`.,`%RQ8$]+#H':.8`EY`OKP/ZR,?$
MQPQYPMQ]JV1V%-_LA**L!.A:.O0LZ'VD`O%[NIDDLT:<L`4D^!]M3];.\H?L
MCK<Y6W,S;,8\PMP+*(\8ND=/XGU`O<\Y7_B"E=H]ZT>UV-YPR1\?H5`7TG_>
M1QP3Q+E>@[^''&NORNO0^=5.?G6'%T2NOCQ(Q(6G]]:8+&XET!Z6'*V\I:$H
MNP^\+?M`3BK(Q()4;@?[3K"/U<9X@6<!NN`<[3Y"-)%C!7QX7`8\$PFTS`[A
M'1%^D/\H6^\.K46`'=-A%=-$5@?F3F".$,,/>F\U)EPP'8[B<A+^%?D+.1I>
M>+)(*HUV[L=[56!WAI.R,_P/,@;5NE#-Y<D/D"D`;C"<X4#N-#IGV=%99F)W
M/S#SVB$^+4.LQ'3H[82>W%:OL$C[GUQUJ^4.(MX>G;NE2#O6/Y2QSDG7/;H@
MOW."W5;E0@)1B+HHVEWQ;R[-#OVK,O2QL`[CW3".9AS]'<G+*[4X:KO9JN6V
M8_BZLK_:"`*QI`[.9]Q(IS<.N*'>B+0#_Z;EQAI\FUYUSTN>TR/NH=SI'M(?
M$H%V;ZB$VK9Z0RRV\X5GB[>T<(3FTNQ>4`FVE6,O'>S/%X1IA?=6,5:@3PQ!
MMD1BA_#7B\RT\(`#5&/WD$K(KG&4IO.@1@?6-FT;/]2:S--'6A)%_4!K,L\_
MSKKP?:TI#*HGVPXBRNX.E:!=FT=QDCRK,W]4#GP[0@+B[@1.0U>Q+O@:><@.
M$NR.40GU;5LX=KYP(%^(5HKP'PE;/-BO)_/[);IEU(\\,45R/H_011#01W7R
M38X$R?GZ2SF%+"C;[#D/*M'N*Y50858C2*M48X=8(I#4"I)JP:9>/<PD-8.L
MZLY]VKE/$=4I\JCLMO\@7\(Z0G/$6'H*MQV+W0$J`<,RRIE0#7,JM@.W';B7
M,,0"!@DX5T^A/H]5QK.&R@YA)5Z8DQ(?B$_D=)BUPRS>N4L@-@OI#PBJ`O]"
M7$/,?H-!A"9$]I"(27D+O=(J0[J;$#OBE4!A7(D&.UOTI_4`*("J">BJU$MJ
MF\J2Q6'G%^WZLC[O.B89?-GANMS>K]*Y&[+9L:^$!6.QZO!M'N0YV,@&.>$=
MU.V@+H7Q&BWH&_'80=X>]>O6[(>:EQE;RY$PZ9`E[*KSLY7:"NII)<*72LOZ
M;#6XVZ'9KKLF,=-JGTP+[!C5'XOKH-@1BH9CII7:#EHE$I:!U@V3AT$S#37+
M=6QRF<69-RO.1DCO(<GN!96P5_/P>.<EA_62>WH;,6\).5(GSRC1;ZCQ2214
ME@>5:J/.*;8SVGV@$L[:^("@(!4-8MD@%@YRTCN\V^&MSI`VZO3UA'8\*]$I
M):CKKH=:^]8?.FV$:FM^.]C5.);MV&KG!0?R@N25X2:`VTCMV%8B5K&H#L0#
M@5@^:]KLR6,C)CNPU5-JY<.J'<;RMOJCTE5-T1SH3%1G*@W3>8_C51B@7G(/
M,D_QVW-8#4)&0\3429)!*C854.$N)LW23E-JOT2K5,*2H?EY3Z6KZJ=IA_Z2
M'$=/JR`E$5BH6BXS.4`)XM\#&`2]@;N6%V%L8+AD,!@^VHAY(78'<(:"AB9+
M6H/)-TK""[&VW,T;&"U9#$87SLL8;'\WR*?,DK^**;7>2=,I$X`84WS5Y+\#
M<8J]&^II0186]:N?\O75K?[PI'\Z/'KB?J)B&PVREFZG0<K75@-C?KFF=:<,
MJM)7C:JSINFKJU97:<P+.$"!X!M9_4Q6^]:OI.1KU`AE+M42;U7S#U_OHT(N
MFV!+-2CYN)LFMKR+>P"C[K3%95L20ZLZ)K[TQWZ*&%(B-M,DS[CYU<_$M->E
ME&>QD1HIC[K8JR'*&1L;U;YATE=[U5_-_=A(@QQ;<KV7%N5<DHUTV##IJW[&
MGJ\_R2RI%3CO96OV6\0\-0^J9]<"R4E13*%`MT@6B>1!BYI._VK,$2\-Y$!S
M%L:$8X%6:M'<`W#&!8.>.._-8:#G?94Y5M%AZM]KOGC.DY,%P4&@CC6?]P2+
MU,0E=QYRZHZ4#K\P&H7GO9@;2_$U1BX8TK^OGD(<)R\;24WS1M51Q$;$%:AT
M2JUL\".6[,@.880>=R$9H5`E[(-LK2.;']!JAEC>%#M=@HK..GOFTQ7$Q&13
MK.:7-8DFJO)M-E4(7X)1]S3^/U55-;"M1)]WQ%`]2ON*CL@F!/T:$9^IK;')
M`\T$+J'T'M-0-N]*#L"1SD59L:*6PBDSDE<`1N@!!314)2.M4=Z0>AK'3>$7
M3^E)NSI+$I)\[Y!:8[)X5CM\<>;CE4JX2'6#F2U2J?94T$RM#L?D@6(/W2.V
MREM43U*8>!+]OEZ?S^N93/LU5FQ*W9G^E7JW$/NC2#G&K:[EFK*+1(N2(5;*
M+^QG5JN2<X;J<0FCP606X(667O`O"U'>EA4E2"T5=L,H+IK%J7ZEF6B&#X2<
M2DD\F2>/=R=,?[#@ZDGZ$^;('Y,8H;R]#1D*..II]BOV+;/.-2O51M2Q>6G@
M0B]<[VJ]]<OT09/:8\XCM!6^E&I/S)[=&C5P;[,EIME[;#^H+4UR$MW(>5=I
M6!A;6C*Z-'8VRL.D*FEK;\+TY=<CR[6:9J,9LJQ'Z"J4X[Q*-9PD\2:+2\I%
M]@Y*#<S-N=S">(O>!H";<3B);C%AG`G)6@J'4"NEO2LA9"QU%HWLA8P/ZIUM
M+-9J=OX#058RR4:8MVZA;GV]A8I2=3*?(]7$E>VRJ="E[67Z1F/RPJ-^*WI=
MRO25&&(G+!@ETOM?$Y587YU;[A/!@H_N/E5#:'8RMY"J9M@PF%-/Y*8QZ3ED
ME2%*K@AY#,<]K>8$-)K9AGWOG5W6!,^VM<O%<*X12C)CBL)NH)[D^0ST9*,>
MRL+D:U47AN]>&6(/S<@=FJJOGCS$>?::XP-BM^H0&PYAH._DC&M`^VSAB`-"
MNC%`OWEO2`147K`T97!R#9,I+W?@JU"'C?3G(YFJX@^,`CG^I"L6H]&-^/8+
M%![4I3>:CTD8J72]D=P03(L!&`N-2Y;HUX*KSV9*]UV:*J\QXT)]^B9^Q*WB
MKOI!TI^(4=-CIH;T3ID8,?7!IC9&-N5PRTR5HNH#)G@5K7Z)H`J`(70+U[D7
MYA/K[(0O84[09,,*<,7;+J&CR4[,"I\XJ_"I6>%3%Q4>$^E?D*,1BO^/R0W2
MQU,#]4&NW$H^9TT+GI>PO*]/C&J*3#6B=FCI:TG[6EH`;J5T<N5W`Y]\&,C&
MEQLNY%=ZGKG8I1Z8ZR]RPLQ'[HLG"K;0.7FLH%;GRLF/K90N099N".)'M)^X
M"FXDGZ1=C_6!RO+JH3&'6V<I/E*BSAE4>E7IODO8?(R43I/YYIAD'@938:'%
MD8=7,/B*#9XH*/L`P@MRF1R1EC\?(=,/\I0VU1?7"]:U8<Y;C^6*=H':1>T/
M^7AWX@DJ#;A_E+?6:L_P4<ZHMSH2@6X#Z"%C>+45ETN>.HG##<F1#R6L<D:D
MGL2M<2+1\Q>]*2H<2:H:8R1RZ,#$A,F>`6O/]YJ+G?*KPWR`U;3X/;QHAU;*
MA_IP;6E9?5BQ3J[!)W'<1X41\8-*`;M@<&7H.E8RE[I0/"R5%N#YFTZNMF,%
M*TOKXFWWFOE:.D/%5ZI%#BI.(U:G>*[(/<5-T=M*B7MJWR_EJKU&\4*9@ZH_
MTCK%LQ*GU*9"#=,P^`#99Z2.EUV$(:,/,#`Z3Q/JEV&>$:DFU$Z9QZB'D,^O
M&5VE1\HG<WW^(EF%9\GN"E-<.[Z7$-W-FY0S)+5.VJ.7)36-8.5XP>;SS8L&
M4@ZO<P$;PTLS/O':U`QNL[N&]B697!W#2@6.#5?J"P]W,$`E2'*WGZ_U#_B$
M=8IF<NO&+Y>0+>2E]UD-F.G[9E50FI&[!-44J>U;[K-`C!)Y&4?9>/U1U99\
M!9,=.+DJU8^C]<G1ALG<?-R1YE(.0.R/2?+EBV)+["GJ)8Q#R9%D;HHB&<H<
M"@.EVNF`B]F5S02N^>R=['%0RC8MV`UE+HTR=]X2^5$@UY[JI9;)/&GR6D@:
MTKN'4*IVP:>,AI4HG(P#6C\<9QH)FC(X-#S8OZ=<AJ\!L?-(9B=CQR3>`-\R
M[*7[PAIKMS$E7=&%\Z?5UQ+4)U6-[KJ-TB4_->I:<5`;E9N>J33.'B+(A4O\
MY/<J4`-D=:)K1.[4W*<UUB^2YY^1)CTG%W^YINP.L0?9J_B$70805WUU9S$O
M8K-58V*2HM]FZ/9V:B1DSZ?67\)M8CMT86K")I+3M!7JN%^`^?KMAUVMMS*_
MG!Z216ZG2`WCGLB_6FD>,9OQ.#5LZL_$KB=SA5K\?#W]&FS]5JX-DW.;AR@,
M`XS8J(I@N<0MG&+EC+O2:IF+JIN?0QI+G53?\(3+4.:2ZLGX:WS@;BAS4'63
MNU>+'%2<Q_/B?Z-@73QB66?.5@9WC30>)=UBIY7'05/-@Y>IT$7E#4-7M<@I
MQ9'*I87\BP?$X`+%1[35-XX]_:0GB-3"JOQ-,<,K]WO*<2@P46])G1F-FJ&>
M^2MN4]X-XES8\O+_4$L!`AX#%`````@`9H%G0^-3-ODM!`$`R0@+`!$`&```
M`````0```*2!`````&%M<FXM,C`Q,S`Y,S`N>&UL550%``/O`7Q2=7@+``$$
M)0X```0Y`0``4$L!`AX#%`````@`9H%G0Y0X(BW'"P``)9L``!4`&```````
M`0```*2!>`0!`&%M<FXM,C`Q,S`Y,S!?8V%L+GAM;%54!0`#[P%\4G5X"P`!
M!"4.```$.0$``%!+`0(>`Q0````(`&:!9T-E$XH>ASD``/0D!``5`!@`````
M``$```"D@8X0`0!A;7)N+3(P,3,P.3,P7V1E9BYX;6Q55`4``^\!?%)U>`L`
M`00E#@``!#D!``!02P$"'@,4````"`!F@6=#DI5&GXQU```.'`8`%0`8````
M```!````I(%D2@$`86UR;BTR,#$S,#DS,%]L86(N>&UL550%``/O`7Q2=7@+
M``$$)0X```0Y`0``4$L!`AX#%`````@`9H%G0\#,5S\?.P``5,$$`!4`&```
M`````0```*2!/\`!`&%M<FXM,C`Q,S`Y,S!?<')E+GAM;%54!0`#[P%\4G5X
M"P`!!"4.```$.0$``%!+`0(>`Q0````(`&:!9T-/-*Y_G!```.BQ```1`!@`
M``````$```"D@:W[`0!A;7)N+3(P,3,P.3,P+GAS9%54!0`#[P%\4G5X"P`!
@!"4.```$.0$``%!+!08`````!@`&`!H"``"4#`(`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EIDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Capitalized and Expensed (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ComponentOfOperatingCostAndExpenseLineItems', window );"><strong>Component Of Operating Cost And Expense [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold expensed</a></td>
        <td class="nump">$ 3,682<span></span></td>
        <td class="nump">$ 7,813<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Finished goods inventory held by others</a></td>
        <td class="nump">641<span></span></td>
        <td class="nump">641<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DirectOperatingCosts', window );">Direct Operating Costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 8,454<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ComponentOfOperatingCostAndExpenseLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_ComponentOfOperatingCostAndExpenseLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to goods produced and sold during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfGoodsSold</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectOperatingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate direct operating costs incurred during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DirectOperatingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.2.Q2 Response)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQNBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (150,816)<span></span></td>
        <td class="num">$ (168,617)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">179<span></span></td>
        <td class="nump">123<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Shares issued for services</a></td>
        <td class="nump">27<span></span></td>
        <td class="nump">24<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities', window );">Excess tax benefit from stock-based awards</a></td>
        <td class="num">(966)<span></span></td>
        <td class="num">(10,106)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest payable</a></td>
        <td class="nump">8,381<span></span></td>
        <td class="nump">1,094<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible asset</a></td>
        <td class="nump">485<span></span></td>
        <td class="nump">108<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
        <td class="nump">13,232<span></span></td>
        <td class="nump">9,365<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
        <td class="num">(6,389)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_IncreaseDecreaseInLeaseRelatedLiabilities', window );">Change in lease liability</a></td>
        <td class="nump">3<span></span></td>
        <td class="num">(55)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">(Gain) loss on change in fair value of derivative liabilities</a></td>
        <td class="num">(21,059)<span></span></td>
        <td class="nump">68,686<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Restricted cash</a></td>
        <td class="num">(1,400)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="num">(3,721)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
        <td class="num">(5,821)<span></span></td>
        <td class="num">(8,989)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
        <td class="num">(283)<span></span></td>
        <td class="num">(2,273)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
        <td class="num">(384)<span></span></td>
        <td class="num">(17,355)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable, accrued expenses and other liabilities</a></td>
        <td class="num">(1,714)<span></span></td>
        <td class="nump">33,075<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(157,255)<span></span></td>
        <td class="num">(78,539)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Purchase of long-term investment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,238)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
        <td class="num">(14)<span></span></td>
        <td class="num">(477)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(14)<span></span></td>
        <td class="num">(1,715)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of transaction costs</a></td>
        <td class="nump">121,206<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options, net of transaction costs</a></td>
        <td class="nump">627<span></span></td>
        <td class="nump">7,834<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants, net of transaction costs</a></td>
        <td class="nump">120<span></span></td>
        <td class="nump">16,526<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation', window );">Excess tax benefit from stock-based awards</a></td>
        <td class="nump">966<span></span></td>
        <td class="nump">10,106<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of exchangeable debt, net of transaction costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">144,316<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payments under capital leases</a></td>
        <td class="num">(7)<span></span></td>
        <td class="num">(20)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">122,912<span></span></td>
        <td class="nump">178,762<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
        <td class="num">(34,357)<span></span></td>
        <td class="nump">98,508<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</a></td>
        <td class="nump">260,242<span></span></td>
        <td class="nump">116,602<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
        <td class="nump">225,885<span></span></td>
        <td class="nump">215,110<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
        <td class="nump">5,250<span></span></td>
        <td class="nump">2,713<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
        <td class="nump">1,395<span></span></td>
        <td class="nump">697<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash transactions:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital', window );">Transfer from derivative liability to equity, fair value of warrants exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">103,885<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Options and Restricted Stock Units</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">14,170<span></span></td>
        <td class="nump">13,344<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="num">$ (1,179)<span></span></td>
        <td class="nump">$ 3,037<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_CashPaidDuringPeriodForAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_CashPaidDuringPeriodForAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_IncreaseDecreaseInLeaseRelatedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase (Decrease) In Lease Related Liabilities</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_IncreaseDecreaseInLeaseRelatedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reclassification Of Derivative Liabilities To Additional Paid In Capital</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCostsAndDiscounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredIncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11374-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of obligations incurred but not paid and other operating obligations not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInterestPayableNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherCurrentAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other noncurrent operating assets not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestrictedCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireLongtermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate cash inflow comprised of the amount received from (a) employees to acquire the entity's shares under incentive awards, including stock option exercises and restricted stock arrangements, and (b) the excess tax benefit arising from such transactions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrealizedGainLossOnDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
        <td class="text"><div>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(2)</b></font></td>
 <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Significant Accounting
 Policies</b></font></td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Use of
 Estimates</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The preparation of the
 Company&#x2019;s consolidated financial statements in conformity
 with accounting principles generally accepted in the United States
 of America, or GAAP, requires management to make estimates and
 assumptions that affect the reported amounts of assets and
 liabilities, disclosure of contingent assets and liabilities at the
 date of the financial statements, and the reported amounts of
 revenues and expenses during the reporting period. Accounting
 estimates are based on historical experience and other factors that
 are considered reasonable under the circumstances. Actual results
 could differ from those estimates. The preparation of the
 Company&#x2019;s condensed consolidated financial statements in
 accordance with GAAP requires management to make estimates,
 judgments and assumptions that may affect the reported amounts of
 assets, liabilities, revenues and expenses, and related disclosure
 of contingent assets and liabilities. On an on-going basis, the
 Company evaluates its estimates and judgments and methodologies,
 including those related to revenue recognition and related
 allowances, clinical trial expenses, the valuation of inventory,
 impairment and amortization of intangibles, share-based
 compensation, income taxes including the valuation allowance for
 deferred tax assets, valuation of investments and derivative
 instruments. The Company bases its estimates on historical
 experience and on various other assumptions that are believed to be
 reasonable, the results of which form the basis for making
 judgments about the carrying values of assets and liabilities.
 Actual results may differ from these estimates.</font></p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Revenue Recognition</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company sells Vascepa
 principally to a limited number of major wholesalers, as well as
 selected regional wholesalers and specialty pharmacy providers, or
 collectively, its Distributors, that in turn resell Vascepa to
 retail pharmacies for subsequent resale to patients and health care
 providers. Patients are required to have a prescription in order to
 purchase Vascepa. In accordance with GAAP, the Company&#x2019;s
 revenue recognition policy requires that: (i)&#xA0;there is
 persuasive evidence that an arrangement exists between the Company
 and the Distributor, (ii)&#xA0;delivery has occurred,
 (iii)&#xA0;collectability is reasonably assured and (iv)&#xA0;the
 price is fixed or determinable.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company commenced its
 commercial launch in the United States on January&#xA0;28, 2013.
 Prior to 2013, the Company recognized no revenue from Vascepa
 sales. In accordance with GAAP, until the Company has the ability
 to reliably estimate returns of Vascepa from its Distributors,
 revenue will be recognized based on the resale of Vascepa for the
 purposes of filling patient prescriptions, and not based on sales
 from the Company to such Distributors. Consistent with industry
 practice, once the Company achieves sufficient history such that it
 can reliably estimate returns, the Company will recognize revenue
 based on sales to its Distributors. The Company currently defers
 Vascepa revenue recognition until the earlier of the product being
 resold for purposes of filling patient prescriptions; or the
 expiration of the right of return (twelve months after the
 expiration date of the product). The Company also defers the
 related cost of product sales and records such amounts as finished
 goods inventory held by others until revenue related to such
 product sales is recognized.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company has contracts
 with its primary Distributors and delivery occurs when a
 Distributor receives Vascepa. The Company evaluates the
 creditworthiness of each of its Distributors to determine whether
 revenues can be recognized upon delivery, subject to satisfaction
 of the other requirements, or whether recognition is required to be
 delayed until receipt of payment or when the product is utilized.
 In order to conclude that the price is fixed or determinable, the
 Company must be able to (i)&#xA0;calculate its gross product
 revenues from the sales to Distributors and (ii)&#xA0;reasonably
 estimate its net product revenues. The Company calculates gross
 product revenues based on the wholesale acquisition cost that the
 Company charges its Distributors for Vascepa. The Company estimates
 its net product revenues by deducting from its gross product
 revenues (a)&#xA0;trade allowances, such as invoice discounts for
 prompt payment and distributor fees, (b)&#xA0;estimated government
 and private payor rebates, chargebacks and discounts, such as
 Medicaid reimbursements, (c)&#xA0;reserves for expected product
 returns and (d)&#xA0;estimated costs of incentives offered to
 certain indirect customers, including patients.</font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><i>Trade
 Allowances:</i> The Company generally provides invoice discounts on
 Vascepa sales to its Distributors for prompt payment and pays fees
 for distribution services, such as fees for certain data that
 Distributors provide to the Company. The payment terms for sales to
 Distributors generally include a 2% discount for payment within
 30&#xA0;days. Based on the Company&#x2019;s judgment and experience,
 the Company expects its Distributors to earn these discounts and
 fees, and deducts the full amount of these discounts and fees from
 its gross product revenues and accounts receivable at the time such
 revenues are recognized.</font></p>
 <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><i>Rebates,
 Chargebacks and Discounts:</i> The Company contracts with Medicaid,
 other government agencies and various private organizations, or
 collectively, Third-party Payors, so that Vascepa will be eligible
 for purchase by, or partial or full reimbursement from, such
 Third-party Payors. The Company estimates the rebates, chargebacks
 and discounts it will provide to Third-party Payors and deducts
 these estimated amounts from its gross product revenues at the time
 the revenues are recognized. The Company estimates the rebates,
 chargebacks and discounts that it will provide to Third-party
 Payors based upon (i)&#xA0;the Company&#x2019;s contracts with these
 Third-party Payors, (ii)&#xA0;the government-mandated discounts
 applicable to government-funded programs, (iii)&#xA0;information
 obtained from the Company&#x2019;s Distributors and
 (iv)&#xA0;information obtained from other third parties regarding
 the payor mix for Vascepa.</font></p>
 <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><i>Product
 Returns:</i> The Company&#x2019;s Distributors have the right to
 return unopened unprescribed Vascepa during the 18-month period
 beginning six months prior to the labeled expiration date and
 ending twelve months after the labeled expiration date. The
 expiration date for Vascepa is three years after it has been
 converted into capsule form, which is the last step in the
 manufacturing process for Vascepa and generally occurs within a few
 months before Vascepa is delivered to Distributors. As of
 September&#xA0;30, 2013, the Company had experienced a deminimus
 quantity of product returns. During the nine months ended
 September&#xA0;30, 2013, the period in which the Company began
 selling Vascepa, the Company was not able to reasonably estimate
 product returns for all product sold to Distributors but the
 Company was able to reasonably estimate product returns for certain
 sales of Vascepa based on product used to fill patient
 prescriptions as determined by inventory estimated to be in the
 distribution channel and third party reports of prescriptions
 filled. In making this assessment, the Company used (i)&#xA0;data
 provided to the Company by its Distributors (including weekly
 reporting of Distributors&#x2019; sales and inventory held by
 Distributors that provided the Company with visibility into the
 distribution channel in order to determine what quantities were
 sold to retail pharmacies and other providers),
 (ii)&#xA0;information provided to the Company from retail
 pharmacies, (iii)&#xA0;data provided to the Company by a third
 party data provider which collects and publishes prescription data,
 and other third parties, (iv)&#xA0;historical industry information
 regarding return rates for similar pharmaceutical products,
 (v)&#xA0;the estimated remaining shelf life of Vascepa previously
 shipped and currently being shipped to Distributors and
 (vi)&#xA0;contractual agreements intended to limit the amount of
 inventory maintained by the Company&#x2019;s
 Distributors.</font></p>
 <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><i>Other
 Incentives:&#xA0;</i>Other incentives that the Company offers to
 indirect customers include co-pay mitigation rebates provided by
 the Company to commercially insured patients who have coverage for
 Vascepa and who reside in states that permit co-pay mitigation
 programs. The Company&#x2019;s co-pay mitigation program is intended
 to reduce each participating patient&#x2019;s portion of the
 financial responsibility for Vascepa&#x2019;s purchase price to a
 specified dollar amount. Based upon the terms of the program and
 information regarding programs provided for similar specialty
 pharmaceutical products, the Company estimates the average co-pay
 mitigation amounts and the percentage of patients that it expects
 to participate in the program in order to establish its accruals
 for co-pay mitigation rebates and deducts these estimated amounts
 from its gross product revenues at the time the revenues are
 recognized. The Company&#x2019;s co-pay mitigation rebates offered
 to date will expire on December&#xA0;31, 2013. The Company adjusts
 its accruals for co-pay mitigation rebates based on its estimates
 regarding the portion of issued rebates that it estimates will not
 be redeemed. In addition, as is customary prior to the launch of
 new drugs, the Company provided certain of its Distributors with
 financial incentives to begin stocking Vascepa prior to the
 Company&#x2019;s commercial launch of Vascepa in order to ensure
 that Vascepa was readily available to fill patient prescriptions
 upon launch. Such incentives were only offered on purchases of
 initial launch quantities of Vascepa stocked by Distributors in
 January 2013. The amount of these financial incentives were
 recorded by the Company as a reduction to revenues on a pro-rata
 basis for each of the bottles subject to such financial incentives.
 The Company estimates that all of these initial launch quantities
 stocked by its primary Distributors in January 2013 were resold by
 such Distributors prior to September&#xA0;30, 2013.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The following table
 summarizes activity in each of the product revenue allowance and
 reserve categories described above for the nine months ended
 September&#xA0;30, 2013 (in thousands):</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Trade<br />
 Allowances</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Rebates,<br />
 Chargebacks<br />
 and&#xA0;Discounts</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Product<br />
 Returns</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Other<br />
 Incentives</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 January&#xA0;1, 2013</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Provision related to
 current period and deferred sales</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,839</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,418</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">72</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,018</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,347</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Credits/payments made for
 current period and deferred sales</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,951</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,484</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,835</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(5,270</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 September&#xA0;30, 2013</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>888</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>934</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>72</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>183</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2,077</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The following table
 summarizes product revenue recognized and deferred during the nine
 months ended September&#xA0;30, 2013 (in thousands):</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="14%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="14%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>September&#xA0;30,&#xA0;2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Product revenue
 recognized</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,245</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred product
 revenue</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,617</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>17,862</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">In conjunction with the
 Company&#x2019;s recognition and deferral of product revenues, the
 Company expensed and capitalized the associated cost of goods, as
 follows, during the nine months ended September&#xA0;30, 2013 (in
 thousands):</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="14%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="14%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>September&#xA0;30,&#xA0;2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cost of goods sold
 expensed</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,813</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Finished goods inventory
 held by others</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">641</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>8,454</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Cash
 and Cash Equivalents</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Cash and cash equivalents
 consist of cash, deposits held at call with banks and short term
 highly liquid instruments with remaining maturities at the date of
 purchase of 90&#xA0;days or less. Restricted cash represents cash
 and cash equivalents pledged to guarantee repayment of certain
 expenses which may be incurred for business travel under corporate
 credit cards held by employees.</font></p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Inventory</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company states
 inventories at the lower of cost or market value. Cost is
 determined based on actual cost using the average cost method. An
 allowance is established when management determines that certain
 inventories may not be saleable. If inventory cost exceeds expected
 market value due to obsolescence, damage or quantities in excess of
 expected demand, the Company will record a reserve for the
 difference between cost and market value. The Company received FDA
 approval for Vascepa on July&#xA0;26, 2012 and after that date
 began capitalizing inventory purchases of saleable product from
 approved suppliers. Until an API supplier is approved, all Vascepa
 API purchased from such supplier is included as a component of
 research and development expense. Upon sNDA approval of each
 additional supplier, the Company capitalizes subsequent Vascepa API
 purchases from such supplier as inventory. Purchases of Vascepa API
 received and expensed before such regulatory approvals is not
 subsequently capitalized, and all such purchases are quarantined
 and not used for commercial supply until such time as the sNDA for
 the supplier that produced the API is approved.</font></p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Intangible Asset, net</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Intangible assets consist
 of a milestone payment paid to the former shareholders of Laxdale
 Limited related to the 2004 acquisition of our rights to Vascepa,
 which is the result of Vascepa receiving marketing approval for the
 first indication and is amortized over its estimated useful life on
 a straight-line basis. The Company concluded that use of the
 straight-line method was appropriate as the majority of cash flows
 are expected to be generated ratably over the estimated useful life
 and no degradation of the cash flows over time is currently
 anticipated. See Note 7&#x2014;Commitments and Contingencies for
 further information regarding other obligations related to the
 acquisition of Laxdale Limited.</font></p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Deferred Revenue</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred revenue represents
 product shipments to Distributors for which the Company has
 invoiced the Distributors but not recognized revenue because the
 product was not reported to the Company as having been resold for
 the purpose of filling prescriptions on or before
 September&#xA0;30, 2013.</font></p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Research and Development Costs</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company charges
 research and development costs to operations as incurred. Research
 and development expenses are comprised of costs incurred by the
 Company in performing research and development activities,
 including salary and benefits; stock-based compensation expense;
 laboratory supplies and other direct expenses; contractual
 services, including clinical trial and pharmaceutical development
 costs; commercial supply investment in its drug candidates; and
 infrastructure costs, including facilities costs and depreciation
 expense. In addition, research and development costs include the
 costs of product supply received from suppliers when such receipt
 by the Company is prior to regulatory approval of the
 supplier.</font></p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Selling, General and Administrative
 Costs</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company charges sales,
 general and administrative costs to operations as incurred.
 Selling, general and administrative costs include costs of
 salaries, programs and infrastructure necessary for the general
 conduct of the Company&#x2019;s business, including the 2013
 commercial launch of Vascepa in the United States for the MARINE
 indication. Included as part of selling, general and administrative
 costs is warrant-related expense from non-cash changes in fair
 value of the derivative liability associated with warrants issued
 in October 2009 to former officers of Amarin which is recorded as
 compensation income (expense).</font></p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Income
 Taxes</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax assets and
 liabilities are recognized for the future tax consequences of
 differences between the carrying amounts and tax bases of assets
 and liabilities and operating loss carry-forwards and other
 attributes using enacted rates expected to be in effect when those
 differences reverse. Valuation allowances are provided against
 deferred tax assets that are not more likely than not to be
 realized.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company provides
 reserves for potential payments of tax to various tax authorities
 or does not recognize tax benefits related to uncertain tax
 positions and other issues. Tax benefits for uncertain tax
 positions are based on a determination of whether a tax benefit
 taken by the Company in its tax filings or positions is more likely
 than not to be realized, assuming that the matter in question will
 be decided based on its technical merits. The Company&#x2019;s
 policy is to record interest and penalties in the provision for
 income taxes.</font></p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Derivative Instruments</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Derivative financial
 liabilities are recorded at fair value, with gains and losses
 arising for changes in fair value recognized in the statement of
 operations at each period end while such instruments are
 outstanding. If the Company issues shares to discharge the
 liability, the derivative financial liability is derecognized and
 common stock and additional paid-in capital are recognized on the
 issuance of those shares. The warrants are valued using a
 Black-Scholes option pricing model due to the nature of the
 instrument. The long term debt redemption feature is valued using a
 probability-weighted model incorporating management estimates for
 potential change in control, and by determining the fair value of
 the debt with and without the change in control provision
 included.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">If the terms of warrants
 that initially require the warrant to be classified as a derivative
 financial liability lapse, the derivative financial liability is
 reclassified out of financial liabilities into equity at its fair
 value on that date. At the applicable settlement date, if the
 instruments are settled in shares, the carrying value of the
 warrants are derecognized and transferred to equity at their fair
 value at that date. The cash proceeds received from exercises of
 warrants are recorded in common stock and additional paid-in
 capital.</font></p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Loss
 per Share</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Basic net loss per share is
 determined by dividing net loss by the weighted average shares of
 common stock outstanding during the period. Diluted net loss per
 share is determined by dividing net loss by diluted weighted
 average shares outstanding. Diluted weighted average shares
 reflects the dilutive effect, if any, of potentially dilutive
 common shares, such as common stock options and warrants calculated
 using the treasury stock method and convertible notes using the
 &#x201C;if-converted&#x201D; method. In periods with reported net
 operating losses, all common stock options and warrants are deemed
 anti-dilutive such that basic net loss per share and diluted net
 loss per share are equal.</font></p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Debt
 Instruments</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Debt instruments are
 initially recorded at fair value, with coupon interest and
 amortization of debt issuance discounts recognized in the statement
 of operations as interest expense at each period end while such
 instruments are outstanding. If the Company issues shares to
 discharge the liability, the debt obligation is derecognized and
 common stock and additional paid-in capital are recognized on the
 issuance of those shares.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s
 exchangeable notes contain a conversion option which is classified
 as equity. The fair value of the liability component of the debt
 instrument was deducted from the initial proceeds to determine the
 proceeds to be allocated to the conversion option. The embedded
 conversion option is indexed to the Company&#x2019;s stock and
 treated as equity on the balance sheet. The conversion option is
 evaluated on a quarterly basis to determine if it still meets the
 criteria to be equity classified. The excess principal amount of
 the debt over the carrying value of the liability is amortized to
 interest expense over the term of the debt.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s
 December 2012 debt financing agreement contains a redemption
 feature triggered upon a change of control, which has been
 classified as an embedded derivative. The fair value of the
 derivative was recorded as a reduction to the fair value of the
 note payable. The fair value of this warrant derivative liability
 is remeasured at each reporting period, with changes in fair value
 recognized in the statement of operations. The discount recorded to
 the note payable is being amortized to interest expense over the
 term of the note payable.</font></p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Fair
 Value of Financial Instruments</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company provides
 disclosure of financial assets and financial liabilities that are
 carried at fair value based on the price that would be received
 upon sale of an asset or paid to transfer a liability in an orderly
 transaction between market participants at the measurement
 date.&#xA0;Fair value measurements may be classified based on the
 amount of subjectivity associated with the inputs to fair valuation
 of these assets and liabilities using the following three
 levels:</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Level 1&#x2014;Inputs are
 unadjusted quoted prices in active markets for identical assets or
 liabilities that the Company has the ability to access at the
 measurement date.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Level 2&#x2014;Inputs
 include quoted prices for similar assets and liabilities in active
 markets, quoted prices for identical or similar assets or
 liabilities in markets that are not active, inputs other than
 quoted prices that are observable for the asset or liability (i.e.,
 interest rates, yield curves, etc.) and inputs that are derived
 principally from or corroborated by observable market data by
 correlation or other means (market corroborated inputs).</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Level 3&#x2014;Unobservable
 inputs that reflect the Company&#x2019;s estimates of the
 assumptions that market participants would use in pricing the asset
 or liability.&#xA0;The Company develops these inputs based on the
 best information available, including its own data.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The following table
 presents information about the Company&#x2019;s assets and
 liabilities as of September&#xA0;30, 2013 and December&#xA0;31,
 2012 that are measured at fair value on a recurring basis and
 indicates the fair value hierarchy of the valuation techniques the
 Company utilized to determine such fair value:</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>September&#xA0;30,
 2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="1"><b><i>In millions</i></b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;1</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;2</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;3</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Asset:</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash
 equivalents&#x2014;money markets</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">113.5</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">113.5</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Liabilities:</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Warrant derivative
 liability</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">39.6</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">39.6</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term debt redemption
 feature</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.2</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.2</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign currency
 contracts</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.4</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.4</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,
 2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="1"><b><i>In millions</i></b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;1</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;2</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;3</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Asset:</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash
 equivalents&#x2014;money markets</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;64.1</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;64.1</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Liability:</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Warrant derivative
 liability</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">54.9</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">54.9</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term debt redemption
 feature</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14.6</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14.6</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The carrying amounts of
 cash, cash equivalents, accounts receivable, accounts payable and
 accrued liabilities approximate fair value because of their
 short-term nature.</font></p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Warrant Derivative Liability</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">At December&#xA0;31, 2012,
 the fair value of the warrant derivative liability was determined
 to be $54.9 million using the Black-Scholes option valuation model
 applying the following assumptions: (i)&#xA0;risk-free rate of
 0.25%, (ii)&#xA0;remaining term of 1.8 years, (iii)&#xA0;no
 dividend yield, (iv)&#xA0;volatility of 95% and (v)&#xA0;the stock
 price on the date of measurement.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">At September&#xA0;30, 2013,
 the fair value of the warrant derivative liability was determined
 to be $39.6 million using the Black-Scholes option valuation model
 applying the following assumptions: (i)&#xA0;risk-free rate of
 0.1%, (ii)&#xA0;remaining term of 1.0 year, (iii)&#xA0;no dividend
 yield, (iv)&#xA0;volatility of 91%, and (v)&#xA0;the stock price on
 the date of measurement.&#xA0;The $3.6 million increase in the fair
 value of the warrant liability during the three months ended
 September&#xA0;30, 2013 was recognized as: (i)&#xA0;a $3.3 million
 loss on change in fair value of the remaining derivative liability
 and (ii)&#xA0;$0.3 million in compensation expense for change in
 fair value of warrants issued to former employees. The $15.3
 million decrease in the fair value of the warrant liability during
 the nine months ended September&#xA0;30, 2013 was recognized as:
 (i)&#xA0;a $14.1 million gain on change in fair value of the
 remaining derivative liability and (ii)&#xA0;$1.2 million in
 compensation income for change in fair value of warrants issued to
 former employees. Both amounts are included in the consolidated
 statement of operations for the nine months ended
 September&#xA0;30, 2013.&#xA0;The fair value of this warrant
 liability is determined using the Black-Scholes option valuation
 model and is therefore sensitive to changes in the market price and
 volatility of the Company&#x2019;s common stock among other
 factors.&#xA0;In the event of a hypothetical 10% increase in the
 market price of the Company&#x2019;s common shares ($6.95 based on
 the $6.32 market price of the Company&#x2019;s stock at
 September&#xA0;30, 2013) on which the September&#xA0;30, 2013
 valuation was based, the value of the derivative liability would
 have increased by $5.0 million.&#xA0;Such increase would have been
 reflected as a loss on change in fair value of the warrant
 derivative liability in the Company&#x2019;s statement of
 operations. Significant increases (decreases) in this input in
 isolation would result in a significantly higher (lower) fair value
 asset measurement.</font></p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Long
 Term Debt Redemption Feature</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s
 December 2012 financing agreement with BioPharma Secured Debt Fund
 II Holdings Cayman, L.P, or BioPharma, contains a redemption
 feature whereby, upon a change of control, the Company would be
 required to pay $140 million, less any previously repaid amount, if
 the change of control occurs on or before December&#xA0;31, 2013,
 or required to repay $150 million, less any previously repaid
 amount, if the change of control event occurs after
 December&#xA0;31, 2013. The Company determined this redemption
 feature to be an embedded derivative, which is carried at fair
 value and is classified as Level 3 in the fair value hierarchy due
 to the use of significant unobservable inputs.&#xA0;The fair value
 of the embedded derivative was calculated using a
 probability-weighted model incorporating management estimates for
 potential change in control, and by determining the fair value of
 the debt with and without the change in control provision included.
 The difference between the two fair values of the debt was
 determined to be the fair value of the embedded derivative. At
 December&#xA0;31, 2012, the fair value of the derivative was
 determined to be $14.6 million, and the debt was valued by
 comparing debt issues of similar companies with (i)&#xA0;terms of
 between 4.8 and 8.0 years, (ii)&#xA0;coupon rates of between 3.0%
 and 11.5% and (iii)&#xA0;market yields of between 10.7% and 27.7%.
 At September&#xA0;30, 2013, the fair value of the derivative was
 determined to be $7.2 million, and the debt was valued by comparing
 debt issues of similar companies with (i)&#xA0;remaining terms of
 between 3.5 and 4.4 years, (ii)&#xA0;coupon rates of between 9.9%
 and 12.5% and (iii)&#xA0;market yields of between 10.4% and 25.8%.
 The Company recognized a gain of $1.4 million and $7.4 million on
 the change in fair value of this derivative liability for the three
 and nine months ended September&#xA0;30, 2013,
 respectively.</font></p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Foreign Currency</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">All subsidiaries use the
 United States dollar as the functional currency. Monetary assets
 and liabilities denominated in a foreign currency are remeasured
 into United States dollars at period-end exchange rates.
 Non-monetary assets and liabilities carried in a foreign currency
 are remeasured into United States dollars using rates of exchange
 prevailing when such assets or liabilities were obtained or
 incurred, and expenses are generally remeasured using rates of
 exchange prevailing when such expenses are incurred. Gains and
 losses from the remeasurement are included in other (expense)
 income, net in the consolidated statements of operations. For
 transactions settled during the applicable period, gains and losses
 are included in other (expense) income, net in the consolidated
 statements of operations. The Company periodically uses foreign
 exchange forward contracts to hedge against changes in exchange
 rates for inventory purchases denominated in foreign currency. As
 of&#xA0;September 30, 2013, the Company held one foreign exchange
 forward contract with a notional amount of $4.5 million. As
 of&#xA0;September 30, 2013, the outstanding foreign exchange
 forward contract derivative liability had a net fair value of $0.4
 million. The Company included this $0.4 million as a component of
 change in fair value of derivative liabilities and in other current
 liabilities at September&#xA0;30, 2013.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The change in the fair
 value of financial instruments is as follows (in
 thousands):</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>October</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>2009</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Warrants&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Debt</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Redemption&#xA0; &#xA0;</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Feature</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Foreign</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Exchange</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Contracts&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;&#xA0;&#xA0;Totals&#xA0;&#xA0;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 January&#xA0;1, 2012</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>123,125</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#x2014;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#x2014;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>123,125</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Loss on change in fair
 value of derivative liability</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">68,686</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">68,686</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Compensation expense for
 change in fair value of warrants issued to former
 employees</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,037</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,037</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Transfers to
 equity</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(103,885</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(103,885</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 September&#xA0;30, 2012</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>90,963</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#x2014;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#x2014;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>90,963</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>October</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>2009</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Warrants&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Debt</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Redemption&#xA0; &#xA0;</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Feature</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Foreign</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Exchange</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Contracts&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;&#xA0;&#xA0;Totals&#xA0;&#xA0;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 January&#xA0;1, 2013</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>54,854</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>14,577</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#x2014;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>69,431</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">(Gain) loss on change in
 fair value of derivative liabilities</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,077</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(7,377</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">395</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(21,059</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Compensation income for
 change in fair value of warrants issued to former
 employees</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,179</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,179</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Transfers to
 equity</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 September&#xA0;30, 2013</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>39,598</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>7,200</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>395</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>47,193</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Segment and Geographical
 Information</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">For the three and nine
 months ended September&#xA0;30, 2013 and 2012, the Company has
 reported its business as a single reporting segment. The
 Company&#x2019;s chief decision maker, who is the Chief Executive
 Officer, regularly evaluates the Company on a consolidated
 basis.</font></p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Recent
 Accounting Pronouncements</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">From time to time, new
 accounting pronouncements are issued by the Financial Accounting
 Standards Board, or FASB, and are adopted by the Company as of the
 specified effective date. The Company believes that the impact of
 recently issued but not yet adopted accounting pronouncements will
 not have a material impact on consolidated financial position,
 results of operations, and cash flows, or do not apply to the
 Company&#x2019;s operations.</font></p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrants and Warrant Derivative Liability<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Warrants and Warrant Derivative Liability</a></td>
        <td class="text"><div>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(5)</b></font></td>
 <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Warrants and Warrant
 Derivative Liability</b></font></td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company had 9,816,826
 warrants to purchase common shares outstanding at
 September&#xA0;30, 2013 at a weighted-average exercise price of
 $1.44, as summarized in the following table:</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="84%" align="center">
 <tr>
 <td style="WIDTH: 17pt"></td>
 <td></td>
 <td></td>
 <td style="WIDTH: 17pt"></td>
 <td valign="bottom" width="23%"></td>
 <td style="WIDTH: 14pt"></td>
 <td></td>
 <td></td>
 <td style="WIDTH: 14pt"></td>
 <td valign="bottom" width="23%"></td>
 <td style="WIDTH: 24pt"></td>
 <td></td>
 <td></td>
 <td style="WIDTH: 24pt"></td>
 <td valign="bottom" width="23%"></td>
 <td style="WIDTH: 27pt"></td>
 <td></td>
 <td></td>
 <td style="WIDTH: 27pt"></td>
 </tr>
 <tr>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Issue
 Date</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Amount</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Exercise&#xA0;Price</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Expiration&#xA0;Date</b></font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4/27/07</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17,500</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17.90</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1/17/14</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7/31/09</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,684,888</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.00</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7/30/14</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10/16/09</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,487,388</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.50</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10/15/14</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10/16/09</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">627,050</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.50</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10/15/14</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>9,816,826</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1.44</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><i><u>October
 2009 Warrant derivative liability</u></i></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">On October&#xA0;16, 2009,
 the Company completed a $70.0 million private placement with both
 existing and new investors resulting in $62.3 million in net
 proceeds and an additional $3.6 million from bridge notes converted
 in conjunction with the private placement. In consideration for the
 $62.3 million in net cash proceeds Amarin issued 66.4&#xA0;million
 units, each unit consisting of (i)&#xA0;one ADS (representing one
 ordinary share) at a purchase price of $1.00 and (ii)&#xA0;a
 warrant with a five year term to purchase 0.5 of an ADS at an
 exercise price of $1.50 per ADS. In consideration for the
 conversion of $3.6 million of convertible bridge notes, Amarin
 issued 4.0&#xA0;million units, each unit consisting of (i)&#xA0;one
 ADS (representing one ordinary share) at a purchase price of $0.90
 and (ii)&#xA0;a warrant with a five year term to purchase 0.5 of an
 ADS at an exercise price of $1.50 per ADS. The total number of
 warrants issued in conjunction with the financing was
 35.2&#xA0;million of which 7.5&#xA0;million are outstanding at
 September&#xA0;30, 2013.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">In conjunction with the
 October 2009 financing, the Company issued an additional
 0.9&#xA0;million warrants to three former officers of which
 0.6&#xA0;million are outstanding as of September&#xA0;30, 2013. The
 warrants issued in connection with the October 2009 financing
 contained a pricing variability feature which provided for an
 increase to the exercise price if the exchange rate between the
 U.S. dollar and British pound adjusts such that the warrants could
 be exercised at a price less than the &#xA3;0.5 par value of the
 common stock &#x2013; that is, if the exchange rate exceeded U.S.
 $3.00 per &#xA3;1.0 sterling. Due to the potential variable nature
 of the exercise price, the warrants are not considered to be
 indexed to the Company&#x2019;s common stock. Accordingly, the
 warrants do not qualify for the exception to classify the warrants
 within equity and are classified as a derivative
 liability.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The fair value of this
 warrant derivative liability is remeasured at each reporting
 period, with changes in fair value recognized in the statement of
 operations. Upon exercise, the fair value of the warrants exercised
 is remeasured and reclassified from warrant liability to additional
 paid-in capital. Although the warrants contain a pricing
 variability feature, the number of warrants issuable remains fixed.
 Therefore, the maximum number of common shares issuable as a result
 of the October 2009 private placement is 36.1 million. The change
 in fair value of the warrant derivative liability is discussed in
 Note 2.</font></p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><i><u>July 2009
 and April 2007 Warrants</u></i></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company issued certain
 warrants in July 2009 and April 2007. As of September&#xA0;30, 2013
 and December&#xA0;31, 2012 these warrants have been classified as
 equity instruments and have been included in the Company&#x2019;s
 consolidated balance sheet within additional paid-in-capital.
 During the nine months ended September&#xA0;30, 2013, 120,000 of
 the July 2009 warrants were exercised resulting in proceeds to the
 Company of $0.1 million.</font></p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5708775-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624163-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5708773-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 25<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41635-113959<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4H<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624258-113959<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5618551-113959<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668309&amp;loc=d3e80748-113994<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4E<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624181-113959<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668309&amp;loc=d3e80784-113994<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41620-113959<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4D<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624177-113959<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579245-113959<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5580258-113959<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579240-113959<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41641-113959<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41638-113959<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Asset<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Asset</a></td>
        <td class="text"><div>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(3)</b></font></td>
 <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Intangible
 Asset</b></font></td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Intangible asset consists
 of technology rights for Vascepa and have an estimated remaining
 useful life of 16.8 years. The carrying value as of
 September&#xA0;30, 2013 and December&#xA0;31, 2012 is as follows
 (in thousands):</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>September&#xA0;30,&#xA0;2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Technology
 rights</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,624</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,624</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Accumulated
 amortization</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(754</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(269</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,870</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,355</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all or part of the information related to intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Asset - Additional Information (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_IntangibleAssetsDisclosureLineItems', window );"><strong>Intangible Assets Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets estimated remaining useful life</a></td>
        <td class="text">16 years 9 months 18 days<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_IntangibleAssetsDisclosureLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_IntangibleAssetsDisclosureLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETIBI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrants and Warrant Derivative Liability - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Warrants Issued July 2009</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2009

</div>
          <div>October 2009 Private Placement</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>October 2009 Private Placement

</div>
          <div>Warrants issued to three former officers</div>
        </th>
        <th class="th">
          <div>Oct. 16, 2009

</div>
          <div>October 2009 Private Placement

</div>
          <div>Warrants issued to three former officers</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2009

</div>
          <div>October 2009 Private Placement

</div>
          <div>Bridge Loan</div>
        </th>
        <th class="th">
          <div>Oct. 16, 2009

</div>
          <div>October 2009 Private Placement

</div>
          <div>Bridge Loan</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>October 2009 Private Placement

</div>
          <div>Warrants Issued October 2009</div>
        </th>
        <th class="th">
          <div>Oct. 16, 2009

</div>
          <div>October 2009 Private Placement

</div>
          <div>Warrants Issued October 2009</div>
        </th>
        <th class="th">
          <div>Oct. 16, 2009

</div>
          <div>October 2009 Private Placement

</div>
          <div>Warrants Issued October 2009

</div>
          <div>American Depositary Share</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>October 2009 Private Placement

</div>
          <div>Warrants Issued October 2009

</div>
          <div>Maximum</div>
        </th>
        <th class="th">
          <div>Oct. 16, 2009

</div>
          <div>October 2009 Private Placement

</div>
          <div>Warrants Issued October 2009

</div>
          <div>Bridge Loan

</div>
          <div>American Depositary Share</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant outstanding</a></td>
        <td class="nump">9,816,826<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise Price</a></td>
        <td class="nump">1.44<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.50<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued under private placement, value</a></td>
        <td class="nump">$ 121,206,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 70,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Common stock issued under private placement, net proceeds</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">62,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Bridge notes converted in conjunction with the private placement, amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued under private placement, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">66,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_AmericanDepositorySharesToSharesRatio', window );">Number of shares that each ADS represents</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Common stock issued under private placement, price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ClassOfWarrantOrRightTerm', window );">Warrant term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued, number of shares called by the warrant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.5<span></span></td>
        <td class="nump">36,100,000<span></span></td>
        <td class="nump">0.5<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Bridge notes converted in conjunction with the private placement, price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.90<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">35,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeDescriptionOfHostContract', window );">Description of pricing variability feature and classification of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The warrants issued in connection with the October 2009 financing contained apricing variability feature which provided for an increase to the exercise priceif the exchange rate between the U.S. dollar and British pound adjusts such thatthe warrants could be exercised at a price less than the 0.5 par value of thecommon stock - that is, if the exchange rate exceeded U.S. $3.00 per 1.0sterling. Due to the potential variable nature of the exercise price, thewarrants are not considered to be indexed to the Company's common stock.Accordingly, the warrants do not qualify for the exception to classify thewarrants within equity and are classified as a derivative liability.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ClassOfWarrantOrRightExercisedInPeriod', window );">Warrants exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">120,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceed from exercise of warrants</a></td>
        <td class="nump">$ 120,000<span></span></td>
        <td class="nump">$ 16,526,000<span></span></td>
        <td class="nump">$ 100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_AmericanDepositorySharesToSharesRatio">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>American Depository Shares to Shares Ratio</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_AmericanDepositorySharesToSharesRatio</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ClassOfWarrantOrRightExercisedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class of Warrant or Right, Exercised in Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_ClassOfWarrantOrRightExercisedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ClassOfWarrantOrRightIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class of Warrant or Right, Issued</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_ClassOfWarrantOrRightIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ClassOfWarrantOrRightTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class of Warrant or Right, Term</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_ClassOfWarrantOrRightTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionOriginalDebtAmount1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleConversionPrice1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeDescriptionOfHostContract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Identification of the host contract (such as a debt instrument, lease, an agreement to settle payments in other than the functional currency), description of the terms of the contract, and discussion of a hybrid instrument with an embedded feature which is separated from the host contract and accounted for as a derivative.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 15<br><br> -Section 25<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7659996&amp;loc=d3e48542-113965<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 15<br><br> -Section 25<br><br> -Paragraph 54<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7659996&amp;loc=d3e49467-113965<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmbeddedDerivativeDescriptionOfHostContract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuancePerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityIssuancePerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPrivatePlacement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) (Subsequent Event, USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Oct. 22, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Subsequent Event</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Staff reduction in force, approximate percentage</a></td>
        <td class="nump">50.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost', window );">Cost due to staff reduction in force</a></td>
        <td class="nump">$ 3<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount expected to be recognized in earnings for the specified restructuring cost.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB Topic 5.P.4(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringAndRelatedCostExpectedCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>31
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O
M;G-O;&ED871E9%]"86QA;F-E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O;G-O;&ED871E9%]"86QA;F-E,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E
M9%]#;VYS;VQI9&%T961?4W1A=&5M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M
M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VYD
M96YS961?0V]N<V]L:61A=&5D7U-T871E;64R/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^3F%T=7)E7V]F7T)U<VEN97-S7V%N9%]"
M87-I<U]O/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4VEG;FEF:6-A;G1?06-C;W5N=&EN9U]0;VQI8VEE/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YT86YG:6)L95]!<W-E=#PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN=F5N=&]R>3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E=A<G)A;G1S
M7V%N9%]787)R86YT7T1E<FEV871I=CPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D1E8G0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N=&EN9V5N8VEE<SPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D5Q=6ET>3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U8G-E<75E
M;G1?179E;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^4VEG;FEF:6-A;G1?06-C;W5N=&EN9U]0;VQI8VEE,3PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-I9VYI9FEC86YT7T%C8V]U
M;G1I;F=?4&]L:6-I93(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3<N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y);G1A;F=I8FQE7T%S<V5T7U1A8FQE<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q
M."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN=F5N=&]R>5]486)L97,\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y787)R86YT<U]A
M;F1?5V%R<F%N=%]$97)I=F%T:78Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3F%T=7)E7V]F7T)U<VEN97-S7V%N9%]"87-I<U]O
M,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-I9VYI
M9FEC86YT7T%C8V]U;G1I;F=?4&]L:6-I93,\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C(N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM87)I>F5S7T%C=&EV:71Y7V]F7W1H
M95]0<F\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,C,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0
M<F]D=6-T7U)E=F5N=65?4F5C;V=N:7IE9%]A;F0\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C0N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#87!I=&%L:7IE9%]A;F1?17AP96YS
M961?1&5T86D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,C4N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y!<W-E='-?86YD7TQI86)I;&ET>5]-96%S=7)E9%\\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,C8N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#:&%N9V5?:6Y?1F%I<E]686QU
M95]O9E]&:6YA;F,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,C<N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y);G1A;F=I8FQE7T%S<V5T7T%D9&ET:6]N86Q?26X\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,C@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#87)R>6EN9U]686QU95]O
M9E]);G1A;F=I8FQE7T$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,CDN:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y);G9E;G1O<GE?1&5T86EL/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,P+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^26YV96YT;W)Y7T%D9&ET:6]N86Q?26YF;W)M
M871I/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#,Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^5V%R
M<F%N='-?86YD7U=A<G)A;G1?1&5R:79A=&EV,CPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,BYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E=A<G)A;G1S7W1O7U!U<F-H87-E7T-O
M;6UO;E]3:#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970S,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/D1E8G1?061D:71I;VYA;%]);F9O<FUA=&EO;E]$93PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S
M-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT
M:6YG96YC:65S7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D5Q=6ET>5]!9&1I=&EO;F%L7TEN9F]R;6%T:6]N7SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970S-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U8G-E<75E;G1?179E;G1S
M7T%D9&ET:6]N86Q?23PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-RYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX
M.E-T>6QE<VAE970@2%)E9CTS1")7;W)K<VAE971S+W)E<&]R="YC<W,B+SX-
M"B`@/'@Z06-T:79E4VAE970^,#PO>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O
M=&5C=%-T<G5C='5R93Y&86QS93PO>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\
M>#I0<F]T96-T5VEN9&]W<SY&86QS93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\
M+W@Z17AC96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D
M/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D
M('=I=&@@36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4P9CAE,64X7S(V
M-F1?-&)F-%]A.#DV7S-C93DX8V8U-6%A-@T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]E,&8X93%E.%\R-C9D7S1B9C1?83@Y-E\S8V4Y.&-F-35A
M838O5V]R:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5$Q!13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN9F]R
M;6%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3F]V+B`P
M,2P@,C`Q,SQB<CY/<F1I;F%R>2!3:&%R97,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^3F]V+B`P,2P@,C`Q,SQB<CY!;65R:6-A;B!$97!O
M<VET;W)Y(%-H87)E<SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY$;V-U;65N="!);F9O<FUA=&EO;B!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&]C=6UE;G0@5'EP93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)S$P+5$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06UE;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B=F86QS93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!097)I;V0@16YD($1A
M=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E-E<"`S,"P-"@D)
M,C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S(P,3,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L
M(%!E<FEO9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)U$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1R861I;F<@4WEM8F]L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG04U23CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4F5G:7-T<F%N="!.86UE/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG04U!4DE.($-/4E`@4$Q#7%5+
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N=&ET>2!#96YT<F%L($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)S`P,#`X.3<T-#@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@
M665A<B!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)RTM,3(M,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A=&5G;W)Y/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG3&%R9V4@06-C96QE<F%T960@1FEL97(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8X+#4T-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W,BPQ.34L
M-#8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14\T04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]N9&5N<V5D($-O;G-O
M;&ED871E9"!"86QA;F-E(%-H965T<R`H55-$("0I/&)R/DEN(%1H;W5S86YD
M<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N
M="!!<W-E=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,C4L.#@U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-C`L,C0R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T
M<FEC=&5D(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C;W5N=',@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPW,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O<GDL(&YE=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L,#@S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L,C8R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!T
M87@@87-S970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L-3,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPR-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&%S<V5T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8R+#4V,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X-2PV.30\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;W!E<G1Y+"!P;&%N="!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8T-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Q,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@=&%X(&%S
M<V5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PT,S,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#`T
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W1H97(@;F]N+6-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU+#,S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0L.34Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1A;F=I8FQE(&%S<V5T+"!N
M970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#@W,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#,U
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1/5$%,($%34T544SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,CDS+#@T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,Q,"PX-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!,:6%B:6QI=&EE
M<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV+#(S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$W+#0U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!I;G1E<F5S="!P87EA8FQE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PY,#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4R,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F
M97)R960@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PV,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!8V-R=65D(&5X<&5N<V5S(&%N9"!O=&AE<B!L:6%B:6QI=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L-30X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PR,C0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!C=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,2PR.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR-2PR,#(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&]N9RU497)M
M($QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5X8VAA;F=E86)L92!S96YI;W(@;F]T97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-2PS,38\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S0L,C4P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;VYG
M+71E<FT@9&5B=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#<L
M,S$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#4L,34S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/=&AE<B!L;VYG+71E<FT@;&EA8FEL:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Q,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Q-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q,2PU-#,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,30L.#4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM:71M96YT<R!A;F0@8V]N=&EN9V5N8VEE<R`H3F]T92`W
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!$969I8VET
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S=&]C:RP@)B-X83,[,"XU,"!P87(@=F%L=64L('5N;&EM:71E
M9"!A=71H;W)I>F5D.R`Q-S(L-C8T+#`Q,R!I<W-U960L(#$W,BPV-#,L.3,T
M(&]U='-T86YD:6YG(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,SL@,34P+#,V,"PY
M,S,@:7-S=65D+"`Q-3`L,S0P+#@U-"!O=71S=&%N9&EN9R!A="!$96-E;6)E
M<B`S,2P@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30Q
M+#0U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$R-"PU.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<&%I9"UI;B!C87!I=&%L/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,SDL-3(T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$Y+#(V-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')E
M87-U<GD@<W1O8VL[(#(P+#`W.2!S:&%R97,@870@4V5P=&5M8F5R(#,P+"`R
M,#$S(&%N9"!$96-E;6)E<B`S,2P@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,C$W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(Q-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&1E9FEC:70\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@Y."PT-3DI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S0W+#8T,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!S=&]C:VAO;&1E<G,G(&1E9FEC:70\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$W+#8Y-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#DY-RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y43U1!3"!,24%"24Q)
M5$E%4R!!3D0@4U1/0TM(3TQ$15)3)R!$149)0TE4/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR.3,L.#0V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$P+#@U-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&]N9RU4
M97)M($QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I=F4@;&EA8FEL:71Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.2PU.3@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-"PX-30\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO;F<@5&5R
M;2!$96)T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY,;VYG+51E<FT@3&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV92!L:6%B:6QI
M='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RPR,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$T
M+#4W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M93!F.&4Q93A?,C8V9%\T8F8T7V$X.39?,V-E.3AC9C4U86$V#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4P9CAE,64X7S(V-F1?-&)F-%]A.#DV
M7S-C93DX8V8U-6%A-B]7;W)K<VAE971S+U-H965T,#,N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5#14%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;F1E;G-E9"!#;VYS
M;VQI9&%T960@0F%L86YC92!3:&5E=',@*%!A<F5N=&AE=&EC86PI("A'0E`@
M)B-X83,[*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XF(WAA,SL@,"XU/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)B-X83,[(#`N-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N('-T;V-K+"!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$W,BPV-C0L,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,34P+#,V,"PY,S,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@
M;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W
M,BPV-#,L.3,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,34P+#,T,"PX-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R96%S=7)Y('-T;V-K+"!S:&%R97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#`W.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#`W.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93!F.&4Q
M93A?,C8V9%\T8F8T7V$X.39?,V-E.3AC9C4U86$V#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V4P9CAE,64X7S(V-F1?-&)F-%]A.#DV7S-C93DX
M8V8U-6%A-B]7;W)K<VAE971S+U-H965T,#0N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-1D%'
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;F1E;G-E9"!#;VYS;VQI9&%T
M960@4W1A=&5M96YT<R!O9B!/<&5R871I;VYS("A54T0@)"D\8G(^26X@5&AO
M=7-A;F1S+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S
M<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;V1U8W0@<F5V96YU97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@."PT,#,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-BPR-#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D]P97)A=&EN9R!%>'!E;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O<W0@;V8@9V]O9',@<V]L9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPV.#(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPX,3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E
M87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$V+#@R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(P+#DQ,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4V+#$T.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y+#<S-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5L;&EN9RP@9V5N
M97)A;"!A;F0@861M:6YI<W1R871I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(X+#(W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$S+#,Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,2PU,#(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,2PP-3D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O
M<&5R871I;F<@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0X+#<W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,T+#,Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$V-2PT-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,"PW.30\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<&5R871I;F<@;&]S
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#`L,S<T*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,T+#,Q
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q-#DL,C$X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#@P+#<Y-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/BA,;W-S*2!G86EN(&]N(&-H86YG92!I;B!F
M86ER('9A;'5E(&]F(&1E<FEV871I=F4@;&EA8FEL:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-#`R*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#0U-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#`U.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8X+#8X
M-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DEN=&5R97-T(&5X<&5N<V4L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH."PT-#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-"PU-S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C8L-C0V*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$R+#@S."D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R
M("AE>'!E;G-E*2!I;F-O;64L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,S`R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#0R-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@X,S@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-#$Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@9G)O;2!O<&5R871I
M;VYS(&)E9F]R92!I;F-O;64@=&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#4P+#4Q.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R,BPX-3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,34U+#8T,RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-C(L-S(Y*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5N
M969I="!F<F]M("AP<F]V:7-I;VX@9F]R*2!I;F-O;64@=&%X97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C,U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPU-S,I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PX,C<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#@X
M."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@T."PX.#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@R-BPT,C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@Q-3`L.#$V*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,38X+#8Q-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^3&]S<R!P97(@<VAA<F4Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I8R!A;F0@9&EL=71E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C(Y*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XQ."D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N.38I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@Q+C$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY796EG:'1E9"!A=F5R86=E('-H87)E<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A
M<VEC(&%N9"!D:6QU=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-S`L,3@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,30Y+#(P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$U-RPQ,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#$L.30W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15<Q0TD^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0Q/CQS=')O;F<^0V]N9&5N<V5D($-O;G-O;&ED871E9"!3=&%T96UE;G1S
M(&]F($-H86YG97,@:6X@1&5F:6-I="`H55-$("0I/&)R/DEN(%1H;W5S86YD
M<RP@97AC97!T(%-H87)E(&1A=&$\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y4;W1A;#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y#;VUM;VX@4VAA<F5S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D%D9&ET:6]N86P@4&%I9"UI;B!#87!I=&%L/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E1R96%S=7)Y('-T;V-K/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%C8W5M=6QA=&5D($1E9FEC
M:70\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN
M;FEN9R!"86QA;F-E(&%T($1E8RX@,S$L(#(P,3$\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H-2PY-C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,3,L,S(Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T-#DL,SDS/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R
M,3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@U-C@L-#4Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG($)A;&%N8V4@*&EN('-H87)E<RD@
M870@1&5C+B`S,2P@,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$S-2PX,S(L-30R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!O9B!W87)R86YT<R`H:6X@
M<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L.#@Q
M+#(W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P+#@X,2PR-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F('=A<G)A;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPU,C8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#0P-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,3$Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E9E<W1I;F<@;V8@<F5S=')I8W1E9"!S=&]C:R!U;FET<R`H:6X@<VAA<F5S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDW+#,Y.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5')A;G-F97(@;V8@9F%I<B!V86QU92!O9B!W87)R86YT<R!E>&5R8VES960@
M9G)O;2!L:6%B:6QI=&EE<R!T;R!E<75I='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P,RPX.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`S+#@X-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y697-T:6YG(&]F(')E
M<W1R:6-T960@<W1O8VL@=6YI=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#<V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)S:6]N(&]P=&EO;B!C;VYT86EN960@
M:6X@97AC:&%N9V5A8FQE(&YO=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,BPX.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C(L.#DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F('-T;V-K(&]P
M=&EO;G,@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L,3`W+#DQ,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L,3`W+#DQ,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@;V8@<W1O8VL@
M;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPX,S0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#0S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4L,SDU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1A>"!B96YE9FET<R!R96%L:7IE9"!F<F]M('-T;V-K
M+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`L,3`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P+#$P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92!I<W-U960@9F]R('-E<G9I
M8V5S("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPR.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U960@9F]R('-E<G9I8V5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E
M9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$S+#,T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,RPS-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&]S<R!F;W(@=&AE('!E<FEO9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,38X+#8Q-RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-C@L-C$W*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YD:6YG($)A;&%N8V4@870@4V5P+B`S,"P@,C`Q,CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,C0L,C0T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$S+#`X-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W,S<L,#<V
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16YD:6YG($)A;&%N8V4@*&EN('-H87)E<RD@870@4V5P+B`S,"P@,C`Q
M,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T.2PY,C$L-#(R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y"96=I;FYI;F<@0F%L86YC92!A="!$96,N(#,Q+"`R,#$R/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#DY-RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C0L-3DW/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$Y+#(V
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(Q-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@W-#<L-C0S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG($)A;&%N8V4@*&EN('-H87)E<RD@
M870@1&5C+B`S,2P@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$U,"PS-C`L.3,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!I<W-U960@:6X@97%U:71Y(&9I
M;F%N8VEN9R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(Q+#<P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5E9"!I;B!E<75I='D@
M9FEN86YC:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C$L
M,C`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,38L-#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`T+#@P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!O9B!W87)R86YT<R`H:6X@
M<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$R,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F('=A<G)A;G1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9E<W1I;F<@;V8@<F5S
M=')I8W1E9"!S=&]C:R!U;FET<R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDS+#`T.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F5S=&EN9R!O9B!R97-T
M<FEC=&5D('-T;V-K('5N:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@W,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N<R`H:6X@
M<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@V+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,X-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F('-T;V-K(&]P=&EO;G,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,S-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y487@@8F5N
M969I=',@<F5A;&EZ960@9G)O;2!S=&]C:RUB87-E9"!C;VUP96YS871I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDV-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-C8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA
M<F4@:7-S=65D(&9O<B!S97)V:6-E<R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,#,R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@:7-S=65D
M(&9O<B!S97)V:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PQ-S`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30L,3<P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@9F]R
M('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$U
M,"PX,38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,34P+#@Q-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E(&%T(%-E<"X@,S`L
M(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3<L-CDW
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,30Q+#0U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-S,Y+#4R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,C$W*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H.#DX+#0U.2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"
M86QA;F-E("AI;B!S:&%R97,I(&%T(%-E<"X@,S`L(#(P,3,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S(L-C8T+#`Q,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93!F.&4Q93A?,C8V
M9%\T8F8T7V$X.39?,V-E.3AC9C4U86$V#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V4P9CAE,64X7S(V-F1?-&)F-%]A.#DV7S-C93DX8V8U-6%A
M-B]7;W)K<VAE971S+U-H965T,#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$513D)'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D-O;F1E;G-E9"!#;VYS;VQI9&%T960@4W1A
M=&5M96YT<R!O9B!#87-H($9L;W=S("A54T0@)"D\8G(^26X@5&AO=7-A;F1S
M+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#05-(($9,3U=3($923TT@
M3U!%4D%424Y'($%#5$E6251)15,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,34P+#@Q-BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$V."PV,3<I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D%D:G5S=&UE;G1S('1O(')E8V]N8VEL92!N970@;&]S<R!T;R!N970@8V%S
M:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!A
M;F0@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E<R!I<W-U960@9F]R('-E<G9I8V5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&-E<W,@=&%X(&)E;F5F
M:70@9G)O;2!S=&]C:RUB87-E9"!A=V%R9',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#DV-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q,"PQ,#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&EN=&5R97-T('!A
M>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,S@Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP
M.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%M;W)T:7IA=&EO;B!O9B!I;G1A;F=I8FQE(&%S<V5T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.#4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA=&EO;B!O
M9B!D96)T(&1I<V-O=6YT(&%N9"!D96)T(&ES<W5A;F-E(&-O<W1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPR,S(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#,V-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R
M960@:6YC;VUE('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@V+#,X.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#:&%N9V4@:6X@;&5A<V4@;&EA8FEL:71Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-34I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XH1V%I;BD@;&]S<R!O;B!C
M:&%N9V4@:6X@9F%I<B!V86QU92!O9B!D97)I=F%T:79E(&QI86)I;&ET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,2PP-3DI/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C@L-C@V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-H86YG97,@:6X@87-S971S(&%N9"!L:6%B:6QI=&EE<SH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M97-T<FEC=&5D(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$L-#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#,L-S(Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-2PX,C$I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PY.#DI/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!C=7)R
M96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C@S
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(L,C<S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W1H97(@;F]N+6-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@S.#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<L,S4U*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y
M86)L92P@86-C<G5E9"!E>'!E;G-E<R!A;F0@;W1H97(@;&EA8FEL:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-S$T*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,S+#`W-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,34W+#(U-2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W."PU,SDI/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D-!4T@@1DQ/5U,@1E)/32!)3E9%4U1)3D<@04-4259)5$E%4SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C
M:&%S92!O9B!L;VYG+71E<FT@:6YV97-T;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$L,C,X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V5S(&]F(&5Q=6EP;65N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,30I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#<W*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!C87-H('5S960@:6X@:6YV97-T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-S$U*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#05-(
M($9,3U=3($923TT@1DE.04Y#24Y'($%#5$E6251)15,Z/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O
M;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O8VLL(&YE="!O9B!T<F%N<V%C=&EO
M;B!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(Q+#(P
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R;V-E961S(&9R;VT@97AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N<RP@
M;F5T(&]F('1R86YS86-T:6]N(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW+#@S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!E>&5R8VES92!O
M9B!W87)R86YT<RP@;F5T(&]F('1R86YS86-T:6]N(&-O<W1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPU,C8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X8V5S<R!T87@@
M8F5N969I="!F<F]M('-T;V-K+6)A<V5D(&%W87)D<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.38V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,3`V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&ES
M<W5A;F-E(&]F(&5X8VAA;F=E86)L92!D96)T+"!N970@;V8@=')A;G-A8W1I
M;VX@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#0L
M,S$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y087EM96YT<R!U;F1E<B!C87!I=&%L(&QE87-E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!P<F]V:61E
M9"!B>2!F:6YA;F-I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3(R+#DQ,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$W."PW-C(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.150@*$1%0U)%05-%*2!)
M3D-214%312!)3B!#05-(($%.1"!#05-(($5154E604Q%3E13/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-"PS-3<I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3@L-3`X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#05-(($%.
M1"!#05-(($5154E604Q%3E13+"!"14=)3DY)3D<@3T8@4$5224]$/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C`L,C0R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$V+#8P,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0T%3
M2"!!3D0@0T%32"!%455)5D%,14Y44RP@14Y$($]&(%!%4DE/1#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(U+#@X-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q-2PQ,3`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0V%S:"!P86ED(&1U<FEN9R!T:&4@>65A<B!F;W(Z/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,C4P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPW,3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M
M92!T87AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS.34\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3F]N+6-A<V@@=')A;G-A8W1I;VYS.CPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R86YS9F5R(&9R
M;VT@9&5R:79A=&EV92!L:6%B:6QI='D@=&\@97%U:71Y+"!F86ER('9A;'5E
M(&]F('=A<G)A;G1S(&5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P,RPX.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@86YD(%)E<W1R:6-T960@4W1O
M8VL@56YI=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D%D:G5S=&UE;G1S('1O(')E8V]N8VEL92!N970@;&]S<R!T;R!N
M970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A
M<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,30L,3<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3,L,S0T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!9&IU<W1M96YT<R!T;R!R96-O;F-I
M;&4@;F5T(&QO<W,@=&\@;F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T
M:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,2PQ-SDI/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#`S-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93!F.&4Q93A?,C8V9%\T
M8F8T7V$X.39?,V-E.3AC9C4U86$V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V4P9CAE,64X7S(V-F1?-&)F-%]A.#DV7S-C93DX8V8U-6%A-B]7
M;W)K<VAE971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY.871U<F4@;V8@0G5S:6YE<W,@86YD($)A<VES(&]F
M(%!R97-E;G1A=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.871U<F4@;V8@0G5S:6YE<W,@86YD($)A<VES(&]F(%!R97-E
M;G1A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^
M#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G
M(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#$P,"4^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0T)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^*#$I/"]B/CPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/CQB/DYA='5R92!O9B!"=7-I;F5S<R!A;F0-"B!"87-I<R!O9B!0<F5S96YT
M871I;VX\+V(^/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@,'!X
M.R!-05)'24XM3$5&5#H@,B4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/CQU/DYA='5R
M90T*(&]F($)U<VEN97-S/"]U/CPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`V<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^06UA<FEN($-O<G!O<F%T:6]N('!L8RP-"B`F(W@R,#%#.T%M
M87)I;B8C>#(P,40[(&]R('1H92`F(W@R,#%#.T-O;7!A;GDF(W@R,#%$.RP@
M:7,@82!P=6)L:6,-"B!L:6UI=&5D(&-O;7!A;GD@=VET:"!I=',@<')I;6%R
M>2!S=&]C:R!M87)K970@;&ES=&EN9R!I;B!T:&4@56YI=&5D#0H@4W1A=&5S
M(&]N('1H92!.05-$05$@1VQO8F%L($UA<FME="X@06UA<FEN('=A<R!O<FEG
M:6YA;&QY#0H@:6YC;W)P;W)A=&5D(&EN($5N9VQA;F0@87,@82!P<FEV871E
M(&QI;6ET960@8V]M<&%N>2!O;@T*($UA<F-H)B-X03`[,2P@,3DX.2!U;F1E
M<B!T:&4@0V]M<&%N:65S($%C="`Q.3@U+"!A;F0@<F4M<F5G:7-T97)E9`T*
M(&EN($5N9VQA;F0@87,@82!P=6)L:6,@;&EM:71E9"!C;VUP86YY(&]N($UA
M<F-H)B-X03`[,3DL#0H@,3DY,RX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[($U!4D=)
M3BU"3U143TTZ(#!P>"<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^06UA<FEN(&ES(&$-"B!B:6]P
M:&%R;6%C975T:6-A;"!C;VUP86YY('=I=&@@97AP97)T:7-E(&EN(&QI<&ED
M('-C:65N8V4@9F]C=7-E9`T*(&]N('1H92!C;VUM97)C:6%L:7IA=&EO;B!A
M;F0@9&5V96QO<&UE;G0@;V8@=&AE<F%P975T:6-S('1O(&EM<')O=F4-"B!C
M87)D:6]V87-C=6QA<B!H96%L=&@N($]N($IU;'DF(WA!,#LR-BP@,C`Q,BP@
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M,"XX97@[(%9%4E1)0T%,+4%,24=..B!B87-E;&EN92<^)B-X044[/"]S=7`^
M/"]F;VYT/@T*("AI8V]S87!E;G0@971H>6PI(&-A<'-U;&5S("AF;W)M97)L
M>2!K;F]W;B!A<R!!35(@,3`Q*2!A<R!A;@T*(&%D:G5N8W0@=&\@9&EE="!T
M;R!R961U8V4@=')I9VQY8V5R:61E(&QE=F5L<R!I;B!A9'5L="!P871I96YT
M<PT*('=I=&@@<V5V97)E("A41R`\=3XF9W0[/"]U/C4P,&UG+V1,*2!H>7!E
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M.S(X+"`R,#$S+"!T:&4@0V]M<&%N>2!C;VUM96YC960@:71S(&9U;&P@8V]M
M;65R8VEA;`T*(&QA=6YC:"!O9B!687-C97!A(&EN('1H92!5;FET960@4W1A
M=&5S(&9O<B!U<V4@:6X@=&AE($U!4DE.10T*(&EN9&EC871I;VXN/"]F;VYT
M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'24XM
M0D]45$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/D%M87)I;B!I<R!A;'-O(&1E=F5L;W!I
M;F<-"B!687-C97!A(&9O<B!T:&4@=')E871M96YT(&]F('!A=&EE;G1S('=I
M=&@@:&EG:"!T<FEG;'EC97)I9&4@;&5V96QS#0H@*%1'(#QU/B9G=#L\+W4^
M,C`P(&UG+V1,(&%N9"`F;'0[-3`P(&UG+V1,*2!W:&\@87)E(&%L<V\@;VX@
M<W1A=&EN#0H@=&AE<F%P>2!F;W(@96QE=F%T960@3$1,+4,@;&5V96QS+B!4
M:&ES(&EN9&EC871I;VX@:7,@<F5F97)R960@=&\-"B!A<R!M:7AE9"!D>7-L
M:7!I9&5M:6$@;W(@=&AE($%.0TA/4B!I;F1I8V%T:6]N+B!);B!&96)R=6%R
M>2`R,#$S+`T*('1H92!#;VUP86YY('-U8FUI='1E9"!A('-U<'!L96UE;G1A
M;"!.97<@1')U9R!!<'!L:6-A=&EO;BP@;W(@<TY$02P-"B!T;R!T:&4@1D1!
M('-E96MI;F<@87!P<F]V86P@;V8@5F%S8V5P82!F;W(@=&AE($%.0TA/4B!I
M;F1I8V%T:6]N+@T*($]N($]C=&]B97(F(WA!,#LQ-BP@,C`Q,RP@=&AE($9$
M02!C;VYV96YE9"!A;B!A9'9I<V]R>2!C;VUM:71T964@=&\-"B!R979I97<@
M=&AE($-O;7!A;GDF(W@R,#$Y.W,@<TY$02!F;W(@=&AE($%.0TA/4B!I;F1I
M8V%T:6]N(&%N9"!T:&4-"B!A9'9I<V]R>2!C;VUM:71T964@=F]T960@.2!T
M;R`R(&%G86EN<W0@<F5C;VUM96YD:6YG(&%P<')O=F%L(&]F#0H@=&AE($%.
M0TA/4B!I;F1I8V%T:6]N(&)A<V5D(&]N(&EN9F]R;6%T:6]N('!R97-E;G1E
M9"!A="!T:&4-"B!M965T:6YG+B!4:&4@1D1!('=I;&P@8V]N<VED97(@=&AE
M(')E8V]M;65N9&%T:6]N(&]F('1H92!A9'9I<V]R>0T*(&-O;6UI='1E92P@
M8G5T('1H92!F:6YA;"!D96-I<VEO;B!R96=A<F1I;F<@=&AE(&%P<')O=F%L
M(&]F('1H90T*('-.1$$@=VEL;"!B92!M861E(&)Y('1H92!&1$$N(%1H92!A
M<'!L:6-A=&EO;B!I<R!S=6)J96-T('1O(&$-"B!S=&%N9&%R9"!R979I97<@
M86YD(&AA<R!B965N(&%S<VEG;F5D(&$@4')E<V-R:7!T:6]N($1R=6<@57-E
M<B!&964-"B!!8W0L(&]R(%!$549!+"!D871E(&]F($1E8V5M8F5R)B-X03`[
M,C`L(#(P,3,N(%1H92!01%5&02!D871E(&ES#0H@=&AE('1A<F=E="!D871E
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M=65N="!%=F5N=',I+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@,3AP>#L@34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM3$5&5#H@
M,B4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/CQB/CQI/CQU/D)A<VES#0H@;V8@4')E<V5N=&%T
M:6]N/"]U/CPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM5$]0.B`V<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@<W1Y;&4]
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M=&AE(%5N:71E9"!3=&%T97,@;V8@06UE<FEC82`H=&AE#0H@)B-X,C`Q0SM5
M+E,N)B-X,C`Q1#L@;W(@=&AE("8C>#(P,4,[56YI=&5D(%-T871E<R8C>#(P
M,40[*2!A;F0@<'5R<W5A;G0-"B!T;R!T:&4@<G5L97,@86YD(')E9W5L871I
M;VYS(&]F('1H92!396-U<FET:65S(&%N9"!%>&-H86YG90T*($-O;6UI<W-I
M;VX@*'1H92`F(W@R,#%#.U-%0R8C>#(P,40[*2X@0V5R=&%I;B!I;F9O<FUA
M=&EO;B!I;B!T:&4-"B!N;W1E<R!T;R!T:&4@9FEN86YC:6%L('-T871E;65N
M=',@*'1H92`F(W@R,#%#.TYO=&5S)B-X,C`Q1#LI(&AA<PT*(&)E96X@8V]N
M9&5N<V5D(&]R(&]M:71T960@=VAE<F4@:70@<W5B<W1A;G1I86QL>2!D=7!L
M:6-A=&5S#0H@:6YF;W)M871I;VX@<')O=FED960@:6X@=&AE($-O;7!A;GDF
M(W@R,#$Y.W,@;&%T97-T(&%U9&ET960-"B!C;VYS;VQI9&%T960@9FEN86YC
M:6%L('-T871E;65N=',L(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@<G5L97,@
M86YD#0H@<F5G=6QA=&EO;G,@;V8@=&AE(%-%0RX@5&AE<V4@8V]N9&5N<V5D
M(&-O;G-O;&ED871E9"!F:6YA;F-I86P-"B!S=&%T96UE;G1S('-H;W5L9"!B
M92!R96%D(&EN(&-O;FIU;F-T:6]N('=I=&@@=&AE($-O;7!A;GDF(W@R,#$Y
M.W,-"B!A=61I=&5D(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT
M<R!A;F0@;F]T97,@:6YC;'5D960@:6X@:71S#0H@06YN=6%L(%)E<&]R="!O
M;B!&;W)M(#$P+4L@9F]R('1H92!F:7-C86P@>65A<B!E;F1E9`T*($1E8V5M
M8F5R)B-X03`[,S$L(#(P,3(L(&9I;&5D('=I=&@@=&AE(%-%0R`H=&AE("8C
M>#(P,4,[,C`Q,B!&;W)M#0H@,3`M2R8C>#(P,40[*2X@5&AE(&)A;&%N8V4@
M<VAE970@86UO=6YT<R!A="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$R#0H@:6X@
M=&AI<R!R97!O<G0@=V5R92!D97)I=F5D(&9R;VT@=&AE($-O;7!A;GDF(W@R
M,#$Y.W,@875D:71E9"`R,#$R#0H@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S
M=&%T96UE;G1S(&EN8VQU9&5D(&EN('1H92`R,#$R($9O<FT@,3`M2RX-"B!4
M:&4@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT
M<R!R969L96-T(&%L;`T*(&%D:G5S=&UE;G1S('1H870L(&EN('1H92!O<&EN
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M#0H@1V5N97)A;&QY($%C8V5P=&5D($%C8V]U;G1I;F<@4')I;F-I<&QE<R`H
M)B-X,C`Q0SM'04%0)B-X,C`Q1#LI#0H@<F5Q=6ER97,@;6%N86=E;65N="!T
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M9"!A;6]U;G1S(&]F(')E=F5N=65S(&%N9`T*(&5X<&5N<V5S(&1U<FEN9R!T
M:&4@<F5P;W)T:6YG('!E<FEO9"X@5&AE(')E<W5L=',@;V8@;W!E<F%T:6]N
M<R!F;W(-"B!T:&4@=&AR964@86YD(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E
M;6)E<B8C>$$P.S,P+"`R,#$S(&%N9"`R,#$R+`T*(')E<W!E8W1I=F5L>2P@
M87)E(&YO="!N96-E<W-A<FEL>2!I;F1I8V%T:79E(&]F('1H92!R97-U;'1S
M(&9O<B!T:&4-"B!E;G1I<F4@9FES8V%L('EE87(@;W(@86YY(&9U='5R92!P
M97)I;V0N(%1H92!#;VUP86YY(&AA<R!E=F%L=6%T960-"B!S=6)S97%U96YT
M(&5V96YT<R!F<F]M(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S('1H<F]U9V@@
M=&AE(&1A=&4@;V8-"B!T:&4@:7-S=6%N8V4@;V8@=&AE<V4@8V]N9&5N<V5D
M(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<PT*(&%N9"!H87,@
M9&ES8VQO<V5D('-U8G-E<75E;G0@979E;G1S(&EN($YO=&4@.2X\+V9O;G0^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[($U!4D=)3BU"
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M(&%N9"!D979E;&]P;65N="!O9B!687-C97!A+"!W:&EC:"!R96-E:79E9`T*
M(&%P<')O=F%L(&9R;VT@=&AE($9$02!I;B`R,#$R(&%N9"!F;W(@=VAI8V@@
M=&AE($-O;7!A;GD@8V]M;65N8V5D#0H@;6%R:V5T:6YG(&%N9"!S86QE<R!I
M;B`R,#$S+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M,3)P>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#%P>"<^#0H@
M)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%2
M1TE.+4)/5%1/33H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!="!397!T96UB97(F(WA!,#LS
M,"P@,C`Q,RP-"B!T:&4@0V]M<&%N>2!H860@8V%S:"!A;F0@8V%S:"!E<75I
M=F%L96YT<R!O9B`D,C(U+CDF(WA!,#MM:6QL:6]N+@T*(%-E92!A;'-O($YO
M=&4@."8C>#(P,30[17%U:71Y(&9O<B!A(&1E<V-R:7!T:6]N(&]F(&$@<'5B
M;&EC(&]F9F5R:6YG#0H@8V]M<&QE=&5D(&EN($IU;'D@,C`Q,R!R97-U;'1I
M;F<@:6X@;F5T('!R;V-E961S('1O('1H92!#;VUP86YY(&]F#0H@87!P<F]X
M:6UA=&5L>2`D,3(Q+C(@;6EL;&EO;BX\+V9O;G0^/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#$R<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^5&AE($-O;7!A;GDF(W@R,#$Y.W,-"B!C;VYS;VQI9&%T960@8F%L
M86YC92!S:&5E="!A;'-O(&EN8VQU9&5S(&1E<FEV871I=F4@;&EA8FEL:71I
M97,-"B`H<V5E($YO=&4@-28C>#(P,30[5V%R<F%N=',@86YD(%=A<G)A;G0@
M1&5R:79A=&EV92!,:6%B:6QI='DI(&%S#0H@=V5L;"!A<R!L;VYG('1E<FT@
M9&5B="!A;F0@97AC:&%N9V5A8FQE('-E;FEO<B!N;W1E<R`H<V5E($YO=&4-
M"B`V)B-X,C`Q-#M$96)T*2X@5&AE('=A<G)A;G0@9&5R:79A=&EV92!L:6%B
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M961E96UE9"!O;B!O<B!A9G1E<B!*86YU87)Y)B-X03`[,3DL(#(P,3<-"B!A
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M('1H92!#;VUP86YY+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
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M=&AS+CPO9F]N=#X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VEG;FEF:6-A;G0@06-C
M;W5N=&EN9R!0;VQI8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQD:78^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@
M8V]L;&%P<V4G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0T)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^*#(I/"]B
M/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/CQB/E-I9VYI9FEC86YT($%C8V]U;G1I;F<-"B!0;VQI8VEE
M<SPO8CX\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@-G!X.R!-05)'24XM0D]45$]-.B`P<'@[($U!
M4D=)3BU,1494.B`R)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^/'4^57-E(&]F#0H@
M17-T:6UA=&5S/"]U/CPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`V<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@
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M9`T*(&%S<W5M<'1I;VYS('1H870@869F96-T('1H92!R97!O<G1E9"!A;6]U
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M;B!O9B!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS(&-O;F1E;G-E9"!C;VYS;VQI
M9&%T960@9FEN86YC:6%L('-T871E;65N=',@:6X-"B!A8V-O<F1A;F-E('=I
M=&@@1T%!4"!R97%U:7)E<R!M86YA9V5M96YT('1O(&UA:V4@97-T:6UA=&5S
M+`T*(&IU9&=M96YT<R!A;F0@87-S=6UP=&EO;G,@=&AA="!M87D@869F96-T
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M+`T*(&EN8VQU9&EN9R!T:&]S92!R96QA=&5D('1O(')E=F5N=64@<F5C;V=N
M:71I;VX@86YD(')E;&%T960-"B!A;&QO=V%N8V5S+"!C;&EN:6-A;"!T<FEA
M;"!E>'!E;G-E<RP@=&AE('9A;'5A=&EO;B!O9B!I;G9E;G1O<GDL#0H@:6UP
M86ER;65N="!A;F0@86UO<G1I>F%T:6]N(&]F(&EN=&%N9VEB;&5S+"!S:&%R
M92UB87-E9`T*(&-O;7!E;G-A=&EO;BP@:6YC;VUE('1A>&5S(&EN8VQU9&EN
M9R!T:&4@=F%L=6%T:6]N(&%L;&]W86YC92!F;W(-"B!D969E<G)E9"!T87@@
M87-S971S+"!V86QU871I;VX@;V8@:6YV97-T;65N=',@86YD(&1E<FEV871I
M=F4-"B!I;G-T<G5M96YT<RX@5&AE($-O;7!A;GD@8F%S97,@:71S(&5S=&EM
M871E<R!O;B!H:7-T;W)I8V%L#0H@97AP97)I96YC92!A;F0@;VX@=F%R:6]U
M<R!O=&AE<B!A<W-U;7!T:6]N<R!T:&%T(&%R92!B96QI979E9"!T;R!B90T*
M(')E87-O;F%B;&4L('1H92!R97-U;'1S(&]F('=H:6-H(&9O<FT@=&AE(&)A
M<VES(&9O<B!M86MI;F<-"B!J=61G;65N=',@86)O=70@=&AE(&-A<G)Y:6YG
M('9A;'5E<R!O9B!A<W-E=',@86YD(&QI86)I;&ET:65S+@T*($%C='5A;"!R
M97-U;'1S(&UA>2!D:69F97(@9G)O;2!T:&5S92!E<W1I;6%T97,N/"]F;VYT
M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!X.R!-05)'24XM
M0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R)2<^#0H@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^
M/&D^/'4^4F5V96YU92!296-O9VYI=&EO;CPO=3X\+VD^/"]B/CPO9F]N=#X\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!X.R!-05)'24XM0D]4
M5$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
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M8V-U<G)E9"P-"B`H:6EI*28C>$$P.V-O;&QE8W1A8FEL:71Y(&ES(')E87-O
M;F%B;'D@87-S=7)E9"!A;F0@*&EV*28C>$$P.W1H90T*('!R:6-E(&ES(&9I
M>&5D(&]R(&1E=&5R;6EN86)L92X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#$R<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^5&AE($-O;7!A;GD@8V]M;65N8V5D(&ET<PT*(&-O;6UE<F-I86P@;&%U
M;F-H(&EN('1H92!5;FET960@4W1A=&5S(&]N($IA;G5A<GDF(WA!,#LR."P@
M,C`Q,RX-"B!0<FEO<B!T;R`R,#$S+"!T:&4@0V]M<&%N>2!R96-O9VYI>F5D
M(&YO(')E=F5N=64@9G)O;2!687-C97!A#0H@<V%L97,N($EN(&%C8V]R9&%N
M8V4@=VET:"!'04%0+"!U;G1I;"!T:&4@0V]M<&%N>2!H87,@=&AE(&%B:6QI
M='D-"B!T;R!R96QI86)L>2!E<W1I;6%T92!R971U<FYS(&]F(%9A<V-E<&$@
M9G)O;2!I=',@1&ES=')I8G5T;W)S+`T*(')E=F5N=64@=VEL;"!B92!R96-O
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M9"!R96-O<F1S('-U8V@@86UO=6YT<R!A<R!F:6YI<VAE9`T*(&=O;V1S(&EN
M=F5N=&]R>2!H96QD(&)Y(&]T:&5R<R!U;G1I;"!R979E;G5E(')E;&%T960@
M=&\@<W5C:`T*('!R;V1U8W0@<V%L97,@:7,@<F5C;V=N:7IE9"X\+V9O;G0^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[($U!4D=)3BU"
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M.V-A;&-U;&%T92!I=',@9W)O<W,@<')O9'5C=`T*(')E=F5N=65S(&9R;VT@
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M8W0-"B!R979E;G5E<R`H82DF(WA!,#MT<F%D92!A;&QO=V%N8V5S+"!S=6-H
M(&%S(&EN=F]I8V4@9&ES8V]U;G1S(&9O<@T*('!R;VUP="!P87EM96YT(&%N
M9"!D:7-T<FEB=71O<B!F965S+"`H8BDF(WA!,#ME<W1I;6%T960@9V]V97)N
M;65N=`T*(&%N9"!P<FEV871E('!A>6]R(')E8F%T97,L(&-H87)G96)A8VMS
M(&%N9"!D:7-C;W5N=',L('-U8V@@87,-"B!-961I8V%I9"!R96EM8G5R<V5M
M96YT<RP@*&,I)B-X03`[<F5S97)V97,@9F]R(&5X<&5C=&5D('!R;V1U8W0-
M"B!R971U<FYS(&%N9"`H9"DF(WA!,#ME<W1I;6%T960@8V]S=',@;V8@:6YC
M96YT:79E<R!O9F9E<F5D('1O#0H@8V5R=&%I;B!I;F1I<F5C="!C=7-T;VUE
M<G,L(&EN8VQU9&EN9R!P871I96YT<RX\+V9O;G0^/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4
M+5-)6D4Z(#%P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#!P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P
M<'@[($U!4D=)3BU,1494.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&
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M<B!C97)T86EN(&1A=&$@=&AA=`T*($1I<W1R:6)U=&]R<R!P<F]V:61E('1O
M('1H92!#;VUP86YY+B!4:&4@<&%Y;65N="!T97)M<R!F;W(@<V%L97,@=&\-
M"B!$:7-T<FEB=71O<G,@9V5N97)A;&QY(&EN8VQU9&4@82`R)2!D:7-C;W5N
M="!F;W(@<&%Y;65N="!W:71H:6X-"B`S,"8C>$$P.V1A>7,N($)A<V5D(&]N
M('1H92!#;VUP86YY)B-X,C`Q.3MS(&IU9&=M96YT(&%N9"!E>'!E<FEE;F-E
M+`T*('1H92!#;VUP86YY(&5X<&5C=',@:71S($1I<W1R:6)U=&]R<R!T;R!E
M87)N('1H97-E(&1I<V-O=6YT<R!A;F0-"B!F965S+"!A;F0@9&5D=6-T<R!T
M:&4@9G5L;"!A;6]U;G0@;V8@=&AE<V4@9&ES8V]U;G1S(&%N9"!F965S(&9R
M;VT-"B!I=',@9W)O<W,@<')O9'5C="!R979E;G5E<R!A;F0@86-C;W5N=',@
M<F5C96EV86)L92!A="!T:&4@=&EM92!S=6-H#0H@<F5V96YU97,@87)E(')E
M8V]G;FEZ960N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0
M.B`V<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X.R!-
M05)'24XM3$5&5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQI/E)E8F%T97,L#0H@0VAA
M<F=E8F%C:W,@86YD($1I<V-O=6YT<SH\+VD^(%1H92!#;VUP86YY(&-O;G1R
M86-T<R!W:71H($UE9&EC86ED+`T*(&]T:&5R(&=O=F5R;FUE;G0@86=E;F-I
M97,@86YD('9A<FEO=7,@<')I=F%T92!O<F=A;FEZ871I;VYS+"!O<@T*(&-O
M;&QE8W1I=F5L>2P@5&AI<F0M<&%R='D@4&%Y;W)S+"!S;R!T:&%T(%9A<V-E
M<&$@=VEL;"!B92!E;&EG:6)L90T*(&9O<B!P=7)C:&%S92!B>2P@;W(@<&%R
M=&EA;"!O<B!F=6QL(')E:6UB=7)S96UE;G0@9G)O;2P@<W5C:`T*(%1H:7)D
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M(%1H:7)D+7!A<G1Y#0H@4&%Y;W)S(&)A<V5D('5P;VX@*&DI)B-X03`[=&AE
M($-O;7!A;GDF(W@R,#$Y.W,@8V]N=')A8W1S('=I=&@@=&AE<V4-"B!4:&ER
M9"UP87)T>2!087EO<G,L("AI:2DF(WA!,#MT:&4@9V]V97)N;65N="UM86YD
M871E9"!D:7-C;W5N=',-"B!A<'!L:6-A8FQE('1O(&=O=F5R;FUE;G0M9G5N
M9&5D('!R;V=R86US+"`H:6EI*28C>$$P.VEN9F]R;6%T:6]N#0H@;V)T86EN
M960@9G)O;2!T:&4@0V]M<&%N>28C>#(P,3D[<R!$:7-T<FEB=71O<G,@86YD
M#0H@*&EV*28C>$$P.VEN9F]R;6%T:6]N(&]B=&%I;F5D(&9R;VT@;W1H97(@
M=&AI<F0@<&%R=&EE<R!R96=A<F1I;F<-"B!T:&4@<&%Y;W(@;6EX(&9O<B!6
M87-C97!A+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M-G!X.R!415A4+4E.1$5.5#H@-"4[($U!4D=)3BU"3U143TTZ(#!P>#L@34%2
M1TE.+4Q%1E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\:3Y0<F]D=6-T#0H@4F5T=7)N
M<SH\+VD^(%1H92!#;VUP86YY)B-X,C`Q.3MS($1I<W1R:6)U=&]R<R!H879E
M('1H92!R:6=H="!T;PT*(')E='5R;B!U;F]P96YE9"!U;G!R97-C<FEB960@
M5F%S8V5P82!D=7)I;F<@=&AE(#$X+6UO;G1H('!E<FEO9`T*(&)E9VEN;FEN
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M<G,N($%S(&]F#0H@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,L('1H92!#;VUP
M86YY(&AA9"!E>'!E<FEE;F-E9"!A(&1E;6EN:6UU<PT*('%U86YT:71Y(&]F
M('!R;V1U8W0@<F5T=7)N<RX@1'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E
M9`T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S+"!T:&4@<&5R:6]D(&EN('=H
M:6-H('1H92!#;VUP86YY(&)E9V%N#0H@<V5L;&EN9R!687-C97!A+"!T:&4@
M0V]M<&%N>2!W87,@;F]T(&%B;&4@=&\@<F5A<V]N86)L>2!E<W1I;6%T90T*
M('!R;V1U8W0@<F5T=7)N<R!F;W(@86QL('!R;V1U8W0@<V]L9"!T;R!$:7-T
M<FEB=71O<G,@8G5T('1H90T*($-O;7!A;GD@=V%S(&%B;&4@=&\@<F5A<V]N
M86)L>2!E<W1I;6%T92!P<F]D=6-T(')E='5R;G,@9F]R(&-E<G1A:6X-"B!S
M86QE<R!O9B!687-C97!A(&)A<V5D(&]N('!R;V1U8W0@=7-E9"!T;R!F:6QL
M('!A=&EE;G0-"B!P<F5S8W)I<'1I;VYS(&%S(&1E=&5R;6EN960@8GD@:6YV
M96YT;W)Y(&5S=&EM871E9"!T;R!B92!I;B!T:&4-"B!D:7-T<FEB=71I;VX@
M8VAA;FYE;"!A;F0@=&AI<F0@<&%R='D@<F5P;W)T<R!O9B!P<F5S8W)I<'1I
M;VYS#0H@9FEL;&5D+B!);B!M86MI;F<@=&AI<R!A<W-E<W-M96YT+"!T:&4@
M0V]M<&%N>2!U<V5D("AI*28C>$$P.V1A=&$-"B!P<F]V:61E9"!T;R!T:&4@
M0V]M<&%N>2!B>2!I=',@1&ES=')I8G5T;W)S("AI;F-L=61I;F<@=V5E:VQY
M#0H@<F5P;W)T:6YG(&]F($1I<W1R:6)U=&]R<R8C>#(P,3D[('-A;&5S(&%N
M9"!I;G9E;G1O<GD@:&5L9"!B>0T*($1I<W1R:6)U=&]R<R!T:&%T('!R;W9I
M9&5D('1H92!#;VUP86YY('=I=&@@=FES:6)I;&ET>2!I;G1O('1H90T*(&1I
M<W1R:6)U=&EO;B!C:&%N;F5L(&EN(&]R9&5R('1O(&1E=&5R;6EN92!W:&%T
M('%U86YT:71I97,@=V5R90T*('-O;&0@=&\@<F5T86EL('!H87)M86-I97,@
M86YD(&]T:&5R('!R;W9I9&5R<RDL#0H@*&EI*28C>$$P.VEN9F]R;6%T:6]N
M('!R;W9I9&5D('1O('1H92!#;VUP86YY(&9R;VT@<F5T86EL#0H@<&AA<FUA
M8VEE<RP@*&EI:2DF(WA!,#MD871A('!R;W9I9&5D('1O('1H92!#;VUP86YY
M(&)Y(&$@=&AI<F0-"B!P87)T>2!D871A('!R;W9I9&5R('=H:6-H(&-O;&QE
M8W1S(&%N9"!P=6)L:7-H97,@<')E<V-R:7!T:6]N(&1A=&$L#0H@86YD(&]T
M:&5R('1H:7)D('!A<G1I97,L("AI=BDF(WA!,#MH:7-T;W)I8V%L(&EN9'5S
M=')Y(&EN9F]R;6%T:6]N#0H@<F5G87)D:6YG(')E='5R;B!R871E<R!F;W(@
M<VEM:6QA<B!P:&%R;6%C975T:6-A;"!P<F]D=6-T<RP-"B`H=BDF(WA!,#MT
M:&4@97-T:6UA=&5D(')E;6%I;FEN9R!S:&5L9B!L:69E(&]F(%9A<V-E<&$@
M<')E=FEO=7-L>0T*('-H:7!P960@86YD(&-U<G)E;G1L>2!B96EN9R!S:&EP
M<&5D('1O($1I<W1R:6)U=&]R<R!A;F0-"B`H=FDI)B-X03`[8V]N=')A8W1U
M86P@86=R965M96YT<R!I;G1E;F1E9"!T;R!L:6UI="!T:&4@86UO=6YT(&]F
M#0H@:6YV96YT;W)Y(&UA:6YT86EN960@8GD@=&AE($-O;7!A;GDF(W@R,#$Y
M.W,-"B!$:7-T<FEB=71O<G,N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/
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M=&EC:7!A=&EN9R!P871I96YT)B-X,C`Q.3MS('!O<G1I;VX@;V8@=&AE#0H@
M9FEN86YC:6%L(')E<W!O;G-I8FEL:71Y(&9O<B!687-C97!A)B-X,C`Q.3MS
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M8F5R)B-X03`[,S$L(#(P,3,N(%1H92!#;VUP86YY(&%D:G5S=',-"B!I=',@
M86-C<G5A;',@9F]R(&-O+7!A>2!M:71I9V%T:6]N(')E8F%T97,@8F%S960@
M;VX@:71S(&5S=&EM871E<PT*(')E9V%R9&EN9R!T:&4@<&]R=&EO;B!O9B!I
M<W-U960@<F5B871E<R!T:&%T(&ET(&5S=&EM871E<R!W:6QL(&YO=`T*(&)E
M(')E9&5E;65D+B!);B!A9&1I=&EO;BP@87,@:7,@8W5S=&]M87)Y('!R:6]R
M('1O('1H92!L875N8V@@;V8-"B!N97<@9')U9W,L('1H92!#;VUP86YY('!R
M;W9I9&5D(&-E<G1A:6X@;V8@:71S($1I<W1R:6)U=&]R<R!W:71H#0H@9FEN
M86YC:6%L(&EN8V5N=&EV97,@=&\@8F5G:6X@<W1O8VMI;F<@5F%S8V5P82!P
M<FEO<B!T;R!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS(&-O;6UE<F-I86P@;&%U
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M;W)S(&EN#0H@2F%N=6%R>2`R,#$S+B!4:&4@86UO=6YT(&]F('1H97-E(&9I
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M2F%N=6%R>2`R,#$S('=E<F4@<F5S;VQD(&)Y#0H@<W5C:"!$:7-T<FEB=71O
M<G,@<')I;W(@=&\@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,N/"]F;VYT/CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'24XM0D]4
M5$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/E1H92!F;VQL;W=I;F<@=&%B;&4-"B!S=6UM
M87)I>F5S(&%C=&EV:71Y(&EN(&5A8V@@;V8@=&AE('!R;V1U8W0@<F5V96YU
M92!A;&QO=V%N8V4@86YD#0H@<F5S97)V92!C871E9V]R:65S(&1E<V-R:6)E
M9"!A8F]V92!F;W(@=&AE(&YI;F4@;6]N=&AS(&5N9&5D#0H@4V5P=&5M8F5R
M)B-X03`[,S`L(#(P,3,@*&EN('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($U!4D=)3BU"3U143TTZ(#!P
M>#L@1D].5"U325I%.B`Q,G!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T
M>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&)O<F1E<CTS1#`@
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M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY4<F%D93QB<B`O/@T*($%L
M;&]W86YC97,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
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M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/E!R;V1U8W0\8G(@
M+SX-"B!2971U<FYS/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY/=&AE<CQB<B`O/@T*($EN8V5N
M=&EV97,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0Q/CQB/E1O=&%L/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/"]T<CX-"B`\='(^#0H@/'1D/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T
M/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/'1D(&-O;'-P86X]
M,T0T/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/'1D(&-O;'-P
M86X],T0T/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3%E;3L@34%21TE.+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^0F%L86YC
M92!A=`T*($IA;G5A<GDF(WA!,#LQ+"`R,#$S/"]B/CPO9F]N=#X\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
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M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3%E;3L@34%21TE.+4Q%1E0Z(#-E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4')O=FES:6]N(')E
M;&%T960@=&\-"B!C=7)R96YT('!E<FEO9"!A;F0@9&5F97)R960@<V%L97,\
M+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
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M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^,BPT,3@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C<R/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXR+#`Q.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^-RPS-#<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,V5M)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#<F5D
M:71S+W!A>6UE;G1S(&UA9&4@9F]R#0H@8W5R<F5N="!P97)I;V0@86YD(&1E
M9F5R<F5D('-A;&5S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^*#$L.34Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^*#$L-#@T/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B@Q+#@S-3PO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@U+#(W,#PO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@
M34%21TE.+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^0F%L86YC92!A=`T*(%-E
M<'1E;6)E<B8C>$$P.S,P+"`R,#$S/"]B/CPO9F]N=#X\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^/&(^)#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^.#@X/"]B/CPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/CQB/B8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)#PO8CX\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^/&(^.3,T/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B8C>$$P.R8C
M>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^/&(^)#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^-S(\
M+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^/&(^)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CX\8CXD/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXQ.#,\+V(^/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^/&(^)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXD/"]B
M/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CX\8CXR+#`W-SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXF
M(WA!,#LF(WA!,#L\+V(^/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO
M=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P>#L@34%21TE.
M+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#%P>"<^#0H@)B-X03`[/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/33H@
M,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CY4:&4@9F]L;&]W:6YG('1A8FQE#0H@<W5M;6%R:7IE
M<R!P<F]D=6-T(')E=F5N=64@<F5C;V=N:7IE9"!A;F0@9&5F97)R960@9'5R
M:6YG('1H92!N:6YE#0H@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C>$$P.S,P
M+"`R,#$S("AI;B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,'!X.R!-05)'24XM0D]45$]-.B`P<'@[($9/3E0M
M4TE:13H@,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="
M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!B;W)D97(],T0P(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@86QI9VX],T1C
M96YT97(^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#8S)3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,30E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY397!T96UB
M97(F(WA!,#LS,"PF(WA!,#LR,#$S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#$^/&(^1&5C96UB97(F(WA!,#LS,2PF(WA!,#LR,#$R/"]B/CPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3%E;3L@34%21TE.+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4')O9'5C
M="!R979E;G5E#0H@<F5C;V=N:7IE9#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\
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M;6%N)R!S:7IE/3-$,CXQ-BPR-#4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
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M='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,1494.B`Q96TG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/D1E9F5R<F5D('!R;V1U8W0-"B!R979E;G5E/"]F;VYT/CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2PV,3<\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^/&(^)#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@
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M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
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M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A
M8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[($U!4D=)3BU"
M3U143TTZ(#!P>"<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^26X@8V]N:G5N8W1I;VX@=VET:"!T:&4-
M"B!#;VUP86YY)B-X,C`Q.3MS(')E8V]G;FET:6]N(&%N9"!D969E<G)A;"!O
M9B!P<F]D=6-T(')E=F5N=65S+"!T:&4-"B!#;VUP86YY(&5X<&5N<V5D(&%N
M9"!C87!I=&%L:7IE9"!T:&4@87-S;V-I871E9"!C;W-T(&]F(&=O;V1S+"!A
M<PT*(&9O;&QO=W,L(&1U<FEN9R!T:&4@;FEN92!M;VYT:',@96YD960@4V5P
M=&5M8F5R)B-X03`[,S`L(#(P,3,@*&EN#0H@=&AO=7-A;F1S*3H\+V9O;G0^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/
M5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*("8C>$$P.SPO<#X-"B`\
M=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8F]R
M9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$-S8E(&%L:6=N/3-$8V5N=&5R/@T*(#QT<CX-"B`\=&0@=VED=&@],T0V
M-"4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)3X\+W1D/@T*(#QT9#X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#$^/&(^4V5P=&5M8F5R)B-X03`[,S`L)B-X03`[,C`Q,SPO8CX\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0Q/CQB/D1E8V5M8F5R)B-X03`[,S$L)B-X03`[
M,C`Q,CPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,1494.B`Q96TG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/D-O<W0@;V8@9V]O9',@<V]L9`T*(&5X<&5N<V5D/"]F;VYT
M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C<L.#$S/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&
M5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CY&:6YI<VAE9"!G;V]D<R!I;G9E;G1O<GD-"B!H
M96QD(&)Y(&]T:&5R<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F
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M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CX\8CXD/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXX+#0U-#PO8CX\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CX\8CXF(WA!,#LF(WA!,#L\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
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M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#$X<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E)SX-
M"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CX\8CX\:3X\=3Y#87-H#0H@86YD($-A<V@@17%U:79A;&5N
M=',\+W4^/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#87-H
M(&%N9"!C87-H(&5Q=6EV86QE;G1S#0H@8V]N<VES="!O9B!C87-H+"!D97!O
M<VET<R!H96QD(&%T(&-A;&P@=VET:"!B86YK<R!A;F0@<VAO<G0@=&5R;0T*
M(&AI9VAL>2!L:7%U:60@:6YS=')U;65N=',@=VET:"!R96UA:6YI;F<@;6%T
M=7)I=&EE<R!A="!T:&4@9&%T92!O9@T*('!U<F-H87-E(&]F(#DP)B-X03`[
M9&%Y<R!O<B!L97-S+B!297-T<FEC=&5D(&-A<V@@<F5P<F5S96YT<R!C87-H
M#0H@86YD(&-A<V@@97%U:79A;&5N=',@<&QE9&=E9"!T;R!G=6%R86YT964@
M<F5P87EM96YT(&]F(&-E<G1A:6X-"B!E>'!E;G-E<R!W:&EC:"!M87D@8F4@
M:6YC=7)R960@9F]R(&)U<VEN97-S('1R879E;"!U;F1E<B!C;W)P;W)A=&4-
M"B!C<F5D:70@8V%R9',@:&5L9"!B>2!E;7!L;WEE97,N/"]F;VYT/CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!X.R!-05)'24XM0D]45$]-
M.B`P<'@[($U!4D=)3BU,1494.B`R)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^/'4^
M26YV96YT;W)Y/"]U/CPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`V<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@
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M97AC965D<R!E>'!E8W1E9`T*(&UA<FME="!V86QU92!D=64@=&\@;V)S;VQE
M<V-E;F-E+"!D86UA9V4@;W(@<75A;G1I=&EE<R!I;B!E>&-E<W,@;V8-"B!E
M>'!E8W1E9"!D96UA;F0L('1H92!#;VUP86YY('=I;&P@<F5C;W)D(&$@<F5S
M97)V92!F;W(@=&AE#0H@9&EF9F5R96YC92!B971W965N(&-O<W0@86YD(&UA
M<FME="!V86QU92X@5&AE($-O;7!A;GD@<F5C96EV960@1D1!#0H@87!P<F]V
M86P@9F]R(%9A<V-E<&$@;VX@2G5L>28C>$$P.S(V+"`R,#$R(&%N9"!A9G1E
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M96%C:`T*(&%D9&ET:6]N86P@<W5P<&QI97(L('1H92!#;VUP86YY(&-A<&ET
M86QI>F5S('-U8G-E<75E;G0@5F%S8V5P82!!4$D-"B!P=7)C:&%S97,@9G)O
M;2!S=6-H('-U<'!L:65R(&%S(&EN=F5N=&]R>2X@4'5R8VAA<V5S(&]F(%9A
M<V-E<&$@05!)#0H@<F5C96EV960@86YD(&5X<&5N<V5D(&)E9F]R92!S=6-H
M(')E9W5L871O<GD@87!P<F]V86QS(&ES(&YO=`T*('-U8G-E<75E;G1L>2!C
M87!I=&%L:7IE9"P@86YD(&%L;"!S=6-H('!U<F-H87-E<R!A<F4@<75A<F%N
M=&EN960-"B!A;F0@;F]T('5S960@9F]R(&-O;6UE<F-I86P@<W5P<&QY('5N
M=&EL('-U8V@@=&EM92!A<R!T:&4@<TY$02!F;W(-"B!T:&4@<W5P<&QI97(@
M=&AA="!P<F]D=6-E9"!T:&4@05!)(&ES(&%P<')O=F5D+CPO9F]N=#X\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP>#L@34%21TE.+4)/5%1/
M33H@,'!X.R!-05)'24XM3$5&5#H@,B4G/@T*(#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/CQU
M/DEN=&%N9VEB;&4@07-S970L(&YE=#PO=3X\+VD^/"]B/CPO9F]N=#X\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!X.R!-05)'24XM0D]45$]-
M.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/DEN=&%N9VEB;&4@87-S971S(&-O;G-I<W0-"B!O
M9B!A(&UI;&5S=&]N92!P87EM96YT('!A:60@=&\@=&AE(&9O<FUE<B!S:&%R
M96AO;&1E<G,@;V8@3&%X9&%L90T*($QI;6ET960@<F5L871E9"!T;R!T:&4@
M,C`P-"!A8W%U:7-I=&EO;B!O9B!O=7(@<FEG:'1S('1O(%9A<V-E<&$L#0H@
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M:7-I=&EO;B!O9B!,87AD86QE($QI;6ET960N/"]F;VYT/CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`Q.'!X.R!-05)'24XM0D]45$]-.B`P<'@[
M($U!4D=)3BU,1494.B`R)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^/'4^1&5F97)R
M960@4F5V96YU93PO=3X\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@-G!X.R!-05)'24XM0D]45$]-.B`P<'@G/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/D1E9F5R<F5D(')E=F5N=64@<F5P<F5S96YT<PT*('!R;V1U8W0@<VAI
M<&UE;G1S('1O($1I<W1R:6)U=&]R<R!F;W(@=VAI8V@@=&AE($-O;7!A;GD@
M:&%S#0H@:6YV;VEC960@=&AE($1I<W1R:6)U=&]R<R!B=70@;F]T(')E8V]G
M;FEZ960@<F5V96YU92!B96-A=7-E('1H90T*('!R;V1U8W0@=V%S(&YO="!R
M97!O<G1E9"!T;R!T:&4@0V]M<&%N>2!A<R!H879I;F<@8F5E;B!R97-O;&0@
M9F]R#0H@=&AE('!U<G!O<V4@;V8@9FEL;&EN9R!P<F5S8W)I<'1I;VYS(&]N
M(&]R(&)E9F]R90T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S+CPO9F]N=#X\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP>#L@34%21TE.+4)/
M5%1/33H@,'!X.R!-05)'24XM3$5&5#H@,B4G/@T*(#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI
M/CQU/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!#;W-T<SPO=3X\+VD^/"]B
M/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!X.R!-
M05)'24XM0D]45$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
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M:6%L(&%N9"!P:&%R;6%C975T:6-A;"!D979E;&]P;65N=`T*(&-O<W1S.R!C
M;VUM97)C:6%L('-U<'!L>2!I;G9E<W1M96YT(&EN(&ET<R!D<G5G(&-A;F1I
M9&%T97,[(&%N9`T*(&EN9G)A<W1R=6-T=7)E(&-O<W1S+"!I;F-L=61I;F<@
M9F%C:6QI=&EE<R!C;W-T<R!A;F0@9&5P<F5C:6%T:6]N#0H@97AP96YS92X@
M26X@861D:71I;VXL(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!C;W-T<R!I
M;F-L=61E('1H90T*(&-O<W1S(&]F('!R;V1U8W0@<W5P<&QY(')E8V5I=F5D
M(&9R;VT@<W5P<&QI97)S('=H96X@<W5C:"!R96-E:7!T#0H@8GD@=&AE($-O
M;7!A;GD@:7,@<')I;W(@=&\@<F5G=6QA=&]R>2!A<'!R;W9A;"!O9B!T:&4-
M"B!S=7!P;&EE<BX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@G
M/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[
M($U!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E)SX-"B`\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CX\8CX\:3X\=3Y396QL:6YG+"!'96YE<F%L(&%N9"!!9&UI;FES=')A
M=&EV90T*($-O<W1S/"]U/CPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM5$]0.B`V<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O
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M;VYD=6-T(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&)U<VEN97-S+"!I;F-L
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M;G-A=&EO;B!I;F-O;64@*&5X<&5N<V4I+CPO9F]N=#X\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@,3AP>#L@34%21TE.+4)/5%1/33H@,'!X.R!-
M05)'24XM3$5&5#H@,B4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/CQU/DEN8V]M90T*
M(%1A>&5S/"]U/CPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM5$]0.B`V<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@<W1Y
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M="!T;R!B90T*(')E86QI>F5D+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G
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M<75E<W1I;VX@=VEL;`T*(&)E(&1E8VED960@8F%S960@;VX@:71S('1E8VAN
M:6-A;"!M97)I=',N(%1H92!#;VUP86YY)B-X,C`Q.3MS#0H@<&]L:6-Y(&ES
M('1O(')E8V]R9"!I;G1E<F5S="!A;F0@<&5N86QT:65S(&EN('1H92!P<F]V
M:7-I;VX@9F]R#0H@:6YC;VUE('1A>&5S+CPO9F]N=#X\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@,3AP>#L@34%21TE.+4)/5%1/33H@,'!X.R!-
M05)'24XM3$5&5#H@,B4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/CQU/D1E<FEV871I
M=F4@26YS=')U;65N=',\+W4^/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@,'!X)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CY$97)I=F%T:79E(&9I;F%N8VEA;`T*(&QI86)I;&ET:65S(&%R
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M=61E9"X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R
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M:6X-"B!C87!I=&%L+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@,3AP>#L@34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM3$5&5#H@
M,B4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/CQB/CQI/CQU/DQO<W,-"B!P97(@4VAA<F4\+W4^
M/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#9P>#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY"87-I8R!N970@
M;&]S<R!P97(@<VAA<F4@:7,-"B!D971E<FUI;F5D(&)Y(&1I=FED:6YG(&YE
M="!L;W-S(&)Y('1H92!W96EG:'1E9"!A=F5R86=E('-H87)E<R!O9@T*(&-O
M;6UO;B!S=&]C:R!O=71S=&%N9&EN9R!D=7)I;F<@=&AE('!E<FEO9"X@1&EL
M=71E9"!N970@;&]S<R!P97(-"B!S:&%R92!I<R!D971E<FUI;F5D(&)Y(&1I
M=FED:6YG(&YE="!L;W-S(&)Y(&1I;'5T960@=V5I9VAT960-"B!A=F5R86=E
M('-H87)E<R!O=71S=&%N9&EN9RX@1&EL=71E9"!W96EG:'1E9"!A=F5R86=E
M('-H87)E<PT*(')E9FQE8W1S('1H92!D:6QU=&EV92!E9F9E8W0L(&EF(&%N
M>2P@;V8@<&]T96YT:6%L;'D@9&EL=71I=F4-"B!C;VUM;VX@<VAA<F5S+"!S
M=6-H(&%S(&-O;6UO;B!S=&]C:R!O<'1I;VYS(&%N9"!W87)R86YT<R!C86QC
M=6QA=&5D#0H@=7-I;F<@=&AE('1R96%S=7)Y('-T;V-K(&UE=&AO9"!A;F0@
M8V]N=F5R=&EB;&4@;F]T97,@=7-I;F<@=&AE#0H@)B-X,C`Q0SMI9BUC;VYV
M97)T960F(W@R,#%$.R!M971H;V0N($EN('!E<FEO9',@=VET:"!R97!O<G1E
M9"!N970-"B!O<&5R871I;F<@;&]S<V5S+"!A;&P@8V]M;6]N('-T;V-K(&]P
M=&EO;G,@86YD('=A<G)A;G1S(&%R92!D965M960-"B!A;G1I+61I;'5T:79E
M('-U8V@@=&AA="!B87-I8R!N970@;&]S<R!P97(@<VAA<F4@86YD(&1I;'5T
M960@;F5T#0H@;&]S<R!P97(@<VAA<F4@87)E(&5Q=6%L+CPO9F]N=#X\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP>#L@34%21TE.+4)/5%1/
M33H@,'!X.R!-05)'24XM3$5&5#H@,B4G/@T*(#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/CQU
M/D1E8G0-"B!);G-T<G5M96YT<SPO=3X\+VD^/"]B/CPO9F]N=#X\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!X.R!-05)'24XM0D]45$]-.B`P
M<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/D1E8G0@:6YS=')U;65N=',@87)E#0H@:6YI=&EA;&QY
M(')E8V]R9&5D(&%T(&9A:7(@=F%L=64L('=I=&@@8V]U<&]N(&EN=&5R97-T
M(&%N9`T*(&%M;W)T:7IA=&EO;B!O9B!D96)T(&ES<W5A;F-E(&1I<V-O=6YT
M<R!R96-O9VYI>F5D(&EN('1H92!S=&%T96UE;G0-"B!O9B!O<&5R871I;VYS
M(&%S(&EN=&5R97-T(&5X<&5N<V4@870@96%C:"!P97)I;V0@96YD('=H:6QE
M('-U8V@-"B!I;G-T<G5M96YT<R!A<F4@;W5T<W1A;F1I;F<N($EF('1H92!#
M;VUP86YY(&ES<W5E<R!S:&%R97,@=&\-"B!D:7-C:&%R9V4@=&AE(&QI86)I
M;&ET>2P@=&AE(&1E8G0@;V)L:6=A=&EO;B!I<R!D97)E8V]G;FEZ960@86YD
M#0H@8V]M;6]N('-T;V-K(&%N9"!A9&1I=&EO;F%L('!A:60M:6X@8V%P:71A
M;"!A<F4@<F5C;V=N:7IE9"!O;B!T:&4-"B!I<W-U86YC92!O9B!T:&]S92!S
M:&%R97,N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q
M,G!X.R!-05)'24XM0D]45$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!#;VUP86YY
M)B-X,C`Q.3MS#0H@97AC:&%N9V5A8FQE(&YO=&5S(&-O;G1A:6X@82!C;VYV
M97)S:6]N(&]P=&EO;B!W:&EC:"!I<R!C;&%S<VEF:65D#0H@87,@97%U:71Y
M+B!4:&4@9F%I<B!V86QU92!O9B!T:&4@;&EA8FEL:71Y(&-O;7!O;F5N="!O
M9B!T:&4@9&5B=`T*(&EN<W1R=6UE;G0@=V%S(&1E9'5C=&5D(&9R;VT@=&AE
M(&EN:71I86P@<')O8V5E9',@=&\@9&5T97)M:6YE('1H90T*('!R;V-E961S
M('1O(&)E(&%L;&]C871E9"!T;R!T:&4@8V]N=F5R<VEO;B!O<'1I;VXN(%1H
M92!E;6)E9&1E9`T*(&-O;G9E<G-I;VX@;W!T:6]N(&ES(&EN9&5X960@=&\@
M=&AE($-O;7!A;GDF(W@R,#$Y.W,@<W1O8VL@86YD#0H@=')E871E9"!A<R!E
M<75I='D@;VX@=&AE(&)A;&%N8V4@<VAE970N(%1H92!C;VYV97)S:6]N(&]P
M=&EO;B!I<PT*(&5V86QU871E9"!O;B!A('%U87)T97)L>2!B87-I<R!T;R!D
M971E<FUI;F4@:68@:70@<W1I;&P@;65E=',@=&AE#0H@8W)I=&5R:6$@=&\@
M8F4@97%U:71Y(&-L87-S:69I960N(%1H92!E>&-E<W,@<')I;F-I<&%L(&%M
M;W5N="!O9@T*('1H92!D96)T(&]V97(@=&AE(&-A<G)Y:6YG('9A;'5E(&]F
M('1H92!L:6%B:6QI='D@:7,@86UO<G1I>F5D('1O#0H@:6YT97)E<W0@97AP
M96YS92!O=F5R('1H92!T97)M(&]F('1H92!D96)T+CPO9F]N=#X\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P>#L@34%21TE.+4)/5%1/33H@
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M;&4N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!X
M.R!-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X)SX-"B`F(WA!
M,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!X.R!-05)'24XM
M0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R)2<^#0H@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^
M/&D^/'4^1F%I<@T*(%9A;'5E(&]F($9I;F%N8VEA;"!);G-T<G5M96YT<SPO
M=3X\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@-G!X.R!-05)'24XM0D]45$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/
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M=7)E;65N=`T*(&1A=&4N)B-X03`[1F%I<B!V86QU92!M96%S=7)E;65N=',@
M;6%Y(&)E(&-L87-S:69I960@8F%S960@;VX@=&AE#0H@86UO=6YT(&]F('-U
M8FIE8W1I=FET>2!A<W-O8VEA=&5D('=I=&@@=&AE(&EN<'5T<R!T;R!F86ER
M('9A;'5A=&EO;@T*(&]F('1H97-E(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@
M=7-I;F<@=&AE(&9O;&QO=VEN9R!T:')E90T*(&QE=F5L<SH\+V9O;G0^/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[($U!4D=)3BU"3U14
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M96%S=7)E;65N="!D871E+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,3)P>#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,
M979E;"`R)B-X,C`Q-#M);G!U=',-"B!I;F-L=61E('%U;W1E9"!P<FEC97,@
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M8FEL:71Y("AI+F4N+`T*(&EN=&5R97-T(')A=&5S+"!Y:65L9"!C=7)V97,L
M(&5T8RXI(&%N9"!I;G!U=',@=&AA="!A<F4@9&5R:79E9`T*('!R:6YC:7!A
M;&QY(&9R;VT@;W(@8V]R<F]B;W)A=&5D(&)Y(&]B<V5R=F%B;&4@;6%R:V5T
M(&1A=&$@8GD-"B!C;W)R96QA=&EO;B!O<B!O=&AE<B!M96%N<R`H;6%R:V5T
M(&-O<G)O8F]R871E9"!I;G!U=',I+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,3)P>#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CY,979E;"`S)B-X,C`Q-#M5;F]B<V5R=F%B;&4-"B!I;G!U=',@=&AA
M="!R969L96-T('1H92!#;VUP86YY)B-X,C`Q.3MS(&5S=&EM871E<R!O9B!T
M:&4-"B!A<W-U;7!T:6]N<R!T:&%T(&UA<FME="!P87)T:6-I<&%N=',@=V]U
M;&0@=7-E(&EN('!R:6-I;F<@=&AE(&%S<V5T#0H@;W(@;&EA8FEL:71Y+B8C
M>$$P.U1H92!#;VUP86YY(&1E=F5L;W!S('1H97-E(&EN<'5T<R!B87-E9"!O
M;B!T:&4-"B!B97-T(&EN9F]R;6%T:6]N(&%V86EL86)L92P@:6YC;'5D:6YG
M(&ET<R!O=VX@9&%T82X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#$R<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE
M(&9O;&QO=VEN9R!T86)L90T*('!R97-E;G1S(&EN9F]R;6%T:6]N(&%B;W5T
M('1H92!#;VUP86YY)B-X,C`Q.3MS(&%S<V5T<R!A;F0-"B!L:6%B:6QI=&EE
M<R!A<R!O9B!397!T96UB97(F(WA!,#LS,"P@,C`Q,R!A;F0@1&5C96UB97(F
M(WA!,#LS,2P-"B`R,#$R('1H870@87)E(&UE87-U<F5D(&%T(&9A:7(@=F%L
M=64@;VX@82!R96-U<G)I;F<@8F%S:7,@86YD#0H@:6YD:6-A=&5S('1H92!F
M86ER('9A;'5E(&AI97)A<F-H>2!O9B!T:&4@=F%L=6%T:6]N('1E8VAN:7%U
M97,@=&AE#0H@0V]M<&%N>2!U=&EL:7IE9"!T;R!D971E<FUI;F4@<W5C:"!F
M86ER('9A;'5E.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@,'!X.R!-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,3)P>"<^
M#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%0
M4T4Z(&-O;&QA<'-E)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0V."4@86QI9VX],T1C96YT97(^#0H@/'1R
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M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,30@86QI9VX],T1C96YT97(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#$^/&(^4V5P=&5M8F5R)B-X03`[,S`L#0H@,C`Q,SPO8CX\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#$^/&(^/&D^26X@;6EL;&EO;G,\+VD^/"]B/CPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0Q/CQB/E1O=&%L/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^
M3&5V96PF(WA!,#LQ/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^3&5V
M96PF(WA!,#LR/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^3&5V96PF
M(WA!,#LS/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\
M='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@34%21TE.+4Q%1E0Z(#%E
M;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^/&(^07-S970Z/"]B/CPO9F]N=#X\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,1494.B`Q96TG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/D-A<V@-"B!E<75I=F%L96YT<R8C>#(P,30[;6]N97D@;6%R:V5T<SPO
M9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
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M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT
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M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
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M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(^#0H@
M/'1D/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/'1D(&-O;'-P
M86X],T0T/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/'1D(&-O
M;'-P86X],T0T/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3%E;3L@34%21TE.+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^3&EA
M8FEL:71I97,Z/"]B/CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ96T[($U!4D=)3BU,1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E=A<G)A;G0@
M9&5R:79A=&EV90T*(&QI86)I;&ET>3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\
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M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
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M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C,Y+C8\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*
M(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@
M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CY,;VYG+71E<FT@9&5B="!R961E;7!T:6]N#0H@9F5A
M='5R93PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
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M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
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M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^-RXR/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@34%21TE.
M+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^1F]R96EG;B!C=7)R96YC>0T*(&-O;G1R
M86-T<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
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M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
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M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^,"XT/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B
M;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!X.R!-05)'24XM0D]4
M5$]-.B`P<'@[($9/3E0M4TE:13H@,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QT
M86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!B;W)D
M97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0V."4@86QI9VX],T1C96YT97(^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#4Y
M)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\+W1D/@T*(#QT9#X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0V)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0S)3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,30@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^1&5C96UB97(F(WA!
M,#LS,2P-"B`R,#$R/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T
M<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CX\
M:3Y);B!M:6QL:6]N<SPO:3X\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^5&]T86P\+V(^
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY,979E;"8C>$$P.S$\+V(^/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY,979E;"8C>$$P.S(\+V(^/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,3X\8CY,979E;"8C>$$P.S,\+V(^/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY!<W-E
M=#H\+V(^/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E
M;3L@34%21TE.+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0V%S:`T*(&5Q=6EV86QE
M;G1S)B-X,C`Q-#MM;VYE>2!M87)K971S/"]F;VYT/CPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.S8T+C$\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
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M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(^
M#0H@/'1D/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/'1D(&-O
M;'-P86X],T0T/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/'1D
M(&-O;'-P86X],T0T/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3%E;3L@34%21TE.+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^
M3&EA8FEL:71Y.CPO8CX\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT
M<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY787)R86YT
M(&1E<FEV871I=F4-"B!L:6%B:6QI='D\+V9O;G0^/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^-30N.3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
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M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-
M"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@34%21TE.+4Q%1E0Z
M(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^3&]N9RUT97)M(&1E8G0@<F5D96UP=&EO;@T*(&9E
M871U<F4\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\
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M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
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M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO
M=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P>#L@34%21TE.
M+4)/5%1/33H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@8V%R<GEI;F<@86UO=6YT<R!O
M9@T*(&-A<V@L(&-A<V@@97%U:79A;&5N=',L(&%C8V]U;G1S(')E8V5I=F%B
M;&4L(&%C8V]U;G1S('!A>6%B;&4@86YD#0H@86-C<G5E9"!L:6%B:6QI=&EE
M<R!A<'!R;WAI;6%T92!F86ER('9A;'5E(&)E8V%U<V4@;V8@=&AE:7(-"B!S
M:&]R="UT97)M(&YA='5R92X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%
M1E0Z(#(E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3X\=3Y787)R86YT($1E<FEV871I
M=F4@3&EA8FEL:71Y/"]U/CPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM5$]0.B`V<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^070@1&5C96UB97(F(WA!,#LS,2P@,C`Q,BP-"B!T:&4@9F%I<B!V
M86QU92!O9B!T:&4@=V%R<F%N="!D97)I=F%T:79E(&QI86)I;&ET>2!W87,@
M9&5T97)M:6YE9`T*('1O(&)E("0U-"XY(&UI;&QI;VX@=7-I;F<@=&AE($)L
M86-K+5-C:&]L97,@;W!T:6]N('9A;'5A=&EO;B!M;V1E;`T*(&%P<&QY:6YG
M('1H92!F;VQL;W=I;F<@87-S=6UP=&EO;G,Z("AI*28C>$$P.W)I<VLM9G)E
M92!R871E(&]F#0H@,"XR-24L("AI:2DF(WA!,#MR96UA:6YI;F<@=&5R;2!O
M9B`Q+C@@>65A<G,L("AI:6DI)B-X03`[;F\-"B!D:79I9&5N9"!Y:65L9"P@
M*&EV*28C>$$P.W9O;&%T:6QI='D@;V8@.34E(&%N9"`H=BDF(WA!,#MT:&4@
M<W1O8VL-"B!P<FEC92!O;B!T:&4@9&%T92!O9B!M96%S=7)E;65N="X\+V9O
M;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[($U!4D=)
M3BU"3U143TTZ(#!P>"<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^070@4V5P=&5M8F5R)B-X03`[,S`L
M(#(P,3,L#0H@=&AE(&9A:7(@=F%L=64@;V8@=&AE('=A<G)A;G0@9&5R:79A
M=&EV92!L:6%B:6QI='D@=V%S(&1E=&5R;6EN960-"B!T;R!B92`D,SDN-B!M
M:6QL:6]N('5S:6YG('1H92!";&%C:RU38VAO;&5S(&]P=&EO;B!V86QU871I
M;VX@;6]D96P-"B!A<'!L>6EN9R!T:&4@9F]L;&]W:6YG(&%S<W5M<'1I;VYS
M.B`H:2DF(WA!,#MR:7-K+69R964@<F%T92!O9@T*(#`N,24L("AI:2DF(WA!
M,#MR96UA:6YI;F<@=&5R;2!O9B`Q+C`@>65A<BP@*&EI:2DF(WA!,#MN;R!D
M:79I9&5N9`T*('EI96QD+"`H:78I)B-X03`[=F]L871I;&ET>2!O9B`Y,24L
M(&%N9"`H=BDF(WA!,#MT:&4@<W1O8VL@<')I8V4@;VX-"B!T:&4@9&%T92!O
M9B!M96%S=7)E;65N="XF(WA!,#M4:&4@)#,N-B!M:6QL:6]N(&EN8W)E87-E
M(&EN('1H92!F86ER#0H@=F%L=64@;V8@=&AE('=A<G)A;G0@;&EA8FEL:71Y
M(&1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D#0H@4V5P=&5M8F5R)B-X
M03`[,S`L(#(P,3,@=V%S(')E8V]G;FEZ960@87,Z("AI*28C>$$P.V$@)#,N
M,R!M:6QL:6]N#0H@;&]S<R!O;B!C:&%N9V4@:6X@9F%I<B!V86QU92!O9B!T
M:&4@<F5M86EN:6YG(&1E<FEV871I=F4@;&EA8FEL:71Y#0H@86YD("AI:2DF
M(WA!,#LD,"XS(&UI;&QI;VX@:6X@8V]M<&5N<V%T:6]N(&5X<&5N<V4@9F]R
M(&-H86YG92!I;@T*(&9A:7(@=F%L=64@;V8@=V%R<F%N=',@:7-S=65D('1O
M(&9O<FUE<B!E;7!L;WEE97,N(%1H92`D,34N,PT*(&UI;&QI;VX@9&5C<F5A
M<V4@:6X@=&AE(&9A:7(@=F%L=64@;V8@=&AE('=A<G)A;G0@;&EA8FEL:71Y
M(&1U<FEN9PT*('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F(WA!
M,#LS,"P@,C`Q,R!W87,@<F5C;V=N:7IE9"!A<SH-"B`H:2DF(WA!,#MA("0Q
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M<R!F;W(@=&AE(&YI;F4@;6]N=&AS(&5N9&5D#0H@4V5P=&5M8F5R)B-X03`[
M,S`L(#(P,3,N)B-X03`[5&AE(&9A:7(@=F%L=64@;V8@=&AI<R!W87)R86YT
M#0H@;&EA8FEL:71Y(&ES(&1E=&5R;6EN960@=7-I;F<@=&AE($)L86-K+5-C
M:&]L97,@;W!T:6]N('9A;'5A=&EO;@T*(&UO9&5L(&%N9"!I<R!T:&5R969O
M<F4@<V5N<VET:79E('1O(&-H86YG97,@:6X@=&AE(&UA<FME="!P<FEC92!A
M;F0-"B!V;VQA=&EL:71Y(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O;6UO
M;B!S=&]C:R!A;6]N9R!O=&AE<@T*(&9A8W1O<G,N)B-X03`[26X@=&AE(&5V
M96YT(&]F(&$@:'EP;W1H971I8V%L(#$P)2!I;F-R96%S92!I;B!T:&4-"B!M
M87)K970@<')I8V4@;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@8V]M;6]N('-H
M87)E<R`H)#8N.34@8F%S960@;VX-"B!T:&4@)#8N,S(@;6%R:V5T('!R:6-E
M(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS('-T;V-K(&%T#0H@4V5P=&5M8F5R
M)B-X03`[,S`L(#(P,3,I(&]N('=H:6-H('1H92!397!T96UB97(F(WA!,#LS
M,"P@,C`Q,PT*('9A;'5A=&EO;B!W87,@8F%S960L('1H92!V86QU92!O9B!T
M:&4@9&5R:79A=&EV92!L:6%B:6QI='D@=V]U;&0-"B!H879E(&EN8W)E87-E
M9"!B>2`D-2XP(&UI;&QI;VXN)B-X03`[4W5C:"!I;F-R96%S92!W;W5L9"!H
M879E(&)E96X-"B!R969L96-T960@87,@82!L;W-S(&]N(&-H86YG92!I;B!F
M86ER('9A;'5E(&]F('1H92!W87)R86YT#0H@9&5R:79A=&EV92!L:6%B:6QI
M='D@:6X@=&AE($-O;7!A;GDF(W@R,#$Y.W,@<W1A=&5M96YT(&]F#0H@;W!E
M<F%T:6]N<RX@4VEG;FEF:6-A;G0@:6YC<F5A<V5S("AD96-R96%S97,I(&EN
M('1H:7,@:6YP=70@:6X-"B!I<V]L871I;VX@=V]U;&0@<F5S=6QT(&EN(&$@
M<VEG;FEF:6-A;G1L>2!H:6=H97(@*&QO=V5R*2!F86ER('9A;'5E#0H@87-S
M970@;65A<W5R96UE;G0N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM5$]0.B`Q.'!X.R!-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@
M,7!X)SX-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M,'!X.R!-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R)2<^#0H@
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^/&(^/&D^/'4^3&]N9PT*(%1E<FT@1&5B="!2961E;7!T:6]N
M($9E871U<F4\+W4^/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CY4:&4@0V]M<&%N>28C>#(P,3D[<PT*($1E8V5M8F5R(#(P,3(@9FEN86YC
M:6YG(&%G<F5E;65N="!W:71H($)I;U!H87)M82!396-U<F5D($1E8G0@1G5N
M9`T*($E)($AO;&1I;F=S($-A>6UA;BP@3"Y0+"!O<B!":6]0:&%R;6$L(&-O
M;G1A:6YS(&$@<F5D96UP=&EO;@T*(&9E871U<F4@=VAE<F5B>2P@=7!O;B!A
M(&-H86YG92!O9B!C;VYT<F]L+"!T:&4@0V]M<&%N>2!W;W5L9"!B90T*(')E
M<75I<F5D('1O('!A>2`D,30P(&UI;&QI;VXL(&QE<W,@86YY('!R979I;W5S
M;'D@<F5P86ED(&%M;W5N="P@:68-"B!T:&4@8VAA;F=E(&]F(&-O;G1R;VP@
M;V-C=7)S(&]N(&]R(&)E9F]R92!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S+`T*
M(&]R(')E<75I<F5D('1O(')E<&%Y("0Q-3`@;6EL;&EO;BP@;&5S<R!A;GD@
M<')E=FEO=7-L>2!R97!A:60-"B!A;6]U;G0L(&EF('1H92!C:&%N9V4@;V8@
M8V]N=')O;"!E=F5N="!O8V-U<G,@869T97(-"B!$96-E;6)E<B8C>$$P.S,Q
M+"`R,#$S+B!4:&4@0V]M<&%N>2!D971E<FUI;F5D('1H:7,@<F5D96UP=&EO
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M($%T#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,BP@=&AE(&9A:7(@=F%L=64@
M;V8@=&AE(&1E<FEV871I=F4@=V%S#0H@9&5T97)M:6YE9"!T;R!B92`D,30N
M-B!M:6QL:6]N+"!A;F0@=&AE(&1E8G0@=V%S('9A;'5E9"!B>0T*(&-O;7!A
M<FEN9R!D96)T(&ES<W5E<R!O9B!S:6UI;&%R(&-O;7!A;FEE<R!W:71H("AI
M*28C>$$P.W1E<FUS(&]F#0H@8F5T=V5E;B`T+C@@86YD(#@N,"!Y96%R<RP@
M*&EI*28C>$$P.V-O=7!O;B!R871E<R!O9B!B971W965N(#,N,"4-"B!A;F0@
M,3$N-24@86YD("AI:6DI)B-X03`[;6%R:V5T('EI96QD<R!O9B!B971W965N
M(#$P+C<E(&%N9"`R-RXW)2X-"B!!="!397!T96UB97(F(WA!,#LS,"P@,C`Q
M,RP@=&AE(&9A:7(@=F%L=64@;V8@=&AE(&1E<FEV871I=F4@=V%S#0H@9&5T
M97)M:6YE9"!T;R!B92`D-RXR(&UI;&QI;VXL(&%N9"!T:&4@9&5B="!W87,@
M=F%L=65D(&)Y(&-O;7!A<FEN9PT*(&1E8G0@:7-S=65S(&]F('-I;6EL87(@
M8V]M<&%N:65S('=I=&@@*&DI)B-X03`[<F5M86EN:6YG('1E<FUS(&]F#0H@
M8F5T=V5E;B`S+C4@86YD(#0N-"!Y96%R<RP@*&EI*28C>$$P.V-O=7!O;B!R
M871E<R!O9B!B971W965N(#DN.24-"B!A;F0@,3(N-24@86YD("AI:6DI)B-X
M03`[;6%R:V5T('EI96QD<R!O9B!B971W965N(#$P+C0E(&%N9"`R-2XX)2X-
M"B!4:&4@0V]M<&%N>2!R96-O9VYI>F5D(&$@9V%I;B!O9B`D,2XT(&UI;&QI
M;VX@86YD("0W+C0@;6EL;&EO;B!O;@T*('1H92!C:&%N9V4@:6X@9F%I<B!V
M86QU92!O9B!T:&ES(&1E<FEV871I=F4@;&EA8FEL:71Y(&9O<B!T:&4@=&AR
M964-"B!A;F0@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B-X03`[,S`L
M(#(P,3,L#0H@<F5S<&5C=&EV96QY+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,3AP>#L@34%21TE.+4)/5%1/33H@,'!X.R!-05)'
M24XM3$5&5#H@,B4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/CQU/D9O<F5I9VX@0W5R
M<F5N8WD\+W4^/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!
M;&P@<W5B<VED:6%R:65S('5S92!T:&4-"B!5;FET960@4W1A=&5S(&1O;&QA
M<B!A<R!T:&4@9G5N8W1I;VYA;"!C=7)R96YC>2X@36]N971A<GD@87-S971S
M#0H@86YD(&QI86)I;&ET:65S(&1E;F]M:6YA=&5D(&EN(&$@9F]R96EG;B!C
M=7)R96YC>2!A<F4@<F5M96%S=7)E9`T*(&EN=&\@56YI=&5D(%-T871E<R!D
M;VQL87)S(&%T('!E<FEO9"UE;F0@97AC:&%N9V4@<F%T97,N#0H@3F]N+6UO
M;F5T87)Y(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@8V%R<FEE9"!I;B!A(&9O
M<F5I9VX@8W5R<F5N8WD-"B!A<F4@<F5M96%S=7)E9"!I;G1O(%5N:71E9"!3
M=&%T97,@9&]L;&%R<R!U<VEN9R!R871E<R!O9B!E>&-H86YG90T*('!R979A
M:6QI;F<@=VAE;B!S=6-H(&%S<V5T<R!O<B!L:6%B:6QI=&EE<R!W97)E(&]B
M=&%I;F5D(&]R#0H@:6YC=7)R960L(&%N9"!E>'!E;G-E<R!A<F4@9V5N97)A
M;&QY(')E;65A<W5R960@=7-I;F<@<F%T97,@;V8-"B!E>&-H86YG92!P<F5V
M86EL:6YG('=H96X@<W5C:"!E>'!E;G-E<R!A<F4@:6YC=7)R960N($=A:6YS
M(&%N9`T*(&QO<W-E<R!F<F]M('1H92!R96UE87-U<F5M96YT(&%R92!I;F-L
M=61E9"!I;B!O=&AE<B`H97AP96YS92D-"B!I;F-O;64L(&YE="!I;B!T:&4@
M8V]N<V]L:61A=&5D('-T871E;65N=',@;V8@;W!E<F%T:6]N<RX@1F]R#0H@
M=')A;G-A8W1I;VYS('-E='1L960@9'5R:6YG('1H92!A<'!L:6-A8FQE('!E
M<FEO9"P@9V%I;G,@86YD(&QO<W-E<PT*(&%R92!I;F-L=61E9"!I;B!O=&AE
M<B`H97AP96YS92D@:6YC;VUE+"!N970@:6X@=&AE(&-O;G-O;&ED871E9`T*
M('-T871E;65N=',@;V8@;W!E<F%T:6]N<RX@5&AE($-O;7!A;GD@<&5R:6]D
M:6-A;&QY('5S97,@9F]R96EG;@T*(&5X8VAA;F=E(&9O<G=A<F0@8V]N=')A
M8W1S('1O(&AE9&=E(&%G86EN<W0@8VAA;F=E<R!I;B!E>&-H86YG90T*(')A
M=&5S(&9O<B!I;G9E;G1O<GD@<'5R8VAA<V5S(&1E;F]M:6YA=&5D(&EN(&9O
M<F5I9VX@8W5R<F5N8WDN($%S#0H@;V8F(WA!,#M397!T96UB97(@,S`L(#(P
M,3,L('1H92!#;VUP86YY(&AE;&0@;VYE(&9O<F5I9VX@97AC:&%N9V4-"B!F
M;W)W87)D(&-O;G1R86-T('=I=&@@82!N;W1I;VYA;"!A;6]U;G0@;V8@)#0N
M-2!M:6QL:6]N+B!!<PT*(&]F)B-X03`[4V5P=&5M8F5R(#,P+"`R,#$S+"!T
M:&4@;W5T<W1A;F1I;F<@9F]R96EG;B!E>&-H86YG90T*(&9O<G=A<F0@8V]N
M=')A8W0@9&5R:79A=&EV92!L:6%B:6QI='D@:&%D(&$@;F5T(&9A:7(@=F%L
M=64@;V8@)#`N-`T*(&UI;&QI;VXN(%1H92!#;VUP86YY(&EN8VQU9&5D('1H
M:7,@)#`N-"!M:6QL:6]N(&%S(&$@8V]M<&]N96YT(&]F#0H@8VAA;F=E(&EN
M(&9A:7(@=F%L=64@;V8@9&5R:79A=&EV92!L:6%B:6QI=&EE<R!A;F0@:6X@
M;W1H97(@8W5R<F5N=`T*(&QI86)I;&ET:65S(&%T(%-E<'1E;6)E<B8C>$$P
M.S,P+"`R,#$S+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@,3)P>#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@8VAA
M;F=E(&EN('1H92!F86ER#0H@=F%L=64@;V8@9FEN86YC:6%L(&EN<W1R=6UE
M;G1S(&ES(&%S(&9O;&QO=W,@*&EN#0H@=&AO=7-A;F1S*3H\+V9O;G0^/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/
M33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B
M;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8F]R9&5R
M/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M.3(E(&%L:6=N/3-$8V5N=&5R/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U.24^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*
M(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0Q/CQB/D]C=&]B97(\+V(^/"]F;VYT/CQB<B`O/@T*
M(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0Q/CQB/C(P,#D\+V(^/"]F;VYT/CQB<B`O/@T*(#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q
M/CQB/B8C>$$P.R8C>$$P.U=A<G)A;G1S)B-X03`[)B-X03`[/"]B/CPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT
M97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#$^/&(^1&5B=#PO8CX\+V9O;G0^/&)R("\^#0H@/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#$^/&(^)B-X03`[)B-X03`[4F5D96UP=&EO;B8C>$$P.R`F(WA!,#L\+V(^
M/"]F;VYT/CQB<B`O/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/D9E871U<F4\+V(^/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E
M<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,3X\8CY&;W)E:6=N/"]B/CPO9F]N=#X\8G(@+SX-"B`\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,3X\8CY%>&-H86YG93PO8CX\+V9O;G0^/&)R("\^#0H@/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^
M/&(^)B-X03`[)B-X03`[0V]N=')A8W1S)B-X03`[)B-X03`[/"]B/CPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#$^/&(^)B-X03`[)B-X03`[)B-X03`[)B-X03`[
M5&]T86QS)B-X03`[)B-X03`[)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D/CPO=&0^#0H@/'1D
M(&-O;'-P86X],T0T/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@
M/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^
M#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@34%2
M1TE.+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^0F%L86YC92!A=`T*($IA;G5A
M<GDF(WA!,#LQ+"`R,#$R/"]B/CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^
M)#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^/&(^,3(S+#$R-3PO8CX\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CX\8CXF(WA!,#LF(WA!,#L\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B0\+V(^/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/CQB/B8C>#(P,30[)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/CQB/B8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)#PO8CX\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^/&(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V(^/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M/&(^)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
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M>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9#X\
M+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$
M-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N
M/3-$-#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,1494
M.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/DQO<W,@;VX@8VAA;F=E(&EN(&9A:7(-"B!V86QU
M92!O9B!D97)I=F%T:79E(&QI86)I;&ET>3PO9F]N=#X\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
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M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXV."PV.#8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M
M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#;VUP96YS871I;VX@97AP
M96YS92!F;W(-"B!C:&%N9V4@:6X@9F%I<B!V86QU92!O9B!W87)R86YT<R!I
M<W-U960@=&\@9F]R;65R#0H@96UP;&]Y965S/"]F;VYT/CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,RPP,S<\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXS+#`S-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,1494
M.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/E1R86YS9F5R<R!T;PT*(&5Q=6ET>3PO9F]N=#X\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@Q,#,L.#@U/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXH,3`S+#@X-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L<W!A
M;CTS1#0^/"]T9#X-"B`\=&0@8V]L<W!A;CTS1#0^/"]T9#X-"B`\=&0@8V]L
M<W!A;CTS1#0^/"]T9#X-"B`\=&0@8V]L<W!A;CTS1#0^/"]T9#X-"B`\+W1R
M/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&
M5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CX\8CY"86QA;F-E(&%T#0H@4V5P=&5M8F5R)B-X
M03`[,S`L(#(P,3(\+V(^/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT
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M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^
M)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXD/"]B/CPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CX\8CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\
M8CXF(WA!,#L\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B0\+V(^/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB
M/B8C>#(P,30[)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B8C
M>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)#PO8CX\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M/&(^.3`L.38S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B8C>$$P.R8C>$$P.SPO
M8CX\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL
M93TS1"=-05)'24XM5$]0.B`P<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@1D].
M5"U325I%.B`Q,G!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$
M)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&)O<F1E<CTS1#`@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS
M1&-E;G1E<CX-"B`\='(^#0H@/'1D('=I9'1H/3-$-3@E/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,3X\8CY/8W1O8F5R/"]B/CPO9F]N=#X\8G(@+SX-"B`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\
M8CXR,#`Y/"]B/CPO9F]N=#X\8G(@+SX-"B`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXF(WA!,#LF
M(WA!,#M787)R86YT<R8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q
M/CQB/D1E8G0\+V(^/"]F;VYT/CQB<B`O/@T*(#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/B8C>$$P
M.R8C>$$P.U)E9&5M<'1I;VXF(WA!,#L@)B-X03`[/"]B/CPO9F]N=#X\8G(@
M+SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,3X\8CY&96%T=7)E/"]B/CPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^
M/&(^1F]R96EG;CPO8CX\+V9O;G0^/&)R("\^#0H@/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^17AC
M:&%N9V4\+V(^/"]F;VYT/CQB<B`O/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/B8C>$$P.R8C
M>$$P.T-O;G1R86-T<R8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0Q/CQB/B8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.U1O=&%L<R8C>$$P
M.R8C>$$P.R8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#PO='(^#0H@/'1R/@T*(#QT9#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$
M-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N
M/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#PO='(^#0H@
M/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,1494.B`Q
M96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/CQB/D)A;&%N8V4@870-"B!*86YU87)Y)B-X03`[,2P@
M,C`Q,SPO8CX\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B0\+V(^/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/CQB/C4T+#@U-#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXF(WA!,#LF
M(WA!,#L\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/CQB/B0\+V(^/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/C$T
M+#4W-SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXF(WA!,#LF(WA!,#L\+V(^/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/CQB/B0\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B8C>#(P,30[)B-X03`[
M)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B8C>$$P.SPO8CX\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^/&(^)#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^-CDL-#,Q/"]B/CPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/CQB/B8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R/@T*(#QT9#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$
M-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N
M/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#PO='(^#0H@
M/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ96T[($U!4D=)3BU,1494.B`Q96TG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BA'86EN
M*2!L;W-S(&]N(&-H86YG92!I;@T*(&9A:7(@=F%L=64@;V8@9&5R:79A=&EV
M92!L:6%B:6QI=&EE<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B@Q-"PP-S<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH-RPS-S<\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS.34\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B@R,2PP-3D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E
M;3L@34%21TE.+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0V]M<&5N<V%T:6]N(&EN
M8V]M92!F;W(-"B!C:&%N9V4@:6X@9F%I<B!V86QU92!O9B!W87)R86YT<R!I
M<W-U960@=&\@9F]R;65R#0H@96UP;&]Y965S/"]F;VYT/CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#$L,3<Y/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT
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M9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CY4<F%N<V9E<G,@=&\-"B!E<75I='D\+V9O;G0^/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
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M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
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M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9#X\+W1D
M/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\
M+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$
M-#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M96T[($U!4D=)3BU,1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/D)A;&%N8V4@870-
M"B!397!T96UB97(F(WA!,#LS,"P@,C`Q,SPO8CX\+V9O;G0^/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/CQB/B0\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/C,Y+#4Y.#PO8CX\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CX\8CXF(WA!,#LF(WA!,#L\+V(^/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B0\
M+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/CQB/C<L,C`P/"]B/CPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB
M/B8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)#PO8CX\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^/&(^,SDU/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B8C>$$P.R8C>$$P.SPO
M8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^/&(^)#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^-#<L
M,3DS/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B8C>$$P.R8C>$$P.SPO8CX\+V9O
M;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-
M05)'24XM5$]0.B`Q.'!X.R!-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:
M13H@,7!X)SX-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@,'!X.R!-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R)2<^
M#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^/&(^/&D^/'4^4V5G;65N="!A;F0@1V5O9W)A<&AI8V%L
M#0H@26YF;W)M871I;VX\+W4^/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@,'!X)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CY&;W(@=&AE('1H<F5E(&%N9"!N:6YE#0H@;6]N=&AS(&5N9&5D
M(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S(&%N9"`R,#$R+"!T:&4@0V]M<&%N
M>2!H87,-"B!R97!O<G1E9"!I=',@8G5S:6YE<W,@87,@82!S:6YG;&4@<F5P
M;W)T:6YG('-E9VUE;G0N(%1H90T*($-O;7!A;GDF(W@R,#$Y.W,@8VAI968@
M9&5C:7-I;VX@;6%K97(L('=H;R!I<R!T:&4@0VAI968@17AE8W5T:79E#0H@
M3V9F:6-E<BP@<F5G=6QA<FQY(&5V86QU871E<R!T:&4@0V]M<&%N>2!O;B!A
M(&-O;G-O;&ED871E9`T*(&)A<VES+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,3AP>#L@34%21TE.+4)/5%1/33H@,'!X.R!-05)'
M24XM3$5&5#H@,B4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/CQU/E)E8V5N=`T*($%C
M8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+W4^/"]I/CPO8CX\+V9O;G0^/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/
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M>28C>#(P,3D[<R!O<&5R871I;VYS+CPO9F]N=#X\+W`^#0H@/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN=&%N9VEB;&4@07-S970\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT86YG:6)L92!!
M<W-E=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@
M/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&)O
M<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#$P,"4^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0T
M)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^*#,I/"]B/CPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB
M/DEN=&%N9VEB;&4-"B!!<W-E=#PO8CX\+V9O;G0^/"]T9#X-"B`\+W1R/@T*
M(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!X.R!-05)'
M24XM0D]45$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN=&%N9VEB;&4@87-S970@8V]N
M<VES=',-"B!O9B!T96-H;F]L;V=Y(')I9VAT<R!F;W(@5F%S8V5P82!A;F0@
M:&%V92!A;B!E<W1I;6%T960@<F5M86EN:6YG#0H@=7-E9G5L(&QI9F4@;V8@
M,38N."!Y96%R<RX@5&AE(&-A<G)Y:6YG('9A;'5E(&%S(&]F#0H@4V5P=&5M
M8F5R)B-X03`[,S`L(#(P,3,@86YD($1E8V5M8F5R)B-X03`[,S$L(#(P,3(@
M:7,@87,@9F]L;&]W<PT*("AI;B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!X.R!-05)'24XM0D]45$]-.B`P
M<'@[($9/3E0M4TE:13H@,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S
M='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!B;W)D97(],T0P
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@
M86QI9VX],T1C96YT97(^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#8T)3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\
M8CY397!T96UB97(F(WA!,#LS,"PF(WA!,#LR,#$S/"]B/CPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#$^/&(^1&5C96UB97(F(WA!,#LS,2PF(WA!,#LR,#$R/"]B/CPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3%E;3L@34%21TE.+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&5C
M:&YO;&]G>0T*(')I9VAT<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
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M:7IE/3-$,CXQ,2PV,C0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,2PV,C0\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-
M05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!8V-U;75L871E9`T*(&%M;W)T
M:7IA=&EO;CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B@W-30\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXH,C8Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N
M=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3`L.#<P/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3$L,S4U/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^
M#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN=F5N=&]R>3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O
M<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QT
M86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!B;W)D
M97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0Q,#`E/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$-"4@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B@T*3PO8CX\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY)
M;G9E;G1O<GD\+V(^/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@
M,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CY!9G1E<B!A<'!R;W9A;"!O9B!687-C97!A#0H@;VX@
M2G5L>28C>$$P.S(V+"`R,#$R(&)Y('1H92!&1$$L('1H92!#;VUP86YY(&)E
M9V%N(&-A<&ET86QI>FEN9PT*(&ET<R!P=7)C:&%S97,@;V8@<V%L96%B;&4@
M:6YV96YT;W)Y(&]F(%9A<V-E<&$@9G)O;2!S=7!P;&EE<G,@=&AA=`T*(&AA
M=F4@8F5E;B!Q=6%L:69I960@8GD@=&AE($9$02X@26YV96YT;W)I97,@8V]N
M<VES="!O9B!T:&4-"B!F;VQL;W=I;F<@870@4V5P=&5M8F5R)B-X03`[,S`L
M(#(P,3,@86YD($1E8V5M8F5R)B-X03`[,S$L(#(P,3(@*&EN#0H@=&AO=7-A
M;F1S*3H\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P
M>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*("8C
M>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C
M;VQL87!S92<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$-S8E(&%L:6=N/3-$8V5N=&5R/@T*(#QT<CX-"B`\
M=&0@=VED=&@],T0V-"4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^
M#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#$^/&(^4V5P=&5M8F5R)B-X03`[,S`L)B-X03`[
M,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/D1E8V5M8F5R)B-X
M03`[,S$L)B-X03`[,C`Q,CPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)
M3BU,1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/E)A=R!M871E<FEA;',\+V9O;G0^/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-"PY.3,\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,1494.B`Q96TG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/E=O<FL@:6X@<')O8V5S<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
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M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,34L-#<Q
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T
M<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@34%21TE.+4Q%
M1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^1FEN:7-H960@9V]O9',\+V9O;G0^/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
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M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^,S(V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@34%21TE.+4Q%1E0Z(#%E;2<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^1FEN:7-H960@9V]O9',@:6YV96YT;W)Y#0H@:&5L9"!B>2!O
M=&AE<G,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXV-#$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@=F%L
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M:7IE/3-$,CXR-RPP.#,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
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M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\
M<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'24XM0D]45$]-.B`P
M<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/DEN=F5N=&]R>2!I<R!V86QU960@870-"B!L;W=E<B!O
M9B!C;W-T(&]R(&UA<FME="!V86QU92X@1'5R:6YG('1H92!T:')E92!M;VYT
M:',@96YD960-"B!397!T96UB97(F(WA!,#LS,"P@,C`Q,RP@=&AE($-O;7!A
M;GD@<F5C;W)D960@86X@:6YV96YT;W)Y(')E<V5R=F4-"B!O9B`D,2XX(&UI
M;&QI;VX@<F5L871E9"!T;R!C97)T86EN(&EN=F5N=&]R:65S('1H870@87)E
M(&YO=`T*(')E8V]V97)A8FQE(&EN('1H96ER(&-U<G)E;G0@9F]R;2X@5&AE
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M(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?93!F.&4Q93A?,C8V9%\T8F8T7V$X.39?,V-E.3AC9C4U86$V#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4P9CAE,64X7S(V-F1?-&)F-%]A
M.#DV7S-C93DX8V8U-6%A-B]7;W)K<VAE971S+U-H965T,3$N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY787)R86YT<R!A;F0@
M5V%R<F%N="!$97)I=F%T:79E($QI86)I;&ET>3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!A;F0@5V%R<F%N="!$
M97)I=F%T:79E($QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQD:78^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!3
M13H@8V]L;&%P<V4G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H@/'1R/@T*(#QT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0T)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^*#4I
M/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/CQB/E=A<G)A;G1S(&%N9"!787)R86YT#0H@1&5R:79A
M=&EV92!,:6%B:6QI='D\+V(^/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\+W1A
M8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/
M5%1/33H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!H860@.2PX,38L.#(V
M#0H@=V%R<F%N=',@=&\@<'5R8VAA<V4@8V]M;6]N('-H87)E<R!O=71S=&%N
M9&EN9R!A=`T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S(&%T(&$@=V5I9VAT
M960M879E<F%G92!E>&5R8VES92!P<FEC92!O9@T*("0Q+C0T+"!A<R!S=6UM
M87)I>F5D(&EN('1H92!F;VQL;W=I;F<@=&%B;&4Z/"]F;VYT/CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($U!4D=)3BU"3U143TTZ(#!P
M>#L@1D].5"U325I%.B`Q,G!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T
M>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&)O<F1E<CTS1#`@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T)2!A
M;&EG;CTS1&-E;G1E<CX-"B`\='(^#0H@/'1D('-T>6QE/3-$)U=)1%1(.B`Q
M-W!T)SX\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!S='EL
M93TS1"=724142#H@,3=P="<^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,C,E/CPO=&0^#0H@/'1D('-T>6QE/3-$)U=)1%1(.B`Q-'!T
M)SX\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!S='EL93TS
M1"=724142#H@,31P="<^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,C,E/CPO=&0^#0H@/'1D('-T>6QE/3-$)U=)1%1(.B`R-'!T)SX\
M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!S='EL93TS1"=7
M24142#H@,C1P="<^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,C,E/CPO=&0^#0H@/'1D('-T>6QE/3-$)U=)1%1(.B`R-W!T)SX\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!S='EL93TS1"=72414
M2#H@,C=P="<^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$-"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY)
M<W-U90T*($1A=&4\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-"!A;&EG;CTS1&-E;G1E
M<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,3X\8CY!;6]U;G0\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-"!A;&EG
M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY%>&5R8VES928C>$$P.U!R:6-E/"]B
M/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#0@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^
M17AP:7)A=&EO;B8C>$$P.T1A=&4\+V(^/"]F;VYT/CPO=&0^#0H@/"]T<CX-
M"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT+S(W
M+S`W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$W+#4P,#PO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^,3<N.3`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
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M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
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M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#8X
M-"PX.#@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXW+S,P+S$T/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
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M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW+#0X-RPS
M.#@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
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M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
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M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3`O,38O,#D\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^-C(W+#`U,#PO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
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M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$P+S$U+S$T/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B8C>$$P.SPO8CX\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^/&(^.2PX,38L.#(V/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B8C>$$P
M.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^
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M8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\
M+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'@[($U!4D=)
M3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@G/@T*("8C>$$P.SPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($U!4D=)3BU"3U143TTZ
M(#!P>#L@34%21TE.+4Q%1E0Z(#(E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\:3X\=3Y/8W1O
M8F5R#0H@,C`P.2!787)R86YT(&1E<FEV871I=F4@;&EA8FEL:71Y/"]U/CPO
M:3X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@
M34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/;B!/8W1O8F5R)B-X03`[
M,38L(#(P,#DL#0H@=&AE($-O;7!A;GD@8V]M<&QE=&5D(&$@)#<P+C`@;6EL
M;&EO;B!P<FEV871E('!L86-E;65N="!W:71H(&)O=&@-"B!E>&ES=&EN9R!A
M;F0@;F5W(&EN=F5S=&]R<R!R97-U;'1I;F<@:6X@)#8R+C,@;6EL;&EO;B!I
M;B!N970-"B!P<F]C965D<R!A;F0@86X@861D:71I;VYA;"`D,RXV(&UI;&QI
M;VX@9G)O;2!B<FED9V4@;F]T97,@8V]N=F5R=&5D#0H@:6X@8V]N:G5N8W1I
M;VX@=VET:"!T:&4@<')I=F%T92!P;&%C96UE;G0N($EN(&-O;G-I9&5R871I
M;VX@9F]R('1H90T*("0V,BXS(&UI;&QI;VX@:6X@;F5T(&-A<V@@<')O8V5E
M9',@06UA<FEN(&ES<W5E9"`V-BXT)B-X03`[;6EL;&EO;@T*('5N:71S+"!E
M86-H('5N:70@8V]N<VES=&EN9R!O9B`H:2DF(WA!,#MO;F4@0413("AR97!R
M97-E;G1I;F<@;VYE#0H@;W)D:6YA<GD@<VAA<F4I(&%T(&$@<'5R8VAA<V4@
M<')I8V4@;V8@)#$N,#`@86YD("AI:2DF(WA!,#MA#0H@=V%R<F%N="!W:71H
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M:6YG(&]F("AI*28C>$$P.V]N90T*($%$4R`H<F5P<F5S96YT:6YG(&]N92!O
M<F1I;F%R>2!S:&%R92D@870@82!P=7)C:&%S92!P<FEC92!O9B`D,"XY,`T*
M(&%N9"`H:6DI)B-X03`[82!W87)R86YT('=I=&@@82!F:79E('EE87(@=&5R
M;2!T;R!P=7)C:&%S92`P+C4@;V8@86X-"B!!1%,@870@86X@97AE<F-I<V4@
M<')I8V4@;V8@)#$N-3`@<&5R($%$4RX@5&AE('1O=&%L(&YU;6)E<B!O9@T*
M('=A<G)A;G1S(&ES<W5E9"!I;B!C;VYJ=6YC=&EO;B!W:71H('1H92!F:6YA
M;F-I;F<@=V%S#0H@,S4N,B8C>$$P.VUI;&QI;VX@;V8@=VAI8V@@-RXU)B-X
M03`[;6EL;&EO;B!A<F4@;W5T<W1A;F1I;F<@870-"B!397!T96UB97(F(WA!
M,#LS,"P@,C`Q,RX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#$R<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^26X@8V]N
M:G5N8W1I;VX@=VET:"!T:&4-"B!/8W1O8F5R(#(P,#D@9FEN86YC:6YG+"!T
M:&4@0V]M<&%N>2!I<W-U960@86X@861D:71I;VYA;`T*(#`N.28C>$$P.VUI
M;&QI;VX@=V%R<F%N=',@=&\@=&AR964@9F]R;65R(&]F9FEC97)S(&]F('=H
M:6-H#0H@,"XV)B-X03`[;6EL;&EO;B!A<F4@;W5T<W1A;F1I;F<@87,@;V8@
M4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,N(%1H90T*('=A<G)A;G1S(&ES<W5E
M9"!I;B!C;VYN96-T:6]N('=I=&@@=&AE($]C=&]B97(@,C`P.2!F:6YA;F-I
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M8V4@;&5S<R!T:&%N('1H92`F(WA!,SLP+C4@<&%R('9A;'5E(&]F('1H90T*
M(&-O;6UO;B!S=&]C:R`F(W@R,#$S.R!T:&%T(&ES+"!I9B!T:&4@97AC:&%N
M9V4@<F%T92!E>&-E961E9"!5+E,N#0H@)#,N,#`@<&5R("8C>$$S.S$N,"!S
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M<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'24XM0D]4
M5$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
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M86)L92!A<R!A(')E<W5L=`T*(&]F('1H92!/8W1O8F5R(#(P,#D@<')I=F%T
M92!P;&%C96UE;G0@:7,@,S8N,2!M:6QL:6]N+B!4:&4@8VAA;F=E#0H@:6X@
M9F%I<B!V86QU92!O9B!T:&4@=V%R<F%N="!D97)I=F%T:79E(&QI86)I;&ET
M>2!I<R!D:7-C=7-S960@:6X-"B!.;W1E(#(N/"]F;VYT/CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`Q.'!X.R!-05)'24XM0D]45$]-.B`P<'@[
M($U!4D=)3BU,1494.B`R)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&D^/'4^2G5L>2`R,#`Y
M#0H@86YD($%P<FEL(#(P,#<@5V%R<F%N=',\+W4^/"]I/CPO9F]N=#X\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!X.R!-05)'24XM0D]45$]-
M.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/E1H92!#;VUP86YY(&ES<W5E9"!C97)T86EN#0H@
M=V%R<F%N=',@:6X@2G5L>2`R,#`Y(&%N9"!!<')I;"`R,#`W+B!!<R!O9B!3
M97!T96UB97(F(WA!,#LS,"P@,C`Q,PT*(&%N9"!$96-E;6)E<B8C>$$P.S,Q
M+"`R,#$R('1H97-E('=A<G)A;G1S(&AA=F4@8F5E;B!C;&%S<VEF:65D(&%S
M#0H@97%U:71Y(&EN<W1R=6UE;G1S(&%N9"!H879E(&)E96X@:6YC;'5D960@
M:6X@=&AE($-O;7!A;GDF(W@R,#$Y.W,-"B!C;VYS;VQI9&%T960@8F%L86YC
M92!S:&5E="!W:71H:6X@861D:71I;VYA;"!P86ED+6EN+6-A<&ET86PN#0H@
M1'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F(WA!,#LS
M,"P@,C`Q,RP@,3(P+#`P,"!O9@T*('1H92!*=6QY(#(P,#D@=V%R<F%N=',@
M=V5R92!E>&5R8VES960@<F5S=6QT:6YG(&EN('!R;V-E961S('1O('1H90T*
M($-O;7!A;GD@;V8@)#`N,2!M:6QL:6]N+CPO9F]N=#X\+W`^#0H@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1E8G0\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5B=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'1A8FQE('-T>6QE/3-$0D]21$52
M+4-/3$Q!4%-%.D-/3$Q!4%-%(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P
M(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H@/'1R/@T*(#QT9"!W
M:61T:#TS1#0E('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\
M8CXH-BD\+V(^/"]F;VYT/CPO=&0^#0H@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CX\8CY$96)T/"]B/CPO9F]N=#X\+W1D/@T*(#PO
M='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM
M87)G:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z,B4G/@T*(#QF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M/&D^/'4^3&]N9R!T97)M#0H@9&5B="8C>#(P,30[1&5C96UB97(@,C`Q,B!&
M:6YA;F-I;F<\+W4^/"]I/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T1M87)G
M:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]N($1E8V5M
M8F5R)B-X03`[-BP@,C`Q,BP-"B!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@
M86X@86=R965M96YT('=I=&@@0FEO4&AA<FUA+B!5;F1E<B!T:&ES#0H@86=R
M965M96YT+"!T:&4@0V]M<&%N>2!G<F%N=&5D('1O($)I;U!H87)M82!A('-E
M8W5R:71Y(&EN=&5R97-T(&EN#0H@9G5T=7)E(')E8V5I=F%B;&5S(&%S<V]C
M:6%T960@=VET:"!T:&4@5F%S8V5P82!P871E;G0@<FEG:'1S(&EN#0H@97AC
M:&%N9V4@9F]R("0Q,#`N,"!M:6QL:6]N(')E8V5I=F5D(&%T('1H92!C;&]S
M:6YG(&]F('1H90T*(&%G<F5E;65N="P@=VAI8V@@8VQO<VEN9R!O8V-U<G)E
M9"!I;B!$96-E;6)E<B`R,#$R+B!4:&4@0V]M<&%N>2!H87,-"B!A9W)E960@
M=&\@<F5P87D@0FEO4&AA<FUA('5P('1O("0Q-3`F(WA!,#MM:6QL:6]N(&]F
M(&9U='5R92!R979E;G5E#0H@86YD(')E8V5I=F%B;&5S+B!4:&4@9FER<W0@
M<V-H961U;&5D(')E<&%Y;65N="!U;F1E<B!T:&4@86=R965M96YT#0H@:7,@
M82!R97!A>6UE;G0@;V8@)#(N-28C>$$P.VUI;&QI;VX@;V8@:6YT97)E<W0@
M9'5E('1O(&)E('!A:60@=&\-"B!":6]0:&%R;6$@:6X@3F]V96UB97(@,C`Q
M,R!F;W(@=&AE(&9I<V-A;"!Q=6%R=&5R(&5N9&5D#0H@4V5P=&5M8F5R)B-X
M03`[,S`L(#(P,3,L('-U8FIE8W0@=&\@=&AE(&QI;6ET871I;VX@9&5S8W)I
M8F5D(&)E;&]W+@T*($%D9&ET:6]N86P@<75A<G1E<FQY(')E<&%Y;65N=',@
M87)E('-C:&5D=6QE9"!T;R!B92!P86ED('1H97)E869T97(-"B!I;B!A8V-O
M<F1A;F-E('=I=&@@=&AE(&9O;&QO=VEN9R!S8VAE9'5L93H@)#(N-2!M:6QL
M:6]N(&]F(&EN=&5R97-T#0H@:6X@=&AE(&9I<G-T('%U87)T97(@;V8@,C`Q
M-#L@)#@N,"!M:6QL:6]N('!E<B!Q=6%R=&5R(&EN(&5A8V@@;V8-"B!T:&4@
M;F5X="!F;W5R('%U87)T97)S+"`D,3`N,"!M:6QL:6]N('!E<B!Q=6%R=&5R
M(&EN(&5A8V@@;V8@=&AE#0H@;F5X="!F;W5R('%U87)T97)S+"`D,34N,"!M
M:6QL:6]N('!E<B!Q=6%R=&5R(&EN(&5A8V@@;V8@=&AE(&YE>'0-"B!F;W5R
M('%U87)T97)S(&%N9"!A(&9I;F%L('!A>6UE;G0@;V8@)#$S+C`@;6EL;&EO
M;B!S8VAE9'5L960@9F]R#0H@<&%Y;65N="!I;B!-87D@,C`Q-RX@5&AE('%U
M87)T97)L>2!R97!A>6UE;G1S('1H<F]U9V@@=&AE('1H:7)D#0H@<75A<G1E
M<B!O9B!397!T96UB97(@,C`Q-"!R97!R97-E;G0@:6YT97)E<W0@;VYL>2X@
M475A<G1E<FQY#0H@<&%Y;65N=',@9&\@;F]T(&)E9VEN('1O(')E9'5C92!T
M:&4@<')I;F-I<&%L(&)A;&%N8V4@=6YT:6P@=&AE#0H@9F]U<G1H('%U87)T
M97(@;V8@,C`Q-"X@5&AE<V4@<75A<G1E<FQY('!A>6UE;G1S(&%R92!S=6)J
M96-T('1O(&$-"B!Q=6%R=&5R;'D@=&AR97-H;VQD(&%M;W5N="!W:&5R96)Y
M+"!I9B!A(&-A;&-U;&%T960@=&AR97-H;VQD+`T*(&)A<V5D(&]N('%U87)T
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M5&AE('!A>6UE;G0@;V8@86YY(&-A<G)I960@9F]R=V%R9`T*(&%M;W5N="!I
M<R!S=6)J96-T('1O('-I;6EL87)L>2!C86QC=6QA=&5D('1H<F5S:&]L9"!R
M97!A>6UE;G0-"B!A;6]U;G1S(&)A<V5D(&]N(%9A<V-E<&$@<F5V96YU92!L
M979E;',N($5X8V5P="!U<&]N(&$@8VAA;F=E(&]F#0H@8V]N=')O;"!I;B!!
M;6%R:6XL('1H92!A9W)E96UE;G0@9&]E<R!N;W0@97AP:7)E('5N=&EL("0Q
M-3`@;6EL;&EO;@T*(&AA<R!B965N(')E<&%I9"X@56YD97(@=&AE(&%G<F5E
M;65N="P@=7!O;B!A(&-H86YG92!O9B!C;VYT<F]L+"!T:&4-"B!#;VUP86YY
M('=O=6QD(&)E(')E<75I<F5D('1O('!A>2`D,30P(&UI;&QI;VXL(&QE<W,@
M86YY('!R979I;W5S;'D-"B!R97!A:60@86UO=6YT+"!I9B!T:&4@8VAA;F=E
M(&]F(&-O;G1R;VP@;V-C=7)S(&]N(&]R(&)E9F]R90T*($1E8V5M8F5R)B-X
M03`[,S$L(#(P,3,L(&]R(')E<75I<F5D('1O(')E<&%Y("0Q-3`@;6EL;&EO
M;BP@;&5S<R!A;GD-"B!P<F5V:6]U<VQY(')E<&%I9"!A;6]U;G0L(&EF('1H
M92!C:&%N9V4@;V8@8V]N=')O;"!E=F5N="!O8V-U<G,-"B!A9G1E<B!$96-E
M;6)E<B8C>$$P.S,Q+"`R,#$S+B!4:&4@0V]M<&%N>2!C86X@<')E<&%Y(&%F
M=&5R#0H@3V-T;V)E<B8C>$$P.S$L(#(P,3,L(&%N(&%M;W5N="!E<75A;"!T
M;R`D,34P(&UI;&QI;VX@;&5S<R!A;GD-"B!P<F5V:6]U<VQY(')E<&%I9"!A
M;6]U;G0N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1&UA<F=I;BUT;W`Z,3)P
M>#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!#;VUP86YY(&1E=&5R
M;6EN960@=&AE#0H@<F5D96UP=&EO;B!F96%T=7)E('5P;VX@82!C:&%N9V4@
M;V8@8V]N=')O;"!T;R!B92!A;B!E;6)E9&1E9`T*(&1E<FEV871I=F4@<F5Q
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M92!L:6%B:6QI='D@:7,@<F5M96%S=7)E9`T*(&%T(&5A8V@@<F5P;W)T:6YG
M('!E<FEO9"P@=VET:"!C:&%N9V5S(&EN(&9A:7(@=F%L=64@<F5C;V=N:7IE
M9"!I;@T*('1H92!S=&%T96UE;G0@;V8@;W!E<F%T:6]N<RX@5&AE(&9A:7(@
M=F%L=64@;V8@=&AE(&1E<FEV871I=F4-"B!L:6%B:6QI='D@870@4V5P=&5M
M8F5R)B-X03`[,S`L(#(P,3,@=V%S("0W+C(@;6EL;&EO;B!A;F0@=&AE#0H@
M0V]M<&%N>2!R96-O9VYI>F5D(&$@9V%I;B!O;B!C:&%N9V4@:6X@9F%I<B!V
M86QU92!O9B!D97)I=F%T:79E#0H@;&EA8FEL:71Y(&]F("0Q+C0@;6EL;&EO
M;B!A;F0@)#<N-"!M:6QL:6]N(&9O<B!T:&4@=&AR964@86YD(&YI;F4-"B!M
M;VYT:"!P97)I;V1S(&5N9&5D(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S+"!R
M97-P96-T:79E;'DN($9O<B!T:&4-"B!N:6YE(&UO;G1H<R!E;F1E9"!397!T
M96UB97(F(WA!,#LS,"P@,C`Q,RP@=&AE($-O;7!A;GD@<F5C;W)D960-"B`D
M.2XW)B-X03`[;6EL;&EO;B!A;F0@)#(N,B!M:6QL:6]N(&]F(&-A<V@@86YD
M(&YO;BUC87-H(&EN=&5R97-T#0H@97AP96YS92P@<F5S<&5C=&EV96QY(')E
M;&%T960@=&\@=&AE($)I;U!H87)M82!D96)T+B!&;W(@=&AE('1H<F5E#0H@
M;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S+"!T:&4@0V]M
M<&%N>2!R96-O<F1E9`T*("0R+C<F(WA!,#MM:6QL:6]N(&%N9"`D,"XV(&UI
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M<FEO9"!B87-E9"!O;@T*('1H92!#;VUP86YY)B-X,C`Q.3MS(&UO<W0@8W5R
M<F5N="!E<W1I;6%T92!O9B!R97!A>6UE;G0N/"]F;VYT/CPO<#X-"B`\<"!S
M='EL93TS1&UA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N
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M#0H@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S+"!R979E
M;G5E<R!W97)E(&)E;&]W('1H90T*(&-O;G1R86-T=6%L('1H<F5S:&]L9"!A
M;6]U;G0@<W5C:"!T:&%T(&$@8V%S:"!P87EM96YT(&]F("0P+C@-"B!M:6QL
M:6]N(&ES(&1U92!I;B!.;W9E;6)E<B`R,#$S(')E9FQE8W1I;F<@=&AE(&-A
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M;F0@<75A<G1E<B!O9B`R,#$W+B!!;GD@<W5C:"!D969E<G)E9`T*(')E<&%Y
M;65N=',@=VEL;"!R96UA:6X@<W5B:F5C="!T;R!C;VYT:6YU960@87!P;&EC
M871I;VX@;V8@=&AE#0H@<75A<G1E<FQY(&-E:6QI;F<@:6X@86UO=6YT<R!D
M=64@97-T86)L:7-H960@8GD@=&AE(&-A;&-U;&%T960-"B!T:')E<VAO;&0@
M8F%S960@;VX@<75A<G1E<FQY(%9A<V-E<&$@<F5V96YU97,N($%D9&ET:6]N
M86QL>2P@=&AE#0H@<F5V:7-E9"!A<W-U;7!T:6]N<R!Y:65L9&5D(&$@9&5C
M<F5A<V4@:6X@=&AE(&-A;&-U;&%T960@969F96-T:79E#0H@:6YT97)E<W0@
M<F%T92!R97-U;'1I;F<@:6X@82!D96-R96%S92!I;B!I;G1E<F5S="!E>'!E
M;G-E(&1U<FEN9PT*('1H92!T:')E92!M;VYT:',@96YD960@4V5P=&5M8F5R
M)B-X03`[,S`L(#(P,3,@87,@8V]M<&%R960@=&\@=&AE#0H@=&AR964@;6]N
M=&AS(&5N9&5D($IU;F4F(WA!,#LS,"P@,C`Q,R!A;F0@36%R8V@F(WA!,#LS
M,2P-"B`R,#$S+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O
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M;VUP86YY#0H@:7-S=65D("0Q-3`N,"!M:6QL:6]N(&EN('!R:6YC:7!A;"!A
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M9`T*('-U8G-I9&EA<GD@;V8@06UA<FEN+B!4:&4@9V5N97)A;"P@=6YS96-U
M<F5D+"!S96YI;W(@;V)L:6=A=&EO;G,-"B!A<F4@9G5L;'D@86YD('5N8V]N
M9&ET:6]N86QL>2!G=6%R86YT965D(&)Y($%M87)I;B!B=70@;F]T(&)Y(&%N
M>0T*(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS('-U8G-I9&EA<FEE<RX@0V]R
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M9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T1M87)G:6XM=&]P.C$R<'@[;6%R9VEN
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M;F<-"B!O;B!*=6QY)B-X03`[,34L(#(P,3(L(&%N9"!E;F1I;F<@=7!O;B!T
M:&4@4V5N:6]R($YO=&5S)B-X,C`Q.3L-"B!M871U<FET>2!O;B!*86YU87)Y
M)B-X03`[,34L(#(P,S(N(%1H92!396YI;W(@3F]T97,@87)E('-U8FIE8W0@
M=&\-"B!R97!U<F-H87-E(&)Y('1H92!#;VUP86YY(&%T('1H92!O<'1I;VX@
M;V8@=&AE(&AO;&1E<G,@;VX@96%C:"!O9@T*($IA;G5A<GDF(WA!,#LQ.2P@
M,C`Q-RPF(WA!,#M*86YU87)Y)B-X03`[,3DL(#(P,C(L(&%N9`T*($IA;G5A
M<GDF(WA!,#LQ.2P@,C`R-RP@870@82!P<FEC92!E<75A;"!T;R`Q,#`E(&]F
M('1H92!P<FEN8VEP86P-"B!A;6]U;G0@;V8@=&AE(%-E;FEO<B!.;W1E<R!T
M;R!B92!R97!U<F-H87-E9"P@<&QU<R!A8V-R=65D(&%N9`T*('5N<&%I9"!I
M;G1E<F5S="!T;RP@8G5T(&5X8VQU9&EN9RP@=&AE(')E<'5R8VAA<V4@9&%T
M92X@5&AE(%-E;FEO<@T*($YO=&5S(&%R92!E>&-H86YG96%B;&4@=6YD97(@
M8V5R=&%I;B!C:7)C=6US=&%N8V5S(&EN=&\@8V%S:"P@0413<RP-"B!O<B!A
M(&-O;6)I;F%T:6]N(&]F(&-A<V@@86YD($%$4W,L(&%T('1H92!#;VUP86YY
M)B-X,C`Q.3MS(&5L96-T:6]N+`T*('=I=&@@86X@:6YI=&EA;"!E>&-H86YG
M92!R871E(&]F(#$Q,RXT-S4R($%$4W,@<&5R("0Q+#`P,"!P<FEN8VEP86P-
M"B!A;6]U;G0@;V8@4V5N:6]R($YO=&5S+B!)="!I<R!T:&4@0V]M<&%N>28C
M>#(P,3D[<R!C=7)R96YT(&EN=&5N=&EO;@T*('1O('-E='1L92!T:&5S92!O
M8FQI9V%T:6]N<R!I;B!C87-H+B!)9B!T:&4@0V]M<&%N>2!E;&5C=&5D#0H@
M<&AY<VEC86P@<V5T=&QE;65N="P@=&AE(%-E;FEO<B!.;W1E<R!W;W5L9"!I
M;FET:6%L;'D@8F4-"B!E>&-H86YG96%B;&4@:6YT;R`Q-RPP,C$L,C@P($%$
M4W,N($)A<V5D(&]N('1H92!C;&]S:6YG('!R:6-E(&]F#0H@=&AE($-O;7!A
M;GDF(W@R,#$Y.W,@<W1O8VL@870@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,L
M('1H92!P<FEN8VEP86P-"B!A;6]U;G0@;V8@=&AE(%-E;FEO<B!.;W1E<R!W
M;W5L9"!E>&-E960@=&AE('9A;'5E(&]F('1H92!S:&%R97,@:68-"B!C;VYV
M97)T960@;VX@=&AA="!D871E(&)Y("0T,BXT(&UI;&QI;VXN/"]F;VYT/CPO
M<#X-"B`\<"!S='EL93TS1&UA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M
M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/D%D9&ET:6]N86P@8V]V96YA;G1S#0H@:6YC;'5D93H@
M*&DI)B-X03`[;&EM:71A=&EO;G,@;VX@9G5T=7)E(&EN9&5B=&5D;F5S<R!U
M;F1E<B!C97)T86EN#0H@8VER8W5M<W1A;F-E<RP@*&EI*28C>$$P.W1H92!T
M:6UE;'D@9FEL:6YG(&]F(&1O8W5M96YT<R!A;F0@<F5P;W)T<PT*('!U<G-U
M86YT('1O(%-E8W1I;VXF(WA!,#LQ,R!O<B`Q-2AD*2!O9B!T:&4@17AC:&%N
M9V4@06-T('=I=&@@8F]T:`T*('1H92!314,@86YD('1H92!4<G5S=&5E+"!A
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M2G5L>28C>$$P.S$U+`T*(#(P,3(N($EF('1H92!396YI;W(@3F]T97,@87)E
M(&YO="!F<F5E;'D@=')A9&%B;&4L(&%S(&$@<F5S=6QT(&]F#0H@<F5S=')I
M8W1I;VYS('!U<G-U86YT('1O(%4N4RX@<V5C=7)I=&EE<R!L87<@;W(@=&AE
M('1E<FUS(&]F('1H90T*($EN9&5N='5R92!O<B!T:&4@4V5N:6]R($YO=&5S
M+"!T:&4@0V]M<&%N>2!S:&%L;"!P87D@861D:71I;VYA;`T*(&EN=&5R97-T
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M;G5A<GDF(WA!,#LQ.2P@,C`Q-RP@;W1H97(@=&AA;B!I;@T*(&-O;FYE8W1I
M;VX@=VET:"!C97)T86EN(&-H86YG97,@:6X@=&AE('1A>"!L87<@;V8@82!R
M96QE=F%N="!T87AI;F<-"B!J=7)I<V1I8W1I;VX@=&AA="!R97-U;'1S(&EN
M(&%D9&ET:6]N86P@86UO=6YT<R!B96-O;6EN9R!D=64@=VET:`T*(')E<W!E
M8W0@=&\@<&%Y;65N=',@86YD+V]R(&1E;&EV97)I97,@;VX@=&AE(%-E;FEO
M<B!.;W1E<RX@3VX@;W(-"B!A9G1E<B!*86YU87)Y)B-X03`[,3DL(#(P,3<@
M86YD('!R:6]R('1O('1H92!M871U<FET>2!D871E+"!T:&4-"B!#;VUP86YY
M(&UA>2!R961E96T@9F]R(&-A<V@@86QL(&]R('!A<G0@;V8@=&AE(%-E;FEO
M<B!.;W1E<R!A="!A#0H@<F5D96UP=&EO;B!P<FEC92!E<75A;"!T;R`Q,#`E
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M<'5R8VAA<V5D+"!P;'5S(&%C8W)U960@86YD('5N<&%I9"!I;G1E<F5S=`T*
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M;65N="!T;R!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS(&9U='5R92!U;G-E8W5R
M960@:6YD96)T961N97-S('1H870@:7,@;F]T('-O#0H@<W5B;W)D:6YA=&5D
M+B!4:&4@4V5N:6]R($YO=&5S(&%R92!E9F9E8W1I=F5L>2!J=6YI;W(@:6X@
M<FEG:'0@;V8-"B!P87EM96YT('1O(&9U='5R92!S96-U<F5D(&EN9&5B=&5D
M;F5S<R!T;R!T:&4@97AT96YT(&]F('1H92!V86QU90T*(&]F('1H92!A<W-E
M=',@<V5C=7)I;F<@<W5C:"!I;F1E8G1E9&YE<W,N/"]F;VYT/CPO<#X-"B`\
M<"!S='EL93TS1&UA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/E1H92!396YI;W(@3F]T97,@87)E#0H@97AC:&%N9V5A8FQE('5N
M9&5R(&-E<G1A:6X@8VER8W5M<W1A;F-E<RX@5&AE($-O;7!A;GD@8V%L8W5L
M871E9`T*('1H92!F86ER('9A;'5E(&]F('1H92!L:6%B:6QI='D@8V]M<&]N
M96YT(&]F('1H92!396YI;W(@3F]T97,@=&\@8F4-"B`D,3(V+C(@;6EL;&EO
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M=&5S(&ES(#$T+C4E+B!!<R!O9@T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S
M+"!T:&4@=6YA;6]R=&EZ960@9&ES8V]U;G0@8W)E871E9"!F<F]M('1H90T*
M(&%L;&]C871I;VX@;V8@=&AE('!R;V-E961S('1O('1H92!C;VYV97)S:6]N
M(&]P=&EO;B!W87,@)#,N.0T*(&UI;&QI;VXN(%1H92!C;VYV97)S:6]N(&]P
M=&EO;B!W:6QL(&YO="!B92!S=6)S97%U96YT;'D@<F5M96%S=7)E9`T*(&%S
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M,C`Q.3L-"B!D:7-C;W5N=',@86YD(&]F9F5R:6YG(&-O<W1S+B!!('!O<G1I
M;VX@;V8@=&AE(&1E8G0@9&ES8V]U;G0@9G)O;0T*('5N9&5R=W)I=&5R)B-X
M,C`Q.3MS(&1I<V-O=6YT<R!A;F0@;V9F97)I;F<@8V]S=',@=V%S(&%L;&]C
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M(&UO;G1H<RX@07,@;V8@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,L('1H92!U
M;F%M;W)T:7IE9`T*(&1E8G0@9&ES8V]U;G0@=V%S("0P+C@@;6EL;&EO;B!A
M;F0@=V%S(')E8V]R9&5D(&%S(&$@9&ER96-T#0H@<F5D=6-T:6]N(&]F('1H
M92!R96QA=&5D(&1E8G0@;VX@=&AE(&)A;&%N8V4@<VAE970N(%1H92!C87)R
M>6EN9PT*('9A;'5E(&]F('1H92!.;W1E<RP@;F5T(&]F('1H92!U;F%M;W)T
M:7IE9"!D:7-C;W5N="P@=V%S("0Q-#4N,PT*(&UI;&QI;VXN($1U<FEN9R!T
M:&4@=&AR964@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S
M+"!T:&4-"B!#;VUP86YY(')E8V]G;FEZ960@:6YT97)E<W0@97AP96YS92!O
M9B`D-2XR(&UI;&QI;VX@<F5L871E9"!T;R!T:&4-"B!.;W1E<RP@;V8@=VAI
M8V@@)#,N,B!M:6QL:6]N(')E<')E<V5N=',@86UO<G1I>F%T:6]N(&]F('1H
M92!D96)T#0H@9&ES8V]U;G0@8W)E871E9"!U<&]N(&%L;&]C871I;VX@;V8@
M<')O8V5E9',@=&\@=&AE(&-O;G9E<G-I;VX-"B!O<'1I;VXL("0Q+C,@;6EL
M;&EO;B!R97!R97-E;G1S(&-O;G1R86-T=6%L(&-O=7!O;B!I;G1E<F5S="P@
M86YD#0H@)#`N-R!M:6QL:6]N(')E<')E<V5N=',@=&AE(&%M;W)T:7IA=&EO
M;B!O9B!T:&4@9&ES8V]U;G0@9G)O;2!T:&4-"B!U;F1E<G=R:71E<B8C>#(P
M,3D[<R!D:7-C;W5N=',@86YD(&]F9F5R:6YG(&-O<W1S+B!$=7)I;F<@=&AE
M(&YI;F4-"B!M;VYT:',@96YD960@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,L
M('1H92!#;VUP86YY(')E8V]G;FEZ960-"B!I;G1E<F5S="!E>'!E;G-E(&]F
M("0Q-2XP(&UI;&QI;VX@<F5L871E9"!T;R!T:&4@3F]T97,L(&]F('=H:6-H
M#0H@)#DN,B!M:6QL:6]N(')E<')E<V5N=',@86UO<G1I>F%T:6]N(&]F('1H
M92!D96)T(&1I<V-O=6YT(&-R96%T960-"B!U<&]N(&%L;&]C871I;VX@;V8@
M<')O8V5E9',@=&\@=&AE(&-O;G9E<G-I;VX@;W!T:6]N+"`D,RXY(&UI;&QI
M;VX-"B!R97!R97-E;G1S(&-O;G1R86-T=6%L(&-O=7!O;B!I;G1E<F5S="P@
M86YD("0Q+CD@;6EL;&EO;B!R97!R97-E;G1S#0H@=&AE(&%M;W)T:7IA=&EO
M;B!O9B!T:&4@9&ES8V]U;G0@9G)O;2!T:&4@=6YD97)W<FET97(F(W@R,#$Y
M.W,-"B!D:7-C;W5N=',@86YD(&]F9F5R:6YG(&-O<W1S+B!!="!397!T96UB
M97(F(WA!,#LS,"P@,C`Q,RP@=&AE#0H@0V]M<&%N>2!H860@86-C<G5E9"!I
M;G1E<F5S="!O9B`D,2XQ(&UI;&QI;VXN/"]F;VYT/CPO<#X-"B`\<"!S='EL
M93TS1&UA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/DEN($IA;G5A<GD@86YD($IU;'D@,C`Q,RP-"B!T:&4@:6YT97)E<W0@<&%Y
M;65N=',@9'5E(&]F("0R+C8@;6EL;&EO;B!W97)E('!A:60@87,-"B!S8VAE
M9'5L960N/"]F;VYT/CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V4P9CAE,64X7S(V-F1?-&)F-%]A.#DV
M7S-C93DX8V8U-6%A-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E
M,&8X93%E.%\R-C9D7S1B9C1?83@Y-E\S8V4Y.&-F-35A838O5V]R:W-H965T
M<R]3:&5E=#$S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N=',@86YD
M($-O;G1I;F=E;F-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\9&EV/@T*(#QT86)L92!S='EL93TS1$)/4D1%4BU#3TQ,05!313I#3TQ,
M05!312!B;W)D97(],T0P(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS
M1#`@=VED=&@],T0Q,#`E/@T*(#QT<CX-"B`\=&0@=VED=&@],T0T)2!V86QI
M9VX],T1T;W`@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^*#<I/"]B/CPO9F]N
M=#X\+W1D/@T*(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^/&(^0V]M;6ET;65N=',@86YD#0H@0V]N=&EN9V5N8VEE<SPO8CX\+V9O
M;G0^/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G;6%R
M9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL969T.C(E
M)SX-"B`\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
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M;'1Y(&]B;&EG871I;VYS('5N9&5R('-E=F5R86P@<')O9'5C=`T*(&1E=F5L
M;W!M96YT(&%G<F5E;65N=',L(&%S(&9O;&QO=W,Z/"]F;VYT/CPO<#X-"B`\
M<"!S='EL93TS1&9O;G0M<VEZ93HV<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN
M+6)O='1O;3HP<'@^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1$)/
M4D1%4BU#3TQ,05!313I#3TQ,05!312!B;W)D97(],T0P(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E/@T*(#QT<CX-"B`\
M=&0@=VED=&@],T0U)3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=VED=&@],T0R)2!V86QI9VX],T1T;W`@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X,C`R,CL\+V9O;G0^/"]T9#X-"B`\=&0@=VED=&@],T0Q
M)2!V86QI9VX],T1T;W`^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`^#0H@/'`@86QI
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M<RX@07,@;V8-"B!397!T96UB97(F(WA!,#LS,"P@,C`Q,RP@=&AE($%022!A
M9V=R96=A=&4@;6EN:6UU;2!P=7)C:&%S90T*(&]B;&EG871I;VYS('5N9&5R
M('1H:7,@<W5P<&QY(&%G<F5E;65N="!H860@8F5E;B!A8VAI979E9"!A;F0@
M87,@80T*(')E<W5L="P@=&AE($-O;7!A;GD@:&%S(&YO(&9U='5R92!M:6YI
M;75M('!U<F-H87-E(&]B;&EG871I;VX@9G)O;0T*($YI<W-H:6XN/"]F;VYT
M/CPO<#X-"B`\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS
M1&9O;G0M<VEZ93HV<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP
M<'@^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1$)/4D1%4BU#3TQ,
M05!313I#3TQ,05!312!B;W)D97(],T0P(&-E;&QP861D:6YG/3-$,"!C96QL
M<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E/@T*(#QT<CX-"B`\=&0@=VED=&@]
M,T0U)3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=VED=&@],T0R)2!V86QI9VX],T1T;W`@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X,C`R,CL\+V9O;G0^/"]T9#X-"B`\=&0@=VED=&@],T0Q)2!V86QI9VX]
M,T1T;W`^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`^#0H@/'`@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^26X@,C`Q,2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&%G
M<F5E;65N=',@=VET:"!T=V\-"B!A9&1I=&EO;F%L('-U<'!L:65R<RP@0VAE
M;7!O<G0L($EN8RX@*"8C>#(P,4,[0VAE;7!O<G0F(W@R,#%$.RD@86YD#0H@
M0D%31B`H9F]R;65R;'D@17%U871E<2!,:6UI=&5D*2!F;W(@=&AE('-U<'!L
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M:65R+"!A;F0@=&\@<')E=F5N=`T*('!O=&5N=&EA;"!T97)M:6YA=&EO;B!O
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M;"!S86QE(&EN#0H@07!R:6P@,C`Q,RX@5&AE($-O;7!A;GD@:&%S(&)E9W5N
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M;GD@=&\@9G5N9`T*("AI*28C>$$P.V1E=F5L;W!M96YT(&9E97,@=7`@=&\@
M82!M87AI;75M(&]F("0P+C4F(WA!,#MM:6QL:6]N#0H@*&EI*28C>$$P.VUA
M=&5R:6%L('!U<F-H87-E<R!O9B!U<"!T;R`D-2XP(&UI;&QI;VX@9F]R(&EN
M:71I86P@<F%W#0H@;6%T97)I86QS+"!W:&EC:"!A;6]U;G0@=VEL;"!B92!C
M<F5D:71E9"!A9V%I;G-T(&9U='5R92!!4$D-"B!P=7)C:&%S97,@86YD("AI
M:6DI)B-X03`[82!R87<@;6%T97)I86P@<'5R8VAA<V4@8V]M;6ET;65N="!O
M9@T*("0Q+C$F(WA!,#MM:6QL:6]N+B!5;F1E<B!T:&5S92!A9W)E96UE;G1S
M+"!D=7)I;F<@=&AE(&YI;F4@;6]N=&AS#0H@96YD960@4V5P=&5M8F5R)B-X
M03`[,S`L(#(P,3,L('1H92!#;VUP86YY(&UA9&4@<&%Y;65N=',@;V8@)#0N
M.`T*(&UI;&QI;VX@86YD("0P+C$@;6EL;&EO;B!T;R!#:&5M<&]R="!A;F0@
M0D%31BP@<F5S<&5C=&EV96QY+B!4:&4-"B!A9W)E96UE;G0@=VET:"!3;&%N
M;6AO<B!P<F]V:61E<R!F;W(@9&5V96QO<&UE;G0@9F5E<R!O9B!U<"!T;R`D
M,BXS#0H@;6EL;&EO;B!A;F0@82!C;VUM:71M96YT(&]F('5P('1O("0Q-2XP
M(&UI;&QI;VXL('=H:6-H('=I;&P@8F4-"B!C<F5D:71E9"!A9V%I;G-T(&9U
M='5R92!!4$D@;6%T97)I86P@<'5R8VAA<V5S+B!4:&4@)#$U+C`@;6EL;&EO
M;@T*(&-O;6UI=&UE;G0@9F5E(&ES(&-O;G1I;F=E;G0@=7!O;B!T:&4@;75T
M=6%L;'D@86=R965D('5P;VX-"B!E>'!A;G-I;VX@;V8@4VQA;FUH;W(F(W@R
M,#$Y.W,@05!)(&UA;G5F86-T=7)I;F<@8V%P86-I='DN(%5N9&5R#0H@=&AI
M<R!A9W)E96UE;G0L(&1U<FEN9R!T:&4@;FEN92!M;VYT:',@96YD960@4V5P
M=&5M8F5R)B-X03`[,S`L#0H@,C`Q,RP@=&AE($-O;7!A;GD@;6%D92!P87EM
M96YT<R!O9B`D-BXQ(&UI;&QI;VX@=&\@4VQA;FUH;W(@<F5L871E9`T*('1O
M('-T86)I;&ET>2!A;F0@=&5C:&YI8V%L(&)A=&-H97,@86YD(&%D=F%N8V5S
M(&]N(&9U='5R92!!4$D-"B!P=7)C:&%S97,N/"]F;VYT/CPO<#X-"B`\+W1D
M/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1&9O;G0M<VEZ93HV
M<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^#0H@)B-X03`[
M/"]P/@T*(#QT86)L92!S='EL93TS1$)/4D1%4BU#3TQ,05!313I#3TQ,05!3
M12!B;W)D97(],T0P(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@
M=VED=&@],T0Q,#`E/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U)3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=VED=&@],T0R)2!V
M86QI9VX],T1T;W`@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`R,CL\+V9O
M;G0^/"]T9#X-"B`\=&0@=VED=&@],T0Q)2!V86QI9VX],T1T;W`^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1T;W`^#0H@/'`@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^56YD
M97(@=&AE(#(P,#0@<VAA<F4@<F5P=7)C:&%S92!A9W)E96UE;G0@=VET:"!,
M87AD86QE($QI;6ET960L#0H@;W(@3&%X9&%L92P@=7!O;B!A<'!R;W9A;"!O
M9B!687-C97!A(&)Y('1H92!&1$$@;VX@2G5L>28C>$$P.S(V+`T*(#(P,3(L
M('1H92!#;VUP86YY('=A<R!R97%U:7)E9"!T;R!M86ME(&$@;6EL97-T;VYE
M('!A>6UE;G0@=&\-"B!,87AD86QE(&]F("8C>$$S.S<N-28C>$$P.VUI;&QI
M;VXN(%1H92!#;VUP86YY(&UA9&4@=&AI<R!P87EM96YT(&EN#0H@,C`Q,B!A
M;F0@8V%P:71A;&EZ960@=&AI<R!,87AD86QE(&UI;&5S=&]N92`H)#$Q+C8@
M;6EL;&EO;B!O;@T*($IU;'DF(WA!,#LR-BP@,C`Q,BD@87,@86X@:6YT86YG
M:6)L92!A<W-E="X@5&AI<R!L;VYG+71E<FT@87-S970@:7,-"B!B96EN9R!A
M;6]R=&EZ960@;W9E<B!T:&4@97-T:6UA=&5D('5S969U;"!L:69E(&]F('1H
M92!I;G1E;&QE8W1U86P-"B!P<F]P97)T>2!T:&4@0V]M<&%N>2!A8W%U:7)E
M9"!F<F]M($QA>&1A;&4@86YD('1H92!#;VUP86YY#0H@<F5C;V=N:7IE9"!A
M;6]R=&EZ871I;VX@97AP96YS92!O9B`D,"XU(&UI;&QI;VX@9'5R:6YG('1H
M92!N:6YE#0H@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S
M+B!!;'-O('5N9&5R('1H92!,87AD86QE#0H@86=R965M96YT+"!U<&]N(')E
M8V5I<'0@;V8@;6%R:V5T:6YG(&%P<')O=F%L(&EN($5U<F]P92!F;W(@=&AE
M#0H@9FER<W0@:6YD:6-A=&EO;B!F;W(@5F%S8V5P82`H;W(@9FER<W0@:6YD
M:6-A=&EO;B!O9B!A;GD@<')O9'5C=`T*(&-O;G1A:6YI;F<@06UA<FEN($YE
M=7)O<V-I96YC92!I;G1E;&QE8W1U86P@<')O<&5R='D@86-Q=6ER960@9G)O
M;0T*($QA>&1A;&4@:6X@,C`P-"DL('1H92!#;VUP86YY(&UU<W0@;6%K92!A
M;B!A9V=R96=A=&4@<W1O8VL@;W(@8V%S:`T*('!A>6UE;G0@=&\@=&AE(&9O
M<FUE<B!S:&%R96AO;&1E<G,@;V8@3&%X9&%L92`H870@=&AE('-O;&4@;W!T
M:6]N#0H@;V8@96%C:"!O9B!T:&4@<V5L;&5R<RD@;V8@)B-X03,[-RXU)B-X
M03`[;6EL;&EO;B`H87!P<F]X:6UA=&5L>0T*("0Q,BXQ(&UI;&QI;VX@870@
M4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,I+B!!;'-O('5N9&5R('1H92!,87AD
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M=7-T(&UA:V4@86X@86=G<F5G871E('-T;V-K(&]R(&-A<V@@<&%Y;65N=`T*
M("AA="!T:&4@<V]L92!O<'1I;VX@;V8@96%C:"!O9B!T:&4@<V5L;&5R<RD@
M;V8@)B-X03,[-28C>$$P.VUI;&QI;VX-"B`H87!P<F]X:6UA=&5L>2`D."XQ
M(&UI;&QI;VX@870@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,I(&9O<B!E86-H
M(&]F#0H@=&AE('1W;R!P;W1E;G1I86P@;6%R:V5T(&%P<')O=F%L<R`H:2YE
M+B`F(WA!,SLQ,"8C>$$P.VUI;&QI;VX-"B!M87AI;75M+"!O<B!A<'!R;WAI
M;6%T96QY("0Q-BXQ(&UI;&QI;VX@870@4V5P=&5M8F5R)B-X03`[,S`L#0H@
M,C`Q,RDN/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-
M"B`\<"!S='EL93TS1&UA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P
M>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/E1H92!#;VUP86YY(&AA<R!N;R!P<F]V:7-I;VX-"B!F;W(@
M86YY(&]F('1H92!O8FQI9V%T:6]N<R!A8F]V92!S:6YC92!T:&4@86UO=6YT
M<R!A<F4@96ET:&5R(&YO=`T*('!R;V)A8FQE(&]R(&5S=&EM86)L92!A="!3
M97!T96UB97(F(WA!,#LS,"P@,C`Q,RX\+V9O;G0^/"]P/@T*(#PO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93!F.&4Q
M93A?,C8V9%\T8F8T7V$X.39?,V-E.3AC9C4U86$V#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V4P9CAE,64X7S(V-F1?-&)F-%]A.#DV7S-C93DX
M8V8U-6%A-B]7;W)K<VAE971S+U-H965T,30N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!1#X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY%<75I='D\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17%U:71Y/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\=&%B;&4@<W1Y;&4],T1"3U)$
M15(M0T],3$%04T4Z0T],3$%04T4@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS
M1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`\='(^#0H@/'1D
M('=I9'1H/3-$-"4@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/CQB/B@X*3PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/CQB/D5Q=6ET>3PO8CX\+V9O;G0^/"]T9#X-
M"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV
M<'@[;6%R9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL969T.C(E)SX-"B`\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/CQI/CQU/D-O;6UO;@T*('-T;V-K/"]U/CPO:3X\+V9O;G0^/"]P/@T*
M(#QP('-T>6QE/3-$;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CY/;B!*=6QY)B-X03`[,3(L(#(P,3,L('1H90T*($-O;7!A;GD@
M8V]M<&QE=&5D(&$@<'5B;&EC(&]F9F5R:6YG(&]F(#(Q+#<P,"PP,#`@0413
M<RX@5&AE#0H@=6YD97)W<FET97)S('!U<F-H87-E9"!T:&4@0413<R!F<F]M
M($%M87)I;B!A="!A('!R:6-E(&]F("0U+C8P('!E<@T*($%$4RP@<F5S=6QT
M:6YG(&EN(&YE="!P<F]C965D<R!T;R!!;6%R:6X@;V8@87!P<F]X:6UA=&5L
M>2`D,3(Q+C(-"B!M:6QL:6]N+"!A9G1E<B!D961U8W1I;F<@97-T:6UA=&5D
M(&]F9F5R:6YG(&5X<&5N<V5S('!A>6%B;&4@8GD@=&AE#0H@0V]M<&%N>2X@
M06UA<FEN(&%L<V\@9W)A;G1E9"!T:&4@=6YD97)W<FET97)S(&$@,S`M9&%Y
M(&]P=&EO;B!T;PT*('!U<F-H87-E(&%N(&%D9&ET:6]N86P@,RPR-34L,#`P
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M92!N:6YE(&UO;G1H<R!E;F1E9`T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S
M(&%N9"`R,#$R+"!T:&4@0V]M<&%N>2!I<W-U960@,S@V+#`P,"!A;F0-"B`S
M+#$P-RPY,3,@<VAA<F5S+"!R97-P96-T:79E;'DL(&%S(&$@<F5S=6QT(&]F
M('1H92!E>&5R8VES92!O9@T*('-T;V-K(&]P=&EO;G,N($=R;W-S(&%N9"!N
M970@<')O8V5E9',@<F5S=6QT:6YG(&9R;VT@=&AE(&5X97)C:7-E#0H@;V8@
M<W1O8VL@;W!T:6]N<R!A;6]U;G1E9"!T;R`D,"XV(&UI;&QI;VX@9F]R('1H
M92!N:6YE(&UO;G1H<R!E;F1E9`T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S
M+B!&;W(@=&AE(&YI;F4@;6]N=&AS(&5N9&5D#0H@4V5P=&5M8F5R)B-X03`[
M,S`L(#(P,3(L(&=R;W-S('!R;V-E961S(&%M;W5N=&5D('1O("0W+CD@;6EL
M;&EO;@T*(&%N9"!N970@<')O8V5E9',@86UO=6YT960@=&\@)#<N."!M:6QL
M:6]N(')E<W5L=&EN9R!F<F]M('1H90T*(&5X97)C:7-E(&]F('-T;V-K(&]P
M=&EO;G,N($EN(&%D9&ET:6]N+"!D=7)I;F<@=&AE(&YI;F4@;6]N=&AS#0H@
M96YD960@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,@86YD(#(P,3(L('1H92!#
M;VUP86YY(&ES<W5E9"`Q,C`L,#`P#0H@86YD(#$P+#@X,2PR-S8@<VAA<F5S
M+"!R97-P96-T:79E;'DL(&%S(&$@<F5S=6QT(&]F('1H92!E>&5R8VES92!O
M9@T*('=A<G)A;G1S+B!'<F]S<R!A;F0@;F5T('!R;V-E961S(')E<W5L=&EN
M9R!F<F]M('1H92!E>&5R8VES92!O9@T*('=A<G)A;G1S(&%M;W5N=&5D('1O
M("0P+C$@;6EL;&EO;B!F;W(@=&AE(&YI;F4@;6]N=&AS(&5N9&5D#0H@4V5P
M=&5M8F5R)B-X03`[,S`L(#(P,3,N($9O<B!T:&4@;FEN92!M;VYT:',@96YD
M960-"B!397!T96UB97(F(WA!,#LS,"P@,C`Q,BP@9W)O<W,@<')O8V5E9',@
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M26X@075G=7-T(&%N9"!397!T96UB97(@;V8-"B`R,#$S+"!T:&4@0V]M<&%N
M>2!G<F%N=&5D(&$@=&]T86P@;V8@-#0L,#`P(')E<W1R:6-T960@<W1O8VL@
M=6YI=',-"B`H)B-X,C`Q0SM24U5S)B-X,C`Q1#LI('1O('-E=F5R86P@96UP
M;&]Y965S('5N9&5R('1H92!!;6%R:6X-"B!#;W)P;W)A=&EO;B!P;&,@,C`Q
M,2!3=&]C:R!);F-E;G1I=F4@4&QA;B`H)B-X,C`Q0SLR,#$Q#0H@4&QA;B8C
M>#(P,40[*2X@07,@;V8@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,L(&YO(%)3
M528C>#(P,3D[<R!W97)E#0H@9F]R9F5I=&5D(&%N9"!N;R!S:&%R97,@=V5R
M92!I<W-U960@87,@82!R97-U;'0@;V8@=F5S=&EN9RX@5&AE<V4-"B!24U5S
M('9E<W0@=7!O;B!T:&4@86-H:65V96UE;G0@;V8@8V5R=&%I;B!O<&5R871I
M;VYA;"!M:6QE<W1O;F5S#0H@86YD(&5X<&ER92!O;B!$96-E;6)E<B8C>$$P
M.S,Q+"`R,#$S(&EF(&YO;F4@;V8@=&AE(&UI;&5S=&]N97,@87)E#0H@86-H
M:65V960@8GD@<W5C:"!D871E+B!4:&4@4E-5<R!W:6QL(&)E8V]M92!F=6QL
M>2!V97-T960@=7!O;B!A#0H@8VAA;F=E(&]F(&-O;G1R;VP@;V8@=&AE($-O
M;7!A;GDN(%5P;VX@=F5S=&EN9R!O9B!E86-H(%)352P@=&AE#0H@<&%R=&EC
M:7!A;G0@<VAA;&P@8F4@96YT:71L960@=&\@82!P87EM96YT(&5Q=6%L('1O
M('1H92!F86ER(&UA<FME=`T*('9A;'5E(&]F(&]N92!S:&%R92!O9B!!;6%R
M:6X@8V]M;6]N('-T;V-K+B!4:&4@<&%Y;65N="!S:&%L;"!B90T*('!A:60@
M=&\@=&AE('!A<G1I8VEP86YT(&EN(&-A<V@L(&]R(&%T('1H92!S;VQE(&1I
M<V-R971I;VX@;V8@=&AE#0H@0V]M<&5N<V%T:6]N($-O;6UI='1E92!I;B!S
M:&%R97,@;W(@82!C;VUB:6YA=&EO;B!O9B!C87-H(&]R#0H@<VAA<F5S+B!4
M:&4@9F%I<B!V86QU92!O9B!T:&4@4E-5<R!W87,@9&5T97)M:6YE9"!O;B!T
M:&4@9&%T92!O9@T*(&=R86YT+"!A;F0@8V]M<&5N<V%T:6]N(&5X<&5N<V4@
M<F5L871E9"!T;R!T:&4@4E-5<R!I<R!R96-O9VYI>F5D#0H@;VYC92!T:&4@
M<F5L871E9"!M:6QE<W1O;F4@:7,@9&5E;65D('!R;V)A8FQE+B!4:&4@0V]M
M<&%N>2!R96-O<F1E9`T*(&YO(&5X<&5N<V4@9'5R:6YG('1H92!N:6YE(&UO
M;G1H<R!E;F1E9"!397!T96UB97(F(WA!,#LS,"P@,C`Q,PT*(')E;&%T960@
M=&\@=&AE('9E<W1I;F<@;V8@=&AE<V4@4E-5<RX\+V9O;G0^/"]P/@T*(#QP
M('-T>6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^26X@2G5L>2!O9B`R,#$S+"!T:&4@0V]M<&%N>0T*(&=R86YT960@
M82!T;W1A;"!O9B`U-"PP,#`@9&5F97)R960@<W1O8VL@=6YI=',@*"8C>#(P
M,4,[1%-5<R8C>#(P,40[*0T*('1O(&UE;6)E<G,@;V8@=&AE($-O;7!A;GDF
M(W@R,#$Y.W,@0F]A<F0@;V8@1&ER96-T;W)S('5N9&5R('1H90T*($%M87)I
M;B!#;W)P;W)A=&EO;B!P;&,@,C`Q,2!3=&]C:R!);F-E;G1I=F4@4&QA;B`H
M)B-X,C`Q0SLR,#$Q#0H@4&QA;B8C>#(P,40[*2X@07,@;V8@4V5P=&5M8F5R
M)B-X03`[,S`L(#(P,3,L(&YO($13528C>#(P,3D[<R!W97)E#0H@9F]R9F5I
M=&5D(&%N9"!N;R!S:&%R97,@=V5R92!I<W-U960@87,@82!R97-U;'0@;V8@
M=F5S=&EN9RX@5&AE#0H@1%-5)B-X,C`Q.3MS('9E<W0@;W9E<B!A('1H<F5E
M('EE87(@<&5R:6]D+B!4:&4@1%-5<R!W:6QL(&)E8V]M90T*(&9U;&QY('9E
M<W1E9"!U<&]N(&$@8VAA;F=E(&]F(&-O;G1R;VP@;V8@=&AE($-O;7!A;GDN
M(%5P;VX-"B!T97)M:6YA=&EO;B!O9B!S97)V:6-E('1O('1H92!#;VUP86YY
M+"!E86-H($1I<F5C=&]R('-H86QL(&)E#0H@96YT:71L960@=&\@82!P87EM
M96YT(&5Q=6%L('1O('1H92!F86ER(&UA<FME="!V86QU92!O9B!O;F4@<VAA
M<F4-"B!O9B!!;6%R:6X@8V]M;6]N('-T;V-K+"!W:&EC:"!I<R!R97%U:7)E
M9"!T;R!B92!M861E(&EN('-H87)E<RX@5&AE#0H@0V]M<&%N>2!R96-O<F1E
M9"!E>'!E;G-E(&1U<FEN9R!T:&4@;FEN92!M;VYT:',@96YD960-"B!397!T
M96UB97(F(WA!,#LS,"P@,C`Q,R!O9B`D-#<L,#`P(')E;&%T960@=&\@=&AE
M('9E<W1I;F<@;V8@=&AE<V4-"B!$4U5S+CPO9F]N=#X\+W`^#0H@/'`@<W1Y
M;&4],T1M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CY);B!*86YU87)Y(#(P,3,L('1H92!#;VUP86YY#0H@9W)A;G1E9"`T-30L
M.#<U(%)357,@=&\@<V5V97)A;"!E;7!L;WEE97,@=6YD97(@=&AE(#(P,3$@
M4&QA;BX@07,-"B!O9B!397!T96UB97(F(WA!,#LS,"P@,C`Q,RP@,S(L-3`P
M(%)357,@=V5R92!F;W)F96ET960@86YD(&YO#0H@<VAA<F5S('=E<F4@:7-S
M=65D(&%S(&$@<F5S=6QT(&]F('9E<W1I;F<N(%1H97-E(%)357,@=F5S="!U
M<&]N('1H90T*(&%C:&EE=F5M96YT(&]F(&-E<G1A:6X@;W!E<F%T:6]N86P@
M;6EL97-T;VYE<R!A;F0@97AP:7)E(&]N#0H@075G=7-T)B-X03`[,RP@,C`Q
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M;V8@9W)A;G0L(&%N9`T*(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T960@
M=&\@=&AE(%)357,@:7,@<F5C;V=N:7IE9"!O;F-E('1H90T*(')E;&%T960@
M;6EL97-T;VYE(&ES(&1E96UE9"!P<F]B86)L92X@5&AE($-O;7!A;GD@<F5C
M;W)D960@;F\-"B!E>'!E;G-E(&1U<FEN9R!T:&4@;FEN92!M;VYT:',@96YD
M960@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,-"B!R96QA=&5D('1O('1H92!V
M97-T:6YG(&]F('1H97-E(%)357,N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS
M1&UA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN
M($9E8G)U87)Y(#(P,3(L('1H90T*($-O;7!A;GD@9W)A;G1E9"`U.#0L-#`P
M(%)357,@=&\@<V5V97)A;"!E;7!L;WEE97,@=6YD97(@=&AE(#(P,3$-"B!0
M;&%N+B!!<R!O9B!397!T96UB97(F(WA!,#LS,"P@,C`Q,RP@82!T;W1A;"!O
M9B`Y,"PV.#0@4E-5<R!W97)E#0H@9F]R9F5I=&5D+B!4:&5S92!24U5S('9E
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M97(F(WA!,#LS,"P-"B`R,#$S(&%N9"`R,#$R+"!T:&4@0V]M<&%N>2!I<W-U
M960@.3,L,#0X(&%N9"`Y-RPS.3@@<VAA<F5S+`T*(')E<W!E8W1I=F5L>2P@
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M=&AE(&YI;F4@;6]N=&AS(&5N9&5D#0H@4V5P=&5M8F5R)B-X03`[,S`L(#(P
M,3,@86YD(#(P,3(L('1H92!#;VUP86YY(')E8V]R9&5D(&5X<&5N<V4@;V8-
M"B`D,"XS(&UI;&QI;VX@86YD("0Q+C(@;6EL;&EO;BP@<F5S<&5C=&EV96QY
M+"!R96QA=&5D('1O('1H92!V97-T:6YG#0H@;V8@=&AE<V4@4E-5<RX\+V9O
M;G0^/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?93!F.&4Q93A?,C8V9%\T8F8T7V$X.39?,V-E.3AC9C4U
M86$V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4P9CAE,64X7S(V
M-F1?-&)F-%]A.#DV7S-C93DX8V8U-6%A-B]7;W)K<VAE971S+U-H965T,34N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6)S
M97%U96YT($5V96YT<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=6)S97%U96YT($5V96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M,3)P>#L@34%21TE.+4)/5%1/33H@,'!X)SX\+W`^#0H@/'1A8FQE('-T>6QE
M/3-$)U1%6%0M5%)!3E-&3U)-.B!N;VYE.R!415A4+4E.1$5.5#H@,'!X.R!,
M151415(M4U!!0TE.1SH@;F]R;6%L.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA
M<'-E.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<[(%=/4D0M4U!!
M0TE.1SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@G(&)O
M<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#$P,"4^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0T
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M='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=415A4+51204Y31D]233H@
M;F]N93L@34%21TE.+51/4#H@-G!X.R!415A4+4E.1$5.5#H@,'!X.R!,1514
M15(M4U!!0TE.1SH@;F]R;6%L.R!&3TY4.B!M961I=6T@)U1I;65S($YE=R!2
M;VUA;B<[(%=(251%+5-004-%.B!N;W)M86P[($U!4D=)3BU"3U143TTZ(#!P
M>#L@0T],3U(Z(')G8B@P+#`L,"D[(%=/4D0M4U!!0TE.1SH@,'!X.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@G/@T*(#QF;VYT('-I>F4],T0R
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)R<@<VEZ93TS1#(^3VX@3V-T;V)E<B8C>$$P.S$V+"`R,#$S+"!T:&4@0V]M
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M($1E8V5M8F5R)B-X03`[,C`L(#(P,3,@4$151D$@9V]A;"!D871E(&9O<B!T
M:&4-"B!A<'!L:6-A=&EO;BP@:&]W979E<BP@=&AE($9$02!C;W5L9"!C;VUP
M;&5T92!I=',@<F5V:65W(&]F('1H92!S3D1!#0H@<')I;W(@=&\@=&AI<R!D
M871E(&%N9"!T:&5R92!C86X@8F4@;F\@87-S=7)A;F-E('1H870@=&AE($9$
M02!W:6QL#0H@8V]M<&QE=&4@:71S(')E=FEE=R!O9B!T:&4@<TY$02!B>2!T
M:&ES(&1A=&4N/"]F;VYT/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G5$58
M5"U44D%.4T9/4DTZ(&YO;F4[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$
M14Y4.B`P<'@[($Q%5%1%4BU34$%#24Y'.B!N;W)M86P[($9/3E0Z(&UE9&EU
M;2`G5&EM97,@3F5W(%)O;6%N)SL@5TA)5$4M4U!!0T4Z(&YO<FUA;#L@34%2
M1TE.+4)/5%1/33H@,'!X.R!#3TQ/4CH@<F=B*#`L,"PP*3L@5T]21"U34$%#
M24Y'.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^#0H@
M/&9O;G0@<VEZ93TS1#(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4
M:6UE<R!.97<@4F]M86XG)R!S:7IE/3-$,CY/;B!/8W1O8F5R)B-X03`[,C(L
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M=&5R(&]F(#(P,30N/"]F;VYT/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G
M5$585"U44D%.4T9/4DTZ(&YO;F4[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M
M24Y$14Y4.B`P<'@[($Q%5%1%4BU34$%#24Y'.B!N;W)M86P[($9/3E0Z(&UE
M9&EU;2`G5&EM97,@3F5W(%)O;6%N)SL@5TA)5$4M4U!!0T4Z(&YO<FUA;#L@
M34%21TE.+4)/5%1/33H@,'!X.R!#3TQ/4CH@<F=B*#`L,"PP*3L@5T]21"U3
M4$%#24Y'.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^
M#0H@/&9O;G0@<VEZ93TS1#(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M("=4:6UE<R!.97<@4F]M86XG)R!S:7IE/3-$,CY/;B!/8W1O8F5R)B-X03`[
M,CDL(#(P,3,L('1H92!&1$$@;F]T:69I960@=&AE($-O;7!A;GD@=&AA="!I
M=`T*(&AA<R!R97-C:6YD960@=&AE($%.0TA/4B!S='5D>2!3<&5C:6%L(%!R
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M=&AE($9$02!S=&%T960@:6X@:71S#0H@3V-T;V)E<B8C>$$P.S(Y+"`R,#$S
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M(&QE=F5L<R!B96QO=R`U,#`@;6<O9$PN/"]F;VYT/CPO9F]N=#X\+W`^#0H@
M/'`@<W1Y;&4],T0G5$585"U44D%.4T9/4DTZ(&YO;F4[($U!4D=)3BU43U`Z
M(#$R<'@[(%1%6%0M24Y$14Y4.B`P<'@[($Q%5%1%4BU34$%#24Y'.B!N;W)M
M86P[($9/3E0Z(&UE9&EU;2`G5&EM97,@3F5W(%)O;6%N)SL@5TA)5$4M4U!!
M0T4Z(&YO<FUA;#L@34%21TE.+4)/5%1/33H@,'!X.R!#3TQ/4CH@<F=B*#`L
M,"PP*3L@5T]21"U34$%#24Y'.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>"<^#0H@/&9O;G0@<VEZ93TS1#(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG)R!S:7IE/3-$,CY/;B!.
M;W9E;6)E<B`Q+"`R,#$S+"!A('!U<G!O<G1E9"!I;G9E<W1O<B!O9B!!;6%R
M:6X@9FEL960@80T*('!U=&%T:79E(&-L87-S(&%C=&EO;B!L87=S=6ET(&%G
M86EN<W0@06UA<FEN(&%N9"!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS($-H:65F
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M97)I;V0@2G5L>2`Y+"`R,#`Y('1H<F]U9V@-"B!/8W1O8F5R(#$U+"`R,#$S
M+"!T:&4@0V]M<&%N>2!M:7-L960@:6YV97-T;W)S(')E9V%R9&EN9R!T:&4-
M"B!&1$$F(W@R,#$Y.W,@=VEL;&EN9VYE<W,@=&\@87!P<F]V92!687-C97!A
M)B-X,C`Q.3MS($%.0TA/4@T*(&EN9&EC871I;VX@86YD('1H92!P;W1E;G1I
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M9"!A9V%I;G-T('1H90T*(&-L86EM<RX\+V9O;G0^/"]F;VYT/CPO<#X-"B`\
M<"!S='EL93TS1"=415A4+51204Y31D]233H@;F]N93L@34%21TE.+51/4#H@
M,3)P>#L@5$585"U)3D1%3E0Z(#!P>#L@3$545$52+5-004-)3D<Z(&YO<FUA
M;#L@1D].5#H@;65D:75M("=4:6UE<R!.97<@4F]M86XG.R!72$E412U34$%#
M13H@;F]R;6%L.R!-05)'24XM0D]45$]-.B`P<'@[($-/3$]2.B!R9V(H,"PP
M+#`I.R!73U)$+5-004-)3D<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X)SX-"B`\9F]N="!S:7IE/3-$,CX\9F]N="!S='EL93TS1"=&
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M<F\L(&%N9`T*(%-T979E;B!"+B!+971C:'5M+"!.;RX@,3,M0TE6+3<X.#(@
M*%,N1"Y.+EDN($YO=BX@-2P@,C`Q,RDN(%1H90T*(&QA=W-U:70@86QL96=E
M<RP@<VEM:6QA<B!T;R!T:&4F(WA!,#L\:3Y3:VQA<CPO:3XF(WA!,#MC87-E
M+"!T:&%T+"!D=7)I;F<@=&AE('!E<FEO9`T*($%U9W5S="`X+"`R,#$R('5N
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M<R!U;F1E<B!T:&4@4V5C=7)I=&EE<PT*($5X8VAA;F=E($%C="!O9B`Q.3,T
M(&%N9"!S965K<R!U;G-P96-I9FEE9"!M;VYE=&%R>2!D86UA9V5S(&%N9`T*
M(&%T=&]R;F5Y<R8C>#(P,3D[(&9E97,@86YD(&-O<W1S+B!4:&4@0V]M<&%N
M>2!B96QI979E<R!T:&%T(&ET(&AA<PT*('9A;&ED(&1E9F5N<V5S(&%N9"!W
M:6QL('9I9V]R;W5S;'D@9&5F96YD(&%G86EN<W0@=&AE#0H@8VQA:6US+CPO
M9F]N=#X\+V9O;G0^/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?93!F.&4Q93A?,C8V9%\T8F8T7V$X.39?
M,V-E.3AC9C4U86$V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4P
M9CAE,64X7S(V-F1?-&)F-%]A.#DV7S-C93DX8V8U-6%A-B]7;W)K<VAE971S
M+U-H965T,38N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$4V1T%%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*%!O;&EC
M:65S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5
M<V4@;V8@17-T:6UA=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'@[($U!4D=)
M3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E)SX-"B`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\
M8CX\:3X\=3Y5<V4@;V8-"B!%<W1I;6%T97,\+W4^/"]I/CPO8CX\+V9O;G0^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/
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M(&]F($%M97)I8V$L(&]R($=!05`L(')E<75I<F5S(&UA;F%G96UE;G0@=&\@
M;6%K92!E<W1I;6%T97,@86YD#0H@87-S=6UP=&EO;G,@=&AA="!A9F9E8W0@
M=&AE(')E<&]R=&5D(&%M;W5N=',@;V8@87-S971S(&%N9`T*(&QI86)I;&ET
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M=&\@<F5V96YU92!R96-O9VYI=&EO;B!A;F0@<F5L871E9`T*(&%L;&]W86YC
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M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU92!296-O
M9VYI=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP>#L@34%21TE.+4)/5%1/
M33H@,'!X.R!-05)'24XM3$5&5#H@,B4G/@T*(#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/CQU
M/E)E=F5N=64@4F5C;V=N:71I;VX\+W4^/"]I/CPO8CX\+V9O;G0^/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@
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M979E;G5E(')E8V]G;FET:6]N('!O;&EC>2!R97%U:7)E<R!T:&%T.B`H:2DF
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M<B!D971E<FUI;F%B;&4N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM5$]0.B`Q,G!X.R!-05)'24XM0D]45$]-.B`P<'@G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H
M92!#;VUP86YY(&-O;6UE;F-E9"!I=',-"B!C;VUM97)C:6%L(&QA=6YC:"!I
M;B!T:&4@56YI=&5D(%-T871E<R!O;B!*86YU87)Y)B-X03`[,C@L(#(P,3,N
M#0H@4')I;W(@=&\@,C`Q,RP@=&AE($-O;7!A;GD@<F5C;V=N:7IE9"!N;R!R
M979E;G5E(&9R;VT@5F%S8V5P80T*('-A;&5S+B!);B!A8V-O<F1A;F-E('=I
M=&@@1T%!4"P@=6YT:6P@=&AE($-O;7!A;GD@:&%S('1H92!A8FEL:71Y#0H@
M=&\@<F5L:6%B;'D@97-T:6UA=&4@<F5T=7)N<R!O9B!687-C97!A(&9R;VT@
M:71S($1I<W1R:6)U=&]R<RP-"B!R979E;G5E('=I;&P@8F4@<F5C;V=N:7IE
M9"!B87-E9"!O;B!T:&4@<F5S86QE(&]F(%9A<V-E<&$@9F]R('1H90T*('!U
M<G!O<V5S(&]F(&9I;&QI;F<@<&%T:65N="!P<F5S8W)I<'1I;VYS+"!A;F0@
M;F]T(&)A<V5D(&]N('-A;&5S#0H@9G)O;2!T:&4@0V]M<&%N>2!T;R!S=6-H
M($1I<W1R:6)U=&]R<RX@0V]N<VES=&5N="!W:71H(&EN9'5S=')Y#0H@<')A
M8W1I8V4L(&]N8V4@=&AE($-O;7!A;GD@86-H:65V97,@<W5F9FEC:65N="!H
M:7-T;W)Y('-U8V@@=&AA="!I=`T*(&-A;B!R96QI86)L>2!E<W1I;6%T92!R
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M(')E='5R;B`H='=E;'9E(&UO;G1H<R!A9G1E<B!T:&4-"B!E>'!I<F%T:6]N
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M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'24XM0D]45$]-
M.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
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M+"!T:&4-"B!#;VUP86YY(&UU<W0@8F4@86)L92!T;R`H:2DF(WA!,#MC86QC
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M<F5V96YU97,@*&$I)B-X03`[=')A9&4@86QL;W=A;F-E<RP@<W5C:"!A<R!I
M;G9O:6-E(&1I<V-O=6YT<R!F;W(-"B!P<F]M<'0@<&%Y;65N="!A;F0@9&ES
M=')I8G5T;W(@9F5E<RP@*&(I)B-X03`[97-T:6UA=&5D(&=O=F5R;FUE;G0-
M"B!A;F0@<')I=F%T92!P87EO<B!R96)A=&5S+"!C:&%R9V5B86-K<R!A;F0@
M9&ES8V]U;G1S+"!S=6-H(&%S#0H@365D:6-A:60@<F5I;6)U<G-E;65N=',L
M("AC*28C>$$P.W)E<V5R=F5S(&9O<B!E>'!E8W1E9"!P<F]D=6-T#0H@<F5T
M=7)N<R!A;F0@*&0I)B-X03`[97-T:6UA=&5D(&-O<W1S(&]F(&EN8V5N=&EV
M97,@;V9F97)E9"!T;PT*(&-E<G1A:6X@:6YD:7)E8W0@8W5S=&]M97)S+"!I
M;F-L=61I;F<@<&%T:65N=',N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM5$]0.B`V<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%
M.B`Q<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0
M.B`P<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X.R!-
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M('!A>6UE;G0@=VET:&EN#0H@,S`F(WA!,#MD87ES+B!"87-E9"!O;B!T:&4@
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M=F%B;&4@870@=&AE('1I;64@<W5C:`T*(')E=F5N=65S(&%R92!R96-O9VYI
M>F5D+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!X
M.R!415A4+4E.1$5.5#H@-"4[($U!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.
M+4Q%1E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\:3Y296)A=&5S+`T*($-H87)G96)A
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M86YY)B-X,C`Q.3MS(&-O;G1R86-T<R!W:71H('1H97-E#0H@5&AI<F0M<&%R
M='D@4&%Y;W)S+"`H:6DI)B-X03`[=&AE(&=O=F5R;FUE;G0M;6%N9&%T960@
M9&ES8V]U;G1S#0H@87!P;&EC86)L92!T;R!G;W9E<FYM96YT+69U;F1E9"!P
M<F]G<F%M<RP@*&EI:2DF(WA!,#MI;F9O<FUA=&EO;@T*(&]B=&%I;F5D(&9R
M;VT@=&AE($-O;7!A;GDF(W@R,#$Y.W,@1&ES=')I8G5T;W)S(&%N9`T*("AI
M=BDF(WA!,#MI;F9O<FUA=&EO;B!O8G1A:6YE9"!F<F]M(&]T:&5R('1H:7)D
M('!A<G1I97,@<F5G87)D:6YG#0H@=&AE('!A>6]R(&UI>"!F;W(@5F%S8V5P
M82X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@
M5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,
M1494.B`T)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^/&D^4')O9'5C=`T*(%)E='5R;G,Z/"]I
M/B!4:&4@0V]M<&%N>28C>#(P,3D[<R!$:7-T<FEB=71O<G,@:&%V92!T:&4@
M<FEG:'0@=&\-"B!R971U<FX@=6YO<&5N960@=6YP<F5S8W)I8F5D(%9A<V-E
M<&$@9'5R:6YG('1H92`Q."UM;VYT:"!P97)I;V0-"B!B96=I;FYI;F<@<VEX
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M97`@:6X@=&AE#0H@;6%N=69A8W1U<FEN9R!P<F]C97-S(&9O<B!687-C97!A
M(&%N9"!G96YE<F%L;'D@;V-C=7)S('=I=&AI;B!A(&9E=PT*(&UO;G1H<R!B
M969O<F4@5F%S8V5P82!I<R!D96QI=F5R960@=&\@1&ES=')I8G5T;W)S+B!!
M<R!O9@T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S+"!T:&4@0V]M<&%N>2!H
M860@97AP97)I96YC960@82!D96UI;FEM=7,-"B!Q=6%N=&ET>2!O9B!P<F]D
M=6-T(')E='5R;G,N($1U<FEN9R!T:&4@;FEN92!M;VYT:',@96YD960-"B!3
M97!T96UB97(F(WA!,#LS,"P@,C`Q,RP@=&AE('!E<FEO9"!I;B!W:&EC:"!T
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M;GD@=7-E9"`H:2DF(WA!,#MD871A#0H@<')O=FED960@=&\@=&AE($-O;7!A
M;GD@8GD@:71S($1I<W1R:6)U=&]R<R`H:6YC;'5D:6YG('=E96ML>0T*(')E
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M=&AE<B!P<F]V:61E<G,I+`T*("AI:2DF(WA!,#MI;F9O<FUA=&EO;B!P<F]V
M:61E9"!T;R!T:&4@0V]M<&%N>2!F<F]M(')E=&%I;`T*('!H87)M86-I97,L
M("AI:6DI)B-X03`[9&%T82!P<F]V:61E9"!T;R!T:&4@0V]M<&%N>2!B>2!A
M('1H:7)D#0H@<&%R='D@9&%T82!P<F]V:61E<B!W:&EC:"!C;VQL96-T<R!A
M;F0@<'5B;&ES:&5S('!R97-C<FEP=&EO;B!D871A+`T*(&%N9"!O=&AE<B!T
M:&ER9"!P87)T:65S+"`H:78I)B-X03`[:&ES=&]R:6-A;"!I;F1U<W1R>2!I
M;F9O<FUA=&EO;@T*(')E9V%R9&EN9R!R971U<FX@<F%T97,@9F]R('-I;6EL
M87(@<&AA<FUA8V5U=&EC86P@<')O9'5C=',L#0H@*'8I)B-X03`[=&AE(&5S
M=&EM871E9"!R96UA:6YI;F<@<VAE;&8@;&EF92!O9B!687-C97!A('!R979I
M;W5S;'D-"B!S:&EP<&5D(&%N9"!C=7)R96YT;'D@8F5I;F<@<VAI<'!E9"!T
M;R!$:7-T<FEB=71O<G,@86YD#0H@*'9I*28C>$$P.V-O;G1R86-T=6%L(&%G
M<F5E;65N=',@:6YT96YD960@=&\@;&EM:70@=&AE(&%M;W5N="!O9@T*(&EN
M=F5N=&]R>2!M86EN=&%I;F5D(&)Y('1H92!#;VUP86YY)B-X,C`Q.3MS#0H@
M1&ES=')I8G5T;W)S+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@-G!X.R!415A4+4E.1$5.5#H@-"4[($U!4D=)3BU"3U143TTZ(#!P
M>#L@34%21TE.+4Q%1E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\:3Y/=&AE<@T*($EN
M8V5N=&EV97,Z)B-X03`[/"]I/D]T:&5R(&EN8V5N=&EV97,@=&AA="!T:&4@
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M<')O9W)A;2!I<R!I;G1E;F1E9`T*('1O(')E9'5C92!E86-H('!A<G1I8VEP
M871I;F<@<&%T:65N="8C>#(P,3D[<R!P;W)T:6]N(&]F('1H90T*(&9I;F%N
M8VEA;"!R97-P;VYS:6)I;&ET>2!F;W(@5F%S8V5P828C>#(P,3D[<R!P=7)C
M:&%S92!P<FEC92!T;R!A#0H@<W!E8VEF:65D(&1O;&QA<B!A;6]U;G0N($)A
M<V5D('5P;VX@=&AE('1E<FUS(&]F('1H92!P<F]G<F%M(&%N9`T*(&EN9F]R
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M>$$P.S,Q+"`R,#$S+B!4:&4@0V]M<&%N>2!A9&IU<W1S#0H@:71S(&%C8W)U
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M9"!C97)T86EN(&]F(&ET<R!$:7-T<FEB=71O<G,@=VET:`T*(&9I;F%N8VEA
M;"!I;F-E;G1I=F5S('1O(&)E9VEN('-T;V-K:6YG(%9A<V-E<&$@<')I;W(@
M=&\@=&AE#0H@0V]M<&%N>28C>#(P,3D[<R!C;VUM97)C:6%L(&QA=6YC:"!O
M9B!687-C97!A(&EN(&]R9&5R('1O(&5N<W5R90T*('1H870@5F%S8V5P82!W
M87,@<F5A9&EL>2!A=F%I;&%B;&4@=&\@9FEL;"!P871I96YT('!R97-C<FEP
M=&EO;G,-"B!U<&]N(&QA=6YC:"X@4W5C:"!I;F-E;G1I=F5S('=E<F4@;VYL
M>2!O9F9E<F5D(&]N('!U<F-H87-E<R!O9@T*(&EN:71I86P@;&%U;F-H('%U
M86YT:71I97,@;V8@5F%S8V5P82!S=&]C:V5D(&)Y($1I<W1R:6)U=&]R<R!I
M;@T*($IA;G5A<GD@,C`Q,RX@5&AE(&%M;W5N="!O9B!T:&5S92!F:6YA;F-I
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M<GD@,C`Q,R!W97)E(')E<V]L9"!B>0T*('-U8V@@1&ES=')I8G5T;W)S('!R
M:6]R('1O(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S+CPO9F]N=#X\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P>#L@34%21TE.+4)/5%1/33H@
M,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CY4:&4@9F]L;&]W:6YG('1A8FQE#0H@<W5M;6%R:7IE
M<R!A8W1I=FET>2!I;B!E86-H(&]F('1H92!P<F]D=6-T(')E=F5N=64@86QL
M;W=A;F-E(&%N9`T*(')E<V5R=F4@8V%T96=O<FEE<R!D97-C<FEB960@86)O
M=F4@9F]R('1H92!N:6YE(&UO;G1H<R!E;F1E9`T*(%-E<'1E;6)E<B8C>$$P
M.S,P+"`R,#$S("AI;B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@,'!X.R!-05)'24XM0D]45$]-.B`P<'@[($9/
M3E0M4TE:13H@,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS
M1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!B;W)D97(],T0P(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N
M/3-$8V5N=&5R/@T*(#QT<CX-"B`\=&0@=VED=&@],T0V,"4^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^5')A9&4\8G(@+SX-"B!!;&QO=V%N
M8V5S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,3X\8CY296)A=&5S+#QB<B`O/@T*($-H87)G96)A8VMS/&)R("\^
M#0H@86YD)B-X03`[1&ES8V]U;G1S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY0<F]D=6-T/&)R("\^#0H@
M4F5T=7)N<SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#$^/&(^3W1H97(\8G(@+SX-"B!);F-E;G1I=F5S
M/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,3X\8CY4;W1A;#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
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M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M96T[($U!4D=)3BU,1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/D)A;&%N8V4@870-
M"B!*86YU87)Y)B-X03`[,2P@,C`Q,SPO8CX\+V9O;G0^/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
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M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[
M($U!4D=)3BU,1494.B`S96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E!R;W9I<VEO;B!R96QA=&5D
M('1O#0H@8W5R<F5N="!P97)I;V0@86YD(&1E9F5R<F5D('-A;&5S/"]F;VYT
M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,BPX,SD\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/C(L-#$X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
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M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,BPP
M,3@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/C<L,S0W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3%E;3L@34%21TE.+4Q%1E0Z(#-E;2<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0W)E9&ET<R]P
M87EM96YT<R!M861E(&9O<@T*(&-U<G)E;G0@<&5R:6]D(&%N9"!D969E<G)E
M9"!S86QE<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO
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M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B@Q+#0X-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXH,2PX,S4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH-2PR-S`\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)
M3BU,1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/CQB/D)A;&%N8V4@870-"B!397!T96UB
M97(F(WA!,#LS,"P@,C`Q,SPO8CX\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB
M/B0\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/CQB/C@X.#PO8CX\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\
M8CXF(WA!,#LF(WA!,#L\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B0\+V(^/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/CQB/CDS-#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXF(WA!,#LF(WA!,#L\
M+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^/&(^)#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^,3@S/"]B/CPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/CQB/B8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)#PO8CX\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^/&(^,BPP-S<\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)B-X03`[
M)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[($U!4D=)3BU"3U14
M3TTZ(#!P>#L@1D].5"U325I%.B`Q<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`P<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^5&AE(&9O;&QO=VEN9R!T86)L90T*('-U;6UA<FEZ97,@<')O
M9'5C="!R979E;G5E(')E8V]G;FEZ960@86YD(&1E9F5R<F5D(&1U<FEN9R!T
M:&4@;FEN90T*(&UO;G1H<R!E;F1E9"!397!T96UB97(F(WA!,#LS,"P@,C`Q
M,R`H:6X@=&AO=7-A;F1S*3H\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z
M(#$R<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52
M+4-/3$Q!4%-%.B!C;VQL87!S92<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-S8E(&%L:6=N/3-$8V5N=&5R
M/@T*(#QT<CX-"B`\=&0@=VED=&@],T0V,R4^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,30E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$T)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^4V5P=&5M8F5R)B-X
M03`[,S`L)B-X03`[,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB
M/D1E8V5M8F5R)B-X03`[,S$L)B-X03`[,C`Q,CPO8CX\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ96T[($U!4D=)3BU,1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E!R;V1U8W0@<F5V
M96YU90T*(')E8V]G;FEZ960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^,38L,C0U/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*
M(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$969E
M<G)E9"!P<F]D=6-T#0H@<F5V96YU93PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/C$L-C$W/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
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M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/CQB/B0\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/C$W+#@V,CPO
M8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CX\8CXF(WA!,#LF(WA!,#L\+V(^/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-
M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'24XM0D]45$]-
M.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/DEN(&-O;FIU;F-T:6]N('=I=&@@=&AE#0H@0V]M
M<&%N>28C>#(P,3D[<R!R96-O9VYI=&EO;B!A;F0@9&5F97)R86P@;V8@<')O
M9'5C="!R979E;G5E<RP@=&AE#0H@0V]M<&%N>2!E>'!E;G-E9"!A;F0@8V%P
M:71A;&EZ960@=&AE(&%S<V]C:6%T960@8V]S="!O9B!G;V]D<RP@87,-"B!F
M;VQL;W=S+"!D=7)I;F<@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E
M<B8C>$$P.S,P+"`R,#$S("AI;@T*('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($U!4D=)3BU"3U143TTZ
M(#!P>#L@1D].5"U325I%.B`Q,G!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE
M('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&)O<F1E<CTS
M1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#<V
M)2!A;&EG;CTS1&-E;G1E<CX-"B`\='(^#0H@/'1D('=I9'1H/3-$-C0E/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)3X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q
M/CQB/E-E<'1E;6)E<B8C>$$P.S,P+"8C>$$P.S(P,3,\+V(^/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,3X\8CY$96-E;6)E<B8C>$$P.S,Q+"8C>$$P.S(P,3(\
M+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CY#;W-T(&]F(&=O;V1S('-O;&0-"B!E>'!E;G-E9#PO9F]N=#X\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
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M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@34%21TE.+4Q%1E0Z(#%E
M;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^1FEN:7-H960@9V]O9',@:6YV96YT;W)Y#0H@:&5L9"!B
M>2!O=&AE<G,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXV-#$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^
M)#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^/&(^."PT-30\+V(^/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M/&(^)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD($-A<V@@17%U:79A
M;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ
M(#!P>#L@34%21TE.+4Q%1E0Z(#(E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3X\=3Y#
M87-H#0H@86YD($-A<V@@17%U:79A;&5N=',\+W4^/"]I/CPO8CX\+V9O;G0^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/
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M9@T*('!U<F-H87-E(&]F(#DP)B-X03`[9&%Y<R!O<B!L97-S+B!297-T<FEC
M=&5D(&-A<V@@<F5P<F5S96YT<R!C87-H#0H@86YD(&-A<V@@97%U:79A;&5N
M=',@<&QE9&=E9"!T;R!G=6%R86YT964@<F5P87EM96YT(&]F(&-E<G1A:6X-
M"B!E>'!E;G-E<R!W:&EC:"!M87D@8F4@:6YC=7)R960@9F]R(&)U<VEN97-S
M('1R879E;"!U;F1E<B!C;W)P;W)A=&4-"B!C<F5D:70@8V%R9',@:&5L9"!B
M>2!E;7!L;WEE97,N/"]F;VYT/CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@,3AP>#L@34%21TE.+4)/5%1/33H@,'!X.R!-
M05)'24XM3$5&5#H@,B4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/CQU/DEN=F5N=&]R
M>3PO=3X\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@-G!X.R!-05)'24XM0D]45$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$
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M87-C97!A(&]N($IU;'DF(WA!,#LR-BP@,C`Q,B!A;F0@869T97(@=&AA="!D
M871E#0H@8F5G86X@8V%P:71A;&EZ:6YG(&EN=F5N=&]R>2!P=7)C:&%S97,@
M;V8@<V%L96%B;&4@<')O9'5C="!F<F]M#0H@87!P<F]V960@<W5P<&QI97)S
M+B!5;G1I;"!A;B!!4$D@<W5P<&QI97(@:7,@87!P<F]V960L(&%L;"!687-C
M97!A#0H@05!)('!U<F-H87-E9"!F<F]M('-U8V@@<W5P<&QI97(@:7,@:6YC
M;'5D960@87,@82!C;VUP;VYE;G0@;V8-"B!R97-E87)C:"!A;F0@9&5V96QO
M<&UE;G0@97AP96YS92X@57!O;B!S3D1!(&%P<')O=F%L(&]F(&5A8V@-"B!A
M9&1I=&EO;F%L('-U<'!L:65R+"!T:&4@0V]M<&%N>2!C87!I=&%L:7IE<R!S
M=6)S97%U96YT(%9A<V-E<&$@05!)#0H@<'5R8VAA<V5S(&9R;VT@<W5C:"!S
M=7!P;&EE<B!A<R!I;G9E;G1O<GDN(%!U<F-H87-E<R!O9B!687-C97!A($%0
M20T*(')E8V5I=F5D(&%N9"!E>'!E;G-E9"!B969O<F4@<W5C:"!R96=U;&%T
M;W)Y(&%P<')O=F%L<R!I<R!N;W0-"B!S=6)S97%U96YT;'D@8V%P:71A;&EZ
M960L(&%N9"!A;&P@<W5C:"!P=7)C:&%S97,@87)E('%U87)A;G1I;F5D#0H@
M86YD(&YO="!U<V5D(&9O<B!C;VUM97)C:6%L('-U<'!L>2!U;G1I;"!S=6-H
M('1I;64@87,@=&AE('-.1$$@9F]R#0H@=&AE('-U<'!L:65R('1H870@<')O
M9'5C960@=&AE($%022!I<R!A<'!R;W9E9"X\+V9O;G0^/"]P/@T*(#PO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YT86YG:6)L92!!<W-E="P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q
M.'!X.R!-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R)2<^#0H@
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^/&(^/&D^/'4^26YT86YG:6)L92!!<W-E="P@;F5T/"]U/CPO
M:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V
M<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^26YT86YG:6)L92!A
M<W-E=',@8V]N<VES=`T*(&]F(&$@;6EL97-T;VYE('!A>6UE;G0@<&%I9"!T
M;R!T:&4@9F]R;65R('-H87)E:&]L9&5R<R!O9B!,87AD86QE#0H@3&EM:71E
M9"!R96QA=&5D('1O('1H92`R,#`T(&%C<75I<VET:6]N(&]F(&]U<B!R:6=H
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M(&ES(&-U<G)E;G1L>0T*(&%N=&EC:7!A=&5D+B!3964@3F]T92`W)B-X,C`Q
M-#M#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R!F;W(-"B!F=7)T:&5R
M(&EN9F]R;6%T:6]N(')E9V%R9&EN9R!O=&AE<B!O8FQI9V%T:6]N<R!R96QA
M=&5D('1O('1H90T*(&%C<75I<VET:6]N(&]F($QA>&1A;&4@3&EM:71E9"X\
M+V9O;G0^/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@4F5V96YU93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,3AP>#L@34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM
M3$5&5#H@,B4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/CQU/D1E9F5R<F5D(%)E=F5N
M=64\+W4^/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S='EL93TS
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M<F4-"B!397!T96UB97(F(WA!,#LS,"P@,C`Q,RX\+V9O;G0^/"]P/@T*(#PO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5S96%R8V@@86YD($1E=F5L;W!M96YT($-O<W1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-
M05)'24XM5$]0.B`Q.'!X.R!-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,
M1494.B`R)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^/'4^4F5S96%R8V@@86YD($1E
M=F5L;W!M96YT($-O<W1S/"]U/CPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`V<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^5&AE($-O;7!A;GD@8VAA<F=E<PT*(')E<V5A<F-H(&%N9"!D
M979E;&]P;65N="!C;W-T<R!T;R!O<&5R871I;VYS(&%S(&EN8W5R<F5D+B!2
M97-E87)C:`T*(&%N9"!D979E;&]P;65N="!E>'!E;G-E<R!A<F4@8V]M<')I
M<V5D(&]F(&-O<W1S(&EN8W5R<F5D(&)Y('1H90T*($-O;7!A;GD@:6X@<&5R
M9F]R;6EN9R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@86-T:79I=&EE<RP-
M"B!I;F-L=61I;F<@<V%L87)Y(&%N9"!B96YE9FET<SL@<W1O8VLM8F%S960@
M8V]M<&5N<V%T:6]N(&5X<&5N<V4[#0H@;&%B;W)A=&]R>2!S=7!P;&EE<R!A
M;F0@;W1H97(@9&ER96-T(&5X<&5N<V5S.R!C;VYT<F%C='5A;`T*('-E<G9I
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M+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y396QL:6YG+"!'96YE<F%L(&%N9"!!9&UI;FES=')A
M=&EV92!#;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD
M:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!X.R!-05)'24XM0D]4
M5$]-.B`P<'@[($U!4D=)3BU,1494.B`R)2<^#0H@/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^
M/'4^4V5L;&EN9RP@1V5N97)A;"!A;F0@061M:6YI<W1R871I=F4-"B!#;W-T
M<SPO=3X\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@-G!X.R!-05)'24XM0D]45$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!#
M;VUP86YY(&-H87)G97,@<V%L97,L#0H@9V5N97)A;"!A;F0@861M:6YI<W1R
M871I=F4@8V]S=',@=&\@;W!E<F%T:6]N<R!A<R!I;F-U<G)E9"X-"B!396QL
M:6YG+"!G96YE<F%L(&%N9"!A9&UI;FES=')A=&EV92!C;W-T<R!I;F-L=61E
M(&-O<W1S(&]F#0H@<V%L87)I97,L('!R;V=R86US(&%N9"!I;F9R87-T<G5C
M='5R92!N96-E<W-A<GD@9F]R('1H92!G96YE<F%L#0H@8V]N9'5C="!O9B!T
M:&4@0V]M<&%N>28C>#(P,3D[<R!B=7-I;F5S<RP@:6YC;'5D:6YG('1H92`R
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M=65D#0H@:6X@3V-T;V)E<B`R,#`Y('1O(&9O<FUE<B!O9F9I8V5R<R!O9B!!
M;6%R:6X@=VAI8V@@:7,@<F5C;W)D960@87,-"B!C;VUP96YS871I;VX@:6YC
M;VUE("AE>'!E;G-E*2X\+V9O;G0^/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE(%1A
M>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\
M<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!X.R!-05)'24XM0D]45$]-.B`P
M<'@[($U!4D=)3BU,1494.B`R)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^/'4^26YC
M;VUE#0H@5&%X97,\+W4^/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CY$969E<G)E9"!T87@@87-S971S(&%N9`T*(&QI86)I;&ET:65S(&%R
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M86QU871I;VX@86QL;W=A;F-E<R!A<F4@<')O=FED960@86=A:6YS=`T*(&1E
M9F5R<F5D('1A>"!A<W-E=',@=&AA="!A<F4@;F]T(&UO<F4@;&EK96QY('1H
M86X@;F]T('1O(&)E#0H@<F5A;&EZ960N/"]F;VYT/CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'24XM0D]45$]-.B`P<'@G/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/E1H92!#;VUP86YY('!R;W9I9&5S#0H@<F5S97)V97,@9F]R('!O
M=&5N=&EA;"!P87EM96YT<R!O9B!T87@@=&\@=F%R:6]U<R!T87@@875T:&]R
M:71I97,-"B!O<B!D;V5S(&YO="!R96-O9VYI>F4@=&%X(&)E;F5F:71S(')E
M;&%T960@=&\@=6YC97)T86EN('1A>`T*('!O<VET:6]N<R!A;F0@;W1H97(@
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M('!R;W9I<VEO;B!F;W(-"B!I;F-O;64@=&%X97,N/"]F;VYT/CPO<#X-"B`\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E<FEV871I=F4@26YS=')U;65N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E
M)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CX\8CX\:3X\=3Y$97)I=F%T:79E($EN<W1R=6UE;G1S
M/"]U/CPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M5$]0.B`V<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^1&5R:79A
M=&EV92!F:6YA;F-I86P-"B!L:6%B:6QI=&EE<R!A<F4@<F5C;W)D960@870@
M9F%I<B!V86QU92P@=VET:"!G86EN<R!A;F0@;&]S<V5S#0H@87)I<VEN9R!F
M;W(@8VAA;F=E<R!I;B!F86ER('9A;'5E(')E8V]G;FEZ960@:6X@=&AE('-T
M871E;65N="!O9@T*(&]P97)A=&EO;G,@870@96%C:"!P97)I;V0@96YD('=H
M:6QE('-U8V@@:6YS=')U;65N=',@87)E#0H@;W5T<W1A;F1I;F<N($EF('1H
M92!#;VUP86YY(&ES<W5E<R!S:&%R97,@=&\@9&ES8VAA<F=E('1H90T*(&QI
M86)I;&ET>2P@=&AE(&1E<FEV871I=F4@9FEN86YC:6%L(&QI86)I;&ET>2!I
M<R!D97)E8V]G;FEZ960@86YD#0H@8V]M;6]N('-T;V-K(&%N9"!A9&1I=&EO
M;F%L('!A:60M:6X@8V%P:71A;"!A<F4@<F5C;V=N:7IE9"!O;B!T:&4-"B!I
M<W-U86YC92!O9B!T:&]S92!S:&%R97,N(%1H92!W87)R86YT<R!A<F4@=F%L
M=65D('5S:6YG(&$-"B!";&%C:RU38VAO;&5S(&]P=&EO;B!P<FEC:6YG(&UO
M9&5L(&1U92!T;R!T:&4@;F%T=7)E(&]F('1H90T*(&EN<W1R=6UE;G0N(%1H
M92!L;VYG('1E<FT@9&5B="!R961E;7!T:6]N(&9E871U<F4@:7,@=F%L=65D
M('5S:6YG(&$-"B!P<F]B86)I;&ET>2UW96EG:'1E9"!M;V1E;"!I;F-O<G!O
M<F%T:6YG(&UA;F%G96UE;G0@97-T:6UA=&5S(&9O<@T*('!O=&5N=&EA;"!C
M:&%N9V4@:6X@8V]N=')O;"P@86YD(&)Y(&1E=&5R;6EN:6YG('1H92!F86ER
M('9A;'5E(&]F#0H@=&AE(&1E8G0@=VET:"!A;F0@=VET:&]U="!T:&4@8VAA
M;F=E(&EN(&-O;G1R;VP@<')O=FES:6]N#0H@:6YC;'5D960N/"]F;VYT/CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'24XM0D]4
M5$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
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M+V9O;G0^/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!P97(@4VAA<F4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%
M1E0Z(#(E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3X\=3Y,;W-S#0H@<&5R(%-H87)E
M/"]U/CPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M5$]0.B`V<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@<W1Y;&4],T0G
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M8V%L8W5L871E9`T*('5S:6YG('1H92!T<F5A<W5R>2!S=&]C:R!M971H;V0@
M86YD(&-O;G9E<G1I8FQE(&YO=&5S('5S:6YG('1H90T*("8C>#(P,4,[:68M
M8V]N=F5R=&5D)B-X,C`Q1#L@;65T:&]D+B!);B!P97)I;V1S('=I=&@@<F5P
M;W)T960@;F5T#0H@;W!E<F%T:6YG(&QO<W-E<RP@86QL(&-O;6UO;B!S=&]C
M:R!O<'1I;VYS(&%N9"!W87)R86YT<R!A<F4@9&5E;65D#0H@86YT:2UD:6QU
M=&EV92!S=6-H('1H870@8F%S:6,@;F5T(&QO<W,@<&5R('-H87)E(&%N9"!D
M:6QU=&5D(&YE=`T*(&QO<W,@<&5R('-H87)E(&%R92!E<75A;"X\+V9O;G0^
M/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5B="!);G-T<G5M96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@,3AP>#L@34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM3$5&5#H@
M,B4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/CQB/CQI/CQU/D1E8G0-"B!);G-T<G5M96YT<SPO
M=3X\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@-G!X.R!-05)'24XM0D]45$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D1E8G0@:6YS
M=')U;65N=',@87)E#0H@:6YI=&EA;&QY(')E8V]R9&5D(&%T(&9A:7(@=F%L
M=64L('=I=&@@8V]U<&]N(&EN=&5R97-T(&%N9`T*(&%M;W)T:7IA=&EO;B!O
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M:&4-"B!I<W-U86YC92!O9B!T:&]S92!S:&%R97,N/"]F;VYT/CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'24XM0D]45$]-.B`P
M<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/E1H92!#;VUP86YY)B-X,C`Q.3MS#0H@97AC:&%N9V5A
M8FQE(&YO=&5S(&-O;G1A:6X@82!C;VYV97)S:6]N(&]P=&EO;B!W:&EC:"!I
M<R!C;&%S<VEF:65D#0H@87,@97%U:71Y+B!4:&4@9F%I<B!V86QU92!O9B!T
M:&4@;&EA8FEL:71Y(&-O;7!O;F5N="!O9B!T:&4@9&5B=`T*(&EN<W1R=6UE
M;G0@=V%S(&1E9'5C=&5D(&9R;VT@=&AE(&EN:71I86P@<')O8V5E9',@=&\@
M9&5T97)M:6YE('1H90T*('!R;V-E961S('1O(&)E(&%L;&]C871E9"!T;R!T
M:&4@8V]N=F5R<VEO;B!O<'1I;VXN(%1H92!E;6)E9&1E9`T*(&-O;G9E<G-I
M;VX@;W!T:6]N(&ES(&EN9&5X960@=&\@=&AE($-O;7!A;GDF(W@R,#$Y.W,@
M<W1O8VL@86YD#0H@=')E871E9"!A<R!E<75I='D@;VX@=&AE(&)A;&%N8V4@
M<VAE970N(%1H92!C;VYV97)S:6]N(&]P=&EO;B!I<PT*(&5V86QU871E9"!O
M;B!A('%U87)T97)L>2!B87-I<R!T;R!D971E<FUI;F4@:68@:70@<W1I;&P@
M;65E=',@=&AE#0H@8W)I=&5R:6$@=&\@8F4@97%U:71Y(&-L87-S:69I960N
M(%1H92!E>&-E<W,@<')I;F-I<&%L(&%M;W5N="!O9@T*('1H92!D96)T(&]V
M97(@=&AE(&-A<G)Y:6YG('9A;'5E(&]F('1H92!L:6%B:6QI='D@:7,@86UO
M<G1I>F5D('1O#0H@:6YT97)E<W0@97AP96YS92!O=F5R('1H92!T97)M(&]F
M('1H92!D96)T+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
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M"B!T97)M(&]F('1H92!N;W1E('!A>6%B;&4N/"]F;VYT/CPO<#X-"B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9A:7(@5F%L=64@;V8@1FEN86YC:6%L($EN<W1R=6UE;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.
M+4Q%1E0Z(#(E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3X\=3Y&86ER#0H@5F%L=64@
M;V8@1FEN86YC:6%L($EN<W1R=6UE;G1S/"]U/CPO:3X\+V(^/"]F;VYT/CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'@[($U!4D=)3BU"3U14
M3TTZ(#!P>"<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A;GD@<')O=FED97,-"B!D:7-C
M;&]S=7)E(&]F(&9I;F%N8VEA;"!A<W-E=',@86YD(&9I;F%N8VEA;"!L:6%B
M:6QI=&EE<R!T:&%T(&%R90T*(&-A<G)I960@870@9F%I<B!V86QU92!B87-E
M9"!O;B!T:&4@<')I8V4@=&AA="!W;W5L9"!B92!R96-E:79E9`T*('5P;VX@
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M('1H<F5E#0H@;&5V96QS.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,3)P>#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,
M979E;"`Q)B-X,C`Q-#M);G!U=',@87)E#0H@=6YA9&IU<W1E9"!Q=6]T960@
M<')I8V5S(&EN(&%C=&EV92!M87)K971S(&9O<B!I9&5N=&EC86P@87-S971S
M(&]R#0H@;&EA8FEL:71I97,@=&AA="!T:&4@0V]M<&%N>2!H87,@=&AE(&%B
M:6QI='D@=&\@86-C97-S(&%T('1H90T*(&UE87-U<F5M96YT(&1A=&4N/"]F
M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'
M24XM0D]45$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
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M<RDN/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X
M.R!-05)'24XM0D]45$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DQE=F5L(#,F(W@R,#$T
M.U5N;V)S97)V86)L90T*(&EN<'5T<R!T:&%T(')E9FQE8W0@=&AE($-O;7!A
M;GDF(W@R,#$Y.W,@97-T:6UA=&5S(&]F('1H90T*(&%S<W5M<'1I;VYS('1H
M870@;6%R:V5T('!A<G1I8VEP86YT<R!W;W5L9"!U<V4@:6X@<')I8VEN9R!T
M:&4@87-S970-"B!O<B!L:6%B:6QI='DN)B-X03`[5&AE($-O;7!A;GD@9&5V
M96QO<',@=&AE<V4@:6YP=71S(&)A<V5D(&]N('1H90T*(&)E<W0@:6YF;W)M
M871I;VX@879A:6QA8FQE+"!I;F-L=61I;F<@:71S(&]W;B!D871A+CPO9F]N
M=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P>#L@34%21TE.
M+4)/5%1/33H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@9F]L;&]W:6YG('1A8FQE#0H@
M<')E<V5N=',@:6YF;W)M871I;VX@86)O=70@=&AE($-O;7!A;GDF(W@R,#$Y
M.W,@87-S971S(&%N9`T*(&QI86)I;&ET:65S(&%S(&]F(%-E<'1E;6)E<B8C
M>$$P.S,P+"`R,#$S(&%N9"!$96-E;6)E<B8C>$$P.S,Q+`T*(#(P,3(@=&AA
M="!A<F4@;65A<W5R960@870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!B
M87-I<R!A;F0-"B!I;F1I8V%T97,@=&AE(&9A:7(@=F%L=64@:&EE<F%R8VAY
M(&]F('1H92!V86QU871I;VX@=&5C:&YI<75E<R!T:&4-"B!#;VUP86YY('5T
M:6QI>F5D('1O(&1E=&5R;6EN92!S=6-H(&9A:7(@=F%L=64Z/"]F;VYT/CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($U!4D=)3BU"3U14
M3TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A
M8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&)O<F1E
M<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#8X)2!A;&EG;CTS1&-E;G1E<CX-"B`\='(^#0H@/'1D('=I9'1H/3-$-3DE
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,E/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0Q-"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY397!T96UB97(F(WA!
M,#LS,"P-"B`R,#$S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T
M<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CX\
M:3Y);B!M:6QL:6]N<SPO:3X\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^5&]T86P\+V(^
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY,979E;"8C>$$P.S$\+V(^/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY,979E;"8C>$$P.S(\+V(^/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,3X\8CY,979E;"8C>$$P.S,\+V(^/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY!<W-E
M=#H\+V(^/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E
M;3L@34%21TE.+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0V%S:`T*(&5Q=6EV86QE
M;G1S)B-X,C`Q-#MM;VYE>2!M87)K971S/"]F;VYT/CPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/C$Q,RXU/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3$S+C4\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
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M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L
M<W!A;CTS1#0^/"]T9#X-"B`\=&0@8V]L<W!A;CTS1#0^/"]T9#X-"B`\=&0@
M8V]L<W!A;CTS1#0^/"]T9#X-"B`\=&0@8V]L<W!A;CTS1#0^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM
M3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY,:6%B:6QI=&EE<SH\+V(^/"]F;VYT
M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@34%21TE.+4Q%
M1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^5V%R<F%N="!D97)I=F%T:79E#0H@;&EA8FEL
M:71Y/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C,Y+C8\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
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M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
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M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ96T[($U!4D=)3BU,1494.B`Q96TG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DQO;F<M
M=&5R;2!D96)T(')E9&5M<'1I;VX-"B!F96%T=7)E/"]F;VYT/CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/C<N,CPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW
M+C(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CY&;W)E:6=N(&-U<G)E;F-Y#0H@8V]N=')A8W1S/"]F;VYT/CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/C`N-#PO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M+C0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-
M05)'24XM5$]0.B`P<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%
M.B`Q,G!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%
M4BU#3TQ,05!313H@8V]L;&%P<V4G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#8X)2!A;&EG;CTS1&-E;G1E
M<CX-"B`\='(^#0H@/'1D('=I9'1H/3-$-3DE/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^
M#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1E
M<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,3X\8CY$96-E;6)E<B8C>$$P.S,Q+`T*(#(P,3(\+V(^/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/CQI/DEN(&UI;&QI;VYS/"]I/CPO
M8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,3X\8CY4;W1A;#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0Q/CQB/DQE=F5L)B-X03`[,3PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q
M/CQB/DQE=F5L)B-X03`[,CPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB
M/DQE=F5L)B-X03`[,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO
M='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,
M1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/CQB/D%S<V5T.CPO8CX\+V9O;G0^/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CY#87-H#0H@97%U:79A;&5N=',F(W@R,#$T.VUO;F5Y(&UA
M<FME=',\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[)B-X03`[-C0N,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.S8T+C$\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0^/"]T9#X-"B`\=&0@
M8V]L<W!A;CTS1#0^/"]T9#X-"B`\=&0@8V]L<W!A;CTS1#0^/"]T9#X-"B`\
M=&0@8V]L<W!A;CTS1#0^/"]T9#X-"B`\=&0@8V]L<W!A;CTS1#0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'
M24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY,:6%B:6QI='DZ/"]B/CPO9F]N
M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,
M1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/E=A<G)A;G0@9&5R:79A=&EV90T*(&QI86)I
M;&ET>3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
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M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
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M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/C4T+CD\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,;VYG
M+71E<FT@9&5B="!R961E;7!T:6]N#0H@9F5A='5R93PO9F]N=#X\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-"XV/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
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M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/C$T+C8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'24XM0D]45$]-.B`P<'@G/CQF;VYT
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M9F]N=#X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y,;VYG(%1E<FT@1&5B="!2961E;7!T:6]N
M($9E871U<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/
M33H@,'!X.R!-05)'24XM3$5&5#H@,B4G/@T*(#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/CQU
M/DQO;F<-"B!497)M($1E8G0@4F5D96UP=&EO;B!&96%T=7)E/"]U/CPO:3X\
M+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'@[
M($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A;GDF(W@R
M,#$Y.W,-"B!$96-E;6)E<B`R,#$R(&9I;F%N8VEN9R!A9W)E96UE;G0@=VET
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M<F4@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RP-"B!O<B!R97%U:7)E9"!T;R!R
M97!A>2`D,34P(&UI;&QI;VXL(&QE<W,@86YY('!R979I;W5S;'D@<F5P86ED
M#0H@86UO=6YT+"!I9B!T:&4@8VAA;F=E(&]F(&-O;G1R;VP@979E;G0@;V-C
M=7)S(&%F=&5R#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RX@5&AE($-O;7!A
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M(&]F('1H92!E;6)E9&1E9"!D97)I=F%T:79E+B!!=`T*($1E8V5M8F5R)B-X
M03`[,S$L(#(P,3(L('1H92!F86ER('9A;'5E(&]F('1H92!D97)I=F%T:79E
M('=A<PT*(&1E=&5R;6EN960@=&\@8F4@)#$T+C8@;6EL;&EO;BP@86YD('1H
M92!D96)T('=A<R!V86QU960@8GD-"B!C;VUP87)I;F<@9&5B="!I<W-U97,@
M;V8@<VEM:6QA<B!C;VUP86YI97,@=VET:"`H:2DF(WA!,#MT97)M<R!O9@T*
M(&)E='=E96X@-"XX(&%N9"`X+C`@>65A<G,L("AI:2DF(WA!,#MC;W5P;VX@
M<F%T97,@;V8@8F5T=V5E;B`S+C`E#0H@86YD(#$Q+C4E(&%N9"`H:6EI*28C
M>$$P.VUA<FME="!Y:65L9',@;V8@8F5T=V5E;B`Q,"XW)2!A;F0@,C<N-R4N
M#0H@070@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,L('1H92!F86ER('9A;'5E
M(&]F('1H92!D97)I=F%T:79E('=A<PT*(&1E=&5R;6EN960@=&\@8F4@)#<N
M,B!M:6QL:6]N+"!A;F0@=&AE(&1E8G0@=V%S('9A;'5E9"!B>2!C;VUP87)I
M;F<-"B!D96)T(&ES<W5E<R!O9B!S:6UI;&%R(&-O;7!A;FEE<R!W:71H("AI
M*28C>$$P.W)E;6%I;FEN9R!T97)M<R!O9@T*(&)E='=E96X@,RXU(&%N9"`T
M+C0@>65A<G,L("AI:2DF(WA!,#MC;W5P;VX@<F%T97,@;V8@8F5T=V5E;B`Y
M+CDE#0H@86YD(#$R+C4E(&%N9"`H:6EI*28C>$$P.VUA<FME="!Y:65L9',@
M;V8@8F5T=V5E;B`Q,"XT)2!A;F0@,C4N."4N#0H@5&AE($-O;7!A;GD@<F5C
M;V=N:7IE9"!A(&=A:6X@;V8@)#$N-"!M:6QL:6]N(&%N9"`D-RXT(&UI;&QI
M;VX@;VX-"B!T:&4@8VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@=&AI<R!D97)I
M=F%T:79E(&QI86)I;&ET>2!F;W(@=&AE('1H<F5E#0H@86YD(&YI;F4@;6]N
M=&AS(&5N9&5D(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S+`T*(')E<W!E8W1I
M=F5L>2X\+V9O;G0^/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F]R96EG;B!#=7)R96YC>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@,3AP>#L@34%21TE.+4)/5%1/33H@,'!X.R!-
M05)'24XM3$5&5#H@,B4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/CQU/D9O<F5I9VX@
M0W5R<F5N8WD\+W4^/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CY!;&P@<W5B<VED:6%R:65S('5S92!T:&4-"B!5;FET960@4W1A=&5S(&1O
M;&QA<B!A<R!T:&4@9G5N8W1I;VYA;"!C=7)R96YC>2X@36]N971A<GD@87-S
M971S#0H@86YD(&QI86)I;&ET:65S(&1E;F]M:6YA=&5D(&EN(&$@9F]R96EG
M;B!C=7)R96YC>2!A<F4@<F5M96%S=7)E9`T*(&EN=&\@56YI=&5D(%-T871E
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M:6YS(&%N9`T*(&QO<W-E<R!F<F]M('1H92!R96UE87-U<F5M96YT(&%R92!I
M;F-L=61E9"!I;B!O=&AE<B`H97AP96YS92D-"B!I;F-O;64L(&YE="!I;B!T
M:&4@8V]N<V]L:61A=&5D('-T871E;65N=',@;V8@;W!E<F%T:6]N<RX@1F]R
M#0H@=')A;G-A8W1I;VYS('-E='1L960@9'5R:6YG('1H92!A<'!L:6-A8FQE
M('!E<FEO9"P@9V%I;G,@86YD(&QO<W-E<PT*(&%R92!I;F-L=61E9"!I;B!O
M=&AE<B`H97AP96YS92D@:6YC;VUE+"!N970@:6X@=&AE(&-O;G-O;&ED871E
M9`T*('-T871E;65N=',@;V8@;W!E<F%T:6]N<RX@5&AE($-O;7!A;GD@<&5R
M:6]D:6-A;&QY('5S97,@9F]R96EG;@T*(&5X8VAA;F=E(&9O<G=A<F0@8V]N
M=')A8W1S('1O(&AE9&=E(&%G86EN<W0@8VAA;F=E<R!I;B!E>&-H86YG90T*
M(')A=&5S(&9O<B!I;G9E;G1O<GD@<'5R8VAA<V5S(&1E;F]M:6YA=&5D(&EN
M(&9O<F5I9VX@8W5R<F5N8WDN($%S#0H@;V8F(WA!,#M397!T96UB97(@,S`L
M(#(P,3,L('1H92!#;VUP86YY(&AE;&0@;VYE(&9O<F5I9VX@97AC:&%N9V4-
M"B!F;W)W87)D(&-O;G1R86-T('=I=&@@82!N;W1I;VYA;"!A;6]U;G0@;V8@
M)#0N-2!M:6QL:6]N+B!!<PT*(&]F)B-X03`[4V5P=&5M8F5R(#,P+"`R,#$S
M+"!T:&4@;W5T<W1A;F1I;F<@9F]R96EG;B!E>&-H86YG90T*(&9O<G=A<F0@
M8V]N=')A8W0@9&5R:79A=&EV92!L:6%B:6QI='D@:&%D(&$@;F5T(&9A:7(@
M=F%L=64@;V8@)#`N-`T*(&UI;&QI;VXN(%1H92!#;VUP86YY(&EN8VQU9&5D
M('1H:7,@)#`N-"!M:6QL:6]N(&%S(&$@8V]M<&]N96YT(&]F#0H@8VAA;F=E
M(&EN(&9A:7(@=F%L=64@;V8@9&5R:79A=&EV92!L:6%B:6QI=&EE<R!A;F0@
M:6X@;W1H97(@8W5R<F5N=`T*(&QI86)I;&ET:65S(&%T(%-E<'1E;6)E<B8C
M>$$P.S,P+"`R,#$S+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@,3)P>#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@
M8VAA;F=E(&EN('1H92!F86ER#0H@=F%L=64@;V8@9FEN86YC:6%L(&EN<W1R
M=6UE;G1S(&ES(&%S(&9O;&QO=W,@*&EN#0H@=&AO=7-A;F1S*3H\+V9O;G0^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/
M5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*("8C>$$P.SPO<#X-"B`\
M=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8F]R
M9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$.3(E(&%L:6=N/3-$8V5N=&5R/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U
M.24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R
M/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0Q/CQB/D]C=&]B97(\+V(^/"]F;VYT/CQB<B`O
M/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0Q/CQB/C(P,#D\+V(^/"]F;VYT/CQB<B`O/@T*(#QF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0Q/CQB/B8C>$$P.R8C>$$P.U=A<G)A;G1S)B-X03`[)B-X03`[/"]B/CPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX],T1C
M96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#$^/&(^1&5B=#PO8CX\+V9O;G0^/&)R("\^#0H@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#$^/&(^)B-X03`[)B-X03`[4F5D96UP=&EO;B8C>$$P.R`F(WA!,#L\
M+V(^/"]F;VYT/CQB<B`O/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/D9E871U<F4\+V(^/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,3X\8CY&;W)E:6=N/"]B/CPO9F]N=#X\8G(@+SX-"B`\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,3X\8CY%>&-H86YG93PO8CX\+V9O;G0^/&)R("\^#0H@/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#$^/&(^)B-X03`[)B-X03`[0V]N=')A8W1S)B-X03`[)B-X03`[/"]B/CPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^)B-X03`[)B-X03`[)B-X03`[)B-X
M03`[5&]T86QS)B-X03`[)B-X03`[)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D/CPO=&0^#0H@
M/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^
M#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO
M=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@
M34%21TE.+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^0F%L86YC92!A=`T*($IA
M;G5A<GDF(WA!,#LQ+"`R,#$R/"]B/CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M/&(^)#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^,3(S+#$R-3PO8CX\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CX\8CXF(WA!,#LF(WA!,#L\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B0\+V(^/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/CQB/B8C>#(P,30[)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/CQB/B8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)#PO8CX\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^/&(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V(^/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^/&(^)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXD/"]B/CPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CX\8CXQ,C,L,3(U/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B8C>$$P
M.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT
M9#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N
M/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS
M<&%N/3-$-#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,
M1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/DQO<W,@;VX@8VAA;F=E(&EN(&9A:7(-"B!V
M86QU92!O9B!D97)I=F%T:79E(&QI86)I;&ET>3PO9F]N=#X\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
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M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXV."PV.#8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#;VUP96YS871I;VX@
M97AP96YS92!F;W(-"B!C:&%N9V4@:6X@9F%I<B!V86QU92!O9B!W87)R86YT
M<R!I<W-U960@=&\@9F]R;65R#0H@96UP;&]Y965S/"]F;VYT/CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,RPP,S<\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXS+#`S-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,
M1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/E1R86YS9F5R<R!T;PT*(&5Q=6ET>3PO9F]N
M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@Q,#,L.#@U
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXH,3`S+#@X-3PO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L
M<W!A;CTS1#0^/"]T9#X-"B`\=&0@8V]L<W!A;CTS1#0^/"]T9#X-"B`\=&0@
M8V]L<W!A;CTS1#0^/"]T9#X-"B`\=&0@8V]L<W!A;CTS1#0^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM
M3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY"86QA;F-E(&%T#0H@4V5P=&5M8F5R
M)B-X03`[,S`L(#(P,3(\+V(^/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
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M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M/&(^)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@
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M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CX\8CXF(WA!,#L\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B0\+V(^/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/CQB/B8C>#(P,30[)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB
M/B8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)#PO8CX\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^/&(^.3`L.38S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B8C>$$P.R8C>$$P
M.SPO8CX\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`P<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@
M1D].5"U325I%.B`Q,G!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE
M/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&)O<F1E<CTS1#`@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG
M;CTS1&-E;G1E<CX-"B`\='(^#0H@/'1D('=I9'1H/3-$-3@E/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<CX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,3X\8CY/8W1O8F5R/"]B/CPO9F]N=#X\8G(@+SX-"B`\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,3X\8CXR,#`Y/"]B/CPO9F]N=#X\8G(@+SX-"B`\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXF(WA!
M,#LF(WA!,#M787)R86YT<R8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0Q/CQB/D1E8G0\+V(^/"]F;VYT/CQB<B`O/@T*(#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/B8C
M>$$P.R8C>$$P.U)E9&5M<'1I;VXF(WA!,#L@)B-X03`[/"]B/CPO9F]N=#X\
M8G(@+SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,3X\8CY&96%T=7)E/"]B/CPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#$^/&(^1F]R96EG;CPO8CX\+V9O;G0^/&)R("\^#0H@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^
M17AC:&%N9V4\+V(^/"]F;VYT/CQB<B`O/@T*(#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/B8C>$$P
M.R8C>$$P.T-O;G1R86-T<R8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0Q/CQB/B8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.U1O=&%L<R8C
M>$$P.R8C>$$P.R8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9#X\+W1D/@T*(#QT9"!C;VQS<&%N
M/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS
M<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#PO='(^
M#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,1494
M.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/CQB/D)A;&%N8V4@870-"B!*86YU87)Y)B-X03`[
M,2P@,C`Q,SPO8CX\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B0\+V(^/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/CQB/C4T+#@U-#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXF(WA!
M,#LF(WA!,#L\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B0\+V(^/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB
M/C$T+#4W-SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXF(WA!,#LF(WA!,#L\+V(^
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/CQB/B0\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B8C>#(P,30[)B-X
M03`[)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B8C>$$P.SPO8CX\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^/&(^)#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
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M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9#X\+W1D/@T*(#QT9"!C;VQS<&%N
M/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS
M<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#PO='(^
M#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,1494.B`Q96TG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BA'
M86EN*2!L;W-S(&]N(&-H86YG92!I;@T*(&9A:7(@=F%L=64@;V8@9&5R:79A
M=&EV92!L:6%B:6QI=&EE<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B@Q-"PP-S<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH-RPS-S<\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS.34\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B@R,2PP-3D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3%E;3L@34%21TE.+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0V]M<&5N<V%T:6]N
M(&EN8V]M92!F;W(-"B!C:&%N9V4@:6X@9F%I<B!V86QU92!O9B!W87)R86YT
M<R!I<W-U960@=&\@9F]R;65R#0H@96UP;&]Y965S/"]F;VYT/CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#$L,3<Y/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B@Q+#$W.3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CY4<F%N<V9E<G,@=&\-"B!E<75I='D\+V9O;G0^/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
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M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9#X\
M+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$
M-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N
M/3-$-#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ96T[($U!4D=)3BU,1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/D)A;&%N8V4@
M870-"B!397!T96UB97(F(WA!,#LS,"P@,C`Q,SPO8CX\+V9O;G0^/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/CQB/B0\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/C,Y+#4Y.#PO8CX\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CX\8CXF(WA!,#LF(WA!,#L\+V(^/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB
M/B0\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/CQB/C<L,C`P/"]B/CPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/CQB/B8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)#PO8CX\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^/&(^,SDU/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B8C>$$P.R8C>$$P
M.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)#PO8CX\+V9O;G0^/"]T9#X-"B`\
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M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E
M9VUE;G0@86YD($=E;V=R87!H:6-A;"!);F9O<FUA=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,'!X.R!-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494
M.B`R)2<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^/'4^4V5G;65N="!A;F0@1V5O9W)A
M<&AI8V%L#0H@26YF;W)M871I;VX\+W4^/"]I/CPO8CX\+V9O;G0^/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@
M,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CY&;W(@=&AE('1H<F5E(&%N9"!N:6YE#0H@;6]N=&AS
M(&5N9&5D(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S(&%N9"`R,#$R+"!T:&4@
M0V]M<&%N>2!H87,-"B!R97!O<G1E9"!I=',@8G5S:6YE<W,@87,@82!S:6YG
M;&4@<F5P;W)T:6YG('-E9VUE;G0N(%1H90T*($-O;7!A;GDF(W@R,#$Y.W,@
M8VAI968@9&5C:7-I;VX@;6%K97(L('=H;R!I<R!T:&4@0VAI968@17AE8W5T
M:79E#0H@3V9F:6-E<BP@<F5G=6QA<FQY(&5V86QU871E<R!T:&4@0V]M<&%N
M>2!O;B!A(&-O;G-O;&ED871E9`T*(&)A<VES+CPO9F]N=#X\+W`^#0H@/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y296-E;G0@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,3AP>#L@34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM
M3$5&5#H@,B4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/CQU/E)E8V5N=`T*($%C8V]U
M;G1I;F<@4')O;F]U;F-E;65N=',\+W4^/"]I/CPO8CX\+V9O;G0^/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@
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M>#(P,3D[<R!O<&5R871I;VYS+CPO9F]N=#X\+W`^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R
M86YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I=F%T
M:79E($EN<W1R=6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!X.R!-05)'
M24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R)2<^#0H@/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M/&(^/&D^/'4^5V%R<F%N="!$97)I=F%T:79E($QI86)I;&ET>3PO=3X\+VD^
M/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!X
M.R!-05)'24XM0D]45$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D%T($1E8V5M8F5R)B-X
M03`[,S$L(#(P,3(L#0H@=&AE(&9A:7(@=F%L=64@;V8@=&AE('=A<G)A;G0@
M9&5R:79A=&EV92!L:6%B:6QI='D@=V%S(&1E=&5R;6EN960-"B!T;R!B92`D
M-30N.2!M:6QL:6]N('5S:6YG('1H92!";&%C:RU38VAO;&5S(&]P=&EO;B!V
M86QU871I;VX@;6]D96P-"B!A<'!L>6EN9R!T:&4@9F]L;&]W:6YG(&%S<W5M
M<'1I;VYS.B`H:2DF(WA!,#MR:7-K+69R964@<F%T92!O9@T*(#`N,C4E+"`H
M:6DI)B-X03`[<F5M86EN:6YG('1E<FT@;V8@,2XX('EE87)S+"`H:6EI*28C
M>$$P.VYO#0H@9&EV:61E;F0@>6EE;&0L("AI=BDF(WA!,#MV;VQA=&EL:71Y
M(&]F(#DU)2!A;F0@*'8I)B-X03`[=&AE('-T;V-K#0H@<')I8V4@;VX@=&AE
M(&1A=&4@;V8@;65A<W5R96UE;G0N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'24XM0D]45$]-.B`P<'@G/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/D%T(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S+`T*('1H92!F86ER('9A
M;'5E(&]F('1H92!W87)R86YT(&1E<FEV871I=F4@;&EA8FEL:71Y('=A<R!D
M971E<FUI;F5D#0H@=&\@8F4@)#,Y+C8@;6EL;&EO;B!U<VEN9R!T:&4@0FQA
M8VLM4V-H;VQE<R!O<'1I;VX@=F%L=6%T:6]N(&UO9&5L#0H@87!P;'EI;F<@
M=&AE(&9O;&QO=VEN9R!A<W-U;7!T:6]N<SH@*&DI)B-X03`[<FES:RUF<F5E
M(')A=&4@;V8-"B`P+C$E+"`H:6DI)B-X03`[<F5M86EN:6YG('1E<FT@;V8@
M,2XP('EE87(L("AI:6DI)B-X03`[;F\@9&EV:61E;F0-"B!Y:65L9"P@*&EV
M*28C>$$P.W9O;&%T:6QI='D@;V8@.3$E+"!A;F0@*'8I)B-X03`[=&AE('-T
M;V-K('!R:6-E(&]N#0H@=&AE(&1A=&4@;V8@;65A<W5R96UE;G0N)B-X03`[
M5&AE("0S+C8@;6EL;&EO;B!I;F-R96%S92!I;B!T:&4@9F%I<@T*('9A;'5E
M(&]F('1H92!W87)R86YT(&QI86)I;&ET>2!D=7)I;F<@=&AE('1H<F5E(&UO
M;G1H<R!E;F1E9`T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S('=A<R!R96-O
M9VYI>F5D(&%S.B`H:2DF(WA!,#MA("0S+C,@;6EL;&EO;@T*(&QO<W,@;VX@
M8VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@=&AE(')E;6%I;FEN9R!D97)I=F%T
M:79E(&QI86)I;&ET>0T*(&%N9"`H:6DI)B-X03`[)#`N,R!M:6QL:6]N(&EN
M(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&9O<B!C:&%N9V4@:6X-"B!F86ER('9A
M;'5E(&]F('=A<G)A;G1S(&ES<W5E9"!T;R!F;W)M97(@96UP;&]Y965S+B!4
M:&4@)#$U+C,-"B!M:6QL:6]N(&1E8W)E87-E(&EN('1H92!F86ER('9A;'5E
M(&]F('1H92!W87)R86YT(&QI86)I;&ET>2!D=7)I;F<-"B!T:&4@;FEN92!M
M;VYT:',@96YD960@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,@=V%S(')E8V]G
M;FEZ960@87,Z#0H@*&DI)B-X03`[82`D,30N,2!M:6QL:6]N(&=A:6X@;VX@
M8VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@=&AE#0H@<F5M86EN:6YG(&1E<FEV
M871I=F4@;&EA8FEL:71Y(&%N9"`H:6DI)B-X03`[)#$N,B!M:6QL:6]N(&EN
M#0H@8V]M<&5N<V%T:6]N(&EN8V]M92!F;W(@8VAA;F=E(&EN(&9A:7(@=F%L
M=64@;V8@=V%R<F%N=',@:7-S=65D('1O#0H@9F]R;65R(&5M<&QO>65E<RX@
M0F]T:"!A;6]U;G1S(&%R92!I;F-L=61E9"!I;B!T:&4@8V]N<V]L:61A=&5D
M#0H@<W1A=&5M96YT(&]F(&]P97)A=&EO;G,@9F]R('1H92!N:6YE(&UO;G1H
M<R!E;F1E9`T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S+B8C>$$P.U1H92!F
M86ER('9A;'5E(&]F('1H:7,@=V%R<F%N=`T*(&QI86)I;&ET>2!I<R!D971E
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M;"`Q,"4@:6YC<F5A<V4@:6X@=&AE#0H@;6%R:V5T('!R:6-E(&]F('1H92!#
M;VUP86YY)B-X,C`Q.3MS(&-O;6UO;B!S:&%R97,@*"0V+CDU(&)A<V5D(&]N
M#0H@=&AE("0V+C,R(&UA<FME="!P<FEC92!O9B!T:&4@0V]M<&%N>28C>#(P
M,3D[<R!S=&]C:R!A=`T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S*2!O;B!W
M:&EC:"!T:&4@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,-"B!V86QU871I;VX@
M=V%S(&)A<V5D+"!T:&4@=F%L=64@;V8@=&AE(&1E<FEV871I=F4@;&EA8FEL
M:71Y('=O=6QD#0H@:&%V92!I;F-R96%S960@8GD@)#4N,"!M:6QL:6]N+B8C
M>$$P.U-U8V@@:6YC<F5A<V4@=V]U;&0@:&%V92!B965N#0H@<F5F;&5C=&5D
M(&%S(&$@;&]S<R!O;B!C:&%N9V4@:6X@9F%I<B!V86QU92!O9B!T:&4@=V%R
M<F%N=`T*(&1E<FEV871I=F4@;&EA8FEL:71Y(&EN('1H92!#;VUP86YY)B-X
M,C`Q.3MS('-T871E;65N="!O9@T*(&]P97)A=&EO;G,N(%-I9VYI9FEC86YT
M(&EN8W)E87-E<R`H9&5C<F5A<V5S*2!I;B!T:&ES(&EN<'5T(&EN#0H@:7-O
M;&%T:6]N('=O=6QD(')E<W5L="!I;B!A('-I9VYI9FEC86YT;'D@:&EG:&5R
M("AL;W=E<BD@9F%I<B!V86QU90T*(&%S<V5T(&UE87-U<F5M96YT+CPO9F]N
M=#X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P131!04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4VEG
M;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H5&%B;&5S*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)I>F5S($%C
M=&EV:71Y(&]F('1H92!0<F]D=6-T(%)E=F5N=64@06QL;W=A;F-E(&%N9"!2
M97-E<G9E($-A=&5G;W)I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[($U!
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M97!T96UB97(F(WA!,#LS,"P@,C`Q,R`H:6X@=&AO=7-A;F1S*3H\+V9O;G0^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/
M5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*("8C>$$P.SPO<#X-"B`\
M=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8F]R
M9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$,3`P)2!A;&EG;CTS1&-E;G1E<CX-"B`\='(^#0H@/'1D('=I9'1H/3-$
M-C`E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/E1R861E/&)R
M("\^#0H@06QL;W=A;F-E<SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^4F5B871E<RP\8G(@+SX-"B!#:&%R
M9V5B86-K<SQB<B`O/@T*(&%N9"8C>$$P.T1I<V-O=6YT<SPO8CX\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^4')O
M9'5C=#QB<B`O/@T*(%)E='5R;G,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/D]T:&5R/&)R("\^
M#0H@26YC96YT:79E<SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#$^/&(^5&]T86P\+V(^/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L
M<W!A;CTS1#0^/"]T9#X-"B`\=&0@8V]L<W!A;CTS1#0^/"]T9#X-"B`\=&0@
M8V]L<W!A;CTS1#0^/"]T9#X-"B`\=&0@8V]L<W!A;CTS1#0^/"]T9#X-"B`\
M=&0@8V]L<W!A;CTS1#0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\
M8CY"86QA;F-E(&%T#0H@2F%N=6%R>28C>$$P.S$L(#(P,3,\+V(^/"]F;VYT
M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
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M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*
M(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,V5M)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY0<F]V
M:7-I;VX@<F5L871E9"!T;PT*(&-U<G)E;G0@<&5R:6]D(&%N9"!D969E<G)E
M9"!S86QE<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/C(L.#,Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
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M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-S(\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/C(L,#$X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
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M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,1494.B`S96TG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/D-R961I=',O<&%Y;65N=',@;6%D92!F;W(-"B!C=7)R96YT('!E<FEO
M9"!A;F0@9&5F97)R960@<V%L97,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXH,2PY-3$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,2PT.#0\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
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M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#$L.#,U/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#4L,C<P
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY"86QA;F-E
M(&%T#0H@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,\+V(^/"]F;VYT/CPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CX\8CXD/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXX.#@\+V(^/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^/&(^)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F
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M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^
M)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXD/"]B/CPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CX\8CXW,CPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXF(WA!,#LF(WA!,#L\+V(^
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/CQB/B0\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/C$X,SPO
M8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CX\8CXF(WA!,#LF(WA!,#L\+V(^/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
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M,T0R/CQB/B8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V1U8W0@4F5V96YU92!296-O
M9VYI>F5D(&%N9"!$969E<G)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!X.R!-
M05)'24XM0D]45$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!F;VQL;W=I;F<@=&%B
M;&4-"B!S=6UM87)I>F5S('!R;V1U8W0@<F5V96YU92!R96-O9VYI>F5D(&%N
M9"!D969E<G)E9"!D=7)I;F<@=&AE(&YI;F4-"B!M;VYT:',@96YD960@4V5P
M=&5M8F5R)B-X03`[,S`L(#(P,3,@*&EN('1H;W5S86YD<RDZ/"]F;VYT/CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($U!4D=)3BU"3U14
M3TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A
M8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&)O<F1E
M<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#<V)2!A;&EG;CTS1&-E;G1E<CX-"B`\='(^#0H@/'1D('=I9'1H/3-$-C,E
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)3X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0Q/CQB/E-E<'1E;6)E<B8C>$$P.S,P+"8C>$$P.S(P,3,\+V(^/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,3X\8CY$96-E;6)E<B8C>$$P.S,Q+"8C>$$P.S(P
M,3(\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CY0<F]D=6-T(')E=F5N=64-"B!R96-O9VYI>F5D/"]F;VYT/CPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
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M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@34%21TE.+4Q%1E0Z
M(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^1&5F97)R960@<')O9'5C=`T*(')E=F5N=64\+V9O
M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
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M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
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M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)B-X03`[
M)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P
M,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E;G-E9"!A;F0@0V%P
M:71A;&EZ960@0V]S="!O9B!';V]D<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P
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M<R!E;F1E9"!397!T96UB97(F(WA!,#LS,"P@,C`Q,R`H:6X-"B!T:&]U<V%N
M9',I.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!X
M.R!-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,3)P>"<^#0H@)B-X
M03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O
M;&QA<'-E)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0W-B4@86QI9VX],T1C96YT97(^#0H@/'1R/@T*(#QT
M9"!W:61T:#TS1#8T)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-
M"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,3X\8CY397!T96UB97(F(WA!,#LS,"PF(WA!,#LR
M,#$S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^1&5C96UB97(F(WA!
M,#LS,2PF(WA!,#LR,#$R/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@34%21TE.
M+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^0V]S="!O9B!G;V]D<R!S;VQD#0H@97AP
M96YS960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-RPX
M,3,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
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M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[
M($U!4D=)3BU,1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D9I;FES:&5D(&=O;V1S(&EN
M=F5N=&]R>0T*(&AE;&0@8GD@;W1H97)S/"]F;VYT/CPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^-C0Q/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
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M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<W-E
M=',@86YD($QI86)I;&ET>2!-96%S=7)E9"!A="!&86ER(%9A;'5E(&]N(&$@
M4F5C=7)R:6YG($)A<VES/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'
M24XM0D]45$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!F;VQL;W=I;F<@=&%B;&4-
M"B!P<F5S96YT<R!I;F9O<FUA=&EO;B!A8F]U="!T:&4@0V]M<&%N>28C>#(P
M,3D[<R!A<W-E=',@86YD#0H@;&EA8FEL:71I97,@87,@;V8@4V5P=&5M8F5R
M)B-X03`[,S`L(#(P,3,@86YD($1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q,B!T
M:&%T(&%R92!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG
M(&)A<VES(&%N9`T*(&EN9&EC871E<R!T:&4@9F%I<B!V86QU92!H:65R87)C
M:'D@;V8@=&AE('9A;'5A=&EO;B!T96-H;FEQ=65S('1H90T*($-O;7!A;GD@
M=71I;&EZ960@=&\@9&5T97)M:6YE('-U8V@@9F%I<B!V86QU93H\+V9O;G0^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/
M5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*("8C>$$P.SPO<#X-"B`\
M=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8F]R
M9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$-C@E(&%L:6=N/3-$8V5N=&5R/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U
M.24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#$T(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/E-E<'1E;6)E<B8C
M>$$P.S,P+`T*(#(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB
M/CQI/DEN(&UI;&QI;VYS/"]I/CPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY4;W1A;#PO
M8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/DQE=F5L)B-X03`[,3PO8CX\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/DQE=F5L)B-X03`[,CPO8CX\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0Q/CQB/DQE=F5L)B-X03`[,SPO8CX\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ96T[($U!4D=)3BU,1494.B`Q96TG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/D%S
M<V5T.CPO8CX\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#87-H#0H@97%U:79A
M;&5N=',F(W@R,#$T.VUO;F5Y(&UA<FME=',\+V9O;G0^/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^,3$S+C4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
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M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9#X\+W1D/@T*(#QT9"!C
M;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT
M9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*
M(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)
M3BU,1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/CQB/DQI86)I;&ET:65S.CPO8CX\+V9O
M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM
M3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY787)R86YT(&1E<FEV871I=F4-"B!L:6%B
M:6QI='D\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\
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M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
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M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3%E;3L@34%21TE.+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3&]N
M9RUT97)M(&1E8G0@<F5D96UP=&EO;@T*(&9E871U<F4\+V9O;G0^/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-RXR/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
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M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,1494.B`Q96TG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/D9O<F5I9VX@8W5R<F5N8WD-"B!C;VYT<F%C=',\+V9O;G0^/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,"XT/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/C`N-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)
M6D4Z(#$R<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]2
M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8F]R9&5R/3-$,"!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-C@E(&%L:6=N/3-$8V5N
M=&5R/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U.24^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T
M9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$T(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0Q/CQB/D1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q,CPO8CX\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^/&D^26X@;6EL;&EO;G,\+VD^
M/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0Q/CQB/E1O=&%L/"]B/CPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#$^/&(^3&5V96PF(WA!,#LQ/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#$^/&(^3&5V96PF(WA!,#LR/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^
M/&(^3&5V96PF(WA!,#LS/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@34%21TE.
M+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^07-S970Z/"]B/CPO9F]N=#X\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,1494.B`Q
M96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/D-A<V@-"B!E<75I=F%L96YT<R8C>#(P,30[;6]N97D@
M;6%R:V5T<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[-C0N,3PO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9#X\+W1D/@T*(#QT
M9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*
M(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D
M/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($U!
M4D=)3BU,1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/DQI86)I;&ET>3H\+V(^/"]F
M;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@34%21TE.
M+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^5V%R<F%N="!D97)I=F%T:79E#0H@;&EA
M8FEL:71Y/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C4T
M+CD\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P
M,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
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M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,1494.B`Q96TG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DQO
M;F<M=&5R;2!D96)T(')E9&5M<'1I;VX-"B!F96%T=7)E/"]F;VYT/CPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$T+C8\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
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M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^,30N-CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0VAA;F=E(&EN($9A:7(@5F%L=64@;V8@1FEN86YC:6%L($EN<W1R=6UE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'24XM0D]45$]-.B`P<'@G
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/E1H92!C:&%N9V4@:6X@=&AE(&9A:7(-"B!V86QU92!O9B!F
M:6YA;F-I86P@:6YS=')U;65N=',@:7,@87,@9F]L;&]W<R`H:6X-"B!T:&]U
M<V%N9',I.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M,'!X.R!-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,3)P>"<^#0H@
M)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z
M(&-O;&QA<'-E)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(^#0H@/'1R/@T*
M(#QT9"!W:61T:#TS1#4Y)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0V)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\+W1D/@T*(#QT9#X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0V)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^3V-T;V)E<CPO
M8CX\+V9O;G0^/&)R("\^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`P.3PO8CX\+V9O;G0^
M/&)R("\^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#$^/&(^)B-X03`[)B-X03`[5V%R<F%N=',F(WA!
M,#LF(WA!,#L\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY$96)T/"]B/CPO9F]N
M=#X\8G(@+SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXF(WA!,#LF(WA!,#M2961E;7!T:6]N
M)B-X03`[("8C>$$P.SPO8CX\+V9O;G0^/&)R("\^#0H@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^
M1F5A='5R93PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/D9O<F5I9VX\+V(^/"]F
M;VYT/CQB<B`O/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/D5X8VAA;F=E/"]B/CPO9F]N=#X\
M8G(@+SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,3X\8CXF(WA!,#LF(WA!,#M#;VYT<F%C=',F(WA!
M,#LF(WA!,#L\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
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M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-
M"B`\=&0^/"]T9#X-"B`\=&0@8V]L<W!A;CTS1#0^/"]T9#X-"B`\=&0@8V]L
M<W!A;CTS1#0^/"]T9#X-"B`\=&0@8V]L<W!A;CTS1#0^/"]T9#X-"B`\=&0@
M8V]L<W!A;CTS1#0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY"
M86QA;F-E(&%T#0H@2F%N=6%R>28C>$$P.S$L(#(P,3(\+V(^/"]F;VYT/CPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
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M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^/&(^)#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)B-X03`[/"]B/CPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
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M8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CX\8CXF(WA!,#L\+V(^/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/CQB/B0\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/CQB/C$R,RPQ,C4\+V(^/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^/&(^)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(^#0H@/'1D/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^
M#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO
M=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3%E;3L@34%21TE.+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3&]S<R!O;B!C:&%N
M9V4@:6X@9F%I<@T*('9A;'5E(&]F(&1E<FEV871I=F4@;&EA8FEL:71Y/"]F
M;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-C@L-C@V
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
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M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#LF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
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M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,1494.B`Q96TG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/D-O;7!E;G-A=&EO;B!E>'!E;G-E(&9O<@T*(&-H86YG92!I;B!F86ER('9A
M;'5E(&]F('=A<G)A;G1S(&ES<W5E9"!T;R!F;W)M97(-"B!E;7!L;WEE97,\
M+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS+#`S
M-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C,L,#,W/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3%E;3L@34%21TE.+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5')A;G-F97)S('1O
M#0H@97%U:71Y/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^*#$P,RPX.#4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@Q,#,L.#@U/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9#X\
M+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$
M-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N
M/3-$-#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ96T[($U!4D=)3BU,1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/D)A;&%N8V4@
M870-"B!397!T96UB97(F(WA!,#LS,"P@,C`Q,CPO8CX\+V9O;G0^/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/CQB/B0\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CDP+#DV,SPO8CX\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CX\8CXF(WA!,#LF(WA!,#L\+V(^/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB
M/B0\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/CQB/B8C>#(P,30[)B-X03`[)B-X03`[/"]B
M/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/CQB/B8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)#PO
M8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^/&(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V(^/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^/&(^)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
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M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M/&(^)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.
M+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*("8C>$$P.SPO<#X-
M"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@
M8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R/@T*(#QT<CX-"B`\=&0@=VED=&@]
M,T0U."4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/D]C=&]B97(\+V(^/"]F;VYT/CQB
M<B`O/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0Q/CQB/C(P,#D\+V(^/"]F;VYT/CQB<B`O/@T*(#QF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0Q/CQB/B8C>$$P.R8C>$$P.U=A<G)A;G1S)B-X03`[)B-X03`[/"]B
M/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#$^/&(^1&5B=#PO8CX\+V9O;G0^/&)R("\^#0H@
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#$^/&(^)B-X03`[)B-X03`[4F5D96UP=&EO;B8C>$$P.R`F(WA!
M,#L\+V(^/"]F;VYT/CQB<B`O/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/D9E871U<F4\+V(^
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,3X\8CY&;W)E:6=N/"]B/CPO9F]N=#X\8G(@+SX-
M"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,3X\8CY%>&-H86YG93PO8CX\+V9O;G0^/&)R("\^#0H@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#$^/&(^)B-X03`[)B-X03`[0V]N=')A8W1S)B-X03`[)B-X03`[/"]B
M/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^)B-X03`[)B-X03`[)B-X03`[
M)B-X03`[5&]T86QS)B-X03`[)B-X03`[)B-X03`[)B-X03`[/"]B/CPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D/CPO=&0^
M#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO
M=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T
M/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E
M;3L@34%21TE.+4Q%1E0Z(#%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^0F%L86YC92!A=`T*
M($IA;G5A<GDF(WA!,#LQ+"`R,#$S/"]B/CPO9F]N=#X\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^/&(^)#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^-30L.#4T/"]B/CPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/CQB/B8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)#PO8CX\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^/&(^,30L-3<W/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B8C
M>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)#PO8CX\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M/&(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V(^/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^
M)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
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M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)B-X03`[)B-X03`[
M/"]B/CPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D/CPO=&0^
M#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO
M=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T
M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@34%21TE.+4Q%1E0Z(#%E
M;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^*$=A:6XI(&QO<W,@;VX@8VAA;F=E(&EN#0H@9F%I<B!V
M86QU92!O9B!D97)I=F%T:79E(&QI86)I;&ET:65S/"]F;VYT/CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#$T+#`W-SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@W+#,W
M-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT
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M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#(Q+#`U.3PO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CY#;VUP96YS871I;VX@:6YC;VUE(&9O<@T*(&-H86YG92!I;B!F86ER('9A
M;'5E(&]F('=A<G)A;G1S(&ES<W5E9"!T;R!F;W)M97(-"B!E;7!L;WEE97,\
M+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,2PQ
M-SD\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#$L,3<Y/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M*28C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($U!
M4D=)3BU,1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1R86YS9F5R<R!T;PT*(&5Q=6ET
M>3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
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M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(^#0H@/'1D/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@
M/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^
M#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3%E;3L@34%21TE.+4Q%1E0Z(#%E;2<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^/&(^0F%L86YC92!A=`T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S/"]B
M/CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)#PO8CX\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M/&(^,SDL-3DX/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/B8C>$$P.R8C>$$P.SPO
M8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^/&(^)#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^-RPR,#`\+V(^
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^/&(^)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\
M8CXD/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXS.34\+V(^/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M/&(^)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO
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M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^)B-X
M03`[)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE
M/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?93!F.&4Q93A?,C8V9%\T8F8T7V$X.39?,V-E.3AC9C4U86$V#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4P9CAE,64X7S(V-F1?-&)F
M-%]A.#DV7S-C93DX8V8U-6%A-B]7;W)K<VAE971S+U-H965T,3@N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);G1A;F=I8FQE
M($%S<V5T("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-C:&5D=6QE(&]F($-A<G)Y:6YG(%9A;'5E(&]F($EN=&%N
M9VEB;&4@07-S970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/
M5%1/33H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@8V%R<GEI;F<@=F%L=64@87,@;V8-
M"B!397!T96UB97(F(WA!,#LS,"P@,C`Q,R!A;F0@1&5C96UB97(F(WA!,#LS
M,2P@,C`Q,B!I<R!A<R!F;VQL;W=S#0H@*&EN('1H;W5S86YD<RDZ/"]F;VYT
M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($U!4D=)3BU"
M3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X)SX-"B`F(WA!,#L\+W`^#0H@
M/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&)O
M<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#<V)2!A;&EG;CTS1&-E;G1E<CX-"B`\='(^#0H@/'1D('=I9'1H/3-$
M-C0E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X\
M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0Q/CQB/E-E<'1E;6)E<B8C>$$P.S,P+"8C>$$P.S(P,3,\+V(^/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,3X\8CY$96-E;6)E<B8C>$$P.S,Q+"8C>$$P.S(P,3(\
M+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CY496-H;F]L;V=Y#0H@<FEG:'1S/"]F;VYT/CPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/C$Q+#8R-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
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M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ96T[($U!4D=)3BU,1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D%C8W5M=6QA=&5D
M#0H@86UO<G1I>F%T:6]N/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^*#<U-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B@R-CD\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,"PX-S`\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
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M,2PS-34\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
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M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YV
M96YT;W)Y("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-C:&5D=6QE(&]F($EN=F5N=&]R>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@-G!X.R!-05)'24XM0D]45$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN=F5N
M=&]R:65S(&-O;G-I<W0@;V8@=&AE#0H@9F]L;&]W:6YG(&%T(%-E<'1E;6)E
M<B8C>$$P.S,P+"`R,#$S(&%N9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$R("AI
M;@T*('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM5$]0.B`P<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q
M,G!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#
M3TQ,05!313H@8V]L;&%P<V4G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#<V)2!A;&EG;CTS1&-E;G1E<CX-
M"B`\='(^#0H@/'1D('=I9'1H/3-$-C0E/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$R)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/E-E<'1E;6)E<B8C>$$P
M.S,P+"8C>$$P.S(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY$
M96-E;6)E<B8C>$$P.S,Q+"8C>$$P.S(P,3(\+V(^/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY287<@;6%T97)I86QS
M/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C0L.3DS/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^-2PT-C4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@
M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CY7;W)K(&EN('!R;V-E<W,\+V9O;G0^/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,BPQ-C8\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO
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M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[
M($U!4D=)3BU,1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D9I;FES:&5D(&=O;V1S/"]F
M;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^.2PR.#,\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
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M;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($U!4D=)3BU,
M1494.B`Q96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/D9I;FES:&5D(&=O;V1S(&EN=F5N=&]R>0T*
M(&AE;&0@8GD@;W1H97)S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^-C0Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^,C<L,#@S/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,C$L,C8R/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO
M=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E=A<G)A
M;G1S(&%N9"!787)R86YT($1E<FEV871I=F4@3&EA8FEL:71Y("A486)L97,I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A
M;G1S('1O(%!U<F-H87-E($-O;6UO;B!3:&%R97,@3W5T<W1A;F1I;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CY4:&4@0V]M<&%N>2!H860@.2PX,38L.#(V#0H@=V%R<F%N=',@=&\@
M<'5R8VAA<V4@8V]M;6]N('-H87)E<R!O=71S=&%N9&EN9R!A=`T*(%-E<'1E
M;6)E<B8C>$$P.S,P+"`R,#$S(&%T(&$@=V5I9VAT960M879E<F%G92!E>&5R
M8VES92!P<FEC92!O9@T*("0Q+C0T+"!A<R!S=6UM87)I>F5D(&EN('1H92!F
M;VQL;W=I;F<@=&%B;&4Z/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM5$]0.B`P<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q
M,G!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#
M3TQ,05!313H@8V]L;&%P<V4G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E<CX-
M"B`\='(^#0H@/'1D('-T>6QE/3-$)U=)1%1(.B`Q-W!T)SX\+W1D/@T*(#QT
M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!S='EL93TS1"=724142#H@,3=P
M="<^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C,E/CPO
M=&0^#0H@/'1D('-T>6QE/3-$)U=)1%1(.B`Q-'!T)SX\+W1D/@T*(#QT9#X\
M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!S='EL93TS1"=724142#H@,31P="<^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C,E/CPO=&0^
M#0H@/'1D('-T>6QE/3-$)U=)1%1(.B`R-'!T)SX\+W1D/@T*(#QT9#X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9"!S='EL93TS1"=724142#H@,C1P="<^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C,E/CPO=&0^#0H@
M/'1D('-T>6QE/3-$)U=)1%1(.B`R-W!T)SX\+W1D/@T*(#QT9#X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9"!S='EL93TS1"=724142#H@,C=P="<^/"]T9#X-
M"B`\+W1R/@T*(#QT<CX-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M-"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY)<W-U90T*($1A=&4\+V(^
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$-"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY!
M;6]U;G0\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-"!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,3X\8CY%>&5R8VES928C>$$P.U!R:6-E/"]B/CPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#0@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^17AP:7)A=&EO;B8C>$$P
M.T1A=&4\+V(^/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT+S(W+S`W/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/C$W+#4P,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3<N.3`\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
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M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
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M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#8X-"PX.#@\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
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M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW+S,P+S$T
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\
M='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
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M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW+#0X-RPS.#@\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^,2XU,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,"\Q-2\Q-#PO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^,3`O,38O,#D\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^-C(W+#`U,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+C4P/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/C$P+S$U+S$T/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/CQB/B8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
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M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
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M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93!F
M.&4Q93A?,C8V9%\T8F8T7V$X.39?,V-E.3AC9C4U86$V#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V4P9CAE,64X7S(V-F1?-&)F-%]A.#DV7S-C
M93DX8V8U-6%A-B]7;W)K<VAE971S+U-H965T,C$N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$53
M3D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYA='5R92!O9B!"=7-I;F5S
M<R!A;F0@0F%S:7,@;V8@4')E<V5N=&%T:6]N("T@061D:71I;VYA;"!);F9O
M<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5L+B`Q,BP@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA
M=&EO;BP@0V]N<V]L:61A=&EO;B!A;F0@4')E<V5N=&%T:6]N(&]F($9I;F%N
M8VEA;"!3=&%T96UE;G1S($1I<V-L;W-U<F4@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S
M:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,C(U+#@X-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(V,"PR-#(L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,34L,3$P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3$V+#8P,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!P<F]C965D<R!F<F]M('!U8FQI8R!O
M9F9E<FEN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,C$L
M,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('-E;FEO<B!N;W1E<RP@96%R;&EE
M<W0@<F5D96UP=&EO;B!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^2F%N(#$Y+`T*"0DR,#$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%]E,&8X93%E.%\R-C9D7S1B9C1?83@Y-E\S
M8V4Y.&-F-35A838-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93!F
M.&4Q93A?,C8V9%\T8F8T7V$X.39?,V-E.3AC9C4U86$V+U=O<FMS:&5E=',O
M4VAE970R,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14)'1$D^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`M($%D9&ET
M:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:6=N:69I8V%N="!!8V-O=6YT:6YG
M(%!O;&EC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A;&5S(&1I<V-O=6YT('!E<F-E
M;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-A;&5S(&1I<V-O=6YT('1E<FT\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)S,P(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!D97)I=F%T:79E
M(&QI86)I;&ET>2!F86ER('9A;'5E(&%S<W5M<'1I;VYS+"!R:7-K+69R964@
M<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C$P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M+C(U)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5R:79A=&EV92!L:6%B:6QI='D@9F%I<B!V86QU92!A<W-U;7!T
M:6]N<RP@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M,2!Y96%R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<Q('EE87(@.2!M;VYT:',@,3@@9&%Y<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!D97)I
M=F%T:79E(&QI86)I;&ET>2!F86ER('9A;'5E(&%S<W5M<'1I;VYS+"!D:79I
M9&5N9"!Y:65L9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V%R<F%N="!D97)I=F%T:79E(&QI86)I;&ET>2!F86ER
M('9A;'5E(&%S<W5M<'1I;VYS+"!V;VQA=&EL:71Y(')A=&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3$N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDU+C`P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V%I;B`H
M;&]S<RD@;VX@8VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@9&5R:79A=&EV92!L
M:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q
M+#0P,BPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q-BPT-30L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,2PP-3DL,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@V."PV.#8L,#`P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DUA<FME="!P<FEC92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-BXS,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8N,S(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^2'EP;W1H971I
M8V%L(&EN8W)E87-E(&EN(&UA<FME="!P<FEC92!O9B!C;VUM;VX@<VAA<F5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+C`P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M;VYG('1E<FT@9&5B="!R961E;7!T:6]N(&9E871U<F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PV,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H;W)T('1E<FT@:&EG:&QY(&QI<75I9"!I;G-T<G5M96YT<RP@;6%T=7)I
M='D@9&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG.3`@
M9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%;6)E9&1E9"!$97)I=F%T:79E($9I;F%N8VEA;"!);G-T<G5M
M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y'86EN("AL;W-S*2!O;B!C:&%N9V4@:6X@9F%I<B!V86QU92!O
M9B!D97)I=F%T:79E(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-RPT,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!O9B!C
M;VYT<F]L(&]B;&EG871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU;2!R97!A>6UE;G0@;V8@9G5T
M=7)E(')E=F5N=64@86YD(')E8V5I=F%B;&5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,34P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO;F<@=&5R;2!D96)T
M(')E9&5M<'1I;VX@9F5A='5R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-RPR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<L,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PV,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;6)E9&1E
M9"!$97)I=F%T:79E($9I;F%N8VEA;"!);G-T<G5M96YT<R!\($UA>&EM=6T\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&5R:79A=&EV92!L:6%B:6QI='D@9F%I<B!V86QU92!A<W-U;7!T:6]N
M<RP@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-"!Y
M96%R<R`T(&UO;G1H<R`R-"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<X('EE87)S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E(&QI
M86)I;&ET>2!F86ER('9A;'5E(&%S<W5M<'1I;VXL(&-O=7!O;B!R871E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+C4P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2XU,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1E<FEV871I=F4@;&EA8FEL:71Y(&9A:7(@=F%L=64@87-S=6UP=&EO;G,L
M(&UA<FME="!Y:65L9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C4N.#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(W+C<P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^16UB961D960@1&5R:79A=&EV92!&:6YA;F-I
M86P@26YS=')U;65N=',@?"!-:6YI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:6=N:69I8V%N="!!8V-O=6YT
M:6YG(%!O;&EC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I=F4@;&EA8FEL
M:71Y(&9A:7(@=F%L=64@87-S=6UP=&EO;G,L('1E<FT\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S,@>65A<G,@-B!M;VYT:',\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S0@>65A
M<G,@.2!M;VYT:',@,3@@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV92!L:6%B:6QI='D@9F%I
M<B!V86QU92!A<W-U;7!T:6]N+"!C;W5P;VX@<F%T93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY+CDP)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV92!L
M:6%B:6QI='D@9F%I<B!V86QU92!A<W-U;7!T:6]N<RP@;6%R:V5T('EI96QD
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"XT,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`N
M-S`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y&;W)E:6=N($5X8VAA;F=E($9O<G=A<F0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-I9VYI9FEC86YT($%C
M8V]U;G1I;F<@4&]L:6-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]T:6]N86P@86UO
M=6YT<RP@9F]R96EG;B!E>&-H86YG92!F;W)W87)D(&-O;G1R86-T<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PU,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-3`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.=6UB97(@;V8@9F]R96EG;B!E>&-H86YG92!F;W)W87)D(&-O;G1R
M86-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M(&9A:7(@=F%L=64L(&9O<F5I9VX@97AC:&%N9V4@9F]R=V%R9"!C;VYT<F%C
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&;W)E:6=N($5X8VAA;F=E($9O<G=A<F0@?"!/=&AE<B!#=7)R
M96YT($QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC
M:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=A:6X@*&QO<W,I(&]N(&-H86YG92!I;B!F
M86ER('9A;'5E(&]F(&1E<FEV871I=F4@;&EA8FEL:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%9F9E8W0@;V8@
M82!H>7!O=&AE=&EC86P@,3`E(&EN8W)E87-E(&EN('1H92!M87)K970@<')I
M8V4@;V8@8V]M;6]N('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0
M;VQI8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S92`H1&5C<F5A<V4I(&EN
M('1H92!F86ER('9A;'5E(&]F('=A<G)A;G0@9&5R:79A=&EV92!L:6%B:6QI
M='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DUA<FME="!P<FEC92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-BXY-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8N.34\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y787)R86YT(&1E<FEV871I=F4@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS.2PV,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y+#8P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30L.#4T
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5V%R<F%N=',@27-S=65D($]C=&]B97(@,C`P.3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VEG;FEF:6-A
M;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S
M92`H1&5C<F5A<V4I(&EN('1H92!F86ER('9A;'5E(&]F('=A<G)A;G0@9&5R
M:79A=&EV92!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q-2PS,#`L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'86EN("AL;W-S*2!O;B!C
M:&%N9V4@:6X@9F%I<B!V86QU92!O9B!D97)I=F%T:79E(&QI86)I;&ET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#,P,"PP,#`I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T
M+#$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M<&5N<V%T:6]N(&5X<&5N<V4@*&EN8V]M92D@9F]R
M(&-H86YG92!I;B!F86ER('9A;'5E(&]F('=A<G)A;G1S(&ES<W5E9"!T;R!F
M;W)M97(@96UP;&]Y965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@Q+#(P,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%3E=!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY3=6UM87)I>F5S($%C=&EV:71Y(&]F('1H92!0<F]D=6-T(%)E
M=F5N=64@06QL;W=A;F-E(&%N9"!297-E<G9E($-A=&5G;W)I97,@*$1E=&%I
M;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@
M<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY686QU871I;VX@86YD(%%U86QI9GEI;F<@06-C;W5N=',@1&ES
M8VQO<W5R92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W9I<VEO;B!R96QA=&5D('1O(&-U<G)E
M;G0@<&5R:6]D(&%N9"!D969E<G)E9"!S86QE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`W+#,T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W)E9&ET<R]P87EM96YT<R!M861E
M(&9O<B!C=7)R96YT('!E<FEO9"!A;F0@9&5F97)R960@<V%L97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L,C<P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!3
M97!T96UB97(@,S`L(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,#<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!;&QO=V%N8V4@9F]R(%1R861E(%)E8V5I=F%B;&5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E9A;'5A
M=&EO;B!A;F0@475A;&EF>6EN9R!!8V-O=6YT<R!$:7-C;&]S=7)E(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')O=FES:6]N(')E;&%T960@=&\@8W5R<F5N="!P97)I;V0@86YD
M(&1E9F5R<F5D('-A;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#@S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0W)E9&ET<R]P87EM96YT<R!M861E(&9O<B!C=7)R96YT('!E
M<FEO9"!A;F0@9&5F97)R960@<V%L97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$L.34Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!397!T96UB97(@,S`L(#(P
M,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@X.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5B871E
M<R!#:&%R9V5B86-K<R!!;F0@1&ES8V]U;G1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E9A;'5A=&EO;B!A;F0@475A;&EF
M>6EN9R!!8V-O=6YT<R!$:7-C;&]S=7)E(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O=FES:6]N
M(')E;&%T960@=&\@8W5R<F5N="!P97)I;V0@86YD(&1E9F5R<F5D('-A;&5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0Q.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W)E9&ET
M<R]P87EM96YT<R!M861E(&9O<B!C=7)R96YT('!E<FEO9"!A;F0@9&5F97)R
M960@<V%L97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-#@T
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0F%L86YC92!A="!397!T96UB97(@,S`L(#(P,3,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDS-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06QL;W=A;F-E(&9O<B!386QE<R!2
M971U<FYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E9A;'5A=&EO;B!A;F0@475A;&EF>6EN9R!!8V-O=6YT<R!$:7-C;&]S
M=7)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')O=FES:6]N(')E;&%T960@=&\@8W5R<F5N="!P
M97)I;V0@86YD(&1E9F5R<F5D('-A;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!397!T96UB97(@,S`L(#(P,3,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!);F-E
M;G1I=F4@4')O9W)A;7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^5F%L=6%T:6]N(&%N9"!1=6%L:69Y:6YG($%C8V]U;G1S
M($1I<V-L;W-U<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]V:7-I;VX@<F5L871E9"!T;R!C
M=7)R96YT('!E<FEO9"!A;F0@9&5F97)R960@<V%L97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L,#$X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#<F5D:71S+W!A>6UE;G1S(&UA
M9&4@9F]R(&-U<G)E;G0@<&5R:6]D(&%N9"!D969E<G)E9"!S86QE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PX,S4I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T
M(%-E<'1E;6)E<B`S,"P@,C`Q,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
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M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%241!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY0<F]D=6-T
M(%)E=F5N=64@4F5C;V=N:7IE9"!A;F0@1&5F97)R960@*$1E=&%I;"D@*%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4F5V96YU97,@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O9'5C="!R
M979E;G5E(')E8V]G;FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@."PT,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$V+#(T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<')O9'5C="!R979E;G5E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8Q-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C$W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]D=6-T(%-A;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q-RPX-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
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M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%241!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#87!I=&%L:7IE
M9"!A;F0@17AP96YS960@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N
M9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M
M<&]N96YT($]F($]P97)A=&EN9R!#;W-T($%N9"!%>'!E;G-E(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O<W0@;V8@9V]O9',@<V]L9"!E>'!E;G-E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`S+#8X,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RPX,3,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I;FES:&5D(&=O
M;V1S(&EN=F5N=&]R>2!H96QD(&)Y(&]T:&5R<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-C0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:7)E8W0@3W!E<F%T:6YG($-O<W1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X+#0U-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93!F.&4Q93A?
M,C8V9%\T8F8T7V$X.39?,V-E.3AC9C4U86$V#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V4P9CAE,64X7S(V-F1?-&)F-%]A.#DV7S-C93DX8V8U
M-6%A-B]7;W)K<VAE971S+U-H965T,C8N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5/44%'/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D%S<V5T<R!A;F0@3&EA8FEL:71Y($UE
M87-U<F5D(&%T($9A:7(@5F%L=64@;VX@4F5C=7)R:6YG($)A<VES("A$971A
M:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6%B:6QI=&EE<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A
M<G)A;G0@9&5R:79A=&EV92!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-#<L,3DS+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-CDL-#,Q+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.3`L.38S
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3(S+#$R-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DQO;F<M=&5R;2!D96)T(')E9&5M<'1I;VX@
M9F5A='5R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#8P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1F%I<B!686QU92P@365A<W5R96UE;G1S+"!296-U<G)I;F<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M07-S970Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#87-H(&5Q=6EV86QE;G1S+6UO;F5Y(&UA<FME=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,RPU,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C0L,3`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/DQI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!D97)I=F%T:79E
M(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDL
M-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4T+#DP,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3&]N9RUT97)M(&1E8G0@<F5D96UP=&EO
M;B!F96%T=7)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#(P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-"PV,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D9O<F5I9VX@8W5R<F5N8WD@8V]N=')A8W1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&
M86ER(%9A;'5E+"!-96%S=7)E;65N=',L(%)E8W5R<FEN9R!\($9A:7(@5F%L
M=64L($EN<'5T<RP@3&5V96P@,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY!<W-E=#H\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@97%U:79A;&5N=',M
M;6]N97D@;6%R:V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3$S+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV-"PQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64L($UE87-U<F5M
M96YT<RP@4F5C=7)R:6YG('P@1F%I<B!686QU92P@26YP=71S+"!,979E;"`S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/DQI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V%R<F%N="!D97)I=F%T:79E(&QI86)I;&ET>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDL-C`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4T+#DP
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&]N9RUT97)M(&1E8G0@<F5D96UP=&EO;B!F96%T=7)E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#(P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PV,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9O<F5I9VX@8W5R<F5N8WD@8V]N=')A8W1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,U9"1SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY#:&%N9V4@:6X@1F%I<B!686QU92!O9B!&:6YA;F-I
M86P@26YS=')U;65N=',@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N
M9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M-SXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0T/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY$97)I
M=F%T:79E($EN<W1R=6UE;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CY$97)I=F%T:79E($EN<W1R=6UE;G0\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CY787)R86YT/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3(\8G(^5V%R<F%N=#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/E=A<G)A;G1S($ES<W5E
M9"!/8W1O8F5R(#(P,#D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,SQB<CY787)R86YT<R!)<W-U960@3V-T;V)E<B`R
M,#`Y/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3(\8G(^5V%R<F%N=',@27-S=65D($]C=&]B97(@,C`P.3QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/E=A
M<G)A;G1S($ES<W5E9"!/8W1O8F5R(#(P,#D\8G(^1&5R:79A=&EV92!);G-T
M<G5M96YT/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3(\8G(^5V%R<F%N=',@27-S=65D($]C=&]B97(@,C`P.3QB<CY$
M97)I=F%T:79E($EN<W1R=6UE;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY787)R86YT<R!)<W-U960@3V-T
M;V)E<B`R,#`Y/&)R/E=A<G)A;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CY787)R86YT<R!)<W-U960@3V-T
M;V)E<B`R,#`Y/&)R/E=A<G)A;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY%;6)E9&1E9"!$97)I=F%T:79E
M($9I;F%N8VEA;"!);G-T<G5M96YT<SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/D5M8F5D9&5D($1E<FEV871I
M=F4@1FEN86YC:6%L($EN<W1R=6UE;G1S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^16UB961D960@1&5R:79A
M=&EV92!&:6YA;F-I86P@26YS=')U;65N=',\8G(^1&5R:79A=&EV92!);G-T
M<G5M96YT/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^1F]R96EG;B!%>&-H86YG92!#;VYT<F%C=#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/D9O
M<F5I9VX@17AC:&%N9V4@0V]N=')A8W0\8G(^1&5R:79A=&EV92!);G-T<G5M
M96YT/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D1E<FEV871I=F5S+"!&86ER(%9A;'5E(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-CDL-#,Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,C,L,3(U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(S
M+#$R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,SDL-3DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`U-"PX-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,30L-3<W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,SDU/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^*$=A
M:6XI(&QO<W,@;VX@8VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@9&5R:79A=&EV
M92!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PT,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q-BPT-30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,C$L,#4Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8X+#8X-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q+#`U.2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV."PV.#8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$T
M+#`W-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV."PV.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$L-#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#<L-#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<L,S<W*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.34\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!E;G-A
M=&EO;B!E>'!E;G-E("AI;F-O;64I(&9O<B!C:&%N9V4@:6X@9F%I<B!V86QU
M92!O9B!W87)R86YT<R!I<W-U960@=&\@9F]R;65R(&5M<&QO>65E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PQ-SDI/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP,S<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$L,3<Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L,#,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R86YS9F5R<R!T;R!E<75I='D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P,RPX.#4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P
M,RPX.#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#0W+#$Y,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.3`L.38S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T-RPQ.3,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#DP+#DV,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#DP+#DV,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,SDL-3DX/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U-"PX-30\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W+#(P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-RPR,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`S.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14Y%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN=&%N
M9VEB;&4@07-S970@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^26YT86YG:6)L92!!<W-E=',@1&ES8VQO<W5R92!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN
M=&%N9VEB;&4@87-S971S(&5S=&EM871E9"!R96UA:6YI;F<@=7-E9G5L(&QI
M9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q-B!Y96%R<R`Y
M(&UO;G1H<R`Q."!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14%$04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V%R
M<GEI;F<@5F%L=64@;V8@26YT86YG:6)L92!!<W-E="`H1&5T86EL*2`H55-$
M("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I
M960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^1FEN:71E+4QI=F5D($EN=&%N9VEB;&4@07-S971S(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1E8VAN;VQO9WD@<FEG:'1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$Q+#8R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3$L-C(T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!A
M;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<U
M-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@R-CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YT86YG:6)L92!A<W-E="P@;F5T/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$P+#@W,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3$L,S4U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%(04,^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0Q/CQS=')O;F<^26YV96YT;W)Y("A$971A:6PI("A54T0@)"D\8G(^
M26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY);G9E;G1O<GD@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%W(&UA=&5R:6%L<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#DY,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2PT-C4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=O
M<FL@:6X@<')O8V5S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3(L,38V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,34L-#<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y&:6YI<VAE9"!G;V]D<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.2PR.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I;FES:&5D(&=O;V1S(&EN=F5N
M=&]R>2!H96QD(&)Y(&]T:&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DEN=F5N=&]R>2P@;F5T/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#(W+#`X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C$L,C8R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P151%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,3X\<W1R;VYG/DEN=F5N=&]R>2`M($%D9&ET:6]N86P@26YF;W)M871I;VX@
M*$1E=&%I;"D@*%531"`D*3QB<CY);B!-:6QL:6]N<RP@=6YL97-S(&]T:&5R
M=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN=F5N=&]R>2!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN
M=F5N=&]R>2!R97-E<G9E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$N.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?93!F.&4Q93A?,C8V9%\T8F8T7V$X.39?,V-E.3AC9C4U86$V#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4P9CAE,64X7S(V-F1?-&)F-%]A
M.#DV7S-C93DX8V8U-6%A-B]7;W)K<VAE971S+U-H965T,S(N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5424))/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E=A<G)A;G1S(&%N
M9"!787)R86YT($1E<FEV871I=F4@3&EA8FEL:71Y("T@061D:71I;VYA;"!)
M;F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/CD@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$S/&)R/E=A<G)A;G1S($ES<W5E9"!*=6QY(#(P,#D\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`S,2P@,C`P.3QB<CY/8W1O8F5R
M(#(P,#D@4')I=F%T92!0;&%C96UE;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY/8W1O8F5R(#(P,#D@4')I
M=F%T92!0;&%C96UE;G0\8G(^5V%R<F%N=',@:7-S=65D('1O('1H<F5E(&9O
M<FUE<B!O9F9I8V5R<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y/8W0N(#$V+"`R,#`Y/&)R/D]C=&]B97(@,C`P.2!0<FEV871E(%!L86-E
M;65N=#QB<CY787)R86YT<R!I<W-U960@=&\@=&AR964@9F]R;65R(&]F9FEC
M97)S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,S$L
M(#(P,#D\8G(^3V-T;V)E<B`R,#`Y(%!R:79A=&4@4&QA8V5M96YT/&)R/D)R
M:61G92!,;V%N/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C
M="X@,38L(#(P,#D\8G(^3V-T;V)E<B`R,#`Y(%!R:79A=&4@4&QA8V5M96YT
M/&)R/D)R:61G92!,;V%N/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3,\8G(^3V-T;V)E<B`R,#`Y(%!R:79A=&4@4&QA
M8V5M96YT/&)R/E=A<G)A;G1S($ES<W5E9"!/8W1O8F5R(#(P,#D\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`Q-BP@,C`P.3QB<CY/
M8W1O8F5R(#(P,#D@4')I=F%T92!0;&%C96UE;G0\8G(^5V%R<F%N=',@27-S
M=65D($]C=&]B97(@,C`P.3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y/8W0N(#$V+"`R,#`Y/&)R/D]C=&]B97(@,C`P.2!0<FEV871E(%!L
M86-E;65N=#QB<CY787)R86YT<R!)<W-U960@3V-T;V)E<B`R,#`Y/&)R/D%M
M97)I8V%N($1E<&]S:71A<GD@4VAA<F4\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY/8W1O8F5R(#(P,#D@4')I
M=F%T92!0;&%C96UE;G0\8G(^5V%R<F%N=',@27-S=65D($]C=&]B97(@,C`P
M.3QB<CY-87AI;75M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D]C="X@,38L(#(P,#D\8G(^3V-T;V)E<B`R,#`Y(%!R:79A=&4@4&QA8V5M
M96YT/&)R/E=A<G)A;G1S($ES<W5E9"!/8W1O8F5R(#(P,#D\8G(^0G)I9&=E
M($QO86X\8G(^06UE<FEC86X@1&5P;W-I=&%R>2!3:&%R93QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$97)I=F%T:79E
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('=A<G)A;G0@;W5T
M<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL.#$V
M+#@R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!0<FEC
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XT-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!I<W-U960@=6YD97(@<')I=F%T92!P
M;&%C96UE;G0L('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$R,2PR,#8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#<P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO
M;B!S=&]C:R!I<W-U960@=6YD97(@<')I=F%T92!P;&%C96UE;G0L(&YE="!P
M<F]C965D<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C(L
M,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0G)I9&=E(&YO=&5S(&-O;G9E<G1E9"!I;B!C
M;VYJ=6YC=&EO;B!W:71H('1H92!P<FEV871E('!L86-E;65N="P@86UO=6YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#8P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!I<W-U960@=6YD97(@<')I=F%T92!P
M;&%C96UE;G0L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C8L-#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@
M<VAA<F5S('1H870@96%C:"!!1%,@<F5P<F5S96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M(&ES<W5E9"!U;F1E<B!P<FEV871E('!L86-E;65N="P@<')I8V4@<&5R('-H
M87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G0@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<U('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!I
M<W-U960L(&YU;6)E<B!O9B!S:&%R97,@8V%L;&5D(&)Y('1H92!W87)R86YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XU
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S8L,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0G)I9&=E(&YO=&5S(&-O;G9E<G1E9"!I;B!C;VYJ
M=6YC=&EO;B!W:71H('1H92!P<FEV871E('!L86-E;65N="P@<')I8V4@<&5R
M('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3G5M8F5R(&]F('=A<G)A;G1S(&ES<W5E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4L,C`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5S8W)I<'1I;VX@;V8@<')I8VEN9R!V87)I86)I;&ET>2!F
M96%T=7)E(&%N9"!C;&%S<VEF:6-A=&EO;B!O9B!W87)R86YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG5&AE('=A<G)A;G1S
M(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@=&AE($]C=&]B97(@,C`P.2!F
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M("0S+C`P('!E<B`Q+C!S=&5R;&EN9RX@1'5E('1O('1H92!P;W1E;G1I86P@
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M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S
M(&5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,C`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')O8V5E9"!F<F]M(&5X97)C:7-E(&]F('=A
M<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$V+#4R-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14DS044^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0Q/CQS=')O;F<^5V%R<F%N=',@=&\@4'5R8VAA<V4@0V]M;6]N(%-H
M87)E<R!/=71S=&%N9&EN9R`H1&5T86EL*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-L87-S(&]F
M(%=A<G)A;G0@;W(@4FEG:'0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDL.#$V+#@R-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@4')I
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N-#0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A
M;G0@:7-S=65D(&]N(#0O,C<O,#<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^0VQA<W,@;V8@5V%R<F%N="!O<B!2:6=H="!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3<L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3<N.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17AP:7)A=&EO;B!$871E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG,2\Q-R\Q-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!I<W-U960@
M;VX@-R\S,2\P.3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY#;&%S<R!O9B!787)R86YT(&]R(%)I9VAT(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8X-"PX
M.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%>'!I<F%T:6]N($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<W+S,P+S$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(&ES<W5E9"!O;B`Q,"\Q-B\P
M.3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M;&%S<R!O9B!787)R86YT(&]R(%)I9VAT(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO=6YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#0X-RPS.#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C
M:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5X<&ER871I;VX@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)S$P+S$U+S$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y787)R86YT(&ES<W5E9"!O;B`Q,"\Q-B\P.3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O
M9B!787)R86YT(&]R(%)I9VAT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO=6YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,C<L,#4P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!0<FEC
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XU/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!I<F%T
M:6]N($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"\Q
M-2\Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M93!F.&4Q93A?,C8V9%\T8F8T7V$X.39?,V-E.3AC9C4U86$V#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4P9CAE,64X7S(V-F1?-&)F-%]A.#DV
M7S-C93DX8V8U-6%A-B]7;W)K<VAE971S+U-H965T,S0N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5/24)-/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1E8G0@+2!!9&1I=&EO
M;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$-3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N+B`S,2P@
M,C`Q,CQB<CY#;VYV97)T:6)L92!$96)T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^0V]N=F5R=&EB;&4@1&5B
M=#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$S/&)R/D-O;G9E<G1I8FQE($1E8G0\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY#;VYV97)T:6)L92!$96)T
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^0V]N=F5R=&EB;&4@1&5B=#QB<CY!;65R:6-A;B!$97!O<VET;W)Y
M(%-H87)E<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN
M(#,Q+"`R,#$S/&)R/C,N-24@97AC:&%N9V5A8FQE('-E;FEO<B!N;W1E<R!D
M=64@,C`S,CQB<CY&:6YA;F-E/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIA;BX@,S$L(#(P,3,\8G(^,RXU)2!E>&-H86YG96%B;&4@<V5N
M:6]R(&YO=&5S(&1U92`R,#,R/&)R/D9I;F%N8V4\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY0<F]C965D<SQB
M<CY#;VYV97)T:6)L92!$96)T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^1&5B="!/9F9E<FEN9SQB<CY#;VYV
M97)T:6)L92!$96)T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3,\8G(^1&5B="!/9F9E<FEN9SQB<CY#;VYV97)T:6)L
M92!$96)T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3(\8G(^0FEO4&AA<FUA($1E8G0\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY":6]0:&%R;6$@1&5B
M=#QB<CY.;W9E;6)E<B`R,#$S(&9O<B!T:&4@9FES8V%L('%U87)T97(@96YD
M960@4V5P=&5M8F5R(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^0FEO4&AA<FUA($1E8G0\8G(^
M3F]V96UB97(@,C`Q,R!F;W(@=&AE(&9I<V-A;"!Q=6%R=&5R(&5N9&5D(%-E
M<'1E;6)E<B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/D)I;U!H87)M82!$96)T/&)R/E!E<B!Q
M=6%R=&5R(&EN(&5A8V@@;V8@=&AE(&YE>'0@9F]U<B!Q=6%R=&5R<SQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R
M/D)I;U!H87)M82!$96)T/&)R/E!E<B!Q=6%R=&5R(&EN(&5A8V@@;V8@=&AE
M(&YE>'0@9F]U<B!Q=6%R=&5R<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/D)I;U!H87)M82!$96)T/&)R/E!E
M<B!Q=6%R=&5R(&EN(&5A8V@@;V8@=&AE(&YE>'0@9F]U<B!Q=6%R=&5R<SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/D)I;U!H87)M82!$96)T/&)R/D9I;F%L('!A>6UE;G0\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY":6]0
M:&%R;6$@1&5B=#QB<CY#87-H/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^0FEO4&AA<FUA($1E8G0\8G(^0V%S
M:#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$S/&)R/D)I;U!H87)M82!$96)T/&)R/DYO;B!#87-H/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^0FEO4&AA
M<FUA($1E8G0\8G(^3F]N($-A<V@\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5B="!$:7-C;&]S=7)E(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W5N="!R96-E:79E9"!A
M="!T:&4@8VQO<VEN9R!O9B!T:&4@86=R965M96YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P,"PP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^36%X:6UU;2!R97!A>6UE;G0@;V8@9G5T=7)E(')E=F5N
M=64@86YD(')E8V5I=F%B;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U
M='5R92!M:6YI;75M(')E<&%Y;65N="!U;F1E<B!A9W)E96UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^."PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06=R965M96YT(&5X<&ER871I;VX@9&%T93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^1&5C(#,Q
M+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E(&]F(&-O;G1R;VP@;V)L:6=A
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,30P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F($5M
M8F5D9&5D(&1E<FEV871I=F4@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,30L-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1F%I<B!V86QU92!O9B!D97)I=F%T:79E(&QI86)I;&ET>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,C`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,C`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'86EN(&]N(&-H86YG92!I;B!F
M86ER('9A;'5E(&]F(&1E<FEV871I=F4@;&EA8FEL:71Y/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPT,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(&5X<&5N<V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#<P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY+#<P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L
M92!S96YI;W(@;F]T97,L('!R:6YC:7!A;"!A;6]U;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34P+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<V5N:6]R(&YO=&5S+"!S=&%T960@
M:6YT97)E<W0@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+C4P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!S
M96YI;W(@;F]T97,L(&1U92!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<R,#,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E
M<G1I8FQE('-E;FEO<B!N;W1E<RP@;F5T('!R;V-E961S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#0L,S$V+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#0L,S`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!S96YI;W(@;F]T
M97,L(&5X8VAA;F=E(')A=&4@;V8@0413('!E<B`D,2PP,#`@<')I;F-I<&%L
M(&%M;W5N="!O9B!N;W1E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3$S+C0W-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T
M:6)L92!S96YI;W(@;F]T97,L('1O=&%L($%$4R!I;G1O('=H:6-H('1H92!D
M96)T(&ES(&5X8VAA;F=E86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3<L,#(Q+#(X,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;G9E<G1I8FQE('-E;FEO<B!N;W1E<RP@<&%Y;65N="!S=&%R="!D871E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DIU;"`Q-2P-"@D)
M,C`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!S96YI;W(@
M;F]T97,L(&UA='5R:71Y(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^2F%N(#$U+`T*"0DR,#,R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E9A;'5E(&]F('-H87)E<R!I;B!E>&-E<W,@;V8@<')I;F-I<&%L(&%M
M;W5N="!O9B!.;W1E<R!B87-E9"!O;B!C;&]S:6YG('!R:6-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(L-#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R+#0P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!I;G1E<F5S="!R
M871E(&]N(&YO=&5S('!E<B!A;FYU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP+C4P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV
M97)T:6)L92!S96YI;W(@;F]T97,L(')E<'5R8VAA<V4@<')I8V4@870@;W!T
M:6]N(&]F('1H92!I<W-U97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D
M<R!A;&QO8V%T960@=&\@8V]N=F5R<VEO;B!O<'1I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPX,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F('1H92!L:6%B:6QI='D@8V]M<&]N
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C8L
M,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$R-BPR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;W1E+"!E
M<W1I;6%T960@<F5M86EN:6YG(&QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG,C0@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%9F9E8W1I=F4@:6YT97)E<W0@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,30N-3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30N-3`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y5;F%M;W)T:7IE9"!D96)T(&1I<V-O=6YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#DP
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$96)T(&1I<V-O=6YT(&%M;W)T:7IA=&EO
M;B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG,C0@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!S
M96YI;W(@;F]T97,L(&-A<G)Y:6YG(&%M;W5N="!N970@;V8@=6YA;6]R=&EZ
M960@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$T-2PS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,30U+#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;G9E<G1I8FQE('-E;FEO<B!N;W1E<RP@:6YT97)E<W0@97AP96YS93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PR,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,34L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@97AP96YS
M92P@8V]N=')A8W1U86P@8V]U<&]N(&EN=&5R97-T(&%C8W)U86P\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.3`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@97AP96YS92P@86UO
M<G1I>F%T:6]N(&]F(&1I<V-O=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#(P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#DP,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!I;G1E<F5S="!O;B!C;VYV
M97)T:6)L92!N;W1E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`L.3`Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P+#DP,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPU,C`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,3`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,3`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@<&%Y;65N="!O;B!N
M;W1E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L,C4P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,BPW,3,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#8P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L-C`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P131-04D^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]M;6ET
M;65N=',@86YD($-O;G1I;F=E;F-I97,@+2!!9&1I=&EO;F%L($EN9F]R;6%T
M:6]N("A$971A:6PI/&)R/DEN($UI;&QI;VYS+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#8^.2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3`^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3,\8G(^3&%X9&%L92!,:6UI=&5D/&)R/E531"`H)"D\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`R-BP@,C`Q
M,CQB<CY,87AD86QE($QI;6ET960\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/D%M<B!/;F4@
M2'5N9')E9"!/;F4\8G(^55-$("@D*3QB<CY#;VYT<F%C=#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/D%M<B!/
M;F4@2'5N9')E9"!/;F4\8G(^36%X:6UU;3QB<CY54T0@*"0I/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^0VAE
M;7!O<G0\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$S/&)R/D)!4T8\8G(^55-$("@D*3QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/D9O
M=7)T:"!!4$D@<W5P<&QI97(\8G(^36%X:6UU;3QB<CY54T0@*"0I/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M4VQA;FAM;W(\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/D9U<G1H97(@26YD:6-A=&EO;B!F
M;W(@04U2,3`Q/&)R/DQA>&1A;&4@3&EM:71E9#QB<CY0;W1E;G1I86P@36%R
M:V5T:6YG($%P<')O=F%L(#$\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/D9U<G1H97(@26YD
M:6-A=&EO;B!F;W(@04U2,3`Q/&)R/DQA>&1A;&4@3&EM:71E9#QB<CY0;W1E
M;G1I86P@36%R:V5T:6YG($%P<')O=F%L(#$\8G(^1T)0("@F(WAA,SLI/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\
M8G(^1G5R=&AE<B!);F1I8V%T:6]N(&9O<B!!35(Q,#$\8G(^3&%X9&%L92!,
M:6UI=&5D/&)R/E!O=&5N=&EA;"!-87)K971I;F<@07!P<F]V86P@,CQB<CY5
M4T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^1G5R=&AE<B!);F1I8V%T:6]N(&9O<B!!35(Q,#$\8G(^
M3&%X9&%L92!,:6UI=&5D/&)R/E!O=&5N=&EA;"!-87)K971I;F<@07!P<F]V
M86P@,CQB<CY'0E`@*"8C>&$S.RD\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY&=7)T:&5R($EN9&EC871I;VX@
M9F]R($%-4C$P,3QB<CY,87AD86QE($QI;6ET960\8G(^36%X:6UU;3QB<CY5
M4T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^1G5R=&AE<B!);F1I8V%T:6]N(&9O<B!!35(Q,#$\8G(^
M3&%X9&%L92!,:6UI=&5D/&)R/DUA>&EM=6T\8G(^1T)0("@F(WAA,SLI/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\
M8G(^1FER<W0@26YD:6-A=&EO;B!F;W(@04U2,3`Q/&)R/DQA>&1A;&4@3&EM
M:71E9#QB<CY0;W1E;G1I86P@36%R:V5T:6YG($%P<')O=F%L(#$\8G(^55-$
M("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/D9I<G-T($EN9&EC871I;VX@9F]R($%-4C$P,3QB<CY,87AD
M86QE($QI;6ET960\8G(^4&]T96YT:6%L($UA<FME=&EN9R!!<'!R;W9A;"`Q
M/&)R/D="4"`H)B-X83,[*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$S/&)R/D9I<G-T($EN9&EC871I;VX@9F]R($%-
M4C$P,3QB<CY,87AD86QE($QI;6ET960\8G(^4&]T96YT:6%L($UA<FME=&EN
M9R!!<'!R;W9A;"`R/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY&:7)S="!);F1I8V%T:6]N
M(&9O<B!!35(Q,#$\8G(^3&%X9&%L92!,:6UI=&5D/&)R/E!O=&5N=&EA;"!-
M87)K971I;F<@07!P<F]V86P@,CQB<CY'0E`@*"8C>&$S.RD\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N
M=',@86YD($-O;G1I;F=E;F-I97,@1&ES8VQO<W5R92!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-I9VYE9"!A9W)E96UE;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E=F5L;W!M96YT(&9E97,@8V]M;6ET=&5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F%W(&UA=&5R:6%L('!U<F-H87-E(&-O;6UI=&UE;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y
M;65N="!M861E('5N9&5R('1H92!A9W)E96UE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-"XX/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XQ/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8N,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!O
M=&5N=&EA;"!A9V=R96=A=&4@<W1O8VL@;W(@8V%S:"!P87EM96YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@N,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+C$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38N
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3(N,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$R+C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW+C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@;&EA8FEL:71Y('!A>6%B;&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2XV/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06UO<G1I>F%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%24A#23X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY%<75I='D@+2!!9&1I=&EO;F%L($EN9F]R
M;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^26X@36EL;&EO;G,L(&5X8V5P
M="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#0^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5L+B`Q,BP@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2F%N+B`S,2P@,C`Q,SQB<CY3=&]C:R!);F-E
M;G1I=F4@4&QA;B`R,#$Q/&)R/E)E<W1R:6-T960@4W1O8VL@56YI=',@*%)3
M57,I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@,CDL
M(#(P,3(\8G(^4W1O8VL@26YC96YT:79E(%!L86X@,C`Q,3QB<CY297-T<FEC
M=&5D(%-T;V-K(%5N:71S("A24U5S*3QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/E-T;V-K($EN8V5N=&EV92!0
M;&%N(#(P,3$\8G(^4F5S=')I8W1E9"!3=&]C:R!5;FET<R`H4E-5<RD\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB
M<CY3=&]C:R!);F-E;G1I=F4@4&QA;B`R,#$Q/&)R/E)E<W1R:6-T960@4W1O
M8VL@56YI=',@*%)357,I/&)R/D=R;W5P(#$\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY3=&]C:R!);F-E;G1I
M=F4@4&QA;B`R,#$Q/&)R/E)E<W1R:6-T960@4W1O8VL@56YI=',@*%)357,I
M/&)R/D=R;W5P(#(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CY3=&]C:R!);F-E;G1I=F4@4&QA;B`R,#$Q/&)R
M/E)E<W1R:6-T960@4W1O8VL@56YI=',@*%)357,I/&)R/D=R;W5P(#,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB
M<CY3=&]C:R!);F-E;G1I=F4@4&QA;B`R,#$Q/&)R/E)E<W1R:6-T960@4W1O
M8VL@56YI=',@*%)357,I/&)R/D=R;W5P(#,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY3=&]C:R!);F-E;G1I
M=F4@4&QA;B`R,#$Q/&)R/D1E9F5R<F5D(%-T;V-K(%5N:71S("A$4U5S*3QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S
M/&)R/E-T;V-K($EN8V5N=&EV92!0;&%N(#(P,3$\8G(^1&5F97)R960@4W1O
M8VL@56YI=',@*$1357,I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;"X@,3(L(#(P,3,\8G(^06UE<FEC86X@1&5P;W-I=&]R>2!3:&%R
M97,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4W1O8VMH;VQD97)S($5Q=6ET>2!.;W1E(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0413(&ES<W5E9"!I;B!P=6)L:6,@;V9F97)I;F<L(&YU;6)E<CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L
M-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0413(&ES<W5E9"!I;B!P=6)L:6,@;V9F97)I;F<L('!R:6-E
M('!E<B!!1%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-2XV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!1%,@:7-S=65D(&EN('!U8FQI8R!O9F9E<FEN9RP@
M;F5T('!R;V-E961S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$R,2XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$R,2XR/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS(&=R86YT960@9F]R
M('!U<F-H87-E(&]F(&%D9&ET:6]N86P@<VAA<F5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(U-2PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO
M;BQE>&5R8VES86)L92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<S,"!D87ES/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@:7-S=65D+"!E
M>&5R8VES92!O9B!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S@V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,L,3`W+#DQ,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S
M('!R;V-E961S(&9R;VT@97AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<N.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!P<F]C965D<R!F<F]M(&5X97)C:7-E(&]F('-T;V-K(&]P=&EO;G,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3:&%R97,@:7-S=65D+"!E>&5R8VES92!O9B!W87)R86YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PX.#$L,C<V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1W)O<W,@<')O8V5E9',@9G)O;2!E>&5R8VES92!O9B!W
M87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V
M+C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@<')O8V5E9',@9G)O;2!E>&5R8VES92!O9B!W
M87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V
M+C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3=&]C:R!U;FET<R!G<F%N=&5D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-30L.#<U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3@T+#0P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4W1O8VL@=6YI=',L($5X<&ER871I;VX@9&%T93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^075G(#,L#0H)"3(P,34\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M1&5C(#,Q+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@=6YI=',L(&9O<F9E:71E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,R+#4P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/CDP+#8X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@<W1O8VL@=6YI=',L:7-S=65D(&%S
M(&$@<F5S=6QT(&]F('9E<W1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.3,L,#0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.3<L,SDX/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D(%-T
M;V-K('5N:71S+"!%>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP+C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K('5N:71S+%9E<W1I;F<@
M4&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<S('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5F97)R960@4W1O8VL@=6YI=',L($5X<&5N<V5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-#<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5F97)R960@4W1O8VL@=6YI=',L(&ES<W5E9"!A<R!A(')E
M<W5L="!O9B!V97-T:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P141&04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5B
M<V5Q=65N="!%=F5N=',@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A
M:6PI("A3=6)S97%U96YT($5V96YT+"!54T0@)"D\8G(^26X@36EL;&EO;G,L
M('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^3V-T+B`R,BP@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4W5B<V5Q=65N="!%=F5N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT($5V
M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1A9F8@<F5D=6-T:6]N(&EN(&9O<F-E+"!A<'!R
M;WAI;6%T92!P97)C96YT86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O<W0@9'5E('1O('-T869F(')E9'5C=&EO;B!I;B!F
M;W)C93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M.D9I;&4@2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P."YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3(N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$S+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,34N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$V+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q-RYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,3@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,"YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C$N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#(R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970R,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C0N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(U+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970R-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,C<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(X+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R.2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,S`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#,Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,BYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S,N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#,T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970S-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S8N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,W+FAT;6PB+SX-"CPO>&UL
M/@T*+2TM+2TM/5].97AT4&%R=%]E,&8X93%E.%\R-C9D7S1B9C1?83@Y-E\S
/8V4Y.&-F-35A838M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>154</ContextCount>
  <ElementCount>236</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/StatementOfIncomeAlternative</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Condensed Consolidated Statements of Changes in Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Deficit</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Intangible Asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock</Role>
      <ShortName>Intangible Asset</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock</Role>
      <ShortName>Inventory</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Warrants and Warrant Derivative Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</Role>
      <ShortName>Warrants and Warrant Derivative Liability</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock</Role>
      <ShortName>Debt</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Intangible Asset (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables</Role>
      <ShortName>Intangible Asset (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Warrants and Warrant Derivative Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlockTables</Role>
      <ShortName>Warrants and Warrant Derivative Liability (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation</Role>
      <ShortName>Nature of Business and Basis of Presentation - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Summarizes Activity of the Product Revenue Allowance and Reserve Categories (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesActivityOfTheProductRevenueAllowanceAndReserveCategories</Role>
      <ShortName>Summarizes Activity of the Product Revenue Allowance and Reserve Categories (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Product Revenue Recognized and Deferred (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureProductRevenueRecognizedAndDeferred</Role>
      <ShortName>Product Revenue Recognized and Deferred (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Capitalized and Expensed (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureCapitalizedAndExpensed</Role>
      <ShortName>Capitalized and Expensed (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Assets and Liability Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis</Role>
      <ShortName>Assets and Liability Measured at Fair Value on Recurring Basis (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Change in Fair Value of Financial Instruments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureChangeInFairValueOfFinancialInstruments</Role>
      <ShortName>Change in Fair Value of Financial Instruments (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Intangible Asset - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssetAdditionalInformation</Role>
      <ShortName>Intangible Asset - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Carrying Value of Intangible Asset (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureCarryingValueOfIntangibleAsset</Role>
      <ShortName>Carrying Value of Intangible Asset (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureInventory</Role>
      <ShortName>Inventory (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Inventory - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureInventoryAdditionalInformation</Role>
      <ShortName>Inventory - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - Warrants and Warrant Derivative Liability - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation</Role>
      <ShortName>Warrants and Warrant Derivative Liability - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Warrants to Purchase Common Shares Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsToPurchaseCommonSharesOutstanding</Role>
      <ShortName>Warrants to Purchase Common Shares Outstanding (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - Debt - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureDebtAdditionalInformation</Role>
      <ShortName>Debt - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureEquityAdditionalInformation</Role>
      <ShortName>Equity - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>138 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_InterestPaid had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_InterestPayableCurrent had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_ProceedsFromConvertibleDebt had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_ProceedsFromWarrantExercises had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_StockIssuedDuringPeriodSharesNewIssues had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_StockIssuedDuringPeriodValueNewIssues had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">'Monetary' elements on report '122 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '123 - Disclosure - Significant Accounting Policies - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '127 - Disclosure - Assets and Liability Measured at Fair Value on Recurring Basis (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '133 - Disclosure - Warrants and Warrant Derivative Liability - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '135 - Disclosure - Debt - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 103 - Statement - Condensed Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - Condensed Consolidated Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 107 - Statement - Condensed Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>amrn-20130930.xml</File>
    <File>amrn-20130930.xsd</File>
    <File>amrn-20130930_cal.xml</File>
    <File>amrn-20130930_def.xml</File>
    <File>amrn-20130930_lab.xml</File>
    <File>amrn-20130930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) (GBP &#xA3;)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">&#xA3; 0.50<span></span></td>
        <td class="nump">&#xA3; 0.50<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
        <td class="nump">172,664,013<span></span></td>
        <td class="nump">150,360,933<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
        <td class="nump">172,643,934<span></span></td>
        <td class="nump">150,340,854<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
        <td class="nump">20,079<span></span></td>
        <td class="nump">20,079<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
        <td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="4%" valign="top" align="left"><font style="font-family:Times New Roman" size="2"><b>(8)</b></font></td>
 <td align="left" valign="top"><font style="font-family:Times New Roman" size="2"><b>Equity</b></font></td>
 </tr>
 </table>
 <p style="margin-top:6px;margin-bottom:0px; margin-left:2%">
 <font style="font-family:Times New Roman" size="2"><i><u>Common
 stock</u></i></font></p>
 <p style="margin-top:6px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">On July&#xA0;12, 2013, the
 Company completed a public offering of 21,700,000 ADSs. The
 underwriters purchased the ADSs from Amarin at a price of $5.60 per
 ADS, resulting in net proceeds to Amarin of approximately $121.2
 million, after deducting estimated offering expenses payable by the
 Company. Amarin also granted the underwriters a 30-day option to
 purchase an additional 3,255,000 ADSs, which was not exercised. The
 stated use of proceeds in connection with this offering were as
 follows: primarily to continue the commercial launch of Vascepa
 capsules in the MARINE indication, prepare for and commercially
 launch Vascepa in the ANCHOR indication, if approved, advance the
 Company&#x2019;s REDUCE-IT cardiovascular outcomes trial, and for
 general corporate and working capital purposes.</font></p>
 <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">During the nine months ended
 September&#xA0;30, 2013 and 2012, the Company issued 386,000 and
 3,107,913 shares, respectively, as a result of the exercise of
 stock options. Gross and net proceeds resulting from the exercise
 of stock options amounted to $0.6 million for the nine months ended
 September&#xA0;30, 2013. For the nine months ended
 September&#xA0;30, 2012, gross proceeds amounted to $7.9 million
 and net proceeds amounted to $7.8 million resulting from the
 exercise of stock options. In addition, during the nine months
 ended September&#xA0;30, 2013 and 2012, the Company issued 120,000
 and 10,881,276 shares, respectively, as a result of the exercise of
 warrants. Gross and net proceeds resulting from the exercise of
 warrants amounted to $0.1 million for the nine months ended
 September&#xA0;30, 2013. For the nine months ended
 September&#xA0;30, 2012, gross proceeds amounted to $16.6 million
 and net proceeds amounted to $16.5 million resulting from the
 exercise of warrants.</font></p>
 <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">In August and September of
 2013, the Company granted a total of 44,000 restricted stock units
 (&#x201C;RSUs&#x201D;) to several employees under the Amarin
 Corporation plc 2011 Stock Incentive Plan (&#x201C;2011
 Plan&#x201D;). As of September&#xA0;30, 2013, no RSU&#x2019;s were
 forfeited and no shares were issued as a result of vesting. These
 RSUs vest upon the achievement of certain operational milestones
 and expire on December&#xA0;31, 2013 if none of the milestones are
 achieved by such date. The RSUs will become fully vested upon a
 change of control of the Company. Upon vesting of each RSU, the
 participant shall be entitled to a payment equal to the fair market
 value of one share of Amarin common stock. The payment shall be
 paid to the participant in cash, or at the sole discretion of the
 Compensation Committee in shares or a combination of cash or
 shares. The fair value of the RSUs was determined on the date of
 grant, and compensation expense related to the RSUs is recognized
 once the related milestone is deemed probable. The Company recorded
 no expense during the nine months ended September&#xA0;30, 2013
 related to the vesting of these RSUs.</font></p>
 <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">In July of 2013, the Company
 granted a total of 54,000 deferred stock units (&#x201C;DSUs&#x201D;)
 to members of the Company&#x2019;s Board of Directors under the
 Amarin Corporation plc 2011 Stock Incentive Plan (&#x201C;2011
 Plan&#x201D;). As of September&#xA0;30, 2013, no DSU&#x2019;s were
 forfeited and no shares were issued as a result of vesting. The
 DSU&#x2019;s vest over a three year period. The DSUs will become
 fully vested upon a change of control of the Company. Upon
 termination of service to the Company, each Director shall be
 entitled to a payment equal to the fair market value of one share
 of Amarin common stock, which is required to be made in shares. The
 Company recorded expense during the nine months ended
 September&#xA0;30, 2013 of $47,000 related to the vesting of these
 DSUs.</font></p>
 <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">In January 2013, the Company
 granted 454,875 RSUs to several employees under the 2011 Plan. As
 of September&#xA0;30, 2013, 32,500 RSUs were forfeited and no
 shares were issued as a result of vesting. These RSUs vest upon the
 achievement of certain operational milestones and expire on
 August&#xA0;3, 2015 if none of the milestones are achieved by such
 date. The RSUs will become fully vested upon a change of control of
 the Company. Upon vesting of each RSU, the participant shall be
 entitled to a payment equal to the fair market value of one share
 of Amarin common stock. The payment shall be paid to the
 participant in cash, or at the sole discretion of the Compensation
 Committee in shares or a combination of cash or shares. The fair
 value of the RSUs was determined on the date of grant, and
 compensation expense related to the RSUs is recognized once the
 related milestone is deemed probable. The Company recorded no
 expense during the nine months ended September&#xA0;30, 2013
 related to the vesting of these RSUs.</font></p>
 <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">In February 2012, the
 Company granted 584,400 RSUs to several employees under the 2011
 Plan. As of September&#xA0;30, 2013, a total of 90,684 RSUs were
 forfeited. These RSUs vest upon the achievement of certain
 regulatory and time-based milestones. The RSUs will become fully
 vested upon a change of control of the Company. Upon vesting of
 each RSU, the participant shall be entitled to a payment equal to
 the fair market value of one share of Amarin common stock. The
 payment shall be paid to the participant in cash, or at the sole
 discretion of the Compensation Committee in shares or a combination
 of cash or shares. During the nine months ended September&#xA0;30,
 2013 and 2012, the Company issued 93,048 and 97,398 shares,
 respectively, as a result of the vesting of these RSUs. The fair
 value of the RSUs was determined on the date of grant, and
 compensation expense related to the RSUs is recognized once the
 related milestone is deemed probable. During the nine months ended
 September&#xA0;30, 2013 and 2012, the Company recorded expense of
 $0.3 million and $1.2 million, respectively, related to the vesting
 of these RSUs.</font></p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EW1CI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Deficit (USD $)<br>In Thousands, except Share data</strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Common Shares</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital</div>
        </th>
        <th class="th">
          <div>Treasury stock</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2011</a></td>
        <td class="num">$ (5,962)<span></span></td>
        <td class="nump">$ 113,321<span></span></td>
        <td class="nump">$ 449,393<span></span></td>
        <td class="num">$ (217)<span></span></td>
        <td class="num">$ (568,459)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">135,832,542<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
        <td class="nump">10,881,276<span></span></td>
        <td class="nump">10,881,276<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Exercise of warrants</a></td>
        <td class="nump">16,526<span></span></td>
        <td class="nump">8,407<span></span></td>
        <td class="nump">8,119<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">97,398<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Transfer of fair value of warrants exercised from liabilities to equity</a></td>
        <td class="nump">103,885<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">103,885<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">76<span></span></td>
        <td class="num">(76)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Conversion option contained in exchangeable notes</a></td>
        <td class="nump">22,898<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">22,898<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
        <td class="nump">3,107,913<span></span></td>
        <td class="nump">3,107,913<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
        <td class="nump">7,834<span></span></td>
        <td class="nump">2,439<span></span></td>
        <td class="nump">5,395<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Tax benefits realized from stock-based compensation</a></td>
        <td class="nump">10,106<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,106<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices', window );">Share issued for services (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,293<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims', window );">Shares issued for services</a></td>
        <td class="nump">24<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">23<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
        <td class="nump">13,344<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13,344<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
        <td class="num">(168,617)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(168,617)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2012</a></td>
        <td class="nump">38<span></span></td>
        <td class="nump">124,244<span></span></td>
        <td class="nump">613,087<span></span></td>
        <td class="num">(217)<span></span></td>
        <td class="num">(737,076)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">149,921,422<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2012</a></td>
        <td class="num">(3,997)<span></span></td>
        <td class="nump">124,597<span></span></td>
        <td class="nump">619,266<span></span></td>
        <td class="num">(217)<span></span></td>
        <td class="num">(747,643)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,360,933<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued in equity financing (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">21,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued in equity financing</a></td>
        <td class="nump">121,206<span></span></td>
        <td class="nump">16,401<span></span></td>
        <td class="nump">104,805<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
        <td class="nump">120,000<span></span></td>
        <td class="nump">120,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Exercise of warrants</a></td>
        <td class="nump">120<span></span></td>
        <td class="nump">91<span></span></td>
        <td class="nump">29<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93,048<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">71<span></span></td>
        <td class="num">(71)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
        <td class="nump">386,000<span></span></td>
        <td class="nump">386,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
        <td class="nump">627<span></span></td>
        <td class="nump">292<span></span></td>
        <td class="nump">335<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Tax benefits realized from stock-based compensation</a></td>
        <td class="nump">966<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">966<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices', window );">Share issued for services (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,032<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims', window );">Shares issued for services</a></td>
        <td class="nump">27<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="nump">24<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
        <td class="nump">14,170<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,170<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
        <td class="num">(150,816)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(150,816)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2013</a></td>
        <td class="num">$ (17,697)<span></span></td>
        <td class="nump">$ 141,455<span></span></td>
        <td class="nump">$ 739,524<span></span></td>
        <td class="num">$ (217)<span></span></td>
        <td class="num">$ (898,459)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">172,664,013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of restricted stock or stock options granted to nonemployees as payment for services rendered or acknowledged claims.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued During Period Shares Of Stock And Warrants For Services</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the exercise of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_StockIssuedDuringPeriodValueStockWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value stock issued during the period as a result of the exercise of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_StockIssuedDuringPeriodValueStockWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 22<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26072319&amp;loc=SL6014347-161799<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 65<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7667209&amp;loc=SL6052262-162007<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of other increase (decrease) in additional paid in capital (APIC).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 740<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6419406&amp;loc=d3e23524-113945<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued which are neither cancelled nor held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EO4AG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 225,885<span></span></td>
        <td class="nump">$ 260,242<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
        <td class="nump">1,400<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
        <td class="nump">3,721<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
        <td class="nump">27,083<span></span></td>
        <td class="nump">21,262<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetCurrent', window );">Deferred tax asset</a></td>
        <td class="nump">936<span></span></td>
        <td class="nump">937<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
        <td class="nump">3,537<span></span></td>
        <td class="nump">3,253<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">262,562<span></span></td>
        <td class="nump">285,694<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
        <td class="nump">646<span></span></td>
        <td class="nump">811<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetNoncurrent', window );">Deferred tax asset</a></td>
        <td class="nump">14,433<span></span></td>
        <td class="nump">8,044<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
        <td class="nump">5,335<span></span></td>
        <td class="nump">4,951<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible asset, net</a></td>
        <td class="nump">10,870<span></span></td>
        <td class="nump">11,355<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
        <td class="nump">293,846<span></span></td>
        <td class="nump">310,855<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">6,233<span></span></td>
        <td class="nump">17,458<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
        <td class="nump">10,901<span></span></td>
        <td class="nump">2,520<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump">1,617<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other liabilities</a></td>
        <td class="nump">12,548<span></span></td>
        <td class="nump">5,224<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">31,299<span></span></td>
        <td class="nump">25,202<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Exchangeable senior notes</a></td>
        <td class="nump">145,316<span></span></td>
        <td class="nump">134,250<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
        <td class="nump">87,319<span></span></td>
        <td class="nump">85,153<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
        <td class="nump">811<span></span></td>
        <td class="nump">816<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">311,543<span></span></td>
        <td class="nump">314,852<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, &#xA3;0.50 par value, unlimited authorized; 172,664,013 issued, 172,643,934 outstanding at September 30, 2013; 150,360,933 issued, 150,340,854 outstanding at December 31, 2012</a></td>
        <td class="nump">141,455<span></span></td>
        <td class="nump">124,597<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">739,524<span></span></td>
        <td class="nump">619,266<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock; 20,079 shares at September 30, 2013 and December 31, 2012</a></td>
        <td class="num">(217)<span></span></td>
        <td class="num">(217)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(898,459)<span></span></td>
        <td class="num">(747,643)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
        <td class="num">(17,697)<span></span></td>
        <td class="num">(3,997)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</a></td>
        <td class="nump">293,846<span></span></td>
        <td class="nump">310,855<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
        <td class="nump">39,598<span></span></td>
        <td class="nump">54,854<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Long Term Debt</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
        <td class="nump">$ 7,200<span></span></td>
        <td class="nump">$ 14,577<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of obligations incurred and payable, pertaining to costs that are statutory in nature, incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include, but not limited to, taxes, interest, rent and utilities. Also includes the aggregate carrying amount of liabilities not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesAndOtherLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e31917-109318<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e31931-109318<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e31928-109318<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e31958-109318<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of noncurrent deferred tax asset attributable to deductible temporary differences and carryforwards. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e31917-109318<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e31931-109318<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e31928-109318<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e31958-109318<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsNetNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=20225523&amp;loc=SL20225862-175312<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SeniorLongTermNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EADAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Carrying Value of Intangible Asset (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Technology rights</a></td>
        <td class="nump">$ 11,624<span></span></td>
        <td class="nump">$ 11,624<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
        <td class="num">(754)<span></span></td>
        <td class="num">(269)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible asset, net</a></td>
        <td class="nump">$ 10,870<span></span></td>
        <td class="nump">$ 11,355<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENWAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summarizes Activity of the Product Revenue Allowance and Reserve Categories (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period and deferred sales</a></td>
        <td class="nump">$ 7,347<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits/payments made for current period and deferred sales</a></td>
        <td class="num">(5,270)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September 30, 2013</a></td>
        <td class="nump">2,077<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Allowance for Trade Receivables</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period and deferred sales</a></td>
        <td class="nump">2,839<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits/payments made for current period and deferred sales</a></td>
        <td class="num">(1,951)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September 30, 2013</a></td>
        <td class="nump">888<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Rebates Chargebacks And Discounts</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period and deferred sales</a></td>
        <td class="nump">2,418<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits/payments made for current period and deferred sales</a></td>
        <td class="num">(1,484)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September 30, 2013</a></td>
        <td class="nump">934<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Allowance for Sales Returns</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period and deferred sales</a></td>
        <td class="nump">72<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September 30, 2013</a></td>
        <td class="nump">72<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Other Incentive Programs</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period and deferred sales</a></td>
        <td class="nump">2,018<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits/payments made for current period and deferred sales</a></td>
        <td class="num">(1,835)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September 30, 2013</a></td>
        <td class="nump">$ 183<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 09<br><br> -Article 12<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ValuationAllowancesAndReservesBalance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, charged to costs and expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 09<br><br> -Article 12<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the deductions in a given period to allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, representing receivables written off as uncollectible and portions of the reserves utilized, respectively.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 09<br><br> -Article 12<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ValuationAllowancesAndReservesDeductions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4MAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="6">9 Months Ended</th>
        <th class="th" colspan="10"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Laxdale Limited

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Jul. 26, 2012

</div>
          <div>Laxdale Limited

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Amr One Hundred One

</div>
          <div>USD ($)

</div>
          <div>Contract</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Amr One Hundred One

</div>
          <div>Maximum

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Chemport

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>BASF

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Fourth API supplier

</div>
          <div>Maximum

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Slanhmor

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Further Indication for AMR101

</div>
          <div>Laxdale Limited

</div>
          <div>Potential Marketing Approval 1

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Further Indication for AMR101

</div>
          <div>Laxdale Limited

</div>
          <div>Potential Marketing Approval 1

</div>
          <div>GBP (&#xA3;)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Further Indication for AMR101

</div>
          <div>Laxdale Limited

</div>
          <div>Potential Marketing Approval 2

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Further Indication for AMR101

</div>
          <div>Laxdale Limited

</div>
          <div>Potential Marketing Approval 2

</div>
          <div>GBP (&#xA3;)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Further Indication for AMR101

</div>
          <div>Laxdale Limited

</div>
          <div>Maximum

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Further Indication for AMR101

</div>
          <div>Laxdale Limited

</div>
          <div>Maximum

</div>
          <div>GBP (&#xA3;)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>First Indication for AMR101

</div>
          <div>Laxdale Limited

</div>
          <div>Potential Marketing Approval 1

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>First Indication for AMR101

</div>
          <div>Laxdale Limited

</div>
          <div>Potential Marketing Approval 1

</div>
          <div>GBP (&#xA3;)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>First Indication for AMR101

</div>
          <div>Laxdale Limited

</div>
          <div>Potential Marketing Approval 2

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>First Indication for AMR101

</div>
          <div>Laxdale Limited

</div>
          <div>Potential Marketing Approval 2

</div>
          <div>GBP (&#xA3;)</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_NumberOfAgreements', window );">Number of signed agreements</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DevelopmentFeesCommitted', window );">Development fees committed</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Raw material purchase commitment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.1<span></span></td>
        <td class="nump">5.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForPurchaseOfOtherAssets1', window );">Payment made under the agreements</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4.8<span></span></td>
        <td class="nump">0.1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6.1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Potential aggregate stock or cash payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8.1<span></span></td>
        <td class="nump">5.0<span></span></td>
        <td class="nump">8.1<span></span></td>
        <td class="nump">5.0<span></span></td>
        <td class="nump">16.1<span></span></td>
        <td class="nump">10.0<span></span></td>
        <td class="nump">12.1<span></span></td>
        <td class="nump">7.5<span></span></td>
        <td class="nump">12.1<span></span></td>
        <td class="nump">7.5<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Accrued liability payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11.6<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expense</a></td>
        <td class="nump">$ 0.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_CommitmentsAndContingenciesDisclosureLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_CommitmentsAndContingenciesDisclosureLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_DevelopmentFeesCommitted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Development Fees Committed</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_DevelopmentFeesCommitted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_NumberOfAgreements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of Agreements</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_NumberOfAgreements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:decimalItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentForAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermPurchaseCommitmentAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion (due beyond one year or one operating cycle) of other accrued expenses (expenses incurred at the end of the reporting period but not yet paid) not otherwise defined in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 24<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAccruedLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPurchaseOfOtherAssets1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash paid to purchase other assets as part of operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 17<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3367-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForPurchaseOfOtherAssets1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount the entity has committed to make for future royalty guarantees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 928<br><br> -SubTopic 440<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RoyaltyGuaranteesCommitmentsAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EIHCI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity - Additional Information (Detail) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">2 Months Ended</th>
        <th class="th" colspan="4">9 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 12, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2013

</div>
          <div>Stock Incentive Plan 2011

</div>
          <div>Restricted Stock Units (RSUs)</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012

</div>
          <div>Stock Incentive Plan 2011

</div>
          <div>Restricted Stock Units (RSUs)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Stock Incentive Plan 2011

</div>
          <div>Restricted Stock Units (RSUs)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Stock Incentive Plan 2011

</div>
          <div>Restricted Stock Units (RSUs)

</div>
          <div>Group 1</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Stock Incentive Plan 2011

</div>
          <div>Restricted Stock Units (RSUs)

</div>
          <div>Group 2</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Stock Incentive Plan 2011

</div>
          <div>Restricted Stock Units (RSUs)

</div>
          <div>Group 3</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Stock Incentive Plan 2011

</div>
          <div>Restricted Stock Units (RSUs)

</div>
          <div>Group 3</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Stock Incentive Plan 2011

</div>
          <div>Deferred Stock Units (DSUs)</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Stock Incentive Plan 2011

</div>
          <div>Deferred Stock Units (DSUs)</div>
        </th>
        <th class="th">
          <div>Jul. 12, 2013

</div>
          <div>American Depository Shares</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">ADS issued in public offering, number</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">21,700,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">ADS issued in public offering, price per ADS</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5.60<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">ADS issued in public offering, net proceeds</a></td>
        <td class="nump">$ 121.2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 121.2<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_OptionsGrantedDuringPeriod', window );">Options granted for purchase of additional shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,255,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_OptionsExercisablePeriod', window );">Option,exercisable period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">30 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued, exercise of stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">386,000<span></span></td>
        <td class="nump">3,107,913<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ProceedsFromStockOptionsExercisedGross', window );">Gross proceeds from exercise of stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.6<span></span></td>
        <td class="nump">7.9<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ProceedsFromStockOptionExerciseAndOther', window );">Net proceeds from exercise of stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.6<span></span></td>
        <td class="nump">7.8<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Shares issued, exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">120,000<span></span></td>
        <td class="nump">10,881,276<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ProceedsFromWarrantExercisesGross', window );">Gross proceeds from exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.1<span></span></td>
        <td class="nump">16.6<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ProceedsFromExerciseOfStockOptionsAndWarrants', window );">Net proceeds from exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.1<span></span></td>
        <td class="nump">16.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock units granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">454,875<span></span></td>
        <td class="nump">584,400<span></span></td>
        <td class="nump">44,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">54,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock units, Expiration date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Aug.
				03,
				 2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Dec. 31,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Stock units, forfeited</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">32,500<span></span></td>
        <td class="nump">90,684<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units,issued as a result of vesting</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">93,048<span></span></td>
        <td class="nump">97,398<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted Stock units, Expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0.3<span></span></td>
        <td class="nump">1.2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock units,Vesting Period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense', window );">Deferred Stock units, Expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 47,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Deferred Stock units, issued as a result of vesting</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_OptionsExercisablePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options Exercisable Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_OptionsExercisablePeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_OptionsGrantedDuringPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options Granted During Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_OptionsGrantedDuringPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ProceedsFromExerciseOfStockOptionsAndWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds From Exercise Of Stock Options And Warrants</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_ProceedsFromExerciseOfStockOptionsAndWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ProceedsFromStockOptionExerciseAndOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds From Stock Option Exercise And Other</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_ProceedsFromStockOptionExerciseAndOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ProceedsFromStockOptionsExercisedGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from Stock Options Exercised Gross</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_ProceedsFromStockOptionsExercisedGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ProceedsFromWarrantExercisesGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from Warrant Exercises Gross</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_ProceedsFromWarrantExercisesGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_StockholdersEquityNoteLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_StockholdersEquityNoteLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the exercise of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedStockExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date the equity-based award expires, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit of equity securities issued by non-development stage entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesIssuedPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 25<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418455&amp;loc=d3e16649-113920<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="4%" valign="top" align="left"><font style="font-family:Times New Roman" size="2"><b>(7)</b></font></td>
 <td align="left" valign="top"><font style="font-family:Times New Roman" size="2"><b>Commitments and
 Contingencies</b></font></td>
 </tr>
 </table>
 <p style="margin-top:6px;margin-bottom:0px; margin-left:2%">
 <font style="font-family:Times New Roman" size="2"><i><u>Royalty
 and Milestone Obligations</u></i></font></p>
 <p style="margin-top:6px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">The Company is party to
 certain milestone and royalty obligations under several product
 development agreements, as follows:</font></p>
 <p style="font-size:6px;margin-top:0px;margin-bottom:0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="5%"><font size="1">&#xA0;</font></td>
 <td width="2%" valign="top" align="left"><font style="font-family:Times New Roman" size="2">&#x2022;</font></td>
 <td width="1%" valign="top"><font size="1">&#xA0;</font></td>
 <td align="left" valign="top">
 <p align="left"><font style="font-family:Times New Roman" size="2">The Company&#x2019;s active pharmaceutical ingredient, or API,
 supply agreement with Nisshin Pharma, Inc. (&#x201C;Nisshin&#x201D;),
 provided for minimum supply purchase obligations on behalf of the
 Company to enable Amarin to maintain exclusivity with this
 supplier, and to prevent potential termination of the agreement
 based on Company estimated minimum purchase requirements. As of
 September&#xA0;30, 2013, the API aggregate minimum purchase
 obligations under this supply agreement had been achieved and as a
 result, the Company has no future minimum purchase obligation from
 Nisshin.</font></p>
 </td>
 </tr>
 </table>
 <p style="font-size:6px;margin-top:0px;margin-bottom:0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="5%"><font size="1">&#xA0;</font></td>
 <td width="2%" valign="top" align="left"><font style="font-family:Times New Roman" size="2">&#x2022;</font></td>
 <td width="1%" valign="top"><font size="1">&#xA0;</font></td>
 <td align="left" valign="top">
 <p align="left"><font style="font-family:Times New Roman" size="2">In 2011, the Company entered into agreements with two
 additional suppliers, Chemport, Inc. (&#x201C;Chemport&#x201D;) and
 BASF (formerly Equateq Limited) for the supply of API materials for
 Vascepa. In 2012, the Company agreed to terms with a fourth API
 supplier, Slanmhor Pharmaceutical, Inc., or Slanmhor. These
 agreements include requirements for the suppliers to qualify their
 materials and facilities with applicable regulatory authorities
 including the FDA. The Company anticipates incurring certain costs
 associated with the qualification of product produced by these
 suppliers as described below. In each case, following qualification
 of the supplier for the manufacture of API for commercial sale,
 these agreements include annual purchase levels to enable Amarin to
 maintain exclusivity with each respective supplier, and to prevent
 potential termination of the agreements. The Company is not
 obligated to pay in cash any shortfall in the minimum purchase
 obligations pursuant to the Chemport and BASF agreements. The
 agreement with Slanmhor contains a provision requiring the Company
 to pay Slanmhor in cash for any shortfall in the minimum purchase
 obligations, which will become effective upon the approval for
 manufacture by the FDA of supply from Slanmhor. Chemport and BASF
 were approved by the FDA to manufacture API for commercial sale in
 April 2013. The Company has begun to purchase commercial supply
 from Chemport. BASF must complete production of validation batches
 before the Company will begin to purchase commercial supply. The
 2011 supply agreements include commitments for the Company to fund
 (i)&#xA0;development fees up to a maximum of $0.5&#xA0;million
 (ii)&#xA0;material purchases of up to $5.0 million for initial raw
 materials, which amount will be credited against future API
 purchases and (iii)&#xA0;a raw material purchase commitment of
 $1.1&#xA0;million. Under these agreements, during the nine months
 ended September&#xA0;30, 2013, the Company made payments of $4.8
 million and $0.1 million to Chemport and BASF, respectively. The
 agreement with Slanmhor provides for development fees of up to $2.3
 million and a commitment of up to $15.0 million, which will be
 credited against future API material purchases. The $15.0 million
 commitment fee is contingent upon the mutually agreed upon
 expansion of Slanmhor&#x2019;s API manufacturing capacity. Under
 this agreement, during the nine months ended September&#xA0;30,
 2013, the Company made payments of $6.1 million to Slanmhor related
 to stability and technical batches and advances on future API
 purchases.</font></p>
 </td>
 </tr>
 </table>
 <p style="font-size:6px;margin-top:0px;margin-bottom:0px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="5%"><font size="1">&#xA0;</font></td>
 <td width="2%" valign="top" align="left"><font style="font-family:Times New Roman" size="2">&#x2022;</font></td>
 <td width="1%" valign="top"><font size="1">&#xA0;</font></td>
 <td align="left" valign="top">
 <p align="left"><font style="font-family:Times New Roman" size="2">Under the 2004 share repurchase agreement with Laxdale Limited,
 or Laxdale, upon approval of Vascepa by the FDA on July&#xA0;26,
 2012, the Company was required to make a milestone payment to
 Laxdale of &#xA3;7.5&#xA0;million. The Company made this payment in
 2012 and capitalized this Laxdale milestone ($11.6 million on
 July&#xA0;26, 2012) as an intangible asset. This long-term asset is
 being amortized over the estimated useful life of the intellectual
 property the Company acquired from Laxdale and the Company
 recognized amortization expense of $0.5 million during the nine
 months ended September&#xA0;30, 2013. Also under the Laxdale
 agreement, upon receipt of marketing approval in Europe for the
 first indication for Vascepa (or first indication of any product
 containing Amarin Neuroscience intellectual property acquired from
 Laxdale in 2004), the Company must make an aggregate stock or cash
 payment to the former shareholders of Laxdale (at the sole option
 of each of the sellers) of &#xA3;7.5&#xA0;million (approximately
 $12.1 million at September&#xA0;30, 2013). Also under the Laxdale
 agreement, upon receipt of a marketing approval in the U.S. or
 Europe for a further indication of Vascepa (or further indication
 of any other product using Amarin Neuroscience intellectual
 property), the Company must make an aggregate stock or cash payment
 (at the sole option of each of the sellers) of &#xA3;5&#xA0;million
 (approximately $8.1 million at September&#xA0;30, 2013) for each of
 the two potential market approvals (i.e. &#xA3;10&#xA0;million
 maximum, or approximately $16.1 million at September&#xA0;30,
 2013).</font></p>
 </td>
 </tr>
 </table>
 <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">The Company has no provision
 for any of the obligations above since the amounts are either not
 probable or estimable at September&#xA0;30, 2013.</font></p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Inventory (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
        <td class="nump">$ 4,993<span></span></td>
        <td class="nump">$ 5,465<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
        <td class="nump">12,166<span></span></td>
        <td class="nump">15,471<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
        <td class="nump">9,283<span></span></td>
        <td class="nump">326<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Finished goods inventory held by others</a></td>
        <td class="nump">641<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
        <td class="nump">$ 27,083<span></span></td>
        <td class="nump">$ 21,262<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryFinishedGoodsNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryRawMaterialsNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryWorkInProcessNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.2.Q2 Response)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6GAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Use of
 Estimates</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The preparation of the
 Company&#x2019;s consolidated financial statements in conformity
 with accounting principles generally accepted in the United States
 of America, or GAAP, requires management to make estimates and
 assumptions that affect the reported amounts of assets and
 liabilities, disclosure of contingent assets and liabilities at the
 date of the financial statements, and the reported amounts of
 revenues and expenses during the reporting period. Accounting
 estimates are based on historical experience and other factors that
 are considered reasonable under the circumstances. Actual results
 could differ from those estimates. The preparation of the
 Company&#x2019;s condensed consolidated financial statements in
 accordance with GAAP requires management to make estimates,
 judgments and assumptions that may affect the reported amounts of
 assets, liabilities, revenues and expenses, and related disclosure
 of contingent assets and liabilities. On an on-going basis, the
 Company evaluates its estimates and judgments and methodologies,
 including those related to revenue recognition and related
 allowances, clinical trial expenses, the valuation of inventory,
 impairment and amortization of intangibles, share-based
 compensation, income taxes including the valuation allowance for
 deferred tax assets, valuation of investments and derivative
 instruments. The Company bases its estimates on historical
 experience and on various other assumptions that are believed to be
 reasonable, the results of which form the basis for making
 judgments about the carrying values of assets and liabilities.
 Actual results may differ from these estimates.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Revenue Recognition</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company sells Vascepa
 principally to a limited number of major wholesalers, as well as
 selected regional wholesalers and specialty pharmacy providers, or
 collectively, its Distributors, that in turn resell Vascepa to
 retail pharmacies for subsequent resale to patients and health care
 providers. Patients are required to have a prescription in order to
 purchase Vascepa. In accordance with GAAP, the Company&#x2019;s
 revenue recognition policy requires that: (i)&#xA0;there is
 persuasive evidence that an arrangement exists between the Company
 and the Distributor, (ii)&#xA0;delivery has occurred,
 (iii)&#xA0;collectability is reasonably assured and (iv)&#xA0;the
 price is fixed or determinable.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company commenced its
 commercial launch in the United States on January&#xA0;28, 2013.
 Prior to 2013, the Company recognized no revenue from Vascepa
 sales. In accordance with GAAP, until the Company has the ability
 to reliably estimate returns of Vascepa from its Distributors,
 revenue will be recognized based on the resale of Vascepa for the
 purposes of filling patient prescriptions, and not based on sales
 from the Company to such Distributors. Consistent with industry
 practice, once the Company achieves sufficient history such that it
 can reliably estimate returns, the Company will recognize revenue
 based on sales to its Distributors. The Company currently defers
 Vascepa revenue recognition until the earlier of the product being
 resold for purposes of filling patient prescriptions; or the
 expiration of the right of return (twelve months after the
 expiration date of the product). The Company also defers the
 related cost of product sales and records such amounts as finished
 goods inventory held by others until revenue related to such
 product sales is recognized.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company has contracts
 with its primary Distributors and delivery occurs when a
 Distributor receives Vascepa. The Company evaluates the
 creditworthiness of each of its Distributors to determine whether
 revenues can be recognized upon delivery, subject to satisfaction
 of the other requirements, or whether recognition is required to be
 delayed until receipt of payment or when the product is utilized.
 In order to conclude that the price is fixed or determinable, the
 Company must be able to (i)&#xA0;calculate its gross product
 revenues from the sales to Distributors and (ii)&#xA0;reasonably
 estimate its net product revenues. The Company calculates gross
 product revenues based on the wholesale acquisition cost that the
 Company charges its Distributors for Vascepa. The Company estimates
 its net product revenues by deducting from its gross product
 revenues (a)&#xA0;trade allowances, such as invoice discounts for
 prompt payment and distributor fees, (b)&#xA0;estimated government
 and private payor rebates, chargebacks and discounts, such as
 Medicaid reimbursements, (c)&#xA0;reserves for expected product
 returns and (d)&#xA0;estimated costs of incentives offered to
 certain indirect customers, including patients.</font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><i>Trade
 Allowances:</i> The Company generally provides invoice discounts on
 Vascepa sales to its Distributors for prompt payment and pays fees
 for distribution services, such as fees for certain data that
 Distributors provide to the Company. The payment terms for sales to
 Distributors generally include a 2% discount for payment within
 30&#xA0;days. Based on the Company&#x2019;s judgment and experience,
 the Company expects its Distributors to earn these discounts and
 fees, and deducts the full amount of these discounts and fees from
 its gross product revenues and accounts receivable at the time such
 revenues are recognized.</font></p>
 <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><i>Rebates,
 Chargebacks and Discounts:</i> The Company contracts with Medicaid,
 other government agencies and various private organizations, or
 collectively, Third-party Payors, so that Vascepa will be eligible
 for purchase by, or partial or full reimbursement from, such
 Third-party Payors. The Company estimates the rebates, chargebacks
 and discounts it will provide to Third-party Payors and deducts
 these estimated amounts from its gross product revenues at the time
 the revenues are recognized. The Company estimates the rebates,
 chargebacks and discounts that it will provide to Third-party
 Payors based upon (i)&#xA0;the Company&#x2019;s contracts with these
 Third-party Payors, (ii)&#xA0;the government-mandated discounts
 applicable to government-funded programs, (iii)&#xA0;information
 obtained from the Company&#x2019;s Distributors and
 (iv)&#xA0;information obtained from other third parties regarding
 the payor mix for Vascepa.</font></p>
 <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><i>Product
 Returns:</i> The Company&#x2019;s Distributors have the right to
 return unopened unprescribed Vascepa during the 18-month period
 beginning six months prior to the labeled expiration date and
 ending twelve months after the labeled expiration date. The
 expiration date for Vascepa is three years after it has been
 converted into capsule form, which is the last step in the
 manufacturing process for Vascepa and generally occurs within a few
 months before Vascepa is delivered to Distributors. As of
 September&#xA0;30, 2013, the Company had experienced a deminimus
 quantity of product returns. During the nine months ended
 September&#xA0;30, 2013, the period in which the Company began
 selling Vascepa, the Company was not able to reasonably estimate
 product returns for all product sold to Distributors but the
 Company was able to reasonably estimate product returns for certain
 sales of Vascepa based on product used to fill patient
 prescriptions as determined by inventory estimated to be in the
 distribution channel and third party reports of prescriptions
 filled. In making this assessment, the Company used (i)&#xA0;data
 provided to the Company by its Distributors (including weekly
 reporting of Distributors&#x2019; sales and inventory held by
 Distributors that provided the Company with visibility into the
 distribution channel in order to determine what quantities were
 sold to retail pharmacies and other providers),
 (ii)&#xA0;information provided to the Company from retail
 pharmacies, (iii)&#xA0;data provided to the Company by a third
 party data provider which collects and publishes prescription data,
 and other third parties, (iv)&#xA0;historical industry information
 regarding return rates for similar pharmaceutical products,
 (v)&#xA0;the estimated remaining shelf life of Vascepa previously
 shipped and currently being shipped to Distributors and
 (vi)&#xA0;contractual agreements intended to limit the amount of
 inventory maintained by the Company&#x2019;s
 Distributors.</font></p>
 <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><i>Other
 Incentives:&#xA0;</i>Other incentives that the Company offers to
 indirect customers include co-pay mitigation rebates provided by
 the Company to commercially insured patients who have coverage for
 Vascepa and who reside in states that permit co-pay mitigation
 programs. The Company&#x2019;s co-pay mitigation program is intended
 to reduce each participating patient&#x2019;s portion of the
 financial responsibility for Vascepa&#x2019;s purchase price to a
 specified dollar amount. Based upon the terms of the program and
 information regarding programs provided for similar specialty
 pharmaceutical products, the Company estimates the average co-pay
 mitigation amounts and the percentage of patients that it expects
 to participate in the program in order to establish its accruals
 for co-pay mitigation rebates and deducts these estimated amounts
 from its gross product revenues at the time the revenues are
 recognized. The Company&#x2019;s co-pay mitigation rebates offered
 to date will expire on December&#xA0;31, 2013. The Company adjusts
 its accruals for co-pay mitigation rebates based on its estimates
 regarding the portion of issued rebates that it estimates will not
 be redeemed. In addition, as is customary prior to the launch of
 new drugs, the Company provided certain of its Distributors with
 financial incentives to begin stocking Vascepa prior to the
 Company&#x2019;s commercial launch of Vascepa in order to ensure
 that Vascepa was readily available to fill patient prescriptions
 upon launch. Such incentives were only offered on purchases of
 initial launch quantities of Vascepa stocked by Distributors in
 January 2013. The amount of these financial incentives were
 recorded by the Company as a reduction to revenues on a pro-rata
 basis for each of the bottles subject to such financial incentives.
 The Company estimates that all of these initial launch quantities
 stocked by its primary Distributors in January 2013 were resold by
 such Distributors prior to September&#xA0;30, 2013.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The following table
 summarizes activity in each of the product revenue allowance and
 reserve categories described above for the nine months ended
 September&#xA0;30, 2013 (in thousands):</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Trade<br />
 Allowances</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Rebates,<br />
 Chargebacks<br />
 and&#xA0;Discounts</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Product<br />
 Returns</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Other<br />
 Incentives</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 January&#xA0;1, 2013</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Provision related to
 current period and deferred sales</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,839</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,418</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">72</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,018</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,347</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Credits/payments made for
 current period and deferred sales</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,951</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,484</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,835</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(5,270</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 September&#xA0;30, 2013</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>888</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>934</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>72</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>183</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2,077</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The following table
 summarizes product revenue recognized and deferred during the nine
 months ended September&#xA0;30, 2013 (in thousands):</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="14%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="14%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>September&#xA0;30,&#xA0;2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Product revenue
 recognized</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,245</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred product
 revenue</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,617</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>17,862</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">In conjunction with the
 Company&#x2019;s recognition and deferral of product revenues, the
 Company expensed and capitalized the associated cost of goods, as
 follows, during the nine months ended September&#xA0;30, 2013 (in
 thousands):</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="14%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="14%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>September&#xA0;30,&#xA0;2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cost of goods sold
 expensed</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,813</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Finished goods inventory
 held by others</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">641</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>8,454</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Cash
 and Cash Equivalents</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Cash and cash equivalents
 consist of cash, deposits held at call with banks and short term
 highly liquid instruments with remaining maturities at the date of
 purchase of 90&#xA0;days or less. Restricted cash represents cash
 and cash equivalents pledged to guarantee repayment of certain
 expenses which may be incurred for business travel under corporate
 credit cards held by employees.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Inventory</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company states
 inventories at the lower of cost or market value. Cost is
 determined based on actual cost using the average cost method. An
 allowance is established when management determines that certain
 inventories may not be saleable. If inventory cost exceeds expected
 market value due to obsolescence, damage or quantities in excess of
 expected demand, the Company will record a reserve for the
 difference between cost and market value. The Company received FDA
 approval for Vascepa on July&#xA0;26, 2012 and after that date
 began capitalizing inventory purchases of saleable product from
 approved suppliers. Until an API supplier is approved, all Vascepa
 API purchased from such supplier is included as a component of
 research and development expense. Upon sNDA approval of each
 additional supplier, the Company capitalizes subsequent Vascepa API
 purchases from such supplier as inventory. Purchases of Vascepa API
 received and expensed before such regulatory approvals is not
 subsequently capitalized, and all such purchases are quarantined
 and not used for commercial supply until such time as the sNDA for
 the supplier that produced the API is approved.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Asset, net</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Intangible Asset, net</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Intangible assets consist
 of a milestone payment paid to the former shareholders of Laxdale
 Limited related to the 2004 acquisition of our rights to Vascepa,
 which is the result of Vascepa receiving marketing approval for the
 first indication and is amortized over its estimated useful life on
 a straight-line basis. The Company concluded that use of the
 straight-line method was appropriate as the majority of cash flows
 are expected to be generated ratably over the estimated useful life
 and no degradation of the cash flows over time is currently
 anticipated. See Note 7&#x2014;Commitments and Contingencies for
 further information regarding other obligations related to the
 acquisition of Laxdale Limited.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DeferredRevenuePolicyTextBlock', window );">Deferred Revenue</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Deferred Revenue</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred revenue represents
 product shipments to Distributors for which the Company has
 invoiced the Distributors but not recognized revenue because the
 product was not reported to the Company as having been resold for
 the purpose of filling prescriptions on or before
 September&#xA0;30, 2013.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Research and Development Costs</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company charges
 research and development costs to operations as incurred. Research
 and development expenses are comprised of costs incurred by the
 Company in performing research and development activities,
 including salary and benefits; stock-based compensation expense;
 laboratory supplies and other direct expenses; contractual
 services, including clinical trial and pharmaceutical development
 costs; commercial supply investment in its drug candidates; and
 infrastructure costs, including facilities costs and depreciation
 expense. In addition, research and development costs include the
 costs of product supply received from suppliers when such receipt
 by the Company is prior to regulatory approval of the
 supplier.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Costs</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Selling, General and Administrative
 Costs</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company charges sales,
 general and administrative costs to operations as incurred.
 Selling, general and administrative costs include costs of
 salaries, programs and infrastructure necessary for the general
 conduct of the Company&#x2019;s business, including the 2013
 commercial launch of Vascepa in the United States for the MARINE
 indication. Included as part of selling, general and administrative
 costs is warrant-related expense from non-cash changes in fair
 value of the derivative liability associated with warrants issued
 in October 2009 to former officers of Amarin which is recorded as
 compensation income (expense).</font></p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Income
 Taxes</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax assets and
 liabilities are recognized for the future tax consequences of
 differences between the carrying amounts and tax bases of assets
 and liabilities and operating loss carry-forwards and other
 attributes using enacted rates expected to be in effect when those
 differences reverse. Valuation allowances are provided against
 deferred tax assets that are not more likely than not to be
 realized.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company provides
 reserves for potential payments of tax to various tax authorities
 or does not recognize tax benefits related to uncertain tax
 positions and other issues. Tax benefits for uncertain tax
 positions are based on a determination of whether a tax benefit
 taken by the Company in its tax filings or positions is more likely
 than not to be realized, assuming that the matter in question will
 be decided based on its technical merits. The Company&#x2019;s
 policy is to record interest and penalties in the provision for
 income taxes.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Derivative Instruments</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Derivative financial
 liabilities are recorded at fair value, with gains and losses
 arising for changes in fair value recognized in the statement of
 operations at each period end while such instruments are
 outstanding. If the Company issues shares to discharge the
 liability, the derivative financial liability is derecognized and
 common stock and additional paid-in capital are recognized on the
 issuance of those shares. The warrants are valued using a
 Black-Scholes option pricing model due to the nature of the
 instrument. The long term debt redemption feature is valued using a
 probability-weighted model incorporating management estimates for
 potential change in control, and by determining the fair value of
 the debt with and without the change in control provision
 included.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">If the terms of warrants
 that initially require the warrant to be classified as a derivative
 financial liability lapse, the derivative financial liability is
 reclassified out of financial liabilities into equity at its fair
 value on that date. At the applicable settlement date, if the
 instruments are settled in shares, the carrying value of the
 warrants are derecognized and transferred to equity at their fair
 value at that date. The cash proceeds received from exercises of
 warrants are recorded in common stock and additional paid-in
 capital.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per Share</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Loss
 per Share</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Basic net loss per share is
 determined by dividing net loss by the weighted average shares of
 common stock outstanding during the period. Diluted net loss per
 share is determined by dividing net loss by diluted weighted
 average shares outstanding. Diluted weighted average shares
 reflects the dilutive effect, if any, of potentially dilutive
 common shares, such as common stock options and warrants calculated
 using the treasury stock method and convertible notes using the
 &#x201C;if-converted&#x201D; method. In periods with reported net
 operating losses, all common stock options and warrants are deemed
 anti-dilutive such that basic net loss per share and diluted net
 loss per share are equal.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Instruments</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Debt
 Instruments</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Debt instruments are
 initially recorded at fair value, with coupon interest and
 amortization of debt issuance discounts recognized in the statement
 of operations as interest expense at each period end while such
 instruments are outstanding. If the Company issues shares to
 discharge the liability, the debt obligation is derecognized and
 common stock and additional paid-in capital are recognized on the
 issuance of those shares.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s
 exchangeable notes contain a conversion option which is classified
 as equity. The fair value of the liability component of the debt
 instrument was deducted from the initial proceeds to determine the
 proceeds to be allocated to the conversion option. The embedded
 conversion option is indexed to the Company&#x2019;s stock and
 treated as equity on the balance sheet. The conversion option is
 evaluated on a quarterly basis to determine if it still meets the
 criteria to be equity classified. The excess principal amount of
 the debt over the carrying value of the liability is amortized to
 interest expense over the term of the debt.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s
 December 2012 debt financing agreement contains a redemption
 feature triggered upon a change of control, which has been
 classified as an embedded derivative. The fair value of the
 derivative was recorded as a reduction to the fair value of the
 note payable. The fair value of this warrant derivative liability
 is remeasured at each reporting period, with changes in fair value
 recognized in the statement of operations. The discount recorded to
 the note payable is being amortized to interest expense over the
 term of the note payable.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Fair
 Value of Financial Instruments</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company provides
 disclosure of financial assets and financial liabilities that are
 carried at fair value based on the price that would be received
 upon sale of an asset or paid to transfer a liability in an orderly
 transaction between market participants at the measurement
 date.&#xA0;Fair value measurements may be classified based on the
 amount of subjectivity associated with the inputs to fair valuation
 of these assets and liabilities using the following three
 levels:</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Level 1&#x2014;Inputs are
 unadjusted quoted prices in active markets for identical assets or
 liabilities that the Company has the ability to access at the
 measurement date.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Level 2&#x2014;Inputs
 include quoted prices for similar assets and liabilities in active
 markets, quoted prices for identical or similar assets or
 liabilities in markets that are not active, inputs other than
 quoted prices that are observable for the asset or liability (i.e.,
 interest rates, yield curves, etc.) and inputs that are derived
 principally from or corroborated by observable market data by
 correlation or other means (market corroborated inputs).</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Level 3&#x2014;Unobservable
 inputs that reflect the Company&#x2019;s estimates of the
 assumptions that market participants would use in pricing the asset
 or liability.&#xA0;The Company develops these inputs based on the
 best information available, including its own data.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The following table
 presents information about the Company&#x2019;s assets and
 liabilities as of September&#xA0;30, 2013 and December&#xA0;31,
 2012 that are measured at fair value on a recurring basis and
 indicates the fair value hierarchy of the valuation techniques the
 Company utilized to determine such fair value:</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>September&#xA0;30,
 2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="1"><b><i>In millions</i></b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;1</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;2</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;3</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Asset:</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash
 equivalents&#x2014;money markets</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">113.5</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">113.5</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Liabilities:</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Warrant derivative
 liability</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">39.6</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">39.6</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term debt redemption
 feature</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.2</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.2</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign currency
 contracts</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.4</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.4</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,
 2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="1"><b><i>In millions</i></b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;1</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;2</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Level&#xA0;3</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Asset:</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash
 equivalents&#x2014;money markets</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;64.1</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;64.1</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Liability:</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Warrant derivative
 liability</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">54.9</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">54.9</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term debt redemption
 feature</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14.6</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14.6</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The carrying amounts of
 cash, cash equivalents, accounts receivable, accounts payable and
 accrued liabilities approximate fair value because of their
 short-term nature.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesEmbeddedDerivatives', window );">Long Term Debt Redemption Feature</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Long
 Term Debt Redemption Feature</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s
 December 2012 financing agreement with BioPharma Secured Debt Fund
 II Holdings Cayman, L.P, or BioPharma, contains a redemption
 feature whereby, upon a change of control, the Company would be
 required to pay $140 million, less any previously repaid amount, if
 the change of control occurs on or before December&#xA0;31, 2013,
 or required to repay $150 million, less any previously repaid
 amount, if the change of control event occurs after
 December&#xA0;31, 2013. The Company determined this redemption
 feature to be an embedded derivative, which is carried at fair
 value and is classified as Level 3 in the fair value hierarchy due
 to the use of significant unobservable inputs.&#xA0;The fair value
 of the embedded derivative was calculated using a
 probability-weighted model incorporating management estimates for
 potential change in control, and by determining the fair value of
 the debt with and without the change in control provision included.
 The difference between the two fair values of the debt was
 determined to be the fair value of the embedded derivative. At
 December&#xA0;31, 2012, the fair value of the derivative was
 determined to be $14.6 million, and the debt was valued by
 comparing debt issues of similar companies with (i)&#xA0;terms of
 between 4.8 and 8.0 years, (ii)&#xA0;coupon rates of between 3.0%
 and 11.5% and (iii)&#xA0;market yields of between 10.7% and 27.7%.
 At September&#xA0;30, 2013, the fair value of the derivative was
 determined to be $7.2 million, and the debt was valued by comparing
 debt issues of similar companies with (i)&#xA0;remaining terms of
 between 3.5 and 4.4 years, (ii)&#xA0;coupon rates of between 9.9%
 and 12.5% and (iii)&#xA0;market yields of between 10.4% and 25.8%.
 The Company recognized a gain of $1.4 million and $7.4 million on
 the change in fair value of this derivative liability for the three
 and nine months ended September&#xA0;30, 2013,
 respectively.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Foreign Currency</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">All subsidiaries use the
 United States dollar as the functional currency. Monetary assets
 and liabilities denominated in a foreign currency are remeasured
 into United States dollars at period-end exchange rates.
 Non-monetary assets and liabilities carried in a foreign currency
 are remeasured into United States dollars using rates of exchange
 prevailing when such assets or liabilities were obtained or
 incurred, and expenses are generally remeasured using rates of
 exchange prevailing when such expenses are incurred. Gains and
 losses from the remeasurement are included in other (expense)
 income, net in the consolidated statements of operations. For
 transactions settled during the applicable period, gains and losses
 are included in other (expense) income, net in the consolidated
 statements of operations. The Company periodically uses foreign
 exchange forward contracts to hedge against changes in exchange
 rates for inventory purchases denominated in foreign currency. As
 of&#xA0;September 30, 2013, the Company held one foreign exchange
 forward contract with a notional amount of $4.5 million. As
 of&#xA0;September 30, 2013, the outstanding foreign exchange
 forward contract derivative liability had a net fair value of $0.4
 million. The Company included this $0.4 million as a component of
 change in fair value of derivative liabilities and in other current
 liabilities at September&#xA0;30, 2013.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The change in the fair
 value of financial instruments is as follows (in
 thousands):</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>October</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>2009</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Warrants&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Debt</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Redemption&#xA0; &#xA0;</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Feature</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Foreign</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Exchange</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Contracts&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;&#xA0;&#xA0;Totals&#xA0;&#xA0;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 January&#xA0;1, 2012</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>123,125</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#x2014;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#x2014;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>123,125</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Loss on change in fair
 value of derivative liability</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">68,686</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">68,686</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Compensation expense for
 change in fair value of warrants issued to former
 employees</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,037</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,037</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Transfers to
 equity</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(103,885</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(103,885</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 September&#xA0;30, 2012</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>90,963</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#x2014;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#x2014;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>90,963</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>October</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>2009</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Warrants&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Debt</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Redemption&#xA0; &#xA0;</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Feature</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Foreign</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>Exchange</b></font><br />
 <font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Contracts&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;&#xA0;&#xA0;Totals&#xA0;&#xA0;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 January&#xA0;1, 2013</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>54,854</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>14,577</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#x2014;&#xA0;&#xA0;</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>69,431</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">(Gain) loss on change in
 fair value of derivative liabilities</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,077</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(7,377</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">395</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(21,059</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Compensation income for
 change in fair value of warrants issued to former
 employees</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,179</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,179</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Transfers to
 equity</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Balance at
 September&#xA0;30, 2013</b></font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>39,598</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>7,200</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>395</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>47,193</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;&#xA0;</b></font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographical Information</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Segment and Geographical
 Information</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">For the three and nine
 months ended September&#xA0;30, 2013 and 2012, the Company has
 reported its business as a single reporting segment. The
 Company&#x2019;s chief decision maker, who is the Chief Executive
 Officer, regularly evaluates the Company on a consolidated
 basis.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_RecentAccountingPronouncementsPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Recent
 Accounting Pronouncements</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">From time to time, new
 accounting pronouncements are issued by the Financial Accounting
 Standards Board, or FASB, and are adopted by the Company as of the
 specified effective date. The Company believes that the impact of
 recently issued but not yet adopted accounting pronouncements will
 not have a material impact on consolidated financial position,
 results of operations, and cash flows, or do not apply to the
 Company&#x2019;s operations.</font></p>
 </div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Warrant Derivative Liability</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">At December&#xA0;31, 2012,
 the fair value of the warrant derivative liability was determined
 to be $54.9 million using the Black-Scholes option valuation model
 applying the following assumptions: (i)&#xA0;risk-free rate of
 0.25%, (ii)&#xA0;remaining term of 1.8 years, (iii)&#xA0;no
 dividend yield, (iv)&#xA0;volatility of 95% and (v)&#xA0;the stock
 price on the date of measurement.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">At September&#xA0;30, 2013,
 the fair value of the warrant derivative liability was determined
 to be $39.6 million using the Black-Scholes option valuation model
 applying the following assumptions: (i)&#xA0;risk-free rate of
 0.1%, (ii)&#xA0;remaining term of 1.0 year, (iii)&#xA0;no dividend
 yield, (iv)&#xA0;volatility of 91%, and (v)&#xA0;the stock price on
 the date of measurement.&#xA0;The $3.6 million increase in the fair
 value of the warrant liability during the three months ended
 September&#xA0;30, 2013 was recognized as: (i)&#xA0;a $3.3 million
 loss on change in fair value of the remaining derivative liability
 and (ii)&#xA0;$0.3 million in compensation expense for change in
 fair value of warrants issued to former employees. The $15.3
 million decrease in the fair value of the warrant liability during
 the nine months ended September&#xA0;30, 2013 was recognized as:
 (i)&#xA0;a $14.1 million gain on change in fair value of the
 remaining derivative liability and (ii)&#xA0;$1.2 million in
 compensation income for change in fair value of warrants issued to
 former employees. Both amounts are included in the consolidated
 statement of operations for the nine months ended
 September&#xA0;30, 2013.&#xA0;The fair value of this warrant
 liability is determined using the Black-Scholes option valuation
 model and is therefore sensitive to changes in the market price and
 volatility of the Company&#x2019;s common stock among other
 factors.&#xA0;In the event of a hypothetical 10% increase in the
 market price of the Company&#x2019;s common shares ($6.95 based on
 the $6.32 market price of the Company&#x2019;s stock at
 September&#xA0;30, 2013) on which the September&#xA0;30, 2013
 valuation was based, the value of the derivative liability would
 have increased by $5.0 million.&#xA0;Such increase would have been
 reflected as a loss on change in fair value of the warrant
 derivative liability in the Company&#x2019;s statement of
 operations. Significant increases (decreases) in this input in
 isolation would result in a significantly higher (lower) fair value
 asset measurement.</font></p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_DeferredRevenuePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred Revenue, Policy [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_DeferredRevenuePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_RecentAccountingPronouncementsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Recent accounting pronouncements , Policy [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_RecentAccountingPronouncementsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs incurred to obtain or issue debt, the effects of refinancings, method of amortizing deferred financing costs and original issue discount, and classifications of debt on the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2208565<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesEmbeddedDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2229141<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Embedded Derivative<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6511375<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativesEmbeddedDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41620-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579245-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579240-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41638-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph n<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41675-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2175856<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2175826<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2175892<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144681<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144749<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32247-109318<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144471<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsFiniteLivedPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2126999<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 206<br><br> -Paragraph b<br><br> -Subparagraph i, ii<br><br> -Chapter 2<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for segment reporting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Debt<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
        <td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="4%" valign="top" align="left"><font style="font-family:Times New Roman" size="2"><b>(6)</b></font></td>
 <td align="left" valign="top"><font style="font-family:Times New Roman" size="2"><b>Debt</b></font></td>
 </tr>
 </table>
 <p style="margin-top:6px;margin-bottom:0px; margin-left:2%">
 <font style="font-family:Times New Roman" size="2"><i><u>Long term
 debt&#x2014;December 2012 Financing</u></i></font></p>
 <p style="margin-top:6px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">On December&#xA0;6, 2012,
 the Company entered into an agreement with BioPharma. Under this
 agreement, the Company granted to BioPharma a security interest in
 future receivables associated with the Vascepa patent rights in
 exchange for $100.0 million received at the closing of the
 agreement, which closing occurred in December 2012. The Company has
 agreed to repay BioPharma up to $150&#xA0;million of future revenue
 and receivables. The first scheduled repayment under the agreement
 is a repayment of $2.5&#xA0;million of interest due to be paid to
 BioPharma in November 2013 for the fiscal quarter ended
 September&#xA0;30, 2013, subject to the limitation described below.
 Additional quarterly repayments are scheduled to be paid thereafter
 in accordance with the following schedule: $2.5 million of interest
 in the first quarter of 2014; $8.0 million per quarter in each of
 the next four quarters, $10.0 million per quarter in each of the
 next four quarters, $15.0 million per quarter in each of the next
 four quarters and a final payment of $13.0 million scheduled for
 payment in May 2017. The quarterly repayments through the third
 quarter of September 2014 represent interest only. Quarterly
 payments do not begin to reduce the principal balance until the
 fourth quarter of 2014. These quarterly payments are subject to a
 quarterly threshold amount whereby, if a calculated threshold,
 based on quarterly Vascepa revenues, is not achieved, the quarterly
 payment payable in that quarter can at the Company&#x2019;s election
 be reduced, with the reduction carried forward without interest for
 payment in a future period. The payment of any carried forward
 amount is subject to similarly calculated threshold repayment
 amounts based on Vascepa revenue levels. Except upon a change of
 control in Amarin, the agreement does not expire until $150 million
 has been repaid. Under the agreement, upon a change of control, the
 Company would be required to pay $140 million, less any previously
 repaid amount, if the change of control occurs on or before
 December&#xA0;31, 2013, or required to repay $150 million, less any
 previously repaid amount, if the change of control event occurs
 after December&#xA0;31, 2013. The Company can prepay after
 October&#xA0;1, 2013, an amount equal to $150 million less any
 previously repaid amount.</font></p>
 <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">The Company determined the
 redemption feature upon a change of control to be an embedded
 derivative requiring bifurcation. The fair value of the embedded
 derivative was calculated by determining the fair value of the debt
 with the change in control provision included and also without the
 change in control provision. The difference between the two fair
 values of the debt was determined to be the fair value of the
 embedded derivative, and upon closing, the Company recorded a
 derivative liability of $14.6 million as a reduction to the note
 payable. The fair value of this derivative liability is remeasured
 at each reporting period, with changes in fair value recognized in
 the statement of operations. The fair value of the derivative
 liability at September&#xA0;30, 2013 was $7.2 million and the
 Company recognized a gain on change in fair value of derivative
 liability of $1.4 million and $7.4 million for the three and nine
 month periods ended September&#xA0;30, 2013, respectively. For the
 nine months ended September&#xA0;30, 2013, the Company recorded
 $9.7&#xA0;million and $2.2 million of cash and non-cash interest
 expense, respectively related to the BioPharma debt. For the three
 months ended September&#xA0;30, 2013, the Company recorded
 $2.7&#xA0;million and $0.6 million of cash and non-cash interest
 expense, respectively related to the BioPharma debt. The Company
 will periodically evaluate the remaining term of the agreement and
 the effective interest will be recalculated each period based on
 the Company&#x2019;s most current estimate of repayment.</font></p>
 <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">The Company currently
 estimates that its Vascepa revenue levels will not be high enough
 in each quarter to support repayment to BioPharma in accordance
 with threshold amounts in the repayment schedule. For the three
 months ended September&#xA0;30, 2013, revenues were below the
 contractual threshold amount such that a cash payment of $0.8
 million is due in November 2013 reflecting the calculated optional
 reduction amount as opposed to the contractual threshold payment of
 $2.5 million. In accordance with the agreement with BioPharma,
 quarterly differences between the calculated optional reduction
 amounts and the repayment schedule amounts are rescheduled for
 payment beginning in the second quarter of 2017. Any such deferred
 repayments will remain subject to continued application of the
 quarterly ceiling in amounts due established by the calculated
 threshold based on quarterly Vascepa revenues. Additionally, the
 revised assumptions yielded a decrease in the calculated effective
 interest rate resulting in a decrease in interest expense during
 the three months ended September&#xA0;30, 2013 as compared to the
 three months ended June&#xA0;30, 2013 and March&#xA0;31,
 2013.</font></p>
 <p style="margin-top:18px;margin-bottom:0px; margin-left:2%">
 <font style="font-family:Times New Roman" size="2"><i><u>Exchangeable Senior Notes</u></i></font></p>
 <p style="margin-top:6px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">In January 2012, the Company
 issued $150.0 million in principal amount of 3.5% exchangeable
 senior notes due 2032, or the Senior Notes. The Senior Notes were
 issued by Corsicanto Limited, an Irish limited company acquired by
 Amarin in January 2012. Corsicanto Limited is a wholly-owned
 subsidiary of Amarin. The general, unsecured, senior obligations
 are fully and unconditionally guaranteed by Amarin but not by any
 of the Company&#x2019;s subsidiaries. Corsicanto Limited has no
 assets, operations, revenues or cash flows other than those related
 to the issuance, administration and repayment of the Senior
 Notes.&#xA0;There are no significant restrictions on the ability of
 Amarin to obtain funds from Corsicanto Limited in the form of cash
 dividends, loans, or advances.&#xA0;Net proceeds to the Company,
 after payment of underwriting fees and expenses, were approximately
 $144.3 million.</font></p>
 <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">The Senior Notes have a
 stated interest rate of 3.5%&#xA0;per year, payable semiannually in
 arrears on January&#xA0;15 and July&#xA0;15 of each year beginning
 on July&#xA0;15, 2012, and ending upon the Senior Notes&#x2019;
 maturity on January&#xA0;15, 2032. The Senior Notes are subject to
 repurchase by the Company at the option of the holders on each of
 January&#xA0;19, 2017,&#xA0;January&#xA0;19, 2022, and
 January&#xA0;19, 2027, at a price equal to 100% of the principal
 amount of the Senior Notes to be repurchased, plus accrued and
 unpaid interest to, but excluding, the repurchase date. The Senior
 Notes are exchangeable under certain circumstances into cash, ADSs,
 or a combination of cash and ADSs, at the Company&#x2019;s election,
 with an initial exchange rate of 113.4752 ADSs per $1,000 principal
 amount of Senior Notes. It is the Company&#x2019;s current intention
 to settle these obligations in cash. If the Company elected
 physical settlement, the Senior Notes would initially be
 exchangeable into 17,021,280 ADSs. Based on the closing price of
 the Company&#x2019;s stock at September&#xA0;30, 2013, the principal
 amount of the Senior Notes would exceed the value of the shares if
 converted on that date by $42.4 million.</font></p>
 <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">Additional covenants
 include: (i)&#xA0;limitations on future indebtedness under certain
 circumstances, (ii)&#xA0;the timely filing of documents and reports
 pursuant to Section&#xA0;13 or 15(d) of the Exchange Act with both
 the SEC and the Trustee, and (iii)&#xA0;maintaining the tradability
 of the Senior Notes. The Company is required to use commercially
 reasonable efforts to procure and maintain the listing of the
 Senior Notes on the Global Exchange Market operated under the
 supervision of the Irish Stock Exchange (or other recognized stock
 exchange as defined in the Note Indenture) prior to July&#xA0;15,
 2012. If the Senior Notes are not freely tradable, as a result of
 restrictions pursuant to U.S. securities law or the terms of the
 Indenture or the Senior Notes, the Company shall pay additional
 interest on the Senior Notes at the rate of 0.50%&#xA0;per annum of
 the principal amount of Senior Notes outstanding for each day
 during such period for which the Company&#x2019;s failure to file
 has occurred and is continuing or for which the Senior Notes are
 not freely tradable.</font></p>
 <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">The Company may not redeem
 the Senior Notes prior to January&#xA0;19, 2017, other than in
 connection with certain changes in the tax law of a relevant taxing
 jurisdiction that results in additional amounts becoming due with
 respect to payments and/or deliveries on the Senior Notes. On or
 after January&#xA0;19, 2017 and prior to the maturity date, the
 Company may redeem for cash all or part of the Senior Notes at a
 redemption price equal to 100% of the principal amount of the
 Senior Notes to be redeemed, plus accrued and unpaid interest to,
 but excluding, the redemption date. There is no prepayment penalty
 or sinking fund provided for the Senior Notes. If the Company
 undergoes a fundamental change, holders may require the Company to
 repurchase for cash all or part of their Senior Notes at a
 repurchase price equal to 100% of the principal amount of the
 Senior Notes to be repurchased, plus accrued and unpaid interest
 to, but excluding, the fundamental change repurchase date. The
 Senior Notes are the Company&#x2019;s senior unsecured obligations
 and rank senior in right of payment to the Company&#x2019;s future
 indebtedness that is expressly subordinated in right of payment to
 the Senior Notes and equal in right of payment to the
 Company&#x2019;s future unsecured indebtedness that is not so
 subordinated. The Senior Notes are effectively junior in right of
 payment to future secured indebtedness to the extent of the value
 of the assets securing such indebtedness.</font></p>
 <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">The Senior Notes are
 exchangeable under certain circumstances. The Company calculated
 the fair value of the liability component of the Senior Notes to be
 $126.2 million, and the excess of the principal amount of the debt
 over the liability component of $23.8 million was allocated to the
 conversion option resulting in a discount on the debt. The discount
 created from allocating proceeds to the conversion option is being
 amortized to interest expense using the effective interest method
 over the Senior Notes&#x2019; estimated remaining life, which was
 calculated to be a period of twenty-four months. The effective
 interest rate of the Senior Notes is 14.5%. As of
 September&#xA0;30, 2013, the unamortized discount created from the
 allocation of the proceeds to the conversion option was $3.9
 million. The conversion option will not be subsequently remeasured
 as long as it continues to meet the criteria for equity
 classification.</font></p>
 <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">The Company also recorded a
 debt discount to reflect the value of the underwriters&#x2019;
 discounts and offering costs. A portion of the debt discount from
 underwriter&#x2019;s discounts and offering costs was allocated to
 the equity and liability components of the Notes in proportion to
 the proceeds allocated to each component. The portion of the debt
 discount from underwriters&#x2019; discounts and offering costs
 allocated to the liability component is being amortized as interest
 expense over the estimated remaining life of the Senior Notes of
 twenty-four months. As of September&#xA0;30, 2013, the unamortized
 debt discount was $0.8 million and was recorded as a direct
 reduction of the related debt on the balance sheet. The carrying
 value of the Notes, net of the unamortized discount, was $145.3
 million. During the three months ended September&#xA0;30, 2013, the
 Company recognized interest expense of $5.2 million related to the
 Notes, of which $3.2 million represents amortization of the debt
 discount created upon allocation of proceeds to the conversion
 option, $1.3 million represents contractual coupon interest, and
 $0.7 million represents the amortization of the discount from the
 underwriter&#x2019;s discounts and offering costs. During the nine
 months ended September&#xA0;30, 2013, the Company recognized
 interest expense of $15.0 million related to the Notes, of which
 $9.2 million represents amortization of the debt discount created
 upon allocation of proceeds to the conversion option, $3.9 million
 represents contractual coupon interest, and $1.9 million represents
 the amortization of the discount from the underwriter&#x2019;s
 discounts and offering costs. At September&#xA0;30, 2013, the
 Company had accrued interest of $1.1 million.</font></p>
 <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2">In January and July 2013,
 the interest payments due of $2.6 million were paid as
 scheduled.</font></p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
        <td class="text"><div>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(1)</b></font></td>
 <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Nature of Business and
 Basis of Presentation</b></font></td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Nature
 of Business</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Amarin Corporation plc,
 &#x201C;Amarin&#x201D; or the &#x201C;Company&#x201D;, is a public
 limited company with its primary stock market listing in the United
 States on the NASDAQ Global Market. Amarin was originally
 incorporated in England as a private limited company on
 March&#xA0;1, 1989 under the Companies Act 1985, and re-registered
 in England as a public limited company on March&#xA0;19,
 1993.</font></p>
 <p style="PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px">
 <font style="FONT-FAMILY: Times New Roman" size="2">Amarin is a
 biopharmaceutical company with expertise in lipid science focused
 on the commercialization and development of therapeutics to improve
 cardiovascular health. On July&#xA0;26, 2012, the Company received
 approval from the U.S. Food and Drug Administration, or FDA, to
 market and sell its lead product Vascepa<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="POSITION: relative; BOTTOM: 0.8ex; VERTICAL-ALIGN: baseline">&#xAE;</sup></font>
 (icosapent ethyl) capsules (formerly known as AMR 101) as an
 adjunct to diet to reduce triglyceride levels in adult patients
 with severe (TG <u>&gt;</u>500mg/dL) hypertriglyceridemia, which
 the Company sometimes refers to as the MARINE indication.
 Triglycerides are fats in the blood. Vascepa became commercially
 available in the United States by prescription in January 2013,
 when the Company commenced sales and shipments to its network of
 U.S.-based wholesalers and specialty pharmacy providers. On
 January&#xA0;28, 2013, the Company commenced its full commercial
 launch of Vascepa in the United States for use in the MARINE
 indication.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Amarin is also developing
 Vascepa for the treatment of patients with high triglyceride levels
 (TG <u>&gt;</u>200 mg/dL and &lt;500 mg/dL) who are also on statin
 therapy for elevated LDL-C levels. This indication is referred to
 as mixed dyslipidemia or the ANCHOR indication. In February 2013,
 the Company submitted a supplemental New Drug Application, or sNDA,
 to the FDA seeking approval of Vascepa for the ANCHOR indication.
 On October&#xA0;16, 2013, the FDA convened an advisory committee to
 review the Company&#x2019;s sNDA for the ANCHOR indication and the
 advisory committee voted 9 to 2 against recommending approval of
 the ANCHOR indication based on information presented at the
 meeting. The FDA will consider the recommendation of the advisory
 committee, but the final decision regarding the approval of the
 sNDA will be made by the FDA. The application is subject to a
 standard review and has been assigned a Prescription Drug User Fee
 Act, or PDUFA, date of December&#xA0;20, 2013. The PDUFA date is
 the target date for the FDA to complete its review of the sNDA. The
 FDA could complete its review of the sNDA prior to this date and
 there can be no assurance that the FDA will complete its review of
 the sNDA by this date. If the FDA does not approve the ANCHOR
 indication, it would have a material impact on the Company&#x2019;s
 future results of operations and financial condition (see Note
 9&#x2014;Subsequent Events).</font></p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%">
 <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Basis
 of Presentation</u></i></b></font></p>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The condensed consolidated
 financial statements included herein have been prepared by the
 Company, without audit, in accordance with accounting principles
 generally accepted in the United States of America (the
 &#x201C;U.S.&#x201D; or the &#x201C;United States&#x201D;) and pursuant
 to the rules and regulations of the Securities and Exchange
 Commission (the &#x201C;SEC&#x201D;). Certain information in the
 notes to the financial statements (the &#x201C;Notes&#x201D;) has
 been condensed or omitted where it substantially duplicates
 information provided in the Company&#x2019;s latest audited
 consolidated financial statements, in accordance with the rules and
 regulations of the SEC. These condensed consolidated financial
 statements should be read in conjunction with the Company&#x2019;s
 audited consolidated financial statements and notes included in its
 Annual Report on Form 10-K for the fiscal year ended
 December&#xA0;31, 2012, filed with the SEC (the &#x201C;2012 Form
 10-K&#x201D;). The balance sheet amounts at December&#xA0;31, 2012
 in this report were derived from the Company&#x2019;s audited 2012
 consolidated financial statements included in the 2012 Form 10-K.
 The condensed consolidated financial statements reflect all
 adjustments that, in the opinion of management, are necessary to
 present fairly the Company&#x2019;s financial position, results of
 operations and cash flows for the periods indicated. The
 preparation of financial statements in conformity with U.S.
 Generally Accepted Accounting Principles (&#x201C;GAAP&#x201D;)
 requires management to make estimates and assumptions that affect
 the reported amounts and classifications of assets and liabilities
 and disclosure of contingent assets and liabilities at the date of
 the financial statements and the reported amounts of revenues and
 expenses during the reporting period. The results of operations for
 the three and nine months ended September&#xA0;30, 2013 and 2012,
 respectively, are not necessarily indicative of the results for the
 entire fiscal year or any future period. The Company has evaluated
 subsequent events from September&#xA0;30, 2013 through the date of
 the issuance of these condensed consolidated financial statements
 and has disclosed subsequent events in Note 9.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The accompanying
 consolidated financial statements of the Company and subsidiaries
 have been prepared on a basis which assumes that the Company will
 continue as a going concern, which contemplates the realization of
 assets and the satisfaction of liabilities and commitments in the
 normal course of business. Prior to 2004, the Company was in the
 business of selling a previous biopharmaceutical compound, which
 has since been discontinued. The Company&#x2019;s current focus is
 on the commercialization and development of Vascepa, which received
 approval from the FDA in 2012 and for which the Company commenced
 marketing and sales in 2013.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">At September&#xA0;30, 2013,
 the Company had cash and cash equivalents of $225.9&#xA0;million.
 See also Note 8&#x2014;Equity for a description of a public offering
 completed in July 2013 resulting in net proceeds to the Company of
 approximately $121.2 million.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s
 consolidated balance sheet also includes derivative liabilities
 (see Note 5&#x2014;Warrants and Warrant Derivative Liability) as
 well as long term debt and exchangeable senior notes (see Note
 6&#x2014;Debt). The warrant derivative liability reflects the fair
 value of outstanding warrants to purchase shares of the
 Company&#x2019;s common stock. This liability can only be settled in
 shares of the Company&#x2019;s stock. The long term debt is not
 callable except upon a change in control. The Exchangeable Senior
 Notes (the Notes) may be redeemed on or after January&#xA0;19, 2017
 at the option of the holders. The Notes are exchangeable under
 certain circumstances into cash, American Depository Shares, or
 ADSs, or a combination of cash and ADSs, at the Company&#x2019;s
 election. Accordingly, the warrant derivative liability, long term
 debt and Exchangeable Senior Notes do not present a short term
 claim on the liquid assets of the Company.</font></p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company believes its
 cash and cash equivalents will be sufficient to fund its projected
 operations for at least the next twelve months.</font></p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28200181&amp;loc=SL6228881-111685<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668296&amp;loc=d3e288-107754<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EI3AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Warrants to Purchase Common Shares Outstanding (Detail)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Amount</a></td>
        <td class="nump">9,816,826<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise Price</a></td>
        <td class="nump">1.44<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant issued on 4/27/07</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Amount</a></td>
        <td class="nump">17,500<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise Price</a></td>
        <td class="nump">17.90<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ClassOfWarrantOrRightExpirationDate', window );">Expiration Date</a></td>
        <td class="text">1/17/14<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant issued on 7/31/09</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Amount</a></td>
        <td class="nump">1,684,888<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise Price</a></td>
        <td class="nump">1.00<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ClassOfWarrantOrRightExpirationDate', window );">Expiration Date</a></td>
        <td class="text">7/30/14<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant issued on 10/16/09</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Amount</a></td>
        <td class="nump">7,487,388<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise Price</a></td>
        <td class="nump">1.50<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ClassOfWarrantOrRightExpirationDate', window );">Expiration Date</a></td>
        <td class="text">10/15/14<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant issued on 10/16/09</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Amount</a></td>
        <td class="nump">627,050<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise Price</a></td>
        <td class="nump">1.50<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ClassOfWarrantOrRightExpirationDate', window );">Expiration Date</a></td>
        <td class="text">10/15/14<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ClassOfWarrantOrRightExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class of Warrant or Right, Expiration Date</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_ClassOfWarrantOrRightExpirationDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:dateStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Inventories consist of the
 following at September&#xA0;30, 2013 and December&#xA0;31, 2012 (in
 thousands):</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>September&#xA0;30,&#xA0;2013</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2012</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Raw materials</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,993</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,465</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Work in process</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12,166</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,471</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Finished goods</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9,283</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">326</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="top">
 <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Finished goods inventory
 held by others</font></p>
 </td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">641</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,083</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21,262</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 2<br><br> -Paragraph 6<br><br> -Subparagraph a,b,c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfInventoryCurrentTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"></p>
 <table style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; LETTER-SPACING: normal; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; -webkit-text-stroke-width: 0px" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>(9)</b></font></td>
 <td valign="top" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>Subsequent
 Events</b></font></td>
 </tr>
 </table>
 <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
 <font size="2"><font style="FONT-FAMILY: 'Times New Roman'" size="2">On October&#xA0;16, 2013, the Company announced that an
 advisory committee to the FDA voted 9 to 2 against recommending
 approval of the use of Vascepa capsules for the ANCHOR indication
 based on information presented at the advisory committee meeting.
 The FDA is scheduled to make its decision on whether to approve the
 ANCHOR sNDA on the December&#xA0;20, 2013 PDUFA goal date for the
 application, however, the FDA could complete its review of the sNDA
 prior to this date and there can be no assurance that the FDA will
 complete its review of the sNDA by this date.</font></font></p>
 <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
 <font size="2"><font style="FONT-FAMILY: 'Times New Roman'" size="2">On October&#xA0;22, 2013, in an effort to reduce operating
 expenses following the recommendation of the advisory committee to
 the FDA, the Company implemented a worldwide reduction in force of
 approximately fifty percent of its staff positions worldwide. The
 majority of affected staff members are sales professionals who have
 supported the initial commercial launch of Vascepa. The Company
 estimates that it will incur approximately $3 million in charges
 related to the reduction in force, all of which includes cash
 expenditures for one-time termination benefits and associated
 costs. The Company expects to record the charges in the fourth
 quarter of 2013 and make the related payments by the end of the
 first quarter of 2014.</font></font></p>
 <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
 <font size="2"><font style="FONT-FAMILY: 'Times New Roman'" size="2">On October&#xA0;29, 2013, the FDA notified the Company that it
 has rescinded the ANCHOR study Special Protocol Assessment, or SPA,
 agreement because in their view a substantial scientific issue
 essential to determining the effectiveness of Vascepa in the
 studied population from the ACCORD-Lipid and AIM-HIGH outcome
 trials, as well as the publicly presented results from the
 HPS2-THRIVE outcome trial, which the FDA stated in its
 October&#xA0;29, 2013 notice to the Company, fail to support the
 hypothesis that a triglyceride-lowering drug significantly reduces
 the risk for cardiovascular events among statin-treated patients.
 Thus, the FDA stated that it no longer considers a change in serum
 triglyceride levels as sufficient to establish the effectiveness of
 a drug intended to reduce cardiovascular risk in subjects with
 serum triglyceride levels below 500 mg/dL.</font></font></p>
 <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
 <font size="2"><font style="FONT-FAMILY: 'Times New Roman'" size="2">On November 1, 2013, a purported investor of Amarin filed a
 putative class action lawsuit against Amarin and the
 Company&#x2019;s Chief Executive Officer in the U.S. District Court
 for the District of New Jersey, Steven Sklar v. Amarin Corporation
 plc and Joseph S. Zakrzewski, No. 13-cv-6954 (D.N.J. Nov. 1, 2013).
 The lawsuit alleges that, during the period July 9, 2009 through
 October 15, 2013, the Company misled investors regarding the
 FDA&#x2019;s willingness to approve Vascepa&#x2019;s ANCHOR
 indication and the potential relevance of data from the ongoing
 REDUCE-IT trial to that approval, thereby artificially inflating
 the price of the Company&#x2019;s securities. Based on these
 allegations, the suit asserts claims under the Securities Exchange
 Act of 1934 and seeks unspecified monetary damages and
 attorneys&#x2019; fees and costs. The Company believes that it has
 valid defenses and will vigorously defend against the
 claims.</font></font></p>
 <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
 <font size="2"><font style="FONT-FAMILY: 'Times New Roman'" size="2">On November 5, 2013, a purported investor of Amarin filed a
 putative class action lawsuit against Amarin and certain of the
 Company&#x2019;s officers in the U.S. District Court for the
 Southern District of New York, Joseph A. Bove and Joseph J. Bove v.
 Amarin Corporation, PLC., Joseph S. Zakrzewski, John F. Thero, and
 Steven B. Ketchum, No. 13-CIV-7882 (S.D.N.Y. Nov. 5, 2013). The
 lawsuit alleges, similar to the&#xA0;<i>Sklar</i>&#xA0;case, that, during the period
 August 8, 2012 until October 16, 2013, the Company misled investors
 regarding the FDA&#x2019;s willingness to approve Vascepa&#x2019;s
 ANCHOR indication and the potential relevance of data from the
 ongoing REDUCE-IT trial to that approval, thereby artificially
 inflating the price of the Company&#x2019;s securities. Based on
 these allegations, the suit asserts claims under the Securities
 Exchange Act of 1934 and seeks unspecified monetary damages and
 attorneys&#x2019; fees and costs. The Company believes that it has
 valid defenses and will vigorously defend against the
 claims.</font></font></p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBGDI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CashDiscountPercent', window );">Sales discount percentage</a></td>
        <td class="nump">2.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CashDiscountInvoiceTerms', window );">Sales discount term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">30 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Warrant derivative liability fair value assumptions, risk-free rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.10%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.25%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Derivative liability fair value assumptions, term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 year 9 months 18 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Warrant derivative liability fair value assumptions, dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Warrant derivative liability fair value assumptions, volatility rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">91.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">95.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on change in fair value of derivative liabilities</a></td>
        <td class="num">$ (1,402,000)<span></span></td>
        <td class="nump">$ 16,454,000<span></span></td>
        <td class="nump">$ 21,059,000<span></span></td>
        <td class="num">$ (68,686,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market price of common stock</a></td>
        <td class="nump">$ 6.32<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.32<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAssumptionsInMarketPriceOfStock', window );">Hypothetical increase in market price of common shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Long term debt redemption feature</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,600,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_MaturityPeriodUsedToClassifyInvestments', window );">Short term highly liquid instruments, maturity date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">90 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Embedded Derivative Financial Instruments</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on change in fair value of derivative liabilities</a></td>
        <td class="nump">1,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ChangeInControlObligations', window );">Change of control obligation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">140,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Maximum repayment of future revenue and receivables</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Long term debt redemption feature</a></td>
        <td class="nump">7,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,600,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Embedded Derivative Financial Instruments | Maximum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Derivative liability fair value assumptions, term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years 4 months 24 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">8 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_FairValueInputsCouponRate', window );">Derivative liability fair value assumption, coupon rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11.50%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_FairValueAssumptionsComparableYieldToMaturity', window );">Derivative liability fair value assumptions, market yields</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25.80%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">27.70%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Embedded Derivative Financial Instruments | Minimum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Derivative liability fair value assumptions, term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years 6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years 9 months 18 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_FairValueInputsCouponRate', window );">Derivative liability fair value assumption, coupon rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9.90%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_FairValueAssumptionsComparableYieldToMaturity', window );">Derivative liability fair value assumptions, market yields</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10.40%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10.70%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Foreign Exchange Forward</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts, foreign exchange forward contracts</a></td>
        <td class="nump">4,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_NumberOfForeignCurrencyForwardContractsOutstanding', window );">Number of foreign exchange forward contract</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativesAtFairValueNet', window );">Net fair value, foreign exchange forward contracts</a></td>
        <td class="nump">400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Foreign Exchange Forward | Other Current Liabilities</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on change in fair value of derivative liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Effect of a hypothetical 10% increase in the market price of common shares</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Increase (Decrease) in the fair value of warrant derivative liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market price of common stock</a></td>
        <td class="nump">$ 6.95<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.95<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
        <td class="nump">39,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">39,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">54,854,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants Issued October 2009</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Increase (Decrease) in the fair value of warrant derivative liability</a></td>
        <td class="nump">3,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(15,300,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on change in fair value of derivative liabilities</a></td>
        <td class="num">(3,300,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation expense (income) for change in fair value of warrants issued to former employees</a></td>
        <td class="nump">$ 300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (1,200,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_CashDiscountInvoiceTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash Discount Invoice Terms</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_CashDiscountInvoiceTerms</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_CashDiscountPercent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash Discount Percent</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_CashDiscountPercent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ChangeInControlObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change In Control Obligations</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_ChangeInControlObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_FairValueAssumptionsComparableYieldToMaturity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair Value Assumptions, Comparable Yield to Maturity</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_FairValueAssumptionsComparableYieldToMaturity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_FairValueInputsCouponRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair Value Inputs Coupon Rate</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_FairValueInputsCouponRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_MaturityPeriodUsedToClassifyInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maturity Period Used to Classify Investments</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_MaturityPeriodUsedToClassifyInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_NumberOfForeignCurrencyForwardContractsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number Of Foreign Currency Forward Contracts Outstanding</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_NumberOfForeignCurrencyForwardContractsOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_SignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_SignificantAccountingPoliciesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_SignificantAssumptionsInMarketPriceOfStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Significant Assumptions in Market Price Of Stock</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_SignificantAssumptionsInMarketPriceOfStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Nominal or face amount used to calculate payments on the derivative asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5580258-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579245-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Notional Amount<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519104<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeAssetNotionalAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20225523&amp;loc=SL20225862-175312<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624163-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativesAtFairValueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value as of the balance sheet date of foreign currency derivative assets, net of foreign currency derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized on the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyDerivativesAtFairValueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDerivativeLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherCommitment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrealizedGainLossOnDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrants and Warrant Derivative Liability (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Warrants to Purchase Common Shares Outstanding</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company had 9,816,826
 warrants to purchase common shares outstanding at
 September&#xA0;30, 2013 at a weighted-average exercise price of
 $1.44, as summarized in the following table:</font></p>
 <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="84%" align="center">
 <tr>
 <td style="WIDTH: 17pt"></td>
 <td></td>
 <td></td>
 <td style="WIDTH: 17pt"></td>
 <td valign="bottom" width="23%"></td>
 <td style="WIDTH: 14pt"></td>
 <td></td>
 <td></td>
 <td style="WIDTH: 14pt"></td>
 <td valign="bottom" width="23%"></td>
 <td style="WIDTH: 24pt"></td>
 <td></td>
 <td></td>
 <td style="WIDTH: 24pt"></td>
 <td valign="bottom" width="23%"></td>
 <td style="WIDTH: 27pt"></td>
 <td></td>
 <td></td>
 <td style="WIDTH: 27pt"></td>
 </tr>
 <tr>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Issue
 Date</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Amount</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Exercise&#xA0;Price</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Expiration&#xA0;Date</b></font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4/27/07</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17,500</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17.90</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1/17/14</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7/31/09</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,684,888</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.00</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7/30/14</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10/16/09</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,487,388</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.50</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10/15/14</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10/16/09</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">627,050</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.50</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10/15/14</font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr bgcolor="#CCEEFF">
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>9,816,826</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"><b>$</b></font></td>
 <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1.44</b></font></td>
 <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"><b>&#xA0;</b></font></td>
 <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><font size="1">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETLAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="2"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Nov. 01, 2013

</div>
          <div>Ordinary Shares</div>
        </th>
        <th class="th">
          <div>Nov. 01, 2013

</div>
          <div>American Depository Shares</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">AMRN<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">AMARIN CORP PLC\UK<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000897448<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Large Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">468,546<span></span></td>
        <td class="nump">172,195,467<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentInformationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESNAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Nature of Business and Basis of Presentation - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 12, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 225,885,000<span></span></td>
        <td class="nump">$ 260,242,000<span></span></td>
        <td class="nump">$ 215,110,000<span></span></td>
        <td class="nump">$ 116,602,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from public offering</a></td>
        <td class="nump">$ 121,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCallDateEarliest', window );">Convertible senior notes, earliest redemption date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jan. 19,
				 2017<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>amrn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCallDateEarliest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Earliest date before maturity when the issuer can call the outstanding debt instrument for repayment or conversion to equity, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 470<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentCallDateEarliest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
